8752018
D008094_D003072 CID lithium_0\NN\metallic_element.n.01| (r_npadvmod) associated_2\VBN\think.v.03|lithium|- (r_amod) deficits_6\NNS\insufficiency.n.03|associated|cognitive|reduced|.
D008094_D003072 CID lithium_15\NN\metallic_element.n.01| (r_pobj) of_14\IN\entity.n.01|lithium (r_prep) effects_13\NNS\personal_property.n.01|the|common|adverse|of|,|as (r_pobj) of_8\IN\entity.n.01|effects (r_prep) management_7\NN\social_control.n.01|the|of (r_pobj) about_5\IN\about.s.01|management (r_prep) written_4\VBN\create_verbally.v.01|although|much|has|been|about (r_advcl) remain_40\VBP\be.v.01|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (l_prep) as_29\IN\chemical_element.n.01|such|deficits (l_pobj) deficits_31\NNS\insufficiency.n.03|cognitive|,|loss
D008094_D003072 CID lithium_15\NN\metallic_element.n.01| (r_pobj) of_14\IN\entity.n.01|lithium (r_prep) effects_13\NNS\personal_property.n.01|the|common|adverse|of|,|as (r_pobj) of_8\IN\entity.n.01|effects (r_prep) management_7\NN\social_control.n.01|the|of (r_pobj) about_5\IN\about.s.01|management (r_prep) written_4\VBN\create_verbally.v.01|although|much|has|been|about (r_advcl) remain_40\VBP\be.v.01|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (l_prep) as_29\IN\chemical_element.n.01|such|deficits (l_pobj) deficits_31\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_33\NN\transferred_property.n.01|of|,|and|impairments (l_prep) of_34\IN\entity.n.01|creativity (l_pobj) creativity_35\NN\ability.n.02|
D008094_D003072 CID lithium_15\NN\metallic_element.n.01| (r_pobj) of_14\IN\entity.n.01|lithium (r_prep) effects_13\NNS\personal_property.n.01|the|common|adverse|of|,|as (r_pobj) of_8\IN\entity.n.01|effects (r_prep) management_7\NN\social_control.n.01|the|of (r_pobj) about_5\IN\about.s.01|management (r_prep) written_4\VBN\create_verbally.v.01|although|much|has|been|about (r_advcl) remain_40\VBP\be.v.01|written|,|effects|understudied|. (l_nsubj) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (l_prep) as_29\IN\chemical_element.n.01|such|deficits (l_pobj) deficits_31\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_33\NN\transferred_property.n.01|of|,|and|impairments (l_conj) impairments_39\NNS\change.n.01|functional
D008094_D003072 CID lithium_25\NN\metallic_element.n.01| (r_compound) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (l_prep) as_29\IN\chemical_element.n.01|such|deficits (l_pobj) deficits_31\NNS\insufficiency.n.03|cognitive|,|loss
D008094_D003072 CID lithium_25\NN\metallic_element.n.01| (r_compound) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (l_prep) as_29\IN\chemical_element.n.01|such|deficits (l_pobj) deficits_31\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_33\NN\transferred_property.n.01|of|,|and|impairments (l_prep) of_34\IN\entity.n.01|creativity (l_pobj) creativity_35\NN\ability.n.02|
D008094_D003072 CID lithium_25\NN\metallic_element.n.01| (r_compound) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (l_prep) as_29\IN\chemical_element.n.01|such|deficits (l_pobj) deficits_31\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_33\NN\transferred_property.n.01|of|,|and|impairments (l_conj) impairments_39\NNS\change.n.01|functional
D008094_D003072 CID lithium_10\NN\metallic_element.n.01| (r_pobj) from_9\IN\entity.n.01|lithium (r_prep) switching_6\VBG\change.n.03|patients|from|divalproex (l_advcl) divalproex_12\NN\entity.n.01|to|sodium|alleviate (l_xcomp) alleviate_15\VB\better.v.02|to|impairments (l_dobj) impairments_20\NNS\change.n.01|such|cognitive
D008094_D003072 CID lithium_8\NN\metallic_element.n.01| (r_pobj) of_7\IN\entity.n.01|lithium (r_prep) substitution_6\NN\variation.n.01|of|,|fully|,|with (r_nsubj) was_18\VBD\washington.n.02|where|substitution|helpful (l_acomp) helpful_20\JJ\helpful.a.01|extremely|in (l_prep) in_21\IN\linear_unit.n.01|reducing (l_pcomp) reducing_22\VBG\chemical_reaction.n.01|cognitive (l_dobj) cognitive_24\JJ\cognitive.a.01|the|,|motivational|attributed (l_conj) motivational_26\JJ\motivational.a.01|,|or|deficits (l_conj) deficits_30\NNS\insufficiency.n.03|creative
D008094_D003072 CID lithium_33\NN\metallic_element.n.01|in (r_pobj) to_32\IN\entity.n.01|lithium (r_prep) attributed_31\VBN\evaluate.v.02|to (r_acl) cognitive_24\JJ\cognitive.a.01|the|,|motivational|attributed (l_conj) motivational_26\JJ\motivational.a.01|,|or|deficits (l_conj) deficits_30\NNS\insufficiency.n.03|creative
D008094_D003072 CID lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_acl) experiencing_16\VBG\undergo.v.01|deficits (l_dobj) deficits_18\NNS\insufficiency.n.03|cognitive|,|loss
D008094_D003072 CID lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_acl) experiencing_16\VBG\undergo.v.01|deficits (l_dobj) deficits_18\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_20\NN\transferred_property.n.01|of (l_prep) of_21\IN\entity.n.01|creativity (l_pobj) creativity_22\NN\ability.n.02|,|and|impairments
D008094_D003072 CID lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_acl) experiencing_16\VBG\undergo.v.01|deficits (l_dobj) deficits_18\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_20\NN\transferred_property.n.01|of (l_prep) of_21\IN\entity.n.01|creativity (l_pobj) creativity_22\NN\ability.n.02|,|and|impairments (l_conj) impairments_26\NNS\change.n.01|functional
D014635_D003072 NONE sodium_13\NN\metallic_element.n.01|:|series (r_dobj) divalproex_12\NN\entity.n.01|to|sodium (r_advcl) reduced_7\VBN\decrease.v.02|by|divalproex (r_acl) deficits_6\NNS\insufficiency.n.03|associated|cognitive|reduced|.
D014635_D003072 NONE sodium_13\NN\metallic_element.n.01| (r_dobj) divalproex_12\NN\entity.n.01|to|sodium|alleviate (l_xcomp) alleviate_15\VB\better.v.02|to|impairments (l_dobj) impairments_20\NNS\change.n.01|such|cognitive
D014635_D003072 NONE sodium_17\NN\metallic_element.n.01|divalproex (r_pobj) with_15\IN\entity.n.01|sodium (r_prep) substitution_6\NN\variation.n.01|of|,|fully|,|with (r_nsubj) was_18\VBD\washington.n.02|where|substitution|helpful (l_acomp) helpful_20\JJ\helpful.a.01|extremely|in (l_prep) in_21\IN\linear_unit.n.01|reducing (l_pcomp) reducing_22\VBG\chemical_reaction.n.01|cognitive (l_dobj) cognitive_24\JJ\cognitive.a.01|the|,|motivational|attributed (l_conj) motivational_26\JJ\motivational.a.01|,|or|deficits (l_conj) deficits_30\NNS\insufficiency.n.03|creative
D014635_D003072 NONE sodium_6\NN\metallic_element.n.01|divalproex (r_nsubj) was_7\VBD\washington.n.02|in|,|sodium|alternative|. (l_attr) alternative_10\NN\decision_making.n.01|a|superior|to (l_prep) to_11\IN\entity.n.01|lithium (l_pobj) lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_acl) experiencing_16\VBG\undergo.v.01|deficits (l_dobj) deficits_18\NNS\insufficiency.n.03|cognitive|,|loss
D014635_D003072 NONE sodium_6\NN\metallic_element.n.01|divalproex (r_nsubj) was_7\VBD\washington.n.02|in|,|sodium|alternative|. (l_attr) alternative_10\NN\decision_making.n.01|a|superior|to (l_prep) to_11\IN\entity.n.01|lithium (l_pobj) lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_acl) experiencing_16\VBG\undergo.v.01|deficits (l_dobj) deficits_18\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_20\NN\transferred_property.n.01|of (l_prep) of_21\IN\entity.n.01|creativity (l_pobj) creativity_22\NN\ability.n.02|,|and|impairments
D014635_D003072 NONE sodium_6\NN\metallic_element.n.01|divalproex (r_nsubj) was_7\VBD\washington.n.02|in|,|sodium|alternative|. (l_attr) alternative_10\NN\decision_making.n.01|a|superior|to (l_prep) to_11\IN\entity.n.01|lithium (l_pobj) lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_acl) experiencing_16\VBG\undergo.v.01|deficits (l_dobj) deficits_18\NNS\insufficiency.n.03|cognitive|,|loss (l_conj) loss_20\NN\transferred_property.n.01|of (l_prep) of_21\IN\entity.n.01|creativity (l_pobj) creativity_22\NN\ability.n.02|,|and|impairments (l_conj) impairments_26\NNS\change.n.01|functional
D008094_D001714 NONE lithium_0\NN\metallic_element.n.01| (r_nsubj) remains_1\VBZ\object.n.01|lithium|treatment|. (l_attr) treatment_6\NN\care.n.01|a|line|for (l_prep) for_7\IN\entity.n.01|treatment (l_pobj) treatment_12\NN\care.n.01|the|acute|of (l_prep) of_13\IN\entity.n.01|disorder (l_pobj) disorder_15\NN\physical_condition.n.01|bipolar
D008094_D001714 NONE lithium_10\NN\metallic_element.n.01| (r_pobj) from_9\IN\entity.n.01|lithium (r_prep) switching_6\VBG\change.n.03|patients|from|divalproex (l_dobj) patients_8\NNS\case.n.06|bipolar (l_amod) bipolar_7\JJ\bipolar.a.01|
D008094_D001714 NONE lithium_8\NN\metallic_element.n.01| (r_pobj) of_7\IN\entity.n.01|lithium (r_prep) substitution_6\NN\variation.n.01|of|,|fully|,|with (r_nsubj) was_18\VBD\washington.n.02|where|substitution|helpful (l_acomp) helpful_20\JJ\helpful.a.01|extremely|in (l_prep) in_21\IN\linear_unit.n.01|reducing (l_pcomp) reducing_22\VBG\chemical_reaction.n.01|cognitive (l_dobj) cognitive_24\JJ\cognitive.a.01|the|,|motivational|attributed (l_acl) attributed_31\VBN\evaluate.v.02|to (l_prep) to_32\IN\entity.n.01|lithium (l_pobj) lithium_33\NN\metallic_element.n.01|in (l_prep) in_34\IN\linear_unit.n.01|patients (l_pobj) patients_37\NNS\case.n.06|our|bipolar (l_amod) bipolar_36\JJ\bipolar.a.01|
D008094_D001714 NONE lithium_33\NN\metallic_element.n.01|in (l_prep) in_34\IN\linear_unit.n.01|patients (l_pobj) patients_37\NNS\case.n.06|our|bipolar (l_amod) bipolar_36\JJ\bipolar.a.01|
D008094_D001714 NONE lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_amod) bipolar_14\JJ\bipolar.a.01|
D008094_D011141 NONE lithium_15\NN\metallic_element.n.01| (r_pobj) of_14\IN\entity.n.01|lithium (r_prep) effects_13\NNS\personal_property.n.01|the|common|adverse|of|,|as (l_prep) as_18\IN\chemical_element.n.01|such|polyuria (l_pobj) polyuria_19\NN\kidney_disease.n.01|and|tremor
D008094_D011141 NONE lithium_25\NN\metallic_element.n.01| (r_compound) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (r_nsubj) remain_40\VBP\be.v.01|written|,|effects|understudied|. (l_advcl) written_4\VBN\create_verbally.v.01|although|much|has|been|about (l_prep) about_5\IN\about.s.01|management (l_pobj) management_7\NN\social_control.n.01|the|of (l_prep) of_8\IN\entity.n.01|effects (l_pobj) effects_13\NNS\personal_property.n.01|the|common|adverse|of|,|as (l_prep) as_18\IN\chemical_element.n.01|such|polyuria (l_pobj) polyuria_19\NN\kidney_disease.n.01|and|tremor
D008094_D014202 NONE lithium_15\NN\metallic_element.n.01| (r_pobj) of_14\IN\entity.n.01|lithium (r_prep) effects_13\NNS\personal_property.n.01|the|common|adverse|of|,|as (l_prep) as_18\IN\chemical_element.n.01|such|polyuria (l_pobj) polyuria_19\NN\kidney_disease.n.01|and|tremor (l_conj) tremor_21\NN\vibration.n.01|
D008094_D014202 NONE lithium_25\NN\metallic_element.n.01| (r_compound) effects_27\NNS\personal_property.n.01|subtle|lithium|side|as (r_nsubj) remain_40\VBP\be.v.01|written|,|effects|understudied|. (l_advcl) written_4\VBN\create_verbally.v.01|although|much|has|been|about (l_prep) about_5\IN\about.s.01|management (l_pobj) management_7\NN\social_control.n.01|the|of (l_prep) of_8\IN\entity.n.01|effects (l_pobj) effects_13\NNS\personal_property.n.01|the|common|adverse|of|,|as (l_prep) as_18\IN\chemical_element.n.01|such|polyuria (l_pobj) polyuria_19\NN\kidney_disease.n.01|and|tremor (l_conj) tremor_21\NN\vibration.n.01|
D014635_D001714 NONE sodium_13\NN\metallic_element.n.01| (r_dobj) divalproex_12\NN\entity.n.01|to|sodium|alleviate (r_advcl) switching_6\VBG\change.n.03|patients|from|divalproex (l_dobj) patients_8\NNS\case.n.06|bipolar (l_amod) bipolar_7\JJ\bipolar.a.01|
D014635_D001714 NONE sodium_17\NN\metallic_element.n.01|divalproex (r_pobj) with_15\IN\entity.n.01|sodium (r_prep) substitution_6\NN\variation.n.01|of|,|fully|,|with (r_nsubj) was_18\VBD\washington.n.02|where|substitution|helpful (l_acomp) helpful_20\JJ\helpful.a.01|extremely|in (l_prep) in_21\IN\linear_unit.n.01|reducing (l_pcomp) reducing_22\VBG\chemical_reaction.n.01|cognitive (l_dobj) cognitive_24\JJ\cognitive.a.01|the|,|motivational|attributed (l_acl) attributed_31\VBN\evaluate.v.02|to (l_prep) to_32\IN\entity.n.01|lithium (l_pobj) lithium_33\NN\metallic_element.n.01|in (l_prep) in_34\IN\linear_unit.n.01|patients (l_pobj) patients_37\NNS\case.n.06|our|bipolar (l_amod) bipolar_36\JJ\bipolar.a.01|
D014635_D001714 NONE sodium_6\NN\metallic_element.n.01|divalproex (r_nsubj) was_7\VBD\washington.n.02|in|,|sodium|alternative|. (l_attr) alternative_10\NN\decision_making.n.01|a|superior|to (l_prep) to_11\IN\entity.n.01|lithium (l_pobj) lithium_12\NN\metallic_element.n.01|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|bipolar|experiencing (l_amod) bipolar_14\JJ\bipolar.a.01|
18464113
D019259_D006509 NONE lamivudine_0\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01|for|. (l_prep) for_1\IN\entity.n.01|prevention (l_pobj) prevention_3\NN\hindrance.n.03|the|of (l_prep) of_4\IN\entity.n.01|reactivation (l_pobj) reactivation_8\NN\entity.n.01|virus|in (l_compound) virus_7\NN\infectious_agent.n.01|b (l_compound) b_6\NNP\eubacteria.n.01|hepatitis
D019259_D006509 NONE lamivudine_20\NN\nucleoside_reverse_transcriptase_inhibitor.n.01|the|agent (r_dobj) received_16\VBD\get.v.01|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\case.n.06|cancer|have (l_relcl) have_7\VBP\person.n.01|who|malignancies (l_dobj) malignancies_11\NNS\disease.n.01|solid|with (l_prep) with_12\IN\entity.n.01|infection (l_pobj) infection_15\NN\ill_health.n.01|chronic|hbv
D019259_D006509 NONE lamivudine_34\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_dobj) receive_33\VB\get.v.01|who|did|not|lamivudine (r_relcl) group_29\NN\abstraction.n.06|historical|control|receive (r_pobj) with_26\IN\entity.n.01|group (r_prep) compared_25\VBN\analyze.v.01|with (r_prep) received_16\VBD\get.v.01|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\case.n.06|cancer|have (l_relcl) have_7\VBP\person.n.01|who|malignancies (l_dobj) malignancies_11\NNS\disease.n.01|solid|with (l_prep) with_12\IN\entity.n.01|infection (l_pobj) infection_15\NN\ill_health.n.01|chronic|hbv
D019259_D009369 NONE lamivudine_0\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01|for|. (l_prep) for_1\IN\entity.n.01|prevention (l_pobj) prevention_3\NN\hindrance.n.03|the|of (l_prep) of_4\IN\entity.n.01|reactivation (l_pobj) reactivation_8\NN\entity.n.01|virus|in (l_prep) in_9\IN\linear_unit.n.01|patients (l_pobj) patients_20\NNS\case.n.06|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN\malignant_tumor.n.01|
D019259_D009369 NONE lamivudine_20\NN\nucleoside_reverse_transcriptase_inhibitor.n.01|the|agent (r_dobj) received_16\VBD\get.v.01|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\case.n.06|cancer|have (l_compound) cancer_4\NN\malignant_tumor.n.01|
D019259_D009369 NONE lamivudine_34\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_dobj) receive_33\VB\get.v.01|who|did|not|lamivudine (r_relcl) group_29\NN\abstraction.n.06|historical|control|receive (r_pobj) with_26\IN\entity.n.01|group (r_prep) compared_25\VBN\analyze.v.01|with (r_prep) received_16\VBD\get.v.01|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\case.n.06|cancer|have (l_compound) cancer_4\NN\malignant_tumor.n.01|
D019259_D009369 NONE lamivudine_5\NN\nucleoside_reverse_transcriptase_inhibitor.n.01|prophylactic (r_nsubj) decreases_7\VBZ\change.n.01|that|lamivudine|significantly|incidence|during (l_dobj) incidence_9\NN\frequency.n.02|the|of (l_prep) of_10\IN\entity.n.01|reactivation (l_pobj) reactivation_12\NN\entity.n.01|hbv|and|morbidity (l_conj) morbidity_15\NN\incidence.n.01|overall|in (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|cancer (l_compound) cancer_17\NN\malignant_tumor.n.01|
D006514_D006509 CID antigen_14\NN\substance.n.07|b|surface (r_nmod) patients_20\NNS\case.n.06|antigen|(|hbsag|)|seropositive|cancer|undergoing (r_pobj) in_9\IN\linear_unit.n.01|patients (r_prep) reactivation_8\NN\entity.n.01|virus|in (l_compound) virus_7\NN\infectious_agent.n.01|b (l_compound) b_6\NNP\eubacteria.n.01|hepatitis
D006514_D006509 CID hbsag_16\NNP\entity.n.01| (r_nmod) patients_20\NNS\case.n.06|antigen|(|hbsag|)|seropositive|cancer|undergoing (r_pobj) in_9\IN\linear_unit.n.01|patients (r_prep) reactivation_8\NN\entity.n.01|virus|in (l_compound) virus_7\NN\infectious_agent.n.01|b (l_compound) b_6\NNP\eubacteria.n.01|hepatitis
D006514_D009369 NONE antigen_14\NN\substance.n.07|b|surface (r_nmod) patients_20\NNS\case.n.06|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN\malignant_tumor.n.01|
D006514_D009369 NONE hbsag_16\NNP\entity.n.01| (r_nmod) patients_20\NNS\case.n.06|antigen|(|hbsag|)|seropositive|cancer|undergoing (l_compound) cancer_19\NN\malignant_tumor.n.01|
D019259_D019337 NONE lamivudine_20\NN\nucleoside_reverse_transcriptase_inhibitor.n.01|the|agent (r_dobj) received_16\VBD\get.v.01|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\case.n.06|cancer|have (l_relcl) have_7\VBP\person.n.01|who|malignancies (l_dobj) malignancies_11\NNS\disease.n.01|solid|with
D019259_D019337 NONE lamivudine_34\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_dobj) receive_33\VB\get.v.01|who|did|not|lamivudine (r_relcl) group_29\NN\abstraction.n.06|historical|control|receive (r_pobj) with_26\IN\entity.n.01|group (r_prep) compared_25\VBN\analyze.v.01|with (r_prep) received_16\VBD\get.v.01|in|,|patients|lamivudine|prior|compared|. (l_nsubj) patients_5\NNS\case.n.06|cancer|have (l_relcl) have_7\VBP\person.n.01|who|malignancies (l_dobj) malignancies_11\NNS\disease.n.01|solid|with
D019259_D056486 NONE lamivudine_3\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) group_4\NN\abstraction.n.06|the|prophylactic|lamivudine (r_pobj) in_0\IN\linear_unit.n.01|group (r_prep) observed_8\VBN\spy.v.03|in|hepatitis|were|patient|. (l_nsubjpass) hepatitis_6\NN\infectious_disease.n.01|severe
7504976
D002231_D056486 CID carbimazole_16\NN\entity.n.01|and|benzylthiouracil (r_pobj) between_15\IN\between.r.01|carbimazole (r_prep) reactivity_14\NN\sensitivity.n.01|cross|-|between (r_pobj) with_11\IN\entity.n.01|reactivity (r_prep) one_10\CD\digit.n.01|with (r_pobj) including_9\VBG\include.v.01|one (r_prep) cases_8\NNS\happening.n.01|four|including (r_appos) induced_2\VBN\generate.v.01|hepatitis|by|:|cases|. (l_nsubj) hepatitis_1\NN\infectious_disease.n.01|toxic
D002231_D056486 CID carbimazole_8\NN\entity.n.01|(|omercazole|) (r_pobj) by_7\IN\by.r.01|carbimazole (r_agent) induced_6\VBN\generate.v.01|hepatitis|by (l_nsubj) hepatitis_5\NN\infectious_disease.n.01|a|cholestatic
D002231_D056486 CID omercazole_11\NN\entity.n.01|n (r_appos) carbimazole_8\NN\entity.n.01|(|omercazole|) (r_pobj) by_7\IN\by.r.01|carbimazole (r_agent) induced_6\VBN\generate.v.01|hepatitis|by (l_nsubj) hepatitis_5\NN\infectious_disease.n.01|a|cholestatic
D002231_D056486 CID carbimazole_12\NN\entity.n.01|a|mixed|)|following (l_amod) following_11\VBG\multitude.n.03|hepatitis (l_compound) hepatitis_10\NN\infectious_disease.n.01|
D002231_D056486 CID carbimazole_21\NN\entity.n.01| (r_dobj) replaced_20\VBN\regenerate.v.01|experienced|had|carbimazole|. (l_nsubj) experienced_7\VBD\undergo.v.01|one|further|hepatitis|) (l_dobj) hepatitis_10\NN\infectious_disease.n.01|a|cytolytic|appeared
C019269_D056486 NONE benzylthiouracil_18\NN\entity.n.01| (r_conj) carbimazole_16\NN\entity.n.01|and|benzylthiouracil (r_pobj) between_15\IN\between.r.01|carbimazole (r_prep) reactivity_14\NN\sensitivity.n.01|cross|-|between (r_pobj) with_11\IN\entity.n.01|reactivity (r_prep) one_10\CD\digit.n.01|with (r_pobj) including_9\VBG\include.v.01|one (r_prep) cases_8\NNS\happening.n.01|four|including (r_appos) induced_2\VBN\generate.v.01|hepatitis|by|:|cases|. (l_nsubj) hepatitis_1\NN\infectious_disease.n.01|toxic
C019269_D056486 NONE benzylthiouracil_14\NNP\entity.n.01|ne (r_pobj) after_13\IN\after.s.01|benzylthiouracil (r_prep) appeared_12\VBD\be.v.01|which|after (r_relcl) hepatitis_10\NN\infectious_disease.n.01|a|cytolytic|appeared
C019269_D056486 NONE ne_17\NNP\chemical_element.n.01|(|basd (r_appos) benzylthiouracil_14\NNP\entity.n.01|ne (r_pobj) after_13\IN\after.s.01|benzylthiouracil (r_prep) appeared_12\VBD\be.v.01|which|after (r_relcl) hepatitis_10\NN\infectious_disease.n.01|a|cytolytic|appeared
D002231_D002779 CID carbimazole_8\NN\entity.n.01|(|omercazole|) (r_pobj) by_7\IN\by.r.01|carbimazole (r_agent) induced_6\VBN\generate.v.01|hepatitis|by (l_nsubj) hepatitis_5\NN\infectious_disease.n.01|a|cholestatic
D002231_D002779 CID omercazole_11\NN\entity.n.01|n (r_appos) carbimazole_8\NN\entity.n.01|(|omercazole|) (r_pobj) by_7\IN\by.r.01|carbimazole (r_agent) induced_6\VBN\generate.v.01|hepatitis|by (l_nsubj) hepatitis_5\NN\infectious_disease.n.01|a|cholestatic
D002231_D002779 CID carbimazole_12\NN\entity.n.01|a|mixed|)|following (l_amod) mixed_4\JJ\change_integrity.v.01|(|cholestatic (l_conj) cholestatic_6\JJ\entity.n.01|and|cytolytic
15515654
D003676_D006311 NONE dfo_6\NNP\entity.n.01| (r_pobj) than_5\IN\entity.n.01|dfo (r_prep) other_4\JJ\other.a.01|than (r_amod) factor_2\NN\cause.n.01|no|ototoxic|,|other|, (l_compound) ototoxic_1\JJ\ototoxic.s.01|
D003676_D006319 CID dfo_6\NNP\entity.n.01| (r_compound) reduction_7\NN\change_of_magnitude.n.01|dfo|or|withdrawal (r_pobj) to_5\IN\entity.n.01|reduction (r_prep) submitted_4\VBN\refer.v.04|subjects|were|to|. (l_nsubjpass) subjects_0\NNS\message.n.02|with (l_prep) with_1\IN\entity.n.01|snhl (l_pobj) snhl_2\NNP\entity.n.01|
D003676_D034381 NONE dfo_5\NNP\entity.n.01|'s (r_poss) role_8\NN\duty.n.02|dfo|contributing|in (l_prep) in_9\IN\linear_unit.n.01|development (l_pobj) development_11\NN\improvement.n.02|the|of (l_prep) of_12\IN\entity.n.01|impairment (l_pobj) impairment_14\NN\change.n.01|hearing
3409645
D008727_D007172 CID methotrexate_23\NNP\antimetabolite.n.01| (r_pobj) of_22\IN\entity.n.01|methotrexate (r_prep) taking_21\NN\action.n.01|the|of (r_conj) was_1\VBD\washington.n.02|impotence|common|and|found|and|taking|. (l_nsubj) impotence_0\NN\quality.n.01|
16740173
2024540
D004656_D006333 NONE enalapril_11\NN\ace_inhibitor.n.01|and|prazosin (r_pobj) of_10\IN\entity.n.01|enalapril (r_prep) safety_9\NN\condition.n.01|of|in (l_prep) in_14\IN\linear_unit.n.01|phase (l_pobj) phase_18\NN\time_period.n.01|the|initial|treatment|of (l_prep) of_19\IN\entity.n.01|patients (l_pobj) patients_20\NNS\case.n.06|with (l_prep) with_21\IN\entity.n.01|failure (l_pobj) failure_24\NN\nonaccomplishment.n.01|heart
D011224_D006333 NONE prazosin_13\NN\alpha_blocker.n.01| (r_conj) enalapril_11\NN\ace_inhibitor.n.01|and|prazosin (r_pobj) of_10\IN\entity.n.01|enalapril (r_prep) safety_9\NN\condition.n.01|of|in (l_prep) in_14\IN\linear_unit.n.01|phase (l_pobj) phase_18\NN\time_period.n.01|the|initial|treatment|of (l_prep) of_19\IN\entity.n.01|patients (l_pobj) patients_20\NNS\case.n.06|with (l_prep) with_21\IN\entity.n.01|failure (l_pobj) failure_24\NN\nonaccomplishment.n.01|heart
D000806_D006333 NONE inhibitors_10\NNS\substance.n.07|(|ace|) (r_appos) enzyme_6\NN\catalyst.n.01|inhibitors (r_dobj) converting_5\VBG\change.v.01|enzyme|into (l_prep) into_11\IN\entity.n.01|treatment (l_pobj) treatment_14\NN\care.n.01|the|adjunctive|of (l_prep) of_15\IN\entity.n.01|patients (l_pobj) patients_16\NNS\case.n.06|with (l_prep) with_17\IN\entity.n.01|failure (l_pobj) failure_20\NN\nonaccomplishment.n.01|congestive|heart|,|cases
D000806_D007022 CID inhibitors_10\NNS\substance.n.07|(|ace|) (r_appos) enzyme_6\NN\catalyst.n.01|inhibitors (r_dobj) converting_5\VBG\change.v.01|enzyme|into (l_prep) into_11\IN\entity.n.01|treatment (l_pobj) treatment_14\NN\care.n.01|the|adjunctive|of (l_prep) of_15\IN\entity.n.01|patients (l_pobj) patients_16\NNS\case.n.06|with (l_prep) with_17\IN\entity.n.01|failure (l_pobj) failure_20\NN\nonaccomplishment.n.01|congestive|heart|,|cases (l_conj) cases_22\NNS\happening.n.01|of (l_prep) of_23\IN\entity.n.01|hypotension (l_pobj) hypotension_25\NN\cardiovascular_disease.n.01|severe
D000806_D007022 CID inhibitor_7\NN\substance.n.07|the|ace|enalapril (r_pobj) of_4\IN\entity.n.01|inhibitor (r_prep) safety_3\NN\condition.n.01|the|of (r_dobj) assess_1\VB\body_part.n.01|to|safety (r_advcl) designed_19\VBN\create_by_mental_act.v.01|assess|trial|was|that|compared|. (l_prep) compared_21\VBD\analyze.v.01|incidence (l_pobj) incidence_23\NN\frequency.n.02|the|and|severity|of (l_prep) of_26\IN\entity.n.01|hypotension (l_pobj) hypotension_28\NN\cardiovascular_disease.n.01|symptomatic|on
D004656_D007022 NONE enalapril_8\NN\ace_inhibitor.n.01| (r_appos) inhibitor_7\NN\substance.n.07|the|ace|enalapril (r_pobj) of_4\IN\entity.n.01|inhibitor (r_prep) safety_3\NN\condition.n.01|the|of (r_dobj) assess_1\VB\body_part.n.01|to|safety (r_advcl) designed_19\VBN\create_by_mental_act.v.01|assess|trial|was|that|compared|. (l_prep) compared_21\VBD\analyze.v.01|incidence (l_pobj) incidence_23\NN\frequency.n.02|the|and|severity|of (l_prep) of_26\IN\entity.n.01|hypotension (l_pobj) hypotension_28\NN\cardiovascular_disease.n.01|symptomatic|on
D004656_D007022 NONE enalapril_3\RB\ace_inhibitor.n.01| (r_dobj) received_2\VBD\get.v.01|who|enalapril (r_relcl) patients_0\NNS\case.n.06|received (r_nsubj) experienced_4\VBD\undergo.v.01|patients|hypotension|. (l_dobj) hypotension_11\NN\cardiovascular_disease.n.01|clinically|(|%|)|than
D011224_D007022 CID prazosin_14\NN\alpha_blocker.n.01| (r_npadvmod) controlled_16\VBN\control.v.01|prazosin|- (r_amod) trial_17\NN\attempt.n.01|a|multicenter|,|randomized|,|controlled (r_nsubjpass) designed_19\VBN\create_by_mental_act.v.01|assess|trial|was|that|compared|. (l_prep) compared_21\VBD\analyze.v.01|incidence (l_pobj) incidence_23\NN\frequency.n.02|the|and|severity|of (l_prep) of_26\IN\entity.n.01|hypotension (l_pobj) hypotension_28\NN\cardiovascular_disease.n.01|symptomatic|on
D011224_D007022 CID prazosin_21\NN\alpha_blocker.n.01|(|%|) (r_dobj) received_20\VBD\get.v.01|who|prazosin (r_relcl) patients_18\NNS\case.n.06|the|received (r_pobj) than_16\IN\entity.n.01|patients (r_prep) hypotension_11\NN\cardiovascular_disease.n.01|clinically|(|%|)|than
10791295
D001058_D010554 CID apomorphine_2\NN\morphine.n.01| (r_pobj) of_1\IN\entity.n.01|apomorphine (r_prep) development_0\NN\improvement.n.02|of (r_nsubj) induced_4\VBN\generate.v.01|development|-|behavior|:|comparison|. (l_dobj) behavior_6\NN\activity.n.01|aggressive
D001058_D010554 CID apomorphine_3\NN\morphine.n.01| (r_pobj) of_2\IN\entity.n.01|apomorphine (r_prep) development_1\NN\improvement.n.02|the|of (r_nsubj) induced_5\VBN\generate.v.01|development|-|s.c.|daily|)|behavior|studied|. (l_dobj) behavior_14\NN\activity.n.01|aggressive|of|obtained
D001058_D010554 CID apomorphine_5\NN\morphine.n.01| (r_compound) treatment_6\NN\care.n.01|repeated|apomorphine (r_nsubj) induced_7\VBD\generate.v.01|in|,|treatment|development|evidenced|. (l_dobj) development_10\NN\improvement.n.02|a|gradual|of (l_prep) of_11\IN\entity.n.01|behavior (l_pobj) behavior_13\NN\activity.n.01|aggressive
D001058_D010554 CID apomorphine_5\NN\morphine.n.01| (r_compound) treatment_6\NN\care.n.01|repeated|apomorphine (r_nsubj) induced_7\VBD\generate.v.01|in|,|treatment|development|evidenced|. (l_advcl) evidenced_15\VBN\testify.v.02|as|by|and|shortened (l_agent) by_16\IN\by.r.01|intensity (l_pobj) intensity_19\NN\magnitude.n.01|the|increased|of (l_prep) of_20\IN\entity.n.01|aggressiveness (l_pobj) aggressiveness_21\NN\drive.n.05|
D001058_D010554 CID apomorphine_14\NN\morphine.n.01| (r_preconj) the_13\DT\entity.n.01|apomorphine (r_det) behavior_18\NN\activity.n.01|the|induced|aggressive
14698717
D010672_D011605 NONE phenytoin_6\NN\hydantoin.n.01| (r_pobj) with_5\IN\entity.n.01|phenytoin (r_prep) treatment_4\NN\care.n.01|with|in (r_pobj) due_2\IN\right.n.01|to|treatment (r_amod) psychosis_1\NN\mental_illness.n.01|acute|due|.
D010672_D011605 NONE phenytoin_10\JJ\hydantoin.n.01| (r_compound) treatment_11\NN\care.n.01|phenytoin|for (r_dobj) following_9\VBG\multitude.n.03|treatment (r_acl) psychosis_8\NN\mental_illness.n.01|following
D010672_D011605 NONE phenytoin_10\JJ\hydantoin.n.01| (r_compound) treatment_11\NN\care.n.01|phenytoin|in (r_pobj) following_9\VBG\multitude.n.03|treatment (r_prep) occur_8\VBP\happen.v.01|that|following (r_relcl) symptoms_6\NNS\evidence.n.01|the|psychotic|occur
D010672_D014277 NONE phenytoin_10\JJ\hydantoin.n.01| (r_compound) treatment_11\NN\care.n.01|phenytoin|for (l_prep) for_12\IN\entity.n.01|neuralgia (l_pobj) neuralgia_14\NN\pain.n.01|trigeminal
D010672_D004827 NONE phenytoin_10\JJ\hydantoin.n.01| (r_compound) treatment_11\NN\care.n.01|phenytoin|in (l_prep) in_12\IN\linear_unit.n.01|patients (l_pobj) patients_15\NNS\case.n.06|some|epileptic (l_amod) epileptic_14\JJ\sick_person.n.01|
D010672_D012640 NONE phenytoin_10\JJ\hydantoin.n.01| (r_compound) treatment_11\NN\care.n.01|phenytoin|in (r_pobj) following_9\VBG\multitude.n.03|treatment (r_prep) occur_8\VBP\happen.v.01|that|following (r_relcl) symptoms_6\NNS\evidence.n.01|the|psychotic|occur (r_nsubj) be_17\VB\metallic_element.n.01|that|symptoms|may|result (l_attr) result_20\NN\phenomenon.n.01|the|direct|of|,|unrelated (l_amod) unrelated_24\JJ\unrelated.a.01|to (l_prep) to_25\IN\entity.n.01|seizures (l_pobj) seizures_26\NNS\attack.n.07|
150790
D011736_D002653 NONE pyridoxine_1\JJ\b-complex_vitamin.n.01| (r_advmod) dependent_3\JJ\recipient.n.01|pyridoxine|- (r_amod) disorder_5\NN\physical_condition.n.01|a|dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_8\NN\antibacterial.n.01| (r_pobj) by_7\IN\by.r.01|isoniazid (r_agent) unmasked_6\VBD\debunk.v.01|by (r_acl) disorder_5\NN\physical_condition.n.01|a|dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_22\NN\antibacterial.n.01| (r_pobj) of_21\IN\entity.n.01|isoniazid (r_prep) administration_20\NN\management.n.01|the|therapeutic|of (r_pobj) after_17\IN\after.s.01|administration (r_prep) sleeping_15\VBG\sleep.n.01|difficulties|after (r_conj) irritability_12\NN\ill_humor.n.01|,|and|sleeping (r_conj) hyperkinesis_10\NN\entity.n.01|,|irritability (r_pobj) with_9\IN\entity.n.01|hyperkinesis (r_prep) had_5\VBD\have.v.01|girl|deterioration|,|with|. (l_dobj) deterioration_7\NN\decay.n.04|behavioral
D007538_D006948 CID isoniazid_22\NN\antibacterial.n.01| (r_pobj) of_21\IN\entity.n.01|isoniazid (r_prep) administration_20\NN\management.n.01|the|therapeutic|of (r_pobj) after_17\IN\after.s.01|administration (r_prep) sleeping_15\VBG\sleep.n.01|difficulties|after (r_conj) irritability_12\NN\ill_humor.n.01|,|and|sleeping (r_conj) hyperkinesis_10\NN\entity.n.01|,|irritability
D007538_D001523 NONE isoniazid_22\NN\antibacterial.n.01| (r_pobj) of_21\IN\entity.n.01|isoniazid (r_prep) administration_20\NN\management.n.01|the|therapeutic|of (r_pobj) after_17\IN\after.s.01|administration (r_prep) sleeping_15\VBG\sleep.n.01|difficulties|after (r_conj) irritability_12\NN\ill_humor.n.01|,|and|sleeping
D007538_D012893 NONE isoniazid_22\NN\antibacterial.n.01| (r_pobj) of_21\IN\entity.n.01|isoniazid (r_prep) administration_20\NN\management.n.01|the|therapeutic|of (r_pobj) after_17\IN\after.s.01|administration (r_prep) sleeping_15\VBG\sleep.n.01|difficulties|after (l_dobj) difficulties_16\NNS\effort.n.02|
D011736_D006948 NONE pyridoxine_3\NN\b-complex_vitamin.n.01| (r_pobj) of_2\IN\entity.n.01|pyridoxine (r_prep) withdrawal_1\NN\retraction.n.01|periodic|of (r_nsubjpass) associated_5\VBN\think.v.03|withdrawal|was|with|. (l_prep) with_6\IN\entity.n.01|return (l_pobj) return_7\NN\legal_document.n.01|of (l_prep) of_8\IN\entity.n.01|hyperkinesis (l_pobj) hyperkinesis_10\NN\entity.n.01|the
20698227
D012254_D000743 NONE ribavirin_8\RB\antiviral.n.01| (r_pobj) for_7\IN\entity.n.01|ribavirin (r_prep) treatment_6\NN\care.n.01|for (r_pobj) of_5\IN\entity.n.01|treatment (r_prep) target_4\NN\reference_point.n.01|a|of|associated (l_acl) associated_9\VBN\think.v.03|anemia (l_dobj) anemia_11\NN\blood_disease.n.01|hemolytic
D012254_D006461 NONE ribavirin_1\RB\antiviral.n.01|recently (r_nsubjpass) found_4\VBN\wage.n.01|ribavirin|has|been|inhibit|found (l_conj) found_21\VBN\wage.n.01|number|have|been|cause|. (l_advcl) cause_23\VB\origin.n.03|to|hemolysis (l_dobj) hemolysis_25\NN\lysis.n.02|acute
C473478_D006461 CID sunitinib_16\JJ\entity.n.01|and|sorafenib (r_pobj) as_15\IN\chemical_element.n.01|such|sunitinib (r_prep) inhibitors_13\NNS\substance.n.07|angiogenesis|as (r_pobj) of_11\IN\entity.n.01|inhibitors (r_prep) number_10\NN\amount.n.02|a|of (r_nsubjpass) found_21\VBN\wage.n.01|number|have|been|cause|. (l_advcl) cause_23\VB\origin.n.03|to|hemolysis (l_dobj) hemolysis_25\NN\lysis.n.02|acute
C471405_D006461 CID sorafenib_18\NNS\entity.n.01| (r_conj) sunitinib_16\JJ\entity.n.01|and|sorafenib (r_pobj) as_15\IN\chemical_element.n.01|such|sunitinib (r_prep) inhibitors_13\NNS\substance.n.07|angiogenesis|as (r_pobj) of_11\IN\entity.n.01|inhibitors (r_prep) number_10\NN\amount.n.02|a|of (r_nsubjpass) found_21\VBN\wage.n.01|number|have|been|cause|. (l_advcl) cause_23\VB\origin.n.03|to|hemolysis (l_dobj) hemolysis_25\NN\lysis.n.02|acute
C100416_D019698 NONE 2a_14\CD\entity.n.01|pegylated|interferon|alpha|and|ribavirin (r_pobj) by_10\IN\by.r.01|2a (r_agent) treated_9\VBN\interact.v.01|infected|were|by|. (l_csubjpass) infected_3\VBN\give.v.01|patients|chronically|with (l_prep) with_4\IN\entity.n.01|virus (l_pobj) virus_7\NN\infectious_agent.n.01|c
D012254_D019698 NONE ribavirin_16\RB\antiviral.n.01| (r_conj) 2a_14\CD\entity.n.01|pegylated|interferon|alpha|and|ribavirin (r_pobj) by_10\IN\by.r.01|2a (r_agent) treated_9\VBN\interact.v.01|infected|were|by|. (l_csubjpass) infected_3\VBN\give.v.01|patients|chronically|with (l_prep) with_4\IN\entity.n.01|virus (l_pobj) virus_7\NN\infectious_agent.n.01|c
D012254_D019698 NONE ribavirin_16\RB\antiviral.n.01| (r_conj) markers_14\NNS\artifact.n.01|soluble|and|ribavirin (r_dobj) angiogenesis_12\NN\growth.n.01|markers (r_pobj) between_11\IN\between.r.01|angiogenesis (r_prep) link_10\NN\linkage.n.01|a|between (r_dobj) investigating_8\VBG\work.n.01|link (r_acl) study_4\NN\examination.n.01|the|first|in|investigating (r_attr) is_1\VBZ\be.v.01|this|study|induced (l_advcl) induced_17\VBD\generate.v.01|anemia|and|find (l_dobj) anemia_18\NN\blood_disease.n.01|in (l_prep) in_19\IN\linear_unit.n.01|patients (l_pobj) patients_20\NNS\case.n.06|with (l_prep) with_21\IN\entity.n.01|c (l_pobj) c_23\NNP\degree.n.06|hepatitis
D012254_D000740 NONE ribavirin_16\RB\antiviral.n.01| (r_conj) markers_14\NNS\artifact.n.01|soluble|and|ribavirin (r_dobj) angiogenesis_12\NN\growth.n.01|markers (r_pobj) between_11\IN\between.r.01|angiogenesis (r_prep) link_10\NN\linkage.n.01|a|between (r_dobj) investigating_8\VBG\work.n.01|link (r_acl) study_4\NN\examination.n.01|the|first|in|investigating (r_attr) is_1\VBZ\be.v.01|this|study|induced (l_advcl) induced_17\VBD\generate.v.01|anemia|and|find (l_dobj) anemia_18\NN\blood_disease.n.01|in
3107448
D005905_D056486 CID glyburide_0\NN\antidiabetic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|glyburide|- (r_amod) hepatitis_3\NN\infectious_disease.n.01|induced|.
D005905_D056486 CID glyburide_1\NN\antidiabetic.n.01| (r_pobj) for_0\IN\entity.n.01|glyburide (r_prep) exist_15\VBP\exist.v.01|for|,|sulfonylurea|,|reports|. (l_nsubj) reports_12\NNS\document.n.01|two|brief|of (l_prep) of_13\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_14\NN\entity.n.01|
D005905_D056486 CID glyburide_18\NN\antidiabetic.n.01| (r_amod) therapy_19\NN\medical_care.n.01|glyburide (r_pobj) of_17\IN\entity.n.01|therapy (r_prep) initiation_16\NN\ceremony.n.01|of (r_pobj) after_15\IN\after.s.01|soon|initiation (r_prep) developed_7\VBD\create.v.02|patients|syndrome|after|. (l_dobj) syndrome_13\NN\complex.n.01|an|acute|like
D005905_D056486 CID glyburide_0\NNP\antidiabetic.n.01| (r_nsubj) produce_2\VB\food.n.02|glyburide|can|illness|. (l_dobj) illness_8\NN\ill_health.n.01|an|acute|like|in
D013453_D056486 NONE sulfonylureas_14\NNS\antidiabetic.n.01| (r_pobj) with_13\IN\entity.n.01|sulfonylureas (r_prep) reported_10\VBN\inform.v.01|hepatotoxicity|,|common|,|has|been|infrequently|with|. (l_nsubjpass) hepatotoxicity_3\NN\entity.n.01|induced
D013453_D056486 NONE sulfonylurea_7\NN\antidiabetic.n.01|a|generation (r_nsubj) exist_15\VBP\exist.v.01|for|,|sulfonylurea|,|reports|. (l_nsubj) reports_12\NNS\document.n.01|two|brief|of (l_prep) of_13\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_14\NN\entity.n.01|
D005905_D003924 NONE glyburide_18\NN\antidiabetic.n.01| (r_amod) therapy_19\NN\medical_care.n.01|glyburide (r_pobj) of_17\IN\entity.n.01|therapy (r_prep) initiation_16\NN\ceremony.n.01|of (r_pobj) after_15\IN\after.s.01|soon|initiation (r_prep) developed_7\VBD\create.v.02|patients|syndrome|after|. (l_nsubj) patients_1\NNS\case.n.06|two|with (l_prep) with_2\IN\entity.n.01|mellitus (l_pobj) mellitus_6\NN\entity.n.01|diabetes
20520283
C522667_D012559 NONE asenapine_4\NN\entity.n.01| (r_pobj) of_3\IN\entity.n.01|asenapine (r_prep) efficacy_0\NN\effectiveness.n.01|and|safety|of|in|. (l_prep) in_5\IN\linear_unit.n.01|trial (l_pobj) trial_12\NN\attempt.n.01|placebo-|controlled|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|exacerbation (l_pobj) exacerbation_17\NN\intensification.n.01|acute|of (l_prep) of_18\IN\entity.n.01|schizophrenia (l_pobj) schizophrenia_19\NN\psychosis.n.01|
C522667_D012559 NONE asenapine_0\NNP\entity.n.01| (r_nsubjpass) approved_2\VBN\authorize.v.01|asenapine|is|by|in|. (l_prep) in_9\IN\linear_unit.n.01|adults (l_pobj) adults_10\NNS\person.n.01|for (l_prep) for_11\IN\entity.n.01|treatment|or|of (l_pobj) treatment_13\NN\care.n.01|acute|of (l_prep) of_14\IN\entity.n.01|schizophrenia (l_pobj) schizophrenia_15\NN\psychosis.n.01|
C522667_D012559 NONE asenapine_22\NN\entity.n.01| (r_pobj) with_21\IN\entity.n.01|asenapine (r_prep) treatment_20\NN\care.n.01|dose|with (r_pobj) to_16\IN\entity.n.01|treatment (r_prep) assigned_15\VBN\appoint.v.02|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS\case.n.06|458|with (l_prep) with_10\IN\entity.n.01|schizophrenia (l_pobj) schizophrenia_12\NN\psychosis.n.01|acute
C522667_D012559 NONE asenapine_32\NN\entity.n.01|at|verify (r_dep) assigned_15\VBN\appoint.v.02|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS\case.n.06|458|with (l_prep) with_10\IN\entity.n.01|schizophrenia (l_pobj) schizophrenia_12\NN\psychosis.n.01|acute
D006220_D012559 NONE haloperidol_9\NN\major_tranquilizer.n.01| (r_npadvmod) controlled_11\VBN\control.v.01|haloperidol|- (r_amod) trial_12\NN\attempt.n.01|placebo-|controlled|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|exacerbation (l_pobj) exacerbation_17\NN\intensification.n.01|acute|of (l_prep) of_18\IN\entity.n.01|schizophrenia (l_pobj) schizophrenia_19\NN\psychosis.n.01|
D006220_D012559 NONE haloperidol_41\NN\major_tranquilizer.n.01|at (r_conj) placebo_38\NN\medicine.n.02|,|or|haloperidol (r_conj) bid_36\NN\speech_act.n.01|mg|,|placebo (r_pobj) at_33\IN\chemical_element.n.01|bid (r_prep) asenapine_32\NN\entity.n.01|at|verify (r_dep) assigned_15\VBN\appoint.v.02|in|,|patients|were|randomly|to|at|,|asenapine|)|. (l_nsubjpass) patients_9\NNS\case.n.06|458|with (l_prep) with_10\IN\entity.n.01|schizophrenia (l_pobj) schizophrenia_12\NN\psychosis.n.01|acute
C522667_D001714 NONE asenapine_0\NNP\entity.n.01| (r_nsubjpass) approved_2\VBN\authorize.v.01|asenapine|is|by|in|. (l_prep) in_9\IN\linear_unit.n.01|adults (l_pobj) adults_10\NNS\person.n.01|for (l_prep) for_11\IN\entity.n.01|treatment|or|of (l_conj) of_17\IN\entity.n.01|episodes (l_pobj) episodes_21\NNS\happening.n.01|manic|associated (l_amod) manic_18\JJ\frenzied.s.01|or|mixed
C522667_D001714 NONE asenapine_0\NNP\entity.n.01| (r_nsubjpass) approved_2\VBN\authorize.v.01|asenapine|is|by|in|. (l_prep) in_9\IN\linear_unit.n.01|adults (l_pobj) adults_10\NNS\person.n.01|for (l_prep) for_11\IN\entity.n.01|treatment|or|of (l_conj) of_17\IN\entity.n.01|episodes (l_pobj) episodes_21\NNS\happening.n.01|manic|associated (l_acl) associated_22\VBN\think.v.03|with (l_prep) with_23\IN\entity.n.01|disorder (l_pobj) disorder_26\NN\physical_condition.n.01|bipolar|i|with
C522667_D011618 NONE asenapine_0\NNP\entity.n.01| (r_nsubjpass) approved_2\VBN\authorize.v.01|asenapine|is|by|in|. (l_prep) in_9\IN\linear_unit.n.01|adults (l_pobj) adults_10\NNS\person.n.01|for (l_prep) for_11\IN\entity.n.01|treatment|or|of (l_conj) of_17\IN\entity.n.01|episodes (l_pobj) episodes_21\NNS\happening.n.01|manic|associated (l_acl) associated_22\VBN\think.v.03|with (l_prep) with_23\IN\entity.n.01|disorder (l_pobj) disorder_26\NN\physical_condition.n.01|bipolar|i|with (l_prep) with_27\IN\entity.n.01|or|without (l_conj) without_29\IN\entity.n.01|features (l_pobj) features_31\NNS\property.n.04|psychotic (l_amod) psychotic_30\JJ\sick_person.n.01|
C522667_D001480 CID asenapine_21\NN\entity.n.01|the (r_pobj) of_19\IN\entity.n.01|asenapine (r_prep) %_18\NN\entity.n.01|10|of|at (r_conj) %_14\NN\entity.n.01|34|,|and|% (r_appos) %_8\NN\entity.n.01|15|and|%|,|%|respectively (r_pobj) in_6\IN\linear_unit.n.01|% (r_prep) occurred_5\VBD\happen.v.01|as|aes|in (r_advcl) reported_2\VBD\inform.v.01|symptoms|occurred|. (l_nsubj) symptoms_1\NNS\evidence.n.01|extrapyramidal
C522667_D001480 CID asenapine_9\NN\entity.n.01|and|haloperidol (r_pobj) with_8\IN\entity.n.01|asenapine (r_prep) similar_7\JJ\similar.a.01|with (r_acomp) was_6\VBD\washington.n.02|that|efficacy|similar (r_ccomp) indicated_3\VBD\tell.v.02|analyses|was (r_ccomp) seen_16\VBN\perceive.v.01|indicated|;|contrasts|were|in|. (l_prep) in_17\IN\linear_unit.n.01|aes (l_pobj) aes_18\NNS\entity.n.01|,|symptoms (l_appos) symptoms_22\NNS\evidence.n.01|extrapyramidal
D006220_D001480 CID haloperidol_29\NN\major_tranquilizer.n.01|,|and|groups (r_conj) bid_27\NN\speech_act.n.01|mg|,|haloperidol (r_pobj) at_22\IN\chemical_element.n.01|bid (r_prep) %_18\NN\entity.n.01|10|of|at (r_conj) %_14\NN\entity.n.01|34|,|and|% (r_appos) %_8\NN\entity.n.01|15|and|%|,|%|respectively (r_pobj) in_6\IN\linear_unit.n.01|% (r_prep) occurred_5\VBD\happen.v.01|as|aes|in (r_advcl) reported_2\VBD\inform.v.01|symptoms|occurred|. (l_nsubj) symptoms_1\NNS\evidence.n.01|extrapyramidal
D006220_D001480 CID haloperidol_11\NN\major_tranquilizer.n.01| (r_conj) asenapine_9\NN\entity.n.01|and|haloperidol (r_pobj) with_8\IN\entity.n.01|asenapine (r_prep) similar_7\JJ\similar.a.01|with (r_acomp) was_6\VBD\washington.n.02|that|efficacy|similar (r_ccomp) indicated_3\VBD\tell.v.02|analyses|was (r_ccomp) seen_16\VBN\perceive.v.01|indicated|;|contrasts|were|in|. (l_prep) in_17\IN\linear_unit.n.01|aes (l_pobj) aes_18\NNS\entity.n.01|,|symptoms (l_appos) symptoms_22\NNS\evidence.n.01|extrapyramidal
17466854
D008775_D002386 NONE methylprednisolone_13\NN\entity.n.01| (r_pobj) of_12\IN\entity.n.01|methylprednisolone (r_prep) administration_11\NN\management.n.01|the|of (r_pobj) after_9\IN\after.s.01|administration (r_prep) incidence_3\NN\frequency.n.02|the|of|after (r_dobj) assess_1\VB\body_part.n.01|to|incidence|and|gentamicin|. (l_conj) gentamicin_15\NN\antibiotic.n.01|into|at (l_prep) at_24\IN\chemical_element.n.01|end (l_pobj) end_26\NN\extremity.n.04|the|of (l_prep) of_27\IN\entity.n.01|surgery (l_pobj) surgery_30\NN\medical_science.n.01|routine|cataract (l_compound) cataract_29\NN\eye_disease.n.01|
D005839_D002386 NONE gentamicin_15\NN\antibiotic.n.01|into|at (l_prep) at_24\IN\chemical_element.n.01|end (l_pobj) end_26\NN\extremity.n.04|the|of (l_prep) of_27\IN\entity.n.01|surgery (l_pobj) surgery_30\NN\medical_science.n.01|routine|cataract (l_compound) cataract_29\NN\eye_disease.n.01|
D008775_D020250 CID methylprednisolone_3\NN\entity.n.01| (r_pobj) of_2\IN\entity.n.01|methylprednisolone (r_prep) administration_1\NN\management.n.01|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\think.v.03|administration|was|to|. (l_prep) to_16\IN\entity.n.01|incidence (l_pobj) incidence_19\NN\frequency.n.02|a|high|of (l_prep) of_20\IN\entity.n.01|effects (l_pobj) effects_22\NNS\personal_property.n.01|side|including (l_prep) including_23\VBG\include.v.01|nausea (l_pobj) nausea_24\NN\symptom.n.01|,|vomiting (l_conj) vomiting_26\NN\expulsion.n.03|,|and|headache
D008775_D006261 CID methylprednisolone_3\NN\entity.n.01| (r_pobj) of_2\IN\entity.n.01|methylprednisolone (r_prep) administration_1\NN\management.n.01|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\think.v.03|administration|was|to|. (l_prep) to_16\IN\entity.n.01|incidence (l_pobj) incidence_19\NN\frequency.n.02|a|high|of (l_prep) of_20\IN\entity.n.01|effects (l_pobj) effects_22\NNS\personal_property.n.01|side|including (l_prep) including_23\VBG\include.v.01|nausea (l_pobj) nausea_24\NN\symptom.n.01|,|vomiting (l_conj) vomiting_26\NN\expulsion.n.03|,|and|headache (l_conj) headache_29\NN\negative_stimulus.n.01|
D005839_D020250 CID gentamicin_5\NN\antibiotic.n.01|in (r_conj) administration_1\NN\management.n.01|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\think.v.03|administration|was|to|. (l_prep) to_16\IN\entity.n.01|incidence (l_pobj) incidence_19\NN\frequency.n.02|a|high|of (l_prep) of_20\IN\entity.n.01|effects (l_pobj) effects_22\NNS\personal_property.n.01|side|including (l_prep) including_23\VBG\include.v.01|nausea (l_pobj) nausea_24\NN\symptom.n.01|,|vomiting (l_conj) vomiting_26\NN\expulsion.n.03|,|and|headache
D005839_D006261 CID gentamicin_5\NN\antibiotic.n.01|in (r_conj) administration_1\NN\management.n.01|the|of|and|gentamicin (r_nsubjpass) related_15\VBN\think.v.03|administration|was|to|. (l_prep) to_16\IN\entity.n.01|incidence (l_pobj) incidence_19\NN\frequency.n.02|a|high|of (l_prep) of_20\IN\entity.n.01|effects (l_pobj) effects_22\NNS\personal_property.n.01|side|including (l_prep) including_23\VBG\include.v.01|nausea (l_pobj) nausea_24\NN\symptom.n.01|,|vomiting (l_conj) vomiting_26\NN\expulsion.n.03|,|and|headache (l_conj) headache_29\NN\negative_stimulus.n.01|
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NNP\entity.n.01|pirarubicin (r_dobj) bolus_9\NN\ball.n.03|4'-0-tetrahydropyranyladriamycin (r_appos) phase_1\NN\time_period.n.01|a|study|bolus|) (r_nsubjpass) done_15\VBN\make.v.01|phase|was|in|. (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|55|in (l_prep) in_19\IN\linear_unit.n.01|status (l_pobj) status_22\NN\state.n.02|good|performance|with (l_prep) with_23\IN\entity.n.01|tumors (l_pobj) tumors_25\NNS\growth.n.06|refractory
C027260_D009369 NONE pirarubicin_12\NNP\entity.n.01|( (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NNP\entity.n.01|pirarubicin (r_dobj) bolus_9\NN\ball.n.03|4'-0-tetrahydropyranyladriamycin (r_appos) phase_1\NN\time_period.n.01|a|study|bolus|) (r_nsubjpass) done_15\VBN\make.v.01|phase|was|in|. (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|55|in (l_prep) in_19\IN\linear_unit.n.01|status (l_pobj) status_22\NN\state.n.02|good|performance|with (l_prep) with_23\IN\entity.n.01|tumors (l_pobj) tumors_25\NNS\growth.n.06|refractory
19299179
D015662_D002779 NONE trimoxazole_11\NN\entity.n.01|- (r_amod) treatment_12\NN\care.n.01|dose|trimoxazole|for|--|report (r_pobj) after_5\IN\after.s.01|treatment (r_prep) cholestasis_4\NN\disorder.n.01|severe|after|.
D015662_D011020 NONE trimoxazole_11\NN\entity.n.01|- (r_amod) treatment_12\NN\care.n.01|dose|trimoxazole|for|--|report (l_prep) for_13\IN\entity.n.01|pneumonia (l_pobj) pneumonia_15\NN\respiratory_disease.n.01|pneumocystis|in
D015662_D011020 NONE trimoxazole_25\NN\entity.n.01|- (r_punct) ._26\.\entity.n.01|trimoxazole (r_punct) treated_18\VBN\interact.v.01|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\respiratory_disease.n.01|pneumocystis|(|pcp|)|,|infection|,
D015662_D011020 NONE trimoxazole_25\NN\entity.n.01|- (r_punct) ._26\.\entity.n.01|trimoxazole (r_punct) treated_18\VBN\interact.v.01|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\respiratory_disease.n.01|pneumocystis|(|pcp|)|,|infection|, (l_appos) pcp_3\NNP\professional.n.01|
D015662_D011020 NONE trimoxazole_35\NN\entity.n.01|- (r_amod) treatment_36\NN\care.n.01|trimoxazole|for (l_prep) for_37\IN\entity.n.01|pcp (l_pobj) pcp_38\NNP\professional.n.01|
D015662_D015658 NONE trimoxazole_11\NN\entity.n.01|- (r_amod) treatment_12\NN\care.n.01|dose|trimoxazole|for|--|report (l_prep) for_13\IN\entity.n.01|pneumonia (l_pobj) pneumonia_15\NN\respiratory_disease.n.01|pneumocystis|in (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_20\NNS\case.n.06|infected (l_amod) infected_19\VBN\give.v.01|hiv|-
D015662_D015658 NONE trimoxazole_25\NN\entity.n.01|- (r_punct) ._26\.\entity.n.01|trimoxazole (r_punct) treated_18\VBN\interact.v.01|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\respiratory_disease.n.01|pneumocystis|(|pcp|)|,|infection|, (l_appos) infection_9\NN\ill_health.n.01|a|common|opportunistic|in (l_prep) in_10\IN\linear_unit.n.01|individuals (l_pobj) individuals_14\NNS\causal_agent.n.01|infected (l_amod) infected_13\VBN\give.v.01|hiv|-
D015662_D015658 NONE trimoxazole_35\NN\entity.n.01|- (r_amod) treatment_36\NN\care.n.01|trimoxazole|for (r_dobj) report_3\VBP\document.n.01|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS\happening.n.01|two|of|and|in (l_prep) of_6\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|immunocompromised|infected|developed (l_amod) infected_11\VBN\give.v.01|hiv|-
D015662_D009894 NONE trimoxazole_25\NN\entity.n.01|- (r_punct) ._26\.\entity.n.01|trimoxazole (r_punct) treated_18\VBN\interact.v.01|pneumonia|is|generally|with|. (l_nsubjpass) pneumonia_1\NN\respiratory_disease.n.01|pneumocystis|(|pcp|)|,|infection|, (l_appos) infection_9\NN\ill_health.n.01|a|common|opportunistic|in
D015662_D002780 CID trimoxazole_35\NN\entity.n.01|- (r_amod) treatment_36\NN\care.n.01|trimoxazole|for (r_dobj) report_3\VBP\document.n.01|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS\happening.n.01|two|of|and|in (l_prep) of_6\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|immunocompromised|infected|developed (l_relcl) developed_14\VBD\create.v.02|who|cholestasis|, (l_dobj) cholestasis_17\NN\disorder.n.01|severe|intrahepatic
D015662_D008100 NONE trimoxazole_35\NN\entity.n.01|- (r_amod) treatment_36\NN\care.n.01|trimoxazole|for (r_dobj) report_3\VBP\document.n.01|here|,|we|cases|treatment|. (l_dobj) cases_5\NNS\happening.n.01|two|of|and|in (l_conj) in_20\IN\linear_unit.n.01|lesions|, (l_pobj) lesions_23\NNS\pathology.n.02|one|patient|mimicking (l_acl) mimicking_24\VBG\imitate.v.01|formation (l_dobj) formation_27\NN\arrangement.n.02|liver|abscess|on (l_compound) abscess_26\NN\symptom.n.01|
424937
D008750_D056486 CID methyldopa_6\NN\antihypertensive.n.01| (r_pobj) by_5\IN\by.r.01|methyldopa (r_agent) induced_4\VBN\generate.v.01|patterns|by|. (l_nsubj) patterns_0\NNS\structure.n.03|of (l_prep) of_1\IN\entity.n.01|injury (l_pobj) injury_3\NN\ill_health.n.01|hepatic
D008750_D056486 CID methyldopa_22\NN\antihypertensive.n.01| (r_npadvmod) induced_24\VBN\generate.v.01|methyldopa|- (r_amod) hepatitis_25\NN\infectious_disease.n.01|induced
D008750_D056486 CID methyldopa_14\NN\antihypertensive.n.01|and|dysfunction (r_pobj) between_13\IN\between.r.01|methyldopa (r_prep) relationship_12\NN\relation.n.01|the|causal|between (r_nsubjpass) proved_19\VBN\be.v.01|in|in|,|relationship|was|with|. (l_prep) with_20\IN\entity.n.01|recurrence (l_pobj) recurrence_22\NN\repeat.n.01|the|of|within|to (l_prep) of_23\IN\entity.n.01|hepatitis (l_pobj) hepatitis_24\NN\infectious_disease.n.01|
D008750_D008107 NONE methyldopa_7\NN\antihypertensive.n.01| (r_pobj) to_6\IN\entity.n.01|methyldopa (r_prep) related_5\VBN\think.v.03|to (r_acl) disease_4\NN\illness.n.01|liver|related
D008750_D008107 NONE methyldopa_14\NN\antihypertensive.n.01|and|dysfunction (l_conj) dysfunction_17\NN\pathology.n.02|hepatic
D008750_D017093 NONE methyldopa_17\NN\antihypertensive.n.01| (r_dobj) taking_16\VBG\action.n.01|who|had|been|methyldopa|for (r_relcl) another_11\DT\another.s.01|,|taking|, (r_nsubj) showed_22\VBD\show.v.04|another|resolution|over (r_conj) presented_5\VBN\show.v.04|having|in|,|and|showed (l_prep) in_6\IN\linear_unit.n.01|failure (l_pobj) failure_8\NN\nonaccomplishment.n.01|hepatic
D008750_D017114 NONE methyldopa_22\NN\antihypertensive.n.01| (r_npadvmod) induced_24\VBN\generate.v.01|methyldopa|- (r_amod) hepatitis_25\NN\infectious_disease.n.01|induced (r_pobj) of_21\IN\entity.n.01|hepatitis (r_prep) episode_20\NN\happening.n.01|a|prior|of (r_pobj) after_17\IN\after.s.01|episode (r_prep) recommenced_14\VBN\begin.v.03|when|drug|was|accidentally|year|after (r_advcl) developed_6\VBD\create.v.02|patient|hepatitis|recommenced|. (l_dobj) hepatitis_8\NN\infectious_disease.n.01|fulminant
12041669
D000961_D000741 NONE globulin_1\NN\simple_protein.n.01|antithymocyte|in|. (l_prep) in_2\IN\linear_unit.n.01|treatment (l_pobj) treatment_4\NN\care.n.01|the|of (l_prep) of_5\IN\entity.n.01|anemia (l_pobj) anemia_12\NN\blood_disease.n.01|induced|aplastic
D000961_D000741 NONE globulin_5\NN\simple_protein.n.01| (r_compound) therapy_6\NN\medical_care.n.01|globulin (r_dobj) received_3\VBD\get.v.01|who|antithymocyte|therapy|for|due (l_prep) for_7\IN\entity.n.01|anemia (l_pobj) anemia_9\NN\blood_disease.n.01|aplastic
D000961_D000741 NONE globulin_3\NN\simple_protein.n.01| (r_dobj) use_0\NN\activity.n.01|of|globulin (r_nsubj) be_5\VB\metallic_element.n.01|use|may|treatment|. (l_attr) treatment_8\NN\care.n.01|the|optimal|of (l_prep) of_9\IN\entity.n.01|anemia (l_pobj) anemia_16\NN\blood_disease.n.01|induced|aplastic
D010396_D000741 CID penicillamine_8\NN\medicine.n.02|d|- (r_npadvmod) induced_10\VBN\generate.v.01|penicillamine|- (r_amod) anemia_12\NN\blood_disease.n.01|induced|aplastic
D010396_D000741 CID penicillamine_14\NN\medicine.n.02|d|- (r_compound) therapy_15\NN\medical_care.n.01|penicillamine (r_nsubjpass) described_17\VBN\set_forth.v.01|patient|therapy|is|. (l_nsubjpass) patient_1\NN\case.n.06|a|received (l_relcl) received_3\VBD\get.v.01|who|antithymocyte|therapy|for|due (l_prep) for_7\IN\entity.n.01|anemia (l_pobj) anemia_9\NN\blood_disease.n.01|aplastic
D010396_D000741 CID penicillamine_12\NN\medicine.n.02|d|- (r_npadvmod) induced_14\VBN\generate.v.01|penicillamine|- (r_amod) anemia_16\NN\blood_disease.n.01|induced|aplastic
6133211
D012460_D015212 NONE sulphasalazine_15\NN\entity.n.01|throughout (r_pobj) with_14\IN\entity.n.01|sulphasalazine (r_prep) treatment_13\NN\care.n.01|with (r_dobj) received_12\VBD\get.v.01|who|treatment (r_relcl) disease_10\NN\illness.n.01|inflammatory|bowel|received
D012460_D000013 NONE sulphasalazine_15\NN\entity.n.01|throughout (r_pobj) with_14\IN\entity.n.01|sulphasalazine (r_prep) treatment_13\NN\care.n.01|with (r_dobj) received_12\VBD\get.v.01|who|treatment (r_relcl) disease_10\NN\illness.n.01|inflammatory|bowel|received (r_pobj) with_7\IN\entity.n.01|disease (r_prep) mothers_6\NNS\parent.n.01|two|with (r_pobj) of_4\IN\entity.n.01|mothers (r_prep) born_3\VBN\born.n.01|of (r_acl) infants_1\NNS\child.n.02|three|,|born|, (r_nsubjpass) found_20\VBN\wage.n.01|infants|were|have|. (l_xcomp) have_22\VB\person.n.01|to|anomalies (l_dobj) anomalies_25\NNS\abnormality.n.01|major|congenital
2802551
D012964_D007674 NONE sodium_0\NN\metallic_element.n.01| (r_compound) status_1\NN\state.n.02|sodium (r_nsubj) influences_2\VBZ\power.n.01|status|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN\entity.n.01|chronic|b|in
D000666_D007674 CID b_5\NN\eubacteria.n.01|amphotericin (r_compound) nephrotoxicity_6\NN\entity.n.01|chronic|b|in
D000666_D007674 CID b_5\NNP\eubacteria.n.01|amphotericin|mg/kg (r_pobj) of_3\IN\entity.n.01|b (r_prep) potential_2\NN\possibility.n.02|the|nephrotoxic|of (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
8073369
C007112_D001176 CID coniine_2\NN\entity.n.01| (r_nsubj) failed_4\VBN\fail.v.01|however|,|coniine|has|produce|and|is|. (l_xcomp) produce_6\VB\food.n.02|to|arthrogryposis (l_dobj) arthrogryposis_7\NN\entity.n.01|in
C007112_D001176 CID coniine_15\RB\entity.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|coniine|- (r_amod) arthrogryposis_18\NN\entity.n.01|induced
C007112_D009140 NONE coniine_5\NN\entity.n.01|both|and|sulfate (r_pobj) by_3\IN\by.r.01|coniine (r_agent) caused_2\VBN\make.v.03|by (r_acl) deformations_1\NNS\damage.n.01|the|caused
C007112_D009140 NONE coniine_5\NN\entity.n.01|both|and|sulfate (r_pobj) by_3\IN\by.r.01|coniine (r_agent) caused_2\VBN\make.v.03|by (r_acl) deformations_1\NNS\damage.n.01|the|caused (r_nsubj) were_9\VBD\be.v.01|deformations|flexion|. (l_attr) flexion_11\NN\physical_condition.n.01|excessive|or|extension|of (l_prep) of_14\IN\entity.n.01|toes (l_pobj) toes_18\NNS\digit.n.03|one
D009538_D009140 NONE nicotine_7\NN\alkaloid.n.01| (r_compound) sulfate_8\NN\salt.n.01|nicotine (r_conj) coniine_5\NN\entity.n.01|both|and|sulfate (r_pobj) by_3\IN\by.r.01|coniine (r_agent) caused_2\VBN\make.v.03|by (r_acl) deformations_1\NNS\damage.n.01|the|caused
D009538_D009140 NONE nicotine_7\NN\alkaloid.n.01| (r_compound) sulfate_8\NN\salt.n.01|nicotine (r_conj) coniine_5\NN\entity.n.01|both|and|sulfate (r_pobj) by_3\IN\by.r.01|coniine (r_agent) caused_2\VBN\make.v.03|by (r_acl) deformations_1\NNS\damage.n.01|the|caused (r_nsubj) were_9\VBD\be.v.01|deformations|flexion|. (l_attr) flexion_11\NN\physical_condition.n.01|excessive|or|extension|of (l_prep) of_14\IN\entity.n.01|toes (l_pobj) toes_18\NNS\digit.n.03|one
D009538_D002543 CID nicotine_30\NN\alkaloid.n.01| (r_nmod) chicks_34\NNS\chicken.n.02|all|nicotine|treated (r_pobj) in_28\IN\linear_unit.n.01|chicks (r_prep) occurred_27\VBD\happen.v.01|seen|;|however|,|hemorrhage|in|. (l_nsubj) hemorrhage_26\NN\injury.n.01|extensive|cranial
15009014
D002211_D006940 CID capsaicin_0\NNS\chemical_irritant.n.01|mm (r_nsubj) applied_7\VBN\use.v.01|capsaicin|to|induced|. (l_conj) induced_13\VBN\generate.v.01|increases|provoked (l_dobj) increases_14\NNS\indefinite_quantity.n.01|in|and (l_prep) in_15\IN\linear_unit.n.01|flow (l_pobj) flow_20\NN\change_of_location.n.01|dural|blood
D001285_D006940 NONE atropine_16\NN\alkaloid.n.01|of|mm (r_pobj) by_10\IN\by.r.01|atropine (r_agent) abolished_9\VBN\abolish.v.01|increases|were|also|by|. (l_nsubjpass) increases_2\NNS\indefinite_quantity.n.01|the|evoked|in (l_prep) in_3\IN\linear_unit.n.01|flow (l_pobj) flow_6\NN\change_of_location.n.01|dural|blood
15338796
D000420_D014202 CID salbutamol_4\NN\entity.n.01| (r_pobj) of_3\IN\entity.n.01|salbutamol (r_prep) effects_2\NNS\personal_property.n.01|tremor|side|of|,|quantified|. (l_compound) tremor_0\NNP\vibration.n.01|
D000420_D014202 CID salbutamol_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|salbutamol (r_prep) effects_4\NNS\personal_property.n.01|tremor|side|of (l_compound) tremor_2\JJ\vibration.n.01|
D000420_D014202 CID salbutamol_19\NN\entity.n.01| (r_pobj) of_18\IN\entity.n.01|salbutamol (r_prep) doses_17\NNS\medicine.n.02|cumulative|of (r_pobj) of_15\IN\entity.n.01|doses (r_prep) administration_14\NN\management.n.01|of (r_pobj) after_13\IN\after.s.01|administration (r_prep) disease_12\NN\illness.n.01|obstructive|lung|after (r_pobj) with_9\IN\entity.n.01|disease (r_prep) patients_8\NNS\case.n.06|44|with (r_pobj) in_6\IN\linear_unit.n.01|patients (r_prep) assessed_4\VBD\evaluate.v.02|determine|we|tremor|in|. (l_dobj) tremor_5\NN\vibration.n.01|
D000420_D014202 CID salbutamol_0\NNP\entity.n.01| (r_nsubj) increased_2\VBD\change_magnitude.v.01|salbutamol|significantly|severity|in|. (l_dobj) severity_4\NN\intensity.n.02|tremor (l_compound) tremor_3\NN\vibration.n.01|
D000420_D008173 NONE salbutamol_19\NN\entity.n.01| (r_pobj) of_18\IN\entity.n.01|salbutamol (r_prep) doses_17\NNS\medicine.n.02|cumulative|of (r_pobj) of_15\IN\entity.n.01|doses (r_prep) administration_14\NN\management.n.01|of (r_pobj) after_13\IN\after.s.01|administration (r_prep) disease_12\NN\illness.n.01|obstructive|lung|after
11642480
D015283_D004409 CID citalopram_7\NN\entity.n.01| (r_pobj) on_6\IN\on.a.01|citalopram (r_prep) adolescent_5\NN\juvenile.n.01|a|depressed|on (r_pobj) in_2\IN\linear_unit.n.01|adolescent (r_prep) twitching_1\VBG\spasm.n.01|palpebral|in|.
D015283_D004409 CID citalopram_8\NN\entity.n.01| (r_pobj) with_7\IN\entity.n.01|citalopram (r_prep) treatment_6\NN\care.n.01|with|by (l_prep) by_9\IN\by.r.01|boy (l_pobj) boy_14\NN\male.n.02|a|old|with (l_prep) with_15\IN\entity.n.01|depression (l_pobj) depression_17\NN\psychological_state.n.01|major|exhibited (l_relcl) exhibited_19\VBD\possess.v.01|who|twitching|during (l_dobj) twitching_21\NN\spasm.n.01|palpebral
D015283_D003866 NONE citalopram_7\NN\entity.n.01| (r_pobj) on_6\IN\on.a.01|citalopram (r_prep) adolescent_5\NN\juvenile.n.01|a|depressed|on (l_amod) depressed_4\JJ\discourage.v.02|
D015283_D003865 NONE citalopram_8\NN\entity.n.01| (r_pobj) with_7\IN\entity.n.01|citalopram (r_prep) treatment_6\NN\care.n.01|with|by (l_prep) by_9\IN\by.r.01|boy (l_pobj) boy_14\NN\male.n.02|a|old|with (l_prep) with_15\IN\entity.n.01|depression (l_pobj) depression_17\NN\psychological_state.n.01|major|exhibited
18261172
D020123_D011507 CID sirolimus_6\NN\entity.n.01| (r_npadvmod) based_8\VBN\establish.v.08|sirolimus|- (r_amod) immunosuppression_9\NN\immunological_disorder.n.01|based|in (r_pobj) to_5\IN\entity.n.01|immunosuppression (r_prep) switch_4\NN\control.n.09|to (r_pobj) after_3\IN\after.s.01|switch (r_prep) development_0\NN\improvement.n.02|of|after|. (l_prep) of_1\IN\entity.n.01|proteinuria (l_pobj) proteinuria_2\NN\symptom.n.01|
D020123_D011507 CID sirolmus_7\NN\entity.n.01|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\need.n.01|immunosuppressive|(|is|sirolmus|effects (r_ccomp) reported_23\VBN\inform.v.01|lacks|;|however|,|proteinuria|has|been|following|. (l_nsubjpass) proteinuria_17\NN\symptom.n.01|associated
D020123_D011507 CID srl_9\NNP\entity.n.01| (r_appos) sirolmus_7\NN\entity.n.01|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\need.n.01|immunosuppressive|(|is|sirolmus|effects (r_ccomp) reported_23\VBN\inform.v.01|lacks|;|however|,|proteinuria|has|been|following|. (l_nsubjpass) proteinuria_17\NN\symptom.n.01|associated
D020123_D011507 CID srl_20\NNP\entity.n.01| (r_pobj) with_19\IN\entity.n.01|srl (r_prep) associated_18\VBN\think.v.03|with (r_acl) proteinuria_17\NN\symptom.n.01|associated
D020123_D011507 CID srl_10\NNP\entity.n.01| (r_pobj) with_9\IN\entity.n.01|srl (r_prep) associated_8\VBN\think.v.03|with (r_acl) incidence_5\NN\frequency.n.02|the|of|associated (l_prep) of_6\IN\entity.n.01|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|
D020123_D011507 CID srl_12\NNP\entity.n.01|,|have (r_pobj) to_11\IN\entity.n.01|srl (r_prep) switch_10\NN\control.n.09|to (r_pobj) after_9\IN\after.s.01|switch (r_prep) develop_4\VB\create.v.02|thus|,|proteinuria|may|in|after|. (l_nsubj) proteinuria_2\NN\symptom.n.01|
D020123_D011507 CID srl_0\NNP\entity.n.01| (r_nsubjpass) used_3\VBN\use.v.01|srl|should|be|with|and|increased|. (l_prep) with_4\IN\entity.n.01|therapy (l_pobj) therapy_8\NN\medical_care.n.01|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD\observe.v.04|for (l_prep) for_12\IN\entity.n.01|proteinuria (l_pobj) proteinuria_13\NN\symptom.n.01|
D020123_D007674 NONE sirolmus_7\NN\entity.n.01|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\need.n.01|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS\personal_property.n.01|nephrotoxic (l_amod) nephrotoxic_12\JJ\nephrotoxic.s.01|
D020123_D007674 NONE srl_9\NNP\entity.n.01| (r_appos) sirolmus_7\NN\entity.n.01|)|drug|(|srl|) (r_nsubj) lacks_11\VBZ\need.n.01|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS\personal_property.n.01|nephrotoxic (l_amod) nephrotoxic_12\JJ\nephrotoxic.s.01|
D020123_D007674 NONE srl_20\NNP\entity.n.01| (r_pobj) with_19\IN\entity.n.01|srl (r_prep) associated_18\VBN\think.v.03|with (r_acl) proteinuria_17\NN\symptom.n.01|associated (r_nsubjpass) reported_23\VBN\inform.v.01|lacks|;|however|,|proteinuria|has|been|following|. (l_ccomp) lacks_11\VBZ\need.n.01|immunosuppressive|(|is|sirolmus|effects (l_dobj) effects_13\NNS\personal_property.n.01|nephrotoxic (l_amod) nephrotoxic_12\JJ\nephrotoxic.s.01|
D020123_D007674 NONE srl_0\NNP\entity.n.01| (r_nsubjpass) used_3\VBN\use.v.01|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD\change_magnitude.v.01|dysfunction (l_dobj) dysfunction_17\NN\pathology.n.02|renal
D000806_D011507 NONE inhibitor_1\NN\substance.n.07|ace|and|therapy (r_nsubj) reduced_11\VBN\decrease.v.02|inhibitor|development|. (l_dobj) development_13\NN\improvement.n.02|proteinuria (l_compound) proteinuria_12\NN\symptom.n.01|
D000806_D011507 NONE acei_5\NNP\entity.n.01| (r_nmod) therapy_8\NN\medical_care.n.01|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD\observe.v.04|for (l_prep) for_12\IN\entity.n.01|proteinuria (l_pobj) proteinuria_13\NN\symptom.n.01|
D057911_D011507 NONE blocker_6\NN\football_player.n.01|releasing (r_nmod) therapy_10\NN\medical_care.n.01|blocker|(|arb|) (r_conj) inhibitor_1\NN\substance.n.07|ace|and|therapy (r_nsubj) reduced_11\VBN\decrease.v.02|inhibitor|development|. (l_dobj) development_13\NN\improvement.n.02|proteinuria (l_compound) proteinuria_12\NN\symptom.n.01|
D057911_D011507 NONE arb_8\NNP\businessman.n.01| (r_nmod) therapy_10\NN\medical_care.n.01|blocker|(|arb|) (r_conj) inhibitor_1\NN\substance.n.07|ace|and|therapy (r_nsubj) reduced_11\VBN\decrease.v.02|inhibitor|development|. (l_dobj) development_13\NN\improvement.n.02|proteinuria (l_compound) proteinuria_12\NN\symptom.n.01|
D057911_D011507 NONE arb_7\NNP\businessman.n.01| (r_compound) therapy_8\NN\medical_care.n.01|acei|/|arb|and|patients|monitored (l_acl) monitored_11\VBD\observe.v.04|for (l_prep) for_12\IN\entity.n.01|proteinuria (l_pobj) proteinuria_13\NN\symptom.n.01|
D000806_D007674 NONE acei_5\NNP\entity.n.01| (r_nmod) therapy_8\NN\medical_care.n.01|acei|/|arb|and|patients|monitored (r_pobj) with_4\IN\entity.n.01|therapy (r_prep) used_3\VBN\use.v.01|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD\change_magnitude.v.01|dysfunction (l_dobj) dysfunction_17\NN\pathology.n.02|renal
D057911_D007674 NONE arb_7\NNP\businessman.n.01| (r_compound) therapy_8\NN\medical_care.n.01|acei|/|arb|and|patients|monitored (r_pobj) with_4\IN\entity.n.01|therapy (r_prep) used_3\VBN\use.v.01|srl|should|be|with|and|increased|. (l_conj) increased_15\VBD\change_magnitude.v.01|dysfunction (l_dobj) dysfunction_17\NN\pathology.n.02|renal
7628595
D014805_D064420 NONE b12_6\NN\entity.n.01|vitamin|and|supplementation (l_conj) supplementation_10\NN\increase.n.04|folinic|acid|in (l_prep) in_11\IN\linear_unit.n.01|preventing (l_pcomp) preventing_12\VBG\prevent.v.01|toxicity (l_dobj) toxicity_14\NN\definite_quantity.n.01|hematologic|of
D002955_D064420 NONE acid_9\NN\compound.n.02| (r_compound) supplementation_10\NN\increase.n.04|folinic|acid|in (l_prep) in_11\IN\linear_unit.n.01|preventing (l_pcomp) preventing_12\VBG\prevent.v.01|toxicity (l_dobj) toxicity_14\NN\definite_quantity.n.01|hematologic|of
D015215_D064420 NONE zidovudine_16\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) of_15\IN\entity.n.01|zidovudine (r_prep) toxicity_14\NN\definite_quantity.n.01|hematologic|of
D014805_D001855 NONE b12_13\NN\entity.n.01|vitamin|and|supplementation (l_conj) supplementation_17\NN\increase.n.04|folinic|acid|in (l_prep) in_18\IN\linear_unit.n.01|preventing (l_pcomp) preventing_19\VBG\prevent.v.01|suppression (l_dobj) suppression_25\NN\growth.n.01|zidovudine|(|zdv)-induced|marrow
D014805_D001855 NONE b12_6\NN\entity.n.01|vitamin|or|levels (l_conj) levels_9\NNS\property.n.02|folate|and|development (l_conj) development_11\NN\improvement.n.02|of (l_prep) of_12\IN\entity.n.01|myelosuppression (l_pobj) myelosuppression_13\NN\entity.n.01|
D014805_D001855 NONE b12_1\NN\entity.n.01|vitamin|and|supplementation (r_nsubj) seem_11\VB\be.v.01|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ\useful.a.01|in (l_prep) in_13\IN\linear_unit.n.01|preventing (l_pcomp) preventing_14\VBG\prevent.v.01|or|reducing (l_conj) reducing_16\VBG\chemical_reaction.n.01|myelotoxicity|in (l_dobj) myelotoxicity_20\NN\entity.n.01|induced
D002955_D001855 NONE acid_16\NN\compound.n.02| (r_compound) supplementation_17\NN\increase.n.04|folinic|acid|in (l_prep) in_18\IN\linear_unit.n.01|preventing (l_pcomp) preventing_19\VBG\prevent.v.01|suppression (l_dobj) suppression_25\NN\growth.n.01|zidovudine|(|zdv)-induced|marrow
D002955_D001855 NONE acid_4\NN\compound.n.02| (r_compound) supplementation_5\NN\increase.n.04|folinic|acid|of (r_conj) b12_1\NN\entity.n.01|vitamin|and|supplementation (r_nsubj) seem_11\VB\be.v.01|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ\useful.a.01|in (l_prep) in_13\IN\linear_unit.n.01|preventing (l_pcomp) preventing_14\VBG\prevent.v.01|or|reducing (l_conj) reducing_16\VBG\chemical_reaction.n.01|myelotoxicity|in (l_dobj) myelotoxicity_20\NN\entity.n.01|induced
D015215_D001855 CID zidovudine_20\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_nmod) suppression_25\NN\growth.n.01|zidovudine|(|zdv)-induced|marrow
D015215_D001855 CID zdv)-induced_22\VBN\entity.n.01| (r_amod) suppression_25\NN\growth.n.01|zidovudine|(|zdv)-induced|marrow
D015215_D001855 CID zdv_7\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) therapy_8\NN\medical_care.n.01|zdv (r_pobj) of_6\IN\entity.n.01|therapy (r_prep) supplementation_5\NN\increase.n.04|folinic|acid|of (r_conj) b12_1\NN\entity.n.01|vitamin|and|supplementation (r_nsubj) seem_11\VB\be.v.01|b12|does|not|useful|,|excluded|. (l_oprd) useful_12\JJ\useful.a.01|in (l_prep) in_13\IN\linear_unit.n.01|preventing (l_pcomp) preventing_14\VBG\prevent.v.01|or|reducing (l_conj) reducing_16\VBG\chemical_reaction.n.01|myelotoxicity|in (l_dobj) myelotoxicity_20\NN\entity.n.01|induced
D015215_D001855 CID zdv_17\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|zdv|- (r_amod) myelotoxicity_20\NN\entity.n.01|induced
D015215_D015658 NONE zdv_21\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01|either|(|daily|) (r_dobj) receive_19\VB\get.v.01|to|zdv|alone (r_xcomp) randomized_17\VBN\disarrange.v.02|virus|were|receive (l_nsubjpass) virus_5\NN\infectious_agent.n.01|five|human|immunodeficiency|patients (l_appos) patients_8\NNS\case.n.06|(|hiv)-infected|with (l_amod) hiv)-infected_7\VBN\entity.n.01|
D005492_D001855 NONE folate_8\JJ\b-complex_vitamin.n.01| (r_compound) levels_9\NNS\property.n.02|folate|and|development (l_conj) development_11\NN\improvement.n.02|of (l_prep) of_12\IN\entity.n.01|myelosuppression (l_pobj) myelosuppression_13\NN\entity.n.01|
20882060
D009496_D002375 NONE neurotensin_3\NN\entity.n.01|pallidal|on (l_prep) on_4\IN\on.a.01|catalepsy (l_pobj) catalepsy_9\NN\hypersomnia.n.01|induced|parkinsonian|:|studies
D009496_D002375 NONE neurotensin_3\NN\entity.n.01|into (r_pobj) of_2\IN\entity.n.01|neurotensin (r_prep) infusions_1\NNS\solution.n.01|bilateral|of (r_nsubj) reversed_8\VBD\change.v.02|infusions|catalepsy|in|. (l_dobj) catalepsy_13\NN\hypersomnia.n.01|induced|parkinsonian
D006220_D002375 CID haloperidol_5\NN\major_tranquilizer.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|haloperidol|- (r_amod) catalepsy_9\NN\hypersomnia.n.01|induced|parkinsonian|:|studies
D006220_D002375 CID haloperidol_9\NN\major_tranquilizer.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|haloperidol|- (r_amod) catalepsy_13\NN\hypersomnia.n.01|induced|parkinsonian
D009496_D010302 NONE neurotensin_10\NN\entity.n.01|pallidal|on (l_prep) on_11\IN\on.a.01|symptoms (l_pobj) symptoms_16\NNS\evidence.n.01|induced|parkinsonian
D006220_D010302 NONE haloperidol_12\NN\major_tranquilizer.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|haloperidol|- (r_amod) symptoms_16\NNS\evidence.n.01|induced|parkinsonian
16755009
D003975_D000647 CID diazepam-_0\NN\entity.n.01|,|amnesia|. (l_appos) amnesia_7\NN\cognitive_state.n.01|scopolamine-|served
D003975_D000647 CID diazepam_16\NN\benzodiazepine.n.01|mg/kg (r_conj) scopolamine_8\NN\alkaloid.n.01|(|mg/kg|)|and|diazepam (r_pobj) by_7\IN\by.r.01|scopolamine (r_agent) induced_6\VBN\generate.v.01|by (r_acl) amnesia_5\NN\cognitive_state.n.01|the|induced
D012601_D000647 CID scopolamine-_2\NN\entity.n.01|and|induced (r_nmod) amnesia_7\NN\cognitive_state.n.01|scopolamine-|served
D012601_D000647 CID scopolamine_8\NN\alkaloid.n.01|(|mg/kg|)|and|diazepam (r_pobj) by_7\IN\by.r.01|scopolamine (r_agent) induced_6\VBN\generate.v.01|by (r_acl) amnesia_5\NN\cognitive_state.n.01|the|induced
D010936_D000647 NONE dce_2\NNP\entity.n.01| (r_nsubj) reversed_3\VBD\change.v.02|furthermore|,|dce|amnesia|. (l_dobj) amnesia_5\NN\cognitive_state.n.01|the|induced
D010936_D003072 NONE dce_2\NNP\entity.n.01| (r_nsubj) prove_4\VB\be.v.01|therefore|,|dce|may|be|. (l_xcomp) be_6\VB\metallic_element.n.01|to|remedy (l_attr) remedy_9\NN\correction.n.01|a|useful|for|improving (l_prep) for_10\IN\entity.n.01|management (l_pobj) management_12\NN\social_control.n.01|the|of (l_prep) of_13\IN\entity.n.01|dysfunctions (l_pobj) dysfunctions_15\NNS\pathology.n.02|cognitive|on
D002784_D003072 NONE cholesterol_30\NN\sterol.n.01| (r_nsubj) lowering_31\VBG\decrease.n.04|cholesterol|activity (r_conj) property_28\NN\possession.n.02|,|lowering (r_dobj) improving_27\VBG\change.v.01|memory|property (r_acl) remedy_9\NN\correction.n.01|a|useful|for|improving (l_prep) for_10\IN\entity.n.01|management (l_pobj) management_12\NN\social_control.n.01|the|of (l_prep) of_13\IN\entity.n.01|dysfunctions (l_pobj) dysfunctions_15\NNS\pathology.n.02|cognitive|on
6773726
D005996_D007022 CID nitroglycerin_5\NN\nitrate.n.01|in (r_pobj) by_4\IN\by.r.01|nitroglycerin (r_prep) hypotension_3\NN\cardiovascular_disease.n.01|postural|by
D005996_D003929 NONE nitroglycerin_5\NN\nitrate.n.01|in (l_prep) in_6\IN\linear_unit.n.01|neuropathy (l_pobj) neuropathy_9\NN\pathology.n.02|diabetic|autonomic
D005996_D003920 NONE nitroglycerin_3\NN\nitrate.n.01|on (r_pobj) of_2\IN\entity.n.01|nitroglycerin (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) compared_12\VBN\analyze.v.01|effect|was|in|. (l_prep) in_13\IN\linear_unit.n.01|subjects (l_pobj) subjects_16\NNS\message.n.02|5|normal|,|subjects (l_appos) subjects_20\NNS\message.n.02|12|diabetic|without|,|and|subjects (l_amod) diabetic_19\JJ\sick_person.n.01|
D005996_D003920 NONE nitroglycerin_3\NN\nitrate.n.01|on (r_pobj) of_2\IN\entity.n.01|nitroglycerin (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) compared_12\VBN\analyze.v.01|effect|was|in|. (l_prep) in_13\IN\linear_unit.n.01|subjects (l_pobj) subjects_16\NNS\message.n.02|5|normal|,|subjects (l_appos) subjects_20\NNS\message.n.02|12|diabetic|without|,|and|subjects (l_conj) subjects_28\NNS\message.n.02|5|diabetic|with (l_amod) diabetic_27\JJ\sick_person.n.01|
D005996_D003920 NONE nitroglycerin_19\NN\nitrate.n.01| (r_pobj) after_18\IN\after.s.01|nitroglycerin (r_prep) decrease_13\NN\change.n.01|the|in|after (r_conj) increase_7\NN\indefinite_quantity.n.01|the|in|and|decrease (r_pobj) of_5\IN\entity.n.01|increase (r_prep) course_4\NN\education.n.01|magnitude|of (r_nsubj) were_20\VBD\be.v.01|course|similar|,|occurred|. (l_acomp) similar_21\JJ\similar.a.01|in (l_prep) in_22\IN\linear_unit.n.01|subjects (l_pobj) subjects_27\NNS\message.n.02|the|normal|without (l_amod) normal_24\JJ\practice.n.05|and|diabetic (l_conj) diabetic_26\JJ\sick_person.n.01|
D005996_D003920 NONE nitroglycerin_19\NN\nitrate.n.01| (r_pobj) after_18\IN\after.s.01|nitroglycerin (r_prep) decrease_13\NN\change.n.01|the|in|after (r_conj) increase_7\NN\indefinite_quantity.n.01|the|in|and|decrease (r_pobj) of_5\IN\entity.n.01|increase (r_prep) course_4\NN\education.n.01|magnitude|of (r_nsubj) were_20\VBD\be.v.01|course|similar|,|occurred|. (l_advcl) occurred_47\VBD\happen.v.01|whereas|increase|in (l_prep) in_48\IN\linear_unit.n.01|subjects (l_pobj) subjects_51\NNS\message.n.02|the|diabetic|with (l_amod) diabetic_50\JJ\sick_person.n.01|
D005996_D009422 NONE nitroglycerin_3\NN\nitrate.n.01|on (r_pobj) of_2\IN\entity.n.01|nitroglycerin (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) compared_12\VBN\analyze.v.01|effect|was|in|. (l_prep) in_13\IN\linear_unit.n.01|subjects (l_pobj) subjects_16\NNS\message.n.02|5|normal|,|subjects (l_appos) subjects_20\NNS\message.n.02|12|diabetic|without|,|and|subjects (l_prep) without_21\IN\entity.n.01|neuropathy (l_pobj) neuropathy_23\NN\pathology.n.02|autonomic
D005996_D009422 NONE nitroglycerin_3\NN\nitrate.n.01|on (r_pobj) of_2\IN\entity.n.01|nitroglycerin (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) compared_12\VBN\analyze.v.01|effect|was|in|. (l_prep) in_13\IN\linear_unit.n.01|subjects (l_pobj) subjects_16\NNS\message.n.02|5|normal|,|subjects (l_appos) subjects_20\NNS\message.n.02|12|diabetic|without|,|and|subjects (l_conj) subjects_28\NNS\message.n.02|5|diabetic|with (l_prep) with_29\IN\entity.n.01|neuropathy (l_pobj) neuropathy_31\NN\pathology.n.02|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\nitrate.n.01| (r_pobj) after_18\IN\after.s.01|nitroglycerin (r_prep) decrease_13\NN\change.n.01|the|in|after (r_conj) increase_7\NN\indefinite_quantity.n.01|the|in|and|decrease (r_pobj) of_5\IN\entity.n.01|increase (r_prep) course_4\NN\education.n.01|magnitude|of (r_nsubj) were_20\VBD\be.v.01|course|similar|,|occurred|. (l_acomp) similar_21\JJ\similar.a.01|in (l_prep) in_22\IN\linear_unit.n.01|subjects (l_pobj) subjects_27\NNS\message.n.02|the|normal|without (l_prep) without_28\IN\entity.n.01|neuropathy (l_pobj) neuropathy_30\NN\pathology.n.02|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\nitrate.n.01| (r_pobj) after_18\IN\after.s.01|nitroglycerin (r_prep) decrease_13\NN\change.n.01|the|in|after (r_conj) increase_7\NN\indefinite_quantity.n.01|the|in|and|decrease (r_pobj) of_5\IN\entity.n.01|increase (r_prep) course_4\NN\education.n.01|magnitude|of (r_nsubj) were_20\VBD\be.v.01|course|similar|,|occurred|. (l_advcl) occurred_47\VBD\happen.v.01|whereas|increase|in (l_prep) in_48\IN\linear_unit.n.01|subjects (l_pobj) subjects_51\NNS\message.n.02|the|diabetic|with (l_prep) with_52\IN\entity.n.01|neuropathy (l_pobj) neuropathy_54\NN\pathology.n.02|autonomic
12574103
D003907_D006973 CID dexamethasone_1\NN\anti-inflammatory.n.01| (r_compound) programs_2\NNS\idea.n.01|prenatal|dexamethasone (r_compound) hypertension_3\NN\cardiovascular_disease.n.01|programs|and|injury|in|.
D003907_D006973 CID dexamethasone_11\NN\anti-inflammatory.n.01|prenatal (r_nsubj) programmed_12\VBD\schedule.v.02|if|dexamethasone|increase (l_dobj) increase_15\NN\indefinite_quantity.n.01|a|progressive|in (l_prep) in_16\IN\linear_unit.n.01|pressure (l_pobj) pressure_18\NN\physical_phenomenon.n.01|blood|and|injury
D003907_D006973 CID dexamethasone_5\NN\anti-inflammatory.n.01|prenatal (r_dobj) received_3\VBD\get.v.01|that|dexamethasone|on (r_relcl) rats_1\NNS\rodent.n.01|male|received (r_nsubj) elevated_23\VBN\railway.n.01|rats|had|pressures|at (l_dobj) pressures_25\NNS\physical_phenomenon.n.01|blood
D003907_D006973 CID dexamethasone_5\NN\anti-inflammatory.n.01|prenatal|in (r_nsubj) results_8\VBZ\phenomenon.n.01|that|dexamethasone|in (l_prep) in_9\IN\linear_unit.n.01|reduction (l_pobj) reduction_11\NN\change_of_magnitude.n.01|a|in (l_prep) in_12\IN\linear_unit.n.01|number (l_pobj) number_14\NN\amount.n.02|glomerular|,|glomerulosclerosis|administered (l_conj) glomerulosclerosis_16\NN\entity.n.01|,|and|hypertension (l_conj) hypertension_19\NN\cardiovascular_disease.n.01|
D003907_D007674 CID dexamethasone_1\NN\anti-inflammatory.n.01| (r_compound) programs_2\NNS\idea.n.01|prenatal|dexamethasone (r_compound) hypertension_3\NN\cardiovascular_disease.n.01|programs|and|injury|in|. (l_conj) injury_6\NN\ill_health.n.01|renal
D003907_D007674 CID dexamethasone_11\NN\anti-inflammatory.n.01|prenatal (r_nsubj) programmed_12\VBD\schedule.v.02|if|dexamethasone|increase (l_dobj) increase_15\NN\indefinite_quantity.n.01|a|progressive|in (l_prep) in_16\IN\linear_unit.n.01|pressure (l_pobj) pressure_18\NN\physical_phenomenon.n.01|blood|and|injury (l_conj) injury_21\NN\ill_health.n.01|renal|in
D003907_D007674 CID dexamethasone_4\NN\anti-inflammatory.n.01| (r_dobj) administered_3\VBN\manage.v.02|offspring|dexamethasone|on (r_csubj) had_11\VBD\have.v.01|administered|reduction|compared|. (l_dobj) reduction_15\NN\change_of_magnitude.n.01|a|%|in (l_prep) in_16\IN\linear_unit.n.01|number (l_pobj) number_18\NN\amount.n.02|glomerular
D003907_D007674 CID dexamethasone_5\NN\anti-inflammatory.n.01|prenatal (r_dobj) received_3\VBD\get.v.01|that|dexamethasone|on (r_relcl) rats_1\NNS\rodent.n.01|male|received (r_nsubj) elevated_23\VBN\railway.n.01|rats|had|pressures|at (r_ccomp) have_37\VB\person.n.01|elevated|;|group|did|not|reduction|. (l_dobj) reduction_39\NN\change_of_magnitude.n.01|a|in (l_prep) in_40\IN\linear_unit.n.01|number (l_pobj) number_42\NN\amount.n.02|glomerular
D003907_D007674 CID dexamethasone_5\NN\anti-inflammatory.n.01|prenatal|in (r_nsubj) results_8\VBZ\phenomenon.n.01|that|dexamethasone|in (l_prep) in_9\IN\linear_unit.n.01|reduction (l_pobj) reduction_11\NN\change_of_magnitude.n.01|a|in (l_prep) in_12\IN\linear_unit.n.01|number (l_pobj) number_14\NN\amount.n.02|glomerular|,|glomerulosclerosis|administered
D003907_D005921 NONE dexamethasone_3\NN\anti-inflammatory.n.01| (r_dobj) given_2\VBN\assumption.n.02|rats|dexamethasone|on|had|. (l_advcl) had_11\VBD\have.v.01|glomeruli (l_dobj) glomeruli_13\NNS\capillary.n.02|more|with|than (l_prep) with_14\IN\entity.n.01|glomerulosclerosis (l_pobj) glomerulosclerosis_15\NN\entity.n.01|
D003907_D005921 NONE dexamethasone_5\NN\anti-inflammatory.n.01|prenatal|in (r_nsubj) results_8\VBZ\phenomenon.n.01|that|dexamethasone|in (l_prep) in_9\IN\linear_unit.n.01|reduction (l_pobj) reduction_11\NN\change_of_magnitude.n.01|a|in (l_prep) in_12\IN\linear_unit.n.01|number (l_pobj) number_14\NN\amount.n.02|glomerular|,|glomerulosclerosis|administered (l_conj) glomerulosclerosis_16\NN\entity.n.01|,|and|hypertension
17639754
D014859_D006470 CID warfarin_18\NN\anticoagulant.n.01|and|levofloxacin (r_pobj) between_17\IN\between.r.01|warfarin (r_prep) interaction_16\NN\action.n.01|the|between (r_pobj) of_14\IN\entity.n.01|interaction (r_prep) result_13\NN\phenomenon.n.01|the|of (r_attr) be_11\VB\metallic_element.n.01|to|result (r_xcomp) appear_9\VBP\be.v.01|that|be (r_relcl) complications_7\NNS\hindrance.n.03|serious|bleeding|appear (l_compound) bleeding_6\NN\injury.n.01|
D064704_D006470 CID levofloxacin_20\JJ\entity.n.01| (r_conj) warfarin_18\NN\anticoagulant.n.01|and|levofloxacin (r_pobj) between_17\IN\between.r.01|warfarin (r_prep) interaction_16\NN\action.n.01|the|between (r_pobj) of_14\IN\entity.n.01|interaction (r_prep) result_13\NN\phenomenon.n.01|the|of (r_attr) be_11\VB\metallic_element.n.01|to|result (r_xcomp) appear_9\VBP\be.v.01|that|be (r_relcl) complications_7\NNS\hindrance.n.03|serious|bleeding|appear (l_compound) bleeding_6\NN\injury.n.01|
2549018
D005473_D017109 CID fluoxetine_0\NNP\selective-serotonin_reuptake_inhibitor.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|fluoxetine|- (r_amod) akathisia_3\NN\entity.n.01|induced|:|implications|.
D005473_D017109 CID fluoxetine_3\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_dobj) receiving_2\VBG\get.v.01|fluoxetine|for (r_acl) patients_1\NNS\case.n.06|five|receiving (r_nsubj) developed_14\VBD\create.v.02|patients|akathisia|. (l_dobj) akathisia_15\NN\entity.n.01|
D005473_D017109 CID fluoxetine_2\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|fluoxetine|- (r_amod) symptoms_5\NNS\evidence.n.01|the|typical|induced|of (r_nsubj) were_23\VBD\be.v.01|symptoms|indistinguishable|. (l_acomp) indistinguishable_24\JJ\identical.s.01|from (l_prep) from_25\IN\entity.n.01|those (l_pobj) those_26\DT\entity.n.01|of (l_prep) of_27\IN\entity.n.01|akathisia (l_pobj) akathisia_31\NN\entity.n.01|induced
D005473_D017109 CID fluoxetine_17\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_advmod) induced_19\VBN\generate.v.01|fluoxetine|- (r_amod) akathisia_20\NN\entity.n.01|induced (r_pobj) of_16\IN\entity.n.01|akathisia (r_prep) symptoms_15\NNS\evidence.n.01|the|of (r_nsubj) were_21\VBD\be.v.01|that|symptoms|identical|,|milder (r_ccomp) reported_12\VBD\inform.v.01|patients|were|. (l_nsubj) patients_1\NNS\case.n.06|three|experienced (l_relcl) experienced_4\VBN\undergo.v.01|who|had|akathisia (l_dobj) akathisia_8\NN\entity.n.01|induced|in
D005473_D017109 CID fluoxetine_17\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_advmod) induced_19\VBN\generate.v.01|fluoxetine|- (r_amod) akathisia_20\NN\entity.n.01|induced
D005473_D017109 CID fluoxetine_9\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_pobj) of_8\IN\entity.n.01|fluoxetine (r_prep) effect_7\NN\phenomenon.n.01|a|common|side|of (r_attr) be_3\VB\metallic_element.n.01|to|effect (r_xcomp) appeared_1\VBD\be.v.01|akathisia|be|and|responded|. (l_nsubj) akathisia_0\NNP\entity.n.01|
D005473_D017109 CID fluoxetine_4\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_advmod) induced_6\VBN\generate.v.01|fluoxetine|- (r_amod) akathisia_7\NN\entity.n.01|induced
D005473_D017109 CID fluoxetine_4\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_advmod) induced_6\VBN\generate.v.01|fluoxetine|- (r_amod) akathisia_7\NN\entity.n.01|induced (r_nsubjpass) caused_10\VBN\make.v.03|that|akathisia|may|be|by|be (l_conj) be_36\VB\metallic_element.n.01|that|pathophysiology|"|may|identical (l_nsubj) pathophysiology_21\NN\entity.n.01|the|of (l_prep) of_22\IN\entity.n.01|akathisia (l_pobj) akathisia_26\NN\entity.n.01|induced|and|jitteriness
D005473_D017109 CID fluoxetine_23\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_advmod) induced_25\VBN\generate.v.01|fluoxetine|- (r_amod) akathisia_26\NN\entity.n.01|induced|and|jitteriness (r_pobj) of_22\IN\entity.n.01|akathisia (r_prep) pathophysiology_21\NN\entity.n.01|the|of (r_nsubj) be_36\VB\metallic_element.n.01|that|pathophysiology|"|may|identical (r_conj) caused_10\VBN\make.v.03|that|akathisia|may|be|by|be (l_nsubjpass) akathisia_7\NN\entity.n.01|induced
D005473_D017109 CID fluoxetine_23\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_advmod) induced_25\VBN\generate.v.01|fluoxetine|- (r_amod) akathisia_26\NN\entity.n.01|induced|and|jitteriness
D005473_D009771 NONE fluoxetine_3\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_dobj) receiving_2\VBG\get.v.01|fluoxetine|for (l_prep) for_4\IN\entity.n.01|treatment (l_pobj) treatment_6\NN\care.n.01|the|of (l_prep) of_7\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|obsessive|compulsive|or|depression
D005473_D003865 NONE fluoxetine_3\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_dobj) receiving_2\VBG\get.v.01|fluoxetine|for (l_prep) for_4\IN\entity.n.01|treatment (l_pobj) treatment_6\NN\care.n.01|the|of (l_prep) of_7\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|obsessive|compulsive|or|depression (l_conj) depression_13\NN\psychological_state.n.01|major
D005473_D001008 NONE fluoxetine_2\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|fluoxetine|- (r_amod) symptoms_5\NNS\evidence.n.01|the|typical|induced|of (l_prep) of_6\IN\entity.n.01|restlessness (l_pobj) restlessness_7\NN\mobility.n.01|,|pacing (l_conj) pacing_10\NN\musical_time.n.01|constant|,|movements (l_conj) movements_13\NNS\change.n.03|purposeless|of|,|and|anxiety (l_conj) anxiety_22\NN\psychological_state.n.01|marked
D011433_D017109 NONE propranolol_22\NN\entity.n.01| (r_acl) antagonist_21\NN\person.n.01|the|adrenergic|propranolol|,|reduction (r_pobj) with_16\IN\entity.n.01|antagonist (r_prep) treatment_15\NN\care.n.01|with (r_pobj) to_14\IN\entity.n.01|treatment (r_prep) responded_12\VBD\act.v.01|generally|well|to (r_conj) appeared_1\VBD\be.v.01|akathisia|be|and|responded|. (l_nsubj) akathisia_0\NNP\entity.n.01|
D000928_D017109 NONE antidepressant_29\NN\medicine.n.02| (r_npadvmod) induced_31\VBN\generate.v.01|antidepressant|- (r_amod) jitteriness_33\NN\anxiety.n.02|tricyclic|induced|" (r_conj) akathisia_26\NN\entity.n.01|induced|and|jitteriness (r_pobj) of_22\IN\entity.n.01|akathisia (r_prep) pathophysiology_21\NN\entity.n.01|the|of (r_nsubj) be_36\VB\metallic_element.n.01|that|pathophysiology|"|may|identical (r_conj) caused_10\VBN\make.v.03|that|akathisia|may|be|by|be (l_nsubjpass) akathisia_7\NN\entity.n.01|induced
D000928_D017109 NONE antidepressant_29\NN\medicine.n.02| (r_npadvmod) induced_31\VBN\generate.v.01|antidepressant|- (r_amod) jitteriness_33\NN\anxiety.n.02|tricyclic|induced|" (r_conj) akathisia_26\NN\entity.n.01|induced|and|jitteriness
6692345
D001241_D001749 NONE aspirin_5\NN\analgesic.n.01|with (r_pobj) of_4\IN\entity.n.01|aspirin (r_prep) administration_3\NN\management.n.01|the|-|of|to (r_nsubj) resulted_13\VBD\prove.v.01|administration|in|. (l_prep) in_14\IN\linear_unit.n.01|incidence (l_pobj) incidence_17\NN\frequency.n.02|a|reduced|of|but|induction (l_prep) of_18\IN\entity.n.01|carcinomas (l_pobj) carcinomas_23\NNS\cancer.n.01|induced|bladder
D001241_D013274 NONE aspirin_5\NN\analgesic.n.01|with (r_pobj) of_4\IN\entity.n.01|aspirin (r_prep) administration_3\NN\management.n.01|the|-|of|to (r_nsubj) resulted_13\VBD\prove.v.01|administration|in|. (l_prep) in_14\IN\linear_unit.n.01|incidence (l_pobj) incidence_17\NN\frequency.n.02|a|reduced|of|but|induction (l_conj) induction_27\NN\ceremony.n.01|a|concomitant|of (l_prep) of_28\IN\entity.n.01|tumors (l_pobj) tumors_30\NNS\growth.n.06|forestomach
D005200_D001749 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\entity.n.01|fanft (r_pobj) with_6\IN\entity.n.01|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\analgesic.n.01|with (r_pobj) of_4\IN\entity.n.01|aspirin (r_prep) administration_3\NN\management.n.01|the|-|of|to (r_nsubj) resulted_13\VBD\prove.v.01|administration|in|. (l_prep) in_14\IN\linear_unit.n.01|incidence (l_pobj) incidence_17\NN\frequency.n.02|a|reduced|of|but|induction (l_prep) of_18\IN\entity.n.01|carcinomas (l_pobj) carcinomas_23\NNS\cancer.n.01|induced|bladder
D005200_D001749 CID fanft_9\NNP\entity.n.01|(|) (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\entity.n.01|fanft (r_pobj) with_6\IN\entity.n.01|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\analgesic.n.01|with (r_pobj) of_4\IN\entity.n.01|aspirin (r_prep) administration_3\NN\management.n.01|the|-|of|to (r_nsubj) resulted_13\VBD\prove.v.01|administration|in|. (l_prep) in_14\IN\linear_unit.n.01|incidence (l_pobj) incidence_17\NN\frequency.n.02|a|reduced|of|but|induction (l_prep) of_18\IN\entity.n.01|carcinomas (l_pobj) carcinomas_23\NNS\cancer.n.01|induced|bladder
D005200_D001749 CID fanft_19\NNP\entity.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|fanft|- (r_amod) carcinomas_23\NNS\cancer.n.01|induced|bladder
D005200_D013274 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\entity.n.01|fanft (r_pobj) with_6\IN\entity.n.01|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\analgesic.n.01|with (r_pobj) of_4\IN\entity.n.01|aspirin (r_prep) administration_3\NN\management.n.01|the|-|of|to (r_nsubj) resulted_13\VBD\prove.v.01|administration|in|. (l_prep) in_14\IN\linear_unit.n.01|incidence (l_pobj) incidence_17\NN\frequency.n.02|a|reduced|of|but|induction (l_conj) induction_27\NN\ceremony.n.01|a|concomitant|of (l_prep) of_28\IN\entity.n.01|tumors (l_pobj) tumors_30\NNS\growth.n.06|forestomach
D005200_D013274 CID fanft_9\NNP\entity.n.01|(|) (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\entity.n.01|fanft (r_pobj) with_6\IN\entity.n.01|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_prep) aspirin_5\NN\analgesic.n.01|with (r_pobj) of_4\IN\entity.n.01|aspirin (r_prep) administration_3\NN\management.n.01|the|-|of|to (r_nsubj) resulted_13\VBD\prove.v.01|administration|in|. (l_prep) in_14\IN\linear_unit.n.01|incidence (l_pobj) incidence_17\NN\frequency.n.02|a|reduced|of|but|induction (l_conj) induction_27\NN\ceremony.n.01|a|concomitant|of (l_prep) of_28\IN\entity.n.01|tumors (l_pobj) tumors_30\NNS\growth.n.06|forestomach
D005200_D013274 CID fanft_19\NNP\entity.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|fanft|- (r_amod) carcinomas_23\NNS\cancer.n.01|induced|bladder (r_pobj) of_18\IN\entity.n.01|carcinomas (r_prep) incidence_17\NN\frequency.n.02|a|reduced|of|but|induction (l_conj) induction_27\NN\ceremony.n.01|a|concomitant|of (l_prep) of_28\IN\entity.n.01|tumors (l_pobj) tumors_30\NNS\growth.n.06|forestomach
D005200_D063646 NONE fanft_16\NNP\entity.n.01| (r_compound) carcinogenesis_17\NN\entity.n.01|fanft|in
D005200_D063646 NONE fanft_30\NNP\entity.n.01| (r_pobj) on_29\IN\on.a.01|fanft (r_prep) effect_28\NN\phenomenon.n.01|aspirin|on|in (r_nsubj) is_34\VBZ\be.v.01|that|effect|not|due (r_conj) involved_14\VBN\refer.v.02|that|mechanisms|are|in|,|and|is (l_prep) in_15\IN\linear_unit.n.01|carcinogenesis (l_pobj) carcinogenesis_17\NN\entity.n.01|fanft|in
D001241_D063646 NONE aspirin_26\NN\analgesic.n.01|'s (r_poss) effect_28\NN\phenomenon.n.01|aspirin|on|in (r_nsubj) is_34\VBZ\be.v.01|that|effect|not|due (r_conj) involved_14\VBN\refer.v.02|that|mechanisms|are|in|,|and|is (l_prep) in_15\IN\linear_unit.n.01|carcinogenesis (l_pobj) carcinogenesis_17\NN\entity.n.01|fanft|in
11431197
D011899_D009395 CID ranitidine_0\NNP\antacid.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|ranitidine|- (r_amod) nephritis_5\NN\kidney_disease.n.01|induced|acute|interstitial|in|.
D011899_D009395 CID ranitidine_5\NN\antacid.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|ranitidine|- (r_amod) nephritis_10\NN\kidney_disease.n.01|induced|acute|interstitial
18410508
D008694_D020258 NONE methamphetamine_0\NN\amphetamine.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|methamphetamine|- (r_amod) activation_6\NN\stimulation.n.03|induced|neurotoxicity (l_nmod) neurotoxicity_3\NN\entity.n.01|and|microglial
D008694_D020258 NONE meth_6\NNP\amphetamine.n.01|and|mptp (r_pobj) by_5\IN\by.r.01|meth (r_agent) caused_4\VBN\make.v.03|by (r_acl) damage_3\NN\change.n.01|the|cns|caused (r_nsubj) is_9\VBZ\be.v.01|because|damage|selective|for (l_prep) for_12\IN\entity.n.01|system (l_pobj) system_16\NN\instrumentality.n.03|the|da|neuronal|in (l_prep) in_17\IN\linear_unit.n.01|models (l_pobj) models_19\NNS\hypothesis.n.02|mouse|of (l_prep) of_20\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_21\NN\entity.n.01|
D008694_D020258 NONE meth_6\NNP\amphetamine.n.01|and|mptp (r_pobj) by_5\IN\by.r.01|meth (r_agent) caused_4\VBN\make.v.03|by (r_acl) damage_3\NN\change.n.01|the|cns|caused (r_nsubj) is_9\VBZ\be.v.01|because|damage|selective|for (r_advcl) hypothesized_24\VBD\expect.v.01|is|,|we|plays|. (l_ccomp) plays_28\VBZ\dramatic_composition.n.01|that|cx3cr1|role (l_dobj) role_30\NN\duty.n.02|a|in (l_prep) in_31\IN\linear_unit.n.01|neurotoxicity (l_pobj) neurotoxicity_35\NN\entity.n.01|induced|and|activation
D008694_D020258 NONE meth_32\NNP\amphetamine.n.01| (r_npadvmod) induced_34\VBN\generate.v.01|meth|- (r_amod) neurotoxicity_35\NN\entity.n.01|induced|and|activation (r_pobj) in_31\IN\linear_unit.n.01|neurotoxicity (r_prep) role_30\NN\duty.n.02|a|in (r_dobj) plays_28\VBZ\dramatic_composition.n.01|that|cx3cr1|role (r_ccomp) hypothesized_24\VBD\expect.v.01|is|,|we|plays|. (l_advcl) is_9\VBZ\be.v.01|because|damage|selective|for (l_prep) for_12\IN\entity.n.01|system (l_pobj) system_16\NN\instrumentality.n.03|the|da|neuronal|in (l_prep) in_17\IN\linear_unit.n.01|models (l_pobj) models_19\NNS\hypothesis.n.02|mouse|of (l_prep) of_20\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_21\NN\entity.n.01|
D008694_D020258 NONE meth_32\NNP\amphetamine.n.01| (r_npadvmod) induced_34\VBN\generate.v.01|meth|- (r_amod) neurotoxicity_35\NN\entity.n.01|induced|and|activation
D008694_D020258 NONE meth_25\NNP\amphetamine.n.01| (r_pobj) with_24\IN\entity.n.01|meth (r_prep) treated_23\VBN\interact.v.01|mice|were|with|and|examined|. (l_conj) examined_27\VBN\analyze.v.01|for (l_prep) for_28\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_30\NN\entity.n.01|striatal
D008694_D020258 NONE meth_11\NNP\amphetamine.n.01| (r_compound) neurotoxicity_12\NN\entity.n.01|meth|or|activation
D015632_D009422 CID mptp_17\NNP\entity.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|mptp|- (r_amod) neurodegeneration_20\NN\entity.n.01|induced|of
D015632_D009422 CID mptp_8\NNP\entity.n.01| (r_conj) meth_6\NNP\amphetamine.n.01|and|mptp (r_pobj) by_5\IN\by.r.01|meth (r_agent) caused_4\VBN\make.v.03|by (r_acl) damage_3\NN\change.n.01|the|cns|caused
D004298_D009422 NONE da_22\NNP\prosecutor.n.01| (r_compound) neurons_23\NNS\somatic_cell.n.01|da (r_pobj) of_21\IN\entity.n.01|neurons (r_prep) neurodegeneration_20\NN\entity.n.01|induced|of
D004298_D009422 NONE da_14\NNP\prosecutor.n.01| (r_compound) system_16\NN\instrumentality.n.03|the|da|neuronal|in (r_pobj) for_12\IN\entity.n.01|system (r_prep) is_9\VBZ\be.v.01|because|damage|selective|for (l_nsubj) damage_3\NN\change.n.01|the|cns|caused
D008694_D009422 CID meth_6\NNP\amphetamine.n.01|and|mptp (r_pobj) by_5\IN\by.r.01|meth (r_agent) caused_4\VBN\make.v.03|by (r_acl) damage_3\NN\change.n.01|the|cns|caused
D008694_D009422 CID meth_32\NNP\amphetamine.n.01| (r_npadvmod) induced_34\VBN\generate.v.01|meth|- (r_amod) neurotoxicity_35\NN\entity.n.01|induced|and|activation (r_pobj) in_31\IN\linear_unit.n.01|neurotoxicity (r_prep) role_30\NN\duty.n.02|a|in (r_dobj) plays_28\VBZ\dramatic_composition.n.01|that|cx3cr1|role (r_ccomp) hypothesized_24\VBD\expect.v.01|is|,|we|plays|. (l_advcl) is_9\VBZ\be.v.01|because|damage|selective|for (l_nsubj) damage_3\NN\change.n.01|the|cns|caused
D015632_D020258 NONE mptp_8\NNP\entity.n.01| (r_conj) meth_6\NNP\amphetamine.n.01|and|mptp (r_pobj) by_5\IN\by.r.01|meth (r_agent) caused_4\VBN\make.v.03|by (r_acl) damage_3\NN\change.n.01|the|cns|caused (r_nsubj) is_9\VBZ\be.v.01|because|damage|selective|for (l_prep) for_12\IN\entity.n.01|system (l_pobj) system_16\NN\instrumentality.n.03|the|da|neuronal|in (l_prep) in_17\IN\linear_unit.n.01|models (l_pobj) models_19\NNS\hypothesis.n.02|mouse|of (l_prep) of_20\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_21\NN\entity.n.01|
D015632_D020258 NONE mptp_8\NNP\entity.n.01| (r_conj) meth_6\NNP\amphetamine.n.01|and|mptp (r_pobj) by_5\IN\by.r.01|meth (r_agent) caused_4\VBN\make.v.03|by (r_acl) damage_3\NN\change.n.01|the|cns|caused (r_nsubj) is_9\VBZ\be.v.01|because|damage|selective|for (r_advcl) hypothesized_24\VBD\expect.v.01|is|,|we|plays|. (l_ccomp) plays_28\VBZ\dramatic_composition.n.01|that|cx3cr1|role (l_dobj) role_30\NN\duty.n.02|a|in (l_prep) in_31\IN\linear_unit.n.01|neurotoxicity (l_pobj) neurotoxicity_35\NN\entity.n.01|induced|and|activation
D004298_D020258 NONE da_14\NNP\prosecutor.n.01| (r_compound) system_16\NN\instrumentality.n.03|the|da|neuronal|in (l_prep) in_17\IN\linear_unit.n.01|models (l_pobj) models_19\NNS\hypothesis.n.02|mouse|of (l_prep) of_20\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_21\NN\entity.n.01|
D004298_D020258 NONE da_14\NNP\prosecutor.n.01| (r_compound) system_16\NN\instrumentality.n.03|the|da|neuronal|in (r_pobj) for_12\IN\entity.n.01|system (r_prep) is_9\VBZ\be.v.01|because|damage|selective|for (r_advcl) hypothesized_24\VBD\expect.v.01|is|,|we|plays|. (l_ccomp) plays_28\VBZ\dramatic_composition.n.01|that|cx3cr1|role (l_dobj) role_30\NN\duty.n.02|a|in (l_prep) in_31\IN\linear_unit.n.01|neurotoxicity (l_pobj) neurotoxicity_35\NN\entity.n.01|induced|and|activation
11379838
D000928_D001714 CID antidepressant_0\NNP\medicine.n.02| (r_npadvmod) induced_2\VBN\generate.v.01|antidepressant|- (r_amod) mania_3\NN\irrational_motive.n.01|induced|in|:|identification|.
D000928_D001714 CID antidepressant_0\NNP\medicine.n.02| (r_npadvmod) induced_2\VBN\generate.v.01|antidepressant|- (r_amod) mania_3\NN\irrational_motive.n.01|induced|in|:|identification|. (l_prep) in_4\IN\linear_unit.n.01|patients (l_pobj) patients_6\NNS\case.n.06|bipolar (l_amod) bipolar_5\JJ\bipolar.a.01|
D000928_D001714 CID antidepressants_10\NNS\medicine.n.02| (r_pobj) with_9\IN\entity.n.01|antidepressants (r_prep) associated_8\VBN\think.v.03|with (r_acl) mania_7\NN\irrational_motive.n.01|associated
D000928_D001714 CID antidepressants_10\NNS\medicine.n.02| (r_pobj) with_9\IN\entity.n.01|antidepressants (r_prep) associated_8\VBN\think.v.03|with (r_acl) mania_7\NN\irrational_motive.n.01|associated (r_pobj) to_6\IN\entity.n.01|mania (r_prep) switching_5\VBG\change.n.03|to (r_pcomp) of_4\IN\entity.n.01|switching (r_prep) risks_3\NNS\danger.n.03|possible|of (r_pobj) about_1\IN\about.s.01|risks (r_prep) concerns_0\NNS\interest.n.01|about (r_nsubj) continue_11\VBP\act.v.01|concerns|interfere|. (l_xcomp) interfere_13\VB\impede.v.01|to|with (l_prep) with_14\IN\entity.n.01|establishment (l_pobj) establishment_16\NN\beginning.n.05|the|of (l_prep) of_17\IN\entity.n.01|paradigm (l_pobj) paradigm_21\NN\inflection.n.01|an|optimal|treatment|for (l_prep) for_22\IN\entity.n.01|depression (l_pobj) depression_24\NN\psychological_state.n.01|bipolar
D000928_D001714 CID antidepressant_43\NN\medicine.n.02| (r_amod) therapy_44\NN\medical_care.n.01|antidepressant (r_pobj) of_42\IN\entity.n.01|therapy (r_prep) type_41\NN\kind.n.01|of (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic
D000928_D001714 CID antidepressant_43\NN\medicine.n.02| (r_amod) therapy_44\NN\medical_care.n.01|antidepressant (r_pobj) of_42\IN\entity.n.01|therapy (r_prep) type_41\NN\kind.n.01|of (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic (l_conj) hypomanic_6\JJ\entity.n.01|
D000928_D001714 CID antidepressant_43\NN\medicine.n.02| (r_amod) therapy_44\NN\medical_care.n.01|antidepressant (r_pobj) of_42\IN\entity.n.01|therapy (r_prep) type_41\NN\kind.n.01|of (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs.
D000928_D001714 CID antidepressant_43\NN\medicine.n.02| (r_amod) therapy_44\NN\medical_care.n.01|antidepressant (r_pobj) of_42\IN\entity.n.01|therapy (r_prep) type_41\NN\kind.n.01|of (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs. (l_prep) vs._30\IN\entity.n.01|ii (l_pobj) ii_32\NNP\digit.n.01|bipolar
D000928_D001714 CID antidepressant_43\NN\medicine.n.02| (r_amod) therapy_44\NN\medical_care.n.01|antidepressant (r_pobj) of_42\IN\entity.n.01|therapy (r_prep) type_41\NN\kind.n.01|of (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\frenzied.s.01|
D000928_D001714 CID antidepressant_50\NN\medicine.n.02| (r_amod) drugs_51\NNS\agent.n.03|antidepressant (r_pobj) vs._49\IN\entity.n.01|drugs (r_prep) therapy_48\NN\medical_care.n.01|electroconvulsive|vs.|and (r_dobj) used_45\VBN\use.v.01|therapy|, (r_acl) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic
D000928_D001714 CID antidepressant_50\NN\medicine.n.02| (r_amod) drugs_51\NNS\agent.n.03|antidepressant (r_pobj) vs._49\IN\entity.n.01|drugs (r_prep) therapy_48\NN\medical_care.n.01|electroconvulsive|vs.|and (r_dobj) used_45\VBN\use.v.01|therapy|, (r_acl) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic (l_conj) hypomanic_6\JJ\entity.n.01|
D000928_D001714 CID antidepressant_50\NN\medicine.n.02| (r_amod) drugs_51\NNS\agent.n.03|antidepressant (r_pobj) vs._49\IN\entity.n.01|drugs (r_prep) therapy_48\NN\medical_care.n.01|electroconvulsive|vs.|and (r_dobj) used_45\VBN\use.v.01|therapy|, (r_acl) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs.
D000928_D001714 CID antidepressant_50\NN\medicine.n.02| (r_amod) drugs_51\NNS\agent.n.03|antidepressant (r_pobj) vs._49\IN\entity.n.01|drugs (r_prep) therapy_48\NN\medical_care.n.01|electroconvulsive|vs.|and (r_dobj) used_45\VBN\use.v.01|therapy|, (r_acl) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs. (l_prep) vs._30\IN\entity.n.01|ii (l_pobj) ii_32\NNP\digit.n.01|bipolar
D000928_D001714 CID antidepressant_50\NN\medicine.n.02| (r_amod) drugs_51\NNS\agent.n.03|antidepressant (r_pobj) vs._49\IN\entity.n.01|drugs (r_prep) therapy_48\NN\medical_care.n.01|electroconvulsive|vs.|and (r_dobj) used_45\VBN\use.v.01|therapy|, (r_acl) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\frenzied.s.01|
D017367_D001714 CID inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic
D017367_D001714 CID inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic (l_conj) hypomanic_6\JJ\entity.n.01|
D017367_D001714 CID inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs.
D017367_D001714 CID inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs. (l_prep) vs._30\IN\entity.n.01|ii (l_pobj) ii_32\NNP\digit.n.01|bipolar
D017367_D001714 CID inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\frenzied.s.01|
D017367_D001714 CID ssris_62\NNPS\antidepressant.n.01|[|]|) (r_appos) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic
D017367_D001714 CID ssris_62\NNPS\antidepressant.n.01|[|]|) (r_appos) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic (l_conj) hypomanic_6\JJ\entity.n.01|
D017367_D001714 CID ssris_62\NNPS\antidepressant.n.01|[|]|) (r_appos) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs.
D017367_D001714 CID ssris_62\NNPS\antidepressant.n.01|[|]|) (r_appos) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs. (l_prep) vs._30\IN\entity.n.01|ii (l_pobj) ii_32\NNP\digit.n.01|bipolar
D017367_D001714 CID ssris_62\NNPS\antidepressant.n.01|[|]|) (r_appos) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\frenzied.s.01|
D017367_D001714 CID ssris_29\NNS\antidepressant.n.01|[|8/33|] (r_pobj) with_28\IN\entity.n.01|ssris (r_prep) treated_27\VBN\interact.v.01|with (r_acl) patients_26\NNS\case.n.06|treated (r_pobj) of_25\IN\entity.n.01|patients (r_prep) subgroup_24\NN\group.n.01|the|of (r_pobj) of_22\IN\entity.n.01|subgroup (r_prep) %_21\NN\entity.n.01|24|of (r_pobj) in_19\IN\linear_unit.n.01|%|) (r_prep) experienced_42\JJ\undergo.v.01|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS\case.n.06|all|experienced (r_pobj) of_9\IN\entity.n.01|patients (r_prep) %_8\NN\entity.n.01|27|of|and|% (r_pobj) in_6\IN\linear_unit.n.01|% (r_prep) occurred_5\VBD\happen.v.01|switches|in|episodes|. (l_nsubj) switches_0\NNS\control.n.09|to (l_prep) to_1\IN\entity.n.01|hypomania (l_pobj) hypomania_2\NN\entity.n.01|or|mania
D017367_D001714 CID ssris_29\NNS\antidepressant.n.01|[|8/33|] (r_pobj) with_28\IN\entity.n.01|ssris (r_prep) treated_27\VBN\interact.v.01|with (r_acl) patients_26\NNS\case.n.06|treated (r_pobj) of_25\IN\entity.n.01|patients (r_prep) subgroup_24\NN\group.n.01|the|of (r_pobj) of_22\IN\entity.n.01|subgroup (r_prep) %_21\NN\entity.n.01|24|of (r_pobj) in_19\IN\linear_unit.n.01|%|) (r_prep) experienced_42\JJ\undergo.v.01|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS\case.n.06|all|experienced (r_pobj) of_9\IN\entity.n.01|patients (r_prep) %_8\NN\entity.n.01|27|of|and|% (r_pobj) in_6\IN\linear_unit.n.01|% (r_prep) occurred_5\VBD\happen.v.01|switches|in|episodes|. (l_nsubj) switches_0\NNS\control.n.09|to (l_prep) to_1\IN\entity.n.01|hypomania (l_pobj) hypomania_2\NN\entity.n.01|or|mania (l_conj) mania_4\NN\irrational_motive.n.01|
D017367_D001714 CID ssris_29\NNS\antidepressant.n.01|[|8/33|] (r_pobj) with_28\IN\entity.n.01|ssris (r_prep) treated_27\VBN\interact.v.01|with (r_acl) patients_26\NNS\case.n.06|treated (r_pobj) of_25\IN\entity.n.01|patients (r_prep) subgroup_24\NN\group.n.01|the|of (r_pobj) of_22\IN\entity.n.01|subgroup (r_prep) %_21\NN\entity.n.01|24|of (r_pobj) in_19\IN\linear_unit.n.01|%|) (r_prep) experienced_42\JJ\undergo.v.01|(|(|and|in|;|%|episodes|, (l_dobj) episodes_44\NNS\happening.n.01|manic (l_amod) manic_43\JJ\frenzied.s.01|
D017367_D001714 CID ssris_29\NNS\antidepressant.n.01|[|8/33|] (r_pobj) with_28\IN\entity.n.01|ssris (r_prep) treated_27\VBN\interact.v.01|with (r_acl) patients_26\NNS\case.n.06|treated (r_pobj) of_25\IN\entity.n.01|patients (r_prep) subgroup_24\NN\group.n.01|the|of (r_pobj) of_22\IN\entity.n.01|subgroup (r_prep) %_21\NN\entity.n.01|24|of (r_pobj) in_19\IN\linear_unit.n.01|%|) (r_prep) experienced_42\JJ\undergo.v.01|(|(|and|in|;|%|episodes|, (r_parataxis) patients_11\NNS\case.n.06|all|experienced (r_pobj) of_9\IN\entity.n.01|patients (r_prep) %_8\NN\entity.n.01|27|of|and|% (r_pobj) in_6\IN\linear_unit.n.01|% (r_prep) occurred_5\VBD\happen.v.01|switches|in|episodes|. (l_npadvmod) episodes_56\NNS\happening.n.01|experienced|hypomanic (l_amod) hypomanic_55\JJ\entity.n.01|
D008094_D001714 NONE lithium_73\NN\metallic_element.n.01|vs. (r_appos) stabilizers_71\NNS\chemical.n.01|mood|(|lithium|) (r_pobj) of_69\IN\entity.n.01|stabilizers (r_prep) type_68\NN\kind.n.01|of (r_conj) use_66\NN\activity.n.01|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic
D008094_D001714 NONE lithium_73\NN\metallic_element.n.01|vs. (r_appos) stabilizers_71\NNS\chemical.n.01|mood|(|lithium|) (r_pobj) of_69\IN\entity.n.01|stabilizers (r_prep) type_68\NN\kind.n.01|of (r_conj) use_66\NN\activity.n.01|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (r_pobj) with_10\IN\entity.n.01|those (r_prep) compared_9\VBN\analyze.v.01|patients|were|with|. (l_nsubjpass) patients_0\NNS\case.n.06|experienced (l_relcl) experienced_2\VBD\undergo.v.01|who|switch (l_dobj) switch_7\NN\control.n.09|a|manic (l_amod) manic_4\JJ\frenzied.s.01|or|hypomanic (l_conj) hypomanic_6\JJ\entity.n.01|
D008094_D001714 NONE lithium_73\NN\metallic_element.n.01|vs. (r_appos) stabilizers_71\NNS\chemical.n.01|mood|(|lithium|) (r_pobj) of_69\IN\entity.n.01|stabilizers (r_prep) type_68\NN\kind.n.01|of (r_conj) use_66\NN\activity.n.01|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs.
D008094_D001714 NONE lithium_73\NN\metallic_element.n.01|vs. (r_appos) stabilizers_71\NNS\chemical.n.01|mood|(|lithium|) (r_pobj) of_69\IN\entity.n.01|stabilizers (r_prep) type_68\NN\kind.n.01|of (r_conj) use_66\NN\activity.n.01|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (r_pobj) of_36\IN\entity.n.01|episodes (r_prep) number_35\NN\amount.n.02|of (r_appos) those_11\DT\entity.n.01|did|,|number (l_relcl) did_13\VBD\make.v.01|who|not|on (l_prep) on_15\IN\on.a.01|variables (l_pobj) variables_17\NNS\thing.n.12|several|including (l_prep) including_18\VBG\include.v.01|age (l_pobj) age_19\NN\property.n.02|,|sex (l_conj) sex_21\NN\bodily_process.n.01|,|diagnosis (l_conj) diagnosis_23\NN\designation.n.03|iv (l_appos) iv_27\NNP\digit.n.01|(|dsm|-|bipolar|i|) (l_appos) i_29\PRP\chemical_element.n.01|vs. (l_prep) vs._30\IN\entity.n.01|ii (l_pobj) ii_32\NNP\digit.n.01|bipolar
D008094_D001714 NONE lithium_73\NN\metallic_element.n.01|vs. (r_appos) stabilizers_71\NNS\chemical.n.01|mood|(|lithium|) (r_pobj) of_69\IN\entity.n.01|stabilizers (r_prep) type_68\NN\kind.n.01|of (r_conj) use_66\NN\activity.n.01|and|type|,|and|temperament (r_conj) inhibitors_60\NNS\substance.n.07|particularly|,|selective|serotonin|reuptake|ssris|,|use|, (r_appos) episodes_39\NNS\happening.n.01|previous|manic|,|type|used|inhibitors|assessed (l_amod) manic_38\JJ\frenzied.s.01|
6534871
D007545_D009203 CID isoproterenol_8\NN\medicine.n.02| (r_npadvmod) induced_10\VBN\generate.v.01|isoproterenol|- (r_amod) infarction_12\NN\pathology.n.02|induced|myocardial
19957053
D010656_D002534 CID phenylephrine_0\NNP\adrenergic.n.01|but|ephedrine (r_nsubj) reduces_4\VBZ\decrease.v.02|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\natural_process.n.01|frontal|lobe|following
D010656_D007022 NONE phenylephrine_0\NNP\adrenergic.n.01|but|ephedrine (r_nsubj) reduces_4\VBZ\decrease.v.02|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\natural_process.n.01|frontal|lobe|following (l_prep) following_8\VBG\multitude.n.03|hypotension (l_dobj) hypotension_12\NN\cardiovascular_disease.n.01|induced
D010656_D007022 NONE phenylephrine_5\NN\adrenergic.n.01|and|ephedrine (r_pobj) of_4\IN\entity.n.01|phenylephrine (r_prep) effect_3\NN\phenomenon.n.01|the|of|on (r_dobj) describe_1\VBP\set_forth.v.01|we|effect|following|. (l_prep) following_16\VBG\multitude.n.03|hypotension (l_dobj) hypotension_20\NN\cardiovascular_disease.n.01|induced
D010656_D007022 NONE phenylephrine_3\NN\adrenergic.n.01| (r_pobj) of_2\IN\entity.n.01|phenylephrine (r_prep) utilization_1\NN\activity.n.01|the|of|correct (l_acl) correct_5\VB\change_by_reversal.v.01|to|hypotension (l_dobj) hypotension_6\NN\cardiovascular_disease.n.01|induced
D004809_D002534 NONE ephedrine_3\JJ\alkaloid.n.01|not (r_conj) phenylephrine_0\NNP\adrenergic.n.01|but|ephedrine (r_nsubj) reduces_4\VBZ\decrease.v.02|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\natural_process.n.01|frontal|lobe|following
D004809_D007022 NONE ephedrine_3\JJ\alkaloid.n.01|not (r_conj) phenylephrine_0\NNP\adrenergic.n.01|but|ephedrine (r_nsubj) reduces_4\VBZ\decrease.v.02|phenylephrine|oxygenation|. (l_dobj) oxygenation_7\NN\natural_process.n.01|frontal|lobe|following (l_prep) following_8\VBG\multitude.n.03|hypotension (l_dobj) hypotension_12\NN\cardiovascular_disease.n.01|induced
D004809_D007022 NONE ephedrine_7\JJ\alkaloid.n.01| (r_conj) phenylephrine_5\NN\adrenergic.n.01|and|ephedrine (r_pobj) of_4\IN\entity.n.01|phenylephrine (r_prep) effect_3\NN\phenomenon.n.01|the|of|on (r_dobj) describe_1\VBP\set_forth.v.01|we|effect|following|. (l_prep) following_16\VBG\multitude.n.03|hypotension (l_dobj) hypotension_20\NN\cardiovascular_disease.n.01|induced
D004809_D007022 NONE ephedrine_18\JJ\alkaloid.n.01| (r_nsubj) maintains_19\VBZ\keep.v.01|while|ephedrine|oxygenation (r_advcl) has_10\VBZ\angular_distance.n.01|utilization|impact|)|maintains|. (l_nsubj) utilization_1\NN\activity.n.01|the|of|correct (l_acl) correct_5\VB\change_by_reversal.v.01|to|hypotension (l_dobj) hypotension_6\NN\cardiovascular_disease.n.01|induced
18631865
D020123_D051436 NONE rapamycin_16\NNS\entity.n.01| (r_nmod) inhibitors_20\NNS\substance.n.07|rapamycin|mtor|,|sirolimus|, (r_pobj) of_15\IN\entity.n.01|inhibitors (r_prep) target_14\NN\reference_point.n.01|mammalian|of (r_pobj) to_12\IN\entity.n.01|target (r_prep) conversion_8\NN\transformation.n.01|from|to|in (l_prep) in_25\IN\linear_unit.n.01|recipients (l_pobj) recipients_28\NNS\acquirer.n.01|renal|transplant|with (l_prep) with_29\IN\entity.n.01|nephropathy (l_pobj) nephropathy_32\NN\uropathy.n.01|chronic|allograft
D020123_D051436 NONE sirolimus_23\NN\entity.n.01|especially (r_appos) inhibitors_20\NNS\substance.n.07|rapamycin|mtor|,|sirolimus|, (r_pobj) of_15\IN\entity.n.01|inhibitors (r_prep) target_14\NN\reference_point.n.01|mammalian|of (r_pobj) to_12\IN\entity.n.01|target (r_prep) conversion_8\NN\transformation.n.01|from|to|in (l_prep) in_25\IN\linear_unit.n.01|recipients (l_pobj) recipients_28\NNS\acquirer.n.01|renal|transplant|with (l_prep) with_29\IN\entity.n.01|nephropathy (l_pobj) nephropathy_32\NN\uropathy.n.01|chronic|allograft
D020123_D011507 CID sirolimus_5\NN\entity.n.01|or|consequence (r_pobj) to_4\IN\entity.n.01|sirolimus (r_prep) due_3\JJ\right.n.01|to (r_acomp) was_2\VBD\washington.n.02|whether|proteinuria|due (l_nsubj) proteinuria_1\NN\symptom.n.01|
D020123_D011507 CID sirolimus_5\NN\entity.n.01|or|consequence (r_pobj) to_4\IN\entity.n.01|sirolimus (r_prep) due_3\JJ\right.n.01|to (r_acomp) was_2\VBD\washington.n.02|whether|proteinuria|due (r_csubj) remained_14\VBD\be.v.01|was|unsolved|observed|. (l_advcl) observed_22\VBN\spy.v.03|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN\symptom.n.01|range
D020123_D011507 CID sirolimus_24\NN\entity.n.01| (r_compound) therapy_25\NN\medical_care.n.01|sirolimus (r_pobj) during_23\IN\entity.n.01|therapy (r_prep) observed_22\VBN\spy.v.03|until|proteinuria|has|been|during|in (r_advcl) remained_14\VBD\be.v.01|was|unsolved|observed|. (l_csubj) was_2\VBD\washington.n.02|whether|proteinuria|due (l_nsubj) proteinuria_1\NN\symptom.n.01|
D020123_D011507 CID sirolimus_24\NN\entity.n.01| (r_compound) therapy_25\NN\medical_care.n.01|sirolimus (r_pobj) during_23\IN\entity.n.01|therapy (r_prep) observed_22\VBN\spy.v.03|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN\symptom.n.01|range
D020123_D011507 CID sirolimus_34\NN\entity.n.01| (r_nmod) novo_36\NNP\entity.n.01|sirolimus|de (r_dobj) received_33\VBD\get.v.01|who|novo (r_relcl) patients_31\NNS\case.n.06|received (r_pobj) in_30\IN\linear_unit.n.01|patients (r_conj) in_26\IN\linear_unit.n.01|transplantation|and|in (r_prep) observed_22\VBN\spy.v.03|until|proteinuria|has|been|during|in (r_advcl) remained_14\VBD\be.v.01|was|unsolved|observed|. (l_csubj) was_2\VBD\washington.n.02|whether|proteinuria|due (l_nsubj) proteinuria_1\NN\symptom.n.01|
D020123_D011507 CID sirolimus_34\NN\entity.n.01| (r_nmod) novo_36\NNP\entity.n.01|sirolimus|de (r_dobj) received_33\VBD\get.v.01|who|novo (r_relcl) patients_31\NNS\case.n.06|received (r_pobj) in_30\IN\linear_unit.n.01|patients (r_conj) in_26\IN\linear_unit.n.01|transplantation|and|in (r_prep) observed_22\VBN\spy.v.03|until|proteinuria|has|been|during|in (l_nsubjpass) proteinuria_19\NN\symptom.n.01|range
7088431
D004054_D018262 CID des_6\NNP\estrogen.n.01| (r_npadvmod) exposed_8\VBN\subject.v.01|des|- (r_amod) offspring_9\NN\relative.n.01|exposed|under (r_pobj) in_5\IN\linear_unit.n.01|offspring (r_prep) development_0\NN\improvement.n.02|of|in|. (l_prep) of_1\IN\entity.n.01|adenocarcinoma (l_pobj) adenocarcinoma_4\NN\carcinoma.n.01|clear|cell
D004054_D018262 CID diethylstilbestrol_21\NN\estrogen.n.01| (r_pobj) to_20\IN\entity.n.01|diethylstilbestrol (r_prep) exposed_17\VBN\subject.v.01|in|to (r_acl) women_16\NNS\adult.n.01|young|exposed (r_pobj) in_14\IN\linear_unit.n.01|women (r_prep) up_13\NN\increase.v.02|follow|-|in (r_pobj) at_10\IN\chemical_element.n.01|up (r_prep) detected_9\VBD\spy.v.03|cases|at (l_nsubj) cases_1\NNS\happening.n.01|two|of (l_prep) of_2\IN\entity.n.01|adenocarcinoma (l_pobj) adenocarcinoma_5\NN\carcinoma.n.01|clear|cell|of (l_prep) of_6\IN\entity.n.01|vagina (l_pobj) vagina_8\NN\duct.n.01|the
D004054_D014625 CID diethylstilbestrol_21\NN\estrogen.n.01| (r_pobj) to_20\IN\entity.n.01|diethylstilbestrol (r_prep) exposed_17\VBN\subject.v.01|in|to (r_acl) women_16\NNS\adult.n.01|young|exposed (r_pobj) in_14\IN\linear_unit.n.01|women (r_prep) up_13\NN\increase.v.02|follow|-|in (r_pobj) at_10\IN\chemical_element.n.01|up (r_prep) detected_9\VBD\spy.v.03|cases|at (l_nsubj) cases_1\NNS\happening.n.01|two|of (l_prep) of_2\IN\entity.n.01|adenocarcinoma (l_pobj) adenocarcinoma_5\NN\carcinoma.n.01|clear|cell|of (l_prep) of_6\IN\entity.n.01|vagina (l_pobj) vagina_8\NN\duct.n.01|the
16160878
D014579_D006973 NONE ii_8\NNP\digit.n.01|u|- (r_pobj) of_5\IN\entity.n.01|ii (r_prep) injection_4\NN\insertion.n.02|of (r_nsubj) causes_9\NNS\origin.n.03|intracerebroventricular|injection|hypertension|and|stimulates|. (l_dobj) hypertension_10\NN\cardiovascular_disease.n.01|and|bradycardia
D014579_D001919 NONE ii_8\NNP\digit.n.01|u|- (r_pobj) of_5\IN\entity.n.01|ii (r_prep) injection_4\NN\insertion.n.02|of (r_nsubj) causes_9\NNS\origin.n.03|intracerebroventricular|injection|hypertension|and|stimulates|. (l_dobj) hypertension_10\NN\cardiovascular_disease.n.01|and|bradycardia (l_conj) bradycardia_12\NN\cardiac_arrhythmia.n.01|
D014579_D010409 NONE ii_11\NNP\digit.n.01|u|- (r_pobj) of_8\IN\entity.n.01|ii (r_prep) administration_7\NN\management.n.01|the|central|of (r_nsubj) had_12\VBD\have.v.01|was|,|administration|effect|erection|,|and|level|. (l_dobj) erection_25\NN\sexual_arousal.n.01|induced|penile|and|behavior
D001058_D010409 CID apomorphine_21\NN\morphine.n.01| (r_npadvmod) induced_23\VBN\generate.v.01|apomorphine|- (r_amod) erection_25\NN\sexual_arousal.n.01|induced|penile|and|behavior
D003345_D010409 NONE corticosterone_35\NN\glucocorticoid.n.01|plasma (r_compound) level_36\NN\property.n.02|induced|corticosterone (r_conj) had_12\VBD\have.v.01|was|,|administration|effect|erection|,|and|level|. (l_dobj) erection_25\NN\sexual_arousal.n.01|induced|penile|and|behavior
D014579_D001523 NONE ii_6\NNP\digit.n.01|u|- (r_nsubjpass) involved_9\VBN\refer.v.02|that|ii|may|be|in (l_prep) in_10\IN\linear_unit.n.01|aspects (l_pobj) aspects_12\NNS\feature.n.01|some|of (l_prep) of_13\IN\entity.n.01|disorders (l_pobj) disorders_15\NNS\physical_condition.n.01|psychiatric
16298782
D019331_D006311 NONE ester_6\NN\organic_compound.n.01|arginine|methyl|:|protector|. (l_appos) protector_10\NN\preserver.n.03|a|potential|against (l_prep) against_11\IN\entity.n.01|ototoxicity (l_pobj) ototoxicity_13\NN\entity.n.01|gentamicin
D005839_D006311 NONE gentamicin_12\NN\antibiotic.n.01| (r_compound) ototoxicity_13\NN\entity.n.01|gentamicin
D009569_D006316 NONE oxide_2\NN\compound.n.02|the|nitric|(|ester (r_nsubj) act_20\VB\legal_document.n.01|oxide|may|as|,|but|needed (l_prep) as_21\IN\chemical_element.n.01|otoprotectant (l_pobj) otoprotectant_23\NN\entity.n.01|an|against (l_prep) against_24\IN\entity.n.01|loss (l_pobj) loss_29\NN\transferred_property.n.01|frequency|hearing|caused
D009569_D006316 NONE no_4\NNP\negative.n.01| (r_intj) ester_13\NN\organic_compound.n.01|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN\compound.n.02|the|nitric|(|ester (r_nsubj) act_20\VB\legal_document.n.01|oxide|may|as|,|but|needed (l_prep) as_21\IN\chemical_element.n.01|otoprotectant (l_pobj) otoprotectant_23\NN\entity.n.01|an|against (l_prep) against_24\IN\entity.n.01|loss (l_pobj) loss_29\NN\transferred_property.n.01|frequency|hearing|caused
D019331_D006316 NONE ester_13\NN\organic_compound.n.01|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN\compound.n.02|the|nitric|(|ester (r_nsubj) act_20\VB\legal_document.n.01|oxide|may|as|,|but|needed (l_prep) as_21\IN\chemical_element.n.01|otoprotectant (l_pobj) otoprotectant_23\NN\entity.n.01|an|against (l_prep) against_24\IN\entity.n.01|loss (l_pobj) loss_29\NN\transferred_property.n.01|frequency|hearing|caused
D019331_D006316 NONE name_17\NN\language_unit.n.01|l|- (r_appos) ester_13\NN\organic_compound.n.01|no|inhibitor|arginine|methyl|(|name|) (r_appos) oxide_2\NN\compound.n.02|the|nitric|(|ester (r_nsubj) act_20\VB\legal_document.n.01|oxide|may|as|,|but|needed (l_prep) as_21\IN\chemical_element.n.01|otoprotectant (l_pobj) otoprotectant_23\NN\entity.n.01|an|against (l_prep) against_24\IN\entity.n.01|loss (l_pobj) loss_29\NN\transferred_property.n.01|frequency|hearing|caused
D005839_D006316 NONE gentamicin_32\NN\antibiotic.n.01| (r_pobj) by_31\IN\by.r.01|gentamicin (r_agent) caused_30\VBN\make.v.03|by (r_acl) loss_29\NN\transferred_property.n.01|frequency|hearing|caused
D009569_D006311 NONE no_17\DT\negative.n.01| (r_pobj) of_16\IN\entity.n.01|no (r_prep) production_15\NN\act.n.02|the|of (r_dobj) involves_13\VBZ\refer.v.02|as|mechanism|production (r_conj) is_2\VBZ\be.v.01|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN\entity.n.01|their
D009569_D006311 NONE no_17\DT\negative.n.01| (r_pobj) of_16\IN\entity.n.01|no (r_prep) production_15\NN\act.n.02|the|of (r_dobj) involves_13\VBZ\refer.v.02|as|mechanism|production (l_nsubj) mechanism_12\NN\chemical_process.n.01|their|ototoxic (l_compound) ototoxic_11\JJ\ototoxic.s.01|
D009569_D006311 NONE no_26\DT\negative.n.01| (r_det) inhibitors_27\NNS\substance.n.07|no (r_pobj) of_25\IN\entity.n.01|inhibitors (r_prep) use_24\NN\activity.n.01|the|of|for (r_dobj) assess_22\VB\body_part.n.01|to|use (r_xcomp) need_20\VBP\condition.n.01|is|,|we|assess|. (l_ccomp) is_2\VBZ\be.v.01|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN\entity.n.01|their
D009569_D006311 NONE no_26\DT\negative.n.01| (r_det) inhibitors_27\NNS\substance.n.07|no (r_pobj) of_25\IN\entity.n.01|inhibitors (r_prep) use_24\NN\activity.n.01|the|of|for (r_dobj) assess_22\VB\body_part.n.01|to|use (r_xcomp) need_20\VBP\condition.n.01|is|,|we|assess|. (l_ccomp) is_2\VBZ\be.v.01|ototoxicity|problem|and|,|involves (l_conj) involves_13\VBZ\refer.v.02|as|mechanism|production (l_nsubj) mechanism_12\NN\chemical_process.n.01|their|ototoxic (l_compound) ototoxic_11\JJ\ototoxic.s.01|
D009569_D006319 NONE no_17\DT\negative.n.01| (r_pobj) of_16\IN\entity.n.01|no (r_prep) production_15\NN\act.n.02|the|of (r_dobj) involves_13\VBZ\refer.v.02|as|mechanism|production (r_conj) is_2\VBZ\be.v.01|ototoxicity|problem|and|,|involves (r_ccomp) need_20\VBP\condition.n.01|is|,|we|assess|. (l_xcomp) assess_22\VB\body_part.n.01|to|use (l_dobj) use_24\NN\activity.n.01|the|of|for (l_prep) for_28\IN\entity.n.01|prevention (l_pobj) prevention_30\NN\hindrance.n.03|the|of (l_prep) of_31\IN\entity.n.01|loss (l_pobj) loss_37\NN\transferred_property.n.01|induced|hearing
D009569_D006319 NONE no_26\DT\negative.n.01| (r_det) inhibitors_27\NNS\substance.n.07|no (r_pobj) of_25\IN\entity.n.01|inhibitors (r_prep) use_24\NN\activity.n.01|the|of|for (l_prep) for_28\IN\entity.n.01|prevention (l_pobj) prevention_30\NN\hindrance.n.03|the|of (l_prep) of_31\IN\entity.n.01|loss (l_pobj) loss_37\NN\transferred_property.n.01|induced|hearing
D000617_D006311 NONE aminoglycoside_32\NN\entity.n.01| (r_npadvmod) induced_34\VBN\generate.v.01|aminoglycoside|- (r_amod) loss_37\NN\transferred_property.n.01|induced|hearing (r_pobj) of_31\IN\entity.n.01|loss (r_prep) prevention_30\NN\hindrance.n.03|the|of (r_pobj) for_28\IN\entity.n.01|prevention (r_prep) use_24\NN\activity.n.01|the|of|for (r_dobj) assess_22\VB\body_part.n.01|to|use (r_xcomp) need_20\VBP\condition.n.01|is|,|we|assess|. (l_ccomp) is_2\VBZ\be.v.01|ototoxicity|problem|and|,|involves (l_nsubj) ototoxicity_1\NN\entity.n.01|their
D000617_D006311 NONE aminoglycoside_32\NN\entity.n.01| (r_npadvmod) induced_34\VBN\generate.v.01|aminoglycoside|- (r_amod) loss_37\NN\transferred_property.n.01|induced|hearing (r_pobj) of_31\IN\entity.n.01|loss (r_prep) prevention_30\NN\hindrance.n.03|the|of (r_pobj) for_28\IN\entity.n.01|prevention (r_prep) use_24\NN\activity.n.01|the|of|for (r_dobj) assess_22\VB\body_part.n.01|to|use (r_xcomp) need_20\VBP\condition.n.01|is|,|we|assess|. (l_ccomp) is_2\VBZ\be.v.01|ototoxicity|problem|and|,|involves (l_conj) involves_13\VBZ\refer.v.02|as|mechanism|production (l_nsubj) mechanism_12\NN\chemical_process.n.01|their|ototoxic (l_compound) ototoxic_11\JJ\ototoxic.s.01|
D000617_D006319 NONE aminoglycoside_32\NN\entity.n.01| (r_npadvmod) induced_34\VBN\generate.v.01|aminoglycoside|- (r_amod) loss_37\NN\transferred_property.n.01|induced|hearing
D019331_D034381 NONE name_2\NN\language_unit.n.01|l|- (r_nsubj) reduced_3\VBN\decrease.v.02|name|loss|in|,|but|gave|. (l_dobj) loss_8\NN\transferred_property.n.01|induced|hearing
D005839_D034381 CID gentamicin_4\NN\antibiotic.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|gentamicin|- (r_amod) loss_8\NN\transferred_property.n.01|induced|hearing
16680561
D003891_D009325 CID desipramine_8\NN\tricyclic.n.01| (r_pobj) with_7\IN\entity.n.01|desipramine (r_prep) treatment_6\NN\care.n.01|with (r_dobj) following_5\VBG\multitude.n.03|treatment (r_acl) events_4\NNS\psychological_feature.n.01|adverse|following|alone (r_dobj) reported_2\VBD\inform.v.01|subjects|events (r_ccomp) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|)
D003891_D009325 CID desipramine_13\NN\tricyclic.n.01| (r_dobj) receiving_12\VBG\get.v.01|when|desipramine|with|% (r_pcomp) than_10\IN\entity.n.01|receiving (r_prep) alone_9\RB\alone.s.01|than (r_amod) events_4\NNS\psychological_feature.n.01|adverse|following|alone (r_dobj) reported_2\VBD\inform.v.01|subjects|events (r_ccomp) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|)
D003891_D009325 CID desipramine_41\NN\tricyclic.n.01|either|or|cinacalcet (r_pobj) with_39\IN\entity.n.01|desipramine (r_prep) treated_38\VBN\interact.v.01|with (r_acl) patients_37\NNS\case.n.06|treated (r_pobj) for_36\IN\entity.n.01|patients (r_prep) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|)
D003891_D006261 CID desipramine_8\NN\tricyclic.n.01| (r_pobj) with_7\IN\entity.n.01|desipramine (r_prep) treatment_6\NN\care.n.01|with (r_dobj) following_5\VBG\multitude.n.03|treatment (r_acl) events_4\NNS\psychological_feature.n.01|adverse|following|alone (r_dobj) reported_2\VBD\inform.v.01|subjects|events (r_ccomp) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|) (l_conj) headache_31\NN\negative_stimulus.n.01|
D003891_D006261 CID desipramine_13\NN\tricyclic.n.01| (r_dobj) receiving_12\VBG\get.v.01|when|desipramine|with|% (r_pcomp) than_10\IN\entity.n.01|receiving (r_prep) alone_9\RB\alone.s.01|than (r_amod) events_4\NNS\psychological_feature.n.01|adverse|following|alone (r_dobj) reported_2\VBD\inform.v.01|subjects|events (r_ccomp) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|) (l_conj) headache_31\NN\negative_stimulus.n.01|
D003891_D006261 CID desipramine_41\NN\tricyclic.n.01|either|or|cinacalcet (r_pobj) with_39\IN\entity.n.01|desipramine (r_prep) treated_38\VBN\interact.v.01|with (r_acl) patients_37\NNS\case.n.06|treated (r_pobj) for_36\IN\entity.n.01|patients (r_prep) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|) (l_conj) headache_31\NN\negative_stimulus.n.01|
C476217_D009325 CID cinacalcet_15\NN\entity.n.01| (r_pobj) with_14\IN\entity.n.01|cinacalcet (r_prep) receiving_12\VBG\get.v.01|when|desipramine|with|% (r_pcomp) than_10\IN\entity.n.01|receiving (r_prep) alone_9\RB\alone.s.01|than (r_amod) events_4\NNS\psychological_feature.n.01|adverse|following|alone (r_dobj) reported_2\VBD\inform.v.01|subjects|events (r_ccomp) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|)
C476217_D009325 CID cinacalcet_43\NN\entity.n.01| (r_conj) desipramine_41\NN\tricyclic.n.01|either|or|cinacalcet (r_pobj) with_39\IN\entity.n.01|desipramine (r_prep) treated_38\VBN\interact.v.01|with (r_acl) patients_37\NNS\case.n.06|treated (r_pobj) for_36\IN\entity.n.01|patients (r_prep) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|)
C476217_D006261 CID cinacalcet_15\NN\entity.n.01| (r_pobj) with_14\IN\entity.n.01|cinacalcet (r_prep) receiving_12\VBG\get.v.01|when|desipramine|with|% (r_pcomp) than_10\IN\entity.n.01|receiving (r_prep) alone_9\RB\alone.s.01|than (r_amod) events_4\NNS\psychological_feature.n.01|adverse|following|alone (r_dobj) reported_2\VBD\inform.v.01|subjects|events (r_ccomp) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|) (l_conj) headache_31\NN\negative_stimulus.n.01|
C476217_D006261 CID cinacalcet_43\NN\entity.n.01| (r_conj) desipramine_41\NN\tricyclic.n.01|either|or|cinacalcet (r_pobj) with_39\IN\entity.n.01|desipramine (r_prep) treated_38\VBN\interact.v.01|with (r_acl) patients_37\NNS\case.n.06|treated (r_pobj) for_36\IN\entity.n.01|patients (r_prep) reported_35\VBN\inform.v.01|reported|,|frequent|nausea|have|been|for|. (l_nsubjpass) nausea_29\NN\symptom.n.01|(|and|headache|) (l_conj) headache_31\NN\negative_stimulus.n.01|
435349
D013390_D005207 CID suxamethonium_0\JJ\entity.n.01| (r_compound) rate_2\NN\magnitude_relation.n.01|suxamethonium|infusion|and|observed|. (l_conj) observed_4\JJ\spy.v.03|fasciculations (l_dobj) fasciculations_5\NNS\twitch.n.01|
D013390_D013746 NONE sch_20\NNP\entity.n.01| (r_nsubjpass) exceeded_24\VBN\exceed.v.01|when|sch|mg|was (r_advcl) was_7\VBD\washington.n.02|either|when|there|response|exceeded (l_attr) response_10\NN\consequence.n.01|no|muscular|to (l_prep) to_11\IN\entity.n.01|stimulation (l_pobj) stimulation_13\NN\arousal.n.01|tetanic|of|or (l_compound) tetanic_12\JJ\tetanic.a.01|
16181582
D014635_D001927 CID valproate_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|valproate|- (r_amod) encephalopathy_3\NN\nervous_disorder.n.01|induced|.
D014635_D001927 CID valproate_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|valproate|- (r_amod) encephalopathy_3\NN\nervous_disorder.n.01|induced
D014635_D001927 CID valproate_3\NN\entity.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|valproate|- (r_amod) encephalopathy_6\NN\nervous_disorder.n.01|induced
D014635_D004827 NONE valproate_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|valproate|- (r_amod) encephalopathy_3\NN\nervous_disorder.n.01|induced (r_nsubj) is_4\VBZ\be.v.01|encephalopathy|syndrome|. (l_attr) syndrome_7\NN\complex.n.01|a|rare|manifest (l_relcl) manifest_10\VB\legal_document.n.01|that|may|in (l_prep) in_11\RP\linear_unit.n.01|individuals (l_pobj) individuals_15\NNS\causal_agent.n.01|normal|epileptic (l_amod) epileptic_14\JJ\sick_person.n.01|
1728522
D019980_D006099 CID acid_9\NN\compound.n.02|amoxicillin (r_pobj) of_5\IN\entity.n.01|acid (r_prep) combination_4\NN\collection.n.01|of (r_pobj) due_2\JJ\right.n.01|to|combination (r_prep) hepatitis_1\NN\infectious_disease.n.01|granulomatous|due|.
D019980_D006099 CID acid_11\NN\compound.n.02| (r_npadvmod) induced_13\VBN\generate.v.01|acid|- (r_amod) hepatitis_14\NN\infectious_disease.n.01|clavulanic|induced (r_pobj) with_7\IN\entity.n.01|hepatitis (r_prep) patient_6\NN\case.n.06|a|with (r_pobj) of_4\IN\entity.n.01|patient (r_prep) case_3\NN\happening.n.01|the|of|with (l_prep) with_15\IN\entity.n.01|granulomas (l_pobj) granulomas_18\NNS\tumor.n.01|histologic|multiple
D019980_D056486 CID acid_9\NN\compound.n.02|amoxicillin (r_pobj) of_5\IN\entity.n.01|acid (r_prep) combination_4\NN\collection.n.01|of (r_pobj) due_2\JJ\right.n.01|to|combination (r_prep) hepatitis_1\NN\infectious_disease.n.01|granulomatous|due|.
D019980_D056486 CID acid_11\NN\compound.n.02| (r_npadvmod) induced_13\VBN\generate.v.01|acid|- (r_amod) hepatitis_14\NN\infectious_disease.n.01|clavulanic|induced
16574712
D018817_D003072 CID mdma_0\NN\club_drug.n.01| (r_compound) users_2\NNS\person.n.01|mdma|polydrug (r_nsubj) show_3\VBP\entertainment.n.01|users|impairments|. (l_dobj) impairments_9\NNS\change.n.01|specific|central|executive|coupled (l_acl) coupled_10\VBN\join.v.02|with (l_prep) with_11\IN\entity.n.01|processes (l_pobj) processes_17\NNS\activity.n.01|impaired|social|judgement
D018817_D008569 NONE mdma_12\NNP\club_drug.n.01|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN\entity.n.01|mdma (r_prep) users_10\NNS\person.n.01|of (r_pobj) in_9\IN\linear_unit.n.01|users (r_prep) reported_8\VBN\inform.v.01|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS\insufficiency.n.03|working|memory
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\CD\entity.n.01| (r_intj) mdma_12\NNP\club_drug.n.01|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN\entity.n.01|mdma (r_prep) users_10\NNS\person.n.01|of (r_pobj) in_9\IN\linear_unit.n.01|users (r_prep) reported_8\VBN\inform.v.01|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS\insufficiency.n.03|working|memory
D018817_D008569 NONE ecstasy_16\NN\emotional_state.n.01|,|) (r_appos) mdma_12\NNP\club_drug.n.01|(|3,4-methylenedioxymethamphetamine|ecstasy (r_pobj) of_11\IN\entity.n.01|mdma (r_prep) users_10\NNS\person.n.01|of (r_pobj) in_9\IN\linear_unit.n.01|users (r_prep) reported_8\VBN\inform.v.01|in|deficits|have|been|in|. (l_nsubjpass) deficits_5\NNS\insufficiency.n.03|working|memory
20196116
D000995_D017114 CID antituberculosis_0\NNP\entity.n.01| (r_nsubj) induced_3\VBN\generate.v.01|antituberculosis|therapy|-|failure|profile|. (l_dobj) failure_6\NN\nonaccomplishment.n.01|acute|liver|:
D000995_D017114 CID antituberculosis_0\NN\entity.n.01| (r_compound) therapy_1\NN\medical_care.n.01|antituberculosis|(|failure (l_appos) failure_6\NN\nonaccomplishment.n.01|att)-associated|acute|liver|(|alf|)
D000995_D017114 CID antituberculosis_0\NN\entity.n.01| (r_compound) therapy_1\NN\medical_care.n.01|antituberculosis|(|failure (l_appos) failure_6\NN\nonaccomplishment.n.01|att)-associated|acute|liver|(|alf|) (l_appos) alf_10\NNP\entity.n.01|att|-
D000995_D017114 CID antituberculosis_0\NN\entity.n.01| (r_compound) therapy_1\NN\medical_care.n.01|antituberculosis|(|failure (r_nsubj) is_12\VBZ\be.v.01|therapy|alf|. (l_attr) alf_18\NNP\entity.n.01|the|commonest|induced|in
D001663_D001927 NONE bilirubin_11\NN\animal_pigment.n.01|serum|(|dl|)|,|time (l_appos) time_21\NN\case.n.01|prothrombin|prolongation|,|and|encephalopathy (l_conj) encephalopathy_37\NN\nervous_disorder.n.01|grade|iv|at
18208574
D006493_D013927 CID heparin_12\NN\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_15\NN\blood_disease.n.01|induced (r_pobj) with_11\IN\entity.n.01|thrombocytopenia (r_prep) patients_10\NNS\case.n.06|with (r_pobj) in_9\IN\linear_unit.n.01|patients (r_prep) thrombosis_8\NN\occlusion.n.01|in
D006493_D013927 CID heparin_12\NN\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_15\NN\blood_disease.n.01|a|step|induced|assay (l_appos) assay_20\NN\appraisal.n.01|(|hit|)|antigen|with (l_prep) with_21\IN\entity.n.01|thrombosis (l_pobj) thrombosis_22\NN\occlusion.n.01|
D006493_D013927 CID heparin_33\JJ\anticoagulant.n.01| (r_compound) concentration_34\NN\property.n.02|a|high|heparin (r_pobj) of_30\IN\entity.n.01|concentration (r_prep) characteristics_29\NNS\property.n.04|inhibition|of (r_dobj) utilizes_26\VBZ\use.v.01|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB\variable.n.02|to|density (l_dobj) density_3\NN\compactness.n.02|optical|and|inhibition|of (l_prep) of_7\IN\entity.n.01|thrombocytopenia (l_pobj) thrombocytopenia_15\NN\blood_disease.n.01|a|step|induced|assay (l_appos) assay_20\NN\appraisal.n.01|(|hit|)|antigen|with (l_prep) with_21\IN\entity.n.01|thrombosis (l_pobj) thrombosis_22\NN\occlusion.n.01|
D006493_D013921 CID heparin_12\NN\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_15\NN\blood_disease.n.01|induced
D006493_D013921 CID heparin_12\NN\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_15\NN\blood_disease.n.01|a|step|induced|assay
D006493_D013921 CID heparin_12\NN\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_15\NN\blood_disease.n.01|a|step|induced|assay (l_appos) assay_20\NN\appraisal.n.01|(|hit|)|antigen|with (l_nmod) hit_17\NN\feat.n.01|
D006493_D013921 CID heparin_33\JJ\anticoagulant.n.01| (r_compound) concentration_34\NN\property.n.02|a|high|heparin (r_pobj) of_30\IN\entity.n.01|concentration (r_prep) characteristics_29\NNS\property.n.04|inhibition|of (r_dobj) utilizes_26\VBZ\use.v.01|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB\variable.n.02|to|density (l_dobj) density_3\NN\compactness.n.02|optical|and|inhibition|of (l_prep) of_7\IN\entity.n.01|thrombocytopenia (l_pobj) thrombocytopenia_15\NN\blood_disease.n.01|a|step|induced|assay
D006493_D013921 CID heparin_33\JJ\anticoagulant.n.01| (r_compound) concentration_34\NN\property.n.02|a|high|heparin (r_pobj) of_30\IN\entity.n.01|concentration (r_prep) characteristics_29\NNS\property.n.04|inhibition|of (r_dobj) utilizes_26\VBZ\use.v.01|correlate|;|assay|characteristics|. (l_advcl) correlate_1\VB\variable.n.02|to|density (l_dobj) density_3\NN\compactness.n.02|optical|and|inhibition|of (l_prep) of_7\IN\entity.n.01|thrombocytopenia (l_pobj) thrombocytopenia_15\NN\blood_disease.n.01|a|step|induced|assay (l_appos) assay_20\NN\appraisal.n.01|(|hit|)|antigen|with (l_nmod) hit_17\NN\feat.n.01|
D006493_D013921 CID heparin_21\NN\anticoagulant.n.01|,|had|] (r_pobj) to_20\IN\entity.n.01|heparin (r_prep) exposure_19\NN\vulnerability.n.02|to (r_pobj) after_18\IN\after.s.01|exposure (r_prep) patients_0\NNS\case.n.06|with|after (l_prep) with_1\IN\entity.n.01|decrease (l_pobj) decrease_6\NN\change.n.01|%|in|or|thrombocytopenia|) (l_conj) thrombocytopenia_11\NNP\blood_disease.n.01|10(9)/l
D006493_D013921 CID heparin_48\NN\anticoagulant.n.01| (r_pobj) of_47\IN\entity.n.01|heparin (r_prep) concentration_46\NN\property.n.02|high|of (r_pobj) with_44\IN\entity.n.01|concentration (r_prep) inhibition_43\NN\abstinence.n.02|50|with (r_dobj) had_24\VBD\have.v.01|who|assay|inhibition (r_relcl) heparin_21\NN\anticoagulant.n.01|,|had|] (r_pobj) to_20\IN\entity.n.01|heparin (r_prep) exposure_19\NN\vulnerability.n.02|to (r_pobj) after_18\IN\after.s.01|exposure (r_prep) patients_0\NNS\case.n.06|with|after (l_prep) with_1\IN\entity.n.01|decrease (l_pobj) decrease_6\NN\change.n.01|%|in|or|thrombocytopenia|) (l_conj) thrombocytopenia_11\NNP\blood_disease.n.01|10(9)/l
16787750
D014635_D001927 CID acid_1\NN\compound.n.02|valproic (r_nsubj) induced_2\VBD\generate.v.01|acid|encephalopathy--19|cases|from|to|. (l_advmod) encephalopathy--19_3\NNP\entity.n.01|
D014635_D001927 CID vpa_18\NNP\entity.n.01| (r_compound) therapy_20\NN\medical_care.n.01|vpa|- (r_pobj) to_17\IN\entity.n.01|therapy (r_prep) associated_16\VBN\think.v.03|to|in (r_acl) effect_15\NN\phenomenon.n.01|2003|-a|side|associated (r_pobj) to_10\IN\entity.n.01|effect (r_prep) induced_2\VBD\generate.v.01|acid|encephalopathy--19|cases|from|to|. (l_advmod) encephalopathy--19_3\NNP\entity.n.01|
D014635_D001927 CID vpa_17\NNP\entity.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|vpa|- (r_amod) hepatotoxicity_20\NN\entity.n.01|,|induced|and|encephalopathy (l_conj) encephalopathy_25\NN\nervous_disorder.n.01|induced
D014635_D001927 CID vpa_22\NNP\entity.n.01| (r_npadvmod) induced_24\VBN\generate.v.01|vpa|- (r_compound) encephalopathy_25\NN\nervous_disorder.n.01|induced
D014635_D001927 CID vpa_4\NNP\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|vpa|- (r_amod) encephalopathy_7\NN\nervous_disorder.n.01|induced
D014635_D001927 CID vpa_9\NNP\entity.n.01| (r_pobj) of_8\IN\entity.n.01|vpa (r_prep) effect_7\NN\phenomenon.n.01|causative|of|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|with (l_prep) with_12\IN\entity.n.01|encephalopathy (l_pobj) encephalopathy_13\JJ\nervous_disorder.n.01|
D014635_D001927 CID vpa_5\NNP\entity.n.01| (r_npadvmod) associated_7\VBN\think.v.03|vpa|- (r_amod) encephalopathy_8\NN\nervous_disorder.n.01|associated|in
D014635_D010195 CID vpa_17\NNP\entity.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|vpa|- (r_amod) hepatotoxicity_20\NN\entity.n.01|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\happen.v.01|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|some|,|including (l_prep) including_9\VBG\include.v.01|pancreatitis (l_pobj) pancreatitis_11\NN\inflammation.n.01|haemorrhagic|,|suppression
D014635_D010195 CID vpa_22\NNP\entity.n.01| (r_npadvmod) induced_24\VBN\generate.v.01|vpa|- (r_compound) encephalopathy_25\NN\nervous_disorder.n.01|induced (r_conj) hepatotoxicity_20\NN\entity.n.01|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\happen.v.01|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|some|,|including (l_prep) including_9\VBG\include.v.01|pancreatitis (l_pobj) pancreatitis_11\NN\inflammation.n.01|haemorrhagic|,|suppression
D014635_D001855 CID vpa_17\NNP\entity.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|vpa|- (r_amod) hepatotoxicity_20\NN\entity.n.01|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\happen.v.01|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|some|,|including (l_prep) including_9\VBG\include.v.01|pancreatitis (l_pobj) pancreatitis_11\NN\inflammation.n.01|haemorrhagic|,|suppression (l_conj) suppression_15\NN\growth.n.01|bone|marrow
D014635_D001855 CID vpa_22\NNP\entity.n.01| (r_npadvmod) induced_24\VBN\generate.v.01|vpa|- (r_compound) encephalopathy_25\NN\nervous_disorder.n.01|induced (r_conj) hepatotoxicity_20\NN\entity.n.01|,|induced|and|encephalopathy (r_npadvmod) occur_4\VB\happen.v.01|complications|may|in|hepatotoxicity|. (l_prep) in_5\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|some|,|including (l_prep) including_9\VBG\include.v.01|pancreatitis (l_pobj) pancreatitis_11\NN\inflammation.n.01|haemorrhagic|,|suppression (l_conj) suppression_15\NN\growth.n.01|bone|marrow
D014635_D056486 CID vpa_17\NNP\entity.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|vpa|- (r_amod) hepatotoxicity_20\NN\entity.n.01|,|induced|and|encephalopathy
D014635_D056486 CID vpa_22\NNP\entity.n.01| (r_npadvmod) induced_24\VBN\generate.v.01|vpa|- (r_compound) encephalopathy_25\NN\nervous_disorder.n.01|induced (r_conj) hepatotoxicity_20\NN\entity.n.01|,|induced|and|encephalopathy
D014635_D003244 CID vpa_4\NNP\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|vpa|- (r_amod) encephalopathy_7\NN\nervous_disorder.n.01|induced (r_pobj) of_3\IN\entity.n.01|encephalopathy (r_prep) signs_2\NNS\clue.n.02|the|typical|of (r_nsubj) are_8\VBP\area_unit.n.01|signs|consciousness|,|marked|. (l_attr) consciousness_10\NN\cognitive_state.n.01|impaired
D014635_D012640 NONE vpa_4\NNP\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|vpa|- (r_amod) encephalopathy_7\NN\nervous_disorder.n.01|induced (r_pobj) of_3\IN\entity.n.01|encephalopathy (r_prep) signs_2\NNS\clue.n.02|the|typical|of (r_nsubj) are_8\VBP\area_unit.n.01|signs|consciousness|,|marked|. (l_advcl) marked_13\VBD\attach.v.01|sometimes|slowing (l_ccomp) slowing_16\VBG\change.n.01|background|,|frequency (l_dobj) frequency_20\NN\rate.n.01|increased|seizure|,|with (l_compound) seizure_19\NN\attack.n.07|
D014635_D022124 NONE vpa_4\NNP\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|vpa|- (r_amod) encephalopathy_7\NN\nervous_disorder.n.01|induced (r_pobj) of_3\IN\entity.n.01|encephalopathy (r_prep) signs_2\NNS\clue.n.02|the|typical|of (r_nsubj) are_8\VBP\area_unit.n.01|signs|consciousness|,|marked|. (l_advcl) marked_13\VBD\attach.v.01|sometimes|slowing (l_ccomp) slowing_16\VBG\change.n.01|background|,|frequency (l_dobj) frequency_20\NN\rate.n.01|increased|seizure|,|with (l_prep) with_22\IN\entity.n.01|or|without (l_conj) without_24\IN\entity.n.01|hyperammonemia (l_pobj) hyperammonemia_25\NN\entity.n.01|
9862868
D004997_D002780 CID estradiol_9\NNP\estrogen.n.01| (r_nmod) treatment_13\NN\care.n.01|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\disorder.n.01|treatment|by (r_dobj) used_1\VBD\use.v.01|we|models|cholestasis|determine|. (l_dobj) models_3\NNS\hypothesis.n.02|rat|of (l_prep) of_4\IN\entity.n.01|cholestasis (l_pobj) cholestasis_6\NN\disorder.n.01|intrahepatic|by
D004997_D002780 CID ee_11\NNP\engineering.n.02| (r_nmod) treatment_13\NN\care.n.01|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\disorder.n.01|treatment|by (r_dobj) used_1\VBD\use.v.01|we|models|cholestasis|determine|. (l_dobj) models_3\NNS\hypothesis.n.02|rat|of (l_prep) of_4\IN\entity.n.01|cholestasis (l_pobj) cholestasis_6\NN\disorder.n.01|intrahepatic|by
D004997_D001651 NONE estradiol_9\NNP\estrogen.n.01| (r_nmod) treatment_13\NN\care.n.01|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\disorder.n.01|treatment|by
D004997_D001651 NONE ee_11\NNP\engineering.n.02| (r_nmod) treatment_13\NN\care.n.01|estradiol|(|ee|)|and|extrahepatic (r_nmod) cholestasis_16\NN\disorder.n.01|treatment|by
18308784
C035054_D007859 NONE rg1_1\NNP\entity.n.01|ginsenoside (r_nsubj) restores_2\VBZ\regenerate.v.01|rg1|impairment|. (l_dobj) impairment_4\NN\change.n.01|the|of|induced (l_prep) of_5\IN\entity.n.01|learning (l_pobj) learning_6\VBG\basic_cognitive_process.n.01|
C035054_D007859 NONE rg1_0\NNP\entity.n.01|,|ameliorate|. (l_advcl) ameliorate_11\VB\change.v.01|as|,|could|impairment (l_dobj) impairment_14\NN\change.n.01|spatial|learning
C035054_D007859 NONE rg1_11\NN\entity.n.01| (r_pobj) of_10\IN\entity.n.01|rg1 (r_prep) effect_9\NN\phenomenon.n.01|the|of|on (l_prep) on_12\IN\on.a.01|impairment (l_pobj) impairment_14\NN\change.n.01|learning|by
D009020_D007859 CID morphine_10\NN\analgesic.n.01| (r_compound) administration_11\NN\management.n.01|chronic|morphine|in (r_pobj) by_8\IN\by.r.01|administration (r_agent) induced_7\VBN\generate.v.01|by (r_acl) impairment_4\NN\change.n.01|the|of|induced (l_prep) of_5\IN\entity.n.01|learning (l_pobj) learning_6\VBG\basic_cognitive_process.n.01|
D009020_D007859 CID morphine_17\NN\analgesic.n.01| (r_compound) administration_18\NN\management.n.01|chronic|morphine|and|mechanism (r_pobj) by_15\IN\by.r.01|administration (r_prep) impairment_14\NN\change.n.01|learning|by
D036145_D007859 NONE ginsenoside_4\NN\entity.n.01|a|extracted (r_pobj) as_2\IN\chemical_element.n.01|ginsenoside (r_prep) ameliorate_11\VB\change.v.01|as|,|could|impairment (l_dobj) impairment_14\NN\change.n.01|spatial|learning
16867021
D006632_D002375 NONE histamine_10\NN\amine.n.01| (r_nmod) ligands_12\NNS\substance.n.07|histamine|h(3)-receptor|on (l_prep) on_13\IN\on.a.01|catalepsy (l_pobj) catalepsy_17\NN\hypersomnia.n.01|induced|,
D001058_D002375 NONE apomorphine_19\NN\morphine.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|apomorphine|- (r_amod) behavior_23\NN\activity.n.01|induced|climbing|and|activities (r_dobj) study_6\VB\examination.n.01|to|effect|behavior (l_dobj) effect_8\NN\phenomenon.n.01|the|of (l_prep) of_9\IN\entity.n.01|ligands (l_pobj) ligands_12\NNS\substance.n.07|histamine|h(3)-receptor|on (l_prep) on_13\IN\on.a.01|catalepsy (l_pobj) catalepsy_17\NN\hypersomnia.n.01|induced|,
D001058_D002375 NONE apomorphine_12\NN\morphine.n.01|(|mg/kg|)|and|amphetamine (r_nsubjpass) used_26\VBN\use.v.01|while|apomorphine|were|for (r_advcl) induced_2\VBN\generate.v.01|catalepsy|was|by|,|used|. (l_nsubjpass) catalepsy_0\NNP\hypersomnia.n.01|
D001058_D002375 NONE apomorphine_21\NN\morphine.n.01| (r_dobj) reducing_20\VBG\chemical_reaction.n.01|apomorphine (r_conj) reducing_14\VBG\chemical_reaction.n.01|hyperactivity|and|reducing (r_conj) potentiating_8\VBG\enhance.v.01|catalepsy|,|reducing (l_dobj) catalepsy_12\NN\hypersomnia.n.01|induced
D000661_D002375 NONE amphetamine_25\NN\drug_of_abuse.n.01| (r_npadvmod) induced_27\VBN\generate.v.01|amphetamine|- (r_amod) activities_29\NNS\act.n.02|induced|locomotor|in (r_conj) behavior_23\NN\activity.n.01|induced|climbing|and|activities (r_dobj) study_6\VB\examination.n.01|to|effect|behavior (l_dobj) effect_8\NN\phenomenon.n.01|the|of (l_prep) of_9\IN\entity.n.01|ligands (l_pobj) ligands_12\NNS\substance.n.07|histamine|h(3)-receptor|on (l_prep) on_13\IN\on.a.01|catalepsy (l_pobj) catalepsy_17\NN\hypersomnia.n.01|induced|,
D000661_D002375 NONE amphetamine_19\NN\drug_of_abuse.n.01|(|mg/kg|) (r_conj) apomorphine_12\NN\morphine.n.01|(|mg/kg|)|and|amphetamine (r_nsubjpass) used_26\VBN\use.v.01|while|apomorphine|were|for (r_advcl) induced_2\VBN\generate.v.01|catalepsy|was|by|,|used|. (l_nsubjpass) catalepsy_0\NNP\hypersomnia.n.01|
D000661_D002375 NONE amphetamine_15\NN\drug_of_abuse.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|amphetamine|- (r_amod) hyperactivity_18\NN\disorder.n.01|induced (r_dobj) reducing_14\VBG\chemical_reaction.n.01|hyperactivity|and|reducing (r_conj) potentiating_8\VBG\enhance.v.01|catalepsy|,|reducing (l_dobj) catalepsy_12\NN\hypersomnia.n.01|induced
D006220_D002375 CID haloperidol_4\NN\major_tranquilizer.n.01|(|mg/kg|) (r_pobj) by_3\IN\by.r.01|haloperidol (r_agent) induced_2\VBN\generate.v.01|catalepsy|was|by|,|used|. (l_nsubjpass) catalepsy_0\NNP\hypersomnia.n.01|
D006220_D002375 CID haloperidol_4\NN\major_tranquilizer.n.01| (r_pobj) to_3\IN\entity.n.01|haloperidol (r_prep) prior_2\RB\superior.n.02|to (r_advmod) resulted_5\VBD\prove.v.01|1|h|prior|in|. (l_prep) in_6\IN\linear_unit.n.01|increase (l_pobj) increase_11\NN\indefinite_quantity.n.01|a|dependent|in|(|p|) (l_prep) in_12\IN\linear_unit.n.01|catalepsy (l_pobj) catalepsy_14\NN\hypersomnia.n.01|the|times
D006220_D002375 CID haloperidol_9\NN\major_tranquilizer.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|haloperidol|- (r_amod) catalepsy_12\NN\hypersomnia.n.01|induced
C069357_D002375 NONE methylhistamine_3\NN\entity.n.01|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\origin.n.03|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\hypersomnia.n.01|
C069357_D002375 NONE ramh_5\NNP\entity.n.01|(|) (r_appos) methylhistamine_3\NN\entity.n.01|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\origin.n.03|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\hypersomnia.n.01|
C052075_D002375 CID thioperamide_13\JJ\entity.n.01|(|thp|) (r_conj) microg_9\NN\entity.n.01|(|5|i.c.v.|)|and|thioperamide|(|mg/kg|) (r_parataxis) methylhistamine_3\NN\entity.n.01|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\origin.n.03|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\hypersomnia.n.01|
C052075_D002375 CID thp_15\NNP\entity.n.01| (r_appos) thioperamide_13\JJ\entity.n.01|(|thp|) (r_conj) microg_9\NN\entity.n.01|(|5|i.c.v.|)|and|thioperamide|(|mg/kg|) (r_parataxis) methylhistamine_3\NN\entity.n.01|r)-alpha|-|ramh|microg (r_nsubj) cause_27\VB\origin.n.03|(|methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_28\NN\hypersomnia.n.01|
C052075_D002375 CID thp_0\NNP\entity.n.01| (r_nsubj) exhibited_1\VBD\possess.v.01|thp|profile|climbing|. (l_dobj) profile_6\NN\chart.n.01|an|like|by (l_prep) by_7\IN\by.r.01|potentiating (l_pcomp) potentiating_8\VBG\enhance.v.01|catalepsy|,|reducing (l_dobj) catalepsy_12\NN\hypersomnia.n.01|induced
D000661_D006948 CID amphetamine_1\NN\drug_of_abuse.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|amphetamine|- (r_amod) hyperactivity_4\NN\disorder.n.01|induced
D000661_D006948 CID amphetamine_15\NN\drug_of_abuse.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|amphetamine|- (r_amod) hyperactivity_18\NN\disorder.n.01|induced
C052075_D006948 NONE thp_6\NNP\entity.n.01| (r_nmod) time_16\NN\case.n.01|thp|mg/kg|i.p.|)|reduced|locomotor (r_npadvmod) traveled_19\VBD\travel.v.01|on|,|time|,|distance|and|speed|. (l_prep) on_0\IN\on.a.01|hyperactivity (l_pobj) hyperactivity_4\NN\disorder.n.01|induced
C052075_D006948 NONE thp_0\NNP\entity.n.01| (r_nsubj) exhibited_1\VBD\possess.v.01|thp|profile|climbing|. (l_dobj) profile_6\NN\chart.n.01|an|like|by (l_prep) by_7\IN\by.r.01|potentiating (l_pcomp) potentiating_8\VBG\enhance.v.01|catalepsy|,|reducing (l_conj) reducing_14\VBG\chemical_reaction.n.01|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN\disorder.n.01|induced
D006220_D006948 NONE haloperidol_9\NN\major_tranquilizer.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|haloperidol|- (r_amod) catalepsy_12\NN\hypersomnia.n.01|induced (r_dobj) potentiating_8\VBG\enhance.v.01|catalepsy|,|reducing (l_conj) reducing_14\VBG\chemical_reaction.n.01|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN\disorder.n.01|induced
D001058_D006948 NONE apomorphine_21\NN\morphine.n.01| (r_dobj) reducing_20\VBG\chemical_reaction.n.01|apomorphine (r_conj) reducing_14\VBG\chemical_reaction.n.01|hyperactivity|and|reducing (l_dobj) hyperactivity_18\NN\disorder.n.01|induced
9698967
D008619_D006973 CID mepivacaine_43\NN\entity.n.01| (r_amod) mg_45\NN\metric_weight_unit.n.01|mepivacaine|850 (r_pobj) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_prep) in_2\IN\linear_unit.n.01|pressure (l_pobj) pressure_4\NN\physical_phenomenon.n.01|blood
D008619_D001281 CID mepivacaine_43\NN\entity.n.01| (r_amod) mg_45\NN\metric_weight_unit.n.01|mepivacaine|850 (r_pobj) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation
D008619_D011595 NONE mepivacaine_43\NN\entity.n.01| (r_amod) mg_45\NN\metric_weight_unit.n.01|mepivacaine|850 (r_pobj) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation (l_conj) agitation_11\NN\psychological_state.n.01|,|shouts
D008619_D019954 NONE mepivacaine_43\NN\entity.n.01| (r_amod) mg_45\NN\metric_weight_unit.n.01|mepivacaine|850 (r_pobj) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation (l_conj) agitation_11\NN\psychological_state.n.01|,|shouts (l_conj) shouts_14\NNS\utterance.n.01|incomprehensible|and|loss|of
D008619_D014474 NONE mepivacaine_43\NN\entity.n.01| (r_amod) mg_45\NN\metric_weight_unit.n.01|mepivacaine|850 (r_pobj) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation (l_conj) agitation_11\NN\psychological_state.n.01|,|shouts (l_conj) shouts_14\NNS\utterance.n.01|incomprehensible|and|loss|of (l_prep) of_17\IN\entity.n.01|consciousness (l_pobj) consciousness_18\NN\cognitive_state.n.01|
D008619_D004387 NONE mepivacaine_43\NN\entity.n.01| (r_amod) mg_45\NN\metric_weight_unit.n.01|mepivacaine|850 (r_pobj) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (l_prep) for_51\IN\entity.n.01|correction (l_pobj) correction_52\NN\improvement.n.02|of (l_prep) of_53\IN\entity.n.01|contracture (l_pobj) contracture_56\NN\contraction.n.01|dupuytren
D004837_D006973 CID adrenaline_47\NN\catecholamine.n.01|mg (r_dobj) containing_46\VBG\include.v.01|adrenaline (r_pcomp) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_prep) in_2\IN\linear_unit.n.01|pressure (l_pobj) pressure_4\NN\physical_phenomenon.n.01|blood
D004837_D001281 CID adrenaline_47\NN\catecholamine.n.01|mg (r_dobj) containing_46\VBG\include.v.01|adrenaline (r_pcomp) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation
D004837_D011595 NONE adrenaline_47\NN\catecholamine.n.01|mg (r_dobj) containing_46\VBG\include.v.01|adrenaline (r_pcomp) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation (l_conj) agitation_11\NN\psychological_state.n.01|,|shouts
D004837_D019954 NONE adrenaline_47\NN\catecholamine.n.01|mg (r_dobj) containing_46\VBG\include.v.01|adrenaline (r_pcomp) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation (l_conj) agitation_11\NN\psychological_state.n.01|,|shouts (l_conj) shouts_14\NNS\utterance.n.01|incomprehensible|and|loss|of
D004837_D014474 NONE adrenaline_47\NN\catecholamine.n.01|mg (r_dobj) containing_46\VBG\include.v.01|adrenaline (r_pcomp) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (r_appos) observed_21\VBN\spy.v.03|increase|was|in|,|group|. (l_nsubjpass) increase_1\NN\indefinite_quantity.n.01|an|in|,|accompanied|, (l_acl) accompanied_6\VBN\attach_to.v.01|by (l_agent) by_7\IN\by.r.01|fibrillation (l_pobj) fibrillation_9\NN\twitch.n.01|atrial|,|agitation (l_conj) agitation_11\NN\psychological_state.n.01|,|shouts (l_conj) shouts_14\NNS\utterance.n.01|incomprehensible|and|loss|of (l_prep) of_17\IN\entity.n.01|consciousness (l_pobj) consciousness_18\NN\cognitive_state.n.01|
D004837_D004387 NONE adrenaline_47\NN\catecholamine.n.01|mg (r_dobj) containing_46\VBG\include.v.01|adrenaline (r_pcomp) with_42\IN\entity.n.01|mg|containing (r_prep) block_41\NN\artifact.n.01|axillary|with (r_pobj) of_39\IN\entity.n.01|block (r_prep) performance_38\NN\show.n.03|of (r_pobj) after_37\IN\after.s.01|performance (r_prep) min_36\NN\time_unit.n.01|12|after (r_appos) group_28\NN\abstraction.n.06|asa|classification|ii|,|male|min|,|for (l_prep) for_51\IN\entity.n.01|correction (l_pobj) correction_52\NN\improvement.n.02|of (l_prep) of_53\IN\entity.n.01|contracture (l_pobj) contracture_56\NN\contraction.n.01|dupuytren
8919272
D014635_D001927 CID valproate_11\NN\entity.n.01|features|to|. (l_nsubj) features_1\NNS\property.n.04|morphological|of|after (l_prep) of_2\IN\entity.n.01|encephalopathy (l_pobj) encephalopathy_3\NN\nervous_disorder.n.01|
D014635_D001927 CID valproate_10\NN\entity.n.01|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS\physical_condition.n.01|revealed|neurological|indicating (l_acl) indicating_44\VBG\tell.v.02|damage (l_dobj) damage_46\NN\change.n.01|cerebellum|encephalopathy (l_appos) encephalopathy_50\JJ\nervous_disorder.n.01|(|"|valproate|"|)
D014635_D001927 CID valproate_49\NNP\entity.n.01| (r_amod) encephalopathy_50\JJ\nervous_disorder.n.01|(|"|valproate|"|)
D014635_D001927 CID valproate_15\NNP\entity.n.01| (r_amod) encephalopathy_16\NNP\nervous_disorder.n.01|valproate
D014635_D009422 NONE valproate_10\NN\entity.n.01|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS\physical_condition.n.01|revealed|neurological|indicating
D014635_D009422 NONE valproate_49\NNP\entity.n.01| (r_amod) encephalopathy_50\JJ\nervous_disorder.n.01|(|"|valproate|"|) (r_appos) damage_46\NN\change.n.01|cerebellum|encephalopathy (r_dobj) indicating_44\VBG\tell.v.02|damage (r_acl) disorders_43\NNS\physical_condition.n.01|revealed|neurological|indicating
D014635_D002526 NONE valproate_10\NN\entity.n.01|application|polfa|at|to|disorders|. (l_dobj) disorders_43\NNS\physical_condition.n.01|revealed|neurological|indicating (l_acl) indicating_44\VBG\tell.v.02|damage (l_dobj) damage_46\NN\change.n.01|cerebellum|encephalopathy
D014635_D002526 NONE valproate_49\NNP\entity.n.01| (r_amod) encephalopathy_50\JJ\nervous_disorder.n.01|(|"|valproate|"|) (r_appos) damage_46\NN\change.n.01|cerebellum|encephalopathy
D014635_D056486 NONE valproate_15\NNP\entity.n.01| (r_amod) encephalopathy_16\NNP\nervous_disorder.n.01|valproate (r_pobj) of_14\IN\entity.n.01|encephalopathy (r_prep) development_13\NN\improvement.n.02|the|of (r_pobj) upon_11\IN\entity.n.01|development (r_prep) hyperammonemia_9\NN\entity.n.01|influence|mainly|,|upon (l_nsubj) influence_2\NN\power.n.01|the|possible|of|, (l_prep) of_3\IN\entity.n.01|damage (l_pobj) damage_6\NN\change.n.01|the|hepatic
D014635_D022124 NONE valproate_15\NNP\entity.n.01| (r_amod) encephalopathy_16\NNP\nervous_disorder.n.01|valproate (r_pobj) of_14\IN\entity.n.01|encephalopathy (r_prep) development_13\NN\improvement.n.02|the|of (r_pobj) upon_11\IN\entity.n.01|development (r_prep) hyperammonemia_9\NN\entity.n.01|influence|mainly|,|upon
17615423
D019821_D012206 CID simvastatin_11\NN\lipid-lowering_medicine.n.01|,|amiodarone (r_pobj) of_10\IN\entity.n.01|simvastatin (r_prep) use_9\NN\activity.n.01|concomitant|of (r_pobj) to_7\IN\entity.n.01|use (r_prep) secondary_6\JJ\formation.n.01|to (r_amod) failure_5\NN\nonaccomplishment.n.01|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN\entity.n.01|severe|and|failure|.
D019821_D012206 CID simvastatin_9\NN\lipid-lowering_medicine.n.01|,|amiodarone (l_conj) amiodarone_11\NN\antiarrhythmic.n.01|,|and|atazanavir (l_conj) atazanavir_14\NNS\entity.n.01|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\entity.n.01|and|failure
D019821_D012206 CID simvastatin_14\NN\lipid-lowering_medicine.n.01| (r_amod) metabolism_15\NN\organic_process.n.01|simvastatin (r_dobj) inhibit_13\VBP\control.v.02|that|metabolism (r_relcl) drugs_11\NNS\agent.n.03|concomitant|inhibit (r_pobj) of_9\IN\entity.n.01|drugs (r_prep) presence_8\NN\being.n.01|the|of (r_pobj) in_6\IN\linear_unit.n.01|presence (r_prep) increased_5\VBN\change_magnitude.v.01|risk|is|in|. (l_nsubjpass) risk_1\NN\danger.n.03|the|of (l_prep) of_2\IN\entity.n.01|rhabdomyolysis (l_pobj) rhabdomyolysis_3\NN\entity.n.01|
D019821_D058186 CID simvastatin_11\NN\lipid-lowering_medicine.n.01|,|amiodarone (r_pobj) of_10\IN\entity.n.01|simvastatin (r_prep) use_9\NN\activity.n.01|concomitant|of (r_pobj) to_7\IN\entity.n.01|use (r_prep) secondary_6\JJ\formation.n.01|to (r_amod) failure_5\NN\nonaccomplishment.n.01|acute|renal|secondary
D019821_D058186 CID simvastatin_9\NN\lipid-lowering_medicine.n.01|,|amiodarone (l_conj) amiodarone_11\NN\antiarrhythmic.n.01|,|and|atazanavir (l_conj) atazanavir_14\NNS\entity.n.01|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\entity.n.01|and|failure (l_conj) failure_21\NN\nonaccomplishment.n.01|acute|renal
D000638_D012206 CID amiodarone_13\NN\antiarrhythmic.n.01|,|and|atazanavir (r_conj) simvastatin_11\NN\lipid-lowering_medicine.n.01|,|amiodarone (r_pobj) of_10\IN\entity.n.01|simvastatin (r_prep) use_9\NN\activity.n.01|concomitant|of (r_pobj) to_7\IN\entity.n.01|use (r_prep) secondary_6\JJ\formation.n.01|to (r_amod) failure_5\NN\nonaccomplishment.n.01|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN\entity.n.01|severe|and|failure|.
D000638_D012206 CID amiodarone_11\NN\antiarrhythmic.n.01|,|and|atazanavir (l_conj) atazanavir_14\NNS\entity.n.01|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\entity.n.01|and|failure
D000638_D058186 CID amiodarone_13\NN\antiarrhythmic.n.01|,|and|atazanavir (r_conj) simvastatin_11\NN\lipid-lowering_medicine.n.01|,|amiodarone (r_pobj) of_10\IN\entity.n.01|simvastatin (r_prep) use_9\NN\activity.n.01|concomitant|of (r_pobj) to_7\IN\entity.n.01|use (r_prep) secondary_6\JJ\formation.n.01|to (r_amod) failure_5\NN\nonaccomplishment.n.01|acute|renal|secondary
D000638_D058186 CID amiodarone_11\NN\antiarrhythmic.n.01|,|and|atazanavir (l_conj) atazanavir_14\NNS\entity.n.01|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\entity.n.01|and|failure (l_conj) failure_21\NN\nonaccomplishment.n.01|acute|renal
C413408_D012206 CID atazanavir_16\NNS\entity.n.01| (r_conj) amiodarone_13\NN\antiarrhythmic.n.01|,|and|atazanavir (r_conj) simvastatin_11\NN\lipid-lowering_medicine.n.01|,|amiodarone (r_pobj) of_10\IN\entity.n.01|simvastatin (r_prep) use_9\NN\activity.n.01|concomitant|of (r_pobj) to_7\IN\entity.n.01|use (r_prep) secondary_6\JJ\formation.n.01|to (r_amod) failure_5\NN\nonaccomplishment.n.01|acute|renal|secondary (r_conj) rhabdomyolysis_1\NN\entity.n.01|severe|and|failure|.
C413408_D012206 CID atazanavir_14\NNS\entity.n.01|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\entity.n.01|and|failure
C413408_D058186 CID atazanavir_16\NNS\entity.n.01| (r_conj) amiodarone_13\NN\antiarrhythmic.n.01|,|and|atazanavir (r_conj) simvastatin_11\NN\lipid-lowering_medicine.n.01|,|amiodarone (r_pobj) of_10\IN\entity.n.01|simvastatin (r_prep) use_9\NN\activity.n.01|concomitant|of (r_pobj) to_7\IN\entity.n.01|use (r_prep) secondary_6\JJ\formation.n.01|to (r_amod) failure_5\NN\nonaccomplishment.n.01|acute|renal|secondary
C413408_D058186 CID atazanavir_14\NNS\entity.n.01|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|rhabdomyolysis (l_pobj) rhabdomyolysis_17\NN\entity.n.01|and|failure (l_conj) failure_21\NN\nonaccomplishment.n.01|acute|renal
D019821_D015658 NONE simvastatin_0\NNP\lipid-lowering_medicine.n.01|,|amiodarone (r_nmod) medications_11\NNS\drug.n.01|simvastatin|patient|human|virus (l_compound) virus_10\NN\infectious_agent.n.01|immunodeficiency
D000638_D015658 NONE amiodarone_2\NN\antiarrhythmic.n.01|,|and (r_conj) simvastatin_0\NNP\lipid-lowering_medicine.n.01|,|amiodarone (r_nmod) medications_11\NNS\drug.n.01|simvastatin|patient|human|virus (l_compound) virus_10\NN\infectious_agent.n.01|immunodeficiency
9855119
D016559_D005922 NONE fk506_28\NN\entity.n.01| (r_compound) nephropathy_29\NN\uropathy.n.01|type|chronic|fk506|(|n|)|,|and|nephropathy (r_conj) findings_17\NNS\collection.n.01|,|normal|n|,|nephropathy (r_conj) nephropathy_9\NN\uropathy.n.01|,|recurrent|iga|n|findings|.
D016559_D005922 NONE fk506_40\NN\entity.n.01|type (r_compound) nephropathy_41\NN\uropathy.n.01|fk506|(|n|) (r_conj) nephropathy_29\NN\uropathy.n.01|type|chronic|fk506|(|n|)|,|and|nephropathy (r_conj) findings_17\NNS\collection.n.01|,|normal|n|,|nephropathy (r_conj) nephropathy_9\NN\uropathy.n.01|,|recurrent|iga|n|findings|.
D016559_D007674 NONE fk506_28\NN\entity.n.01| (r_compound) nephropathy_29\NN\uropathy.n.01|type|chronic|fk506|(|n|)|,|and|nephropathy
D016559_D007674 NONE fk506_28\NN\entity.n.01| (r_compound) nephropathy_29\NN\uropathy.n.01|type|chronic|fk506|(|n|)|,|and|nephropathy (l_conj) nephropathy_41\NN\uropathy.n.01|fk506|(|n|)
D016559_D007674 NONE fk506_40\NN\entity.n.01|type (r_compound) nephropathy_41\NN\uropathy.n.01|fk506|(|n|) (r_conj) nephropathy_29\NN\uropathy.n.01|type|chronic|fk506|(|n|)|,|and|nephropathy
D016559_D007674 NONE fk506_40\NN\entity.n.01|type (r_compound) nephropathy_41\NN\uropathy.n.01|fk506|(|n|)
D016559_D007674 NONE fk506_18\NN\entity.n.01| (r_compound) nephropathy_19\NN\uropathy.n.01|type|chronic|fk506
D016559_D007674 NONE fk506_1\NNP\entity.n.01|chronic (r_compound) nephropathy_2\NN\uropathy.n.01|fk506
D016559_D007674 NONE fk506_12\NN\entity.n.01| (r_compound) nephropathy_13\NN\uropathy.n.01|fk506
D016559_D007674 NONE fk506_12\NN\entity.n.01| (r_compound) nephropathy_13\NN\uropathy.n.01|fk506 (r_compound) group_14\NN\abstraction.n.06|the|type|chronic|nephropathy|,|included|, (r_pobj) in_6\IN\linear_unit.n.01|group (r_prep) patients_5\NNS\case.n.06|in (r_pobj) of_4\IN\entity.n.01|patients (r_prep) levels_3\NNS\property.n.02|the|serum|creatinine|of (r_nsubj) were_22\VBD\be.v.01|levels|higher|. (l_acomp) higher_24\JJR\higher.s.01|statistically|than (l_prep) than_25\IN\entity.n.01|those (l_pobj) those_26\DT\entity.n.01|in (l_prep) in_27\IN\linear_unit.n.01|group (l_pobj) group_34\NN\abstraction.n.06|the|type|fk506-nephropathy|(|p|) (l_compound) fk506-nephropathy_33\NNP\entity.n.01|chronic
D016559_D007674 NONE fk506-nephropathy_33\NNP\entity.n.01|chronic (r_compound) group_34\NN\abstraction.n.06|the|type|fk506-nephropathy|(|p|) (r_pobj) in_27\IN\linear_unit.n.01|group (r_prep) those_26\DT\entity.n.01|in (r_pobj) than_25\IN\entity.n.01|those (r_prep) higher_24\JJR\higher.s.01|statistically|than (r_acomp) were_22\VBD\be.v.01|levels|higher|. (l_nsubj) levels_3\NNS\property.n.02|the|serum|creatinine|of (l_prep) of_4\IN\entity.n.01|patients (l_pobj) patients_5\NNS\case.n.06|in (l_prep) in_6\IN\linear_unit.n.01|group (l_pobj) group_14\NN\abstraction.n.06|the|type|chronic|nephropathy|,|included|, (l_compound) nephropathy_13\NN\uropathy.n.01|fk506
D016559_D007674 NONE fk506-nephropathy_33\NNP\entity.n.01|chronic
D016559_D007674 NONE fk506_5\NNP\entity.n.01| (r_compound) nephropathy_6\NN\uropathy.n.01|chronic|fk506
D016559_D007674 NONE fk506_5\NNP\entity.n.01| (r_compound) nephropathy_6\NN\uropathy.n.01|chronic|fk506 (r_nsubj) consists_7\VBZ\exist.v.01|that|nephropathy|primarily|of|, (r_ccomp) demonstrates_2\VBZ\show.v.04|study|consists|and|suggests|. (l_conj) suggests_21\VBZ\declare.v.01|is (l_ccomp) is_29\VBZ\be.v.01|that|nephropathy|condition (l_nsubj) nephropathy_28\NN\uropathy.n.01|type|chronic|fk506
D016559_D007674 NONE fk506_27\NN\entity.n.01| (r_compound) nephropathy_28\NN\uropathy.n.01|type|chronic|fk506 (r_nsubj) is_29\VBZ\be.v.01|that|nephropathy|condition (r_ccomp) suggests_21\VBZ\declare.v.01|is (r_conj) demonstrates_2\VBZ\show.v.04|study|consists|and|suggests|. (l_ccomp) consists_7\VBZ\exist.v.01|that|nephropathy|primarily|of|, (l_nsubj) nephropathy_6\NN\uropathy.n.01|chronic|fk506
D016559_D007674 NONE fk506_27\NN\entity.n.01| (r_compound) nephropathy_28\NN\uropathy.n.01|type|chronic|fk506
D016559_D005923 CID fk506_1\NNP\entity.n.01|chronic (r_compound) nephropathy_2\NN\uropathy.n.01|fk506 (r_nsubj) consisted_3\VBD\exist.v.01|nephropathy|of|, (r_ccomp) angiodegeneration_17\NN\entity.n.01|consisted|arteriolopathy|(|of|;|biopsies|. (l_appos) biopsies_24\NNS\diagnostic_test.n.01|20|)|,|glomerulosclerosis (l_conj) glomerulosclerosis_29\NN\entity.n.01|focal|segmental|(|biopsies|)|and|form
D016559_D005355 NONE fk506_1\NNP\entity.n.01|chronic (r_compound) nephropathy_2\NN\uropathy.n.01|fk506 (r_nsubj) consisted_3\VBD\exist.v.01|nephropathy|of|, (r_ccomp) angiodegeneration_17\NN\entity.n.01|consisted|arteriolopathy|(|of|;|biopsies|. (l_appos) biopsies_24\NNS\diagnostic_test.n.01|20|)|,|glomerulosclerosis (l_conj) glomerulosclerosis_29\NN\entity.n.01|focal|segmental|(|biopsies|)|and|form (l_conj) form_37\NN\word.n.01|the|striped|of (l_prep) of_38\IN\entity.n.01|fibrosis (l_pobj) fibrosis_40\NN\pathology.n.02|interstitial|(|biopsies|)
D003404_D007674 NONE creatinine_2\NN\entity.n.01| (r_compound) levels_3\NNS\property.n.02|the|serum|creatinine|of (l_prep) of_4\IN\entity.n.01|patients (l_pobj) patients_5\NNS\case.n.06|in (l_prep) in_6\IN\linear_unit.n.01|group (l_pobj) group_14\NN\abstraction.n.06|the|type|chronic|nephropathy|,|included|, (l_compound) nephropathy_13\NN\uropathy.n.01|fk506
D003404_D007674 NONE creatinine_2\NN\entity.n.01| (r_compound) levels_3\NNS\property.n.02|the|serum|creatinine|of (r_nsubj) were_22\VBD\be.v.01|levels|higher|. (l_acomp) higher_24\JJR\higher.s.01|statistically|than (l_prep) than_25\IN\entity.n.01|those (l_pobj) those_26\DT\entity.n.01|in (l_prep) in_27\IN\linear_unit.n.01|group (l_pobj) group_34\NN\abstraction.n.06|the|type|fk506-nephropathy|(|p|) (l_compound) fk506-nephropathy_33\NNP\entity.n.01|chronic
8955532
D001920_D006973 NONE bradykinin_4\NN\entity.n.01|receptors|in (l_prep) in_7\IN\linear_unit.n.01|disruption (l_pobj) disruption_8\NN\delay.n.02|of|during (l_prep) during_15\IN\entity.n.01|hypertension (l_pobj) hypertension_17\NN\cardiovascular_disease.n.01|acute
D001920_D006973 NONE bradykinin_15\NN\entity.n.01| (r_pobj) of_14\IN\entity.n.01|bradykinin (r_prep) release_13\NN\merchandise.n.01|synthesis|/|of (r_pobj) of_10\IN\entity.n.01|release (r_prep) role_9\NN\duty.n.02|the|of (r_dobj) determine_7\VB\determine.v.01|to|role|activate (l_xcomp) activate_17\VB\initiate.v.02|to|receptors|in (l_prep) in_20\IN\linear_unit.n.01|disruption (l_pobj) disruption_21\NN\delay.n.02|of|during (l_prep) during_28\IN\entity.n.01|hypertension (l_pobj) hypertension_30\NN\cardiovascular_disease.n.01|acute
D001920_D006973 NONE bradykinin_23\NN\entity.n.01| (r_pobj) of_22\IN\entity.n.01|bradykinin (r_prep) release_21\NN\merchandise.n.01|the|synthesis|/|of (r_pobj) to_17\IN\entity.n.01|release (r_prep) related_16\VBN\think.v.03|is|not|to|activate (l_auxpass) is_14\VBZ\be.v.01|that|disruption (l_nsubj) disruption_4\NN\delay.n.02|of|during (l_prep) during_11\IN\entity.n.01|hypertension (l_pobj) hypertension_13\NN\cardiovascular_disease.n.01|acute
D003911_D006973 NONE dextran_15\NN\entity.n.01|labeled (r_pobj) of_11\IN\entity.n.01|dextran (r_prep) clearance_10\NN\interval.n.03|of|before (l_prep) before_16\IN\earlier.r.01|and|during (l_conj) during_18\IN\entity.n.01|hypertension (l_pobj) hypertension_23\NN\cardiovascular_disease.n.01|induced|acute|in
D010656_D006973 CID phenylephrine_19\NN\adrenergic.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|phenylephrine|- (r_amod) hypertension_23\NN\cardiovascular_disease.n.01|induced|acute|in
C065679_D006973 NONE hoe-140_30\NNP\entity.n.01| (r_conj) vehicle_28\NN\conveyance.n.03|and|hoe-140|microm (r_pobj) with_27\IN\entity.n.01|vehicle (r_prep) treated_26\VBN\interact.v.01|with (r_acl) rats_25\NNS\rodent.n.01|treated (r_pobj) in_24\IN\linear_unit.n.01|rats (r_prep) hypertension_23\NN\cardiovascular_disease.n.01|induced|acute|in
8638206
D001279_D010243 CID atracurium_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|atracurium (r_prep) use_4\NN\activity.n.01|prolonged|of|in (r_pobj) after_2\IN\after.s.01|use (r_prep) paralysis_1\NN\dysfunction.n.01|persistent|after|.
D001279_D010243 CID besylate_1\NN\entity.n.01|atracurium|,|nmba|, (r_nsubjpass) associated_22\VBN\think.v.03|besylate|has|also|been|with|,|but|used (l_prep) with_23\IN\entity.n.01|paralysis (l_pobj) paralysis_25\NN\dysfunction.n.01|persistent
D001279_D010243 CID atracurium_5\NN\entity.n.01| (r_npadvmod) related_7\VBN\think.v.03|atracurium|- (r_amod) paralysis_8\NN\dysfunction.n.01|related|persisting
D014673_D010243 CID bromide_21\NN\halide.n.01|vecuronium (r_pobj) as_19\IN\chemical_element.n.01|such|bromide (r_prep) nmbas_17\NNS\entity.n.01|based|as (r_dobj) involved_13\VBN\refer.v.02|reports|have|often|nmbas|,|used|. (l_nsubj) reports_0\NNS\document.n.01|of|after (l_prep) of_1\IN\entity.n.01|paralysis (l_pobj) paralysis_3\NN\dysfunction.n.01|persistent
-1_D010243 NONE benzylisoquinolinium_7\NN\entity.n.01| (r_amod) nmba_8\NNP\entity.n.01|a|acting|benzylisoquinolinium|eliminated (r_appos) besylate_1\NN\entity.n.01|atracurium|,|nmba|, (r_nsubjpass) associated_22\VBN\think.v.03|besylate|has|also|been|with|,|but|used (l_prep) with_23\IN\entity.n.01|paralysis (l_pobj) paralysis_25\NN\dysfunction.n.01|persistent
8953972
D004837_D013345 CID epinephrine_8\NN\catecholamine.n.01| (r_pobj) of_7\IN\entity.n.01|epinephrine (r_prep) use_6\NN\activity.n.01|prehospital|of (r_pobj) with_4\IN\entity.n.01|use (r_prep) associated_3\VBN\think.v.03|with (r_acl) bleeding_2\NN\injury.n.01|fatal|intracranial|associated|.
D004837_D012128 NONE epinephrine_26\NN\catecholamine.n.01|subcutaneous (r_dobj) administer_24\VB\manage.v.02|to|epinephrine (r_xcomp) led_16\VBD\diode.n.02|onset|paramedics|administer|. (l_nsubj) onset_2\NN\start.n.01|the|sudden|of (l_prep) of_3\IN\entity.n.01|distress (l_pobj) distress_5\NN\pain.n.02|respiratory|,|rash
D004837_D005076 NONE epinephrine_26\NN\catecholamine.n.01|subcutaneous (r_dobj) administer_24\VB\manage.v.02|to|epinephrine (r_xcomp) led_16\VBD\diode.n.02|onset|paramedics|administer|. (l_nsubj) onset_2\NN\start.n.01|the|sudden|of (l_prep) of_3\IN\entity.n.01|distress (l_pobj) distress_5\NN\pain.n.02|respiratory|,|rash (l_conj) rash_7\JJ\eruption.n.02|,|and|history
D004837_D006323 CID epinephrine_0\NN\catecholamine.n.01| (r_nsubj) has_1\VBZ\angular_distance.n.01|epinephrine|role (l_dobj) role_4\NN\duty.n.02|a|proven|in (l_prep) in_5\IN\linear_unit.n.01|arrest (l_pobj) arrest_7\NN\capture.n.01|cardiac|in
D004837_D004342 NONE epinephrine_0\NN\catecholamine.n.01| (r_nsubj) has_1\VBZ\angular_distance.n.01|epinephrine|role (r_ccomp) use_14\NN\activity.n.01|has|;|however|,|by (l_prep) by_15\IN\by.r.01|paramedics (l_pobj) paramedics_16\NNS\paraprofessional.n.01|in (l_prep) in_17\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|with (l_prep) with_19\IN\entity.n.01|reaction (l_pobj) reaction_22\NN\chemical_process.n.01|suspected|allergic|and|hypertension
D004837_D006973 NONE epinephrine_0\NN\catecholamine.n.01| (r_nsubj) has_1\VBZ\angular_distance.n.01|epinephrine|role (r_ccomp) use_14\NN\activity.n.01|has|;|however|,|by (l_prep) by_15\IN\by.r.01|paramedics (l_pobj) paramedics_16\NNS\paraprofessional.n.01|in (l_prep) in_17\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|with (l_prep) with_19\IN\entity.n.01|reaction (l_pobj) reaction_22\NN\chemical_process.n.01|suspected|allergic|and|hypertension (l_conj) hypertension_25\NN\cardiovascular_disease.n.01|severe
2334618
D009020_D001049 NONE morphine_17\NN\analgesic.n.01| (r_pobj) of_16\IN\entity.n.01|morphine (r_prep) infusion_15\NN\solution.n.01|a|continuous|i.v.|of (r_dobj) receiving_11\VBG\get.v.01|infusion (r_acl) patients_10\NNS\case.n.06|five|receiving|mean|and|patients (r_pobj) between_8\IN\between.r.01|patients (r_prep) compared_7\VBN\analyze.v.01|incidence|was|between|. (l_nsubjpass) incidence_1\NN\frequency.n.02|the|of (l_prep) of_2\IN\entity.n.01|apnoea (l_pobj) apnoea_5\NN\entity.n.01|postoperative|respiratory
D002045_D001049 NONE bupivacaine_34\NN\entity.n.01|% (r_pobj) of_31\IN\entity.n.01|bupivacaine (r_prep) infusion_30\NN\solution.n.01|a|continuous|extradural|of (r_dobj) receiving_26\VBG\get.v.01|infusion (r_acl) patients_25\NNS\case.n.06|five|receiving|mean|in (r_conj) patients_10\NNS\case.n.06|five|receiving|mean|and|patients (r_pobj) between_8\IN\between.r.01|patients (r_prep) compared_7\VBN\analyze.v.01|incidence|was|between|. (l_nsubjpass) incidence_1\NN\frequency.n.02|the|of (l_prep) of_2\IN\entity.n.01|apnoea (l_pobj) apnoea_5\NN\entity.n.01|postoperative|respiratory
D009020_D020181 CID morphine_25\NN\analgesic.n.01| (r_compound) infusion_26\NN\solution.n.01|a|morphine (r_dobj) had_23\VBD\have.v.01|who|infusion (r_relcl) patients_21\NNS\case.n.06|had (r_pobj) in_20\IN\linear_unit.n.01|patients (r_prep) occurred_17\VBD\happen.v.01|obstructive|frequently|in|. (l_nsubj) obstructive_1\JJ\clogging.s.01|both|(|p (l_appos) p_3\NN\chemical_element.n.01|0.05|)|and|apnoea (l_conj) apnoea_10\NN\entity.n.01|central|(|p|)
D009020_D020182 CID morphine_25\NN\analgesic.n.01| (r_compound) infusion_26\NN\solution.n.01|a|morphine (r_dobj) had_23\VBD\have.v.01|who|infusion (r_relcl) patients_21\NNS\case.n.06|had (r_pobj) in_20\IN\linear_unit.n.01|patients (r_prep) occurred_17\VBD\happen.v.01|obstructive|frequently|in|. (l_nsubj) obstructive_1\JJ\clogging.s.01|both|(|p (l_appos) p_3\NN\chemical_element.n.01|0.05|)|and|apnoea (l_conj) apnoea_10\NN\entity.n.01|central|(|p|)
D009020_D013610 NONE morphine_26\NN\analgesic.n.01| (r_compound) infusion_27\NN\solution.n.01|morphine (r_compound) group_28\NN\abstraction.n.06|the|infusion (r_pobj) in_24\IN\linear_unit.n.01|group (r_prep) beats_17\NNS\youth_subculture.n.01|ventricular|ectopic|(|p|)|in (r_conj) tachyarrhythmias_7\NNS\entity.n.01|(|p|)|and|beats
D009020_D018879 CID morphine_26\NN\analgesic.n.01| (r_compound) infusion_27\NN\solution.n.01|morphine (r_compound) group_28\NN\abstraction.n.06|the|infusion (r_pobj) in_24\IN\linear_unit.n.01|group (r_prep) beats_17\NNS\youth_subculture.n.01|ventricular|ectopic|(|p|)|in
3997294
D000638_D010996 CID amiodarone_9\NN\antiarrhythmic.n.01| (r_compound) therapy_10\NN\medical_care.n.01|amiodarone (r_pobj) during_8\IN\entity.n.01|therapy (r_prep) effusion_5\NN\expression.n.02|pleural|and|neuropathy|during
D000638_D010490 CID amiodarone_9\NN\antiarrhythmic.n.01| (r_compound) therapy_10\NN\medical_care.n.01|amiodarone (r_pobj) during_8\IN\entity.n.01|therapy (r_prep) effusion_5\NN\expression.n.02|pleural|and|neuropathy|during
D000638_D009422 NONE amiodarone_9\NN\antiarrhythmic.n.01| (r_compound) therapy_10\NN\medical_care.n.01|amiodarone (r_pobj) during_8\IN\entity.n.01|therapy (r_prep) effusion_5\NN\expression.n.02|pleural|and|neuropathy|during (l_conj) neuropathy_7\NN\pathology.n.02|
D000638_D002318 NONE amiodarone_11\NN\antiarrhythmic.n.01|(|dose|,|for (r_pobj) with_10\IN\entity.n.01|amiodarone (r_prep) treated_9\VBN\interact.v.01|patient|was|with|. (l_nsubjpass) patient_1\NN\case.n.06|a|with|and|pacemaker (l_prep) with_2\IN\entity.n.01|disease (l_pobj) disease_4\NN\illness.n.01|sinuatrial
D000638_D013617 NONE amiodarone_11\NN\antiarrhythmic.n.01|(|dose|,|for (l_prep) for_28\IN\entity.n.01|control (l_pobj) control_29\NN\power.n.01|of (l_prep) of_30\IN\entity.n.01|tachyarrhythmias (l_pobj) tachyarrhythmias_32\NNS\entity.n.01|supraventricular
D000638_D011014 CID amiodarone_14\NN\antiarrhythmic.n.01| (r_compound) pneumonitis_15\NN\inflammation.n.01|amiodarone
D000638_D011014 CID amiodarone_20\NN\antiarrhythmic.n.01| (r_pobj) of_19\IN\entity.n.01|amiodarone (r_prep) withdrawal_18\NN\retraction.n.01|immediate|of|,|and|prompt (r_dobj) indicates_7\VBZ\tell.v.02|review|need|,|withdrawal|. (l_dobj) need_9\NN\condition.n.01|the|for (l_prep) for_10\IN\entity.n.01|diagnosis (l_pobj) diagnosis_12\NN\designation.n.03|early|of (l_prep) of_13\IN\entity.n.01|pneumonitis (l_pobj) pneumonitis_15\NN\inflammation.n.01|amiodarone
D013256_D011014 NONE steroid_26\NN\organic_compound.n.01| (r_compound) therapy_27\NN\medical_care.n.01|continued|steroid (r_conj) prompt_23\JJ\cue.n.01|but|therapy|ensure (r_conj) withdrawal_18\NN\retraction.n.01|immediate|of|,|and|prompt (r_dobj) indicates_7\VBZ\tell.v.02|review|need|,|withdrawal|. (l_dobj) need_9\NN\condition.n.01|the|for (l_prep) for_10\IN\entity.n.01|diagnosis (l_pobj) diagnosis_12\NN\designation.n.03|early|of (l_prep) of_13\IN\entity.n.01|pneumonitis (l_pobj) pneumonitis_15\NN\inflammation.n.01|amiodarone
9869257
C087567_D000647 NONE pg-9_8\NNP\entity.n.01|mg/kg|, (r_nsubj) administered_18\VBN\manage.v.02|in|,|pg-9|before|,|prevented|. (l_conj) prevented_26\VBN\prevent.v.01|amnesia (l_dobj) amnesia_27\NN\cognitive_state.n.01|induced
C087567_D000647 NONE pg-9_6\NNP\entity.n.01|20 (r_nmod) microg_11\NN\entity.n.01|pg-9|per|,|i.c.v.|) (r_nsubj) was_17\VBD\washington.n.02|in|,|microg|also|able|,|demonstrating|. (l_acomp) able_19\JJ\able.a.01|prevent (l_xcomp) prevent_21\VB\prevent.v.01|to|amnesia (l_dobj) amnesia_25\NN\cognitive_state.n.01|induced
D012601_D000647 CID scopolamine_36\NN\alkaloid.n.01|both|the|non|selective|antimuscarinic|drug|and|antagonist (r_pobj) by_29\IN\by.r.01|scopolamine (r_agent) induced_28\VBN\generate.v.01|by (r_acl) amnesia_27\NN\cognitive_state.n.01|induced
C098725_D000647 CID s-(-)-et-126_41\NNP\entity.n.01| (r_appos) antagonist_40\NN\person.n.01|the|m1-selective|s-(-)-et-126 (r_conj) scopolamine_36\NN\alkaloid.n.01|both|the|non|selective|antimuscarinic|drug|and|antagonist (r_pobj) by_29\IN\by.r.01|scopolamine (r_agent) induced_28\VBN\generate.v.01|by (r_acl) amnesia_27\NN\cognitive_state.n.01|induced
10526274
C056507_D002289 NONE gemcitabine_0\NNP\entity.n.01|plus|vinorelbine (l_conj) vinorelbine_2\NN\entity.n.01|in (l_prep) in_3\IN\linear_unit.n.01|patients (l_pobj) patients_8\NNS\case.n.06|nonsmall|carcinoma (l_compound) carcinoma_7\NN\cancer.n.01|lung
C056507_D002289 NONE gem_12\NNP\art.n.01|and|vnb (r_pobj) of_11\IN\entity.n.01|gem (r_prep) combination_10\NN\collection.n.01|the|of|in (l_prep) in_15\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|elderly|with (l_prep) with_18\IN\entity.n.01|nsclc (l_pobj) nsclc_20\NNP\entity.n.01|advanced|or|those
C030852_D002289 NONE vinorelbine_2\NN\entity.n.01|in (l_prep) in_3\IN\linear_unit.n.01|patients (l_pobj) patients_8\NNS\case.n.06|nonsmall|carcinoma (l_compound) carcinoma_7\NN\cancer.n.01|lung
C030852_D002289 NONE vnb_14\NNP\entity.n.01| (r_conj) gem_12\NNP\art.n.01|and|vnb (r_pobj) of_11\IN\entity.n.01|gem (r_prep) combination_10\NN\collection.n.01|the|of|in (l_prep) in_15\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|elderly|with (l_prep) with_18\IN\entity.n.01|nsclc (l_pobj) nsclc_20\NNP\entity.n.01|advanced|or|those
D002945_D002289 NONE cisplatin_20\NN\entity.n.01| (r_dobj) receive_19\VB\get.v.01|who|can|not|cisplatin (r_relcl) years_11\NNS\time_of_life.n.01|70|or|older|or|patients|receive (r_npadvmod) age_9\NN\property.n.02|gemcitabine|years|. (l_nsubj) gemcitabine_0\NNP\entity.n.01|plus|vinorelbine (l_conj) vinorelbine_2\NN\entity.n.01|in (l_prep) in_3\IN\linear_unit.n.01|patients (l_pobj) patients_8\NNS\case.n.06|nonsmall|carcinoma (l_compound) carcinoma_7\NN\cancer.n.01|lung
D002945_D002289 NONE cisplatin_28\NN\entity.n.01| (r_dobj) receiving_27\VBG\get.v.01|cisplatin (r_pcomp) to_26\IN\entity.n.01|receiving (r_prep) contraindication_25\NN\reason.n.06|some|to (r_pobj) with_23\IN\entity.n.01|contraindication (r_prep) those_22\DT\entity.n.01|with (r_conj) nsclc_20\NNP\entity.n.01|advanced|or|those
D002945_D002289 NONE cisplatin_33\NN\entity.n.01| (r_dobj) receiving_32\VBG\get.v.01|cisplatin (r_pcomp) to_31\IN\entity.n.01|receiving (r_prep) contraindication_30\NN\reason.n.06|some|to (r_dobj) had_28\VBD\have.v.01|who|contraindication (r_conj) were_21\VBD\be.v.01|11|age|but|had (r_conj) /=_16\NFP\entity.n.01|years|and|were (r_punct) included_8\VBN\include.v.01|patients|were|,|were|/=|. (l_nsubjpass) patients_3\NNS\case.n.06|nine|with (l_prep) with_4\IN\entity.n.01|nsclc (l_pobj) nsclc_6\NNP\entity.n.01|advanced
C056507_D064420 NONE gem_1\NNP\art.n.01| (r_nsubj) obtain_4\VB\get.v.01|(|gem|)|may|rate|,|with|. (l_prep) with_17\IN\entity.n.01|toxicity (l_pobj) toxicity_19\NN\definite_quantity.n.01|acceptable|and|improvement|in
C056507_D064420 NONE gem_12\NNP\art.n.01|and|vnb (r_pobj) of_11\IN\entity.n.01|gem (r_prep) combination_10\NN\collection.n.01|the|of|in (r_pobj) of_8\IN\entity.n.01|combination (r_prep) efficacy_5\NN\effectiveness.n.01|the|and|toxicity|of (l_conj) toxicity_7\NN\definite_quantity.n.01|
C030852_D064420 NONE vnb_14\NNP\entity.n.01| (r_conj) gem_12\NNP\art.n.01|and|vnb (r_pobj) of_11\IN\entity.n.01|gem (r_prep) combination_10\NN\collection.n.01|the|of|in (r_pobj) of_8\IN\entity.n.01|combination (r_prep) efficacy_5\NN\effectiveness.n.01|the|and|toxicity|of (l_conj) toxicity_7\NN\definite_quantity.n.01|
D002945_D064420 NONE cisplatin_28\NN\entity.n.01| (r_dobj) receiving_27\VBG\get.v.01|cisplatin (r_pcomp) to_26\IN\entity.n.01|receiving (r_prep) contraindication_25\NN\reason.n.06|some|to (r_pobj) with_23\IN\entity.n.01|contraindication (r_prep) those_22\DT\entity.n.01|with (r_conj) nsclc_20\NNP\entity.n.01|advanced|or|those (r_pobj) with_18\IN\entity.n.01|nsclc (r_prep) patients_17\NNS\case.n.06|elderly|with (r_pobj) in_15\IN\linear_unit.n.01|patients (r_prep) combination_10\NN\collection.n.01|the|of|in (r_pobj) of_8\IN\entity.n.01|combination (r_prep) efficacy_5\NN\effectiveness.n.01|the|and|toxicity|of (l_conj) toxicity_7\NN\definite_quantity.n.01|
20098969
D008694_D001145 NONE methamphetamine_0\NN\amphetamine.n.01| (r_nsubj) is_1\VBZ\be.v.01|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\information.n.02|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\indefinite_quantity.n.01|that|wakefulness|and|produce (l_conj) produce_16\VB\food.n.02|can|effects (l_dobj) effects_18\NNS\personal_property.n.01|other|as (l_prep) as_20\IN\chemical_element.n.01|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\entity.n.01|cardiac|,|hypertension
D008694_D006973 NONE methamphetamine_0\NN\amphetamine.n.01| (r_nsubj) is_1\VBZ\be.v.01|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\information.n.02|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\indefinite_quantity.n.01|that|wakefulness|and|produce (l_conj) produce_16\VB\food.n.02|can|effects (l_dobj) effects_18\NNS\personal_property.n.01|other|as (l_prep) as_20\IN\chemical_element.n.01|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\entity.n.01|cardiac|,|hypertension (l_conj) hypertension_24\NN\cardiovascular_disease.n.01|,|hallucinations
D008694_D006212 NONE methamphetamine_0\NN\amphetamine.n.01| (r_nsubj) is_1\VBZ\be.v.01|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\information.n.02|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\indefinite_quantity.n.01|that|wakefulness|and|produce (l_conj) produce_16\VB\food.n.02|can|effects (l_dobj) effects_18\NNS\personal_property.n.01|other|as (l_prep) as_20\IN\chemical_element.n.01|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\entity.n.01|cardiac|,|hypertension (l_conj) hypertension_24\NN\cardiovascular_disease.n.01|,|hallucinations (l_conj) hallucinations_26\NNS\delusion.n.01|,|and|behavior
D008694_D001523 NONE methamphetamine_0\NN\amphetamine.n.01| (r_nsubj) is_1\VBZ\be.v.01|methamphetamine|stimulant|. (l_attr) stimulant_7\NN\information.n.02|a|addictive|,|powerful|increases (l_relcl) increases_9\VBZ\indefinite_quantity.n.01|that|wakefulness|and|produce (l_conj) produce_16\VB\food.n.02|can|effects (l_dobj) effects_18\NNS\personal_property.n.01|other|as (l_prep) as_20\IN\chemical_element.n.01|such|dysrhythmias (l_pobj) dysrhythmias_22\NNS\entity.n.01|cardiac|,|hypertension (l_conj) hypertension_24\NN\cardiovascular_disease.n.01|,|hallucinations (l_conj) hallucinations_26\NNS\delusion.n.01|,|and|behavior (l_conj) behavior_30\NN\activity.n.01|violent
D008694_D014987 NONE methamphetamine_3\NN\amphetamine.n.01| (r_dobj) abusing_2\VBG\treat.v.01|methamphetamine (r_acl) patients_1\NNS\case.n.06|dental|abusing (r_nsubj) present_5\VB\time.n.05|patients|can|with|. (l_prep) with_6\IN\entity.n.01|hygiene (l_pobj) hygiene_9\NN\sanitariness.n.01|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\dryness.n.01|,|caries
D008694_D003731 CID methamphetamine_3\NN\amphetamine.n.01| (r_dobj) abusing_2\VBG\treat.v.01|methamphetamine (r_acl) patients_1\NNS\case.n.06|dental|abusing (r_nsubj) present_5\VB\time.n.05|patients|can|with|. (l_prep) with_6\IN\entity.n.01|hygiene (l_pobj) hygiene_9\NN\sanitariness.n.01|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\dryness.n.01|,|caries (l_conj) caries_14\NNS\decay.n.01|rampant|(|mouth|,|and|wear
D008694_D003731 CID methamphetamine_5\NN\amphetamine.n.01| (r_pobj) of_4\IN\entity.n.01|methamphetamine (r_prep) use_3\NN\activity.n.01|her|of|for (r_dobj) reported_1\VBD\inform.v.01|she|use|and|experienced|. (l_conj) experienced_12\VBN\undergo.v.01|had|not|episodes|started (l_dobj) episodes_16\NNS\happening.n.01|any|major|carious
D008694_-1 NONE methamphetamine_3\NN\amphetamine.n.01| (r_dobj) abusing_2\VBG\treat.v.01|methamphetamine (r_acl) patients_1\NNS\case.n.06|dental|abusing (r_nsubj) present_5\VB\time.n.05|patients|can|with|. (l_prep) with_6\IN\entity.n.01|hygiene (l_pobj) hygiene_9\NN\sanitariness.n.01|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\dryness.n.01|,|caries (l_conj) caries_14\NNS\decay.n.01|rampant|(|mouth|,|and|wear (l_appos) mouth_18\NN\rima.n.01|"|meth|"|)
D008694_-1 NONE methamphetamines_23\NNS\amphetamine.n.01| (r_dobj) abusing_22\VBG\treat.v.01|who|may|be|methamphetamines (r_relcl) patients_18\NNS\case.n.06|abusing (r_dobj) manage_17\VBP\succeed.v.01|patients (r_conj) recognize_15\VBP\accept.v.01|practitioners|and|manage (r_ccomp) help_12\VB\activity.n.01|to|recognize (r_advcl) presented_10\VBN\show.v.04|case|was|help|. (l_nsubjpass) case_2\NN\happening.n.01|this|clinical|showing (l_acl) showing_3\VBG\display.n.05|manifestations (l_dobj) manifestations_5\NNS\appearance.n.02|oral|of (l_prep) of_6\IN\entity.n.01|mouth (l_pobj) mouth_8\NN\rima.n.01|meth
D008694_D057085 NONE methamphetamine_3\NN\amphetamine.n.01| (r_dobj) abusing_2\VBG\treat.v.01|methamphetamine (r_acl) patients_1\NNS\case.n.06|dental|abusing (r_nsubj) present_5\VB\time.n.05|patients|can|with|. (l_prep) with_6\IN\entity.n.01|hygiene (l_pobj) hygiene_9\NN\sanitariness.n.01|poor|oral|,|xerostomia (l_conj) xerostomia_11\NN\dryness.n.01|,|caries (l_conj) caries_14\NNS\decay.n.01|rampant|(|mouth|,|and|wear (l_conj) wear_25\NN\deterioration.n.01|excessive|tooth
3425586
D003622_D000743 CID dapsone_0\NN\antibacterial.n.01| (r_npadvmod) associated_2\VBN\think.v.03|dapsone|- (r_amod) anemia_6\NN\blood_disease.n.01|associated|heinz|body|hemolytic|in|.
D003622_D000743 CID dapsone_23\NN\antibacterial.n.01|day|) (r_pobj) of_22\IN\entity.n.01|dapsone (r_prep) dose_21\NN\medicine.n.02|a|of|associated (r_dobj) taking_19\VBG\action.n.01|while|dose (r_advcl) developed_12\VBD\create.v.02|woman|anemia|taking|. (l_dobj) anemia_17\NN\blood_disease.n.01|a|heinz|body|hemolytic
D003622_D000743 CID dapsone_21\NN\antibacterial.n.01| (r_nsubj) cause_24\VB\origin.n.03|since|dapsone|does|not|anemia|at (l_dobj) anemia_26\NN\blood_disease.n.01|hemolytic
D003622_D007918 NONE dapsone_23\NN\antibacterial.n.01|day|) (r_pobj) of_22\IN\entity.n.01|dapsone (r_prep) dose_21\NN\medicine.n.02|a|of|associated (r_dobj) taking_19\VBG\action.n.01|while|dose (r_advcl) developed_12\VBD\create.v.02|woman|anemia|taking|. (l_nsubj) woman_2\NN\adult.n.01|a|cambodian|with|leprosy (l_conj) leprosy_11\NN\infectious_disease.n.01|
D003622_D006461 NONE dapsone_23\NN\antibacterial.n.01|day|) (r_pobj) of_22\IN\entity.n.01|dapsone (r_prep) dose_21\NN\medicine.n.02|a|of|associated (l_acl) associated_32\VBN\think.v.03|not|usually|with (l_prep) with_33\IN\entity.n.01|hemolysis (l_pobj) hemolysis_35\NN\lysis.n.02|clinical
354896
D008012_D006323 CID lidocaine_0\NN\local_anesthetic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|lidocaine|- (r_amod) asystole_4\NN\pathology.n.02|induced|cardiac|.
D008012_D003866 NONE lidocaine_8\NN\local_anesthetic.n.01| (r_pobj) of_7\IN\entity.n.01|lidocaine (r_prep) bolus_6\NN\ball.n.03|a|single|50-mg|of|in (r_pobj) of_2\IN\entity.n.01|bolus (r_prep) administration_1\NN\management.n.01|intravenous|of (r_nsubj) resulted_15\VBD\prove.v.01|administration|in|. (l_prep) in_16\IN\linear_unit.n.01|depression (l_pobj) depression_18\NN\psychological_state.n.01|profound|of
D008012_D001919 NONE lidocaine_29\NN\local_anesthetic.n.01| (r_pobj) to_28\IN\entity.n.01|lidocaine (r_prep) idiosyncrasy_27\NN\peculiarity.n.02|a|true|to (r_dobj) represented_24\VBD\equal.v.01|,|thus|,|this|probably|idiosyncrasy|. (r_conj) had_2\VBD\have.v.01|patient|conditions|;|and|represented (l_dobj) conditions_6\NNS\context.n.02|no|apparent|associated|predisposed (l_relcl) predisposed_10\VBN\dispose.v.03|which|might|have|him|to (l_prep) to_12\IN\entity.n.01|development (l_pobj) development_14\NN\improvement.n.02|the|of (l_prep) of_15\IN\entity.n.01|bradyarrhythmias (l_pobj) bradyarrhythmias_16\NNS\entity.n.01|
2670794
D000809_D011665 NONE angiotensin_5\NN\vasoconstrictor.n.01|converting (l_acl) converting_6\VBG\change.v.01|enzyme|on (l_prep) on_11\IN\on.a.01|insufficiency (l_pobj) insufficiency_15\NN\failing.n.01|pulmonary
D000809_D011665 NONE angiotensin_11\NN\vasoconstrictor.n.01|converting (r_pobj) of_10\IN\entity.n.01|angiotensin (r_prep) inhibitor_9\NN\substance.n.07|an|of (r_appos) injection_0\NN\insertion.n.02|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\decrease.v.02|injection|insufficiency|. (l_dobj) insufficiency_23\NN\failing.n.01|pulmonary|in
D000809_D051437 NONE angiotensin_5\NN\vasoconstrictor.n.01|converting (l_acl) converting_6\VBG\change.v.01|enzyme|on (l_prep) on_11\IN\on.a.01|insufficiency (l_pobj) insufficiency_15\NN\failing.n.01|pulmonary
D000809_D051437 NONE angiotensin_11\NN\vasoconstrictor.n.01|converting (r_pobj) of_10\IN\entity.n.01|angiotensin (r_prep) inhibitor_9\NN\substance.n.07|an|of (r_appos) injection_0\NN\insertion.n.02|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\decrease.v.02|injection|insufficiency|. (l_dobj) insufficiency_23\NN\failing.n.01|pulmonary|in
D000809_D004211 NONE angiotensin_5\NN\vasoconstrictor.n.01|converting (r_pobj) of_4\IN\entity.n.01|angiotensin (r_prep) inhibitor_3\NN\substance.n.07|an|of (r_pobj) of_1\IN\entity.n.01|inhibitor (r_prep) effects_0\NNS\personal_property.n.01|of|due|. (l_amod) due_16\IN\right.n.01|to|coagulation (l_pobj) coagulation_19\NN\natural_process.n.01|intravascular|in
D002216_D011665 NONE captopril_9\NNP\ace_inhibitor.n.01| (r_appos) enzyme_7\NN\catalyst.n.01|(|captopril|) (r_dobj) converting_6\VBG\change.v.01|enzyme|on (l_prep) on_11\IN\on.a.01|insufficiency (l_pobj) insufficiency_15\NN\failing.n.01|pulmonary
D002216_D011665 NONE captopril_2\NNP\ace_inhibitor.n.01| (r_pobj) of_1\IN\entity.n.01|captopril (r_prep) injection_0\NN\insertion.n.02|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\decrease.v.02|injection|insufficiency|. (l_dobj) insufficiency_23\NN\failing.n.01|pulmonary|in
D002216_D051437 NONE captopril_9\NNP\ace_inhibitor.n.01| (r_appos) enzyme_7\NN\catalyst.n.01|(|captopril|) (r_dobj) converting_6\VBG\change.v.01|enzyme|on (l_prep) on_11\IN\on.a.01|insufficiency (l_pobj) insufficiency_15\NN\failing.n.01|pulmonary
D002216_D051437 NONE captopril_2\NNP\ace_inhibitor.n.01| (r_pobj) of_1\IN\entity.n.01|captopril (r_prep) injection_0\NN\insertion.n.02|of|(|mg/kg|)|,|inhibitor|, (r_nsubj) reduced_18\VBD\decrease.v.02|injection|insufficiency|. (l_dobj) insufficiency_23\NN\failing.n.01|pulmonary|in
D002216_D004211 NONE captopril_9\NNP\ace_inhibitor.n.01| (r_appos) enzyme_7\NN\catalyst.n.01|(|captopril|) (r_dobj) converting_6\VBG\change.v.01|enzyme|on (r_acl) angiotensin_5\NN\vasoconstrictor.n.01|converting (r_pobj) of_4\IN\entity.n.01|angiotensin (r_prep) inhibitor_3\NN\substance.n.07|an|of (r_pobj) of_1\IN\entity.n.01|inhibitor (r_prep) effects_0\NNS\personal_property.n.01|of|due|. (l_amod) due_16\IN\right.n.01|to|coagulation (l_pobj) coagulation_19\NN\natural_process.n.01|intravascular|in
D014148_D004211 CID acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (l_prep) of_1\IN\entity.n.01|coagulation (l_pobj) coagulation_3\NN\natural_process.n.01|intravascular|and|inhibition
D014148_D004211 CID amca_16\NNP\entity.n.01|(|) (r_appos) acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (l_prep) of_1\IN\entity.n.01|coagulation (l_pobj) coagulation_3\NN\natural_process.n.01|intravascular|and|inhibition
D014148_D011665 NONE acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_dobj) rise_22\NN\emergence.n.01|to (l_prep) to_23\IN\entity.n.01|insufficiency (l_pobj) insufficiency_27\NN\failing.n.01|pulmonary
D014148_D011665 NONE amca_16\NNP\entity.n.01|(|) (r_appos) acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_dobj) rise_22\NN\emergence.n.01|to (l_prep) to_23\IN\entity.n.01|insufficiency (l_pobj) insufficiency_27\NN\failing.n.01|pulmonary
D014148_D051437 NONE acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_dobj) rise_22\NN\emergence.n.01|to (l_prep) to_23\IN\entity.n.01|insufficiency (l_pobj) insufficiency_27\NN\failing.n.01|pulmonary
D014148_D051437 NONE amca_16\NNP\entity.n.01|(|) (r_appos) acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_dobj) rise_22\NN\emergence.n.01|to (l_prep) to_23\IN\entity.n.01|insufficiency (l_pobj) insufficiency_27\NN\failing.n.01|pulmonary
D014148_D014947 NONE acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_advcl) resembling_28\VBG\match.v.01|occurring (l_ccomp) occurring_30\VBG\happen.v.01|that|after (l_prep) after_31\IN\after.s.01|trauma (l_pobj) trauma_32\NN\ill_health.n.01|or|sepsis|in
D014148_D014947 NONE amca_16\NNP\entity.n.01|(|) (r_appos) acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_advcl) resembling_28\VBG\match.v.01|occurring (l_ccomp) occurring_30\VBG\happen.v.01|that|after (l_prep) after_31\IN\after.s.01|trauma (l_pobj) trauma_32\NN\ill_health.n.01|or|sepsis|in
D014148_D018805 NONE acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_advcl) resembling_28\VBG\match.v.01|occurring (l_ccomp) occurring_30\VBG\happen.v.01|that|after (l_prep) after_31\IN\after.s.01|trauma (l_pobj) trauma_32\NN\ill_health.n.01|or|sepsis|in (l_conj) sepsis_34\NN\infection.n.01|
D014148_D018805 NONE amca_16\NNP\entity.n.01|(|) (r_appos) acid_14\NN\compound.n.02|tranexamic|amca (r_conj) thrombin_11\NN\coagulase.n.01|and|acid (r_pobj) of_10\IN\entity.n.01|thrombin (r_prep) injection_9\NN\insertion.n.02|of|in (r_pobj) by_8\IN\by.r.01|injection (r_prep) induction_0\NN\ceremony.n.01|of|by (r_nsubj) gives_21\VBZ\elasticity.n.01|induction|rise|resembling|. (l_advcl) resembling_28\VBG\match.v.01|occurring (l_ccomp) occurring_30\VBG\happen.v.01|that|after (l_prep) after_31\IN\after.s.01|trauma (l_pobj) trauma_32\NN\ill_health.n.01|or|sepsis|in (l_conj) sepsis_34\NN\infection.n.01|
D014508_D007674 NONE urea_9\NN\organic_compound.n.01|serum (r_pobj) in_7\IN\linear_unit.n.01|urea|and|in (r_prep) increase_6\NN\indefinite_quantity.n.01|an|in (r_pobj) by_4\IN\by.r.01|increase (r_agent) reflected_3\VBN\indicate.v.02|as|by (r_advcl) damage_1\NN\change.n.01|renal|reflected
D002216_D007674 NONE captopril_17\NNP\ace_inhibitor.n.01| (r_pobj) by_16\IN\by.r.01|captopril (r_agent) prevented_15\VBN\prevent.v.01|damage|was|by|. (l_nsubjpass) damage_1\NN\change.n.01|renal|reflected
D002216_D007674 NONE captopril_0\NNP\ace_inhibitor.n.01| (r_nsubj) reduce_8\VB\decrease.v.02|captopril|may|,|by|,|increase|,|diminishing|. (l_advcl) diminishing_26\VBG\change_magnitude.v.01|thereby|aggregation|,|with (l_prep) with_36\IN\entity.n.01|result (l_pobj) result_38\NN\phenomenon.n.01|the|deposited (l_acl) deposited_44\VBN\fasten.v.01|that|fibrin|will|be|and|produced (l_conj) produced_52\VBN\make.v.03|damage|will|be (l_nsubjpass) damage_49\NN\change.n.01|less|kidney
9931093
D016559_D006973 CID 506-induced_3\JJ\entity.n.01|mechanisms (r_nummod) hypertension_4\NN\cardiovascular_disease.n.01|506-induced|in|.
D016559_D006973 CID 506_5\CD\entity.n.01| (r_nummod) fk_4\NNP\entity.n.01|506 (r_pobj) of_3\IN\entity.n.01|fk (r_prep) utility_2\NN\service.n.04|the|clinical|of (r_nsubjpass) complicated_7\VBN\change.v.01|utility|is|by|. (l_agent) by_8\IN\by.r.01|hypertension (l_pobj) hypertension_10\NN\cardiovascular_disease.n.01|substantial|and|nephrotoxicity
D016559_D006973 CID 506-induced_6\JJ\entity.n.01| (r_compound) hypertension_7\NN\cardiovascular_disease.n.01|fk|506-induced
D016559_D006973 CID 506_16\CD\entity.n.01| (r_nummod) fk_15\NNP\entity.n.01|506 (r_pobj) of_14\IN\entity.n.01|fk (r_prep) effects_13\NNS\personal_property.n.01|the|chronic|of|on (r_dobj) studied_10\VBD\analyze.v.01|clarify|,|we|effects|expression (l_advcl) clarify_1\VB\explain.v.01|to|mechanisms (l_dobj) mechanisms_3\NNS\chemical_process.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypertension (l_pobj) hypertension_7\NN\cardiovascular_disease.n.01|fk|506-induced
D016559_D006973 CID 506-induced_17\JJ\entity.n.01| (r_nummod) fk_16\NNP\entity.n.01|506-induced (r_poss) hypertension_18\NN\cardiovascular_disease.n.01|fk|in
D016559_D006973 CID 506-induced_4\JJ\entity.n.01| (r_nummod) hypertension_5\NN\cardiovascular_disease.n.01|fk|506-induced|in
D016559_D007674 NONE 506_5\CD\entity.n.01| (r_nummod) fk_4\NNP\entity.n.01|506 (r_pobj) of_3\IN\entity.n.01|fk (r_prep) utility_2\NN\service.n.04|the|clinical|of (r_nsubjpass) complicated_7\VBN\change.v.01|utility|is|by|. (l_agent) by_8\IN\by.r.01|hypertension (l_pobj) hypertension_10\NN\cardiovascular_disease.n.01|substantial|and|nephrotoxicity (l_conj) nephrotoxicity_12\NN\entity.n.01|
D009569_D006973 NONE oxide_44\NN\compound.n.02| (r_compound) synthase_45\NN\entity.n.01|,|the|endothelial|nitric|oxide|(|activity|. (r_conj) expression_27\NN\countenance.n.01|,|the|of|et-1|and|converting|synthase (r_dobj) studied_10\VBD\analyze.v.01|clarify|,|we|effects|expression (l_advcl) clarify_1\VB\explain.v.01|to|mechanisms (l_dobj) mechanisms_3\NNS\chemical_process.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypertension (l_pobj) hypertension_7\NN\cardiovascular_disease.n.01|fk|506-induced
C079574_D006973 NONE 139317_14\CD\entity.n.01| (r_nummod) fr_13\NNP\metallic_element.n.01|139317|on (l_prep) on_15\IN\on.a.01|hypertension (l_pobj) hypertension_18\NN\cardiovascular_disease.n.01|fk|in
1919871
D001241_D007681 CID aspirin_20\NN\analgesic.n.01|and|paracetamol|in (r_pobj) with_19\IN\entity.n.01|aspirin (r_prep) treatment_18\NN\care.n.01|continuous|term|with (r_pobj) during_13\IN\entity.n.01|treatment (r_prep) developed_12\VBN\create.v.02|during (r_acl) ability_11\NN\quality.n.01|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\death.n.02|renal|papillary|(|rpn|)|and|ability|.
D001241_D007681 CID aspirin_20\NN\analgesic.n.01|and|paracetamol|in (r_pobj) with_19\IN\entity.n.01|aspirin (r_prep) treatment_18\NN\care.n.01|continuous|term|with (r_pobj) during_13\IN\entity.n.01|treatment (r_prep) developed_12\VBN\create.v.02|during (r_acl) ability_11\NN\quality.n.01|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\death.n.02|renal|papillary|(|rpn|)|and|ability|. (l_appos) rpn_4\NNP\entity.n.01|
D000082_D007681 CID paracetamol_22\JJ\entity.n.01| (r_conj) aspirin_20\NN\analgesic.n.01|and|paracetamol|in (r_pobj) with_19\IN\entity.n.01|aspirin (r_prep) treatment_18\NN\care.n.01|continuous|term|with (r_pobj) during_13\IN\entity.n.01|treatment (r_prep) developed_12\VBN\create.v.02|during (r_acl) ability_11\NN\quality.n.01|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\death.n.02|renal|papillary|(|rpn|)|and|ability|.
D000082_D007681 CID paracetamol_22\JJ\entity.n.01| (r_conj) aspirin_20\NN\analgesic.n.01|and|paracetamol|in (r_pobj) with_19\IN\entity.n.01|aspirin (r_prep) treatment_18\NN\care.n.01|continuous|term|with (r_pobj) during_13\IN\entity.n.01|treatment (r_prep) developed_12\VBN\create.v.02|during (r_acl) ability_11\NN\quality.n.01|a|decreased|urinary|concentrating|developed (r_conj) necrosis_2\NN\death.n.02|renal|papillary|(|rpn|)|and|ability|. (l_appos) rpn_4\NNP\entity.n.01|
18996674
D004837_D011317 NONE epinephrine_1\NN\catecholamine.n.01|intracavernous|:|treatment|. (l_appos) treatment_6\NN\care.n.01|a|invasive|for (l_prep) for_7\IN\entity.n.01|priapism (l_pobj) priapism_8\NN\pathology.n.02|in
D003042_D011317 CID cocaine_9\NN\hard_drug.n.01| (r_compound) user_10\NN\person.n.01|an|admitted|frequent|cocaine (r_appos) man_4\NN\adult.n.01|a|old|,|user|, (r_nsubj) presented_12\VBN\show.v.04|man|to|on|. (l_prep) on_20\IN\on.a.01|occasions (l_pobj) occasions_23\NNS\business.n.05|two|separate|with (l_prep) with_24\IN\entity.n.01|history (l_pobj) history_26\NN\past.n.01|a|of|after (l_prep) of_27\IN\entity.n.01|priapism (l_pobj) priapism_28\NN\pathology.n.02|
D003042_D011317 CID cocaine_30\NN\hard_drug.n.01| (r_compound) use_31\NN\activity.n.01|cocaine (r_pobj) after_29\IN\after.s.01|use (r_prep) history_26\NN\past.n.01|a|of|after (l_prep) of_27\IN\entity.n.01|priapism (l_pobj) priapism_28\NN\pathology.n.02|
8386779
D017693_D004414 NONE bicarbonate_1\NN\carbonate.n.01|sodium (r_nsubj) alleviates_2\VBZ\better.v.02|bicarbonate|pain|induced|. (l_dobj) pain_4\NN\symptom.n.01|penile
D017693_D004414 NONE bicarbonate_43\NN\carbonate.n.01|sodium|to (r_pobj) of_41\IN\entity.n.01|bicarbonate (r_prep) addition_40\NN\component.n.03|the|of (r_pobj) without_38\IN\entity.n.01|addition (r_conj) with_36\IN\entity.n.01|or|without (r_prep) injections_35\NNS\insertion.n.02|intracorporeal|with (r_pobj) following_33\VBG\multitude.n.03|injections (r_prep) comparing_27\VBG\examination.n.01|incidence|following (r_acl) study_26\NN\examination.n.01|a|randomized|comparing (r_dobj) performed_23\VBD\perform.v.01|in|,|we|study|medications. (l_prep) in_0\IN\linear_unit.n.01|attempt (l_pobj) attempt_2\NN\activity.n.01|an|determine (l_acl) determine_4\VB\determine.v.01|to|be (l_ccomp) be_13\VB\metallic_element.n.01|whether|pain|could|due (l_nsubj) pain_7\NN\symptom.n.01|penile|associated
D017693_D004414 NONE bicarbonate_43\NN\carbonate.n.01|sodium|to (r_pobj) of_41\IN\entity.n.01|bicarbonate (r_prep) addition_40\NN\component.n.03|the|of (r_pobj) without_38\IN\entity.n.01|addition (r_conj) with_36\IN\entity.n.01|or|without (r_prep) injections_35\NNS\insertion.n.02|intracorporeal|with (r_pobj) following_33\VBG\multitude.n.03|injections (r_prep) comparing_27\VBG\examination.n.01|incidence|following (l_dobj) incidence_29\NN\frequency.n.02|the|of (l_prep) of_30\IN\entity.n.01|pain (l_pobj) pain_32\NN\symptom.n.01|penile
D017693_D004414 NONE bicarbonate_6\NN\carbonate.n.01|sodium (r_pobj) without_4\IN\entity.n.01|bicarbonate (r_prep) patients_3\NNS\case.n.06|the|19|without|added (r_pobj) of_0\IN\entity.n.01|patients (r_prep) complained_16\VBD\complain.v.01|of|of|due|,|complained|. (l_prep) of_17\IN\entity.n.01|pain (l_pobj) pain_19\NN\symptom.n.01|penile
D017693_D004414 NONE bicarbonate_6\NN\carbonate.n.01|sodium (r_pobj) without_4\IN\entity.n.01|bicarbonate (r_prep) patients_3\NNS\case.n.06|the|19|without|added (r_pobj) of_0\IN\entity.n.01|patients (r_prep) complained_16\VBD\complain.v.01|of|of|due|,|complained|. (l_advcl) complained_40\VBD\complain.v.01|while|1|of (l_prep) of_41\IN\entity.n.01|pain (l_pobj) pain_43\NN\symptom.n.01|penile
D017693_D004414 NONE bicarbonate_39\NN\carbonate.n.01|sodium (r_dobj) received_37\VBD\get.v.01|who|bicarbonate (r_relcl) men_31\NNS\force.n.04|the|19|(|%|)|received (r_pobj) of_28\IN\entity.n.01|men (r_prep) 1_27\CD\digit.n.01|only|of (r_nsubj) complained_40\VBD\complain.v.01|while|1|of (r_advcl) complained_16\VBD\complain.v.01|of|of|due|,|complained|. (l_prep) of_17\IN\entity.n.01|pain (l_pobj) pain_19\NN\symptom.n.01|penile
D017693_D004414 NONE bicarbonate_39\NN\carbonate.n.01|sodium (r_dobj) received_37\VBD\get.v.01|who|bicarbonate (r_relcl) men_31\NNS\force.n.04|the|19|(|%|)|received (r_pobj) of_28\IN\entity.n.01|men (r_prep) 1_27\CD\digit.n.01|only|of (r_nsubj) complained_40\VBD\complain.v.01|while|1|of (l_prep) of_41\IN\entity.n.01|pain (l_pobj) pain_43\NN\symptom.n.01|penile
D017693_D007172 NONE bicarbonate_1\NN\carbonate.n.01|sodium (r_nsubj) alleviates_2\VBZ\better.v.02|bicarbonate|pain|induced|. (l_advcl) induced_5\VBN\generate.v.01|by (l_agent) by_6\IN\by.r.01|injections (l_pobj) injections_8\NNS\insertion.n.02|intracavernous|for (l_prep) for_9\IN\entity.n.01|dysfunction (l_pobj) dysfunction_11\NN\pathology.n.02|erectile
D010208_D007172 NONE papaverine_25\NN\muscle_relaxant.n.01|6|mg.|,|micrograms (r_appos) drugs_21\NNS\agent.n.03|3|:|papaverine (r_pobj) of_19\IN\entity.n.01|drugs (r_prep) combination_18\NN\collection.n.01|a|of (r_pobj) of_16\IN\entity.n.01|combination (r_prep) ml._15\NN\entity.n.01|0.2|of (r_dobj) received_13\VBD\get.v.01|total|ml.|. (l_nsubj) total_1\NN\whole.n.02|a|of (l_prep) of_2\IN\entity.n.01|patients (l_pobj) patients_5\NNS\case.n.06|38|consecutive|presented (l_relcl) presented_7\VBD\show.v.04|who|to|with (l_prep) with_11\IN\entity.n.01|impotence (l_pobj) impotence_12\NN\quality.n.01|
3187073
D005472_D002637 CID 5-fu_6\CD\entity.n.01| (r_compound) treatment_7\NN\care.n.01|5-fu (r_pobj) on_5\IN\on.a.01|treatment (r_prep) patients_4\NNS\case.n.06|on (r_nsubj) be_9\VB\metallic_element.n.01|that|patients|should|under|and|discontinued (l_conj) discontinued_19\VBN\discontinue.v.01|that|treatment|should|be|observed (l_advcl) observed_26\VBN\spy.v.03|if|pain|is (l_nsubjpass) pain_22\NN\symptom.n.01|chest|or|tachyarrhythmia
D005472_D013610 NONE 5-fu_6\CD\entity.n.01| (r_compound) treatment_7\NN\care.n.01|5-fu (r_pobj) on_5\IN\on.a.01|treatment (r_prep) patients_4\NNS\case.n.06|on (r_nsubj) be_9\VB\metallic_element.n.01|that|patients|should|under|and|discontinued (l_conj) discontinued_19\VBN\discontinue.v.01|that|treatment|should|be|observed (l_advcl) observed_26\VBN\spy.v.03|if|pain|is (l_nsubjpass) pain_22\NN\symptom.n.01|chest|or|tachyarrhythmia (l_conj) tachyarrhythmia_24\NN\entity.n.01|
16274958
D017255_D055154 CID acitretin_3\NN\entity.n.01| (r_conj) dysphonia_1\NN\speech_disorder.n.01|recurrent|and|acitretin|.
D017255_D055154 CID acitretin_15\NN\entity.n.01| (r_pobj) by_14\IN\by.r.01|acitretin (r_agent) treated_13\VBN\interact.v.01|while|she|was|by (r_advcl) report_1\VBP\document.n.01|we|case|treated|. (l_dobj) case_3\NN\happening.n.01|the|of (l_prep) of_4\IN\entity.n.01|woman (l_pobj) woman_6\NN\adult.n.01|a|complaining (l_acl) complaining_7\VBG\complain.v.01|of (l_prep) of_8\IN\entity.n.01|dysphonia (l_pobj) dysphonia_9\NN\speech_disorder.n.01|
D017255_D055154 CID acitretin_10\NN\entity.n.01| (r_advmod) induced_12\VBN\generate.v.01|acitretin|- (r_amod) dysphonia_13\NN\speech_disorder.n.01|induced
1732369
D004280_D009369 NONE dobutamine_0\NNP\entity.n.01| (r_nsubj) stress_1\VBP\prosody.n.01|dobutamine|echocardiography|:|indicator|. (l_appos) indicator_6\NN\fact.n.02|a|sensitive|of (l_prep) of_7\IN\entity.n.01|function (l_pobj) function_10\NN\mathematical_relation.n.01|diminished|myocardial|in (l_prep) in_11\IN\linear_unit.n.01|survivors (l_pobj) survivors_19\NNS\unfortunate.n.01|asymptomatic|treated|term|of (l_prep) of_20\IN\entity.n.01|cancer (l_pobj) cancer_22\NN\malignant_tumor.n.01|childhood
D004280_D009369 NONE dobutamine_21\NN\entity.n.01| (r_compound) infusion_22\NN\solution.n.01|dobutamine (r_dobj) using_20\VBG\mistreatment.n.01|infusion|differentiate (l_xcomp) differentiate_24\VB\identify.v.01|to|survivors (l_dobj) survivors_29\NNS\unfortunate.n.01|asymptomatic|term|of|treated (l_prep) of_30\IN\entity.n.01|cancer (l_pobj) cancer_32\NN\malignant_tumor.n.01|childhood
D004317_D009369 NONE doxorubicin_13\NN\antibiotic.n.01| (r_npadvmod) treated_15\VBN\interact.v.01|doxorubicin|- (r_amod) survivors_19\NNS\unfortunate.n.01|asymptomatic|treated|term|of (l_prep) of_20\IN\entity.n.01|cancer (l_pobj) cancer_22\NN\malignant_tumor.n.01|childhood
D004317_D009369 NONE doxorubicin_13\NN\antibiotic.n.01| (r_pobj) due_11\IN\right.n.01|to|doxorubicin (r_amod) damage_10\NN\change.n.01|cardiac|due (r_pobj) for_8\IN\entity.n.01|damage (r_prep) test_7\NN\experiment.n.02|a|sensitive|echocardiographic|screening|for (r_dobj) develop_1\VB\create.v.02|to|test (r_advcl) performed_19\VBN\perform.v.01|develop|,|study|was|using|. (l_xcomp) using_20\VBG\mistreatment.n.01|infusion|differentiate (l_xcomp) differentiate_24\VB\identify.v.01|to|survivors (l_dobj) survivors_29\NNS\unfortunate.n.01|asymptomatic|term|of|treated (l_prep) of_30\IN\entity.n.01|cancer (l_pobj) cancer_32\NN\malignant_tumor.n.01|childhood
D004317_D009369 NONE doxorubicin_35\NN\antibiotic.n.01| (r_pobj) with_34\IN\entity.n.01|doxorubicin (r_prep) treated_33\VBN\interact.v.01|with|from (r_acl) survivors_29\NNS\unfortunate.n.01|asymptomatic|term|of|treated (l_prep) of_30\IN\entity.n.01|cancer (l_pobj) cancer_32\NN\malignant_tumor.n.01|childhood
D004317_D009202 CID doxorubicin_0\NNP\antibiotic.n.01| (r_nsubj) is_1\VBZ\be.v.01|doxorubicin|agent|. (l_attr) agent_6\NN\causal_agent.n.01|an|effective|anticancer|chemotherapeutic|known (l_acl) known_7\VBN\know.v.01|cause (l_xcomp) cause_9\VB\origin.n.03|to|cardiomyopathy (l_dobj) cardiomyopathy_13\NN\heart_disease.n.01|acute
D004317_D006331 NONE doxorubicin_13\NN\antibiotic.n.01| (r_pobj) due_11\IN\right.n.01|to|doxorubicin (r_amod) damage_10\NN\change.n.01|cardiac|due
D004317_D006331 NONE doxorubicin_35\NN\antibiotic.n.01| (r_pobj) with_34\IN\entity.n.01|doxorubicin (r_prep) treated_33\VBN\interact.v.01|with|from (r_acl) survivors_29\NNS\unfortunate.n.01|asymptomatic|term|of|treated (r_dobj) differentiate_24\VB\identify.v.01|to|survivors (r_xcomp) using_20\VBG\mistreatment.n.01|infusion|differentiate (r_xcomp) performed_19\VBN\perform.v.01|develop|,|study|was|using|. (l_advcl) develop_1\VB\create.v.02|to|test (l_dobj) test_7\NN\experiment.n.02|a|sensitive|echocardiographic|screening|for (l_prep) for_8\IN\entity.n.01|damage (l_pobj) damage_10\NN\change.n.01|cardiac|due
D004280_D006331 NONE dobutamine_21\NN\entity.n.01| (r_compound) infusion_22\NN\solution.n.01|dobutamine (r_dobj) using_20\VBG\mistreatment.n.01|infusion|differentiate (r_xcomp) performed_19\VBN\perform.v.01|develop|,|study|was|using|. (l_advcl) develop_1\VB\create.v.02|to|test (l_dobj) test_7\NN\experiment.n.02|a|sensitive|echocardiographic|screening|for (l_prep) for_8\IN\entity.n.01|damage (l_pobj) damage_10\NN\change.n.01|cardiac|due
11166519
D003042_D012640 CID cocaine_1\NN\hard_drug.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|cocaine|- (r_amod) seizures_4\NNS\attack.n.07|acute|induced|:|sensitivity|.
D003042_D012640 CID cocaine_22\NN\hard_drug.n.01| (r_pobj) of_21\IN\entity.n.01|cocaine (r_prep) injection_20\NN\insertion.n.02|a|single|of (r_pobj) by_17\IN\by.r.01|injection (r_agent) induced_16\VBN\generate.v.01|by (r_acl) seizures_15\NNS\attack.n.07|behavioral|induced
D003042_D012640 CID cocaine_14\NN\hard_drug.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|cocaine|- (r_amod) seizures_17\NNS\attack.n.07|induced
9625142
D002443_D056486 CID ceftriaxone_11\NN\cephalosporin.n.01| (r_pobj) by_10\IN\by.r.01|ceftriaxone (r_prep) induced_9\VBN\generate.v.01|hepatitis|by|. (l_nsubj) hepatitis_1\NNP\infectious_disease.n.01|acute|,|anemia
D002443_D056486 CID ceftriaxone_12\NN\cephalosporin.n.01|oral (r_dobj) ingesting_10\VBG\consume.v.02|ceftriaxone (r_pcomp) after_9\IN\after.s.01|shortly|ingesting (r_prep) developed_5\VBD\create.v.02|man|hepatitis|after|. (l_dobj) hepatitis_7\NN\infectious_disease.n.01|acute
D002443_D000744 CID ceftriaxone_11\NN\cephalosporin.n.01| (r_pobj) by_10\IN\by.r.01|ceftriaxone (r_prep) induced_9\VBN\generate.v.01|hepatitis|by|. (l_nsubj) hepatitis_1\NNP\infectious_disease.n.01|acute|,|anemia (l_appos) anemia_5\NN\blood_disease.n.01|autoimmune|hemolytic|,|and|erythroblastocytopenia
D002443_-1 NONE ceftriaxone_11\NN\cephalosporin.n.01| (r_pobj) by_10\IN\by.r.01|ceftriaxone (r_prep) induced_9\VBN\generate.v.01|hepatitis|by|. (l_nsubj) hepatitis_1\NNP\infectious_disease.n.01|acute|,|anemia (l_appos) anemia_5\NN\blood_disease.n.01|autoimmune|hemolytic|,|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_8\NN\entity.n.01|
D047090_D000744 NONE lactam_11\NN\entity.n.01|beta (r_compound) antibiotic_12\NN\antibacterial.n.01|the|lactam (r_dobj) withholding_8\VBG\subtraction.n.02|antibiotic (r_pcomp) after_7\IN\after.s.01|withholding (r_prep) returned_4\VBD\travel.v.01|although|transaminases|gradually|to|after (r_advcl) was_15\VBD\washington.n.02|returned|,|there|increase|. (l_attr) increase_18\NN\indefinite_quantity.n.01|a|gradual|in|and|decrease (l_conj) decrease_24\NN\change.n.01|a|in (l_prep) in_25\IN\linear_unit.n.01|concentration (l_pobj) concentration_27\NN\property.n.02|hemoglobin|caused (l_acl) caused_28\VBN\make.v.03|by (l_agent) by_29\IN\by.r.01|anemia (l_pobj) anemia_33\NN\blood_disease.n.01|an|autoimmune|hemolytic|and|erythroblastocytopenia
D047090_-1 NONE lactam_11\NN\entity.n.01|beta (r_compound) antibiotic_12\NN\antibacterial.n.01|the|lactam (r_dobj) withholding_8\VBG\subtraction.n.02|antibiotic (r_pcomp) after_7\IN\after.s.01|withholding (r_prep) returned_4\VBD\travel.v.01|although|transaminases|gradually|to|after (r_advcl) was_15\VBD\washington.n.02|returned|,|there|increase|. (l_attr) increase_18\NN\indefinite_quantity.n.01|a|gradual|in|and|decrease (l_conj) decrease_24\NN\change.n.01|a|in (l_prep) in_25\IN\linear_unit.n.01|concentration (l_pobj) concentration_27\NN\property.n.02|hemoglobin|caused (l_acl) caused_28\VBN\make.v.03|by (l_agent) by_29\IN\by.r.01|anemia (l_pobj) anemia_33\NN\blood_disease.n.01|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\entity.n.01|
D001663_D000744 NONE bilirubin_21\NN\animal_pigment.n.01|serum (r_pobj) in_19\IN\linear_unit.n.01|bilirubin (r_prep) increase_18\NN\indefinite_quantity.n.01|a|gradual|in|and|decrease (l_conj) decrease_24\NN\change.n.01|a|in (l_prep) in_25\IN\linear_unit.n.01|concentration (l_pobj) concentration_27\NN\property.n.02|hemoglobin|caused (l_acl) caused_28\VBN\make.v.03|by (l_agent) by_29\IN\by.r.01|anemia (l_pobj) anemia_33\NN\blood_disease.n.01|an|autoimmune|hemolytic|and|erythroblastocytopenia
D001663_-1 NONE bilirubin_21\NN\animal_pigment.n.01|serum (r_pobj) in_19\IN\linear_unit.n.01|bilirubin (r_prep) increase_18\NN\indefinite_quantity.n.01|a|gradual|in|and|decrease (l_conj) decrease_24\NN\change.n.01|a|in (l_prep) in_25\IN\linear_unit.n.01|concentration (l_pobj) concentration_27\NN\property.n.02|hemoglobin|caused (l_acl) caused_28\VBN\make.v.03|by (l_agent) by_29\IN\by.r.01|anemia (l_pobj) anemia_33\NN\blood_disease.n.01|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\entity.n.01|
9284778
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS\chlorofluorocarbon.n.01|used (r_pobj) by_5\IN\by.r.01|hydrochlorofluorocarbons (r_agent) caused_4\VBN\make.v.03|by (r_acl) epidemic_0\NN\outbreak.n.01|of|caused|. (l_prep) of_1\IN\entity.n.01|disease (l_pobj) disease_3\NN\illness.n.01|liver
D010126_D008107 NONE ozone_9\NN\gas.n.02| (r_npadvmod) sparing_11\VBG\refrain.v.01|ozone|- (r_amod) substitutes_12\NNS\equivalent.n.01|sparing|of (r_pobj) as_8\IN\chemical_element.n.01|substitutes (r_prep) used_7\VBN\use.v.01|as (r_acl) hydrochlorofluorocarbons_6\NNS\chlorofluorocarbon.n.01|used (r_pobj) by_5\IN\by.r.01|hydrochlorofluorocarbons (r_agent) caused_4\VBN\make.v.03|by (r_acl) epidemic_0\NN\outbreak.n.01|of|caused|. (l_prep) of_1\IN\entity.n.01|disease (l_pobj) disease_3\NN\illness.n.01|liver
D017402_D008107 NONE chlorofluorocarbons_14\NNS\fluorocarbon.n.01| (r_pobj) of_13\IN\entity.n.01|chlorofluorocarbons (r_prep) substitutes_12\NNS\equivalent.n.01|sparing|of (r_pobj) as_8\IN\chemical_element.n.01|substitutes (r_prep) used_7\VBN\use.v.01|as (r_acl) hydrochlorofluorocarbons_6\NNS\chlorofluorocarbon.n.01|used (r_pobj) by_5\IN\by.r.01|hydrochlorofluorocarbons (r_agent) caused_4\VBN\make.v.03|by (r_acl) epidemic_0\NN\outbreak.n.01|of|caused|. (l_prep) of_1\IN\entity.n.01|disease (l_pobj) disease_3\NN\illness.n.01|liver
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\CD\entity.n.01|(|hcfc (r_pobj) of_20\IN\entity.n.01|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\substance.n.01|a|of (r_pobj) to_17\IN\entity.n.01|mixture (r_prep) exposure_16\NN\vulnerability.n.02|accidental|to (r_dobj) repeated_14\VBN\tell.v.02|who|had|had|exposure (r_relcl) workers_10\NNS\person.n.01|nine|industrial|repeated (r_pobj) in_7\IN\linear_unit.n.01|workers (r_prep) epidemic_3\NN\outbreak.n.01|an|of|in (l_prep) of_4\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|liver
C067411_D008107 CID 123_24\CD\entity.n.01| (r_nummod) hcfc_23\NNP\chlorofluorocarbon.n.01|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\entity.n.01|(|hcfc (r_pobj) of_20\IN\entity.n.01|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\substance.n.01|a|of (r_pobj) to_17\IN\entity.n.01|mixture (r_prep) exposure_16\NN\vulnerability.n.02|accidental|to (r_dobj) repeated_14\VBN\tell.v.02|who|had|had|exposure (r_relcl) workers_10\NNS\person.n.01|nine|industrial|repeated (r_pobj) in_7\IN\linear_unit.n.01|workers (r_prep) epidemic_3\NN\outbreak.n.01|an|of|in (l_prep) of_4\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|liver
C067411_D008107 CID 124_8\CD\entity.n.01| (r_conj) hcfcs_5\NNS\chlorofluorocarbon.n.01|123|and|124 (r_nsubj) result_10\VB\phenomenon.n.01|whether|hcfcs|can|in (l_prep) in_11\IN\linear_unit.n.01|disease (l_pobj) disease_14\NN\illness.n.01|serious|liver
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\entity.n.01| (r_conj) hcfc_23\NNP\chlorofluorocarbon.n.01|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\entity.n.01|(|hcfc (r_pobj) of_20\IN\entity.n.01|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\substance.n.01|a|of (r_pobj) to_17\IN\entity.n.01|mixture (r_prep) exposure_16\NN\vulnerability.n.02|accidental|to (r_dobj) repeated_14\VBN\tell.v.02|who|had|had|exposure (r_relcl) workers_10\NNS\person.n.01|nine|industrial|repeated (r_pobj) in_7\IN\linear_unit.n.01|workers (r_prep) epidemic_3\NN\outbreak.n.01|an|of|in (l_prep) of_4\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|liver
C072959_D008107 CID 124_30\CD\entity.n.01| (r_nummod) hcfc_29\NNP\chlorofluorocarbon.n.01|124 (r_appos) hcfc_23\NNP\chlorofluorocarbon.n.01|123|)|and|1-chloro-1,2,2,2-tetrafluoroethane|(|hcfc|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\entity.n.01|(|hcfc (r_pobj) of_20\IN\entity.n.01|1,1-dichloro-2,2,2-trifluoroethane (r_prep) mixture_19\NN\substance.n.01|a|of (r_pobj) to_17\IN\entity.n.01|mixture (r_prep) exposure_16\NN\vulnerability.n.02|accidental|to (r_dobj) repeated_14\VBN\tell.v.02|who|had|had|exposure (r_relcl) workers_10\NNS\person.n.01|nine|industrial|repeated (r_pobj) in_7\IN\linear_unit.n.01|workers (r_prep) epidemic_3\NN\outbreak.n.01|an|of|in (l_prep) of_4\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|liver
C072959_D008107 CID 124_8\CD\entity.n.01| (r_conj) hcfcs_5\NNS\chlorofluorocarbon.n.01|123|and|124 (r_nsubj) result_10\VB\phenomenon.n.01|whether|hcfcs|can|in (l_prep) in_11\IN\linear_unit.n.01|disease (l_pobj) disease_14\NN\illness.n.01|serious|liver
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD\entity.n.01|halothane (r_pobj) as_8\IN\chemical_element.n.01|1-bromo-1-chloro-2,2,2-trifluoroethane (r_prep) way_7\NN\property.n.02|the|same|as (r_pobj) in_4\IN\linear_unit.n.01|way (r_prep) metabolised_3\VBN\metabolize.v.01|compounds|are|in|form|. (l_advcl) form_14\VB\word.n.01|to|intermediates (l_dobj) intermediates_18\NNS\chemical.n.01|reactive|halide|,|implicated (l_relcl) implicated_23\VBN\involve.v.01|which|have|been|in (l_prep) in_24\IN\linear_unit.n.01|hepatotoxicity (l_pobj) hepatotoxicity_26\NN\entity.n.01|the|of
D006221_D056486 NONE halothane_11\NN\inhalation_anesthetic.n.01|(|) (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD\entity.n.01|halothane (r_pobj) as_8\IN\chemical_element.n.01|1-bromo-1-chloro-2,2,2-trifluoroethane (r_prep) way_7\NN\property.n.02|the|same|as (r_pobj) in_4\IN\linear_unit.n.01|way (r_prep) metabolised_3\VBN\metabolize.v.01|compounds|are|in|form|. (l_advcl) form_14\VB\word.n.01|to|intermediates (l_dobj) intermediates_18\NNS\chemical.n.01|reactive|halide|,|implicated (l_relcl) implicated_23\VBN\involve.v.01|which|have|been|in (l_prep) in_24\IN\linear_unit.n.01|hepatotoxicity (l_pobj) hepatotoxicity_26\NN\entity.n.01|the|of
D006221_D056486 NONE halothane_28\NN\inhalation_anesthetic.n.01| (r_pobj) of_27\IN\entity.n.01|halothane (r_prep) hepatotoxicity_26\NN\entity.n.01|the|of
D014269_D056486 NONE trifluoroacetyl_16\NNS\entity.n.01| (r_compound) halide_17\NN\salt.n.01|trifluoroacetyl (r_compound) intermediates_18\NNS\chemical.n.01|reactive|halide|,|implicated (l_relcl) implicated_23\VBN\involve.v.01|which|have|been|in (l_prep) in_24\IN\linear_unit.n.01|hepatotoxicity (l_pobj) hepatotoxicity_26\NN\entity.n.01|the|of
D014269_D056486 NONE trifluoroacetyl_17\NN\entity.n.01| (r_npadvmod) altered_19\VBN\change.v.01|trifluoroacetyl|- (r_amod) proteins_21\NNS\macromolecule.n.01|altered|liver (r_nsubjpass) involved_23\VBN\refer.v.02|that|proteins|are (r_ccomp) suggest_15\VBP\declare.v.01|known|,|results|involved|. (l_advcl) known_11\VBN\know.v.01|although|mechanism|is|not (l_nsubjpass) mechanism_3\NN\chemical_process.n.01|the|exact|of (l_prep) of_4\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_5\NN\entity.n.01|of
C067411_D056486 NONE 124_9\CD\entity.n.01| (r_conj) hcfcs_6\NNS\chlorofluorocarbon.n.01|123|and|124 (r_pobj) to_5\IN\entity.n.01|hcfcs (r_prep) exposure_1\NN\vulnerability.n.02|repeated|of|to (r_nsubj) result_11\VB\phenomenon.n.01|exposure|can|in|. (l_prep) in_12\IN\linear_unit.n.01|injury (l_pobj) injury_15\NN\ill_health.n.01|serious|liver|in
C072959_D056486 NONE 124_9\CD\entity.n.01| (r_conj) hcfcs_6\NNS\chlorofluorocarbon.n.01|123|and|124 (r_pobj) to_5\IN\entity.n.01|hcfcs (r_prep) exposure_1\NN\vulnerability.n.02|repeated|of|to (r_nsubj) result_11\VB\phenomenon.n.01|exposure|can|in|. (l_prep) in_12\IN\linear_unit.n.01|injury (l_pobj) injury_15\NN\ill_health.n.01|serious|liver|in
7292072
D003891_D017180 CID desipramine_4\JJ\tricyclic.n.01| (r_amod) toxicity_5\NN\definite_quantity.n.01|desipramine (r_pobj) in_3\IN\linear_unit.n.01|toxicity (r_prep) tachycardia_2\NN\cardiac_arrhythmia.n.01|variant|ventricular|in|.
D003891_D017180 CID desipramine_10\NN\tricyclic.n.01| (r_amod) toxicity_11\NN\definite_quantity.n.01|desipramine (r_pobj) by_9\IN\by.r.01|toxicity (r_agent) induced_8\VBN\generate.v.01|by (r_acl) tachycardia_7\NN\cardiac_arrhythmia.n.01|variant|ventricular|induced
D003891_D064420 NONE desipramine_4\JJ\tricyclic.n.01| (r_amod) toxicity_5\NN\definite_quantity.n.01|desipramine
D003891_D064420 NONE desipramine_10\NN\tricyclic.n.01| (r_amod) toxicity_11\NN\definite_quantity.n.01|desipramine
12905102
D003024_D003693 CID clozapine_2\NN\major_tranquilizer.n.01| (r_amod) treatment_3\NN\care.n.01|clozapine (r_pobj) during_1\IN\entity.n.01|treatment (r_prep) delirium_0\NN\mania.n.02|during|:|factors|.
D003024_D003693 CID clozapine_7\NN\major_tranquilizer.n.01| (r_compound) treatment_8\NN\care.n.01|clozapine (r_pobj) during_6\IN\entity.n.01|treatment (r_prep) factors_3\NNS\cause.n.01|incidence|for|during (l_prep) for_4\IN\entity.n.01|delirium (l_pobj) delirium_5\NN\mania.n.02|
D003024_D003693 CID clozapine_13\NN\major_tranquilizer.n.01|(|1995|) (r_pobj) with_12\IN\entity.n.01|clozapine (r_prep) treated_11\VBN\interact.v.01|with (r_acl) inpatients_10\NNS\patient.n.01|all|adult|psychiatric|treated (r_dobj) identify_6\VB\determine.v.03|to|inpatients (r_xcomp) used_1\VBD\use.v.01|we|records|identify|,|reviewed|. (l_conj) reviewed_20\VBD\analyze.v.01|records|score|,|and|tested (l_advcl) score_25\VB\evaluation.n.02|to|incidence (l_dobj) incidence_26\NN\frequency.n.02|and|severity|of (l_prep) of_29\IN\entity.n.01|delirium (l_pobj) delirium_30\NN\mania.n.02|
D003024_D003693 CID clozapine_7\NN\major_tranquilizer.n.01| (r_npadvmod) treated_9\VBN\interact.v.01|clozapine|- (r_amod) inpatients_10\NNS\patient.n.01|treated (r_pobj) of_6\IN\entity.n.01|inpatients (r_prep) %_5\NN\entity.n.01|10|of (r_pobj) in_3\IN\linear_unit.n.01|% (r_prep) found_2\VBN\wage.n.01|delirium|was|in|,|in|. (l_nsubjpass) delirium_0\NNP\mania.n.02|
D003024_D001523 NONE clozapine_13\NN\major_tranquilizer.n.01|(|1995|) (r_pobj) with_12\IN\entity.n.01|clozapine (r_prep) treated_11\VBN\interact.v.01|with (r_acl) inpatients_10\NNS\patient.n.01|all|adult|psychiatric|treated (l_amod) psychiatric_9\JJ\psychiatric.a.01|
10091617
D012642_D007024 CID selegiline_0\NNP\entity.n.01| (r_advmod) induced_2\VBN\generate.v.01|selegiline|-|hypotension|:|study|. (l_dobj) hypotension_4\NN\cardiovascular_disease.n.01|postural|in
D012642_D007024 CID selegiline_7\NN\entity.n.01| (r_pobj) with_6\IN\entity.n.01|selegiline (r_prep) therapy_5\NN\medical_care.n.01|with|and|dopa (r_nsubjpass) associated_13\VBN\think.v.03|that|therapy|was|with (l_prep) with_14\IN\entity.n.01|hypotension (l_pobj) hypotension_18\NN\cardiovascular_disease.n.01|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_25\NN\entity.n.01| (r_pobj) of_24\IN\entity.n.01|selegiline (r_prep) withdrawal_23\NN\retraction.n.01|of (r_pobj) by_22\IN\by.r.01|withdrawal (r_agent) abolished_21\VBN\abolish.v.01|which|was|by (r_relcl) hypotension_18\NN\cardiovascular_disease.n.01|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_29\NN\entity.n.01| (r_dobj) stopping_28\VBG\fastener.n.02|selegiline|in (l_prep) in_30\IN\linear_unit.n.01|expectation (l_pobj) expectation_32\NN\belief.n.01|the|shed (l_acl) shed_36\VB\outbuilding.n.01|that|this|might|light|on (l_prep) on_38\IN\on.a.01|mechanisms (l_pobj) mechanisms_40\NNS\chemical_process.n.01|the|causes (l_relcl) causes_45\VBZ\origin.n.03|by|drug|hypotension (l_dobj) hypotension_47\NN\cardiovascular_disease.n.01|orthostatic
D012642_D007024 CID selegiline_18\NN\entity.n.01| (r_pobj) on_17\IN\on.a.01|selegiline (r_prep) marked_10\VBN\attach.v.01|which|was|in|on (r_relcl) hypotension_7\NN\cardiovascular_disease.n.01|systolic|orthostatic|marked|,|lost
D012642_D007024 CID selegiline_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|selegiline (r_prep) withdrawal_7\NN\retraction.n.01|of (r_pobj) after_6\IN\after.s.01|days|withdrawal (r_prep) ameliorated_3\VBN\change.v.01|hypotension|was|after|and|abolished|. (l_nsubjpass) hypotension_1\NN\cardiovascular_disease.n.01|orthostatic
D012642_D007024 CID selegiline_1\NN\entity.n.01| (r_dobj) stopping_0\VBG\fastener.n.02|selegiline (r_csubj) reduced_4\VBD\decrease.v.02|stopping|also|significantly|pressures|. (l_dobj) pressures_11\NNS\physical_phenomenon.n.01|the|supine|systolic|blood|consistent
D012642_D007024 CID selegiline_7\NN\entity.n.01|that|in (r_nsubjpass) associated_15\VBN\think.v.03|selegiline|is|with (l_prep) with_16\IN\entity.n.01|hypotension (l_pobj) hypotension_19\NN\cardiovascular_disease.n.01|selective|orthostatic
D012642_D010300 NONE selegiline_0\NNP\entity.n.01| (r_advmod) induced_2\VBN\generate.v.01|selegiline|-|hypotension|:|study|. (l_dobj) hypotension_4\NN\cardiovascular_disease.n.01|postural|in (l_prep) in_5\IN\linear_unit.n.01|disease (l_pobj) disease_8\NN\illness.n.01|parkinson
D012642_D010300 NONE selegiline_30\NN\entity.n.01|mg|per (r_dobj) receive_27\VB\get.v.01|to|selegiline (r_xcomp) randomized_25\VBN\disarrange.v.02|receive (r_acl) mortality_15\NN\impermanence.n.01|an|increased|in|randomized (r_dobj) found_12\VBD\wage.n.01|trial|mortality|and|compared (l_nsubj) trial_11\NN\attempt.n.01|group|(|ukpdrg|) (l_nmod) group_7\NNP\abstraction.n.06|parkinson|disease|research (l_compound) disease_5\NNP\illness.n.01|
D012642_D010300 NONE selegiline_30\NN\entity.n.01|mg|per (r_dobj) receive_27\VB\get.v.01|to|selegiline (r_xcomp) randomized_25\VBN\disarrange.v.02|receive (r_acl) mortality_15\NN\impermanence.n.01|an|increased|in|randomized (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|with (l_prep) with_18\IN\entity.n.01|disease (l_pobj) disease_21\NN\illness.n.01|parkinson|(|pd|)
D012642_D010300 NONE selegiline_30\NN\entity.n.01|mg|per (r_dobj) receive_27\VB\get.v.01|to|selegiline (r_xcomp) randomized_25\VBN\disarrange.v.02|receive (r_acl) mortality_15\NN\impermanence.n.01|an|increased|in|randomized (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|with (l_prep) with_18\IN\entity.n.01|disease (l_pobj) disease_21\NN\illness.n.01|parkinson|(|pd|) (l_appos) pd_23\NNP\metallic_element.n.01|
D012642_D010300 NONE selegiline_17\RB\entity.n.01| (r_dobj) receiving_16\VBG\get.v.01|selegiline (r_acl) patients_15\NNS\case.n.06|pd|receiving (l_compound) pd_14\NNP\metallic_element.n.01|
D012642_D010300 NONE selegiline_18\NN\entity.n.01| (r_pobj) on_17\IN\on.a.01|selegiline (r_prep) marked_10\VBN\attach.v.01|which|was|in|on (l_prep) in_11\IN\linear_unit.n.01|patients (l_pobj) patients_16\NNS\case.n.06|20|pd (l_compound) pd_15\NNP\metallic_element.n.01|
D007980_D010300 NONE dopa_36\NN\amino_acid.n.01|l|- (r_nsubj) compared_37\VBN\analyze.v.01|dopa|with|. (r_conj) found_12\VBD\wage.n.01|trial|mortality|and|compared (l_nsubj) trial_11\NN\attempt.n.01|group|(|ukpdrg|) (l_nmod) group_7\NNP\abstraction.n.06|parkinson|disease|research (l_compound) disease_5\NNP\illness.n.01|
D007980_D010300 NONE dopa_36\NN\amino_acid.n.01|l|- (r_nsubj) compared_37\VBN\analyze.v.01|dopa|with|. (r_conj) found_12\VBD\wage.n.01|trial|mortality|and|compared (l_dobj) mortality_15\NN\impermanence.n.01|an|increased|in|randomized (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|with (l_prep) with_18\IN\entity.n.01|disease (l_pobj) disease_21\NN\illness.n.01|parkinson|(|pd|)
D007980_D010300 NONE dopa_36\NN\amino_acid.n.01|l|- (r_nsubj) compared_37\VBN\analyze.v.01|dopa|with|. (r_conj) found_12\VBD\wage.n.01|trial|mortality|and|compared (l_dobj) mortality_15\NN\impermanence.n.01|an|increased|in|randomized (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|with (l_prep) with_18\IN\entity.n.01|disease (l_pobj) disease_21\NN\illness.n.01|parkinson|(|pd|) (l_appos) pd_23\NNP\metallic_element.n.01|
D007980_D010300 NONE dopa_43\NN\amino_acid.n.01|l|- (r_dobj) taking_40\VBG\action.n.01|dopa|alone (r_acl) those_39\DT\entity.n.01|taking (r_pobj) with_38\IN\entity.n.01|those (r_prep) compared_37\VBN\analyze.v.01|dopa|with|. (r_conj) found_12\VBD\wage.n.01|trial|mortality|and|compared (l_nsubj) trial_11\NN\attempt.n.01|group|(|ukpdrg|) (l_nmod) group_7\NNP\abstraction.n.06|parkinson|disease|research (l_compound) disease_5\NNP\illness.n.01|
D007980_D010300 NONE dopa_43\NN\amino_acid.n.01|l|- (r_dobj) taking_40\VBG\action.n.01|dopa|alone (r_acl) those_39\DT\entity.n.01|taking (r_pobj) with_38\IN\entity.n.01|those (r_prep) compared_37\VBN\analyze.v.01|dopa|with|. (r_conj) found_12\VBD\wage.n.01|trial|mortality|and|compared (l_dobj) mortality_15\NN\impermanence.n.01|an|increased|in|randomized (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|with (l_prep) with_18\IN\entity.n.01|disease (l_pobj) disease_21\NN\illness.n.01|parkinson|(|pd|)
D007980_D010300 NONE dopa_43\NN\amino_acid.n.01|l|- (r_dobj) taking_40\VBG\action.n.01|dopa|alone (r_acl) those_39\DT\entity.n.01|taking (r_pobj) with_38\IN\entity.n.01|those (r_prep) compared_37\VBN\analyze.v.01|dopa|with|. (r_conj) found_12\VBD\wage.n.01|trial|mortality|and|compared (l_dobj) mortality_15\NN\impermanence.n.01|an|increased|in|randomized (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|with (l_prep) with_18\IN\entity.n.01|disease (l_pobj) disease_21\NN\illness.n.01|parkinson|(|pd|) (l_appos) pd_23\NNP\metallic_element.n.01|
D007980_D007024 NONE dopa_11\NNP\amino_acid.n.01|l|- (r_conj) therapy_5\NN\medical_care.n.01|with|and|dopa (r_nsubjpass) associated_13\VBN\think.v.03|that|therapy|was|with (l_prep) with_14\IN\entity.n.01|hypotension (l_pobj) hypotension_18\NN\cardiovascular_disease.n.01|selective|systolic|orthostatic|abolished
D007980_D007024 NONE dopa_13\NNP\amino_acid.n.01|l|- (r_pobj) with_10\IN\entity.n.01|dopa (r_prep) combination_9\NN\collection.n.01|with (r_pobj) in_8\IN\linear_unit.n.01|combination (r_prep) selegiline_7\NN\entity.n.01|that|in (r_nsubjpass) associated_15\VBN\think.v.03|selegiline|is|with (l_prep) with_16\IN\entity.n.01|hypotension (l_pobj) hypotension_19\NN\cardiovascular_disease.n.01|selective|orthostatic
3560095
D005480_D001171 NONE flurbiprofen_0\NNP\nonsteroidal_anti-inflammatory.n.01|in|. (l_prep) in_1\IN\linear_unit.n.01|treatment (l_pobj) treatment_3\NN\care.n.01|the|of (l_prep) of_4\IN\entity.n.01|arthritis (l_pobj) arthritis_7\NN\inflammatory_disease.n.01|juvenile|rheumatoid
D005480_D001171 NONE flurbiprofen_13\JJ\nonsteroidal_anti-inflammatory.n.01| (r_pobj) with_12\IN\entity.n.01|flurbiprofen (r_prep) treated_11\VBN\interact.v.01|who|were|with|at|day (r_relcl) arthritis_7\NN\inflammatory_disease.n.01|juvenile|rheumatoid|,|treated
D005480_D001168 NONE flurbiprofen_13\JJ\nonsteroidal_anti-inflammatory.n.01| (r_pobj) with_12\IN\entity.n.01|flurbiprofen (r_prep) treated_11\VBN\interact.v.01|who|were|with|at|day (r_relcl) arthritis_7\NN\inflammatory_disease.n.01|juvenile|rheumatoid|,|treated (r_pobj) with_4\IN\entity.n.01|arthritis (r_prep) patients_3\NNS\case.n.06|four|with|, (r_nsubj) had_26\VBD\have.v.01|patients|decreases|. (l_dobj) decreases_29\NNS\change.n.01|significant|from|in|after (l_prep) in_32\IN\linear_unit.n.01|indices (l_pobj) indices_35\NNS\scale.n.01|6|arthritis (l_compound) arthritis_34\NN\inflammatory_disease.n.01|
20722491
D005472_D009369 NONE 5-fu_1\CD\entity.n.01|(|) (r_nsubj) been_5\VBN\be.v.01|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\supporter.n.01|the|of|for (l_prep) of_8\IN\entity.n.01|treatment (l_pobj) treatment_9\NN\care.n.01|for (l_prep) for_10\IN\entity.n.01|tumors (l_pobj) tumors_13\NNS\growth.n.06|several|solid|,|including|,
D005472_D015179 NONE 5-fu_1\CD\entity.n.01|(|) (r_nsubj) been_5\VBN\be.v.01|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\supporter.n.01|the|of|for (l_prep) of_8\IN\entity.n.01|treatment (l_pobj) treatment_9\NN\care.n.01|for (l_prep) for_10\IN\entity.n.01|tumors (l_pobj) tumors_13\NNS\growth.n.06|several|solid|,|including|, (l_prep) including_15\VBG\include.v.01|colorectal (l_pobj) colorectal_16\NN\colorectal.a.01|,|breast (l_conj) breast_18\NN\external_body_part.n.01|and|cancers (l_conj) cancers_23\NNS\malignant_tumor.n.01|head
D005472_D001943 NONE 5-fu_1\CD\entity.n.01|(|) (r_nsubj) been_5\VBN\be.v.01|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\supporter.n.01|the|of|for (l_prep) of_8\IN\entity.n.01|treatment (l_pobj) treatment_9\NN\care.n.01|for (l_prep) for_10\IN\entity.n.01|tumors (l_pobj) tumors_13\NNS\growth.n.06|several|solid|,|including|, (l_prep) including_15\VBG\include.v.01|colorectal (l_pobj) colorectal_16\NN\colorectal.a.01|,|breast (l_conj) breast_18\NN\external_body_part.n.01|and|cancers (l_conj) cancers_23\NNS\malignant_tumor.n.01|head
D005472_D006258 NONE 5-fu_1\CD\entity.n.01|(|) (r_nsubj) been_5\VBN\be.v.01|5-fu|,|have|mainstay|. (l_attr) mainstay_7\NN\supporter.n.01|the|of|for (l_prep) of_8\IN\entity.n.01|treatment (l_pobj) treatment_9\NN\care.n.01|for (l_prep) for_10\IN\entity.n.01|tumors (l_pobj) tumors_13\NNS\growth.n.06|several|solid|,|including|, (l_prep) including_15\VBG\include.v.01|colorectal (l_pobj) colorectal_16\NN\colorectal.a.01|,|breast (l_conj) breast_18\NN\external_body_part.n.01|and|cancers (l_conj) cancers_23\NNS\malignant_tumor.n.01|head
C110904_D007674 NONE capecitabine_10\NN\entity.n.01| (r_pobj) of_9\IN\entity.n.01|capecitabine (r_prep) safety_8\NN\condition.n.01|the|of|in (l_prep) in_11\IN\linear_unit.n.01|populations (l_pobj) populations_13\NNS\people.n.01|special|as (l_prep) as_15\IN\chemical_element.n.01|such|patients (l_pobj) patients_16\NNS\case.n.06|with (l_prep) with_17\IN\entity.n.01|disease (l_pobj) disease_24\NN\illness.n.01|age|renal
C110904_D007674 NONE capecitabine_0\NNP\entity.n.01| (r_nsubj) has_1\VBZ\angular_distance.n.01|capecitabine|profile|and|given|. (l_conj) given_11\VBN\assumption.n.02|can|be|safely|to (l_prep) to_13\IN\entity.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|dysfunctions (l_pobj) dysfunctions_22\NNS\pathology.n.02|age
C110904_D003967 CID capecitabine_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|capecitabine (r_prep) effects_5\NNS\personal_property.n.01|the|reported|toxic|of (r_nsubj) are_8\VBP\area_unit.n.01|effects|diarrhea|. (l_attr) diarrhea_9\NN\symptom.n.01|,|nausea
C110904_D009325 CID capecitabine_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|capecitabine (r_prep) effects_5\NNS\personal_property.n.01|the|reported|toxic|of (r_nsubj) are_8\VBP\area_unit.n.01|effects|diarrhea|. (l_attr) diarrhea_9\NN\symptom.n.01|,|nausea (l_appos) nausea_11\NN\symptom.n.01|,|vomiting
C110904_D014839 CID capecitabine_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|capecitabine (r_prep) effects_5\NNS\personal_property.n.01|the|reported|toxic|of (r_nsubj) are_8\VBP\area_unit.n.01|effects|diarrhea|. (l_attr) diarrhea_9\NN\symptom.n.01|,|nausea (l_appos) nausea_11\NN\symptom.n.01|,|vomiting (l_conj) vomiting_13\NN\expulsion.n.03|,|stomatitis
C110904_D013280 CID capecitabine_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|capecitabine (r_prep) effects_5\NNS\personal_property.n.01|the|reported|toxic|of (r_nsubj) are_8\VBP\area_unit.n.01|effects|diarrhea|. (l_attr) diarrhea_9\NN\symptom.n.01|,|nausea (l_appos) nausea_11\NN\symptom.n.01|,|vomiting (l_conj) vomiting_13\NN\expulsion.n.03|,|stomatitis (l_conj) stomatitis_15\JJ\inflammation.n.01|and|syndrome
C110904_D060831 CID capecitabine_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|capecitabine (r_prep) effects_5\NNS\personal_property.n.01|the|reported|toxic|of (r_nsubj) are_8\VBP\area_unit.n.01|effects|diarrhea|. (l_attr) diarrhea_9\NN\symptom.n.01|,|nausea (l_appos) nausea_11\NN\symptom.n.01|,|vomiting (l_conj) vomiting_13\NN\expulsion.n.03|,|stomatitis (l_conj) stomatitis_15\JJ\inflammation.n.01|and|syndrome (l_conj) syndrome_20\NN\complex.n.01|foot
C110904_D008107 NONE capecitabine_0\NNP\entity.n.01| (r_nsubj) has_1\VBZ\angular_distance.n.01|capecitabine|profile|and|given|. (l_conj) given_11\VBN\assumption.n.02|can|be|safely|to (l_prep) to_13\IN\entity.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|dysfunctions (l_pobj) dysfunctions_22\NNS\pathology.n.02|age
12921865
D013256_D012640 NONE steroids_4\NNS\organic_compound.n.01|neuroactive|against (l_prep) against_5\IN\entity.n.01|seizures (l_pobj) seizures_9\NNS\attack.n.07|cocaine|kindled|-
D013256_D012640 NONE steroid_13\NN\organic_compound.n.01|two|endogenous|one|synthetic|neuroactive|modulate (l_relcl) modulate_16\VBP\play.v.06|that|positively|acid (l_dobj) acid_21\NN\compound.n.02|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN\structure.n.04|against (l_prep) against_27\IN\entity.n.01|increase (l_pobj) increase_29\NN\indefinite_quantity.n.01|the|in (l_prep) in_30\IN\linear_unit.n.01|sensitivity (l_pobj) sensitivity_31\NN\sense.n.03|to (l_prep) to_32\IN\entity.n.01|effects (l_pobj) effects_35\NNS\personal_property.n.01|the|convulsant|of (l_prep) of_36\IN\entity.n.01|cocaine (l_pobj) cocaine_37\NN\hard_drug.n.01|engendered (l_acl) engendered_38\VBN\cause.v.01|by (l_agent) by_39\IN\by.r.01|administration (l_pobj) administration_42\NN\management.n.01|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\igniter.n.01|seizure (l_compound) seizure_44\NN\attack.n.07|
D003042_D012640 CID cocaine_6\NN\hard_drug.n.01| (r_compound) seizures_9\NNS\attack.n.07|cocaine|kindled|-
D003042_D012640 CID cocaine_37\NN\hard_drug.n.01|engendered (l_acl) engendered_38\VBN\cause.v.01|by (l_agent) by_39\IN\by.r.01|administration (l_pobj) administration_42\NN\management.n.01|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\igniter.n.01|seizure (l_compound) seizure_44\NN\attack.n.07|
D003042_D012640 CID cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\igniter.n.01|seizure (l_compound) seizure_44\NN\attack.n.07|
D003042_D012640 CID cocaine_53\NN\hard_drug.n.01| (r_npadvmod) kindled_55\VBN\flare_up.v.01|cocaine|- (r_amod) seizures_56\NNS\attack.n.07|kindled|in
D003042_D012640 CID cocaine_10\NN\hard_drug.n.01|mg/kg (r_pobj) of_7\IN\entity.n.01|cocaine (r_prep) administration_6\NN\management.n.01|daily|of (r_pobj) by_4\IN\by.r.01|administration (r_agent) induced_3\VBN\generate.v.01|kindled|were|by|for|. (l_csubjpass) kindled_0\VBN\flare_up.v.01|seizures (l_dobj) seizures_1\NNS\attack.n.07|
D013256_D009422 NONE steroids_1\NNS\organic_compound.n.01|neuroactive (r_nsubj) demonstrate_2\VBP\show.v.04|steroids|actions|. (l_dobj) actions_4\NNS\act.n.02|pharmacological|have (l_relcl) have_6\VBP\person.n.01|that|relevance (l_dobj) relevance_7\NN\connection.n.01|for (l_prep) for_8\IN\entity.n.01|host (l_pobj) host_10\NN\adult.n.01|a|of (l_prep) of_11\IN\entity.n.01|disorders (l_pobj) disorders_15\NNS\physical_condition.n.01|neurological
D013256_D001523 NONE steroids_1\NNS\organic_compound.n.01|neuroactive (r_nsubj) demonstrate_2\VBP\show.v.04|steroids|actions|. (l_dobj) actions_4\NNS\act.n.02|pharmacological|have (l_relcl) have_6\VBP\person.n.01|that|relevance (l_dobj) relevance_7\NN\connection.n.01|for (l_prep) for_8\IN\entity.n.01|host (l_pobj) host_10\NN\adult.n.01|a|of (l_prep) of_11\IN\entity.n.01|disorders (l_pobj) disorders_15\NNS\physical_condition.n.01|neurological
D005680_D012640 NONE acid_21\NN\compound.n.02|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN\structure.n.04|against (l_prep) against_27\IN\entity.n.01|increase (l_pobj) increase_29\NN\indefinite_quantity.n.01|the|in (l_prep) in_30\IN\linear_unit.n.01|sensitivity (l_pobj) sensitivity_31\NN\sense.n.03|to (l_prep) to_32\IN\entity.n.01|effects (l_pobj) effects_35\NNS\personal_property.n.01|the|convulsant|of (l_prep) of_36\IN\entity.n.01|cocaine (l_pobj) cocaine_37\NN\hard_drug.n.01|engendered (l_acl) engendered_38\VBN\cause.v.01|by (l_agent) by_39\IN\by.r.01|administration (l_pobj) administration_42\NN\management.n.01|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\igniter.n.01|seizure (l_compound) seizure_44\NN\attack.n.07|
D005680_D012640 NONE gaba(a_23\NNP\entity.n.01| (r_appos) acid_21\NN\compound.n.02|the|aminobutyric|(|gaba(a|)|)|receptor (l_appos) receptor_26\NN\structure.n.04|against (l_prep) against_27\IN\entity.n.01|increase (l_pobj) increase_29\NN\indefinite_quantity.n.01|the|in (l_prep) in_30\IN\linear_unit.n.01|sensitivity (l_pobj) sensitivity_31\NN\sense.n.03|to (l_prep) to_32\IN\entity.n.01|effects (l_pobj) effects_35\NNS\personal_property.n.01|the|convulsant|of (l_prep) of_36\IN\entity.n.01|cocaine (l_pobj) cocaine_37\NN\hard_drug.n.01|engendered (l_acl) engendered_38\VBN\cause.v.01|by (l_agent) by_39\IN\by.r.01|administration (l_pobj) administration_42\NN\management.n.01|repeated|cocaine|(|kindling|) (l_appos) kindling_45\NN\igniter.n.01|seizure (l_compound) seizure_44\NN\attack.n.07|
D005680_D012640 NONE gaba(a_4\NN\entity.n.01| (r_nmod) modulators_6\NNS\entity.n.01|these|positive|gaba(a|) (r_pobj) of_1\IN\entity.n.01|modulators (r_prep) all_0\DT\all.a.01|of (r_nsubj) suppressed_7\VBD\control.v.02|all|expression|,|inhibited|. (l_dobj) expression_9\NN\countenance.n.01|the|of (l_prep) of_10\IN\entity.n.01|seizures (l_pobj) seizures_12\NNS\attack.n.07|kindled
D011280_D012640 NONE allopregnanolone_0\NN\entity.n.01|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\evaluate.v.02|allopregnanolone|were|for|. (l_prep) for_35\IN\entity.n.01|ability (l_pobj) ability_37\NN\quality.n.01|their|suppress (l_acl) suppress_39\VB\control.v.02|to|expression (l_dobj) expression_41\NN\countenance.n.01|the|(|effect (l_appos) effect_44\NN\phenomenon.n.01|anticonvulsant|)|and|development (l_conj) development_47\NN\improvement.n.02|(|effect|)|of (l_prep) of_52\IN\entity.n.01|seizures (l_pobj) seizures_56\NNS\attack.n.07|kindled|in
D011280_D012640 NONE pregnan-20-one_6\NNP\entity.n.01|hydroxy-5alpha|- (r_advmod) 3alpha_2\CD\entity.n.01|pregnan-20-one (r_appos) allopregnanolone_0\NN\entity.n.01|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\evaluate.v.02|allopregnanolone|were|for|. (l_prep) for_35\IN\entity.n.01|ability (l_pobj) ability_37\NN\quality.n.01|their|suppress (l_acl) suppress_39\VB\control.v.02|to|expression (l_dobj) expression_41\NN\countenance.n.01|the|(|effect (l_appos) effect_44\NN\phenomenon.n.01|anticonvulsant|)|and|development (l_conj) development_47\NN\improvement.n.02|(|effect|)|of (l_prep) of_52\IN\entity.n.01|seizures (l_pobj) seizures_56\NNS\attack.n.07|kindled|in
D011280_D012640 NONE pregnanolone_9\NN\entity.n.01|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\entity.n.01|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\evaluate.v.02|allopregnanolone|were|for|. (l_prep) for_35\IN\entity.n.01|ability (l_pobj) ability_37\NN\quality.n.01|their|suppress (l_acl) suppress_39\VB\control.v.02|to|expression (l_dobj) expression_41\NN\countenance.n.01|the|(|effect (l_appos) effect_44\NN\phenomenon.n.01|anticonvulsant|)|and|development (l_conj) development_47\NN\improvement.n.02|(|effect|)|of (l_prep) of_52\IN\entity.n.01|seizures (l_pobj) seizures_56\NNS\attack.n.07|kindled|in
D011280_D012640 NONE pregnan-20-one_15\NNP\entity.n.01|(|3alpha|-|hydroxy-5beta|-|) (r_parataxis) pregnanolone_9\NN\entity.n.01|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\entity.n.01|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\evaluate.v.02|allopregnanolone|were|for|. (l_prep) for_35\IN\entity.n.01|ability (l_pobj) ability_37\NN\quality.n.01|their|suppress (l_acl) suppress_39\VB\control.v.02|to|expression (l_dobj) expression_41\NN\countenance.n.01|the|(|effect (l_appos) effect_44\NN\phenomenon.n.01|anticonvulsant|)|and|development (l_conj) development_47\NN\improvement.n.02|(|effect|)|of (l_prep) of_52\IN\entity.n.01|seizures (l_pobj) seizures_56\NNS\attack.n.07|kindled|in
D011280_D012640 NONE allopregnanolone_24\NN\entity.n.01|3alpha (r_pobj) of_23\IN\entity.n.01|allopregnanolone (r_prep) derivative_22\NN\calculation.n.02|a|synthetic|of (r_appos) ganaxolone_18\NN\entity.n.01|(|derivative|) (r_conj) pregnanolone_9\NN\entity.n.01|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\entity.n.01|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\evaluate.v.02|allopregnanolone|were|for|. (l_prep) for_35\IN\entity.n.01|ability (l_pobj) ability_37\NN\quality.n.01|their|suppress (l_acl) suppress_39\VB\control.v.02|to|expression (l_dobj) expression_41\NN\countenance.n.01|the|(|effect (l_appos) effect_44\NN\phenomenon.n.01|anticonvulsant|)|and|development (l_conj) development_47\NN\improvement.n.02|(|effect|)|of (l_prep) of_52\IN\entity.n.01|seizures (l_pobj) seizures_56\NNS\attack.n.07|kindled|in
D011280_D012640 NONE allopregnanolone_16\NN\entity.n.01|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\control.v.02|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\control.v.02|all|expression|,|inhibited|. (l_dobj) expression_9\NN\countenance.n.01|the|of (l_prep) of_10\IN\entity.n.01|seizures (l_pobj) seizures_12\NNS\attack.n.07|kindled
C105051_D012640 NONE ganaxolone_18\NN\entity.n.01|(|derivative|) (r_conj) pregnanolone_9\NN\entity.n.01|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\entity.n.01|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\evaluate.v.02|allopregnanolone|were|for|. (l_prep) for_35\IN\entity.n.01|ability (l_pobj) ability_37\NN\quality.n.01|their|suppress (l_acl) suppress_39\VB\control.v.02|to|expression (l_dobj) expression_41\NN\countenance.n.01|the|(|effect (l_appos) effect_44\NN\phenomenon.n.01|anticonvulsant|)|and|development (l_conj) development_47\NN\improvement.n.02|(|effect|)|of (l_prep) of_52\IN\entity.n.01|seizures (l_pobj) seizures_56\NNS\attack.n.07|kindled|in
C105051_D012640 NONE pregnan-20-one_31\NNP\entity.n.01|methyl-5alpha|- (r_appos) 3alpha_25\CD\entity.n.01|pregnan-20-one (r_appos) allopregnanolone_24\NN\entity.n.01|3alpha (r_pobj) of_23\IN\entity.n.01|allopregnanolone (r_prep) derivative_22\NN\calculation.n.02|a|synthetic|of (r_appos) ganaxolone_18\NN\entity.n.01|(|derivative|) (r_conj) pregnanolone_9\NN\entity.n.01|pregnan-20-one|and|ganaxolone (r_appos) allopregnanolone_0\NN\entity.n.01|(|3alpha|)|,|pregnanolone (r_nsubjpass) tested_34\VBN\evaluate.v.02|allopregnanolone|were|for|. (l_prep) for_35\IN\entity.n.01|ability (l_pobj) ability_37\NN\quality.n.01|their|suppress (l_acl) suppress_39\VB\control.v.02|to|expression (l_dobj) expression_41\NN\countenance.n.01|the|(|effect (l_appos) effect_44\NN\phenomenon.n.01|anticonvulsant|)|and|development (l_conj) development_47\NN\improvement.n.02|(|effect|)|of (l_prep) of_52\IN\entity.n.01|seizures (l_pobj) seizures_56\NNS\attack.n.07|kindled|in
C105051_D012640 NONE ganaxolone_18\NN\entity.n.01| (r_conj) allopregnanolone_16\NN\entity.n.01|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\control.v.02|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\control.v.02|all|expression|,|inhibited|. (l_dobj) expression_9\NN\countenance.n.01|the|of (l_prep) of_10\IN\entity.n.01|seizures (l_pobj) seizures_12\NNS\attack.n.07|kindled
16167916
D020849_D054556 CID raloxifene_11\NN\entity.n.01| (r_compound) treatment_12\NN\care.n.01|raloxifene (r_pobj) to_10\IN\entity.n.01|treatment (r_pcomp) due_9\IN\right.n.01|to (r_amod) thromboembolism_8\NN\occlusion.n.01|venous|due
220563
C023470_D010523 CID maleate_1\NN\antidepressant.n.01|perhexiline|and|neuropathy|. (l_conj) neuropathy_4\NN\pathology.n.02|peripheral
C023470_D010523 CID maleate_12\NN\antidepressant.n.01|perhexiline|,|drug|( (r_pobj) with_10\IN\entity.n.01|maleate|and|in (r_prep) complication_7\NN\hindrance.n.03|a|of|with|for (r_pobj) as_5\IN\chemical_element.n.01|complication (r_prep) noted_4\VBN\state.v.01|neuropathy|has|been|as|. (l_nsubjpass) neuropathy_1\NN\pathology.n.02|peripheral
C023470_D000787 NONE maleate_12\NN\antidepressant.n.01|perhexiline|,|drug|( (r_pobj) with_10\IN\entity.n.01|maleate|and|in (r_prep) complication_7\NN\hindrance.n.03|a|of|with|for (l_prep) for_30\IN\entity.n.01|treatment (l_pobj) treatment_33\NN\care.n.01|the|prophylactic|of (l_prep) of_34\IN\entity.n.01|pectoris (l_pobj) pectoris_36\NN\entity.n.01|angina
12084448
D007069_D001927 CID ifosfamide_0\NNP\entity.n.01| (r_compound) encephalopathy_1\NN\nervous_disorder.n.01|ifosfamide|presenting|.
D007069_D020820 NONE ifosfamide_0\NNP\entity.n.01| (r_compound) encephalopathy_1\NN\nervous_disorder.n.01|ifosfamide|presenting|. (l_acl) presenting_2\VBG\show.v.04|with (l_prep) with_3\IN\entity.n.01|asterixis (l_pobj) asterixis_4\NNS\entity.n.01|
D007069_D020820 NONE ifosfamide_3\NN\entity.n.01| (r_pobj) of_2\IN\entity.n.01|ifosfamide (r_prep) administration_1\NN\management.n.01|the|of (r_nsubjpass) discontinued_5\VBN\discontinue.v.01|administration|was|and|resolved (l_conj) resolved_12\VBD\end.v.02|within|asterixis|completely|. (l_nsubj) asterixis_11\NNS\entity.n.01|the
D007069_D020820 NONE ifosfamide_12\JJ\entity.n.01| (r_pobj) of_11\IN\entity.n.01|ifosfamide (r_prep) infusion_10\NN\solution.n.01|of (r_pobj) during_9\IN\entity.n.01|infusion (r_prep) presence_6\NN\being.n.01|the|of|during|,|findings|following (l_prep) of_7\IN\entity.n.01|asterixis (l_pobj) asterixis_8\NNS\entity.n.01|
D007069_D020820 NONE ifx_41\NNP\entity.n.01| (r_pobj) of_40\IN\entity.n.01|ifx (r_prep) use_39\NN\activity.n.01|the|of (r_pobj) with_37\IN\entity.n.01|use (r_prep) associated_36\VBN\think.v.03|that|myoclonus|is|with (r_ccomp) suggest_31\VBP\declare.v.01|in|,|presence|associated|. (l_nsubj) presence_6\NN\being.n.01|the|of|during|,|findings|following (l_prep) of_7\IN\entity.n.01|asterixis (l_pobj) asterixis_8\NNS\entity.n.01|
D007069_D009207 CID ifosfamide_27\NN\entity.n.01| (r_pobj) of_26\IN\entity.n.01|ifosfamide (r_prep) infusion_25\NN\solution.n.01|the|of|for (r_pobj) after_23\IN\after.s.01|infusion (r_prep) disabling_14\VBG\change.v.01|myoclonus|after (l_dobj) myoclonus_16\NN\spasm.n.01|negative|of
D007069_D009207 CID ifosfamide_12\JJ\entity.n.01| (r_pobj) of_11\IN\entity.n.01|ifosfamide (r_prep) infusion_10\NN\solution.n.01|of (r_pobj) during_9\IN\entity.n.01|infusion (r_prep) presence_6\NN\being.n.01|the|of|during|,|findings|following (r_nsubj) suggest_31\VBP\declare.v.01|in|,|presence|associated|. (l_ccomp) associated_36\VBN\think.v.03|that|myoclonus|is|with (l_nsubjpass) myoclonus_34\NN\spasm.n.01|negative
D007069_D009207 CID ifx_41\NNP\entity.n.01| (r_pobj) of_40\IN\entity.n.01|ifx (r_prep) use_39\NN\activity.n.01|the|of (r_pobj) with_37\IN\entity.n.01|use (r_prep) associated_36\VBN\think.v.03|that|myoclonus|is|with (l_nsubjpass) myoclonus_34\NN\spasm.n.01|negative
D007069_D010954 NONE ifosfamide_27\NN\entity.n.01| (r_pobj) of_26\IN\entity.n.01|ifosfamide (r_prep) infusion_25\NN\solution.n.01|the|of|for (l_prep) for_28\IN\entity.n.01|plasmacytoma (l_pobj) plasmacytoma_29\NN\tumor.n.01|
12063090
D004177_D003248 NONE metamizol_0\NNP\entity.n.01| (r_nsubj) potentiates_1\VBZ\enhance.v.01|metamizol|antinociception|. (l_dobj) antinociception_3\NN\entity.n.01|morphine|but|constipation (l_conj) constipation_6\NN\symptom.n.01|not|after
D004177_D003248 NONE metamizol_20\NN\entity.n.01|mg/kg|s.c. (r_pobj) with_16\IN\entity.n.01|metamizol (r_prep) effects_7\NNS\personal_property.n.01|the|antinociceptive|of|with|in (l_amod) antinociceptive_4\NN\entity.n.01|and|constipating (l_conj) constipating_6\JJ\slow.v.03|
D004177_D003248 NONE metamizol_20\NN\entity.n.01|that (r_nsubj) potentiate_23\VB\enhance.v.01|metamizol|did|not|constipation (l_dobj) constipation_27\NN\symptom.n.01|induced
D009020_D003248 CID morphine_2\NN\analgesic.n.01| (r_compound) antinociception_3\NN\entity.n.01|morphine|but|constipation (l_conj) constipation_6\NN\symptom.n.01|not|after
D009020_D003248 CID morphine_15\NN\analgesic.n.01|mg/kg|s.c. (r_pobj) of_11\IN\entity.n.01|morphine (r_prep) combination_10\NN\collection.n.01|the|of (r_pobj) of_8\IN\entity.n.01|combination (r_prep) effects_7\NNS\personal_property.n.01|the|antinociceptive|of|with|in (l_amod) antinociceptive_4\NN\entity.n.01|and|constipating (l_conj) constipating_6\JJ\slow.v.03|
D009020_D003248 CID morphine_4\NN\analgesic.n.01| (r_nsubj) inhibited_5\VBD\control.v.02|in|,|morphine|transit|after|,|respectively|,|suggesting|. (l_advcl) suggesting_23\VBG\declare.v.01|develop (l_ccomp) develop_28\VB\create.v.02|that|tolerance|did|not|to (l_prep) to_29\IN\entity.n.01|effects (l_pobj) effects_32\NNS\personal_property.n.01|the|constipating (l_amod) constipating_31\JJ\slow.v.03|
D009020_D003248 CID morphine_10\NN\analgesic.n.01| (r_pobj) by_9\IN\by.r.01|morphine (r_agent) produced_8\VBN\make.v.03|by|regardless (r_acl) that_7\DT\entity.n.01|produced (r_pobj) to_6\IN\entity.n.01|that (r_prep) similar_5\JJ\similar.a.01|to (r_amod) transit_4\NN\surveying_instrument.n.01|intestinal|similar (r_dobj) inhibited_2\VBD\control.v.02|combination|transit|,|suggesting|. (l_advcl) suggesting_18\VBG\declare.v.01|potentiate (l_ccomp) potentiate_23\VB\enhance.v.01|metamizol|did|not|constipation (l_dobj) constipation_27\NN\symptom.n.01|induced
D009020_D003248 CID morphine_24\NN\analgesic.n.01| (r_npadvmod) induced_26\VBN\generate.v.01|morphine|- (r_amod) constipation_27\NN\symptom.n.01|induced
D002606_D010146 NONE charcoal_25\NN\carbon.n.01| (r_compound) meal_26\NN\nutriment.n.01|charcoal (r_compound) test_27\NN\experiment.n.02|the|meal (r_nsubjpass) used_29\VBN\use.v.01|test|was|evaluate|. (r_conj) assessed_8\VBN\evaluate.v.02|on|,|effects|were|using|,|model|used (l_conj) model_21\NN\hypothesis.n.02|induced|impairment|,|and (l_amod) induced_18\VBN\generate.v.01|pain|- (l_npadvmod) pain_16\NN\symptom.n.01|
D009020_D059350 NONE morphine_7\NN\analgesic.n.01|and|metamizol|in (r_pobj) between_6\IN\between.r.01|morphine (r_prep) interaction_5\NN\action.n.01|a|significant|between (r_dobj) show_2\VBP\entertainment.n.01|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\declare.v.01|be (l_ccomp) be_20\VB\metallic_element.n.01|that|combination|could|useful (l_acomp) useful_21\JJ\useful.a.01|for (l_prep) for_22\IN\entity.n.01|treatment (l_pobj) treatment_24\NN\care.n.01|the|of (l_prep) of_25\IN\entity.n.01|pain (l_pobj) pain_27\NN\symptom.n.01|chronic
D004177_D059350 NONE metamizol_9\NN\entity.n.01| (r_conj) morphine_7\NN\analgesic.n.01|and|metamizol|in (r_pobj) between_6\IN\between.r.01|morphine (r_prep) interaction_5\NN\action.n.01|a|significant|between (r_dobj) show_2\VBP\entertainment.n.01|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\declare.v.01|be (l_ccomp) be_20\VB\metallic_element.n.01|that|combination|could|useful (l_acomp) useful_21\JJ\useful.a.01|for (l_prep) for_22\IN\entity.n.01|treatment (l_pobj) treatment_24\NN\care.n.01|the|of (l_prep) of_25\IN\entity.n.01|pain (l_pobj) pain_27\NN\symptom.n.01|chronic
15957009
C507242_D008569 NONE ro4368554_5\NN\entity.n.01| (r_nsubj) restores_6\VBZ\regenerate.v.01|antagonist|ro4368554|performance|in|. (l_prep) in_9\IN\linear_unit.n.01|models (l_pobj) models_13\NNS\hypothesis.n.02|cholinergic|of|in (l_prep) of_14\IN\entity.n.01|deficiency (l_pobj) deficiency_16\NN\need.n.01|memory
C507242_D008569 NONE ro4368554_2\NNP\entity.n.01|(|3|mg/kg|,|intraperitoneally|and|metrifonate|p.o. (r_nsubj) reversed_24\VBD\change.v.02|both|,|ro4368554|deficits|)|. (l_dobj) deficits_26\NNS\insufficiency.n.03|memory|induced
C507242_D008569 NONE ro4368554_4\NN\entity.n.01| (r_nsubj) improve_7\VB\change.v.01|although|ro4368554|did|not|deficit (r_advcl) reversed_16\VBD\change.v.02|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ\cholinergic.a.01|a|and|deficit (l_conj) deficit_23\NN\insufficiency.n.03|a|serotonergic|memory
C507242_D008569 NONE ro4368554_39\NN\entity.n.01| (r_pobj) by_38\IN\by.r.01|ro4368554 (r_prep) facilitation_34\NN\condition.n.01|the|of|by (r_pobj) in_32\IN\linear_unit.n.01|facilitation (r_prep) involved_31\VBN\refer.v.02|that|mechanisms|may|be|in|and|antagonists (r_ccomp) suggesting_25\VBG\declare.v.01|involved (r_advcl) reversed_16\VBD\change.v.02|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ\cholinergic.a.01|a|and|deficit (l_conj) deficit_23\NN\insufficiency.n.03|a|serotonergic|memory
D014236_D008569 NONE metrifonate_15\NN\entity.n.01|(|mg/kg|, (r_conj) ro4368554_2\NNP\entity.n.01|(|3|mg/kg|,|intraperitoneally|and|metrifonate|p.o. (r_nsubj) reversed_24\VBD\change.v.02|both|,|ro4368554|deficits|)|. (l_dobj) deficits_26\NNS\insufficiency.n.03|memory|induced
D012601_D008569 CID scopolamine_29\NN\alkaloid.n.01|and|depletion|(|mg/kg|,|i.p.|,|and|mg/kg (r_pobj) by_28\IN\by.r.01|scopolamine (r_agent) induced_27\VBN\generate.v.01|by (r_acl) deficits_26\NNS\insufficiency.n.03|memory|induced
D014364_D008569 NONE trp_31\NNP\entity.n.01| (r_compound) depletion_32\NN\decrease.n.04|trp (r_conj) scopolamine_29\NN\alkaloid.n.01|and|depletion|(|mg/kg|,|i.p.|,|and|mg/kg (r_pobj) by_28\IN\by.r.01|scopolamine (r_agent) induced_27\VBN\generate.v.01|by (r_acl) deficits_26\NNS\insufficiency.n.03|memory|induced
D012701_D008569 NONE 5-ht(6_45\CD\entity.n.01| (r_compound) antagonists_48\NNS\person.n.01|,|possibly|,|other|5-ht(6|receptor (r_conj) involved_31\VBN\refer.v.02|that|mechanisms|may|be|in|and|antagonists (r_ccomp) suggesting_25\VBG\declare.v.01|involved (r_advcl) reversed_16\VBD\change.v.02|in|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_18\JJ\cholinergic.a.01|a|and|deficit (l_conj) deficit_23\NN\insufficiency.n.03|a|serotonergic|memory
9401499
D013988_D000741 CID ticlopidine_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|ticlopidine|- (r_amod) anemia_4\NN\blood_disease.n.01|induced|aplastic|:|report|.
D013988_D000741 CID ticlopidine_8\NN\entity.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|ticlopidine|- (r_amod) anemia_12\NN\blood_disease.n.01|induced|aplastic
D013988_D000741 CID ticlopidine_2\NN\entity.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|ticlopidine|- (r_amod) anemia_6\NN\blood_disease.n.01|induced|aplastic|with
D013988_D000380 CID ticlopidine_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|ticlopidine (r_prep) initiation_7\NN\ceremony.n.01|of (r_pobj) after_6\IN\after.s.01|weeks|initiation (r_prep) occurred_1\VBD\happen.v.01|agranulocytosis|after|, (l_nsubj) agranulocytosis_0\NN\blood_disease.n.01|
1833784
D004298_D006948 NONE dopamine_8\NN\monoamine_neurotransmitter.n.01|d2 (r_conj) d1_5\NN\entity.n.01|and|dopamine (r_nmod) receptors_9\NNS\structure.n.04|d1 (r_pobj) of_4\IN\entity.n.01|receptors (r_prep) involvement_3\NN\group_action.n.01|an|of|in (l_prep) in_10\IN\linear_unit.n.01|mediating (l_pcomp) mediating_11\VBG\negociate.v.06|hyperactivity (l_dobj) hyperactivity_15\NN\disorder.n.01|induced|in
D009538_D006948 CID nicotine_12\NN\alkaloid.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|nicotine|- (r_amod) hyperactivity_15\NN\disorder.n.01|induced|in
D009538_D006948 CID nicotine_0\NNP\alkaloid.n.01|mg/kg (r_nsubj) caused_5\VBD\make.v.03|nicotine|increase|,|but|had|. (l_dobj) increase_8\NN\indefinite_quantity.n.01|a|significant|in|habituated (l_prep) in_9\IN\linear_unit.n.01|activity (l_pobj) activity_11\NN\act.n.02|locomotor|in
D009538_D006948 CID nicotine_0\NN\alkaloid.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|nicotine|- (r_amod) hyperactivity_3\NN\disorder.n.01|induced
D009538_D006948 CID nicotine_7\NN\alkaloid.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|nicotine|- (r_amod) hyperactivity_10\NN\disorder.n.01|enhanced|induced
D009538_D006948 CID nicotine_5\NN\alkaloid.n.01| (r_compound) injection_6\NN\insertion.n.02|acute|nicotine (r_nsubj) induces_7\VBZ\generate.v.01|that|injection|hyperactivity (l_dobj) hyperactivity_10\NN\disorder.n.01|a|pronounced|in
C534628_D006948 NONE 23390_12\CD\entity.n.01| (r_nummod) sch_11\NNP\entity.n.01|23390 (r_appos) antagonist_10\NN\person.n.01|the|selective|d1|sch (r_pobj) by_6\IN\by.r.01|antagonist (r_agent) blocked_5\VBN\obstruct.v.02|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN\disorder.n.01|induced
D020891_D006948 NONE raclopride_18\NN\entity.n.01|blocked|,|antagonist|and|fluphenazine|. (l_ccomp) blocked_5\VBN\obstruct.v.02|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN\disorder.n.01|induced
D005476_D006948 NONE fluphenazine_23\NN\major_tranquilizer.n.01|the|d1/d2|antagonist (r_conj) raclopride_18\NN\entity.n.01|blocked|,|antagonist|and|fluphenazine|. (l_ccomp) blocked_5\VBN\obstruct.v.02|hyperactivity|was|by (l_nsubjpass) hyperactivity_3\NN\disorder.n.01|induced
-1_D006948 NONE phno_5\NNP\entity.n.01| (r_npadvmod) enhanced_6\VBN\intensify.v.02|phno (r_amod) hyperactivity_10\NN\disorder.n.01|enhanced|induced
D015647_D006948 NONE 38393_17\CD\entity.n.01| (r_nummod) skf_16\NNP\entity.n.01|38393 (r_appos) agonist_15\NN\protagonist.n.02|the|d1|skf (r_nsubj) had_18\VBD\have.v.01|whereas|agonist|effect (r_advcl) pretreatment_0\NN\entity.n.01|with|,|had|. (l_prep) with_1\IN\entity.n.01|agonist (l_pobj) agonist_4\NN\protagonist.n.02|the|d2|hyperactivity (l_appos) hyperactivity_10\NN\disorder.n.01|enhanced|induced
3750012
D010396_D009157 CID penicillamine_4\NN\medicine.n.02|and|therapy (r_pobj) by_3\IN\by.r.01|penicillamine (r_agent) caused_2\VBN\make.v.03|by (r_acl) gravis_1\NN\entity.n.01|myasthenia|caused|.
D010396_D009157 CID penicillamine_16\NN\medicine.n.02|and|therapy (r_pobj) after_15\IN\after.s.01|penicillamine (r_prep) had_7\VBD\have.v.01|who|gravis|after (l_dobj) gravis_14\NN\entity.n.01|reversible|myasthenia
D010396_D001172 NONE penicillamine_4\NN\medicine.n.02|and|therapy (l_conj) therapy_7\NN\medical_care.n.01|chloroquine|for (l_prep) for_8\IN\entity.n.01|arthritis (l_pobj) arthritis_10\NN\inflammatory_disease.n.01|rheumatoid
D010396_D001172 NONE penicillamine_16\NN\medicine.n.02|and|therapy (l_conj) therapy_19\NN\medical_care.n.01|chloroquine|for (l_prep) for_20\IN\entity.n.01|arthritis (l_pobj) arthritis_22\NN\inflammatory_disease.n.01|rheumatoid
D002738_D009157 CID chloroquine_6\NN\antimalarial.n.01| (r_amod) therapy_7\NN\medical_care.n.01|chloroquine|for (r_conj) penicillamine_4\NN\medicine.n.02|and|therapy (r_pobj) by_3\IN\by.r.01|penicillamine (r_agent) caused_2\VBN\make.v.03|by (r_acl) gravis_1\NN\entity.n.01|myasthenia|caused|.
D002738_D009157 CID chloroquine_18\NN\antimalarial.n.01| (r_compound) therapy_19\NN\medical_care.n.01|chloroquine|for (r_conj) penicillamine_16\NN\medicine.n.02|and|therapy (r_pobj) after_15\IN\after.s.01|penicillamine (r_prep) had_7\VBD\have.v.01|who|gravis|after (l_dobj) gravis_14\NN\entity.n.01|reversible|myasthenia
D002738_D001172 NONE chloroquine_6\NN\antimalarial.n.01| (r_amod) therapy_7\NN\medical_care.n.01|chloroquine|for (l_prep) for_8\IN\entity.n.01|arthritis (l_pobj) arthritis_10\NN\inflammatory_disease.n.01|rheumatoid
D002738_D001172 NONE chloroquine_18\NN\antimalarial.n.01| (r_compound) therapy_19\NN\medical_care.n.01|chloroquine|for (l_prep) for_20\IN\entity.n.01|arthritis (l_pobj) arthritis_22\NN\inflammatory_disease.n.01|rheumatoid
18703024
D006220_D002375 CID haloperidol_3\NN\major_tranquilizer.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|haloperidol|- (r_amod) catalepsy_6\NN\hypersomnia.n.01|induced|or|locomotion
D016291_D002375 NONE mk-801-induced_8\JJ\entity.n.01| (r_compound) locomotion_9\NN\mobility.n.01|mk-801-induced (r_conj) catalepsy_6\NN\hypersomnia.n.01|induced|or|locomotion
11426838
-1_D012640 NONE bd1018_10\NN\entity.n.01|,|bd1063 (r_pobj) with_9\IN\entity.n.01|bd1018 (r_punct) attenuated_17\VBD\weaken.v.01|treatment|with|significantly (r_amod) convulsions_21\NNS\attack.n.07|attenuated|induced|and|lethality
-1_D012640 NONE lr132_15\NNS\entity.n.01| (r_conj) bd1063_12\NNP\entity.n.01|,|or|lr132 (r_conj) bd1018_10\NN\entity.n.01|,|bd1063 (r_pobj) with_9\IN\entity.n.01|bd1018 (r_punct) attenuated_17\VBD\weaken.v.01|treatment|with|significantly (r_amod) convulsions_21\NNS\attack.n.07|attenuated|induced|and|lethality
C093337_D012640 NONE bd1063_12\NNP\entity.n.01|,|or|lr132 (r_conj) bd1018_10\NN\entity.n.01|,|bd1063 (r_pobj) with_9\IN\entity.n.01|bd1018 (r_punct) attenuated_17\VBD\weaken.v.01|treatment|with|significantly (r_amod) convulsions_21\NNS\attack.n.07|attenuated|induced|and|lethality
D003042_D012640 CID cocaine_18\NN\hard_drug.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|cocaine|- (r_amod) convulsions_21\NNS\attack.n.07|attenuated|induced|and|lethality
D003042_D012640 CID cocaine_9\NN\hard_drug.n.01|anti|- (r_compound) effects_10\NNS\personal_property.n.01|the|cocaine|of (r_nsubjpass) shown_29\VBN\show.v.04|that|effects|was|also|attenuate (l_xcomp) attenuate_32\VB\weaken.v.01|to|significantly|effects (l_dobj) effects_38\NNS\personal_property.n.01|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ\convulsive.s.01|and|locomotor
D003042_D012640 CID cocaine_40\NN\hard_drug.n.01| (r_pobj) of_39\IN\entity.n.01|cocaine (r_prep) effects_38\NNS\personal_property.n.01|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ\convulsive.s.01|and|locomotor
C050232_D064420 NONE tolylguanidine_22\NN\entity.n.01|di|o|-|( (r_nmod) dtg_24\NNP\entity.n.01|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\person.n.01|the|putative|,|dtg (r_pobj) by_6\IN\by.r.01|antagonists (r_agent) provided_5\VBN\give.v.03|by (r_acl) protection_4\NN\activity.n.01|the|provided (r_pobj) to_2\IN\entity.n.01|protection (r_prep) contrast_1\NN\opposition.n.02|to (r_pobj) in_0\IN\linear_unit.n.01|contrast (r_prep) worsened_37\VBD\change_state.v.01|in|each|toxicity|. (l_dobj) toxicity_40\NN\definite_quantity.n.01|the|behavioral|of
C050232_D064420 NONE dtg_24\NNP\entity.n.01|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\person.n.01|the|putative|,|dtg (r_pobj) by_6\IN\by.r.01|antagonists (r_agent) provided_5\VBN\give.v.03|by (r_acl) protection_4\NN\activity.n.01|the|provided (r_pobj) to_2\IN\entity.n.01|protection (r_prep) contrast_1\NN\opposition.n.02|to (r_pobj) in_0\IN\linear_unit.n.01|contrast (r_prep) worsened_37\VBD\change_state.v.01|in|each|toxicity|. (l_dobj) toxicity_40\NN\definite_quantity.n.01|the|behavioral|of
-1_D064420 NONE bd1031_32\NN\entity.n.01|the|novel|agonist|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_conj) dtg_24\NNP\entity.n.01|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\person.n.01|the|putative|,|dtg (r_pobj) by_6\IN\by.r.01|antagonists (r_agent) provided_5\VBN\give.v.03|by (r_acl) protection_4\NN\activity.n.01|the|provided (r_pobj) to_2\IN\entity.n.01|protection (r_prep) contrast_1\NN\opposition.n.02|to (r_pobj) in_0\IN\linear_unit.n.01|contrast (r_prep) worsened_37\VBD\change_state.v.01|in|each|toxicity|. (l_dobj) toxicity_40\NN\definite_quantity.n.01|the|behavioral|of
-1_D064420 NONE 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_34\NN\entity.n.01|(|) (r_appos) bd1031_32\NN\entity.n.01|the|novel|agonist|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_conj) dtg_24\NNP\entity.n.01|the|agonist|tolylguanidine|)|and|bd1031 (r_appos) antagonists_9\NNS\person.n.01|the|putative|,|dtg (r_pobj) by_6\IN\by.r.01|antagonists (r_agent) provided_5\VBN\give.v.03|by (r_acl) protection_4\NN\activity.n.01|the|provided (r_pobj) to_2\IN\entity.n.01|protection (r_prep) contrast_1\NN\opposition.n.02|to (r_pobj) in_0\IN\linear_unit.n.01|contrast (r_prep) worsened_37\VBD\change_state.v.01|in|each|toxicity|. (l_dobj) toxicity_40\NN\definite_quantity.n.01|the|behavioral|of
D003042_D064420 NONE cocaine_42\NN\hard_drug.n.01| (r_pobj) of_41\IN\entity.n.01|cocaine (r_prep) toxicity_40\NN\definite_quantity.n.01|the|behavioral|of
D009838_D012640 NONE oligodeoxynucleotide_23\NN\entity.n.01|an|antisense|against (r_appos) receptors_19\NNS\structure.n.04|sigma|,|oligodeoxynucleotide (r_pobj) of_17\IN\entity.n.01|receptors (r_prep) antagonism_16\NN\state.n.02|of (r_dobj) involved_15\VBD\refer.v.02|antagonism (r_acl) ligands_14\NNS\substance.n.07|the|novel|involved (r_pobj) of_11\IN\entity.n.01|ligands (r_prep) effects_10\NNS\personal_property.n.01|the|cocaine|of (r_nsubjpass) shown_29\VBN\show.v.04|that|effects|was|also|attenuate (l_xcomp) attenuate_32\VB\weaken.v.01|to|significantly|effects (l_dobj) effects_38\NNS\personal_property.n.01|the|convulsive|stimulatory|of (l_amod) convulsive_34\JJ\convulsive.s.01|and|locomotor
2924746
D002220_D064420 NONE carbamazepine_1\NN\entity.n.01|chronic (r_compound) treatment_2\NN\care.n.01|carbamazepine|in|:|efficacy|. (l_appos) efficacy_7\NN\effectiveness.n.01|,|toxicity (l_conj) toxicity_9\NN\definite_quantity.n.01|,|and|effect
D005492_D064420 NONE folate_17\JJ\b-complex_vitamin.n.01| (r_compound) concentrations_18\NNS\property.n.02|tissue|folate (r_conj) plasma_14\NN\extracellular_fluid.n.01|and|concentrations (r_pobj) on_13\IN\on.a.01|plasma (r_prep) effect_12\NN\phenomenon.n.01|on (r_conj) toxicity_9\NN\definite_quantity.n.01|,|and|effect
D019946_D012640 NONE glycol_13\NN\antifreeze.n.01|propylene (r_appos) vehicle_10\NN\conveyance.n.03|a|common|,|glycol (r_nsubjpass) found_22\VBN\wage.n.01|in|,|vehicle|,|by|,|was|exhibit|. (l_xcomp) exhibit_24\VB\evidence.n.03|to|properties (l_dobj) properties_26\NNS\possession.n.02|protective|against (l_prep) against_27\IN\entity.n.01|seizures (l_pobj) seizures_29\NNS\attack.n.07|induced|and|gain
D019946_D015430 NONE glycol_13\NN\antifreeze.n.01|propylene (r_appos) vehicle_10\NN\conveyance.n.03|a|common|,|glycol (r_nsubjpass) found_22\VBN\wage.n.01|in|,|vehicle|,|by|,|was|exhibit|. (l_xcomp) exhibit_24\VB\evidence.n.03|to|properties (l_dobj) properties_26\NNS\possession.n.02|protective|against (l_prep) against_27\IN\entity.n.01|seizures (l_pobj) seizures_29\NNS\attack.n.07|induced|and|gain (l_conj) gain_33\NN\indefinite_quantity.n.01|inhibited|weight
D005481_D012640 CID ether_4\NN\element.n.05|hexafluorodiethyl|hfde (r_pobj) by_2\IN\by.r.01|ether (r_prep) induced_1\VBN\generate.v.01|seizures|by|found|. (l_nsubj) seizures_0\NNS\attack.n.07|
D005481_D012640 CID ether_4\NN\element.n.05|hexafluorodiethyl|hfde (r_pobj) by_2\IN\by.r.01|ether (r_prep) induced_1\VBN\generate.v.01|seizures|by|found|. (l_conj) found_10\VBN\wage.n.01|were|also|be (l_xcomp) be_12\VB\metallic_element.n.01|to|measure|than (l_prep) than_21\IN\entity.n.01|seizures (l_pobj) seizures_22\NNS\attack.n.07|induced
D005481_D012640 CID hfde_6\NNP\entity.n.01|(|) (r_appos) ether_4\NN\element.n.05|hexafluorodiethyl|hfde (r_pobj) by_2\IN\by.r.01|ether (r_prep) induced_1\VBN\generate.v.01|seizures|by|found|. (l_nsubj) seizures_0\NNS\attack.n.07|
D005481_D012640 CID hfde_6\NNP\entity.n.01|(|) (r_appos) ether_4\NN\element.n.05|hexafluorodiethyl|hfde (r_pobj) by_2\IN\by.r.01|ether (r_prep) induced_1\VBN\generate.v.01|seizures|by|found|. (l_conj) found_10\VBN\wage.n.01|were|also|be (l_xcomp) be_12\VB\metallic_element.n.01|to|measure|than (l_prep) than_21\IN\entity.n.01|seizures (l_pobj) seizures_22\NNS\attack.n.07|induced
D005481_D012640 CID hfde_21\NNP\entity.n.01| (r_npadvmod) induced_23\VBN\generate.v.01|hfde|- (r_amod) seizures_24\NNS\attack.n.07|induced
D002220_D012640 NONE cbz_20\NN\entity.n.01| (r_pobj) by_19\IN\by.r.01|cbz (r_prep) protection_18\NN\activity.n.01|by (r_pobj) of_17\IN\entity.n.01|protection (r_prep) measure_16\NN\maneuver.n.04|a|sensitive|of (r_attr) be_12\VB\metallic_element.n.01|to|measure|than (r_xcomp) found_10\VBN\wage.n.01|were|also|be (r_conj) induced_1\VBN\generate.v.01|seizures|by|found|. (l_nsubj) seizures_0\NNS\attack.n.07|
D002220_D012640 NONE cbz_20\NN\entity.n.01| (r_pobj) by_19\IN\by.r.01|cbz (r_prep) protection_18\NN\activity.n.01|by (r_pobj) of_17\IN\entity.n.01|protection (r_prep) measure_16\NN\maneuver.n.04|a|sensitive|of (r_attr) be_12\VB\metallic_element.n.01|to|measure|than (l_prep) than_21\IN\entity.n.01|seizures (l_pobj) seizures_22\NNS\attack.n.07|induced
D002220_D012640 NONE cbz_3\NNP\entity.n.01| (r_pobj) of_2\IN\entity.n.01|cbz (r_prep) administration_1\NN\management.n.01|oral|of|as|h (r_nsubj) was_17\VBD\washington.n.02|administration|protective|and|was|. (l_acomp) protective_19\JJ\protective.a.01|continuously|against (l_prep) against_20\IN\entity.n.01|seizures (l_pobj) seizures_24\NNS\attack.n.07|induced
D002220_D015430 NONE cbz_3\NNP\entity.n.01| (r_pobj) of_2\IN\entity.n.01|cbz (r_prep) administration_1\NN\management.n.01|oral|of|as|h (r_nsubj) was_17\VBD\washington.n.02|administration|protective|and|was|. (l_conj) was_26\VBD\washington.n.02|toxic|measured (l_advcl) measured_30\VBN\decide.v.01|as|by|over (l_agent) by_31\IN\by.r.01|gain (l_pobj) gain_33\NN\indefinite_quantity.n.01|weight
D005481_D015430 NONE hfde_21\NNP\entity.n.01| (r_npadvmod) induced_23\VBN\generate.v.01|hfde|- (r_amod) seizures_24\NNS\attack.n.07|induced (r_pobj) against_20\IN\entity.n.01|seizures (r_prep) protective_19\JJ\protective.a.01|continuously|against (r_acomp) was_17\VBD\washington.n.02|administration|protective|and|was|. (l_conj) was_26\VBD\washington.n.02|toxic|measured (l_advcl) measured_30\VBN\decide.v.01|as|by|over (l_agent) by_31\IN\by.r.01|gain (l_pobj) gain_33\NN\indefinite_quantity.n.01|weight
15188772
D004837_D018487 NONE epinephrine_12\NN\catecholamine.n.01| (r_amod) overdose_13\NN\drug.v.01|accidental|iatrogenic|epinephrine (r_pobj) due_8\IN\right.n.01|to|overdose (r_prep) dysfunction_7\NN\pathology.n.02|severe|left|ventricular|systolic|due|.
D004837_D018487 NONE epinephrine_15\NN\catecholamine.n.01| (r_pobj) of_14\IN\entity.n.01|epinephrine (r_prep) mg_13\NN\metric_weight_unit.n.01|8|of (r_nsubj) developed_16\VBN\create.v.02|woman|mg|markers|. (l_dobj) markers_44\NNS\artifact.n.01|stunning|elevated|biochemical|of (l_amod) stunning_18\JJ\immobilize.v.06|myocardial|characterized (l_relcl) characterized_21\VBN\remember.v.02|that|was|by|left|,|and (l_conj) left_32\VBD\position.n.01|dysfunction (l_dobj) dysfunction_37\NN\pathology.n.02|ventricular|systolic
D004837_D062787 NONE epinephrine_12\NN\catecholamine.n.01| (r_amod) overdose_13\NN\drug.v.01|accidental|iatrogenic|epinephrine
D002395_D009202 NONE catecholamine_0\NN\hormone.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|catecholamine|- (r_amod) cardiomyopathy_3\NN\heart_disease.n.01|induced|due
D002395_D009202 NONE catecholamines_10\NNS\hormone.n.01|endogenous (r_pobj) of_8\IN\entity.n.01|catecholamines (r_prep) excess_7\NN\overabundance.n.02|chronic|of (r_pobj) due_4\IN\right.n.01|to|excess (r_prep) cardiomyopathy_3\NN\heart_disease.n.01|induced|due
D004837_D017682 CID epinephrine_15\NN\catecholamine.n.01| (r_pobj) of_14\IN\entity.n.01|epinephrine (r_prep) mg_13\NN\metric_weight_unit.n.01|8|of (r_nsubj) developed_16\VBN\create.v.02|woman|mg|markers|. (l_dobj) markers_44\NNS\artifact.n.01|stunning|elevated|biochemical|of (l_amod) stunning_18\JJ\immobilize.v.06|myocardial|characterized
D004837_D009202 NONE epinephrine_15\NN\catecholamine.n.01| (r_pobj) of_14\IN\entity.n.01|epinephrine (r_prep) mg_13\NN\metric_weight_unit.n.01|8|of (r_nsubj) developed_16\VBN\create.v.02|woman|mg|markers|. (l_dobj) markers_44\NNS\artifact.n.01|stunning|elevated|biochemical|of (l_prep) of_45\IN\entity.n.01|necrosis (l_pobj) necrosis_47\NN\death.n.02|myocardial
19631624
D018817_D007859 CID ecstasy_5\NN\emotional_state.n.01| (r_compound) users_6\NNS\person.n.01|ecstasy (r_pobj) in_4\IN\linear_unit.n.01|users (r_prep) deficits_3\NNS\insufficiency.n.03|learning|in|and|correlates
D018817_D007859 CID ecstasy_6\NN\emotional_state.n.01| (r_compound) users_7\NNS\person.n.01|ecstasy (r_nsubj) display_8\VBP\demonstration.n.05|that|users|impairments (l_dobj) impairments_9\NNS\change.n.01|in (l_prep) in_10\IN\linear_unit.n.01|performance (l_pobj) performance_14\NN\show.n.03|learning (l_nmod) learning_11\NN\basic_cognitive_process.n.01|and|memory (l_conj) memory_13\NN\representation.n.01|
D018817_D008569 CID ecstasy_5\NN\emotional_state.n.01| (r_compound) users_6\NNS\person.n.01|ecstasy (r_pobj) in_4\IN\linear_unit.n.01|users (r_prep) deficits_3\NNS\insufficiency.n.03|learning|in|and|correlates
D018817_D008569 CID ecstasy_6\NN\emotional_state.n.01| (r_compound) users_7\NNS\person.n.01|ecstasy (r_nsubj) display_8\VBP\demonstration.n.05|that|users|impairments (l_dobj) impairments_9\NNS\change.n.01|in (l_prep) in_10\IN\linear_unit.n.01|performance (l_pobj) performance_14\NN\show.n.03|learning (l_nmod) learning_11\NN\basic_cognitive_process.n.01|and|memory (l_conj) memory_13\NN\representation.n.01|
D002188_D007859 NONE cannabis_12\NN\shrub.n.01| (r_compound) users_13\NNS\person.n.01|cannabis (r_pobj) in_11\IN\linear_unit.n.01|users (r_prep) hypoactivity_10\NN\entity.n.01|frontocortical|in (r_conj) hyperactivity_7\NN\disorder.n.01|parahippocampal|and|hypoactivity (r_appos) deficits_0\NNS\insufficiency.n.03|in|:|hyperactivity|. (l_prep) in_1\IN\linear_unit.n.01|learning (l_pobj) learning_2\NN\basic_cognitive_process.n.01|and|memory (l_conj) memory_4\NN\representation.n.01|
D002188_D008569 NONE cannabis_12\NN\shrub.n.01| (r_compound) users_13\NNS\person.n.01|cannabis (r_pobj) in_11\IN\linear_unit.n.01|users (r_prep) hypoactivity_10\NN\entity.n.01|frontocortical|in (r_conj) hyperactivity_7\NN\disorder.n.01|parahippocampal|and|hypoactivity (r_appos) deficits_0\NNS\insufficiency.n.03|in|:|hyperactivity|. (l_prep) in_1\IN\linear_unit.n.01|learning (l_pobj) learning_2\NN\basic_cognitive_process.n.01|and|memory (l_conj) memory_4\NN\representation.n.01|
D002188_D006948 NONE cannabis_12\NN\shrub.n.01| (r_compound) users_13\NNS\person.n.01|cannabis (r_pobj) in_11\IN\linear_unit.n.01|users (r_prep) hypoactivity_10\NN\entity.n.01|frontocortical|in (r_conj) hyperactivity_7\NN\disorder.n.01|parahippocampal|and|hypoactivity
D018817_D006948 NONE ecstasy_13\NN\emotional_state.n.01| (r_npadvmod) specific_15\JJ\fact.n.01|ecstasy|- (r_amod) hyperactivity_16\NN\disorder.n.01|specific|in
D018817_D020258 NONE ecstasy_1\NN\emotional_state.n.01| (r_npadvmod) specific_3\JJ\fact.n.01|ecstasy|- (r_amod) effects_4\NNS\personal_property.n.01|these|specific (r_nsubjpass) related_7\VBN\think.v.03|effects|may|be|to|. (l_prep) to_8\IN\entity.n.01|vulnerability (l_pobj) vulnerability_10\NN\danger.n.01|the|of|to (l_prep) to_16\IN\entity.n.01|effects (l_pobj) effects_19\NNS\personal_property.n.01|the|neurotoxic|of (l_amod) neurotoxic_18\JJ\neurotoxic.a.01|
D018817_D020258 NONE ecstasy_21\NN\emotional_state.n.01| (r_pobj) of_20\IN\entity.n.01|ecstasy (r_prep) effects_19\NNS\personal_property.n.01|the|neurotoxic|of (l_amod) neurotoxic_18\JJ\neurotoxic.a.01|
11147747
D018490_D014549 CID antidepressants_1\NNS\medicine.n.02|serotonergic|and|incontinence|. (l_conj) incontinence_4\NN\elimination.n.02|urinary
D018490_D014549 CID antidepressants_8\NNS\medicine.n.02|serotonergic (r_pobj) to_6\IN\entity.n.01|antidepressants (r_prep) secondary_5\JJ\formation.n.01|to (r_amod) incontinence_4\NN\elimination.n.02|secondary
C047426_D014549 CID venlafaxine_10\NN\entity.n.01| (r_dobj) taking_9\VBG\action.n.01|while|venlafaxine (r_advcl) experienced_6\VBD\undergo.v.01|who|incontinence|taking (l_dobj) incontinence_7\NN\elimination.n.02|
C047426_D014549 CID venlafaxine_35\NNP\entity.n.01| (r_pobj) on_34\IN\on.a.01|venlafaxine (r_prep) developed_30\VBD\create.v.02|who|effect|on (r_relcl) third_28\NN\common_fraction.n.01|a|developed (r_conj) paroxetine_20\NN\entity.n.01|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\entity.n.01|paroxetine (r_prep) developed_11\VBD\create.v.02|who|secondary|to (l_dobj) secondary_13\JJ\formation.n.01|incontinence (l_compound) incontinence_12\NN\elimination.n.02|
D012701_D014549 NONE serotonin_17\NN\monoamine_neurotransmitter.n.01| (r_compound) paroxetine_20\NN\entity.n.01|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\entity.n.01|paroxetine (r_prep) developed_11\VBD\create.v.02|who|secondary|to (l_dobj) secondary_13\JJ\formation.n.01|incontinence (l_compound) incontinence_12\NN\elimination.n.02|
D017374_D014549 CID paroxetine_20\NN\entity.n.01|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\entity.n.01|paroxetine (r_prep) developed_11\VBD\create.v.02|who|secondary|to (l_dobj) secondary_13\JJ\formation.n.01|incontinence (l_compound) incontinence_12\NN\elimination.n.02|
D020280_D014549 CID sertraline_22\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_conj) paroxetine_20\NN\entity.n.01|the|selective|serotonin|inhibitors|and|sertraline|,|as|third (r_pobj) to_14\IN\entity.n.01|paroxetine (r_prep) developed_11\VBD\create.v.02|who|secondary|to (l_dobj) secondary_13\JJ\formation.n.01|incontinence (l_compound) incontinence_12\NN\elimination.n.02|
D016651_D014549 CID carbonate_12\NN\salt.n.01|lithium|and|blockers (r_dobj) taking_10\VBG\action.n.01|patients|were|also|carbonate (r_relcl) cases_5\NNS\happening.n.01|the|3|taking (r_pobj) of_2\IN\entity.n.01|cases (r_prep) 2_1\CD\digit.n.01|of (r_pobj) in_0\IN\linear_unit.n.01|2 (r_prep) contributed_23\VBN\change.v.01|in|,|both|could|have|to|. (l_prep) to_24\IN\entity.n.01|incontinence (l_pobj) incontinence_26\NN\elimination.n.02|the
19300402
D001920_D006930 NONE bradykinin_0\NN\entity.n.01| (r_compound) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in
D001920_D006930 NONE bradykinin_9\NN\entity.n.01| (r_compound) receptors_10\NNS\structure.n.04|bradykinin (r_pobj) of_8\IN\entity.n.01|receptors (r_prep) inhibition_7\NN\abstinence.n.02|of|and|synthase|but (r_nsubj) reduces_21\VBZ\decrease.v.02|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN\entity.n.01|diabetic
D001920_D006930 NONE bradykinin_19\NN\entity.n.01| (r_conj) activation_15\NN\stimulation.n.03|neuronal|no|synthase|as|bradykinin (r_conj) synthase_10\NN\entity.n.01|inducible|no|and|activation (r_pobj) of_7\IN\entity.n.01|synthase (r_prep) products_6\NNS\commodity.n.01|both|of (r_nsubjpass) involved_21\VBN\refer.v.02|that|products|are|in (l_prep) in_22\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_23\NN\entity.n.01|produced
D001920_D006930 NONE bradykinin_14\NN\entity.n.01| (r_pobj) of_13\IN\entity.n.01|bradykinin (r_prep) activity_12\NN\act.n.02|pronociceptive|of (r_pobj) in_10\IN\linear_unit.n.01|activity (r_prep) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_4\NN\entity.n.01|induced
D001920_D006930 NONE bradykinin_14\NN\entity.n.01| (r_pobj) of_13\IN\entity.n.01|bradykinin (r_prep) activity_12\NN\act.n.02|pronociceptive|of (r_pobj) in_10\IN\linear_unit.n.01|activity (r_prep) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\generate.v.01|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\entity.n.01|
D001920_D006930 NONE bradykinin_22\NN\entity.n.01| (r_nsubj) seemed_23\VBD\be.v.01|bradykinin|activate|. (r_conj) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_4\NN\entity.n.01|induced
D001920_D006930 NONE bradykinin_22\NN\entity.n.01| (r_nsubj) seemed_23\VBD\be.v.01|bradykinin|activate|. (r_conj) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\generate.v.01|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\entity.n.01|
D001920_D003929 NONE bradykinin_0\NN\entity.n.01| (r_compound) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in (l_prep) in_14\IN\linear_unit.n.01|chemotherapy (l_pobj) chemotherapy_15\NN\therapy.n.01|and|model (l_conj) model_20\NN\hypothesis.n.02|diabetic|rat (l_compound) rat_19\NN\rodent.n.01|neuropathy (l_compound) neuropathy_18\NN\pathology.n.02|
D009569_D006930 NONE oxide_5\NN\compound.n.02| (r_compound) synthase_6\NN\entity.n.01|nitric|oxide (r_compound) inhibitors_7\NNS\substance.n.07|synthase (r_conj) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in
D009569_D006930 NONE no_13\DT\negative.n.01| (r_det) synthase_14\NN\entity.n.01|inducible|no (r_conj) inhibition_7\NN\abstinence.n.02|of|and|synthase|but (r_nsubj) reduces_21\VBZ\decrease.v.02|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN\entity.n.01|diabetic
D009569_D006930 NONE no_18\DT\negative.n.01| (r_det) activity_20\NN\act.n.02|not|neuronal|no|synthase (r_nsubj) reduces_21\VBZ\decrease.v.02|that|inhibition|activity|hyperalgesia (l_dobj) hyperalgesia_23\NN\entity.n.01|diabetic
D009569_D006930 NONE no_9\DT\negative.n.01| (r_compound) synthase_10\NN\entity.n.01|inducible|no|and|activation (r_pobj) of_7\IN\entity.n.01|synthase (r_prep) products_6\NNS\commodity.n.01|both|of (r_nsubjpass) involved_21\VBN\refer.v.02|that|products|are|in (l_prep) in_22\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_23\NN\entity.n.01|produced
D009569_D006930 NONE no_13\DT\negative.n.01| (r_det) activation_15\NN\stimulation.n.03|neuronal|no|synthase|as|bradykinin (r_conj) synthase_10\NN\entity.n.01|inducible|no|and|activation (r_pobj) of_7\IN\entity.n.01|synthase (r_prep) products_6\NNS\commodity.n.01|both|of (r_nsubjpass) involved_21\VBN\refer.v.02|that|products|are|in (l_prep) in_22\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_23\NN\entity.n.01|produced
D009569_D006930 NONE no_7\DT\negative.n.01| (r_compound) synthase_8\NN\entity.n.01|inducible|no (r_nsubj) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_4\NN\entity.n.01|induced
D009569_D006930 NONE no_7\DT\negative.n.01| (r_compound) synthase_8\NN\entity.n.01|inducible|no (r_nsubj) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\generate.v.01|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\entity.n.01|
D009569_D006930 NONE no_27\DT\negative.n.01| (r_det) pathway_29\NN\white_matter.n.01|neuronal|no|synthase (r_dobj) activate_25\VB\initiate.v.02|to|pathway (r_xcomp) seemed_23\VBD\be.v.01|bradykinin|activate|. (r_conj) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_4\NN\entity.n.01|induced
D009569_D006930 NONE no_27\DT\negative.n.01| (r_det) pathway_29\NN\white_matter.n.01|neuronal|no|synthase (r_dobj) activate_25\VB\initiate.v.02|to|pathway (r_xcomp) seemed_23\VBD\be.v.01|bradykinin|activate|. (r_conj) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\generate.v.01|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\entity.n.01|
D009569_D003929 NONE oxide_5\NN\compound.n.02| (r_compound) synthase_6\NN\entity.n.01|nitric|oxide (r_compound) inhibitors_7\NNS\substance.n.07|synthase (r_conj) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in (l_prep) in_14\IN\linear_unit.n.01|chemotherapy (l_pobj) chemotherapy_15\NN\therapy.n.01|and|model (l_conj) model_20\NN\hypothesis.n.02|diabetic|rat (l_compound) rat_19\NN\rodent.n.01|neuropathy (l_compound) neuropathy_18\NN\pathology.n.02|
D014750_D006930 CID vincristine_9\NN\periwinkle_plant_derivative.n.01| (r_pobj) in_8\IN\linear_unit.n.01|vincristine (r_prep) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in
D014750_D006930 CID vincristine_26\NN\periwinkle_plant_derivative.n.01| (r_pobj) by_25\IN\by.r.01|vincristine (r_agent) produced_24\VBN\make.v.03|by (r_acl) hyperalgesia_23\NN\entity.n.01|produced
D014750_D006930 CID vincristine_18\NN\periwinkle_plant_derivative.n.01| (r_pobj) in_17\IN\linear_unit.n.01|vincristine (r_prep) induced_20\VBN\generate.v.01|whereas|in|-|hyperalgesia (r_advcl) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_prep) in_0\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_4\NN\entity.n.01|induced
D014750_D006930 CID vincristine_18\NN\periwinkle_plant_derivative.n.01| (r_pobj) in_17\IN\linear_unit.n.01|vincristine (r_prep) induced_20\VBN\generate.v.01|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\entity.n.01|
D014750_D003929 NONE vincristine_9\NN\periwinkle_plant_derivative.n.01| (r_pobj) in_8\IN\linear_unit.n.01|vincristine (r_prep) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in (l_prep) in_14\IN\linear_unit.n.01|chemotherapy (l_pobj) chemotherapy_15\NN\therapy.n.01|and|model (l_conj) model_20\NN\hypothesis.n.02|diabetic|rat (l_compound) rat_19\NN\rodent.n.01|neuropathy (l_compound) neuropathy_18\NN\pathology.n.02|
D013311_D006930 CID streptozotocin_11\NNS\entity.n.01| (r_conj) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in
D013311_D006930 CID streptozotocin_1\JJ\entity.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|streptozotocin|- (r_amod) hyperalgesia_4\NN\entity.n.01|induced
D013311_D006930 CID streptozotocin_1\JJ\entity.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|streptozotocin|- (r_amod) hyperalgesia_4\NN\entity.n.01|induced (r_pobj) in_0\IN\linear_unit.n.01|hyperalgesia (r_prep) participates_9\VBZ\act.v.01|in|,|synthase|in|,|induced|seemed (l_advcl) induced_20\VBN\generate.v.01|whereas|in|-|hyperalgesia (l_dobj) hyperalgesia_21\NN\entity.n.01|
D013311_D003929 CID streptozotocin_11\NNS\entity.n.01| (r_conj) antagonists_2\NNS\person.n.01|bradykinin|receptors|and|inhibitors|in|and|streptozotocin (r_nsubj) induced_12\VBD\generate.v.01|antagonists|hyperalgesia|. (l_dobj) hyperalgesia_13\NN\entity.n.01|in (l_prep) in_14\IN\linear_unit.n.01|chemotherapy (l_pobj) chemotherapy_15\NN\therapy.n.01|and|model (l_conj) model_20\NN\hypothesis.n.02|diabetic|rat (l_compound) rat_19\NN\rodent.n.01|neuropathy (l_compound) neuropathy_18\NN\pathology.n.02|
D001920_D009437 NONE bradykinin_8\NN\entity.n.01|antagonists (r_pobj) of_7\IN\entity.n.01|bradykinin (r_prep) doses_6\NNS\medicine.n.02|small|of (r_pobj) of_4\IN\entity.n.01|doses (r_prep) administration_3\NN\management.n.01|concomitant|of (r_nsubj) be_16\VB\metallic_element.n.01|therefore|,|administration|can|effective|,|in|. (l_acomp) effective_17\JJ\effective.a.01|in (l_prep) in_18\IN\linear_unit.n.01|alleviation (l_pobj) alleviation_19\NN\comfort.n.02|of (l_prep) of_20\IN\entity.n.01|pain (l_pobj) pain_22\NN\symptom.n.01|neuropathic
D009569_D009437 NONE no_12\DT\negative.n.01| (r_det) inhibitors_14\NNS\substance.n.07|no|synthase (r_conj) antagonists_10\NNS\person.n.01|receptor|and|inhibitors (r_dobj) bradykinin_8\NN\entity.n.01|antagonists (r_pobj) of_7\IN\entity.n.01|bradykinin (r_prep) doses_6\NNS\medicine.n.02|small|of (r_pobj) of_4\IN\entity.n.01|doses (r_prep) administration_3\NN\management.n.01|concomitant|of (r_nsubj) be_16\VB\metallic_element.n.01|therefore|,|administration|can|effective|,|in|. (l_acomp) effective_17\JJ\effective.a.01|in (l_prep) in_18\IN\linear_unit.n.01|alleviation (l_pobj) alleviation_19\NN\comfort.n.02|of (l_prep) of_20\IN\entity.n.01|pain (l_pobj) pain_22\NN\symptom.n.01|neuropathic
21029050
D013390_D001049 CID succinylcholine_9\NN\muscle_relaxant.n.01|for (r_pobj) after_8\IN\after.s.01|succinylcholine (r_prep) mutations_2\NNS\organism.n.01|gene|in|after|. (l_prep) in_3\IN\linear_unit.n.01|patients (l_pobj) patients_4\NNS\case.n.06|with (l_prep) with_5\IN\entity.n.01|apnea (l_pobj) apnea_7\NN\symptom.n.01|prolonged
D013390_D001049 CID succinylcholine_11\NN\muscle_relaxant.n.01| (r_pobj) of_10\IN\entity.n.01|succinylcholine (r_prep) action_9\NN\act.n.02|of (r_pobj) of_8\IN\entity.n.01|action (r_prep) duration_7\NN\time_period.n.01|a|prolonged|of (r_pobj) with_4\IN\entity.n.01|duration (r_prep) patients_3\NNS\case.n.06|13|with (r_pobj) of_1\IN\entity.n.01|patients (r_prep) eleven_0\CD\large_integer.n.01|of (r_nsubj) had_12\VBD\have.v.01|eleven|mutations|,|indicating|. (l_advcl) indicating_17\VBG\tell.v.02|is (l_ccomp) is_20\VBZ\be.v.01|that|this|reason (l_attr) reason_23\NN\rational_motive.n.01|the|possible|for (l_prep) for_24\IN\entity.n.01|period (l_pobj) period_27\NN\fundamental_quantity.n.01|a|prolonged|of (l_prep) of_28\IN\entity.n.01|apnea (l_pobj) apnea_29\NN\symptom.n.01|
10737864
D003000_D001919 CID clonidine_14\NN\antihypertensive.n.01|that (r_pobj) given_12\VBN\assumption.n.02|clonidine (r_prep) induces_15\VBZ\generate.v.01|given|withdrawal (l_dobj) withdrawal_17\NN\retraction.n.01|sympathetic|and|bradycardia (l_conj) bradycardia_19\NNP\cardiac_arrhythmia.n.01|
D003000_D001919 CID clonidine_24\NN\antihypertensive.n.01|'s (r_poss) effects_27\NNS\personal_property.n.01|clonidine|developmental|on (r_nsubj) mirror_35\VB\reflector.n.01|that|effects|would|other (r_ccomp) hypothesized_22\VBD\expect.v.01|exhibits|,|we|mirror|. (l_ccomp) exhibits_5\VBZ\evidence.n.03|given|pattern|,|and|induces (l_conj) induces_15\VBZ\generate.v.01|given|withdrawal (l_dobj) withdrawal_17\NN\retraction.n.01|sympathetic|and|bradycardia (l_conj) bradycardia_19\NNP\cardiac_arrhythmia.n.01|
D003000_D001919 CID clonidine_19\NN\antihypertensive.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|clonidine|- (r_amod) bradycardia_22\NN\cardiac_arrhythmia.n.01|induced
18544179
D005283_D009325 NONE fentanyl_1\NN\analgesic.n.01| (r_dobj) omitting_0\VBG\extinguish.v.04|fentanyl (r_csubj) reduces_2\VBZ\decrease.v.02|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\symptom.n.01|and|vomiting
D005283_D009325 NONE fentanyl_2\NN\analgesic.n.01| (r_pobj) of_1\IN\entity.n.01|fentanyl (r_prep) omission_0\NN\mistake.n.01|of (r_nsubj) reduce_5\VB\decrease.v.02|omission|did|not|incidence|,|but|reduce|. (l_conj) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\adult.n.01|to (l_prep) to_24\TO\entity.n.01|nausea (l_pobj) nausea_26\NN\symptom.n.01|severe
D005283_D009325 NONE fentanyl_37\NN\analgesic.n.01|and (r_nmod) dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\adult.n.01|to (l_prep) to_24\TO\entity.n.01|nausea (l_pobj) nausea_26\NN\symptom.n.01|severe
D005283_D009325 NONE fentanyl_39\NN\analgesic.n.01| (r_compound) dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\adult.n.01|to (l_prep) to_24\TO\entity.n.01|nausea (l_pobj) nausea_26\NN\symptom.n.01|severe
D005283_D009325 NONE fentanyl_3\NN\analgesic.n.01|two (r_compound) groups_4\NNS\abstraction.n.06|the|fentanyl (r_dobj) combining_0\VBG\union.n.09|groups (r_csubj) revealed_5\VBD\show.v.04|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) reducing_15\VBG\chemical_reaction.n.01|nausea|prior (l_dobj) nausea_17\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_19\NN\expulsion.n.03|and|nausea (l_conj) nausea_21\NN\symptom.n.01|
D005283_D009325 NONE fentanyl_3\NN\analgesic.n.01|two (r_compound) groups_4\NNS\abstraction.n.06|the|fentanyl (r_dobj) combining_0\VBG\union.n.09|groups (r_csubj) revealed_5\VBD\show.v.04|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) decreased_57\VBN\change_magnitude.v.01|while|nausea|was|from|(|p|) (l_nsubjpass) nausea_50\NN\symptom.n.01|in|h
D005283_D014839 NONE fentanyl_1\NN\analgesic.n.01| (r_dobj) omitting_0\VBG\extinguish.v.04|fentanyl (r_csubj) reduces_2\VBZ\decrease.v.02|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\symptom.n.01|and|vomiting (l_conj) vomiting_5\NN\expulsion.n.03|
D005283_D014839 NONE fentanyl_2\NN\analgesic.n.01| (r_pobj) of_1\IN\entity.n.01|fentanyl (r_prep) omission_0\NN\mistake.n.01|of (r_nsubj) reduce_5\VB\decrease.v.02|omission|did|not|incidence|,|but|reduce|. (l_conj) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\frequency.n.02|the|of (l_prep) of_20\IN\entity.n.01|vomiting (l_pobj) vomiting_21\NN\expulsion.n.03|
D005283_D014839 NONE fentanyl_37\NN\analgesic.n.01|and (r_nmod) dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\frequency.n.02|the|of (l_prep) of_20\IN\entity.n.01|vomiting (l_pobj) vomiting_21\NN\expulsion.n.03|
D005283_D014839 NONE fentanyl_39\NN\analgesic.n.01| (r_compound) dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\frequency.n.02|the|of (l_prep) of_20\IN\entity.n.01|vomiting (l_pobj) vomiting_21\NN\expulsion.n.03|
D005283_D010146 NONE fentanyl_1\NN\analgesic.n.01| (r_dobj) omitting_0\VBG\extinguish.v.04|fentanyl (r_csubj) reduces_2\VBZ\decrease.v.02|omitting|nausea|,|without|,|after|. (l_prep) without_7\IN\entity.n.01|increasing (l_pcomp) increasing_8\VBG\change_magnitude.v.01|pain (l_dobj) pain_9\NN\symptom.n.01|
D005283_D010146 NONE fentanyl_11\NN\analgesic.n.01| (r_pobj) of_10\IN\entity.n.01|fentanyl (r_prep) omission_9\NN\mistake.n.01|the|of (r_pobj) by_7\IN\by.r.01|omission (r_prep) unaffected_6\JJ\unaffected.a.01|by (r_acomp) were_5\VBD\be.v.01|severity|unaffected|. (l_nsubj) severity_1\NN\intensity.n.02|pain|and|requirements (l_compound) pain_0\NN\symptom.n.01|
C009250_D009325 NONE sevoflurane_12\NN\entity.n.01|for (r_pobj) after_11\IN\after.s.01|sevoflurane (r_prep) reduces_2\VBZ\decrease.v.02|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\symptom.n.01|and|vomiting
C009250_D014839 NONE sevoflurane_12\NN\entity.n.01|for (r_pobj) after_11\IN\after.s.01|sevoflurane (r_prep) reduces_2\VBZ\decrease.v.02|omitting|nausea|,|without|,|after|. (l_dobj) nausea_3\NN\symptom.n.01|and|vomiting (l_conj) vomiting_5\NN\expulsion.n.03|
C009250_D010146 NONE sevoflurane_12\NN\entity.n.01|for (r_pobj) after_11\IN\after.s.01|sevoflurane (r_prep) reduces_2\VBZ\decrease.v.02|omitting|nausea|,|without|,|after|. (l_prep) without_7\IN\entity.n.01|increasing (l_pcomp) increasing_8\VBG\change_magnitude.v.01|pain (l_dobj) pain_9\NN\symptom.n.01|
C009250_D010146 NONE sevoflurane_23\NN\entity.n.01| (r_compound) anaesthesia_24\NN\physical_condition.n.01|sevoflurane|in (r_pobj) after_22\IN\after.s.01|anaesthesia (r_prep) h_21\NN\chemical_element.n.01|the|first|24|after (r_pobj) in_17\IN\linear_unit.n.01|h (r_prep) examined_5\VBD\analyze.v.01|study|incidence|in|. (l_dobj) incidence_7\NN\frequency.n.02|the|and|severity|of (l_prep) of_10\IN\entity.n.01|nausea (l_pobj) nausea_12\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_14\NN\expulsion.n.03|and|pain (l_conj) pain_16\NN\symptom.n.01|
C009250_D020250 NONE sevoflurane_9\NN\entity.n.01|, (r_pobj) with_8\IN\entity.n.01|sevoflurane (r_prep) advantages_1\NNS\asset.n.01|of|with (r_pobj) despite_0\IN\dislike.n.02|advantages (r_prep) occurs_15\VBZ\happen.v.01|despite|nausea|frequently|. (l_nsubj) nausea_12\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_14\NN\expulsion.n.03|
C009250_D020250 NONE sevoflurane_23\NN\entity.n.01| (r_compound) anaesthesia_24\NN\physical_condition.n.01|sevoflurane|in (r_pobj) after_22\IN\after.s.01|anaesthesia (r_prep) h_21\NN\chemical_element.n.01|the|first|24|after (r_pobj) in_17\IN\linear_unit.n.01|h (r_prep) examined_5\VBD\analyze.v.01|study|incidence|in|. (l_dobj) incidence_7\NN\frequency.n.02|the|and|severity|of (l_prep) of_10\IN\entity.n.01|nausea (l_pobj) nausea_12\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_14\NN\expulsion.n.03|and|pain
C009250_D020250 NONE sevoflurane_31\NN\entity.n.01|to|in (r_relcl) supplement_29\NN\matter.n.06|an|unnecessary|sevoflurane (r_attr) be_23\VB\metallic_element.n.01|to|supplement (r_xcomp) appears_21\VBZ\be.v.01|exacerbated|,|it|be|. (l_advcl) exacerbated_2\VBD\change.v.01|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_6\VBG\expulsion.n.03|without
D005283_D020250 CID fentanyl_2\NN\analgesic.n.01| (r_pobj) of_1\IN\entity.n.01|fentanyl (r_prep) omission_0\NN\mistake.n.01|of (r_nsubj) reduce_5\VB\decrease.v.02|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\frequency.n.02|the|overall|of (l_prep) of_9\IN\entity.n.01|nausea (l_pobj) nausea_11\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_13\NN\expulsion.n.03|
D005283_D020250 CID fentanyl_37\NN\analgesic.n.01|and (r_nmod) dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB\decrease.v.02|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\frequency.n.02|the|overall|of (l_prep) of_9\IN\entity.n.01|nausea (l_pobj) nausea_11\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_13\NN\expulsion.n.03|
D005283_D020250 CID fentanyl_39\NN\analgesic.n.01| (r_compound) dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB\decrease.v.02|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\frequency.n.02|the|overall|of (l_prep) of_9\IN\entity.n.01|nausea (l_pobj) nausea_11\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_13\NN\expulsion.n.03|
D005283_D020250 CID fentanyl_3\NN\analgesic.n.01|two (r_compound) groups_4\NNS\abstraction.n.06|the|fentanyl (r_dobj) combining_0\VBG\union.n.09|groups (r_csubj) revealed_5\VBD\show.v.04|combining|benefits|,|reducing|(|p|decreased|. (l_advcl) reducing_15\VBG\chemical_reaction.n.01|nausea|prior (l_dobj) nausea_17\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_19\NN\expulsion.n.03|and|nausea
D005283_D020250 CID fentanyl_1\NN\analgesic.n.01| (r_nsubj) exacerbated_2\VBD\change.v.01|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_6\VBG\expulsion.n.03|without
D003907_D020250 NONE dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (r_conj) reduce_5\VB\decrease.v.02|omission|did|not|incidence|,|but|reduce|. (l_dobj) incidence_8\NN\frequency.n.02|the|overall|of (l_prep) of_9\IN\entity.n.01|nausea (l_pobj) nausea_11\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_13\NN\expulsion.n.03|
D003907_D020250 NONE dexamethasone_0\NNP\anti-inflammatory.n.01| (r_nsubj) had_1\VBD\have.v.01|dexamethasone|effect|. (l_dobj) effect_4\NN\phenomenon.n.01|no|significant|on (l_prep) on_5\IN\on.a.01|incidence (l_pobj) incidence_7\NN\frequency.n.02|the|or|severity|of (l_prep) of_10\IN\entity.n.01|nausea (l_pobj) nausea_12\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_14\NN\expulsion.n.03|
D003907_D014839 NONE dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_dobj) incidence_19\NN\frequency.n.02|the|of (l_prep) of_20\IN\entity.n.01|vomiting (l_pobj) vomiting_21\NN\expulsion.n.03|
D003907_D009325 NONE dexamethasone_41\NN\anti-inflammatory.n.01|fentanyl|fentanyl|- (r_pobj) with_36\IN\entity.n.01|dexamethasone (r_prep) %_35\NN\entity.n.01|17|with (r_conj) %_32\NN\entity.n.01|20|and|% (r_pobj) from_30\IN\entity.n.01|% (r_prep) discharge_29\NN\happening.n.01|from|,|respectively (r_pobj) to_28\IN\entity.n.01|discharge (r_prep) prior_27\RB\superior.n.02|to (r_advmod) reduce_17\VB\decrease.v.02|did|incidence|and/or|moderate|prior|,|to (l_conj) moderate_23\JJ\adult.n.01|to (l_prep) to_24\TO\entity.n.01|nausea (l_pobj) nausea_26\NN\symptom.n.01|severe
D005283_D012131 CID fentanyl_0\NNP\analgesic.n.01| (r_nsubj) reduce_2\VB\decrease.v.02|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\have.v.01|effect|and|depression (l_conj) depression_16\NN\psychological_state.n.01|increased|respiratory|,|hypotension
D005283_D007022 CID fentanyl_0\NNP\analgesic.n.01| (r_nsubj) reduce_2\VB\decrease.v.02|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\have.v.01|effect|and|depression (l_conj) depression_16\NN\psychological_state.n.01|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\cardiovascular_disease.n.01|and|bradycardia
D005283_D001919 CID fentanyl_0\NNP\analgesic.n.01| (r_nsubj) reduce_2\VB\decrease.v.02|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\have.v.01|effect|and|depression (l_conj) depression_16\NN\psychological_state.n.01|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\cardiovascular_disease.n.01|and|bradycardia (l_conj) bradycardia_20\NN\cardiac_arrhythmia.n.01|
C009250_D012131 NONE sevoflurane_9\NN\entity.n.01| (r_npadvmod) sparing_11\VBG\refrain.v.01|sevoflurane|- (r_amod) effect_12\NN\phenomenon.n.01|no|sparing (r_dobj) had_7\VBD\have.v.01|effect|and|depression (l_conj) depression_16\NN\psychological_state.n.01|increased|respiratory|,|hypotension
C009250_D007022 NONE sevoflurane_9\NN\entity.n.01| (r_npadvmod) sparing_11\VBG\refrain.v.01|sevoflurane|- (r_amod) effect_12\NN\phenomenon.n.01|no|sparing (r_dobj) had_7\VBD\have.v.01|effect|and|depression (l_conj) depression_16\NN\psychological_state.n.01|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\cardiovascular_disease.n.01|and|bradycardia
C009250_D001919 NONE sevoflurane_9\NN\entity.n.01| (r_npadvmod) sparing_11\VBG\refrain.v.01|sevoflurane|- (r_amod) effect_12\NN\phenomenon.n.01|no|sparing (r_dobj) had_7\VBD\have.v.01|effect|and|depression (l_conj) depression_16\NN\psychological_state.n.01|increased|respiratory|,|hypotension (l_conj) hypotension_18\NN\cardiovascular_disease.n.01|and|bradycardia (l_conj) bradycardia_20\NN\cardiac_arrhythmia.n.01|
D005283_D010149 NONE fentanyl_1\NN\analgesic.n.01| (r_nsubj) exacerbated_2\VBD\change.v.01|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_6\VBG\expulsion.n.03|without (l_prep) without_7\IN\entity.n.01|improvement (l_pobj) improvement_9\NN\transformation.n.01|an|in (l_prep) in_10\IN\linear_unit.n.01|pain (l_pobj) pain_12\NN\symptom.n.01|postoperative
C009250_D010149 NONE sevoflurane_31\NN\entity.n.01|to|in (r_relcl) supplement_29\NN\matter.n.06|an|unnecessary|sevoflurane (r_attr) be_23\VB\metallic_element.n.01|to|supplement (r_xcomp) appears_21\VBZ\be.v.01|exacerbated|,|it|be|. (l_advcl) exacerbated_2\VBD\change.v.01|as|fentanyl|nausea|and|had (l_dobj) nausea_4\NN\symptom.n.01|postoperative|and|vomiting (l_conj) vomiting_6\VBG\expulsion.n.03|without (l_prep) without_7\IN\entity.n.01|improvement (l_pobj) improvement_9\NN\transformation.n.01|an|in (l_prep) in_10\IN\linear_unit.n.01|pain (l_pobj) pain_12\NN\symptom.n.01|postoperative
11672959
D012460_D003872 CID sulphasalazine_27\NN\entity.n.01|oral|for (r_pobj) of_25\IN\entity.n.01|sulphasalazine (r_prep) course_24\NN\education.n.01|a|of (r_pobj) of_22\IN\entity.n.01|course (r_prep) day_21\NN\time_unit.n.01|the|17th|of (r_pobj) on_18\IN\on.a.01|day (r_prep) beginning_17\VBG\happening.n.01|on (r_advcl) developed_5\VBD\create.v.02|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\design.n.02|a|of (l_prep) of_8\IN\entity.n.01|dermatitis (l_pobj) dermatitis_9\NN\eczema.n.01|,|fever
D012460_D005334 CID sulphasalazine_27\NN\entity.n.01|oral|for (r_pobj) of_25\IN\entity.n.01|sulphasalazine (r_prep) course_24\NN\education.n.01|a|of (r_pobj) of_22\IN\entity.n.01|course (r_prep) day_21\NN\time_unit.n.01|the|17th|of (r_pobj) on_18\IN\on.a.01|day (r_prep) beginning_17\VBG\happening.n.01|on (r_advcl) developed_5\VBD\create.v.02|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\design.n.02|a|of (l_prep) of_8\IN\entity.n.01|dermatitis (l_pobj) dermatitis_9\NN\eczema.n.01|,|fever (l_conj) fever_11\NN\symptom.n.01|,|lymphadenopathy
D012460_D008206 CID sulphasalazine_27\NN\entity.n.01|oral|for (r_pobj) of_25\IN\entity.n.01|sulphasalazine (r_prep) course_24\NN\education.n.01|a|of (r_pobj) of_22\IN\entity.n.01|course (r_prep) day_21\NN\time_unit.n.01|the|17th|of (r_pobj) on_18\IN\on.a.01|day (r_prep) beginning_17\VBG\happening.n.01|on (r_advcl) developed_5\VBD\create.v.02|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\design.n.02|a|of (l_prep) of_8\IN\entity.n.01|dermatitis (l_pobj) dermatitis_9\NN\eczema.n.01|,|fever (l_conj) fever_11\NN\symptom.n.01|,|lymphadenopathy (l_conj) lymphadenopathy_13\NN\pathology.n.02|and|hepatitis
D012460_D056486 CID sulphasalazine_27\NN\entity.n.01|oral|for (r_pobj) of_25\IN\entity.n.01|sulphasalazine (r_prep) course_24\NN\education.n.01|a|of (r_pobj) of_22\IN\entity.n.01|course (r_prep) day_21\NN\time_unit.n.01|the|17th|of (r_pobj) on_18\IN\on.a.01|day (r_prep) beginning_17\VBG\happening.n.01|on (r_advcl) developed_5\VBD\create.v.02|lady|constellation|,|beginning|. (l_dobj) constellation_7\NN\design.n.02|a|of (l_prep) of_8\IN\entity.n.01|dermatitis (l_pobj) dermatitis_9\NN\eczema.n.01|,|fever (l_conj) fever_11\NN\symptom.n.01|,|lymphadenopathy (l_conj) lymphadenopathy_13\NN\pathology.n.02|and|hepatitis (l_conj) hepatitis_15\NN\infectious_disease.n.01|
D012460_D001172 NONE sulphasalazine_27\NN\entity.n.01|oral|for (l_prep) for_28\IN\entity.n.01|arthritis (l_pobj) arthritis_33\NN\inflammatory_disease.n.01|negative|rheumatoid
15649445
D012110_D004409 CID reserpine_1\NN\antihypertensive.n.01|acute|and|subchronic (r_nsubj) change_6\VBP\happening.n.01|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\make.v.03|dyskinesia (l_dobj) dyskinesia_14\NN\nervous_disorder.n.01|orofacial|in
D012110_D004409 CID reserpine-_0\NNP\entity.n.01|and|dyskinesia (l_conj) dyskinesia_6\NN\nervous_disorder.n.01|induced|orofacial
D012110_D004409 CID reserpine-_0\NNP\entity.n.01|and|dyskinesia (r_nsubj) are_7\VBP\area_unit.n.01|reserpine-|models|. (l_attr) models_10\NNS\hypothesis.n.02|putative|animal|of|related (l_prep) of_11\IN\entity.n.01|dyskinesia (l_pobj) dyskinesia_13\JJ\nervous_disorder.n.01|tardive|td
D012110_D004409 CID reserpine-_0\NNP\entity.n.01|and|dyskinesia (r_nsubj) are_7\VBP\area_unit.n.01|reserpine-|models|. (l_attr) models_10\NNS\hypothesis.n.02|putative|animal|of|related (l_prep) of_11\IN\entity.n.01|dyskinesia (l_pobj) dyskinesia_13\JJ\nervous_disorder.n.01|tardive|td (l_appos) td_15\NN\entity.n.01|(|)
D012110_D004409 CID reserpine_12\NN\antihypertensive.n.01|acute|and|administration|to (r_pobj) by_10\IN\by.r.01|reserpine (r_prep) induced_7\VBD\generate.v.01|in|,|authors|dyskinesia|by|. (l_dobj) dyskinesia_9\NN\nervous_disorder.n.01|orofacial
D006220_D004409 CID haloperidol_4\NN\major_tranquilizer.n.01| (r_compound) change_6\VBP\happening.n.01|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\make.v.03|dyskinesia (l_dobj) dyskinesia_14\NN\nervous_disorder.n.01|orofacial|in
D006220_D004409 CID haloperidol_2\NN\major_tranquilizer.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|haloperidol|- (r_amod) dyskinesia_6\NN\nervous_disorder.n.01|induced|orofacial
D006220_D004409 CID haloperidol_2\NN\major_tranquilizer.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|haloperidol|- (r_amod) dyskinesia_6\NN\nervous_disorder.n.01|induced|orofacial (r_conj) reserpine-_0\NNP\entity.n.01|and|dyskinesia (r_nsubj) are_7\VBP\area_unit.n.01|reserpine-|models|. (l_attr) models_10\NNS\hypothesis.n.02|putative|animal|of|related (l_prep) of_11\IN\entity.n.01|dyskinesia (l_pobj) dyskinesia_13\JJ\nervous_disorder.n.01|tardive|td
D006220_D004409 CID haloperidol_2\NN\major_tranquilizer.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|haloperidol|- (r_amod) dyskinesia_6\NN\nervous_disorder.n.01|induced|orofacial (r_conj) reserpine-_0\NNP\entity.n.01|and|dyskinesia (r_nsubj) are_7\VBP\area_unit.n.01|reserpine-|models|. (l_attr) models_10\NNS\hypothesis.n.02|putative|animal|of|related (l_prep) of_11\IN\entity.n.01|dyskinesia (l_pobj) dyskinesia_13\JJ\nervous_disorder.n.01|tardive|td (l_appos) td_15\NN\entity.n.01|(|)
D006220_D004409 CID haloperidol_15\NN\major_tranquilizer.n.01| (r_compound) administration_16\NN\management.n.01|subchronic|haloperidol (r_conj) reserpine_12\NN\antihypertensive.n.01|acute|and|administration|to (r_pobj) by_10\IN\by.r.01|reserpine (r_prep) induced_7\VBD\generate.v.01|in|,|authors|dyskinesia|by|. (l_dobj) dyskinesia_9\NN\nervous_disorder.n.01|orofacial
D018698_D004409 NONE glutamate_9\NN\salt.n.01|brain (r_compound) uptake_10\NN\bodily_process.n.01|synaptosomal|glutamate (r_dobj) change_6\VBP\happening.n.01|reserpine|haloperidol|treatments|uptake|and|elicit|. (l_conj) elicit_12\VBP\make.v.03|dyskinesia (l_dobj) dyskinesia_14\NN\nervous_disorder.n.01|orofacial|in
D018698_D004409 NONE glutamate_5\NN\salt.n.01| (r_compound) uptake_6\NN\bodily_process.n.01|glutamate (r_pobj) in_4\IN\linear_unit.n.01|uptake (r_prep) decrease_3\NN\change.n.01|a|in (r_nsubj) correlates_7\VBZ\variable.n.02|importantly|,|decrease|negatively|with|. (l_prep) with_9\IN\entity.n.01|increase (l_pobj) increase_11\NN\indefinite_quantity.n.01|an|in (l_prep) in_12\IN\linear_unit.n.01|incidence (l_pobj) incidence_14\NN\frequency.n.02|the|of (l_prep) of_15\IN\entity.n.01|diskinesia (l_pobj) diskinesia_17\NN\entity.n.01|orofacial
12707296
D001120_D006973 NONE arginine_2\NN\essential_amino_acid.n.01|l|- (r_compound) transport_3\NN\instrumentality.n.03|arginine|in|with|. (l_prep) with_6\IN\entity.n.01|hypertension (l_pobj) hypertension_10\NN\cardiovascular_disease.n.01|induced
D001120_D006973 NONE arginine_4\NN\essential_amino_acid.n.01| (r_compound) nitric_6\NN\azotic.a.01|l|-|arginine|- (r_compound) system_8\NN\instrumentality.n.03|a|deficient|nitric|oxide (r_nsubjpass) implicated_10\VBN\involve.v.01|system|is|in|. (l_prep) in_11\IN\linear_unit.n.01|hypertension (l_pobj) hypertension_15\NN\cardiovascular_disease.n.01|induced
D001120_D006973 NONE arginine_19\NN\essential_amino_acid.n.01|l|- (r_compound) system_21\NN\instrumentality.n.03|the|arginine|transport (r_pobj) in_15\IN\linear_unit.n.01|system (r_prep) abnormalities_14\NNS\physical_condition.n.01|in (r_pobj) with_13\IN\entity.n.01|abnormalities (r_prep) associated_12\VBN\think.v.03|that|increases|are|not|with (l_nsubjpass) increases_6\NNS\indefinite_quantity.n.01|induced|in (l_prep) in_7\IN\linear_unit.n.01|pressure (l_pobj) pressure_9\NN\physical_phenomenon.n.01|blood
D006854_D006973 NONE cortisol_7\NN\corticosteroid.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|cortisol|- (r_amod) hypertension_10\NN\cardiovascular_disease.n.01|induced
D006854_D006973 NONE cortisol_12\NN\corticosteroid.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|cortisol|- (r_amod) hypertension_15\NN\cardiovascular_disease.n.01|induced
D006854_D006973 NONE cortisol_3\NN\corticosteroid.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|cortisol|- (r_amod) increases_6\NNS\indefinite_quantity.n.01|induced|in (l_prep) in_7\IN\linear_unit.n.01|pressure (l_pobj) pressure_9\NN\physical_phenomenon.n.01|blood
D009569_D006973 NONE oxide_7\NN\compound.n.02| (r_compound) system_8\NN\instrumentality.n.03|a|deficient|nitric|oxide (r_nsubjpass) implicated_10\VBN\involve.v.01|system|is|in|. (l_prep) in_11\IN\linear_unit.n.01|hypertension (l_pobj) hypertension_15\NN\cardiovascular_disease.n.01|induced
6466532
D006024_D001919 NONE glycopyrrolate_3\NN\entity.n.01|i.v.|and|atropine|in (l_prep) in_6\IN\linear_unit.n.01|prevention (l_pobj) prevention_8\NN\hindrance.n.03|the|of (l_prep) of_9\IN\entity.n.01|bradycardia (l_pobj) bradycardia_10\NN\cardiac_arrhythmia.n.01|and|arrhythmias|following
D006024_D001919 NONE glycopyrrolate_5\NN\entity.n.01|kg-1 (r_pobj) of_4\IN\entity.n.01|glycopyrrolate (r_prep) administration_3\NN\management.n.01|of (r_pobj) of_2\IN\entity.n.01|administration (r_prep) effectiveness_1\NN\power.n.01|the|of|before|,|prevent (l_acl) prevent_27\VB\prevent.v.01|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\heart_disease.n.01|and|bradycardia (l_conj) bradycardia_30\NNP\cardiac_arrhythmia.n.01|
D006024_D001145 NONE glycopyrrolate_3\NN\entity.n.01|i.v.|and|atropine|in (l_prep) in_6\IN\linear_unit.n.01|prevention (l_pobj) prevention_8\NN\hindrance.n.03|the|of (l_prep) of_9\IN\entity.n.01|bradycardia (l_pobj) bradycardia_10\NN\cardiac_arrhythmia.n.01|and|arrhythmias|following (l_conj) arrhythmias_12\NNS\heart_disease.n.01|
D006024_D001145 NONE glycopyrrolate_5\NN\entity.n.01|kg-1 (r_pobj) of_4\IN\entity.n.01|glycopyrrolate (r_prep) administration_3\NN\management.n.01|of (r_pobj) of_2\IN\entity.n.01|administration (r_prep) effectiveness_1\NN\power.n.01|the|of|before|,|prevent (l_acl) prevent_27\VB\prevent.v.01|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\heart_disease.n.01|and|bradycardia
D001285_D001919 NONE atropine_5\NN\alkaloid.n.01| (r_conj) glycopyrrolate_3\NN\entity.n.01|i.v.|and|atropine|in (l_prep) in_6\IN\linear_unit.n.01|prevention (l_pobj) prevention_8\NN\hindrance.n.03|the|of (l_prep) of_9\IN\entity.n.01|bradycardia (l_pobj) bradycardia_10\NN\cardiac_arrhythmia.n.01|and|arrhythmias|following
D001285_D001919 NONE atropine_12\NN\alkaloid.n.01|micrograms (r_conj) kg-1_10\NNS\entity.n.01|micrograms|and|atropine (r_dobj) glycopyrrolate_5\NN\entity.n.01|kg-1 (r_pobj) of_4\IN\entity.n.01|glycopyrrolate (r_prep) administration_3\NN\management.n.01|of (r_pobj) of_2\IN\entity.n.01|administration (r_prep) effectiveness_1\NN\power.n.01|the|of|before|,|prevent (l_acl) prevent_27\VB\prevent.v.01|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\heart_disease.n.01|and|bradycardia (l_conj) bradycardia_30\NNP\cardiac_arrhythmia.n.01|
D001285_D001145 NONE atropine_5\NN\alkaloid.n.01| (r_conj) glycopyrrolate_3\NN\entity.n.01|i.v.|and|atropine|in (l_prep) in_6\IN\linear_unit.n.01|prevention (l_pobj) prevention_8\NN\hindrance.n.03|the|of (l_prep) of_9\IN\entity.n.01|bradycardia (l_pobj) bradycardia_10\NN\cardiac_arrhythmia.n.01|and|arrhythmias|following (l_conj) arrhythmias_12\NNS\heart_disease.n.01|
D001285_D001145 NONE atropine_12\NN\alkaloid.n.01|micrograms (r_conj) kg-1_10\NNS\entity.n.01|micrograms|and|atropine (r_dobj) glycopyrrolate_5\NN\entity.n.01|kg-1 (r_pobj) of_4\IN\entity.n.01|glycopyrrolate (r_prep) administration_3\NN\management.n.01|of (r_pobj) of_2\IN\entity.n.01|administration (r_prep) effectiveness_1\NN\power.n.01|the|of|before|,|prevent (l_acl) prevent_27\VB\prevent.v.01|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\heart_disease.n.01|and|bradycardia
D013390_D001919 CID suxamethonium_17\NN\entity.n.01|in (r_pobj) of_16\IN\entity.n.01|suxamethonium (r_prep) doses_15\NNS\medicine.n.02|repeated|of (r_pobj) following_13\VBG\multitude.n.03|doses (r_prep) bradycardia_10\NN\cardiac_arrhythmia.n.01|and|arrhythmias|following
D013390_D001919 CID suxamethonium_35\NN\entity.n.01|in (r_pobj) of_34\IN\entity.n.01|suxamethonium (r_prep) doses_33\NNS\medicine.n.02|repeated|of (r_pobj) following_31\VBG\multitude.n.03|doses (r_prep) prevent_27\VB\prevent.v.01|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\heart_disease.n.01|and|bradycardia (l_conj) bradycardia_30\NNP\cardiac_arrhythmia.n.01|
D013390_D001145 NONE suxamethonium_17\NN\entity.n.01|in (r_pobj) of_16\IN\entity.n.01|suxamethonium (r_prep) doses_15\NNS\medicine.n.02|repeated|of (r_pobj) following_13\VBG\multitude.n.03|doses (r_prep) bradycardia_10\NN\cardiac_arrhythmia.n.01|and|arrhythmias|following (l_conj) arrhythmias_12\NNS\heart_disease.n.01|
D013390_D001145 NONE suxamethonium_35\NN\entity.n.01|in (r_pobj) of_34\IN\entity.n.01|suxamethonium (r_prep) doses_33\NNS\medicine.n.02|repeated|of (r_pobj) following_31\VBG\multitude.n.03|doses (r_prep) prevent_27\VB\prevent.v.01|to|arrhythmia|following (l_dobj) arrhythmia_28\NN\heart_disease.n.01|and|bradycardia
9672936
D008614_D012640 CID pethidine_0\NNP\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|pethidine|- (r_amod) seizure_3\NN\attack.n.07|associated|in|.
D008614_D012640 CID pethidine_9\NN\entity.n.01| (r_dobj) receiving_8\VBG\get.v.01|pethidine|for (r_acl) adolescent_7\JJ\juvenile.n.01|a|healthy|receiving (r_pobj) in_4\IN\linear_unit.n.01|adolescent (r_prep) seizure_3\NN\attack.n.07|associated|in|.
D008614_D010149 NONE pethidine_0\NNP\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|pethidine|- (r_amod) seizure_3\NN\attack.n.07|associated|in|. (l_prep) in_4\IN\linear_unit.n.01|adolescent (l_pobj) adolescent_7\JJ\juvenile.n.01|a|healthy|receiving (l_acl) receiving_8\VBG\get.v.01|pethidine|for (l_prep) for_10\IN\entity.n.01|control (l_pobj) control_13\NN\power.n.01|postoperative|pain (l_compound) pain_12\NN\symptom.n.01|
D008614_D010149 NONE pethidine_9\NN\entity.n.01| (r_dobj) receiving_8\VBG\get.v.01|pethidine|for (l_prep) for_10\IN\entity.n.01|control (l_pobj) control_13\NN\power.n.01|postoperative|pain (l_compound) pain_12\NN\symptom.n.01|
D008614_D010149 NONE pethidine_11\NN\entity.n.01| (r_pobj) of_10\IN\entity.n.01|pethidine (r_prep) doses_9\NNS\medicine.n.02|a|healthy|old|received|standard|intermittent|of|via (r_nsubj) pump_21\NN\mechanical_device.n.01|doses|for|. (l_prep) for_22\IN\entity.n.01|management (l_pobj) management_23\NN\social_control.n.01|of (l_prep) of_24\IN\entity.n.01|control (l_pobj) control_27\NN\power.n.01|postoperative|pain (l_compound) pain_26\NN\symptom.n.01|
10579464
C121249_D006948 NONE nra0160_0\NNP\entity.n.01|and|clozapine (r_nsubj) antagonized_3\VBN\annoy.v.01|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN\disorder.n.01|locomotor|induced
D003024_D006948 NONE clozapine_2\NN\major_tranquilizer.n.01| (r_conj) nra0160_0\NNP\entity.n.01|and|clozapine (r_nsubj) antagonized_3\VBN\annoy.v.01|nra0160|hyperactivity|. (l_dobj) hyperactivity_5\NN\disorder.n.01|locomotor|induced
D008694_D006948 CID methamphetamine_8\NN\amphetamine.n.01|(|map|) (r_pobj) by_7\IN\by.r.01|methamphetamine (r_agent) induced_6\VBN\generate.v.01|by|in (r_acl) hyperactivity_5\NN\disorder.n.01|locomotor|induced
D008694_D006948 CID map_10\NNP\representation.n.02| (r_appos) methamphetamine_8\NN\amphetamine.n.01|(|map|) (r_pobj) by_7\IN\by.r.01|methamphetamine (r_agent) induced_6\VBN\generate.v.01|by|in (r_acl) hyperactivity_5\NN\disorder.n.01|locomotor|induced
C121249_D002375 CID nra0160_0\NNP\entity.n.01|and|clozapine (r_nsubj) induced_4\VBN\generate.v.01|nra0160|significantly|catalepsy|in|,|exceed|. (l_dobj) catalepsy_5\NN\hypersomnia.n.01|
D003024_D002375 CID clozapine_2\NN\major_tranquilizer.n.01| (r_conj) nra0160_0\NNP\entity.n.01|and|clozapine (r_nsubj) induced_4\VBN\generate.v.01|nra0160|significantly|catalepsy|in|,|exceed|. (l_dobj) catalepsy_5\NN\hypersomnia.n.01|
14568327
D007980_D004409 CID levodopa_2\NN\dopa.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_5\NNS\nervous_disorder.n.01|induced|in
D007980_D004409 CID levodopa_0\NNP\dopa.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_3\NNS\nervous_disorder.n.01|induced|(|lids|)
D007980_D004409 CID levodopa_0\NNP\dopa.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_3\NNS\nervous_disorder.n.01|induced|(|lids|) (l_appos) lids_5\NNPS\protective_fold.n.01|
D007980_D004409 CID levodopa_34\NN\dopa.n.01| (r_compound) therapy_35\NN\medical_care.n.01|levodopa (r_pobj) of_33\IN\entity.n.01|therapy (r_prep) duration_32\NN\time_period.n.01|of (r_conj) response_29\NN\consequence.n.01|to|and|duration (r_conj) severity_26\NN\intensity.n.02|rate|,|symptom|,|and|response (r_nsubjpass) involved_38\VBN\refer.v.02|to|severity|may|be|in (l_prep) in_39\IN\linear_unit.n.01|development (l_pobj) development_41\NN\improvement.n.02|the|of (l_prep) of_42\IN\entity.n.01|lids (l_pobj) lids_43\NNS\protective_fold.n.01|
D007980_D004409 CID levodopa_22\NN\dopa.n.01| (r_compound) therapy_23\NN\medical_care.n.01|levodopa (r_pobj) of_21\IN\entity.n.01|therapy (r_prep) initiation_20\NN\ceremony.n.01|of (r_pobj) to_19\IN\entity.n.01|initiation (r_prep) prior_18\RB\superior.n.02|to (r_advmod) developed_24\VBD\create.v.02|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB\nervous_disorder.n.01|
D007980_D004409 CID levodopa_33\JJ\dopa.n.01| (r_compound) administration_34\NN\management.n.01|daily|levodopa (r_pobj) of_31\IN\entity.n.01|administration (r_prep) days_30\NNS\life.n.07|11|of (r_npadvmod) developed_24\VBD\create.v.02|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB\nervous_disorder.n.01|
D007980_D004409 CID levodopa_22\NN\dopa.n.01| (r_compound) therapy_23\NN\medical_care.n.01|levodopa (r_pobj) of_21\IN\entity.n.01|therapy (r_prep) initiation_20\NN\ceremony.n.01|of (r_pobj) to_19\IN\entity.n.01|initiation (r_prep) prior_18\RB\superior.n.02|to (r_advmod) progression_13\NN\series.n.01|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\be.v.01|progression|resistant|developed|. (l_acomp) resistant_26\JJ\immune.s.03|more|to (l_prep) to_27\IN\entity.n.01|developing (l_pcomp) developing_28\VBG\processing.n.01|lids (l_dobj) lids_29\NNS\protective_fold.n.01|
D007980_D004409 CID levodopa_22\NN\dopa.n.01| (r_compound) therapy_23\NN\medical_care.n.01|levodopa (r_pobj) of_21\IN\entity.n.01|therapy (r_prep) initiation_20\NN\ceremony.n.01|of (r_pobj) to_19\IN\entity.n.01|initiation (r_prep) prior_18\RB\superior.n.02|to (r_advmod) progression_13\NN\series.n.01|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\be.v.01|progression|resistant|developed|. (l_parataxis) developed_34\VBD\create.v.02|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN\nervous_disorder.n.01|
D007980_D004409 CID levodopa_42\JJ\dopa.n.01| (r_compound) administration_43\NN\management.n.01|chronic|levodopa (r_pobj) of_40\IN\entity.n.01|administration (r_prep) days_39\NNS\life.n.07|146|of (r_pobj) than_37\IN\entity.n.01|days (r_prep) sooner_36\RBR\american.n.01|no|than (r_advmod) developed_34\VBD\create.v.02|(|e.g.|,|dyskinesia|sooner|) (r_parataxis) were_24\VBD\be.v.01|progression|resistant|developed|. (l_acomp) resistant_26\JJ\immune.s.03|more|to (l_prep) to_27\IN\entity.n.01|developing (l_pcomp) developing_28\VBG\processing.n.01|lids (l_dobj) lids_29\NNS\protective_fold.n.01|
D007980_D004409 CID levodopa_42\JJ\dopa.n.01| (r_compound) administration_43\NN\management.n.01|chronic|levodopa (r_pobj) of_40\IN\entity.n.01|administration (r_prep) days_39\NNS\life.n.07|146|of (r_pobj) than_37\IN\entity.n.01|days (r_prep) sooner_36\RBR\american.n.01|no|than (r_advmod) developed_34\VBD\create.v.02|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN\nervous_disorder.n.01|
D007980_D004409 CID levodopa_24\VB\dopa.n.01| (r_pobj) to_23\IN\entity.n.01|levodopa (r_prep) prior_22\RB\superior.n.02|to (r_advmod) develop_9\VB\create.v.02|to|lids|with|prior (l_dobj) lids_10\NNS\protective_fold.n.01|in
D007980_D004409 CID levodopa_24\VB\dopa.n.01| (r_pobj) to_23\IN\entity.n.01|levodopa (r_prep) prior_22\RB\superior.n.02|to (r_advmod) develop_9\VB\create.v.02|to|lids|with|prior (r_acl) propensity_7\NN\inclination.n.05|the|develop (r_pobj) in_5\IN\linear_unit.n.01|propensity (r_prep) differences_4\NNS\quality.n.01|distinct|in (r_dobj) suggest_2\VBP\declare.v.01|data|differences|and|demonstrate|. (l_conj) demonstrate_26\VB\show.v.04|value (l_dobj) value_28\NN\numerical_quantity.n.01|the|of|for (l_prep) for_32\IN\entity.n.01|studying (l_pcomp) studying_34\VBG\reading.n.01|further|pathophysiology (l_dobj) pathophysiology_36\NN\entity.n.01|the|of (l_prep) of_37\IN\entity.n.01|lids (l_pobj) lids_38\NNS\protective_fold.n.01|
D007980_D010300 NONE levodopa_2\NN\dopa.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_5\NNS\nervous_disorder.n.01|induced|in (l_prep) in_6\IN\linear_unit.n.01|monkeys (l_pobj) monkeys_8\NNS\primate.n.02|parkinsonian (l_amod) parkinsonian_7\JJ\entity.n.01|
D007980_D010300 NONE levodopa_0\NNP\dopa.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_3\NNS\nervous_disorder.n.01|induced|(|lids|) (r_nsubj) present_7\VBP\time.n.05|dyskinesias|problem|. (l_dobj) problem_10\NN\difficulty.n.03|a|major|for (l_prep) for_11\IN\entity.n.01|management (l_pobj) management_16\NN\social_control.n.01|the|term|of (l_prep) of_17\IN\entity.n.01|patients (l_pobj) patients_24\NNS\case.n.06|disease|(|pd|) (l_nmod) disease_20\NN\illness.n.01|parkinson
D007980_D010300 NONE levodopa_0\NNP\dopa.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_3\NNS\nervous_disorder.n.01|induced|(|lids|) (r_nsubj) present_7\VBP\time.n.05|dyskinesias|problem|. (l_dobj) problem_10\NN\difficulty.n.03|a|major|for (l_prep) for_11\IN\entity.n.01|management (l_pobj) management_16\NN\social_control.n.01|the|term|of (l_prep) of_17\IN\entity.n.01|patients (l_pobj) patients_24\NNS\case.n.06|disease|(|pd|) (l_nmod) pd_22\NNP\metallic_element.n.01|
D015632_D010302 CID mptp_7\NNP\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|mptp|- (r_amod) parkinsonism_10\NN\brain_disorder.n.01|induced
D015632_D004409 NONE mptp_7\NNP\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|mptp|- (r_amod) parkinsonism_10\NN\brain_disorder.n.01|induced (r_pobj) of_6\IN\entity.n.01|parkinsonism (r_prep) types_5\NNS\kind.n.01|different|of (r_pobj) with_3\IN\entity.n.01|types (r_prep) using_0\VBG\mistreatment.n.01|monkeys|with (r_advcl) evaluated_15\VBD\evaluate.v.02|using|,|study|degree|. (l_dobj) degree_17\NN\property.n.02|the|involved (l_relcl) involved_38\VBN\refer.v.02|to|severity|may|be|in (l_prep) in_39\IN\linear_unit.n.01|development (l_pobj) development_41\NN\improvement.n.02|the|of (l_prep) of_42\IN\entity.n.01|lids (l_pobj) lids_43\NNS\protective_fold.n.01|
D015632_D004409 NONE mptp_8\NNP\entity.n.01|) (r_compound) exposure_9\NN\vulnerability.n.02|acute|mptp|,|onset (r_pobj) with_1\IN\entity.n.01|exposure (r_prep) monkeys_0\NNS\primate.n.02|with (r_nsubj) developed_24\VBD\create.v.02|monkeys|prior|dyskinesia|days|. (l_dobj) dyskinesia_25\RB\nervous_disorder.n.01|
D015632_D004409 NONE mptp_8\NNP\entity.n.01| (r_compound) exposure_9\NN\vulnerability.n.02|term|mptp (r_pobj) with_4\IN\entity.n.01|exposure (r_prep) monkeys_3\NNS\primate.n.02|with (r_nsubj) progression_13\NN\series.n.01|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\be.v.01|progression|resistant|developed|. (l_acomp) resistant_26\JJ\immune.s.03|more|to (l_prep) to_27\IN\entity.n.01|developing (l_pcomp) developing_28\VBG\processing.n.01|lids (l_dobj) lids_29\NNS\protective_fold.n.01|
D015632_D004409 NONE mptp_8\NNP\entity.n.01| (r_compound) exposure_9\NN\vulnerability.n.02|term|mptp (r_pobj) with_4\IN\entity.n.01|exposure (r_prep) monkeys_3\NNS\primate.n.02|with (r_nsubj) progression_13\NN\series.n.01|in|,|monkeys|,|slow|symptom|and/or|duration|prior (r_nsubj) were_24\VBD\be.v.01|progression|resistant|developed|. (l_parataxis) developed_34\VBD\create.v.02|(|e.g.|,|dyskinesia|sooner|) (l_nsubj) dyskinesia_33\NN\nervous_disorder.n.01|
D007980_D010302 NONE levodopa_34\NN\dopa.n.01| (r_compound) therapy_35\NN\medical_care.n.01|levodopa (r_pobj) of_33\IN\entity.n.01|therapy (r_prep) duration_32\NN\time_period.n.01|of (r_conj) response_29\NN\consequence.n.01|to|and|duration (r_conj) severity_26\NN\intensity.n.02|rate|,|symptom|,|and|response (r_nsubjpass) involved_38\VBN\refer.v.02|to|severity|may|be|in (r_relcl) degree_17\NN\property.n.02|the|involved (r_dobj) evaluated_15\VBD\evaluate.v.02|using|,|study|degree|. (l_advcl) using_0\VBG\mistreatment.n.01|monkeys|with (l_prep) with_3\IN\entity.n.01|types (l_pobj) types_5\NNS\kind.n.01|different|of (l_prep) of_6\IN\entity.n.01|parkinsonism (l_pobj) parkinsonism_10\NN\brain_disorder.n.01|induced
869641
D007980_D001919 NONE dopa_9\NN\amino_acid.n.01|l|- (r_pobj) by_6\IN\by.r.01|dopa (r_prep) mediation_0\NN\negotiation.n.01|of|by|via|. (l_prep) of_1\IN\entity.n.01|bradycardia (l_pobj) bradycardia_5\NNP\cardiac_arrhythmia.n.01|enhanced|reflex|vagal
D007980_D001919 NONE dopa_15\NNP\amino_acid.n.01|l|-|,|dihydroxyphenylserine (r_pobj) by_12\IN\by.r.01|dopa (r_agent) enhanced_11\VBN\intensify.v.02|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN\cardiac_arrhythmia.n.01|reflex|caused
D007980_D001919 NONE dopa_28\NNP\amino_acid.n.01|l|- (r_pobj) of_25\IN\entity.n.01|dopa (r_prep) effect_24\NN\phenomenon.n.01|bradycardia|of (l_amod) bradycardia_19\NN\cardiac_arrhythmia.n.01|or|enhancing
D007980_D001919 NONE dopa_4\NNP\amino_acid.n.01|l|- (r_nsubj) restored_5\VBD\regenerate.v.01|however|,|dopa|bradycardia|. (l_dobj) bradycardia_7\NN\cardiac_arrhythmia.n.01|the|caused
D007980_D001919 NONE dopa_6\NNP\amino_acid.n.01|l|- (r_nsubj) enhances_7\VBZ\intensify.v.02|that|dopa|bradycardia|through (l_dobj) bradycardia_9\NN\cardiac_arrhythmia.n.01|reflex
D004298_D001919 NONE dopamine_12\NN\monoamine_neurotransmitter.n.01| (r_compound) formation_13\NN\arrangement.n.02|central|dopamine|in (r_pobj) via_10\IN\entity.n.01|formation (r_prep) mediation_0\NN\negotiation.n.01|of|by|via|. (l_prep) of_1\IN\entity.n.01|bradycardia (l_pobj) bradycardia_5\NNP\cardiac_arrhythmia.n.01|enhanced|reflex|vagal
D004298_D001919 NONE dopamine_3\NN\monoamine_neurotransmitter.n.01| (r_compound) oxidase_7\NN\enzyme.n.01|dopamine|-|beta|- (r_compound) inhibitor_8\NN\substance.n.07|a|oxidase (r_nsubj) have_12\VB\person.n.01|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\phenomenon.n.01|any|on (l_prep) on_15\IN\on.a.01|hypotension (l_pobj) hypotension_17\NN\cardiovascular_disease.n.01|the|,|effect (l_appos) effect_24\NN\phenomenon.n.01|bradycardia|of (l_amod) bradycardia_19\NN\cardiac_arrhythmia.n.01|or|enhancing
D009638_D001919 CID norepinephrine_8\NN\catecholamine.n.01|injected (r_pobj) by_6\IN\by.r.01|norepinephrine (r_agent) caused_5\VBN\make.v.03|by (r_acl) bradycardia_4\NN\cardiac_arrhythmia.n.01|reflex|caused
D009638_D001919 CID norepinephrine_35\NN\catecholamine.n.01| (r_pobj) to_34\IN\entity.n.01|norepinephrine (r_prep) responses_33\NNS\consequence.n.01|reflex|to (r_conj) rate_30\NN\magnitude_relation.n.01|heart|or|responses (r_conj) pressure_27\NN\physical_phenomenon.n.01|blood|,|rate (r_pobj) on_25\IN\on.a.01|pressure (r_prep) effect_24\NN\phenomenon.n.01|no|on (r_dobj) had_22\VBD\have.v.01|effect (r_conj) enhanced_11\VBN\intensify.v.02|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN\cardiac_arrhythmia.n.01|reflex|caused
D009638_D001919 CID norepinephrine_10\NN\catecholamine.n.01| (r_pobj) by_9\IN\by.r.01|norepinephrine (r_agent) caused_8\VBN\make.v.03|by|in (r_acl) bradycardia_7\NN\cardiac_arrhythmia.n.01|the|caused
D009638_D001919 CID norepinephrine_18\NN\catecholamine.n.01| (r_pobj) to_17\IN\entity.n.01|norepinephrine (r_prep) bradycardia_16\NN\cardiac_arrhythmia.n.01|the|reflex|to
D015103_D001919 NONE dihydroxyphenylserine_21\NN\entity.n.01|threo|- (r_conj) dopa_15\NNP\amino_acid.n.01|l|-|,|dihydroxyphenylserine (r_pobj) by_12\IN\by.r.01|dopa (r_agent) enhanced_11\VBN\intensify.v.02|in|,|bradycardia|was|significantly|by|had|. (l_nsubjpass) bradycardia_4\NN\cardiac_arrhythmia.n.01|reflex|caused
D005406_D007022 NONE fla-63_0\NN\entity.n.01| (r_mark) have_12\VB\person.n.01|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\phenomenon.n.01|any|on (l_prep) on_15\IN\on.a.01|hypotension (l_pobj) hypotension_17\NN\cardiovascular_disease.n.01|the|,|effect
D005406_D001919 NONE fla-63_0\NN\entity.n.01| (r_mark) have_12\VB\person.n.01|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\phenomenon.n.01|any|on (l_prep) on_15\IN\on.a.01|hypotension (l_pobj) hypotension_17\NN\cardiovascular_disease.n.01|the|,|effect (l_appos) effect_24\NN\phenomenon.n.01|bradycardia|of (l_amod) bradycardia_19\NN\cardiac_arrhythmia.n.01|or|enhancing
D004298_D007022 NONE dopamine_3\NN\monoamine_neurotransmitter.n.01| (r_compound) oxidase_7\NN\enzyme.n.01|dopamine|-|beta|- (r_compound) inhibitor_8\NN\substance.n.07|a|oxidase (r_nsubj) have_12\VB\person.n.01|fla-63|,|inhibitor|,|did|not|effect|. (l_dobj) effect_14\NN\phenomenon.n.01|any|on (l_prep) on_15\IN\on.a.01|hypotension (l_pobj) hypotension_17\NN\cardiovascular_disease.n.01|the|,|effect
D007980_D007022 NONE dopa_28\NNP\amino_acid.n.01|l|- (r_pobj) of_25\IN\entity.n.01|dopa (r_prep) effect_24\NN\phenomenon.n.01|bradycardia|of (r_appos) hypotension_17\NN\cardiovascular_disease.n.01|the|,|effect
D006916_D001919 NONE 5-htp_0\NNP\entity.n.01|i.v.|) (r_nsubj) decreased_6\VBD\change_magnitude.v.01|5-htp|pressure|and|decreased|. (l_conj) decreased_13\VBD\change_magnitude.v.01|bradycardia (l_dobj) bradycardia_16\NN\cardiac_arrhythmia.n.01|the|reflex|to
3412544
D000082_D014523 NONE paracetamol_1\JJ\entity.n.01| (r_nsubj) cause_2\VB\origin.n.03|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\malignant_tumor.n.01|urothelial|or|necrosis
D000082_D007681 NONE paracetamol_1\JJ\entity.n.01| (r_nsubj) cause_2\VB\origin.n.03|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\malignant_tumor.n.01|urothelial|or|necrosis (l_conj) necrosis_8\NN\death.n.02|renal|papillary
D000082_D007681 NONE paracetamol_24\NNP\entity.n.01| (r_conj) phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (r_pobj) of_9\IN\entity.n.01|pelvis (r_prep) necrosis_6\NN\death.n.02|renal|papillary|or|cancer|of
D000082_D007681 NONE paracetamol_12\JJ\entity.n.01| (r_compound) consumption_13\NN\bodily_process.n.01|paracetamol (r_pobj) from_11\IN\entity.n.01|consumption (r_prep) risk_10\NN\danger.n.03|an|increased|from|for|or|any (l_prep) for_14\IN\entity.n.01|necrosis (l_pobj) necrosis_17\NN\death.n.02|renal|papillary
D010615_D007681 CID phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (r_pobj) of_9\IN\entity.n.01|pelvis (r_prep) necrosis_6\NN\death.n.02|renal|papillary|or|cancer|of
D010615_D007681 CID phenacetin_13\NN\analgesic.n.01| (r_pobj) of_12\IN\entity.n.01|phenacetin (r_prep) consumption_11\NN\bodily_process.n.01|of|,|increased (r_pobj) by_10\IN\by.r.01|consumption (r_agent) increased_7\VBN\change_magnitude.v.01|risk|was|20-fold|by|. (l_nsubjpass) risk_1\NN\danger.n.03|the|of (l_prep) of_2\IN\entity.n.01|necrosis (l_pobj) necrosis_5\NN\death.n.02|renal|papillary
D010615_D007680 CID phenacetin_13\NN\analgesic.n.01| (r_pobj) of_12\IN\entity.n.01|phenacetin (r_prep) consumption_11\NN\bodily_process.n.01|of|,|increased (l_relcl) increased_17\VBD\change_magnitude.v.01|which|also|risk|but|for (l_dobj) risk_19\NN\danger.n.03|the|for (l_prep) for_20\IN\entity.n.01|cancer (l_pobj) cancer_21\NN\malignant_tumor.n.01|of (l_prep) of_22\IN\entity.n.01|pelvis (l_pobj) pelvis_25\NN\girdle.n.01|the|renal|and|bladder (l_conj) bladder_27\NN\sac.n.04|
D010615_D007680 NONE phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (l_conj) ureter_14\NN\duct.n.01|or|bladder (l_conj) bladder_16\NN\sac.n.04|
D010615_D014516 NONE phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (l_conj) ureter_14\NN\duct.n.01|or|bladder (l_conj) bladder_16\NN\sac.n.04|
D010615_D014516 NONE phenacetin_13\NN\analgesic.n.01| (r_pobj) of_12\IN\entity.n.01|phenacetin (r_prep) consumption_11\NN\bodily_process.n.01|of|,|increased (l_relcl) increased_17\VBD\change_magnitude.v.01|which|also|risk|but|for (l_conj) for_30\IN\entity.n.01|not|cancer (l_pobj) cancer_32\NN\malignant_tumor.n.01|ureteric
D010615_D001749 CID phenacetin_13\NN\analgesic.n.01| (r_pobj) of_12\IN\entity.n.01|phenacetin (r_prep) consumption_11\NN\bodily_process.n.01|of|,|increased (l_relcl) increased_17\VBD\change_magnitude.v.01|which|also|risk|but|for (l_dobj) risk_19\NN\danger.n.03|the|for (l_prep) for_20\IN\entity.n.01|cancer (l_pobj) cancer_21\NN\malignant_tumor.n.01|of (l_prep) of_22\IN\entity.n.01|pelvis (l_pobj) pelvis_25\NN\girdle.n.01|the|renal|and|bladder (l_conj) bladder_27\NN\sac.n.04|
D010615_D001749 NONE phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (l_conj) ureter_14\NN\duct.n.01|or|bladder (l_conj) bladder_16\NN\sac.n.04|
D000082_D007680 NONE paracetamol_24\NNP\entity.n.01| (r_conj) phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (l_conj) ureter_14\NN\duct.n.01|or|bladder (l_conj) bladder_16\NN\sac.n.04|
D000082_D014516 NONE paracetamol_24\NNP\entity.n.01| (r_conj) phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (l_conj) ureter_14\NN\duct.n.01|or|bladder (l_conj) bladder_16\NN\sac.n.04|
D000082_D014516 NONE paracetamol_12\JJ\entity.n.01| (r_compound) consumption_13\NN\bodily_process.n.01|paracetamol (r_pobj) from_11\IN\entity.n.01|consumption (r_prep) risk_10\NN\danger.n.03|an|increased|from|for|or|any (r_dobj) substantiate_7\VB\confirm.v.01|to|risk (r_xcomp) unable_5\JJ\unable.a.01|substantiate (r_acomp) were_4\VBD\be.v.01|by|,|we|unable|was|. (l_advcl) was_25\VBD\washington.n.02|although|there|suggestion (l_attr) suggestion_27\NN\idea.n.01|a|of (l_prep) of_28\IN\entity.n.01|association (l_pobj) association_30\NN\organization.n.01|an|with (l_prep) with_31\IN\entity.n.01|cancer (l_pobj) cancer_32\NN\malignant_tumor.n.01|of (l_prep) of_33\IN\entity.n.01|ureter (l_pobj) ureter_35\NN\duct.n.01|the
D000082_D001749 NONE paracetamol_24\NNP\entity.n.01| (r_conj) phenacetin_22\JJ\analgesic.n.01|either|or|paracetamol (r_pobj) of_20\IN\entity.n.01|phenacetin (r_prep) consumption_19\NN\bodily_process.n.01|of (r_pobj) with_18\IN\entity.n.01|consumption (r_prep) associated_17\VBN\think.v.03|with (r_acl) pelvis_12\NN\girdle.n.01|the|renal|,|ureter|associated (l_conj) ureter_14\NN\duct.n.01|or|bladder (l_conj) bladder_16\NN\sac.n.04|
D000082_D009369 NONE paracetamol_12\JJ\entity.n.01| (r_compound) consumption_13\NN\bodily_process.n.01|paracetamol (r_pobj) from_11\IN\entity.n.01|consumption (r_prep) risk_10\NN\danger.n.03|an|increased|from|for|or|any (l_conj) any_19\DT\any.s.01|of (l_prep) of_20\IN\entity.n.01|cancers (l_pobj) cancers_22\NNS\malignant_tumor.n.01|these
11961407
D014443_D009401 NONE tyrosine_2\NN\amino_acid.n.01| (r_compound) phosphatase_3\NN\enzyme.n.01|glepp1|receptor|tyrosine|ptpro|in|. (l_prep) in_7\IN\linear_unit.n.01|nephrosis (l_pobj) nephrosis_10\NN\syndrome.n.02|rat|pan
D011692_D009401 CID pan_9\NNP\cooking_utensil.n.01| (r_compound) nephrosis_10\NN\syndrome.n.02|rat|pan
D011692_D009401 CID aminonucleoside_1\JJ\entity.n.01| (r_amod) nephrosis_2\NN\syndrome.n.02|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_11\NN\entity.n.01|pan (r_advmod) induced_4\VBN\generate.v.01|nephrosis|was|by|aminonucleoside|. (l_nsubjpass) nephrosis_2\NN\syndrome.n.02|puromycin|aminonucleoside
D011692_D009401 CID pan_13\NNP\cooking_utensil.n.01|(|,|mg/100|bw|) (r_appos) aminonucleoside_11\NN\entity.n.01|pan (r_advmod) induced_4\VBN\generate.v.01|nephrosis|was|by|aminonucleoside|. (l_nsubjpass) nephrosis_2\NN\syndrome.n.02|puromycin|aminonucleoside
D011692_D011507 CID pan_21\NNP\cooking_utensil.n.01| (r_compound) injection_22\NN\insertion.n.02|pan (r_pobj) after_20\IN\after.s.01|injection (r_prep) days_19\NNS\life.n.07|5|80|after (r_npadvmod) analyzed_2\VBN\analyze.v.01|tissues|were|at|days|include|. (l_advcl) include_26\VB\include.v.01|so|as|to|phase (l_dobj) phase_30\NN\time_period.n.01|both|the|acute|of|associated|(|days (l_prep) of_31\IN\entity.n.01|proteinuria (l_pobj) proteinuria_32\NN\symptom.n.01|
D011692_D011507 CID pan_21\NNP\cooking_utensil.n.01| (r_compound) injection_22\NN\insertion.n.02|pan (r_pobj) after_20\IN\after.s.01|injection (r_prep) days_19\NNS\life.n.07|5|80|after (r_npadvmod) analyzed_2\VBN\analyze.v.01|tissues|were|at|days|include|. (l_advcl) include_26\VB\include.v.01|so|as|to|phase (l_dobj) phase_30\NN\time_period.n.01|both|the|acute|of|associated|(|days (l_appos) days_39\NNS\life.n.07|5|)|and|phase (l_conj) phase_47\NN\time_period.n.01|the|chronic|of|associated (l_prep) of_48\IN\entity.n.01|proteinuria (l_pobj) proteinuria_49\NN\symptom.n.01|
D011692_D005921 NONE pan_21\NNP\cooking_utensil.n.01| (r_compound) injection_22\NN\insertion.n.02|pan (r_pobj) after_20\IN\after.s.01|injection (r_prep) days_19\NNS\life.n.07|5|80|after (r_npadvmod) analyzed_2\VBN\analyze.v.01|tissues|were|at|days|include|. (l_advcl) include_26\VB\include.v.01|so|as|to|phase (l_dobj) phase_30\NN\time_period.n.01|both|the|acute|of|associated|(|days (l_appos) days_39\NNS\life.n.07|5|)|and|phase (l_conj) phase_47\NN\time_period.n.01|the|chronic|of|associated (l_acl) associated_50\VBN\think.v.03|with (l_prep) with_51\IN\entity.n.01|glomerulosclerosis (l_pobj) glomerulosclerosis_52\NN\entity.n.01|(|days|)
3800626
D010423_D009408 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|induced|fibrous (r_pobj) due_6\IN\right.n.01|to|myopathy (r_prep) neuropathy_1\NN\pathology.n.02|compression|of|due|. (l_prep) of_2\IN\entity.n.01|nerve (l_pobj) nerve_5\NN\fiber_bundle.n.01|the|radial
D010423_D009408 CID pentazocine_10\NN\analgesic.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|pentazocine|- (r_compound) myopathy_13\NN\pathology.n.02|induced (r_pobj) by_9\IN\by.r.01|myopathy (r_agent) affected_8\VBN\change.v.01|by (r_acl) muscle_7\NN\contractile_organ.n.01|fibrotic|affected (r_pobj) due_4\IN\right.n.01|to|muscle (r_amod) neuropathy_3\NN\pathology.n.02|compression|due
D010423_D020425 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|induced|fibrous (r_pobj) due_6\IN\right.n.01|to|myopathy (r_prep) neuropathy_1\NN\pathology.n.02|compression|of|due|. (l_prep) of_2\IN\entity.n.01|nerve (l_pobj) nerve_5\NN\fiber_bundle.n.01|the|radial
D010423_D005355 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|induced|fibrous
D010423_D005355 CID pentazocine_13\NN\analgesic.n.01| (r_compound) injection_14\NN\insertion.n.02|repeated|pentazocine (r_pobj) of_11\IN\entity.n.01|injection (r_prep) effect_10\NN\phenomenon.n.01|a|common|,|known|side|of (r_attr) is_2\VBZ\be.v.01|myopathy|effect|. (l_nsubj) myopathy_1\NN\pathology.n.02|fibrous
D010423_D005355 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|documented|induced|fibrous|of
D010423_D005355 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|documented|induced|fibrous|of (r_pobj) with_6\IN\entity.n.01|myopathy (r_prep) woman_5\NN\adult.n.01|a|old|with|bilaterally|and|history (r_pobj) in_0\IN\linear_unit.n.01|woman (r_prep) showed_32\VBD\show.v.04|in|,|examination|lesion|,|in|. (l_prep) in_51\IN\linear_unit.n.01|addition (l_pobj) addition_52\NN\component.n.03|to (l_prep) to_53\IN\entity.n.01|myopathy (l_pobj) myopathy_56\NN\pathology.n.02|the|fibrous
D010423_D009135 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|induced|fibrous
D010423_D009135 CID pentazocine_13\NN\analgesic.n.01| (r_compound) injection_14\NN\insertion.n.02|repeated|pentazocine (r_pobj) of_11\IN\entity.n.01|injection (r_prep) effect_10\NN\phenomenon.n.01|a|common|,|known|side|of (r_attr) is_2\VBZ\be.v.01|myopathy|effect|. (l_nsubj) myopathy_1\NN\pathology.n.02|fibrous
D010423_D009135 CID pentazocine_10\NN\analgesic.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|pentazocine|- (r_compound) myopathy_13\NN\pathology.n.02|induced
D010423_D009135 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|documented|induced|fibrous|of
D010423_D009135 CID pentazocine_8\NN\analgesic.n.01| (r_advmod) induced_10\VBN\generate.v.01|pentazocine|- (r_amod) myopathy_12\NNS\pathology.n.02|documented|induced|fibrous|of (r_pobj) with_6\IN\entity.n.01|myopathy (r_prep) woman_5\NN\adult.n.01|a|old|with|bilaterally|and|history (r_pobj) in_0\IN\linear_unit.n.01|woman (r_prep) showed_32\VBD\show.v.04|in|,|examination|lesion|,|in|. (l_prep) in_51\IN\linear_unit.n.01|addition (l_pobj) addition_52\NN\component.n.03|to (l_prep) to_53\IN\entity.n.01|myopathy (l_pobj) myopathy_56\NN\pathology.n.02|the|fibrous
19387625
D002211_D010146 NONE capsaicin_7\NN\chemical_irritant.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|capsaicin|- (r_amod) hyperalgesia_11\NN\entity.n.01|induced|secondary (r_pobj) in_6\IN\linear_unit.n.01|hyperalgesia (r_prep) intensity_5\NN\magnitude.n.01|perceived|pain|in (l_compound) pain_4\NN\symptom.n.01|
D002211_D010146 NONE capsaicin_16\NN\chemical_irritant.n.01| (r_npadvmod) induced_18\VBN\generate.v.01|capsaicin|- (r_amod) hyperalgesia_20\NN\entity.n.01|induced|secondary (r_pobj) in_15\IN\linear_unit.n.01|hyperalgesia (r_prep) attention_14\NN\basic_cognitive_process.n.01|in (r_pobj) by_13\IN\by.r.01|attention (r_agent) affected_12\VBN\change.v.01|that|how|ratings|are|by (l_nsubjpass) ratings_10\NNS\appraisal.n.01|intensity (l_compound) intensity_9\NN\magnitude.n.01|pain (l_compound) pain_8\NN\symptom.n.01|
D002211_D010146 NONE capsaicin_7\NN\chemical_irritant.n.01| (r_compound) treatment_8\NN\care.n.01|capsaicin|and|modulation (r_pobj) between_6\IN\between.r.01|treatment (r_prep) interaction_5\NN\action.n.01|no|between (r_dobj) showing_3\VBG\display.n.05|interaction (r_csubj) suggest_12\VBP\declare.v.01|findings|,|showing|affect|. (l_ccomp) affect_22\VB\feeling.n.01|that|hyperalgesia|might|pain|through (l_dobj) pain_24\NN\symptom.n.01|mechanical
D002211_D010146 NONE capsaicin_14\NN\chemical_irritant.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|capsaicin|- (r_amod) hyperalgesia_18\NN\entity.n.01|induced|secondary|and|attention (r_nsubj) affect_22\VB\feeling.n.01|that|hyperalgesia|might|pain|through (l_dobj) pain_24\NN\symptom.n.01|mechanical
D002211_D006930 CID capsaicin_7\NN\chemical_irritant.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|capsaicin|- (r_amod) hyperalgesia_11\NN\entity.n.01|induced|secondary
D002211_D006930 CID capsaicin_16\NN\chemical_irritant.n.01| (r_npadvmod) induced_18\VBN\generate.v.01|capsaicin|- (r_amod) hyperalgesia_20\NN\entity.n.01|induced|secondary
D002211_D006930 CID capsaicin_20\NN\chemical_irritant.n.01| (r_npadvmod) untreated_22\VBN\untreated.a.01|capsaicin|- (r_amod) condition_25\NN\state.n.02|untreated|,|control (r_pobj) of_19\IN\entity.n.01|condition (r_prep) that_18\DT\entity.n.01|of (r_pobj) to_17\IN\entity.n.01|that (r_prep) similar_16\JJ\similar.a.01|very|to (r_acomp) is_14\VBZ\be.v.01|that|magnitude|similar (l_nsubj) magnitude_7\NN\property.n.02|the|of (l_prep) of_8\IN\entity.n.01|modulation (l_pobj) modulation_10\NN\passage.n.06|attentional|in (l_prep) in_11\IN\linear_unit.n.01|hyperalgesia (l_pobj) hyperalgesia_13\NN\entity.n.01|secondary
D002211_D006930 CID capsaicin_7\NN\chemical_irritant.n.01| (r_compound) treatment_8\NN\care.n.01|capsaicin|and|modulation (r_pobj) between_6\IN\between.r.01|treatment (r_prep) interaction_5\NN\action.n.01|no|between (r_dobj) showing_3\VBG\display.n.05|interaction (r_csubj) suggest_12\VBP\declare.v.01|findings|,|showing|affect|. (l_ccomp) affect_22\VB\feeling.n.01|that|hyperalgesia|might|pain|through (l_nsubj) hyperalgesia_18\NN\entity.n.01|induced|secondary|and|attention
D002211_D006930 CID capsaicin_14\NN\chemical_irritant.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|capsaicin|- (r_amod) hyperalgesia_18\NN\entity.n.01|induced|secondary|and|attention
26094
D008750_D003866 CID dopa_13\NN\amino_acid.n.01|methyl (r_pobj) in_11\IN\linear_unit.n.01|dopa (r_prep) occurring_10\VBG\happen.v.01|in (r_acl) depressions_9\NNS\psychological_state.n.01|occurring
D008750_D001523 NONE dopa_13\NN\amino_acid.n.01|methyl (r_pobj) in_11\IN\linear_unit.n.01|dopa (r_prep) occurring_10\VBG\happen.v.01|in (r_acl) depressions_9\NNS\psychological_state.n.01|occurring (r_pobj) of_8\IN\entity.n.01|depressions (r_prep) number_7\NN\amount.n.02|a|significant|of|treated (l_acl) treated_14\VBD\interact.v.01|patients (l_dobj) patients_15\NNS\case.n.06|with (l_prep) with_16\IN\entity.n.01|histories (l_pobj) histories_18\NNS\past.n.01|psychiatric (l_amod) psychiatric_17\JJ\psychiatric.a.01|
10365197
D003042_D019964 CID cocaine_0\NN\hard_drug.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|cocaine|- (r_amod) disorder_4\NN\physical_condition.n.01|induced|mood|:|rates|.
D003042_D019964 CID cocaine_14\NN\hard_drug.n.01| (r_npadvmod) dependent_16\JJ\recipient.n.01|cocaine|- (r_amod) sample_17\NN\example.n.01|an|outpatient|dependent (r_pobj) in_11\IN\linear_unit.n.01|sample (r_prep) rates_7\NNS\tax.n.01|prevalence|and|symptoms|in (r_appos) disorder_4\NN\physical_condition.n.01|induced|mood|:|rates|.
D003042_D019964 CID cocaine_1\NN\hard_drug.n.01| (r_npadvmod) dependent_3\JJ\recipient.n.01|cocaine|- (r_amod) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (l_prep) with_5\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|induced|mood|(|cimd|)
D003042_D019964 CID cocaine_1\NN\hard_drug.n.01| (r_npadvmod) dependent_3\JJ\recipient.n.01|cocaine|- (r_amod) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\physical_condition.n.01|other|mood|,|or|disorder
D003042_D019964 CID cocaine_1\NN\hard_drug.n.01| (r_npadvmod) dependent_3\JJ\recipient.n.01|cocaine|- (r_amod) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\physical_condition.n.01|other|mood|,|or|disorder (l_conj) disorder_22\NN\physical_condition.n.01|no|mood
D003042_D019964 CID cocaine_6\NN\hard_drug.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|cocaine|- (r_amod) disorder_10\NN\physical_condition.n.01|induced|mood|(|cimd|)
D003042_D019964 CID cocaine_6\NN\hard_drug.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|cocaine|- (r_amod) disorder_10\NN\physical_condition.n.01|induced|mood|(|cimd|) (r_pobj) with_5\IN\entity.n.01|disorder (r_prep) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\physical_condition.n.01|other|mood|,|or|disorder
D003042_D019964 CID cocaine_6\NN\hard_drug.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|cocaine|- (r_amod) disorder_10\NN\physical_condition.n.01|induced|mood|(|cimd|) (r_pobj) with_5\IN\entity.n.01|disorder (r_prep) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (l_conj) disorders_17\NNS\physical_condition.n.01|other|mood|,|or|disorder (l_conj) disorder_22\NN\physical_condition.n.01|no|mood
D003042_D001523 NONE cocaine_0\NN\hard_drug.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|cocaine|- (r_amod) disorder_4\NN\physical_condition.n.01|induced|mood|:|rates|. (l_appos) rates_7\NNS\tax.n.01|prevalence|and|symptoms|in (l_conj) symptoms_10\NNS\evidence.n.01|psychiatric (l_amod) psychiatric_9\JJ\psychiatric.a.01|
D003042_D001523 NONE cocaine_14\NN\hard_drug.n.01| (r_npadvmod) dependent_16\JJ\recipient.n.01|cocaine|- (r_amod) sample_17\NN\example.n.01|an|outpatient|dependent (r_pobj) in_11\IN\linear_unit.n.01|sample (r_prep) rates_7\NNS\tax.n.01|prevalence|and|symptoms|in (l_conj) symptoms_10\NNS\evidence.n.01|psychiatric (l_amod) psychiatric_9\JJ\psychiatric.a.01|
D003042_D001523 NONE cocaine_1\NN\hard_drug.n.01| (r_npadvmod) dependent_3\JJ\recipient.n.01|cocaine|- (r_amod) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (r_nsubjpass) compared_24\VBN\analyze.v.01|outpatients|were|on|. (l_prep) on_25\IN\on.a.01|measures (l_pobj) measures_26\NNS\maneuver.n.04|of (l_prep) of_27\IN\entity.n.01|symptoms (l_pobj) symptoms_29\NNS\evidence.n.01|psychiatric (l_amod) psychiatric_28\JJ\psychiatric.a.01|
D003042_D001523 NONE cocaine_6\NN\hard_drug.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|cocaine|- (r_amod) disorder_10\NN\physical_condition.n.01|induced|mood|(|cimd|) (r_pobj) with_5\IN\entity.n.01|disorder (r_prep) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (r_nsubjpass) compared_24\VBN\analyze.v.01|outpatients|were|on|. (l_prep) on_25\IN\on.a.01|measures (l_pobj) measures_26\NNS\maneuver.n.04|of (l_prep) of_27\IN\entity.n.01|symptoms (l_pobj) symptoms_29\NNS\evidence.n.01|psychiatric (l_amod) psychiatric_28\JJ\psychiatric.a.01|
D003042_D019970 NONE cocaine_1\NN\hard_drug.n.01| (r_npadvmod) dependent_3\JJ\recipient.n.01|cocaine|- (r_amod) outpatients_4\NNS\patient.n.01|243|dependent|with|,|disorders (l_prep) with_5\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|induced|mood|(|cimd|) (l_appos) cimd_12\NNP\entity.n.01|
D003042_D019970 NONE cocaine_6\NN\hard_drug.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|cocaine|- (r_amod) disorder_10\NN\physical_condition.n.01|induced|mood|(|cimd|) (l_appos) cimd_12\NNP\entity.n.01|
7881871
D011692_D007674 CID aminonucleoside_7\NN\entity.n.01| (r_advmod) induced_9\VBN\generate.v.01|aminonucleoside|- (r_amod) nephropathy_10\NN\uropathy.n.01|puromycin|induced
D011692_D007674 CID aminonucleoside_12\NN\entity.n.01| (r_nmod) nephropathy_15\NN\uropathy.n.01|puromycin|aminonucleoside|(|pan)-induced
D011692_D007674 CID pan)-induced_14\JJ\entity.n.01| (r_amod) nephropathy_15\NN\uropathy.n.01|puromycin|aminonucleoside|(|pan)-induced
D011692_D007674 CID pan_14\NNP\cooking_utensil.n.01| (r_compound) nephropathy_15\NN\uropathy.n.01|pan
D010100_D007674 NONE oxygen_1\NN\chemical_element.n.01| (r_compound) species_2\NNS\taxonomic_group.n.01|reactive|oxygen (r_nsubjpass) implicated_5\VBN\involve.v.01|species|have|been|in|,|with|. (l_prep) in_6\IN\linear_unit.n.01|pathogenesis (l_pobj) pathogenesis_8\NN\pathologic_process.n.01|the|of (l_prep) of_9\IN\entity.n.01|nephropathy (l_pobj) nephropathy_15\NN\uropathy.n.01|puromycin|aminonucleoside|(|pan)-induced
D010100_D011507 NONE oxygen_1\NN\chemical_element.n.01| (r_compound) species_2\NNS\taxonomic_group.n.01|reactive|oxygen (r_nsubjpass) implicated_5\VBN\involve.v.01|species|have|been|in|,|with|. (l_prep) with_17\IN\entity.n.01|reducing (l_pcomp) reducing_20\VBG\chemical_reaction.n.01|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN\symptom.n.01|the
D011692_D011507 CID aminonucleoside_12\NN\entity.n.01| (r_nmod) nephropathy_15\NN\uropathy.n.01|puromycin|aminonucleoside|(|pan)-induced (r_pobj) of_9\IN\entity.n.01|nephropathy (r_prep) pathogenesis_8\NN\pathologic_process.n.01|the|of (r_pobj) in_6\IN\linear_unit.n.01|pathogenesis (r_prep) implicated_5\VBN\involve.v.01|species|have|been|in|,|with|. (l_prep) with_17\IN\entity.n.01|reducing (l_pcomp) reducing_20\VBG\chemical_reaction.n.01|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN\symptom.n.01|the
D011692_D011507 CID pan)-induced_14\JJ\entity.n.01| (r_amod) nephropathy_15\NN\uropathy.n.01|puromycin|aminonucleoside|(|pan)-induced (r_pobj) of_9\IN\entity.n.01|nephropathy (r_prep) pathogenesis_8\NN\pathologic_process.n.01|the|of (r_pobj) in_6\IN\linear_unit.n.01|pathogenesis (r_prep) implicated_5\VBN\involve.v.01|species|have|been|in|,|with|. (l_prep) with_17\IN\entity.n.01|reducing (l_pcomp) reducing_20\VBG\chemical_reaction.n.01|antioxidants|significantly|proteinuria (l_dobj) proteinuria_22\NN\symptom.n.01|the
D011692_D011507 CID pan_14\NNP\cooking_utensil.n.01| (r_compound) nephropathy_15\NN\uropathy.n.01|pan (r_pobj) in_13\IN\linear_unit.n.01|nephropathy (r_prep) injury_12\NN\ill_health.n.01|the|proteinuric|in
1009330
C004658_D003556 NONE choloroaniline_10\NN\entity.n.01|p|- (r_appos) product_7\NN\commodity.n.01|the|degradation|choloroaniline (r_nsubj) is_11\VBZ\be.v.01|that|product|not|factor (l_attr) factor_15\NN\cause.n.01|a|significant|in (l_prep) in_16\IN\linear_unit.n.01|cystitis (l_pobj) cystitis_22\NN\urinary_tract_infection.n.01|associated|erosive
C010882_D003556 CID digluconate_19\NN\entity.n.01|chlorhexidine|- (r_npadvmod) associated_20\VBN\think.v.03|digluconate (r_amod) cystitis_22\NN\urinary_tract_infection.n.01|associated|erosive
D007612_D003556 CID kanamycin_4\NN\antibiotic.n.01| (r_compound) colistin_6\NN\entity.n.01|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS\provision.n.02|colistin (r_pobj) of_3\IN\entity.n.01|irrigations (r_prep) percentage_2\NN\proportion.n.01|a|high|of (r_nsubjpass) associated_13\VBN\think.v.03|percentage|were|with|and|suggested|. (l_prep) with_14\IN\entity.n.01|cystitis (l_pobj) cystitis_16\NN\urinary_tract_infection.n.01|erosive
D003091_D003556 CID colistin_6\NN\entity.n.01|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS\provision.n.02|colistin (r_pobj) of_3\IN\entity.n.01|irrigations (r_prep) percentage_2\NN\proportion.n.01|a|high|of (r_nsubjpass) associated_13\VBN\think.v.03|percentage|were|with|and|suggested|. (l_prep) with_14\IN\entity.n.01|cystitis (l_pobj) cystitis_16\NN\urinary_tract_infection.n.01|erosive
D011206_D003556 CID iodine_10\NN\chemical_element.n.01|povidone|- (r_conj) colistin_6\NN\entity.n.01|kanamycin|-|and|iodine (r_nmod) irrigations_11\NNS\provision.n.02|colistin (r_pobj) of_3\IN\entity.n.01|irrigations (r_prep) percentage_2\NN\proportion.n.01|a|high|of (r_nsubjpass) associated_13\VBN\think.v.03|percentage|were|with|and|suggested|. (l_prep) with_14\IN\entity.n.01|cystitis (l_pobj) cystitis_16\NN\urinary_tract_infection.n.01|erosive
C005253_D003556 NONE picloxydine_0\NNP\entity.n.01| (r_compound) irrigations_1\NNS\provision.n.02|picloxydine (r_nsubj) appeared_2\VBD\be.v.01|irrigations|have|but|have (l_xcomp) have_4\VB\person.n.01|to|incidence (l_dobj) incidence_7\NN\frequency.n.02|a|lower|of (l_prep) of_8\IN\entity.n.01|cystitis (l_pobj) cystitis_10\NN\urinary_tract_infection.n.01|erosive
19729346
D010098_D010146 NONE oxycodone_18\NN\entity.n.01|release (r_pobj) of_14\IN\entity.n.01|oxycodone (r_prep) dose_13\NN\medicine.n.02|a|single|10-mg|of|in (r_pobj) of_9\IN\entity.n.01|dose (r_prep) effects_8\NNS\personal_property.n.01|the|objective|neurocognitive|of (r_dobj) measured_2\VBD\decide.v.01|study|effects|)|,|and|years|adults|. (l_dobj) adults_39\NNS\person.n.01|suffering (l_relcl) suffering_43\VBG\pain.n.01|who|were|not|from (l_prep) from_44\IN\entity.n.01|pain (l_pobj) pain_49\NN\symptom.n.01|chronic|daily
D010098_D059350 NONE oxycodone_30\NN\entity.n.01|release (r_pobj) of_26\IN\entity.n.01|oxycodone (r_prep) dose_25\NN\medicine.n.02|a|10-mg|of (r_pobj) to_22\IN\entity.n.01|dose (r_prep) response_21\NN\consequence.n.01|to (r_pobj) in_20\IN\linear_unit.n.01|response (r_prep) changes_19\NNS\happening.n.01|in (r_dobj) suffering_11\VBG\pain.n.01|who|are|not|from|changes (l_prep) from_12\IN\entity.n.01|pain (l_pobj) pain_14\NN\symptom.n.01|chronic|,|neurocognitive
12202650
D002211_D063806 NONE capsaicin_0\NN\chemical_irritant.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|capsaicin|- (r_amod) pain_4\NN\symptom.n.01|induced|muscle
D002211_D010146 CID capsaicin_0\NNS\chemical_irritant.n.01|g (r_nsubjpass) injected_7\VBN\administer.v.04|capsaicin|was|into|induce|. (l_advcl) induce_13\VB\generate.v.01|to|pain|in (l_dobj) pain_14\NN\symptom.n.01|
18439803
C108761_D012640 NONE n-(2-propylpentanoyl)urea_3\NNP\entity.n.01| (r_pobj) of_2\IN\entity.n.01|n-(2-propylpentanoyl)urea (r_prep) effects_1\NNS\personal_property.n.01|acute|of|on|in|. (l_prep) in_9\IN\linear_unit.n.01|seizure (l_pobj) seizure_13\NN\attack.n.07|induced|in
C108761_D012640 NONE vpu_0\NNS\entity.n.01| (r_nsubj) was_1\VBD\washington.n.02|vpu|potent|,|exhibiting|. (l_advcl) exhibiting_7\VBG\possess.v.01|dose|was (l_dobj) dose_11\NN\medicine.n.02|the|median|effective|ed(50|)|of (l_prep) of_16\IN\entity.n.01|mg/kg (l_pobj) mg/kg_18\NNS\entity.n.01|49|in (l_prep) in_19\IN\linear_unit.n.01|protecting (l_pcomp) protecting_20\VBG\defend.v.02|rats|against (l_prep) against_22\IN\entity.n.01|seizure (l_pobj) seizure_26\NN\attack.n.07|induced
C108761_D012640 NONE vpu_5\NNPS\entity.n.01|and|vpa (r_nsubj) protect_9\VB\defend.v.02|that|vpu|could|animals (l_dobj) animals_11\NNS\organism.n.01|the|against (l_prep) against_12\IN\entity.n.01|seizure (l_pobj) seizure_16\NN\attack.n.07|induced
C108761_D012640 NONE vpu_8\NNP\entity.n.01| (r_nsubj) reduce_11\VB\decrease.v.02|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\discovery.n.01|the|reduce (r_appos) vpa_3\NNP\entity.n.01|,|finding (r_pobj) like_2\IN\kind.n.01|vpa (r_prep) account_21\VB\record.n.01|therefore|,|like|should|,|for|. (l_prep) for_27\IN\entity.n.01|partly|,|activity (l_pobj) activity_30\NN\act.n.02|its|anticonvulsant|observed (l_acl) observed_31\VBN\spy.v.03|in (l_prep) in_32\IN\linear_unit.n.01|seizure (l_pobj) seizure_36\NN\attack.n.07|induced|in
D000596_D012640 NONE acid_7\NN\compound.n.02|amino (r_compound) neurotransmitters_8\NNS\neurochemical.n.01|hippocampal|acid (r_pobj) on_4\IN\on.a.01|neurotransmitters (r_prep) effects_1\NNS\personal_property.n.01|acute|of|on|in|. (l_prep) in_9\IN\linear_unit.n.01|seizure (l_pobj) seizure_13\NN\attack.n.07|induced|in
D000596_D012640 NONE acid_26\NN\compound.n.02|amino (r_compound) neurotransmitters_27\NNS\neurochemical.n.01|inhibitory|acid (r_pobj) of_23\IN\entity.n.01|neurotransmitters (r_prep) reduction_22\NN\change_of_magnitude.n.01|the|of (r_nsubj) was_28\VBD\washington.n.02|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN\declare.v.01|based|it|is|was|. (l_prep) based_0\VBN\establish.v.08|on (l_prep) on_1\IN\on.a.01|finding (l_pobj) finding_3\NN\discovery.n.01|the|protect (l_acl) protect_9\VB\defend.v.02|that|vpu|could|animals (l_dobj) animals_11\NNS\organism.n.01|the|against (l_prep) against_12\IN\entity.n.01|seizure (l_pobj) seizure_16\NN\attack.n.07|induced
D010862_D012640 CID pilocarpine_10\NN\alkaloid.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|pilocarpine|- (r_amod) seizure_13\NN\attack.n.07|induced|in
D010862_D012640 CID pilocarpine_23\NN\alkaloid.n.01| (r_npadvmod) induced_25\VBN\generate.v.01|pilocarpine|- (r_amod) seizure_26\NN\attack.n.07|induced
D010862_D012640 CID pilocarpine_13\NN\alkaloid.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|pilocarpine|- (r_amod) seizure_16\NN\attack.n.07|induced
D010862_D012640 CID pilocarpine_12\NN\alkaloid.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|pilocarpine|- (r_amod) increases_15\NNS\indefinite_quantity.n.01|induced|in (r_dobj) reduce_11\VB\decrease.v.02|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\discovery.n.01|the|reduce (r_appos) vpa_3\NNP\entity.n.01|,|finding (r_pobj) like_2\IN\kind.n.01|vpa (r_prep) account_21\VB\record.n.01|therefore|,|like|should|,|for|. (l_prep) for_27\IN\entity.n.01|partly|,|activity (l_pobj) activity_30\NN\act.n.02|its|anticonvulsant|observed (l_acl) observed_31\VBN\spy.v.03|in (l_prep) in_32\IN\linear_unit.n.01|seizure (l_pobj) seizure_36\NN\attack.n.07|induced|in
D010862_D012640 CID pilocarpine_33\NN\alkaloid.n.01| (r_npadvmod) induced_35\VBN\generate.v.01|pilocarpine|- (r_amod) seizure_36\NN\attack.n.07|induced|in
D014635_D012640 NONE vpa_5\NNP\entity.n.01| (r_pobj) than_4\IN\entity.n.01|vpa (r_prep) potent_3\JJ\potent.s.01|more|than (r_acomp) was_1\VBD\washington.n.02|vpu|potent|,|exhibiting|. (l_advcl) exhibiting_7\VBG\possess.v.01|dose|was (l_dobj) dose_11\NN\medicine.n.02|the|median|effective|ed(50|)|of (l_prep) of_16\IN\entity.n.01|mg/kg (l_pobj) mg/kg_18\NNS\entity.n.01|49|in (l_prep) in_19\IN\linear_unit.n.01|protecting (l_pcomp) protecting_20\VBG\defend.v.02|rats|against (l_prep) against_22\IN\entity.n.01|seizure (l_pobj) seizure_26\NN\attack.n.07|induced
D014635_D012640 NONE vpa_32\NNP\entity.n.01| (r_pobj) for_31\IN\entity.n.01|vpa (r_prep) value_30\NN\numerical_quantity.n.01|the|corresponding|for (r_nsubj) was_33\VBD\washington.n.02|whereas|value|mg/kg (r_advcl) exhibiting_7\VBG\possess.v.01|dose|was (l_dobj) dose_11\NN\medicine.n.02|the|median|effective|ed(50|)|of (l_prep) of_16\IN\entity.n.01|mg/kg (l_pobj) mg/kg_18\NNS\entity.n.01|49|in (l_prep) in_19\IN\linear_unit.n.01|protecting (l_pcomp) protecting_20\VBG\defend.v.02|rats|against (l_prep) against_22\IN\entity.n.01|seizure (l_pobj) seizure_26\NN\attack.n.07|induced
D014635_D012640 NONE vpa_7\NNP\entity.n.01| (r_conj) vpu_5\NNPS\entity.n.01|and|vpa (r_nsubj) protect_9\VB\defend.v.02|that|vpu|could|animals (l_dobj) animals_11\NNS\organism.n.01|the|against (l_prep) against_12\IN\entity.n.01|seizure (l_pobj) seizure_16\NN\attack.n.07|induced
D014635_D012640 NONE vpa_3\NNP\entity.n.01|,|finding (r_pobj) like_2\IN\kind.n.01|vpa (r_prep) account_21\VB\record.n.01|therefore|,|like|should|,|for|. (l_prep) for_27\IN\entity.n.01|partly|,|activity (l_pobj) activity_30\NN\act.n.02|its|anticonvulsant|observed (l_acl) observed_31\VBN\spy.v.03|in (l_prep) in_32\IN\linear_unit.n.01|seizure (l_pobj) seizure_36\NN\attack.n.07|induced|in
D018698_D012640 NONE glutamate_38\NN\salt.n.01|and|aspartate (r_pobj) of_37\IN\entity.n.01|glutamate (r_prep) reduction_36\NN\change_of_magnitude.n.01|a|pronounced|of (r_pobj) by_33\IN\by.r.01|reduction (r_agent) offset_32\VBN\point.n.06|by (r_conj) was_28\VBD\washington.n.02|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN\declare.v.01|based|it|is|was|. (l_prep) based_0\VBN\establish.v.08|on (l_prep) on_1\IN\on.a.01|finding (l_pobj) finding_3\NN\discovery.n.01|the|protect (l_acl) protect_9\VB\defend.v.02|that|vpu|could|animals (l_dobj) animals_11\NNS\organism.n.01|the|against (l_prep) against_12\IN\entity.n.01|seizure (l_pobj) seizure_16\NN\attack.n.07|induced
D018698_D012640 NONE glutamate_17\NN\salt.n.01|and|aspartate (r_pobj) in_16\IN\linear_unit.n.01|glutamate (r_prep) increases_15\NNS\indefinite_quantity.n.01|induced|in (r_dobj) reduce_11\VB\decrease.v.02|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\discovery.n.01|the|reduce (r_appos) vpa_3\NNP\entity.n.01|,|finding (r_pobj) like_2\IN\kind.n.01|vpa (r_prep) account_21\VB\record.n.01|therefore|,|like|should|,|for|. (l_prep) for_27\IN\entity.n.01|partly|,|activity (l_pobj) activity_30\NN\act.n.02|its|anticonvulsant|observed (l_acl) observed_31\VBN\spy.v.03|in (l_prep) in_32\IN\linear_unit.n.01|seizure (l_pobj) seizure_36\NN\attack.n.07|induced|in
D001224_D012640 NONE aspartate_40\NN\entity.n.01| (r_conj) glutamate_38\NN\salt.n.01|and|aspartate (r_pobj) of_37\IN\entity.n.01|glutamate (r_prep) reduction_36\NN\change_of_magnitude.n.01|a|pronounced|of (r_pobj) by_33\IN\by.r.01|reduction (r_agent) offset_32\VBN\point.n.06|by (r_conj) was_28\VBD\washington.n.02|that|reduction|minor|and|offset (r_ccomp) suggested_19\VBN\declare.v.01|based|it|is|was|. (l_prep) based_0\VBN\establish.v.08|on (l_prep) on_1\IN\on.a.01|finding (l_pobj) finding_3\NN\discovery.n.01|the|protect (l_acl) protect_9\VB\defend.v.02|that|vpu|could|animals (l_dobj) animals_11\NNS\organism.n.01|the|against (l_prep) against_12\IN\entity.n.01|seizure (l_pobj) seizure_16\NN\attack.n.07|induced
D001224_D012640 NONE aspartate_19\NN\entity.n.01| (r_conj) glutamate_17\NN\salt.n.01|and|aspartate (r_pobj) in_16\IN\linear_unit.n.01|glutamate (r_prep) increases_15\NNS\indefinite_quantity.n.01|induced|in (r_dobj) reduce_11\VB\decrease.v.02|that|vpu|could|drastically|increases (r_relcl) finding_6\NN\discovery.n.01|the|reduce (r_appos) vpa_3\NNP\entity.n.01|,|finding (r_pobj) like_2\IN\kind.n.01|vpa (r_prep) account_21\VB\record.n.01|therefore|,|like|should|,|for|. (l_prep) for_27\IN\entity.n.01|partly|,|activity (l_pobj) activity_30\NN\act.n.02|its|anticonvulsant|observed (l_acl) observed_31\VBN\spy.v.03|in (l_prep) in_32\IN\linear_unit.n.01|seizure (l_pobj) seizure_36\NN\attack.n.07|induced|in
8590259
C016986_D015814 CID apraclonidine_8\NN\entity.n.01| (r_npadvmod) treated_10\VBN\interact.v.01|apraclonidine|- (r_amod) eyes_11\NNS\opinion.n.01|treated (r_pobj) for_7\IN\entity.n.01|eyes (r_prep) significant_6\JJ\significant.a.01|statistically|for|throughout|and|significant (r_acomp) were_4\VBD\be.v.01|effects|significant|. (l_nsubj) effects_3\NNS\personal_property.n.01|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\patient.n.01|
C016986_D015814 CID apraclonidine_31\NN\entity.n.01|% (r_pobj) of_28\IN\entity.n.01|apraclonidine (r_prep) administration_27\NN\management.n.01|topical|of (r_pobj) after_25\IN\after.s.01|administration (r_prep) hours_24\NNS\work_time.n.01|three|after (r_pobj) from_22\IN\entity.n.01|hours (r_prep) significant_18\JJ\significant.a.01|also|statistically|for|from (r_conj) significant_6\JJ\significant.a.01|statistically|for|throughout|and|significant (r_acomp) were_4\VBD\be.v.01|effects|significant|. (l_nsubj) effects_3\NNS\personal_property.n.01|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\patient.n.01|
12596116
D015282_D000860 NONE octreotide_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|octreotide|-|hypoxemia|. (l_dobj) hypoxemia_3\NN\entity.n.01|and|hypertension|in
D015282_D006976 CID octreotide_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|octreotide|-|hypoxemia|. (l_dobj) hypoxemia_3\NN\entity.n.01|and|hypertension|in (l_conj) hypertension_6\NN\cardiovascular_disease.n.01|pulmonary
D015282_D006976 CID octreotide_10\NN\entity.n.01| (r_advmod) developed_2\VBD\create.v.02|hypertension|after|octreotide|,|enhance|. (l_nsubj) hypertension_1\NN\cardiovascular_disease.n.01|pulmonary
D015282_D005402 NONE octreotide_10\NN\entity.n.01| (r_advmod) developed_2\VBD\create.v.02|hypertension|after|octreotide|,|enhance|. (l_advcl) enhance_13\VB\intensify.v.02|to|resolution (l_dobj) resolution_14\NN\document.n.01|of (l_prep) of_15\IN\entity.n.01|fistula (l_pobj) fistula_17\NN\animal_disease.n.01|the
2304736
D011224_D014550 CID prazosin_0\NN\alpha_blocker.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|prazosin|- (r_amod) incontinence_4\NN\elimination.n.02|induced|stress|.
D011224_D014550 CID prazosin_8\NN\alpha_blocker.n.01|,|drug|, (r_pobj) due_6\IN\right.n.01|to|prazosin (r_amod) case_1\NN\happening.n.01|a|of|due (l_prep) of_2\IN\entity.n.01|incontinence (l_pobj) incontinence_5\NN\elimination.n.02|genuine|stress
D011224_D014550 CID prazosin_8\NN\alpha_blocker.n.01| (r_dobj) taking_7\VBG\action.n.01|while|prazosin (r_advcl) present_2\VBP\time.n.05|who|with|taking (l_prep) with_3\IN\entity.n.01|incontinence (l_pobj) incontinence_5\NN\elimination.n.02|stress
D011224_D014549 NONE prazosin_8\NN\alpha_blocker.n.01| (r_dobj) taking_7\VBG\action.n.01|while|prazosin (r_advcl) present_2\VBP\time.n.05|who|with|taking (r_relcl) patients_0\NNS\case.n.06|present (r_nsubj) change_10\VB\happening.n.01|patients|should|medication|before|,|resolve|. (l_advcl) resolve_22\VB\trait.n.01|because|incontinence|may|spontaneously|with (l_nsubj) incontinence_20\NN\elimination.n.02|their
18821488
C080436_D064420 NONE 8-aminoquinoline_8\JJ\entity.n.01| (r_compound) 8-[(4-amino_9\CD\entity.n.01|8-aminoquinoline (r_compound) l_11\NN\metric_capacity_unit.n.01|8-[(4-amino|- (r_compound) methylbutyl)amino]-_13\NN\entity.n.01|l|- (r_punct) wr242511_18\NNP\entity.n.01|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN\entity.n.01|wr242511 (r_prep) administration_5\NN\management.n.01|of (r_pobj) following_4\VBG\multitude.n.03|administration (r_prep) toxicity_0\NN\definite_quantity.n.01|in|following|)|.
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16\NNP\entity.n.01|5-(l|- (r_nmod) wr242511_18\NNP\entity.n.01|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN\entity.n.01|wr242511 (r_prep) administration_5\NN\management.n.01|of (r_pobj) following_4\VBG\multitude.n.03|administration (r_prep) toxicity_0\NN\definite_quantity.n.01|in|following|)|.
C068820_D064420 NONE wr242511_18\NNP\entity.n.01|the|methylbutyl)amino]-|hexyloxy)-6-methoxy-4-methylquinoline|( (r_pobj) of_6\IN\entity.n.01|wr242511 (r_prep) administration_5\NN\management.n.01|of (r_pobj) following_4\VBG\multitude.n.03|administration (r_prep) toxicity_0\NN\definite_quantity.n.01|in|following|)|.
C068820_D064420 NONE wr242511_4\NNP\entity.n.01| (r_nsubjpass) pursued_8\VBN\hunted_person.n.01|that|wr242511|should|not|be|as|dissociated (l_advcl) dissociated_27\VBN\separate.v.08|unless|characteristics|can|be|successfully|from (l_prep) from_28\IN\entity.n.01|those (l_pobj) those_29\DT\entity.n.01|producing (l_acl) producing_30\VBG\make.v.03|toxicity (l_dobj) toxicity_32\NN\definite_quantity.n.01|undesirable
C068820_D008708 NONE wr242511_4\NNP\entity.n.01|,|produced|, (l_relcl) produced_7\VBD\make.v.03|which|methemoglobinemia|in (l_dobj) methemoglobinemia_9\NN\entity.n.01|significant|in
C068820_D006456 CID wr242511_11\NNP\entity.n.01|(|3.5|) (r_pobj) of_10\IN\entity.n.01|wr242511 (r_prep) postinjection_9\NN\entity.n.01|minutes|of (r_dobj) noted_5\VBN\state.v.01|furthermore|,|hemoglobinuria|was|postinjection|,|and|occurred (l_nsubjpass) hemoglobinuria_3\NN\symptom.n.01|transient
C068820_D011041 NONE wr242511_4\NNP\entity.n.01| (r_nsubjpass) pursued_8\VBN\hunted_person.n.01|that|wr242511|should|not|be|as|dissociated (l_prep) as_9\IN\chemical_element.n.01|pretreatment (l_pobj) pretreatment_11\NN\entity.n.01|a|for (l_prep) for_12\IN\entity.n.01|poisoning (l_pobj) poisoning_14\NN\physical_condition.n.01|cn
8319760
D019808_D009401 NONE 753_1\CD\entity.n.01| (r_nummod) dup_0\NN\entity.n.01|753 (r_nsubj) prevents_2\VBZ\prevent.v.01|dup|development|. (l_dobj) development_4\NN\improvement.n.02|the|of (l_prep) of_5\IN\entity.n.01|puromycin|nephrosis (l_pobj) nephrosis_10\NN\syndrome.n.02|induced
D011692_D009401 NONE aminonucleoside_7\NN\entity.n.01| (r_advmod) induced_9\VBN\generate.v.01|aminonucleoside|- (r_amod) nephrosis_10\NN\syndrome.n.02|induced
D011692_D009401 NONE aminonucleoside_17\NN\entity.n.01| (r_advmod) induced_19\VBN\generate.v.01|aminonucleoside|- (r_amod) nephrosis_20\NN\syndrome.n.02|induced
D001806_D009404 NONE urea_17\NN\organic_compound.n.01|nitrogen (r_pobj) in_14\IN\linear_unit.n.01|urea (r_prep) increase_13\NN\indefinite_quantity.n.01|in (r_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase (r_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia (r_conj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (r_pobj) as_6\IN\chemical_element.n.01|such|proteinuria (r_prep) syndromes_4\NNS\complex.n.01|nephrotic|as
D001806_D011507 NONE urea_17\NN\organic_compound.n.01|nitrogen (r_pobj) in_14\IN\linear_unit.n.01|urea (r_prep) increase_13\NN\indefinite_quantity.n.01|in (r_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase (r_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia (r_conj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia
D001806_D034141 NONE urea_17\NN\organic_compound.n.01|nitrogen (r_pobj) in_14\IN\linear_unit.n.01|urea (r_prep) increase_13\NN\indefinite_quantity.n.01|in (r_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase (r_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia
D001806_D006937 NONE urea_17\NN\organic_compound.n.01|nitrogen (r_pobj) in_14\IN\linear_unit.n.01|urea (r_prep) increase_13\NN\indefinite_quantity.n.01|in (r_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase
D011692_D009404 CID aminonucleoside_26\NN\entity.n.01| (r_advmod) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as
D011692_D011507 CID aminonucleoside_26\NN\entity.n.01| (r_advmod) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia
D011692_D034141 CID aminonucleoside_26\NN\entity.n.01| (r_advmod) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia
D011692_D006937 CID aminonucleoside_26\NN\entity.n.01| (r_advmod) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase
D019808_D009404 NONE 753_35\CD\entity.n.01| (r_nummod) dup_34\NN\entity.n.01|753 (r_nmod) losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as
D019808_D009404 NONE losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as
D019808_D011507 NONE 753_35\CD\entity.n.01| (r_nummod) dup_34\NN\entity.n.01|753 (r_nmod) losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia
D019808_D011507 NONE losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia
D019808_D034141 NONE 753_35\CD\entity.n.01| (r_nummod) dup_34\NN\entity.n.01|753 (r_nmod) losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia
D019808_D034141 NONE losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia
D019808_D006937 NONE 753_35\CD\entity.n.01| (r_nummod) dup_34\NN\entity.n.01|753 (r_nmod) losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase
D019808_D006937 NONE losartan_37\NN\entity.n.01|dup|( (r_pobj) of_33\IN\entity.n.01|losartan (r_prep) administration_32\NN\management.n.01|oral|of (r_pobj) by_30\IN\by.r.01|administration (r_agent) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase
D000804_D009404 NONE ii_43\NNP\digit.n.01| (r_compound) antagonist_45\NN\person.n.01|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as
D000804_D011507 NONE ii_43\NNP\digit.n.01| (r_compound) antagonist_45\NN\person.n.01|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia
D000804_D034141 NONE ii_43\NNP\digit.n.01| (r_compound) antagonist_45\NN\person.n.01|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia
D000804_D006937 NONE ii_43\NNP\digit.n.01| (r_compound) antagonist_45\NN\person.n.01|a|angiotensin|ii|receptor|,|at (r_appos) inhibited_29\VBN\control.v.02|induced|was|markedly|by|)|,|antagonist|. (l_ccomp) induced_19\VBN\generate.v.01|appearance|,|in|by|aminonucleoside (l_nsubj) appearance_1\NN\quality.n.01|the|of (l_prep) of_2\IN\entity.n.01|syndromes (l_pobj) syndromes_4\NNS\complex.n.01|nephrotic|as (l_prep) as_6\IN\chemical_element.n.01|such|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\entity.n.01|,|hypercholesterolemia (l_conj) hypercholesterolemia_11\NN\symptom.n.01|and|increase
D000809_D009401 NONE angiotensin_10\NN\vasoconstrictor.n.01|renin|- (r_compound) system_11\NN\instrumentality.n.03|the|angiotensin|in (l_prep) in_12\IN\linear_unit.n.01|development (l_pobj) development_14\NN\improvement.n.02|the|of (l_prep) of_15\IN\entity.n.01|puromycin|nephrosis (l_pobj) nephrosis_20\NN\syndrome.n.02|induced
12820454
D016729_D000740 CID acetate_6\NN\salt.n.01|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD\get.v.01|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN\evaluate.v.02|were|for|by (l_prep) for_33\IN\entity.n.01|anemia (l_pobj) anemia_34\NN\blood_disease.n.01|
D016729_D000740 CID a_10\NNP\metric_linear_unit.n.01|lhrh|- (r_appos) acetate_6\NN\salt.n.01|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD\get.v.01|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN\evaluate.v.02|were|for|by (l_prep) for_33\IN\entity.n.01|anemia (l_pobj) anemia_34\NN\blood_disease.n.01|
D005485_D000740 CID flutamide_23\NN\entity.n.01| (r_nmod) tid_25\NN\entity.n.01|mg|flutamide|,|,|per (r_conj) days_19\NNS\life.n.07|every|28|plus|tid (r_appos) acetate_6\NN\salt.n.01|cab|[|leuprolide|(|a|)|mg|,|intramuscularly|,|days (r_dobj) received_2\VBD\get.v.01|patients|acetate|and|evaluated|. (l_conj) evaluated_32\VBN\evaluate.v.02|were|for|by (l_prep) for_33\IN\entity.n.01|anemia (l_pobj) anemia_34\NN\blood_disease.n.01|
19767176
C020972_D013226 NONE dithiocarbamate_1\NN\entity.n.01|pyrrolidine (r_nsubj) protects_2\VBZ\defend.v.02|dithiocarbamate|cortex|. (l_dobj) cortex_5\NN\neural_structure.n.01|the|piriform|in (l_prep) in_6\IN\linear_unit.n.01|model (l_pobj) model_11\NN\hypothesis.n.02|the|pilocarpine|status|epilepticus (l_amod) epilepticus_10\NN\entity.n.01|
C020972_D013226 NONE pdtc_3\NNP\entity.n.01| (r_pobj) of_2\IN\entity.n.01|pdtc (r_prep) effect_1\NN\phenomenon.n.01|the|of|on (l_prep) on_4\IN\on.a.01|loss (l_pobj) loss_10\NN\transferred_property.n.01|status|associated|cell|in (l_amod) associated_8\VBN\think.v.03|epilepticus|- (l_npadvmod) epilepticus_6\NN\entity.n.01|
C020972_D013226 NONE pdtc_4\NNP\entity.n.01|mg/kg (r_pobj) with_1\IN\entity.n.01|pdtc (r_prep) treatment_0\NN\care.n.01|with|before (r_nsubj) increased_11\VBD\change_magnitude.v.01|treatment|epilepticus|significantly|rate|to|. (l_advmod) epilepticus_9\NN\entity.n.01|
C020972_D013226 NONE pdtc_4\NNP\entity.n.01| (r_nmod) dose_8\NN\medicine.n.02|mg/kg|pdtc|(|low|- (r_pobj) of_1\IN\entity.n.01|dose (r_prep) administration_0\NN\management.n.01|of|) (r_nsubj) exert_12\VB\use.v.01|administration|did|not|effects|. (l_dobj) effects_14\NNS\personal_property.n.01|major|on (l_prep) on_15\IN\on.a.01|development (l_pobj) development_17\NN\improvement.n.02|the|of (l_prep) of_18\IN\entity.n.01|epilepticus (l_pobj) epilepticus_21\NN\entity.n.01|status|or|rate
C020972_D013226 NONE pdtc_16\NNP\entity.n.01| (r_npadvmod) treated_18\VBN\interact.v.01|pdtc|- (r_amod) rats_19\NNS\rodent.n.01|treated (r_conj) vehicle-_14\NN\entity.n.01|and|rats (r_pobj) in_13\IN\linear_unit.n.01|vehicle- (r_prep) identified_12\VBN\determine.v.03|decrease|was|in|following|. (l_prep) following_20\VBG\multitude.n.03|epilepticus (l_pobj) epilepticus_22\NN\entity.n.01|status
D010862_D013226 CID pilocarpine_8\NN\alkaloid.n.01| (r_amod) model_11\NN\hypothesis.n.02|the|pilocarpine|status|epilepticus (l_amod) epilepticus_10\NN\entity.n.01|
D010862_D013226 CID pilocarpine_23\NN\alkaloid.n.01| (r_compound) model_24\NN\hypothesis.n.02|the|rat|fractionated|pilocarpine (r_pobj) in_19\IN\linear_unit.n.01|model (r_prep) evaluated_18\VBN\evaluate.v.02|effect|was|in|. (l_nsubjpass) effect_1\NN\phenomenon.n.01|the|of|on (l_prep) on_4\IN\on.a.01|loss (l_pobj) loss_10\NN\transferred_property.n.01|status|associated|cell|in (l_amod) associated_8\VBN\think.v.03|epilepticus|- (l_npadvmod) epilepticus_6\NN\entity.n.01|
D010100_D009410 NONE oxygen_5\NN\chemical_element.n.01| (r_compound) species_6\NNS\taxonomic_group.n.01|reactive|oxygen (r_pobj) of_3\IN\entity.n.01|species (r_prep) production_2\NN\act.n.02|of|as|activation (r_nsubjpass) implicated_17\VBN\involve.v.01|both|,|production|have|been|in|. (l_prep) in_18\IN\linear_unit.n.01|damage (l_pobj) damage_21\NN\change.n.01|severe|neuronal|in
D010100_D009410 NONE oxygen_9\NN\chemical_element.n.01| (r_compound) species_10\NNS\taxonomic_group.n.01|reactive|oxygen|and|activation|of (r_pobj) of_7\IN\entity.n.01|species (r_prep) generation_6\NN\people.n.01|the|of (r_nsubj) plays_17\VBZ\dramatic_composition.n.01|that|generation|role|compared (l_dobj) role_21\NN\duty.n.02|a|central|in (l_prep) in_22\IN\linear_unit.n.01|damage (l_pobj) damage_27\NN\change.n.01|associated|neuronal|in
C020972_D009410 NONE pdtc_10\NNP\entity.n.01|antioxidant (r_conj) inhibitor_7\NN\substance.n.07|the|kappab|and|pdtc (r_nsubj) protected_11\VBD\defend.v.02|in|,|inhibitor|cortex|,|affect|. (l_advcl) affect_20\VB\feeling.n.01|whereas|it|did|not|loss (l_dobj) loss_23\NN\transferred_property.n.01|hilar|neuronal
D010100_D012640 NONE oxygen_9\NN\chemical_element.n.01| (r_compound) species_10\NNS\taxonomic_group.n.01|reactive|oxygen|and|activation|of (r_pobj) of_7\IN\entity.n.01|species (r_prep) generation_6\NN\people.n.01|the|of (r_nsubj) plays_17\VBZ\dramatic_composition.n.01|that|generation|role|compared (l_dobj) role_21\NN\duty.n.02|a|central|in (l_prep) in_22\IN\linear_unit.n.01|damage (l_pobj) damage_27\NN\change.n.01|associated|neuronal|in (l_amod) associated_25\VBN\think.v.03|seizure|- (l_npadvmod) seizure_23\NN\attack.n.07|
2312209
D007548_D009203 CID dinitrate_7\NN\entity.n.01|isosorbide (r_pobj) of_5\IN\entity.n.01|dinitrate (r_prep) administration_4\NN\management.n.01|sublingual|of (r_dobj) following_2\VBG\multitude.n.03|administration (r_prep) infarction_1\NN\pathology.n.02|myocardial|following|.
D007548_D009203 CID dinitrate_22\NN\entity.n.01|isosorbide (r_pobj) of_20\IN\entity.n.01|dinitrate (r_prep) administration_19\NN\management.n.01|the|of (r_pobj) following_17\VBG\multitude.n.03|administration (r_prep) suffered_8\VBD\experience.v.01|necrosis|infarction|following|sublingually|. (l_dobj) infarction_12\NN\pathology.n.02|a|recurrent|myocardial|of
D007548_D009336 NONE dinitrate_22\NN\entity.n.01|isosorbide (r_pobj) of_20\IN\entity.n.01|dinitrate (r_prep) administration_19\NN\management.n.01|the|of (r_pobj) following_17\VBG\multitude.n.03|administration (r_prep) suffered_8\VBD\experience.v.01|necrosis|infarction|following|sublingually|. (l_nsubj) necrosis_7\NN\death.n.02|a|old|with|healed|septal
2476560
D001556_D012532 NONE lindane_12\NN\insecticide.n.01|(|hexachloride|)|treatment (r_dobj) consider_11\VBP\think.v.01|initiated|;|most|lindane|. (l_ccomp) initiated_5\VBN\make.v.03|treatment|is|usually|by (l_nsubjpass) treatment_0\NN\care.n.01|for (l_prep) for_1\IN\entity.n.01|scabies (l_pobj) scabies_2\NNS\infection.n.01|
D001556_D012532 NONE hexachloride_16\NN\entity.n.01|gamma|benzene (r_appos) lindane_12\NN\insecticide.n.01|(|hexachloride|)|treatment (r_dobj) consider_11\VBP\think.v.01|initiated|;|most|lindane|. (l_ccomp) initiated_5\VBN\make.v.03|treatment|is|usually|by (l_nsubjpass) treatment_0\NN\care.n.01|for (l_prep) for_1\IN\entity.n.01|scabies (l_pobj) scabies_2\NNS\infection.n.01|
D001556_D002493 CID lindane_4\NN\insecticide.n.01|that (r_dobj) accumulating_2\VBG\store.v.01|evidence|is|lindane (r_csubj) be_6\VB\metallic_element.n.01|accumulating|can|toxic|and|associated|. (l_acomp) toxic_7\JJ\toxic.a.01|to (l_prep) to_8\IN\entity.n.01|system (l_pobj) system_12\NN\instrumentality.n.03|the|central|nervous
D001556_D000741 CID lindane_4\NN\insecticide.n.01|that (r_dobj) accumulating_2\VBG\store.v.01|evidence|is|lindane (r_csubj) be_6\VB\metallic_element.n.01|accumulating|can|toxic|and|associated|. (l_conj) associated_16\VBN\think.v.03|may|be|with (l_prep) with_17\IN\entity.n.01|anaemia (l_pobj) anaemia_19\NN\symptom.n.01|aplastic
10835440
D009553_D020521 NONE nimodipine_3\NN\entity.n.01|intravenous|on (r_pobj) of_1\IN\entity.n.01|nimodipine (r_prep) effect_0\NN\phenomenon.n.01|of|after|. (l_prep) after_9\IN\after.s.01|stroke (l_pobj) stroke_11\NN\maneuver.n.03|acute
D009553_D020521 NONE nimodipine_2\NNP\entity.n.01| (r_compound) trial_6\NN\attempt.n.01|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (l_compound) stroke_5\NNP\maneuver.n.03|
D009553_D020521 NONE nimodipine_2\NNP\entity.n.01| (r_compound) trial_6\NN\attempt.n.01|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (r_nsubj) found_10\VBD\wage.n.01|trial|correlation|. (l_dobj) correlation_12\NN\reciprocality.n.01|a|between (l_prep) between_13\IN\between.r.01|reduction (l_pobj) reduction_17\NN\change_of_magnitude.n.01|induced|in|and|outcome (l_conj) outcome_27\NN\ending.n.04|an|unfavorable|in (l_prep) in_28\IN\linear_unit.n.01|stroke (l_pobj) stroke_30\NN\maneuver.n.03|acute
D009553_D020521 NONE nimodipine_14\NN\entity.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|nimodipine|- (r_amod) reduction_17\NN\change_of_magnitude.n.01|induced|in|and|outcome (r_pobj) between_13\IN\between.r.01|reduction (r_prep) correlation_12\NN\reciprocality.n.01|a|between (r_dobj) found_10\VBD\wage.n.01|trial|correlation|. (l_nsubj) trial_6\NN\attempt.n.01|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (l_compound) stroke_5\NNP\maneuver.n.03|
D009553_D020521 NONE nimodipine_14\NN\entity.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|nimodipine|- (r_amod) reduction_17\NN\change_of_magnitude.n.01|induced|in|and|outcome (l_conj) outcome_27\NN\ending.n.04|an|unfavorable|in (l_prep) in_28\IN\linear_unit.n.01|stroke (l_pobj) stroke_30\NN\maneuver.n.03|acute
D009553_D020521 NONE nimodipine_15\NN\entity.n.01|dose (r_pobj) of_11\IN\entity.n.01|nimodipine (r_prep) administration_10\NN\management.n.01|the|intravenous|of (r_pobj) after_7\IN\after.s.01|administration (r_prep) worsening_6\VBG\decline.n.01|neurological|after|after (l_prep) after_16\IN\after.s.01|stroke (l_pobj) stroke_18\NN\maneuver.n.03|acute
D009553_D007022 CID nimodipine_2\NNP\entity.n.01| (r_compound) trial_6\NN\attempt.n.01|the|intravenous|nimodipine|west|european|stroke|(|inwest|) (r_nsubj) found_10\VBD\wage.n.01|trial|correlation|. (l_dobj) correlation_12\NN\reciprocality.n.01|a|between (l_prep) between_13\IN\between.r.01|reduction (l_pobj) reduction_17\NN\change_of_magnitude.n.01|induced|in|and|outcome (l_prep) in_18\IN\linear_unit.n.01|pressure (l_pobj) pressure_20\NN\physical_phenomenon.n.01|blood|(|bp|)
D009553_D007022 CID nimodipine_14\NN\entity.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|nimodipine|- (r_amod) reduction_17\NN\change_of_magnitude.n.01|induced|in|and|outcome (l_prep) in_18\IN\linear_unit.n.01|pressure (l_pobj) pressure_20\NN\physical_phenomenon.n.01|blood|(|bp|)
D009553_D007022 CID nimodipine_0\NNP\entity.n.01| (r_compound) treatment_1\NN\care.n.01|nimodipine (r_nsubj) resulted_2\VBD\prove.v.01|treatment|in|. (l_prep) in_3\IN\linear_unit.n.01|reduction (l_pobj) reduction_7\NN\change_of_magnitude.n.01|a|significant|in (l_prep) in_8\IN\linear_unit.n.01|bp (l_pobj) bp_10\NNP\entity.n.01|systolic|sbp|and|bp
D009553_D002544 NONE nimodipine_34\NN\entity.n.01|(|dose|)|n=101|or|nimodipine (r_parataxis) h_28\NN\chemical_element.n.01|1|mg|/|nimodipine (r_appos) receive_19\VB\get.v.01|to|placebo|,|h (r_advcl) allocated_17\VBN\assign.v.02|methods|were|consecutively|receive|. (l_nsubjpass) methods_0\NNS\know-how.n.01|:|patients (l_appos) patients_2\NNS\case.n.06|with|(|within|) (l_prep) with_3\IN\entity.n.01|diagnosis (l_pobj) diagnosis_6\NN\designation.n.03|a|clinical|of (l_prep) of_7\IN\entity.n.01|stroke (l_pobj) stroke_9\NN\maneuver.n.03|ischemic
D009553_D002544 NONE nimodipine_49\NN\entity.n.01|h|(|dose|)|n=94 (r_conj) nimodipine_34\NN\entity.n.01|(|dose|)|n=101|or|nimodipine (r_parataxis) h_28\NN\chemical_element.n.01|1|mg|/|nimodipine (r_appos) receive_19\VB\get.v.01|to|placebo|,|h (r_advcl) allocated_17\VBN\assign.v.02|methods|were|consecutively|receive|. (l_nsubjpass) methods_0\NNS\know-how.n.01|:|patients (l_appos) patients_2\NNS\case.n.06|with|(|within|) (l_prep) with_3\IN\entity.n.01|diagnosis (l_pobj) diagnosis_6\NN\designation.n.03|a|clinical|of (l_prep) of_7\IN\entity.n.01|stroke (l_pobj) stroke_9\NN\maneuver.n.03|ischemic
10406016
C007789_D002543 NONE fucoidan_2\JJ\entity.n.01| (r_compound) treatment_3\NN\care.n.01|fucoidan|on (l_prep) on_4\IN\on.a.01|hemorrhage (l_pobj) hemorrhage_9\NN\injury.n.01|induced|intracerebral|in
C007789_D002543 NONE fucoidan_5\RB\entity.n.01|the|sulfated|polysaccharide|,|reported|, (r_dobj) tested_1\VBD\evaluate.v.02|we|fucoidan|in|. (l_prep) in_17\IN\linear_unit.n.01|model (l_pobj) model_20\NN\hypothesis.n.02|a|rat|of|induced (l_prep) of_21\IN\entity.n.01|hemorrhage (l_pobj) hemorrhage_23\NN\injury.n.01|intracerebral
C007789_D001925 NONE fucoidan_5\RB\entity.n.01|the|sulfated|polysaccharide|,|reported|, (l_relcl) reported_10\VBN\inform.v.01|which|has|been|reduce (l_xcomp) reduce_12\VB\decrease.v.02|to|damage (l_dobj) damage_15\NN\change.n.01|inflammatory|brain
C007789_D020141 CID fucoidan_0\NNP\entity.n.01| (r_npadvmod) treated_2\VBN\interact.v.01|fucoidan|- (r_amod) rats_3\NNS\rodent.n.01|treated (r_nsubj) exhibited_4\VBD\possess.v.01|rats|evidence|,|had|. (l_dobj) evidence_5\NN\information.n.02|of (l_prep) of_6\IN\entity.n.01|clotting (l_pobj) clotting_9\NN\natural_process.n.01|impaired|blood|and|hemodilution
C007789_D020141 CID fucoidan_0\NNP\entity.n.01| (r_npadvmod) treated_2\VBN\interact.v.01|fucoidan|- (r_amod) rats_3\NNS\rodent.n.01|treated (r_nsubj) exhibited_4\VBD\possess.v.01|rats|evidence|,|had|. (l_dobj) evidence_5\NN\information.n.02|of (l_prep) of_6\IN\entity.n.01|clotting (l_pobj) clotting_9\NN\natural_process.n.01|impaired|blood|and|hemodilution (l_conj) hemodilution_11\NN\entity.n.01|
C007789_D006406 NONE fucoidan_0\NNP\entity.n.01| (r_npadvmod) treated_2\VBN\interact.v.01|fucoidan|- (r_amod) rats_3\NNS\rodent.n.01|treated (r_nsubj) exhibited_4\VBD\possess.v.01|rats|evidence|,|had|. (l_conj) had_13\VBD\have.v.01|hematomas|,|and|tended (l_dobj) hematomas_15\NNS\intumescence.n.01|larger
C007789_D006406 NONE fucoidan_0\NNP\entity.n.01| (r_npadvmod) treated_2\VBN\interact.v.01|fucoidan|- (r_amod) rats_3\NNS\rodent.n.01|treated (r_nsubj) exhibited_4\VBD\possess.v.01|rats|evidence|,|had|. (l_conj) had_13\VBD\have.v.01|hematomas|,|and|tended (l_conj) tended_18\VBD\be.v.01|have (l_xcomp) have_20\VB\person.n.01|to|inflammation|after (l_dobj) inflammation_22\NN\symptom.n.01|less|in (l_prep) in_23\IN\linear_unit.n.01|vicinity (l_pobj) vicinity_25\NN\section.n.03|the|of (l_prep) of_26\IN\entity.n.01|hematoma (l_pobj) hematoma_28\NN\intumescence.n.01|the
C007789_D007249 NONE fucoidan_0\NNP\entity.n.01| (r_npadvmod) treated_2\VBN\interact.v.01|fucoidan|- (r_amod) rats_3\NNS\rodent.n.01|treated (r_nsubj) exhibited_4\VBD\possess.v.01|rats|evidence|,|had|. (l_conj) had_13\VBD\have.v.01|hematomas|,|and|tended (l_conj) tended_18\VBD\be.v.01|have (l_xcomp) have_20\VB\person.n.01|to|inflammation|after (l_dobj) inflammation_22\NN\symptom.n.01|less|in
19356053
D020123_D011507 CID sirolimus_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|sirolimus (r_prep) administration_5\NN\management.n.01|the|of (r_pobj) following_3\VBG\multitude.n.03|administration|to (r_prep) proteinuria_2\NN\symptom.n.01|significant|following|.
D020123_D011507 CID sirolimus_16\NN\entity.n.01| (r_pobj) of_15\IN\entity.n.01|sirolimus (r_prep) use_14\NN\activity.n.01|the|of (r_pobj) with_12\IN\entity.n.01|use (r_prep) linked_11\VBN\think.v.03|with (r_acl) proteinuria_10\NN\symptom.n.01|significant|linked
D020123_D011507 CID sirolimus_11\NN\entity.n.01| (r_compound) use_12\NN\activity.n.01|sirolimus (r_pobj) with_10\IN\entity.n.01|use (r_prep) associated_9\VBN\think.v.03|with (r_acl) proteinuria_8\NN\symptom.n.01|substantial|associated
D020123_D011507 CID sirolimus_12\NN\entity.n.01| (r_compound) therapy_13\NN\medical_care.n.01|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN\symptom.n.01|
D020123_D011507 CID sirolimus_12\NN\entity.n.01| (r_compound) therapy_13\NN\medical_care.n.01|sirolimus|and|proteinuria (r_pobj) of_11\IN\entity.n.01|therapy (r_prep) commencement_10\NN\point.n.06|the|of (r_pobj) between_8\IN\between.r.01|commencement (r_prep) association_7\NN\organization.n.01|the|close|temporal|between (r_nsubj) implicated_16\VBN\involve.v.01|in|,|association|sirolimus|as|. (l_prep) as_18\IN\chemical_element.n.01|etiology (l_pobj) etiology_22\NN\cause.n.01|the|likely|of (l_prep) of_23\IN\entity.n.01|proteinuria (l_pobj) proteinuria_25\NN\symptom.n.01|the
D020123_D011507 CID sirolimus_17\NN\entity.n.01| (r_dobj) implicated_16\VBN\involve.v.01|in|,|association|sirolimus|as|. (l_nsubj) association_7\NN\organization.n.01|the|close|temporal|between (l_prep) between_8\IN\between.r.01|commencement (l_pobj) commencement_10\NN\point.n.06|the|of (l_prep) of_11\IN\entity.n.01|therapy (l_pobj) therapy_13\NN\medical_care.n.01|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN\symptom.n.01|
D020123_D011507 CID sirolimus_17\NN\entity.n.01| (r_dobj) implicated_16\VBN\involve.v.01|in|,|association|sirolimus|as|. (l_prep) as_18\IN\chemical_element.n.01|etiology (l_pobj) etiology_22\NN\cause.n.01|the|likely|of (l_prep) of_23\IN\entity.n.01|proteinuria (l_pobj) proteinuria_25\NN\symptom.n.01|the
D020123_D011507 CID sirolimus_16\NN\entity.n.01| (r_pobj) of_15\IN\entity.n.01|sirolimus (r_prep) initiation_14\NN\ceremony.n.01|the|of|and|development (l_conj) development_19\NN\improvement.n.02|the|of (l_prep) of_20\IN\entity.n.01|proteinuria (l_pobj) proteinuria_24\NN\symptom.n.01|range
D020123_D011507 CID sirolimus_5\NN\entity.n.01| (r_compound) therapy_6\NN\medical_care.n.01|sirolimus (r_pobj) with_4\IN\entity.n.01|therapy (r_prep) correlated_1\VBD\match.v.01|proteinuria|strongly|with|compared|. (l_nsubj) proteinuria_0\NNP\symptom.n.01|
D020123_D011507 CID sirolimus_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|sirolimus (r_prep) discontinuation_4\NN\termination.n.05|of (r_nsubj) resulted_7\VBD\prove.v.01|in|,|discontinuation|in|,|but|resolution|. (l_conj) resolution_14\NN\document.n.01|not|,|of (l_prep) of_16\IN\entity.n.01|proteinuria (l_pobj) proteinuria_17\NN\symptom.n.01|
D020123_D011507 CID sirolimus_0\NNP\entity.n.01| (r_nsubj) induces_1\VBZ\generate.v.01|sirolimus|or|aggravates|. (l_conj) aggravates_3\VBZ\change.v.01|proteinuria|in (l_dobj) proteinuria_7\NN\symptom.n.01|existing
D020123_D011507 CID sirolimus_10\NN\entity.n.01| (r_nsubjpass) withdrawn_12\VBN\travel.v.01|when|sirolimus|is (r_advcl) resolve_7\VB\trait.n.01|does|not|,|withdrawn (r_conj) improve_2\VB\change.v.01|proteinuria|may|,|but|resolve|. (l_nsubj) proteinuria_0\NNP\symptom.n.01|
D020123_D007674 NONE sirolimus_0\NNP\entity.n.01| (r_nsubj) is_1\VBZ\be.v.01|sirolimus|agent|,|and|have|. (l_conj) have_13\VB\person.n.01|may|nephrotoxicity (l_dobj) nephrotoxicity_15\NN\entity.n.01|less|than
D003404_D011507 NONE creatinine_22\NN\entity.n.01| (r_compound) ratios_23\NNS\magnitude_relation.n.01|creatinine|,|estimate (r_conj) measurement_16\NN\activity.n.01|turbidometric|or|protein|ratios (r_pobj) by_14\IN\by.r.01|measurement (r_agent) assessed_9\VBN\evaluate.v.02|in|,|magnitude|was|on|by|. (l_nsubjpass) magnitude_5\NN\property.n.02|the|of (l_prep) of_6\IN\entity.n.01|proteinuria (l_pobj) proteinuria_7\NN\symptom.n.01|
D003404_D011507 NONE creatinine_22\NN\entity.n.01| (r_compound) ratios_23\NNS\magnitude_relation.n.01|creatinine|,|estimate (l_appos) estimate_26\NN\calculation.n.02|an|of|day (l_prep) of_27\IN\entity.n.01|grams (l_pobj) grams_28\NNS\metric_weight_unit.n.01|of (l_prep) of_29\IN\entity.n.01|proteinuria (l_pobj) proteinuria_30\NN\symptom.n.01|
D020123_D009404 NONE sirolimus_16\NN\entity.n.01| (r_pobj) of_15\IN\entity.n.01|sirolimus (r_prep) initiation_14\NN\ceremony.n.01|the|of|and|development (l_conj) development_19\NN\improvement.n.02|the|of (l_prep) of_20\IN\entity.n.01|proteinuria (l_pobj) proteinuria_24\NN\symptom.n.01|range (l_compound) range_23\NN\extent.n.02|nephrotic|- (l_amod) nephrotic_21\JJ\entity.n.01|
17042910
C065179_D006973 NONE atorvastatin_5\NN\lipid-lowering_medicine.n.01| (r_pobj) of_4\IN\entity.n.01|atorvastatin (r_prep) effects_3\NNS\personal_property.n.01|oxidant|of|in|. (l_prep) in_6\IN\linear_unit.n.01|hypertension (l_pobj) hypertension_10\NN\cardiovascular_disease.n.01|induced|in
C065179_D006973 NONE atorvastatin_0\NNP\lipid-lowering_medicine.n.01|ato|) (r_nsubj) possesses_4\VBZ\police.n.01|atorvastatin|properties|. (l_dobj) properties_6\NNS\possession.n.02|pleiotropic|reported (l_relcl) reported_10\VBN\inform.v.01|that|have|been|improve (l_xcomp) improve_12\VB\change.v.01|to|function|through (l_prep) through_15\IN\done.s.01|availability (l_pobj) availability_17\NN\convenience.n.02|increased|of (l_prep) of_18\IN\entity.n.01|production (l_pobj) production_23\NN\act.n.02|no|reduced|o2-|in (l_prep) in_24\IN\linear_unit.n.01|forms (l_pobj) forms_26\NNS\word.n.01|various|of (l_prep) of_27\IN\entity.n.01|hypertension (l_pobj) hypertension_28\NN\cardiovascular_disease.n.01|
C065179_D006973 NONE ato_2\NNP\entity.n.01|( (r_appos) atorvastatin_0\NNP\lipid-lowering_medicine.n.01|ato|) (r_nsubj) possesses_4\VBZ\police.n.01|atorvastatin|properties|. (l_dobj) properties_6\NNS\possession.n.02|pleiotropic|reported (l_relcl) reported_10\VBN\inform.v.01|that|have|been|improve (l_xcomp) improve_12\VB\change.v.01|to|function|through (l_prep) through_15\IN\done.s.01|availability (l_pobj) availability_17\NN\convenience.n.02|increased|of (l_prep) of_18\IN\entity.n.01|production (l_pobj) production_23\NN\act.n.02|no|reduced|o2-|in (l_prep) in_24\IN\linear_unit.n.01|forms (l_pobj) forms_26\NNS\word.n.01|various|of (l_prep) of_27\IN\entity.n.01|hypertension (l_pobj) hypertension_28\NN\cardiovascular_disease.n.01|
D003907_D006973 CID dexamethasone_7\NN\anti-inflammatory.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|dexamethasone|- (r_amod) hypertension_10\NN\cardiovascular_disease.n.01|induced|in
D003907_D006973 CID dexamethasone_0\NNP\anti-inflammatory.n.01|characterized|production (l_parataxis) characterized_5\VBN\remember.v.02|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\cardiovascular_disease.n.01|dex)-induced
D003907_D006973 CID dex)-induced_2\JJ\entity.n.01| (r_amod) hypertension_3\NN\cardiovascular_disease.n.01|dex)-induced
D009569_D006973 NONE oxide_12\NN\compound.n.02|nitric (r_nmod) deficiency_16\NN\need.n.01|oxide|(|no|) (r_pobj) with_10\IN\entity.n.01|deficiency (r_prep) associated_9\VBN\think.v.03|with (r_acl) dysfunction_8\NN\pathology.n.02|endothelial|associated (r_pobj) by_6\IN\by.r.01|dysfunction (r_agent) characterized_5\VBN\remember.v.02|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\cardiovascular_disease.n.01|dex)-induced
D009569_D006973 NONE no_14\NNP\negative.n.01| (r_intj) deficiency_16\NN\need.n.01|oxide|(|no|) (r_pobj) with_10\IN\entity.n.01|deficiency (r_prep) associated_9\VBN\think.v.03|with (r_acl) dysfunction_8\NN\pathology.n.02|endothelial|associated (r_pobj) by_6\IN\by.r.01|dysfunction (r_agent) characterized_5\VBN\remember.v.02|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\cardiovascular_disease.n.01|dex)-induced
D009569_D006973 NONE no_19\DT\negative.n.01|and (r_amod) production_23\NN\act.n.02|no|reduced|o2-|in (l_prep) in_24\IN\linear_unit.n.01|forms (l_pobj) forms_26\NNS\word.n.01|various|of (l_prep) of_27\IN\entity.n.01|hypertension (l_pobj) hypertension_28\NN\cardiovascular_disease.n.01|
D013481_D006973 NONE superoxide_19\NN\oxide.n.01| (r_advmod) increased_18\VBN\change_magnitude.v.01|superoxide (r_conj) characterized_5\VBN\remember.v.02|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\cardiovascular_disease.n.01|dex)-induced
D013481_D006973 NONE o2-_21\NNPS\entity.n.01| (r_nmod) production_23\NN\act.n.02|(|o2-|)|. (r_appos) dexamethasone_0\NNP\anti-inflammatory.n.01|characterized|production (l_parataxis) characterized_5\VBN\remember.v.02|(|hypertension|is|by|and|increased (l_nsubjpass) hypertension_3\NN\cardiovascular_disease.n.01|dex)-induced
D013481_D006973 NONE o2-_22\JJ\entity.n.01| (r_compound) production_23\NN\act.n.02|no|reduced|o2-|in (l_prep) in_24\IN\linear_unit.n.01|forms (l_pobj) forms_26\NNS\word.n.01|various|of (l_prep) of_27\IN\entity.n.01|hypertension (l_pobj) hypertension_28\NN\cardiovascular_disease.n.01|
17600377
C524754_D003072 NONE coumarate_7\NN\entity.n.01|maltolyl|p|- (r_appos) compound_2\NN\whole.n.01|a|novel|,|coumarate|, (r_nsubj) attenuates_9\VBZ\weaken.v.01|compound|deficits|and|shows|. (l_dobj) deficits_11\NNS\insufficiency.n.03|cognitive
C524754_D003072 NONE coumarate_11\NN\entity.n.01|p|- (r_nsubj) improve_13\VB\change.v.01|whether|coumarate|could|decline (l_dobj) decline_15\NN\decrease.n.02|cognitive|in
C524754_D003072 NONE coumarate_3\NN\entity.n.01|maltolyl|p|- (r_nsubjpass) found_5\VBN\wage.n.01|coumarate|was|attenuate|beta|. (l_xcomp) attenuate_7\VB\weaken.v.01|to|deficits (l_dobj) deficits_9\NNS\insufficiency.n.03|cognitive|in|using|observed
C524754_D003072 NONE coumarate_17\NN\entity.n.01|p|- (r_nsubj) is_18\VBZ\be.v.01|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN\politician.n.02|a|effective|against|characterized (l_relcl) characterized_29\VBN\remember.v.02|that|is|by (l_agent) by_30\IN\by.r.01|death (l_pobj) death_34\NN\change.n.01|spread|neuronal|and|decline (l_conj) decline_37\NN\decrease.n.02|progressive|of (l_prep) of_38\IN\entity.n.01|function (l_pobj) function_40\NN\mathematical_relation.n.01|cognitive
C524754_D003704 NONE coumarate_7\NN\entity.n.01|maltolyl|p|- (r_appos) compound_2\NN\whole.n.01|a|novel|,|coumarate|, (r_nsubj) attenuates_9\VBZ\weaken.v.01|compound|deficits|and|shows|. (l_conj) shows_13\VBZ\entertainment.n.01|effects (l_dobj) effects_15\NNS\personal_property.n.01|neuroprotective|in (l_prep) in_16\IN\linear_unit.n.01|vitro (l_amod) vitro_17\FW\entity.n.01|and|in (l_conj) in_19\IN\linear_unit.n.01|models (l_pobj) models_22\NNS\hypothesis.n.02|dementia (l_compound) dementia_21\NN\insanity.n.01|vivo
D012601_D003072 CID scopolamine_17\NN\alkaloid.n.01| (r_npadvmod) injected_19\VBN\administer.v.04|scopolamine|- (r_amod) rats_20\NNS\rodent.n.01|injected (r_pobj) in_16\IN\linear_unit.n.01|rats|and|in (r_prep) decline_15\NN\decrease.n.02|cognitive|in
C544092_D003072 NONE beta_24\NN\letter.n.02|amyloid (r_pobj) in_22\IN\linear_unit.n.01|beta (r_conj) in_16\IN\linear_unit.n.01|rats|and|in (r_prep) decline_15\NN\decrease.n.02|cognitive|in
C544092_D003072 NONE 42)-infused_34\VBN\entity.n.01|peptide(1|- (r_amod) rats_35\NNS\rodent.n.01|42)-infused (r_dobj) beta_31\NN\letter.n.02|amyloid|rats (r_advcl) found_5\VBN\wage.n.01|coumarate|was|attenuate|beta|. (l_xcomp) attenuate_7\VB\weaken.v.01|to|deficits (l_dobj) deficits_9\NNS\insufficiency.n.03|cognitive|in|using|observed
C524754_D000544 NONE coumarate_17\NN\entity.n.01|p|- (r_nsubj) is_18\VBZ\be.v.01|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN\politician.n.02|a|effective|against|characterized (l_prep) against_23\IN\entity.n.01|disease (l_pobj) disease_26\NN\illness.n.01|alzheimer
C524754_D009410 NONE coumarate_17\NN\entity.n.01|p|- (r_nsubj) is_18\VBZ\be.v.01|that|maltolyl|coumarate|candidate (l_attr) candidate_22\NN\politician.n.02|a|effective|against|characterized (l_relcl) characterized_29\VBN\remember.v.02|that|is|by (l_agent) by_30\IN\by.r.01|death (l_pobj) death_34\NN\change.n.01|spread|neuronal|and|decline
6747681
D002330_D005910 NONE bcnu_3\NNP\entity.n.01| (r_compound) chemotherapy_4\NN\therapy.n.01|arterial|bcnu|for|. (l_prep) for_5\IN\entity.n.01|treatment (l_pobj) treatment_6\NN\care.n.01|of (l_prep) of_7\IN\entity.n.01|gliomas (l_pobj) gliomas_9\NNS\brain_tumor.n.01|malignant|of
D002330_D005910 NONE bcnu_7\NNP\entity.n.01| (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\entity.n.01|bcnu|(|) (r_pobj) of_6\IN\entity.n.01|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_prep) clearance_5\NN\interval.n.03|the|rapid|systemic|of (r_pobj) because_0\IN\entity.n.01|of|clearance (r_prep) provide_17\VB\give.v.03|because|,|administration|should|advantage|. (l_dobj) advantage_20\NN\asset.n.01|a|substantial|over (l_prep) over_21\IN\part.n.09|administration (l_pobj) administration_23\NN\management.n.01|intravenous|for (l_prep) for_24\IN\entity.n.01|treatment (l_pobj) treatment_26\NN\care.n.01|the|of (l_prep) of_27\IN\entity.n.01|gliomas (l_pobj) gliomas_29\NNS\brain_tumor.n.01|malignant
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\entity.n.01|bcnu|(|) (r_pobj) of_6\IN\entity.n.01|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_prep) clearance_5\NN\interval.n.03|the|rapid|systemic|of (r_pobj) because_0\IN\entity.n.01|of|clearance (r_prep) provide_17\VB\give.v.03|because|,|administration|should|advantage|. (l_dobj) advantage_20\NN\asset.n.01|a|substantial|over (l_prep) over_21\IN\part.n.09|administration (l_pobj) administration_23\NN\management.n.01|intravenous|for (l_prep) for_24\IN\entity.n.01|treatment (l_pobj) treatment_26\NN\care.n.01|the|of (l_prep) of_27\IN\entity.n.01|gliomas (l_pobj) gliomas_29\NNS\brain_tumor.n.01|malignant
D002330_D001254 NONE bcnu_29\NNP\entity.n.01| (r_compound) therapy_30\NN\medical_care.n.01|arterial|bcnu (r_pobj) of_25\IN\entity.n.01|therapy (r_prep) courses_24\NNS\education.n.01|eight|of (r_dobj) received_20\VBD\get.v.01|patients|courses|. (l_nsubj) patients_3\NNS\case.n.06|four|with|to (l_prep) to_8\IN\entity.n.01|astrocytomas (l_pobj) astrocytomas_10\NN\entity.n.01|iv|,|failed|,
D000431_D014786 NONE ethanol_11\NN\alcohol.n.02| (r_compound) diluent_12\NN\agent.n.03|the|ethanol (r_pobj) of_9\IN\entity.n.01|diluent (r_prep) concentration_8\NN\property.n.02|the|of (r_nsubjpass) lowered_14\VBN\move.v.02|after|concentration|was (r_advcl) decreased_5\VBD\change_magnitude.v.01|frequency|lowered|. (l_nsubj) frequency_1\NN\rate.n.01|the|of (l_prep) of_2\IN\entity.n.01|loss (l_pobj) loss_4\NN\transferred_property.n.01|visual
4027862
D003891_D003693 CID desipramine_0\NN\tricyclic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|desipramine|- (r_amod) delirium_3\NN\mania.n.02|induced|at|.
D003891_D003693 CID desipramine_7\NNP\tricyclic.n.01| (r_nsubj) developed_8\VBD\create.v.02|patient|desipramine|delirium|was|. (l_dobj) delirium_10\NN\mania.n.02|a
18768591
D004317_D009404 CID doxorubicin_8\NN\antibiotic.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|doxorubicin|- (r_amod) syndrome_12\NN\complex.n.01|induced|nephrotic
D004317_D009404 CID doxorubicin_0\NNP\antibiotic.n.01| (r_compound) treatment_1\NN\care.n.01|doxorubicin (r_nsubj) resulted_2\VBD\prove.v.01|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\entity.n.01|of (l_prep) of_22\IN\entity.n.01|mice (l_pobj) mice_25\NNS\rodent.n.01|sgk1(-/-|)|leading (l_acl) leading_26\VBG\strip.n.02|to (l_prep) to_27\IN\entity.n.01|syndrome (l_pobj) syndrome_30\NN\complex.n.01|severe|nephrotic|with
D004317_D007674 NONE doxorubicin_0\NNP\antibiotic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|doxorubicin|- (r_amod) nephropathy_3\NN\uropathy.n.01|induced
D004317_D016055 NONE doxorubicin_0\NNP\antibiotic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|doxorubicin|- (r_amod) nephropathy_3\NN\uropathy.n.01|induced (r_nsubj) leads_4\VBZ\advantage.n.01|nephropathy|to|. (l_prep) to_5\IN\entity.n.01|channel (l_pobj) channel_8\NN\transmission.n.02|epithelial|sodium|retention (l_appos) retention_12\NN\possession.n.01|(|enac)-dependent|volume|and|fibrosis
D004317_D005355 NONE doxorubicin_0\NNP\antibiotic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|doxorubicin|- (r_amod) nephropathy_3\NN\uropathy.n.01|induced (r_nsubj) leads_4\VBZ\advantage.n.01|nephropathy|to|. (l_prep) to_5\IN\entity.n.01|channel (l_pobj) channel_8\NN\transmission.n.02|epithelial|sodium|retention (l_appos) retention_12\NN\possession.n.01|(|enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_15\NN\pathology.n.02|renal
D012964_D007674 NONE sodium_7\NN\metallic_element.n.01| (r_compound) channel_8\NN\transmission.n.02|epithelial|sodium|retention (r_pobj) to_5\IN\entity.n.01|channel (r_prep) leads_4\VBZ\advantage.n.01|nephropathy|to|. (l_nsubj) nephropathy_3\NN\uropathy.n.01|induced
D012964_D016055 NONE sodium_7\NN\metallic_element.n.01| (r_compound) channel_8\NN\transmission.n.02|epithelial|sodium|retention (l_appos) retention_12\NN\possession.n.01|(|enac)-dependent|volume|and|fibrosis
D012964_D005355 NONE sodium_7\NN\metallic_element.n.01| (r_compound) channel_8\NN\transmission.n.02|epithelial|sodium|retention (l_appos) retention_12\NN\possession.n.01|(|enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_15\NN\pathology.n.02|renal
D000450_D005355 NONE aldosterone_1\NN\mineralocorticoid.n.01| (r_npadvmod) sensitive_3\JJ\psychic.n.01|aldosterone|- (r_amod) sgk1_10\NNP\entity.n.01|the|sensitive|kinase (r_nsubjpass) shown_13\VBN\show.v.04|sgk1|has|been|participate|. (l_xcomp) participate_15\VB\act.v.01|to|in|and|mediate (l_conj) mediate_23\VB\negociate.v.06|to|fibrosis (l_dobj) fibrosis_25\NN\pathology.n.02|renal|following
D004317_D011507 CID doxorubicin_0\NNP\antibiotic.n.01| (r_compound) treatment_1\NN\care.n.01|doxorubicin (r_nsubj) resulted_2\VBD\prove.v.01|treatment|in|)|and|15/44|. (l_prep) in_3\IN\linear_unit.n.01|proteinuria (l_pobj) proteinuria_5\NN\symptom.n.01|heavy|(|crea|)|in
D004317_D001201 CID doxorubicin_0\NNP\antibiotic.n.01| (r_compound) treatment_1\NN\care.n.01|doxorubicin (r_nsubj) resulted_2\VBD\prove.v.01|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\entity.n.01|of (l_prep) of_22\IN\entity.n.01|mice (l_pobj) mice_25\NNS\rodent.n.01|sgk1(-/-|)|leading (l_acl) leading_26\VBG\strip.n.02|to (l_prep) to_27\IN\entity.n.01|syndrome (l_pobj) syndrome_30\NN\complex.n.01|severe|nephrotic|with (l_prep) with_31\IN\entity.n.01|ascites (l_pobj) ascites_32\NNS\pathology.n.02|,|lipidemia
D004317_D006949 CID doxorubicin_0\NNP\antibiotic.n.01| (r_compound) treatment_1\NN\care.n.01|doxorubicin (r_nsubj) resulted_2\VBD\prove.v.01|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\entity.n.01|of (l_prep) of_22\IN\entity.n.01|mice (l_pobj) mice_25\NNS\rodent.n.01|sgk1(-/-|)|leading (l_acl) leading_26\VBG\strip.n.02|to (l_prep) to_27\IN\entity.n.01|syndrome (l_pobj) syndrome_30\NN\complex.n.01|severe|nephrotic|with (l_prep) with_31\IN\entity.n.01|ascites (l_pobj) ascites_32\NNS\pathology.n.02|,|lipidemia (l_conj) lipidemia_34\NN\symptom.n.01|,|and|hypoalbuminemia
D004317_D034141 CID doxorubicin_0\NNP\antibiotic.n.01| (r_compound) treatment_1\NN\care.n.01|doxorubicin (r_nsubj) resulted_2\VBD\prove.v.01|treatment|in|)|and|15/44|. (l_conj) 15/44_21\CD\entity.n.01|of (l_prep) of_22\IN\entity.n.01|mice (l_pobj) mice_25\NNS\rodent.n.01|sgk1(-/-|)|leading (l_acl) leading_26\VBG\strip.n.02|to (l_prep) to_27\IN\entity.n.01|syndrome (l_pobj) syndrome_30\NN\complex.n.01|severe|nephrotic|with (l_prep) with_31\IN\entity.n.01|ascites (l_pobj) ascites_32\NNS\pathology.n.02|,|lipidemia (l_conj) lipidemia_34\NN\symptom.n.01|,|and|hypoalbuminemia (l_conj) hypoalbuminemia_37\VB\entity.n.01|in
D000450_D009404 NONE aldosterone_1\NN\mineralocorticoid.n.01| (r_compound) levels_2\NNS\property.n.02|plasma|aldosterone (r_nsubj) increased_3\VBD\change_magnitude.v.01|levels|in|and|followed|. (l_prep) in_4\IN\linear_unit.n.01|mice (l_pobj) mice_6\NNS\rodent.n.01|nephrotic|of (l_amod) nephrotic_5\JJ\entity.n.01|
D014508_D009404 NONE urea_8\NN\organic_compound.n.01| (r_compound) concentrations_9\NNS\property.n.02|serum|urea (r_nsubj) increased_10\VBD\change_magnitude.v.01|during|,|concentrations|faster|in|than|) (l_prep) during_0\IN\entity.n.01|course (l_pobj) course_2\NN\education.n.01|the|of (l_prep) of_3\IN\entity.n.01|syndrome (l_pobj) syndrome_5\NN\complex.n.01|nephrotic
12584269
D020123_D007674 CID srl_5\NN\entity.n.01| (r_nsubj) seems_6\VBZ\be.v.01|srl|act|,|is|. (r_conj) are_1\VBP\area_unit.n.01|these|nephrotoxic|,|but|seems (l_acomp) nephrotoxic_2\JJ\nephrotoxic.s.01|
D020123_D007674 CID srl_5\NN\entity.n.01| (r_nsubj) seems_6\VBZ\be.v.01|srl|act|,|is|. (l_xcomp) act_8\VB\legal_document.n.01|to|differently|displaying (l_advcl) displaying_10\VBG\show.v.04|effects (l_dobj) effects_14\NNS\personal_property.n.01|only|minor|nephrotoxic (l_amod) nephrotoxic_13\JJ\nephrotoxic.s.01|
D020123_D007674 CID srl_7\NN\entity.n.01| (r_nsubjpass) combined_9\VBN\have.v.02|where|srl|was|with (l_prep) with_10\IN\entity.n.01|indications (l_pobj) indications_14\NNS\communication.n.02|a|calcineurin|inhibitor|of (l_prep) of_15\IN\entity.n.01|effect (l_pobj) effect_19\NN\phenomenon.n.01|a|synergistic|nephrotoxic (l_amod) nephrotoxic_18\JJ\nephrotoxic.s.01|
D020123_D007674 CID srl_11\NNP\entity.n.01| (r_conj) csa_9\NNP\entity.n.01|plus|srl (r_pobj) of_8\IN\entity.n.01|csa (r_prep) effect_7\NN\phenomenon.n.01|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\nephrotoxic.s.01|
D020123_D007674 CID srl_16\NNP\entity.n.01| (r_conj) fk506_14\NNP\entity.n.01|plus|srl (r_nsubjpass) tolerated_19\VBN\permit.v.01|whereas|fk506|was|better (r_advcl) demonstrated_3\VBD\show.v.04|study|effect|,|tolerated|. (l_dobj) effect_7\NN\phenomenon.n.01|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\nephrotoxic.s.01|
D016559_D005355 NONE fk506_1\NNP\entity.n.01|the|plus (r_nmod) combination_4\NN\collection.n.01|fk506|srl (r_nsubj) showed_5\VBD\show.v.04|combination|degree|compared|. (l_dobj) degree_10\NN\property.n.02|only|a|higher|of (l_prep) of_11\IN\entity.n.01|fibrosis (l_pobj) fibrosis_12\NN\pathology.n.02|
D020123_D005355 NONE srl_3\NNP\entity.n.01| (r_compound) combination_4\NN\collection.n.01|fk506|srl (r_nsubj) showed_5\VBD\show.v.04|combination|degree|compared|. (l_dobj) degree_10\NN\property.n.02|only|a|higher|of (l_prep) of_11\IN\entity.n.01|fibrosis (l_pobj) fibrosis_12\NN\pathology.n.02|
D016572_D007674 CID csa_9\NNP\entity.n.01|plus|srl (r_pobj) of_8\IN\entity.n.01|csa (r_prep) effect_7\NN\phenomenon.n.01|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\nephrotoxic.s.01|
D016559_D007674 CID fk506_14\NNP\entity.n.01|plus|srl (r_nsubjpass) tolerated_19\VBN\permit.v.01|whereas|fk506|was|better (r_advcl) demonstrated_3\VBD\show.v.04|study|effect|,|tolerated|. (l_dobj) effect_7\NN\phenomenon.n.01|a|synergistic|nephrotoxic|of (l_amod) nephrotoxic_6\JJ\nephrotoxic.s.01|
8669433
D000082_D007676 NONE acetaminophen_3\NN\analgesic.n.01| (r_pobj) of_2\IN\entity.n.01|acetaminophen (r_prep) use_1\NN\activity.n.01|habitual|of|as|:|comparison|. (l_prep) as_4\IN\chemical_element.n.01|factor (l_pobj) factor_7\NN\cause.n.01|a|risk|for (l_prep) for_8\IN\entity.n.01|failure (l_pobj) failure_11\NN\nonaccomplishment.n.01|chronic|renal
D000082_D007676 NONE acetaminophen_27\NN\analgesic.n.01| (r_pobj) of_26\IN\entity.n.01|acetaminophen (r_prep) use_25\NN\activity.n.01|habitual|of (r_nsubjpass) associated_30\VBN\think.v.03|that|use|is|also|with|,|with (l_prep) with_31\IN\entity.n.01|failure (l_pobj) failure_34\NN\nonaccomplishment.n.01|chronic|renal|and|esrd
D000082_D007676 NONE acetaminophen_27\NN\analgesic.n.01| (r_pobj) of_26\IN\entity.n.01|acetaminophen (r_prep) use_25\NN\activity.n.01|habitual|of (r_nsubjpass) associated_30\VBN\think.v.03|that|use|is|also|with|,|with (l_prep) with_31\IN\entity.n.01|failure (l_pobj) failure_34\NN\nonaccomplishment.n.01|chronic|renal|and|esrd (l_conj) esrd_36\NNP\entity.n.01|
D000082_D007676 NONE acetaminophen_7\RB\analgesic.n.01| (r_conj) phenacetin_5\NN\analgesic.n.01|both|and|acetaminophen (r_nsubj) contribute_9\VB\change.v.01|that|phenacetin|may|to|,|with (l_prep) to_10\IN\entity.n.01|burden (l_pobj) burden_12\NN\concern.n.04|the|of (l_prep) of_13\IN\entity.n.01|esrd (l_pobj) esrd_14\NNP\entity.n.01|
D000082_D007676 NONE acetaminophen_6\NN\analgesic.n.01| (r_pobj) of_5\IN\entity.n.01|acetaminophen (r_prep) use_4\NN\activity.n.01|habitual|of|alone (r_nsubj) increases_8\VBZ\indefinite_quantity.n.01|that|use|risk (l_dobj) risk_10\NN\danger.n.03|the|of (l_prep) of_11\IN\entity.n.01|esrd (l_pobj) esrd_12\NNP\entity.n.01|
D010615_D007676 CID phenacetin_16\NN\analgesic.n.01| (r_pobj) with_15\IN\entity.n.01|phenacetin (r_prep) comparison_14\NN\examination.n.01|a|with (r_appos) use_1\NN\activity.n.01|habitual|of|as|:|comparison|. (l_prep) as_4\IN\chemical_element.n.01|factor (l_pobj) factor_7\NN\cause.n.01|a|risk|for (l_prep) for_8\IN\entity.n.01|failure (l_pobj) failure_11\NN\nonaccomplishment.n.01|chronic|renal
D010615_D007676 CID phenacetin_14\NN\analgesic.n.01| (r_pobj) of_13\IN\entity.n.01|phenacetin (r_prep) use_12\NN\activity.n.01|habitual|of (r_nsubjpass) associated_16\VBN\think.v.03|that|use|is|with|,|with (l_prep) with_17\IN\entity.n.01|development (l_pobj) development_19\NN\improvement.n.02|the|of (l_prep) of_20\IN\entity.n.01|failure (l_pobj) failure_23\NN\nonaccomplishment.n.01|chronic|renal|and|disease
D010615_D007676 CID phenacetin_14\NN\analgesic.n.01| (r_pobj) of_13\IN\entity.n.01|phenacetin (r_prep) use_12\NN\activity.n.01|habitual|of (r_nsubjpass) associated_16\VBN\think.v.03|that|use|is|with|,|with (l_prep) with_17\IN\entity.n.01|development (l_pobj) development_19\NN\improvement.n.02|the|of (l_prep) of_20\IN\entity.n.01|failure (l_pobj) failure_23\NN\nonaccomplishment.n.01|chronic|renal|and|disease (l_conj) disease_29\NN\illness.n.01|stage|renal|(|esrd|)
D010615_D007676 CID phenacetin_14\NN\analgesic.n.01| (r_pobj) of_13\IN\entity.n.01|phenacetin (r_prep) use_12\NN\activity.n.01|habitual|of (r_nsubjpass) associated_16\VBN\think.v.03|that|use|is|with|,|with (l_prep) with_17\IN\entity.n.01|development (l_pobj) development_19\NN\improvement.n.02|the|of (l_prep) of_20\IN\entity.n.01|failure (l_pobj) failure_23\NN\nonaccomplishment.n.01|chronic|renal|and|disease (l_conj) disease_29\NN\illness.n.01|stage|renal|(|esrd|) (l_appos) esrd_31\NNP\entity.n.01|
D010615_D007676 CID phenacetin_5\NN\analgesic.n.01|both|and|acetaminophen (r_nsubj) contribute_9\VB\change.v.01|that|phenacetin|may|to|,|with (l_prep) to_10\IN\entity.n.01|burden (l_pobj) burden_12\NN\concern.n.04|the|of (l_prep) of_13\IN\entity.n.01|esrd (l_pobj) esrd_14\NNP\entity.n.01|
234669
D000628_D014693 CID aminophylline_2\NN\bronchodilator.n.01|on (r_pobj) of_1\IN\entity.n.01|aminophylline (r_prep) effects_0\NNS\personal_property.n.01|of|for|. (l_prep) for_6\IN\entity.n.01|initiating (l_pcomp) initiating_7\VBG\make.v.03|fibrillation|during (l_dobj) fibrillation_9\NN\twitch.n.01|ventricular
D000628_D014693 CID aminophylline_3\NN\bronchodilator.n.01|on (l_prep) on_4\IN\on.a.01|threshold (l_pobj) threshold_8\NN\beginning.n.02|the|fibrillation|during (l_compound) fibrillation_7\NN\twitch.n.01|ventricular
D000628_D014693 CID aminophylline_4\NN\bronchodilator.n.01| (r_pobj) of_3\IN\entity.n.01|aminophylline (r_prep) infusion_2\NN\solution.n.01|the|of (r_pobj) during_0\IN\entity.n.01|infusion (r_prep) reduced_11\VBN\decrease.v.02|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\beginning.n.02|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\twitch.n.01|
D000628_D014693 CID aminophylline_30\NN\bronchodilator.n.01| (r_pobj) of_29\IN\entity.n.01|aminophylline (r_prep) infusion_28\NN\solution.n.01|of (r_nsubj) resulted_31\VBD\prove.v.01|produced|pc02|,|infusion|in|. (l_prep) in_32\IN\linear_unit.n.01|decrease (l_pobj) decrease_36\NN\change.n.01|an|greater|in (l_prep) in_37\IN\linear_unit.n.01|threshold (l_pobj) threshold_40\NN\beginning.n.02|fibrillation|to (l_compound) fibrillation_39\NN\twitch.n.01|ventricular
D000628_D012131 NONE aminophylline_2\NN\bronchodilator.n.01|on (r_pobj) of_1\IN\entity.n.01|aminophylline (r_prep) effects_0\NNS\personal_property.n.01|of|for|. (l_prep) for_6\IN\entity.n.01|initiating (l_pcomp) initiating_7\VBG\make.v.03|fibrillation|during (l_prep) during_10\IN\entity.n.01|failure (l_pobj) failure_12\NN\nonaccomplishment.n.01|respiratory
D000628_D012131 NONE aminophylline_3\NN\bronchodilator.n.01|on (r_pobj) of_2\IN\entity.n.01|aminophylline (r_prep) effects_1\NNS\personal_property.n.01|the|of|and|during (l_conj) during_16\IN\entity.n.01|failure (l_pobj) failure_18\NN\nonaccomplishment.n.01|respiratory
D000628_D012131 NONE aminophylline_30\NN\bronchodilator.n.01| (r_pobj) of_29\IN\entity.n.01|aminophylline (r_prep) infusion_28\NN\solution.n.01|of (r_nsubj) resulted_31\VBD\prove.v.01|produced|pc02|,|infusion|in|. (l_advcl) produced_4\VBN\make.v.03|when|failure|was|by (l_nsubjpass) failure_2\NN\nonaccomplishment.n.01|respiratory
D000628_D012131 NONE aminophylline_24\NN\bronchodilator.n.01|particularly (r_appos) agents_21\NNS\causal_agent.n.01|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB\dramatic_composition.n.01|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB\change.v.01|although|factors|may|to (l_prep) to_9\IN\entity.n.01|incidence (l_pobj) incidence_12\NN\frequency.n.02|the|increased|of (l_prep) of_13\IN\entity.n.01|arrhythmias (l_pobj) arrhythmias_15\NNS\heart_disease.n.01|ventricular|in (l_prep) in_16\IN\linear_unit.n.01|failure (l_pobj) failure_18\NN\nonaccomplishment.n.01|respiratory
D010100_D014693 NONE oxygen_26\NN\chemical_element.n.01|(|po2 (r_pobj) of_25\IN\entity.n.01|oxygen (r_prep) pressures_24\NNS\physical_phenomenon.n.01|ph|of (r_nsubjpass) kept_37\VBN\keep.v.01|when|pressures|were|within (r_advcl) reduced_11\VBN\decrease.v.02|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\beginning.n.02|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\twitch.n.01|
C093415_D014693 NONE po2_28\NNP\entity.n.01|)|and|dioxide (r_appos) oxygen_26\NN\chemical_element.n.01|(|po2 (r_pobj) of_25\IN\entity.n.01|oxygen (r_prep) pressures_24\NNS\physical_phenomenon.n.01|ph|of (r_nsubjpass) kept_37\VBN\keep.v.01|when|pressures|were|within (r_advcl) reduced_11\VBN\decrease.v.02|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\beginning.n.02|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\twitch.n.01|
D002245_D014693 NONE dioxide_32\NN\oxide.n.01|carbon|co2 (r_conj) po2_28\NNP\entity.n.01|)|and|dioxide (r_appos) oxygen_26\NN\chemical_element.n.01|(|po2 (r_pobj) of_25\IN\entity.n.01|oxygen (r_prep) pressures_24\NNS\physical_phenomenon.n.01|ph|of (r_nsubjpass) kept_37\VBN\keep.v.01|when|pressures|were|within (r_advcl) reduced_11\VBN\decrease.v.02|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\beginning.n.02|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\twitch.n.01|
D002245_D014693 NONE co2_34\NNP\dioxide.n.01|(|) (r_appos) dioxide_32\NN\oxide.n.01|carbon|co2 (r_conj) po2_28\NNP\entity.n.01|)|and|dioxide (r_appos) oxygen_26\NN\chemical_element.n.01|(|po2 (r_pobj) of_25\IN\entity.n.01|oxygen (r_prep) pressures_24\NNS\physical_phenomenon.n.01|ph|of (r_nsubjpass) kept_37\VBN\keep.v.01|when|pressures|were|within (r_advcl) reduced_11\VBN\decrease.v.02|during|,|threshold|was|by|kept|. (l_nsubjpass) threshold_9\NN\beginning.n.02|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\twitch.n.01|
D000628_D007040 NONE aminophylline_30\NN\bronchodilator.n.01| (r_pobj) of_29\IN\entity.n.01|aminophylline (r_prep) infusion_28\NN\solution.n.01|of (r_nsubj) resulted_31\VBD\prove.v.01|produced|pc02|,|infusion|in|. (l_advcl) produced_4\VBN\make.v.03|when|failure|was|by (l_agent) by_5\IN\by.r.01|hypoventilation (l_pobj) hypoventilation_6\NN\entity.n.01|(|ph|;
D000628_D001145 NONE aminophylline_24\NN\bronchodilator.n.01|particularly (r_appos) agents_21\NNS\causal_agent.n.01|pharmacologic|,|aminophylline|, (r_nsubj) play_27\VB\dramatic_composition.n.01|that|contribute|,|agents|may|role (l_advcl) contribute_8\VB\change.v.01|although|factors|may|to (l_prep) to_9\IN\entity.n.01|incidence (l_pobj) incidence_12\NN\frequency.n.02|the|increased|of (l_prep) of_13\IN\entity.n.01|arrhythmias (l_pobj) arrhythmias_15\NNS\heart_disease.n.01|ventricular|in
11263551
D016572_D010146 CID cyclosporine-_3\NN\entity.n.01|or (r_nmod) levels_7\NNS\property.n.02|cyclosporine-|trough (r_pobj) of_2\IN\entity.n.01|levels (r_prep) reduction_1\NN\change_of_magnitude.n.01|the|of|and|administration (r_nsubj) led_15\VBD\diode.n.02|reduction|to|. (l_prep) to_16\IN\entity.n.01|relief (l_pobj) relief_17\NN\comfort.n.02|of (l_prep) of_18\IN\entity.n.01|pain (l_pobj) pain_19\NN\symptom.n.01|
D016572_D010146 CID cyclosporine_18\NN\entity.n.01|or|tacrolimus (r_pobj) of_17\IN\entity.n.01|cyclosporine (r_prep) effect_16\NN\phenomenon.n.01|a|rare|side|of (r_attr) is_10\VBZ\be.v.01|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\complex.n.01|the|inhibitor|pain|(|cips|) (l_compound) pain_5\NNP\symptom.n.01|induced
D016559_D010146 CID tacrolimus_5\VB\entity.n.01| (r_compound) trough_6\NN\natural_depression.n.01|tacrolimus (r_compound) levels_7\NNS\property.n.02|cyclosporine-|trough (r_pobj) of_2\IN\entity.n.01|levels (r_prep) reduction_1\NN\change_of_magnitude.n.01|the|of|and|administration (r_nsubj) led_15\VBD\diode.n.02|reduction|to|. (l_prep) to_16\IN\entity.n.01|relief (l_pobj) relief_17\NN\comfort.n.02|of (l_prep) of_18\IN\entity.n.01|pain (l_pobj) pain_19\NN\symptom.n.01|
D016559_D010146 CID tacrolimus_20\NN\entity.n.01| (r_conj) cyclosporine_18\NN\entity.n.01|or|tacrolimus (r_pobj) of_17\IN\entity.n.01|cyclosporine (r_prep) effect_16\NN\phenomenon.n.01|a|rare|side|of (r_attr) is_10\VBZ\be.v.01|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\complex.n.01|the|inhibitor|pain|(|cips|) (l_compound) pain_5\NNP\symptom.n.01|induced
D002118_D010146 NONE calcium_12\NN\metallic_element.n.01| (r_compound) channel_13\NN\transmission.n.02|calcium (r_compound) blockers_14\NNS\football_player.n.01|channel (r_pobj) of_11\IN\entity.n.01|blockers (r_prep) administration_10\NN\management.n.01|the|of (r_conj) reduction_1\NN\change_of_magnitude.n.01|the|of|and|administration (r_nsubj) led_15\VBD\diode.n.02|reduction|to|. (l_prep) to_16\IN\entity.n.01|relief (l_pobj) relief_17\NN\comfort.n.02|of (l_prep) of_18\IN\entity.n.01|pain (l_pobj) pain_19\NN\symptom.n.01|
D016572_-1 NONE cyclosporine_18\NN\entity.n.01|or|tacrolimus (r_pobj) of_17\IN\entity.n.01|cyclosporine (r_prep) effect_16\NN\phenomenon.n.01|a|rare|side|of (r_attr) is_10\VBZ\be.v.01|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\complex.n.01|the|inhibitor|pain|(|cips|) (l_appos) cips_8\NNP\entity.n.01|
D016559_-1 NONE tacrolimus_20\NN\entity.n.01| (r_conj) cyclosporine_18\NN\entity.n.01|or|tacrolimus (r_pobj) of_17\IN\entity.n.01|cyclosporine (r_prep) effect_16\NN\phenomenon.n.01|a|rare|side|of (r_attr) is_10\VBZ\be.v.01|syndrome|effect|and|diagnosed|. (l_nsubj) syndrome_6\NNP\complex.n.01|the|inhibitor|pain|(|cips|) (l_appos) cips_8\NNP\entity.n.01|
6503301
D003606_D006504 CID dacarbazine_6\NN\entity.n.01| (r_compound) therapy_7\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (r_pobj) after_5\IN\after.s.01|therapy (r_prep) disease_4\NN\illness.n.01|occlusive|liver|after|.
D003606_D006504 CID dtic_9\NNP\agency.n.01| (r_appos) therapy_7\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (r_pobj) after_5\IN\after.s.01|therapy (r_prep) disease_4\NN\illness.n.01|occlusive|liver|after|.
D003606_D006504 CID dacarbazine_14\NN\entity.n.01| (r_nmod) therapy_18\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (r_nsubjpass) reported_22\VBN\inform.v.01|case|after|therapy|is|. (l_nsubjpass) case_1\NN\happening.n.01|a|of (l_prep) of_2\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|occlusive|of|with (l_prep) of_7\IN\entity.n.01|liver (l_pobj) liver_9\NN\internal_organ.n.01|the
D003606_D006504 CID dtic_16\NNP\agency.n.01| (r_nmod) therapy_18\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (r_nsubjpass) reported_22\VBN\inform.v.01|case|after|therapy|is|. (l_nsubjpass) case_1\NN\happening.n.01|a|of (l_prep) of_2\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|occlusive|of|with (l_prep) of_7\IN\entity.n.01|liver (l_pobj) liver_9\NN\internal_organ.n.01|the
D003606_D008545 NONE dacarbazine_6\NN\entity.n.01| (r_compound) therapy_7\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (l_prep) for_11\IN\entity.n.01|melanoma (l_pobj) melanoma_12\NN\skin_cancer.n.01|
D003606_D008545 NONE dtic_9\NNP\agency.n.01| (r_appos) therapy_7\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (l_prep) for_11\IN\entity.n.01|melanoma (l_pobj) melanoma_12\NN\skin_cancer.n.01|
D003606_D008545 NONE dacarbazine_14\NN\entity.n.01| (r_nmod) therapy_18\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (l_prep) for_19\IN\entity.n.01|melanoma (l_pobj) melanoma_20\NN\skin_cancer.n.01|
D003606_D008545 NONE dtic_16\NNP\agency.n.01| (r_nmod) therapy_18\NN\medical_care.n.01|dacarbazine|(|dtic|)|for (l_prep) for_19\IN\entity.n.01|melanoma (l_pobj) melanoma_20\NN\skin_cancer.n.01|
15458908
D020849_D010024 NONE raloxifene_4\NNP\entity.n.01| (r_compound) evaluation_5\NNP\judgment.n.02|raloxifene|,|trial|, (r_pobj) of_3\IN\entity.n.01|evaluation (r_prep) outcomes_2\NNPS\ending.n.04|the|multiple|of (r_nsubj) enrolled_17\VBD\register.v.01|outcomes|women|with|. (l_prep) with_21\IN\entity.n.01|osteoporosis (l_pobj) osteoporosis_22\NN\pathology.n.02|
D020849_D054556 CID raloxifene_11\NN\entity.n.01| (r_nsubjpass) associated_13\VBN\think.v.03|:|during|,|raloxifene|was|with|. (l_prep) with_14\IN\entity.n.01|risk (l_pobj) risk_17\NN\danger.n.03|an|increased|for (l_prep) for_18\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_20\NN\occlusion.n.01|venous|(|risk|;|interval
D020849_D054556 CID raloxifene_0\NNP\entity.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|raloxifene|was|with|,|but|was (l_prep) with_3\IN\entity.n.01|risk (l_pobj) risk_6\NN\danger.n.03|an|increased|for (l_prep) for_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous
D020849_D002386 NONE raloxifene_0\NNP\entity.n.01| (r_nsubj) increase_3\VB\indefinite_quantity.n.01|raloxifene|did|not|risk|,|disease|. (l_dobj) risk_4\NN\danger.n.03|for (l_prep) for_5\IN\entity.n.01|cataracts (l_pobj) cataracts_6\NNS\eye_disease.n.01|(|ci|)
D020849_D002386 NONE raloxifene_0\NNP\entity.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\washington.n.02|there|risk|. (l_attr) risk_16\NN\danger.n.03|no|increased|for (l_prep) for_17\IN\entity.n.01|cataracts (l_pobj) cataracts_18\NNS\eye_disease.n.01|,|disease
D020849_D005705 NONE raloxifene_0\NNP\entity.n.01| (r_nsubj) increase_3\VB\indefinite_quantity.n.01|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN\illness.n.01|gallbladder|(|rr|;|ci
D020849_D005705 NONE raloxifene_0\NNP\entity.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\washington.n.02|there|risk|. (l_attr) risk_16\NN\danger.n.03|no|increased|for (l_prep) for_17\IN\entity.n.01|cataracts (l_pobj) cataracts_18\NNS\eye_disease.n.01|,|disease (l_conj) disease_21\NN\illness.n.01|gallbladder|,|hyperplasia
D020849_D004714 NONE raloxifene_0\NNP\entity.n.01| (r_nsubj) increase_3\VB\indefinite_quantity.n.01|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN\illness.n.01|gallbladder|(|rr|;|ci (l_appos) ci_27\NNP\radioactivity_unit.n.01|%|1.3|)|,|hyperplasia (l_appos) hyperplasia_34\NN\dysplasia.n.01|endometrial|(|%
D020849_D004714 NONE raloxifene_0\NNP\entity.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\washington.n.02|there|risk|. (l_attr) risk_16\NN\danger.n.03|no|increased|for (l_prep) for_17\IN\entity.n.01|cataracts (l_pobj) cataracts_18\NNS\eye_disease.n.01|,|disease (l_conj) disease_21\NN\illness.n.01|gallbladder|,|hyperplasia (l_conj) hyperplasia_24\NN\dysplasia.n.01|endometrial|,|or|cancer
D020849_D016889 NONE raloxifene_0\NNP\entity.n.01| (r_nsubj) increase_3\VB\indefinite_quantity.n.01|raloxifene|did|not|risk|,|disease|. (l_dep) disease_20\NN\illness.n.01|gallbladder|(|rr|;|ci (l_appos) ci_27\NNP\radioactivity_unit.n.01|%|1.3|)|,|hyperplasia (l_appos) hyperplasia_34\NN\dysplasia.n.01|endometrial|(|% (l_appos) %_40\NN\entity.n.01|rr|;|95|0.4|,|or|cancer|;|% (l_conj) cancer_49\NN\malignant_tumor.n.01|endometrial|(|rr
D020849_D016889 NONE raloxifene_0\NNP\entity.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|raloxifene|was|with|,|but|was (l_conj) was_13\VBD\washington.n.02|there|risk|. (l_attr) risk_16\NN\danger.n.03|no|increased|for (l_prep) for_17\IN\entity.n.01|cataracts (l_pobj) cataracts_18\NNS\eye_disease.n.01|,|disease (l_conj) disease_21\NN\illness.n.01|gallbladder|,|hyperplasia (l_conj) hyperplasia_24\NN\dysplasia.n.01|endometrial|,|or|cancer (l_conj) cancer_28\NN\malignant_tumor.n.01|endometrial
227508
D003000_D006973 NONE clonidine_17\NN\antihypertensive.n.01|intravenous (r_pobj) by_15\IN\by.r.01|clonidine (r_agent) produced_14\VBN\make.v.03|by (r_acl) pressure_10\NN\physical_phenomenon.n.01|blood|and|rate|produced (r_pobj) in_8\IN\linear_unit.n.01|pressure (r_prep) decrease_7\NN\change.n.01|the|in (r_dobj) rats_5\NNS\rodent.n.01|in|,|hypertensive|decrease|,|inhibited|. (l_amod) hypertensive_4\JJ\patient.n.01|spontaneously
D003000_D006973 NONE clonidine_7\NN\antihypertensive.n.01|10(-8|to (r_preconj) in_0\IN\linear_unit.n.01|membranes|clonidine (l_pobj) membranes_2\NNS\sheet.n.06|brain|from (l_prep) from_3\IN\entity.n.01|rats (l_pobj) rats_6\NNS\rodent.n.01|hypertensive (l_amod) hypertensive_5\JJ\patient.n.01|spontaneously
D003000_D006973 NONE clonidine_42\NN\antihypertensive.n.01| (r_npadvmod) suppressible_44\NN\entity.n.01|clonidine|- (r_amod) binding_45\NN\attraction.n.03|suppressible|of (r_dobj) influence_41\VB\power.n.01|naloxone|did|not|binding|)|. (r_conj) influence_18\VB\power.n.01|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\linear_unit.n.01|membranes|clonidine (l_pobj) membranes_2\NNS\sheet.n.06|brain|from (l_prep) from_3\IN\entity.n.01|rats (l_pobj) rats_6\NNS\rodent.n.01|hypertensive (l_amod) hypertensive_5\JJ\patient.n.01|spontaneously
-1_D006973 NONE nalozone_31\NN\entity.n.01| (r_pobj) by_30\IN\by.r.01|nalozone (r_agent) reversed_29\VBN\change.v.02|by (r_conj) inhibited_27\VBN\control.v.02|micrograms|,|was|or|reversed|,|mg/kg (r_conj) rats_5\NNS\rodent.n.01|in|,|hypertensive|decrease|,|inhibited|. (l_amod) hypertensive_4\JJ\patient.n.01|spontaneously
-1_D006973 NONE 3h]-naloxone_23\CD\entity.n.01|[|(|nm|) (r_pobj) of_21\IN\entity.n.01|3h]-naloxone (r_prep) binding_20\NN\attraction.n.03|stereoselective|of (r_dobj) influence_18\VB\power.n.01|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\linear_unit.n.01|membranes|clonidine (l_pobj) membranes_2\NNS\sheet.n.06|brain|from (l_prep) from_3\IN\entity.n.01|rats (l_pobj) rats_6\NNS\rodent.n.01|hypertensive (l_amod) hypertensive_5\JJ\patient.n.01|spontaneously
-1_D006973 NONE 3h]-dihydroergocryptine_48\CD\entity.n.01|[ (r_nummod) nm_51\NNP\metric_linear_unit.n.01|3h]-dihydroergocryptine|(|1 (r_pobj) of_46\IN\entity.n.01|nm (r_prep) binding_45\NN\attraction.n.03|suppressible|of (r_dobj) influence_41\VB\power.n.01|naloxone|did|not|binding|)|. (r_conj) influence_18\VB\power.n.01|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\linear_unit.n.01|membranes|clonidine (l_pobj) membranes_2\NNS\sheet.n.06|brain|from (l_prep) from_3\IN\entity.n.01|rats (l_pobj) rats_6\NNS\rodent.n.01|hypertensive (l_amod) hypertensive_5\JJ\patient.n.01|spontaneously
D008750_D007022 CID methyldopa_8\NN\antihypertensive.n.01|mg/kg|alpha|- (r_pobj) of_3\IN\entity.n.01|methyldopa (r_prep) effect_2\NN\phenomenon.n.01|the|hypotensive|of (l_amod) hypotensive_1\JJ\patient.n.01|
D009270_D007022 NONE naloxone_14\NN\narcotic_antagonist.n.01| (r_pobj) by_13\IN\by.r.01|naloxone (r_agent) reversed_12\VBN\change.v.02|effect|was|also|partially|by|. (l_nsubjpass) effect_2\NN\phenomenon.n.01|the|hypotensive|of (l_amod) hypotensive_1\JJ\patient.n.01|
D009270_D006973 NONE naloxone_30\NN\narcotic_antagonist.n.01|10(-8|to|, (r_nsubj) influence_41\VB\power.n.01|naloxone|did|not|binding|)|. (r_conj) influence_18\VB\power.n.01|in|,|did|not|binding|,|and|influence (l_prep) in_0\IN\linear_unit.n.01|membranes|clonidine (l_pobj) membranes_2\NNS\sheet.n.06|brain|from (l_prep) from_3\IN\entity.n.01|rats (l_pobj) rats_6\NNS\rodent.n.01|hypertensive (l_amod) hypertensive_5\JJ\patient.n.01|spontaneously
6286738
D002762_D064420 NONE d3_1\NN\entity.n.01|vitamin (r_compound) toxicity_2\NN\definite_quantity.n.01|d3|in|.
D002762_D064420 NONE d3_3\NNP\entity.n.01|vitamin (r_compound) toxicity_4\NN\definite_quantity.n.01|d3
D002762_D064420 NONE d3_3\NNP\entity.n.01|vitamin (r_compound) toxicity_4\NN\definite_quantity.n.01|d3 (r_pobj) of_1\IN\entity.n.01|toxicity (r_prep) signs_0\NNS\clue.n.02|of (r_nsubjpass) observed_7\VBN\spy.v.03|signs|were|not|in (r_ccomp) developed_18\VBN\create.v.02|observed|;|however|,|cows|commonly|signs|died|. (l_dobj) signs_20\NNS\clue.n.02|severe|of (l_prep) of_21\IN\entity.n.01|toxicity (l_pobj) toxicity_24\NN\definite_quantity.n.01|d3|and|cows
D002762_D064420 NONE d3_23\NNP\entity.n.01|vitamin (r_compound) toxicity_24\NN\definite_quantity.n.01|d3|and|cows (r_pobj) of_21\IN\entity.n.01|toxicity (r_prep) signs_20\NNS\clue.n.02|severe|of (r_dobj) developed_18\VBN\create.v.02|observed|;|however|,|cows|commonly|signs|died|. (l_ccomp) observed_7\VBN\spy.v.03|signs|were|not|in (l_nsubjpass) signs_0\NNS\clue.n.02|of (l_prep) of_1\IN\entity.n.01|toxicity (l_pobj) toxicity_4\NN\definite_quantity.n.01|d3
D002762_D064420 NONE d3_23\NNP\entity.n.01|vitamin (r_compound) toxicity_24\NN\definite_quantity.n.01|d3|and|cows
D002762_D064420 NONE d3_7\NN\entity.n.01|vitamin (r_pobj) of_5\IN\entity.n.01|d3 (r_prep) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin
D002762_D064420 NONE d3_22\NNP\entity.n.01|vitamin|prevent (r_pobj) of_20\IN\entity.n.01|d3 (r_prep) doses_19\NNS\medicine.n.02|of (r_pobj) between_18\IN\between.r.01|doses (r_prep) safety_17\NN\condition.n.01|between (r_pobj) of_16\IN\entity.n.01|safety (r_prep) margin_15\NN\boundary.n.02|the|low|of (r_conj) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin
D002762_D064420 NONE d3_38\NNP\entity.n.01|vitamin (r_nsubjpass) used_42\VBN\use.v.01|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD\think.v.03|because|,|we|used|. (l_prep) because_0\IN\entity.n.01|of|toxicity (l_pobj) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin
D002762_D006934 CID d3_5\NNP\entity.n.01|vitamin (r_pobj) of_3\IN\entity.n.01|d3 (r_prep) doses_2\NNS\medicine.n.02|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\think.v.03|doses|were|with|. (l_prep) with_19\IN\entity.n.01|hypercalcemia (l_pobj) hypercalcemia_21\NN\symptom.n.01|prolonged|,|hyperphosphatemia
D002762_D006934 CID d3_15\NNP\entity.n.01|17.5|x|iu|vitamin (r_appos) doses_2\NNS\medicine.n.02|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\think.v.03|doses|were|with|. (l_prep) with_19\IN\entity.n.01|hypercalcemia (l_pobj) hypercalcemia_21\NN\symptom.n.01|prolonged|,|hyperphosphatemia
D002762_D006934 CID d3_30\NNP\entity.n.01|vitamin|and|metabolites (r_pobj) of_28\IN\entity.n.01|d3 (r_prep) increases_27\NNS\indefinite_quantity.n.01|large|of (r_conj) hyperphosphatemia_23\NN\entity.n.01|,|and|increases (r_conj) hypercalcemia_21\NN\symptom.n.01|prolonged|,|hyperphosphatemia
D002762_D054559 CID d3_5\NNP\entity.n.01|vitamin (r_pobj) of_3\IN\entity.n.01|d3 (r_prep) doses_2\NNS\medicine.n.02|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\think.v.03|doses|were|with|. (l_prep) with_19\IN\entity.n.01|hypercalcemia (l_pobj) hypercalcemia_21\NN\symptom.n.01|prolonged|,|hyperphosphatemia (l_conj) hyperphosphatemia_23\NN\entity.n.01|,|and|increases
D002762_D054559 CID d3_15\NNP\entity.n.01|17.5|x|iu|vitamin (r_appos) doses_2\NNS\medicine.n.02|large|parenteral|of|(|d3|) (r_nsubjpass) associated_18\VBN\think.v.03|doses|were|with|. (l_prep) with_19\IN\entity.n.01|hypercalcemia (l_pobj) hypercalcemia_21\NN\symptom.n.01|prolonged|,|hyperphosphatemia (l_conj) hyperphosphatemia_23\NN\entity.n.01|,|and|increases
D002762_D054559 CID d3_30\NNP\entity.n.01|vitamin|and|metabolites (r_pobj) of_28\IN\entity.n.01|d3 (r_prep) increases_27\NNS\indefinite_quantity.n.01|large|of (r_conj) hyperphosphatemia_23\NN\entity.n.01|,|and|increases
D002762_D010319 NONE d3_7\NNP\entity.n.01|vitamin (r_pobj) with_5\IN\entity.n.01|d3 (r_prep) treated_4\VBN\interact.v.01|with (r_acl) cows_3\NNS\bovine.n.01|the|treated (r_pobj) of_1\IN\entity.n.01|cows (r_prep) none_0\NN\hour.n.02|of (r_nsubj) showed_8\VBD\show.v.04|none|signs|during (l_dobj) signs_9\NNS\clue.n.02|of (l_prep) of_10\IN\entity.n.01|fever (l_pobj) fever_12\NN\symptom.n.01|milk
D002762_D010319 NONE d3_7\NNP\entity.n.01|vitamin (r_pobj) with_5\IN\entity.n.01|d3 (r_prep) treated_4\VBN\interact.v.01|with (r_acl) cows_3\NNS\bovine.n.01|the|treated (r_pobj) of_1\IN\entity.n.01|cows (r_prep) none_0\NN\hour.n.02|of (r_nsubj) showed_8\VBD\show.v.04|none|signs|during (r_ccomp) developed_26\VBD\create.v.02|showed|;|however|,|%|signs|during|. (l_dobj) signs_28\NNS\clue.n.02|clinical|of (l_prep) of_29\IN\entity.n.01|fever (l_pobj) fever_31\NN\symptom.n.01|milk
D002762_D010319 NONE d3_7\NN\entity.n.01|vitamin (r_pobj) of_5\IN\entity.n.01|d3 (r_prep) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin (l_conj) margin_15\NN\boundary.n.02|the|low|of (l_prep) of_16\IN\entity.n.01|safety (l_pobj) safety_17\NN\condition.n.01|between (l_prep) between_18\IN\between.r.01|doses (l_pobj) doses_19\NNS\medicine.n.02|of (l_prep) of_20\IN\entity.n.01|d3 (l_pobj) d3_22\NNP\entity.n.01|vitamin|prevent (l_relcl) prevent_24\VBP\prevent.v.01|that|fever (l_dobj) fever_26\NN\symptom.n.01|milk|and|doses|induce
D002762_D010319 NONE d3_7\NN\entity.n.01|vitamin (r_pobj) of_5\IN\entity.n.01|d3 (r_prep) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin (l_conj) margin_15\NN\boundary.n.02|the|low|of (l_prep) of_16\IN\entity.n.01|safety (l_pobj) safety_17\NN\condition.n.01|between (l_prep) between_18\IN\between.r.01|doses (l_pobj) doses_19\NNS\medicine.n.02|of (l_prep) of_20\IN\entity.n.01|d3 (l_pobj) d3_22\NNP\entity.n.01|vitamin|prevent (l_relcl) prevent_24\VBP\prevent.v.01|that|fever (l_dobj) fever_26\NN\symptom.n.01|milk|and|doses|induce (l_relcl) induce_30\VBP\generate.v.01|that|fever (l_dobj) fever_32\NN\symptom.n.01|milk
D002762_D010319 NONE d3_7\NN\entity.n.01|vitamin (r_pobj) of_5\IN\entity.n.01|d3 (r_prep) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin (r_pobj) because_0\IN\entity.n.01|of|toxicity (r_prep) concluded_35\VBD\think.v.03|because|,|we|used|. (l_ccomp) used_42\VBN\use.v.01|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB\prevent.v.01|practically|to|fever (l_dobj) fever_47\NN\symptom.n.01|milk
D002762_D010319 NONE d3_22\NNP\entity.n.01|vitamin|prevent (l_relcl) prevent_24\VBP\prevent.v.01|that|fever (l_dobj) fever_26\NN\symptom.n.01|milk|and|doses|induce
D002762_D010319 NONE d3_22\NNP\entity.n.01|vitamin|prevent (l_relcl) prevent_24\VBP\prevent.v.01|that|fever (l_dobj) fever_26\NN\symptom.n.01|milk|and|doses|induce (l_relcl) induce_30\VBP\generate.v.01|that|fever (l_dobj) fever_32\NN\symptom.n.01|milk
D002762_D010319 NONE d3_22\NNP\entity.n.01|vitamin|prevent (r_pobj) of_20\IN\entity.n.01|d3 (r_prep) doses_19\NNS\medicine.n.02|of (r_pobj) between_18\IN\between.r.01|doses (r_prep) safety_17\NN\condition.n.01|between (r_pobj) of_16\IN\entity.n.01|safety (r_prep) margin_15\NN\boundary.n.02|the|low|of (r_conj) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin (r_pobj) because_0\IN\entity.n.01|of|toxicity (r_prep) concluded_35\VBD\think.v.03|because|,|we|used|. (l_ccomp) used_42\VBN\use.v.01|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB\prevent.v.01|practically|to|fever (l_dobj) fever_47\NN\symptom.n.01|milk
D002762_D010319 NONE d3_38\NNP\entity.n.01|vitamin (r_nsubjpass) used_42\VBN\use.v.01|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD\think.v.03|because|,|we|used|. (l_prep) because_0\IN\entity.n.01|of|toxicity (l_pobj) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin (l_conj) margin_15\NN\boundary.n.02|the|low|of (l_prep) of_16\IN\entity.n.01|safety (l_pobj) safety_17\NN\condition.n.01|between (l_prep) between_18\IN\between.r.01|doses (l_pobj) doses_19\NNS\medicine.n.02|of (l_prep) of_20\IN\entity.n.01|d3 (l_pobj) d3_22\NNP\entity.n.01|vitamin|prevent (l_relcl) prevent_24\VBP\prevent.v.01|that|fever (l_dobj) fever_26\NN\symptom.n.01|milk|and|doses|induce
D002762_D010319 NONE d3_38\NNP\entity.n.01|vitamin (r_nsubjpass) used_42\VBN\use.v.01|that|d3|can|not|be|prevent|injected (r_ccomp) concluded_35\VBD\think.v.03|because|,|we|used|. (l_prep) because_0\IN\entity.n.01|of|toxicity (l_pobj) toxicity_4\NN\definite_quantity.n.01|the|extreme|of|in|and|margin (l_conj) margin_15\NN\boundary.n.02|the|low|of (l_prep) of_16\IN\entity.n.01|safety (l_pobj) safety_17\NN\condition.n.01|between (l_prep) between_18\IN\between.r.01|doses (l_pobj) doses_19\NNS\medicine.n.02|of (l_prep) of_20\IN\entity.n.01|d3 (l_pobj) d3_22\NNP\entity.n.01|vitamin|prevent (l_relcl) prevent_24\VBP\prevent.v.01|that|fever (l_dobj) fever_26\NN\symptom.n.01|milk|and|doses|induce (l_relcl) induce_30\VBP\generate.v.01|that|fever (l_dobj) fever_32\NN\symptom.n.01|milk
D002762_D010319 NONE d3_38\NNP\entity.n.01|vitamin (r_nsubjpass) used_42\VBN\use.v.01|that|d3|can|not|be|prevent|injected (l_xcomp) prevent_45\VB\prevent.v.01|practically|to|fever (l_dobj) fever_47\NN\symptom.n.01|milk
11135224
D017239_D002289 NONE paclitaxel_0\NNP\entity.n.01|,|cisplatin|. (l_conj) cisplatin_2\NN\entity.n.01|,|and|chemotherapy (l_conj) chemotherapy_7\NN\therapy.n.01|combination|within (l_prep) within_8\IN\inside.r.02|approach (l_pobj) approach_12\NN\conceptualization.n.01|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_18\NN\cancer.n.01|metastatic|nonsmall|lung
D017239_D002289 NONE paclitaxel_18\NN\entity.n.01|a|,|cisplatin|combination (r_pobj) of_16\IN\entity.n.01|paclitaxel (r_prep) toxicity_15\NN\definite_quantity.n.01|of (r_conj) rate_12\NN\magnitude_relation.n.01|response|,|and|toxicity (r_conj) feasibility_9\NN\practicability.n.01|the|,|rate (r_dobj) determine_7\VB\determine.v.01|to|feasibility|treat (l_xcomp) treat_26\VB\nutriment.n.01|to|nsclc (l_dobj) nsclc_28\NN\entity.n.01|metastatic
D017239_D002289 NONE paclitaxel_30\NN\entity.n.01| (r_pobj) of_29\IN\entity.n.01|paclitaxel (r_prep) combination_28\NN\collection.n.01|a|of|(|m(2|) (r_pobj) with_26\IN\entity.n.01|combination (r_prep) treated_25\VBN\interact.v.01|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS\case.n.06|five|consecutive|naive|with (l_prep) with_8\IN\entity.n.01|nsclc (l_pobj) nsclc_11\NNP\entity.n.01|iv|and|status
D017239_D002289 NONE paclitaxel_3\NN\entity.n.01|,|cisplatin (r_pobj) of_2\IN\entity.n.01|paclitaxel (r_prep) combination_1\NN\collection.n.01|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN\permit.v.01|combination|is|well|and|shows|. (l_conj) shows_13\VBZ\entertainment.n.01|activity|in (l_prep) in_16\IN\linear_unit.n.01|nsclc (l_pobj) nsclc_18\NNP\entity.n.01|metastatic
D002945_D002289 NONE cisplatin_2\NN\entity.n.01|,|and|chemotherapy (l_conj) chemotherapy_7\NN\therapy.n.01|combination|within (l_prep) within_8\IN\inside.r.02|approach (l_pobj) approach_12\NN\conceptualization.n.01|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_18\NN\cancer.n.01|metastatic|nonsmall|lung
D002945_D002289 NONE cisplatin_0\NN\entity.n.01| (r_npadvmod) based_2\VBN\establish.v.08|cisplatin|- (r_amod) combinations_4\NNS\collection.n.01|based|chemotherapy (r_nsubj) improve_5\VBP\change.v.01|combinations|quality|. (l_dobj) quality_6\NN\attribute.n.02|of|in (l_prep) in_11\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_16\NN\cancer.n.01|advanced|nonsmall|lung|(|nsclc|)
D002945_D002289 NONE cisplatin_0\NN\entity.n.01| (r_npadvmod) based_2\VBN\establish.v.08|cisplatin|- (r_amod) combinations_4\NNS\collection.n.01|based|chemotherapy (r_nsubj) improve_5\VBP\change.v.01|combinations|quality|. (l_dobj) quality_6\NN\attribute.n.02|of|in (l_prep) in_11\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_16\NN\cancer.n.01|advanced|nonsmall|lung|(|nsclc|) (l_appos) nsclc_18\NNP\entity.n.01|
D002945_D002289 NONE cisplatin_20\NN\entity.n.01|,|and (r_conj) paclitaxel_18\NN\entity.n.01|a|,|cisplatin|combination (r_pobj) of_16\IN\entity.n.01|paclitaxel (r_prep) toxicity_15\NN\definite_quantity.n.01|of (r_conj) rate_12\NN\magnitude_relation.n.01|response|,|and|toxicity (r_conj) feasibility_9\NN\practicability.n.01|the|,|rate (r_dobj) determine_7\VB\determine.v.01|to|feasibility|treat (l_xcomp) treat_26\VB\nutriment.n.01|to|nsclc (l_dobj) nsclc_28\NN\entity.n.01|metastatic
D002945_D002289 NONE cisplatin_47\NN\entity.n.01| (r_conj) treated_25\VBN\interact.v.01|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS\case.n.06|five|consecutive|naive|with (l_prep) with_8\IN\entity.n.01|nsclc (l_pobj) nsclc_11\NNP\entity.n.01|iv|and|status
D002945_D002289 NONE cisplatin_5\NN\entity.n.01| (r_conj) paclitaxel_3\NN\entity.n.01|,|cisplatin (r_pobj) of_2\IN\entity.n.01|paclitaxel (r_prep) combination_1\NN\collection.n.01|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN\permit.v.01|combination|is|well|and|shows|. (l_conj) shows_13\VBZ\entertainment.n.01|activity|in (l_prep) in_16\IN\linear_unit.n.01|nsclc (l_pobj) nsclc_18\NNP\entity.n.01|metastatic
C056507_D002289 NONE gemcitabine_5\NN\entity.n.01| (r_compound) combination_6\NN\collection.n.01|gemcitabine (r_compound) chemotherapy_7\NN\therapy.n.01|combination|within (l_prep) within_8\IN\inside.r.02|approach (l_pobj) approach_12\NN\conceptualization.n.01|a|multidisciplinary|therapeutic|in (l_prep) in_13\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_18\NN\cancer.n.01|metastatic|nonsmall|lung
C056507_D002289 NONE gemcitabine_23\NN\entity.n.01| (r_compound) combination_24\NN\collection.n.01|gemcitabine (r_conj) paclitaxel_18\NN\entity.n.01|a|,|cisplatin|combination (r_pobj) of_16\IN\entity.n.01|paclitaxel (r_prep) toxicity_15\NN\definite_quantity.n.01|of (r_conj) rate_12\NN\magnitude_relation.n.01|response|,|and|toxicity (r_conj) feasibility_9\NN\practicability.n.01|the|,|rate (r_dobj) determine_7\VB\determine.v.01|to|feasibility|treat (l_xcomp) treat_26\VB\nutriment.n.01|to|nsclc (l_dobj) nsclc_28\NN\entity.n.01|metastatic
C056507_D002289 NONE gemcitabine_65\NN\entity.n.01|) (r_conj) treated_25\VBN\interact.v.01|patients|were|with|given|)|on|,|cisplatin|)|given|)|on|,|and|gemcitabine|given|. (l_nsubjpass) patients_7\NNS\case.n.06|five|consecutive|naive|with (l_prep) with_8\IN\entity.n.01|nsclc (l_pobj) nsclc_11\NNP\entity.n.01|iv|and|status
C056507_D002289 NONE gemcitabine_8\NN\entity.n.01| (r_conj) combination_1\NN\collection.n.01|the|of|,|and|gemcitabine (r_nsubjpass) tolerated_11\VBN\permit.v.01|combination|is|well|and|shows|. (l_conj) shows_13\VBZ\entertainment.n.01|activity|in (l_prep) in_16\IN\linear_unit.n.01|nsclc (l_pobj) nsclc_18\NNP\entity.n.01|metastatic
D017239_D064420 NONE paclitaxel_18\NN\entity.n.01|a|,|cisplatin|combination (r_pobj) of_16\IN\entity.n.01|paclitaxel (r_prep) toxicity_15\NN\definite_quantity.n.01|of
D002945_D064420 NONE cisplatin_20\NN\entity.n.01|,|and (r_conj) paclitaxel_18\NN\entity.n.01|a|,|cisplatin|combination (r_pobj) of_16\IN\entity.n.01|paclitaxel (r_prep) toxicity_15\NN\definite_quantity.n.01|of
C056507_D064420 NONE gemcitabine_23\NN\entity.n.01| (r_compound) combination_24\NN\collection.n.01|gemcitabine (r_conj) paclitaxel_18\NN\entity.n.01|a|,|cisplatin|combination (r_pobj) of_16\IN\entity.n.01|paclitaxel (r_prep) toxicity_15\NN\definite_quantity.n.01|of
17343925
D012906_D034381 CID smoking_3\NN\breathing.n.01|during|on (r_pobj) of_2\IN\entity.n.01|smoking (r_prep) influence_1\NN\power.n.01|the|of (r_nsubjpass) estimated_13\VBN\calculate.v.01|influence|has|not|been|,|associated|. (l_advcl) associated_20\VBN\think.v.03|although|smoking|has|been|positively|with (l_prep) with_21\IN\entity.n.01|hearing (l_pcomp) hearing_22\VBG\proceeding.n.01|loss (l_dobj) loss_23\NN\transferred_property.n.01|in
D012906_D034381 CID smoking_16\NN\breathing.n.01| (r_nsubjpass) associated_20\VBN\think.v.03|although|smoking|has|been|positively|with (l_prep) with_21\IN\entity.n.01|hearing (l_pcomp) hearing_22\VBG\proceeding.n.01|loss (l_dobj) loss_23\NN\transferred_property.n.01|in
6518066
D008094_D004437 CID lithium_1\NN\metallic_element.n.01|maternal|and|anomaly|. (l_conj) anomaly_6\NN\abnormality.n.01|ebstein|:|evaluation
D008094_D006331 NONE lithium_9\NN\metallic_element.n.01| (r_pobj) to_8\IN\entity.n.01|lithium (r_prep) exposed_7\VBN\subject.v.01|screening|to|during (r_csubj) provide_13\VB\give.v.03|exposed|can|assessment|. (l_dobj) assessment_18\NN\classification.n.03|accurate|,|noninvasive|of (l_prep) of_19\IN\entity.n.01|presence (l_pobj) presence_21\NN\being.n.01|the|or|absence|of (l_prep) of_24\IN\entity.n.01|malformations (l_pobj) malformations_29\NNS\affliction.n.02|induced|cardiac
D008094_D006331 NONE lithium_25\NN\metallic_element.n.01| (r_npadvmod) induced_27\VBN\generate.v.01|lithium|- (r_amod) malformations_29\NNS\affliction.n.02|induced|cardiac
18442015
D014700_D006471 NONE verapamil_3\NN\calcium_blocker.n.01| (r_pobj) of_2\IN\entity.n.01|verapamil (r_prep) effect_1\NN\phenomenon.n.01|protective|of|on|. (l_prep) on_4\IN\on.a.01|ulcers (l_pobj) ulcers_7\NNS\lesion.n.01|gastric|hemorrhagic|in (l_amod) hemorrhagic_6\JJ\hemorrhagic.a.01|
D014700_D006471 NONE verapamil_15\NN\calcium_blocker.n.01|daily|intragastric (r_pobj) by_12\IN\by.r.01|verapamil (r_agent) ameliorated_11\VBN\change.v.01|dependently|by (r_acomp) were_7\VBD\be.v.01|ulcer|ameliorated|. (l_nsubj) ulcer_2\NN\lesion.n.01|this|hemorrhagic|and|parameters (l_amod) hemorrhagic_1\JJ\hemorrhagic.a.01|
D014700_D006471 NONE verapamil_28\NN\calcium_blocker.n.01| (r_pobj) by_27\IN\by.r.01|verapamil (r_agent) ameliorated_26\VBN\change.v.01|that|could|be|by|in (r_relcl) generation_16\NN\people.n.01|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\food.n.02|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\lesion.n.01|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\hemorrhagic.a.01|
D014700_D014456 NONE verapamil_3\NN\calcium_blocker.n.01| (r_pobj) of_2\IN\entity.n.01|verapamil (r_prep) effect_1\NN\phenomenon.n.01|protective|of|on|. (l_prep) on_4\IN\on.a.01|ulcers (l_pobj) ulcers_7\NNS\lesion.n.01|gastric|hemorrhagic|in
D014700_D014456 NONE verapamil_6\NN\calcium_blocker.n.01| (r_pobj) of_5\IN\entity.n.01|verapamil (r_prep) effect_4\NN\phenomenon.n.01|the|protective|of|on (l_prep) on_7\IN\on.a.01|model (l_pobj) model_10\NN\hypothesis.n.02|this|ulcer (l_compound) ulcer_9\NN\lesion.n.01|
D014700_D014456 NONE verapamil_15\NN\calcium_blocker.n.01|daily|intragastric (r_pobj) by_12\IN\by.r.01|verapamil (r_agent) ameliorated_11\VBN\change.v.01|dependently|by (r_acomp) were_7\VBD\be.v.01|ulcer|ameliorated|. (l_nsubj) ulcer_2\NN\lesion.n.01|this|hemorrhagic|and|parameters
D014700_D014456 NONE verapamil_28\NN\calcium_blocker.n.01| (r_pobj) by_27\IN\by.r.01|verapamil (r_agent) ameliorated_26\VBN\change.v.01|that|could|be|by|in (r_relcl) generation_16\NN\people.n.01|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\food.n.02|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\lesion.n.01|gastric|hemorrhagic
D014700_D050197 NONE verapamil_3\NN\calcium_blocker.n.01| (r_pobj) of_2\IN\entity.n.01|verapamil (r_prep) effect_1\NN\phenomenon.n.01|protective|of|on|. (l_prep) on_4\IN\on.a.01|ulcers (l_pobj) ulcers_7\NNS\lesion.n.01|gastric|hemorrhagic|in (l_prep) in_8\IN\linear_unit.n.01|rats (l_pobj) rats_11\NNS\rodent.n.01|severe|atherosclerotic (l_amod) atherosclerotic_10\JJ\atherosclerotic.a.01|
D014700_D050197 NONE verapamil_28\NN\calcium_blocker.n.01| (r_pobj) by_27\IN\by.r.01|verapamil (r_agent) ameliorated_26\VBN\change.v.01|that|could|be|by|in (r_relcl) generation_16\NN\people.n.01|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\food.n.02|atherosclerosis|could|ulcer|via (l_nsubj) atherosclerosis_0\NN\arteriosclerosis.n.01|
D006632_D006471 NONE histamine_19\NN\amine.n.01|cell (r_compound) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in
D006632_D006471 NONE histamine_6\NN\amine.n.01| (r_pobj) of_5\IN\entity.n.01|histamine (r_prep) correlation_4\NN\reciprocality.n.01|a|positive|of|to (l_prep) to_7\IN\entity.n.01|hemorrhage|and|to (l_pobj) hemorrhage_9\NN\injury.n.01|gastric
D006632_D006471 NONE histamine_18\NN\amine.n.01| (r_compound) release_19\NN\merchandise.n.01|histamine|and|permeability (r_conj) generation_16\NN\people.n.01|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\food.n.02|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\lesion.n.01|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\hemorrhagic.a.01|
D006632_D014456 NONE histamine_19\NN\amine.n.01|cell (r_compound) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in (l_conj) ulcer_37\NN\lesion.n.01|
D006632_D014456 NONE histamine_10\NN\amine.n.01| (r_compound) concentration_11\NN\property.n.02|histamine|,|permeability (l_conj) permeability_14\NN\porosity.n.01|microvascular|,|content (l_conj) content_18\NN\collection.n.01|luminal|hemoglobin|and|areas (l_conj) areas_21\NNS\region.n.03|ulcer (l_compound) ulcer_20\NN\lesion.n.01|
D006632_D014456 NONE histamine_16\NN\amine.n.01| (r_compound) release_17\NN\merchandise.n.01|histamine|,|generation (r_conj) diffusion_14\NN\natural_process.n.01|gastric|acid|back|-|,|release (r_pobj) including_9\VBG\include.v.01|diffusion (r_prep) factors_7\NNS\cause.n.01|increased|ulcerogenic|,|including (r_pobj) with_4\IN\entity.n.01|factors (r_prep) accompanied_3\VBN\attach_to.v.01|ulcers|with (l_nsubj) ulcers_2\NNS\lesion.n.01|severe|gastric
D006632_D014456 NONE histamine_6\NN\amine.n.01| (r_pobj) of_5\IN\entity.n.01|histamine (r_prep) correlation_4\NN\reciprocality.n.01|a|positive|of|to (l_prep) to_7\IN\entity.n.01|hemorrhage|and|to (l_conj) to_11\IN\entity.n.01|ulcer (l_pobj) ulcer_12\NN\lesion.n.01|
D006632_D014456 NONE histamine_18\NN\amine.n.01| (r_compound) release_19\NN\merchandise.n.01|histamine|and|permeability (r_conj) generation_16\NN\people.n.01|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\food.n.02|atherosclerosis|could|ulcer|via (l_dobj) ulcer_5\NN\lesion.n.01|gastric|hemorrhagic
D006632_D050197 NONE histamine_19\NN\amine.n.01|cell (r_compound) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in (l_prep) in_38\IN\linear_unit.n.01|rats (l_pobj) rats_39\NNS\rodent.n.01|with (l_prep) with_40\IN\entity.n.01|atherosclerosis (l_pobj) atherosclerosis_41\NN\arteriosclerosis.n.01|
D006632_D050197 NONE histamine_6\NN\amine.n.01| (r_pobj) of_5\IN\entity.n.01|histamine (r_prep) correlation_4\NN\reciprocality.n.01|a|positive|of|to (r_nsubjpass) found_14\VBN\wage.n.01|moreover|,|correlation|was|in|. (l_prep) in_15\IN\linear_unit.n.01|rats (l_pobj) rats_18\NNS\rodent.n.01|those|atherosclerotic (l_amod) atherosclerotic_17\JJ\atherosclerotic.a.01|
D006632_D050197 NONE histamine_18\NN\amine.n.01| (r_compound) release_19\NN\merchandise.n.01|histamine|and|permeability (r_conj) generation_16\NN\people.n.01|produce|,|lpo|,|release|ameliorated|. (l_ccomp) produce_2\VB\food.n.02|atherosclerosis|could|ulcer|via (l_nsubj) atherosclerosis_0\NN\arteriosclerosis.n.01|
D004872_D006471 CID d2_47\NN\entity.n.01|vitamin|and|cholesterol (r_pobj) of_45\IN\entity.n.01|d2 (r_prep) coadministration_44\NN\entity.n.01|of (r_pobj) by_43\IN\by.r.01|coadministration (r_prep) induced_42\VBN\generate.v.01|,|release|by (l_nsubj) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in
D004872_D014456 CID d2_47\NN\entity.n.01|vitamin|and|cholesterol (r_pobj) of_45\IN\entity.n.01|d2 (r_prep) coadministration_44\NN\entity.n.01|of (r_pobj) by_43\IN\by.r.01|coadministration (r_prep) induced_42\VBN\generate.v.01|,|release|by (l_nsubj) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in (l_conj) ulcer_37\NN\lesion.n.01|
D004872_D050197 CID d2_47\NN\entity.n.01|vitamin|and|cholesterol (r_pobj) of_45\IN\entity.n.01|d2 (r_prep) coadministration_44\NN\entity.n.01|of (r_pobj) by_43\IN\by.r.01|coadministration (r_prep) induced_42\VBN\generate.v.01|,|release|by (l_nsubj) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in (l_prep) in_38\IN\linear_unit.n.01|rats (l_pobj) rats_39\NNS\rodent.n.01|with (l_prep) with_40\IN\entity.n.01|atherosclerosis (l_pobj) atherosclerosis_41\NN\arteriosclerosis.n.01|
D004872_D050197 CID d2_21\NN\entity.n.01|vitamin|and|cholesterol (r_dobj) containing_19\VBG\include.v.01|kg|d2|induce (l_advcl) induce_25\VB\generate.v.01|to|atherosclerosis (l_dobj) atherosclerosis_26\NN\arteriosclerosis.n.01|
D002784_D006471 CID cholesterol_49\NN\sterol.n.01| (r_conj) d2_47\NN\entity.n.01|vitamin|and|cholesterol (r_pobj) of_45\IN\entity.n.01|d2 (r_prep) coadministration_44\NN\entity.n.01|of (r_pobj) by_43\IN\by.r.01|coadministration (r_prep) induced_42\VBN\generate.v.01|,|release|by (l_nsubj) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in
D002784_D014456 CID cholesterol_49\NN\sterol.n.01| (r_conj) d2_47\NN\entity.n.01|vitamin|and|cholesterol (r_pobj) of_45\IN\entity.n.01|d2 (r_prep) coadministration_44\NN\entity.n.01|of (r_pobj) by_43\IN\by.r.01|coadministration (r_prep) induced_42\VBN\generate.v.01|,|release|by (l_nsubj) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in (l_conj) ulcer_37\NN\lesion.n.01|
D002784_D050197 CID cholesterol_49\NN\sterol.n.01| (r_conj) d2_47\NN\entity.n.01|vitamin|and|cholesterol (r_pobj) of_45\IN\entity.n.01|d2 (r_prep) coadministration_44\NN\entity.n.01|of (r_pobj) by_43\IN\by.r.01|coadministration (r_prep) induced_42\VBN\generate.v.01|,|release|by (l_nsubj) release_20\NN\merchandise.n.01|mast|histamine|,|peroxide (l_conj) peroxide_23\NN\oxidant.n.01|lipid|permeability (l_appos) permeability_31\NN\porosity.n.01|generation|microvascular|in (l_prep) in_32\IN\linear_unit.n.01|modulating (l_pcomp) modulating_33\VBG\play.v.06|hemorrhage (l_dobj) hemorrhage_35\NN\injury.n.01|gastric|and|ulcer|in (l_prep) in_38\IN\linear_unit.n.01|rats (l_pobj) rats_39\NNS\rodent.n.01|with (l_prep) with_40\IN\entity.n.01|atherosclerosis (l_pobj) atherosclerosis_41\NN\arteriosclerosis.n.01|
D002784_D050197 CID cholesterol_23\NN\sterol.n.01| (r_conj) d2_21\NN\entity.n.01|vitamin|and|cholesterol (r_dobj) containing_19\VBG\include.v.01|kg|d2|induce (l_advcl) induce_25\VB\generate.v.01|to|atherosclerosis (l_dobj) atherosclerosis_26\NN\arteriosclerosis.n.01|
D002784_D050197 CID cholesterol_10\NN\sterol.n.01|total|and|concentration (r_conj) calcium_7\NN\metallic_element.n.01|serum|,|cholesterol (r_pobj) as_5\IN\chemical_element.n.01|such|calcium (r_prep) parameters_2\NNS\constant.n.01|elevated|atherosclerotic|,|as (l_amod) atherosclerotic_1\JJ\atherosclerotic.a.01|
D002784_D050197 CID cholesterol_10\NN\sterol.n.01|total|and|concentration (r_conj) calcium_7\NN\metallic_element.n.01|serum|,|cholesterol (r_pobj) as_5\IN\chemical_element.n.01|such|calcium (r_prep) parameters_2\NNS\constant.n.01|elevated|atherosclerotic|,|as (r_nsubjpass) obtained_18\VBN\get.v.01|parameters|were|in|. (l_prep) in_19\IN\linear_unit.n.01|rats (l_pobj) rats_21\NNS\rodent.n.01|atherosclerotic (l_amod) atherosclerotic_20\JJ\atherosclerotic.a.01|
D010634_D014456 NONE luminal_16\JJ\barbiturate.n.01| (r_amod) content_18\NN\collection.n.01|luminal|hemoglobin|and|areas (l_conj) areas_21\NNS\region.n.03|ulcer (l_compound) ulcer_20\NN\lesion.n.01|
D010634_D014456 NONE luminal_22\JJ\barbiturate.n.01| (r_amod) content_24\NN\collection.n.01|luminal|hemoglobin (r_conj) generation_20\NN\people.n.01|lpo|and|content (r_conj) release_17\NN\merchandise.n.01|histamine|,|generation (r_conj) diffusion_14\NN\natural_process.n.01|gastric|acid|back|-|,|release (r_pobj) including_9\VBG\include.v.01|diffusion (r_prep) factors_7\NNS\cause.n.01|increased|ulcerogenic|,|including (r_pobj) with_4\IN\entity.n.01|factors (r_prep) accompanied_3\VBN\attach_to.v.01|ulcers|with (l_nsubj) ulcers_2\NNS\lesion.n.01|severe|gastric
D002118_D050197 NONE calcium_7\NN\metallic_element.n.01|serum|,|cholesterol (r_pobj) as_5\IN\chemical_element.n.01|such|calcium (r_prep) parameters_2\NNS\constant.n.01|elevated|atherosclerotic|,|as (l_amod) atherosclerotic_1\JJ\atherosclerotic.a.01|
D002118_D050197 NONE calcium_7\NN\metallic_element.n.01|serum|,|cholesterol (r_pobj) as_5\IN\chemical_element.n.01|such|calcium (r_prep) parameters_2\NNS\constant.n.01|elevated|atherosclerotic|,|as (r_nsubjpass) obtained_18\VBN\get.v.01|parameters|were|in|. (l_prep) in_19\IN\linear_unit.n.01|rats (l_pobj) rats_21\NNS\rodent.n.01|atherosclerotic (l_amod) atherosclerotic_20\JJ\atherosclerotic.a.01|
17931375
D006493_D003288 CID heparin_10\JJ\anticoagulant.n.01| (r_compound) injection_11\NN\insertion.n.02|subcutaneous|heparin|on (l_prep) on_12\IN\on.a.01|bruising (l_pobj) bruising_13\VBG\injure.v.01|and|pain
D006493_D003288 CID heparin_24\NN\anticoagulant.n.01| (r_pobj) of_23\IN\entity.n.01|heparin (r_prep) injection_22\NN\insertion.n.02|the|subcutaneous|of (r_pobj) of_19\IN\entity.n.01|injection (r_prep) administration_18\NN\management.n.01|the|of (r_pobj) following_16\VBG\multitude.n.03|administration (r_prep) effect_8\NN\phenomenon.n.01|the|of|following (l_prep) of_9\IN\entity.n.01|duration (l_pobj) duration_11\NN\time_period.n.01|injection|on (l_prep) on_12\IN\on.a.01|bruising (l_pobj) bruising_13\VBG\injure.v.01|and|pain
D006493_D003288 CID heparin_13\NN\anticoagulant.n.01| (r_pobj) of_12\IN\entity.n.01|heparin (r_prep) injection_11\NN\insertion.n.02|the|subcutaneous|of (r_pobj) following_8\VBG\multitude.n.03|injection (r_prep) prevent_4\VB\prevent.v.01|to|bruising|following (l_dobj) bruising_5\NN\injure.v.01|and|pain
D006493_D003288 CID heparin_13\NN\anticoagulant.n.01| (r_pobj) of_12\IN\entity.n.01|heparin (r_prep) injection_11\NN\insertion.n.02|the|subcutaneous|of (r_pobj) following_8\VBG\multitude.n.03|injection (r_prep) prevent_4\VB\prevent.v.01|to|bruising|following (r_acl) methods_2\NNS\know-how.n.01|different|prevent (r_nsubjpass) studied_17\VBN\analyze.v.01|although|methods|have|been|widely|and|described (r_advcl) documented_35\JJ\record.v.01|studied|,|effect|is|little|. (l_nsubjpass) effect_22\NN\phenomenon.n.01|the|of (l_prep) of_23\IN\entity.n.01|duration (l_pobj) duration_25\NN\time_period.n.01|injection|on (l_prep) on_26\IN\on.a.01|occurrence (l_pobj) occurrence_28\NN\event.n.01|the|of (l_prep) of_29\IN\entity.n.01|bruising (l_pobj) bruising_30\VBG\injure.v.01|and|pain
D006493_D003288 CID heparin_6\NN\anticoagulant.n.01|the (r_pobj) on_4\IN\on.a.01|heparin|areas (r_prep) bruising_3\NN\injure.v.01|the|on
D006493_D003288 CID heparin_18\NN\anticoagulant.n.01| (r_pobj) of_17\IN\entity.n.01|heparin (r_prep) administration_16\NN\management.n.01|the|subcutaneous|of (r_pobj) following_13\VBG\multitude.n.03|administration (r_prep) had_6\VBD\have.v.01|that|duration|effect|following (l_dobj) effect_8\NN\phenomenon.n.01|an|on (l_prep) on_9\IN\on.a.01|bruising (l_pobj) bruising_10\VBG\injure.v.01|and|pain
D006493_D010146 CID heparin_10\JJ\anticoagulant.n.01| (r_compound) injection_11\NN\insertion.n.02|subcutaneous|heparin|on (l_prep) on_12\IN\on.a.01|bruising (l_pobj) bruising_13\VBG\injure.v.01|and|pain (l_conj) pain_15\NN\symptom.n.01|
D006493_D010146 CID heparin_24\NN\anticoagulant.n.01| (r_pobj) of_23\IN\entity.n.01|heparin (r_prep) injection_22\NN\insertion.n.02|the|subcutaneous|of (r_pobj) of_19\IN\entity.n.01|injection (r_prep) administration_18\NN\management.n.01|the|of (r_pobj) following_16\VBG\multitude.n.03|administration (r_prep) effect_8\NN\phenomenon.n.01|the|of|following (l_prep) of_9\IN\entity.n.01|duration (l_pobj) duration_11\NN\time_period.n.01|injection|on (l_prep) on_12\IN\on.a.01|bruising (l_pobj) bruising_13\VBG\injure.v.01|and|pain (l_conj) pain_15\NN\symptom.n.01|
D006493_D010146 CID heparin_13\NN\anticoagulant.n.01| (r_pobj) of_12\IN\entity.n.01|heparin (r_prep) injection_11\NN\insertion.n.02|the|subcutaneous|of (r_pobj) following_8\VBG\multitude.n.03|injection (r_prep) prevent_4\VB\prevent.v.01|to|bruising|following (l_dobj) bruising_5\NN\injure.v.01|and|pain (l_conj) pain_7\NN\symptom.n.01|
D006493_D010146 CID heparin_13\NN\anticoagulant.n.01| (r_pobj) of_12\IN\entity.n.01|heparin (r_prep) injection_11\NN\insertion.n.02|the|subcutaneous|of (r_pobj) following_8\VBG\multitude.n.03|injection (r_prep) prevent_4\VB\prevent.v.01|to|bruising|following (r_acl) methods_2\NNS\know-how.n.01|different|prevent (r_nsubjpass) studied_17\VBN\analyze.v.01|although|methods|have|been|widely|and|described (r_advcl) documented_35\JJ\record.v.01|studied|,|effect|is|little|. (l_nsubjpass) effect_22\NN\phenomenon.n.01|the|of (l_prep) of_23\IN\entity.n.01|duration (l_pobj) duration_25\NN\time_period.n.01|injection|on (l_prep) on_26\IN\on.a.01|occurrence (l_pobj) occurrence_28\NN\event.n.01|the|of (l_prep) of_29\IN\entity.n.01|bruising (l_pobj) bruising_30\VBG\injure.v.01|and|pain (l_conj) pain_32\NN\symptom.n.01|
D006493_D010146 CID heparin_18\NN\anticoagulant.n.01| (r_pobj) of_17\IN\entity.n.01|heparin (r_prep) administration_16\NN\management.n.01|the|subcutaneous|of (r_pobj) following_13\VBG\multitude.n.03|administration (r_prep) had_6\VBD\have.v.01|that|duration|effect|following (l_dobj) effect_8\NN\phenomenon.n.01|an|on (l_prep) on_9\IN\on.a.01|bruising (l_pobj) bruising_10\VBG\injure.v.01|and|pain (l_conj) pain_12\NN\symptom.n.01|
12907309
C121465_D020258 NONE mpep_3\NNP\entity.n.01| (r_pobj) of_2\IN\entity.n.01|mpep (r_prep) action_1\NN\act.n.02|neuroprotective|of|,|antagonist|,|in (l_prep) in_10\IN\linear_unit.n.01|neurotoxicity (l_pobj) neurotoxicity_15\NN\entity.n.01|induced|dopaminergic
C121465_D005334 NONE mpep_3\NNP\entity.n.01| (r_pobj) of_2\IN\entity.n.01|mpep (r_prep) action_1\NN\act.n.02|neuroprotective|of|,|antagonist|,|in (r_nsubjpass) associated_17\VBN\think.v.03|action|is|with|. (l_prep) with_18\IN\entity.n.01|decrease (l_pobj) decrease_20\NN\change.n.01|a|in (l_prep) in_21\IN\linear_unit.n.01|outflow (l_pobj) outflow_23\NN\discharge.n.06|dopamine|and|inhibition|in (l_conj) inhibition_25\NN\abstinence.n.02|of (l_prep) of_26\IN\entity.n.01|hyperthermia (l_pobj) hyperthermia_27\NN\physical_condition.n.01|
C121465_D005334 NONE mpep_3\NNP\entity.n.01| (r_pobj) by_2\IN\by.r.01|mpep (r_agent) rendered_1\VBN\make.v.02|by (r_acl) neuroprotection_0\NNP\entity.n.01|rendered (r_nsubjpass) associated_6\VBN\think.v.03|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN\entity.n.01|decrease (l_pobj) decrease_31\NN\change.n.01|a|in (l_prep) in_32\IN\linear_unit.n.01|hyperthermia (l_pobj) hyperthermia_33\NN\physical_condition.n.01|
D008694_D020258 NONE methamphetamine_11\NN\amphetamine.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|methamphetamine|- (r_amod) neurotoxicity_15\NN\entity.n.01|induced|dopaminergic
D008694_D005334 CID methamphetamine_11\NN\amphetamine.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|methamphetamine|- (r_amod) neurotoxicity_15\NN\entity.n.01|induced|dopaminergic (r_pobj) in_10\IN\linear_unit.n.01|neurotoxicity (r_prep) action_1\NN\act.n.02|neuroprotective|of|,|antagonist|,|in (r_nsubjpass) associated_17\VBN\think.v.03|action|is|with|. (l_prep) with_18\IN\entity.n.01|decrease (l_pobj) decrease_20\NN\change.n.01|a|in (l_prep) in_21\IN\linear_unit.n.01|outflow (l_pobj) outflow_23\NN\discharge.n.06|dopamine|and|inhibition|in (l_conj) inhibition_25\NN\abstinence.n.02|of (l_prep) of_26\IN\entity.n.01|hyperthermia (l_pobj) hyperthermia_27\NN\physical_condition.n.01|
D008694_D005334 CID methamphetamine_12\NN\amphetamine.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|methamphetamine|- (r_amod) efflux_16\NN\flow.n.04|the|induced|dopamine|in (r_pobj) of_10\IN\entity.n.01|efflux (r_prep) reduction_9\NN\change_of_magnitude.n.01|the|of|due (r_pobj) with_7\IN\entity.n.01|reduction (r_prep) associated_6\VBN\think.v.03|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN\entity.n.01|decrease (l_pobj) decrease_31\NN\change.n.01|a|in (l_prep) in_32\IN\linear_unit.n.01|hyperthermia (l_pobj) hyperthermia_33\NN\physical_condition.n.01|
D004298_D020258 NONE dopamine_22\NN\monoamine_neurotransmitter.n.01| (r_compound) outflow_23\NN\discharge.n.06|dopamine|and|inhibition|in (r_pobj) in_21\IN\linear_unit.n.01|outflow (r_prep) decrease_20\NN\change.n.01|a|in (r_pobj) with_18\IN\entity.n.01|decrease (r_prep) associated_17\VBN\think.v.03|action|is|with|. (l_nsubjpass) action_1\NN\act.n.02|neuroprotective|of|,|antagonist|,|in (l_prep) in_10\IN\linear_unit.n.01|neurotoxicity (l_pobj) neurotoxicity_15\NN\entity.n.01|induced|dopaminergic
D004298_D005334 NONE dopamine_22\NN\monoamine_neurotransmitter.n.01| (r_compound) outflow_23\NN\discharge.n.06|dopamine|and|inhibition|in (l_conj) inhibition_25\NN\abstinence.n.02|of (l_prep) of_26\IN\entity.n.01|hyperthermia (l_pobj) hyperthermia_27\NN\physical_condition.n.01|
D004298_D005334 NONE dopamine_15\NN\monoamine_neurotransmitter.n.01| (r_compound) efflux_16\NN\flow.n.04|the|induced|dopamine|in (r_pobj) of_10\IN\entity.n.01|efflux (r_prep) reduction_9\NN\change_of_magnitude.n.01|the|of|due (r_pobj) with_7\IN\entity.n.01|reduction (r_prep) associated_6\VBN\think.v.03|neuroprotection|may|be|with|,|and|with|. (l_conj) with_29\IN\entity.n.01|decrease (l_pobj) decrease_31\NN\change.n.01|a|in (l_prep) in_32\IN\linear_unit.n.01|hyperthermia (l_pobj) hyperthermia_33\NN\physical_condition.n.01|
C121465_D064420 NONE mpep_12\NNP\entity.n.01| (r_pobj) by_11\IN\by.r.01|mpep (r_prep) blockade_8\NN\military_action.n.01|the|of|by (r_nsubj) protect_14\VB\defend.v.02|that|blockade|may|neurones (l_dobj) neurones_16\NNS\entity.n.01|dopaminergic|against (l_prep) against_17\IN\entity.n.01|toxicity (l_pobj) toxicity_21\NN\definite_quantity.n.01|induced
D008694_D064420 NONE methamphetamine_18\NN\amphetamine.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|methamphetamine|- (r_amod) toxicity_21\NN\definite_quantity.n.01|induced
8423889
D005473_D009069 CID fluoxetine_5\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_amod) medication_6\NN\drug.n.01|fluoxetine (r_pobj) after_4\IN\after.s.01|medication (r_prep) increase_0\NNP\indefinite_quantity.n.01|of|after|. (l_prep) of_1\IN\entity.n.01|disability (l_pobj) disability_3\NN\unfitness.n.01|parkinson
D005473_D009069 CID fluoxetine_21\NN\selective-serotonin_reuptake_inhibitor.n.01|the|antidepressant (r_pobj) to_18\IN\entity.n.01|fluoxetine (r_prep) exposure_17\NN\vulnerability.n.02|to (r_pobj) after_16\IN\after.s.01|exposure (r_prep) amount_4\NN\assets.n.01|the|increased|of|in|after (l_prep) of_5\IN\entity.n.01|disability (l_pobj) disability_7\NN\unfitness.n.01|motor
D000928_D009069 NONE antidepressant_20\JJ\medicine.n.02| (r_amod) fluoxetine_21\NN\selective-serotonin_reuptake_inhibitor.n.01|the|antidepressant (r_pobj) to_18\IN\entity.n.01|fluoxetine (r_prep) exposure_17\NN\vulnerability.n.02|to (r_pobj) after_16\IN\after.s.01|exposure (r_prep) amount_4\NN\assets.n.01|the|increased|of|in|after (l_prep) of_5\IN\entity.n.01|disability (l_pobj) disability_7\NN\unfitness.n.01|motor
D000928_D010300 NONE antidepressant_20\JJ\medicine.n.02| (r_amod) fluoxetine_21\NN\selective-serotonin_reuptake_inhibitor.n.01|the|antidepressant (r_pobj) to_18\IN\entity.n.01|fluoxetine (r_prep) exposure_17\NN\vulnerability.n.02|to (r_pobj) after_16\IN\after.s.01|exposure (r_prep) amount_4\NN\assets.n.01|the|increased|of|in|after (l_prep) in_8\IN\linear_unit.n.01|patients (l_pobj) patients_10\NNS\case.n.06|four|with (l_prep) with_11\IN\entity.n.01|disease (l_pobj) disease_15\NN\illness.n.01|parkinson
D005473_D010300 NONE fluoxetine_21\NN\selective-serotonin_reuptake_inhibitor.n.01|the|antidepressant (r_pobj) to_18\IN\entity.n.01|fluoxetine (r_prep) exposure_17\NN\vulnerability.n.02|to (r_pobj) after_16\IN\after.s.01|exposure (r_prep) amount_4\NN\assets.n.01|the|increased|of|in|after (l_prep) in_8\IN\linear_unit.n.01|patients (l_pobj) patients_10\NNS\case.n.06|four|with (l_prep) with_11\IN\entity.n.01|disease (l_pobj) disease_15\NN\illness.n.01|parkinson
D005473_D010300 NONE fluoxetine_11\NN\selective-serotonin_reuptake_inhibitor.n.01| (r_pobj) of_10\IN\entity.n.01|fluoxetine (r_prep) capacity_9\NN\capability.n.01|a|relevant|antagonistic|of|in (l_prep) in_12\IN\linear_unit.n.01|patients (l_pobj) patients_16\NNS\case.n.06|parkinson|disease (l_compound) disease_15\NN\illness.n.01|
D004298_D010300 NONE dopamine_6\NN\monoamine_neurotransmitter.n.01| (r_npadvmod) antagonistic_8\JJ\antagonistic.s.01|dopamine|- (r_amod) capacity_9\NN\capability.n.01|a|relevant|antagonistic|of|in (l_prep) in_12\IN\linear_unit.n.01|patients (l_pobj) patients_16\NNS\case.n.06|parkinson|disease (l_compound) disease_15\NN\illness.n.01|
3076126
D008148_D009135 NONE lovastatin_23\NN\lipid-lowering_medicine.n.01| (r_pobj) with_22\IN\entity.n.01|lovastatin (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (r_acl) myopathy_0\NNP\pathology.n.02|,|associated
D008148_D009212 CID lovastatin_23\NN\lipid-lowering_medicine.n.01| (r_pobj) with_22\IN\entity.n.01|lovastatin (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (l_prep) in_3\IN\linear_unit.n.01|cases (l_pobj) cases_5\NNS\happening.n.01|some|with (l_prep) with_6\IN\entity.n.01|myoglobinuria (l_pobj) myoglobinuria_7\NNS\symptom.n.01|
D008148_D051437 CID lovastatin_23\NN\lipid-lowering_medicine.n.01| (r_pobj) with_22\IN\entity.n.01|lovastatin (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\linear_unit.n.01|cases (l_pobj) cases_12\NNS\happening.n.01|2|with (l_prep) with_13\IN\entity.n.01|failure (l_pobj) failure_16\NN\nonaccomplishment.n.01|transient|renal
D016572_D009135 CID cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (r_acl) myopathy_0\NNP\pathology.n.02|,|associated
D016572_D009212 NONE cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (l_prep) in_3\IN\linear_unit.n.01|cases (l_pobj) cases_5\NNS\happening.n.01|some|with (l_prep) with_6\IN\entity.n.01|myoglobinuria (l_pobj) myoglobinuria_7\NNS\symptom.n.01|
D016572_D051437 NONE cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\linear_unit.n.01|cases (l_pobj) cases_12\NNS\happening.n.01|2|with (l_prep) with_13\IN\entity.n.01|failure (l_pobj) failure_16\NN\nonaccomplishment.n.01|transient|renal
D015248_D009135 CID gemfibrozil_33\NN\medicine.n.02|or|niacin (r_conj) cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (r_acl) myopathy_0\NNP\pathology.n.02|,|associated
D015248_D009212 NONE gemfibrozil_33\NN\medicine.n.02|or|niacin (r_conj) cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (l_prep) in_3\IN\linear_unit.n.01|cases (l_pobj) cases_5\NNS\happening.n.01|some|with (l_prep) with_6\IN\entity.n.01|myoglobinuria (l_pobj) myoglobinuria_7\NNS\symptom.n.01|
D015248_D051437 NONE gemfibrozil_33\NN\medicine.n.02|or|niacin (r_conj) cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\linear_unit.n.01|cases (l_pobj) cases_12\NNS\happening.n.01|2|with (l_prep) with_13\IN\entity.n.01|failure (l_pobj) failure_16\NN\nonaccomplishment.n.01|transient|renal
D009525_D009135 CID niacin_35\NN\b-complex_vitamin.n.01| (r_conj) gemfibrozil_33\NN\medicine.n.02|or|niacin (r_conj) cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (r_acl) myopathy_0\NNP\pathology.n.02|,|associated
D009525_D009212 NONE niacin_35\NN\b-complex_vitamin.n.01| (r_conj) gemfibrozil_33\NN\medicine.n.02|or|niacin (r_conj) cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (r_conj) associated_2\VBN\think.v.03|in|,|and|reported (l_prep) in_3\IN\linear_unit.n.01|cases (l_pobj) cases_5\NNS\happening.n.01|some|with (l_prep) with_6\IN\entity.n.01|myoglobinuria (l_pobj) myoglobinuria_7\NNS\symptom.n.01|
D009525_D051437 NONE niacin_35\NN\b-complex_vitamin.n.01| (r_conj) gemfibrozil_33\NN\medicine.n.02|or|niacin (r_conj) cyclosporin_31\NN\entity.n.01|,|gemfibrozil (r_pobj) with_30\IN\entity.n.01|cyclosporin (r_prep) treated_29\VBN\interact.v.01|concomitantly|with (r_acl) patients_27\NNS\case.n.06|treated (r_pobj) in_26\IN\linear_unit.n.01|especially|patients (r_prep) reported_21\VBN\inform.v.01|in|,|has|been|rarely|with|,|in|. (l_prep) in_10\IN\linear_unit.n.01|cases (l_pobj) cases_12\NNS\happening.n.01|2|with (l_prep) with_13\IN\entity.n.01|failure (l_pobj) failure_16\NN\nonaccomplishment.n.01|transient|renal
2054792
D004317_D005334 NONE adriamycin_2\NNS\entity.n.01| (r_pobj) of_1\IN\entity.n.01|adriamycin (r_prep) effect_0\NN\phenomenon.n.01|of|combined|. (l_acl) combined_3\VBN\have.v.02|with|on (l_prep) with_4\IN\entity.n.01|hyperthermia (l_pobj) hyperthermia_7\NN\physical_condition.n.01|body
D004317_D005334 NONE adriamycin_3\NNP\entity.n.01| (r_npadvmod) mediated_5\VBN\negociate.v.06|adriamycin|- (r_amod) activity_7\NN\act.n.02|mediated|antitumor|and|toxicities (l_conj) toxicities_11\NNS\definite_quantity.n.01|normal|tissue|by (l_prep) by_12\IN\by.r.01|hyperthermia (l_pobj) hyperthermia_15\NN\physical_condition.n.01|whole|body
D004317_D005334 NONE adriamycin_13\NNP\entity.n.01| (r_npadvmod) mediated_15\VBN\negociate.v.06|adriamycin|- (r_amod) activity_17\NN\act.n.02|both|mediated|antitumor|and|effects (r_dobj) enhanced_11\VBD\intensify.v.02|hyperthermia|activity|. (l_nsubj) hyperthermia_2\NN\physical_condition.n.01|whole|body|(|min|)
D004317_D005334 NONE adriamycin_7\NNP\entity.n.01| (r_npadvmod) mediated_9\VBN\negociate.v.06|adriamycin|- (r_amod) effect_11\NN\phenomenon.n.01|mediated|antitumor (r_dobj) enhances_6\VBZ\intensify.v.02|while|hyperthermia|effect (l_nsubj) hyperthermia_5\NN\physical_condition.n.01|body
D004317_D009369 NONE adriamycin_2\NNS\entity.n.01| (r_pobj) of_1\IN\entity.n.01|adriamycin (r_prep) effect_0\NN\phenomenon.n.01|of|combined|. (l_acl) combined_3\VBN\have.v.02|with|on (l_prep) on_8\IN\on.a.01|tumor (l_pobj) tumor_9\NN\growth.n.06|and|tissues
D004317_D064420 NONE adriamycin_3\NNP\entity.n.01| (r_npadvmod) mediated_5\VBN\negociate.v.06|adriamycin|- (r_amod) activity_7\NN\act.n.02|mediated|antitumor|and|toxicities (l_conj) toxicities_11\NNS\definite_quantity.n.01|normal|tissue|by
D004317_D064420 NONE adriamycin_7\NNP\entity.n.01| (r_npadvmod) mediated_9\VBN\negociate.v.06|adriamycin|- (r_amod) effect_11\NN\phenomenon.n.01|mediated|antitumor (r_dobj) enhances_6\VBZ\intensify.v.02|while|hyperthermia|effect (r_advcl) increased_18\VBN\change_magnitude.v.01|thus|,|enhances|,|toxicity|is|also|,|and|eroded (l_nsubjpass) toxicity_15\NN\definite_quantity.n.01|normal|tissue
322550
D009599_D007022 CID nitroprusside_8\RB\entity.n.01| (r_advmod) induced_10\VBN\generate.v.01|nitroprusside|- (r_amod) hypotension_11\NN\cardiovascular_disease.n.01|induced
D009599_D007022 CID nitroprusside_1\JJ\entity.n.01| (r_amod) infusion_2\NN\solution.n.01|nitroprusside (r_nsubj) produced_3\VBD\make.v.03|before|infusion|decrease|and|increased|. (l_dobj) decrease_6\NN\change.n.01|a|further|in (l_prep) in_7\IN\linear_unit.n.01|pressure (l_pobj) pressure_10\NN\physical_phenomenon.n.01|arterial|blood
D009599_D007022 CID nitroprusside_0\NNP\entity.n.01| (r_nsubj) caused_1\VBD\make.v.03|nitroprusside|decreases|,|but|change|. (l_dobj) decreases_3\NNS\change.n.01|significant|in (l_prep) in_4\IN\linear_unit.n.01|pressure (l_pobj) pressure_7\NN\physical_phenomenon.n.01|arterial|blood|and|resistance
D009599_D007022 NONE nitroprusside_1\JJ\entity.n.01| (r_amod) levels_4\NNS\property.n.02|nitroprusside|infusion|low|of (r_pobj) during_0\IN\entity.n.01|levels (r_prep) alter_10\VB\change.v.01|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\food.n.02|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\change.n.01|marked|in (l_prep) in_34\IN\linear_unit.n.01|pressure (l_pobj) pressure_37\NN\physical_phenomenon.n.01|arterial|blood|and|output (l_conj) output_40\NN\product.n.02|cardiac
D009599_D002303 NONE nitroprusside_1\JJ\entity.n.01| (r_amod) infusion_2\NN\solution.n.01|nitroprusside (r_nsubj) produced_3\VBD\make.v.03|before|infusion|decrease|and|increased|. (l_conj) increased_13\VBN\change_magnitude.v.01|significantly|rate|and|decreased (l_conj) decreased_17\VBD\change_magnitude.v.01|output (l_dobj) output_19\NN\product.n.02|cardiac|and|qt
D009599_D002303 NONE nitroprusside_1\JJ\entity.n.01| (r_amod) levels_4\NNS\property.n.02|nitroprusside|infusion|low|of (r_pobj) during_0\IN\entity.n.01|levels (r_prep) alter_10\VB\change.v.01|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\food.n.02|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\change.n.01|marked|in (l_prep) in_34\IN\linear_unit.n.01|pressure (l_pobj) pressure_37\NN\physical_phenomenon.n.01|arterial|blood|and|output (l_conj) output_40\NN\product.n.02|cardiac
D014867_D007022 NONE h2o_22\NNP\binary_compound.n.01|cm (r_punct) levels_16\NNS\property.n.02|high|of|h2o|) (r_conj) alter_10\VB\change.v.01|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\food.n.02|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\change.n.01|marked|in (l_prep) in_34\IN\linear_unit.n.01|pressure (l_pobj) pressure_37\NN\physical_phenomenon.n.01|arterial|blood|and|output (l_conj) output_40\NN\product.n.02|cardiac
D014867_D002303 NONE h2o_22\NNP\binary_compound.n.01|cm (r_punct) levels_16\NNS\property.n.02|high|of|h2o|) (r_conj) alter_10\VB\change.v.01|during|do|not|markedly|dynamics|,|but|levels|produce|. (l_conj) produce_31\VBP\food.n.02|,|decreasing|,|decreases (l_dobj) decreases_33\NNS\change.n.01|marked|in (l_prep) in_34\IN\linear_unit.n.01|pressure (l_pobj) pressure_37\NN\physical_phenomenon.n.01|arterial|blood|and|output (l_conj) output_40\NN\product.n.02|cardiac
12639165
D013988_D002779 CID ticlopidine_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|ticlopidine|- (r_amod) hepatitis_4\NN\infectious_disease.n.01|induced|cholestatic|.
D013988_D002779 CID ticlopidine_5\NN\entity.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|ticlopidine|- (r_amod) hepatitis_9\NN\infectious_disease.n.01|induced|cholestatic
D013988_D002779 CID ticlopidine_8\NN\entity.n.01| (r_advmod) receiving_7\VBG\get.v.01|ticlopidine|following (r_pcomp) after_6\IN\after.s.01|receiving (r_prep) developed_2\VBD\create.v.02|patients|hepatitis|after|,|with|. (l_dobj) hepatitis_5\NN\infectious_disease.n.01|prolonged|cholestatic
D013988_D002779 CID ticlopidine_10\NN\entity.n.01| (r_advmod) complication_5\NN\hindrance.n.03|a|rare|of|ticlopidine (r_attr) is_2\VBZ\be.v.01|hepatitis|complication (l_nsubj) hepatitis_1\NN\infectious_disease.n.01|cholestatic
D013988_D002779 CID ticlopidine_7\NN\entity.n.01| (r_pobj) with_6\IN\entity.n.01|ticlopidine (r_prep) treatment_5\NN\care.n.01|with (r_pobj) following_4\VBG\multitude.n.03|treatment (r_prep) developed_2\VBD\create.v.02|patients|jaundice|following|and|showed|. (l_conj) showed_9\VBD\show.v.04|characteristics (l_dobj) characteristics_14\NNS\property.n.04|the|clinical|of|,|resolved (l_prep) of_15\IN\entity.n.01|hepatitis (l_pobj) hepatitis_17\NN\infectious_disease.n.01|cholestatic
D013988_D002779 CID ticlopidine_4\NN\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|ticlopidine|- (r_amod) cholestasis_7\NN\disorder.n.01|this|induced
D013988_D002779 CID ticlopidine_8\NN\entity.n.01| (r_pobj) of_7\IN\entity.n.01|ticlopidine (r_prep) effect_6\NN\phenomenon.n.01|a|rare|adverse|of|be (r_attr) is_2\VBZ\be.v.01|hepatitis|effect|. (l_nsubj) hepatitis_1\NN\infectious_disease.n.01|cholestatic
D013988_D056486 CID ticlopidine_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|ticlopidine|- (r_amod) hepatitis_4\NN\infectious_disease.n.01|induced|cholestatic|.
D013988_D056486 CID ticlopidine_5\NN\entity.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|ticlopidine|- (r_amod) hepatitis_9\NN\infectious_disease.n.01|induced|cholestatic
D013988_D056486 CID ticlopidine_8\NN\entity.n.01| (r_advmod) receiving_7\VBG\get.v.01|ticlopidine|following (r_pcomp) after_6\IN\after.s.01|receiving (r_prep) developed_2\VBD\create.v.02|patients|hepatitis|after|,|with|. (l_dobj) hepatitis_5\NN\infectious_disease.n.01|prolonged|cholestatic
D013988_D056486 CID ticlopidine_10\NN\entity.n.01| (r_advmod) complication_5\NN\hindrance.n.03|a|rare|of|ticlopidine (r_attr) is_2\VBZ\be.v.01|hepatitis|complication (l_nsubj) hepatitis_1\NN\infectious_disease.n.01|cholestatic
D013988_D056486 CID ticlopidine_7\NN\entity.n.01| (r_pobj) with_6\IN\entity.n.01|ticlopidine (r_prep) treatment_5\NN\care.n.01|with (r_pobj) following_4\VBG\multitude.n.03|treatment (r_prep) developed_2\VBD\create.v.02|patients|jaundice|following|and|showed|. (l_conj) showed_9\VBD\show.v.04|characteristics (l_dobj) characteristics_14\NNS\property.n.04|the|clinical|of|,|resolved (l_prep) of_15\IN\entity.n.01|hepatitis (l_pobj) hepatitis_17\NN\infectious_disease.n.01|cholestatic
D013988_D056486 CID ticlopidine_8\NN\entity.n.01| (r_pobj) of_7\IN\entity.n.01|ticlopidine (r_prep) effect_6\NN\phenomenon.n.01|a|rare|adverse|of|be (r_attr) is_2\VBZ\be.v.01|hepatitis|effect|. (l_nsubj) hepatitis_1\NN\infectious_disease.n.01|cholestatic
D013988_D007565 CID ticlopidine_7\NN\entity.n.01| (r_pobj) with_6\IN\entity.n.01|ticlopidine (r_prep) treatment_5\NN\care.n.01|with (r_pobj) following_4\VBG\multitude.n.03|treatment (r_prep) developed_2\VBD\create.v.02|patients|jaundice|following|and|showed|. (l_dobj) jaundice_3\NN\symptom.n.01|
809711
D010656_D009203 NONE phenylephrine_2\NN\adrenergic.n.01|of (l_prep) of_3\IN\entity.n.01|effects (l_pobj) effects_6\NNS\personal_property.n.01|the|beneficial|of|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|with (l_prep) with_12\IN\entity.n.01|infarction (l_pobj) infarction_15\NN\pathology.n.02|acute|myocardial
D010656_D009203 NONE phenylephrine_6\NN\adrenergic.n.01|to (r_pobj) of_5\IN\entity.n.01|phenylephrine (r_prep) addition_4\NN\component.n.03|of (r_nsubj) is_9\VBZ\be.v.01|that|addition|not|beneficial (l_acomp) beneficial_11\JJ\beneficial.s.01|in (l_prep) in_12\IN\linear_unit.n.01|treatment (l_pobj) treatment_14\NN\care.n.01|the|of (l_prep) of_15\IN\entity.n.01|patients (l_pobj) patients_16\NNS\case.n.06|with (l_prep) with_17\IN\entity.n.01|infarction (l_pobj) infarction_20\NN\pathology.n.02|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\nitrate.n.01|intravenous (r_pobj) of_7\IN\entity.n.01|nitroglycerin (r_prep) effects_6\NNS\personal_property.n.01|the|beneficial|of|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|with (l_prep) with_12\IN\entity.n.01|infarction (l_pobj) infarction_15\NN\pathology.n.02|acute|myocardial
D005996_D009203 NONE nitroglycerin_0\NNP\nitrate.n.01| (r_nsubjpass) shown_3\VBN\show.v.04|nitroglycerin|has|been|reduce (l_xcomp) reduce_5\VB\decrease.v.02|to|elevation|during (l_prep) during_10\IN\entity.n.01|infarction (l_pobj) infarction_13\NN\pathology.n.02|acute|myocardial
D005996_D009203 NONE nitroglycerin_25\NN\nitrate.n.01| (r_npadvmod) induced_27\VBN\generate.v.01|nitroglycerin|- (r_amod) hypotension_28\NN\cardiovascular_disease.n.01|induced (r_dobj) reverse_24\VBP\opposition.n.02|that|hypotension (r_relcl) agents_22\NNS\causal_agent.n.01|reverse (r_pobj) by_21\IN\by.r.01|agents (r_agent) potentiated_17\VBN\enhance.v.01|shown|,|effect|in|by|. (l_ccomp) shown_3\VBN\show.v.04|nitroglycerin|has|been|reduce (l_xcomp) reduce_5\VB\decrease.v.02|to|elevation|during (l_prep) during_10\IN\entity.n.01|infarction (l_pobj) infarction_13\NN\pathology.n.02|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\nitrate.n.01|intravenous|,|sufficient (r_dobj) received_7\VBD\get.v.01|patients|nitroglycerin|+/- (l_nsubj) patients_1\NNS\case.n.06|ten|with (l_prep) with_2\IN\entity.n.01|infarctions (l_pobj) infarctions_6\NNS\pathology.n.02|acute|transmural|myocardial
D005996_D009203 NONE nitroglycerin_8\NN\nitrate.n.01| (r_pobj) to_7\IN\entity.n.01|nitroglycerin (r_prep) phenylephrine_6\NN\adrenergic.n.01|to (r_pobj) of_5\IN\entity.n.01|phenylephrine (r_prep) addition_4\NN\component.n.03|of (r_nsubj) is_9\VBZ\be.v.01|that|addition|not|beneficial (l_acomp) beneficial_11\JJ\beneficial.s.01|in (l_prep) in_12\IN\linear_unit.n.01|treatment (l_pobj) treatment_14\NN\care.n.01|the|of (l_prep) of_15\IN\entity.n.01|patients (l_pobj) patients_16\NNS\case.n.06|with (l_prep) with_17\IN\entity.n.01|infarction (l_pobj) infarction_20\NN\pathology.n.02|acute|myocardial
D005996_D007022 CID nitroglycerin_0\NNP\nitrate.n.01| (r_nsubjpass) shown_3\VBN\show.v.04|nitroglycerin|has|been|reduce (r_ccomp) potentiated_17\VBN\enhance.v.01|shown|,|effect|in|by|. (l_agent) by_21\IN\by.r.01|agents (l_pobj) agents_22\NNS\causal_agent.n.01|reverse (l_relcl) reverse_24\VBP\opposition.n.02|that|hypotension (l_dobj) hypotension_28\NN\cardiovascular_disease.n.01|induced
D005996_D007022 CID nitroglycerin_25\NN\nitrate.n.01| (r_npadvmod) induced_27\VBN\generate.v.01|nitroglycerin|- (r_amod) hypotension_28\NN\cardiovascular_disease.n.01|induced
16858720
D014859_D002543 CID warfarin_4\NN\anticoagulant.n.01|- (r_pobj) by_3\IN\by.r.01|warfarin (r_agent) induced_2\VBN\generate.v.01|by|influence (r_acl) haemorrhage_1\NN\injury.n.01|cerebral|induced|.
D014859_D002543 CID warfarin_9\RB\anticoagulant.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|warfarin|- (r_amod) haemorrhages_13\NNS\injury.n.01|induced|cerebral
D014859_D002543 CID warfarin_16\JJ\anticoagulant.n.01|and|interactions (r_pobj) due_14\IN\right.n.01|to|warfarin (r_prep) evaluate_1\VB\evaluate.v.02|to|frequency|due|. (l_dobj) frequency_3\NN\rate.n.01|the|,|severity|of (l_prep) of_8\IN\entity.n.01|haemorrhages (l_pobj) haemorrhages_13\NNS\injury.n.01|induced|cerebral
D014859_D002543 CID warfarin_18\JJ\anticoagulant.n.01| (r_compound) drug_20\NN\agent.n.03|warfarin|- (r_compound) interactions_21\NNS\action.n.01|drug|in (r_conj) warfarin_16\JJ\anticoagulant.n.01|and|interactions (r_pobj) due_14\IN\right.n.01|to|warfarin (r_prep) evaluate_1\VB\evaluate.v.02|to|frequency|due|. (l_dobj) frequency_3\NN\rate.n.01|the|,|severity|of (l_prep) of_8\IN\entity.n.01|haemorrhages (l_pobj) haemorrhages_13\NNS\injury.n.01|induced|cerebral
D014859_D002543 CID warfarin_8\JJ\anticoagulant.n.01|and|drug (r_nmod) interactions_13\NNS\action.n.01|warfarin (r_nsubj) caused_16\VBN\make.v.03|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_19\NN\injury.n.01|the|cerebral
D014859_D002543 CID warfarin_10\JJ\anticoagulant.n.01| (r_compound) drug_12\NN\agent.n.03|warfarin|- (r_conj) warfarin_8\JJ\anticoagulant.n.01|and|drug (r_nmod) interactions_13\NNS\action.n.01|warfarin (r_nsubj) caused_16\VBN\make.v.03|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_19\NN\injury.n.01|the|cerebral
D014859_D002543 CID warfarin_17\JJ\anticoagulant.n.01| (r_compound) treatment_18\NN\care.n.01|warfarin (r_pobj) to_16\IN\entity.n.01|treatment (r_prep) related_15\VBN\think.v.03|to (r_amod) as_14\IN\chemical_element.n.01|related (r_prep) assessed_13\VBN\evaluate.v.02|among|were|as|. (l_prep) among_0\IN\entity.n.01|patients (l_pobj) patients_2\NNS\case.n.06|593|with (l_prep) with_3\IN\entity.n.01|haemorrhage (l_pobj) haemorrhage_5\NN\injury.n.01|cerebral|,|%|)
D014859_D002543 CID warfarin_0\NNP\anticoagulant.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|warfarin|- (r_amod) haemorrhages_4\NNS\injury.n.01|induced|cerebral
D014859_D002543 CID warfarin_4\RB\anticoagulant.n.01| (r_npadvmod) related_6\VBN\think.v.03|warfarin|- (r_amod) haemorrhages_8\NNS\injury.n.01|related|cerebral
D014859_D002543 CID warfarin_26\NN\anticoagulant.n.01| (r_pobj) with_25\IN\entity.n.01|warfarin (r_prep) interact_24\VB\act.v.01|to|with (r_xcomp) known_22\VBN\know.v.01|interact (r_acl) drugs_21\NNS\agent.n.03|known (r_dobj) prescribing_20\VBG\inflict.v.01|when|drugs (r_advcl) taken_18\VBN\act.v.01|if|caution|had|been|prescribing (r_advcl) prevented_12\VBN\prevent.v.01|proportion|might|have|been|taken|. (l_nsubjpass) proportion_2\NN\quotient.n.01|a|significant|of (l_prep) of_3\IN\entity.n.01|haemorrhages (l_pobj) haemorrhages_8\NNS\injury.n.01|related|cerebral
D014859_D006470 NONE warfarin_1\JJ\anticoagulant.n.01| (r_compound) drug_3\NN\agent.n.03|warfarin|- (r_compound) interaction_4\NN\action.n.01|a|drug (r_nsubj) contributed_7\VBN\change.v.01|interaction|could|have|to|in|considered|. (l_prep) to_8\IN\entity.n.01|haemorrhage (l_pobj) haemorrhage_10\NN\injury.n.01|the
D014859_D006470 NONE warfarin_1\JJ\anticoagulant.n.01| (r_compound) drug_3\NN\agent.n.03|warfarin|- (r_compound) interaction_4\NN\action.n.01|a|drug (r_nsubj) contributed_7\VBN\change.v.01|interaction|could|have|to|in|considered|. (l_conj) considered_34\VBN\think.v.01|complication|was|being (l_nsubjpass) complication_32\NN\hindrance.n.03|the|bleeding (l_amod) bleeding_31\VBG\injury.n.01|
D014859_D006470 NONE warfarin_19\JJ\anticoagulant.n.01| (r_compound) patients_20\NNS\case.n.06|the|warfarin (r_pobj) of_17\IN\entity.n.01|patients (r_prep) %_15\NN\entity.n.01|24|(|41|)|of (r_pobj) in_11\IN\linear_unit.n.01|%|and|in (r_prep) contributed_7\VBN\change.v.01|interaction|could|have|to|in|considered|. (l_prep) to_8\IN\entity.n.01|haemorrhage (l_pobj) haemorrhage_10\NN\injury.n.01|the
D014859_D006470 NONE warfarin_19\JJ\anticoagulant.n.01| (r_compound) patients_20\NNS\case.n.06|the|warfarin (r_pobj) of_17\IN\entity.n.01|patients (r_prep) %_15\NN\entity.n.01|24|(|41|)|of (r_pobj) in_11\IN\linear_unit.n.01|%|and|in (r_prep) contributed_7\VBN\change.v.01|interaction|could|have|to|in|considered|. (l_conj) considered_34\VBN\think.v.01|complication|was|being (l_nsubjpass) complication_32\NN\hindrance.n.03|the|bleeding (l_amod) bleeding_31\VBG\injury.n.01|
20633755
D013390_D001049 CID suxamethonium_0\NNS\entity.n.01| (r_nsubj) induced_1\VBD\generate.v.01|suxamethonium|apnea|. (l_dobj) apnea_3\NN\symptom.n.01|prolonged|in
D013390_D001049 CID suxamethonium_0\JJ\entity.n.01| (r_nsubj) causes_1\VBZ\origin.n.03|suxamethonium|apnea|. (l_dobj) apnea_3\NN\symptom.n.01|prolonged|in
D009943_D001049 CID poisons_17\NNS\substance.n.07|organophosphorus|(|op|) (r_pobj) by_12\IN\by.r.01|poisons (r_agent) deactivated_11\VBN\discharge.v.10|in|enzyme|gets|by (r_relcl) patients_5\NNS\case.n.06|deactivated (r_pobj) in_4\IN\linear_unit.n.01|patients (r_prep) apnea_3\NN\symptom.n.01|prolonged|in
D009943_D001049 CID compound_14\NN\whole.n.01|op (r_pobj) by_12\IN\by.r.01|compound (r_prep) attempt_11\NN\activity.n.01|suicidal|by (r_pobj) about_9\IN\about.s.01|attempt (r_prep) information_8\NN\message.n.02|the|about (r_nsubjpass) concealed_16\VBN\hide.v.01|because|information|was|from (r_advcl) ensued_5\VBD\prove.v.01|apnea|concealed|. (l_nsubj) apnea_1\NN\symptom.n.01|prolonged|in
7858459
D005472_D003221 CID 5-fluorouracil_10\CD\entity.n.01| (r_punct) of_9\IN\entity.n.01|5-fluorouracil (r_prep) infusion_8\NN\solution.n.01|a|dose|of|and|acid (r_pobj) by_3\IN\by.r.01|infusion (r_agent) induced_2\VBN\generate.v.01|confusion|by|. (l_nsubj) confusion_1\NN\disorder.n.03|acute
D005472_D003221 CID 5-fluorouracil_35\CD\entity.n.01| (r_punct) of_34\IN\entity.n.01|5-fluorouracil (r_prep) dose_29\NN\medicine.n.02|the|first|day|of|and (r_nmod) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (r_conj) developed_1\VBD\create.v.02|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\evidence.n.01|acute|neurologic|of (l_prep) of_5\IN\entity.n.01|confusion (l_pobj) confusion_7\NN\disorder.n.03|mental|,|disorientation
D005472_D003221 CID 5-fluorouracil_35\CD\entity.n.01| (r_punct) of_34\IN\entity.n.01|5-fluorouracil (r_prep) dose_29\NN\medicine.n.02|the|first|day|of|and (r_nmod) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (r_conj) developed_1\VBD\create.v.02|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\evidence.n.01|acute|neurologic|of (l_prep) of_5\IN\entity.n.01|confusion (l_pobj) confusion_7\NN\disorder.n.03|mental|,|disorientation (l_conj) disorientation_9\NN\delusion.n.02|and|irritability
D002955_D003221 CID acid_13\NN\compound.n.02|folinic (r_conj) infusion_8\NN\solution.n.01|a|dose|of|and|acid (r_pobj) by_3\IN\by.r.01|infusion (r_agent) induced_2\VBN\generate.v.01|confusion|by|. (l_nsubj) confusion_1\NN\disorder.n.03|acute
D002955_D003221 CID acid_38\NN\compound.n.02| (r_compound) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (r_conj) developed_1\VBD\create.v.02|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\evidence.n.01|acute|neurologic|of (l_prep) of_5\IN\entity.n.01|confusion (l_pobj) confusion_7\NN\disorder.n.03|mental|,|disorientation
D002955_D003221 CID acid_38\NN\compound.n.02| (r_compound) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (r_conj) developed_1\VBD\create.v.02|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\evidence.n.01|acute|neurologic|of (l_prep) of_5\IN\entity.n.01|confusion (l_pobj) confusion_7\NN\disorder.n.03|mental|,|disorientation (l_conj) disorientation_9\NN\delusion.n.02|and|irritability
D002945_D013274 NONE cisplatinum_11\NN\entity.n.01|,|etoposide|hours (l_appos) hours_24\NNS\work_time.n.01|m2/24|)|and|acid (l_conj) acid_28\NN\compound.n.02|folinic|for (l_prep) for_29\IN\entity.n.01|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\carcinoma.n.01|an|inoperable|gastric
D005047_D013274 NONE etoposide_13\NN\entity.n.01| (r_conj) cisplatinum_11\NN\entity.n.01|,|etoposide|hours (l_appos) hours_24\NNS\work_time.n.01|m2/24|)|and|acid (l_conj) acid_28\NN\compound.n.02|folinic|for (l_prep) for_29\IN\entity.n.01|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\carcinoma.n.01|an|inoperable|gastric
D005472_D013274 NONE 5-fluorouracil_18\CD\entity.n.01| (r_punct) m2/24_23\NN\entity.n.01|,|dose|5-fluorouracil|(|mg|/ (r_compound) hours_24\NNS\work_time.n.01|m2/24|)|and|acid (l_conj) acid_28\NN\compound.n.02|folinic|for (l_prep) for_29\IN\entity.n.01|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\carcinoma.n.01|an|inoperable|gastric
D002955_D013274 NONE acid_28\NN\compound.n.02|folinic|for (l_prep) for_29\IN\entity.n.01|adenocarcinoma (l_pobj) adenocarcinoma_33\NN\carcinoma.n.01|an|inoperable|gastric
D005472_D001523 NONE 5-fluorouracil_35\CD\entity.n.01| (r_punct) of_34\IN\entity.n.01|5-fluorouracil (r_prep) dose_29\NN\medicine.n.02|the|first|day|of|and (r_nmod) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (r_conj) developed_1\VBD\create.v.02|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\evidence.n.01|acute|neurologic|of (l_prep) of_5\IN\entity.n.01|confusion (l_pobj) confusion_7\NN\disorder.n.03|mental|,|disorientation (l_conj) disorientation_9\NN\delusion.n.02|and|irritability (l_conj) irritability_11\NN\ill_humor.n.01|
D005472_D003128 CID 5-fluorouracil_35\CD\entity.n.01| (r_punct) of_34\IN\entity.n.01|5-fluorouracil (r_prep) dose_29\NN\medicine.n.02|the|first|day|of|and (r_nmod) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (l_prep) into_16\IN\entity.n.01|coma (l_pobj) coma_19\NN\unconsciousness.n.01|a|deep
D002955_D001523 NONE acid_38\NN\compound.n.02| (r_compound) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (r_conj) developed_1\VBD\create.v.02|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\evidence.n.01|acute|neurologic|of (l_prep) of_5\IN\entity.n.01|confusion (l_pobj) confusion_7\NN\disorder.n.03|mental|,|disorientation (l_conj) disorientation_9\NN\delusion.n.02|and|irritability (l_conj) irritability_11\NN\ill_humor.n.01|
D002955_D003128 CID acid_38\NN\compound.n.02| (r_compound) infusion_39\NN\solution.n.01|dose|folinic|acid (r_pobj) during_26\IN\entity.n.01|infusion (r_prep) lasting_21\VBG\measure.v.03|for|during (r_advcl) lapsed_15\VBD\move.v.07|then|into|,|lasting (l_prep) into_16\IN\entity.n.01|coma (l_pobj) coma_19\NN\unconsciousness.n.01|a|deep
D002955_D020258 NONE acid_2\NN\compound.n.02|folinic (r_nsubj) was_3\VBD\washington.n.02|because|acid|unlikely (r_advcl) suspected_21\VBN\guess.v.02|was|,|neurotoxicity|5-fluorouracil|was|highly|. (l_nsubjpass) neurotoxicity_12\NN\entity.n.01|due
D005472_D020258 NONE 5-fluorouracil_18\CD\entity.n.01| (r_punct) suspected_21\VBN\guess.v.02|was|,|neurotoxicity|5-fluorouracil|was|highly|. (l_nsubjpass) neurotoxicity_12\NN\entity.n.01|due
D005472_D020258 NONE 5-fluorouracil_3\CD\entity.n.01| (r_punct) neurotoxicity_4\NN\entity.n.01|5-fluorouracil
D005463_D020258 NONE fluoroacetate_14\NN\entity.n.01|and|fluorocitrate (r_pobj) by_13\IN\by.r.01|fluoroacetate (r_prep) blockade_12\NN\military_action.n.01|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\entity.n.01|blockade (r_prep) due_7\JJ\right.n.01|to (r_acomp) be_6\VB\metallic_element.n.01|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\pathologic_process.n.01|the|of (l_prep) of_2\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_4\NN\entity.n.01|5-fluorouracil
C007744_D020258 NONE fluorocitrate_16\NN\entity.n.01| (r_conj) fluoroacetate_14\NN\entity.n.01|and|fluorocitrate (r_pobj) by_13\IN\by.r.01|fluoroacetate (r_prep) blockade_12\NN\military_action.n.01|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\entity.n.01|blockade (r_prep) due_7\JJ\right.n.01|to (r_acomp) be_6\VB\metallic_element.n.01|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\pathologic_process.n.01|the|of (l_prep) of_2\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_4\NN\entity.n.01|5-fluorouracil
D013831_D020258 NONE thiamine_18\NN\b-complex_vitamin.n.01| (r_compound) deficiency_19\NN\need.n.01|thiamine|,|or|deficiency (r_conj) blockade_12\NN\military_action.n.01|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\entity.n.01|blockade (r_prep) due_7\JJ\right.n.01|to (r_acomp) be_6\VB\metallic_element.n.01|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\pathologic_process.n.01|the|of (l_prep) of_2\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_4\NN\entity.n.01|5-fluorouracil
C007419_D020258 NONE dihydrouracil_22\VBN\entity.n.01| (r_compound) dehydrogenase_23\NN\entity.n.01|dihydrouracil (r_compound) deficiency_24\NN\need.n.01|dehydrogenase (r_conj) deficiency_19\NN\need.n.01|thiamine|,|or|deficiency (r_conj) blockade_12\NN\military_action.n.01|a|krebs|cycle|by|,|deficiency (r_pobj) to_8\IN\entity.n.01|blockade (r_prep) due_7\JJ\right.n.01|to (r_acomp) be_6\VB\metallic_element.n.01|pathogenesis|may|due|. (l_nsubj) pathogenesis_1\NN\pathologic_process.n.01|the|of (l_prep) of_2\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_4\NN\entity.n.01|5-fluorouracil
D005472_D009369 NONE 5-fluorouracil_3\CD\entity.n.01| (r_punct) folinic_5\JJ\entity.n.01|5-fluorouracil|/ (r_amod) therapy_8\NN\medical_care.n.01|dose|folinic|infusion (r_nsubj) become_11\VBN\change_state.v.01|therapy|has|recently|regimen|. (l_attr) regimen_14\NN\plan.n.01|a|popular|for (l_prep) for_15\IN\entity.n.01|cancers (l_pobj) cancers_17\NNS\malignant_tumor.n.01|various
D002955_D009369 NONE acid_6\NN\compound.n.02| (r_compound) infusion_7\NN\solution.n.01|acid (r_compound) therapy_8\NN\medical_care.n.01|dose|folinic|infusion (r_nsubj) become_11\VBN\change_state.v.01|therapy|has|recently|regimen|. (l_attr) regimen_14\NN\plan.n.01|a|popular|for (l_prep) for_15\IN\entity.n.01|cancers (l_pobj) cancers_17\NNS\malignant_tumor.n.01|various
9249847
D014700_D013611 CID verapamil_7\NN\calcium_blocker.n.01|and (r_nmod) ablation_10\NN\operation.n.06|verapamil|catheter|in|and|cardiomyopathy (r_pobj) after_6\IN\after.s.01|ablation (r_prep) induced_1\VBD\generate.v.01|iatrogenically|tachycardia|after|. (l_dobj) tachycardia_5\NN\cardiac_arrhythmia.n.01|intractable|atrioventricular|reentrant
D014700_D013611 CID verapamil_10\NN\calcium_blocker.n.01|or (r_nmod) block_14\NN\artifact.n.01|verapamil|unidirectional|antegrade|of (r_pobj) after_9\IN\after.s.01|block (r_prep) beats_8\NNS\youth_subculture.n.01|junctional|escape|after|after (r_pobj) by_5\IN\by.r.01|beats (r_agent) caused_4\VBN\make.v.03|by (r_acl) qrs_0\UH\entity.n.01|without|,|caused|, (r_nsubj) established_22\VBD\open.v.02|qrs|attack|. (l_dobj) attack_25\NN\operation.n.05|frequent|avrt (l_compound) avrt_24\NN\entity.n.01|
D014700_D014927 NONE verapamil_7\NN\calcium_blocker.n.01|and (r_nmod) ablation_10\NN\operation.n.06|verapamil|catheter|in|and|cardiomyopathy (l_prep) in_11\IN\linear_unit.n.01|patient (l_pobj) patient_13\NN\case.n.06|a|with (l_prep) with_14\IN\entity.n.01|syndrome (l_pobj) syndrome_20\NN\complex.n.01|white
D014700_D002311 NONE verapamil_7\NN\calcium_blocker.n.01|and (r_nmod) ablation_10\NN\operation.n.06|verapamil|catheter|in|and|cardiomyopathy (l_conj) cardiomyopathy_24\NN\heart_disease.n.01|idiopathic|dilated
20080983
C048833_D012893 NONE modafinil_15\NN\entity.n.01|dosed|on|sleepiness (l_conj) sleepiness_20\NN\temporary_state.n.01|daytime|in
C048833_D012893 NONE modafinil_0\NNP\entity.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|modafinil|was|with|,|measured|. (l_advcl) measured_10\VBN\decide.v.01|as|by|,|and|decrease (l_conj) decrease_22\NN\change.n.01|a|significant|in (l_prep) in_23\IN\linear_unit.n.01|sleepiness (l_pobj) sleepiness_26\NN\temporary_state.n.01|subjective|daytime
C048833_D012893 NONE modafinil_3\NN\entity.n.01|dosed (r_nsubj) promotes_4\VBZ\support.v.01|modafinil|sleep|,|normalizes|. (l_conj) normalizes_8\VBZ\change.v.02|architecture|,|and|decreases (l_conj) decreases_13\VBZ\change.n.01|sleepiness (l_dobj) sleepiness_15\NN\temporary_state.n.01|daytime|in
D003042_D012893 CID cocaine_23\NN\hard_drug.n.01| (r_compound) users_24\NNS\person.n.01|chronic|cocaine (r_pobj) in_21\IN\linear_unit.n.01|users (r_prep) sleepiness_20\NN\temporary_state.n.01|daytime|in
D003042_D012893 CID cocaine_18\NN\hard_drug.n.01| (r_compound) users_19\NNS\person.n.01|abstinent|cocaine (r_pobj) in_16\IN\linear_unit.n.01|users (r_prep) sleepiness_15\NN\temporary_state.n.01|daytime|in
11198499
C023754_D007022 CID tizanidine_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|tizanidine (r_prep) initiation_3\NN\ceremony.n.01|the|of|in (r_dobj) following_1\VBG\multitude.n.03|initiation (r_acl) hypotension_0\NN\cardiovascular_disease.n.01|following|.
C023754_D007022 CID tizanidine_29\NN\entity.n.01|,|agonist|, (r_pobj) of_28\IN\entity.n.01|tizanidine (r_prep) addition_27\NN\component.n.03|the|of|for (r_pobj) following_25\VBG\multitude.n.03|addition (r_prep) developed_23\VBD\create.v.02|who|hypotension|following (l_dobj) hypotension_24\NN\cardiovascular_disease.n.01|
C023754_D006973 NONE tizanidine_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|tizanidine (r_prep) initiation_3\NN\ceremony.n.01|the|of|in (l_prep) in_6\IN\linear_unit.n.01|patient (l_pobj) patient_8\NN\case.n.06|a|treated (l_acl) treated_9\VBN\interact.v.01|with (l_prep) with_10\IN\entity.n.01|angiotensin (l_pobj) angiotensin_12\NN\vasoconstrictor.n.01|an|converting (l_acl) converting_13\VBG\change.v.01|inhibitor|for (l_prep) for_16\IN\entity.n.01|hypertension (l_pobj) hypertension_18\NN\cardiovascular_disease.n.01|chronic
C023754_D006973 NONE tizanidine_29\NN\entity.n.01|,|agonist|, (r_pobj) of_28\IN\entity.n.01|tizanidine (r_prep) addition_27\NN\component.n.03|the|of|for (r_pobj) following_25\VBG\multitude.n.03|addition (r_prep) developed_23\VBD\create.v.02|who|hypotension|following (r_relcl) hypertension_21\NN\cardiovascular_disease.n.01|developed
C023754_D006973 NONE tizanidine_4\NN\entity.n.01|and|agents (r_pobj) of_3\IN\entity.n.01|tizanidine (r_prep) interaction_2\NN\action.n.01|the|possible|of (r_nsubjpass) kept_11\VBN\keep.v.01|interaction|should|be|in|prescribing|. (l_advcl) prescribing_15\VBG\inflict.v.01|when|therapy|treat (l_xcomp) treat_18\VB\nutriment.n.01|to|hypertension (l_dobj) hypertension_20\NN\cardiovascular_disease.n.01|either|or|spasticity|in
D000809_D007022 NONE angiotensin_12\NN\vasoconstrictor.n.01|an|converting (r_pobj) with_10\IN\entity.n.01|angiotensin (r_prep) treated_9\VBN\interact.v.01|with (r_acl) patient_8\NN\case.n.06|a|treated (r_pobj) in_6\IN\linear_unit.n.01|patient (r_prep) initiation_3\NN\ceremony.n.01|the|of|in (r_dobj) following_1\VBG\multitude.n.03|initiation (r_acl) hypotension_0\NN\cardiovascular_disease.n.01|following|.
D000809_D007022 NONE angiotensin_4\NN\vasoconstrictor.n.01|converting (r_pobj) with_3\IN\entity.n.01|angiotensin (r_prep) treated_2\VBN\interact.v.01|adults|chronically|with (r_csubj) have_9\VB\person.n.01|treated|may|ability|. (l_dobj) ability_12\NN\quality.n.01|a|limited|respond (l_acl) respond_14\VB\act.v.01|to|to|blocked (l_prep) to_15\IN\entity.n.01|hypotension (l_pobj) hypotension_16\NN\cardiovascular_disease.n.01|
D000809_D007022 NONE angiotensin_14\NN\vasoconstrictor.n.01|an|converting (r_appos) lisinopril_11\NN\ace_inhibitor.n.01|,|angiotensin (r_pobj) with_10\IN\entity.n.01|lisinopril (r_prep) treated_9\VBN\interact.v.01|chronically|with (r_acl) boy_7\NN\male.n.02|a|old|treated|, (r_dobj) present_2\VBP\time.n.05|authors|boy|control|. (l_advcl) control_20\VB\power.n.01|to|hypertension (l_dobj) hypertension_21\NN\cardiovascular_disease.n.01|developed (l_relcl) developed_23\VBD\create.v.02|who|hypotension|following (l_dobj) hypotension_24\NN\cardiovascular_disease.n.01|
D000809_D006973 NONE angiotensin_12\NN\vasoconstrictor.n.01|an|converting (l_acl) converting_13\VBG\change.v.01|inhibitor|for (l_prep) for_16\IN\entity.n.01|hypertension (l_pobj) hypertension_18\NN\cardiovascular_disease.n.01|chronic
D000809_D006973 NONE angiotensin_14\NN\vasoconstrictor.n.01|an|converting (r_appos) lisinopril_11\NN\ace_inhibitor.n.01|,|angiotensin (r_pobj) with_10\IN\entity.n.01|lisinopril (r_prep) treated_9\VBN\interact.v.01|chronically|with (r_acl) boy_7\NN\male.n.02|a|old|treated|, (r_dobj) present_2\VBP\time.n.05|authors|boy|control|. (l_advcl) control_20\VB\power.n.01|to|hypertension (l_dobj) hypertension_21\NN\cardiovascular_disease.n.01|developed
D017706_D006973 NONE lisinopril_11\NN\ace_inhibitor.n.01|,|angiotensin (r_pobj) with_10\IN\entity.n.01|lisinopril (r_prep) treated_9\VBN\interact.v.01|chronically|with (r_acl) boy_7\NN\male.n.02|a|old|treated|, (r_dobj) present_2\VBP\time.n.05|authors|boy|control|. (l_advcl) control_20\VB\power.n.01|to|hypertension (l_dobj) hypertension_21\NN\cardiovascular_disease.n.01|developed
D017706_D007022 CID lisinopril_11\NN\ace_inhibitor.n.01|,|angiotensin (r_pobj) with_10\IN\entity.n.01|lisinopril (r_prep) treated_9\VBN\interact.v.01|chronically|with (r_acl) boy_7\NN\male.n.02|a|old|treated|, (r_dobj) present_2\VBP\time.n.05|authors|boy|control|. (l_advcl) control_20\VB\power.n.01|to|hypertension (l_dobj) hypertension_21\NN\cardiovascular_disease.n.01|developed (l_relcl) developed_23\VBD\create.v.02|who|hypotension|following (l_dobj) hypotension_24\NN\cardiovascular_disease.n.01|
D017706_D009128 NONE lisinopril_11\NN\ace_inhibitor.n.01|,|angiotensin (r_pobj) with_10\IN\entity.n.01|lisinopril (r_prep) treated_9\VBN\interact.v.01|chronically|with (r_acl) boy_7\NN\male.n.02|a|old|treated|, (r_dobj) present_2\VBP\time.n.05|authors|boy|control|. (l_advcl) control_20\VB\power.n.01|to|hypertension (l_dobj) hypertension_21\NN\cardiovascular_disease.n.01|developed (l_relcl) developed_23\VBD\create.v.02|who|hypotension|following (l_prep) following_25\VBG\multitude.n.03|addition (l_pobj) addition_27\NN\component.n.03|the|of|for (l_prep) for_35\IN\entity.n.01|treatment (l_pobj) treatment_37\NN\care.n.01|the|of (l_prep) of_38\IN\entity.n.01|spasticity (l_pobj) spasticity_39\NN\fitfulness.n.01|
D000809_D009128 NONE angiotensin_14\NN\vasoconstrictor.n.01|an|converting (r_appos) lisinopril_11\NN\ace_inhibitor.n.01|,|angiotensin (r_pobj) with_10\IN\entity.n.01|lisinopril (r_prep) treated_9\VBN\interact.v.01|chronically|with (r_acl) boy_7\NN\male.n.02|a|old|treated|, (r_dobj) present_2\VBP\time.n.05|authors|boy|control|. (l_advcl) control_20\VB\power.n.01|to|hypertension (l_dobj) hypertension_21\NN\cardiovascular_disease.n.01|developed (l_relcl) developed_23\VBD\create.v.02|who|hypotension|following (l_prep) following_25\VBG\multitude.n.03|addition (l_pobj) addition_27\NN\component.n.03|the|of|for (l_prep) for_35\IN\entity.n.01|treatment (l_pobj) treatment_37\NN\care.n.01|the|of (l_prep) of_38\IN\entity.n.01|spasticity (l_pobj) spasticity_39\NN\fitfulness.n.01|
C023754_D009128 NONE tizanidine_29\NN\entity.n.01|,|agonist|, (r_pobj) of_28\IN\entity.n.01|tizanidine (r_prep) addition_27\NN\component.n.03|the|of|for (l_prep) for_35\IN\entity.n.01|treatment (l_pobj) treatment_37\NN\care.n.01|the|of (l_prep) of_38\IN\entity.n.01|spasticity (l_pobj) spasticity_39\NN\fitfulness.n.01|
C023754_D009128 NONE tizanidine_4\NN\entity.n.01|and|agents (r_pobj) of_3\IN\entity.n.01|tizanidine (r_prep) interaction_2\NN\action.n.01|the|possible|of (r_nsubjpass) kept_11\VBN\keep.v.01|interaction|should|be|in|prescribing|. (l_advcl) prescribing_15\VBG\inflict.v.01|when|therapy|treat (l_xcomp) treat_18\VB\nutriment.n.01|to|hypertension (l_dobj) hypertension_20\NN\cardiovascular_disease.n.01|either|or|spasticity|in (l_conj) spasticity_22\NN\fitfulness.n.01|
20588063
D011692_D009401 CID aminonucleoside_17\JJ\entity.n.01| (r_amod) nephrosis_18\NN\syndrome.n.02|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_2\JJ\entity.n.01| (r_amod) nephrosis_3\NN\syndrome.n.02|aminonucleoside
3015567
D009599_D007022 CID nitroprusside_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|nitroprusside|- (r_amod) hypotension_3\NN\cardiovascular_disease.n.01|induced
D009599_D007022 CID nitroprusside_7\RB\entity.n.01| (r_advmod) induced_9\VBN\generate.v.01|nitroprusside|- (r_amod) hypotension_10\NN\cardiovascular_disease.n.01|induced
D003345_D007022 NONE corticosterone_18\NN\glucocorticoid.n.01|plasma (r_compound) level_19\NN\property.n.02|a|corticosterone|between (r_pobj) at_15\IN\chemical_element.n.01|level (r_prep) occurs_14\VBZ\happen.v.01|at (r_conj) observed_12\VBN\spy.v.03|suppression|is|and|occurs|. (l_nsubjpass) suppression_0\NN\growth.n.01|of|secretion (l_appos) secretion_3\NN\organic_process.n.01|in (l_prep) in_4\IN\linear_unit.n.01|response (l_pobj) response_5\NN\consequence.n.01|to (l_prep) to_6\IN\entity.n.01|hypotension (l_pobj) hypotension_10\NN\cardiovascular_disease.n.01|induced
7449470
D004317_D066126 NONE doxorubicin_3\NN\antibiotic.n.01| (r_compound) cardiotoxicity_4\NN\entity.n.01|late|,|late|doxorubicin|.
D004317_D066126 NONE adriamycin_11\NNS\entity.n.01| (r_pobj) of_10\IN\entity.n.01|adriamycin (r_prep) use_9\NN\activity.n.01|the|of|as (r_dobj) limits_7\VBZ\extent.n.02|which|use (r_relcl) complication_5\NN\hindrance.n.03|a|major|limits (r_attr) is_2\VBZ\be.v.01|toxicity|complication|. (l_nsubj) toxicity_1\NN\definite_quantity.n.01|cardiac
8739323
D008466_D007674 NONE nitrogranulogen_8\NN\entity.n.01|ng|,|methotrexate (r_pobj) as_7\IN\chemical_element.n.01|such|nitrogranulogen (r_prep) drugs_5\NNS\agent.n.03|anticancer|as (r_pobj) of_3\IN\entity.n.01|drugs (r_prep) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D008466_D007674 NONE ng_10\NNP\metric_weight_unit.n.01|(|) (r_appos) nitrogranulogen_8\NN\entity.n.01|ng|,|methotrexate (r_pobj) as_7\IN\chemical_element.n.01|such|nitrogranulogen (r_prep) drugs_5\NNS\agent.n.03|anticancer|as (r_pobj) of_3\IN\entity.n.01|drugs (r_prep) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D008727_D007674 NONE methotrexate_13\NNP\antimetabolite.n.01|mtx|, (r_conj) nitrogranulogen_8\NN\entity.n.01|ng|,|methotrexate (r_pobj) as_7\IN\chemical_element.n.01|such|nitrogranulogen (r_prep) drugs_5\NNS\agent.n.03|anticancer|as (r_pobj) of_3\IN\entity.n.01|drugs (r_prep) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D008727_D007674 NONE mtx_15\NNP\entity.n.01|(|) (r_appos) methotrexate_13\NNP\antimetabolite.n.01|mtx|, (r_conj) nitrogranulogen_8\NN\entity.n.01|ng|,|methotrexate (r_pobj) as_7\IN\chemical_element.n.01|such|nitrogranulogen (r_prep) drugs_5\NNS\agent.n.03|anticancer|as (r_pobj) of_3\IN\entity.n.01|drugs (r_prep) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D008727_D007674 NONE mtx_33\NNP\entity.n.01|[|+|5-fu (r_appos) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D008727_D007674 NONE mtx_6\NNP\entity.n.01| (r_pobj) of_5\IN\entity.n.01|mtx (r_prep) nephrotoxicity_4\NN\entity.n.01|that|of|+
D005472_D007674 NONE 5-fluorouracil_18\CD\entity.n.01| (r_punct) 5-fu_20\CD\entity.n.01|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D005472_D007674 NONE 5-fu_20\CD\entity.n.01|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D005472_D007674 NONE 5-fu_35\CD\entity.n.01|+|cy (r_conj) mtx_33\NNP\entity.n.01|[|+|5-fu (r_appos) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D005472_D007674 NONE 5-fu_8\CD\entity.n.01|+|cy|administered (r_nsubj) is_13\VBZ\be.v.01|5-fu|lower (r_ccomp) indicate_2\VBP\tell.v.02|studies|nephrotoxicity|is|. (l_dobj) nephrotoxicity_4\NN\entity.n.01|that|of|+
D003520_D007674 NONE cyclophosphamide_23\NN\entity.n.01|cy (r_conj) 5-fu_20\CD\entity.n.01|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D003520_D007674 NONE cy_25\NNP\entity.n.01|(|) (r_appos) cyclophosphamide_23\NN\entity.n.01|cy (r_conj) 5-fu_20\CD\entity.n.01|5-fluorouracil|(|)|and|cyclophosphamide (r_appos) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D003520_D007674 NONE cy_37\NNP\entity.n.01|cmf|] (r_conj) 5-fu_35\CD\entity.n.01|+|cy (r_conj) mtx_33\NNP\entity.n.01|[|+|5-fu (r_appos) action_2\NN\act.n.02|the|nephrotoxic|of|5-fu|administered|mtx (l_amod) nephrotoxic_1\JJ\nephrotoxic.s.01|
D003520_D007674 NONE cy_10\NNP\entity.n.01| (r_conj) 5-fu_8\CD\entity.n.01|+|cy|administered (r_nsubj) is_13\VBZ\be.v.01|5-fu|lower (r_ccomp) indicate_2\VBP\tell.v.02|studies|nephrotoxicity|is|. (l_dobj) nephrotoxicity_4\NN\entity.n.01|that|of|+
D003520_D006470 CID cy_0\NNP\entity.n.01| (r_nsubj) caused_1\VBD\make.v.03|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\urinary_tract_infection.n.01|hemorrhagic
D003520_D003556 CID cy_0\NNP\entity.n.01| (r_nsubj) caused_1\VBD\make.v.03|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\urinary_tract_infection.n.01|hemorrhagic
D005472_D006470 NONE 5-fu_20\CD\entity.n.01|and|mtx (r_pobj) with_19\IN\entity.n.01|5-fu (r_prep) combined_18\VBN\have.v.02|when|with (r_advcl) cause_14\VB\origin.n.03|it|did|not|complication|combined|. (r_conj) caused_1\VBD\make.v.03|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\urinary_tract_infection.n.01|hemorrhagic
D005472_D003556 NONE 5-fu_20\CD\entity.n.01|and|mtx (r_pobj) with_19\IN\entity.n.01|5-fu (r_prep) combined_18\VBN\have.v.02|when|with (r_advcl) cause_14\VB\origin.n.03|it|did|not|complication|combined|. (r_conj) caused_1\VBD\make.v.03|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\urinary_tract_infection.n.01|hemorrhagic
D008727_D006470 NONE mtx_22\NNP\entity.n.01| (r_conj) 5-fu_20\CD\entity.n.01|and|mtx (r_pobj) with_19\IN\entity.n.01|5-fu (r_prep) combined_18\VBN\have.v.02|when|with (r_advcl) cause_14\VB\origin.n.03|it|did|not|complication|combined|. (r_conj) caused_1\VBD\make.v.03|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\urinary_tract_infection.n.01|hemorrhagic
D008727_D003556 NONE mtx_22\NNP\entity.n.01| (r_conj) 5-fu_20\CD\entity.n.01|and|mtx (r_pobj) with_19\IN\entity.n.01|5-fu (r_prep) combined_18\VBN\have.v.02|when|with (r_advcl) cause_14\VB\origin.n.03|it|did|not|complication|combined|. (r_conj) caused_1\VBD\make.v.03|cy|cystitis|in|,|but|cause (l_dobj) cystitis_3\NN\urinary_tract_infection.n.01|hemorrhagic
7930386
D002997_D012893 CID clomipramine_0\NNP\tricyclic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|clomipramine|- (r_amod) disturbance_4\NN\activity.n.01|induced|sleep
D002997_D012893 CID clomipramine_15\NN\tricyclic.n.01| (r_compound) administration_16\NN\management.n.01|clomipramine (r_pobj) by_14\IN\by.r.01|administration (r_agent) induced_13\VBN\generate.v.01|by (r_conj) examine_6\VB\analyze.v.01|to|role|,|induced|,|on (l_dobj) role_8\NN\duty.n.02|the|of (l_prep) of_9\IN\entity.n.01|disturbance (l_pobj) disturbance_11\NN\activity.n.01|sleep
3564823
D008012_D013035 NONE lidocaine_7\NN\local_anesthetic.n.01| (r_pobj) by_6\IN\by.r.01|lidocaine (r_prep) relieved_5\VBN\better.v.02|spasm|by|. (l_nsubj) spasm_4\NN\symptom.n.01|induced|arterial
D013874_D002545 NONE pentothal_12\NNS\barbiturate.n.01|sodium (r_nsubjpass) infused_15\VBN\drill.v.04|following|,|pentothal|was|intravenously|minimize|. (l_advcl) minimize_17\VB\decrease.v.02|to|ischaemia (l_dobj) ischaemia_19\NN\anemia.n.01|cerebral
D008012_D020301 NONE lidocaine_11\NN\local_anesthetic.n.01| (r_nsubjpass) given_13\VBN\assumption.n.02|precluded|,|lidocaine|was|,|with|,|counteract|. (l_advcl) counteract_24\VB\act.v.01|to|vasospasm (l_dobj) vasospasm_26\NN\entity.n.01|the
7053303
D002927_D003704 CID cimetidine_10\NN\antacid.n.01|(|with|hr|)|in (r_pobj) due_8\IN\right.n.01|possibly|to|cimetidine (r_amod) case_4\NN\happening.n.01|one|of|due (l_prep) of_5\IN\entity.n.01|dementia (l_pobj) dementia_6\NN\insanity.n.01|
D002927_D003704 CID cimetidine_40\JJ\antacid.n.01| (r_compound) levels_41\NNS\property.n.02|cimetidine (r_dobj) had_39\VBD\have.v.01|who|levels|above (r_relcl) disease_37\NN\illness.n.01|liver|had (r_pobj) without_33\IN\entity.n.01|disease (r_prep) patients_32\NNS\case.n.06|13|without (r_pobj) of_30\IN\entity.n.01|patients (r_prep) group_29\NN\abstraction.n.06|a|of (r_pobj) in_27\IN\linear_unit.n.01|group (r_prep) cimetidine_10\NN\antacid.n.01|(|with|hr|)|in (r_pobj) due_8\IN\right.n.01|possibly|to|cimetidine (r_amod) case_4\NN\happening.n.01|one|of|due (l_prep) of_5\IN\entity.n.01|dementia (l_pobj) dementia_6\NN\insanity.n.01|
D002927_D003704 CID cimetidine_3\NN\antacid.n.01| (r_compound) levels_4\NNS\property.n.02|high|cimetidine|alone (r_nsubj) induce_9\VB\generate.v.01|thus|,|levels|do|not|always|dementia|. (l_dobj) dementia_10\NN\insanity.n.01|
D002927_D008107 NONE cimetidine_10\NN\antacid.n.01|(|with|hr|)|in (l_prep) in_27\IN\linear_unit.n.01|group (l_pobj) group_29\NN\abstraction.n.06|a|of (l_prep) of_30\IN\entity.n.01|patients (l_pobj) patients_32\NNS\case.n.06|13|without (l_prep) without_33\IN\entity.n.01|disease (l_pobj) disease_37\NN\illness.n.01|liver|had
D002927_D008107 NONE cimetidine_40\JJ\antacid.n.01| (r_compound) levels_41\NNS\property.n.02|cimetidine (r_dobj) had_39\VBD\have.v.01|who|levels|above (r_relcl) disease_37\NN\illness.n.01|liver|had
D002927_D007674 NONE cimetidine_10\NN\antacid.n.01|(|with|hr|)|in (l_prep) in_27\IN\linear_unit.n.01|group (l_pobj) group_29\NN\abstraction.n.06|a|of (l_prep) of_30\IN\entity.n.01|patients (l_pobj) patients_32\NNS\case.n.06|13|without (l_prep) without_33\IN\entity.n.01|disease (l_pobj) disease_37\NN\illness.n.01|liver|had
D002927_D007674 NONE cimetidine_40\JJ\antacid.n.01| (r_compound) levels_41\NNS\property.n.02|cimetidine (r_dobj) had_39\VBD\have.v.01|who|levels|above (r_relcl) disease_37\NN\illness.n.01|liver|had
19657887
D000431_D005483 CID alcohol_9\NN\beverage.n.01| (r_pobj) of_8\IN\entity.n.01|alcohol (r_prep) ingestion_7\NN\bodily_process.n.01|the|of (r_pobj) after_5\IN\after.s.01|ingestion (r_prep) hour_4\NN\time_unit.n.01|1|after (r_pobj) in_0\IN\linear_unit.n.01|hour (r_prep) developed_12\VBD\create.v.02|in|,|he|malaise|. (l_dobj) malaise_13\NN\discomfort.n.01|with (l_prep) with_14\IN\entity.n.01|flushing (l_pobj) flushing_15\NN\discolor.v.03|of (l_prep) of_16\IN\entity.n.01|face (l_pobj) face_18\NN\external_body_part.n.01|the|,|tachycardia
D000431_D013610 CID alcohol_9\NN\beverage.n.01| (r_pobj) of_8\IN\entity.n.01|alcohol (r_prep) ingestion_7\NN\bodily_process.n.01|the|of (r_pobj) after_5\IN\after.s.01|ingestion (r_prep) hour_4\NN\time_unit.n.01|1|after (r_pobj) in_0\IN\linear_unit.n.01|hour (r_prep) developed_12\VBD\create.v.02|in|,|he|malaise|. (l_dobj) malaise_13\NN\discomfort.n.01|with (l_prep) with_14\IN\entity.n.01|flushing (l_pobj) flushing_15\NN\discolor.v.03|of (l_prep) of_16\IN\entity.n.01|face (l_pobj) face_18\NN\external_body_part.n.01|the|,|tachycardia (l_conj) tachycardia_20\NN\cardiac_arrhythmia.n.01|,|and|dyspnea
D000431_D004417 CID alcohol_9\NN\beverage.n.01| (r_pobj) of_8\IN\entity.n.01|alcohol (r_prep) ingestion_7\NN\bodily_process.n.01|the|of (r_pobj) after_5\IN\after.s.01|ingestion (r_prep) hour_4\NN\time_unit.n.01|1|after (r_pobj) in_0\IN\linear_unit.n.01|hour (r_prep) developed_12\VBD\create.v.02|in|,|he|malaise|. (l_dobj) malaise_13\NN\discomfort.n.01|with (l_prep) with_14\IN\entity.n.01|flushing (l_pobj) flushing_15\NN\discolor.v.03|of (l_prep) of_16\IN\entity.n.01|face (l_pobj) face_18\NN\external_body_part.n.01|the|,|tachycardia (l_conj) tachycardia_20\NN\cardiac_arrhythmia.n.01|,|and|dyspnea (l_conj) dyspnea_23\NN\symptom.n.01|
D004221_D005483 NONE disulfiram_7\NN\medicine.n.02| (r_npadvmod) like_9\JJ\kind.n.01|disulfiram|- (r_amod) syndrome_10\NN\complex.n.01|like|with (l_prep) with_11\IN\entity.n.01|flushing (l_pcomp) flushing_12\NN\discolor.v.03|,|tachycardia|after
D004221_D013610 NONE disulfiram_7\NN\medicine.n.02| (r_npadvmod) like_9\JJ\kind.n.01|disulfiram|- (r_amod) syndrome_10\NN\complex.n.01|like|with (l_prep) with_11\IN\entity.n.01|flushing (l_pcomp) flushing_12\NN\discolor.v.03|,|tachycardia|after (l_conj) tachycardia_14\NN\cardiac_arrhythmia.n.01|,|and|hypotension
D004221_D007022 NONE disulfiram_7\NN\medicine.n.02| (r_npadvmod) like_9\JJ\kind.n.01|disulfiram|- (r_amod) syndrome_10\NN\complex.n.01|like|with (l_prep) with_11\IN\entity.n.01|flushing (l_pcomp) flushing_12\NN\discolor.v.03|,|tachycardia|after (l_conj) tachycardia_14\NN\cardiac_arrhythmia.n.01|,|and|hypotension (l_conj) hypotension_18\NN\cardiovascular_disease.n.01|arterial
11250767
D011441_D014657 NONE propylthiouracil_0\NNP\organic_compound.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|propylthiouracil|- (r_amod) vasculitis_11\NN\inflammation.n.01|induced|staining|antineutrophil|cytoplasmic|positive|in|.
D011441_D014657 NONE propylthiouracil_5\NN\organic_compound.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|propylthiouracil|- (r_amod) vasculitis_8\NN\inflammation.n.01|induced|manifesting
D011441_D014657 NONE uracil_20\NN\nucleotide.n.01| (r_compound) therapy_21\NN\medical_care.n.01|propylthio-|uracil (r_pobj) with_18\IN\entity.n.01|therapy (r_prep) associated_17\VBN\think.v.03|with (r_acl) vasculitis_16\NN\inflammation.n.01|mpo|positive|associated
D011441_D014657 NONE uracil_14\NN\nucleotide.n.01| (r_compound) therapy_15\NN\medical_care.n.01|uracil (r_appos) propylthio-_13\VB\entity.n.01|therapy (r_pobj) to_12\IN\entity.n.01|propylthio- (r_prep) attributable_11\JJ\attributable.a.01|to (r_amod) manifestation_5\NN\appearance.n.02|the|initial|of|attributable (l_prep) of_6\IN\entity.n.01|vasculitis (l_pobj) vasculitis_10\NN\inflammation.n.01|induced
D011441_D010493 CID propylthiouracil_0\NNP\organic_compound.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|propylthiouracil|- (r_amod) vasculitis_11\NN\inflammation.n.01|induced|staining|antineutrophil|cytoplasmic|positive|in|. (l_prep) in_12\IN\linear_unit.n.01|conjunction (l_pobj) conjunction_13\NN\simultaneity.n.01|with (l_prep) with_14\IN\entity.n.01|pericarditis (l_pobj) pericarditis_15\NN\carditis.n.01|
D011441_D010493 CID propylthiouracil_5\NN\organic_compound.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|propylthiouracil|- (r_amod) vasculitis_8\NN\inflammation.n.01|induced|manifesting (l_acl) manifesting_9\VBG\testify.v.02|with (l_prep) with_10\IN\entity.n.01|pericarditis (l_pobj) pericarditis_11\NN\carditis.n.01|
D011441_D010493 CID propylthiouracil_13\NN\organic_compound.n.01|developed (l_relcl) developed_25\VBD\create.v.02|in|syndrome (l_nsubj) syndrome_17\NN\complex.n.01|a|of (l_prep) of_18\IN\entity.n.01|pericarditis (l_pobj) pericarditis_19\NN\carditis.n.01|,|fever
D011441_D010493 CID uracil_20\NN\nucleotide.n.01| (r_compound) therapy_21\NN\medical_care.n.01|propylthio-|uracil (r_pobj) with_18\IN\entity.n.01|therapy (r_prep) associated_17\VBN\think.v.03|with (r_acl) vasculitis_16\NN\inflammation.n.01|mpo|positive|associated (r_pobj) in_9\IN\linear_unit.n.01|vasculitis (r_prep) reports_6\NNS\document.n.01|no|prior|of|in (l_prep) of_7\IN\entity.n.01|pericarditis (l_pobj) pericarditis_8\NN\carditis.n.01|
D011441_D010493 CID uracil_14\NN\nucleotide.n.01| (r_compound) therapy_15\NN\medical_care.n.01|uracil (r_appos) propylthio-_13\VB\entity.n.01|therapy (r_pobj) to_12\IN\entity.n.01|propylthio- (r_prep) attributable_11\JJ\attributable.a.01|to (r_amod) manifestation_5\NN\appearance.n.02|the|initial|of|attributable (r_attr) be_2\VB\metallic_element.n.01|pericarditis|may|manifestation|. (l_nsubj) pericarditis_0\NNP\carditis.n.01|
D011441_D006980 NONE propylthiouracil_13\NN\organic_compound.n.01|developed (r_pobj) with_12\IN\entity.n.01|propylthiouracil (r_prep) treated_11\VBN\interact.v.01|with (r_acl) report_5\NN\document.n.01|the|first|case|of|treated (l_prep) of_6\IN\entity.n.01|woman (l_pobj) woman_8\NN\adult.n.01|a|with (l_prep) with_9\IN\entity.n.01|hyperthyroidism (l_pobj) hyperthyroidism_10\NN\glandular_disease.n.01|
D011441_D005334 CID propylthiouracil_13\NN\organic_compound.n.01|developed (l_relcl) developed_25\VBD\create.v.02|in|syndrome (l_nsubj) syndrome_17\NN\complex.n.01|a|of (l_prep) of_18\IN\entity.n.01|pericarditis (l_pobj) pericarditis_19\NN\carditis.n.01|,|fever (l_conj) fever_21\NN\symptom.n.01|,|and|glomerulonephritis
D011441_D005921 CID propylthiouracil_13\NN\organic_compound.n.01|developed (l_relcl) developed_25\VBD\create.v.02|in|syndrome (l_nsubj) syndrome_17\NN\complex.n.01|a|of (l_prep) of_18\IN\entity.n.01|pericarditis (l_pobj) pericarditis_19\NN\carditis.n.01|,|fever (l_conj) fever_21\NN\symptom.n.01|,|and|glomerulonephritis (l_conj) glomerulonephritis_24\NN\nephritis.n.01|
17242861
D010862_D012640 NONE pilocarpine_4\NN\alkaloid.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|pilocarpine|- (r_amod) seizures_7\NNS\attack.n.07|induced|,|model|,
D010862_D012640 NONE pilocarpine_4\NN\alkaloid.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|pilocarpine|- (r_amod) seizures_7\NNS\attack.n.07|induced|,|model|, (r_pobj) to_3\IN\entity.n.01|seizures (r_prep) susceptibility_2\NN\condition.n.01|to (r_pobj) for_1\IN\entity.n.01|susceptibility (r_prep) qtls_0\NNS\entity.n.01|for (r_nsubjpass) reported_19\VBN\inform.v.01|qtls|have|not|been|,|and|used (l_conj) used_27\VBN\use.v.01|css|have|not|previously|been|localize|. (l_xcomp) localize_29\VB\situate.v.01|to|genes (l_dobj) genes_32\NNS\sequence.n.01|susceptibility (l_compound) susceptibility_31\NN\condition.n.01|seizure (l_compound) seizure_30\NN\attack.n.07|
D010862_D012640 NONE pilocarpine_9\NN\alkaloid.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|pilocarpine|- (r_amod) seizures_12\NNS\attack.n.07|induced
D010862_D012640 NONE pilocarpine_23\NN\alkaloid.n.01| (r_npadvmod) induced_25\VBN\generate.v.01|pilocarpine|- (r_amod) seizures_26\NNS\attack.n.07|induced
D010862_D004833 CID pilocarpine_4\NN\alkaloid.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|pilocarpine|- (r_amod) seizures_7\NNS\attack.n.07|induced|,|model|, (l_appos) model_10\NN\hypothesis.n.02|a|of (l_prep) of_11\IN\entity.n.01|epilepsy (l_pobj) epilepsy_14\NN\brain_disorder.n.01|temporal|lobe
19803309
D013390_D009224 NONE suxamethonium_29\NN\entity.n.01|intravenous (r_pobj) of_27\IN\entity.n.01|suxamethonium (r_prep) dose_26\NN\medicine.n.02|a|standard|of|for (r_pobj) following_23\VBG\multitude.n.03|dose (r_prep) threatening_20\VBG\exist.v.01|life|spasm|following (r_ccomp) developed_18\VBD\create.v.02|who|threatening (r_relcl) primigravida_15\NN\gravida.n.02|a|old|healthy|,|developed (r_pobj) in_8\IN\linear_unit.n.01|primigravida (r_prep) case_4\NN\happening.n.01|an|undiagnosed|of|in (l_prep) of_5\IN\entity.n.01|congenita (l_pobj) congenita_7\NN\entity.n.01|myotonia
D013390_D014313 CID suxamethonium_29\NN\entity.n.01|intravenous (r_pobj) of_27\IN\entity.n.01|suxamethonium (r_prep) dose_26\NN\medicine.n.02|a|standard|of|for (r_pobj) following_23\VBG\multitude.n.03|dose (r_prep) threatening_20\VBG\exist.v.01|life|spasm|following (l_dobj) spasm_22\NN\symptom.n.01|masseter
19356307
D012601_D003704 NONE scopolamine_9\NN\alkaloid.n.01| (r_pobj) by_8\IN\by.r.01|scopolamine (r_agent) induced_7\VBN\generate.v.01|components|by|. (l_nsubj) components_0\NNS\part.n.09|of (l_prep) of_1\IN\entity.n.01|dementia (l_pobj) dementia_6\NN\insanity.n.01|attenuate
C008281_D003704 NONE limonene_8\NN\terpene.n.01|s|-|and|perillyl (r_nmod) alcohol_13\NN\beverage.n.01|limonene (r_pobj) of_5\IN\entity.n.01|alcohol (r_prep) effects_4\NNS\personal_property.n.01|the|dementia|of (l_compound) dementia_3\NN\insanity.n.01|anti|-
C032208_D003704 NONE alcohol_13\NN\beverage.n.01|limonene (r_pobj) of_5\IN\entity.n.01|alcohol (r_prep) effects_4\NNS\personal_property.n.01|the|dementia|of (l_compound) dementia_3\NN\insanity.n.01|anti|-
D012601_D008569 CID scopolamine_12\NN\alkaloid.n.01| (r_pobj) by_11\IN\by.r.01|scopolamine (r_agent) impaired_10\VBN\damage.v.01|by
D012601_D008569 CID scopolamine_12\NN\alkaloid.n.01| (r_pobj) by_11\IN\by.r.01|scopolamine (r_agent) impaired_10\VBN\damage.v.01|by (r_amod) memory_9\NN\representation.n.01|impaired (r_dobj) improve_8\VB\change.v.01|to|memory (r_acl) ability_6\NN\quality.n.01|strong|improve (r_dobj) showed_4\VBD\show.v.04|oils|ability (r_ccomp) relieved_20\VBD\better.v.02|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_dobj) deficit_22\NN\insufficiency.n.03|the|of|in (l_prep) of_23\IN\entity.n.01|memory (l_pobj) memory_25\NN\representation.n.01|associative
C032208_D008569 NONE alcohol_19\NN\beverage.n.01|perillyl (r_nsubj) relieved_20\VBD\better.v.02|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_ccomp) showed_4\VBD\show.v.04|oils|ability (l_dobj) ability_6\NN\quality.n.01|strong|improve (l_acl) improve_8\VB\change.v.01|to|memory (l_dobj) memory_9\NN\representation.n.01|impaired (l_amod) impaired_10\VBN\damage.v.01|by
C032208_D008569 NONE alcohol_19\NN\beverage.n.01|perillyl (r_nsubj) relieved_20\VBD\better.v.02|showed|;|however|,|alcohol|deficit|only|,|and|improve|. (l_dobj) deficit_22\NN\insufficiency.n.03|the|of|in (l_prep) of_23\IN\entity.n.01|memory (l_pobj) memory_25\NN\representation.n.01|associative
10706004
D012964_D006973 NONE sodium_2\NN\metallic_element.n.01|and|atp (r_nmod) affinities_5\NNS\attraction.n.01|sodium|of (r_pobj) of_1\IN\entity.n.01|affinities (r_prep) changes_0\NNS\happening.n.01|of|during|. (l_prep) during_13\IN\entity.n.01|and|after (l_conj) after_15\IN\after.s.01|hypertension (l_pobj) hypertension_19\NN\cardiovascular_disease.n.01|nitric|deficient
D012964_D006973 NONE na_10\UH\metallic_element.n.01| (r_nmod) k)-atpase_12\NNP\entity.n.01|the|cardiac|(|na|, (r_pobj) of_6\IN\entity.n.01|k)-atpase (r_prep) affinities_5\NNS\attraction.n.01|sodium|of (r_pobj) of_1\IN\entity.n.01|affinities (r_prep) changes_0\NNS\happening.n.01|of|during|. (l_prep) during_13\IN\entity.n.01|and|after (l_conj) after_15\IN\after.s.01|hypertension (l_pobj) hypertension_19\NN\cardiovascular_disease.n.01|nitric|deficient
D012964_D006973 NONE sodium_9\NN\metallic_element.n.01| (r_compound) level_10\NN\property.n.02|intracellular|sodium (r_pobj) of_7\IN\entity.n.01|level (r_prep) elevation_6\NN\rise.n.04|of (r_nsubjpass) documented_12\VBN\record.v.01|in|,|elevation|was|in|. (l_prep) in_0\IN\linear_unit.n.01|models (l_pobj) models_2\NNS\hypothesis.n.02|several|of (l_prep) of_3\IN\entity.n.01|hypertension (l_pobj) hypertension_4\NN\cardiovascular_disease.n.01|
D012964_D006973 NONE na+_11\NNP\entity.n.01| (r_pobj) of_10\IN\entity.n.01|na+ (r_prep) transport_9\NN\instrumentality.n.03|transmembraneous|of (r_pobj) in_7\IN\linear_unit.n.01|transport (r_prep) disturbances_6\NNS\activity.n.01|in (r_pobj) of_5\IN\entity.n.01|disturbances (r_prep) basis_4\NN\foundation.n.01|the|molecular|of (r_dobj) assess_1\VB\body_part.n.01|to|basis (r_advcl) studied_14\VBD\analyze.v.01|assess|,|we|response|induced|. (l_dobj) response_16\NN\consequence.n.01|the|of (l_prep) of_17\IN\entity.n.01|k)-atpase (l_pobj) k)-atpase_22\NNP\entity.n.01|cardiac|(|na|,|to (l_prep) to_23\IN\entity.n.01|hypertension (l_pobj) hypertension_27\NN\cardiovascular_disease.n.01|deficient
D012964_D006973 NONE na_20\UH\metallic_element.n.01| (r_nmod) k)-atpase_22\NNP\entity.n.01|cardiac|(|na|,|to (l_prep) to_23\IN\entity.n.01|hypertension (l_pobj) hypertension_27\NN\cardiovascular_disease.n.01|deficient
D012964_D006973 NONE na_9\NNP\metallic_element.n.01| (r_npadvmod) increased_12\VBD\change_magnitude.v.01|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN\act.n.02|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\after.s.01|recovery (l_pobj) recovery_1\NN\improvement.n.01|from (l_prep) from_2\IN\entity.n.01|hypertension (l_pobj) hypertension_3\NN\cardiovascular_disease.n.01|
D012964_D006973 NONE na+-extrusion_12\NN\entity.n.01|depressed (r_pobj) by_10\IN\by.r.01|na+-extrusion (r_agent) accompanied_9\VBN\attach_to.v.01|by|from|as (r_acl) hypertension_8\NN\cardiovascular_disease.n.01|a|reversible|accompanied
D012964_D006973 NONE na+-binding_21\NN\entity.n.01| (r_compound) properties_22\NNS\possession.n.02|deteriorated|na+-binding|of (r_pobj) of_19\IN\entity.n.01|properties (r_prep) consequence_18\NN\phenomenon.n.01|a|of (r_pobj) as_16\IN\chemical_element.n.01|consequence (r_prep) accompanied_9\VBN\attach_to.v.01|by|from|as (r_acl) hypertension_8\NN\cardiovascular_disease.n.01|a|reversible|accompanied
D012964_D006973 NONE na_26\UH\metallic_element.n.01| (r_nmod) k)-atpase_28\NNP\entity.n.01|the|(|na|, (r_pobj) of_23\IN\entity.n.01|k)-atpase (r_prep) properties_22\NNS\possession.n.02|deteriorated|na+-binding|of (r_pobj) of_19\IN\entity.n.01|properties (r_prep) consequence_18\NN\phenomenon.n.01|a|of (r_pobj) as_16\IN\chemical_element.n.01|consequence (r_prep) accompanied_9\VBN\attach_to.v.01|by|from|as (r_acl) hypertension_8\NN\cardiovascular_disease.n.01|a|reversible|accompanied
D000255_D006973 NONE atp_4\NNP\nucleotide.n.01| (r_conj) sodium_2\NN\metallic_element.n.01|and|atp (r_nmod) affinities_5\NNS\attraction.n.01|sodium|of (r_pobj) of_1\IN\entity.n.01|affinities (r_prep) changes_0\NNS\happening.n.01|of|during|. (l_prep) during_13\IN\entity.n.01|and|after (l_conj) after_15\IN\after.s.01|hypertension (l_pobj) hypertension_19\NN\cardiovascular_disease.n.01|nitric|deficient
D000255_D006973 NONE atp_20\NNP\nucleotide.n.01| (r_npadvmod) binding_22\VBG\attraction.n.03|atp|- (r_amod) site_23\NN\tract.n.01|the|binding (r_pobj) of_18\IN\entity.n.01|site (r_prep) affinity_17\NN\attraction.n.01|higher|of (r_pobj) due_14\IN\right.n.01|to|affinity (r_prep) increased_12\VBD\change_magnitude.v.01|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN\act.n.02|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\after.s.01|recovery (l_pobj) recovery_1\NN\improvement.n.01|from (l_prep) from_2\IN\entity.n.01|hypertension (l_pobj) hypertension_3\NN\cardiovascular_disease.n.01|
D000255_D006973 NONE atp_33\NNP\nucleotide.n.01| (r_pobj) for_32\IN\entity.n.01|atp (r_prep) value_31\NN\numerical_quantity.n.01|the|lowered|km|for (r_pobj) from_27\IN\entity.n.01|value (r_prep) revealed_26\VBN\show.v.04|as|from (r_advcl) activity_6\NN\act.n.02|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\after.s.01|recovery (l_pobj) recovery_1\NN\improvement.n.01|from (l_prep) from_2\IN\entity.n.01|hypertension (l_pobj) hypertension_3\NN\cardiovascular_disease.n.01|
D011188_D006973 NONE k)-atpase_12\NNP\entity.n.01|the|cardiac|(|na|, (r_pobj) of_6\IN\entity.n.01|k)-atpase (r_prep) affinities_5\NNS\attraction.n.01|sodium|of (r_pobj) of_1\IN\entity.n.01|affinities (r_prep) changes_0\NNS\happening.n.01|of|during|. (l_prep) during_13\IN\entity.n.01|and|after (l_conj) after_15\IN\after.s.01|hypertension (l_pobj) hypertension_19\NN\cardiovascular_disease.n.01|nitric|deficient
D011188_D006973 NONE k)-atpase_22\NNP\entity.n.01|cardiac|(|na|,|to (l_prep) to_23\IN\entity.n.01|hypertension (l_pobj) hypertension_27\NN\cardiovascular_disease.n.01|deficient
D011188_D006973 NONE k)-atpase_11\NNP\entity.n.01| (r_nsubj) increased_12\VBD\change_magnitude.v.01|(|na|,|k)-atpase|,|due|, (r_parataxis) activity_6\NN\act.n.02|after|,|the|of|increased|revealed|. (l_prep) after_0\IN\after.s.01|recovery (l_pobj) recovery_1\NN\improvement.n.01|from (l_prep) from_2\IN\entity.n.01|hypertension (l_pobj) hypertension_3\NN\cardiovascular_disease.n.01|
D011188_D006973 NONE k)-atpase_28\NNP\entity.n.01|the|(|na|, (r_pobj) of_23\IN\entity.n.01|k)-atpase (r_prep) properties_22\NNS\possession.n.02|deteriorated|na+-binding|of (r_pobj) of_19\IN\entity.n.01|properties (r_prep) consequence_18\NN\phenomenon.n.01|a|of (r_pobj) as_16\IN\chemical_element.n.01|consequence (r_prep) accompanied_9\VBN\attach_to.v.01|by|from|as (r_acl) hypertension_8\NN\cardiovascular_disease.n.01|a|reversible|accompanied
D009569_D006973 CID oxide_17\NN\compound.n.02| (r_npadvmod) deficient_18\JJ\deficient.s.01|oxide (r_amod) hypertension_19\NN\cardiovascular_disease.n.01|nitric|deficient
D009569_D006973 CID no_2\DT\negative.n.01| (r_det) synthesis_3\NN\chemical_process.n.01|no (r_pobj) of_1\IN\entity.n.01|synthesis (r_prep) inhibition_0\NN\abstinence.n.02|of (r_nsubj) induces_4\VBZ\generate.v.01|inhibition|hypertension|. (l_dobj) hypertension_6\NN\cardiovascular_disease.n.01|sustained
D009569_D006973 CID no_24\JJ\negative.n.01| (r_npadvmod) deficient_26\JJ\deficient.s.01|no|- (r_amod) hypertension_27\NN\cardiovascular_disease.n.01|deficient
D009569_D006973 CID no_32\JJ\negative.n.01| (r_compound) synthase_34\NN\entity.n.01|no|- (r_compound) inhibition_35\NN\abstinence.n.02|synthase|with (r_pobj) by_31\IN\by.r.01|inhibition (r_prep) rats_30\NNS\rodent.n.01|by (r_pobj) in_29\IN\linear_unit.n.01|rats (r_prep) induced_28\VBN\generate.v.01|in|for (r_advcl) studied_14\VBD\analyze.v.01|assess|,|we|response|induced|. (l_dobj) response_16\NN\consequence.n.01|the|of (l_prep) of_17\IN\entity.n.01|k)-atpase (l_pobj) k)-atpase_22\NNP\entity.n.01|cardiac|(|na|,|to (l_prep) to_23\IN\entity.n.01|hypertension (l_pobj) hypertension_27\NN\cardiovascular_disease.n.01|deficient
D009569_D006973 CID no_2\JJ\negative.n.01| (r_compound) synthase_4\NN\entity.n.01|no|- (r_pobj) of_1\IN\entity.n.01|synthase (r_prep) inhibition_0\NN\abstinence.n.02|of (r_nsubj) induced_5\VBD\generate.v.01|inhibition|hypertension|. (l_dobj) hypertension_8\NN\cardiovascular_disease.n.01|a|reversible|accompanied
D019331_D006973 NONE ester_49\NN\organic_compound.n.01|arginine|methyl|name|) (r_appos) kg_40\NNS\metric_weight_unit.n.01|40|mg|/|/|day|ester (r_pobj) with_36\IN\entity.n.01|kg (r_prep) inhibition_35\NN\abstinence.n.02|synthase|with (r_pobj) by_31\IN\by.r.01|inhibition (r_prep) rats_30\NNS\rodent.n.01|by (r_pobj) in_29\IN\linear_unit.n.01|rats (r_prep) induced_28\VBN\generate.v.01|in|for (r_advcl) studied_14\VBD\analyze.v.01|assess|,|we|response|induced|. (l_dobj) response_16\NN\consequence.n.01|the|of (l_prep) of_17\IN\entity.n.01|k)-atpase (l_pobj) k)-atpase_22\NNP\entity.n.01|cardiac|(|na|,|to (l_prep) to_23\IN\entity.n.01|hypertension (l_pobj) hypertension_27\NN\cardiovascular_disease.n.01|deficient
D019331_D006973 NONE name_53\NNP\language_unit.n.01|(|l|- (r_appos) ester_49\NN\organic_compound.n.01|arginine|methyl|name|) (r_appos) kg_40\NNS\metric_weight_unit.n.01|40|mg|/|/|day|ester (r_pobj) with_36\IN\entity.n.01|kg (r_prep) inhibition_35\NN\abstinence.n.02|synthase|with (r_pobj) by_31\IN\by.r.01|inhibition (r_prep) rats_30\NNS\rodent.n.01|by (r_pobj) in_29\IN\linear_unit.n.01|rats (r_prep) induced_28\VBN\generate.v.01|in|for (r_advcl) studied_14\VBD\analyze.v.01|assess|,|we|response|induced|. (l_dobj) response_16\NN\consequence.n.01|the|of (l_prep) of_17\IN\entity.n.01|k)-atpase (l_pobj) k)-atpase_22\NNP\entity.n.01|cardiac|(|na|,|to (l_prep) to_23\IN\entity.n.01|hypertension (l_pobj) hypertension_27\NN\cardiovascular_disease.n.01|deficient
D009569_D003866 NONE no_2\JJ\negative.n.01| (r_compound) synthase_4\NN\entity.n.01|no|- (r_pobj) of_1\IN\entity.n.01|synthase (r_prep) inhibition_0\NN\abstinence.n.02|of (r_nsubj) induced_5\VBD\generate.v.01|inhibition|hypertension|. (l_dobj) hypertension_8\NN\cardiovascular_disease.n.01|a|reversible|accompanied (l_acl) accompanied_9\VBN\attach_to.v.01|by|from|as (l_agent) by_10\IN\by.r.01|na+-extrusion (l_pobj) na+-extrusion_12\NN\entity.n.01|depressed (l_amod) depressed_11\JJ\discourage.v.02|
D012964_D003866 NONE na+-extrusion_12\NN\entity.n.01|depressed (l_amod) depressed_11\JJ\discourage.v.02|
D012964_D003866 NONE na+-binding_21\NN\entity.n.01| (r_compound) properties_22\NNS\possession.n.02|deteriorated|na+-binding|of (r_pobj) of_19\IN\entity.n.01|properties (r_prep) consequence_18\NN\phenomenon.n.01|a|of (r_pobj) as_16\IN\chemical_element.n.01|consequence (r_prep) accompanied_9\VBN\attach_to.v.01|by|from|as (l_agent) by_10\IN\by.r.01|na+-extrusion (l_pobj) na+-extrusion_12\NN\entity.n.01|depressed (l_amod) depressed_11\JJ\discourage.v.02|
D012964_D003866 NONE na_26\UH\metallic_element.n.01| (r_nmod) k)-atpase_28\NNP\entity.n.01|the|(|na|, (r_pobj) of_23\IN\entity.n.01|k)-atpase (r_prep) properties_22\NNS\possession.n.02|deteriorated|na+-binding|of (r_pobj) of_19\IN\entity.n.01|properties (r_prep) consequence_18\NN\phenomenon.n.01|a|of (r_pobj) as_16\IN\chemical_element.n.01|consequence (r_prep) accompanied_9\VBN\attach_to.v.01|by|from|as (l_agent) by_10\IN\by.r.01|na+-extrusion (l_pobj) na+-extrusion_12\NN\entity.n.01|depressed (l_amod) depressed_11\JJ\discourage.v.02|
D011188_D003866 NONE k)-atpase_28\NNP\entity.n.01|the|(|na|, (r_pobj) of_23\IN\entity.n.01|k)-atpase (r_prep) properties_22\NNS\possession.n.02|deteriorated|na+-binding|of (r_pobj) of_19\IN\entity.n.01|properties (r_prep) consequence_18\NN\phenomenon.n.01|a|of (r_pobj) as_16\IN\chemical_element.n.01|consequence (r_prep) accompanied_9\VBN\attach_to.v.01|by|from|as (l_agent) by_10\IN\by.r.01|na+-extrusion (l_pobj) na+-extrusion_12\NN\entity.n.01|depressed (l_amod) depressed_11\JJ\discourage.v.02|
3437726
D013034_D064420 NONE sparteine_11\NN\entity.n.01| (r_nmod) debrisoquine_13\JJ\entity.n.01|sparteine|/ (r_compound) polymorphism_14\NN\organic_phenomenon.n.01|debrisoquine|in|,|constitutes|, (r_pobj) of_10\IN\entity.n.01|polymorphism (r_prep) phenotype_9\NN\constitution.n.04|the|metabolizer|of (r_pobj) to_4\IN\entity.n.01|phenotype (r_prep) belonging_3\VBG\happiness.n.02|to (r_acl) patients_2\NNS\case.n.06|belonging (r_nsubj) experience_29\VB\education.n.02|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_32\NNS\chemical_process.n.01|adverse|drug
D003647_D064420 NONE debrisoquine_13\JJ\entity.n.01|sparteine|/ (r_compound) polymorphism_14\NN\organic_phenomenon.n.01|debrisoquine|in|,|constitutes|, (r_pobj) of_10\IN\entity.n.01|polymorphism (r_prep) phenotype_9\NN\constitution.n.04|the|metabolizer|of (r_pobj) to_4\IN\entity.n.01|phenotype (r_prep) belonging_3\VBG\happiness.n.02|to (r_acl) patients_2\NNS\case.n.06|belonging (r_nsubj) experience_29\VB\education.n.02|therefore|,|patients|may|reactions|treated|. (l_dobj) reactions_32\NNS\chemical_process.n.01|adverse|drug
9293063
D003613_D001650 CID danazol_12\NN\entity.n.01| (r_pobj) with_11\IN\entity.n.01|danazol (r_prep) treatment_10\NN\care.n.01|term|with (r_pobj) with_6\IN\entity.n.01|treatment (r_prep) association_5\NN\organization.n.01|with (r_pobj) in_4\IN\linear_unit.n.01|association (r_prep) occurring_3\VBG\happen.v.01|in (r_acl) hamartoma_2\NN\growth.n.06|duct|occurring|.
D003613_D001650 CID danazol_20\NN\entity.n.01| (r_compound) treatment_21\NN\care.n.01|term|danazol (r_pobj) on_16\IN\on.a.01|treatment (r_prep) been_15\VBN\be.v.01|who|had|on (r_relcl) patient_12\NN\case.n.06|a|been (r_pobj) in_10\IN\linear_unit.n.01|patient (r_prep) developed_9\VBD\create.v.02|which|in (r_relcl) hamartoma_7\NN\growth.n.06|duct|developed
D003613_D006222 CID danazol_12\NN\entity.n.01| (r_pobj) with_11\IN\entity.n.01|danazol (r_prep) treatment_10\NN\care.n.01|term|with (r_pobj) with_6\IN\entity.n.01|treatment (r_prep) association_5\NN\organization.n.01|with (r_pobj) in_4\IN\linear_unit.n.01|association (r_prep) occurring_3\VBG\happen.v.01|in (r_acl) hamartoma_2\NN\growth.n.06|duct|occurring|.
D003613_D006222 CID danazol_20\NN\entity.n.01| (r_compound) treatment_21\NN\care.n.01|term|danazol (r_pobj) on_16\IN\on.a.01|treatment (r_prep) been_15\VBN\be.v.01|who|had|on (r_relcl) patient_12\NN\case.n.06|a|been (r_pobj) in_10\IN\linear_unit.n.01|patient (r_prep) developed_9\VBD\create.v.02|which|in (r_relcl) hamartoma_7\NN\growth.n.06|duct|developed
3371379
D014700_D020258 CID verapamil_0\NNP\calcium_blocker.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|verapamil|-|neurotoxicity|. (l_dobj) neurotoxicity_4\NN\entity.n.01|carbamazepine
D014700_D020258 CID verapamil_11\NN\calcium_blocker.n.01| (r_pobj) with_10\IN\entity.n.01|verapamil (r_prep) treatment_9\NN\care.n.01|combined|with (r_pobj) after_7\IN\after.s.01|treatment (r_prep) signs_3\NNS\clue.n.02|of|after (l_prep) of_4\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_6\NN\entity.n.01|carbamazepine
D002220_D020258 CID carbamazepine_3\NN\entity.n.01| (r_compound) neurotoxicity_4\NN\entity.n.01|carbamazepine
D002220_D020258 CID carbamazepine_5\JJ\entity.n.01| (r_compound) neurotoxicity_6\NN\entity.n.01|carbamazepine
D002118_D020258 NONE calcium_19\NN\metallic_element.n.01| (r_compound) entry_20\NN\written_record.n.01|calcium (r_compound) blocker_21\NN\football_player.n.01|the|entry (r_pobj) of_17\IN\entity.n.01|blocker (r_prep) discontinuation_16\NN\termination.n.05|of (r_pobj) after_15\IN\after.s.01|discontinuation (r_prep) recovery_14\NN\improvement.n.01|complete|after (r_dobj) showed_12\VBD\show.v.04|patients|recovery|. (l_nsubj) patients_1\NNS\case.n.06|two|with (l_prep) with_2\IN\entity.n.01|signs (l_pobj) signs_3\NNS\clue.n.02|of|after (l_prep) of_4\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_6\NN\entity.n.01|carbamazepine
7083920
D000638_D006327 CID amiodarone_13\NN\antiarrhythmic.n.01| (r_compound) treatment_14\NN\care.n.01|amiodarone|for (r_pobj) under_12\IN\nether.s.03|treatment (r_prep) occurring_11\VBG\happen.v.01|under|in|without (r_acl) block_10\NN\artifact.n.01|a|reversible|hisian|occurring
D000638_D013617 NONE amiodarone_13\NN\antiarrhythmic.n.01| (r_compound) treatment_14\NN\care.n.01|amiodarone|for (l_prep) for_15\IN\entity.n.01|tachycardia (l_pobj) tachycardia_17\NNS\cardiac_arrhythmia.n.01|atrial
D000638_D006345 NONE amiodarone_13\NN\antiarrhythmic.n.01| (r_compound) treatment_14\NN\care.n.01|amiodarone|for (r_pobj) under_12\IN\nether.s.03|treatment (r_prep) occurring_11\VBG\happen.v.01|under|in|without (l_prep) without_21\IN\entity.n.01|abnormalities (l_pobj) abnormalities_25\NNS\physical_condition.n.01|clear|intraventricular|conduction
D000638_D001282 NONE amiodarone_3\NN\antiarrhythmic.n.01| (r_compound) discontinuation_4\NN\termination.n.05|amiodarone (r_pobj) after_2\IN\after.s.01|days|discontinuation (r_prep) showed_9\VBD\show.v.04|after|,|electrograms|flutter|. (l_dobj) flutter_11\NN\motion.n.03|atrial|without
230316
D006912_D020258 NONE hydroxyquinolines_3\NNS\entity.n.01|halogenated (r_pobj) of_1\IN\entity.n.01|hydroxyquinolines (r_prep) neurotoxicity_0\NN\entity.n.01|of|:|analysis
D006912_D020258 NONE hydroxyquinolines_13\NNS\entity.n.01|halogenated|reported (r_pobj) to_11\IN\entity.n.01|hydroxyquinolines (r_prep) reactions_10\NNS\chemical_process.n.01|possible|neurotoxic|to (l_amod) neurotoxic_9\JJ\neurotoxic.a.01|
D007464_D009422 NONE clioquinol_25\NN\antifungal.n.01| (r_pobj) of_24\IN\entity.n.01|clioquinol (r_prep) dose_23\NN\medicine.n.02|a|high|of|over (r_pobj) of_20\IN\entity.n.01|dose (r_prep) ingestion_19\NN\bodily_process.n.01|the|of (r_pobj) to_17\IN\entity.n.01|ingestion (r_prep) related_16\VBN\think.v.03|usually|to (r_acl) encephalopathy_14\NN\nervous_disorder.n.01|an|acute|reversible|related (r_pobj) of_10\IN\entity.n.01|encephalopathy (r_prep) consisted_9\VBD\exist.v.01|disturbance|of (l_nsubj) disturbance_8\NN\activity.n.01|the|neurological
D007464_D001927 CID clioquinol_25\NN\antifungal.n.01| (r_pobj) of_24\IN\entity.n.01|clioquinol (r_prep) dose_23\NN\medicine.n.02|a|high|of|over (r_pobj) of_20\IN\entity.n.01|dose (r_prep) ingestion_19\NN\bodily_process.n.01|the|of (r_pobj) to_17\IN\entity.n.01|ingestion (r_prep) related_16\VBN\think.v.03|usually|to (r_acl) encephalopathy_14\NN\nervous_disorder.n.01|an|acute|reversible|related
D007464_C538178 NONE clioquinol_13\NN\antifungal.n.01|as (l_prep) as_14\IN\chemical_element.n.01|treatment (l_pobj) treatment_15\NN\care.n.01|for (l_prep) for_16\IN\entity.n.01|enteropathica (l_pobj) enteropathica_18\NN\entity.n.01|acrodermatitis
11875660
D001374_D009436 NONE 5-azacytidine_6\NN\entity.n.01| (r_pobj) by_5\IN\by.r.01|5-azacytidine (r_agent) induced_4\VBN\generate.v.01|by|at (r_acl) exencephaly_3\NNS\entity.n.01|the|induced
603022
D005702_D062787 NONE hydrobromide_1\RB\entity.n.01|galanthamine|,|drug|, (r_nsubjpass) used_16\VBN\use.v.01|hydrobromide|was|in|. (l_prep) in_17\IN\linear_unit.n.01|patient (l_pobj) patient_19\JJ\case.n.06|a|demonstrating (l_acl) demonstrating_20\NN\show.v.04|effects (l_dobj) effects_22\NNS\personal_property.n.01|central|of (l_prep) of_23\IN\entity.n.01|overdosage (l_pobj) overdosage_28\NN\entity.n.01|scopolamine|(|hyoscine|)
D012601_D062787 CID scopolamine_24\NN\alkaloid.n.01| (r_nmod) overdosage_28\NN\entity.n.01|scopolamine|(|hyoscine|)
D012601_D062787 CID hyoscine_26\NN\alkaloid.n.01| (r_nmod) overdosage_28\NN\entity.n.01|scopolamine|(|hyoscine|)
20880751
D007980_D004409 CID levodopa_0\NNP\dopa.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|levodopa|-|dyskinesias|:|filling|. (l_dobj) dyskinesias_3\NNS\nervous_disorder.n.01|in
D007980_D004409 CID levodopa_17\NN\dopa.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_20\NNS\nervous_disorder.n.01|underlying|induced
D007980_D004409 CID levodopa_41\NN\dopa.n.01| (r_npadvmod) induced_43\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_44\NNS\nervous_disorder.n.01|induced
D007980_D010300 NONE levodopa_0\NNP\dopa.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|levodopa|-|dyskinesias|:|filling|. (l_dobj) dyskinesias_3\NNS\nervous_disorder.n.01|in (l_prep) in_4\IN\linear_unit.n.01|patients (l_pobj) patients_5\NNS\case.n.06|with (l_prep) with_6\IN\entity.n.01|disease (l_pobj) disease_9\NN\illness.n.01|parkinson
D007980_D010300 NONE levodopa_0\NNP\dopa.n.01| (r_nsubj) is_1\VBZ\be.v.01|levodopa|drug|. (l_attr) drug_5\NN\agent.n.03|the|effective|for (l_prep) for_6\IN\entity.n.01|treatment (l_pobj) treatment_8\NN\care.n.01|the|of (l_prep) of_9\IN\entity.n.01|disease (l_pobj) disease_12\NN\illness.n.01|parkinson
D004298_D004409 NONE dopamine_9\NN\monoamine_neurotransmitter.n.01| (r_compound) precursor_10\NN\material.n.01|this|dopamine (r_pobj) of_7\IN\entity.n.01|precursor (r_prep) use_6\NN\activity.n.01|the|term|of (r_nsubjpass) complicated_12\VBN\change.v.01|however|,|use|is|by|. (l_agent) by_13\IN\by.r.01|fluctuations (l_pobj) fluctuations_16\NNS\wave.n.03|disabling|and|dyskinesias (l_conj) dyskinesias_18\NNS\nervous_disorder.n.01|
D004298_D004409 NONE dopamine_21\NN\monoamine_neurotransmitter.n.01| (r_compound) subtypes_23\NNS\entity.n.01|dopamine|receptor|,|receptors (l_conj) receptors_29\NNS\structure.n.04|ionotropic|glutamate|,|and|systems (l_conj) systems_36\NNS\instrumentality.n.03|dopaminergic|neurotransmitter|in (l_prep) in_37\IN\linear_unit.n.01|pathophysiology (l_pobj) pathophysiology_39\NN\entity.n.01|the|of (l_prep) of_40\IN\entity.n.01|dyskinesias (l_pobj) dyskinesias_44\NNS\nervous_disorder.n.01|induced
D018698_D004409 NONE glutamate_28\NN\salt.n.01| (r_compound) receptors_29\NNS\structure.n.04|ionotropic|glutamate|,|and|systems (l_conj) systems_36\NNS\instrumentality.n.03|dopaminergic|neurotransmitter|in (l_prep) in_37\IN\linear_unit.n.01|pathophysiology (l_pobj) pathophysiology_39\NN\entity.n.01|the|of (l_prep) of_40\IN\entity.n.01|dyskinesias (l_pobj) dyskinesias_44\NNS\nervous_disorder.n.01|induced
6861444
D009638_D006973 CID noradrenaline_3\NN\catecholamine.n.01| (r_pobj) of_2\IN\entity.n.01|noradrenaline (r_prep) infusion_1\NN\solution.n.01|intrarenal|of (r_nsubj) caused_4\VBD\make.v.03|infusion|hypertension|at|. (l_dobj) hypertension_5\NN\cardiovascular_disease.n.01|
D009638_D006973 CID noradrenaline_8\NN\catecholamine.n.01| (r_amod) infusion_9\NN\solution.n.01|chronic|intrarenal|noradrenaline (r_pobj) after_5\IN\after.s.01|infusion (r_prep) hypertension_4\NN\cardiovascular_disease.n.01|after
D009638_D006973 CID noradrenaline_18\NN\catecholamine.n.01| (r_dobj) circulating_17\VBG\travel.v.01|noradrenaline (r_pcomp) of_16\IN\entity.n.01|circulating (r_prep) levels_15\NNS\property.n.02|higher|of (r_pobj) by_12\IN\by.r.01|levels|and|by (r_agent) produced_11\VBN\make.v.03|that|hypertension|is|by (l_nsubjpass) hypertension_4\NN\cardiovascular_disease.n.01|after
3192036
18186898
D019259_D006509 NONE lamivudine_0\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_nsubjpass) added_2\VBN\increase.v.01|lamivudine|was|because|. (l_prep) because_3\IN\entity.n.01|of|infection (l_pobj) infection_9\NN\ill_health.n.01|de|b|during
D016559_D000138 NONE tacrolimus_1\NN\entity.n.01| (r_nsubjpass) suspected_3\VBN\guess.v.02|although|tacrolimus|was|be|and|replaced (l_xcomp) be_5\VB\metallic_element.n.01|to|cause (l_attr) cause_7\NN\origin.n.03|the|of (l_prep) of_8\IN\entity.n.01|acidosis (l_pobj) acidosis_14\NN\pathology.n.02|transplant|renal
D016559_D000138 NONE tacrolimus_1\NN\entity.n.01| (r_nsubjpass) suspected_3\VBN\guess.v.02|although|tacrolimus|was|be|and|replaced (l_conj) replaced_17\VBN\regenerate.v.01|was|by (l_agent) by_18\IN\by.r.01|sirolimus (l_pobj) sirolimus_19\NN\entity.n.01|,|acidosis (l_conj) acidosis_21\NN\pathology.n.02|,|and|got
D020123_D000138 NONE sirolimus_19\NN\entity.n.01|,|acidosis (r_pobj) by_18\IN\by.r.01|sirolimus (r_agent) replaced_17\VBN\regenerate.v.01|was|by (r_conj) suspected_3\VBN\guess.v.02|although|tacrolimus|was|be|and|replaced (l_xcomp) be_5\VB\metallic_element.n.01|to|cause (l_attr) cause_7\NN\origin.n.03|the|of (l_prep) of_8\IN\entity.n.01|acidosis (l_pobj) acidosis_14\NN\pathology.n.02|transplant|renal
D020123_D000138 NONE sirolimus_19\NN\entity.n.01|,|acidosis (l_conj) acidosis_21\NN\pathology.n.02|,|and|got
D016559_D005198 CID tacrolimus_20\NN\entity.n.01| (r_pobj) by_19\IN\by.r.01|tacrolimus (r_agent) triggered_18\VBN\initiate.v.02|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\pathology.n.02|mitochondrial|triggered (r_pobj) from_13\IN\entity.n.01|dysfunction (r_prep) resulted_12\VBN\prove.v.01|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\pathology.n.02|patient|tubular|and|myopathy
D016559_D009135 CID tacrolimus_20\NN\entity.n.01| (r_pobj) by_19\IN\by.r.01|tacrolimus (r_agent) triggered_18\VBN\initiate.v.02|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\pathology.n.02|mitochondrial|triggered (r_pobj) from_13\IN\entity.n.01|dysfunction (r_prep) resulted_12\VBN\prove.v.01|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\pathology.n.02|patient|tubular|and|myopathy (l_conj) myopathy_9\NNS\pathology.n.02|
D016559_D028361 NONE tacrolimus_20\NN\entity.n.01| (r_pobj) by_19\IN\by.r.01|tacrolimus (r_agent) triggered_18\VBN\initiate.v.02|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\pathology.n.02|mitochondrial|triggered
D019259_D005198 CID lamivudine_24\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) by_23\IN\by.r.01|lamivudine (r_agent) augmented_22\VBN\increase.v.02|by (r_conj) triggered_18\VBN\initiate.v.02|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\pathology.n.02|mitochondrial|triggered (r_pobj) from_13\IN\entity.n.01|dysfunction (r_prep) resulted_12\VBN\prove.v.01|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\pathology.n.02|patient|tubular|and|myopathy
D019259_D009135 CID lamivudine_24\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) by_23\IN\by.r.01|lamivudine (r_agent) augmented_22\VBN\increase.v.02|by (r_conj) triggered_18\VBN\initiate.v.02|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\pathology.n.02|mitochondrial|triggered (r_pobj) from_13\IN\entity.n.01|dysfunction (r_prep) resulted_12\VBN\prove.v.01|that|dysfunction|may|have|from (l_nsubj) dysfunction_7\NN\pathology.n.02|patient|tubular|and|myopathy (l_conj) myopathy_9\NNS\pathology.n.02|
D019259_D028361 NONE lamivudine_24\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) by_23\IN\by.r.01|lamivudine (r_agent) augmented_22\VBN\increase.v.02|by (r_conj) triggered_18\VBN\initiate.v.02|which|is|by|and|augmented (r_relcl) dysfunction_15\NN\pathology.n.02|mitochondrial|triggered
3125768
D015760_D009127 CID alfentanil_4\NN\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|alfentanil|- (r_amod) rigidity_7\NN\inelasticity.n.01|induced
D015760_D009127 CID alfentanil_8\NN\entity.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|alfentanil|- (r_amod) rigidity_11\NN\inelasticity.n.01|induced|in
D015760_D009127 CID alfentanil_9\NN\entity.n.01|when (r_advcl) prevented_7\VBN\prevent.v.01|that|rigidity|should|be|alfentanil|,|and|,|used (l_nsubjpass) rigidity_4\NN\inelasticity.n.01|
C032943_D009127 NONE metocurine_10\NN\entity.n.01| (r_pobj) with_9\IN\entity.n.01|metocurine (r_prep) abolished_8\VBN\abolish.v.01|when|rigidity|was|with (l_nsubjpass) rigidity_6\NN\inelasticity.n.01|
12615818
D017373_D054556 CID acetate_9\NN\salt.n.01|in (r_oprd) prescribed_7\VBD\inflict.v.01|cyproterone|acetate (r_acl) women_6\NNS\adult.n.01|prescribed (r_pobj) in_5\IN\linear_unit.n.01|women (r_prep) thromboembolism_4\NN\occlusion.n.01|venous|in
D017373_D054556 CID cpa_15\NNP\accountant.n.01| (r_nmod) ee_17\NNP\engineering.n.02|cpa|/ (r_pobj) with_14\IN\entity.n.01|ee (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated
D017373_D054556 CID cpa_15\NNP\accountant.n.01| (r_nmod) ee_17\NNP\engineering.n.02|cpa|/ (r_pobj) with_14\IN\entity.n.01|ee (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated (l_appos) vte_11\NNP\entity.n.01|
D017373_D054556 CID cpa_42\NNP\accountant.n.01| (r_nmod) ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated
D017373_D054556 CID cpa_13\NNP\accountant.n.01| (r_nmod) ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (r_pobj) with_9\IN\entity.n.01|use (r_prep) associated_8\VBN\think.v.03|with|confounding (r_acl) risk_5\NN\danger.n.03|an|increased|of|associated (l_prep) of_6\IN\entity.n.01|vte (l_pobj) vte_7\NNP\entity.n.01|
D004997_D054556 CID estradiol_14\NN\estrogen.n.01|:|analysis (r_appos) risk_1\NN\danger.n.03|the|of|estradiol|. (l_prep) of_2\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_4\NN\occlusion.n.01|venous|in
D004997_D054556 CID ee_17\NNP\engineering.n.02|cpa|/ (r_pobj) with_14\IN\entity.n.01|ee (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated
D004997_D054556 CID ee_17\NNP\engineering.n.02|cpa|/ (r_pobj) with_14\IN\entity.n.01|ee (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated (l_appos) vte_11\NNP\entity.n.01|
D004997_D054556 CID ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated
D004997_D054556 CID ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (r_pobj) with_9\IN\entity.n.01|use (r_prep) associated_8\VBN\think.v.03|with|confounding (r_acl) risk_5\NN\danger.n.03|an|increased|of|associated (l_prep) of_6\IN\entity.n.01|vte (l_pobj) vte_7\NNP\entity.n.01|
D017373_D000152 NONE acetate_1\NN\salt.n.01|cyproterone|combined (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism
D017373_D000152 NONE cpa_7\NNP\accountant.n.01| (r_nmod) ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism
D017373_D000152 NONE cpa_42\NNP\accountant.n.01| (r_nmod) ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated (r_pobj) of_38\IN\entity.n.01|vte (r_prep) risk_37\NN\danger.n.03|the|of (r_dobj) estimate_35\VB\calculation.n.02|to|risk (r_advcl) conducted_7\VBD\manage.v.02|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\time_of_life.n.01|15|with (l_prep) with_28\IN\entity.n.01|acne (l_pobj) acne_29\NN\inflammatory_disease.n.01|,|hirsutism
D017373_D000152 NONE cpa_13\NNP\accountant.n.01| (r_nmod) ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (l_prep) in_16\IN\linear_unit.n.01|women (l_pobj) women_17\NNS\adult.n.01|with (l_prep) with_18\IN\entity.n.01|acne (l_pobj) acne_19\NN\inflammatory_disease.n.01|,|hirsutism
D017373_D006628 NONE acetate_1\NN\salt.n.01|cyproterone|combined (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism (l_conj) hirsutism_24\NN\hairiness.n.01|
D017373_D006628 NONE cpa_7\NNP\accountant.n.01| (r_nmod) ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism (l_conj) hirsutism_24\NN\hairiness.n.01|
D017373_D006628 NONE cpa_42\NNP\accountant.n.01| (r_nmod) ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated (r_pobj) of_38\IN\entity.n.01|vte (r_prep) risk_37\NN\danger.n.03|the|of (r_dobj) estimate_35\VB\calculation.n.02|to|risk (r_advcl) conducted_7\VBD\manage.v.02|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\time_of_life.n.01|15|with (l_prep) with_28\IN\entity.n.01|acne (l_pobj) acne_29\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_31\NN\hairiness.n.01|or|pcos
D017373_D006628 NONE cpa_13\NNP\accountant.n.01| (r_nmod) ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (l_prep) in_16\IN\linear_unit.n.01|women (l_pobj) women_17\NNS\adult.n.01|with (l_prep) with_18\IN\entity.n.01|acne (l_pobj) acne_19\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_21\NN\hairiness.n.01|or|pcos
D017373_D011085 NONE acetate_1\NN\salt.n.01|cyproterone|combined (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|)
D017373_D011085 NONE acetate_1\NN\salt.n.01|cyproterone|combined (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\entity.n.01|
D017373_D011085 NONE cpa_7\NNP\accountant.n.01| (r_nmod) ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|)
D017373_D011085 NONE cpa_7\NNP\accountant.n.01| (r_nmod) ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\entity.n.01|
D017373_D011085 NONE cpa_42\NNP\accountant.n.01| (r_nmod) ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated (r_pobj) of_38\IN\entity.n.01|vte (r_prep) risk_37\NN\danger.n.03|the|of (r_dobj) estimate_35\VB\calculation.n.02|to|risk (r_advcl) conducted_7\VBD\manage.v.02|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\time_of_life.n.01|15|with (l_prep) with_28\IN\entity.n.01|acne (l_pobj) acne_29\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_31\NN\hairiness.n.01|or|pcos (l_conj) pcos_33\NNP\entity.n.01|
D017373_D011085 NONE cpa_13\NNP\accountant.n.01| (r_nmod) ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (l_prep) in_16\IN\linear_unit.n.01|women (l_pobj) women_17\NNS\adult.n.01|with (l_prep) with_18\IN\entity.n.01|acne (l_pobj) acne_19\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_21\NN\hairiness.n.01|or|pcos (l_conj) pcos_23\NNP\entity.n.01|
D004997_D000152 NONE estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism
D004997_D000152 NONE ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism
D004997_D000152 NONE ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated (r_pobj) of_38\IN\entity.n.01|vte (r_prep) risk_37\NN\danger.n.03|the|of (r_dobj) estimate_35\VB\calculation.n.02|to|risk (r_advcl) conducted_7\VBD\manage.v.02|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\time_of_life.n.01|15|with (l_prep) with_28\IN\entity.n.01|acne (l_pobj) acne_29\NN\inflammatory_disease.n.01|,|hirsutism
D004997_D000152 NONE ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (l_prep) in_16\IN\linear_unit.n.01|women (l_pobj) women_17\NNS\adult.n.01|with (l_prep) with_18\IN\entity.n.01|acne (l_pobj) acne_19\NN\inflammatory_disease.n.01|,|hirsutism
D004997_D006628 NONE estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism (l_conj) hirsutism_24\NN\hairiness.n.01|
D004997_D006628 NONE ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_prep) for_16\IN\entity.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|women (l_pobj) women_20\NNS\adult.n.01|with (l_prep) with_21\IN\entity.n.01|acne (l_pobj) acne_22\NN\inflammatory_disease.n.01|and|hirsutism (l_conj) hirsutism_24\NN\hairiness.n.01|
D004997_D006628 NONE ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated (r_pobj) of_38\IN\entity.n.01|vte (r_prep) risk_37\NN\danger.n.03|the|of (r_dobj) estimate_35\VB\calculation.n.02|to|risk (r_advcl) conducted_7\VBD\manage.v.02|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\time_of_life.n.01|15|with (l_prep) with_28\IN\entity.n.01|acne (l_pobj) acne_29\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_31\NN\hairiness.n.01|or|pcos
D004997_D006628 NONE ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (l_prep) in_16\IN\linear_unit.n.01|women (l_pobj) women_17\NNS\adult.n.01|with (l_prep) with_18\IN\entity.n.01|acne (l_pobj) acne_19\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_21\NN\hairiness.n.01|or|pcos
D004997_D011085 NONE estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|)
D004997_D011085 NONE estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\entity.n.01|
D004997_D011085 NONE ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|)
D004997_D011085 NONE ee_9\NNP\engineering.n.02|cpa|/ (r_appos) estradiol_5\NN\estrogen.n.01|(|ee|) (r_nsubjpass) licensed_12\VBN\authorize.v.01|acetate|estradiol|is|in|for|and|is|. (l_conj) is_26\VBZ\be.v.01|also|option (l_attr) option_30\NN\derivative_instrument.n.01|a|treatment|for (l_prep) for_31\IN\entity.n.01|syndrome (l_pobj) syndrome_34\NN\complex.n.01|polycystic|ovary|(|pcos|) (l_appos) pcos_36\NNP\entity.n.01|
D004997_D011085 NONE ee_44\NNP\engineering.n.02|cpa|/ (r_pobj) with_41\IN\entity.n.01|ee (r_prep) associated_40\VBN\think.v.03|with (r_acl) vte_39\NNP\entity.n.01|associated (r_pobj) of_38\IN\entity.n.01|vte (r_prep) risk_37\NN\danger.n.03|the|of (r_dobj) estimate_35\VB\calculation.n.02|to|risk (r_advcl) conducted_7\VBD\manage.v.02|using|we|analysis|years|estimate|. (l_npadvmod) years_27\NNS\time_of_life.n.01|15|with (l_prep) with_28\IN\entity.n.01|acne (l_pobj) acne_29\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_31\NN\hairiness.n.01|or|pcos (l_conj) pcos_33\NNP\entity.n.01|
D004997_D011085 NONE ee_15\NNP\engineering.n.02|cpa|/ (r_pobj) of_12\IN\entity.n.01|ee (r_prep) use_11\NN\activity.n.01|the|of|in (l_prep) in_16\IN\linear_unit.n.01|women (l_pobj) women_17\NNS\adult.n.01|with (l_prep) with_18\IN\entity.n.01|acne (l_pobj) acne_19\NN\inflammatory_disease.n.01|,|hirsutism (l_conj) hirsutism_21\NN\hairiness.n.01|or|pcos (l_conj) pcos_23\NNP\entity.n.01|
D003276_D054556 NONE contraceptives_23\NNS\device.n.01|conventional|combined|oral|(|cocs|) (r_pobj) with_19\IN\entity.n.01|contraceptives (r_prep) compared_18\VBN\analyze.v.01|with (r_prep) demonstrated_3\VBN\show.v.04|studies|have|risk|compared|. (l_dobj) risk_6\NN\danger.n.03|an|increased|of (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated
D003276_D054556 NONE contraceptives_23\NNS\device.n.01|conventional|combined|oral|(|cocs|) (r_pobj) with_19\IN\entity.n.01|contraceptives (r_prep) compared_18\VBN\analyze.v.01|with (r_prep) demonstrated_3\VBN\show.v.04|studies|have|risk|compared|. (l_dobj) risk_6\NN\danger.n.03|an|increased|of (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated (l_appos) vte_11\NNP\entity.n.01|
2008831
D008755_D000788 NONE methylergonovine_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|methylergonovine (r_prep) administration_4\NN\management.n.01|direct|intracoronary|of|in (l_prep) in_7\IN\linear_unit.n.01|patients (l_pobj) patients_8\NNS\case.n.06|with (l_prep) with_9\IN\entity.n.01|and|without (l_conj) without_11\IN\entity.n.01|angina (l_pobj) angina_13\NN\inflammatory_disease.n.01|variant
D008755_D000788 NONE methylergonovine_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|methylergonovine (r_prep) administration_4\NN\management.n.01|intracoronary|of (r_pobj) of_2\IN\entity.n.01|administration (r_prep) effects_1\NNS\personal_property.n.01|the|of (r_nsubjpass) studied_8\VBN\analyze.v.01|effects|were|in|without|. (l_prep) in_9\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|21|with (l_prep) with_12\IN\entity.n.01|angina (l_pobj) angina_14\NN\inflammatory_disease.n.01|variant|and|patients
D008755_D000788 NONE methylergonovine_19\NN\entity.n.01| (r_pobj) of_18\IN\entity.n.01|methylergonovine (r_prep) dose_17\NN\medicine.n.02|a|low|of (r_pobj) of_13\IN\entity.n.01|dose (r_prep) injection_12\NN\insertion.n.02|an|intracoronary|of (r_dobj) use_9\VBP\activity.n.01|which|injection (r_relcl) tests_6\NNS\experiment.n.02|spasm|provocation|,|use|, (r_nsubj) have_21\VBP\person.n.01|that|tests|sensitivity|and|be (l_dobj) sensitivity_24\NN\sense.n.03|a|high|in (l_prep) in_25\IN\linear_unit.n.01|angina (l_pobj) angina_27\NN\inflammatory_disease.n.01|variant
D008755_D002637 NONE methylergonovine_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|methylergonovine (r_prep) administration_4\NN\management.n.01|intracoronary|of (r_pobj) of_2\IN\entity.n.01|administration (r_prep) effects_1\NNS\personal_property.n.01|the|of (r_nsubjpass) studied_8\VBN\analyze.v.01|effects|were|in|without|. (l_prep) in_9\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|21|with (l_prep) with_12\IN\entity.n.01|angina (l_pobj) angina_14\NN\inflammatory_disease.n.01|variant|and|patients (l_conj) patients_17\NNS\case.n.06|22|with (l_prep) with_18\IN\entity.n.01|pain|and|in (l_pobj) pain_21\NN\symptom.n.01|atypical|chest
D008755_D000787 NONE methylergonovine_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|methylergonovine (r_prep) administration_4\NN\management.n.01|intracoronary|of (r_pobj) of_2\IN\entity.n.01|administration (r_prep) effects_1\NNS\personal_property.n.01|the|of (r_nsubjpass) studied_8\VBN\analyze.v.01|effects|were|in|without|. (l_prep) without_25\IN\entity.n.01|angina (l_pobj) angina_26\NN\inflammatory_disease.n.01|pectoris (l_appos) pectoris_27\NN\entity.n.01|group
D008755_D013035 NONE methylergonovine_19\NN\entity.n.01| (r_pobj) of_18\IN\entity.n.01|methylergonovine (r_prep) dose_17\NN\medicine.n.02|a|low|of (r_pobj) of_13\IN\entity.n.01|dose (r_prep) injection_12\NN\insertion.n.02|an|intracoronary|of (r_dobj) use_9\VBP\activity.n.01|which|injection (r_relcl) tests_6\NNS\experiment.n.02|spasm|provocation|,|use|, (l_compound) spasm_4\NN\symptom.n.01|
3780846
D009020_D009127 CID morphine_14\NN\analgesic.n.01| (r_pobj) by_13\IN\by.r.01|morphine (r_agent) produced_12\VBN\make.v.03|by|in (r_acl) rigidity_11\NN\inelasticity.n.01|the|muscular|produced
D009020_D009127 CID morphine_10\NN\analgesic.n.01| (r_pobj) by_9\IN\by.r.01|morphine (r_agent) produced_8\VBN\make.v.03|by (r_acl) rigidity_7\NN\inelasticity.n.01|the|muscular|produced
D009020_D009127 CID morphine_9\NN\analgesic.n.01| (r_pobj) of_8\IN\entity.n.01|morphine (r_prep) dose_7\NN\medicine.n.02|a|test|of|(|mg/kg|) (r_dobj) given_4\VBN\assumption.n.02|controls|dose (r_csubj) showed_15\VBD\show.v.04|given|rigidity|. (l_dobj) rigidity_18\NN\inelasticity.n.01|a|pronounced|recorded
D009020_D009127 CID morphine_6\NN\analgesic.n.01| (r_pobj) with_5\IN\entity.n.01|morphine (r_prep) treated_1\VBD\interact.v.01|rats|for|with|and|withdrawn|h|showed|showed|. (l_conj) showed_27\VBD\show.v.04|half|rigidity|after (l_dobj) rigidity_29\NN\inelasticity.n.01|a
D009020_D009127 CID morphine_35\NN\analgesic.n.01| (r_pobj) of_34\IN\entity.n.01|morphine (r_prep) dose_33\NN\medicine.n.02|the|test|of|was|group (r_pobj) after_30\IN\after.s.01|dose (r_prep) showed_27\VBD\show.v.04|half|rigidity|after (l_dobj) rigidity_29\NN\inelasticity.n.01|a
D009020_D009127 CID morphine_16\NN\analgesic.n.01| (r_pobj) of_15\IN\entity.n.01|morphine (r_prep) action_14\NN\act.n.02|an|of|in (r_pobj) to_12\IN\entity.n.01|action (r_prep) due_11\JJ\right.n.01|to (r_acomp) be_10\VB\metallic_element.n.01|to|due (r_xcomp) assumed_8\VBN\expect.v.01|which|is|be (r_relcl) rigidity_4\NN\inelasticity.n.01|,|assumed|,
D009020_D018476 CID morphine_6\NN\analgesic.n.01| (r_pobj) with_5\IN\entity.n.01|morphine (r_prep) treated_1\VBD\interact.v.01|rats|for|with|and|withdrawn|h|showed|showed|. (l_conj) showed_27\VBD\show.v.04|half|rigidity|after (l_prep) after_30\IN\after.s.01|dose (l_pobj) dose_33\NN\medicine.n.02|the|test|of|was|group (l_relcl) was_37\VBD\washington.n.02|that|not|less|and|were (l_conj) were_46\VBD\be.v.01|akinetic (l_acomp) akinetic_47\JJ\entity.n.01|
D009020_D018476 CID morphine_35\NN\analgesic.n.01| (r_pobj) of_34\IN\entity.n.01|morphine (r_prep) dose_33\NN\medicine.n.02|the|test|of|was|group (l_relcl) was_37\VBD\washington.n.02|that|not|less|and|were (l_conj) were_46\VBD\be.v.01|akinetic (l_acomp) akinetic_47\JJ\entity.n.01|
D006220_D009127 CID haloperidol_7\NN\major_tranquilizer.n.01|(|mg/kg|i.p.|) (r_nsubjpass) used_14\VBN\use.v.01|in|,|haloperidol|was|in|. (l_prep) in_15\IN\linear_unit.n.01|order (l_pobj) order_16\NN\command.n.01|block (l_acl) block_18\VB\artifact.n.01|to|activation|and|estimate (l_conj) estimate_24\VB\calculation.n.02|to|degree (l_dobj) degree_27\NN\property.n.02|the|real|of (l_prep) of_28\IN\entity.n.01|tolerance (l_pobj) tolerance_30\NN\endurance.n.01|the|to (l_prep) to_31\IN\entity.n.01|rigidity (l_pobj) rigidity_33\NN\inelasticity.n.01|the|without
D006220_D009127 CID haloperidol_0\NNP\major_tranquilizer.n.01| (r_nsubj) enhanced_1\VBD\intensify.v.02|haloperidol|rigidity|. (l_dobj) rigidity_3\NN\inelasticity.n.01|the|in
2887062
D004967_D015175 CID estrogen_8\NN\steroid_hormone.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|estrogen|- (r_amod) prolactinomas_12\NNS\entity.n.01|induced|rat|after
D004967_D015175 CID estrogen_21\NN\steroid_hormone.n.01| (r_npadvmod) induced_23\VBN\generate.v.01|estrogen|- (r_amod) cells_26\NNS\compartment.n.01|induced|rat|prolactinoma|h|and (r_pobj) to_20\IN\entity.n.01|cells (r_prep) applied_19\VBN\use.v.01|clarify|analyses|were|to|h|. (l_advcl) clarify_1\VB\explain.v.01|to|effects (l_dobj) effects_3\NNS\personal_property.n.01|the|of|on (l_prep) on_6\IN\on.a.01|cells (l_pobj) cells_8\NNS\compartment.n.01|prolactinoma|in (l_compound) prolactinoma_7\NN\entity.n.01|
D004967_D015175 CID estrogen_21\NN\steroid_hormone.n.01| (r_npadvmod) induced_23\VBN\generate.v.01|estrogen|- (r_amod) cells_26\NNS\compartment.n.01|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN\entity.n.01|
D001971_D015175 NONE bromocriptine_14\NN\entity.n.01| (r_amod) treatment_15\NN\care.n.01|bromocriptine (r_pobj) after_13\IN\after.s.01|treatment (r_prep) prolactinomas_12\NNS\entity.n.01|induced|rat|after
D001971_D015175 NONE bromocriptine_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|bromocriptine (r_prep) effects_3\NNS\personal_property.n.01|the|of|on (l_prep) on_6\IN\on.a.01|cells (l_pobj) cells_8\NNS\compartment.n.01|prolactinoma|in (l_compound) prolactinoma_7\NN\entity.n.01|
D001971_D015175 NONE bromocriptine_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|bromocriptine (r_prep) effects_3\NNS\personal_property.n.01|the|of|on (r_dobj) clarify_1\VB\explain.v.01|to|effects (r_advcl) applied_19\VBN\use.v.01|clarify|analyses|were|to|h|. (l_prep) to_20\IN\entity.n.01|cells (l_pobj) cells_26\NNS\compartment.n.01|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN\entity.n.01|
D001971_D015175 NONE bromocriptine_35\NN\entity.n.01| (r_pobj) of_34\IN\entity.n.01|bromocriptine (r_prep) injection_33\NN\insertion.n.02|of (r_pobj) after_32\IN\after.s.01|injection (r_prep) h_31\NN\chemical_element.n.01|6|after|mg/kg (r_conj) applied_19\VBN\use.v.01|clarify|analyses|were|to|h|. (l_advcl) clarify_1\VB\explain.v.01|to|effects (l_dobj) effects_3\NNS\personal_property.n.01|the|of|on (l_prep) on_6\IN\on.a.01|cells (l_pobj) cells_8\NNS\compartment.n.01|prolactinoma|in (l_compound) prolactinoma_7\NN\entity.n.01|
D001971_D015175 NONE bromocriptine_35\NN\entity.n.01| (r_pobj) of_34\IN\entity.n.01|bromocriptine (r_prep) injection_33\NN\insertion.n.02|of (r_pobj) after_32\IN\after.s.01|injection (r_prep) h_31\NN\chemical_element.n.01|6|after|mg/kg (r_conj) applied_19\VBN\use.v.01|clarify|analyses|were|to|h|. (l_prep) to_20\IN\entity.n.01|cells (l_pobj) cells_26\NNS\compartment.n.01|induced|rat|prolactinoma|h|and (l_compound) prolactinoma_25\NN\entity.n.01|
D001971_D000236 NONE bromocriptine_15\JJ\entity.n.01| (r_amod) treatment_16\NN\care.n.01|bromocriptine|of (l_prep) of_17\IN\entity.n.01|cells (l_pobj) cells_20\NNS\compartment.n.01|the|adenoma (l_compound) adenoma_19\NN\benign_tumor.n.01|
11532387
D018967_D013375 CID risperidone_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|risperidone (r_prep) reduction_7\NN\change_of_magnitude.n.01|dose|of (r_pobj) during_5\IN\entity.n.01|reduction (r_prep) syndrome_4\NN\complex.n.01|emergent|rabbit|during|.
D018967_D013375 CID risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D018967_D001480 CID risperidone_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|risperidone (r_prep) reduction_7\NN\change_of_magnitude.n.01|dose|of (r_pobj) during_5\IN\entity.n.01|reduction (r_prep) syndrome_4\NN\complex.n.01|emergent|rabbit|during|.
D018967_D001480 CID risperidone_8\NN\entity.n.01| (r_pobj) of_7\IN\entity.n.01|risperidone (r_prep) reduction_6\NN\change_of_magnitude.n.01|dose|of (r_pobj) during_4\IN\entity.n.01|reduction (r_prep) developed_2\VBN\create.v.02|patient|rs|during|. (l_dobj) rs_3\NN\radioactivity_unit.n.01|
D018967_D001480 CID risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D018967_D001480 CID risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG\declare.v.01|influence (l_dobj) influence_32\NN\power.n.01|the|pathophysiologic|of|in (l_prep) in_37\IN\linear_unit.n.01|development (l_pobj) development_39\NN\improvement.n.02|the|of (l_prep) of_40\IN\entity.n.01|rs (l_pobj) rs_41\NN\radioactivity_unit.n.01|
D012701_D013375 NONE serotonin_24\NN\monoamine_neurotransmitter.n.01| (r_compound) dopamine_26\NN\monoamine_neurotransmitter.n.01|serotonin|- (r_compound) antagonist_27\NN\person.n.01|a|dopamine (r_appos) risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D012701_D013375 NONE serotonin_35\NN\monoamine_neurotransmitter.n.01| (r_compound) system_36\NN\instrumentality.n.03|the|serotonin (r_pobj) of_33\IN\entity.n.01|system (r_prep) influence_32\NN\power.n.01|the|pathophysiologic|of|in (r_dobj) suggesting_29\VBG\declare.v.01|influence (r_advcl) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D012701_D001480 NONE serotonin_24\NN\monoamine_neurotransmitter.n.01| (r_compound) dopamine_26\NN\monoamine_neurotransmitter.n.01|serotonin|- (r_compound) antagonist_27\NN\person.n.01|a|dopamine (r_appos) risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D012701_D001480 NONE serotonin_24\NN\monoamine_neurotransmitter.n.01| (r_compound) dopamine_26\NN\monoamine_neurotransmitter.n.01|serotonin|- (r_compound) antagonist_27\NN\person.n.01|a|dopamine (r_appos) risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG\declare.v.01|influence (l_dobj) influence_32\NN\power.n.01|the|pathophysiologic|of|in (l_prep) in_37\IN\linear_unit.n.01|development (l_pobj) development_39\NN\improvement.n.02|the|of (l_prep) of_40\IN\entity.n.01|rs (l_pobj) rs_41\NN\radioactivity_unit.n.01|
D012701_D001480 NONE serotonin_35\NN\monoamine_neurotransmitter.n.01| (r_compound) system_36\NN\instrumentality.n.03|the|serotonin (r_pobj) of_33\IN\entity.n.01|system (r_prep) influence_32\NN\power.n.01|the|pathophysiologic|of|in (r_dobj) suggesting_29\VBG\declare.v.01|influence (r_advcl) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D012701_D001480 NONE serotonin_35\NN\monoamine_neurotransmitter.n.01| (r_compound) system_36\NN\instrumentality.n.03|the|serotonin (r_pobj) of_33\IN\entity.n.01|system (r_prep) influence_32\NN\power.n.01|the|pathophysiologic|of|in (l_prep) in_37\IN\linear_unit.n.01|development (l_pobj) development_39\NN\improvement.n.02|the|of (l_prep) of_40\IN\entity.n.01|rs (l_pobj) rs_41\NN\radioactivity_unit.n.01|
D004298_D013375 NONE dopamine_26\NN\monoamine_neurotransmitter.n.01|serotonin|- (r_compound) antagonist_27\NN\person.n.01|a|dopamine (r_appos) risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D004298_D001480 NONE dopamine_26\NN\monoamine_neurotransmitter.n.01|serotonin|- (r_compound) antagonist_27\NN\person.n.01|a|dopamine (r_appos) risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_nsubjpass) mechanism_2\NN\chemical_process.n.01|the|underlying|of|in (l_prep) of_3\IN\entity.n.01|rs (l_pobj) rs_7\NN\radioactivity_unit.n.01|emergent
D004298_D001480 NONE dopamine_26\NN\monoamine_neurotransmitter.n.01|serotonin|- (r_compound) antagonist_27\NN\person.n.01|a|dopamine (r_appos) risperidone_21\NN\entity.n.01|,|antagonist (r_pobj) of_20\IN\entity.n.01|risperidone (r_prep) profile_19\NN\chart.n.01|the|pharmacological|of (r_pobj) to_16\IN\entity.n.01|profile (r_prep) related_15\VBN\think.v.03|mechanism|may|have|been|to|,|suggesting|. (l_advcl) suggesting_29\VBG\declare.v.01|influence (l_dobj) influence_32\NN\power.n.01|the|pathophysiologic|of|in (l_prep) in_37\IN\linear_unit.n.01|development (l_pobj) development_39\NN\improvement.n.02|the|of (l_prep) of_40\IN\entity.n.01|rs (l_pobj) rs_41\NN\radioactivity_unit.n.01|
16005948
-1_D062787 NONE gnc92h2_6\NNP\entity.n.01|the|anticocaine|monoclonal|antibody (r_pobj) of_1\IN\entity.n.01|gnc92h2 (r_prep) evaluation_0\NN\judgment.n.02|of|as|. (l_prep) as_7\IN\chemical_element.n.01|immunotherapy (l_pobj) immunotherapy_9\NN\therapy.n.01|an|for (l_prep) for_10\IN\entity.n.01|overdose (l_pobj) overdose_12\NN\drug.v.01|cocaine
-1_D062787 NONE gnc92h2_7\NNP\entity.n.01|the|anticocaine|antibody (r_pobj) of_3\IN\entity.n.01|gnc92h2 (r_prep) potential_2\NN\possibility.n.02|the|therapeutic|of (r_nsubjpass) examined_9\VBN\analyze.v.01|potential|was|using|. (l_advcl) using_10\VBG\mistreatment.n.01|model (l_dobj) model_12\NN\hypothesis.n.02|a|of (l_prep) of_13\IN\entity.n.01|overdose (l_pobj) overdose_15\NN\drug.v.01|cocaine
-1_D062787 NONE gnc92h2_7\NNP\entity.n.01| (r_pobj) of_6\IN\entity.n.01|gnc92h2 (r_prep) potential_5\NN\possibility.n.02|the|important|of|as (l_prep) as_8\IN\chemical_element.n.01|tool (l_pobj) tool_11\NN\implement.n.01|a|therapeutic|against (l_prep) against_12\IN\entity.n.01|overdose (l_pobj) overdose_14\NN\drug.v.01|cocaine
D003042_D062787 NONE cocaine_4\NN\hard_drug.n.01| (r_pobj) of_3\IN\entity.n.01|cocaine (r_prep) use_2\NN\activity.n.01|the|illicit|of (r_nsubj) continues_5\VBZ\act.v.01|use|in (l_prep) in_6\IN\linear_unit.n.01|proportions (l_pobj) proportions_8\NNS\quotient.n.01|epidemic|and|treatment (l_conj) treatment_10\NN\care.n.01|for (l_prep) for_11\IN\entity.n.01|overdose (l_pobj) overdose_13\NN\drug.v.01|cocaine
D003042_D064420 NONE cocaine_3\NN\hard_drug.n.01| (r_compound) toxicity_4\NN\definite_quantity.n.01|cocaine
D003042_D012640 CID cocaine_3\NN\hard_drug.n.01| (r_compound) toxicity_4\NN\definite_quantity.n.01|cocaine (r_pobj) of_2\IN\entity.n.01|toxicity (r_prep) blockade_1\NN\military_action.n.01|significant|of (r_nsubjpass) observed_6\VBN\spy.v.03|blockade|was|with|. (l_prep) with_7\IN\entity.n.01|dose (l_pobj) dose_10\NN\medicine.n.02|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\attack.n.07|up|by
D003042_D003643 NONE cocaine_3\NN\hard_drug.n.01| (r_compound) toxicity_4\NN\definite_quantity.n.01|cocaine (r_pobj) of_2\IN\entity.n.01|toxicity (r_prep) blockade_1\NN\military_action.n.01|significant|of (r_nsubjpass) observed_6\VBN\spy.v.03|blockade|was|with|. (l_prep) with_7\IN\entity.n.01|dose (l_pobj) dose_10\NN\medicine.n.02|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\attack.n.07|up|by (l_prt) up_29\IN\increase.v.02|to (l_prep) to_30\TO\entity.n.01|% (l_pobj) %_32\NN\entity.n.01|77|and|death (l_conj) death_34\NN\change.n.01|
D003042_D003643 NONE cocaine_8\NN\hard_drug.n.01|post|- (r_compound) injection_9\NN\insertion.n.02|even|cocaine (r_dobj) prevented_3\VBD\prevent.v.01|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\change.n.01|
-1_D064420 NONE gnc92h2_12\NNP\entity.n.01| (r_pobj) of_11\IN\entity.n.01|gnc92h2 (r_prep) dose_10\NN\medicine.n.02|the|higher|of|mg/kg|)|,|reduced|,|seizures (r_pobj) with_7\IN\entity.n.01|dose (r_prep) observed_6\VBN\spy.v.03|blockade|was|with|. (l_nsubjpass) blockade_1\NN\military_action.n.01|significant|of (l_prep) of_2\IN\entity.n.01|toxicity (l_pobj) toxicity_4\NN\definite_quantity.n.01|cocaine
-1_D012640 NONE gnc92h2_12\NNP\entity.n.01| (r_pobj) of_11\IN\entity.n.01|gnc92h2 (r_prep) dose_10\NN\medicine.n.02|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\attack.n.07|up|by
-1_D003643 NONE gnc92h2_12\NNP\entity.n.01| (r_pobj) of_11\IN\entity.n.01|gnc92h2 (r_prep) dose_10\NN\medicine.n.02|the|higher|of|mg/kg|)|,|reduced|,|seizures (l_appos) seizures_28\NNS\attack.n.07|up|by (l_prt) up_29\IN\increase.v.02|to (l_prep) to_30\TO\entity.n.01|% (l_pobj) %_32\NN\entity.n.01|77|and|death (l_conj) death_34\NN\change.n.01|
-1_D003643 NONE gnc92h2_2\NNP\entity.n.01| (r_nsubj) prevented_3\VBD\prevent.v.01|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\change.n.01|
1867351
D015767_D008288 NONE mefloquine_10\NN\antimalarial.n.01| (r_pobj) with_9\IN\entity.n.01|mefloquine (r_prep) treatment_8\NN\care.n.01|with (r_conj) prophylaxis_6\NN\prevention.n.01|malaria|and|treatment (l_compound) malaria_5\NN\protozoal_infection.n.01|
11027905
D007649_D009369 NONE ketamine_4\NN\club_drug.n.01|intravenous|in (l_prep) in_5\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|cancer|on (l_compound) cancer_6\NN\malignant_tumor.n.01|
D007649_D009369 NONE ketamine_7\NN\club_drug.n.01| (r_pobj) of_6\IN\entity.n.01|ketamine (r_prep) doses_5\NNS\medicine.n.02|subhypnotic|of|(|0.25|) (r_pobj) of_3\IN\entity.n.01|doses (r_prep) bolus_2\NN\ball.n.03|a|slow|of (r_nsubjpass) given_16\VBN\assumption.n.02|bolus|was|to|. (l_dative) to_17\IN\entity.n.01|patients (l_pobj) patients_20\NNS\case.n.06|10|cancer|was (l_compound) cancer_19\NN\malignant_tumor.n.01|
D009020_D009369 NONE morphine_9\NN\analgesic.n.01| (r_compound) therapy_10\NN\medical_care.n.01|morphine (r_pobj) on_8\IN\on.a.01|therapy (r_prep) patients_7\NNS\case.n.06|cancer|on (l_compound) cancer_6\NN\malignant_tumor.n.01|
D009020_D009369 NONE morphine_26\NN\analgesic.n.01| (r_pobj) by_25\IN\by.r.01|morphine (r_prep) unrelieved_24\JJ\undiminished.s.01|by (r_acomp) was_23\VBD\washington.n.02|pain|unrelieved|in (r_relcl) patients_20\NNS\case.n.06|10|cancer|was (l_compound) cancer_19\NN\malignant_tumor.n.01|
D009020_D010146 NONE morphine_4\NN\analgesic.n.01| (r_pobj) to_3\IN\entity.n.01|morphine (r_prep) responsive_2\JJ\responsive.a.01|not|to (r_amod) pain_0\NN\symptom.n.01|responsive
D009020_D010146 NONE morphine_26\NN\analgesic.n.01| (r_pobj) by_25\IN\by.r.01|morphine (r_prep) unrelieved_24\JJ\undiminished.s.01|by (r_acomp) was_23\VBD\washington.n.02|pain|unrelieved|in (l_nsubj) pain_22\NN\symptom.n.01|whose
D009020_D010146 NONE morphine_3\NN\analgesic.n.01| (r_compound) analgesia_4\NN\physical_condition.n.01|morphine|in (l_prep) in_5\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_8\NNS\complex.n.01|difficult|pain|,|as (l_compound) pain_7\NN\symptom.n.01|
D016202_D010146 NONE aspartate_13\NNP\entity.n.01|methyl|-|d|- (r_nmod) antagonists_17\NNS\person.n.01|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\metallic_element.n.01|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\effective.a.01|in (l_prep) in_26\IN\linear_unit.n.01|improving (l_pcomp) improving_27\VBG\change.v.01|analgesia (l_dobj) analgesia_29\NN\physical_condition.n.01|opioid|in (l_prep) in_30\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_33\NNS\complex.n.01|difficult|pain|,|as (l_compound) pain_32\NN\symptom.n.01|
D016202_D010146 NONE nmda_15\NNP\entity.n.01| (r_nmod) antagonists_17\NNS\person.n.01|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\metallic_element.n.01|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\effective.a.01|in (l_prep) in_26\IN\linear_unit.n.01|improving (l_pcomp) improving_27\VBG\change.v.01|analgesia (l_dobj) analgesia_29\NN\physical_condition.n.01|opioid|in (l_prep) in_30\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_33\NNS\complex.n.01|difficult|pain|,|as (l_compound) pain_32\NN\symptom.n.01|
D016202_D009437 NONE aspartate_13\NNP\entity.n.01|methyl|-|d|- (r_nmod) antagonists_17\NNS\person.n.01|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\metallic_element.n.01|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\effective.a.01|in (l_prep) in_26\IN\linear_unit.n.01|improving (l_pcomp) improving_27\VBG\change.v.01|analgesia (l_dobj) analgesia_29\NN\physical_condition.n.01|opioid|in (l_prep) in_30\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_33\NNS\complex.n.01|difficult|pain|,|as (l_prep) as_36\IN\chemical_element.n.01|such|pain (l_pobj) pain_38\NN\symptom.n.01|neuropathic
D016202_D009437 NONE nmda_15\NNP\entity.n.01| (r_nmod) antagonists_17\NNS\person.n.01|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\metallic_element.n.01|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\effective.a.01|in (l_prep) in_26\IN\linear_unit.n.01|improving (l_pcomp) improving_27\VBG\change.v.01|analgesia (l_dobj) analgesia_29\NN\physical_condition.n.01|opioid|in (l_prep) in_30\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_33\NNS\complex.n.01|difficult|pain|,|as (l_prep) as_36\IN\chemical_element.n.01|such|pain (l_pobj) pain_38\NN\symptom.n.01|neuropathic
D007649_D010146 NONE ketamine_21\NN\club_drug.n.01| (r_pobj) as_20\IN\chemical_element.n.01|such|ketamine (r_prep) antagonists_17\NNS\person.n.01|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\metallic_element.n.01|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\effective.a.01|in (l_prep) in_26\IN\linear_unit.n.01|improving (l_pcomp) improving_27\VBG\change.v.01|analgesia (l_dobj) analgesia_29\NN\physical_condition.n.01|opioid|in (l_prep) in_30\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_33\NNS\complex.n.01|difficult|pain|,|as (l_compound) pain_32\NN\symptom.n.01|
D007649_D010146 NONE ketamine_7\NN\club_drug.n.01| (r_pobj) of_6\IN\entity.n.01|ketamine (r_prep) doses_5\NNS\medicine.n.02|subhypnotic|of|(|0.25|) (r_pobj) of_3\IN\entity.n.01|doses (r_prep) bolus_2\NN\ball.n.03|a|slow|of (r_nsubjpass) given_16\VBN\assumption.n.02|bolus|was|to|. (l_dative) to_17\IN\entity.n.01|patients (l_pobj) patients_20\NNS\case.n.06|10|cancer|was (l_relcl) was_23\VBD\washington.n.02|pain|unrelieved|in (l_nsubj) pain_22\NN\symptom.n.01|whose
D007649_D010146 NONE ketamine_0\NN\club_drug.n.01|,|but|solution (r_nsubj) reduced_8\VBD\decrease.v.02|ketamine|significantly|intensity|in|. (l_dobj) intensity_11\NN\magnitude.n.01|the|pain (l_compound) pain_10\NN\symptom.n.01|
D007649_D010146 NONE ketamine_0\NNP\club_drug.n.01| (r_nsubj) improve_2\VB\change.v.01|ketamine|can|analgesia|. (l_dobj) analgesia_4\NN\physical_condition.n.01|morphine|in (l_prep) in_5\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_8\NNS\complex.n.01|difficult|pain|,|as (l_compound) pain_7\NN\symptom.n.01|
D007649_D009437 NONE ketamine_21\NN\club_drug.n.01| (r_pobj) as_20\IN\chemical_element.n.01|such|ketamine (r_prep) antagonists_17\NNS\person.n.01|aspartate|(|nmda|)|,|as (r_nsubj) be_24\VB\metallic_element.n.01|that|antagonists|,|may|effective (l_acomp) effective_25\JJ\effective.a.01|in (l_prep) in_26\IN\linear_unit.n.01|improving (l_pcomp) improving_27\VBG\change.v.01|analgesia (l_dobj) analgesia_29\NN\physical_condition.n.01|opioid|in (l_prep) in_30\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_33\NNS\complex.n.01|difficult|pain|,|as (l_prep) as_36\IN\chemical_element.n.01|such|pain (l_pobj) pain_38\NN\symptom.n.01|neuropathic
D007649_D009437 NONE ketamine_0\NNP\club_drug.n.01| (r_nsubj) improve_2\VB\change.v.01|ketamine|can|analgesia|. (l_dobj) analgesia_4\NN\physical_condition.n.01|morphine|in (l_prep) in_5\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_8\NNS\complex.n.01|difficult|pain|,|as (l_prep) as_11\IN\chemical_element.n.01|such|pain (l_pobj) pain_13\NN\symptom.n.01|neuropathic
D009020_D009437 NONE morphine_3\NN\analgesic.n.01| (r_compound) analgesia_4\NN\physical_condition.n.01|morphine|in (l_prep) in_5\IN\linear_unit.n.01|syndromes (l_pobj) syndromes_8\NNS\complex.n.01|difficult|pain|,|as (l_prep) as_11\IN\chemical_element.n.01|such|pain (l_pobj) pain_13\NN\symptom.n.01|neuropathic
8558192
C030852_C562729 NONE vinorelbine_4\NN\entity.n.01| (r_pobj) of_3\IN\entity.n.01|vinorelbine (r_prep) trial_2\NN\attempt.n.01|ii|of|in|. (l_prep) in_5\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_10\NN\cancer.n.01|metastatic|esophageal
C030852_C562729 NONE vinorelbine_9\NN\entity.n.01|(|vnb|) (r_pobj) of_8\IN\entity.n.01|vinorelbine (r_prep) effects_7\NNS\personal_property.n.01|toxic|of (r_conj) rate_4\NN\magnitude_relation.n.01|the|response|and|effects|administered (l_acl) administered_13\VBN\manage.v.02|as (l_prep) as_14\IN\chemical_element.n.01|agent (l_pobj) agent_17\NN\causal_agent.n.01|a|single|in (l_prep) in_18\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_23\NN\cancer.n.01|metastatic|esophageal
C030852_C562729 NONE vnb_11\NNP\entity.n.01| (r_appos) vinorelbine_9\NN\entity.n.01|(|vnb|) (r_pobj) of_8\IN\entity.n.01|vinorelbine (r_prep) effects_7\NNS\personal_property.n.01|toxic|of (r_conj) rate_4\NN\magnitude_relation.n.01|the|response|and|effects|administered (l_acl) administered_13\VBN\manage.v.02|as (l_prep) as_14\IN\chemical_element.n.01|agent (l_pobj) agent_17\NN\causal_agent.n.01|a|single|in (l_prep) in_18\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_23\NN\cancer.n.01|metastatic|esophageal
C030852_C562729 NONE vnb_4\NNP\entity.n.01| (r_nsubj) is_5\VBZ\be.v.01|that|vnb|agent (l_attr) agent_8\NN\causal_agent.n.01|an|active|in (l_prep) in_9\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_14\NN\cancer.n.01|metastatic|cell
D002945_D064420 NONE cisplatin_9\NN\entity.n.01| (r_npadvmod) based_11\VBN\establish.v.08|cisplatin|- (r_amod) chemotherapy_12\NN\therapy.n.01|based (r_pobj) with_8\IN\entity.n.01|chemotherapy (r_prep) pretreated_7\VBN\entity.n.01|patients|with (r_csubj) were_13\VBD\be.v.01|pretreated|assessable|. (l_acomp) assessable_14\JJ\assessable.s.01|for (l_prep) for_15\IN\entity.n.01|toxicity (l_pobj) toxicity_16\NN\definite_quantity.n.01|and|response
C030852_D064420 NONE vnb_0\NNP\entity.n.01| (r_nsubjpass) tolerated_3\VBN\permit.v.01|vnb|was|well|and|occurred (l_conj) occurred_13\VBD\happen.v.01|instances|toxicity|. (l_nsubj) toxicity_12\NN\definite_quantity.n.01|nonhematologic
C030852_D064420 NONE vnb_12\NNP\entity.n.01| (r_pobj) of_11\IN\entity.n.01|vnb (r_prep) evaluation_10\NN\judgment.n.02|further|of|in (r_nsubjpass) warranted_17\VBN\confirm.v.02|given|,|evaluation|is|. (l_prep) given_0\VBN\assumption.n.02|profile (l_pobj) profile_4\NN\chart.n.01|its|tolerance|and|toxicity (l_conj) toxicity_7\NN\definite_quantity.n.01|low
1639466
D002118_D009400 NONE calcium_4\NN\metallic_element.n.01| (r_compound) channel_5\NN\transmission.n.02|the|calcium (r_pobj) of_2\IN\entity.n.01|channel (r_prep) effect_1\NN\phenomenon.n.01|adverse|of|nitrendipine|. (l_appos) nitrendipine_7\NN\entity.n.01|blocker|on (l_prep) on_8\IN\on.a.01|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\kidney_disease.n.01|in
D002118_D006978 NONE calcium_4\NN\metallic_element.n.01| (r_compound) channel_5\NN\transmission.n.02|the|calcium (r_pobj) of_2\IN\entity.n.01|channel (r_prep) effect_1\NN\phenomenon.n.01|adverse|of|nitrendipine|. (l_appos) nitrendipine_7\NN\entity.n.01|blocker|on (l_prep) on_8\IN\on.a.01|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\kidney_disease.n.01|in (l_prep) in_10\IN\linear_unit.n.01|rats (l_pobj) rats_11\NNS\rodent.n.01|with (l_prep) with_12\IN\entity.n.01|hypertension (l_pobj) hypertension_14\NN\cardiovascular_disease.n.01|renovascular
D002118_D006978 NONE calcium_8\NN\metallic_element.n.01| (r_compound) channel_9\NN\transmission.n.02|the|calcium|nitrendipine (r_pobj) with_6\IN\entity.n.01|channel (r_prep) treatment_5\NN\care.n.01|a|6-week|with (r_pobj) of_2\IN\entity.n.01|treatment (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) studied_35\VBN\analyze.v.01|effect|was|in|. (l_prep) in_36\IN\linear_unit.n.01|rats (l_pobj) rats_37\NNS\rodent.n.01|with (l_prep) with_38\IN\entity.n.01|kidney (l_pobj) kidney_41\NN\excretory_organ.n.01|two|-|,|hypertension (l_appos) hypertension_46\NN\cardiovascular_disease.n.01|one|renovascular
D009568_D009400 CID nitrendipine_7\NN\entity.n.01|blocker|on (l_prep) on_8\IN\on.a.01|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\kidney_disease.n.01|in
D009568_D006978 NONE nitrendipine_7\NN\entity.n.01|blocker|on (l_prep) on_8\IN\on.a.01|nephrosclerosis (l_pobj) nephrosclerosis_9\NN\kidney_disease.n.01|in (l_prep) in_10\IN\linear_unit.n.01|rats (l_pobj) rats_11\NNS\rodent.n.01|with (l_prep) with_12\IN\entity.n.01|hypertension (l_pobj) hypertension_14\NN\cardiovascular_disease.n.01|renovascular
D009568_D006978 NONE nitrendipine_11\NN\entity.n.01|blocker|or|angiotensin (r_appos) channel_9\NN\transmission.n.02|the|calcium|nitrendipine (r_pobj) with_6\IN\entity.n.01|channel (r_prep) treatment_5\NN\care.n.01|a|6-week|with (r_pobj) of_2\IN\entity.n.01|treatment (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) studied_35\VBN\analyze.v.01|effect|was|in|. (l_prep) in_36\IN\linear_unit.n.01|rats (l_pobj) rats_37\NNS\rodent.n.01|with (l_prep) with_38\IN\entity.n.01|kidney (l_pobj) kidney_41\NN\excretory_organ.n.01|two|-|,|hypertension (l_appos) hypertension_46\NN\cardiovascular_disease.n.01|one|renovascular
D002118_D000419 NONE calcium_8\NN\metallic_element.n.01| (r_compound) channel_9\NN\transmission.n.02|the|calcium|nitrendipine (l_appos) nitrendipine_11\NN\entity.n.01|blocker|or|angiotensin (l_conj) angiotensin_14\NN\vasoconstrictor.n.01|the|converting (l_acl) converting_15\VBG\change.v.01|enalapril|on (l_prep) on_19\IN\on.a.01|pressure (l_pobj) pressure_21\NN\physical_phenomenon.n.01|blood|,|albuminuria (l_conj) albuminuria_23\NN\symptom.n.01|,|hemodynamics
D009568_D000419 CID nitrendipine_11\NN\entity.n.01|blocker|or|angiotensin (l_conj) angiotensin_14\NN\vasoconstrictor.n.01|the|converting (l_acl) converting_15\VBG\change.v.01|enalapril|on (l_prep) on_19\IN\on.a.01|pressure (l_pobj) pressure_21\NN\physical_phenomenon.n.01|blood|,|albuminuria (l_conj) albuminuria_23\NN\symptom.n.01|,|hemodynamics
D009568_D000419 CID nitrendipine_5\NN\entity.n.01| (r_npadvmod) treated_7\VBN\interact.v.01|nitrendipine|- (r_amod) albuminuria_9\NN\symptom.n.01|the|treated|group
D000809_D000419 NONE angiotensin_14\NN\vasoconstrictor.n.01|the|converting (l_acl) converting_15\VBG\change.v.01|enalapril|on (l_prep) on_19\IN\on.a.01|pressure (l_pobj) pressure_21\NN\physical_phenomenon.n.01|blood|,|albuminuria (l_conj) albuminuria_23\NN\symptom.n.01|,|hemodynamics
D000809_D006978 NONE angiotensin_14\NN\vasoconstrictor.n.01|the|converting (r_conj) nitrendipine_11\NN\entity.n.01|blocker|or|angiotensin (r_appos) channel_9\NN\transmission.n.02|the|calcium|nitrendipine (r_pobj) with_6\IN\entity.n.01|channel (r_prep) treatment_5\NN\care.n.01|a|6-week|with (r_pobj) of_2\IN\entity.n.01|treatment (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) studied_35\VBN\analyze.v.01|effect|was|in|. (l_prep) in_36\IN\linear_unit.n.01|rats (l_pobj) rats_37\NNS\rodent.n.01|with (l_prep) with_38\IN\entity.n.01|kidney (l_pobj) kidney_41\NN\excretory_organ.n.01|two|-|,|hypertension (l_appos) hypertension_46\NN\cardiovascular_disease.n.01|one|renovascular
D004656_D000419 NONE enalapril_18\NN\ace_inhibitor.n.01|inhibitor (r_dobj) converting_15\VBG\change.v.01|enalapril|on (l_prep) on_19\IN\on.a.01|pressure (l_pobj) pressure_21\NN\physical_phenomenon.n.01|blood|,|albuminuria (l_conj) albuminuria_23\NN\symptom.n.01|,|hemodynamics
D004656_D006978 NONE enalapril_18\NN\ace_inhibitor.n.01|inhibitor (r_dobj) converting_15\VBG\change.v.01|enalapril|on (r_acl) angiotensin_14\NN\vasoconstrictor.n.01|the|converting (r_conj) nitrendipine_11\NN\entity.n.01|blocker|or|angiotensin (r_appos) channel_9\NN\transmission.n.02|the|calcium|nitrendipine (r_pobj) with_6\IN\entity.n.01|channel (r_prep) treatment_5\NN\care.n.01|a|6-week|with (r_pobj) of_2\IN\entity.n.01|treatment (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) studied_35\VBN\analyze.v.01|effect|was|in|. (l_prep) in_36\IN\linear_unit.n.01|rats (l_pobj) rats_37\NNS\rodent.n.01|with (l_prep) with_38\IN\entity.n.01|kidney (l_pobj) kidney_41\NN\excretory_organ.n.01|two|-|,|hypertension (l_appos) hypertension_46\NN\cardiovascular_disease.n.01|one|renovascular
D004656_D006973 NONE enalapril_33\NN\ace_inhibitor.n.01| (r_npadvmod) treated_35\VBN\interact.v.01|enalapril|- (r_amod) 8)_39\CD\entity.n.01|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\power.n.01|untreated|hypertensive|(|8)|8) (r_appos) groups_23\NNS\abstraction.n.06|three|:|controls (r_pobj) to_21\IN\entity.n.01|groups (r_prep) assigned_20\VBN\appoint.v.02|after|were|randomly|to|. (l_prep) after_2\IN\after.s.01|weeks|clipping (l_pobj) clipping_3\VBG\excerpt.n.01|of (l_prep) of_4\IN\entity.n.01|artery (l_pobj) artery_7\NN\blood_vessel.n.01|one|renal|,|rats|(|hg|) (l_appos) rats_10\NNS\rodent.n.01|hypertensive (l_amod) hypertensive_9\JJ\patient.n.01|
D004656_D006973 NONE enalapril_33\NN\ace_inhibitor.n.01| (r_npadvmod) treated_35\VBN\interact.v.01|enalapril|- (r_amod) 8)_39\CD\entity.n.01|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\power.n.01|untreated|hypertensive|(|8)|8) (l_amod) hypertensive_26\JJ\patient.n.01|
D004656_D006973 NONE enalapril_25\NN\ace_inhibitor.n.01| (r_npadvmod) treated_27\VBN\interact.v.01|enalapril|- (r_amod) group_28\NN\abstraction.n.06|the|treated (r_pobj) in_23\IN\linear_unit.n.01|group (r_prep) lower_22\JJR\berth.n.03|in|(|+/-|compared (l_prep) compared_37\VBN\analyze.v.01|with (l_prep) with_38\IN\entity.n.01|controls (l_pobj) controls_41\NNS\power.n.01|the|hypertensive|(|+/-|) (l_amod) hypertensive_40\JJ\patient.n.01|
D009568_D006973 NONE nitrendipine_42\NN\entity.n.01| (r_advmod) treated_44\VBN\interact.v.01|nitrendipine|-|n (r_conj) 8)_39\CD\entity.n.01|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\power.n.01|untreated|hypertensive|(|8)|8) (r_appos) groups_23\NNS\abstraction.n.06|three|:|controls (r_pobj) to_21\IN\entity.n.01|groups (r_prep) assigned_20\VBN\appoint.v.02|after|were|randomly|to|. (l_prep) after_2\IN\after.s.01|weeks|clipping (l_pobj) clipping_3\VBG\excerpt.n.01|of (l_prep) of_4\IN\entity.n.01|artery (l_pobj) artery_7\NN\blood_vessel.n.01|one|renal|,|rats|(|hg|) (l_appos) rats_10\NNS\rodent.n.01|hypertensive (l_amod) hypertensive_9\JJ\patient.n.01|
D009568_D006973 NONE nitrendipine_42\NN\entity.n.01| (r_advmod) treated_44\VBN\interact.v.01|nitrendipine|-|n (r_conj) 8)_39\CD\entity.n.01|treated|(|n|=|,|or|treated (r_appos) controls_27\NNS\power.n.01|untreated|hypertensive|(|8)|8) (l_amod) hypertensive_26\JJ\patient.n.01|
D009568_D006973 NONE nitrendipine_5\NN\entity.n.01| (r_npadvmod) treated_7\VBN\interact.v.01|nitrendipine|- (r_amod) albuminuria_9\NN\symptom.n.01|the|treated|group (r_pobj) in_3\IN\linear_unit.n.01|albuminuria (r_prep) increased_10\VBD\change_magnitude.v.01|in|,|in|from|progressively|to|compared|. (l_prep) compared_20\VBN\analyze.v.01|with (l_prep) with_21\IN\entity.n.01|hr (l_pobj) hr_26\NN\time_unit.n.01|mg/24|in (l_prep) in_27\IN\linear_unit.n.01|controls (l_pobj) controls_30\NNS\power.n.01|the|hypertensive (l_amod) hypertensive_29\JJ\patient.n.01|
D009568_D006973 NONE nitrendipine_9\NN\entity.n.01| (r_npadvmod) treated_11\VBN\interact.v.01|nitrendipine|- (r_amod) group_12\NN\abstraction.n.06|the|treated (r_pobj) in_7\IN\linear_unit.n.01|group (r_prep) increased_6\VBN\change_magnitude.v.01|furthermore|,|index|was|significantly|in|compared|. (l_prep) compared_13\VBN\analyze.v.01|with (l_prep) with_14\IN\entity.n.01|controls (l_pobj) controls_17\NNS\power.n.01|the|hypertensive|(|0.38|) (l_amod) hypertensive_16\JJ\patient.n.01|
D009568_D006973 NONE nitrendipine_9\NN\entity.n.01| (r_npadvmod) treated_11\VBN\interact.v.01|nitrendipine|- (r_amod) group_12\NN\abstraction.n.06|the|treated|(|+/-|) (r_pobj) in_7\IN\linear_unit.n.01|group (r_prep) was_5\VBD\washington.n.02|in|,|size|higher|in|but|lower|. (l_conj) lower_22\JJR\berth.n.03|in|(|+/-|compared (l_prep) compared_37\VBN\analyze.v.01|with (l_prep) with_38\IN\entity.n.01|controls (l_pobj) controls_41\NNS\power.n.01|the|hypertensive|(|+/-|) (l_amod) hypertensive_40\JJ\patient.n.01|
D004656_D005921 NONE enalapril_14\JJ\ace_inhibitor.n.01| (r_compound) treatment_15\NN\care.n.01|enalapril (r_pobj) after_13\IN\after.s.01|treatment (r_prep) change_12\VB\happening.n.01|excretion|did|not|after|. (l_nsubj) excretion_7\NN\discharge.n.04|albumin|and|glomerulosclerosis (l_conj) glomerulosclerosis_9\NN\entity.n.01|
D009568_D005921 NONE nitrendipine_9\NN\entity.n.01| (r_npadvmod) treated_11\VBN\interact.v.01|nitrendipine|- (r_amod) group_12\NN\abstraction.n.06|the|treated (r_pobj) in_7\IN\linear_unit.n.01|group (r_prep) increased_6\VBN\change_magnitude.v.01|furthermore|,|index|was|significantly|in|compared|. (l_nsubjpass) index_3\NN\scale.n.01|glomerulosclerosis (l_compound) glomerulosclerosis_2\NN\entity.n.01|
7977601
16330766
C040029_D009437 NONE gabapentin_11\NN\anticonvulsant.n.01|,|drug (l_appos) drug_14\NN\agent.n.03|a|effective (l_amod) effective_15\JJ\effective.a.01|in (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_19\NNS\case.n.06|neuropathic|pain (l_compound) pain_18\NN\symptom.n.01|
C040029_D006930 NONE gabapentin_15\NN\anticonvulsant.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|gabapentin|- (r_amod) modulation_18\NN\passage.n.06|the|induced|of|in (l_prep) in_22\IN\linear_unit.n.01|response (l_pobj) response_23\NN\consequence.n.01|to (l_prep) to_24\IN\entity.n.01|stimulation (l_pobj) stimulation_27\NN\arousal.n.01|nociceptive|mechanical|of (l_prep) of_28\IN\entity.n.01|skin (l_pobj) skin_30\NN\body_covering.n.01|normal|and|hyperalgesia (l_conj) hyperalgesia_36\NN\entity.n.01|induced|secondary
D002211_D006930 CID capsaicin_32\NN\chemical_irritant.n.01| (r_npadvmod) induced_34\VBN\generate.v.01|capsaicin|- (r_amod) hyperalgesia_36\NN\entity.n.01|induced|secondary
11206082
C036150_D012640 CID carboline_10\NN\entity.n.01|beta|- (r_npadvmod) induced_12\VBN\generate.v.01|carboline|- (r_amod) seizures_13\NNS\attack.n.07|induced
C036150_D012640 CID carboline-3-carboxylate_32\NN\entity.n.01|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\entity.n.01|carboline-3-carboxylate (r_prep) injection_27\NN\insertion.n.02|a|single|i.p.|of (r_pobj) by_23\IN\by.r.01|injection (r_agent) induced_22\VBN\generate.v.01|by (r_acl) seizures_21\NNS\attack.n.07|induced
C036150_D012640 CID ccm_36\NNP\entity.n.01|(|beta|- (r_appos) carboline-3-carboxylate_32\NN\entity.n.01|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\entity.n.01|carboline-3-carboxylate (r_prep) injection_27\NN\insertion.n.02|a|single|i.p.|of (r_pobj) by_23\IN\by.r.01|injection (r_agent) induced_22\VBN\generate.v.01|by (r_acl) seizures_21\NNS\attack.n.07|induced
D005680_D012640 NONE gaba(a_24\NNP\entity.n.01| (r_nmod) ligands_27\NNS\substance.n.07|other|gaba(a|)|receptor (r_pobj) of_22\IN\entity.n.01|ligands (r_prep) effects_21\NNS\personal_property.n.01|various|pharmacological|of (r_pobj) to_18\IN\entity.n.01|effects (r_prep) sensitive_17\JJ\psychic.n.01|differentially|to (r_acomp) are_14\VBP\area_unit.n.01|lines|also|sensitive|. (l_nsubj) lines_2\NNS\formation.n.01|two|mouse|selected (l_acl) selected_3\VBN\decide.v.01|for (l_prep) for_4\IN\entity.n.01|sensitivities (l_pobj) sensitivities_6\NNS\sense.n.03|differential|to (l_prep) to_7\IN\entity.n.01|seizures (l_pobj) seizures_13\NNS\attack.n.07|induced
D005680_D012640 NONE gaba(a_44\NNP\entity.n.01| (r_nmod) site_48\NN\tract.n.01|the|gaba(a|receptor|benzodiazepine (r_pobj) of_42\IN\entity.n.01|site (r_prep) agonist_41\NN\protagonist.n.02|an|inverse|of (r_appos) carboline-3-carboxylate_32\NN\entity.n.01|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\entity.n.01|carboline-3-carboxylate (r_prep) injection_27\NN\insertion.n.02|a|single|i.p.|of (r_pobj) by_23\IN\by.r.01|injection (r_agent) induced_22\VBN\generate.v.01|by (r_acl) seizures_21\NNS\attack.n.07|induced
D001569_D012640 NONE benzodiazepine_47\NN\minor_tranquilizer.n.01| (r_amod) site_48\NN\tract.n.01|the|gaba(a|receptor|benzodiazepine (r_pobj) of_42\IN\entity.n.01|site (r_prep) agonist_41\NN\protagonist.n.02|an|inverse|of (r_appos) carboline-3-carboxylate_32\NN\entity.n.01|methyl|beta|-|ccm|)|,|agonist (r_pobj) of_28\IN\entity.n.01|carboline-3-carboxylate (r_prep) injection_27\NN\insertion.n.02|a|single|i.p.|of (r_pobj) by_23\IN\by.r.01|injection (r_agent) induced_22\VBN\generate.v.01|by (r_acl) seizures_21\NNS\attack.n.07|induced
D003975_D012640 NONE diazepam_2\NN\benzodiazepine.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|diazepam|- (r_amod) anxiolysis_5\NN\entity.n.01|induced (r_dobj) measured_1\VBD\decide.v.01|we|anxiolysis|with|,|sedation|. (l_dobj) sedation_17\NN\physical_condition.n.01|induced|by (l_prep) by_18\IN\by.r.01|recording (l_pcomp) recording_19\VBG\signal.n.01|states (l_dobj) states_22\NNS\administrative_district.n.01|the|vigilance|,|and|seizures (l_conj) seizures_30\NNS\attack.n.07|picrotoxin-|after
D003975_D012640 NONE diazepam_14\NN\benzodiazepine.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|diazepam|- (r_amod) sedation_17\NN\physical_condition.n.01|induced|by (l_prep) by_18\IN\by.r.01|recording (l_pcomp) recording_19\VBG\signal.n.01|states (l_dobj) states_22\NNS\administrative_district.n.01|the|vigilance|,|and|seizures (l_conj) seizures_30\NNS\attack.n.07|picrotoxin-|after
D010852_D012640 CID picrotoxin-_25\NN\entity.n.01|and|induced (r_amod) seizures_30\NNS\attack.n.07|picrotoxin-|after
D010433_D012640 CID pentylenetetrazol_27\NN\medicine.n.02| (r_npadvmod) induced_29\VBN\generate.v.01|pentylenetetrazol|- (r_conj) picrotoxin-_25\NN\entity.n.01|and|induced (r_amod) seizures_30\NNS\attack.n.07|picrotoxin-|after
20067456
D016642_D012735 NONE bupropion_5\NN\entity.n.01|the|adjunctive|on (l_prep) on_6\IN\on.a.01|dysfunction (l_pobj) dysfunction_9\NN\pathology.n.02|male|sexual|induced
D016642_D012735 NONE bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|)
D016642_D012735 NONE bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|) (l_appos) sd_20\NN\south_dakota.n.01|
D016642_D012735 NONE bupropion_8\NN\entity.n.01|adjunctive|sr|on (r_pobj) of_6\IN\entity.n.01|bupropion (r_prep) safety_3\NN\condition.n.01|the|and|efficacy|of (r_dobj) determine_1\VB\determine.v.01|to|safety (r_csubj) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_advcl) is_35\VBZ\be.v.01|as|sd|effect|have (l_nsubj) sd_34\NN\south_dakota.n.01|
D016642_D012735 NONE bupropion_0\NN\entity.n.01| (r_nsubj) is_1\VBZ\be.v.01|bupropion|treatment|. (l_attr) treatment_4\NN\care.n.01|an|effective|for|induced (l_prep) for_5\IN\entity.n.01|sd (l_pobj) sd_7\NN\south_dakota.n.01|male
D017367_D012735 NONE inhibitor_16\NN\substance.n.07|a|selective|serotonin|reuptake|:|study (r_pobj) by_11\IN\by.r.01|inhibitor (r_agent) induced_10\VBN\generate.v.01|by (r_acl) dysfunction_9\NN\pathology.n.02|male|sexual|induced
D017367_D012735 NONE inhibitor_28\NN\substance.n.07|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\by.r.01|inhibitor (r_agent) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_csubj) determine_1\VB\determine.v.01|to|safety (l_dobj) safety_3\NN\condition.n.01|the|and|efficacy|of (l_prep) of_6\IN\entity.n.01|bupropion (l_pobj) bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|)
D017367_D012735 NONE inhibitor_28\NN\substance.n.07|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\by.r.01|inhibitor (r_agent) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_csubj) determine_1\VB\determine.v.01|to|safety (l_dobj) safety_3\NN\condition.n.01|the|and|efficacy|of (l_prep) of_6\IN\entity.n.01|bupropion (l_pobj) bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|) (l_appos) sd_20\NN\south_dakota.n.01|
D017367_D012735 NONE inhibitor_28\NN\substance.n.07|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\by.r.01|inhibitor (r_agent) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_advcl) is_35\VBZ\be.v.01|as|sd|effect|have (l_nsubj) sd_34\NN\south_dakota.n.01|
D017367_D012735 NONE ssri_30\NNP\antidepressant.n.01| (r_appos) inhibitor_28\NN\substance.n.07|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\by.r.01|inhibitor (r_agent) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_csubj) determine_1\VB\determine.v.01|to|safety (l_dobj) safety_3\NN\condition.n.01|the|and|efficacy|of (l_prep) of_6\IN\entity.n.01|bupropion (l_pobj) bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|)
D017367_D012735 NONE ssri_30\NNP\antidepressant.n.01| (r_appos) inhibitor_28\NN\substance.n.07|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\by.r.01|inhibitor (r_agent) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_csubj) determine_1\VB\determine.v.01|to|safety (l_dobj) safety_3\NN\condition.n.01|the|and|efficacy|of (l_prep) of_6\IN\entity.n.01|bupropion (l_pobj) bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|) (l_appos) sd_20\NN\south_dakota.n.01|
D017367_D012735 NONE ssri_30\NNP\antidepressant.n.01| (r_appos) inhibitor_28\NN\substance.n.07|a|selective|serotonin|reuptake|(|ssri|) (r_pobj) by_23\IN\by.r.01|inhibitor (r_agent) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_advcl) is_35\VBZ\be.v.01|as|sd|effect|have (l_nsubj) sd_34\NN\south_dakota.n.01|
D017367_D012735 NONE ssris_42\NNS\antidepressant.n.01|and|treatments (r_pobj) of_41\IN\entity.n.01|ssris (r_prep) effect_40\NN\phenomenon.n.01|a|common|side|-|of (r_attr) is_35\VBZ\be.v.01|as|sd|effect|have (r_advcl) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_csubj) determine_1\VB\determine.v.01|to|safety (l_dobj) safety_3\NN\condition.n.01|the|and|efficacy|of (l_prep) of_6\IN\entity.n.01|bupropion (l_pobj) bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|)
D017367_D012735 NONE ssris_42\NNS\antidepressant.n.01|and|treatments (r_pobj) of_41\IN\entity.n.01|ssris (r_prep) effect_40\NN\phenomenon.n.01|a|common|side|-|of (r_attr) is_35\VBZ\be.v.01|as|sd|effect|have (r_advcl) induced_22\VBN\generate.v.01|determine|by|,|is|. (l_csubj) determine_1\VB\determine.v.01|to|safety (l_dobj) safety_3\NN\condition.n.01|the|and|efficacy|of (l_prep) of_6\IN\entity.n.01|bupropion (l_pobj) bupropion_8\NN\entity.n.01|adjunctive|sr|on (l_prep) on_15\IN\on.a.01|dysfunction (l_pobj) dysfunction_18\NN\pathology.n.02|male|sexual|(|sd|) (l_appos) sd_20\NN\south_dakota.n.01|
D017367_D012735 NONE ssris_42\NNS\antidepressant.n.01|and|treatments (r_pobj) of_41\IN\entity.n.01|ssris (r_prep) effect_40\NN\phenomenon.n.01|a|common|side|-|of (r_attr) is_35\VBZ\be.v.01|as|sd|effect|have (l_nsubj) sd_34\NN\south_dakota.n.01|
D017367_D012735 NONE ssri_21\NNP\antidepressant.n.01| (r_pobj) of_20\IN\entity.n.01|ssri (r_prep) type_19\NN\kind.n.01|of (r_appos) sd_17\NN\south_dakota.n.01|,|type
D017367_D012735 NONE ssris_10\NNS\antidepressant.n.01| (r_pobj) by_9\IN\by.r.01|ssris (r_agent) induced_8\VBN\generate.v.01|by (r_acl) treatment_4\NN\care.n.01|an|effective|for|induced (l_prep) for_5\IN\entity.n.01|sd (l_pobj) sd_7\NN\south_dakota.n.01|male
2632720
D007654_D006973 CID ketoconazole_7\JJ\entity.n.01| (r_compound) treatment_8\NN\care.n.01|prolonged|ketoconazole (r_pobj) of_5\IN\entity.n.01|treatment (r_prep) complication_4\NN\hindrance.n.03|a|of (r_pobj) as_2\IN\chemical_element.n.01|complication (r_prep) hypertension_1\NN\cardiovascular_disease.n.01|arterial|as|.
D007654_D006973 CID ketoconazole_16\JJ\entity.n.01| (r_pobj) with_15\IN\entity.n.01|ketoconazole (r_prep) basis_14\NN\foundation.n.01|a|term|with (r_pobj) on_9\IN\on.a.01|basis (r_prep) treated_8\VBN\interact.v.01|patients|on|developed|. (l_advcl) developed_17\VBN\create.v.02|hypertension (l_dobj) hypertension_19\NN\cardiovascular_disease.n.01|sustained
D007654_D006973 CID ketoconazole_14\JJ\entity.n.01| (r_compound) therapy_15\NN\medical_care.n.01|ketoconazole|,|yet|monitoring (r_dobj) following_13\VBG\multitude.n.03|therapy (r_prep) achieved_12\VBN\succeed.v.01|in|levels|had|been|following|demonstrated|. (l_conj) demonstrated_22\VBD\show.v.04|hypertension (l_dobj) hypertension_23\NN\cardiovascular_disease.n.01|31|patient
D007654_D006973 CID ketoconazole_12\NN\entity.n.01| (r_pobj) of_11\IN\entity.n.01|ketoconazole (r_prep) doses_10\NNS\medicine.n.02|high|of (r_pobj) with_8\IN\entity.n.01|doses (r_prep) treatment_7\NN\care.n.01|term|with (r_nsubj) induce_14\VB\generate.v.01|that|treatment|may|blockade (l_dobj) blockade_16\NN\military_action.n.01|enzyme|leading (l_acl) leading_17\VBG\strip.n.02|to (l_prep) to_18\IN\entity.n.01|hypertension (l_pobj) hypertension_22\NN\cardiovascular_disease.n.01|related
D007654_D003480 NONE ketoconazole_16\JJ\entity.n.01| (r_pobj) with_15\IN\entity.n.01|ketoconazole (r_prep) basis_14\NN\foundation.n.01|a|term|with (r_pobj) on_9\IN\on.a.01|basis (r_prep) treated_8\VBN\interact.v.01|patients|on|developed|. (l_nsubj) patients_3\NNS\case.n.06|14|with (l_prep) with_4\IN\entity.n.01|syndrome (l_pobj) syndrome_7\NN\complex.n.01|cushing
D006854_D006973 NONE cortisol_8\NN\corticosteroid.n.01|free (r_compound) levels_9\NNS\property.n.02|plasma|urinary|cortisol (r_nsubjpass) achieved_12\VBN\succeed.v.01|in|levels|had|been|following|demonstrated|. (l_conj) demonstrated_22\VBD\show.v.04|hypertension (l_dobj) hypertension_23\NN\cardiovascular_disease.n.01|31|patient
1664218
D000677_D002289 NONE amsacrine_5\NN\entity.n.01| (r_compound) analogue_6\NN\similarity.n.01|the|amsacrine (r_pobj) of_3\IN\entity.n.01|analogue (r_prep) study_2\NN\examination.n.01|ii|of|nsc|in|. (l_prep) in_12\IN\linear_unit.n.01|cancer (l_pobj) cancer_18\NN\malignant_tumor.n.01|small|lung
C042315_D002289 NONE ci-921_7\NNP\entity.n.01| (r_punct) (_8\-LRB-\entity.n.01|ci-921 (r_punct) nsc_9\NNP\executive_agency.n.01|(|343499|) (r_appos) study_2\NN\examination.n.01|ii|of|nsc|in|. (l_prep) in_12\IN\linear_unit.n.01|cancer (l_pobj) cancer_18\NN\malignant_tumor.n.01|small|lung
C042315_D002289 NONE 343499_10\CD\entity.n.01| (r_nummod) nsc_9\NNP\executive_agency.n.01|(|343499|) (r_appos) study_2\NN\examination.n.01|ii|of|nsc|in|. (l_prep) in_12\IN\linear_unit.n.01|cancer (l_pobj) cancer_18\NN\malignant_tumor.n.01|small|lung
6386793
D004308_D003866 NONE hydrochloride_12\NN\complex.n.02|dothiepin (r_pobj) of_10\IN\entity.n.01|hydrochloride (r_prep) efficacy_7\NN\effectiveness.n.01|the|and|safety|of (r_pobj) of_5\IN\entity.n.01|efficacy (r_prep) study_4\NN\examination.n.01|a|blind|of|in|. (l_prep) in_13\IN\linear_unit.n.01|treatment (l_pobj) treatment_15\NN\care.n.01|the|of (l_prep) of_16\IN\entity.n.01|disorder (l_pobj) disorder_19\NN\physical_condition.n.01|major|depressive
D004308_D003866 NONE dothiepin_10\JJ\entity.n.01|and|amitriptyline (r_nsubjpass) compared_14\VBN\analyze.v.01|in|,|dothiepin|were|to|. (l_prep) to_15\IN\entity.n.01|placebo (l_pobj) placebo_16\NN\medicine.n.02|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_19\NN\care.n.01|the|of (l_prep) of_20\IN\entity.n.01|outpatients (l_pobj) outpatients_23\NNS\patient.n.01|33|depressed (l_amod) depressed_22\JJ\discourage.v.02|
D004308_D003866 NONE dothiepin_0\JJ\entity.n.01|and|amitriptyline (r_nsubj) were_3\VBD\be.v.01|dothiepin|effective|,|and|were (l_acomp) effective_5\JJ\effective.a.01|equally|in (l_prep) in_6\IN\linear_unit.n.01|alleviating (l_pcomp) alleviating_7\VBG\better.v.02|symptoms (l_dobj) symptoms_9\NNS\evidence.n.01|the|of (l_prep) of_10\IN\entity.n.01|illness (l_pobj) illness_12\NN\ill_health.n.01|depressive
D004308_D003866 NONE dothiepin_0\NNP\entity.n.01| (r_nsubjpass) found_3\VBN\wage.n.01|dothiepin|thus|was|be|. (l_xcomp) be_5\VB\metallic_element.n.01|to|drug (l_attr) drug_9\NN\agent.n.03|an|effective|antidepressant|associated (l_acl) associated_10\VBN\think.v.03|with (l_prep) with_11\IN\entity.n.01|effects (l_pobj) effects_14\NNS\personal_property.n.01|fewer|side|than (l_prep) than_15\IN\entity.n.01|amitriptyline (l_pobj) amitriptyline_16\NN\tricyclic.n.01|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_19\NN\care.n.01|the|of (l_prep) of_20\IN\entity.n.01|outpatients (l_pobj) outpatients_22\NNS\patient.n.01|depressed (l_amod) depressed_21\JJ\discourage.v.02|
D000639_D003866 NONE amitriptyline_12\NN\tricyclic.n.01| (r_conj) dothiepin_10\JJ\entity.n.01|and|amitriptyline (r_nsubjpass) compared_14\VBN\analyze.v.01|in|,|dothiepin|were|to|. (l_prep) to_15\IN\entity.n.01|placebo (l_pobj) placebo_16\NN\medicine.n.02|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_19\NN\care.n.01|the|of (l_prep) of_20\IN\entity.n.01|outpatients (l_pobj) outpatients_23\NNS\patient.n.01|33|depressed (l_amod) depressed_22\JJ\discourage.v.02|
D000639_D003866 NONE amitriptyline_2\NN\tricyclic.n.01| (r_conj) dothiepin_0\JJ\entity.n.01|and|amitriptyline (r_nsubj) were_3\VBD\be.v.01|dothiepin|effective|,|and|were (l_acomp) effective_5\JJ\effective.a.01|equally|in (l_prep) in_6\IN\linear_unit.n.01|alleviating (l_pcomp) alleviating_7\VBG\better.v.02|symptoms (l_dobj) symptoms_9\NNS\evidence.n.01|the|of (l_prep) of_10\IN\entity.n.01|illness (l_pobj) illness_12\NN\ill_health.n.01|depressive
D000639_D003866 NONE amitriptyline_16\NN\tricyclic.n.01|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_19\NN\care.n.01|the|of (l_prep) of_20\IN\entity.n.01|outpatients (l_pobj) outpatients_22\NNS\patient.n.01|depressed (l_amod) depressed_21\JJ\discourage.v.02|
D004308_D014786 NONE dothiepin_24\JJ\entity.n.01| (r_pobj) with_23\IN\entity.n.01|dothiepin (r_prep) less_22\JJR\autoimmune_disease.n.01|significantly|with|than (r_acomp) were_20\VBD\be.v.01|incidence|less|. (l_nsubj) incidence_2\NN\frequency.n.02|the|overall|of (l_prep) of_3\IN\entity.n.01|effects (l_pobj) effects_5\NNS\personal_property.n.01|side|and|frequency (l_conj) frequency_8\NN\rate.n.01|the|and|severity|of (l_prep) of_11\IN\entity.n.01|vision (l_pobj) vision_13\NN\imagination.n.02|blurred|,|mouth
D004308_D014987 NONE dothiepin_24\JJ\entity.n.01| (r_pobj) with_23\IN\entity.n.01|dothiepin (r_prep) less_22\JJR\autoimmune_disease.n.01|significantly|with|than (r_acomp) were_20\VBD\be.v.01|incidence|less|. (l_nsubj) incidence_2\NN\frequency.n.02|the|overall|of (l_prep) of_3\IN\entity.n.01|effects (l_pobj) effects_5\NNS\personal_property.n.01|side|and|frequency (l_conj) frequency_8\NN\rate.n.01|the|and|severity|of (l_prep) of_11\IN\entity.n.01|vision (l_pobj) vision_13\NN\imagination.n.02|blurred|,|mouth (l_conj) mouth_16\NN\rima.n.01|dry|,|and|drowsiness
D000639_D014786 CID amitriptyline_27\NN\tricyclic.n.01| (r_pobj) with_26\IN\entity.n.01|amitriptyline (r_prep) than_25\IN\entity.n.01|with (r_prep) less_22\JJR\autoimmune_disease.n.01|significantly|with|than (r_acomp) were_20\VBD\be.v.01|incidence|less|. (l_nsubj) incidence_2\NN\frequency.n.02|the|overall|of (l_prep) of_3\IN\entity.n.01|effects (l_pobj) effects_5\NNS\personal_property.n.01|side|and|frequency (l_conj) frequency_8\NN\rate.n.01|the|and|severity|of (l_prep) of_11\IN\entity.n.01|vision (l_pobj) vision_13\NN\imagination.n.02|blurred|,|mouth
D000639_D014987 CID amitriptyline_27\NN\tricyclic.n.01| (r_pobj) with_26\IN\entity.n.01|amitriptyline (r_prep) than_25\IN\entity.n.01|with (r_prep) less_22\JJR\autoimmune_disease.n.01|significantly|with|than (r_acomp) were_20\VBD\be.v.01|incidence|less|. (l_nsubj) incidence_2\NN\frequency.n.02|the|overall|of (l_prep) of_3\IN\entity.n.01|effects (l_pobj) effects_5\NNS\personal_property.n.01|side|and|frequency (l_conj) frequency_8\NN\rate.n.01|the|and|severity|of (l_prep) of_11\IN\entity.n.01|vision (l_pobj) vision_13\NN\imagination.n.02|blurred|,|mouth (l_conj) mouth_16\NN\rima.n.01|dry|,|and|drowsiness
D000928_D003866 NONE antidepressant_8\NN\medicine.n.02| (r_amod) drug_9\NN\agent.n.03|an|effective|antidepressant|associated (l_acl) associated_10\VBN\think.v.03|with (l_prep) with_11\IN\entity.n.01|effects (l_pobj) effects_14\NNS\personal_property.n.01|fewer|side|than (l_prep) than_15\IN\entity.n.01|amitriptyline (l_pobj) amitriptyline_16\NN\tricyclic.n.01|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_19\NN\care.n.01|the|of (l_prep) of_20\IN\entity.n.01|outpatients (l_pobj) outpatients_22\NNS\patient.n.01|depressed (l_amod) depressed_21\JJ\discourage.v.02|
6103707
D005445_D010146 CID flunitrazepam_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|flunitrazepam (r_prep) injection_5\NN\insertion.n.02|i.m.|of (r_pobj) on_3\IN\on.a.01|injection (r_prep) pain_2\NN\symptom.n.01|on
17244258
D003520_D003556 CID cyclophosphamide_9\NN\entity.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|cyclophosphamide|- (r_amod) cystitis_12\NN\urinary_tract_infection.n.01|induced|in
D003520_D003556 CID cyclophosphamide_1\NN\entity.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|cyclophosphamide|- (r_amod) cystitis_4\NN\urinary_tract_infection.n.01|induced|in
3173179
D014700_D009203 CID verapamil_0\NNP\calcium_blocker.n.01| (r_compound) withdrawal_1\NN\retraction.n.01|verapamil|as|. (l_prep) as_2\IN\chemical_element.n.01|cause (l_pobj) cause_5\NN\origin.n.03|a|possible|of (l_prep) of_6\IN\entity.n.01|infarction (l_pobj) infarction_8\NN\pathology.n.02|myocardial|in|with
D014700_D009203 CID verapamil_18\NN\calcium_blocker.n.01| (r_pobj) of_17\IN\entity.n.01|verapamil (r_prep) withdrawal_16\NN\retraction.n.01|the|of|in (r_conj) introduction_11\NN\beginning.n.05|the|of|and|withdrawal (r_pobj) with_9\IN\entity.n.01|introduction (r_prep) coincided_8\VBD\coexist.v.02|in|infarction|with (l_nsubj) infarction_7\NN\pathology.n.02|myocardial
D014700_D006973 NONE verapamil_0\NNP\calcium_blocker.n.01| (r_compound) withdrawal_1\NN\retraction.n.01|verapamil|as|. (l_prep) as_2\IN\chemical_element.n.01|cause (l_pobj) cause_5\NN\origin.n.03|a|possible|of (l_prep) of_6\IN\entity.n.01|infarction (l_pobj) infarction_8\NN\pathology.n.02|myocardial|in|with (l_prep) in_9\IN\linear_unit.n.01|woman (l_pobj) woman_12\NN\adult.n.01|a|hypertensive (l_amod) hypertensive_11\JJ\patient.n.01|
D014700_D006973 NONE verapamil_18\NN\calcium_blocker.n.01| (r_pobj) of_17\IN\entity.n.01|verapamil (r_prep) withdrawal_16\NN\retraction.n.01|the|of|in (l_prep) in_19\IN\linear_unit.n.01|woman (l_pobj) woman_23\NN\adult.n.01|a|asymptomatic|with (l_prep) with_24\IN\entity.n.01|hypertension (l_pobj) hypertension_26\NN\cardiovascular_disease.n.01|severe
D002216_D009203 NONE captopril_13\NN\ace_inhibitor.n.01| (r_pobj) of_12\IN\entity.n.01|captopril (r_prep) introduction_11\NN\beginning.n.05|the|of|and|withdrawal (r_pobj) with_9\IN\entity.n.01|introduction (r_prep) coincided_8\VBD\coexist.v.02|in|infarction|with (l_nsubj) infarction_7\NN\pathology.n.02|myocardial
D002216_D006973 NONE captopril_13\NN\ace_inhibitor.n.01| (r_pobj) of_12\IN\entity.n.01|captopril (r_prep) introduction_11\NN\beginning.n.05|the|of|and|withdrawal (l_conj) withdrawal_16\NN\retraction.n.01|the|of|in (l_prep) in_19\IN\linear_unit.n.01|woman (l_pobj) woman_23\NN\adult.n.01|a|asymptomatic|with (l_prep) with_24\IN\entity.n.01|hypertension (l_pobj) hypertension_26\NN\cardiovascular_disease.n.01|severe
8170551
D000086_D053040 NONE acetazolamide_0\RB\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|acetazolamide|- (r_amod) nephrolithiasis_3\NN\lithiasis.n.01|induced|:|implications|.
D000086_D053040 NONE acetazolamide_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|acetazolamide (r_prep) complication_3\NN\hindrance.n.03|a|of (r_attr) is_1\VBZ\be.v.01|nephrolithiasis|complication|but|preclude|. (l_nsubj) nephrolithiasis_0\NNP\lithiasis.n.01|
D000086_D009468 NONE acetazolamide_0\RB\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|acetazolamide|- (r_amod) nephrolithiasis_3\NN\lithiasis.n.01|induced|:|implications|. (l_appos) implications_5\NNS\inference.n.01|for (l_prep) for_6\IN\entity.n.01|treatment (l_pobj) treatment_7\NN\care.n.01|of (l_prep) of_8\IN\entity.n.01|disorders (l_pobj) disorders_10\NNS\physical_condition.n.01|neuromuscular
D000086_D007669 CID acetazolamide_3\NN\entity.n.01|% (r_pobj) on_2\IN\on.a.01|acetazolamide (r_prep) patients_1\NNS\case.n.06|three|on (r_nsubj) developed_8\VBN\create.v.02|patients|calculi|. (l_dobj) calculi_10\NNS\rock.n.01|renal
19759529
D004298_D012559 NONE dopamine_8\NN\monoamine_neurotransmitter.n.01| (r_compound) neurotransmission_9\NN\entity.n.01|dopamine (r_pobj) in_7\IN\linear_unit.n.01|neurotransmission (r_prep) dysfunction_6\NN\pathology.n.02|in (r_pobj) with_5\IN\entity.n.01|dysfunction (r_prep) associated_4\VBN\think.v.03|schizophrenia|has|been|initially|with|. (l_nsubjpass) schizophrenia_0\NNP\psychosis.n.01|
D018698_D012559 NONE glutamate_8\NN\salt.n.01| (r_nmod) receptor_19\NN\structure.n.04|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN\entity.n.01|receptor (r_prep) antagonists_5\NNS\person.n.01|of (r_nsubj) produce_20\VBP\food.n.02|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\evidence.n.01|like|in (l_amod) like_23\JJ\kind.n.01|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\psychotic.n.01|
D016202_D012559 NONE aspartate_15\NNP\entity.n.01|d|- (r_appos) methyl_11\NN\alkyl.n.01|n|-|aspartate (r_nmod) receptor_19\NN\structure.n.04|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN\entity.n.01|receptor (r_prep) antagonists_5\NNS\person.n.01|of (r_nsubj) produce_20\VBP\food.n.02|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\evidence.n.01|like|in (l_amod) like_23\JJ\kind.n.01|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\psychotic.n.01|
D016202_D012559 NONE nmda_17\NNP\entity.n.01| (r_nmod) receptor_19\NN\structure.n.04|the|glutamate|methyl|(|nmda|) (r_pobj) of_6\IN\entity.n.01|receptor (r_prep) antagonists_5\NNS\person.n.01|of (r_nsubj) produce_20\VBP\food.n.02|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\evidence.n.01|like|in (l_amod) like_23\JJ\kind.n.01|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\psychotic.n.01|
D016202_D012559 NONE nmda_41\NNP\entity.n.01| (r_compound) receptor_42\NN\structure.n.04|its|nmda (r_pobj) via_39\IN\entity.n.01|receptor (r_prep) dysfunctioning_34\NN\entity.n.01|a|of|via (r_pobj) of_32\IN\entity.n.01|dysfunctioning (r_prep) idea_31\NN\content.n.05|the|of (r_pobj) to_29\IN\entity.n.01|idea (r_prep) led_28\VBN\diode.n.02|however|,|observation|has|to|. (l_nsubj) observation_3\NN\measurement.n.01|the|produce (l_relcl) produce_20\VBP\food.n.02|that|antagonists|symptoms (l_dobj) symptoms_24\NNS\evidence.n.01|like|in (l_amod) like_23\JJ\kind.n.01|schizophrenic|- (l_npadvmod) schizophrenic_21\JJ\psychotic.n.01|
-1_D006948 NONE ssr103800_12\NNP\entity.n.01| (r_pobj) of_11\IN\entity.n.01|ssr103800 (r_prep) properties_10\NNS\possession.n.02|the|potential|like|of|involving (r_dobj) investigating_4\VBG\work.n.01|properties|,|with (l_prep) with_14\IN\entity.n.01|focus (l_pobj) focus_17\NN\concentration.n.05|a|particular|on|, (l_prep) on_18\IN\on.a.01|models (l_pobj) models_19\NNS\hypothesis.n.02|of (l_prep) of_20\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_21\NN\disorder.n.01|
-1_D006948 NONE ssr103800_3\NNP\entity.n.01| (r_nmod) hyperactivity_12\NN\disorder.n.01|ssr103800|(|mg/kg|p.o.|)|blocked|induced
-1_D006948 NONE ssr103800_3\NNP\entity.n.01| (r_nmod) hyperactivity_12\NN\disorder.n.01|ssr103800|(|mg/kg|p.o.|)|blocked|induced (r_punct) that_2\IN\entity.n.01|hyperactivity (r_dobj) showed_1\VBD\show.v.04|results|that|and|reversed|. (l_conj) reversed_26\VBD\change.v.02|partially|hyperactivity (l_dobj) hyperactivity_28\NN\disorder.n.01|spontaneous|of
-1_D006948 NONE ssr103800_3\NNP\entity.n.01| (r_nsubj) failed_4\VBD\fail.v.01|in|,|ssr103800|affect|or|observed|) (l_xcomp) affect_6\VB\feeling.n.01|to|hyperactivity (l_dobj) hyperactivity_7\NN\disorder.n.01|induced
D000661_D006948 CID amphetamine_30\NN\drug_of_abuse.n.01|(|ie|,|and|) (r_appos) challenge_26\NN\situation.n.01|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG\refer.v.02|challenge (r_prep) properties_10\NNS\possession.n.02|the|potential|like|of|involving (r_dobj) investigating_4\VBG\work.n.01|properties|,|with (l_prep) with_14\IN\entity.n.01|focus (l_pobj) focus_17\NN\concentration.n.05|a|particular|on|, (l_prep) on_18\IN\on.a.01|models (l_pobj) models_19\NNS\hypothesis.n.02|of (l_prep) of_20\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_21\NN\disorder.n.01|
D000661_D006948 CID amphetamine_10\NN\drug_of_abuse.n.01| (r_pobj) by_9\IN\by.r.01|amphetamine (r_agent) induced_8\VBN\generate.v.01|by (r_acl) hyperactivity_7\NN\disorder.n.01|induced
D016291_D006948 CID mk-801_32\NNP\entity.n.01| (r_punct) )_33\-RRB-\entity.n.01|mk-801 (r_punct) amphetamine_30\NN\drug_of_abuse.n.01|(|ie|,|and|) (r_appos) challenge_26\NN\situation.n.01|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG\refer.v.02|challenge (r_prep) properties_10\NNS\possession.n.02|the|potential|like|of|involving (r_dobj) investigating_4\VBG\work.n.01|properties|,|with (l_prep) with_14\IN\entity.n.01|focus (l_pobj) focus_17\NN\concentration.n.05|a|particular|on|, (l_prep) on_18\IN\on.a.01|models (l_pobj) models_19\NNS\hypothesis.n.02|of (l_prep) of_20\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_21\NN\disorder.n.01|
D016291_D006948 CID mk-801_23\NNP\entity.n.01| (r_punct) and_24\CC\entity.n.01|mk-801 (r_cc) showed_1\VBD\show.v.04|results|that|and|reversed|. (l_dobj) that_2\IN\entity.n.01|hyperactivity (l_punct) hyperactivity_12\NN\disorder.n.01|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016291_D006948 CID mk-801_23\NNP\entity.n.01| (r_punct) and_24\CC\entity.n.01|mk-801 (r_cc) showed_1\VBD\show.v.04|results|that|and|reversed|. (l_conj) reversed_26\VBD\change.v.02|partially|hyperactivity (l_dobj) hyperactivity_28\NN\disorder.n.01|spontaneous|of
D016202_D006948 NONE nmda_40\NNP\entity.n.01| (r_compound) nr1(neo-/-_41\NNP\entity.n.01|(|ie|,|nmda|)|and|dat(-/- (r_appos) mice_36\NNS\rodent.n.01|transgenic|nr1(neo-/-|) (r_conj) challenge_26\NN\situation.n.01|either|drug|amphetamine|or|mice (r_dobj) involving_23\VBG\refer.v.02|challenge (r_prep) properties_10\NNS\possession.n.02|the|potential|like|of|involving (r_dobj) investigating_4\VBG\work.n.01|properties|,|with (l_prep) with_14\IN\entity.n.01|focus (l_pobj) focus_17\NN\concentration.n.05|a|particular|on|, (l_prep) on_18\IN\on.a.01|models (l_pobj) models_19\NNS\hypothesis.n.02|of (l_prep) of_20\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_21\NN\disorder.n.01|
D016202_D006948 NONE nmda_19\NNP\entity.n.01| (r_compound) antagonist_21\NN\person.n.01|the|competitive|nmda|receptor|, (r_pobj) by_14\IN\by.r.01|antagonist (r_agent) induced_13\VBN\generate.v.01|by (r_acl) hyperactivity_12\NN\disorder.n.01|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016202_D006948 NONE nmda_19\NNP\entity.n.01| (r_compound) antagonist_21\NN\person.n.01|the|competitive|nmda|receptor|, (r_pobj) by_14\IN\by.r.01|antagonist (r_agent) induced_13\VBN\generate.v.01|by (r_acl) hyperactivity_12\NN\disorder.n.01|ssr103800|(|mg/kg|p.o.|)|blocked|induced (r_punct) that_2\IN\entity.n.01|hyperactivity (r_dobj) showed_1\VBD\show.v.04|results|that|and|reversed|. (l_conj) reversed_26\VBD\change.v.02|partially|hyperactivity (l_dobj) hyperactivity_28\NN\disorder.n.01|spontaneous|of
D016202_D006948 NONE nmda_30\NNP\entity.n.01| (r_nmod) mice_33\NNS\rodent.n.01|nmda|nr1(neo-/-|) (r_pobj) of_29\IN\entity.n.01|mice (r_prep) hyperactivity_28\NN\disorder.n.01|spontaneous|of (r_dobj) reversed_26\VBD\change.v.02|partially|hyperactivity (r_conj) showed_1\VBD\show.v.04|results|that|and|reversed|. (l_dobj) that_2\IN\entity.n.01|hyperactivity (l_punct) hyperactivity_12\NN\disorder.n.01|ssr103800|(|mg/kg|p.o.|)|blocked|induced
D016202_D006948 NONE nmda_30\NNP\entity.n.01| (r_nmod) mice_33\NNS\rodent.n.01|nmda|nr1(neo-/-|) (r_pobj) of_29\IN\entity.n.01|mice (r_prep) hyperactivity_28\NN\disorder.n.01|spontaneous|of
D004298_D006948 NONE dopamine_15\NN\monoamine_neurotransmitter.n.01| (r_compound) transporter_16\NN\truck.n.01|dopamine|(|dat(-/-|) (r_pobj) in_14\IN\linear_unit.n.01|transporter (r_prep) observed_13\VBN\spy.v.03|naturally|in (r_conj) failed_4\VBD\fail.v.01|in|,|ssr103800|affect|or|observed|) (l_xcomp) affect_6\VB\feeling.n.01|to|hyperactivity (l_dobj) hyperactivity_7\NN\disorder.n.01|induced
D006220_D006948 NONE haloperidol_5\NN\major_tranquilizer.n.01|importantly|,|both|classical|(|)|and|atypical (r_nmod) antipsychotics_16\NNS\tranquilizer.n.01|haloperidol|clozapine (r_nsubj) were_17\VBD\be.v.01|antipsychotics|effective|. (l_acomp) effective_18\JJ\effective.a.01|in (l_prep) in_19\IN\linear_unit.n.01|models (l_pobj) models_22\NNS\hypothesis.n.02|all|these|of (l_prep) of_23\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_24\NN\disorder.n.01|
C076029_D006948 NONE olanzapine_10\NN\entity.n.01| (r_nmod) clozapine_12\NN\major_tranquilizer.n.01|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS\tranquilizer.n.01|haloperidol|clozapine (r_nsubj) were_17\VBD\be.v.01|antipsychotics|effective|. (l_acomp) effective_18\JJ\effective.a.01|in (l_prep) in_19\IN\linear_unit.n.01|models (l_pobj) models_22\NNS\hypothesis.n.02|all|these|of (l_prep) of_23\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_24\NN\disorder.n.01|
D003024_D006948 NONE clozapine_12\NN\major_tranquilizer.n.01|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS\tranquilizer.n.01|haloperidol|clozapine (r_nsubj) were_17\VBD\be.v.01|antipsychotics|effective|. (l_acomp) effective_18\JJ\effective.a.01|in (l_prep) in_19\IN\linear_unit.n.01|models (l_pobj) models_22\NNS\hypothesis.n.02|all|these|of (l_prep) of_23\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_24\NN\disorder.n.01|
C094645_D006948 NONE aripiprazole_14\NN\entity.n.01| (r_conj) clozapine_12\NN\major_tranquilizer.n.01|(|olanzapine|,|and|aripiprazole|) (r_nmod) antipsychotics_16\NNS\tranquilizer.n.01|haloperidol|clozapine (r_nsubj) were_17\VBD\be.v.01|antipsychotics|effective|. (l_acomp) effective_18\JJ\effective.a.01|in (l_prep) in_19\IN\linear_unit.n.01|models (l_pobj) models_22\NNS\hypothesis.n.02|all|these|of (l_prep) of_23\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_24\NN\disorder.n.01|
-1_D002375 NONE ssr103800_6\NNP\entity.n.01| (r_nsubj) produce_9\VB\food.n.02|however|,|unlike|,|ssr103800|did|not|catalepsy|retention|up|together (l_dobj) catalepsy_10\NN\hypersomnia.n.01|
9653867
D013974_D013971 CID thyroxine_0\NNP\thyroid_hormone.n.01| (r_compound) abuse_1\NN\mistreatment.n.01|thyroxine|:|case|. (l_appos) case_5\NN\happening.n.01|an|unusual|of (l_prep) of_6\IN\entity.n.01|thyrotoxicosis (l_pobj) thyrotoxicosis_7\NN\glandular_disease.n.01|in
D013974_D013971 CID thyroxine_28\NN\thyroid_hormone.n.01| (r_compound) abuse_29\NN\mistreatment.n.01|thyroxine (r_nsubjpass) considered_32\VBN\think.v.01|that|remains|,|abuse|should|be|and|explored (l_advcl) remains_25\VBZ\object.n.01|when|cause|obscure (l_nsubj) cause_22\NN\origin.n.03|a|for (l_prep) for_23\IN\entity.n.01|thyrotoxicosis (l_pobj) thyrotoxicosis_24\NN\glandular_disease.n.01|
D013974_D001068 NONE thyroxine_28\NN\thyroid_hormone.n.01| (r_compound) abuse_29\NN\mistreatment.n.01|thyroxine (r_nsubjpass) considered_32\VBN\think.v.01|that|remains|,|abuse|should|be|and|explored (r_ccomp) reminds_17\VBZ\remind.v.01|us|considered (r_conj) illustrates_3\VBZ\elaborate.v.01|in|it|derangements|and|reminds|. (l_dobj) derangements_5\NNS\insanity.n.01|the|of (l_prep) of_6\IN\entity.n.01|function (l_pobj) function_8\NN\mathematical_relation.n.01|thyroid|seen (l_acl) seen_9\VBN\perceive.v.01|in|with (l_prep) with_13\IN\entity.n.01|eating (l_pcomp) eating_14\VBG\consumption.n.01|disorders (l_dobj) disorders_15\NNS\physical_condition.n.01|
10807237
D003042_D000783 NONE cocaine_12\NN\hard_drug.n.01| (r_npadvmod) related_14\VBN\think.v.03|cocaine|- (r_amod) aneurysms_15\NNS\cardiovascular_disease.n.01|related
D003042_D000783 NONE cocaine_25\NN\hard_drug.n.01| (r_npadvmod) related_27\VBN\think.v.03|cocaine|- (r_amod) aneurysms_28\NNS\cardiovascular_disease.n.01|related
D003042_D000783 NONE cocaine_0\NN\hard_drug.n.01| (r_compound) use_1\NN\activity.n.01|cocaine (r_nsubj) predisposed_2\VBN\dispose.v.03|use|rupture|at|. (l_prep) at_5\IN\chemical_element.n.01|age|and|in (l_conj) in_11\IN\linear_unit.n.01|aneurysms (l_pobj) aneurysms_14\NNS\cardiovascular_disease.n.01|smaller
D003042_D017542 CID cocaine_0\NN\hard_drug.n.01| (r_compound) use_1\NN\activity.n.01|cocaine (r_nsubj) predisposed_2\VBN\dispose.v.03|use|rupture|at|. (l_dobj) rupture_4\NN\injury.n.01|aneurysmal
7269015
D002066_D006470 CID busulfan_0\NNS\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|busulfan|- (r_amod) cystitis_4\NN\urinary_tract_infection.n.01|induced|hemorrhagic|.
D002066_D006470 CID busulfan_4\NNS\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|busulfan|- (r_amod) cystitis_8\NN\urinary_tract_infection.n.01|a|induced|hemorrhage
D002066_D003556 CID busulfan_0\NNS\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|busulfan|- (r_amod) cystitis_4\NN\urinary_tract_infection.n.01|induced|hemorrhagic|.
D002066_D003556 CID busulfan_4\NNS\entity.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|busulfan|- (r_amod) cystitis_8\NN\urinary_tract_infection.n.01|a|induced|hemorrhage
D002066_D003556 CID busulfan_7\NNS\entity.n.01| (r_amod) cystitis_8\NN\urinary_tract_infection.n.01|busulfan|and|cystitis
D002066_D003556 CID busulfan_7\NNS\entity.n.01| (r_amod) cystitis_8\NN\urinary_tract_infection.n.01|busulfan|and|cystitis (l_conj) cystitis_16\NN\urinary_tract_infection.n.01|radiation
D003520_D003556 NONE cyclophosphamide_13\NN\entity.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|cyclophosphamide|- (r_conj) radiation_11\NN\energy.n.01|both|and|induced (r_nmod) cystitis_16\NN\urinary_tract_infection.n.01|radiation (r_conj) cystitis_8\NN\urinary_tract_infection.n.01|busulfan|and|cystitis
D003520_D003556 NONE cyclophosphamide_13\NN\entity.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|cyclophosphamide|- (r_conj) radiation_11\NN\energy.n.01|both|and|induced (r_nmod) cystitis_16\NN\urinary_tract_infection.n.01|radiation
D002066_D002277 NONE busulfan_7\NNS\entity.n.01| (r_pobj) of_6\IN\entity.n.01|busulfan (r_prep) tendency_5\NN\attitude.n.01|the|known|of (r_pobj) of_2\IN\entity.n.01|tendency (r_prep) view_1\NN\orientation.n.02|of (r_pobj) in_0\IN\linear_unit.n.01|view|induce (l_advcl) induce_9\VB\generate.v.01|to|atypia (l_dobj) atypia_11\NN\entity.n.01|cellular|and|carcinoma|in (l_conj) carcinoma_13\NN\cancer.n.01|
15737522
D002443_D001660 CID ceftriaxone_0\NN\cephalosporin.n.01| (r_npadvmod) associated_2\VBN\think.v.03|ceftriaxone|- (r_amod) pseudolithiasis_4\NN\entity.n.01|associated|biliary|in|.
D002443_D001660 CID ceftriaxone_5\NN\cephalosporin.n.01| (r_nsubj) leads_6\VBZ\advantage.n.01|that|ceftriaxone|pseudolithiasis (l_xcomp) pseudolithiasis_8\NN\entity.n.01|to|in
D002443_D001660 CID ceftriaxone_19\CD\cephalosporin.n.01| (r_compound) treatment_20\NN\care.n.01|ceftriaxone|,|had (r_dobj) receiving_18\VBG\get.v.01|treatment (r_acl) patients_17\NNS\case.n.06|paediatric|surgical|receiving (r_pobj) in_14\IN\linear_unit.n.01|patients (r_prep) pseudolithiasis_13\NN\entity.n.01|in
11587867
D014750_D001927 NONE vincristin_6\NN\entity.n.01| (r_compound) administration_7\NN\management.n.01|accidental|intrathecal|vincristin|:|report (r_pobj) due_2\IN\right.n.01|to|administration (r_prep) myeloencephalopathy_1\NN\entity.n.01|fatal|due|.
D014750_D054198 NONE vincristine_9\NN\periwinkle_plant_derivative.n.01| (r_compound) instillation_10\NN\insertion.n.02|accidental|intrathecal|vincristine|in (l_prep) in_11\IN\linear_unit.n.01|girl (l_pobj) girl_15\NN\woman.n.01|a|5-year|old|with (l_prep) with_16\IN\entity.n.01|leucemia (l_pobj) leucemia_20\NN\entity.n.01|recurrent|acute|lymphoblastic|and|man
D014750_D054198 NONE vincristine_9\NN\periwinkle_plant_derivative.n.01| (r_compound) instillation_10\NN\insertion.n.02|accidental|intrathecal|vincristine|in (l_prep) in_11\IN\linear_unit.n.01|girl (l_pobj) girl_15\NN\woman.n.01|a|5-year|old|with (l_prep) with_16\IN\entity.n.01|leucemia (l_pobj) leucemia_20\NN\entity.n.01|recurrent|acute|lymphoblastic|and|man (l_conj) man_25\NN\adult.n.01|a|57-year|old|with (l_prep) with_26\IN\entity.n.01|lymphoma (l_pobj) lymphoma_28\NN\cancer.n.01|lymphoblastic
D014750_D003711 CID vincristine_28\NN\periwinkle_plant_derivative.n.01| (r_pobj) to_27\IN\entity.n.01|vincristine (r_prep) exposed_26\VBN\subject.v.01|to (r_acl) areas_25\NNS\region.n.03|exposed (r_pobj) in_24\IN\linear_unit.n.01|areas (r_prep) transformation_23\NN\change.n.01|pseudocystic|in|,|accompanied (r_conj) degeneration_14\NN\process.n.06|of|as|transformation (l_prep) of_15\IN\entity.n.01|myelin (l_pobj) myelin_16\NN\fat.n.01|and|axons (l_conj) axons_18\NNS\nerve_fiber.n.01|
D014750_D009410 CID vincristine_28\NN\periwinkle_plant_derivative.n.01| (r_pobj) to_27\IN\entity.n.01|vincristine (r_prep) exposed_26\VBN\subject.v.01|to (r_acl) areas_25\NNS\region.n.03|exposed (r_pobj) in_24\IN\linear_unit.n.01|areas (r_prep) transformation_23\NN\change.n.01|pseudocystic|in|,|accompanied (r_conj) degeneration_14\NN\process.n.06|of|as|transformation (l_prep) of_15\IN\entity.n.01|myelin (l_pobj) myelin_16\NN\fat.n.01|and|axons (l_conj) axons_18\NNS\nerve_fiber.n.01|
D014750_-1 NONE vincristine_28\NN\periwinkle_plant_derivative.n.01| (r_pobj) to_27\IN\entity.n.01|vincristine (r_prep) exposed_26\VBN\subject.v.01|to (r_acl) areas_25\NNS\region.n.03|exposed (r_pobj) in_24\IN\linear_unit.n.01|areas (r_prep) transformation_23\NN\change.n.01|pseudocystic|in|,|accompanied
3031535
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN\entity.n.01|delta (r_pobj) by_5\IN\by.r.01|9-tetrahydrocannabinol (r_agent) induced_4\VBN\generate.v.01|involvement|by|. (l_nsubj) involvement_1\NN\group_action.n.01|noradrenergic|in (l_prep) in_2\IN\linear_unit.n.01|catalepsy (l_pobj) catalepsy_3\NN\hypersomnia.n.01|
D013759_D002375 CID thc_17\NNP\psychoactive_drug.n.01| (r_pobj) by_16\IN\by.r.01|thc (r_agent) induced_15\VBN\generate.v.01|by (r_acl) manifestation_12\NN\appearance.n.02|the|of|induced (l_prep) of_13\IN\entity.n.01|catalepsy (l_pobj) catalepsy_14\NN\hypersomnia.n.01|
D013759_D002375 CID thc_17\NNP\psychoactive_drug.n.01| (r_pobj) by_16\IN\by.r.01|thc (r_agent) induced_15\VBN\generate.v.01|by (r_acl) manifestation_12\NN\appearance.n.02|the|of|induced (r_pobj) in_10\IN\linear_unit.n.01|manifestation (r_prep) role_9\NN\duty.n.02|an|important|in (r_dobj) have_6\VBP\person.n.01|that|neurons|role|,|are (l_advcl) are_22\VBP\area_unit.n.01|whereas|neurons|important|in|induced (l_prep) in_24\IN\linear_unit.n.01|catalepsy (l_pobj) catalepsy_25\NN\hypersomnia.n.01|
D006220_D002375 CID haloperidol_28\NN\major_tranquilizer.n.01| (r_pobj) by_27\IN\by.r.01|haloperidol (r_agent) induced_26\VBN\generate.v.01|by (r_advcl) are_22\VBP\area_unit.n.01|whereas|neurons|important|in|induced (r_advcl) have_6\VBP\person.n.01|that|neurons|role|,|are (l_dobj) role_9\NN\duty.n.02|an|important|in (l_prep) in_10\IN\linear_unit.n.01|manifestation (l_pobj) manifestation_12\NN\appearance.n.02|the|of|induced (l_prep) of_13\IN\entity.n.01|catalepsy (l_pobj) catalepsy_14\NN\hypersomnia.n.01|
D006220_D002375 CID haloperidol_28\NN\major_tranquilizer.n.01| (r_pobj) by_27\IN\by.r.01|haloperidol (r_agent) induced_26\VBN\generate.v.01|by (r_advcl) are_22\VBP\area_unit.n.01|whereas|neurons|important|in|induced (l_prep) in_24\IN\linear_unit.n.01|catalepsy (l_pobj) catalepsy_25\NN\hypersomnia.n.01|
8682684
D000082_D007022 CID acetaminophen_0\NNP\analgesic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|acetaminophen|- (r_amod) hypotension_3\NN\cardiovascular_disease.n.01|induced|.
D000082_D007022 CID acetaminophen_2\RB\analgesic.n.01| (r_nsubjpass) demonstrated_5\VBN\show.v.04|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\food.n.02|to|symptoms (l_dobj) symptoms_8\NNS\evidence.n.01|of|,|including|,|in (l_prep) including_12\VBG\include.v.01|hypotension (l_pobj) hypotension_13\NN\cardiovascular_disease.n.01|
D000082_D007022 CID acetaminophen_18\NN\analgesic.n.01| (r_pobj) of_17\IN\entity.n.01|acetaminophen (r_prep) administration_16\NN\management.n.01|of (r_pobj) after_15\IN\after.s.01|administration (r_prep) developed_14\VBN\create.v.02|in|episodes|reproducibly|after (l_nsubj) episodes_10\NNS\happening.n.01|transient|of (l_prep) of_11\IN\entity.n.01|hypotension (l_pobj) hypotension_12\NN\cardiovascular_disease.n.01|
D000082_D007022 CID acetaminophen_9\NN\analgesic.n.01| (r_dobj) consider_8\VB\think.v.01|for|clinicians|to|acetaminophen|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|with (l_prep) with_12\IN\entity.n.01|hypotension (l_pobj) hypotension_13\NN\cardiovascular_disease.n.01|of
D000082_D002318 NONE acetaminophen_3\NN\analgesic.n.01| (r_pobj) for_2\IN\entity.n.01|acetaminophen (r_prep) potential_1\NN\possibility.n.02|the|for|produce (l_acl) produce_5\VB\food.n.02|to|toxicities (l_dobj) toxicities_7\NNS\definite_quantity.n.01|cardiovascular
D000082_D000707 NONE acetaminophen_2\RB\analgesic.n.01| (r_nsubjpass) demonstrated_5\VBN\show.v.04|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\food.n.02|to|symptoms (l_dobj) symptoms_8\NNS\evidence.n.01|of|,|including|,|in (l_prep) of_9\IN\entity.n.01|anaphylaxis (l_pobj) anaphylaxis_10\NN\hypersensitivity_reaction.n.01|
D000082_D016638 NONE acetaminophen_18\NN\analgesic.n.01| (r_pobj) of_17\IN\entity.n.01|acetaminophen (r_prep) administration_16\NN\management.n.01|of (r_pobj) after_15\IN\after.s.01|administration (r_prep) developed_14\VBN\create.v.02|in|episodes|reproducibly|after (r_relcl) patients_6\NNS\case.n.06|two|ill|developed (l_amod) ill_5\JJ\disorder.n.01|critically
1616457
D010424_D000647 CID pentobarbital_7\NN\barbiturate.n.01| (r_pobj) by_6\IN\by.r.01|pentobarbital (r_agent) caused_5\VBN\make.v.03|by (r_acl) amnesia_4\NN\cognitive_state.n.01|caused
D010424_D000647 CID pentobarbital_15\NN\barbiturate.n.01| (r_nmod) ip_20\NNP\science.n.01|pentobarbital|(|mg/kg|, (r_pobj) by_14\IN\by.r.01|ip (r_agent) produced_13\VBN\make.v.03|by (r_acl) amnesia_12\NN\cognitive_state.n.01|produced
15863244
C106876_D064420 NONE dfu_17\NNP\entity.n.01|and|study (r_appos) inhibitors_11\NNS\substance.n.07|selective|cyclooxygenase-2|in|--|dfu (r_pobj) of_4\IN\entity.n.01|inhibitors (r_prep) toxicity_3\NN\definite_quantity.n.01|developmental|of
C106876_D064420 NONE dfu_22\NNP\entity.n.01|selective|( (r_conj) toxicity_10\NN\definite_quantity.n.01|the|developmental|of|dfu
C106876_D064420 NONE phenyl-2(5h)-furanon_26\XX\entity.n.01|was|;|5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl|)|) (l_ccomp) was_5\VBD\washington.n.02|aim|evaluate (l_xcomp) evaluate_7\VB\evaluate.v.02|to|toxicity (l_dobj) toxicity_10\NN\definite_quantity.n.01|the|developmental|of|dfu
C106876_D064420 NONE dfu_10\NNP\entity.n.01| (r_nmod) toxicity_12\NN\definite_quantity.n.01|the|dfu|developmental|observed
D010894_D064420 NONE piroxicam_19\NN\nonsteroidal_anti-inflammatory.n.01| (r_compound) study_20\NN\examination.n.01|piroxicam (r_conj) dfu_17\NNP\entity.n.01|and|study (r_appos) inhibitors_11\NNS\substance.n.07|selective|cyclooxygenase-2|in|--|dfu (r_pobj) of_4\IN\entity.n.01|inhibitors (r_prep) toxicity_3\NN\definite_quantity.n.01|developmental|of
D010894_D064420 NONE piroxicam_17\NN\nonsteroidal_anti-inflammatory.n.01|the|selective|(|)|and (r_pobj) of_11\IN\entity.n.01|piroxicam (r_prep) toxicity_10\NN\definite_quantity.n.01|the|developmental|of|dfu
D010894_D064420 NONE piroxicam_24\NN\nonsteroidal_anti-inflammatory.n.01| (r_pobj) of_23\IN\entity.n.01|piroxicam (r_prep) dose_22\NN\medicine.n.02|the|highest|of (r_pobj) with_19\IN\entity.n.01|dose (r_prep) treated_18\VBN\interact.v.01|with (r_acl) rats_17\NNS\rodent.n.01|treated (r_pobj) in_16\IN\linear_unit.n.01|rats (r_prep) found_15\VBN\wage.n.01|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN\definite_quantity.n.01|maternal|,|retardation
D010894_D006345 NONE piroxicam_23\NN\nonsteroidal_anti-inflammatory.n.01|, (r_nmod) inhibitor_31\NN\substance.n.07|piroxicam|selective|cox-2|based (r_pobj) to_22\IN\entity.n.01|inhibitor (r_prep) exposed_21\VBN\subject.v.01|to (r_acl) fetuses_20\NNS\vertebrate.n.01|rat|exposed (r_pobj) for_18\IN\entity.n.01|fetuses (r_prep) performed_17\VBN\perform.v.01|analysis|was|for|. (l_nsubjpass) analysis_3\NN\investigation.n.02|the|pooled|statistical|for (l_prep) for_4\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|vsd|(|md|)
D010894_D009436 NONE piroxicam_23\NN\nonsteroidal_anti-inflammatory.n.01|, (r_nmod) inhibitor_31\NN\substance.n.07|piroxicam|selective|cox-2|based (r_pobj) to_22\IN\entity.n.01|inhibitor (r_prep) exposed_21\VBN\subject.v.01|to (r_acl) fetuses_20\NNS\vertebrate.n.01|rat|exposed (r_pobj) for_18\IN\entity.n.01|fetuses (r_prep) performed_17\VBN\perform.v.01|analysis|was|for|. (l_nsubjpass) analysis_3\NN\investigation.n.02|the|pooled|statistical|for (l_prep) for_4\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|vsd|(|md|)
D010894_D005317 CID piroxicam_24\NN\nonsteroidal_anti-inflammatory.n.01| (r_pobj) of_23\IN\entity.n.01|piroxicam (r_prep) dose_22\NN\medicine.n.02|the|highest|of (r_pobj) with_19\IN\entity.n.01|dose (r_prep) treated_18\VBN\interact.v.01|with (r_acl) rats_17\NNS\rodent.n.01|treated (r_pobj) in_16\IN\linear_unit.n.01|rats (r_prep) found_15\VBN\wage.n.01|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN\definite_quantity.n.01|maternal|,|retardation (l_appos) retardation_5\NN\change.n.01|intrauterine|growth|,|and|increase
D010894_D009139 CID piroxicam_24\NN\nonsteroidal_anti-inflammatory.n.01| (r_pobj) of_23\IN\entity.n.01|piroxicam (r_prep) dose_22\NN\medicine.n.02|the|highest|of (r_pobj) with_19\IN\entity.n.01|dose (r_prep) treated_18\VBN\interact.v.01|with (r_acl) rats_17\NNS\rodent.n.01|treated (r_pobj) in_16\IN\linear_unit.n.01|rats (r_prep) found_15\VBN\wage.n.01|toxicity|were|in|. (l_nsubjpass) toxicity_1\NN\definite_quantity.n.01|maternal|,|retardation (l_appos) retardation_5\NN\change.n.01|intrauterine|growth|,|and|increase (l_conj) increase_8\NN\indefinite_quantity.n.01|of (l_prep) of_9\IN\entity.n.01|variations (l_pobj) variations_13\NNS\change.n.01|external
2266990
D008454_D020388 NONE mazindol_7\NN\entity.n.01|in (l_prep) in_8\IN\linear_unit.n.01|dystrophy (l_pobj) dystrophy_10\NN\genetic_disease.n.01|duchenne
D008454_D020388 NONE mazindol_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|mazindol (r_prep) trial_5\NN\attempt.n.01|a|12-month|controlled|of|,|inhibitor|, (r_dobj) conducted_1\VBD\manage.v.02|we|trial|in|. (l_prep) in_16\IN\linear_unit.n.01|boys (l_pobj) boys_18\NNS\male.n.02|83|with (l_prep) with_19\IN\entity.n.01|dystrophy (l_pobj) dystrophy_21\NN\genetic_disease.n.01|duchenne
D008454_D020388 NONE mazindol_0\JJ\entity.n.01| (r_compound) doses_1\NNS\medicine.n.02|mazindol (r_nsubj) slow_3\VBP\decrease.v.01|doses|not|progression|. (l_dobj) progression_5\NN\series.n.01|the|of (l_prep) of_6\IN\entity.n.01|weakness (l_pobj) weakness_7\NN\imperfection.n.01|in (l_prep) in_8\IN\linear_unit.n.01|dystrophy (l_pobj) dystrophy_10\NN\genetic_disease.n.01|duchenne
D008454_D001068 CID mazindol_4\NN\entity.n.01| (r_pobj) to_3\IN\entity.n.01|mazindol (r_prep) attributable_2\JJ\attributable.a.01|to (r_amod) effects_1\NNS\personal_property.n.01|side|attributable (r_nsubj) included_5\VBN\include.v.01|effects|appetite (l_dobj) appetite_7\NN\craving.n.01|decreased|(|%|)|,|mouth|,|change
D008454_D001068 CID mazindol_35\NN\entity.n.01| (r_amod) dosage_36\NN\indefinite_quantity.n.01|mazindol (r_nsubjpass) reduced_38\VBN\decrease.v.02|included|;|dosage|was|in|. (l_ccomp) included_5\VBN\include.v.01|effects|appetite (l_dobj) appetite_7\NN\craving.n.01|decreased|(|%|)|,|mouth|,|change
D008454_D014987 CID mazindol_4\NN\entity.n.01| (r_pobj) to_3\IN\entity.n.01|mazindol (r_prep) attributable_2\JJ\attributable.a.01|to (r_amod) effects_1\NNS\personal_property.n.01|side|attributable (r_nsubj) included_5\VBN\include.v.01|effects|appetite (l_dobj) appetite_7\NN\craving.n.01|decreased|(|%|)|,|mouth|,|change (l_appos) mouth_14\NN\rima.n.01|dry|(|%|)
D008454_D014987 CID mazindol_35\NN\entity.n.01| (r_amod) dosage_36\NN\indefinite_quantity.n.01|mazindol (r_nsubjpass) reduced_38\VBN\decrease.v.02|included|;|dosage|was|in|. (l_ccomp) included_5\VBN\include.v.01|effects|appetite (l_dobj) appetite_7\NN\craving.n.01|decreased|(|%|)|,|mouth|,|change (l_appos) mouth_14\NN\rima.n.01|dry|(|%|)
D008454_D012817 CID mazindol_4\NN\entity.n.01| (r_pobj) to_3\IN\entity.n.01|mazindol (r_prep) attributable_2\JJ\attributable.a.01|to (r_amod) effects_1\NNS\personal_property.n.01|side|attributable (r_nsubj) included_5\VBN\include.v.01|effects|appetite (l_dobj) appetite_7\NN\craving.n.01|decreased|(|%|)|,|mouth|,|change (l_appos) change_21\NN\happening.n.01|behavioral|(|%|)|,|and|symptoms (l_conj) symptoms_29\NNS\evidence.n.01|gastrointestinal|(|%|)
D008454_D012817 CID mazindol_35\NN\entity.n.01| (r_amod) dosage_36\NN\indefinite_quantity.n.01|mazindol (r_nsubjpass) reduced_38\VBN\decrease.v.02|included|;|dosage|was|in|. (l_ccomp) included_5\VBN\include.v.01|effects|appetite (l_dobj) appetite_7\NN\craving.n.01|decreased|(|%|)|,|mouth|,|change (l_appos) change_21\NN\happening.n.01|behavioral|(|%|)|,|and|symptoms (l_conj) symptoms_29\NNS\evidence.n.01|gastrointestinal|(|%|)
D008454_D018908 NONE mazindol_0\JJ\entity.n.01| (r_compound) doses_1\NNS\medicine.n.02|mazindol (r_nsubj) slow_3\VBP\decrease.v.01|doses|not|progression|. (l_dobj) progression_5\NN\series.n.01|the|of (l_prep) of_6\IN\entity.n.01|weakness (l_pobj) weakness_7\NN\imperfection.n.01|in
16428221
D008774_D020293 CID methylphenidate_4\NN\stimulant.n.02| (r_compound) intake_5\NN\bodily_process.n.01|oral|methylphenidate|in (r_dobj) following_2\VBG\multitude.n.03|intake (r_prep) vasculitis_1\NNS\inflammation.n.01|cerebral|following|:|report|.
D008774_D020293 CID methylphenidate_20\NN\stimulant.n.02| (r_compound) intake_21\NN\bodily_process.n.01|methylphenidate|in (r_pobj) after_19\IN\after.s.01|intake (r_prep) reported_18\VBN\inform.v.01|in|stroke|has|been|after|. (r_conj) documented_8\VBN\record.v.01|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\inflammation.n.01|cerebral|associated
D008774_D019969 NONE methylphenidate_20\NN\stimulant.n.02| (r_compound) intake_21\NN\bodily_process.n.01|methylphenidate|in (r_pobj) after_19\IN\after.s.01|intake (r_prep) reported_18\VBN\inform.v.01|in|stroke|has|been|after|. (r_conj) documented_8\VBN\record.v.01|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\inflammation.n.01|cerebral|associated (l_acl) associated_2\VBN\think.v.03|with (l_prep) with_3\IN\entity.n.01|abuse (l_pobj) abuse_5\NN\mistreatment.n.01|amphetamine
D008774_D002544 NONE methylphenidate_20\NN\stimulant.n.02| (r_compound) intake_21\NN\bodily_process.n.01|methylphenidate|in (r_pobj) after_19\IN\after.s.01|intake (r_prep) reported_18\VBN\inform.v.01|in|stroke|has|been|after|. (l_nsubjpass) stroke_15\NN\maneuver.n.03|ischaemic
D008774_D002544 NONE methylphenidate_14\NN\stimulant.n.02| (r_pobj) with_13\IN\entity.n.01|methylphenidate (r_prep) treated_12\VBN\interact.v.01|who|was|with|due|and|suffered (l_conj) suffered_19\VBD\experience.v.01|from (l_prep) from_20\IN\entity.n.01|strokes (l_pobj) strokes_23\NNS\maneuver.n.03|multiple|ischaemic
D008774_D006948 NONE methylphenidate_14\NN\stimulant.n.02| (r_pobj) with_13\IN\entity.n.01|methylphenidate (r_prep) treated_12\VBN\interact.v.01|who|was|with|due|and|suffered (l_prep) due_15\IN\right.n.01|to|hyperactivity (l_pobj) hyperactivity_17\NN\disorder.n.01|
D008774_D014657 NONE methylphenidate_3\NN\stimulant.n.02|vasculitis (l_dobj) vasculitis_5\NN\inflammation.n.01|mediated
D008774_D014657 NONE methylphenidate_18\NN\stimulant.n.02| (r_compound) therapy_19\NN\medical_care.n.01|methylphenidate (r_pobj) of_17\IN\entity.n.01|therapy (r_prep) history_16\NN\past.n.01|a|of (r_conj) symptoms_13\NNS\evidence.n.01|neurological|and|history (r_pobj) with_11\IN\entity.n.01|symptoms (r_prep) patients_10\NNS\case.n.06|with (r_pobj) in_9\IN\linear_unit.n.01|patients (r_prep) considered_8\VBN\think.v.01|that|methylphenidate|should|be|in (l_nsubjpass) methylphenidate_3\NN\stimulant.n.02|vasculitis (l_dobj) vasculitis_5\NN\inflammation.n.01|mediated
3985451
D014859_D006470 NONE warfarin_0\NNP\anticoagulant.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|warfarin|- (r_amod) hemorrhage_4\NN\injury.n.01|induced|iliopsoas|with|.
D014859_D020428 CID warfarin_0\NNP\anticoagulant.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|warfarin|- (r_amod) hemorrhage_4\NN\injury.n.01|induced|iliopsoas|with|. (l_prep) with_5\IN\entity.n.01|palsy (l_pobj) palsy_9\JJ\dysfunction.n.01|subsequent|femoral|nerve
D014859_D020428 CID warfarin_12\RB\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|warfarin|- (r_amod) neuropathy_16\NN\pathology.n.02|induced|peripheral (r_pobj) of_11\IN\entity.n.01|neuropathy (r_prep) form_10\NN\word.n.01|the|common|of (r_dobj) represents_6\VBZ\equal.v.01|palsy|form (l_nsubj) palsy_5\JJ\dysfunction.n.01|induced|femoral|nerve
D014859_D009135 CID warfarin_12\NN\anticoagulant.n.01| (r_compound) therapy_13\NN\medical_care.n.01|chronic|warfarin (r_pobj) on_10\IN\on.a.01|therapy (r_prep) man_9\NN\adult.n.01|a|old|on|sustained (l_relcl) sustained_15\VBD\continue.v.03|who|tear|and|developed (l_dobj) tear_19\NN\drop.n.02|a|muscle
D014859_D010146 NONE warfarin_12\NN\anticoagulant.n.01| (r_compound) therapy_13\NN\medical_care.n.01|chronic|warfarin (r_pobj) on_10\IN\on.a.01|therapy (r_prep) man_9\NN\adult.n.01|a|old|on|sustained (l_relcl) sustained_15\VBD\continue.v.03|who|tear|and|developed (l_conj) developed_21\VBD\create.v.02|pain (l_dobj) pain_23\NN\symptom.n.01|increasing|and|contracture
D014859_D010146 NONE warfarin_12\RB\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|warfarin|- (r_amod) neuropathy_16\NN\pathology.n.02|induced|peripheral (r_pobj) of_11\IN\entity.n.01|neuropathy (r_prep) form_10\NN\word.n.01|the|common|of (r_dobj) represents_6\VBZ\equal.v.01|palsy|form (r_ccomp) characterized_20\VBN\remember.v.02|represents|;|it|is|by|. (l_agent) by_21\IN\by.r.01|pain (l_pobj) pain_23\NN\symptom.n.01|severe|in|,|degrees
D014859_D003286 NONE warfarin_12\NN\anticoagulant.n.01| (r_compound) therapy_13\NN\medical_care.n.01|chronic|warfarin (r_pobj) on_10\IN\on.a.01|therapy (r_prep) man_9\NN\adult.n.01|a|old|on|sustained (l_relcl) sustained_15\VBD\continue.v.03|who|tear|and|developed (l_conj) developed_21\VBD\create.v.02|pain (l_dobj) pain_23\NN\symptom.n.01|increasing|and|contracture (l_conj) contracture_27\NN\contraction.n.01|a|flexure|of
D014859_D003286 NONE warfarin_12\RB\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|warfarin|- (r_amod) neuropathy_16\NN\pathology.n.02|induced|peripheral (r_pobj) of_11\IN\entity.n.01|neuropathy (r_prep) form_10\NN\word.n.01|the|common|of (r_dobj) represents_6\VBZ\equal.v.01|palsy|form (r_ccomp) characterized_20\VBN\remember.v.02|represents|;|it|is|by|. (l_agent) by_21\IN\by.r.01|pain (l_pobj) pain_23\NN\symptom.n.01|severe|in|,|degrees (l_conj) degrees_30\NNS\property.n.02|varying|of|,|and|contracture (l_conj) contracture_39\NN\contraction.n.01|flexure|of
D014859_D010523 NONE warfarin_12\RB\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|warfarin|- (r_amod) neuropathy_16\NN\pathology.n.02|induced|peripheral
D014859_D015417 NONE warfarin_12\RB\anticoagulant.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|warfarin|- (r_amod) neuropathy_16\NN\pathology.n.02|induced|peripheral (r_pobj) of_11\IN\entity.n.01|neuropathy (r_prep) form_10\NN\word.n.01|the|common|of (r_dobj) represents_6\VBZ\equal.v.01|palsy|form (r_ccomp) characterized_20\VBN\remember.v.02|represents|;|it|is|by|. (l_agent) by_21\IN\by.r.01|pain (l_pobj) pain_23\NN\symptom.n.01|severe|in|,|degrees (l_conj) degrees_30\NNS\property.n.02|varying|of|,|and|contracture (l_prep) of_31\IN\entity.n.01|impairment (l_pobj) impairment_35\NN\change.n.01|motor
1468485
D010100_D006470 NONE oxygen_1\NN\chemical_element.n.01| (r_compound) therapy_2\NN\medical_care.n.01|hyperbaric|oxygen|for|. (l_prep) for_3\IN\entity.n.01|control (l_pobj) control_4\NN\power.n.01|of (l_prep) of_5\IN\entity.n.01|cystitis (l_pobj) cystitis_11\NN\urinary_tract_infection.n.01|intractable|induced|hemorrhagic
D010100_D003556 NONE oxygen_1\NN\chemical_element.n.01| (r_compound) therapy_2\NN\medical_care.n.01|hyperbaric|oxygen|for|. (l_prep) for_3\IN\entity.n.01|control (l_pobj) control_4\NN\power.n.01|of (l_prep) of_5\IN\entity.n.01|cystitis (l_pobj) cystitis_11\NN\urinary_tract_infection.n.01|intractable|induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|cyclophosphamide|- (r_amod) cystitis_11\NN\urinary_tract_infection.n.01|intractable|induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_10\NN\entity.n.01| (r_compound) therapy_11\NN\medical_care.n.01|cyclophosphamide|for (r_pobj) due_8\IN\right.n.01|to|therapy (r_prep) report_1\VBP\document.n.01|we|case|due|. (l_dobj) case_3\NN\happening.n.01|a|of (l_prep) of_4\IN\entity.n.01|cystitis (l_pobj) cystitis_7\NN\urinary_tract_infection.n.01|intractable|hemorrhagic
D003520_D006470 CID cyclophosphamide_16\NN\entity.n.01| (r_pobj) of_15\IN\entity.n.01|cyclophosphamide (r_prep) treatment_14\NN\care.n.01|the|of (r_pobj) in_12\IN\linear_unit.n.01|treatment (r_prep) alternative_11\NN\decision_making.n.01|a|safe|in (r_dobj) offer_8\VB\speech_act.n.01|in|,|form|can|alternative|cystitis|. (l_dobj) cystitis_20\NN\urinary_tract_infection.n.01|induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|cyclophosphamide|- (r_amod) cystitis_11\NN\urinary_tract_infection.n.01|intractable|induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_10\NN\entity.n.01| (r_compound) therapy_11\NN\medical_care.n.01|cyclophosphamide|for (r_pobj) due_8\IN\right.n.01|to|therapy (r_prep) report_1\VBP\document.n.01|we|case|due|. (l_dobj) case_3\NN\happening.n.01|a|of (l_prep) of_4\IN\entity.n.01|cystitis (l_pobj) cystitis_7\NN\urinary_tract_infection.n.01|intractable|hemorrhagic
D003520_D003556 CID cyclophosphamide_16\NN\entity.n.01| (r_pobj) of_15\IN\entity.n.01|cyclophosphamide (r_prep) treatment_14\NN\care.n.01|the|of (r_pobj) in_12\IN\linear_unit.n.01|treatment (r_prep) alternative_11\NN\decision_making.n.01|a|safe|in (r_dobj) offer_8\VB\speech_act.n.01|in|,|form|can|alternative|cystitis|. (l_dobj) cystitis_20\NN\urinary_tract_infection.n.01|induced|hemorrhagic
D003520_D014890 NONE cyclophosphamide_10\NN\entity.n.01| (r_compound) therapy_11\NN\medical_care.n.01|cyclophosphamide|for (l_prep) for_12\IN\entity.n.01|granulomatosis (l_pobj) granulomatosis_15\NN\entity.n.01|wegener
D015237_D006470 NONE alpha_14\NN\letter.n.02|prostaglandin|f2 (r_pobj) of_11\IN\entity.n.01|alpha (r_prep) saline_8\NN\isotonic_solution.n.01|physiological|and|instillation|of (r_pobj) with_6\IN\entity.n.01|saline (r_prep) irrigation_5\NN\provision.n.02|bladder|with (r_pobj) including_3\VBG\include.v.01|irrigation (r_prep) treatment_1\NN\care.n.01|conservative|,|including|, (r_nsubj) failed_16\VBD\fail.v.01|treatment|control|. (l_xcomp) control_19\VB\power.n.01|to|totally|hemorrhage (l_dobj) hemorrhage_20\NN\injury.n.01|
2445283
D012254_D006478 NONE ribavirin_5\NN\antiviral.n.01| (r_pobj) of_4\IN\entity.n.01|ribavirin (r_prep) effect_3\NN\phenomenon.n.01|antiviral|of (r_conj) tolerance_0\NN\endurance.n.01|and|effect|in|. (l_prep) in_6\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|with (l_prep) with_8\IN\entity.n.01|fever (l_pobj) fever_11\NN\symptom.n.01|argentine|hemorrhagic
D012254_D006478 NONE ribavirin_5\NN\antiviral.n.01| (r_pobj) of_4\IN\entity.n.01|ribavirin (r_prep) effect_3\NN\phenomenon.n.01|antiviral|of (r_conj) tolerance_0\NN\endurance.n.01|and|effect (r_nsubjpass) studied_7\VBN\analyze.v.01|tolerance|was|in|. (l_prep) in_8\IN\linear_unit.n.01|patients (l_pobj) patients_10\NNS\case.n.06|6|with (l_prep) with_11\IN\entity.n.01|fever (l_pobj) fever_14\NN\symptom.n.01|argentine|hemorrhagic|(|ahf|)|of
D012254_D006478 NONE ribavirin_5\NN\antiviral.n.01| (r_pobj) of_4\IN\entity.n.01|ribavirin (r_prep) effect_3\NN\phenomenon.n.01|antiviral|of (r_conj) tolerance_0\NN\endurance.n.01|and|effect (r_nsubjpass) studied_7\VBN\analyze.v.01|tolerance|was|in|. (l_prep) in_8\IN\linear_unit.n.01|patients (l_pobj) patients_10\NNS\case.n.06|6|with (l_prep) with_11\IN\entity.n.01|fever (l_pobj) fever_14\NN\symptom.n.01|argentine|hemorrhagic|(|ahf|)|of (l_appos) ahf_16\NNP\entity.n.01|
D012254_D006478 NONE ribavirin_7\NN\antiviral.n.01| (r_nsubj) has_8\VBZ\angular_distance.n.01|that|ribavirin|effect|,|and|managed (l_dobj) effect_11\NN\phenomenon.n.01|an|antiviral|in (l_prep) in_12\IN\linear_unit.n.01|cases (l_pobj) cases_14\NNS\happening.n.01|advanced|of (l_prep) of_15\IN\entity.n.01|ahf (l_pobj) ahf_16\NNP\entity.n.01|
D012254_D006478 NONE ribavirin_5\RB\antiviral.n.01| (r_pobj) of_4\IN\entity.n.01|ribavirin (r_prep) effect_3\NN\phenomenon.n.01|the|possible|beneficial|of|during (l_prep) during_6\IN\entity.n.01|days (l_pobj) days_9\NNS\life.n.07|the|initial|of (l_prep) of_10\IN\entity.n.01|ahf (l_pobj) ahf_11\NNP\entity.n.01|
D012254_D014766 NONE ribavirin_2\RB\antiviral.n.01| (r_pobj) of_1\IN\entity.n.01|ribavirin (r_prep) administration_0\NN\management.n.01|of (r_nsubj) resulted_3\VBD\prove.v.01|administration|in|. (l_prep) in_4\IN\linear_unit.n.01|neutralization (l_pobj) neutralization_6\NN\nullification.n.02|a|of|and|drop (l_prep) of_7\IN\entity.n.01|viremia (l_pobj) viremia_8\NN\pathology.n.02|
D012254_D000740 CID ribavirin_7\NN\antiviral.n.01| (r_nsubj) has_8\VBZ\angular_distance.n.01|that|ribavirin|effect|,|and|managed (l_conj) managed_31\VBN\succeed.v.01|anemia|can|be|easily|. (l_nsubjpass) anemia_20\NN\blood_disease.n.01|that|,|observed|,
20084309
D008874_D020521 NONE mz_38\NNP\entity.n.01| (r_compound) dose_39\NN\medicine.n.02|the|mz (r_conj) mr_34\NNP\title.n.06|)|and|dose (r_appos) regurgitation_32\NN\backflow.n.01|mitral|(|mr (r_conj) duration_26\NN\time_period.n.01|of|,|regurgitation (r_dobj) test_7\VB\experiment.n.02|to|influence|duration (l_dobj) influence_9\NN\power.n.01|the|of (l_prep) of_10\IN\entity.n.01|variables (l_pobj) variables_13\NNS\thing.n.12|the|clinical|:|age|, (l_appos) age_15\NN\property.n.02|,|sex (l_conj) sex_17\NN\bodily_process.n.01|,|stroke (l_conj) stroke_19\UH\maneuver.n.03|,|mp
D008874_D009202 NONE mz_38\NNP\entity.n.01| (r_compound) dose_39\NN\medicine.n.02|the|mz (r_conj) mr_34\NNP\title.n.06|)|and|dose (r_appos) regurgitation_32\NN\backflow.n.01|mitral|(|mr (r_conj) duration_26\NN\time_period.n.01|of|,|regurgitation (r_dobj) test_7\VB\experiment.n.02|to|influence|duration (l_dobj) influence_9\NN\power.n.01|the|of (l_prep) of_10\IN\entity.n.01|variables (l_pobj) variables_13\NNS\thing.n.12|the|clinical|:|age|, (l_appos) age_15\NN\property.n.02|,|sex (l_conj) sex_17\NN\bodily_process.n.01|,|stroke (l_conj) stroke_19\UH\maneuver.n.03|,|mp (l_conj) mp_23\NNP\lawman.n.01|myocardiopathy|(|) (l_amod) myocardiopathy_21\NN\heart_disease.n.01|
D008874_D009202 NONE mz_38\NNP\entity.n.01| (r_compound) dose_39\NN\medicine.n.02|the|mz (r_conj) mr_34\NNP\title.n.06|)|and|dose (r_appos) regurgitation_32\NN\backflow.n.01|mitral|(|mr (r_conj) duration_26\NN\time_period.n.01|of|,|regurgitation (r_dobj) test_7\VB\experiment.n.02|to|influence|duration (l_dobj) influence_9\NN\power.n.01|the|of (l_prep) of_10\IN\entity.n.01|variables (l_pobj) variables_13\NNS\thing.n.12|the|clinical|:|age|, (l_appos) age_15\NN\property.n.02|,|sex (l_conj) sex_17\NN\bodily_process.n.01|,|stroke (l_conj) stroke_19\UH\maneuver.n.03|,|mp (l_conj) mp_23\NNP\lawman.n.01|myocardiopathy|(|)
D008874_D009202 NONE mz_17\NNP\entity.n.01| (r_pobj) of_16\IN\entity.n.01|mz (r_prep) doses_15\NNS\medicine.n.02|high|of (r_appos) mp_8\NNP\lawman.n.01|severe|mr|,|(|%|doses|associated
D008874_D008944 NONE mz_38\NNP\entity.n.01| (r_compound) dose_39\NN\medicine.n.02|the|mz (r_conj) mr_34\NNP\title.n.06|)|and|dose (r_appos) regurgitation_32\NN\backflow.n.01|mitral|(|mr
D008874_D008944 NONE mz_38\NNP\entity.n.01| (r_compound) dose_39\NN\medicine.n.02|the|mz (r_conj) mr_34\NNP\title.n.06|)|and|dose
D008874_D008944 NONE mz_17\NNP\entity.n.01| (r_pobj) of_16\IN\entity.n.01|mz (r_prep) doses_15\NNS\medicine.n.02|high|of (r_appos) mp_8\NNP\lawman.n.01|severe|mr|,|(|%|doses|associated (l_nmod) mr_6\NNP\title.n.06|
D008874_D000860 CID mz_42\NNP\entity.n.01| (r_compound) use_43\NN\activity.n.01|mz (r_pobj) by_41\IN\by.r.01|use (r_agent) caused_40\VBN\make.v.03|by (r_acl) hypoxia_39\NN\drive.n.09|caused (r_pobj) due_37\JJ\right.n.01|to|hypoxia (r_prep) presented_20\VBD\show.v.04|was|;|patients|hypoxia|due|due|. (l_dobj) hypoxia_22\NN\drive.n.09|transient
D008874_D000860 CID mz_42\NNP\entity.n.01| (r_compound) use_43\NN\activity.n.01|mz (r_pobj) by_41\IN\by.r.01|use (r_agent) caused_40\VBN\make.v.03|by (r_acl) hypoxia_39\NN\drive.n.09|caused
D008874_D000402 NONE mz_42\NNP\entity.n.01| (r_compound) use_43\NN\activity.n.01|mz (r_pobj) by_41\IN\by.r.01|use (r_agent) caused_40\VBN\make.v.03|by (r_acl) hypoxia_39\NN\drive.n.09|caused (r_pobj) due_37\JJ\right.n.01|to|hypoxia (r_prep) presented_20\VBD\show.v.04|was|;|patients|hypoxia|due|due|. (l_prep) due_23\IN\right.n.01|to|obstruction (l_pobj) obstruction_27\NN\structure.n.01|upper|airway|by
17439425
D019820_D006973 NONE xanthine_2\NN\organic_compound.n.01| (r_compound) oxidase_3\NN\enzyme.n.01|xanthine (r_pobj) of_1\IN\entity.n.01|oxidase (r_prep) role_0\NN\duty.n.02|of|in|. (l_prep) in_4\IN\linear_unit.n.01|hypertension (l_pobj) hypertension_8\NN\cardiovascular_disease.n.01|induced|in
D019820_D006973 NONE xanthine_5\NN\organic_compound.n.01| (r_compound) oxidase_6\NN\enzyme.n.01|xanthine|xo|,|implicated|, (r_pobj) of_4\IN\entity.n.01|oxidase (r_prep) role_3\NN\duty.n.02|the|of|in (l_prep) in_22\IN\linear_unit.n.01|hypertension (l_pobj) hypertension_26\NN\cardiovascular_disease.n.01|induced|ht
D019820_D006973 NONE xanthine_5\NN\organic_compound.n.01| (r_compound) oxidase_6\NN\enzyme.n.01|xanthine|xo|,|implicated|, (r_pobj) of_4\IN\entity.n.01|oxidase (r_prep) role_3\NN\duty.n.02|the|of|in (l_prep) in_22\IN\linear_unit.n.01|hypertension (l_pobj) hypertension_26\NN\cardiovascular_disease.n.01|induced|ht (l_appos) ht_30\NNP\entity.n.01|(|dex|-|)
D003907_D006973 CID dexamethasone_5\NN\anti-inflammatory.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|dexamethasone|- (r_amod) hypertension_8\NN\cardiovascular_disease.n.01|induced|in
D003907_D006973 CID dexamethasone_23\NN\anti-inflammatory.n.01| (r_npadvmod) induced_25\VBN\generate.v.01|dexamethasone|- (r_amod) hypertension_26\NN\cardiovascular_disease.n.01|induced|ht
D003907_D006973 CID dexamethasone_23\NN\anti-inflammatory.n.01| (r_npadvmod) induced_25\VBN\generate.v.01|dexamethasone|- (r_amod) hypertension_26\NN\cardiovascular_disease.n.01|induced|ht (l_appos) ht_30\NNP\entity.n.01|(|dex|-|)
D003907_D006973 CID dex_28\NN\entity.n.01| (r_compound) ht_30\NNP\entity.n.01|(|dex|-|) (r_appos) hypertension_26\NN\cardiovascular_disease.n.01|induced|ht
D003907_D006973 CID dex_28\NN\entity.n.01| (r_compound) ht_30\NNP\entity.n.01|(|dex|-|)
D003907_D006973 CID dex_0\NNP\entity.n.01| (r_nsubj) increased_1\VBD\change_magnitude.v.01|dex|sbp|+/-|mmhg|;|p|. (l_dobj) sbp_2\NNP\entity.n.01|
D003907_D006973 CID dex_4\NN\entity.n.01| (r_compound) ht_6\NNP\entity.n.01|dex|-
D009569_D006973 NONE oxide_16\NN\compound.n.02| (r_compound) redox_18\NN\chemical_reaction.n.01|oxide|- (r_compound) imbalance_19\NN\disequilibrium.n.01|nitric|redox (r_pobj) with_14\IN\entity.n.01|imbalance (r_prep) associated_13\VBN\think.v.03|hypertension|is|with|. (l_nsubjpass) hypertension_3\NN\cardiovascular_disease.n.01|induced|ht|in
D009569_D006973 NONE oxide_16\NN\compound.n.02| (r_compound) redox_18\NN\chemical_reaction.n.01|oxide|- (r_compound) imbalance_19\NN\disequilibrium.n.01|nitric|redox (r_pobj) with_14\IN\entity.n.01|imbalance (r_prep) associated_13\VBN\think.v.03|hypertension|is|with|. (l_nsubjpass) hypertension_3\NN\cardiovascular_disease.n.01|induced|ht|in (l_appos) ht_7\NNP\entity.n.01|(|gc|-|)
D003907_D015431 CID dex_0\NNP\entity.n.01| (r_nsubj) increased_1\VBD\change_magnitude.v.01|dex|sbp|+/-|mmhg|;|p|. (l_dep) p_13\NN\chemical_element.n.01|0.001|)|and|decreased (l_conj) decreased_18\VBN\change_magnitude.v.01|thymus (l_dobj) thymus_19\NN\asterid_dicot_genus.n.01|(|p|)|and|bodyweights (l_conj) bodyweights_26\NNS\entity.n.01|(|p
D000493_D006973 NONE allopurinol_0\NNP\medicine.n.02| (r_nsubj) prevent_3\VB\prevent.v.01|allopurinol|did|not|ht|. (l_dobj) ht_6\NNP\entity.n.01|dex|-
D000493_D006973 NONE allopurinol_8\NN\medicine.n.02| (r_nsubj) failed_9\VBD\fail.v.01|that|allopurinol|prevent (r_acl) findings_6\NNS\collection.n.01|our|previous|failed (r_pobj) with_3\IN\entity.n.01|together|findings (r_prep) induced_14\VBN\generate.v.01|this|,|with|hypertension (l_dobj) hypertension_15\NN\cardiovascular_disease.n.01|
D000493_D006973 NONE allopurinol_8\NN\medicine.n.02| (r_nsubj) failed_9\VBD\fail.v.01|that|allopurinol|prevent (r_acl) findings_6\NNS\collection.n.01|our|previous|failed (r_pobj) with_3\IN\entity.n.01|together|findings (r_prep) induced_14\VBN\generate.v.01|this|,|with|hypertension (r_ccomp) suggests_17\VBZ\declare.v.01|induced|,|is|. (l_ccomp) is_21\VBZ\be.v.01|that|activity|not|determinant (l_attr) determinant_25\NN\cognitive_factor.n.01|a|major|of|in (l_prep) of_26\IN\entity.n.01|ht (l_pobj) ht_29\NNP\entity.n.01|gc|-
18329269
D006220_D002375 CID haloperidol_36\NN\major_tranquilizer.n.01| (r_npadvmod) induced_38\VBN\generate.v.01|haloperidol|- (r_amod) model_40\NN\hypothesis.n.02|rat|induced|catalepsy|for (l_compound) catalepsy_39\NN\hypersomnia.n.01|
D006220_D010300 NONE haloperidol_36\NN\major_tranquilizer.n.01| (r_npadvmod) induced_38\VBN\generate.v.01|haloperidol|- (r_amod) model_40\NN\hypothesis.n.02|rat|induced|catalepsy|for (l_prep) for_41\IN\entity.n.01|disease (l_pobj) disease_44\NN\illness.n.01|parkinson
1436384
D000661_D020258 CID amphetamine_2\NN\drug_of_abuse.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|amphetamine|- (r_amod) neurotoxicity_5\NN\entity.n.01|induced|toward
D000661_D020258 CID amphetamine_10\NN\drug_of_abuse.n.01|and (r_nmod) compounds_13\NNS\whole.n.01|amphetamine|related|toward (r_pobj) of_9\IN\entity.n.01|compounds (r_prep) effect_8\NN\phenomenon.n.01|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\neurotoxic.a.01|
D004298_D020258 NONE dopamine_8\NN\monoamine_neurotransmitter.n.01| (r_compound) neurons_9\NNS\somatic_cell.n.01|striatal|dopamine|in (r_pobj) toward_6\IN\entity.n.01|neurons (r_prep) neurotoxicity_5\NN\entity.n.01|induced|toward
D004298_D020258 NONE dopamine_16\NN\monoamine_neurotransmitter.n.01| (r_compound) neurons_17\NNS\somatic_cell.n.01|nigrostriatal|dopamine (r_pobj) toward_14\IN\entity.n.01|neurons (r_prep) compounds_13\NNS\whole.n.01|amphetamine|related|toward (r_pobj) of_9\IN\entity.n.01|compounds (r_prep) effect_8\NN\phenomenon.n.01|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\neurotoxic.a.01|
C070935_D020258 NONE ly274614_13\NNP\entity.n.01|,|antagonist (r_pobj) by_12\IN\by.r.01|ly274614 (r_prep) rodents_11\NNS\placental.n.01|by (r_pobj) in_10\IN\linear_unit.n.01|rodents (r_prep) neurons_9\NNS\somatic_cell.n.01|striatal|dopamine|in (r_pobj) toward_6\IN\entity.n.01|neurons (r_prep) neurotoxicity_5\NN\entity.n.01|induced|toward
C070935_D020258 NONE ly274614_23\NNP\entity.n.01| (r_nsubj) is_24\VBZ\be.v.01|that|ly274614|antagonist (r_conj) involves_18\VBZ\refer.v.02|that|effect|receptors|and|is (l_nsubj) effect_8\NN\phenomenon.n.01|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\neurotoxic.a.01|
D000596_D020258 NONE acid_18\NN\compound.n.02|amino (r_compound) antagonist_19\NN\person.n.01|an|excitatory|acid (r_appos) ly274614_13\NNP\entity.n.01|,|antagonist (r_pobj) by_12\IN\by.r.01|ly274614 (r_prep) rodents_11\NNS\placental.n.01|by (r_pobj) in_10\IN\linear_unit.n.01|rodents (r_prep) neurons_9\NNS\somatic_cell.n.01|striatal|dopamine|in (r_pobj) toward_6\IN\entity.n.01|neurons (r_prep) neurotoxicity_5\NN\entity.n.01|induced|toward
D016202_D020258 NONE nmda_19\NNP\entity.n.01| (r_compound) receptors_20\NNS\structure.n.04|nmda (r_dobj) involves_18\VBZ\refer.v.02|that|effect|receptors|and|is (l_nsubj) effect_8\NN\phenomenon.n.01|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\neurotoxic.a.01|
D016202_D020258 NONE nmda_26\NNP\entity.n.01| (r_compound) antagonist_28\NN\person.n.01|an|nmda|receptor|with (r_attr) is_24\VBZ\be.v.01|that|ly274614|antagonist (r_conj) involves_18\VBZ\refer.v.02|that|effect|receptors|and|is (l_nsubj) effect_8\NN\phenomenon.n.01|the|neurotoxic|of (l_amod) neurotoxic_7\JJ\neurotoxic.a.01|
18020536
D001569_D004244 CID bzds_4\NNP\entity.n.01| (r_nmod) rds_6\NNS\entity.n.01|bzds|/ (r_pobj) of_3\IN\entity.n.01|rds (r_prep) use_2\NN\activity.n.01|of (r_nsubjpass) associated_8\VBN\think.v.03|however|,|use|was|with|,|inability|. (l_prep) with_9\IN\entity.n.01|dizziness (l_pobj) dizziness_10\NN\symptom.n.01|
D001569_D007319 CID bzds_4\NNP\entity.n.01| (r_nmod) rds_6\NNS\entity.n.01|bzds|/ (r_pobj) of_3\IN\entity.n.01|rds (r_prep) use_2\NN\activity.n.01|of (r_nsubjpass) associated_8\VBN\think.v.03|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN\cognition.n.01|sleep (l_acl) sleep_14\VB\physical_condition.n.01|to|after
D001569_D005221 CID bzds_4\NNP\entity.n.01| (r_nmod) rds_6\NNS\entity.n.01|bzds|/ (r_pobj) of_3\IN\entity.n.01|rds (r_prep) use_2\NN\activity.n.01|of (r_nsubjpass) associated_8\VBN\think.v.03|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN\cognition.n.01|sleep (l_acl) sleep_14\VB\physical_condition.n.01|to|after (l_prep) after_15\IN\after.s.01|awaking|and|with (l_pcomp) awaking_16\VBG\change_state.v.01|at|in|during (l_prep) at_17\IN\chemical_element.n.01|night (l_pobj) night_18\NN\time_period.n.01|and|tiredness (l_conj) tiredness_20\NN\temporary_state.n.01|
D001569_D003866 CID bzds_4\NNP\entity.n.01| (r_nmod) rds_6\NNS\entity.n.01|bzds|/ (r_pobj) of_3\IN\entity.n.01|rds (r_prep) use_2\NN\activity.n.01|of (r_nsubjpass) associated_8\VBN\think.v.03|however|,|use|was|with|,|inability|. (l_npadvmod) inability_12\NN\cognition.n.01|sleep (l_acl) sleep_14\VB\physical_condition.n.01|to|after (l_prep) after_15\IN\after.s.01|awaking|and|with (l_conj) with_31\IN\entity.n.01|symptoms (l_pobj) symptoms_34\NNS\evidence.n.01|stronger|depressive|measured
7453952
D008094_D003919 CID lithium_3\NN\metallic_element.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|lithium|- (r_amod) syndrome_11\NN\complex.n.01|the|induced|like|by|in
D008094_D003919 CID lithium_9\NN\metallic_element.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|lithium|- (r_amod) syndrome_17\NN\complex.n.01|the|induced|like|by
D008094_D003919 CID lithium_30\NN\metallic_element.n.01| (r_compound) concentration_31\NN\property.n.02|the|lithium|in|and|elevation (r_pobj) between_28\IN\between.r.01|concentration (r_prep) ratio_27\NN\magnitude_relation.n.01|the|between (r_pobj) of_25\IN\entity.n.01|ratio (r_prep) reduction_24\NN\change_of_magnitude.n.01|a|of (r_pobj) by_22\IN\by.r.01|reduction (r_agent) accompanied_21\VBN\attach_to.v.01|in|,|attenuation|was|by|. (l_nsubjpass) attenuation_6\NN\weakening.n.01|the|of (l_prep) of_7\IN\entity.n.01|syndrome (l_pobj) syndrome_17\NN\complex.n.01|the|induced|like|by
D000584_D003919 NONE amiloride_13\NN\entity.n.01| (r_pobj) by_12\IN\by.r.01|amiloride (r_prep) syndrome_11\NN\complex.n.01|the|induced|like|by|in
D000584_D003919 NONE amiloride_19\NN\entity.n.01| (r_pobj) by_18\IN\by.r.01|amiloride (r_prep) syndrome_17\NN\complex.n.01|the|induced|like|by
D000584_D059606 NONE amiloride_3\NN\entity.n.01| (r_pobj) of_2\IN\entity.n.01|amiloride (r_prep) effect_1\NN\phenomenon.n.01|the|of|on (l_prep) on_4\IN\on.a.01|polydipsia|and|on (l_pobj) polydipsia_8\NN\thirst.n.01|induced|and|polyuria
D000584_D059606 NONE amiloride_5\NN\entity.n.01| (r_compound) administration_6\NN\management.n.01|acute|amiloride|to (l_prep) to_7\IN\entity.n.01|patients (l_pobj) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria
D000584_D059606 NONE amiloride_23\JJ\entity.n.01| (r_compound) supplementation_24\NN\increase.n.04|prolonged|amiloride (r_nsubj) result_26\VB\phenomenon.n.01|supplementation|would|in|and|be (r_conj) relieve_18\VB\better.v.02|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\management.n.01|acute|amiloride|to (l_prep) to_7\IN\entity.n.01|patients (l_pobj) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria
D000584_D011141 NONE amiloride_3\NN\entity.n.01| (r_pobj) of_2\IN\entity.n.01|amiloride (r_prep) effect_1\NN\phenomenon.n.01|the|of|on (l_prep) on_4\IN\on.a.01|polydipsia|and|on (l_pobj) polydipsia_8\NN\thirst.n.01|induced|and|polyuria (l_conj) polyuria_10\NN\kidney_disease.n.01|
D000584_D011141 NONE amiloride_5\NN\entity.n.01| (r_compound) administration_6\NN\management.n.01|acute|amiloride|to (l_prep) to_7\IN\entity.n.01|patients (l_pobj) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria (l_conj) polyuria_16\NN\kidney_disease.n.01|
D000584_D011141 NONE amiloride_23\JJ\entity.n.01| (r_compound) supplementation_24\NN\increase.n.04|prolonged|amiloride (r_nsubj) result_26\VB\phenomenon.n.01|supplementation|would|in|and|be (r_conj) relieve_18\VB\better.v.02|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\management.n.01|acute|amiloride|to (l_prep) to_7\IN\entity.n.01|patients (l_pobj) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria (l_conj) polyuria_16\NN\kidney_disease.n.01|
D008094_D059606 NONE lithium_5\NN\metallic_element.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|lithium|- (r_amod) polydipsia_8\NN\thirst.n.01|induced|and|polyuria
D008094_D059606 NONE lithium_14\NN\metallic_element.n.01| (r_compound) concentration_15\NN\property.n.02|the|lithium|in (r_pobj) on_12\IN\on.a.01|concentration (r_conj) on_4\IN\on.a.01|polydipsia|and|on (l_pobj) polydipsia_8\NN\thirst.n.01|induced|and|polyuria
D008094_D059606 NONE lithium_8\NN\metallic_element.n.01| (r_npadvmod) treated_10\VBN\interact.v.01|lithium|- (r_amod) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria
D008094_D059606 NONE lithium_29\NN\metallic_element.n.01| (r_compound) levels_30\NNS\property.n.02|elevated|lithium (r_pobj) in_27\IN\linear_unit.n.01|levels (r_prep) result_26\VB\phenomenon.n.01|supplementation|would|in|and|be (r_conj) relieve_18\VB\better.v.02|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\management.n.01|acute|amiloride|to (l_prep) to_7\IN\entity.n.01|patients (l_pobj) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria
D008094_D011141 NONE lithium_5\NN\metallic_element.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|lithium|- (r_amod) polydipsia_8\NN\thirst.n.01|induced|and|polyuria (l_conj) polyuria_10\NN\kidney_disease.n.01|
D008094_D011141 NONE lithium_14\NN\metallic_element.n.01| (r_compound) concentration_15\NN\property.n.02|the|lithium|in (r_pobj) on_12\IN\on.a.01|concentration (r_conj) on_4\IN\on.a.01|polydipsia|and|on (l_pobj) polydipsia_8\NN\thirst.n.01|induced|and|polyuria (l_conj) polyuria_10\NN\kidney_disease.n.01|
D008094_D011141 NONE lithium_8\NN\metallic_element.n.01| (r_npadvmod) treated_10\VBN\interact.v.01|lithium|- (r_amod) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria (l_conj) polyuria_16\NN\kidney_disease.n.01|
D008094_D011141 NONE lithium_29\NN\metallic_element.n.01| (r_compound) levels_30\NNS\property.n.02|elevated|lithium (r_pobj) in_27\IN\linear_unit.n.01|levels (r_prep) result_26\VB\phenomenon.n.01|supplementation|would|in|and|be (r_conj) relieve_18\VB\better.v.02|that|administration|might|patients|but|result (l_nsubj) administration_6\NN\management.n.01|acute|amiloride|to (l_prep) to_7\IN\entity.n.01|patients (l_pobj) patients_11\NNS\case.n.06|treated|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|polydipsia (l_pobj) polydipsia_14\NN\thirst.n.01|and|polyuria (l_conj) polyuria_16\NN\kidney_disease.n.01|
D018021_D059606 NONE licl_37\NNP\entity.n.01| (r_pobj) with_36\IN\entity.n.01|licl (r_prep) treated_35\VBN\interact.v.01|chronically|with (r_conj) investigated_30\VBN\analyze.v.01|effect|was|in|,|treated|. (l_nsubjpass) effect_1\NN\phenomenon.n.01|the|of|on (l_prep) on_4\IN\on.a.01|polydipsia|and|on (l_pobj) polydipsia_8\NN\thirst.n.01|induced|and|polyuria
D018021_D011141 NONE licl_37\NNP\entity.n.01| (r_pobj) with_36\IN\entity.n.01|licl (r_prep) treated_35\VBN\interact.v.01|chronically|with (r_conj) investigated_30\VBN\analyze.v.01|effect|was|in|,|treated|. (l_nsubjpass) effect_1\NN\phenomenon.n.01|the|of|on (l_prep) on_4\IN\on.a.01|polydipsia|and|on (l_pobj) polydipsia_8\NN\thirst.n.01|induced|and|polyuria (l_conj) polyuria_10\NN\kidney_disease.n.01|
D011188_D003919 NONE potassium_48\NN\metallic_element.n.01|plasma (r_compound) level_49\NN\property.n.02|the|potassium (r_pobj) in_45\IN\linear_unit.n.01|level (r_prep) elevation_44\NN\rise.n.04|an|in (r_conj) concentration_31\NN\property.n.02|the|lithium|in|and|elevation (r_pobj) between_28\IN\between.r.01|concentration (r_prep) ratio_27\NN\magnitude_relation.n.01|the|between (r_pobj) of_25\IN\entity.n.01|ratio (r_prep) reduction_24\NN\change_of_magnitude.n.01|a|of (r_pobj) by_22\IN\by.r.01|reduction (r_agent) accompanied_21\VBN\attach_to.v.01|in|,|attenuation|was|by|. (l_nsubjpass) attenuation_6\NN\weakening.n.01|the|of (l_prep) of_7\IN\entity.n.01|syndrome (l_pobj) syndrome_17\NN\complex.n.01|the|induced|like|by
10193204
C009438_D013927 NONE tetrandrine_2\NN\entity.n.01|and|fangchinoline (r_pobj) of_1\IN\entity.n.01|tetrandrine (r_prep) effects_0\NNS\personal_property.n.01|of|on|. (l_prep) on_5\IN\on.a.01|thrombosis (l_pobj) thrombosis_7\NN\occlusion.n.01|experimental|in
C009438_D013927 NONE tet_10\NNP\day.n.03|and|fan (r_pobj) of_9\IN\entity.n.01|tet (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (l_prep) on_13\IN\on.a.01|thrombosis (l_pobj) thrombosis_16\NN\occlusion.n.01|the|experimental|induced
C009438_D013927 NONE tet_15\NNP\day.n.03|and|fan (r_pobj) of_14\IN\entity.n.01|tet (r_prep) administration_7\NN\management.n.01|the|(|mg/kg|i.p.|)|of (r_nsubj) showed_20\VBD\show.v.04|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\abstinence.n.02|the|of|by|,|respectively (l_prep) of_23\IN\entity.n.01|thrombosis (l_pobj) thrombosis_24\NN\occlusion.n.01|
C009438_D001791 NONE tetrandrine_2\NN\entity.n.01|and|fangchinoline (r_pobj) of_1\IN\entity.n.01|tetrandrine (r_prep) effects_0\NNS\personal_property.n.01|of|on|. (l_prep) on_5\IN\on.a.01|thrombosis (l_pobj) thrombosis_7\NN\occlusion.n.01|experimental|in (l_prep) in_8\IN\linear_unit.n.01|mice (l_pobj) mice_9\NNS\rodent.n.01|and|aggregation (l_conj) aggregation_13\NN\group.n.01|platelet
C009438_D001791 NONE tet_10\NNP\day.n.03|and|fan (r_pobj) of_9\IN\entity.n.01|tet (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation
C009438_D001791 NONE tet_14\NNP\day.n.03|and|fan (r_nsubj) showed_17\VBD\show.v.04|in|,|tet|dose|dependently|. (l_prep) in_0\IN\linear_unit.n.01|aggregations (l_pobj) aggregations_5\NNS\group.n.01|the|vitro|platelet|induced
C060802_D013927 NONE fangchinoline_4\NN\entity.n.01| (r_conj) tetrandrine_2\NN\entity.n.01|and|fangchinoline (r_pobj) of_1\IN\entity.n.01|tetrandrine (r_prep) effects_0\NNS\personal_property.n.01|of|on|. (l_prep) on_5\IN\on.a.01|thrombosis (l_pobj) thrombosis_7\NN\occlusion.n.01|experimental|in
C060802_D013927 NONE fan_12\NNP\device.n.01| (r_conj) tet_10\NNP\day.n.03|and|fan (r_pobj) of_9\IN\entity.n.01|tet (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (l_prep) on_13\IN\on.a.01|thrombosis (l_pobj) thrombosis_16\NN\occlusion.n.01|the|experimental|induced
C060802_D013927 NONE fan_17\NNP\device.n.01|in (r_conj) tet_15\NNP\day.n.03|and|fan (r_pobj) of_14\IN\entity.n.01|tet (r_prep) administration_7\NN\management.n.01|the|(|mg/kg|i.p.|)|of (r_nsubj) showed_20\VBD\show.v.04|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\abstinence.n.02|the|of|by|,|respectively (l_prep) of_23\IN\entity.n.01|thrombosis (l_pobj) thrombosis_24\NN\occlusion.n.01|
C060802_D001791 NONE fangchinoline_4\NN\entity.n.01| (r_conj) tetrandrine_2\NN\entity.n.01|and|fangchinoline (r_pobj) of_1\IN\entity.n.01|tetrandrine (r_prep) effects_0\NNS\personal_property.n.01|of|on|. (l_prep) on_5\IN\on.a.01|thrombosis (l_pobj) thrombosis_7\NN\occlusion.n.01|experimental|in (l_prep) in_8\IN\linear_unit.n.01|mice (l_pobj) mice_9\NNS\rodent.n.01|and|aggregation (l_conj) aggregation_13\NN\group.n.01|platelet
C060802_D001791 NONE fan_12\NNP\device.n.01| (r_conj) tet_10\NNP\day.n.03|and|fan (r_pobj) of_9\IN\entity.n.01|tet (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation
C060802_D001791 NONE fan_16\NNP\device.n.01| (r_conj) tet_14\NNP\day.n.03|and|fan (r_nsubj) showed_17\VBD\show.v.04|in|,|tet|dose|dependently|. (l_prep) in_0\IN\linear_unit.n.01|aggregations (l_pobj) aggregations_5\NNS\group.n.01|the|vitro|platelet|induced
C009438_D001778 NONE tet_10\NNP\day.n.03|and|fan (r_pobj) of_9\IN\entity.n.01|tet (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation (l_conj) coagulation_33\NN\natural_process.n.01|blood
C060802_D001778 NONE fan_12\NNP\device.n.01| (r_conj) tet_10\NNP\day.n.03|and|fan (r_pobj) of_9\IN\entity.n.01|tet (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation (l_conj) coagulation_33\NN\natural_process.n.01|blood
D004837_D013927 CID epinephrine_21\NN\catecholamine.n.01|ep (r_conj) collagen_19\NN\scleroprotein.n.01|plus|epinephrine (r_pobj) by_18\IN\by.r.01|collagen (r_agent) induced_17\VBN\generate.v.01|by|in (r_acl) thrombosis_16\NN\occlusion.n.01|the|experimental|induced
D004837_D013927 CID ep_23\NN\entity.n.01|(|) (r_appos) epinephrine_21\NN\catecholamine.n.01|ep (r_conj) collagen_19\NN\scleroprotein.n.01|plus|epinephrine (r_pobj) by_18\IN\by.r.01|collagen (r_agent) induced_17\VBN\generate.v.01|by|in (r_acl) thrombosis_16\NN\occlusion.n.01|the|experimental|induced
D004837_D001791 NONE epinephrine_21\NN\catecholamine.n.01|ep (r_conj) collagen_19\NN\scleroprotein.n.01|plus|epinephrine (r_pobj) by_18\IN\by.r.01|collagen (r_agent) induced_17\VBN\generate.v.01|by|in (r_acl) thrombosis_16\NN\occlusion.n.01|the|experimental|induced (r_pobj) on_13\IN\on.a.01|thrombosis (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation
D004837_D001791 NONE ep_23\NN\entity.n.01|(|) (r_appos) epinephrine_21\NN\catecholamine.n.01|ep (r_conj) collagen_19\NN\scleroprotein.n.01|plus|epinephrine (r_pobj) by_18\IN\by.r.01|collagen (r_agent) induced_17\VBN\generate.v.01|by|in (r_acl) thrombosis_16\NN\occlusion.n.01|the|experimental|induced (r_pobj) on_13\IN\on.a.01|thrombosis (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation
D004837_D001778 NONE epinephrine_21\NN\catecholamine.n.01|ep (r_conj) collagen_19\NN\scleroprotein.n.01|plus|epinephrine (r_pobj) by_18\IN\by.r.01|collagen (r_agent) induced_17\VBN\generate.v.01|by|in (r_acl) thrombosis_16\NN\occlusion.n.01|the|experimental|induced (r_pobj) on_13\IN\on.a.01|thrombosis (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation (l_conj) coagulation_33\NN\natural_process.n.01|blood
D004837_D001778 NONE ep_23\NN\entity.n.01|(|) (r_appos) epinephrine_21\NN\catecholamine.n.01|ep (r_conj) collagen_19\NN\scleroprotein.n.01|plus|epinephrine (r_pobj) by_18\IN\by.r.01|collagen (r_agent) induced_17\VBN\generate.v.01|by|in (r_acl) thrombosis_16\NN\occlusion.n.01|the|experimental|induced (r_pobj) on_13\IN\on.a.01|thrombosis (r_prep) effects_8\NNS\personal_property.n.01|the|of|on (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_advcl) undertaken_4\VBN\initiate.v.02|study|was|investigate|,|and|in (l_conj) in_34\IN\linear_unit.n.01|aggregation|vitro|. (l_nsubj) aggregation_30\NN\group.n.01|platelet|and|coagulation (l_conj) coagulation_33\NN\natural_process.n.01|blood
D001241_D013927 NONE acid_36\NN\compound.n.02|asa (r_dobj) acetylsalicylic_35\JJ\entity.n.01|while|acid|mg/kg|,|control|,|showed (r_advcl) showed_20\VBD\show.v.04|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\abstinence.n.02|the|of|by|,|respectively (l_prep) of_23\IN\entity.n.01|thrombosis (l_pobj) thrombosis_24\NN\occlusion.n.01|
D001241_D013927 NONE asa_38\NNP\entity.n.01|(|, (r_appos) acid_36\NN\compound.n.02|asa (r_dobj) acetylsalicylic_35\JJ\entity.n.01|while|acid|mg/kg|,|control|,|showed (r_advcl) showed_20\VBD\show.v.04|in|,|administration|inhibition|,|acetylsalicylic|. (l_dobj) inhibition_22\NN\abstinence.n.02|the|of|by|,|respectively (l_prep) of_23\IN\entity.n.01|thrombosis (l_pobj) thrombosis_24\NN\occlusion.n.01|
1549199
D007980_D064420 NONE levodopa_9\NN\dopa.n.01| (r_compound) therapy_10\NN\medical_care.n.01|levodopa (r_pobj) for_8\IN\entity.n.01|therapy (r_prep) dose_7\NN\medicine.n.02|for (r_dobj) starting_6\NN\turn.n.03|dose (r_acl) correct_5\JJ\change_by_reversal.v.01|no|single|starting (r_attr) is_2\VBZ\be.v.01|while|there|correct (r_advcl) started_16\VBN\get_down.v.07|is|,|individuals|can|be|on|,|following|. (l_prep) following_27\VBG\multitude.n.03|rule (l_pobj) rule_30\NN\concept.n.01|the|general|attempt (l_relcl) attempt_33\VB\activity.n.01|not|to|titrate (l_xcomp) titrate_35\VB\quantify.v.02|to|levodopa (l_dobj) levodopa_38\NN\dopa.n.01|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB\advantage.n.01|which|can|to (l_prep) to_50\IN\entity.n.01|toxicity (l_pobj) toxicity_51\NN\definite_quantity.n.01|
D007980_D064420 NONE levodopa_38\NN\dopa.n.01|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB\advantage.n.01|which|can|to (l_prep) to_50\IN\entity.n.01|toxicity (l_pobj) toxicity_51\NN\definite_quantity.n.01|
D002230_D064420 NONE carbidopa_36\NN\entity.n.01| (r_compound) levodopa_38\NN\dopa.n.01|carbidopa|-|to|,|"|lead (l_relcl) lead_49\VB\advantage.n.01|which|can|to (l_prep) to_50\IN\entity.n.01|toxicity (l_pobj) toxicity_51\NN\definite_quantity.n.01|
D007980_D005767 CID levodopa_13\RB\dopa.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|levodopa|- (r_amod) psychosis_16\NN\mental_illness.n.01|induced|,|disturbances (r_conj) hypotension_11\NN\cardiovascular_disease.n.01|orthostatic|,|psychosis (r_conj) disorders_8\NNS\physical_condition.n.01|gastrointestinal|,|hypotension
D007980_D007024 CID levodopa_13\RB\dopa.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|levodopa|- (r_amod) psychosis_16\NN\mental_illness.n.01|induced|,|disturbances (r_conj) hypotension_11\NN\cardiovascular_disease.n.01|orthostatic|,|psychosis
D007980_D011618 NONE levodopa_13\RB\dopa.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|levodopa|- (r_amod) psychosis_16\NN\mental_illness.n.01|induced|,|disturbances
D007980_D012893 NONE levodopa_13\RB\dopa.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|levodopa|- (r_amod) psychosis_16\NN\mental_illness.n.01|induced|,|disturbances (l_conj) disturbances_19\NNS\activity.n.01|sleep|or|parasomnias
D007980_D020447 CID levodopa_13\RB\dopa.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|levodopa|- (r_amod) psychosis_16\NN\mental_illness.n.01|induced|,|disturbances (l_conj) disturbances_19\NNS\activity.n.01|sleep|or|parasomnias (l_conj) parasomnias_21\NNS\entity.n.01|,|or|interactions
11773892
D016572_D007674 CID cyclosporine_3\VBP\entity.n.01|and|tacrolimus (r_appos) inhibitors_2\NNS\substance.n.07|the|calcineurin|cyclosporine (r_nsubjpass) known_8\VBN\know.v.01|inhibitors|are|both|be|. (l_xcomp) be_10\VB\metallic_element.n.01|to|nephrotoxic (l_acomp) nephrotoxic_11\JJ\nephrotoxic.s.01|
D016559_D007674 CID tacrolimus_5\NN\entity.n.01| (r_conj) cyclosporine_3\VBP\entity.n.01|and|tacrolimus (r_appos) inhibitors_2\NNS\substance.n.07|the|calcineurin|cyclosporine (r_nsubjpass) known_8\VBN\know.v.01|inhibitors|are|both|be|. (l_xcomp) be_10\VB\metallic_element.n.01|to|nephrotoxic (l_acomp) nephrotoxic_11\JJ\nephrotoxic.s.01|
D003404_D007676 NONE creatinine_20\NN\entity.n.01|sustained|serum (r_conj) crf_16\NNP\entity.n.01|,|creatinine (r_conj) controls_7\NNS\power.n.01|,|crf|;|crf (l_conj) crf_10\NNP\entity.n.01|no|or|esrd
D003404_D007676 NONE creatinine_20\NN\entity.n.01|sustained|serum (r_conj) crf_16\NNP\entity.n.01|,|creatinine (r_conj) controls_7\NNS\power.n.01|,|crf|;|crf (l_conj) crf_10\NNP\entity.n.01|no|or|esrd (l_conj) esrd_12\NNP\entity.n.01|,|n=748
D003404_D007676 NONE creatinine_20\NN\entity.n.01|sustained|serum (r_conj) crf_16\NNP\entity.n.01|,|creatinine
D003404_D007676 NONE creatinine_20\NN\entity.n.01|sustained|serum (r_conj) crf_16\NNP\entity.n.01|,|creatinine (r_conj) controls_7\NNS\power.n.01|,|crf|;|crf (r_appos) groups_5\NNS\abstraction.n.06|three|:|controls|>|;|and|n=45 (l_conj) n=45_32\JJ\entity.n.01|esrd|. (l_nmod) esrd_30\NNS\entity.n.01|,
D003404_D007676 NONE creatinine_13\NN\entity.n.01|serum (r_compound) levels_14\NNS\property.n.02|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\have.v.01|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\case.n.06|crf|esrd (l_nmod) crf_5\NNP\entity.n.01|and
D003404_D007676 NONE creatinine_13\NN\entity.n.01|serum (r_compound) levels_14\NNS\property.n.02|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\have.v.01|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\case.n.06|crf|esrd (l_compound) esrd_7\NNP\entity.n.01|
D003404_D007676 NONE creatinine_42\NN\entity.n.01|a|higher|1-year|serum (r_conj) requirement_27\NN\duty.n.01|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS\property.n.02|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\have.v.01|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\case.n.06|crf|esrd (l_nmod) crf_5\NNP\entity.n.01|and
D003404_D007676 NONE creatinine_42\NN\entity.n.01|a|higher|1-year|serum (r_conj) requirement_27\NN\duty.n.01|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS\property.n.02|higher|preoperative|creatinine|,|percentage|,|requirement (r_dobj) had_9\VBD\have.v.01|compared|,|patients|levels|. (l_nsubj) patients_8\NNS\case.n.06|crf|esrd (l_compound) esrd_7\NNP\entity.n.01|
D003404_D007676 NONE creatinine_16\NN\entity.n.01|serum (r_pobj) of_14\IN\entity.n.01|creatinine (r_prep) increase_13\NN\indefinite_quantity.n.01|an|of|compared|,|and (r_nsubj) were_31\VBD\be.v.01|that|increase|postoperatively|factors|respectively (l_attr) factors_34\NNS\cause.n.01|independent|risk|for|with (l_prep) for_35\IN\entity.n.01|development (l_pobj) development_37\NN\improvement.n.02|the|of (l_prep) of_38\IN\entity.n.01|crf (l_pobj) crf_39\NNP\entity.n.01|or|esrd
D003404_D007676 NONE creatinine_16\NN\entity.n.01|serum (r_pobj) of_14\IN\entity.n.01|creatinine (r_prep) increase_13\NN\indefinite_quantity.n.01|an|of|compared|,|and (r_nsubj) were_31\VBD\be.v.01|that|increase|postoperatively|factors|respectively (l_attr) factors_34\NNS\cause.n.01|independent|risk|for|with (l_prep) for_35\IN\entity.n.01|development (l_pobj) development_37\NN\improvement.n.02|the|of (l_prep) of_38\IN\entity.n.01|crf (l_pobj) crf_39\NNP\entity.n.01|or|esrd (l_conj) esrd_41\NNP\entity.n.01|
D003404_D007676 NONE creatinine_11\NN\entity.n.01|a|higher|preoperative (r_dobj) have_4\VBP\person.n.01|patients|creatinine|and|are|. (l_nsubj) patients_0\NNS\case.n.06|develop (l_relcl) develop_2\VBP\create.v.02|who|esrd (l_dobj) esrd_3\NNS\entity.n.01|
D003404_D007676 NONE creatinine_6\NN\entity.n.01|serum (r_pobj) of_4\IN\entity.n.01|creatinine (r_prep) increase_3\NN\indefinite_quantity.n.01|an|of|at|postoperatively (r_nsubj) is_11\VBZ\be.v.01|however|,|increase|predictive|. (l_acomp) predictive_13\JJ\predictive.s.01|more|of (l_prep) of_14\IN\entity.n.01|development (l_pobj) development_16\NN\improvement.n.02|the|of (l_prep) of_17\IN\entity.n.01|crf (l_pobj) crf_18\NNP\entity.n.01|or|esrd
D003404_D007676 NONE creatinine_6\NN\entity.n.01|serum (r_pobj) of_4\IN\entity.n.01|creatinine (r_prep) increase_3\NN\indefinite_quantity.n.01|an|of|at|postoperatively (r_nsubj) is_11\VBZ\be.v.01|however|,|increase|predictive|. (l_acomp) predictive_13\JJ\predictive.s.01|more|of (l_prep) of_14\IN\entity.n.01|development (l_pobj) development_16\NN\improvement.n.02|the|of (l_prep) of_17\IN\entity.n.01|crf (l_pobj) crf_18\NNP\entity.n.01|or|esrd (l_conj) esrd_20\NNP\entity.n.01|
D003404_D006530 NONE creatinine_13\NN\entity.n.01|serum (r_compound) levels_14\NNS\property.n.02|higher|preoperative|creatinine|,|percentage|,|requirement (l_appos) percentage_18\NN\proportion.n.01|a|greater|of (l_prep) of_19\IN\entity.n.01|patients (l_pobj) patients_20\NNS\case.n.06|with (l_prep) with_21\IN\entity.n.01|syndrome (l_pobj) syndrome_23\NN\complex.n.01|hepatorenal
D003404_D006530 NONE creatinine_42\NN\entity.n.01|a|higher|1-year|serum (r_conj) requirement_27\NN\duty.n.01|higher|percentage|for|in|,|and|creatinine (r_appos) levels_14\NNS\property.n.02|higher|preoperative|creatinine|,|percentage|,|requirement (l_appos) percentage_18\NN\proportion.n.01|a|greater|of (l_prep) of_19\IN\entity.n.01|patients (l_pobj) patients_20\NNS\case.n.06|with (l_prep) with_21\IN\entity.n.01|syndrome (l_pobj) syndrome_23\NN\complex.n.01|hepatorenal
D003404_D006530 NONE creatinine_11\NN\entity.n.01|a|higher|preoperative (r_dobj) have_4\VBP\person.n.01|patients|creatinine|and|are|. (l_conj) are_13\VBP\area_unit.n.01|likely (l_acomp) likely_15\JJ\likely.a.01|more|have (l_xcomp) have_17\VB\person.n.01|to|syndrome (l_dobj) syndrome_19\NN\complex.n.01|hepatorenal
2375138
D008874_D006323 CID midazolam_2\RB\benzodiazepine.n.01| (r_npadvmod) associated_4\VBN\think.v.03|midazolam|- (r_amod) arrest_6\NN\capture.n.01|possible|intramuscular|associated|cardiorespiratory|and|death|.
D008874_D006323 CID midazolam_17\NN\benzodiazepine.n.01| (r_pobj) of_16\IN\entity.n.01|midazolam (r_prep) administration_15\NN\management.n.01|intramuscular|of (r_pobj) with_13\IN\entity.n.01|administration (r_prep) associated_12\VBN\think.v.03|with (r_acl) case_6\NN\happening.n.01|the|first|published|of|associated (l_prep) of_7\IN\entity.n.01|arrest (l_pobj) arrest_9\NN\capture.n.01|cardiorespiratory|and|death
D008874_D003643 NONE midazolam_2\RB\benzodiazepine.n.01| (r_npadvmod) associated_4\VBN\think.v.03|midazolam|- (r_amod) arrest_6\NN\capture.n.01|possible|intramuscular|associated|cardiorespiratory|and|death|. (l_conj) death_8\NN\change.n.01|
D008874_D003643 NONE midazolam_17\NN\benzodiazepine.n.01| (r_pobj) of_16\IN\entity.n.01|midazolam (r_prep) administration_15\NN\management.n.01|intramuscular|of (r_pobj) with_13\IN\entity.n.01|administration (r_prep) associated_12\VBN\think.v.03|with (r_acl) case_6\NN\happening.n.01|the|first|published|of|associated (l_prep) of_7\IN\entity.n.01|arrest (l_pobj) arrest_9\NN\capture.n.01|cardiorespiratory|and|death (l_conj) death_11\NN\change.n.01|
9406968
D014667_D003919 NONE vasopressin_5\NN\hormone.n.01| (r_compound) gene_6\NN\sequence.n.01|vasopressin|in (l_prep) in_7\IN\linear_unit.n.01|nuclei (l_pobj) nuclei_12\NNS\organelle.n.01|the|paraventricular|of (l_prep) of_13\IN\entity.n.01|rat (l_pobj) rat_20\NN\rodent.n.01|the|diabetes|insipidus (l_compound) insipidus_19\NN\entity.n.01|
D008094_D003919 NONE lithium_15\NN\metallic_element.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|lithium|- (r_amod) diabetes_18\NN\polygenic_disorder.n.01|induced (r_compound) rat_20\NN\rodent.n.01|the|diabetes|insipidus (l_compound) insipidus_19\NN\entity.n.01|
D008094_D003919 NONE li_35\NNP\metallic_element.n.01| (r_npadvmod) induced_37\VBN\generate.v.01|li|- (r_amod) diabetes_38\NN\polygenic_disorder.n.01|induced (r_compound) rat_40\NN\rodent.n.01|the|diabetes|insipidus (l_compound) insipidus_39\NN\entity.n.01|
D001127_D011141 NONE vasopressin_4\NN\hormone.n.01|arginine (r_pobj) of_2\IN\entity.n.01|vasopressin (r_prep) expression_1\NN\countenance.n.01|the|of (r_nsubjpass) investigated_22\VBN\analyze.v.01|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN\kidney_disease.n.01|(|li)-induced|,
D001127_D011141 NONE avp_6\NNP\entity.n.01| (r_nmod) gene_8\NN\sequence.n.01|(|avp|)|in (r_nsubjpass) investigated_22\VBN\analyze.v.01|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN\kidney_disease.n.01|(|li)-induced|,
D008094_D011141 NONE lithium_26\NN\metallic_element.n.01| (r_pobj) with_25\IN\entity.n.01|lithium (r_prep) rats_24\NNS\rodent.n.01|with (r_pobj) in_23\IN\linear_unit.n.01|rats (r_prep) investigated_22\VBN\analyze.v.01|expression|gene|was|in|polyuria|using|. (l_parataxis) polyuria_29\NN\kidney_disease.n.01|(|li)-induced|,
D008094_D011141 NONE li)-induced_28\JJ\entity.n.01| (r_amod) polyuria_29\NN\kidney_disease.n.01|(|li)-induced|,
D018021_D011141 CID licl_9\NNP\entity.n.01|(|kg|) (r_dobj) contained_8\VBD\include.v.01|that|licl|for (r_relcl) diet_6\NN\fare.n.04|a|contained (r_dobj) consuming_4\VBG\eat.v.01|diet (r_acl) rats_3\NNS\rodent.n.01|the|male|wistar|consuming (r_nsubj) developed_19\VBN\create.v.02|rats|polyuria|. (l_dobj) polyuria_21\NN\kidney_disease.n.01|marked
D001127_D003681 NONE avp_19\NNP\entity.n.01|plasma|and (r_pobj) of_17\IN\entity.n.01|avp (r_prep) elevation_16\NN\rise.n.04|the|of|upregulation (r_pobj) to_14\IN\entity.n.01|elevation (r_prep) contribute_13\VB\change.v.01|that|dehydration|may|to (l_nsubj) dehydration_4\NN\dryness.n.01|and/or|activation
D001127_D003681 NONE avp_24\NNP\entity.n.01| (r_compound) expression_26\NN\countenance.n.01|avp|gene|in (r_pobj) of_23\IN\entity.n.01|expression (r_prep) upregulation_22\NN\entity.n.01|the|of (r_conj) elevation_16\NN\rise.n.04|the|of|upregulation (r_pobj) to_14\IN\entity.n.01|elevation (r_prep) contribute_13\VB\change.v.01|that|dehydration|may|to (l_nsubj) dehydration_4\NN\dryness.n.01|and/or|activation
D001127_D003919 NONE avp_19\NNP\entity.n.01|plasma|and (r_pobj) of_17\IN\entity.n.01|avp (r_prep) elevation_16\NN\rise.n.04|the|of|upregulation (l_conj) upregulation_22\NN\entity.n.01|the|of (l_prep) of_23\IN\entity.n.01|expression (l_pobj) expression_26\NN\countenance.n.01|avp|gene|in (l_prep) in_27\IN\linear_unit.n.01|pvn (l_pobj) pvn_29\NN\entity.n.01|the|and|son (l_conj) son_32\NN\male_offspring.n.01|the|of (l_prep) of_33\IN\entity.n.01|rat (l_pobj) rat_40\NN\rodent.n.01|the|diabetes|insipidus (l_compound) insipidus_39\NN\entity.n.01|
D001127_D003919 NONE avp_24\NNP\entity.n.01| (r_compound) expression_26\NN\countenance.n.01|avp|gene|in (l_prep) in_27\IN\linear_unit.n.01|pvn (l_pobj) pvn_29\NN\entity.n.01|the|and|son (l_conj) son_32\NN\male_offspring.n.01|the|of (l_prep) of_33\IN\entity.n.01|rat (l_pobj) rat_40\NN\rodent.n.01|the|diabetes|insipidus (l_compound) insipidus_39\NN\entity.n.01|
D008094_D003681 NONE li_35\NNP\metallic_element.n.01| (r_npadvmod) induced_37\VBN\generate.v.01|li|- (r_amod) diabetes_38\NN\polygenic_disorder.n.01|induced (r_compound) rat_40\NN\rodent.n.01|the|diabetes|insipidus (r_pobj) of_33\IN\entity.n.01|rat (r_prep) son_32\NN\male_offspring.n.01|the|of (r_conj) pvn_29\NN\entity.n.01|the|and|son (r_pobj) in_27\IN\linear_unit.n.01|pvn (r_prep) expression_26\NN\countenance.n.01|avp|gene|in (r_pobj) of_23\IN\entity.n.01|expression (r_prep) upregulation_22\NN\entity.n.01|the|of (r_conj) elevation_16\NN\rise.n.04|the|of|upregulation (r_pobj) to_14\IN\entity.n.01|elevation (r_prep) contribute_13\VB\change.v.01|that|dehydration|may|to (l_nsubj) dehydration_4\NN\dryness.n.01|and/or|activation
4071154
D007213_D051437 NONE indomethacin_0\NNP\nonsteroidal_anti-inflammatory.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|indomethacin|- (r_amod) insufficiency_4\NN\failing.n.01|induced|renal|:|recurrence|.
D007213_D051437 NONE indomethacin_24\NN\nonsteroidal_anti-inflammatory.n.01|therapy (r_advcl) reported_2\VBN\inform.v.01|we|have|case|indomethacin|. (l_dobj) case_4\NN\happening.n.01|a|of|in (l_prep) of_5\IN\entity.n.01|failure (l_pobj) failure_9\NN\nonaccomplishment.n.01|acute|oliguric|renal|with
D007213_D006947 CID indomethacin_24\NN\nonsteroidal_anti-inflammatory.n.01|therapy (r_advcl) reported_2\VBN\inform.v.01|we|have|case|indomethacin|. (l_dobj) case_4\NN\happening.n.01|a|of|in (l_prep) of_5\IN\entity.n.01|failure (l_pobj) failure_9\NN\nonaccomplishment.n.01|acute|oliguric|renal|with (l_prep) with_10\IN\entity.n.01|hyperkalemia (l_pobj) hyperkalemia_11\NN\symptom.n.01|
D007213_D005355 CID indomethacin_24\NN\nonsteroidal_anti-inflammatory.n.01|therapy (r_advcl) reported_2\VBN\inform.v.01|we|have|case|indomethacin|. (l_dobj) case_4\NN\happening.n.01|a|of|in (l_prep) in_12\IN\linear_unit.n.01|patient (l_pobj) patient_14\NN\case.n.06|a|with (l_prep) with_15\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_16\NN\liver_disease.n.01|,|ascites
D007213_D001201 CID indomethacin_24\NN\nonsteroidal_anti-inflammatory.n.01|therapy (r_advcl) reported_2\VBN\inform.v.01|we|have|case|indomethacin|. (l_dobj) case_4\NN\happening.n.01|a|of|in (l_prep) in_12\IN\linear_unit.n.01|patient (l_pobj) patient_14\NN\case.n.06|a|with (l_prep) with_15\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_16\NN\liver_disease.n.01|,|ascites (l_conj) ascites_18\NNS\pathology.n.02|,|and|pulmonale
D007213_D011660 CID indomethacin_24\NN\nonsteroidal_anti-inflammatory.n.01|therapy (r_advcl) reported_2\VBN\inform.v.01|we|have|case|indomethacin|. (l_dobj) case_4\NN\happening.n.01|a|of|in (l_prep) in_12\IN\linear_unit.n.01|patient (l_pobj) patient_14\NN\case.n.06|a|with (l_prep) with_15\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_16\NN\liver_disease.n.01|,|ascites (l_conj) ascites_18\NNS\pathology.n.02|,|and|pulmonale (l_conj) pulmonale_22\NN\entity.n.01|cor|after
D007213_D009846 CID indomethacin_18\NN\nonsteroidal_anti-inflammatory.n.01| (r_pobj) of_17\IN\entity.n.01|indomethacin (r_prep) dose_16\NN\medicine.n.02|a|single|of (r_pobj) to_13\IN\entity.n.01|exposure|dose (r_punct) caused_19\VBD\make.v.03|to|recurrence (l_dobj) recurrence_20\NN\repeat.n.01|of (l_prep) of_21\IN\entity.n.01|oliguria (l_pobj) oliguria_24\NN\symptom.n.01|acute|reversible
9660111
D014299_D007035 NONE tri_4\NNP\entity.n.01|(|given|) (r_nsubj) antagonize_11\VB\annoy.v.01|in|tri|does|not|hypothermia|in|and|potentiate|. (l_dobj) hypothermia_14\VBN\physical_condition.n.01|the|reserpine
D012110_D007035 CID reserpine_13\NN\antihypertensive.n.01| (r_compound) hypothermia_14\VBN\physical_condition.n.01|the|reserpine
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ\entity.n.01| (r_poss) head_23\NN\external_body_part.n.01|the|5-hydroxytryptophan (r_compound) twitches_24\NNS\spasm.n.01|head|in (r_dobj) potentiate_20\VB\enhance.v.01|does|not|twitches (r_conj) antagonize_11\VB\annoy.v.01|in|tri|does|not|hypothermia|in|and|potentiate|. (l_dobj) hypothermia_14\VBN\physical_condition.n.01|the|reserpine
D014299_D006948 CID tri_0\NNP\entity.n.01|given (r_nsubj) increases_5\VBZ\indefinite_quantity.n.01|tri|hyperactivity|. (l_dobj) hyperactivity_8\NN\disorder.n.01|the|locomotor|induced
D003913_D006948 CID amphetamine_13\NN\drug_of_abuse.n.01|d|-|,|quinpirole (r_pobj) by_10\IN\by.r.01|amphetamine (r_agent) induced_9\VBN\generate.v.01|by (r_acl) hyperactivity_8\NN\disorder.n.01|the|locomotor|induced
D019257_D006948 CID quinpirole_15\NN\entity.n.01|and|(|+|dipropyloaminotetralin (r_conj) amphetamine_13\NN\drug_of_abuse.n.01|d|-|,|quinpirole (r_pobj) by_10\IN\by.r.01|amphetamine (r_agent) induced_9\VBN\generate.v.01|by (r_acl) hyperactivity_8\NN\disorder.n.01|the|locomotor|induced
D004298_D006948 NONE dopamine_24\NN\monoamine_neurotransmitter.n.01| (r_compound) d2_25\NN\entity.n.01|dopamine|and|effects (r_appos) dipropyloaminotetralin_22\NN\entity.n.01|)|-7-hydroxy|-|(|d2|) (r_conj) quinpirole_15\NN\entity.n.01|and|(|+|dipropyloaminotetralin (r_conj) amphetamine_13\NN\drug_of_abuse.n.01|d|-|,|quinpirole (r_pobj) by_10\IN\by.r.01|amphetamine (r_agent) induced_9\VBN\generate.v.01|by (r_acl) hyperactivity_8\NN\disorder.n.01|the|locomotor|induced
D010656_D010554 NONE phenylephrine_7\NN\adrenergic.n.01|given|evaluated (l_acl) evaluated_15\VBN\evaluate.v.02|in|as|aggressiveness (l_conj) aggressiveness_25\NN\drive.n.05|the|evoked
D003000_D010554 NONE clonidine_28\NN\antihypertensive.n.01| (r_pobj) by_27\IN\by.r.01|clonidine (r_agent) evoked_26\VBN\make.v.03|by|in (r_acl) aggressiveness_25\NN\drive.n.05|the|evoked
17879945
D019438_D050197 CID ritonavir_5\VBZ\protease_inhibitor.n.01| (r_compound) treatment_6\NN\care.n.01|ritonavir (r_nsubj) increases_7\VBZ\indefinite_quantity.n.01|that|treatment|formation|to (l_dobj) formation_10\NN\arrangement.n.02|atherosclerotic|lesion|in (l_compound) lesion_9\NN\pathology.n.02|
7802851
D000525_D016584 NONE alprazolam_3\NN\benzodiazepine.n.01|and|placebo (r_pobj) of_2\IN\entity.n.01|alprazolam (r_prep) efficacy_1\NN\effectiveness.n.01|the|of|in|,|and|effect (l_prep) in_6\IN\linear_unit.n.01|disorder (l_pobj) disorder_8\NN\physical_condition.n.01|panic|with
D000525_D016584 NONE alprazolam_20\NN\benzodiazepine.n.01|to|or|placebo (r_xcomp) randomised_18\VBN\disarrange.v.02|in|were|alprazolam|. (l_prep) in_0\IN\linear_unit.n.01|london (l_pobj) london_1\NNP\london.n.01|and|patients (l_conj) patients_5\NNS\case.n.06|toronto|154|met (l_relcl) met_7\VBD\meet.v.01|who|criteria (l_dobj) criteria_11\NNS\system_of_measurement.n.01|iii|for (l_prep) for_12\IN\entity.n.01|disorder (l_pobj) disorder_14\NN\physical_condition.n.01|panic|with
D000525_D000379 NONE alprazolam_3\NN\benzodiazepine.n.01|and|placebo (r_pobj) of_2\IN\entity.n.01|alprazolam (r_prep) efficacy_1\NN\effectiveness.n.01|the|of|in|,|and|effect (l_prep) in_6\IN\linear_unit.n.01|disorder (l_pobj) disorder_8\NN\physical_condition.n.01|panic|with (l_prep) with_9\IN\entity.n.01|agoraphobia (l_pobj) agoraphobia_10\NNP\phobia.n.01|
D000525_D000379 NONE alprazolam_20\NN\benzodiazepine.n.01|to|or|placebo (r_xcomp) randomised_18\VBN\disarrange.v.02|in|were|alprazolam|. (l_prep) in_0\IN\linear_unit.n.01|london (l_pobj) london_1\NNP\london.n.01|and|patients (l_conj) patients_5\NNS\case.n.06|toronto|154|met (l_relcl) met_7\VBD\meet.v.01|who|criteria (l_dobj) criteria_11\NNS\system_of_measurement.n.01|iii|for (l_prep) for_12\IN\entity.n.01|disorder (l_pobj) disorder_14\NN\physical_condition.n.01|panic|with (l_prep) with_15\IN\entity.n.01|agoraphobia (l_pobj) agoraphobia_16\NNP\phobia.n.01|
D000525_D003866 CID alprazolam_5\NN\benzodiazepine.n.01| (r_compound) patients_6\NNS\case.n.06|alprazolam (r_nsubj) developed_7\VBD\create.v.02|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\chemical_process.n.01|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN\entity.n.01|depression (l_pobj) depression_19\NN\psychological_state.n.01|,|enuresis
D000525_D004775 CID alprazolam_5\NN\benzodiazepine.n.01| (r_compound) patients_6\NNS\case.n.06|alprazolam (r_nsubj) developed_7\VBD\create.v.02|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\chemical_process.n.01|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN\entity.n.01|depression (l_pobj) depression_19\NN\psychological_state.n.01|,|enuresis (l_conj) enuresis_21\NN\incontinence.n.01|,|disinhibition
D000525_D001523 NONE alprazolam_5\NN\benzodiazepine.n.01| (r_compound) patients_6\NNS\case.n.06|alprazolam (r_nsubj) developed_7\VBD\create.v.02|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\chemical_process.n.01|adverse|(|%|)|of|;|and|effects (l_prep) of_18\IN\entity.n.01|depression (l_pobj) depression_19\NN\psychological_state.n.01|,|enuresis (l_conj) enuresis_21\NN\incontinence.n.01|,|disinhibition (l_conj) disinhibition_23\NN\entity.n.01|and|aggression (l_conj) aggression_25\NN\unfriendliness.n.02|
D000525_D001523 NONE alprazolam_5\NN\benzodiazepine.n.01| (r_compound) patients_6\NNS\case.n.06|alprazolam (r_nsubj) developed_7\VBD\create.v.02|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\chemical_process.n.01|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\personal_property.n.01|more|side|-|,|sedation (l_appos) sedation_34\NN\physical_condition.n.01|particularly|,|irritability (l_conj) irritability_36\NN\ill_humor.n.01|,|memory
D000525_D008569 CID alprazolam_5\NN\benzodiazepine.n.01| (r_compound) patients_6\NNS\case.n.06|alprazolam (r_nsubj) developed_7\VBD\create.v.02|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\chemical_process.n.01|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\personal_property.n.01|more|side|-|,|sedation (l_appos) sedation_34\NN\physical_condition.n.01|particularly|,|irritability (l_conj) irritability_36\NN\ill_humor.n.01|,|memory (l_conj) memory_39\NN\representation.n.01|impaired|,|loss
D000525_D015431 CID alprazolam_5\NN\benzodiazepine.n.01| (r_compound) patients_6\NNS\case.n.06|alprazolam (r_nsubj) developed_7\VBD\create.v.02|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\chemical_process.n.01|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\personal_property.n.01|more|side|-|,|sedation (l_appos) sedation_34\NN\physical_condition.n.01|particularly|,|irritability (l_conj) irritability_36\NN\ill_humor.n.01|,|memory (l_conj) memory_39\NN\representation.n.01|impaired|,|loss (l_conj) loss_42\NN\transferred_property.n.01|weight|and|ataxia
D000525_D001259 CID alprazolam_5\NN\benzodiazepine.n.01| (r_compound) patients_6\NNS\case.n.06|alprazolam (r_nsubj) developed_7\VBD\create.v.02|compared|,|patients|reactions|. (l_dobj) reactions_10\NNS\chemical_process.n.01|adverse|(|%|)|of|;|and|effects (l_conj) effects_31\NNS\personal_property.n.01|more|side|-|,|sedation (l_appos) sedation_34\NN\physical_condition.n.01|particularly|,|irritability (l_conj) irritability_36\NN\ill_humor.n.01|,|memory (l_conj) memory_39\NN\representation.n.01|impaired|,|loss (l_conj) loss_42\NN\transferred_property.n.01|weight|and|ataxia (l_conj) ataxia_44\NN\nervous_disorder.n.01|
15572383
D004317_D007674 NONE adriamycin_12\NNS\entity.n.01| (r_advmod) induced_14\VBN\generate.v.01|adriamycin|- (r_amod) damage_16\NN\change.n.01|induced|renal
D004317_D007674 NONE adriamycin_23\NNS\entity.n.01| (r_pobj) of_22\IN\entity.n.01|adriamycin (r_prep) injection_21\NN\insertion.n.02|a|single|of|in (r_pobj) by_18\IN\by.r.01|injection (r_agent) induced_17\VBN\generate.v.01|by (r_acl) severity_13\NN\intensity.n.02|the|of|induced (l_prep) of_14\IN\entity.n.01|damage (l_pobj) damage_16\NN\change.n.01|renal
D004317_D007674 NONE adriamycin_3\NNS\entity.n.01|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\symptom.n.01|elicited|nephrotic|range|,|damage (l_conj) damage_11\NN\change.n.01|renal|interstitial|and|glomerulosclerosis
D004317_D007674 NONE adriamycin_10\NNS\entity.n.01| (r_advmod) induced_12\VBN\generate.v.01|adriamycin|- (r_amod) damage_14\NN\change.n.01|induced|renal|in
D004317_D011507 CID adriamycin_10\NNS\entity.n.01|[|intravenously (r_pobj) by_9\IN\by.r.01|adriamycin (r_agent) induced_8\VBN\generate.v.01|after|,|proteinuria|was|by|. (l_nsubjpass) proteinuria_6\NN\symptom.n.01|
D004317_D011507 CID adriamycin_3\NNS\entity.n.01|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\symptom.n.01|elicited|nephrotic|range|,|damage
D004317_D011507 CID adriamycin_12\NNS\entity.n.01|after|0.62|,|actin (r_advcl) correlated_4\VBD\match.v.01|ace|positively|with|adriamycin (l_prep) with_5\IN\entity.n.01|rise (l_pobj) rise_8\NN\emergence.n.01|the|relative|in (l_prep) in_9\IN\linear_unit.n.01|proteinuria (l_pobj) proteinuria_10\NN\symptom.n.01|
D004317_D009404 NONE adriamycin_3\NNS\entity.n.01|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\symptom.n.01|elicited|nephrotic|range|,|damage (l_amod) nephrotic_5\JJ\entity.n.01|
D004317_D005923 NONE adriamycin_3\NNS\entity.n.01|anticipated|,|proteinuria|. (l_pobj) proteinuria_7\NN\symptom.n.01|elicited|nephrotic|range|,|damage (l_conj) damage_11\NN\change.n.01|renal|interstitial|and|glomerulosclerosis (l_conj) glomerulosclerosis_15\NN\entity.n.01|mild|focal
10342929
D000806_D000799 CID inhibitors_4\NNS\substance.n.07|ace|:|common (r_pobj) to_2\IN\entity.n.01|inhibitors (r_pcomp) due_1\IN\right.n.01|to (r_prep) angioedema_0\NNP\edema.n.01|due|.
D000806_D000799 CID inhibitor_13\NN\substance.n.07| (r_compound) treatment_14\NN\care.n.01|ace|)|inhibitor (r_nsubj) is_15\VBZ\be.v.01|incidence|(|treatment|patients|. (l_nsubj) incidence_2\NN\frequency.n.02|the|estimated|of|during (l_prep) of_3\IN\entity.n.01|angioedema (l_pobj) angioedema_4\NN\edema.n.01|
9245658
D009538_D002318 CID nicotine_3\NN\alkaloid.n.01| (r_pobj) of_2\IN\entity.n.01|nicotine (r_prep) role_1\NN\duty.n.02|the|of|in|. (l_prep) in_4\IN\linear_unit.n.01|disease (l_pobj) disease_9\NN\illness.n.01|related|cardiovascular
D009538_D002318 CID nicotine_0\NNP\alkaloid.n.01| (r_nsubj) activates_1\VBZ\initiate.v.02|nicotine|system|and|contribute (l_conj) contribute_11\VB\change.v.01|in|could|to|. (l_prep) to_12\IN\entity.n.01|disease (l_pobj) disease_14\NN\illness.n.01|cardiovascular
D009538_D050197 CID nicotine_7\NN\alkaloid.n.01| (r_nsubj) play_9\VB\dramatic_composition.n.01|that|nicotine|could|role|, (l_dobj) role_11\NN\duty.n.02|a|in (l_prep) in_12\IN\linear_unit.n.01|accelerating (l_pcomp) accelerating_13\VBG\intensify.v.03|atherosclerosis (l_dobj) atherosclerosis_14\NN\arteriosclerosis.n.01|
D009538_D013927 NONE nicotine_0\NN\alkaloid.n.01| (r_nsubj) appear_3\VB\be.v.01|nicotine|does|not|enhance|. (l_xcomp) enhance_5\VB\intensify.v.02|to|thrombosis (l_dobj) thrombosis_6\NN\occlusion.n.01|among
2440413
D001556_D012640 NONE hexachlorocyclohexane_5\NN\entity.n.01|gamma|-|lindane (r_pobj) of_2\IN\entity.n.01|hexachlorocyclohexane (r_prep) effects_1\NNS\personal_property.n.01|differential|of|on|. (l_prep) on_9\IN\on.a.01|seizures (l_pobj) seizures_13\NNS\attack.n.07|induced
D001556_D012640 NONE lindane_7\NN\insecticide.n.01|(|) (r_appos) hexachlorocyclohexane_5\NN\entity.n.01|gamma|-|lindane (r_pobj) of_2\IN\entity.n.01|hexachlorocyclohexane (r_prep) effects_1\NNS\personal_property.n.01|differential|of|on|. (l_prep) on_9\IN\on.a.01|seizures (l_pobj) seizures_13\NNS\attack.n.07|induced
D001556_D012640 NONE hexachlorocyclohexane_2\NN\entity.n.01|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN\show.v.04|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB\change.n.01|to|threshold|to (l_dobj) threshold_23\NN\beginning.n.02|seizure (l_compound) seizure_22\NN\attack.n.07|
D001556_D012640 NONE hch_6\NNP\entity.n.01|gamma|- (r_appos) hexachlorocyclohexane_2\NN\entity.n.01|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN\show.v.04|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB\change.n.01|to|threshold|to (l_dobj) threshold_23\NN\beginning.n.02|seizure (l_compound) seizure_22\NN\attack.n.07|
D001556_D012640 NONE lindane_15\NN\insecticide.n.01|the|insecticide (r_pobj) of_12\IN\entity.n.01|lindane (r_prep) ingredient_11\NN\component.n.03|the|active|of (r_appos) hexachlorocyclohexane_2\NN\entity.n.01|gamma|-|(|hch|)|,|ingredient|, (r_nsubjpass) shown_19\VBN\show.v.04|hexachlorocyclohexane|has|been|decrease|) (l_xcomp) decrease_21\VB\change.n.01|to|threshold|to (l_dobj) threshold_23\NN\beginning.n.02|seizure (l_compound) seizure_22\NN\attack.n.07|
D001556_D012640 NONE hch_7\NNP\entity.n.01|gamma|- (r_pobj) to_4\IN\entity.n.01|hch (r_prep) exposure_3\NN\vulnerability.n.02|to (r_pobj) after_2\IN\after.s.01|exposure (r_prep) h_1\NN\chemical_element.n.01|3|after|and|increase (l_conj) increase_10\VB\indefinite_quantity.n.01|conversely|threshold|to (l_prep) to_12\IN\entity.n.01|seizures (l_pobj) seizures_16\NNS\attack.n.07|induced
D001556_D012640 NONE hch_24\NNP\entity.n.01|gamma|-|al (r_pobj) to_21\IN\entity.n.01|hch (r_prep) exposure_20\NN\vulnerability.n.02|to (r_pobj) after_19\IN\after.s.01|exposure (r_prep) h_18\NN\chemical_element.n.01|h|24|after|)|. (l_dep) h_1\NN\chemical_element.n.01|3|after|and|increase (l_conj) increase_10\VB\indefinite_quantity.n.01|conversely|threshold|to (l_prep) to_12\IN\entity.n.01|seizures (l_pobj) seizures_16\NNS\attack.n.07|induced
D001556_D012640 NONE hch_30\NNP\entity.n.01|mg/kg|gamma|- (r_pobj) of_25\IN\entity.n.01|hch (r_prep) administration_24\NN\management.n.01|intraperitoneal|of (r_pobj) after_22\IN\after.s.01|administration (r_prep) tested_15\VBN\evaluate.v.02|in|,|severity|was|in|h|after|. (l_nsubjpass) severity_5\NN\intensity.n.02|the|of (l_prep) of_6\IN\entity.n.01|response (l_pobj) response_7\NN\consequence.n.01|to (l_prep) to_8\IN\entity.n.01|agents (l_pobj) agents_13\NNS\causal_agent.n.01|other|inducing (l_amod) inducing_12\VBG\causing.n.01|seizure|- (l_npadvmod) seizure_10\NN\attack.n.07|
D001556_D012640 NONE hch_8\NNP\entity.n.01|gamma|- (r_pobj) of_5\IN\entity.n.01|hch (r_prep) administration_4\NN\management.n.01|the|of (r_pobj) after_2\IN\after.s.01|administration (r_prep) increased_18\VBN\change_magnitude.v.01|hour|after|,|activity|was (l_nsubjpass) activity_11\NN\act.n.02|the|of (l_prep) of_12\IN\entity.n.01|agents (l_pobj) agents_16\NNS\causal_agent.n.01|inducing (l_amod) inducing_15\VBG\causing.n.01|seizure|- (l_npadvmod) seizure_13\NN\attack.n.07|
D001556_D012640 NONE hch_31\NNP\entity.n.01|- (r_appos) h_27\NN\chemical_element.n.01|24|after|hch (r_dep) observed_36\VBN\spy.v.03|increased|,|regardless|,|while|h|response|was|. (l_advcl) increased_18\VBN\change_magnitude.v.01|hour|after|,|activity|was (l_nsubjpass) activity_11\NN\act.n.02|the|of (l_prep) of_12\IN\entity.n.01|agents (l_pobj) agents_16\NNS\causal_agent.n.01|inducing (l_amod) inducing_15\VBG\causing.n.01|seizure|- (l_npadvmod) seizure_13\NN\attack.n.07|
D001556_D012640 NONE hch_22\NNP\entity.n.01|gamma|- (r_pobj) after_19\IN\after.s.01|hch (r_prep) h_18\NN\chemical_element.n.01|24|after (r_npadvmod) occur_8\VB\happen.v.01|that|tolerance|may|to|h|,|decreased (l_prep) to_9\IN\entity.n.01|activity (l_pobj) activity_11\NN\act.n.02|seizure|induced (l_compound) seizure_10\NN\attack.n.07|
D001556_D012640 NONE hch_22\NNP\entity.n.01|gamma|- (r_pobj) after_19\IN\after.s.01|hch (r_prep) h_18\NN\chemical_element.n.01|24|after (r_npadvmod) occur_8\VB\happen.v.01|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN\change_magnitude.v.01|since|response|is (l_nsubjpass) response_26\NN\consequence.n.01|the|to (l_prep) to_27\IN\entity.n.01|agents (l_pobj) agents_34\NNS\causal_agent.n.01|only|these|two|inducing (l_amod) inducing_33\VBG\causing.n.01|seizure|- (l_npadvmod) seizure_31\NN\attack.n.07|
D001556_D012640 NONE hch_20\NNP\entity.n.01|gamma|- (r_nsubj) be_22\VB\metallic_element.n.01|that|site|hch|may|channel (l_nsubj) site_7\NN\tract.n.01|the|responsible|h (l_amod) responsible_8\JJ\responsible.a.01|for (l_prep) for_9\IN\entity.n.01|decrease (l_pobj) decrease_11\NN\change.n.01|the|in (l_prep) in_12\IN\linear_unit.n.01|activity (l_pobj) activity_14\NN\act.n.02|seizure (l_compound) seizure_13\NN\attack.n.07|
D010433_D012640 CID ptz_27\NNP\entity.n.01|pentylenetrazol|( (r_pobj) to_24\TO\entity.n.01|ptz (r_prep) decrease_21\VB\change.n.01|to|threshold|to (l_dobj) threshold_23\NN\beginning.n.02|seizure (l_compound) seizure_22\NN\attack.n.07|
D010433_D012640 CID ptz_13\NNP\entity.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|ptz|- (r_amod) seizures_16\NNS\attack.n.07|induced
D010433_D012640 CID ptz_4\NNP\entity.n.01|and|picrotoxin|ptx (r_pobj) due_2\IN\right.n.01|to|ptz (r_amod) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D010433_D012640 CID ptz_4\NNP\entity.n.01|and|picrotoxin|ptx (r_pobj) due_2\IN\right.n.01|to|ptz (r_amod) activity_1\NN\act.n.02|seizure|due (r_nsubjpass) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (r_ccomp) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D010433_D012640 CID ptz_14\NNP\entity.n.01|and|ptx (r_pobj) by_13\IN\by.r.01|ptz (r_agent) induced_12\VBN\generate.v.01|by (r_acl) activity_11\NN\act.n.02|seizure|induced (l_compound) seizure_10\NN\attack.n.07|
D010433_D012640 CID ptz_14\NNP\entity.n.01|and|ptx (r_pobj) by_13\IN\by.r.01|ptz (r_agent) induced_12\VBN\generate.v.01|by (r_acl) activity_11\NN\act.n.02|seizure|induced (r_pobj) to_9\IN\entity.n.01|activity (r_prep) occur_8\VB\happen.v.01|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN\change_magnitude.v.01|since|response|is (l_nsubjpass) response_26\NN\consequence.n.01|the|to (l_prep) to_27\IN\entity.n.01|agents (l_pobj) agents_34\NNS\causal_agent.n.01|only|these|two|inducing (l_amod) inducing_33\VBG\causing.n.01|seizure|- (l_npadvmod) seizure_31\NN\attack.n.07|
D010852_D012640 CID picrotoxin_6\NN\entity.n.01| (r_conj) ptz_4\NNP\entity.n.01|and|picrotoxin|ptx (r_pobj) due_2\IN\right.n.01|to|ptz (r_amod) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D010852_D012640 CID picrotoxin_6\NN\entity.n.01| (r_conj) ptz_4\NNP\entity.n.01|and|picrotoxin|ptx (r_pobj) due_2\IN\right.n.01|to|ptz (r_amod) activity_1\NN\act.n.02|seizure|due (r_nsubjpass) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (r_ccomp) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D010852_D012640 CID ptx_8\NNP\entity.n.01|(|) (r_appos) ptz_4\NNP\entity.n.01|and|picrotoxin|ptx (r_pobj) due_2\IN\right.n.01|to|ptz (r_amod) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D010852_D012640 CID ptx_8\NNP\entity.n.01|(|) (r_appos) ptz_4\NNP\entity.n.01|and|picrotoxin|ptx (r_pobj) due_2\IN\right.n.01|to|ptz (r_amod) activity_1\NN\act.n.02|seizure|due (r_nsubjpass) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (r_ccomp) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_nsubj) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D010852_D012640 CID ptx_16\NNP\entity.n.01| (r_conj) ptz_14\NNP\entity.n.01|and|ptx (r_pobj) by_13\IN\by.r.01|ptz (r_agent) induced_12\VBN\generate.v.01|by (r_acl) activity_11\NN\act.n.02|seizure|induced (l_compound) seizure_10\NN\attack.n.07|
D010852_D012640 CID ptx_16\NNP\entity.n.01| (r_conj) ptz_14\NNP\entity.n.01|and|ptx (r_pobj) by_13\IN\by.r.01|ptz (r_agent) induced_12\VBN\generate.v.01|by (r_acl) activity_11\NN\act.n.02|seizure|induced (r_pobj) to_9\IN\entity.n.01|activity (r_prep) occur_8\VB\happen.v.01|that|tolerance|may|to|h|,|decreased (l_advcl) decreased_36\VBN\change_magnitude.v.01|since|response|is (l_nsubjpass) response_26\NN\consequence.n.01|the|to (l_prep) to_27\IN\entity.n.01|agents (l_pobj) agents_34\NNS\causal_agent.n.01|only|these|two|inducing (l_amod) inducing_33\VBG\causing.n.01|seizure|- (l_npadvmod) seizure_31\NN\attack.n.07|
D015097_D012640 CID acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D015097_D012640 CID acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D015097_D012640 CID mpa_23\NNP\entity.n.01|(|) (r_appos) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D015097_D012640 CID mpa_23\NNP\entity.n.01|(|) (r_appos) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D001640_D012640 CID bicuculline_26\NN\entity.n.01| (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D001640_D012640 CID bicuculline_26\NN\entity.n.01| (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D001640_D012640 CID bcc_28\NNP\entity.n.01|(|) (r_appos) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D001640_D012640 CID bcc_28\NNP\entity.n.01|(|) (r_appos) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
C034818_D012640 CID carboline-3-carboxylate_36\NNP\entity.n.01|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
C034818_D012640 CID carboline-3-carboxylate_36\NNP\entity.n.01|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
C034818_D012640 CID dmcm_38\NNP\entity.n.01| (r_appos) carboline-3-carboxylate_36\NNP\entity.n.01|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
C034818_D012640 CID dmcm_38\NNP\entity.n.01| (r_appos) carboline-3-carboxylate_36\NNP\entity.n.01|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D013331_D012640 CID strychnine_42\NN\alkaloid.n.01| (r_conj) carboline-3-carboxylate_36\NNP\entity.n.01|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D013331_D012640 CID strychnine_42\NN\alkaloid.n.01| (r_conj) carboline-3-carboxylate_36\NNP\entity.n.01|methyl|6,7-dimethoxy-4-ethyl|-|b|-|(|dmcm|)|,|or|strychnine (r_conj) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D013331_D012640 CID str_44\NNP\entity.n.01| (r_appos) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (r_nsubj) was_46\VBD\washington.n.02|decreased|;|however|,|activity|not|different|. (l_ccomp) decreased_12\VBN\change_magnitude.v.01|activity|was|significantly (l_nsubjpass) activity_1\NN\act.n.02|seizure|due (l_compound) seizure_0\NN\attack.n.07|
D013331_D012640 CID str_44\NNP\entity.n.01| (r_appos) acid_21\NN\compound.n.02|3-mercaptopropionic|mpa|,|bicuculline|bcc|,|carboline-3-carboxylate|(|str|) (r_pobj) to_19\IN\entity.n.01|acid (r_pcomp) due_18\IN\right.n.01|to (r_prep) activity_17\NN\act.n.02|seizure|due (l_compound) seizure_16\NN\attack.n.07|
D005680_D012640 NONE gaba_24\NNP\amino_acid.n.01| (r_compound) a_26\NNP\metric_linear_unit.n.01|gaba|- (r_nmod) channel_31\NN\transmission.n.02|the|a|linked|chloride (r_attr) be_22\VB\metallic_element.n.01|that|site|hch|may|channel (l_nsubj) site_7\NN\tract.n.01|the|responsible|h (l_amod) responsible_8\JJ\responsible.a.01|for (l_prep) for_9\IN\entity.n.01|decrease (l_pobj) decrease_11\NN\change.n.01|the|in (l_prep) in_12\IN\linear_unit.n.01|activity (l_pobj) activity_14\NN\act.n.02|seizure (l_compound) seizure_13\NN\attack.n.07|
18417364
D009538_D009759 CID nicotine_0\NN\alkaloid.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|nicotine|- (r_amod) nystagmus_3\NN\eye_movement.n.01|induced
D009538_D009759 CID nicotine_3\NN\alkaloid.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|nicotine|- (r_amod) nystagmus_6\NN\eye_movement.n.01|induced|(|nin|)
D009538_D009759 CID nicotine_3\NN\alkaloid.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|nicotine|- (r_amod) nystagmus_6\NN\eye_movement.n.01|induced|(|nin|) (l_appos) nin_8\NNP\entity.n.01|
D010100_D009759 NONE oxygen_4\NN\chemical_element.n.01|blood (r_nmod) levels_12\NNS\property.n.02|oxygen|dependent|(|bold|)|activity|in (r_pobj) with_2\IN\entity.n.01|levels (r_prep) correlated_1\VBD\match.v.01|nin|with|. (l_nsubj) nin_0\NNP\entity.n.01|
2559236
D004317_D007674 NONE adriamycin_9\NNS\entity.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|adriamycin|- (r_amod) nephropathy_12\NN\uropathy.n.01|induced
D004317_D007674 NONE adriamycin_24\JJ\entity.n.01| (r_amod) nephrosis_25\NN\syndrome.n.02|adriamycin (r_pobj) in_23\IN\linear_unit.n.01|nephrosis (r_prep) injury_22\NN\ill_health.n.01|renal|in
D004656_D009401 NONE enalapril_10\NN\ace_inhibitor.n.01|(|cei|) (r_appos) inhibitor_6\NN\substance.n.07|enzyme|enalapril (r_pobj) of_2\IN\entity.n.01|inhibitor (r_prep) effect_1\NN\phenomenon.n.01|the|of (r_nsubjpass) assessed_12\VBN\evaluate.v.02|effect|was|in|with|. (l_prep) with_18\IN\entity.n.01|nephrosis (l_pobj) nephrosis_21\NN\syndrome.n.02|established|adriamycin
D004656_D009401 NONE enalapril_17\NN\ace_inhibitor.n.01| (r_pobj) of_16\IN\entity.n.01|enalapril (r_prep) effect_15\NN\phenomenon.n.01|the|of|on (l_prep) on_18\IN\on.a.01|progression (l_pobj) progression_19\NN\series.n.01|of (l_prep) of_20\IN\entity.n.01|injury (l_pobj) injury_22\NN\ill_health.n.01|renal|in (l_prep) in_23\IN\linear_unit.n.01|nephrosis (l_pobj) nephrosis_25\NN\syndrome.n.02|adriamycin
D004317_D009401 CID adriamycin_20\NNS\entity.n.01| (r_amod) nephrosis_21\NN\syndrome.n.02|established|adriamycin
D004317_D009401 CID adriamycin_24\JJ\entity.n.01| (r_amod) nephrosis_25\NN\syndrome.n.02|adriamycin
D004317_D000419 CID adriamycin_7\NNS\entity.n.01| (r_pobj) of_6\IN\entity.n.01|adriamycin (r_prep) dose_5\NN\medicine.n.02|a|single|of|and (r_dobj) given_2\VBN\assumption.n.02|rats|were|dose|divided|. (l_advcl) divided_12\VBD\change_integrity.v.01|later|into (l_prep) into_13\IN\entity.n.01|groups (l_pobj) groups_15\NNS\abstraction.n.06|four|matched (l_acl) matched_16\VBN\equal.v.01|for (l_prep) for_17\IN\entity.n.01|albuminuria (l_pobj) albuminuria_18\NN\symptom.n.01|,|pressure
D004656_D000419 NONE enalapril_7\DT\ace_inhibitor.n.01| (r_nsubj) reduced_8\JJ\decrease.v.02|that|enalapril|pressure|2|vs. (l_prep) vs._16\IN\entity.n.01|hg (l_pobj) hg_21\NNP\metallic_element.n.01|mm|,|group|,|p|)|and|pressure (l_conj) pressure_36\NN\physical_phenomenon.n.01|glomerular|capillary|(|+/-|(|+/-|)|or|gfr (l_appos) +/-_39\SYM\entity.n.01|54|1|vs.|without (l_prep) without_53\IN\entity.n.01|reducing (l_pcomp) reducing_54\VBG\chemical_reaction.n.01|albuminuria (l_dobj) albuminuria_55\NN\symptom.n.01|
D004656_D000419 NONE enalapril_1\NN\ace_inhibitor.n.01|chronic (r_compound) treatment_2\NN\care.n.01|enalapril (r_nsubj) reduced_3\VBN\decrease.v.02|treatment (r_amod) pressure_5\NN\physical_phenomenon.n.01|reduced|blood|without|. (l_prep) without_6\IN\entity.n.01|reducing (l_pcomp) reducing_7\VBG\chemical_reaction.n.01|albuminuria|in (l_dobj) albuminuria_8\NN\symptom.n.01|
D004656_D007674 NONE enalapril_17\NN\ace_inhibitor.n.01| (r_pobj) of_16\IN\entity.n.01|enalapril (r_prep) effect_15\NN\phenomenon.n.01|the|of|on (l_prep) on_18\IN\on.a.01|progression (l_pobj) progression_19\NN\series.n.01|of (l_prep) of_20\IN\entity.n.01|injury (l_pobj) injury_22\NN\ill_health.n.01|renal|in
12464714
C093622_D008881 NONE rizatriptan_7\JJ\entity.n.01| (r_pobj) for_6\IN\entity.n.01|rizatriptan (r_prep) preference_5\NN\liking.n.01|for (r_conj) efficacy_3\NN\effectiveness.n.01|and|preference (r_pobj) of_2\IN\entity.n.01|efficacy (r_prep) comparison_1\NN\examination.n.01|crossover|of|caffeine|. (l_conj) caffeine_13\NN\alkaloid.n.01|mg|ergotamine|/|in (l_prep) in_14\IN\linear_unit.n.01|migraine (l_pobj) migraine_15\NN\headache.n.02|
C093622_D008881 NONE rizatriptan_0\NNP\entity.n.01| (r_nsubj) is_1\VBZ\be.v.01|rizatriptan|agonist|. (l_attr) agonist_7\NN\protagonist.n.02|a|selective|receptor|with (l_prep) with_8\IN\entity.n.01|absorption (l_pobj) absorption_11\NN\sorption.n.01|rapid|oral|and|onset (l_conj) onset_14\NN\start.n.01|early|of|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_20\NN\care.n.01|the|acute|of (l_prep) of_21\IN\entity.n.01|migraine (l_pobj) migraine_22\NN\headache.n.02|
C093622_D008881 NONE rizatriptan_12\JJ\entity.n.01|1|tablet (r_pobj) for_10\IN\entity.n.01|rizatriptan (r_prep) preference_9\NN\liking.n.01|the|for (r_dobj) assessed_7\VBD\evaluate.v.02|study|preference|tablets|in|. (l_prep) in_26\IN\linear_unit.n.01|patients (l_pobj) patients_28\NNS\case.n.06|439|treating (l_acl) treating_29\VBG\interact.v.01|attack (l_dobj) attack_33\NN\operation.n.05|a|single|migraine|with (l_compound) migraine_32\JJ\headache.n.02|
D004878_D008881 NONE ergotamine_11\NN\alkaloid.n.01| (r_nmod) caffeine_13\NN\alkaloid.n.01|mg|ergotamine|/|in (l_prep) in_14\IN\linear_unit.n.01|migraine (l_pobj) migraine_15\NN\headache.n.02|
D004878_D008881 NONE ergotamine_18\NN\alkaloid.n.01|2|caffeine (r_pobj) to_16\IN\entity.n.01|ergotamine (r_prep) tablet_15\NN\slab.n.01|mg|to (r_amod) rizatriptan_12\JJ\entity.n.01|1|tablet (r_pobj) for_10\IN\entity.n.01|rizatriptan (r_prep) preference_9\NN\liking.n.01|the|for (r_dobj) assessed_7\VBD\evaluate.v.02|study|preference|tablets|in|. (l_prep) in_26\IN\linear_unit.n.01|patients (l_pobj) patients_28\NNS\case.n.06|439|treating (l_acl) treating_29\VBG\interact.v.01|attack (l_dobj) attack_33\NN\operation.n.05|a|single|migraine|with (l_compound) migraine_32\JJ\headache.n.02|
D002110_D008881 NONE caffeine_13\NN\alkaloid.n.01|mg|ergotamine|/|in (l_prep) in_14\IN\linear_unit.n.01|migraine (l_pobj) migraine_15\NN\headache.n.02|
D002110_D008881 NONE caffeine_22\NN\alkaloid.n.01|1|mg|/ (r_appos) ergotamine_18\NN\alkaloid.n.01|2|caffeine (r_pobj) to_16\IN\entity.n.01|ergotamine (r_prep) tablet_15\NN\slab.n.01|mg|to (r_amod) rizatriptan_12\JJ\entity.n.01|1|tablet (r_pobj) for_10\IN\entity.n.01|rizatriptan (r_prep) preference_9\NN\liking.n.01|the|for (r_dobj) assessed_7\VBD\evaluate.v.02|study|preference|tablets|in|. (l_prep) in_26\IN\linear_unit.n.01|patients (l_pobj) patients_28\NNS\case.n.06|439|treating (l_acl) treating_29\VBG\interact.v.01|attack (l_dobj) attack_33\NN\operation.n.05|a|single|migraine|with (l_compound) migraine_32\JJ\headache.n.02|
D012701_D008881 NONE 5-ht(1b/1d_4\CD\entity.n.01| (r_nummod) receptor_6\NN\structure.n.04|5-ht(1b/1d|) (r_compound) agonist_7\NN\protagonist.n.02|a|selective|receptor|with (l_prep) with_8\IN\entity.n.01|absorption (l_pobj) absorption_11\NN\sorption.n.01|rapid|oral|and|onset (l_conj) onset_14\NN\start.n.01|early|of|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_20\NN\care.n.01|the|acute|of (l_prep) of_21\IN\entity.n.01|migraine (l_pobj) migraine_22\NN\headache.n.02|
C093622_D006261 NONE rizatriptan_19\JJ\entity.n.01|and|% (r_dobj) preferring_18\VBG\like.v.02|rizatriptan (r_acl) patients_17\NNS\case.n.06|preferring (r_pobj) of_16\IN\entity.n.01|patients (r_prep) %_15\NN\entity.n.01|67.3|of (r_pobj) by_13\IN\by.r.01|% (r_agent) cited_12\VBN\think_of.v.04|by (r_acl) reason_8\NN\rational_motive.n.01|the|important|for|,|cited (r_attr) was_4\VBD\washington.n.02|relief|reason|. (l_nsubj) relief_1\NN\comfort.n.02|faster|of (l_prep) of_2\IN\entity.n.01|headache (l_pobj) headache_3\NN\negative_stimulus.n.01|
D004878_D006261 NONE ergotamine_27\NN\alkaloid.n.01| (r_nmod) caffeine_29\NN\alkaloid.n.01|ergotamine|/ (r_dobj) preferred_26\VBD\like.v.02|who|caffeine (r_relcl) patients_24\NNS\case.n.06|preferred (r_pobj) of_23\IN\entity.n.01|patients (r_prep) %_22\NN\entity.n.01|54.2|of (r_conj) rizatriptan_19\JJ\entity.n.01|and|% (r_dobj) preferring_18\VBG\like.v.02|rizatriptan (r_acl) patients_17\NNS\case.n.06|preferring (r_pobj) of_16\IN\entity.n.01|patients (r_prep) %_15\NN\entity.n.01|67.3|of (r_pobj) by_13\IN\by.r.01|% (r_agent) cited_12\VBN\think_of.v.04|by (r_acl) reason_8\NN\rational_motive.n.01|the|important|for|,|cited (r_attr) was_4\VBD\washington.n.02|relief|reason|. (l_nsubj) relief_1\NN\comfort.n.02|faster|of (l_prep) of_2\IN\entity.n.01|headache (l_pobj) headache_3\NN\negative_stimulus.n.01|
D002110_D006261 NONE caffeine_29\NN\alkaloid.n.01|ergotamine|/ (r_dobj) preferred_26\VBD\like.v.02|who|caffeine (r_relcl) patients_24\NNS\case.n.06|preferred (r_pobj) of_23\IN\entity.n.01|patients (r_prep) %_22\NN\entity.n.01|54.2|of (r_conj) rizatriptan_19\JJ\entity.n.01|and|% (r_dobj) preferring_18\VBG\like.v.02|rizatriptan (r_acl) patients_17\NNS\case.n.06|preferring (r_pobj) of_16\IN\entity.n.01|patients (r_prep) %_15\NN\entity.n.01|67.3|of (r_pobj) by_13\IN\by.r.01|% (r_agent) cited_12\VBN\think_of.v.04|by (r_acl) reason_8\NN\rational_motive.n.01|the|important|for|,|cited (r_attr) was_4\VBD\washington.n.02|relief|reason|. (l_nsubj) relief_1\NN\comfort.n.02|faster|of (l_prep) of_2\IN\entity.n.01|headache (l_pobj) headache_3\NN\negative_stimulus.n.01|
C093622_D010146 NONE rizatriptan_12\NN\entity.n.01| (r_pobj) after_11\IN\after.s.01|rizatriptan (r_prep) h_10\NN\chemical_element.n.01|2|after (r_npadvmod) were_6\VBD\be.v.01|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\people.n.01|pain (l_npadvmod) pain_7\NN\symptom.n.01|
C093622_D010146 NONE rizatriptan_31\JJ\entity.n.01| (r_nsubj) being_32\VBG\state.n.02|rizatriptan|superior|within (r_advcl) were_6\VBD\be.v.01|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\people.n.01|pain (l_npadvmod) pain_7\NN\symptom.n.01|
C093622_D010146 NONE rizatriptan_6\NN\entity.n.01| (r_dobj) taking_5\VBG\action.n.01|rizatriptan (r_acl) patients_4\NNS\case.n.06|taking (r_pobj) of_3\IN\entity.n.01|patients (r_prep) %_2\NN\entity.n.01|36|of (r_nsubj) were_7\VBD\be.v.01|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ\people.n.01|pain (l_npadvmod) pain_8\NN\symptom.n.01|
D004878_D010146 NONE ergotamine_20\NN\alkaloid.n.01| (r_nmod) caffeine_22\NN\alkaloid.n.01|ergotamine|/|0.001 (r_pobj) with_19\IN\entity.n.01|caffeine (r_prep) treated_18\VBN\interact.v.01|with (r_acl) %_17\NN\entity.n.01|24.3|treated (r_pobj) with_15\IN\entity.n.01|% (r_prep) compared_14\VBN\analyze.v.01|with (r_prep) were_6\VBD\be.v.01|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\people.n.01|pain (l_npadvmod) pain_7\NN\symptom.n.01|
D004878_D010146 NONE ergotamine_33\NNP\alkaloid.n.01| (r_nmod) caffeine_35\NN\alkaloid.n.01|ergotamine|/|0.001 (r_pobj) on_32\IN\on.a.01|caffeine (r_prep) patients_31\NNS\case.n.06|on (r_pobj) of_30\IN\entity.n.01|patients (r_prep) %_29\NN\entity.n.01|20|of (r_pobj) to_27\IN\entity.n.01|% (r_prep) compared_26\VBN\analyze.v.01|to (r_prep) were_7\VBD\be.v.01|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ\people.n.01|pain (l_npadvmod) pain_8\NN\symptom.n.01|
D002110_D010146 NONE caffeine_22\NN\alkaloid.n.01|ergotamine|/|0.001 (r_pobj) with_19\IN\entity.n.01|caffeine (r_prep) treated_18\VBN\interact.v.01|with (r_acl) %_17\NN\entity.n.01|24.3|treated (r_pobj) with_15\IN\entity.n.01|% (r_prep) compared_14\VBN\analyze.v.01|with (r_prep) were_6\VBD\be.v.01|percent|free|h|,|compared|,|being|. (l_acomp) free_8\JJ\people.n.01|pain (l_npadvmod) pain_7\NN\symptom.n.01|
D002110_D010146 NONE caffeine_35\NN\alkaloid.n.01|ergotamine|/|0.001 (r_pobj) on_32\IN\on.a.01|caffeine (r_prep) patients_31\NNS\case.n.06|on (r_pobj) of_30\IN\entity.n.01|patients (r_prep) %_29\NN\entity.n.01|20|of (r_pobj) to_27\IN\entity.n.01|% (r_prep) compared_26\VBN\analyze.v.01|to (r_prep) were_7\VBD\be.v.01|%|free|at|and|had|,|compared|. (l_acomp) free_9\JJ\people.n.01|pain (l_npadvmod) pain_8\NN\symptom.n.01|
C093622_D009325 CID rizatriptan_0\NNP\entity.n.01| (r_nsubj) was_1\VBD\washington.n.02|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\leader.n.01|to (l_prep) to_4\IN\entity.n.01|caffeine (l_pobj) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting
C093622_D009325 CID rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\symptom.n.01|(|4.2|)|and|somnolence
C093622_D014839 NONE rizatriptan_0\NNP\entity.n.01| (r_nsubj) was_1\VBD\washington.n.02|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\leader.n.01|to (l_prep) to_4\IN\entity.n.01|caffeine (l_pobj) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for
C093622_D012001 NONE rizatriptan_0\NNP\entity.n.01| (r_nsubj) was_1\VBD\washington.n.02|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\leader.n.01|to (l_prep) to_4\IN\entity.n.01|caffeine (l_pobj) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\simple_phobia.n.01|or|photophobia
C093622_D020795 NONE rizatriptan_0\NNP\entity.n.01| (r_nsubj) was_1\VBD\washington.n.02|rizatriptan|also|superior|h|. (l_acomp) superior_3\JJ\leader.n.01|to (l_prep) to_4\IN\entity.n.01|caffeine (l_pobj) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\simple_phobia.n.01|or|photophobia (l_conj) photophobia_21\NNS\simple_phobia.n.01|
D004878_D009325 NONE ergotamine_5\NN\alkaloid.n.01| (r_nmod) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting
D004878_D009325 NONE ergotamine_19\NNP\alkaloid.n.01| (r_nmod) caffeine_21\NN\alkaloid.n.01|ergotamine|/ (r_conj) rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\symptom.n.01|(|4.2|)|and|somnolence
D004878_D014839 NONE ergotamine_5\NN\alkaloid.n.01| (r_nmod) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for
D004878_D012001 NONE ergotamine_5\NN\alkaloid.n.01| (r_nmod) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\simple_phobia.n.01|or|photophobia
D004878_D020795 NONE ergotamine_5\NN\alkaloid.n.01| (r_nmod) caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\simple_phobia.n.01|or|photophobia (l_conj) photophobia_21\NNS\simple_phobia.n.01|
D002110_D009325 NONE caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting
D002110_D009325 NONE caffeine_21\NN\alkaloid.n.01|ergotamine|/ (r_conj) rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\symptom.n.01|(|4.2|)|and|somnolence
D002110_D014839 NONE caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for
D002110_D012001 NONE caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\simple_phobia.n.01|or|photophobia
D002110_D020795 NONE caffeine_7\NN\alkaloid.n.01|ergotamine|/|in (l_prep) in_8\IN\linear_unit.n.01|proportions (l_pobj) proportions_10\NNS\quotient.n.01|the|of (l_prep) of_11\IN\entity.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|nausea (l_pobj) nausea_15\NN\symptom.n.01|no|,|vomiting (l_conj) vomiting_17\VBG\expulsion.n.03|,|phonophobia|and|for (l_conj) phonophobia_19\NNS\simple_phobia.n.01|or|photophobia (l_conj) photophobia_21\NNS\simple_phobia.n.01|
C093622_D004244 CID rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD\be.v.01|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN\symptom.n.01|(|6.7|)
C093622_D006970 NONE rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\symptom.n.01|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN\temporary_state.n.01|(|5.5|)
D004878_D004244 NONE ergotamine_19\NNP\alkaloid.n.01| (r_nmod) caffeine_21\NN\alkaloid.n.01|ergotamine|/ (r_conj) rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD\be.v.01|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN\symptom.n.01|(|6.7|)
D004878_D006970 NONE ergotamine_19\NNP\alkaloid.n.01| (r_nmod) caffeine_21\NN\alkaloid.n.01|ergotamine|/ (r_conj) rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\symptom.n.01|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN\temporary_state.n.01|(|5.5|)
D002110_D004244 NONE caffeine_21\NN\alkaloid.n.01|ergotamine|/ (r_conj) rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (r_nsubj) were_25\VBD\be.v.01|events|respectively|,|dizziness|,|. (l_attr) dizziness_26\NN\symptom.n.01|(|6.7|)
D002110_D006970 NONE caffeine_21\NN\alkaloid.n.01|ergotamine|/ (r_conj) rizatriptan_17\NN\entity.n.01|and|caffeine (r_pobj) after_16\IN\after.s.01|rizatriptan (r_prep) >_7\XX\entity.n.01|incidence|or|%|after (r_appos) events_4\NNS\psychological_feature.n.01|the|common|adverse|(|>|,|nausea (l_appos) nausea_34\NN\symptom.n.01|(|4.2|)|and|somnolence (l_conj) somnolence_42\NN\temporary_state.n.01|(|5.5|)
3827439
D000666_D058186 CID amphotericin_6\JJ\antibiotic.n.01| (r_pobj) from_5\IN\entity.n.01|amphotericin (r_prep) failure_4\NN\nonaccomplishment.n.01|recurrent|reversible|acute|renal|from|.
D000666_D058186 CID b_18\NNP\eubacteria.n.01|amphotericin (r_pobj) of_16\IN\entity.n.01|b (r_prep) administration_15\NN\management.n.01|the|of (r_dobj) following_13\VBG\multitude.n.03|immediately|administration|on (r_acl) failure_11\NN\nonaccomplishment.n.01|acute|renal|following
D000666_D058186 CID amphotericin_3\JJ\antibiotic.n.01| (r_advmod) propose_1\VBP\declare.v.01|we|that|amphotericin|activate|. (l_conj) activate_15\VB\initiate.v.02|,|in|,|may|feedback|,|contributing (l_advcl) contributing_20\VBG\change.v.01|thereby|to (l_prep) to_21\IN\entity.n.01|failure (l_pobj) failure_24\NN\nonaccomplishment.n.01|acute|renal
D000666_D005355 NONE b_18\NNP\eubacteria.n.01|amphotericin (r_pobj) of_16\IN\entity.n.01|b (r_prep) administration_15\NN\management.n.01|the|of (r_dobj) following_13\VBG\multitude.n.03|immediately|administration|on (r_acl) failure_11\NN\nonaccomplishment.n.01|acute|renal|following (r_dobj) developed_8\VBD\create.v.02|patient|failure|. (l_nsubj) patient_1\NN\case.n.06|a|with|and|disseminated (l_prep) with_2\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_4\NN\liver_disease.n.01|cryptogenic
D000666_D013174 NONE b_18\NNP\eubacteria.n.01|amphotericin (r_pobj) of_16\IN\entity.n.01|b (r_prep) administration_15\NN\management.n.01|the|of (r_dobj) following_13\VBG\multitude.n.03|immediately|administration|on (r_acl) failure_11\NN\nonaccomplishment.n.01|acute|renal|following (r_dobj) developed_8\VBD\create.v.02|patient|failure|. (l_nsubj) patient_1\NN\case.n.06|a|with|and|disseminated (l_conj) disseminated_6\VBN\publicize.v.01|sporotrichosis (l_dobj) sporotrichosis_7\NN\fungal_infection.n.01|
20003049
C031942_D013921 NONE argatroban_4\NN\entity.n.01|elevation|in|. (l_prep) in_5\IN\linear_unit.n.01|patient (l_pobj) patient_9\NN\case.n.06|a|transplant|with (l_prep) with_10\IN\entity.n.01|history (l_pobj) history_13\NN\past.n.01|a|suspected|of (l_prep) of_14\IN\entity.n.01|thrombocytopenia (l_pobj) thrombocytopenia_18\NN\blood_disease.n.01|induced|with
C031942_D013921 NONE argatroban_20\NN\entity.n.01|for (r_oprd) administered_19\VBN\manage.v.02|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ\case.n.06|a|old|ill|with (l_prep) with_12\IN\entity.n.01|history (l_pobj) history_15\NN\past.n.01|a|suspected|of (l_prep) of_16\IN\entity.n.01|hitt (l_pobj) hitt_17\NNP\entity.n.01|
C031942_D013927 NONE argatroban_4\NN\entity.n.01|elevation|in|. (l_prep) in_5\IN\linear_unit.n.01|patient (l_pobj) patient_9\NN\case.n.06|a|transplant|with (l_prep) with_10\IN\entity.n.01|history (l_pobj) history_13\NN\past.n.01|a|suspected|of (l_prep) of_14\IN\entity.n.01|thrombocytopenia (l_pobj) thrombocytopenia_18\NN\blood_disease.n.01|induced|with (l_prep) with_19\IN\entity.n.01|thrombosis (l_pobj) thrombosis_20\NN\occlusion.n.01|
C031942_D013927 NONE argatroban_20\NN\entity.n.01|for (r_oprd) administered_19\VBN\manage.v.02|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ\case.n.06|a|old|ill|with (l_prep) with_12\IN\entity.n.01|history (l_pobj) history_15\NN\past.n.01|a|suspected|of (l_prep) of_16\IN\entity.n.01|hitt (l_pobj) hitt_17\NNP\entity.n.01|
D006493_D013921 NONE heparin_15\NN\anticoagulant.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_18\NN\blood_disease.n.01|induced|with
D006493_D013921 NONE heparin_18\NN\anticoagulant.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_21\NN\blood_disease.n.01|induced|(|hit
D006493_D013921 NONE heparin_18\NN\anticoagulant.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_21\NN\blood_disease.n.01|induced|(|hit (l_appos) hit_23\NNP\feat.n.01|)
D006493_D013921 NONE heparin_18\NN\anticoagulant.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_21\NN\blood_disease.n.01|induced|(|hit (r_pobj) of_17\IN\entity.n.01|thrombocytopenia (r_prep) history_16\NN\past.n.01|a|of (r_pobj) with_14\IN\entity.n.01|history (r_prep) patients_13\NNS\case.n.06|with (r_pobj) for_12\IN\entity.n.01|patients (r_prep) anticoagulation_11\NN\medical_care.n.01|for (r_pobj) of_10\IN\entity.n.01|anticoagulation (r_prep) method_9\NN\know-how.n.01|an|alternative|of (r_dobj) provide_6\VBP\give.v.03|inhibitors|method|or|hit|. (l_conj) hit_26\VB\feat.n.01|with|undergoing
D006493_D013921 NONE heparin_18\NN\anticoagulant.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_21\NN\blood_disease.n.01|induced|(|hit (r_pobj) of_17\IN\entity.n.01|thrombocytopenia (r_prep) history_16\NN\past.n.01|a|of (r_pobj) with_14\IN\entity.n.01|history (r_prep) patients_13\NNS\case.n.06|with (r_pobj) for_12\IN\entity.n.01|patients (r_prep) anticoagulation_11\NN\medical_care.n.01|for (r_pobj) of_10\IN\entity.n.01|anticoagulation (r_prep) method_9\NN\know-how.n.01|an|alternative|of (r_dobj) provide_6\VBP\give.v.03|inhibitors|method|or|hit|. (l_conj) hit_26\VB\feat.n.01|with|undergoing (l_prep) with_27\IN\entity.n.01|thrombosis (l_pobj) thrombosis_28\NN\occlusion.n.01|hitt (l_appos) hitt_30\NNP\entity.n.01|(|)
D006493_D013927 NONE heparin_15\NN\anticoagulant.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_18\NN\blood_disease.n.01|induced|with (l_prep) with_19\IN\entity.n.01|thrombosis (l_pobj) thrombosis_20\NN\occlusion.n.01|
D006493_D013927 NONE heparin_18\NN\anticoagulant.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_21\NN\blood_disease.n.01|induced|(|hit (r_pobj) of_17\IN\entity.n.01|thrombocytopenia (r_prep) history_16\NN\past.n.01|a|of (r_pobj) with_14\IN\entity.n.01|history (r_prep) patients_13\NNS\case.n.06|with (r_pobj) for_12\IN\entity.n.01|patients (r_prep) anticoagulation_11\NN\medical_care.n.01|for (r_pobj) of_10\IN\entity.n.01|anticoagulation (r_prep) method_9\NN\know-how.n.01|an|alternative|of (r_dobj) provide_6\VBP\give.v.03|inhibitors|method|or|hit|. (l_conj) hit_26\VB\feat.n.01|with|undergoing (l_prep) with_27\IN\entity.n.01|thrombosis (l_pobj) thrombosis_28\NN\occlusion.n.01|hitt
D006493_D013927 NONE heparin_18\NN\anticoagulant.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|heparin|- (r_amod) thrombocytopenia_21\NN\blood_disease.n.01|induced|(|hit (r_pobj) of_17\IN\entity.n.01|thrombocytopenia (r_prep) history_16\NN\past.n.01|a|of (r_pobj) with_14\IN\entity.n.01|history (r_prep) patients_13\NNS\case.n.06|with (r_pobj) for_12\IN\entity.n.01|patients (r_prep) anticoagulation_11\NN\medical_care.n.01|for (r_pobj) of_10\IN\entity.n.01|anticoagulation (r_prep) method_9\NN\know-how.n.01|an|alternative|of (r_dobj) provide_6\VBP\give.v.03|inhibitors|method|or|hit|. (l_conj) hit_26\VB\feat.n.01|with|undergoing (l_prep) with_27\IN\entity.n.01|thrombosis (l_pobj) thrombosis_28\NN\occlusion.n.01|hitt (l_appos) hitt_30\NNP\entity.n.01|(|)
C031942_D016638 NONE argatroban_20\NN\entity.n.01|for (r_oprd) administered_19\VBN\manage.v.02|in|,|patient|was|argatroban|during|. (l_nsubjpass) patient_11\JJ\case.n.06|a|old|ill|with (l_amod) ill_10\JJ\disorder.n.01|critically
C031942_D008107 NONE argatroban_4\NN\entity.n.01| (r_pobj) of_3\IN\entity.n.01|argatroban (r_prep) concentrations_2\NNS\property.n.02|high|of (r_nsubjpass) measured_6\VBN\decide.v.01|concentrations|were|in|,|and|observed|is|. (l_conj) is_42\VBZ\be.v.01|minutes|) (l_attr) minutes_46\NNS\written_record.n.01|39|51|[|minutes|] (l_appos) minutes_52\NNS\written_record.n.01|<|=|181|with (l_prep) with_53\IN\entity.n.01|impairment (l_pobj) impairment_55\NN\change.n.01|hepatic
C031942_D008107 NONE argatroban_25\JJ\entity.n.01| (r_amod) life_27\NN\being.n.01|argatroban|half|t(1/2 (r_npadvmod) plasma_24\NN\extracellular_fluid.n.01|a|prolonged|life|)|of (r_nsubjpass) observed_36\VBN\spy.v.03|plasma|was|published (r_conj) measured_6\VBN\decide.v.01|concentrations|were|in|,|and|observed|is|. (l_conj) is_42\VBZ\be.v.01|minutes|) (l_attr) minutes_46\NNS\written_record.n.01|39|51|[|minutes|] (l_appos) minutes_52\NNS\written_record.n.01|<|=|181|with (l_prep) with_53\IN\entity.n.01|impairment (l_pobj) impairment_55\NN\change.n.01|hepatic
C031942_D001778 NONE argatroban_3\JJ\entity.n.01| (r_amod) concentration_4\NN\property.n.02|correlation|argatroban|versus (r_nsubj) suggest_14\VBP\declare.v.01|concentration|contributed|. (l_ccomp) contributed_24\VBN\change.v.01|that|levels|may|have|to (l_prep) to_25\IN\entity.n.01|coagulopathy (l_pobj) coagulopathy_30\NN\entity.n.01|patient|extended
C031942_D001778 NONE argatroban_21\NN\entity.n.01| (r_amod) levels_18\NNS\property.n.02|prolonged|elevated|of|argatroban (r_nsubj) contributed_24\VBN\change.v.01|that|levels|may|have|to (l_prep) to_25\IN\entity.n.01|coagulopathy (l_pobj) coagulopathy_30\NN\entity.n.01|patient|extended
C031942_D001778 NONE argatroban_8\JJ\entity.n.01| (r_amod) concentration_9\NN\property.n.02|argatroban|in (r_dobj) measure_6\VB\maneuver.n.04|to|plasma|concentration|and|extended (l_conj) extended_16\VBN\increase.v.02|coagulopathy (l_dobj) coagulopathy_17\NN\entity.n.01|
7265370
D014223_D053040 CID triamterene_0\JJ\entity.n.01| (r_compound) nephrolithiasis_1\JJ\lithiasis.n.01|triamterene
D014223_D053040 CID triamterene_3\JJ\entity.n.01| (r_compound) nephrolithiasis_4\NN\lithiasis.n.01|triamterene
D014223_D053040 CID triamterene_2\JJ\entity.n.01| (r_compound) nephrolithiasis_3\NN\lithiasis.n.01|triamterene
C020743_D053040 NONE dyazide_3\RB\entity.n.01| (r_compound) therapy_4\NN\medical_care.n.01|dyazide (r_dobj) complicating_2\VBG\change.v.01|nephrolithiasis|therapy|. (l_nsubj) nephrolithiasis_1\JJ\lithiasis.n.01|triamterene
C020743_D053040 NONE triamterene_16\JJ\entity.n.01|hydrochlorothiazide|- (r_compound) therapy_17\NN\medical_care.n.01|triamterene (r_pobj) of_13\IN\entity.n.01|therapy (r_prep) years_12\NNS\time_of_life.n.01|4|of|for (r_pobj) after_10\IN\after.s.01|years (r_prep) reported_6\VBN\inform.v.01|case|is|in|after|. (l_nsubjpass) case_1\NN\happening.n.01|a|of (l_prep) of_2\IN\entity.n.01|nephrolithiasis (l_pobj) nephrolithiasis_4\NN\lithiasis.n.01|triamterene
D014223_D006973 NONE triamterene_3\JJ\entity.n.01| (r_compound) nephrolithiasis_4\NN\lithiasis.n.01|triamterene (r_pobj) of_2\IN\entity.n.01|nephrolithiasis (r_prep) case_1\NN\happening.n.01|a|of (r_nsubjpass) reported_6\VBN\inform.v.01|case|is|in|after|. (l_prep) after_10\IN\after.s.01|years (l_pobj) years_12\NNS\time_of_life.n.01|4|of|for (l_prep) for_18\IN\entity.n.01|hypertension (l_pobj) hypertension_19\NN\cardiovascular_disease.n.01|
C020743_D006973 NONE triamterene_16\JJ\entity.n.01|hydrochlorothiazide|- (r_compound) therapy_17\NN\medical_care.n.01|triamterene (r_pobj) of_13\IN\entity.n.01|therapy (r_prep) years_12\NNS\time_of_life.n.01|4|of|for (l_prep) for_18\IN\entity.n.01|hypertension (l_pobj) hypertension_19\NN\cardiovascular_disease.n.01|
9522152
D002045_D009461 NONE bupivacaine_11\NN\entity.n.01|%|hyperbaric|for (r_pobj) of_7\IN\entity.n.01|bupivacaine (r_prep) injection_6\NN\insertion.n.02|intrathecal|of (r_dobj) following_4\VBG\multitude.n.03|injection (r_acl) deficit_3\NN\insufficiency.n.03|a|transient|neurological|following|.
D002045_D009461 NONE bupivacaine_21\NN\entity.n.01|%|hyperbaric (r_pobj) with_14\IN\entity.n.01|bupivacaine (r_prep) anaesthesia_13\NN\physical_condition.n.01|unilateral|spinal|with (r_pobj) after_10\IN\after.s.01|anaesthesia (r_prep) occurred_9\VBD\happen.v.01|that|after (r_relcl) deficit_7\NN\insufficiency.n.03|transient|neurological|occurred
10901305
D007649_D050723 NONE ketamine_0\NN\club_drug.n.01|sedation|. (l_dobj) sedation_1\NN\physical_condition.n.01|for (l_prep) for_2\IN\entity.n.01|reduction (l_pobj) reduction_4\NN\change_of_magnitude.n.01|the|of (l_prep) of_5\IN\entity.n.01|fractures (l_pobj) fractures_8\NNS\injury.n.01|children|in
D007649_D050723 NONE ketamine_14\NN\club_drug.n.01|for (l_prep) for_15\IN\entity.n.01|sedation (l_pobj) sedation_16\NN\physical_condition.n.01|in (l_prep) in_17\IN\linear_unit.n.01|treatment (l_pobj) treatment_19\NN\care.n.01|the|of (l_prep) of_20\IN\entity.n.01|fractures (l_pobj) fractures_23\NNS\injury.n.01|children|in
D007649_D050723 NONE ketamine_7\NN\club_drug.n.01|to (l_prep) to_8\IN\entity.n.01|manipulation (l_pobj) manipulation_9\NN\influence.n.02|of (l_prep) of_10\IN\entity.n.01|fracture (l_pobj) fracture_12\NN\injury.n.01|the|or|dislocation
D007649_D050723 NONE ketamine_0\NNP\club_drug.n.01| (r_nsubj) provided_7\VBD\give.v.03|ketamine|reliably|quickly|sedation|. (l_dobj) sedation_9\NN\physical_condition.n.01|adequate|facilitate (l_acl) facilitate_12\VB\help.v.01|to|effectively|reduction (l_dobj) reduction_14\NN\change_of_magnitude.n.01|the|of (l_prep) of_15\IN\entity.n.01|fractures (l_pobj) fractures_18\NNS\injury.n.01|children|in
D007649_D004204 NONE ketamine_7\NN\club_drug.n.01|to (l_prep) to_8\IN\entity.n.01|manipulation (l_pobj) manipulation_9\NN\influence.n.02|of (l_prep) of_10\IN\entity.n.01|fracture (l_pobj) fracture_12\NN\injury.n.01|the|or|dislocation (l_conj) dislocation_14\NN\interruption.n.02|
8231633
D002118_D064420 NONE calcium_2\NN\metallic_element.n.01| (r_compound) channel_3\NN\transmission.n.02|calcium (r_compound) blockers_4\NNS\football_player.n.01|channel|on (l_prep) on_5\IN\on.a.01|toxicity (l_pobj) toxicity_9\NN\definite_quantity.n.01|induced
D002118_D064420 NONE calcium_11\NN\metallic_element.n.01| (r_compound) channel_12\NN\transmission.n.02|calcium (r_compound) blockers_13\NNS\football_player.n.01|channel|on (l_prep) on_14\IN\on.a.01|toxicity (l_pobj) toxicity_19\NN\definite_quantity.n.01|induced|acute
D002045_D064420 NONE bupivacaine_6\NN\entity.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|bupivacaine|- (r_amod) toxicity_9\NN\definite_quantity.n.01|induced
D002045_D064420 NONE bupivacaine_15\NN\entity.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|bupivacaine|- (r_amod) toxicity_19\NN\definite_quantity.n.01|induced|acute
D002045_D012640 CID bupivacaine_4\NN\entity.n.01| (r_pobj) of_3\IN\entity.n.01|bupivacaine (r_prep) activity_2\NN\act.n.02|the|convulsant|of (r_nsubj) was_5\VBD\washington.n.02|activity (r_auxpass) modified_8\VBN\change.v.02|was|not|significantly|but|decreased (l_conj) decreased_13\VBD\change_magnitude.v.01|blockers|time (l_dobj) time_15\NN\case.n.01|the|of|obtain (l_relcl) obtain_19\VB\get.v.01|to|convulsions (l_dobj) convulsions_23\NNS\attack.n.07|induced
D002045_D012640 CID bupivacaine_20\NN\entity.n.01| (r_npadvmod) induced_22\VBN\generate.v.01|bupivacaine|- (r_amod) convulsions_23\NNS\attack.n.07|induced
D002118_D012640 NONE calcium_10\NN\metallic_element.n.01| (r_compound) channel_11\NN\transmission.n.02|calcium (r_compound) blockers_12\NNS\football_player.n.01|channel (r_nsubj) decreased_13\VBD\change_magnitude.v.01|blockers|time (l_dobj) time_15\NN\case.n.01|the|of|obtain (l_relcl) obtain_19\VB\get.v.01|to|convulsions (l_dobj) convulsions_23\NNS\attack.n.07|induced
D015764_D012640 NONE bepridil_31\NN\entity.n.01| (r_pcomp) with_30\IN\entity.n.01|bepridil (r_prep) pronounced_29\VBN\pronounce.v.01|less|with (r_acomp) was_27\VBD\washington.n.02|modified|;|effect|pronounced|. (l_ccomp) modified_8\VBN\change.v.02|was|not|significantly|but|decreased (l_conj) decreased_13\VBD\change_magnitude.v.01|blockers|time (l_dobj) time_15\NN\case.n.01|the|of|obtain (l_relcl) obtain_19\VB\get.v.01|to|convulsions (l_dobj) convulsions_23\NNS\attack.n.07|induced
6666578
D010396_D001018 CID penicillamine_2\NN\medicine.n.02|d|- (r_compound) induced_4\VBN\generate.v.01|penicillamine|-|angiopathy|in|. (l_advmod) angiopathy_5\NN\pathology.n.02|
14659530
D009569_D008881 NONE no_0\RB\negative.n.01| (r_intj) induced_2\VBN\generate.v.01|no|- (r_amod) attack_4\NN\operation.n.05|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\headache.n.02|
D015740_D008881 NONE peptide_14\NN\amide.n.01|plasma|calcitonin|related|concentration (r_pobj) in_8\IN\linear_unit.n.01|peptide (r_prep) increase_7\NN\indefinite_quantity.n.01|strong|in (r_appos) attack_4\NN\operation.n.05|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\headache.n.02|
D015740_D008881 NONE cgrp_16\NN\entity.n.01| (r_nmod) concentration_18\NN\property.n.02|(|cgrp|)|and|correlation (r_appos) peptide_14\NN\amide.n.01|plasma|calcitonin|related|concentration (r_pobj) in_8\IN\linear_unit.n.01|peptide (r_prep) increase_7\NN\indefinite_quantity.n.01|strong|in (r_appos) attack_4\NN\operation.n.05|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\headache.n.02|
D015740_D008881 NONE peptide_17\NN\amide.n.01|the|plasma|calcitonin|related (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (r_dobj) investigate_8\VB\analyze.v.01|to|changes|and|attack (l_conj) attack_40\NN\operation.n.05|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\headache.n.02|
D015740_D008881 NONE cgrp_19\NN\entity.n.01| (r_nmod) concentration_21\NN\property.n.02|(|cgrp|)|and (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (r_dobj) investigate_8\VB\analyze.v.01|to|changes|and|attack (l_conj) attack_40\NN\operation.n.05|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\headache.n.02|
D015740_D008881 NONE cgrp_1\NN\entity.n.01| (r_compound) concentration_2\NN\property.n.02|plasma|cgrp (r_nsubj) increased_3\VBD\change_magnitude.v.01|concentration|significantly|p<0.01|during|and|returned|. (l_prep) during_8\IN\entity.n.01|attack (l_pobj) attack_11\NN\operation.n.05|the|migraine (l_compound) migraine_10\JJ\headache.n.02|
D015740_D008881 NONE cgrp_1\NN\entity.n.01| (r_compound) concentration_2\NN\property.n.02|plasma|cgrp (r_nsubj) increased_3\VBD\change_magnitude.v.01|concentration|significantly|p<0.01|during|and|returned|. (l_conj) returned_13\VBD\travel.v.01|to|after (l_prep) after_16\IN\after.s.01|cessation (l_pobj) cessation_18\NN\stop.n.01|the|of (l_prep) of_19\IN\entity.n.01|migraine (l_pobj) migraine_21\NN\headache.n.02|the
D015740_D008881 NONE cgrp_3\NNP\entity.n.01| (r_compound) concentrations_4\NNS\property.n.02|plasma|cgrp (r_nsubj) failed_5\VBD\fail.v.01|however|,|concentrations|change|. (l_xcomp) change_7\VB\happening.n.01|to|during (l_prep) during_8\IN\entity.n.01|headache|and|in (l_conj) in_12\IN\linear_unit.n.01|subjects (l_pobj) subjects_14\NNS\message.n.02|the|with (l_prep) with_15\IN\entity.n.01|attack (l_pobj) attack_18\NN\operation.n.05|no|migraine (l_compound) migraine_17\JJ\headache.n.02|
D015740_D008881 NONE cgrp_1\NNP\entity.n.01| (r_compound) concentration_2\NN\property.n.02|basal|cgrp (r_nsubj) was_3\VBD\washington.n.02|concentration|higher|and|platelet|. (l_conj) platelet_7\NN\protoplasm.n.01|tended (l_ccomp) tended_10\VBD\be.v.01|content|be (l_xcomp) be_12\VB\metallic_element.n.01|to|lower|in (l_prep) in_14\IN\linear_unit.n.01|subjects (l_pobj) subjects_15\NNS\message.n.02|experienced (l_relcl) experienced_17\VBD\undergo.v.01|who|attack (l_dobj) attack_20\NN\operation.n.05|a|migraine (l_compound) migraine_19\JJ\headache.n.02|
D015740_D008881 NONE cgrp_7\NN\entity.n.01| (r_compound) concentration_8\NN\property.n.02|plasma|cgrp (r_nsubj) correlates_9\VBZ\variable.n.02|that|concentration|with (l_prep) with_10\IN\entity.n.01|timing (l_pobj) timing_12\NN\temporal_arrangement.n.01|the|and|severity|of (l_prep) of_15\IN\entity.n.01|headache (l_pobj) headache_18\NN\negative_stimulus.n.01|a|migraine (l_compound) migraine_17\JJ\headache.n.02|
D015740_D008881 NONE cgrp_7\NN\entity.n.01| (r_compound) concentration_8\NN\property.n.02|plasma|cgrp (r_nsubj) correlates_9\VBZ\variable.n.02|that|concentration|with (r_acl) fact_4\NN\information.n.02|the|correlates (r_nsubj) suggests_19\VBZ\declare.v.01|in|,|fact|relationship|. (l_dobj) relationship_22\NN\relation.n.01|a|direct|between (l_prep) between_23\IN\between.r.01|cgrp (l_pobj) cgrp_24\NN\entity.n.01|and|migraine (l_conj) migraine_26\NN\headache.n.02|
D015740_D008881 NONE cgrp_24\NN\entity.n.01|and|migraine (r_pobj) between_23\IN\between.r.01|cgrp (r_prep) relationship_22\NN\relation.n.01|a|direct|between (r_dobj) suggests_19\VBZ\declare.v.01|in|,|fact|relationship|. (l_nsubj) fact_4\NN\information.n.02|the|correlates (l_acl) correlates_9\VBZ\variable.n.02|that|concentration|with (l_prep) with_10\IN\entity.n.01|timing (l_pobj) timing_12\NN\temporal_arrangement.n.01|the|and|severity|of (l_prep) of_15\IN\entity.n.01|headache (l_pobj) headache_18\NN\negative_stimulus.n.01|a|migraine (l_compound) migraine_17\JJ\headache.n.02|
D015740_D008881 NONE cgrp_24\NN\entity.n.01|and|migraine (l_conj) migraine_26\NN\headache.n.02|
D015740_D008881 NONE cgrp_21\NN\entity.n.01| (r_compound) release_22\NN\merchandise.n.01|the|concomitant|cgrp|in (r_conj) headache_17\NN\negative_stimulus.n.01|the|and|release (r_dobj) counteract_15\VB\act.v.01|provoke|,|it|may|even|headache|. (l_ccomp) provoke_9\VB\make.v.03|in|,|release|does|not|migraine (l_dobj) migraine_10\NN\headache.n.02|
D012701_D008881 NONE serotonin_24\NN\monoamine_neurotransmitter.n.01|platelet (r_compound) release_25\NN\merchandise.n.01|serotonin (r_pobj) with_22\IN\entity.n.01|release (r_prep) correlation_21\NN\reciprocality.n.01|negative|with (r_conj) concentration_18\NN\property.n.02|(|cgrp|)|and|correlation (r_appos) peptide_14\NN\amide.n.01|plasma|calcitonin|related|concentration (r_pobj) in_8\IN\linear_unit.n.01|peptide (r_prep) increase_7\NN\indefinite_quantity.n.01|strong|in (r_appos) attack_4\NN\operation.n.05|induced|migraine|:|increase|. (l_compound) migraine_3\JJ\headache.n.02|
D012701_D008881 NONE serotonin_24\NN\monoamine_neurotransmitter.n.01|platelet (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (r_dobj) investigate_8\VB\analyze.v.01|to|changes|and|attack (l_conj) attack_40\NN\operation.n.05|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\headache.n.02|
D012701_D008881 NONE 5-hydroxytriptamine_26\NN\entity.n.01|( (r_punct) ,_27\,\entity.n.01|5-hydroxytriptamine (r_punct) 5-ht_28\CD\entity.n.01|, (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (r_dobj) investigate_8\VB\analyze.v.01|to|changes|and|attack (l_conj) attack_40\NN\operation.n.05|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\headache.n.02|
D012701_D008881 NONE 5-ht_28\CD\entity.n.01|, (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (r_dobj) investigate_8\VB\analyze.v.01|to|changes|and|attack (l_conj) attack_40\NN\operation.n.05|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\headache.n.02|
D012701_D008881 NONE 5-ht_8\CD\entity.n.01| (r_nummod) content_9\NN\collection.n.01|5-ht (r_nsubj) tended_10\VBD\be.v.01|content|be (l_xcomp) be_12\VB\metallic_element.n.01|to|lower|in (l_prep) in_14\IN\linear_unit.n.01|subjects (l_pobj) subjects_15\NNS\message.n.02|experienced (l_relcl) experienced_17\VBD\undergo.v.01|who|attack (l_dobj) attack_20\NN\operation.n.05|a|migraine (l_compound) migraine_19\JJ\headache.n.02|
D012701_D008881 NONE serotonin_1\NN\monoamine_neurotransmitter.n.01|platelet (r_compound) content_2\NN\collection.n.01|serotonin (r_nsubj) decreased_3\VBD\change_magnitude.v.01|content|significantly|p<0.01|after|but|observed (l_prep) after_8\IN\after.s.01|nitroglycerin (l_pobj) nitroglycerin_9\NN\nitrate.n.01|in (l_prep) in_10\IN\linear_unit.n.01|subjects (l_pobj) subjects_11\NNS\message.n.02|with (l_prep) with_12\IN\entity.n.01|attack (l_pobj) attack_15\NN\operation.n.05|no|migraine (l_compound) migraine_14\JJ\headache.n.02|
D012701_D008881 NONE serotonin_1\NN\monoamine_neurotransmitter.n.01|platelet (r_compound) content_2\NN\collection.n.01|serotonin (r_nsubj) decreased_3\VBD\change_magnitude.v.01|content|significantly|p<0.01|after|but|observed (l_conj) observed_21\VBN\spy.v.03|change|was|in|. (l_prep) in_22\IN\linear_unit.n.01|patients (l_pobj) patients_23\NNS\case.n.06|with (l_prep) with_24\IN\entity.n.01|attack (l_pobj) attack_26\NN\operation.n.05|migraine (l_compound) migraine_25\JJ\headache.n.02|
D012701_D008881 NONE serotonin_3\NN\monoamine_neurotransmitter.n.01| (r_compound) release_4\NN\merchandise.n.01|serotonin|from (r_nsubj) provoke_9\VB\make.v.03|in|,|release|does|not|migraine (l_dobj) migraine_10\NN\headache.n.02|
D015740_D006261 NONE peptide_17\NN\amide.n.01|the|plasma|calcitonin|related (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (l_prep) during_31\IN\entity.n.01|headache (l_pobj) headache_34\NN\negative_stimulus.n.01|the|immediate
D015740_D006261 NONE cgrp_19\NN\entity.n.01| (r_nmod) concentration_21\NN\property.n.02|(|cgrp|)|and (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (l_prep) during_31\IN\entity.n.01|headache (l_pobj) headache_34\NN\negative_stimulus.n.01|the|immediate
D015740_D006261 NONE cgrp_3\NNP\entity.n.01| (r_compound) concentrations_4\NNS\property.n.02|plasma|cgrp (r_nsubj) failed_5\VBD\fail.v.01|however|,|concentrations|change|. (l_xcomp) change_7\VB\happening.n.01|to|during (l_prep) during_8\IN\entity.n.01|headache|and|in (l_pobj) headache_10\NN\negative_stimulus.n.01|immediate
D015740_D006261 NONE cgrp_7\NN\entity.n.01| (r_compound) concentration_8\NN\property.n.02|plasma|cgrp (r_nsubj) correlates_9\VBZ\variable.n.02|that|concentration|with (l_prep) with_10\IN\entity.n.01|timing (l_pobj) timing_12\NN\temporal_arrangement.n.01|the|and|severity|of (l_prep) of_15\IN\entity.n.01|headache (l_pobj) headache_18\NN\negative_stimulus.n.01|a|migraine
D015740_D006261 NONE cgrp_24\NN\entity.n.01|and|migraine (r_pobj) between_23\IN\between.r.01|cgrp (r_prep) relationship_22\NN\relation.n.01|a|direct|between (r_dobj) suggests_19\VBZ\declare.v.01|in|,|fact|relationship|. (l_nsubj) fact_4\NN\information.n.02|the|correlates (l_acl) correlates_9\VBZ\variable.n.02|that|concentration|with (l_prep) with_10\IN\entity.n.01|timing (l_pobj) timing_12\NN\temporal_arrangement.n.01|the|and|severity|of (l_prep) of_15\IN\entity.n.01|headache (l_pobj) headache_18\NN\negative_stimulus.n.01|a|migraine
D015740_D006261 NONE cgrp_21\NN\entity.n.01| (r_compound) release_22\NN\merchandise.n.01|the|concomitant|cgrp|in (r_conj) headache_17\NN\negative_stimulus.n.01|the|and|release
D012701_D006261 NONE serotonin_24\NN\monoamine_neurotransmitter.n.01|platelet (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (l_prep) during_31\IN\entity.n.01|headache (l_pobj) headache_34\NN\negative_stimulus.n.01|the|immediate
D012701_D006261 NONE 5-hydroxytriptamine_26\NN\entity.n.01|( (r_punct) ,_27\,\entity.n.01|5-hydroxytriptamine (r_punct) 5-ht_28\CD\entity.n.01|, (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (l_prep) during_31\IN\entity.n.01|headache (l_pobj) headache_34\NN\negative_stimulus.n.01|the|immediate
D012701_D006261 NONE 5-ht_28\CD\entity.n.01|, (r_nmod) content_30\NN\collection.n.01|peptide|concentration|serotonin|5-ht|) (r_pobj) in_10\IN\linear_unit.n.01|content (r_prep) changes_9\NNS\happening.n.01|in|during (l_prep) during_31\IN\entity.n.01|headache (l_pobj) headache_34\NN\negative_stimulus.n.01|the|immediate
D012701_D006261 NONE serotonin_3\NN\monoamine_neurotransmitter.n.01| (r_compound) release_4\NN\merchandise.n.01|serotonin|from (r_nsubj) provoke_9\VB\make.v.03|in|,|release|does|not|migraine (r_ccomp) counteract_15\VB\act.v.01|provoke|,|it|may|even|headache|. (l_dobj) headache_17\NN\negative_stimulus.n.01|the|and|release
D005996_D006261 NONE nitroglycerin_43\NN\nitrate.n.01| (r_pobj) by_42\IN\by.r.01|nitroglycerin (r_agent) provoked_41\VBN\make.v.03|by (r_acl) attack_40\NN\operation.n.05|the|delayed|genuine|migraine|provoked (r_conj) investigate_8\VB\analyze.v.01|to|changes|and|attack (l_dobj) changes_9\NNS\happening.n.01|in|during (l_prep) during_31\IN\entity.n.01|headache (l_pobj) headache_34\NN\negative_stimulus.n.01|the|immediate
D005996_D008881 NONE nitroglycerin_43\NN\nitrate.n.01| (r_pobj) by_42\IN\by.r.01|nitroglycerin (r_agent) provoked_41\VBN\make.v.03|by (r_acl) attack_40\NN\operation.n.05|the|delayed|genuine|migraine|provoked (l_compound) migraine_39\JJ\headache.n.02|
D005996_D008881 NONE nitroglycerin_16\NN\nitrate.n.01| (r_compound) application_17\NN\use.n.01|the|nitroglycerin (r_pobj) after_14\IN\after.s.01|application (r_conj) before_12\RB\earlier.r.01|min|and|after (r_advmod) collected_2\VBN\store.v.01|blood|was|from|times|before|,|and|min (l_conj) min_23\NN\time_unit.n.01|60|after|;|subjects|. (l_prep) after_24\IN\after.s.01|beginning (l_pobj) beginning_26\NN\happening.n.01|the|of (l_prep) of_27\IN\entity.n.01|attack (l_pobj) attack_30\NN\operation.n.05|the|migraine|mean (l_compound) migraine_29\JJ\headache.n.02|
D005996_D008881 NONE nitroglycerin_9\NN\nitrate.n.01|in (l_prep) in_10\IN\linear_unit.n.01|subjects (l_pobj) subjects_11\NNS\message.n.02|with (l_prep) with_12\IN\entity.n.01|attack (l_pobj) attack_15\NN\operation.n.05|no|migraine (l_compound) migraine_14\JJ\headache.n.02|
D005996_D008881 NONE nitroglycerin_9\NN\nitrate.n.01|in (r_pobj) after_8\IN\after.s.01|nitroglycerin (r_prep) decreased_3\VBD\change_magnitude.v.01|content|significantly|p<0.01|after|but|observed (l_conj) observed_21\VBN\spy.v.03|change|was|in|. (l_prep) in_22\IN\linear_unit.n.01|patients (l_pobj) patients_23\NNS\case.n.06|with (l_prep) with_24\IN\entity.n.01|attack (l_pobj) attack_26\NN\operation.n.05|migraine (l_compound) migraine_25\JJ\headache.n.02|
17241784
D019821_D009135 CID statin_12\NN\medicine.n.02| (r_compound) therapy_13\NN\medical_care.n.01|statin (r_pobj) with_11\IN\entity.n.01|therapy (r_prep) associated_10\VBD\think.v.03|with (r_acl) myopathy_1\NNS\pathology.n.02|progressive|with|associated|.
D019821_D009135 CID statins_0\NNS\medicine.n.02| (r_nsubj) cause_2\VB\origin.n.03|statins|can|necrotizing|myopathy|. (l_ccomp) myopathy_5\NN\pathology.n.02|and|hyperckaemia
D019821_D009135 CID statins_9\NNS\medicine.n.02| (r_nsubj) induce_11\VB\generate.v.01|whereby|statins|may|myopathy (l_dobj) myopathy_13\NN\pathology.n.02|a
D019821_D009135 CID statins_4\NNS\medicine.n.02| (r_nsubj) initiate_6\VB\unskilled_person.n.01|that|statins|may|myopathy (l_dobj) myopathy_11\NN\pathology.n.02|an|mediated|persists
D019821_D009135 CID statins_13\NNS\medicine.n.02|of (r_pobj) by_12\IN\by.r.01|statins (r_prep) induction_11\NN\ceremony.n.01|the|by (r_dobj) involve_9\VB\refer.v.02|may|induction (r_conj) is_5\VBZ\be.v.01|mechanism|uncertain|but|involve|. (l_nsubj) mechanism_1\NN\chemical_process.n.01|the|of (l_prep) of_2\IN\entity.n.01|myopathy (l_pobj) myopathy_4\NN\pathology.n.02|this
D019821_-1 NONE statins_0\NNS\medicine.n.02| (r_nsubj) cause_2\VB\origin.n.03|statins|can|necrotizing|myopathy|. (l_ccomp) myopathy_5\NN\pathology.n.02|and|hyperckaemia (l_conj) hyperckaemia_7\NN\entity.n.01|
15602202
D017963_D009395 CID azithromycin_6\PRP\antibacterial.n.01| (r_pobj) by_5\IN\by.r.01|azithromycin (r_prep) induced_4\VBN\generate.v.01|nephritis|by|. (l_nsubj) nephritis_3\NN\kidney_disease.n.01|recurrent|acute|interstitial
D017963_D009395 CID azithromycin_10\RB\antibacterial.n.01| (r_advmod) induced_12\VBN\generate.v.01|azithromycin|- (r_amod) nephritis_16\NN\kidney_disease.n.01|induced|,|acute|interstitial
7444978
D013307_D020258 NONE streptomycin_11\NNS\antibiotic.n.01| (r_pobj) of_10\IN\entity.n.01|streptomycin (r_prep) effects_9\NNS\personal_property.n.01|neurotoxic|of (l_amod) neurotoxic_8\JJ\neurotoxic.a.01|
D013307_D004409 CID streptomycin_48\NNS\antibiotic.n.01|than (r_pobj) to_47\IN\entity.n.01|streptomycin (r_prep) sensitive_46\JJ\psychic.n.01|more|to (r_acomp) is_44\VBZ\be.v.01|that|cochlea|sensitive (r_ccomp) indicating_40\VBG\tell.v.02|is (r_advcl) occurred_23\VBD\happen.v.01|occurred|;|within|sensitivities|from|,|indicating|. (l_ccomp) occurred_4\VBD\happen.v.01|movements|in (l_nsubj) movements_1\NNS\change.n.03|abnormal|and|deafness
D013307_D004409 CID streptomycin_48\NNS\antibiotic.n.01|than (l_prep) than_49\IN\entity.n.01|site (l_pobj) site_51\NN\tract.n.01|the|(|vestibular|)|responsible (l_amod) responsible_57\JJ\responsible.a.01|for (l_prep) for_58\IN\entity.n.01|dyskinesias (l_pobj) dyskinesias_60\NNS\nervous_disorder.n.01|the
D013307_D003638 CID streptomycin_48\NNS\antibiotic.n.01|than (r_pobj) to_47\IN\entity.n.01|streptomycin (r_prep) sensitive_46\JJ\psychic.n.01|more|to (r_acomp) is_44\VBZ\be.v.01|that|cochlea|sensitive (r_ccomp) indicating_40\VBG\tell.v.02|is (r_advcl) occurred_23\VBD\happen.v.01|occurred|;|within|sensitivities|from|,|indicating|. (l_ccomp) occurred_4\VBD\happen.v.01|movements|in (l_nsubj) movements_1\NNS\change.n.03|abnormal|and|deafness (l_conj) deafness_3\NN\hearing_impairment.n.01|
8437969
D002927_D054138 CID cimetidine_7\NN\antacid.n.01|infusion (r_pobj) with_3\IN\entity.n.01|cimetidine (r_prep) associated_2\VBN\think.v.03|with (r_acl) arrest_1\NN\capture.n.01|sinus|associated|.
D002927_D054138 CID cimetidine_27\NN\antacid.n.01|infusion (r_dobj) receiving_23\VBG\get.v.01|while|cimetidine|hour (r_advcl) recurrent_14\JJ\perennial.s.03|developed|,|episodes|receiving (l_appos) episodes_17\NNS\happening.n.01|brief|of (l_prep) of_18\IN\entity.n.01|arrest (l_pobj) arrest_21\NN\capture.n.01|apparent|sinus
D002927_D054138 CID cimetidine_14\NN\antacid.n.01|infusion (r_pobj) with_10\IN\entity.n.01|cimetidine (r_prep) associated_9\VBN\think.v.03|with (r_acl) case_5\NN\happening.n.01|the|first|reported|of|associated (l_prep) of_6\IN\entity.n.01|arrest (l_pobj) arrest_8\NN\capture.n.01|sinus
D002927_D001919 CID cimetidine_7\NN\antacid.n.01| (r_pobj) of_6\IN\entity.n.01|cimetidine (r_prep) infusions_5\NNS\solution.n.01|intermittent|intravenous|of (r_pobj) of_2\IN\entity.n.01|infusions (r_prep) administration_1\NN\management.n.01|the|of (r_nsubjpass) associated_10\VBN\think.v.03|administration|is|infrequently|with|. (l_prep) with_11\IN\entity.n.01|development (l_pobj) development_13\NN\improvement.n.02|the|of (l_prep) of_14\IN\entity.n.01|bradyarrhythmias (l_pobj) bradyarrhythmias_15\NNS\entity.n.01|
D002927_D007938 NONE cimetidine_27\NN\antacid.n.01|infusion (r_dobj) receiving_23\VBG\get.v.01|while|cimetidine|hour (r_advcl) recurrent_14\JJ\perennial.s.03|developed|,|episodes|receiving (r_appos) man_4\NN\adult.n.01|a|old|with|and|history|recurrent|. (l_prep) with_5\IN\entity.n.01|leukemia (l_pobj) leukemia_6\NN\cancer.n.01|
D002927_D006331 NONE cimetidine_27\NN\antacid.n.01|infusion (r_dobj) receiving_23\VBG\get.v.01|while|cimetidine|hour (r_advcl) recurrent_14\JJ\perennial.s.03|developed|,|episodes|receiving (r_appos) man_4\NN\adult.n.01|a|old|with|and|history|recurrent|. (l_conj) history_9\NN\past.n.01|no|of (l_prep) of_10\IN\entity.n.01|disease (l_pobj) disease_12\NN\illness.n.01|cardiac
D002927_D001145 NONE cimetidine_6\NN\antacid.n.01| (r_compound) administration_7\NN\management.n.01|cimetidine (r_pobj) to_5\IN\entity.n.01|administration (r_prep) related_4\VBN\think.v.03|arrhythmias|were|temporally|to (l_nsubjpass) arrhythmias_1\NNS\heart_disease.n.01|the
D011899_D001145 NONE ranitidine_18\NN\antacid.n.01| (r_compound) treatment_19\NN\care.n.01|ranitidine (r_pobj) during_17\IN\entity.n.01|treatment (r_prep) recur_16\VB\happen.v.01|did|not|during (r_conj) disappeared_9\VBD\disappear.v.01|related|,|after|,|and|recur|. (l_ccomp) related_4\VBN\think.v.03|arrhythmias|were|temporally|to (l_nsubjpass) arrhythmias_1\NNS\heart_disease.n.01|the
19843802
D004837_D006973 CID epinephrine_5\NN\catecholamine.n.01| (r_pobj) of_4\IN\entity.n.01|epinephrine (r_prep) bolus_3\NN\ball.n.03|a|of|injected (r_nsubj) provoked_11\VBD\make.v.03|however|,|bolus|crisis|. (l_dobj) crisis_14\NN\situation.n.03|a|hypertensive (l_amod) hypertensive_13\JJ\patient.n.01|
17344566
D019821_D003161 CID simvastatin_0\NNP\lipid-lowering_medicine.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|simvastatin|- (r_amod) syndrome_6\NN\complex.n.01|induced|compartment|and|myonecrosis|associated|.
D019821_D003161 CID simvastatin_9\NN\lipid-lowering_medicine.n.01| (r_conj) thyroxine_7\NN\thyroid_hormone.n.01|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\show.v.04|thyroxine|with|. (l_prep) with_11\IN\entity.n.01|syndrome (l_pobj) syndrome_15\NN\complex.n.01|compartment|and|myonecrosis
D019821_D009135 NONE simvastatin_0\NNP\lipid-lowering_medicine.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|simvastatin|- (r_amod) syndrome_6\NN\complex.n.01|induced|compartment|and|myonecrosis|associated|. (l_conj) myonecrosis_8\NN\necrosis.n.01|
D019821_D009135 NONE simvastatin_9\NN\lipid-lowering_medicine.n.01| (r_conj) thyroxine_7\NN\thyroid_hormone.n.01|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\show.v.04|thyroxine|with|. (l_prep) with_11\IN\entity.n.01|syndrome (l_pobj) syndrome_15\NN\complex.n.01|compartment|and|myonecrosis (l_conj) myonecrosis_17\NN\necrosis.n.01|
D019821_D007037 NONE simvastatin_0\NNP\lipid-lowering_medicine.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|simvastatin|- (r_amod) syndrome_6\NN\complex.n.01|induced|compartment|and|myonecrosis|associated|. (l_acl) associated_9\VBN\think.v.03|with (l_prep) with_10\IN\entity.n.01|hypothyroidism (l_pobj) hypothyroidism_11\NN\glandular_disease.n.01|
D019821_D007037 NONE simvastatin_9\NN\lipid-lowering_medicine.n.01| (r_conj) thyroxine_7\NN\thyroid_hormone.n.01|a|old|taking|and|simvastatin (l_compound) taking_6\VBG\action.n.01|male (l_nsubj) male_5\NN\animal.n.01|hypothyroid (l_amod) hypothyroid_4\JJ\entity.n.01|
D013974_D007037 NONE thyroxine_7\NN\thyroid_hormone.n.01|a|old|taking|and|simvastatin (l_compound) taking_6\VBG\action.n.01|male (l_nsubj) male_5\NN\animal.n.01|hypothyroid (l_amod) hypothyroid_4\JJ\entity.n.01|
D013974_D003161 NONE thyroxine_7\NN\thyroid_hormone.n.01|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\show.v.04|thyroxine|with|. (l_prep) with_11\IN\entity.n.01|syndrome (l_pobj) syndrome_15\NN\complex.n.01|compartment|and|myonecrosis
D013974_D009135 NONE thyroxine_7\NN\thyroid_hormone.n.01|a|old|taking|and|simvastatin (r_nsubj) presented_10\VBD\show.v.04|thyroxine|with|. (l_prep) with_11\IN\entity.n.01|syndrome (l_pobj) syndrome_15\NN\complex.n.01|compartment|and|myonecrosis (l_conj) myonecrosis_17\NN\necrosis.n.01|
3173180
D008795_D006463 CID metronidazole_7\NN\antiprotozoal.n.01| (r_pobj) with_6\IN\entity.n.01|metronidazole (r_prep) treatment_5\NN\care.n.01|with (r_pobj) after_4\IN\after.s.01|treatment (r_prep) syndrome_3\NN\complex.n.01|uraemic|after|.
D008795_D006463 CID metronidazole_19\NN\antiprotozoal.n.01| (r_pobj) with_18\IN\entity.n.01|metronidazole (r_prep) treatment_17\NN\care.n.01|with (r_pobj) after_16\IN\after.s.01|treatment (r_prep) developed_10\VBD\create.v.02|who|syndrome|after (l_dobj) syndrome_15\NN\complex.n.01|the|uraemic
D008795_D006463 CID metronidazole_4\NN\antiprotozoal.n.01| (r_pobj) of_3\IN\entity.n.01|metronidazole (r_prep) involvement_2\NN\group_action.n.01|the|of|in (l_prep) in_5\IN\linear_unit.n.01|aetiology (l_pobj) aetiology_7\NN\cause.n.01|the|of (l_prep) of_8\IN\entity.n.01|syndrome (l_pobj) syndrome_13\NN\complex.n.01|the|uraemic
D008795_D006463 CID metronidazole_4\NN\antiprotozoal.n.01| (r_pobj) of_3\IN\entity.n.01|metronidazole (r_prep) involvement_2\NN\group_action.n.01|the|of|in (r_nsubjpass) established_16\VBN\open.v.02|while|involvement|is|not|firmly (r_advcl) suggest_43\VBP\declare.v.01|established|,|action|link|. (l_nsubj) action_20\NN\act.n.02|the|of|in|evidence (l_conj) evidence_33\NN\information.n.02|the|reported|of (l_prep) of_34\IN\entity.n.01|changes (l_pobj) changes_36\NNS\happening.n.01|oxidation|in (l_prep) in_37\IN\linear_unit.n.01|syndrome (l_pobj) syndrome_42\NN\complex.n.01|the|uraemic
D008795_D006463 CID metronidazole_4\NN\antiprotozoal.n.01| (r_pobj) of_3\IN\entity.n.01|metronidazole (r_prep) involvement_2\NN\group_action.n.01|the|of|in (r_nsubjpass) established_16\VBN\open.v.02|while|involvement|is|not|firmly (r_advcl) suggest_43\VBP\declare.v.01|established|,|action|link|. (l_dobj) link_46\NN\linkage.n.01|a|possible|between (l_prep) between_47\IN\between.r.01|treatment (l_pobj) treatment_49\NN\care.n.01|metronidazole|and|cases (l_conj) cases_52\NNS\happening.n.01|some|of (l_prep) of_53\IN\entity.n.01|syndrome (l_pobj) syndrome_58\NN\complex.n.01|the|uraemic
D008795_D006463 CID metronidazole_48\NN\antiprotozoal.n.01| (r_amod) treatment_49\NN\care.n.01|metronidazole|and|cases (r_pobj) between_47\IN\between.r.01|treatment (r_prep) link_46\NN\linkage.n.01|a|possible|between (r_dobj) suggest_43\VBP\declare.v.01|established|,|action|link|. (l_advcl) established_16\VBN\open.v.02|while|involvement|is|not|firmly (l_nsubjpass) involvement_2\NN\group_action.n.01|the|of|in (l_prep) in_5\IN\linear_unit.n.01|aetiology (l_pobj) aetiology_7\NN\cause.n.01|the|of (l_prep) of_8\IN\entity.n.01|syndrome (l_pobj) syndrome_13\NN\complex.n.01|the|uraemic
D008795_D006463 CID metronidazole_48\NN\antiprotozoal.n.01| (r_amod) treatment_49\NN\care.n.01|metronidazole|and|cases (r_pobj) between_47\IN\between.r.01|treatment (r_prep) link_46\NN\linkage.n.01|a|possible|between (r_dobj) suggest_43\VBP\declare.v.01|established|,|action|link|. (l_nsubj) action_20\NN\act.n.02|the|of|in|evidence (l_conj) evidence_33\NN\information.n.02|the|reported|of (l_prep) of_34\IN\entity.n.01|changes (l_pobj) changes_36\NNS\happening.n.01|oxidation|in (l_prep) in_37\IN\linear_unit.n.01|syndrome (l_pobj) syndrome_42\NN\complex.n.01|the|uraemic
D008795_D006463 CID metronidazole_48\NN\antiprotozoal.n.01| (r_amod) treatment_49\NN\care.n.01|metronidazole|and|cases (l_conj) cases_52\NNS\happening.n.01|some|of (l_prep) of_53\IN\entity.n.01|syndrome (l_pobj) syndrome_58\NN\complex.n.01|the|uraemic
20621845
D002122_D017545 CID cacl2-induced_14\VBN\entity.n.01| (r_amod) aneurysm_17\NN\cardiovascular_disease.n.01|cacl2-induced|thoracic|aortic|in
D002122_D017545 CID chloride_18\NN\compound.n.02|calcium|injury (r_pobj) by_16\IN\by.r.01|chloride (r_prep) establish_5\VB\open.v.02|to|model|by|and|explore (l_dobj) model_8\NN\hypothesis.n.02|a|rat|of (l_prep) of_9\IN\entity.n.01|aneurysm (l_pobj) aneurysm_12\NN\cardiovascular_disease.n.01|thoracic|aortic|(|taa|)
D002122_D017545 CID chloride_18\NN\compound.n.02|calcium|injury (r_pobj) by_16\IN\by.r.01|chloride (r_prep) establish_5\VB\open.v.02|to|model|by|and|explore (l_dobj) model_8\NN\hypothesis.n.02|a|rat|of (l_prep) of_9\IN\entity.n.01|aneurysm (l_pobj) aneurysm_12\NN\cardiovascular_disease.n.01|thoracic|aortic|(|taa|) (l_appos) taa_14\NNP\entity.n.01|
D002122_D017545 CID chloride_18\NN\compound.n.02|calcium|injury (r_pobj) by_16\IN\by.r.01|chloride (r_prep) establish_5\VB\open.v.02|to|model|by|and|explore (r_xcomp) designed_3\VBN\create_by_mental_act.v.01|study|was|establish|,|metalloproteinases|. (l_conj) metalloproteinases_39\NNS\entity.n.01|matrix|(|mmps|)|and|inhibitors (l_conj) inhibitors_46\NNS\substance.n.07|their|endogenous|(|timps|)|in (l_prep) in_50\IN\linear_unit.n.01|formation (l_pobj) formation_52\NN\arrangement.n.02|taa (l_compound) taa_51\NNP\entity.n.01|
D002122_D017545 CID cacl(2))-induced_20\VBN\entity.n.01| (r_amod) injury_22\NN\ill_health.n.01|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN\compound.n.02|calcium|injury (r_pobj) by_16\IN\by.r.01|chloride (r_prep) establish_5\VB\open.v.02|to|model|by|and|explore (l_dobj) model_8\NN\hypothesis.n.02|a|rat|of (l_prep) of_9\IN\entity.n.01|aneurysm (l_pobj) aneurysm_12\NN\cardiovascular_disease.n.01|thoracic|aortic|(|taa|)
D002122_D017545 CID cacl(2))-induced_20\VBN\entity.n.01| (r_amod) injury_22\NN\ill_health.n.01|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN\compound.n.02|calcium|injury (r_pobj) by_16\IN\by.r.01|chloride (r_prep) establish_5\VB\open.v.02|to|model|by|and|explore (l_dobj) model_8\NN\hypothesis.n.02|a|rat|of (l_prep) of_9\IN\entity.n.01|aneurysm (l_pobj) aneurysm_12\NN\cardiovascular_disease.n.01|thoracic|aortic|(|taa|) (l_appos) taa_14\NNP\entity.n.01|
D002122_D017545 CID cacl(2))-induced_20\VBN\entity.n.01| (r_amod) injury_22\NN\ill_health.n.01|(|cacl(2))-induced|arterial (r_appos) chloride_18\NN\compound.n.02|calcium|injury (r_pobj) by_16\IN\by.r.01|chloride (r_prep) establish_5\VB\open.v.02|to|model|by|and|explore (r_xcomp) designed_3\VBN\create_by_mental_act.v.01|study|was|establish|,|metalloproteinases|. (l_conj) metalloproteinases_39\NNS\entity.n.01|matrix|(|mmps|)|and|inhibitors (l_conj) inhibitors_46\NNS\substance.n.07|their|endogenous|(|timps|)|in (l_prep) in_50\IN\linear_unit.n.01|formation (l_pobj) formation_52\NN\arrangement.n.02|taa (l_compound) taa_51\NNP\entity.n.01|
D002122_D017545 CID )_9\-RRB-\entity.n.01| (r_punct) establishes_2\VBZ\open.v.02|study|model|by|) (l_dobj) model_5\NN\hypothesis.n.02|a|taa (l_compound) taa_4\NNP\entity.n.01|
D002122_D014652 NONE chloride_18\NN\compound.n.02|calcium|injury (l_appos) injury_22\NN\ill_health.n.01|(|cacl(2))-induced|arterial
D002122_D014652 NONE cacl(2))-induced_20\VBN\entity.n.01| (r_amod) injury_22\NN\ill_health.n.01|(|cacl(2))-induced|arterial
567256
D004054_D006394 CID diethylstilbestrol_6\NN\estrogen.n.01| (r_pobj) with_5\IN\entity.n.01|diethylstilbestrol (r_prep) associated_4\VBN\think.v.03|with (r_acl) liver_3\NN\internal_organ.n.01|the|associated
D004054_D006394 CID diethylstilbestrol_25\NN\estrogen.n.01| (r_pobj) with_24\IN\entity.n.01|diethylstilbestrol (r_prep) liver_23\NN\internal_organ.n.01|the|with (r_pobj) of_21\IN\entity.n.01|liver (r_prep) adenocarcinoma_20\NN\carcinoma.n.01|a|differentiated|of (r_pobj) for_15\IN\entity.n.01|adenocarcinoma (r_prep) treated_14\VBN\interact.v.01|who|had|been|for|for (r_relcl) man_10\NN\adult.n.01|a|old|treated (r_pobj) in_5\IN\linear_unit.n.01|man (r_prep) occurred_4\VBD\happen.v.01|angiosarcoma|in|. (l_nsubj) angiosarcoma_0\NNP\malignant_tumor.n.01|of (l_prep) of_1\IN\entity.n.01|liver (l_pobj) liver_3\NN\internal_organ.n.01|the
D004054_D008113 CID diethylstilbestrol_6\NN\estrogen.n.01| (r_pobj) with_5\IN\entity.n.01|diethylstilbestrol (r_prep) associated_4\VBN\think.v.03|with (r_acl) liver_3\NN\internal_organ.n.01|the|associated
D004054_D008113 CID diethylstilbestrol_25\NN\estrogen.n.01| (r_pobj) with_24\IN\entity.n.01|diethylstilbestrol (r_prep) liver_23\NN\internal_organ.n.01|the|with (r_pobj) of_21\IN\entity.n.01|liver (r_prep) adenocarcinoma_20\NN\carcinoma.n.01|a|differentiated|of (r_pobj) for_15\IN\entity.n.01|adenocarcinoma (r_prep) treated_14\VBN\interact.v.01|who|had|been|for|for (r_relcl) man_10\NN\adult.n.01|a|old|treated (r_pobj) in_5\IN\linear_unit.n.01|man (r_prep) occurred_4\VBD\happen.v.01|angiosarcoma|in|. (l_nsubj) angiosarcoma_0\NNP\malignant_tumor.n.01|of (l_prep) of_1\IN\entity.n.01|liver (l_pobj) liver_3\NN\internal_organ.n.01|the
D004054_D008113 NONE diethylstilbestrol_25\NN\estrogen.n.01| (r_pobj) with_24\IN\entity.n.01|diethylstilbestrol (r_prep) liver_23\NN\internal_organ.n.01|the|with
D004054_D000230 NONE diethylstilbestrol_25\NN\estrogen.n.01| (r_pobj) with_24\IN\entity.n.01|diethylstilbestrol (r_prep) liver_23\NN\internal_organ.n.01|the|with
2870085
C047847_D013610 NONE flestolol_0\NNP\entity.n.01| (r_nsubj) produced_1\VBD\make.v.03|flestolol|attenuation|. (l_dobj) attenuation_6\NN\weakening.n.01|a|dependent|of (l_prep) of_7\IN\entity.n.01|tachycardia (l_pobj) tachycardia_11\NN\cardiac_arrhythmia.n.01|induced
D007545_D013610 CID isoproterenol_8\NN\medicine.n.02| (r_npadvmod) induced_10\VBN\generate.v.01|isoproterenol|- (r_amod) tachycardia_11\NN\cardiac_arrhythmia.n.01|induced
C047847_D013617 NONE flestolol_0\NNP\entity.n.01| (r_nsubj) reduced_2\VBD\decrease.v.02|flestolol|effectively|rate|in|. (l_prep) in_5\IN\linear_unit.n.01|patients (l_pobj) patients_6\NNS\case.n.06|with (l_prep) with_7\IN\entity.n.01|tachyarrhythmia (l_pobj) tachyarrhythmia_9\NN\entity.n.01|supraventricular
C047847_D000789 NONE flestolol_6\NN\entity.n.01| (r_compound) infusion_7\NN\solution.n.01|flestolol (r_nsubjpass) found_9\VBN\wage.n.01|in|,|infusion|was|be|. (l_prep) in_0\IN\linear_unit.n.01|patients (l_pobj) patients_1\NNS\case.n.06|with (l_prep) with_2\IN\entity.n.01|angina (l_pobj) angina_4\NN\inflammatory_disease.n.01|unstable
C047847_D002637 NONE flestolol_6\NN\entity.n.01| (r_compound) infusion_7\NN\solution.n.01|flestolol (r_nsubjpass) found_9\VBN\wage.n.01|in|,|infusion|was|be|. (l_xcomp) be_11\VB\metallic_element.n.01|to|safe (l_acomp) safe_12\JJ\strongbox.n.01|and|effective (l_conj) effective_14\JJ\effective.a.01|in (l_prep) in_15\IN\linear_unit.n.01|controlling (l_pcomp) controlling_16\VBG\control.v.01|pain (l_dobj) pain_18\NN\symptom.n.01|chest
17020434
D014859_D020521 NONE warfarin_12\NN\anticoagulant.n.01| (r_nsubj) reduces_13\VBZ\decrease.v.02|that|warfarin|risk|by|,|and|reduces (l_dobj) risk_15\NN\danger.n.03|the|of (l_prep) of_16\IN\entity.n.01|stroke (l_pobj) stroke_17\NN\maneuver.n.03|
D014859_D020521 NONE warfarin_8\VB\anticoagulant.n.01| (r_nsubj) is_9\VBZ\be.v.01|overall|,|in|,|warfarin|superior|,|with|. (l_acomp) superior_10\JJ\leader.n.01|to (l_prep) to_11\IN\entity.n.01|aspirin (l_pobj) aspirin_12\NN\analgesic.n.01|in (l_prep) in_13\IN\linear_unit.n.01|preventing (l_pcomp) preventing_14\VBG\prevent.v.01|strokes (l_dobj) strokes_15\NNS\maneuver.n.03|
D001241_D020521 NONE aspirin_24\NN\analgesic.n.01|alone (r_nsubj) reduces_26\VBZ\decrease.v.02|that|aspirin|risk|by (r_conj) reduces_13\VBZ\decrease.v.02|that|warfarin|risk|by|,|and|reduces (l_dobj) risk_15\NN\danger.n.03|the|of (l_prep) of_16\IN\entity.n.01|stroke (l_pobj) stroke_17\NN\maneuver.n.03|
D001241_D020521 NONE aspirin_12\NN\analgesic.n.01|in (l_prep) in_13\IN\linear_unit.n.01|preventing (l_pcomp) preventing_14\VBG\prevent.v.01|strokes (l_dobj) strokes_15\NNS\maneuver.n.03|
C426686_D004617 NONE ximelagatran_0\NN\entity.n.01|,|inhibitor|, (r_nsubjpass) found_9\VBN\wage.n.01|ximelagatran|was|be|,|but|withdrawn|. (l_xcomp) be_11\VB\metallic_element.n.01|to|efficient (l_acomp) efficient_13\JJ\efficient.a.01|as|as|in (l_prep) in_19\IN\linear_unit.n.01|prevention (l_pobj) prevention_21\NN\hindrance.n.03|the|of (l_prep) of_22\IN\entity.n.01|events (l_pobj) events_24\NNS\psychological_feature.n.01|embolic
C426686_D056486 CID ximelagatran_0\NN\entity.n.01|,|inhibitor|, (r_nsubjpass) found_9\VBN\wage.n.01|ximelagatran|was|be|,|but|withdrawn|. (l_conj) withdrawn_30\VBN\travel.v.01|has|been|recently|because (l_prep) because_31\IN\entity.n.01|of|tests (l_pobj) tests_36\NNS\experiment.n.02|abnormal|function (l_compound) function_35\NN\mathematical_relation.n.01|liver
D014812_D004617 NONE k_16\NNP\temperature_unit.n.01|vitamin (r_compound) drugs_18\NNS\agent.n.03|k|antagonist (r_pobj) as_14\IN\chemical_element.n.01|drugs (r_prep) efficient_13\JJ\efficient.a.01|as|as|in (l_prep) in_19\IN\linear_unit.n.01|prevention (l_pobj) prevention_21\NN\hindrance.n.03|the|of (l_prep) of_22\IN\entity.n.01|events (l_pobj) events_24\NNS\psychological_feature.n.01|embolic
D014812_D056486 NONE k_16\NNP\temperature_unit.n.01|vitamin (r_compound) drugs_18\NNS\agent.n.03|k|antagonist (r_pobj) as_14\IN\chemical_element.n.01|drugs (r_prep) efficient_13\JJ\efficient.a.01|as|as|in (r_acomp) be_11\VB\metallic_element.n.01|to|efficient (r_xcomp) found_9\VBN\wage.n.01|ximelagatran|was|be|,|but|withdrawn|. (l_conj) withdrawn_30\VBN\travel.v.01|has|been|recently|because (l_prep) because_31\IN\entity.n.01|of|tests (l_pobj) tests_36\NNS\experiment.n.02|abnormal|function (l_compound) function_35\NN\mathematical_relation.n.01|liver
C055162_D001281 NONE clopidogrel_7\NNP\entity.n.01|fibrillation (l_compound) fibrillation_6\NNP\twitch.n.01|
C055162_D001281 NONE clopidogrel_28\JJ\entity.n.01|plus|aspirin (r_dobj) platelet_25\NN\protoplasm.n.01|to|therapy|clopidogrel|)|in (r_xcomp) superior_23\JJ\leader.n.01|platelet (r_acomp) is_22\VBZ\be.v.01|that|warfarin|superior (r_ccomp) demonstrated_19\VBN\show.v.04|trial|has|is|. (l_nsubj) trial_8\NN\attempt.n.01|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\entity.n.01|fibrillation (l_compound) fibrillation_6\NNP\twitch.n.01|
C055162_D004617 NONE clopidogrel_7\NNP\entity.n.01|fibrillation (r_compound) trial_8\NN\attempt.n.01|the|w|(|atrial|clopidogrel|with|)|study (r_nsubj) demonstrated_19\VBN\show.v.04|trial|has|is|. (l_ccomp) is_22\VBZ\be.v.01|that|warfarin|superior (l_acomp) superior_23\JJ\leader.n.01|platelet (l_xcomp) platelet_25\NN\protoplasm.n.01|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\linear_unit.n.01|prevention|events (l_pobj) events_37\NNS\psychological_feature.n.01|af|embolic
C055162_D004617 NONE clopidogrel_28\JJ\entity.n.01|plus|aspirin (r_dobj) platelet_25\NN\protoplasm.n.01|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\linear_unit.n.01|prevention|events (l_pobj) events_37\NNS\psychological_feature.n.01|af|embolic
C081309_D001281 NONE irbesartan_10\NNP\entity.n.01|for (r_pobj) with_9\IN\entity.n.01|irbesartan (r_prep) trial_8\NN\attempt.n.01|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\entity.n.01|fibrillation (l_compound) fibrillation_6\NNP\twitch.n.01|
C081309_D004617 NONE irbesartan_10\NNP\entity.n.01|for (r_pobj) with_9\IN\entity.n.01|irbesartan (r_prep) trial_8\NN\attempt.n.01|the|w|(|atrial|clopidogrel|with|)|study (r_nsubj) demonstrated_19\VBN\show.v.04|trial|has|is|. (l_ccomp) is_22\VBZ\be.v.01|that|warfarin|superior (l_acomp) superior_23\JJ\leader.n.01|platelet (l_xcomp) platelet_25\NN\protoplasm.n.01|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\linear_unit.n.01|prevention|events (l_pobj) events_37\NNS\psychological_feature.n.01|af|embolic
D014859_D001281 NONE warfarin_21\NN\anticoagulant.n.01| (r_nsubj) is_22\VBZ\be.v.01|that|warfarin|superior (r_ccomp) demonstrated_19\VBN\show.v.04|trial|has|is|. (l_nsubj) trial_8\NN\attempt.n.01|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\entity.n.01|fibrillation (l_compound) fibrillation_6\NNP\twitch.n.01|
D014859_D004617 NONE warfarin_21\NN\anticoagulant.n.01| (r_nsubj) is_22\VBZ\be.v.01|that|warfarin|superior (l_acomp) superior_23\JJ\leader.n.01|platelet (l_xcomp) platelet_25\NN\protoplasm.n.01|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\linear_unit.n.01|prevention|events (l_pobj) events_37\NNS\psychological_feature.n.01|af|embolic
D001241_D001281 NONE aspirin_30\NN\analgesic.n.01| (r_conj) clopidogrel_28\JJ\entity.n.01|plus|aspirin (r_dobj) platelet_25\NN\protoplasm.n.01|to|therapy|clopidogrel|)|in (r_xcomp) superior_23\JJ\leader.n.01|platelet (r_acomp) is_22\VBZ\be.v.01|that|warfarin|superior (r_ccomp) demonstrated_19\VBN\show.v.04|trial|has|is|. (l_nsubj) trial_8\NN\attempt.n.01|the|w|(|atrial|clopidogrel|with|)|study (l_compound) clopidogrel_7\NNP\entity.n.01|fibrillation (l_compound) fibrillation_6\NNP\twitch.n.01|
D001241_D004617 NONE aspirin_30\NN\analgesic.n.01| (r_conj) clopidogrel_28\JJ\entity.n.01|plus|aspirin (r_dobj) platelet_25\NN\protoplasm.n.01|to|therapy|clopidogrel|)|in (l_prep) in_32\IN\linear_unit.n.01|prevention|events (l_pobj) events_37\NNS\psychological_feature.n.01|af|embolic
C479958_D001281 NONE idraparinux_0\NNP\entity.n.01|,|inhibitor|, (r_nsubjpass) evaluated_9\VBN\evaluate.v.02|idraparinux|is|being|in|. (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|with (l_prep) with_12\IN\entity.n.01|fibrillation (l_pobj) fibrillation_14\NN\twitch.n.01|atrial
D000809_D001281 NONE angiotensin_0\NN\vasoconstrictor.n.01| (r_npadvmod) converting_2\VBG\change.v.01|angiotensin|- (r_amod) inhibitors_4\NNS\substance.n.07|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\grasping.n.02|inhibitors|promise|. (l_dobj) promise_13\NN\commitment.n.04|in (l_prep) in_14\IN\linear_unit.n.01|fibrillation (l_pobj) fibrillation_16\NN\twitch.n.01|atrial|through
D000809_D020257 NONE angiotensin_0\NN\vasoconstrictor.n.01| (r_npadvmod) converting_2\VBG\change.v.01|angiotensin|- (r_amod) inhibitors_4\NNS\substance.n.07|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\grasping.n.02|inhibitors|promise|. (l_dobj) promise_13\NN\commitment.n.04|in (l_prep) in_14\IN\linear_unit.n.01|fibrillation (l_pobj) fibrillation_16\NN\twitch.n.01|atrial|through (l_prep) through_17\IN\done.s.01|remodelling (l_pobj) remodelling_19\NN\entity.n.01|cardiac
D000804_D001281 NONE ii_7\CD\digit.n.01| (r_nummod) drugs_11\NNS\agent.n.03|angiotensin|ii|blocking (r_conj) inhibitors_4\NNS\substance.n.07|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\grasping.n.02|inhibitors|promise|. (l_dobj) promise_13\NN\commitment.n.04|in (l_prep) in_14\IN\linear_unit.n.01|fibrillation (l_pobj) fibrillation_16\NN\twitch.n.01|atrial|through
D000804_D020257 NONE ii_7\CD\digit.n.01| (r_nummod) drugs_11\NNS\agent.n.03|angiotensin|ii|blocking (r_conj) inhibitors_4\NNS\substance.n.07|converting|enzyme|and|drugs (r_nsubj) hold_12\VBP\grasping.n.02|inhibitors|promise|. (l_dobj) promise_13\NN\commitment.n.04|in (l_prep) in_14\IN\linear_unit.n.01|fibrillation (l_pobj) fibrillation_16\NN\twitch.n.01|atrial|through (l_prep) through_17\IN\done.s.01|remodelling (l_pobj) remodelling_19\NN\entity.n.01|cardiac
3970039
D000477_D015470 CID agents_4\NNS\causal_agent.n.01|alkylating (r_pobj) with_2\IN\entity.n.01|agents (r_prep) treated_1\VBN\interact.v.01|patients|with (r_csubj) have_5\VBP\person.n.01|treated|risk|,|and|associated (l_dobj) risk_8\NN\danger.n.03|an|increased|of (l_prep) of_9\IN\entity.n.01|development (l_pobj) development_10\NN\improvement.n.02|of (l_prep) of_11\IN\entity.n.01|leukemia (l_pobj) leukemia_14\NN\cancer.n.01|acute|nonlymphocytic
D000477_D015470 CID agents_19\NNS\causal_agent.n.01|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\think.v.03|agents|are|with|. (r_conj) have_5\VBP\person.n.01|treated|risk|,|and|associated (l_dobj) risk_8\NN\danger.n.03|an|increased|of (l_prep) of_9\IN\entity.n.01|development (l_pobj) development_10\NN\improvement.n.02|of (l_prep) of_11\IN\entity.n.01|leukemia (l_pobj) leukemia_14\NN\cancer.n.01|acute|nonlymphocytic
D000477_D008228 CID agents_4\NNS\causal_agent.n.01|alkylating (r_pobj) with_2\IN\entity.n.01|agents (r_prep) treated_1\VBN\interact.v.01|patients|with (r_csubj) have_5\VBP\person.n.01|treated|risk|,|and|associated (l_conj) associated_23\VBN\think.v.03|agents|are|with|. (l_prep) with_24\IN\entity.n.01|development (l_pobj) development_26\NN\improvement.n.02|the|of (l_prep) of_27\IN\entity.n.01|lymphoma (l_pobj) lymphoma_32\NN\cancer.n.01|hodgkin
D000477_D008228 CID agents_19\NNS\causal_agent.n.01|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\think.v.03|agents|are|with|. (l_prep) with_24\IN\entity.n.01|development (l_pobj) development_26\NN\improvement.n.02|the|of (l_prep) of_27\IN\entity.n.01|lymphoma (l_pobj) lymphoma_32\NN\cancer.n.01|hodgkin
D001379_D015470 NONE azathioprine_21\NN\medicine.n.02| (r_conj) agents_19\NNS\causal_agent.n.01|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\think.v.03|agents|are|with|. (r_conj) have_5\VBP\person.n.01|treated|risk|,|and|associated (l_dobj) risk_8\NN\danger.n.03|an|increased|of (l_prep) of_9\IN\entity.n.01|development (l_pobj) development_10\NN\improvement.n.02|of (l_prep) of_11\IN\entity.n.01|leukemia (l_pobj) leukemia_14\NN\cancer.n.01|acute|nonlymphocytic
D001379_D008228 CID azathioprine_21\NN\medicine.n.02| (r_conj) agents_19\NNS\causal_agent.n.01|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\think.v.03|agents|are|with|. (l_prep) with_24\IN\entity.n.01|development (l_pobj) development_26\NN\improvement.n.02|the|of (l_prep) of_27\IN\entity.n.01|lymphoma (l_pobj) lymphoma_32\NN\cancer.n.01|hodgkin
D003520_D001749 CID cyclophosphamide_0\NNP\entity.n.01| (r_compound) therapy_1\NN\medical_care.n.01|cyclophosphamide (r_nsubj) increases_2\VBZ\indefinite_quantity.n.01|therapy|risk|. (l_dobj) risk_4\NN\danger.n.03|the|of (l_prep) of_5\IN\entity.n.01|carcinoma (l_pobj) carcinoma_6\NN\cancer.n.01|of (l_prep) of_7\IN\entity.n.01|bladder (l_pobj) bladder_9\NN\sac.n.04|the
D003520_D002277 CID cyclophosphamide_0\NNP\entity.n.01| (r_compound) therapy_1\NN\medical_care.n.01|cyclophosphamide (r_nsubj) increases_2\VBZ\indefinite_quantity.n.01|therapy|risk|. (l_dobj) risk_4\NN\danger.n.03|the|of (l_prep) of_5\IN\entity.n.01|carcinoma (l_pobj) carcinoma_6\NN\cancer.n.01|of (l_prep) of_7\IN\entity.n.01|bladder (l_pobj) bladder_9\NN\sac.n.04|the
D001379_D001172 NONE azathioprine_15\NN\medicine.n.02|and|cyclophosphamide (r_pobj) with_14\IN\entity.n.01|azathioprine (r_prep) treated_13\VBN\interact.v.01|with (r_acl) studies_7\NNS\examination.n.01|several|term|of|treated|and (l_prep) of_8\IN\entity.n.01|patients (l_pobj) patients_9\NNS\case.n.06|with (l_prep) with_10\IN\entity.n.01|arthritis (l_pobj) arthritis_12\NN\inflammatory_disease.n.01|rheumatoid
D001379_D009369 NONE azathioprine_15\NN\medicine.n.02|and|cyclophosphamide (r_pobj) with_14\IN\entity.n.01|azathioprine (r_prep) treated_13\VBN\interact.v.01|with (r_acl) studies_7\NNS\examination.n.01|several|term|of|treated|and (r_attr) been_2\VBN\be.v.01|there|have|studies|increased|. (l_conj) increased_29\VBN\change_magnitude.v.01|incidence|is|not (l_nsubjpass) incidence_20\NN\frequency.n.02|the|of (l_prep) of_21\IN\entity.n.01|most (l_pobj) most_22\JJS\most.a.01|of (l_prep) of_23\IN\entity.n.01|cancers (l_pobj) cancers_26\NNS\malignant_tumor.n.01|the|common
D003520_D001172 NONE cyclophosphamide_17\NN\entity.n.01| (r_conj) azathioprine_15\NN\medicine.n.02|and|cyclophosphamide (r_pobj) with_14\IN\entity.n.01|azathioprine (r_prep) treated_13\VBN\interact.v.01|with (r_acl) studies_7\NNS\examination.n.01|several|term|of|treated|and (l_prep) of_8\IN\entity.n.01|patients (l_pobj) patients_9\NNS\case.n.06|with (l_prep) with_10\IN\entity.n.01|arthritis (l_pobj) arthritis_12\NN\inflammatory_disease.n.01|rheumatoid
D003520_D009369 NONE cyclophosphamide_17\NN\entity.n.01| (r_conj) azathioprine_15\NN\medicine.n.02|and|cyclophosphamide (r_pobj) with_14\IN\entity.n.01|azathioprine (r_prep) treated_13\VBN\interact.v.01|with (r_acl) studies_7\NNS\examination.n.01|several|term|of|treated|and (r_attr) been_2\VBN\be.v.01|there|have|studies|increased|. (l_conj) increased_29\VBN\change_magnitude.v.01|incidence|is|not (l_nsubjpass) incidence_20\NN\frequency.n.02|the|of (l_prep) of_21\IN\entity.n.01|most (l_pobj) most_22\JJS\most.a.01|of (l_prep) of_23\IN\entity.n.01|cancers (l_pobj) cancers_26\NNS\malignant_tumor.n.01|the|common
D000477_D009369 NONE agents_31\NNS\causal_agent.n.01|particularly|alkylating (r_appos) drugs_27\NNS\agent.n.03|immunosuppressive|,|agents|, (r_pobj) of_25\IN\entity.n.01|drugs (r_prep) use_24\NN\activity.n.01|the|of|in (r_nsubjpass) reserved_41\VBN\withhold.v.01|is|,|use|should|be|for|. (r_conj) collected_14\VBN\store.v.01|data|are|still|being|,|and|reserved (l_nsubjpass) data_0\NNS\collection.n.01|on (l_prep) on_1\IN\on.a.01|risk (l_pobj) risk_5\NN\danger.n.03|the|possible|increased|of (l_prep) of_6\IN\entity.n.01|malignancy (l_pobj) malignancy_7\NN\disease.n.01|in
D000477_D001172 NONE agents_31\NNS\causal_agent.n.01|particularly|alkylating (r_appos) drugs_27\NNS\agent.n.03|immunosuppressive|,|agents|, (r_pobj) of_25\IN\entity.n.01|drugs (r_prep) use_24\NN\activity.n.01|the|of|in (r_nsubjpass) reserved_41\VBN\withhold.v.01|is|,|use|should|be|for|. (r_conj) collected_14\VBN\store.v.01|data|are|still|being|,|and|reserved (l_nsubjpass) data_0\NNS\collection.n.01|on (l_prep) on_1\IN\on.a.01|risk (l_pobj) risk_5\NN\danger.n.03|the|possible|increased|of (l_prep) of_6\IN\entity.n.01|malignancy (l_pobj) malignancy_7\NN\disease.n.01|in (l_prep) in_8\IN\linear_unit.n.01|arthritis (l_pobj) arthritis_10\NN\inflammatory_disease.n.01|rheumatoid
D000477_D001172 NONE agents_31\NNS\causal_agent.n.01|particularly|alkylating (r_appos) drugs_27\NNS\agent.n.03|immunosuppressive|,|agents|, (r_pobj) of_25\IN\entity.n.01|drugs (r_prep) use_24\NN\activity.n.01|the|of|in (l_prep) in_33\IN\linear_unit.n.01|treatment (l_pobj) treatment_35\NN\care.n.01|the|of (l_prep) of_36\IN\entity.n.01|arthritis (l_pobj) arthritis_38\NN\inflammatory_disease.n.01|rheumatoid
7516729
D014700_D001919 CID verapamil_6\NN\calcium_blocker.n.01| (r_pobj) by_5\IN\by.r.01|verapamil (r_agent) induced_4\VBN\generate.v.01|by (r_acl) bradycardia_3\NNS\cardiac_arrhythmia.n.01|dependent|induced
18081909
C026098_D001927 CID levetiracetam_3\NN\entity.n.01| (r_pcomp) by_2\IN\by.r.01|levetiracetam (r_prep) induced_1\VBN\generate.v.01|encephalopathy|by|added|. (l_nsubj) encephalopathy_0\JJ\nervous_disorder.n.01|
C026098_D001927 CID levetiracetam_7\FW\entity.n.01| (r_amod) encephalopathy_10\JJ\nervous_disorder.n.01|a|levetiracetam|(|lev)-induced
C026098_D001927 CID lev)-induced_9\VBN\entity.n.01| (r_amod) encephalopathy_10\JJ\nervous_disorder.n.01|a|levetiracetam|(|lev)-induced
D014635_D001927 CID valproate_6\VB\entity.n.01|to (r_xcomp) added_4\VBN\increase.v.01|valproate (r_conj) induced_1\VBN\generate.v.01|encephalopathy|by|added|. (l_nsubj) encephalopathy_0\JJ\nervous_disorder.n.01|
C026098_C562694 NONE lev_15\NNP\bulgarian_monetary_unit.n.01|mg (r_pobj) with_14\IN\entity.n.01|lev (r_prep) treated_13\VBN\interact.v.01|man|was|with|)|added|. (l_nsubjpass) man_4\NN\adult.n.01|a|old|suffering (l_acl) suffering_5\VBG\pain.n.01|from|with (l_prep) from_6\IN\entity.n.01|epilepsy (l_pobj) epilepsy_8\NN\brain_disorder.n.01|idiopathic
C026098_D012640 NONE lev_15\NNP\bulgarian_monetary_unit.n.01|mg (r_pobj) with_14\IN\entity.n.01|lev (r_prep) treated_13\VBN\interact.v.01|man|was|with|)|added|. (l_nsubjpass) man_4\NN\adult.n.01|a|old|suffering (l_acl) suffering_5\VBG\pain.n.01|from|with (l_prep) with_9\IN\entity.n.01|seizures (l_pobj) seizures_11\NNS\attack.n.07|generalized
C026098_D012640 NONE lev_3\NNP\bulgarian_monetary_unit.n.01|,|eeg (r_pobj) of_2\IN\entity.n.01|lev (r_prep) discontinuation_1\NN\termination.n.05|of (r_pobj) following_0\VBG\multitude.n.03|discontinuation|improved (l_preconj) improved_9\VBN\change.v.01|and|decreased (l_conj) decreased_13\VBD\change_magnitude.v.01|frequency|. (l_nsubj) frequency_12\NN\rate.n.01|seizure (l_compound) seizure_11\NN\attack.n.07|
D014635_C562694 NONE valproate_22\VB\entity.n.01|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\increase.v.01|valproate (r_conj) treated_13\VBN\interact.v.01|man|was|with|)|added|. (l_nsubjpass) man_4\NN\adult.n.01|a|old|suffering (l_acl) suffering_5\VBG\pain.n.01|from|with (l_prep) from_6\IN\entity.n.01|epilepsy (l_pobj) epilepsy_8\NN\brain_disorder.n.01|idiopathic
D014635_C562694 NONE vpa_24\NNP\entity.n.01| (r_dobj) valproate_22\VB\entity.n.01|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\increase.v.01|valproate (r_conj) treated_13\VBN\interact.v.01|man|was|with|)|added|. (l_nsubjpass) man_4\NN\adult.n.01|a|old|suffering (l_acl) suffering_5\VBG\pain.n.01|from|with (l_prep) from_6\IN\entity.n.01|epilepsy (l_pobj) epilepsy_8\NN\brain_disorder.n.01|idiopathic
D014635_D012640 NONE valproate_22\VB\entity.n.01|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\increase.v.01|valproate (r_conj) treated_13\VBN\interact.v.01|man|was|with|)|added|. (l_nsubjpass) man_4\NN\adult.n.01|a|old|suffering (l_acl) suffering_5\VBG\pain.n.01|from|with (l_prep) with_9\IN\entity.n.01|seizures (l_pobj) seizures_11\NNS\attack.n.07|generalized
D014635_D012640 NONE vpa_24\NNP\entity.n.01| (r_dobj) valproate_22\VB\entity.n.01|to|(|vpa|)|(|mg|) (r_xcomp) added_20\VBN\increase.v.01|valproate (r_conj) treated_13\VBN\interact.v.01|man|was|with|)|added|. (l_nsubjpass) man_4\NN\adult.n.01|a|old|suffering (l_acl) suffering_5\VBG\pain.n.01|from|with (l_prep) with_9\IN\entity.n.01|seizures (l_pobj) seizures_11\NNS\attack.n.07|generalized
2515254
D005996_D008881 CID nitroglycerin_11\NN\nitrate.n.01|(|patients (r_pobj) of_10\IN\entity.n.01|nitroglycerin (r_prep) application_9\NN\use.n.01|a|one|sided|frontotemporal|of (r_dobj) received_4\VBD\get.v.01|patients|application|. (l_nsubj) patients_3\NNS\case.n.06|twenty|common|migraine (l_compound) migraine_2\NN\headache.n.02|
D005996_D008881 CID nitroglycerin_7\NN\nitrate.n.01| (r_pobj) by_6\IN\by.r.01|nitroglycerin (r_agent) induced_5\VBN\generate.v.01|attacks|were|by|in|. (l_nsubjpass) attacks_3\NNS\operation.n.05|early|onset|migraine (l_compound) migraine_2\NN\headache.n.02|
D005996_D008881 CID nitroglycerin_13\NN\nitrate.n.01|frontotemporal (r_pobj) with_11\IN\entity.n.01|nitroglycerin (r_prep) attack_10\NN\operation.n.05|an|early|onset|with (r_dobj) developed_6\VBD\create.v.02|who|attack (r_relcl) patients_3\NNS\case.n.06|20|migraine|,|developed|, (l_compound) migraine_2\NN\headache.n.02|
D005996_D008881 CID nitroglycerin_7\NN\nitrate.n.01| (r_pobj) of_6\IN\entity.n.01|nitroglycerin (r_prep) effect_5\NN\phenomenon.n.01|the|inducing|of (l_amod) inducing_4\VBG\causing.n.01|migraine|- (l_npadvmod) migraine_2\NN\headache.n.02|
D005996_D008881 CID nitroglycerin_7\NN\nitrate.n.01| (r_pobj) of_6\IN\entity.n.01|nitroglycerin (r_prep) effect_5\NN\phenomenon.n.01|the|inducing|of (r_nsubj) seems_8\VBZ\be.v.01|thus|effect|depend|,|suggesting|. (l_advcl) suggesting_21\VBG\declare.v.01|is (l_ccomp) is_26\VBZ\be.v.01|that|region|of (l_prep) of_27\IN\entity.n.01|importance (l_pobj) importance_29\NN\value.n.02|crucial|in (l_prep) in_30\IN\linear_unit.n.01|development (l_pobj) development_32\NN\improvement.n.02|the|of (l_prep) of_33\IN\entity.n.01|crisis (l_pobj) crisis_36\NN\situation.n.03|a|migraine (l_compound) migraine_35\JJ\headache.n.02|
D005996_D010146 NONE nitroglycerin_7\NN\nitrate.n.01| (r_pobj) of_6\IN\entity.n.01|nitroglycerin (r_prep) effect_5\NN\phenomenon.n.01|the|inducing|of (r_nsubj) seems_8\VBZ\be.v.01|thus|effect|depend|,|suggesting|. (l_xcomp) depend_10\VB\be.v.01|to|on (l_prep) on_11\IN\on.a.01|stimulation (l_pobj) stimulation_13\NN\arousal.n.01|direct|of (l_prep) of_14\IN\entity.n.01|site (l_pobj) site_17\NN\tract.n.01|the|habitual|of (l_prep) of_18\IN\entity.n.01|pain (l_pobj) pain_19\NN\symptom.n.01|
18752389
C492458_D017093 NONE ezetimibe_2\NN\entity.n.01|simvastatin|- (r_npadvmod) induced_4\VBN\generate.v.01|ezetimibe|- (r_amod) failure_6\NN\nonaccomplishment.n.01|induced|hepatic|necessitating|.
C492458_D017093 NONE ezetimibe_13\NN\entity.n.01|simvastatin|- (r_npadvmod) induced_15\VBN\generate.v.01|ezetimibe|- (r_amod) failure_17\NN\nonaccomplishment.n.01|induced|liver|resulted
C108606_D056486 NONE ezetimibe_10\NN\entity.n.01|or|agent (r_pobj) with_9\IN\entity.n.01|ezetimibe (r_prep) published_8\VBN\produce.v.02|however|,|events|have|not|been|widely|with|. (l_nsubjpass) events_3\NNS\psychological_feature.n.01|hepatotoxic (l_amod) hepatotoxic_2\JJ\hepatotoxic.s.01|
C108606_D056486 NONE ezetimibe_0\NNP\entity.n.01| (r_nsubj) undergoes_1\VBZ\change.v.02|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN\control.v.02|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\prove.v.01|in (l_prep) in_28\IN\linear_unit.n.01|exposure (l_pobj) exposure_31\NN\vulnerability.n.02|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\entity.n.01|subsequent
C108606_D056486 NONE ezetimibe_17\NN\entity.n.01| (r_compound) inhibition_18\NN\abstinence.n.02|ezetimibe|of (r_pobj) by_16\IN\by.r.01|inhibition (r_prep) exposure_15\NN\vulnerability.n.02|the|increased|simvastatin|by (r_attr) is_11\VBZ\be.v.01|that|mechanism|exposure (l_nsubj) mechanism_4\NN\chemical_process.n.01|the|of (l_prep) of_5\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_10\NN\entity.n.01|the|induced
C492458_D056486 CID ezetimibe_17\NN\entity.n.01|simvastatin|- (r_appos) agent_14\NN\causal_agent.n.01|the|combination|ezetimibe (r_conj) ezetimibe_10\NN\entity.n.01|or|agent (r_pobj) with_9\IN\entity.n.01|ezetimibe (r_prep) published_8\VBN\produce.v.02|however|,|events|have|not|been|widely|with|. (l_nsubjpass) events_3\NNS\psychological_feature.n.01|hepatotoxic (l_amod) hepatotoxic_2\JJ\hepatotoxic.s.01|
C492458_D056486 CID simvastatinezetimibe_0\NNP\entity.n.01|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN\discontinue.v.01|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\extinguish.v.04|causes|were|. (l_nsubjpass) causes_17\NNS\origin.n.03|other|potential|of (l_prep) of_18\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_19\NN\entity.n.01|
C492458_D056486 CID simvastatinezetimibe_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|simvastatinezetimibe|- (r_amod) hepatotoxicity_10\NN\entity.n.01|the|induced
C492458_D056486 CID ezetimibe_10\NN\entity.n.01|simvastatin|-|in (r_pobj) with_7\IN\entity.n.01|ezetimibe (r_prep) hepatotoxicity_6\NN\entity.n.01|potential|with
D019821_D017114 NONE simvastatin_21\NN\lipid-lowering_medicine.n.01| (r_nmod) day_25\NN\time_unit.n.01|simvastatin|40|mg|/ (r_pobj) from_20\IN\entity.n.01|day (r_prep) conversion_19\NN\transformation.n.01|from (r_pobj) after_18\IN\after.s.01|weeks|conversion (r_prep) necessitating_13\VBG\necessitate.v.01|transplantation|after|simvastatin (r_acl) failure_12\NN\nonaccomplishment.n.01|fulminant|hepatic|necessitating
C492458_D017114 CID mg_33\NN\metric_weight_unit.n.01|40 (r_nummod) day_35\NN\time_unit.n.01|mg|/ (r_npadvmod) ezetimibe_31\NN\entity.n.01|10|mg|-|day (r_dobj) simvastatin_27\NN\lipid-lowering_medicine.n.01|to|ezetimibe (r_advcl) necessitating_13\VBG\necessitate.v.01|transplantation|after|simvastatin (r_acl) failure_12\NN\nonaccomplishment.n.01|fulminant|hepatic|necessitating
D019821_D056486 NONE simvastatin_9\NN\lipid-lowering_medicine.n.01| (r_pobj) with_8\IN\entity.n.01|simvastatin (r_prep) maintained_7\VBN\keep.v.01|panel|had|been|with|for|. (l_prep) for_10\IN\entity.n.01|months (l_pobj) months_12\NNS\time_period.n.01|18|before (l_prep) before_13\IN\earlier.r.01|conversion (l_pobj) conversion_15\NN\transformation.n.01|the|without (l_prep) without_16\IN\entity.n.01|evidence (l_pobj) evidence_17\NN\information.n.02|of (l_prep) of_18\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_19\NN\entity.n.01|
D019821_D056486 NONE simvastatin_30\NN\lipid-lowering_medicine.n.01| (r_amod) exposure_31\NN\vulnerability.n.02|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\entity.n.01|subsequent
D019821_D056486 NONE simvastatin_14\NN\lipid-lowering_medicine.n.01| (r_amod) exposure_15\NN\vulnerability.n.02|the|increased|simvastatin|by (r_attr) is_11\VBZ\be.v.01|that|mechanism|exposure (l_nsubj) mechanism_4\NN\chemical_process.n.01|the|of (l_prep) of_5\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_10\NN\entity.n.01|the|induced
C492458_D003866 NONE simvastatinezetimibe_0\NNP\entity.n.01|and|escitalopram|(|taking|) (l_relcl) taking_7\VBG\action.n.01|which|she|was|for (l_prep) for_8\IN\entity.n.01|depression (l_pobj) depression_9\NN\psychological_state.n.01|
D015283_D003866 NONE escitalopram_2\NNP\entity.n.01| (r_conj) simvastatinezetimibe_0\NNP\entity.n.01|and|escitalopram|(|taking|) (l_relcl) taking_7\VBG\action.n.01|which|she|was|for (l_prep) for_8\IN\entity.n.01|depression (l_pobj) depression_9\NN\psychological_state.n.01|
D015283_D056486 NONE escitalopram_2\NNP\entity.n.01| (r_conj) simvastatinezetimibe_0\NNP\entity.n.01|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN\discontinue.v.01|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\extinguish.v.04|causes|were|. (l_nsubjpass) causes_17\NNS\origin.n.03|other|potential|of (l_prep) of_18\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_19\NN\entity.n.01|
D014530_D056486 NONE diphosphate_6\NN\entity.n.01|uridine (r_compound) glucoronosyltransferases_7\NNS\entity.n.01|diphosphate|ugt|in (r_pobj) by_4\IN\by.r.01|glucoronosyltransferases (r_prep) glucuronidation_3\NN\entity.n.01|extensive|by (r_dobj) undergoes_1\VBZ\change.v.02|ezetimibe|glucuronidation|and|inhibited|. (l_conj) inhibited_19\VBN\control.v.02|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\prove.v.01|in (l_prep) in_28\IN\linear_unit.n.01|exposure (l_pobj) exposure_31\NN\vulnerability.n.02|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\entity.n.01|subsequent
C532833_D056486 NONE acid_25\NN\compound.n.02|simvastatin|hydroxy (r_pobj) of_22\IN\entity.n.01|acid (r_prep) glucuronidation_21\NN\entity.n.01|the|of (r_dobj) inhibited_19\VBN\control.v.02|may|have|glucuronidation|,|resulting (l_advcl) resulting_27\VBG\prove.v.01|in (l_prep) in_28\IN\linear_unit.n.01|exposure (l_pobj) exposure_31\NN\vulnerability.n.02|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\entity.n.01|subsequent
10743446
D007649_D006930 NONE ketamine_5\NN\club_drug.n.01|administered|and|lidocaine|on (l_prep) on_8\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_12\NN\entity.n.01|dynamic
D007649_D006930 NONE ketamine_9\NN\club_drug.n.01|and|lidocaine (r_pobj) of_8\IN\entity.n.01|ketamine (r_prep) administration_7\NN\management.n.01|systemic|of|on (l_prep) on_12\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_27\NN\entity.n.01|pain|evoked|(|static|)
D007649_D006930 NONE ketamine_0\NN\club_drug.n.01| (r_nsubj) reduced_1\VBD\decrease.v.02|ketamine|area|significantly|and|tended (l_dobj) area_4\NN\region.n.03|both|the|of (l_prep) of_5\IN\entity.n.01|hyperalgesia (l_pobj) hyperalgesia_13\NN\entity.n.01|evoked
D007649_D006930 NONE ketamine_4\NN\club_drug.n.01|and|lidocaine (r_pobj) of_3\IN\entity.n.01|ketamine (r_prep) effects_2\NNS\personal_property.n.01|the|differential|of|on (l_prep) on_7\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_11\NN\entity.n.01|static
D007649_D006930 NONE ketamine_4\NN\club_drug.n.01|and|lidocaine (r_pobj) of_3\IN\entity.n.01|ketamine (r_prep) effects_2\NNS\personal_property.n.01|the|differential|of|on (r_nsubj) suggest_12\VBP\declare.v.01|effects|mediated|. (l_ccomp) mediated_20\VBN\negociate.v.06|that|types|are|by|and|have (l_nsubjpass) types_16\NNS\kind.n.01|the|two|of (l_prep) of_17\IN\entity.n.01|hyperalgesia (l_pobj) hyperalgesia_18\NN\entity.n.01|
D008012_D006930 NONE lidocaine_7\NN\local_anesthetic.n.01| (r_conj) ketamine_5\NN\club_drug.n.01|administered|and|lidocaine|on (l_prep) on_8\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_12\NN\entity.n.01|dynamic
D008012_D006930 NONE lidocaine_11\NN\local_anesthetic.n.01| (r_conj) ketamine_9\NN\club_drug.n.01|and|lidocaine (r_pobj) of_8\IN\entity.n.01|ketamine (r_prep) administration_7\NN\management.n.01|systemic|of|on (l_prep) on_12\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_27\NN\entity.n.01|pain|evoked|(|static|)
D008012_D006930 NONE lidocaine_0\NN\local_anesthetic.n.01| (r_nsubj) reduced_1\VBD\decrease.v.02|lidocaine|area|significantly|. (l_dobj) area_3\NN\region.n.03|the|of (l_prep) of_4\IN\entity.n.01|hyperalgesia (l_pobj) hyperalgesia_8\NN\entity.n.01|evoked
D008012_D006930 NONE lidocaine_6\NN\local_anesthetic.n.01| (r_conj) ketamine_4\NN\club_drug.n.01|and|lidocaine (r_pobj) of_3\IN\entity.n.01|ketamine (r_prep) effects_2\NNS\personal_property.n.01|the|differential|of|on (l_prep) on_7\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_11\NN\entity.n.01|static
D008012_D006930 NONE lidocaine_6\NN\local_anesthetic.n.01| (r_conj) ketamine_4\NN\club_drug.n.01|and|lidocaine (r_pobj) of_3\IN\entity.n.01|ketamine (r_prep) effects_2\NNS\personal_property.n.01|the|differential|of|on (r_nsubj) suggest_12\VBP\declare.v.01|effects|mediated|. (l_ccomp) mediated_20\VBN\negociate.v.06|that|types|are|by|and|have (l_nsubjpass) types_16\NNS\kind.n.01|the|two|of (l_prep) of_17\IN\entity.n.01|hyperalgesia (l_pobj) hyperalgesia_18\NN\entity.n.01|
D002211_D006930 CID capsaicin_16\NN\chemical_irritant.n.01|intradermal|in (r_pobj) by_14\IN\by.r.01|capsaicin (r_agent) induced_13\VBN\generate.v.01|by (r_acl) effects_1\NNS\personal_property.n.01|differential|of|induced|. (l_prep) of_2\IN\entity.n.01|ketamine (l_pobj) ketamine_5\NN\club_drug.n.01|administered|and|lidocaine|on (l_prep) on_8\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_12\NN\entity.n.01|dynamic
D002211_D006930 CID capsaicin_30\NN\chemical_irritant.n.01| (r_pobj) by_29\IN\by.r.01|capsaicin (r_agent) induced_28\VBN\generate.v.01|by (r_acl) effect_4\NN\phenomenon.n.01|the|of|induced (l_prep) of_5\IN\entity.n.01|administration (l_pobj) administration_7\NN\management.n.01|systemic|of|on (l_prep) on_12\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_27\NN\entity.n.01|pain|evoked|(|static|)
D007649_D010146 NONE ketamine_9\NN\club_drug.n.01|and|lidocaine (r_pobj) of_8\IN\entity.n.01|ketamine (r_prep) administration_7\NN\management.n.01|systemic|of|on (l_prep) on_12\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_27\NN\entity.n.01|pain|evoked|(|static|) (l_nmod) pain_19\NN\symptom.n.01|evoked|(|dynamic|)|and
D007649_D010146 NONE ketamine_0\NN\club_drug.n.01| (r_nsubj) reduced_1\VBD\decrease.v.02|ketamine|area|significantly|and|tended (l_conj) tended_17\VBD\be.v.01|it|reduce|. (l_xcomp) reduce_19\VB\decrease.v.02|to|pain (l_dobj) pain_23\NN\symptom.n.01|evoked
D008012_D010146 NONE lidocaine_11\NN\local_anesthetic.n.01| (r_conj) ketamine_9\NN\club_drug.n.01|and|lidocaine (r_pobj) of_8\IN\entity.n.01|ketamine (r_prep) administration_7\NN\management.n.01|systemic|of|on (l_prep) on_12\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_27\NN\entity.n.01|pain|evoked|(|static|) (l_nmod) pain_19\NN\symptom.n.01|evoked|(|dynamic|)|and
D002211_D010146 CID capsaicin_30\NN\chemical_irritant.n.01| (r_pobj) by_29\IN\by.r.01|capsaicin (r_agent) induced_28\VBN\generate.v.01|by (r_acl) effect_4\NN\phenomenon.n.01|the|of|induced (l_prep) of_5\IN\entity.n.01|administration (l_pobj) administration_7\NN\management.n.01|systemic|of|on (l_prep) on_12\IN\on.a.01|hyperalgesia (l_pobj) hyperalgesia_27\NN\entity.n.01|pain|evoked|(|static|) (l_nmod) pain_19\NN\symptom.n.01|evoked|(|dynamic|)|and
16938416
D013739_D050197 CID testosterone_3\NN\androgen.n.01|dose (r_nsubjpass) associated_5\VBN\think.v.03|testosterone|is|with|. (l_prep) with_6\IN\entity.n.01|atherosclerosis (l_pobj) atherosclerosis_7\NN\arteriosclerosis.n.01|in
D013739_D050197 CID testosterone_32\NN\androgen.n.01|estrogen|- (r_compound) therapy_33\NN\medical_care.n.01|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN\arteriosclerosis.n.01|aortic
D013739_D050197 CID testosterone_7\NN\androgen.n.01| (r_compound) therapy_8\NN\medical_care.n.01|dose|testosterone (r_nsubj) affect_11\VB\feeling.n.01|that|therapy|may|adversely|atherosclerosis|and|indicate (l_dobj) atherosclerosis_12\NN\arteriosclerosis.n.01|in
D004967_D050197 NONE estrogen_30\NN\steroid_hormone.n.01| (r_compound) testosterone_32\NN\androgen.n.01|estrogen|- (r_compound) therapy_33\NN\medical_care.n.01|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN\arteriosclerosis.n.01|aortic
C032109_D050197 NONE esters_38\NNS\organic_compound.n.01|estradiol- (r_appos) therapy_33\NN\medical_care.n.01|reported|administered|dose|testosterone|esters|)|and|atherosclerosis (l_conj) atherosclerosis_42\NN\arteriosclerosis.n.01|aortic
D002784_D003920 NONE cholesterol_9\NN\sterol.n.01| (r_compound) level_10\NN\property.n.02|cholesterol|,|pressure (r_conj) diabetes_7\NNS\polygenic_disorder.n.01|,|level
D000431_D003920 NONE alcohol_17\NN\beverage.n.01| (r_compound) use_18\NN\activity.n.01|alcohol (r_conj) pressure_14\NN\physical_phenomenon.n.01|systolic|blood|,|or|use (r_conj) level_10\NN\property.n.02|cholesterol|,|pressure (r_conj) diabetes_7\NNS\polygenic_disorder.n.01|,|level
3496378
D014217_D002779 CID troleandomycin_3\NN\entity.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|troleandomycin|- (r_amod) hepatitis_7\NN\infectious_disease.n.01|induced|acute (r_pobj) after_2\IN\after.s.01|hepatitis (r_prep) cholestasis_1\NN\disorder.n.01|prolonged|after|.
D014217_D002779 CID troleandomycin_9\NN\entity.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|in|troleandomycin|- (r_relcl) patient_6\NN\case.n.06|a|induced (r_pobj) of_4\IN\entity.n.01|patient (r_prep) case_3\NN\happening.n.01|the|of (r_dobj) report_1\VBP\document.n.01|we|case|followed|. (l_ccomp) followed_14\VBN\travel.v.01|hepatitis|was|by (l_agent) by_15\IN\by.r.01|cholestasis (l_pobj) cholestasis_18\NN\disorder.n.01|prolonged|anicteric
D014217_D002779 CID troleandomycin_8\NN\entity.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|troleandomycin|- (r_amod) hepatitis_12\NN\infectious_disease.n.01|induced|acute (r_dobj) follow_7\VB\travel.v.01|that|cholestasis|can|hepatitis (l_nsubj) cholestasis_5\NN\disorder.n.01|prolonged
D014217_D056486 CID troleandomycin_3\NN\entity.n.01| (r_npadvmod) induced_5\VBN\generate.v.01|troleandomycin|- (r_amod) hepatitis_7\NN\infectious_disease.n.01|induced|acute
D014217_D056486 CID troleandomycin_9\NN\entity.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|in|troleandomycin|- (r_relcl) patient_6\NN\case.n.06|a|induced (r_pobj) of_4\IN\entity.n.01|patient (r_prep) case_3\NN\happening.n.01|the|of (r_dobj) report_1\VBP\document.n.01|we|case|followed|. (l_ccomp) followed_14\VBN\travel.v.01|hepatitis|was|by (l_nsubjpass) hepatitis_12\NN\infectious_disease.n.01|
D014217_D056486 CID troleandomycin_8\NN\entity.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|troleandomycin|- (r_amod) hepatitis_12\NN\infectious_disease.n.01|induced|acute
D014217_D007565 CID troleandomycin_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|troleandomycin (r_prep) administration_3\NN\management.n.01|of (r_pobj) after_2\IN\after.s.01|administration (r_prep) occurred_1\VBD\happen.v.01|jaundice|after|for|and|associated|. (l_nsubj) jaundice_0\NN\symptom.n.01|
D014217_D004802 CID troleandomycin_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|troleandomycin (r_prep) administration_3\NN\management.n.01|of (r_pobj) after_2\IN\after.s.01|administration (r_prep) occurred_1\VBD\happen.v.01|jaundice|after|for|and|associated|. (l_conj) associated_11\VBN\think.v.03|was|with (l_prep) with_12\IN\entity.n.01|hypereosinophilia (l_pobj) hypereosinophilia_13\NNS\entity.n.01|
7199841
C004616_D010243 CID ce_11\NN\metallic_element.n.01|2-chloroprocaine|- (r_nmod) %_15\NN\entity.n.01|ce|seven|35 (r_pobj) of_8\IN\entity.n.01|% (r_prep) injection_7\NN\insertion.n.02|subarachnoid|of (r_dobj) received_5\VBD\get.v.01|that|injection (r_relcl) animals_3\NNS\organism.n.01|the|20|received|) (r_pobj) of_0\IN\entity.n.01|animals (r_prep) paralysis_21\NN\dysfunction.n.01|of|developed|limb|.
D002045_D010243 NONE bupivacaine_6\NN\entity.n.01| (r_dobj) received_5\VBD\get.v.01|that|bupivacaine (r_relcl) animals_3\NNS\organism.n.01|the|received (r_pobj) of_1\IN\entity.n.01|animals (r_prep) none_0\NN\hour.n.02|of|,|saline (r_nsubj) titrated_14\VBN\quantify.v.02|none|to|. (l_prep) to_15\IN\entity.n.01|paralysis (l_pobj) paralysis_23\NN\dysfunction.n.01|a|ph|3.0|developed|limb
C004616_D013118 CID ce_12\NNP\metallic_element.n.01|2-chloroprocaine|- (r_dobj) received_9\VBD\get.v.01|that|ce (r_relcl) animals_7\NNS\organism.n.01|the|received (r_pobj) of_5\IN\entity.n.01|animals (r_prep) cords_4\NNS\trouser.n.01|the|15|spinal|of (r_pobj) of_0\IN\entity.n.01|cords (r_prep) 13_14\CD\large_integer.n.01|of (r_nsubj) showed_15\VBD\show.v.04|,|13|necrosis (l_dobj) necrosis_17\NN\death.n.02|subpial
8387218
D016049_D064420 NONE didanosine_5\NN\antiviral.n.01|ddi|in (r_pobj) of_4\IN\entity.n.01|didanosine (r_prep) use_1\NN\activity.n.01|the|and|toxicity|of|) (l_conj) toxicity_3\NN\definite_quantity.n.01|
D016049_D064420 NONE ddi_7\NN\antiviral.n.01|(|) (r_appos) didanosine_5\NN\antiviral.n.01|ddi|in (r_pobj) of_4\IN\entity.n.01|didanosine (r_prep) use_1\NN\activity.n.01|the|and|toxicity|of|) (l_conj) toxicity_3\NN\definite_quantity.n.01|
D016049_D015658 NONE didanosine_5\NN\antiviral.n.01|ddi|in (l_prep) in_9\IN\linear_unit.n.01|individuals (l_pobj) individuals_14\NNS\causal_agent.n.01|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\adjective.n.01|antibody|-
D016049_D015658 NONE ddi_7\NN\antiviral.n.01|(|) (r_appos) didanosine_5\NN\antiviral.n.01|ddi|in (l_prep) in_9\IN\linear_unit.n.01|individuals (l_pobj) individuals_14\NNS\causal_agent.n.01|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\adjective.n.01|antibody|-
D015215_D064420 NONE zidovudine_17\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) to_16\IN\entity.n.01|zidovudine (r_prep) intolerant_15\JJ\intolerant.a.01|to (r_amod) individuals_14\NNS\causal_agent.n.01|hiv|positive|intolerant|azt (r_pobj) in_9\IN\linear_unit.n.01|individuals (r_prep) didanosine_5\NN\antiviral.n.01|ddi|in (r_pobj) of_4\IN\entity.n.01|didanosine (r_prep) use_1\NN\activity.n.01|the|and|toxicity|of|) (l_conj) toxicity_3\NN\definite_quantity.n.01|
D015215_D064420 NONE azt_19\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01|( (r_appos) individuals_14\NNS\causal_agent.n.01|hiv|positive|intolerant|azt (r_pobj) in_9\IN\linear_unit.n.01|individuals (r_prep) didanosine_5\NN\antiviral.n.01|ddi|in (r_pobj) of_4\IN\entity.n.01|didanosine (r_prep) use_1\NN\activity.n.01|the|and|toxicity|of|) (l_conj) toxicity_3\NN\definite_quantity.n.01|
D015215_D015658 NONE zidovudine_17\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) to_16\IN\entity.n.01|zidovudine (r_prep) intolerant_15\JJ\intolerant.a.01|to (r_amod) individuals_14\NNS\causal_agent.n.01|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\adjective.n.01|antibody|-
D015215_D015658 NONE azt_19\NNP\nucleoside_reverse_transcriptase_inhibitor.n.01|( (r_appos) individuals_14\NNS\causal_agent.n.01|hiv|positive|intolerant|azt (l_amod) positive_13\JJ\adjective.n.01|antibody|-
D016049_D018149 CID didanosine_24\NN\antiviral.n.01| (r_dobj) ceasing_23\VBG\discontinue.v.01|didanosine (r_pcomp) on_22\IN\on.a.01|ceasing (r_prep) returned_19\VBN\travel.v.01|to|on (r_conj) require_16\VB\necessitate.v.01|,|did|not|treatment|and|returned|. (r_conj) developed_2\VBD\create.v.02|patients|curves|but|were|require (l_dobj) curves_5\VBZ\line.n.04|tolerance|characteristic
D016049_D003920 NONE didanosine_24\NN\antiviral.n.01| (r_dobj) ceasing_23\VBG\discontinue.v.01|didanosine (r_pcomp) on_22\IN\on.a.01|ceasing (r_prep) returned_19\VBN\travel.v.01|to|on (r_conj) require_16\VB\necessitate.v.01|,|did|not|treatment|and|returned|. (r_conj) developed_2\VBD\create.v.02|patients|curves|but|were|require (l_dobj) curves_5\VBZ\line.n.04|tolerance|characteristic (l_amod) characteristic_6\JJ\property.n.04|of (l_prep) of_7\IN\entity.n.01|diabetes (l_pobj) diabetes_8\NNS\polygenic_disorder.n.01|
6888657
D004967_D010911 NONE estrogen_2\NN\steroid_hormone.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|estrogen|- (r_amod) tumors_6\NNS\growth.n.06|induced|adenohypophyseal|in
D004054_D010911 CID diethylstilbestrol_12\NN\estrogen.n.01| (r_pobj) with_11\IN\entity.n.01|diethylstilbestrol (r_prep) treatment_10\NN\care.n.01|chronic|with (r_pobj) by_8\IN\by.r.01|treatment (r_agent) induced_3\VBN\generate.v.01|tumors|were|in|by|implanted|. (l_nsubjpass) tumors_1\NNS\growth.n.06|pituitary
D004054_D010911 CID des_14\NNP\estrogen.n.01| (r_npadvmod) implanted_21\VBN\insert.v.01|(|des|,|subcutaneously|in (r_parataxis) induced_3\VBN\generate.v.01|tumors|were|in|by|implanted|. (l_nsubjpass) tumors_1\NNS\growth.n.06|pituitary
D004054_D009369 NONE des_12\NNP\estrogen.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|des|- (r_amod) tumor_15\NN\growth.n.06|the|induced
8092427
D000658_D004342 CID amoxicillin_4\NNP\penicillin.n.01| (r_pobj) to_3\IN\entity.n.01|amoxicillin (r_prep) reactions_2\NNS\chemical_process.n.01|immediate|allergic|to|.
D000658_D004342 CID amoxicillin_39\NNP\penicillin.n.01|ax (r_pobj) to_38\IN\entity.n.01|amoxicillin (r_prep) responses_37\NNS\consequence.n.01|selective|immediate|allergic|to (r_dobj) had_33\VBD\have.v.01|responses|or|were (r_conj) used_22\VBN\use.v.01|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB\open.v.02|to|allergic (l_ccomp) allergic_27\JJ\allergic.a.01|whether|patients|to
D000658_D004342 CID amoxicillin_39\NNP\penicillin.n.01|ax (r_pobj) to_38\IN\entity.n.01|amoxicillin (r_prep) responses_37\NNS\consequence.n.01|selective|immediate|allergic|to (l_amod) allergic_36\JJ\allergic.a.01|
D000658_D004342 CID ax_41\NN\edge_tool.n.01|(|) (r_appos) amoxicillin_39\NNP\penicillin.n.01|ax (r_pobj) to_38\IN\entity.n.01|amoxicillin (r_prep) responses_37\NNS\consequence.n.01|selective|immediate|allergic|to (r_dobj) had_33\VBD\have.v.01|responses|or|were (r_conj) used_22\VBN\use.v.01|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB\open.v.02|to|allergic (l_ccomp) allergic_27\JJ\allergic.a.01|whether|patients|to
D000658_D004342 CID ax_41\NN\edge_tool.n.01|(|) (r_appos) amoxicillin_39\NNP\penicillin.n.01|ax (r_pobj) to_38\IN\entity.n.01|amoxicillin (r_prep) responses_37\NNS\consequence.n.01|selective|immediate|allergic|to (l_amod) allergic_36\JJ\allergic.a.01|
D000658_D004342 CID ax_11\NNP\edge_tool.n.01| (r_compound) allergy_12\NN\hypersensitivity_reaction.n.01|immediate|ax|with
D000658_D004342 CID ax_3\NN\edge_tool.n.01| (r_pobj) with_2\IN\entity.n.01|ax (r_prep) tests_1\NNS\experiment.n.02|challenge|with (r_nsubjpass) performed_5\VBN\perform.v.01|tests|were|in|establish|and|were (l_advcl) establish_14\VB\open.v.02|to|diagnosis|, (l_dobj) diagnosis_16\NN\designation.n.03|the|of (l_prep) of_17\IN\entity.n.01|reaction (l_pobj) reaction_20\NN\chemical_process.n.01|immediate|allergic|to
D000658_D004342 CID ax_22\NN\edge_tool.n.01| (r_pobj) to_21\IN\entity.n.01|ax (r_prep) reaction_20\NN\chemical_process.n.01|immediate|allergic|to
D000658_D004342 CID ax_38\NN\edge_tool.n.01| (r_pobj) for_37\IN\entity.n.01|ax (r_prep) rast_36\NNP\entity.n.01|for (r_conj) test_34\NN\experiment.n.02|both|skin|and|rast (r_appos) %_30\NN\entity.n.01|28|)|test (r_nsubj) were_39\VBD\be.v.01|in|(|%|negative|. (r_conj) performed_5\VBN\perform.v.01|tests|were|in|establish|and|were (l_advcl) establish_14\VB\open.v.02|to|diagnosis|, (l_dobj) diagnosis_16\NN\designation.n.03|the|of (l_prep) of_17\IN\entity.n.01|reaction (l_pobj) reaction_20\NN\chemical_process.n.01|immediate|allergic|to
D000658_D004342 CID ax_6\NN\edge_tool.n.01| (r_npadvmod) allergic_8\JJ\allergic.a.01|ax|-
D047090_D004342 NONE lactam_12\NN\entity.n.01|beta|- (r_amod) antibiotics_13\NNS\antibacterial.n.01|lactam (r_pobj) to_9\IN\entity.n.01|antibiotics (r_prep) reactions_8\NNS\chemical_process.n.01|suspected|allergic|to
D047090_D004342 NONE lactam_31\NN\entity.n.01|beta|- (r_amod) antibiotics_32\NNS\antibacterial.n.01|lactam (r_pobj) to_28\IN\entity.n.01|antibiotics (r_prep) allergic_27\JJ\allergic.a.01|whether|patients|to
D047090_D004342 NONE lactam_31\NN\entity.n.01|beta|- (r_amod) antibiotics_32\NNS\antibacterial.n.01|lactam (r_pobj) to_28\IN\entity.n.01|antibiotics (r_prep) allergic_27\JJ\allergic.a.01|whether|patients|to (r_ccomp) establish_24\VB\open.v.02|to|allergic (r_xcomp) used_22\VBN\use.v.01|history|,|with|,|rast|was|establish|had|. (l_conj) had_33\VBD\have.v.01|responses|or|were (l_dobj) responses_37\NNS\consequence.n.01|selective|immediate|allergic|to (l_amod) allergic_36\JJ\allergic.a.01|
D047090_D004342 NONE lactam_12\NN\entity.n.01|beta|- (r_amod) antibiotics_13\NNS\antibacterial.n.01|lactam (r_pobj) to_9\IN\entity.n.01|antibiotics (r_prep) allergic_8\JJ\allergic.a.01|to
D010406_D004342 NONE penicillin_50\NN\antibiotic.n.01| (r_compound) derivatives_51\NNS\calculation.n.02|other|penicillin (r_pobj) with_48\IN\entity.n.01|derivatives (r_prep) reacting_47\VBG\act.v.01|cross|-|with (r_acomp) were_44\VBD\be.v.01|reacting (r_conj) had_33\VBD\have.v.01|responses|or|were (r_conj) used_22\VBN\use.v.01|history|,|with|,|rast|was|establish|had|. (l_xcomp) establish_24\VB\open.v.02|to|allergic (l_ccomp) allergic_27\JJ\allergic.a.01|whether|patients|to
D010406_D004342 NONE penicillin_50\NN\antibiotic.n.01| (r_compound) derivatives_51\NNS\calculation.n.02|other|penicillin (r_pobj) with_48\IN\entity.n.01|derivatives (r_prep) reacting_47\VBG\act.v.01|cross|-|with (r_acomp) were_44\VBD\be.v.01|reacting (r_conj) had_33\VBD\have.v.01|responses|or|were (l_dobj) responses_37\NNS\consequence.n.01|selective|immediate|allergic|to (l_amod) allergic_36\JJ\allergic.a.01|
D010400_D004342 NONE pg_17\NNP\entity.n.01| (r_pobj) of_16\IN\entity.n.01|pg (r_prep) tolerance_15\NN\endurance.n.01|good|of (r_pobj) with_13\IN\entity.n.01|tolerance (r_prep) allergy_12\NN\hypersensitivity_reaction.n.01|immediate|ax|with
D010400_D004342 NONE pg_13\NNP\entity.n.01| (r_dobj) tolerated_12\VBN\permit.v.01|who|have|pg (r_relcl) patients_9\NNS\case.n.06|allergic|tolerated (l_amod) allergic_8\JJ\allergic.a.01|ax|-
-1_D007645 NONE bpo_8\NNP\entity.n.01| (r_pobj) to_7\IN\entity.n.01|bpo (r_prep) negative_6\JJ\denial.n.01|to (r_amod) test_5\NN\experiment.n.02|skin|negative (r_attr) were_3\VBD\be.v.01|patients|test (r_ccomp) were_17\VBD\be.v.01|were|;|49|also|negative|,|and|44|. (l_acomp) negative_19\JJ\denial.n.01|to (l_prep) to_20\IN\entity.n.01|mdm (l_pobj) mdm_21\NNP\entity.n.01|
D010400_D007645 NONE pg_32\NNP\entity.n.01| (r_pobj) to_31\IN\entity.n.01|pg (r_prep) 44_24\CD\forty-four.s.01|of|%|)|to (r_conj) were_17\VBD\be.v.01|were|;|49|also|negative|,|and|44|. (l_acomp) negative_19\JJ\denial.n.01|to (l_prep) to_20\IN\entity.n.01|mdm (l_pobj) mdm_21\NNP\entity.n.01|
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN\entity.n.01|caa (r_nsubj) is_11\VBZ\be.v.01|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\substance.n.07|an|important|of|,|carried (l_relcl) carried_23\VBN\move.v.02|study|was|out|in (l_prep) in_25\IN\linear_unit.n.01|order (l_pobj) order_26\NN\command.n.01|elucidate (l_acl) elucidate_28\VB\explain.v.01|to|role|in (l_prep) in_33\IN\linear_unit.n.01|development (l_pobj) development_35\NN\improvement.n.02|the|of (l_prep) of_36\IN\entity.n.01|cystitis (l_pobj) cystitis_38\NN\urinary_tract_infection.n.01|hemorrhagic
C004656_D006470 CID caa_9\NNP\entity.n.01|(|) (r_appos) chloroacetaldehyde_7\NN\entity.n.01|caa (r_nsubj) is_11\VBZ\be.v.01|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\substance.n.07|an|important|of|,|carried (l_relcl) carried_23\VBN\move.v.02|study|was|out|in (l_prep) in_25\IN\linear_unit.n.01|order (l_pobj) order_26\NN\command.n.01|elucidate (l_acl) elucidate_28\VB\explain.v.01|to|role|in (l_prep) in_33\IN\linear_unit.n.01|development (l_pobj) development_35\NN\improvement.n.02|the|of (l_prep) of_36\IN\entity.n.01|cystitis (l_pobj) cystitis_38\NN\urinary_tract_infection.n.01|hemorrhagic
C004656_D006470 CID caa_32\NNP\entity.n.01| (r_pobj) of_31\IN\entity.n.01|caa (r_prep) role_30\NN\duty.n.02|the|of (r_dobj) elucidate_28\VB\explain.v.01|to|role|in (l_prep) in_33\IN\linear_unit.n.01|development (l_pobj) development_35\NN\improvement.n.02|the|of (l_prep) of_36\IN\entity.n.01|cystitis (l_pobj) cystitis_38\NN\urinary_tract_infection.n.01|hemorrhagic
C004656_D003556 CID chloroacetaldehyde_7\NN\entity.n.01|caa (r_nsubj) is_11\VBZ\be.v.01|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\substance.n.07|an|important|of|,|carried (l_relcl) carried_23\VBN\move.v.02|study|was|out|in (l_prep) in_25\IN\linear_unit.n.01|order (l_pobj) order_26\NN\command.n.01|elucidate (l_acl) elucidate_28\VB\explain.v.01|to|role|in (l_prep) in_33\IN\linear_unit.n.01|development (l_pobj) development_35\NN\improvement.n.02|the|of (l_prep) of_36\IN\entity.n.01|cystitis (l_pobj) cystitis_38\NN\urinary_tract_infection.n.01|hemorrhagic
C004656_D003556 CID caa_9\NNP\entity.n.01|(|) (r_appos) chloroacetaldehyde_7\NN\entity.n.01|caa (r_nsubj) is_11\VBZ\be.v.01|that|chloroacetaldehyde|metabolite (l_attr) metabolite_14\NN\substance.n.07|an|important|of|,|carried (l_relcl) carried_23\VBN\move.v.02|study|was|out|in (l_prep) in_25\IN\linear_unit.n.01|order (l_pobj) order_26\NN\command.n.01|elucidate (l_acl) elucidate_28\VB\explain.v.01|to|role|in (l_prep) in_33\IN\linear_unit.n.01|development (l_pobj) development_35\NN\improvement.n.02|the|of (l_prep) of_36\IN\entity.n.01|cystitis (l_pobj) cystitis_38\NN\urinary_tract_infection.n.01|hemorrhagic
C004656_D003556 CID caa_32\NNP\entity.n.01| (r_pobj) of_31\IN\entity.n.01|caa (r_prep) role_30\NN\duty.n.02|the|of (r_dobj) elucidate_28\VB\explain.v.01|to|role|in (l_prep) in_33\IN\linear_unit.n.01|development (l_pobj) development_35\NN\improvement.n.02|the|of (l_prep) of_36\IN\entity.n.01|cystitis (l_pobj) cystitis_38\NN\urinary_tract_infection.n.01|hemorrhagic
C004656_D001745 NONE caa_4\NNP\entity.n.01| (r_nsubj) contribute_10\VB\change.v.01|that|caa|after|administration|does|not|to (l_prep) to_11\IN\entity.n.01|damage (l_pobj) damage_13\NN\change.n.01|bladder
12617329
D006170_D007674 NONE arabic_6\JJ\semitic.n.01|gum (r_pobj) with_4\IN\entity.n.01|arabic (r_prep) treatment_3\NN\care.n.01|with|on (l_prep) on_7\IN\on.a.01|nephrotoxicity (l_pobj) nephrotoxicity_9\NN\entity.n.01|gentamicin|in
D006170_D007674 NONE arabic_14\JJ\semitic.n.01|gum (r_pobj) with_12\IN\entity.n.01|arabic (r_prep) rats_11\NNS\rodent.n.01|with (r_pobj) of_10\IN\entity.n.01|rats (r_prep) treatment_9\NN\care.n.01|of|on (l_prep) on_15\IN\on.a.01|failure (l_pobj) failure_18\NN\nonaccomplishment.n.01|acute|renal|induced (l_acl) induced_19\VBN\generate.v.01|by (l_agent) by_20\IN\by.r.01|nephrotoxicity (l_pobj) nephrotoxicity_25\NN\entity.n.01|gentamicin|(|gm|)
D006170_D007674 NONE arabic_6\JJ\semitic.n.01| (r_amod) treatment_7\NN\care.n.01|gum|arabic (r_nsubj) induced_9\VBN\generate.v.01|that|treatment|has|amelioration (l_dobj) amelioration_12\NN\improvement.n.02|a|modest|of (l_prep) of_13\IN\entity.n.01|some (l_pobj) some_14\DT\some.a.01|of (l_prep) of_15\IN\entity.n.01|indices (l_pobj) indices_20\NNS\scale.n.01|the|histological|of (l_prep) of_21\IN\entity.n.01|nephrotoxicity (l_pobj) nephrotoxicity_23\NN\entity.n.01|gm
D005839_D007674 NONE gentamicin_8\NN\antibiotic.n.01| (r_amod) nephrotoxicity_9\NN\entity.n.01|gentamicin|in
D005839_D007674 NONE gentamicin_21\NN\antibiotic.n.01| (r_nmod) nephrotoxicity_25\NN\entity.n.01|gentamicin|(|gm|)
D005839_D007674 NONE gm_23\NNP\metric_weight_unit.n.01| (r_nmod) nephrotoxicity_25\NN\entity.n.01|gentamicin|(|gm|)
D005839_D007674 NONE gm_22\NNP\metric_weight_unit.n.01| (r_compound) nephrotoxicity_23\NN\entity.n.01|gm
D006170_D058186 CID arabic_14\JJ\semitic.n.01|gum (r_pobj) with_12\IN\entity.n.01|arabic (r_prep) rats_11\NNS\rodent.n.01|with (r_pobj) of_10\IN\entity.n.01|rats (r_prep) treatment_9\NN\care.n.01|of|on (l_prep) on_15\IN\on.a.01|failure (l_pobj) failure_18\NN\nonaccomplishment.n.01|acute|renal|induced
D005839_D058186 CID gentamicin_21\NN\antibiotic.n.01| (r_nmod) nephrotoxicity_25\NN\entity.n.01|gentamicin|(|gm|) (r_pobj) by_20\IN\by.r.01|nephrotoxicity (r_agent) induced_19\VBN\generate.v.01|by (r_acl) failure_18\NN\nonaccomplishment.n.01|acute|renal|induced
D005839_D058186 CID gm_23\NNP\metric_weight_unit.n.01| (r_nmod) nephrotoxicity_25\NN\entity.n.01|gentamicin|(|gm|) (r_pobj) by_20\IN\by.r.01|nephrotoxicity (r_agent) induced_19\VBN\generate.v.01|by (r_acl) failure_18\NN\nonaccomplishment.n.01|acute|renal|induced
D003404_D007674 NONE creatinine_8\NN\entity.n.01|and|urea (r_pobj) of_7\IN\entity.n.01|creatinine (r_prep) concentrations_6\NNS\property.n.02|the|of|in (r_dobj) measuring_4\VBG\activity.n.01|concentrations|and|glutathione (r_pcomp) by_3\IN\by.r.01|measuring|and|by (r_prep) assessed_2\VBN\evaluate.v.02|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\entity.n.01|
D014508_D007674 NONE urea_10\NN\organic_compound.n.01| (r_conj) creatinine_8\NN\entity.n.01|and|urea (r_pobj) of_7\IN\entity.n.01|creatinine (r_prep) concentrations_6\NNS\property.n.02|the|of|in (r_dobj) measuring_4\VBG\activity.n.01|concentrations|and|glutathione (r_pcomp) by_3\IN\by.r.01|measuring|and|by (r_prep) assessed_2\VBN\evaluate.v.02|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\entity.n.01|
D005978_D007674 NONE glutathione_16\NN\entity.n.01|reduced|gsh|in|, (r_conj) measuring_4\VBG\activity.n.01|concentrations|and|glutathione (r_pcomp) by_3\IN\by.r.01|measuring|and|by (r_prep) assessed_2\VBN\evaluate.v.02|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\entity.n.01|
D005978_D007674 NONE gsh_18\NNP\entity.n.01|(|) (r_appos) glutathione_16\NN\entity.n.01|reduced|gsh|in|, (r_conj) measuring_4\VBG\activity.n.01|concentrations|and|glutathione (r_pcomp) by_3\IN\by.r.01|measuring|and|by (r_prep) assessed_2\VBN\evaluate.v.02|nephrotoxicity|was|by|. (l_nsubjpass) nephrotoxicity_0\NN\entity.n.01|
D005839_D007683 NONE gm_1\NNP\metric_weight_unit.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|gm|- (r_amod) necrosis_6\NN\death.n.02|the|induced|proximal|tubular
D005839_D007683 NONE gm_16\NNP\metric_weight_unit.n.01| (r_dobj) given_15\VBN\assumption.n.02|gm|with|than (r_acl) rats_14\NNS\rodent.n.01|given (r_pobj) in_13\IN\linear_unit.n.01|rats (r_prep) severe_12\JJ\severe.s.01|less|in (r_acomp) be_9\VB\metallic_element.n.01|to|severe (r_xcomp) appeared_7\VBD\be.v.01|necrosis|be|. (l_nsubj) necrosis_6\NN\death.n.02|the|induced|proximal|tubular
D005839_D007683 NONE gm_25\NNP\metric_weight_unit.n.01|and|cellulose (r_pobj) given_24\VBN\assumption.n.02|gm (r_acl) those_23\DT\entity.n.01|given (r_pobj) in_22\IN\linear_unit.n.01|those (r_prep) than_21\IN\entity.n.01|in (r_prep) given_15\VBN\assumption.n.02|gm|with|than (r_acl) rats_14\NNS\rodent.n.01|given (r_pobj) in_13\IN\linear_unit.n.01|rats (r_prep) severe_12\JJ\severe.s.01|less|in (r_acomp) be_9\VB\metallic_element.n.01|to|severe (r_xcomp) appeared_7\VBD\be.v.01|necrosis|be|. (l_nsubj) necrosis_6\NN\death.n.02|the|induced|proximal|tubular
D006170_D007683 NONE arabic_20\JJ\semitic.n.01|gum (r_pobj) with_18\IN\entity.n.01|together|arabic (r_prep) given_15\VBN\assumption.n.02|gm|with|than (r_acl) rats_14\NNS\rodent.n.01|given (r_pobj) in_13\IN\linear_unit.n.01|rats (r_prep) severe_12\JJ\severe.s.01|less|in (r_acomp) be_9\VB\metallic_element.n.01|to|severe (r_xcomp) appeared_7\VBD\be.v.01|necrosis|be|. (l_nsubj) necrosis_6\NN\death.n.02|the|induced|proximal|tubular
17491223
D004280_D017202 CID dobutamine_14\NN\entity.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|dobutamine|- (r_amod) ischemia_18\NN\anemia.n.01|induced|myocardial
D004280_D017202 CID dobutamine_8\NN\entity.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|dobutamine|- (r_amod) ischemia_12\NN\anemia.n.01|induced|myocardial
D004280_D017202 CID dobutamine_37\NN\entity.n.01| (r_npadvmod) induced_39\VBN\generate.v.01|dobutamine|- (r_amod) ischemia_41\NN\anemia.n.01|induced|myocardial
D004280_D007511 NONE dobutamine_37\NN\entity.n.01| (r_npadvmod) induced_39\VBN\generate.v.01|dobutamine|- (r_amod) ischemia_41\NN\anemia.n.01|induced|myocardial (r_dobj) detecting_36\VBG\police_work.n.01|ischemia|,|using (r_pcomp) for_35\IN\entity.n.01|detecting (r_prep) assess_3\VB\body_part.n.01|to|value|,|compared|,|for|computed (l_conj) computed_51\VBD\reason.v.03|tomography|assess (l_advcl) assess_60\VB\body_part.n.01|to|presence (l_dobj) presence_62\NN\being.n.01|the|or|absence|of (l_prep) of_65\IN\entity.n.01|ischemia (l_pobj) ischemia_66\NN\anemia.n.01|
D017256_D017202 NONE sestamibi_46\NNP\entity.n.01|tc99m|- (r_nmod) emission_50\NN\egress.n.03|sestamibi|photon (r_dobj) using_43\VBG\mistreatment.n.01|emission (r_conj) detecting_36\VBG\police_work.n.01|ischemia|,|using (l_dobj) ischemia_41\NN\anemia.n.01|induced|myocardial
D017256_D007511 NONE sestamibi_46\NNP\entity.n.01|tc99m|- (r_nmod) emission_50\NN\egress.n.03|sestamibi|photon (r_dobj) using_43\VBG\mistreatment.n.01|emission (r_conj) detecting_36\VBG\police_work.n.01|ischemia|,|using (r_pcomp) for_35\IN\entity.n.01|detecting (r_prep) assess_3\VB\body_part.n.01|to|value|,|compared|,|for|computed (l_conj) computed_51\VBD\reason.v.03|tomography|assess (l_advcl) assess_60\VB\body_part.n.01|to|presence (l_dobj) presence_62\NN\being.n.01|the|or|absence|of (l_prep) of_65\IN\entity.n.01|ischemia (l_pobj) ischemia_66\NN\anemia.n.01|
2348231
D010431_D006940 NONE pentoxifylline_0\NNP\drug.n.01|(|trental|) (r_nsubj) inhibit_6\VB\control.v.02|pentoxifylline|does|not|hyperemia|. (l_dobj) hyperemia_11\NN\congestion.n.01|induced|coronary|:|implications
D010431_D006940 NONE trental_2\NNP\drug.n.01| (r_appos) pentoxifylline_0\NNP\drug.n.01|(|trental|) (r_nsubj) inhibit_6\VB\control.v.02|pentoxifylline|does|not|hyperemia|. (l_dobj) hyperemia_11\NN\congestion.n.01|induced|coronary|:|implications
D010431_D006940 NONE pentoxifylline_1\NN\drug.n.01|whether (r_nsubj) inhibits_2\VBZ\control.v.02|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN\congestion.n.01|induced|coronary|like
D010431_D006940 NONE pentoxifylline_3\NN\drug.n.01| (r_pobj) of_2\IN\entity.n.01|pentoxifylline (r_prep) dose_1\NN\medicine.n.02|neither|of (r_nsubj) decreased_5\VBD\change_magnitude.v.01|dose|significantly|hyperemia|,|peak|less|)|. (l_dobj) hyperemia_10\NN\congestion.n.01|the|induced
D010431_D006940 NONE pentoxyifylline_3\NN\entity.n.01| (r_nsubj) inhibit_6\VB\control.v.02|that|pentoxyifylline|does|not|hyperemia|at (l_dobj) hyperemia_11\NN\congestion.n.01|induced|coronary
D004176_D006940 CID dipyridamole_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|dipyridamole|- (r_amod) hyperemia_11\NN\congestion.n.01|induced|coronary|:|implications
D004176_D006940 CID dipyridamole_15\JJ\entity.n.01| (r_npadvmod) thallium-201_17\NN\entity.n.01|dipyridamole|- (r_nmod) imaging_19\NN\representational_process.n.01|thallium-201|myocardial (r_pobj) for_14\IN\entity.n.01|imaging (r_prep) implications_13\NNS\inference.n.01|for (r_appos) hyperemia_11\NN\congestion.n.01|induced|coronary|:|implications
D004176_D006940 CID dipyridamole_3\NN\entity.n.01| (r_dep) induced_5\VBN\generate.v.01|dipyridamole|- (r_amod) hyperemia_7\NN\congestion.n.01|induced|coronary|like
D004176_D006940 CID dipyridamole_20\NN\entity.n.01| (r_compound) thallium-201_22\NN\entity.n.01|dipyridamole|- (r_compound) imaging_23\NN\representational_process.n.01|thallium-201 (r_pobj) to_19\IN\entity.n.01|imaging (r_prep) prior_18\RB\superior.n.02|to (r_advmod) stopped_17\VBN\stop.v.01|should|be|prior (r_conj) inhibits_2\VBZ\control.v.02|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN\congestion.n.01|induced|coronary|like
D004176_D006940 CID dipyridamole_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|dipyridamole|- (r_amod) hyperemia_10\NN\congestion.n.01|the|induced
D004176_D006940 CID dipyridamole_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|dipyridamole|- (r_amod) hyperemia_11\NN\congestion.n.01|induced|coronary
D013793_D006940 NONE thallium-201_17\NN\entity.n.01|dipyridamole|- (r_nmod) imaging_19\NN\representational_process.n.01|thallium-201|myocardial (r_pobj) for_14\IN\entity.n.01|imaging (r_prep) implications_13\NNS\inference.n.01|for (r_appos) hyperemia_11\NN\congestion.n.01|induced|coronary|:|implications
D013793_D006940 NONE thallium-201_22\NN\entity.n.01|dipyridamole|- (r_compound) imaging_23\NN\representational_process.n.01|thallium-201 (r_pobj) to_19\IN\entity.n.01|imaging (r_prep) prior_18\RB\superior.n.02|to (r_advmod) stopped_17\VBN\stop.v.01|should|be|prior (r_conj) inhibits_2\VBZ\control.v.02|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_7\NN\congestion.n.01|induced|coronary|like
D010431_D007383 CID pentoxifylline_6\NN\drug.n.01| (r_dobj) taking_5\VBG\action.n.01|many|are|pentoxifylline|(|trental|)|,|derivative|. (l_conj) derivative_13\NN\calculation.n.02|a|methylxanthine|improve (l_relcl) improve_16\VB\change.v.01|which|may|claudication (l_dobj) claudication_18\NN\disability_of_walking.n.01|intermittent
D010431_D007383 CID trental_8\NNP\drug.n.01| (r_npadvmod) taking_5\VBG\action.n.01|many|are|pentoxifylline|(|trental|)|,|derivative|. (l_conj) derivative_13\NN\calculation.n.02|a|methylxanthine|improve (l_relcl) improve_16\VB\change.v.01|which|may|claudication (l_dobj) claudication_18\NN\disability_of_walking.n.01|intermittent
C008514_D007383 NONE methylxanthine_12\NN\entity.n.01| (r_compound) derivative_13\NN\calculation.n.02|a|methylxanthine|improve (l_relcl) improve_16\VB\change.v.01|which|may|claudication (l_dobj) claudication_18\NN\disability_of_walking.n.01|intermittent
C008514_D006940 NONE methylxanthines_10\NNS\entity.n.01|other|as (r_pobj) like_8\IN\kind.n.01|methylxanthines (r_prep) hyperemia_7\NN\congestion.n.01|induced|coronary|like
D013806_D006940 NONE theophylline_13\NN\bronchodilator.n.01| (r_pobj) as_12\IN\chemical_element.n.01|such|theophylline (r_prep) methylxanthines_10\NNS\entity.n.01|other|as (r_pobj) like_8\IN\kind.n.01|methylxanthines (r_prep) hyperemia_7\NN\congestion.n.01|induced|coronary|like
D013806_D006940 NONE theophylline_21\NN\bronchodilator.n.01| (r_pobj) after_20\IN\after.s.01|theophylline (r_prep) was_17\VBD\washington.n.02|flow|lower|after (r_ccomp) peak_13\JJ\limit.n.06|while|was (r_advcl) decreased_5\VBD\change_magnitude.v.01|dose|significantly|hyperemia|,|peak|less|)|. (l_dobj) hyperemia_10\NN\congestion.n.01|the|induced
19473225
D018698_D010523 NONE glutamate_3\NN\salt.n.01| (r_compound) supplementation_4\NN\increase.n.04|term|glutamate (r_nsubj) failed_5\VBD\fail.v.01|supplementation|protect|. (l_xcomp) protect_7\VB\defend.v.02|to|against (l_prep) against_8\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_10\NN\entity.n.01|peripheral|of
D018698_D010523 NONE glutamate_18\NN\salt.n.01|and|glutamine (r_nsubjpass) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\pathology.n.02|toxic|peripheral
D018698_D010523 NONE glutamine_25\NN\amino_acid.n.01|its|related|acid (r_conj) glutamate_18\NN\salt.n.01|and|glutamine (r_nsubjpass) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\pathology.n.02|toxic|peripheral
D018698_D010523 NONE glutamate_9\NN\salt.n.01| (r_compound) supplementation_10\NN\increase.n.04|glutamate|for (l_prep) for_11\IN\entity.n.01|preventing (l_pcomp) preventing_12\VBG\prevent.v.01|neuropathy|in (l_dobj) neuropathy_17\NN\pathology.n.02|induced|peripheral
D018698_D010523 NONE glutamate_8\NN\salt.n.01| (r_compound) supplementation_9\NN\increase.n.04|glutamate|at (r_nsubj) fails_14\VBZ\fail.v.01|that|supplementation|protect (l_xcomp) protect_16\VB\defend.v.02|to|against (l_prep) against_17\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_19\NN\entity.n.01|peripheral|of
D017239_D010523 CID paclitaxel_12\NN\entity.n.01| (r_pobj) of_11\IN\entity.n.01|paclitaxel (r_prep) neurotoxicity_10\NN\entity.n.01|peripheral|of
D017239_D010523 CID paclitaxel_12\NN\entity.n.01| (r_pobj) with_11\IN\entity.n.01|paclitaxel (r_prep) chemotherapy_10\NN\therapy.n.01|with|pac (r_pobj) for_9\IN\entity.n.01|chemotherapy (r_prep) factor_8\NN\cause.n.01|a|significant|limiting|for (r_attr) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\pathology.n.02|toxic|peripheral
D017239_D010523 CID pac_14\NNP\committee.n.01|(|) (r_appos) chemotherapy_10\NN\therapy.n.01|with|pac (r_pobj) for_9\IN\entity.n.01|chemotherapy (r_prep) factor_8\NN\cause.n.01|a|significant|limiting|for (r_attr) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\pathology.n.02|toxic|peripheral
D017239_D010523 CID pac_30\NNP\committee.n.01| (r_compound) neurotoxicity_31\NN\entity.n.01|pac (r_dobj) ameliorate_29\VB\change.v.01|to|neurotoxicity (r_xcomp) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\pathology.n.02|toxic|peripheral
D017239_D010523 CID pac_13\NNP\committee.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|pac|- (r_amod) neuropathy_17\NN\pathology.n.02|induced|peripheral
D017239_D010523 CID pac_21\NNP\committee.n.01| (r_pobj) of_20\IN\entity.n.01|pac (r_prep) neurotoxicity_19\NN\entity.n.01|peripheral|of
D017239_D020258 NONE paclitaxel_12\NN\entity.n.01| (r_pobj) with_11\IN\entity.n.01|paclitaxel (r_prep) chemotherapy_10\NN\therapy.n.01|with|pac (r_pobj) for_9\IN\entity.n.01|chemotherapy (r_prep) factor_8\NN\cause.n.01|a|significant|limiting|for (r_attr) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_advcl) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\change.v.01|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\entity.n.01|pac
D017239_D020258 NONE pac_14\NNP\committee.n.01|(|) (r_appos) chemotherapy_10\NN\therapy.n.01|with|pac (r_pobj) for_9\IN\entity.n.01|chemotherapy (r_prep) factor_8\NN\cause.n.01|a|significant|limiting|for (r_attr) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_advcl) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\change.v.01|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\entity.n.01|pac
D017239_D020258 NONE pac_30\NNP\committee.n.01| (r_compound) neurotoxicity_31\NN\entity.n.01|pac
D018698_D020258 NONE glutamate_18\NN\salt.n.01|and|glutamine (r_nsubjpass) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\change.v.01|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\entity.n.01|pac
D018698_D020258 NONE glutamine_25\NN\amino_acid.n.01|its|related|acid (r_conj) glutamate_18\NN\salt.n.01|and|glutamine (r_nsubjpass) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\change.v.01|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\entity.n.01|pac
D000596_D010523 NONE acid_24\NN\compound.n.02|amino (r_compound) glutamine_25\NN\amino_acid.n.01|its|related|acid (r_conj) glutamate_18\NN\salt.n.01|and|glutamine (r_nsubjpass) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (r_advcl) is_3\VBZ\be.v.01|neuropathy|still|factor|,|claimed|. (l_nsubj) neuropathy_2\NN\pathology.n.02|toxic|peripheral
D000596_D020258 NONE acid_24\NN\compound.n.02|amino (r_compound) glutamine_25\NN\amino_acid.n.01|its|related|acid (r_conj) glutamate_18\NN\salt.n.01|and|glutamine (r_nsubjpass) claimed_27\VBN\affirm.v.03|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\change.v.01|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\entity.n.01|pac
D017239_D010051 NONE pac_16\NNP\committee.n.01| (r_npadvmod) containing_18\VBG\include.v.01|pac|- (r_amod) regimen_19\NN\plan.n.01|the|same|containing (r_pobj) of_13\IN\entity.n.01|regimen (r_prep) cycles_12\NNS\time_interval.n.01|six|of (r_pobj) following_10\VBG\multitude.n.03|cycles (r_prep) analysis_9\NN\investigation.n.02|following (r_pobj) for_8\IN\entity.n.01|analysis (r_prep) available_7\JJ\available.a.01|for (r_acomp) were_6\VBD\be.v.01|patients|available (l_nsubj) patients_5\NNS\case.n.06|three|ovarian|cancer (l_compound) cancer_4\NN\malignant_tumor.n.01|
D018698_D010051 NONE glutamate_26\NN\salt.n.01|along (r_pobj) by_25\IN\by.r.01|glutamate (r_agent) supplemented_24\VBN\add.v.01|were|:|23|had|been|by|,|at|,|and|received|. (l_ccomp) were_6\VBD\be.v.01|patients|available (l_nsubj) patients_5\NNS\case.n.06|three|ovarian|cancer (l_compound) cancer_4\NN\malignant_tumor.n.01|
8690168
D006497_D003928 NONE sulphate_3\NN\salt.n.01| (r_npadvmod) associated_5\VBN\think.v.03|sulphate|- (r_amod) sites_7\NNS\tract.n.01|heparan|associated|anionic|in (l_prep) in_8\IN\linear_unit.n.01|membrane (l_pobj) membrane_12\NN\sheet.n.06|the|glomerular|basement|of (l_prep) of_13\IN\entity.n.01|rats (l_pobj) rats_14\NNS\rodent.n.01|with (l_prep) with_15\IN\entity.n.01|nephropathy (l_pobj) nephropathy_20\NN\uropathy.n.01|induced|diabetic
D013311_D003928 CID streptozotocin_16\NNS\entity.n.01| (r_npadvmod) induced_18\VBN\generate.v.01|streptozotocin|- (r_amod) nephropathy_20\NN\uropathy.n.01|induced|diabetic
D006497_D003920 NONE sulphate_1\NN\salt.n.01| (r_npadvmod) associated_3\VBN\think.v.03|sulphate|- (r_amod) sites_5\NNS\tract.n.01|heparan|associated|anionic|in (r_nsubjpass) studied_12\VBN\analyze.v.01|sites|were|in|after|,|employing|. (l_prep) after_17\IN\after.s.01|months|induction (l_pobj) induction_18\NN\ceremony.n.01|of|by (l_prep) of_19\IN\entity.n.01|diabetes (l_pobj) diabetes_20\NNS\polygenic_disorder.n.01|
D006497_D003920 NONE sulphate_18\NN\salt.n.01| (r_compound) charge_19\NN\attack.n.01|sulphate (r_compound) density_22\NN\compactness.n.02|a|reduced|heparan|charge|barrier|/ (r_nsubjpass) found_24\VBN\wage.n.01|that|in|density|is|at (l_prep) in_3\IN\linear_unit.n.01|rats (l_pobj) rats_7\NNS\rodent.n.01|diabetic|with (l_amod) diabetic_6\JJ\sick_person.n.01|streptozotocin|-
D013311_D003920 NONE streptozotocin_22\NNS\entity.n.01| (r_pobj) by_21\IN\by.r.01|streptozotocin|and|in (r_prep) induction_18\NN\ceremony.n.01|of|by (l_prep) of_19\IN\entity.n.01|diabetes (l_pobj) diabetes_20\NNS\polygenic_disorder.n.01|
D013311_D003920 NONE streptozotocin_4\JJ\entity.n.01| (r_amod) diabetic_6\JJ\sick_person.n.01|streptozotocin|-
C015445_D003920 NONE blue_38\JJ\chromatic_color.n.01|the|cationic|dye|cuprolinic (r_dobj) employing_33\VBG\use.v.01|blue (r_advcl) studied_12\VBN\analyze.v.01|sites|were|in|after|,|employing|. (l_prep) after_17\IN\after.s.01|months|induction (l_pobj) induction_18\NN\ceremony.n.01|of|by (l_prep) of_19\IN\entity.n.01|diabetes (l_pobj) diabetes_20\NNS\polygenic_disorder.n.01|
7468724
D013726_D002318 CID terbutaline_4\JJ\entity.n.01| (r_compound) treatment_5\NN\care.n.01|terbutaline|for (r_pobj) with_3\IN\entity.n.01|treatment (r_prep) associated_2\VBN\think.v.03|with (r_acl) complications_1\NNS\hindrance.n.03|cardiovascular|associated|.
D013726_D002318 CID terbutaline_11\NN\entity.n.01|for (r_pobj) with_10\IN\entity.n.01|terbutaline (r_prep) treated_9\VBN\interact.v.01|with (r_acl) patients_8\NNS\case.n.06|160|treated (r_pobj) in_4\IN\linear_unit.n.01|patients (r_prep) occurred_3\VBD\happen.v.01|complications|in|. (l_nsubj) complications_2\NNS\hindrance.n.03|severe|cardiovascular
D013726_D007752 NONE terbutaline_4\JJ\entity.n.01| (r_compound) treatment_5\NN\care.n.01|terbutaline|for (l_prep) for_6\IN\entity.n.01|labor (l_pobj) labor_8\NN\class.n.03|preterm
D013726_D007752 NONE terbutaline_11\NN\entity.n.01|for (l_prep) for_12\IN\entity.n.01|labor (l_pobj) labor_14\NN\class.n.03|preterm
11007689
D016572_D057049 CID cyclosporine_0\NN\entity.n.01|and|microangiopathy|. (l_conj) microangiopathy_6\NN\entity.n.01|associated|thrombotic
D016572_D057049 CID cyclosporine_13\NN\entity.n.01| (r_pobj) of_12\IN\entity.n.01|cyclosporine (r_prep) use_11\NN\activity.n.01|the|of (r_pobj) with_9\IN\entity.n.01|use (r_prep) associated_8\VBN\think.v.03|with (r_acl) microangiopathy_4\NN\entity.n.01|thrombotic|tma|associated
D016572_D057049 CID cyclosporine_13\NN\entity.n.01| (r_pobj) of_12\IN\entity.n.01|cyclosporine (r_prep) use_11\NN\activity.n.01|the|of (r_pobj) with_9\IN\entity.n.01|use (r_prep) associated_8\VBN\think.v.03|with (r_acl) microangiopathy_4\NN\entity.n.01|thrombotic|tma|associated (l_appos) tma_6\NNP\entity.n.01|(|)
D016572_D057049 CID cyclosporine_20\NN\entity.n.01| (r_npadvmod) induced_22\VBN\generate.v.01|cyclosporine|- (r_amod) tma_23\NNP\entity.n.01|induced
D016572_D057049 CID cyclosporine_16\NN\entity.n.01|and|tacrolimus (r_pobj) to_15\IN\entity.n.01|cyclosporine (r_prep) exposed_13\VBN\subject.v.01|sequentially|to (r_acl) patients_12\NNS\case.n.06|exposed (r_pobj) in_11\IN\linear_unit.n.01|patients (r_prep) recurrence_8\NN\repeat.n.01|the|of|in (l_prep) of_9\IN\entity.n.01|tma (l_pobj) tma_10\NNP\entity.n.01|
D016572_D057049 CID cyclosporine_13\NN\entity.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|cyclosporine|- (r_amod) tma_16\NNP\entity.n.01|induced|responded
D016572_D057049 CID cyclosporine_23\NN\entity.n.01| (r_pobj) of_22\IN\entity.n.01|cyclosporine (r_prep) withdrawal_21\NN\retraction.n.01|the|of|in (r_pobj) to_19\IN\entity.n.01|withdrawal (r_prep) responded_18\VBD\act.v.01|that|to (r_relcl) tma_16\NNP\entity.n.01|induced|responded
D016572_D057049 CID cyclosporine_5\NN\entity.n.01| (r_pobj) from_4\IN\entity.n.01|cyclosporine (r_prep) switched_3\VBN\change_by_reversal.v.01|who|are|from|to (r_relcl) patients_0\NNS\case.n.06|switched (r_nsubjpass) monitored_14\VBN\observe.v.04|patients|should|be|closely|for|. (l_prep) for_15\IN\entity.n.01|signs (l_pobj) signs_17\NNS\clue.n.02|the|and|symptoms|of (l_prep) of_20\IN\entity.n.01|tma (l_pobj) tma_22\NNP\entity.n.01|recurrent
D016559_D057049 CID tacrolimus_2\NN\entity.n.01| (r_npadvmod) associated_4\VBN\think.v.03|tacrolimus|- (r_amod) microangiopathy_6\NN\entity.n.01|associated|thrombotic
D016559_D057049 CID tacrolimus_6\NN\entity.n.01| (r_pobj) to_5\IN\entity.n.01|tacrolimus (r_prep) switching_4\VBG\change.n.03|to (r_nsubjpass) reported_9\VBN\inform.v.01|as|,|switching|has|been|be|. (l_xcomp) be_11\VB\metallic_element.n.01|to|option (l_attr) option_15\NN\derivative_instrument.n.01|a|viable|therapeutic|in (l_prep) in_16\IN\linear_unit.n.01|setting (l_pobj) setting_18\NN\environment.n.02|the|of (l_prep) of_19\IN\entity.n.01|tma (l_pobj) tma_23\NNP\entity.n.01|induced
D016559_D057049 CID tacrolimus_6\NN\entity.n.01|in (r_pobj) of_5\IN\entity.n.01|tacrolimus (r_prep) application_4\NN\use.n.01|the|widespread|of (r_pobj) with_0\IN\entity.n.01|application (r_prep) recognized_18\VBN\accept.v.01|with|,|tma|has|also|been|. (l_nsubjpass) tma_14\NNP\entity.n.01|associated
D016559_D057049 CID tacrolimus_11\NN\entity.n.01| (r_npadvmod) associated_13\VBN\think.v.03|tacrolimus|- (r_amod) tma_14\NNP\entity.n.01|associated
D016559_D057049 CID tacrolimus_18\NN\entity.n.01| (r_conj) cyclosporine_16\NN\entity.n.01|and|tacrolimus (r_pobj) to_15\IN\entity.n.01|cyclosporine (r_prep) exposed_13\VBN\subject.v.01|sequentially|to (r_acl) patients_12\NNS\case.n.06|exposed (r_pobj) in_11\IN\linear_unit.n.01|patients (r_prep) recurrence_8\NN\repeat.n.01|the|of|in (l_prep) of_9\IN\entity.n.01|tma (l_pobj) tma_10\NNP\entity.n.01|
D016559_D057049 CID tacrolimus_2\NN\entity.n.01|as (r_pobj) of_1\IN\entity.n.01|tacrolimus (r_prep) introduction_0\NN\beginning.n.05|of (r_nsubj) resulted_8\VBD\prove.v.01|introduction|in|. (l_prep) in_9\IN\linear_unit.n.01|recurrence (l_pobj) recurrence_11\NN\repeat.n.01|the|of|and|loss (l_prep) of_12\IN\entity.n.01|tma (l_pobj) tma_13\NNP\entity.n.01|
D016559_D057049 CID tacrolimus_7\NN\entity.n.01|or|versa (r_pobj) to_6\IN\entity.n.01|tacrolimus (r_prep) switched_3\VBN\change_by_reversal.v.01|who|are|from|to (r_relcl) patients_0\NNS\case.n.06|switched (r_nsubjpass) monitored_14\VBN\observe.v.04|patients|should|be|closely|for|. (l_prep) for_15\IN\entity.n.01|signs (l_pobj) signs_17\NNS\clue.n.02|the|and|symptoms|of (l_prep) of_20\IN\entity.n.01|tma (l_pobj) tma_22\NNP\entity.n.01|recurrent
15632880
D013148_D051437 CID spironolactone_0\NNP\antihypertensive.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN\failing.n.01|renal|and|hyperkalemia|in
D013148_D051437 CID spironolactone_9\NN\antihypertensive.n.01|in (r_pobj) of_8\IN\entity.n.01|spironolactone (r_prep) use_7\NN\activity.n.01|the|of (r_dobj) evaluating_5\VBG\evaluate.v.02|use (r_acl) trial_4\NN\attempt.n.01|a|previous|randomized|controlled|evaluating (r_nsubj) reported_14\VBD\inform.v.01|trial|risk|. (l_dobj) risk_17\NN\danger.n.03|a|low|of (l_prep) of_18\IN\entity.n.01|hyperkalemia (l_pobj) hyperkalemia_19\NN\symptom.n.01|(|%|)|and|insufficiency (l_conj) insufficiency_26\NN\failing.n.01|renal|(|%|)
D013148_D051437 CID spironolactone_21\NN\antihypertensive.n.01| (r_pobj) with_20\IN\entity.n.01|spironolactone (r_prep) treated_19\VBN\interact.v.01|with (r_acl) patients_18\NNS\case.n.06|failure|treated (r_pobj) in_15\IN\linear_unit.n.01|patients (r_prep) insufficiency_14\NN\failing.n.01|renal|in
D013148_D051437 CID spironolactone_13\NN\antihypertensive.n.01| (r_pobj) of_12\IN\entity.n.01|spironolactone (r_prep) discontinuation_11\NN\termination.n.05|of (r_dobj) required_10\VBD\necessitate.v.01|seven|discontinuation|due|. (l_prep) due_14\IN\right.n.01|to|hyperkalemia (l_pobj) hyperkalemia_16\NN\symptom.n.01|(|n|)|or|failure (l_conj) failure_24\NN\nonaccomplishment.n.01|renal|(|34|)
D013148_D051437 CID spironolactone_0\NNP\antihypertensive.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|spironolactone|- (r_amod) hyperkalemia_3\NN\symptom.n.01|induced|and (r_nmod) insufficiency_6\NN\failing.n.01|hyperkalemia|renal
D013148_D006947 CID spironolactone_0\NNP\antihypertensive.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN\failing.n.01|renal|and|hyperkalemia|in (l_conj) hyperkalemia_6\NN\symptom.n.01|
D013148_D006947 CID spironolactone_9\NN\antihypertensive.n.01|in (r_pobj) of_8\IN\entity.n.01|spironolactone (r_prep) use_7\NN\activity.n.01|the|of (r_dobj) evaluating_5\VBG\evaluate.v.02|use (r_acl) trial_4\NN\attempt.n.01|a|previous|randomized|controlled|evaluating (r_nsubj) reported_14\VBD\inform.v.01|trial|risk|. (l_dobj) risk_17\NN\danger.n.03|a|low|of (l_prep) of_18\IN\entity.n.01|hyperkalemia (l_pobj) hyperkalemia_19\NN\symptom.n.01|(|%|)|and|insufficiency
D013148_D006947 CID spironolactone_21\NN\antihypertensive.n.01| (r_pobj) with_20\IN\entity.n.01|spironolactone (r_prep) treated_19\VBN\interact.v.01|with (r_acl) patients_18\NNS\case.n.06|failure|treated (r_pobj) in_15\IN\linear_unit.n.01|patients (r_prep) insufficiency_14\NN\failing.n.01|renal|in (r_conj) hyperkalemia_11\NN\symptom.n.01|and|insufficiency
D013148_D006947 CID spironolactone_13\NN\antihypertensive.n.01| (r_pobj) of_12\IN\entity.n.01|spironolactone (r_prep) discontinuation_11\NN\termination.n.05|of (r_dobj) required_10\VBD\necessitate.v.01|seven|discontinuation|due|. (l_prep) due_14\IN\right.n.01|to|hyperkalemia (l_pobj) hyperkalemia_16\NN\symptom.n.01|(|n|)|or|failure
D013148_D006947 CID spironolactone_0\NNP\antihypertensive.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|spironolactone|- (r_amod) hyperkalemia_3\NN\symptom.n.01|induced|and
D013148_D006333 NONE spironolactone_0\NNP\antihypertensive.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|spironolactone|-|insufficiency|. (l_dobj) insufficiency_4\NN\failing.n.01|renal|and|hyperkalemia|in (l_prep) in_7\IN\linear_unit.n.01|patients (l_pobj) patients_8\NNS\case.n.06|with (l_prep) with_9\IN\entity.n.01|failure (l_pobj) failure_11\NN\nonaccomplishment.n.01|heart
D013148_D006333 NONE spironolactone_9\NN\antihypertensive.n.01|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_13\NNS\case.n.06|failure (l_compound) failure_12\NN\nonaccomplishment.n.01|heart
D013148_D006333 NONE spironolactone_11\NN\antihypertensive.n.01| (r_pobj) of_10\IN\entity.n.01|spironolactone (r_prep) benefits_9\NNS\payment.n.01|the|of (r_nsubjpass) reported_13\VBN\inform.v.01|since|benefits|were (r_advcl) changed_6\VBN\change.v.01|because|treatments|have|reported (l_nsubj) treatments_1\NNS\care.n.01|for (l_prep) for_2\IN\entity.n.01|failure (l_pobj) failure_4\NN\nonaccomplishment.n.01|heart
D013148_D006333 NONE spironolactone_21\NN\antihypertensive.n.01| (r_pobj) with_20\IN\entity.n.01|spironolactone (r_prep) treated_19\VBN\interact.v.01|with (r_acl) patients_18\NNS\case.n.06|failure|treated (l_compound) failure_17\NN\nonaccomplishment.n.01|heart
D013148_D006333 NONE spironolactone_12\NN\antihypertensive.n.01|in (r_pobj) with_11\IN\entity.n.01|spironolactone (r_prep) treated_10\VBN\interact.v.01|with (r_acl) patients_9\NNS\case.n.06|failure|treated (l_compound) failure_8\NN\nonaccomplishment.n.01|heart
D011188_D006947 NONE k(+_7\NNP\entity.n.01|(|) (r_appos) hyperkalemia_5\NN\symptom.n.01|k(+
D011188_D006947 NONE potassium_17\NN\metallic_element.n.01|serum (r_compound) levels_18\NNS\property.n.02|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\have.v.01|levels|,|and|were (r_conj) were_4\VBD\be.v.01|patients|older|,|had|. (l_nsubj) patients_0\NNS\case.n.06|developed (l_relcl) developed_2\VBD\create.v.02|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\symptom.n.01|
D011188_D006947 NONE potassium_22\NN\metallic_element.n.01| (r_compound) supplement_23\NN\matter.n.06|potassium (r_compound) doses_24\NNS\medicine.n.02|lower|baseline|supplement (r_conj) levels_18\NNS\property.n.02|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\have.v.01|levels|,|and|were (r_conj) were_4\VBD\be.v.01|patients|older|,|had|. (l_nsubj) patients_0\NNS\case.n.06|developed (l_relcl) developed_2\VBD\create.v.02|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\symptom.n.01|
D011188_D051437 NONE k(+_7\NNP\entity.n.01|(|) (r_appos) hyperkalemia_5\NN\symptom.n.01|k(+ (r_dobj) developed_4\VBD\create.v.02|who|hyperkalemia (r_relcl) patients_2\NNS\case.n.06|developed (r_attr) were_1\VBD\be.v.01|cases|patients|( (l_nsubj) cases_0\NNS\happening.n.01|l (l_appos) l_13\NN\metric_capacity_unit.n.01|>|meq|/|)|or|insufficiency (l_conj) insufficiency_17\NN\failing.n.01|renal
D011188_D003920 NONE potassium_17\NN\metallic_element.n.01|serum (r_compound) levels_18\NNS\property.n.02|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\have.v.01|levels|,|and|were (r_conj) were_4\VBD\be.v.01|patients|older|,|had|. (l_acomp) older_5\JJR\aged.s.01|and|likely (l_conj) likely_8\JJ\likely.a.01|more|have (l_xcomp) have_10\VB\person.n.01|to|diabetes (l_dobj) diabetes_11\NNS\polygenic_disorder.n.01|
D011188_D003920 NONE potassium_22\NN\metallic_element.n.01| (r_compound) supplement_23\NN\matter.n.06|potassium (r_compound) doses_24\NNS\medicine.n.02|lower|baseline|supplement (r_conj) levels_18\NNS\property.n.02|higher|baseline|potassium|and|doses (r_dobj) had_13\VBD\have.v.01|levels|,|and|were (r_conj) were_4\VBD\be.v.01|patients|older|,|had|. (l_acomp) older_5\JJR\aged.s.01|and|likely (l_conj) likely_8\JJ\likely.a.01|more|have (l_xcomp) have_10\VB\person.n.01|to|diabetes (l_dobj) diabetes_11\NNS\polygenic_disorder.n.01|
D003404_D051437 NONE creatinine_14\NN\entity.n.01|higher|serum (r_conj) weight_9\NN\physical_property.n.01|lower|baseline|body|and|creatinine (r_dobj) had_5\VBD\have.v.01|patients|weight|,|required|. (l_nsubj) patients_0\NNS\case.n.06|developed (l_relcl) developed_2\VBD\create.v.02|who|insufficiency (l_dobj) insufficiency_4\NN\failing.n.01|renal
D049971_D051437 NONE thiazide_31\NN\diuretic_drug.n.01| (r_amod) diuretics_32\NNS\drug.n.01|thiazide|than (r_pobj) with_30\IN\entity.n.01|diuretics (r_prep) treated_29\VBN\interact.v.01|to|be|with (r_xcomp) likely_26\JJ\likely.a.01|more|treated (r_acomp) were_24\VBD\be.v.01|likely (r_conj) required_16\VBD\necessitate.v.01|doses|,|and|were (r_conj) had_5\VBD\have.v.01|patients|weight|,|required|. (l_nsubj) patients_0\NNS\case.n.06|developed (l_relcl) developed_2\VBD\create.v.02|who|insufficiency (l_dobj) insufficiency_4\NN\failing.n.01|renal
20528871
C104457_D015458 NONE nelarabine_3\NN\entity.n.01|,|etoposide|in (l_prep) in_9\IN\linear_unit.n.01|leukaemia (l_pobj) leukaemia_18\NN\cancer.n.01|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\cancer.n.01|
C104457_D015458 NONE nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
C104457_D015458 NONE arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
C104457_D016399 NONE nelarabine_3\NN\entity.n.01|,|etoposide|in (l_prep) in_9\IN\linear_unit.n.01|leukaemia (l_pobj) leukaemia_18\NN\cancer.n.01|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\cancer.n.01|
C104457_D016399 NONE nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
C104457_D016399 NONE arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D005047_D015458 NONE etoposide_5\RB\entity.n.01|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\entity.n.01|,|etoposide|in (l_prep) in_9\IN\linear_unit.n.01|leukaemia (l_pobj) leukaemia_18\NN\cancer.n.01|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\cancer.n.01|
D005047_D015458 NONE etoposide_14\NN\entity.n.01| (r_pobj) of_13\IN\entity.n.01|etoposide (r_prep) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D005047_D015458 NONE vp_16\NNP\entity.n.01|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D005047_D016399 NONE etoposide_5\RB\entity.n.01|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\entity.n.01|,|etoposide|in (l_prep) in_9\IN\linear_unit.n.01|leukaemia (l_pobj) leukaemia_18\NN\cancer.n.01|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\cancer.n.01|
D005047_D016399 NONE etoposide_14\NN\entity.n.01| (r_pobj) of_13\IN\entity.n.01|etoposide (r_prep) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D005047_D016399 NONE vp_16\NNP\entity.n.01|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D003520_D015458 NONE cyclophosphamide_8\NN\entity.n.01| (r_conj) etoposide_5\RB\entity.n.01|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\entity.n.01|,|etoposide|in (l_prep) in_9\IN\linear_unit.n.01|leukaemia (l_pobj) leukaemia_18\NN\cancer.n.01|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\cancer.n.01|
D003520_D015458 NONE cyclophosphamide_19\NN\entity.n.01| (r_conj) vp_16\NNP\entity.n.01|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D003520_D015458 NONE cpm_21\NNP\entity.n.01|(|) (r_appos) vp_16\NNP\entity.n.01|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D003520_D016399 NONE cyclophosphamide_8\NN\entity.n.01| (r_conj) etoposide_5\RB\entity.n.01|,|and|cyclophosphamide (r_conj) nelarabine_3\NN\entity.n.01|,|etoposide|in (l_prep) in_9\IN\linear_unit.n.01|leukaemia (l_pobj) leukaemia_18\NN\cancer.n.01|relapsed|/|refractory|lymphoblastic|and|lymphoma (l_conj) lymphoma_20\NN\cancer.n.01|
D003520_D016399 NONE cyclophosphamide_19\NN\entity.n.01| (r_conj) vp_16\NNP\entity.n.01|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
D003520_D016399 NONE cpm_21\NNP\entity.n.01|(|) (r_appos) vp_16\NNP\entity.n.01|(|)|and|cyclophosphamide|cpm|and|chemotherapy (r_appos) d_12\SYM\fat-soluble_vitamin.n.01|5|of|vp (r_pobj) with_10\IN\entity.n.01|d (r_prep) arag_8\NNP\entity.n.01|(|)|with (r_appos) nelarabine_6\JJ\entity.n.01|arag (r_pobj) of_5\IN\entity.n.01|nelarabine (r_prep) d_4\SYM\fat-soluble_vitamin.n.01|5|of (r_pobj) of_2\IN\entity.n.01|d (r_prep) combination_1\NN\collection.n.01|a|of (r_nsubjpass) used_28\VBN\use.v.01|combination|was|as|in|. (l_prep) in_32\IN\linear_unit.n.01|children (l_pobj) children_34\NNS\juvenile.n.01|seven|with (l_prep) with_35\IN\entity.n.01|leukaemia (l_pobj) leukaemia_42\NN\cancer.n.01|refractory|cell|or|lymphoma (l_conj) lymphoma_44\NN\cancer.n.01|
C104457_D009422 CID arag_8\NNP\entity.n.01|the (r_pobj) to_6\IN\entity.n.01|arag (r_prep) attributable_5\JJ\attributable.a.01|to (r_amod) effects_4\NNS\personal_property.n.01|the|common|side|attributable (r_nsubj) included_9\VBD\include.v.01|effects|neuropathy|. (l_dobj) neuropathy_17\NN\pathology.n.02|grade|sensory|and|pain
C104457_D009422 CID arag_7\NN\entity.n.01| (r_dobj) giving_6\VBG\sharing.n.04|arag|as (r_pcomp) of_5\IN\entity.n.01|giving (r_prep) safety_4\NN\condition.n.01|the|of (r_dobj) supports_2\VBZ\activity.n.01|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\observe.v.04|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\definite_quantity.n.01|neurological
C104457_D059352 CID arag_8\NNP\entity.n.01|the (r_pobj) to_6\IN\entity.n.01|arag (r_prep) attributable_5\JJ\attributable.a.01|to (r_amod) effects_4\NNS\personal_property.n.01|the|common|side|attributable (r_nsubj) included_9\VBD\include.v.01|effects|neuropathy|. (l_dobj) neuropathy_17\NN\pathology.n.02|grade|sensory|and|pain (l_conj) pain_20\NN\symptom.n.01|musculoskeletal
C104457_D006402 CID arag_8\NNP\entity.n.01|alone (r_pobj) than_7\IN\entity.n.01|arag (r_prep) combination_6\NN\collection.n.01|the|than (r_pobj) for_4\IN\entity.n.01|combination (r_prep) greater_3\JJR\greater.a.01|for (r_acomp) was_2\VBD\washington.n.02|toxicity|greater|,|was|. (l_nsubj) toxicity_1\NN\definite_quantity.n.01|haematological
D005047_D009422 NONE etoposide_14\NN\entity.n.01|and|cyclophosphamide (r_pobj) with_13\IN\entity.n.01|etoposide (r_prep) synchrony_12\NN\temporal_relation.n.01|with (r_pobj) in_11\IN\linear_unit.n.01|synchrony (r_prep) therapy_10\NN\medical_care.n.01|salvage|in (r_pobj) as_8\IN\chemical_element.n.01|therapy (r_prep) giving_6\VBG\sharing.n.04|arag|as (r_pcomp) of_5\IN\entity.n.01|giving (r_prep) safety_4\NN\condition.n.01|the|of (r_dobj) supports_2\VBZ\activity.n.01|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\observe.v.04|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\definite_quantity.n.01|neurological
D003520_D009422 NONE cyclophosphamide_16\NN\entity.n.01| (r_conj) etoposide_14\NN\entity.n.01|and|cyclophosphamide (r_pobj) with_13\IN\entity.n.01|etoposide (r_prep) synchrony_12\NN\temporal_relation.n.01|with (r_pobj) in_11\IN\linear_unit.n.01|synchrony (r_prep) therapy_10\NN\medical_care.n.01|salvage|in (r_pobj) as_8\IN\chemical_element.n.01|therapy (r_prep) giving_6\VBG\sharing.n.04|arag|as (r_pcomp) of_5\IN\entity.n.01|giving (r_prep) safety_4\NN\condition.n.01|the|of (r_dobj) supports_2\VBZ\activity.n.01|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\observe.v.04|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\definite_quantity.n.01|neurological
17175308
D020123_D011507 CID sirolimus_4\VB\entity.n.01| (r_pobj) to_3\TO\entity.n.01|sirolimus (r_prep) conversion_2\NN\transformation.n.01|to|in (r_pobj) after_1\IN\after.s.01|conversion (r_prep) proteinuria_0\NNP\symptom.n.01|after|.
D020123_D011507 CID sirolimus_11\NN\entity.n.01| (r_compound) therapy_12\NN\medical_care.n.01|sirolimus (r_pobj) of_10\IN\entity.n.01|therapy (r_prep) consequence_9\NN\phenomenon.n.01|a|of (r_pobj) as_7\IN\chemical_element.n.01|consequence (r_prep) reported_6\VBN\inform.v.01|recently|,|proteinuria|has|been|as|,|remained|. (l_nsubjpass) proteinuria_3\NN\symptom.n.01|
D020123_D011507 CID srl_18\NN\entity.n.01| (r_compound) conversion_19\NN\transformation.n.01|srl (r_pobj) after_17\IN\after.s.01|conversion (r_prep) displayed_14\VBD\show.v.04|proteinuria|after (l_dobj) proteinuria_16\NN\symptom.n.01|increased
D020123_D011507 CID srl_8\NN\entity.n.01| (r_pobj) of_7\IN\entity.n.01|srl (r_prep) use_6\NN\activity.n.01|the|of|as (r_pobj) after_4\IN\after.s.01|use (r_prep) was_2\VBD\washington.n.02|proteinuria|common|after|. (l_nsubj) proteinuria_1\NN\symptom.n.01|heavy
D020123_D051436 NONE srl_13\NNP\entity.n.01| (r_pobj) with_12\IN\entity.n.01|srl (r_prep) treated_11\VBN\interact.v.01|cohort|was|with|as|,|due|) (l_prep) due_18\IN\right.n.01|to|nephropathy (l_pobj) nephropathy_22\NN\uropathy.n.01|chronic|allograft|(|can|(|n
D020123_D007674 NONE srl_13\NNP\entity.n.01| (r_pobj) with_12\IN\entity.n.01|srl (r_prep) treated_11\VBN\interact.v.01|cohort|was|with|as|,|due|) (l_prep) due_18\IN\right.n.01|to|nephropathy (l_pobj) nephropathy_22\NN\uropathy.n.01|chronic|allograft|(|can|(|n (l_advmod) can_24\VB\container.n.01|)
2265898
C009265_D004827 CID carbidopa_6\NN\entity.n.01|epilepsy|/|administration|in|. (l_nsubj) epilepsy_1\NN\brain_disorder.n.01|serial|caused
C009265_D007676 NONE levodopa_38\JJ\dopa.n.01|/ (r_compound) preparation_39\NN\activity.n.01|a|carbidopa|levodopa (r_dobj) receiving_34\VBG\get.v.01|had|;|both|had|been|preparation|;|and|had|. (l_ccomp) had_11\VBD\have.v.01|presented|:|patients|failure|,|on|but|begun (l_dobj) failure_14\NN\nonaccomplishment.n.01|chronic|renal
C009265_D001523 NONE levodopa_38\JJ\dopa.n.01|/ (r_compound) preparation_39\NN\activity.n.01|a|carbidopa|levodopa (r_dobj) receiving_34\VBG\get.v.01|had|;|both|had|been|preparation|;|and|had|. (l_conj) had_43\VBD\have.v.01|both|onset (l_dobj) onset_45\NN\start.n.01|the|of (l_prep) of_46\IN\entity.n.01|seizures (l_pobj) seizures_50\NNS\attack.n.07|hallucinosis|,|were (l_nmod) hallucinosis_47\NN\psychological_state.n.01|and|recurrent
C009265_D012640 NONE levodopa_38\JJ\dopa.n.01|/ (r_compound) preparation_39\NN\activity.n.01|a|carbidopa|levodopa (r_dobj) receiving_34\VBG\get.v.01|had|;|both|had|been|preparation|;|and|had|. (l_conj) had_43\VBD\have.v.01|both|onset (l_dobj) onset_45\NN\start.n.01|the|of (l_prep) of_46\IN\entity.n.01|seizures (l_pobj) seizures_50\NNS\attack.n.07|hallucinosis|,|were
18503483
D016559_D020968 CID tacrolimus_2\NN\entity.n.01| (r_npadvmod) associated_4\VBN\think.v.03|tacrolimus|- (r_amod) neuritis_6\NN\inflammation.n.01|associated|brachial
C107135_D020968 NONE everolimus_10\NN\entity.n.01| (r_pobj) to_9\TO\entity.n.01|everolimus (r_prep) conversion_8\NN\transformation.n.01|to|in (r_pobj) after_7\IN\after.s.01|conversion (r_prep) recovery_0\NN\improvement.n.01|of|after|--|report|. (l_prep) of_1\IN\entity.n.01|neuritis (l_pobj) neuritis_6\NN\inflammation.n.01|associated|brachial
3629586
D015790_D006402 NONE cefonicid_4\NN\entity.n.01|and|cefazedone (r_pobj) of_3\IN\entity.n.01|cefonicid (r_prep) effects_2\NNS\personal_property.n.01|the|hematologic|of|:|model|. (l_appos) model_13\NN\hypothesis.n.02|a|potential|of (l_prep) of_14\IN\entity.n.01|hematotoxicity (l_pobj) hematotoxicity_16\NN\entity.n.01|cephalosporin|in
D015790_D006402 NONE cefonicid_23\NN\entity.n.01|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\get.v.01|cefonicid (r_acl) dogs_17\NNS\canine.n.02|receiving (r_pobj) of_16\IN\entity.n.01|dogs (r_prep) %_15\NN\entity.n.01|50|of (r_pobj) in_12\IN\linear_unit.n.01|% (r_prep) occurred_11\VBD\happen.v.01|in (r_conj) was_3\VBD\washington.n.02|anemia|compromising|and|occurred|. (l_attr) compromising_6\NN\agree.v.07|the|most|of (l_prep) of_7\IN\entity.n.01|cytopenias (l_pobj) cytopenias_9\NNS\blood_disease.n.01|the
D015790_D006402 NONE cefonicid_16\NN\entity.n.01| (r_amod) dogs_21\NNS\canine.n.02|cefonicid|(|cefazedone)-treated (r_nsubj) showed_22\VBD\show.v.04|reproduced|;|dogs|period|compared|. (l_ccomp) reproduced_10\VBN\produce.v.02|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN\complex.n.01|the|hematologic
D015790_D006402 NONE cefonicid_9\NN\entity.n.01|or|cefazedone (r_pobj) of_8\IN\entity.n.01|cefonicid (r_prep) doses_7\NNS\medicine.n.02|high|of (r_pobj) of_5\IN\entity.n.01|doses (r_prep) administration_4\NN\management.n.01|the|of|to (r_nsubj) induce_15\VB\generate.v.01|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\entity.n.01|similar
D015790_D006402 NONE cefonicid_9\NN\entity.n.01|or|cefazedone (r_pobj) of_8\IN\entity.n.01|cefonicid (r_prep) doses_7\NNS\medicine.n.02|high|of (r_pobj) of_5\IN\entity.n.01|doses (r_prep) administration_4\NN\management.n.01|the|of|to (r_nsubj) induce_15\VB\generate.v.01|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\entity.n.01|similar (l_amod) similar_17\JJ\similar.a.01|to (l_prep) to_18\IN\entity.n.01|dyscrasias (l_pobj) dyscrasias_24\NNS\ill_health.n.01|the|induced|blood|described
C021341_D006402 NONE cefazedone_6\NN\entity.n.01|in (r_conj) cefonicid_4\NN\entity.n.01|and|cefazedone (r_pobj) of_3\IN\entity.n.01|cefonicid (r_prep) effects_2\NNS\personal_property.n.01|the|hematologic|of|:|model|. (l_appos) model_13\NN\hypothesis.n.02|a|potential|of (l_prep) of_14\IN\entity.n.01|hematotoxicity (l_pobj) hematotoxicity_16\NN\entity.n.01|cephalosporin|in
C021341_D006402 NONE cefazedone_29\NN\entity.n.01|540|840|mg/kg (r_conj) cefonicid_23\NN\entity.n.01|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\get.v.01|cefonicid (r_acl) dogs_17\NNS\canine.n.02|receiving (r_pobj) of_16\IN\entity.n.01|dogs (r_prep) %_15\NN\entity.n.01|50|of (r_pobj) in_12\IN\linear_unit.n.01|% (r_prep) occurred_11\VBD\happen.v.01|in (r_conj) was_3\VBD\washington.n.02|anemia|compromising|and|occurred|. (l_attr) compromising_6\NN\agree.v.07|the|most|of (l_prep) of_7\IN\entity.n.01|cytopenias (l_pobj) cytopenias_9\NNS\blood_disease.n.01|the
C021341_D006402 NONE cefazedone)-treated_20\VBN\entity.n.01|but|not (r_amod) dogs_21\NNS\canine.n.02|cefonicid|(|cefazedone)-treated (r_nsubj) showed_22\VBD\show.v.04|reproduced|;|dogs|period|compared|. (l_ccomp) reproduced_10\VBN\produce.v.02|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN\complex.n.01|the|hematologic
C021341_D006402 NONE cefazedone_11\NN\entity.n.01| (r_conj) cefonicid_9\NN\entity.n.01|or|cefazedone (r_pobj) of_8\IN\entity.n.01|cefonicid (r_prep) doses_7\NNS\medicine.n.02|high|of (r_pobj) of_5\IN\entity.n.01|doses (r_prep) administration_4\NN\management.n.01|the|of|to (r_nsubj) induce_15\VB\generate.v.01|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\entity.n.01|similar
C021341_D006402 NONE cefazedone_11\NN\entity.n.01| (r_conj) cefonicid_9\NN\entity.n.01|or|cefazedone (r_pobj) of_8\IN\entity.n.01|cefonicid (r_prep) doses_7\NNS\medicine.n.02|high|of (r_pobj) of_5\IN\entity.n.01|doses (r_prep) administration_4\NN\management.n.01|the|of|to (r_nsubj) induce_15\VB\generate.v.01|that|administration|can|hematotoxicity|and|provides (l_dobj) hematotoxicity_16\NN\entity.n.01|similar (l_amod) similar_17\JJ\similar.a.01|to (l_prep) to_18\IN\entity.n.01|dyscrasias (l_pobj) dyscrasias_24\NNS\ill_health.n.01|the|induced|blood|described
D002511_D006402 NONE cephalosporin_15\JJ\antibiotic.n.01| (r_amod) hematotoxicity_16\NN\entity.n.01|cephalosporin|in
D002511_D006402 NONE cephalosporin_0\JJ\antibiotic.n.01| (r_amod) antibiotics_1\NNS\antibacterial.n.01|cephalosporin (r_nsubj) cause_2\VBP\origin.n.03|antibiotics|variety|characterized|. (l_dobj) variety_4\NN\collection.n.01|a|of|, (l_prep) of_5\IN\entity.n.01|disturbances (l_pobj) disturbances_7\NNS\activity.n.01|hematologic|in
D002511_D006402 NONE cephalosporin_4\NN\antibiotic.n.01|either (r_pobj) with_2\IN\entity.n.01|cephalosporin (r_prep) rechallenge_1\VB\entity.n.01|with (r_pobj) upon_0\IN\entity.n.01|rechallenge (r_prep) reproduced_10\VBN\produce.v.02|upon|,|syndrome|was|in (l_nsubjpass) syndrome_8\NN\complex.n.01|the|hematologic
D002511_D006402 NONE cephalosporin_20\NN\antibiotic.n.01| (r_advmod) induced_22\VBN\generate.v.01|cephalosporin|- (r_amod) dyscrasias_24\NNS\ill_health.n.01|the|induced|blood|described (r_pobj) to_18\IN\entity.n.01|dyscrasias (r_prep) similar_17\JJ\similar.a.01|to (r_amod) hematotoxicity_16\NN\entity.n.01|similar
D002511_D006402 NONE cephalosporin_20\NN\antibiotic.n.01| (r_advmod) induced_22\VBN\generate.v.01|cephalosporin|- (r_amod) dyscrasias_24\NNS\ill_health.n.01|the|induced|blood|described
D015790_D064420 NONE cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_prep) in_0\IN\linear_unit.n.01|studies (l_pobj) studies_4\NNS\examination.n.01|four|subacute|toxicity (l_compound) toxicity_3\NN\definite_quantity.n.01|
D015790_D000740 CID cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\frequency.n.02|a|dependent|of (l_prep) of_22\IN\entity.n.01|anemia (l_pobj) anemia_23\NN\blood_disease.n.01|,|neutropenia
D015790_D000740 CID cefonicid_23\NN\entity.n.01|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\get.v.01|cefonicid (r_acl) dogs_17\NNS\canine.n.02|receiving (r_pobj) of_16\IN\entity.n.01|dogs (r_prep) %_15\NN\entity.n.01|50|of (r_pobj) in_12\IN\linear_unit.n.01|% (r_prep) occurred_11\VBD\happen.v.01|in (r_conj) was_3\VBD\washington.n.02|anemia|compromising|and|occurred|. (l_nsubj) anemia_2\NN\blood_disease.n.01|a|nonregenerative
D015790_D009503 CID cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\frequency.n.02|a|dependent|of (l_prep) of_22\IN\entity.n.01|anemia (l_pobj) anemia_23\NN\blood_disease.n.01|,|neutropenia (l_conj) neutropenia_25\NN\leukopenia.n.01|,|and
D015790_D013921 CID cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_ccomp) thrombocytopenia_28\NN\blood_disease.n.01|after
C021341_D064420 NONE cefazedone_12\NN\entity.n.01| (r_conj) cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_prep) in_0\IN\linear_unit.n.01|studies (l_pobj) studies_4\NNS\examination.n.01|four|subacute|toxicity (l_compound) toxicity_3\NN\definite_quantity.n.01|
C021341_D000740 CID cefazedone_12\NN\entity.n.01| (r_conj) cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\frequency.n.02|a|dependent|of (l_prep) of_22\IN\entity.n.01|anemia (l_pobj) anemia_23\NN\blood_disease.n.01|,|neutropenia
C021341_D000740 CID cefazedone_29\NN\entity.n.01|540|840|mg/kg (r_conj) cefonicid_23\NN\entity.n.01|400|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\get.v.01|cefonicid (r_acl) dogs_17\NNS\canine.n.02|receiving (r_pobj) of_16\IN\entity.n.01|dogs (r_prep) %_15\NN\entity.n.01|50|of (r_pobj) in_12\IN\linear_unit.n.01|% (r_prep) occurred_11\VBD\happen.v.01|in (r_conj) was_3\VBD\washington.n.02|anemia|compromising|and|occurred|. (l_nsubj) anemia_2\NN\blood_disease.n.01|a|nonregenerative
C021341_D009503 CID cefazedone_12\NN\entity.n.01| (r_conj) cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_dobj) incidence_21\NN\frequency.n.02|a|dependent|of (l_prep) of_22\IN\entity.n.01|anemia (l_pobj) anemia_23\NN\blood_disease.n.01|,|neutropenia (l_conj) neutropenia_25\NN\leukopenia.n.01|,|and
C021341_D013921 CID cefazedone_12\NN\entity.n.01| (r_conj) cefonicid_10\NN\entity.n.01|or|cefazedone (r_pobj) of_9\IN\entity.n.01|cefonicid (r_prep) administration_8\NN\management.n.01|the|intravenous|of|to (r_nsubj) caused_16\VBD\make.v.03|in|,|administration|incidence|thrombocytopenia|. (l_ccomp) thrombocytopenia_28\NN\blood_disease.n.01|after
11706060
D019344_D009202 NONE lactate_8\NN\ester.n.01|plasma (r_dobj) elevates_6\VBZ\delegate.v.02|lactate|in (r_conj) causes_3\VBZ\origin.n.03|combined|therapy|cardiomyopathy|and|elevates|. (l_advmod) cardiomyopathy_4\NN\heart_disease.n.01|
D019344_D009202 NONE lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\linear_unit.n.01|lactate (r_conj) in_9\IN\linear_unit.n.01|cm|and|in (l_pobj) cm_12\NNP\metric_linear_unit.n.01|cardiomyopathy|(|) (l_amod) cardiomyopathy_10\NN\heart_disease.n.01|
D019344_D009202 NONE lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\linear_unit.n.01|lactate (r_conj) in_9\IN\linear_unit.n.01|cm|and|in (l_pobj) cm_12\NNP\metric_linear_unit.n.01|cardiomyopathy|(|)
D019344_D009202 NONE la_20\NNP\metallic_element.n.01| (r_appos) lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\linear_unit.n.01|lactate (r_conj) in_9\IN\linear_unit.n.01|cm|and|in (l_pobj) cm_12\NNP\metric_linear_unit.n.01|cardiomyopathy|(|) (l_amod) cardiomyopathy_10\NN\heart_disease.n.01|
D019344_D009202 NONE la_20\NNP\metallic_element.n.01| (r_appos) lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\linear_unit.n.01|lactate (r_conj) in_9\IN\linear_unit.n.01|cm|and|in (l_pobj) cm_12\NNP\metric_linear_unit.n.01|cardiomyopathy|(|)
D019344_D009202 NONE la_41\NNP\metallic_element.n.01|plasma (r_pobj) of_39\IN\entity.n.01|la (r_prep) determination_38\NN\discovery.n.01|of (r_conj) underwent_7\VBD\change.v.02|at|,|mice|echocardiography|,|and|determination|. (l_dobj) echocardiography_8\RB\diagnostic_procedure.n.01|,|quantitation (l_appos) quantitation_10\NN\entity.n.01|of|encoding (l_prep) of_11\IN\entity.n.01|abundance (l_pobj) abundance_12\NN\quantity.n.02|of (l_prep) of_13\IN\entity.n.01|markers (l_pobj) markers_15\NNS\artifact.n.01|molecular|of (l_prep) of_16\IN\entity.n.01|cm (l_pobj) cm_17\NNP\metric_linear_unit.n.01|
D019344_D009202 NONE la_10\NNP\metallic_element.n.01|elevated|in (r_pobj) with_8\IN\entity.n.01|la (r_prep) cm_7\NNP\metric_linear_unit.n.01|mitochondrial|with
D019344_D000163 NONE lactate_8\NN\ester.n.01|plasma (r_dobj) elevates_6\VBZ\delegate.v.02|lactate|in (l_prep) in_9\IN\linear_unit.n.01|mice (l_pobj) mice_12\NNS\rodent.n.01|transgenic|aids (l_compound) aids_11\NNP\immunodeficiency.n.01|
D019344_D000163 NONE lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (l_prep) in_22\IN\linear_unit.n.01|aids (l_pobj) aids_23\NNP\immunodeficiency.n.01|
D019344_D000163 NONE la_20\NNP\metallic_element.n.01| (r_appos) lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (l_prep) in_22\IN\linear_unit.n.01|aids (l_pobj) aids_23\NNP\immunodeficiency.n.01|
D019344_D000163 NONE la_10\NNP\metallic_element.n.01|elevated|in (l_prep) in_11\IN\linear_unit.n.01|mice (l_pobj) mice_14\NNS\rodent.n.01|transgenic (l_compound) transgenic_13\JJ\entity.n.01|aids (l_compound) aids_12\NNP\immunodeficiency.n.01|
D019344_D028361 NONE lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\linear_unit.n.01|lactate (r_conj) in_9\IN\linear_unit.n.01|cm|and|in (r_prep) implicated_8\VBN\involve.v.01|therapy|is|in|through|. (l_prep) through_24\IN\done.s.01|mechanisms (l_pobj) mechanisms_25\NNS\chemical_process.n.01|of (l_prep) of_26\IN\entity.n.01|dysfunction (l_pobj) dysfunction_28\NN\pathology.n.02|mitochondrial
D019344_D028361 NONE la_20\NNP\metallic_element.n.01| (r_appos) lactate_18\NN\ester.n.01|elevated|plasma|(|la|)|in (r_pobj) in_15\IN\linear_unit.n.01|lactate (r_conj) in_9\IN\linear_unit.n.01|cm|and|in (r_prep) implicated_8\VBN\involve.v.01|therapy|is|in|through|. (l_prep) through_24\IN\done.s.01|mechanisms (l_pobj) mechanisms_25\NNS\chemical_process.n.01|of (l_prep) of_26\IN\entity.n.01|dysfunction (l_pobj) dysfunction_28\NN\pathology.n.02|mitochondrial
D015215_D000163 NONE zidovudine_41\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_nmod) lamivudine_43\NN\nucleoside_reverse_transcriptase_inhibitor.n.01|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN\entity.n.01|lamivudine (r_prep) combination_39\NN\collection.n.01|the|haart|of (r_pobj) with_36\IN\entity.n.01|combination (r_prep) treated_35\VBN\interact.v.01|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS\rodent.n.01|old|hemizygous|transgenic|aids|pol (l_compound) aids_14\NNP\immunodeficiency.n.01|
D019259_D000163 NONE lamivudine_43\NN\nucleoside_reverse_transcriptase_inhibitor.n.01|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN\entity.n.01|lamivudine (r_prep) combination_39\NN\collection.n.01|the|haart|of (r_pobj) with_36\IN\entity.n.01|combination (r_prep) treated_35\VBN\interact.v.01|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS\rodent.n.01|old|hemizygous|transgenic|aids|pol (l_compound) aids_14\NNP\immunodeficiency.n.01|
D019469_D000163 NONE indinavir_46\NNS\protease_inhibitor.n.01|or|control|for (r_conj) lamivudine_43\NN\nucleoside_reverse_transcriptase_inhibitor.n.01|zidovudine|,|,|and|indinavir (r_pobj) of_40\IN\entity.n.01|lamivudine (r_prep) combination_39\NN\collection.n.01|the|haart|of (r_pobj) with_36\IN\entity.n.01|combination (r_prep) treated_35\VBN\interact.v.01|determine|,|mice|were|with|. (l_nsubjpass) mice_15\NNS\rodent.n.01|old|hemizygous|transgenic|aids|pol (l_compound) aids_14\NNP\immunodeficiency.n.01|
D002118_D009202 NONE calcium_30\NN\metallic_element.n.01| (r_compound) atpase_31\NNP\entity.n.01|sarcoplasmic|calcium|[|serca2|]|) (r_conj) encoding_21\VBG\cryptography.n.02|(|ventricular|mrna|factor|and|atpase (r_parataxis) quantitation_10\NN\entity.n.01|of|encoding (l_prep) of_11\IN\entity.n.01|abundance (l_pobj) abundance_12\NN\quantity.n.02|of (l_prep) of_13\IN\entity.n.01|markers (l_pobj) markers_15\NNS\artifact.n.01|molecular|of (l_prep) of_16\IN\entity.n.01|cm (l_pobj) cm_17\NNP\metric_linear_unit.n.01|
9754849
D008691_D002819 CID methadone_7\NN\narcotic.n.01| (r_pobj) to_6\IN\entity.n.01|methadone (r_prep) adjustment_5\NN\improvement.n.01|rapid|to (r_pobj) with_3\IN\entity.n.01|adjustment (r_prep) associated_2\VBN\think.v.03|with (r_acl) movements_1\NNS\change.n.03|choreoathetoid|associated|.
D008691_D002819 CID methadone_24\NN\narcotic.n.01|the|selective|opioid|agonist (r_pobj) to_16\IN\entity.n.01|methadone (r_prep) adjustment_15\NN\improvement.n.01|rapid|to|in (r_pobj) by_13\IN\by.r.01|adjustment (r_agent) induced_12\VBN\generate.v.01|both|transiently|by (r_xcomp) choreoathetoid_8\JJ\entity.n.01|movements|induced (l_dobj) movements_9\NNS\change.n.03|
D003042_D002819 CID cocaine_12\NN\hard_drug.n.01|but|opiates (r_pobj) with_11\IN\entity.n.01|cocaine (r_prep) intoxications_10\NNS\physical_condition.n.01|with (r_pobj) during_9\IN\entity.n.01|intoxications (r_prep) be_5\VB\metallic_element.n.01|to|abnormalities|during (r_xcomp) known_3\VBN\know.v.01|hyperkinesias|are|be|. (l_nsubjpass) hyperkinesias_1\NNS\entity.n.01|choreatiform
D003042_D002819 CID cocaine_32\NN\hard_drug.n.01| (r_conj) heroine_30\NN\character.n.04|and|cocaine (r_dobj) abusing_29\VBG\treat.v.01|previously|heroine (r_acl) inpatient_27\NN\patient.n.01|an|abusing (r_pobj) in_25\IN\linear_unit.n.01|inpatient (r_prep) adjustment_15\NN\improvement.n.01|rapid|to|in (r_pobj) by_13\IN\by.r.01|adjustment (r_agent) induced_12\VBN\generate.v.01|both|transiently|by (r_xcomp) choreoathetoid_8\JJ\entity.n.01|movements|induced (l_dobj) movements_9\NNS\change.n.03|
D003042_D006948 CID cocaine_12\NN\hard_drug.n.01|but|opiates (r_pobj) with_11\IN\entity.n.01|cocaine (r_prep) intoxications_10\NNS\physical_condition.n.01|with (r_pobj) during_9\IN\entity.n.01|intoxications (r_prep) be_5\VB\metallic_element.n.01|to|abnormalities|during (r_xcomp) known_3\VBN\know.v.01|hyperkinesias|are|be|. (l_nsubjpass) hyperkinesias_1\NNS\entity.n.01|choreatiform
D003042_D020820 NONE cocaine_12\NN\hard_drug.n.01|but|opiates (r_pobj) with_11\IN\entity.n.01|cocaine (r_prep) intoxications_10\NNS\physical_condition.n.01|with (r_pobj) during_9\IN\entity.n.01|intoxications (r_prep) be_5\VB\metallic_element.n.01|to|abnormalities|during (l_attr) abnormalities_8\NNS\physical_condition.n.01|occasional|movement
D003932_D002819 NONE heroine_30\NN\character.n.04|and|cocaine (r_dobj) abusing_29\VBG\treat.v.01|previously|heroine (r_acl) inpatient_27\NN\patient.n.01|an|abusing (r_pobj) in_25\IN\linear_unit.n.01|inpatient (r_prep) adjustment_15\NN\improvement.n.01|rapid|to|in (r_pobj) by_13\IN\by.r.01|adjustment (r_agent) induced_12\VBN\generate.v.01|both|transiently|by (r_xcomp) choreoathetoid_8\JJ\entity.n.01|movements|induced (l_dobj) movements_9\NNS\change.n.03|
18004067
D000431_D017114 NONE alcohol_8\NN\beverage.n.01| (r_compound) consumption_9\NN\bodily_process.n.01|regular|alcohol|ingesting (r_pobj) with_6\IN\entity.n.01|consumption (r_prep) patients_5\NNS\case.n.06|two|with (r_pobj) in_3\IN\linear_unit.n.01|patients (r_prep) failure_2\NN\nonaccomplishment.n.01|acute|liver|in|.
D000082_D017114 NONE paracetamol_11\NN\entity.n.01| (r_dobj) ingesting_10\VBG\consume.v.02|paracetamol|at (r_acl) consumption_9\NN\bodily_process.n.01|regular|alcohol|ingesting (r_pobj) with_6\IN\entity.n.01|consumption (r_prep) patients_5\NNS\case.n.06|two|with (r_pobj) in_3\IN\linear_unit.n.01|patients (r_prep) failure_2\NN\nonaccomplishment.n.01|acute|liver|in|.
D000431_D056486 NONE alcohol_4\NN\beverage.n.01| (r_pobj) of_3\IN\entity.n.01|alcohol (r_prep) role_2\NN\duty.n.02|the|possible|of|in (l_prep) in_5\IN\linear_unit.n.01|development (l_pobj) development_7\NN\improvement.n.02|the|of (l_prep) of_8\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_9\NN\entity.n.01|associated
D000082_D056486 CID paracetamol_15\JJ\entity.n.01|(|acetaminophen|) (r_pobj) of_14\IN\entity.n.01|paracetamol (r_prep) doses_13\NNS\medicine.n.02|therapeutic|of (r_pobj) with_11\IN\entity.n.01|doses (r_prep) associated_10\VBN\think.v.03|with (r_acl) hepatotoxicity_9\NN\entity.n.01|associated
D000082_D056486 CID acetaminophen_17\NN\analgesic.n.01| (r_appos) paracetamol_15\JJ\entity.n.01|(|acetaminophen|) (r_pobj) of_14\IN\entity.n.01|paracetamol (r_prep) doses_13\NNS\medicine.n.02|therapeutic|of (r_pobj) with_11\IN\entity.n.01|doses (r_prep) associated_10\VBN\think.v.03|with (r_acl) hepatotoxicity_9\NN\entity.n.01|associated
D000082_D056486 CID paracetamol_15\NN\entity.n.01| (r_pobj) of_14\IN\entity.n.01|paracetamol (r_prep) doses_13\NNS\medicine.n.02|therapeutic|of (r_pobj) with_11\IN\entity.n.01|doses (r_prep) treated_10\VBN\interact.v.01|with (r_acl) patients_9\NNS\case.n.06|treated (r_pobj) in_8\IN\linear_unit.n.01|patients (r_prep) development_5\NN\improvement.n.02|the|of|in (l_prep) of_6\IN\entity.n.01|hepatotoxicity (l_pobj) hepatotoxicity_7\NN\entity.n.01|
D000431_D017093 NONE alcohol_9\NN\beverage.n.01| (r_pobj) of_8\IN\entity.n.01|alcohol (r_prep) consumers_7\NNS\user.n.01|regular|of (r_attr) were_5\VBD\be.v.01|who|consumers|and|developed (l_conj) developed_12\VBD\create.v.02|who|failure|within|and|stopping (l_dobj) failure_14\NN\nonaccomplishment.n.01|liver
D000431_D017093 NONE alcohol_24\NN\beverage.n.01| (r_compound) consumption_25\NN\bodily_process.n.01|alcohol (r_dobj) stopping_23\VBG\fastener.n.02|consumption|treated (r_conj) developed_12\VBD\create.v.02|who|failure|within|and|stopping (l_dobj) failure_14\NN\nonaccomplishment.n.01|liver
D000431_D017093 NONE alcohol_10\NN\beverage.n.01| (r_pobj) of_9\IN\entity.n.01|alcohol (r_prep) consumption_8\NN\bodily_process.n.01|e.g.|regular|of (r_appos) factors_4\NNS\cause.n.01|risk|,|consumption (r_pobj) with_2\IN\entity.n.01|factors (r_prep) patients_1\NNS\case.n.06|with (r_pobj) in_0\IN\linear_unit.n.01|patients (r_prep) is_14\VBZ\be.v.01|in|,|failure|possible|ingested|. (l_nsubj) failure_13\NN\nonaccomplishment.n.01|liver
D000082_D017093 CID paracetamol_32\JJ\entity.n.01|g (r_advmod) 4_30\CD\digit.n.01|paracetamol (r_nummod) day_34\NN\time_unit.n.01|4|/ (r_pobj) with_29\IN\entity.n.01|day (r_prep) treated_28\VBN\interact.v.01|while|being|with (r_advcl) stopping_23\VBG\fastener.n.02|consumption|treated (r_conj) developed_12\VBD\create.v.02|who|failure|within|and|stopping (l_dobj) failure_14\NN\nonaccomplishment.n.01|liver
9495837
C087567_D000647 NONE /-)-pg-9_2\.\entity.n.01|mg|kg-1|) (r_nsubj) was_11\VBD\washington.n.02|(|+|/-)-pg-9|able|. (l_acomp) able_12\JJ\able.a.01|prevent (l_xcomp) prevent_14\VB\prevent.v.01|to|amnesia (l_dobj) amnesia_15\NN\cognitive_state.n.01|induced
C087567_D000647 NONE /-)-pg-9_5\NFP\entity.n.01|for|, (r_conj) of_2\IN\entity.n.01|(|+|/-)-pg-9 (r_prep) profiles_1\NNS\chart.n.01|affinity|of|determined|deferens (r_nsubj) shown_44\VBN\show.v.04|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN\magnitude_relation.n.01|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB\metallic_element.n.01|that|might|responsible (l_acomp) responsible_54\JJ\responsible.a.01|for (l_prep) for_55\IN\entity.n.01|antinociception (l_pobj) antinociception_57\NN\entity.n.01|the|and|effect|induced (l_conj) effect_63\NN\phenomenon.n.01|the|amnesic (l_amod) amnesic_62\JJ\handicapped_person.n.01|anti|-
C087567_D000647 NONE /-)-pg-9_68\NFP\entity.n.01|through (r_punct) shown_44\VBN\show.v.04|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN\magnitude_relation.n.01|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB\metallic_element.n.01|that|might|responsible (l_acomp) responsible_54\JJ\responsible.a.01|for (l_prep) for_55\IN\entity.n.01|antinociception (l_pobj) antinociception_57\NN\entity.n.01|the|and|effect|induced (l_conj) effect_63\NN\phenomenon.n.01|the|amnesic (l_amod) amnesic_62\JJ\handicapped_person.n.01|anti|-
D012601_D000647 CID scopolamine_18\NN\alkaloid.n.01|(|kg-1|in (r_pobj) by_17\IN\by.r.01|scopolamine (r_agent) induced_16\VBN\generate.v.01|by (r_acl) amnesia_15\NN\cognitive_state.n.01|induced
D004025_D000647 CID dicyclomine_26\NN\entity.n.01|(|kg-1|) (r_conj) kg-1_22\NNP\entity.n.01|mg|i.p.|)|and|dicyclomine (r_appos) scopolamine_18\NN\alkaloid.n.01|(|kg-1|in (r_pobj) by_17\IN\by.r.01|scopolamine (r_agent) induced_16\VBN\generate.v.01|by (r_acl) amnesia_15\NN\cognitive_state.n.01|induced
D000109_D000647 NONE acetylcholine_73\NN\neurotransmitter.n.01| (r_amod) levels_75\NNS\property.n.02|acetylcholine|extracellular (r_pobj) in_72\IN\linear_unit.n.01|levels (r_prep) increase_71\NN\indefinite_quantity.n.01|an|in (r_pobj) through_69\IN\done.s.01|increase (r_prep) /-)-pg-9_68\NFP\entity.n.01|through (r_punct) shown_44\VBN\show.v.04|profiles|,|have|ratio|+|/-)-pg-9|. (l_dobj) ratio_48\NN\magnitude_relation.n.01|an|m4/m1|selectivity|of|be (l_relcl) be_53\VB\metallic_element.n.01|that|might|responsible (l_acomp) responsible_54\JJ\responsible.a.01|for (l_prep) for_55\IN\entity.n.01|antinociception (l_pobj) antinociception_57\NN\entity.n.01|the|and|effect|induced (l_conj) effect_63\NN\phenomenon.n.01|the|amnesic (l_amod) amnesic_62\JJ\handicapped_person.n.01|anti|-
16403073
D007654_D016171 CID ketoconazole_0\NNP\entity.n.01| (r_nsubj) induced_1\VBD\generate.v.01|ketoconazole|pointes|without|. (l_dobj) pointes_4\FW\inform.v.01|torsades|de
D007654_D016171 CID ketoconazole_24\RB\entity.n.01| (r_dobj) taking_23\VBG\action.n.01|ketoconazole|for (r_pcomp) after_22\IN\after.s.01|taking (r_prep) torsades_16\NNS\entity.n.01|pointes|after (l_dobj) pointes_18\FW\inform.v.01|de|(|tdp|)
D007654_D016171 CID ketoconazole_24\RB\entity.n.01| (r_dobj) taking_23\VBG\action.n.01|ketoconazole|for (r_pcomp) after_22\IN\after.s.01|taking (r_prep) torsades_16\NNS\entity.n.01|pointes|after (l_dobj) pointes_18\FW\inform.v.01|de|(|tdp|) (l_appos) tdp_20\NN\entity.n.01|
D007654_D016171 CID ketoconazole_13\RB\entity.n.01|alone (r_nsubj) prolong_16\VB\lengthen.v.01|that|by|,|ketoconazole|may|interval|and|induce (l_conj) induce_20\VB\generate.v.01|tdp. (l_dobj) tdp._21\NN\entity.n.01|
D007654_D003324 NONE ketoconazole_24\RB\entity.n.01| (r_dobj) taking_23\VBG\action.n.01|ketoconazole|for (r_pcomp) after_22\IN\after.s.01|taking (r_prep) torsades_16\NNS\entity.n.01|pointes|after (r_conj) developed_9\VBD\create.v.02|who|interval|and|torsades (r_relcl) woman_3\NN\adult.n.01|a|with|developed (l_prep) with_4\IN\entity.n.01|disease (l_pobj) disease_7\NN\illness.n.01|coronary|artery
D007654_D008133 CID ketoconazole_24\RB\entity.n.01| (r_dobj) taking_23\VBG\action.n.01|ketoconazole|for (r_pcomp) after_22\IN\after.s.01|taking (r_prep) torsades_16\NNS\entity.n.01|pointes|after (r_conj) developed_9\VBD\create.v.02|who|interval|and|torsades (l_dobj) interval_14\NN\measure.n.02|a|prolonged|qt
D007654_D008133 CID ketoconazole_5\JJ\entity.n.01| (r_nsubjpass) administered_7\VBN\manage.v.02|when|ketoconazole|is|to (l_prep) to_8\IN\entity.n.01|patients (l_pobj) patients_9\NNS\case.n.06|with (l_prep) with_10\IN\entity.n.01|factors (l_pobj) factors_12\NNS\cause.n.01|risk|for (l_prep) for_13\IN\entity.n.01|syndrome (l_pobj) syndrome_17\NN\complex.n.01|acquired|long|qt
D007654_D009181 NONE ketoconazole_24\RB\entity.n.01| (r_dobj) taking_23\VBG\action.n.01|ketoconazole|for (l_prep) for_25\IN\entity.n.01|treatment (l_pobj) treatment_26\NN\care.n.01|of (l_prep) of_27\IN\entity.n.01|infection (l_pobj) infection_29\NN\ill_health.n.01|fungal
12757899
D004958_D012640 NONE estradiol_0\NN\estrogen.n.01| (r_nsubj) reduces_1\VBZ\decrease.v.02|estradiol|injury|but|in|. (l_dobj) injury_6\NN\ill_health.n.01|induced|hippocampal|in (l_amod) induced_4\VBN\generate.v.01|seizure|- (l_npadvmod) seizure_2\NN\attack.n.07|
D004958_D012640 NONE estradiol_7\NN\estrogen.n.01| (r_pobj) of_6\IN\entity.n.01|estradiol (r_prep) effects_5\NNS\personal_property.n.01|the|of|on (l_prep) on_8\IN\on.a.01|threshold (l_pobj) threshold_10\NN\beginning.n.02|seizure|and|damage (l_compound) seizure_9\NN\attack.n.07|
D004958_D001930 NONE estradiol_0\NN\estrogen.n.01| (r_nsubj) reduces_1\VBZ\decrease.v.02|estradiol|injury|but|in|. (l_dobj) injury_6\NN\ill_health.n.01|induced|hippocampal|in
D007608_D001930 NONE acid_10\NN\compound.n.02| (r_npadvmod) induced_12\VBN\generate.v.01|acid|- (r_amod) status_13\NN\state.n.02|kainic|induced|se (r_pobj) by_8\IN\by.r.01|status (r_agent) induced_7\VBN\generate.v.01|by (r_advcl) protect_1\VBP\defend.v.02|estrogens|rats|induced|)|. (l_dobj) rats_3\NNS\rodent.n.01|ovariectomized|from (l_prep) from_4\IN\entity.n.01|injury (l_pobj) injury_6\NN\ill_health.n.01|hippocampal
D007608_D013226 NONE acid_10\NN\compound.n.02| (r_npadvmod) induced_12\VBN\generate.v.01|acid|- (r_amod) status_13\NN\state.n.02|kainic|induced|se (l_appos) se_16\NNP\antioxidant.n.01|epilepticus|( (l_amod) epilepticus_14\NN\entity.n.01|
D007608_D013226 NONE acid_10\NN\compound.n.02| (r_npadvmod) induced_12\VBN\generate.v.01|acid|- (r_amod) status_13\NN\state.n.02|kainic|induced|se (l_appos) se_16\NNP\antioxidant.n.01|epilepticus|(
D004958_D013226 NONE estradiol_7\NN\estrogen.n.01|17beta|- (r_pobj) of_4\IN\entity.n.01|estradiol (r_prep) effects_3\NNS\personal_property.n.01|the|of|in|and|rats (l_conj) rats_14\NNS\rodent.n.01|ovariectomized|female|subjected (l_acl) subjected_15\VBN\affect.v.01|to (l_prep) to_16\IN\entity.n.01|se (l_pobj) se_22\NNP\antioxidant.n.01|induced
D008094_D013226 CID lithium_17\NN\metallic_element.n.01| (r_compound) pilocarpine_19\NN\alkaloid.n.01|lithium|- (r_npadvmod) induced_21\VBN\generate.v.01|pilocarpine|- (r_amod) se_22\NNP\antioxidant.n.01|induced
D010862_D013226 CID pilocarpine_19\NN\alkaloid.n.01|lithium|- (r_npadvmod) induced_21\VBN\generate.v.01|pilocarpine|- (r_amod) se_22\NNP\antioxidant.n.01|induced
D012834_D013226 NONE silver_3\NN\conductor.n.02| (r_npadvmod) stained_5\VBN\dye.v.01|silver|- (r_amod) ca3_6\NN\entity.n.01|stained|and|neurons (r_pobj) of_2\IN\entity.n.01|ca3 (r_prep) extent_1\NN\degree.n.02|the|of (r_nsubjpass) evaluated_12\VBN\evaluate.v.02|extent|was|after|. (l_prep) after_15\IN\after.s.01|days|se (l_pobj) se_16\NNP\antioxidant.n.01|
15275829
D000109_D012640 NONE acetylcholine_5\NN\neurotransmitter.n.01| (r_compound) subunits_7\NNS\monetary_unit.n.01|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) are_8\VBP\area_unit.n.01|subunits|necessary|for|. (l_prep) for_10\IN\entity.n.01|seizures (l_pobj) seizures_14\NNS\attack.n.07|induced|and|hypolocomotion
D000109_D012640 NONE acetylcholine_5\NN\neurotransmitter.n.01| (r_compound) receptors_6\NNS\structure.n.04|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN\entity.n.01|receptors (r_prep) binding_0\NN\attraction.n.03|of|to (r_nsubj) elicits_10\VBZ\make.v.03|binding|series|. (l_dobj) series_12\NN\ordering.n.01|a|of (l_prep) of_13\IN\entity.n.01|behaviors (l_pobj) behaviors_17\NNS\activity.n.01|dependent|go (l_relcl) go_19\VBP\shift.n.03|that|from|,|to (l_prep) to_29\IN\entity.n.01|seizures (l_pobj) seizures_30\NNS\attack.n.07|and|death
D000109_D006948 NONE acetylcholine_5\NN\neurotransmitter.n.01| (r_compound) subunits_7\NNS\monetary_unit.n.01|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) are_8\VBP\area_unit.n.01|subunits|necessary|for|. (l_prep) for_10\IN\entity.n.01|seizures (l_pobj) seizures_14\NNS\attack.n.07|induced|and|hypolocomotion (l_conj) hypolocomotion_16\NN\entity.n.01|in
D009538_D012640 CID nicotine_11\NN\alkaloid.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|nicotine|- (r_amod) seizures_14\NNS\attack.n.07|induced|and|hypolocomotion
D009538_D012640 CID nicotine_2\NN\alkaloid.n.01| (r_pobj) of_1\IN\entity.n.01|nicotine (r_prep) binding_0\NN\attraction.n.03|of|to (r_nsubj) elicits_10\VBZ\make.v.03|binding|series|. (l_dobj) series_12\NN\ordering.n.01|a|of (l_prep) of_13\IN\entity.n.01|behaviors (l_pobj) behaviors_17\NNS\activity.n.01|dependent|go (l_relcl) go_19\VBP\shift.n.03|that|from|,|to (l_prep) to_29\IN\entity.n.01|seizures (l_pobj) seizures_30\NNS\attack.n.07|and|death
D009538_D012640 CID nicotine_9\NN\alkaloid.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|nicotine|- (r_amod) seizures_12\NNS\attack.n.07|induced
D009538_D012640 CID nicotine_10\NN\alkaloid.n.01| (r_pobj) of_9\IN\entity.n.01|nicotine (r_prep) effects_8\NNS\personal_property.n.01|the|of|at (r_pobj) to_6\IN\entity.n.01|effects (r_prep) sensitive_5\JJ\psychic.n.01|less|to (r_acomp) were_3\VBD\be.v.01|mice|sensitive|,|measured|. (l_advcl) measured_16\VBN\decide.v.01|as|,|and|at|measured (l_conj) measured_30\VBN\decide.v.01|as (l_prep) as_31\IN\chemical_element.n.01|sensitivity (l_pobj) sensitivity_32\NN\sense.n.03|to (l_prep) to_33\IN\entity.n.01|seizures (l_pobj) seizures_37\NNS\attack.n.07|induced
D009538_D012640 CID nicotine_34\NN\alkaloid.n.01| (r_npadvmod) induced_36\VBN\generate.v.01|nicotine|- (r_amod) seizures_37\NNS\attack.n.07|induced
D009538_D012640 CID nicotine_7\NN\alkaloid.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|nicotine|- (r_amod) seizures_10\NNS\attack.n.07|induced
D009538_D012640 CID nicotine_15\NN\alkaloid.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|nicotine|- (r_amod) seizures_18\NNS\attack.n.07|induced|and|hypolocomotion
D009538_D006948 NONE nicotine_11\NN\alkaloid.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|nicotine|- (r_amod) seizures_14\NNS\attack.n.07|induced|and|hypolocomotion (l_conj) hypolocomotion_16\NN\entity.n.01|in
D009538_D006948 NONE nicotine_9\NN\alkaloid.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|nicotine|- (r_amod) seizures_12\NNS\attack.n.07|induced (r_pobj) in_8\IN\linear_unit.n.01|seizures (r_prep) subunits_7\NNS\monetary_unit.n.01|the|beta4|in|and|hypolocomotion (l_conj) hypolocomotion_14\NN\entity.n.01|in
D009538_D006948 NONE nicotine_15\NN\alkaloid.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|nicotine|- (r_amod) seizures_18\NNS\attack.n.07|induced|and|hypolocomotion (l_conj) hypolocomotion_20\NN\entity.n.01|
D009538_D014202 NONE nicotine_2\NN\alkaloid.n.01| (r_pobj) of_1\IN\entity.n.01|nicotine (r_prep) binding_0\NN\attraction.n.03|of|to (r_nsubj) elicits_10\VBZ\make.v.03|binding|series|. (l_dobj) series_12\NN\ordering.n.01|a|of (l_prep) of_13\IN\entity.n.01|behaviors (l_pobj) behaviors_17\NNS\activity.n.01|dependent|go (l_relcl) go_19\VBP\shift.n.03|that|from|,|to (l_prep) from_20\IN\entity.n.01|exploration (l_pobj) exploration_22\NN\expedition.n.03|altered|,|sedation (l_conj) sedation_24\NN\physical_condition.n.01|,|and|tremors (l_conj) tremors_27\NNS\vibration.n.01|
D009538_D003643 NONE nicotine_2\NN\alkaloid.n.01| (r_pobj) of_1\IN\entity.n.01|nicotine (r_prep) binding_0\NN\attraction.n.03|of|to (r_nsubj) elicits_10\VBZ\make.v.03|binding|series|. (l_dobj) series_12\NN\ordering.n.01|a|of (l_prep) of_13\IN\entity.n.01|behaviors (l_pobj) behaviors_17\NNS\activity.n.01|dependent|go (l_relcl) go_19\VBP\shift.n.03|that|from|,|to (l_prep) to_29\IN\entity.n.01|seizures (l_pobj) seizures_30\NNS\attack.n.07|and|death (l_conj) death_32\NN\change.n.01|
D000109_D014202 NONE acetylcholine_5\NN\neurotransmitter.n.01| (r_compound) receptors_6\NNS\structure.n.04|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN\entity.n.01|receptors (r_prep) binding_0\NN\attraction.n.03|of|to (r_nsubj) elicits_10\VBZ\make.v.03|binding|series|. (l_dobj) series_12\NN\ordering.n.01|a|of (l_prep) of_13\IN\entity.n.01|behaviors (l_pobj) behaviors_17\NNS\activity.n.01|dependent|go (l_relcl) go_19\VBP\shift.n.03|that|from|,|to (l_prep) from_20\IN\entity.n.01|exploration (l_pobj) exploration_22\NN\expedition.n.03|altered|,|sedation (l_conj) sedation_24\NN\physical_condition.n.01|,|and|tremors (l_conj) tremors_27\NNS\vibration.n.01|
D000109_D003643 NONE acetylcholine_5\NN\neurotransmitter.n.01| (r_compound) receptors_6\NNS\structure.n.04|nicotinic|acetylcholine|(|nachrs|) (r_pobj) to_3\IN\entity.n.01|receptors (r_prep) binding_0\NN\attraction.n.03|of|to (r_nsubj) elicits_10\VBZ\make.v.03|binding|series|. (l_dobj) series_12\NN\ordering.n.01|a|of (l_prep) of_13\IN\entity.n.01|behaviors (l_pobj) behaviors_17\NNS\activity.n.01|dependent|go (l_relcl) go_19\VBP\shift.n.03|that|from|,|to (l_prep) to_29\IN\entity.n.01|seizures (l_pobj) seizures_30\NNS\attack.n.07|and|death (l_conj) death_32\NN\change.n.01|
3676049
D007530_D007022 CID isoflurane_6\RB\inhalation_anesthetic.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|isoflurane|- (r_amod) hypotension_9\NN\cardiovascular_disease.n.01|induced|in
D007530_D007022 CID isoflurane_12\RB\inhalation_anesthetic.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|isoflurane|- (r_amod) hypotension_15\NN\cardiovascular_disease.n.01|induced|in
D007530_D007022 CID isoflurane_19\NN\inhalation_anesthetic.n.01| (r_pobj) of_18\IN\entity.n.01|isoflurane (r_prep) dose_17\NN\medicine.n.02|the|of (r_dobj) increasing_15\VBG\change_magnitude.v.01|dose (r_pcomp) by_14\IN\by.r.01|increasing (r_prep) induced_13\VBN\generate.v.01|hypotension|was|by|,|and|maintained|. (l_nsubjpass) hypotension_1\NN\cardiovascular_disease.n.01|controlled|to
D007530_D002532 NONE isoflurane_6\RB\inhalation_anesthetic.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|isoflurane|- (r_amod) hypotension_9\NN\cardiovascular_disease.n.01|induced|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_11\NNS\case.n.06|subjected (l_acl) subjected_12\VBN\affect.v.01|to|for (l_prep) for_15\IN\entity.n.01|aneurysms (l_pobj) aneurysms_17\NNS\cardiovascular_disease.n.01|cerebral
D007530_D002532 NONE isoflurane_12\RB\inhalation_anesthetic.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|isoflurane|- (r_amod) hypotension_15\NN\cardiovascular_disease.n.01|induced|in (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|10|subjected (l_acl) subjected_19\VBN\affect.v.01|to (l_prep) to_20\IN\entity.n.01|craniotomy (l_pobj) craniotomy_21\NN\operation.n.06|for (l_prep) for_22\IN\entity.n.01|clipping (l_pobj) clipping_23\NN\excerpt.n.01|of (l_prep) of_24\IN\entity.n.01|aneurysm (l_pobj) aneurysm_27\NN\cardiovascular_disease.n.01|a|cerebral
D010100_D007022 NONE oxygen_8\NN\chemical_element.n.01| (r_pobj) for_7\IN\entity.n.01|oxygen (r_prep) rate_6\NN\magnitude_relation.n.01|cerebral|metabolic|for (r_conj) flow_2\NN\change_of_location.n.01|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN\decide.v.01|flow|were|during|. (l_prep) during_11\IN\entity.n.01|hypotension (l_pobj) hypotension_15\NN\cardiovascular_disease.n.01|induced|in
D010100_D002532 NONE oxygen_8\NN\chemical_element.n.01| (r_pobj) for_7\IN\entity.n.01|oxygen (r_prep) rate_6\NN\magnitude_relation.n.01|cerebral|metabolic|for (r_conj) flow_2\NN\change_of_location.n.01|cerebral|blood|and|rate (r_nsubjpass) measured_10\VBN\decide.v.01|flow|were|during|. (l_prep) during_11\IN\entity.n.01|hypotension (l_pobj) hypotension_15\NN\cardiovascular_disease.n.01|induced|in (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|10|subjected (l_acl) subjected_19\VBN\affect.v.01|to (l_prep) to_20\IN\entity.n.01|craniotomy (l_pobj) craniotomy_21\NN\operation.n.06|for (l_prep) for_22\IN\entity.n.01|clipping (l_pobj) clipping_23\NN\excerpt.n.01|of (l_prep) of_24\IN\entity.n.01|aneurysm (l_pobj) aneurysm_27\NN\cardiovascular_disease.n.01|a|cerebral
D014978_D013345 NONE xenon-133_24\.\entity.n.01| (r_punct) measured_4\VBN\decide.v.01|flow|were|after|by|xenon-133 (l_prep) after_9\IN\after.s.01|days|haemorrhage (l_pobj) haemorrhage_12\NN\injury.n.01|the|subarachnoid
D008628_D007022 NONE hg_11\NNP\metallic_element.n.01|mm (r_pobj) of_6\IN\entity.n.01|hg (r_prep) map_5\NNP\representation.n.02|an|average|of (r_pobj) to_2\IN\entity.n.01|map (r_prep) hypotension_1\NN\cardiovascular_disease.n.01|controlled|to
D007530_D000783 NONE isoflurane_7\JJ\inhalation_anesthetic.n.01| (r_amod) concentration_8\NN\property.n.02|the|isoflurane (r_nsubjpass) reduced_10\VBN\decrease.v.02|after|concentration|was|to|. (l_prep) after_0\IN\after.s.01|clipping (l_pobj) clipping_2\NN\excerpt.n.01|the|of (l_prep) of_3\IN\entity.n.01|aneurysm (l_pobj) aneurysm_5\NN\cardiovascular_disease.n.01|the
12536034
D002220_D004832 CID carbamazepine_13\NN\entity.n.01|and|vigabatrin (r_pobj) of_12\IN\entity.n.01|carbamazepine (r_prep) administration_11\NN\management.n.01|of (r_pobj) after_10\IN\after.s.01|administration (r_prep) present_2\VBP\time.n.05|authors|patients|after|. (l_dobj) patients_4\NNS\case.n.06|three|with (l_prep) with_5\IN\entity.n.01|epilepsy (l_pobj) epilepsy_9\NN\brain_disorder.n.01|absence
D020888_D004832 CID vigabatrin_15\NN\entity.n.01| (r_conj) carbamazepine_13\NN\entity.n.01|and|vigabatrin (r_pobj) of_12\IN\entity.n.01|carbamazepine (r_prep) administration_11\NN\management.n.01|of (r_pobj) after_10\IN\after.s.01|administration (r_prep) present_2\VBP\time.n.05|authors|patients|after|. (l_dobj) patients_4\NNS\case.n.06|three|with (l_prep) with_5\IN\entity.n.01|epilepsy (l_pobj) epilepsy_9\NN\brain_disorder.n.01|absence
D005680_D004832 NONE acid_4\NN\compound.n.02| (r_npadvmod) transmitted_6\VBN\transfer.v.02|acid|- (r_amod) circuitry_8\NN\electronic_equipment.n.01|transmitted|thalamocortical (r_compound) accounts_9\VBZ\record.n.01|the|aminobutyric|circuitry|for|. (l_prep) for_10\IN\entity.n.01|part (l_pobj) part_13\NN\relation.n.01|a|major|of (l_prep) of_14\IN\entity.n.01|neurophysiology (l_pobj) neurophysiology_17\NN\neuroscience.n.01|the|underlying|of (l_prep) of_18\IN\entity.n.01|epilepsy (l_pobj) epilepsy_21\NN\brain_disorder.n.01|the|absence
19308880
D014635_D003221 CID acid_10\NN\compound.n.02|valproic (r_pobj) with_8\IN\entity.n.01|acid (r_prep) reaction_7\NN\chemical_process.n.01|a|serious|adverse|drug|with (r_appos) confusion_0\NN\disorder.n.03|,|reaction|:|review|.
D014635_D003221 CID acid_10\NN\compound.n.02|valproic (r_pobj) with_8\IN\entity.n.01|acid (r_prep) observed_7\VBD\spy.v.03|frequently|with (r_acl) reaction_5\NN\chemical_process.n.01|an|adverse|drug|observed (r_attr) is_1\VBZ\be.v.01|confusion|reaction|. (l_nsubj) confusion_0\NN\disorder.n.03|
D014635_D003221 CID acid_17\NN\compound.n.02|valproic (r_pobj) with_15\IN\entity.n.01|acid (r_prep) reported_12\VBN\inform.v.01|since|with (r_acl) confusion_11\NN\disorder.n.03|reported
D014635_D003221 CID acid_9\NN\compound.n.02|valproic|:|women (r_pobj) with_7\IN\entity.n.01|acid (r_prep) reported_6\VBN\inform.v.01|:|cases|were|with|. (l_nsubjpass) cases_2\NNS\happening.n.01|272|of (l_prep) of_3\IN\entity.n.01|confusion (l_pobj) confusion_4\NN\disorder.n.03|
D014635_D003221 CID acid_10\NN\compound.n.02|valproic (r_compound) exposure_11\NN\vulnerability.n.02|acid|(|%|) (r_pobj) following_8\VBG\multitude.n.03|exposure (r_prep) weeks_7\NNS\time_period.n.01|the|two|first|following (r_pobj) during_3\IN\entity.n.01|weeks (r_prep) occurred_2\VBD\happen.v.01|confusion|mostly|during|. (l_nsubj) confusion_0\NN\disorder.n.03|
D014635_D003221 CID acid_7\NN\compound.n.02|valproic (r_pobj) with_5\IN\entity.n.01|acid (r_prep) confusion_4\NN\disorder.n.03|with
20477932
D003042_D008569 CID cocaine_0\NN\hard_drug.n.01| (r_nsubj) causes_1\VBZ\origin.n.03|cocaine|memory|. (l_dobj) memory_2\NN\representation.n.01|and|learning|:|involvement (l_conj) learning_4\VBG\basic_cognitive_process.n.01|impairments (l_dobj) impairments_5\NNS\change.n.01|in
D003042_D007859 CID cocaine_0\NN\hard_drug.n.01| (r_nsubj) causes_1\VBZ\origin.n.03|cocaine|memory|. (l_dobj) memory_2\NN\representation.n.01|and|learning|:|involvement (l_conj) learning_4\VBG\basic_cognitive_process.n.01|impairments (l_dobj) impairments_5\NNS\change.n.01|in
C052342_D008569 NONE topiramate_22\NN\entity.n.01| (r_pobj) by_21\IN\by.r.01|topiramate (r_prep) prevention_20\NN\hindrance.n.03|by (r_conj) involvement_9\NN\group_action.n.01|of|,|and|prevention (r_appos) memory_2\NN\representation.n.01|and|learning|:|involvement (l_conj) learning_4\VBG\basic_cognitive_process.n.01|impairments (l_dobj) impairments_5\NNS\change.n.01|in
C052342_D007859 NONE topiramate_22\NN\entity.n.01| (r_pobj) by_21\IN\by.r.01|topiramate (r_prep) prevention_20\NN\hindrance.n.03|by (r_conj) involvement_9\NN\group_action.n.01|of|,|and|prevention (r_appos) memory_2\NN\representation.n.01|and|learning|:|involvement (l_conj) learning_4\VBG\basic_cognitive_process.n.01|impairments (l_dobj) impairments_5\NNS\change.n.01|in
D003042_D064420 NONE cocaine_6\NN\hard_drug.n.01| (r_compound) toxicity_7\NN\definite_quantity.n.01|cocaine|including
D003042_D064420 NONE cocaine_24\NN\hard_drug.n.01| (r_conj) brain_22\NN\neural_structure.n.01|the|and|cocaine (r_nmod) behaviour_27\NN\action.n.02|brain|induced|- (r_pobj) in_20\IN\linear_unit.n.01|behaviour (r_prep) status_19\NN\state.n.02|oxidative|in (r_pobj) between_17\IN\between.r.01|status (r_prep) association_16\NN\organization.n.01|the|between (r_conj) increase_10\NN\indefinite_quantity.n.01|an|in|but|association (r_pobj) including_8\VBG\include.v.01|increase (r_prep) toxicity_7\NN\definite_quantity.n.01|cocaine|including
D009569_D019970 NONE oxide_9\NN\compound.n.02| (r_compound) synthase_10\NN\entity.n.01|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN\medical_care.n.01|a|proposed|for (l_prep) for_32\IN\entity.n.01|addiction (l_pobj) addiction_34\NN\physical_condition.n.01|cocaine
C052342_D019970 NONE topiramate_26\NN\entity.n.01| (r_pobj) of_25\IN\entity.n.01|topiramate (r_prep) effect_24\NN\phenomenon.n.01|the|of (r_conj) learning_17\NN\basic_cognitive_process.n.01|spatial|and|memory|as|effect (r_conj) activity_14\NN\act.n.02|nnos|)|,|learning (r_conj) synthase_10\NN\entity.n.01|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN\medical_care.n.01|a|proposed|for (l_prep) for_32\IN\entity.n.01|addiction (l_pobj) addiction_34\NN\physical_condition.n.01|cocaine
D003042_D019970 NONE cocaine_43\NN\hard_drug.n.01| (r_compound) administration_44\NN\management.n.01|cocaine (r_pobj) of_42\IN\entity.n.01|administration (r_prep) model_41\NN\hypothesis.n.02|an|experimental|of|in (r_pobj) in_38\IN\linear_unit.n.01|model (r_prep) evaluated_37\VBN\evaluate.v.02|therefore|activity|were|in|. (l_nsubjpass) activity_2\NN\act.n.02|nfkappab|,|stress|, (l_appos) stress_5\NN\prosody.n.01|oxidative|,|synthase (l_conj) synthase_10\NN\entity.n.01|neuronal|nitric|oxide|(|activity|,|therapy (l_conj) therapy_31\NN\medical_care.n.01|a|proposed|for (l_prep) for_32\IN\entity.n.01|addiction (l_pobj) addiction_34\NN\physical_condition.n.01|cocaine
84204
D002927_D003221 CID cimetidine_7\NN\antacid.n.01| (r_npadvmod) associated_9\VBN\think.v.03|cimetidine|- (r_amod) confusion_11\NN\disorder.n.03|associated|mental
D002927_D003221 CID cimetidine_3\NN\antacid.n.01| (r_npadvmod) associated_5\VBN\think.v.03|cimetidine|- (r_amod) confusion_7\NN\disorder.n.03|associated|mental
D002927_D051437 NONE cimetidine_19\FW\antacid.n.01|concentrations (r_conj) dysfunction_8\NN\pathology.n.02|both|renal|(|p|)|,|as|cimetidine
D002927_D008107 NONE cimetidine_19\FW\antacid.n.01|concentrations (r_conj) dysfunction_8\NN\pathology.n.02|both|renal|(|p|)|,|as|cimetidine
8372922
2673163
D003042_D020521 NONE cocaine_3\NN\hard_drug.n.01| (r_compound) use_4\NN\activity.n.01|cocaine (r_pobj) with_2\IN\entity.n.01|use (r_prep) associated_1\VBN\think.v.03|with (r_acl) stroke_0\NN\maneuver.n.03|associated|.
D003042_D020521 NONE cocaine_6\NN\hard_drug.n.01| (r_compound) use_7\NN\activity.n.01|cocaine (r_nsubjpass) related_9\VBN\think.v.03|in|use|was|to|and|review (l_prep) to_10\IN\entity.n.01|stroke (l_pobj) stroke_11\NN\maneuver.n.03|
D003042_D020521 NONE cocaine_2\NN\hard_drug.n.01| (r_compound) use_3\NN\activity.n.01|cocaine|by (r_dobj) followed_1\VBD\travel.v.01|stroke|use|. (l_nsubj) stroke_0\NN\maneuver.n.03|
D003042_D020521 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related
D003042_D020521 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\maneuver.n.03|2|)|associated
D003042_D020521 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\maneuver.n.03|3
D003042_D020521 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5
D003042_D020521 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_conj) 5_63\CD\digit.n.01|(|)|in|, (l_prep) in_65\IN\linear_unit.n.01|stroke (l_pobj) stroke_69\NN\maneuver.n.03|associated
D003042_D020521 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\tell.v.02|data|increasing (l_ccomp) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (l_nsubj) incidence_9\NN\frequency.n.02|the|apparent|of (l_prep) of_10\IN\entity.n.01|stroke (l_pobj) stroke_11\NN\maneuver.n.03|related
D003042_D020521 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated
D003042_D020521 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\maneuver.n.03|3
D003042_D020521 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5
D003042_D020521 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_conj) 5_63\CD\digit.n.01|(|)|in|, (l_prep) in_65\IN\linear_unit.n.01|stroke (l_pobj) stroke_69\NN\maneuver.n.03|associated
D003042_D020521 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\tell.v.02|data|increasing (l_ccomp) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (l_nsubj) incidence_9\NN\frequency.n.02|the|apparent|of (l_prep) of_10\IN\entity.n.01|stroke (l_pobj) stroke_11\NN\maneuver.n.03|related
D003042_D020521 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\maneuver.n.03|2|)|associated
D003042_D020521 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\maneuver.n.03|3
D003042_D020521 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5
D003042_D020521 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_conj) 5_63\CD\digit.n.01|(|)|in|, (l_prep) in_65\IN\linear_unit.n.01|stroke (l_pobj) stroke_69\NN\maneuver.n.03|associated
D003042_D020521 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (r_advcl) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\tell.v.02|data|increasing (l_ccomp) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (l_nsubj) incidence_9\NN\frequency.n.02|the|apparent|of (l_prep) of_10\IN\entity.n.01|stroke (l_pobj) stroke_11\NN\maneuver.n.03|related
D003042_D020521 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (r_advcl) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\maneuver.n.03|2|)|associated
D003042_D020521 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (r_advcl) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\maneuver.n.03|3
D003042_D020521 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (r_advcl) stroke_47\NN\maneuver.n.03|4|associated|;|and|5
D003042_D020521 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (r_advcl) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_conj) 5_63\CD\digit.n.01|(|)|in|, (l_prep) in_65\IN\linear_unit.n.01|stroke (l_pobj) stroke_69\NN\maneuver.n.03|associated
D003042_D020521 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_ccomp) indicate_2\VBP\tell.v.02|data|increasing (l_ccomp) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (l_nsubj) incidence_9\NN\frequency.n.02|the|apparent|of (l_prep) of_10\IN\entity.n.01|stroke (l_pobj) stroke_11\NN\maneuver.n.03|related
D003042_D020521 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (l_nsubj) stroke_25\NN\maneuver.n.03|2|)|associated
D003042_D020521 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (l_nsubj) stroke_35\NN\maneuver.n.03|3
D003042_D020521 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5
D003042_D020521 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated
D003042_D002532 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations
D003042_D002532 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations
D003042_D002532 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations
D003042_D002532 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations
D003042_D002532 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations
D003042_D001165 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations (l_conj) malformations_59\NNS\affliction.n.02|arteriovenous
D003042_D001165 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations (l_conj) malformations_59\NNS\affliction.n.02|arteriovenous
D003042_D001165 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_nmod) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations (l_conj) malformations_59\NNS\affliction.n.02|arteriovenous
D003042_D001165 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations (l_conj) malformations_59\NNS\affliction.n.02|arteriovenous
D003042_D001165 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (l_advcl) associated_53\VBN\think.v.03|after|use|is|frequently|with (l_prep) with_54\IN\entity.n.01|aneurysms (l_pobj) aneurysms_56\NNS\cardiovascular_disease.n.01|intracranial|and|malformations (l_conj) malformations_59\NNS\affliction.n.02|arteriovenous
D003042_D020300 NONE cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_prep) of_73\IN\entity.n.01|hemorrhage (l_pobj) hemorrhage_75\NN\injury.n.01|intracranial
D003042_D020300 NONE cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_prep) of_73\IN\entity.n.01|hemorrhage (l_pobj) hemorrhage_75\NN\injury.n.01|intracranial
D003042_D020300 NONE cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_nsubj) frequency_72\NN\rate.n.01|stroke|the|of (l_prep) of_73\IN\entity.n.01|hemorrhage (l_pobj) hemorrhage_75\NN\injury.n.01|intracranial
D003042_D020300 NONE cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (r_advcl) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (l_prep) of_73\IN\entity.n.01|hemorrhage (l_pobj) hemorrhage_75\NN\injury.n.01|intracranial
D003042_D020300 NONE cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (l_prep) of_73\IN\entity.n.01|hemorrhage (l_pobj) hemorrhage_75\NN\injury.n.01|intracranial
D003042_D002544 CID cocaine_14\NN\hard_drug.n.01| (r_compound) use_15\NN\activity.n.01|cocaine (r_pobj) to_13\IN\entity.n.01|use (r_prep) related_12\VBN\think.v.03|to (r_acl) stroke_11\NN\maneuver.n.03|related (r_pobj) of_10\IN\entity.n.01|stroke (r_prep) incidence_9\NN\frequency.n.02|the|apparent|of (r_nsubj) increasing_17\VBG\change_magnitude.v.01|that|incidence|is (r_ccomp) indicate_2\VBP\tell.v.02|data|increasing (r_ccomp) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_dobj) that_77\DT\entity.n.01|of (l_prep) of_78\IN\entity.n.01|infarction (l_pobj) infarction_80\NN\pathology.n.02|cerebral
D003042_D002544 CID cocaine_22\NN\hard_drug.n.01| (r_npadvmod) associated_24\VBN\think.v.03|cocaine|- (r_amod) stroke_25\NN\maneuver.n.03|2|)|associated (r_nsubj) occurs_26\VBZ\happen.v.01|indicate|;|(|stroke|primarily|in (r_ccomp) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_dobj) that_77\DT\entity.n.01|of (l_prep) of_78\IN\entity.n.01|infarction (l_pobj) infarction_80\NN\pathology.n.02|cerebral
D003042_D002544 CID cocaine_41\NN\hard_drug.n.01| (r_compound) administration_42\NN\management.n.01|cocaine (r_pobj) of_40\IN\entity.n.01|administration (r_prep) route_39\NN\line.n.11|any|of (r_dobj) follow_37\VB\travel.v.01|occurs|;|stroke|may|route (r_ccomp) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_dobj) that_77\DT\entity.n.01|of (l_prep) of_78\IN\entity.n.01|infarction (l_pobj) infarction_80\NN\pathology.n.02|cerebral
D003042_D002544 CID cocaine_49\NN\hard_drug.n.01| (r_compound) use_50\NN\activity.n.01|cocaine (r_nsubjpass) associated_53\VBN\think.v.03|after|use|is|frequently|with (r_advcl) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_dobj) that_77\DT\entity.n.01|of (l_prep) of_78\IN\entity.n.01|infarction (l_pobj) infarction_80\NN\pathology.n.02|cerebral
D003042_D002544 CID cocaine_66\NN\hard_drug.n.01| (r_npadvmod) associated_68\VBN\think.v.03|cocaine|- (r_amod) stroke_69\NN\maneuver.n.03|associated (r_pobj) in_65\IN\linear_unit.n.01|stroke (r_prep) 5_63\CD\digit.n.01|(|)|in|, (r_conj) stroke_47\NN\maneuver.n.03|4|associated|;|and|5 (r_nmod) frequency_72\NN\rate.n.01|stroke|the|of (r_nsubj) exceeds_76\VBZ\exceed.v.01|follow|;|frequency|that|. (l_dobj) that_77\DT\entity.n.01|of (l_prep) of_78\IN\entity.n.01|infarction (l_pobj) infarction_80\NN\pathology.n.02|cerebral
7423039
D004317_D066126 CID adriamycin_3\JJ\entity.n.01| (r_amod) cardiotoxicity_4\NN\entity.n.01|adriamycin
D004317_D066126 CID adriamycin_4\NNS\entity.n.01| (r_pobj) of_3\IN\entity.n.01|adriamycin (r_prep) effects_2\NNS\personal_property.n.01|the|cardiotoxic|of (l_amod) cardiotoxic_1\JJ\entity.n.01|
3070035
D002216_D051437 NONE captopril_2\NN\ace_inhibitor.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|captopril|- (r_amod) insufficiency_6\NN\failing.n.01|induced|renal
D002216_D051437 NONE captopril_4\NN\ace_inhibitor.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|captopril|- (r_amod) failure_8\NN\nonaccomplishment.n.01|induced|renal
D002216_D006978 NONE captopril_2\NN\ace_inhibitor.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|captopril|- (r_amod) insufficiency_6\NN\failing.n.01|induced|renal (r_pobj) of_1\IN\entity.n.01|insufficiency (r_prep) reversibility_0\NN\changeableness.n.01|of|after|. (l_prep) after_7\IN\after.s.01|use (l_pobj) use_9\NN\activity.n.01|prolonged|in (l_prep) in_10\IN\linear_unit.n.01|case (l_pobj) case_13\NN\happening.n.01|an|unusual|of (l_prep) of_14\IN\entity.n.01|hypertension (l_pobj) hypertension_16\NN\cardiovascular_disease.n.01|renovascular
D002216_D006973 NONE captopril_27\NN\ace_inhibitor.n.01| (r_pobj) with_26\IN\entity.n.01|captopril (r_prep) treatment_25\NN\care.n.01|with (r_pobj) following_24\VBG\multitude.n.03|treatment (r_prep) deterioration_20\NN\decay.n.04|sudden|of|following (r_dobj) developed_18\VBD\create.v.02|who|deterioration (r_relcl) kidney_15\NN\excretory_organ.n.01|a|solitary|,|developed (r_pobj) to_12\IN\entity.n.01|kidney (r_prep) artery_11\NN\blood_vessel.n.01|an|occluded|renal|to (r_pobj) with_7\IN\entity.n.01|artery (r_prep) hypertension_6\NN\cardiovascular_disease.n.01|severe|with
D002216_D058186 CID captopril_27\NN\ace_inhibitor.n.01| (r_pobj) with_26\IN\entity.n.01|captopril (r_prep) treatment_25\NN\care.n.01|with (r_pobj) following_24\VBG\multitude.n.03|treatment (r_prep) deterioration_20\NN\decay.n.04|sudden|of|following (l_prep) of_21\IN\entity.n.01|function (l_pobj) function_23\NN\mathematical_relation.n.01|renal
3865016
D005047_D054218 NONE etoposide_4\NN\entity.n.01|and|cyclosporin (r_nmod) a_7\NNP\metric_linear_unit.n.01|etoposide (r_pobj) of_3\IN\entity.n.01|a (r_prep) effect_2\NN\phenomenon.n.01|a|synergistic|of (r_nsubjpass) observed_9\VBN\spy.v.03|effect|was|in|in|. (l_prep) in_10\IN\linear_unit.n.01|patient (l_pobj) patient_12\NN\case.n.06|a|with (l_prep) with_13\IN\entity.n.01|leukemia (l_pobj) leukemia_18\NN\cancer.n.01|acute|lymphocytic
D016572_D054218 NONE a_7\NNP\metric_linear_unit.n.01|etoposide (r_pobj) of_3\IN\entity.n.01|a (r_prep) effect_2\NN\phenomenon.n.01|a|synergistic|of (r_nsubjpass) observed_9\VBN\spy.v.03|effect|was|in|in|. (l_prep) in_10\IN\linear_unit.n.01|patient (l_pobj) patient_12\NN\case.n.06|a|with (l_prep) with_13\IN\entity.n.01|leukemia (l_pobj) leukemia_18\NN\cancer.n.01|acute|lymphocytic
D005047_D017254 NONE etoposide_4\NN\entity.n.01|and|cyclosporin (r_nmod) a_7\NNP\metric_linear_unit.n.01|etoposide (r_pobj) of_3\IN\entity.n.01|a (r_prep) administration_2\NN\management.n.01|the|concomitant|of (r_nsubj) resulted_8\VBD\prove.v.01|administration|in|. (l_prep) in_9\IN\linear_unit.n.01|eradication (l_pobj) eradication_10\NN\destruction.n.02|of (l_prep) of_11\IN\entity.n.01|infiltration (l_pobj) infiltration_15\NN\penetration.n.01|hitherto|refractory|leukemic|of
D016572_D017254 NONE a_7\NNP\metric_linear_unit.n.01|etoposide (r_pobj) of_3\IN\entity.n.01|a (r_prep) administration_2\NN\management.n.01|the|concomitant|of (r_nsubj) resulted_8\VBD\prove.v.01|administration|in|. (l_prep) in_9\IN\linear_unit.n.01|eradication (l_pobj) eradication_10\NN\destruction.n.02|of (l_prep) of_11\IN\entity.n.01|infiltration (l_pobj) infiltration_15\NN\penetration.n.01|hitherto|refractory|leukemic|of
17532790
D007980_D004409 CID dopa_12\NNP\amino_acid.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|l|-|dopa|- (r_amod) dyskinesia_15\NN\nervous_disorder.n.01|induced
D007980_D004409 CID dopa_2\NNP\amino_acid.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|l|-|dopa|- (r_amod) dyskinesia_5\NN\nervous_disorder.n.01|induced|lid
D007980_D004409 CID dopa_2\NNP\amino_acid.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|l|-|dopa|- (r_amod) dyskinesia_5\NN\nervous_disorder.n.01|induced|lid (l_appos) lid_7\NNP\protective_fold.n.01|(|)
D007980_D004409 CID dopa_31\NNP\amino_acid.n.01|l|- (r_pobj) with_28\IN\entity.n.01|dopa (r_prep) treatment_27\NN\care.n.01|a|prolonged|with (r_pobj) after_24\IN\after.s.01|treatment (r_prep) arise_15\VBP\become.v.03|that|in|after (r_relcl) complications_13\NNS\hindrance.n.03|the|motor|arise (r_pobj) among_10\IN\entity.n.01|complications (r_prep) is_9\VBZ\be.v.01|dyskinesia|among|. (l_nsubj) dyskinesia_5\NN\nervous_disorder.n.01|induced|lid
D007980_D004409 CID dopa_31\NNP\amino_acid.n.01|l|- (r_pobj) with_28\IN\entity.n.01|dopa (r_prep) treatment_27\NN\care.n.01|a|prolonged|with (r_pobj) after_24\IN\after.s.01|treatment (r_prep) arise_15\VBP\become.v.03|that|in|after (r_relcl) complications_13\NNS\hindrance.n.03|the|motor|arise (r_pobj) among_10\IN\entity.n.01|complications (r_prep) is_9\VBZ\be.v.01|dyskinesia|among|. (l_nsubj) dyskinesia_5\NN\nervous_disorder.n.01|induced|lid (l_appos) lid_7\NNP\protective_fold.n.01|(|)
D007980_D004409 CID dopa_5\NNP\amino_acid.n.01|l|- (r_pobj) with_2\IN\entity.n.01|dopa (r_prep) treated_1\VBD\interact.v.01|rats|with|allocated|. (l_conj) allocated_7\VBN\assign.v.02|were|to (l_prep) to_8\IN\entity.n.01|groups (l_pobj) groups_10\NNS\abstraction.n.06|two|based (l_acl) based_11\VBN\establish.v.08|on (l_prep) on_12\IN\on.a.01|presence (l_pobj) presence_14\NN\being.n.01|the|or|absence (l_conj) absence_16\NN\lack.n.01|of (l_prep) of_17\IN\entity.n.01|lid (l_pobj) lid_18\NNP\protective_fold.n.01|
D007980_D010300 NONE dopa_2\NNP\amino_acid.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|l|-|dopa|- (r_amod) dyskinesia_5\NN\nervous_disorder.n.01|induced|lid (r_nsubj) is_9\VBZ\be.v.01|dyskinesia|among|. (l_prep) among_10\IN\entity.n.01|complications (l_pobj) complications_13\NNS\hindrance.n.03|the|motor|arise (l_relcl) arise_15\VBP\become.v.03|that|in|after (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_23\NNS\case.n.06|disease|(|pd|) (l_nmod) disease_19\NN\illness.n.01|parkinson
D007980_D010300 NONE dopa_2\NNP\amino_acid.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|l|-|dopa|- (r_amod) dyskinesia_5\NN\nervous_disorder.n.01|induced|lid (r_nsubj) is_9\VBZ\be.v.01|dyskinesia|among|. (l_prep) among_10\IN\entity.n.01|complications (l_pobj) complications_13\NNS\hindrance.n.03|the|motor|arise (l_relcl) arise_15\VBP\become.v.03|that|in|after (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_23\NNS\case.n.06|disease|(|pd|) (l_nmod) pd_21\NNP\metallic_element.n.01|
D007980_D010300 NONE dopa_31\NNP\amino_acid.n.01|l|- (r_pobj) with_28\IN\entity.n.01|dopa (r_prep) treatment_27\NN\care.n.01|a|prolonged|with (r_pobj) after_24\IN\after.s.01|treatment (r_prep) arise_15\VBP\become.v.03|that|in|after (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_23\NNS\case.n.06|disease|(|pd|) (l_nmod) disease_19\NN\illness.n.01|parkinson
D007980_D010300 NONE dopa_31\NNP\amino_acid.n.01|l|- (r_pobj) with_28\IN\entity.n.01|dopa (r_prep) treatment_27\NN\care.n.01|a|prolonged|with (r_pobj) after_24\IN\after.s.01|treatment (r_prep) arise_15\VBP\become.v.03|that|in|after (l_prep) in_16\IN\linear_unit.n.01|patients (l_pobj) patients_23\NNS\case.n.06|disease|(|pd|) (l_nmod) pd_21\NNP\metallic_element.n.01|
D007980_D010300 NONE dopa_34\NNP\amino_acid.n.01|l|-|or|bromocriptine (r_appos) changes_8\NNS\happening.n.01|the|occurring|,|dopa|using (l_acl) occurring_9\VBG\happen.v.01|at (l_prep) at_10\IN\chemical_element.n.01|level (l_pobj) level_13\NN\property.n.02|the|protein|in|obtained (l_acl) obtained_17\VBN\get.v.01|from (l_prep) from_18\IN\entity.n.01|model (l_pobj) model_25\NN\hypothesis.n.02|the|unilaterally|rat|of|treated (l_prep) of_26\IN\entity.n.01|pd (l_pobj) pd_27\NNP\metallic_element.n.01|
D016627_D010300 NONE 6-hydroxydopamine_21\CD\entity.n.01| (r_compound) lesion_23\NN\pathology.n.02|6-hydroxydopamine|- (r_compound) rat_24\NN\rodent.n.01|lesion (r_compound) model_25\NN\hypothesis.n.02|the|unilaterally|rat|of|treated (l_prep) of_26\IN\entity.n.01|pd (l_pobj) pd_27\NNP\metallic_element.n.01|
D001971_D010300 NONE bromocriptine_36\NN\entity.n.01| (r_conj) dopa_34\NNP\amino_acid.n.01|l|-|or|bromocriptine (r_appos) changes_8\NNS\happening.n.01|the|occurring|,|dopa|using (l_acl) occurring_9\VBG\happen.v.01|at (l_prep) at_10\IN\chemical_element.n.01|level (l_pobj) level_13\NN\property.n.02|the|protein|in|obtained (l_acl) obtained_17\VBN\get.v.01|from (l_prep) from_18\IN\entity.n.01|model (l_pobj) model_25\NN\hypothesis.n.02|the|unilaterally|rat|of|treated (l_prep) of_26\IN\entity.n.01|pd (l_pobj) pd_27\NNP\metallic_element.n.01|
1085609
D011736_D012640 NONE pyridoxine_1\NN\b-complex_vitamin.n.01| (r_nmod) convulsions_3\NNS\attack.n.07|neonatal|pyridoxine|responsive|due|.
D011736_D012640 NONE pyridoxine_9\NN\b-complex_vitamin.n.01|intramuscular (r_dobj) administering_7\VBG\manage.v.02|pyridoxine (r_pcomp) of_6\IN\entity.n.01|administering (r_prep) hours_5\NNS\work_time.n.01|4|of (r_pobj) within_3\IN\inside.r.02|hours (r_prep) ceased_2\VBD\discontinue.v.01|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS\bad_temper.n.01|the
D011736_D012640 NONE pyridoxine_15\JJ\b-complex_vitamin.n.01| (r_compound) deficiency_16\NN\need.n.01|pyridoxine|secondary (r_pobj) of_14\IN\entity.n.01|deficiency (r_prep) aetiology_13\NN\cause.n.01|an|of|isoniazid (r_dobj) suggesting_11\VBG\declare.v.01|aetiology (r_advcl) ceased_2\VBD\discontinue.v.01|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS\bad_temper.n.01|the
D007538_D012640 CID isoniazid_6\NN\antibacterial.n.01| (r_amod) therapy_7\NN\medical_care.n.01|isoniazid (r_pobj) due_4\IN\right.n.01|to|therapy (r_amod) convulsions_3\NNS\attack.n.07|neonatal|pyridoxine|responsive|due|.
D007538_D012640 CID isoniazid_6\NN\antibacterial.n.01| (r_pobj) on_5\IN\on.a.01|isoniazid|therapy (r_prep) infant_4\NN\child.n.02|a|old|on|daily|because (r_nsubjpass) admitted_18\VBN\declare.v.04|infant|was|after|. (l_prep) after_19\IN\after.s.01|days (l_pobj) days_21\NNS\life.n.07|4|of (l_prep) of_22\IN\entity.n.01|fits (l_pobj) fits_24\NNS\bad_temper.n.01|clonic
D007538_D012640 CID isoniazid_19\NN\antibacterial.n.01|to|medication (r_relcl) aetiology_13\NN\cause.n.01|an|of|isoniazid (r_dobj) suggesting_11\VBG\declare.v.01|aetiology (r_advcl) ceased_2\VBD\discontinue.v.01|fits|within|,|suggesting|. (l_nsubj) fits_1\NNS\bad_temper.n.01|the
D007538_D014376 NONE isoniazid_6\NN\antibacterial.n.01| (r_pobj) on_5\IN\on.a.01|isoniazid|therapy (r_prep) infant_4\NN\child.n.02|a|old|on|daily|because (l_prep) because_13\IN\entity.n.01|of|tuberculosis (l_pobj) tuberculosis_16\NN\infectious_disease.n.01|maternal
11897407
C067171_D009203 NONE glucarate_2\NN\entity.n.01|99mtc|-|for|. (l_prep) for_3\IN\entity.n.01|detection (l_pobj) detection_4\NN\perception.n.03|of (l_prep) of_5\IN\entity.n.01|infarction (l_pobj) infarction_10\NN\pathology.n.02|induced|myocardial|in
C067171_D009203 NONE glucarate_2\NN\entity.n.01|99mtc|- (r_nsubj) was_3\VBD\washington.n.02|glucarate|easy|,|stable|and|used|. (l_conj) used_14\VBN\use.v.01|was|study (l_xcomp) study_16\VB\examination.n.01|to|biodistribution (l_dobj) biodistribution_18\NN\entity.n.01|its|in (l_prep) in_19\IN\linear_unit.n.01|rats (l_pobj) rats_20\NNS\rodent.n.01|with (l_prep) with_21\IN\entity.n.01|infarction (l_pobj) infarction_27\NN\pathology.n.02|induced|acute|myocardial
D007545_D009203 CID isoproterenol_6\NN\medicine.n.02| (r_npadvmod) induced_8\VBN\generate.v.01|isoproterenol|- (r_amod) infarction_10\NN\pathology.n.02|induced|myocardial|in
D007545_D009203 CID isoproterenol_22\NN\medicine.n.02| (r_npadvmod) induced_24\VBN\generate.v.01|isoproterenol|- (r_amod) infarction_27\NN\pathology.n.02|induced|acute|myocardial
D007545_D007238 NONE isoproterenol_18\NN\medicine.n.02| (r_pobj) with_17\IN\entity.n.01|isoproterenol (r_prep) obtained_16\VBN\get.v.01|can|be|easily|with (r_conj) implies_7\VBZ\express.v.01|model|ligation|obtained|. (l_nsubj) model_2\NN\hypothesis.n.02|the|animal|used (l_acl) used_3\VBN\use.v.01|produce (l_xcomp) produce_5\VB\food.n.02|to|infarction (l_dobj) infarction_6\NN\pathology.n.02|
D007545_D007238 NONE isoproterenol_12\JJ\medicine.n.02| (r_compound) administration_13\NN\management.n.01|isoproterenol (r_pobj) after_11\IN\after.s.01|administration (r_prep) h_10\NN\chemical_element.n.01|18|after (r_npadvmod) developed_6\VBD\create.v.02|that|rats|infarct|h (l_dobj) infarct_8\NN\pathology.n.02|an
D005937_D007238 NONE acid_9\NN\compound.n.02|glucaric (r_pobj) on_7\IN\on.a.01|acid (r_prep) based_6\VBN\establish.v.08|on (r_acl) radiopharmaceutical_5\NN\pharmaceutical.n.01|a|new|avid|based (l_amod) avid_4\JJ\avid.s.01|infarct|- (l_npadvmod) infarct_2\NN\pathology.n.02|
7919560
D000667_D004892 CID ampicillin_7\NN\penicillin.n.01| (r_pobj) by_6\IN\by.r.01|ampicillin (r_agent) caused_5\VBN\make.v.03|multiforme|by|. (l_nsubj) multiforme_1\NN\entity.n.01|erythema|and|myocarditis
D000667_D004892 CID ampicillin_12\NN\penicillin.n.01| (r_pobj) by_11\IN\by.r.01|ampicillin (r_agent) caused_10\VBN\make.v.03|by (r_acl) case_3\NN\happening.n.01|a|of|caused (l_prep) of_4\IN\entity.n.01|multiforme (l_pobj) multiforme_6\NNS\entity.n.01|erythema|and|myocarditis
D000667_D009205 CID ampicillin_7\NN\penicillin.n.01| (r_pobj) by_6\IN\by.r.01|ampicillin (r_agent) caused_5\VBN\make.v.03|multiforme|by|. (l_nsubj) multiforme_1\NN\entity.n.01|erythema|and|myocarditis (l_conj) myocarditis_4\NN\carditis.n.01|hypersensitivity
D000667_D009205 CID ampicillin_12\NN\penicillin.n.01| (r_pobj) by_11\IN\by.r.01|ampicillin (r_agent) caused_10\VBN\make.v.03|by (r_acl) case_3\NN\happening.n.01|a|of|caused (l_prep) of_4\IN\entity.n.01|multiforme (l_pobj) multiforme_6\NNS\entity.n.01|erythema|and|myocarditis (l_conj) myocarditis_9\NN\carditis.n.01|hypersensitivity
D000667_D018805 NONE ampicillin_8\NN\penicillin.n.01| (r_pobj) with_7\IN\entity.n.01|ampicillin (r_prep) treated_6\VBN\interact.v.01|boy|was|with|and|gentamicin|. (l_conj) gentamicin_10\NN\antibiotic.n.01|because (l_prep) because_11\IN\entity.n.01|of|septicemia (l_pobj) septicemia_14\NN\blood_disease.n.01|suspected
D005839_D018805 NONE gentamicin_10\NN\antibiotic.n.01|because (l_prep) because_11\IN\entity.n.01|of|septicemia (l_pobj) septicemia_14\NN\blood_disease.n.01|suspected
D010406_D009205 NONE penicillins_11\NNS\antibiotic.n.01| (r_pobj) to_10\IN\entity.n.01|penicillins (r_prep) is_2\VBZ\be.v.01|myocarditis|manifestation|to|. (l_nsubj) myocarditis_1\NN\carditis.n.01|hypersensitivity
D010406_D004342 NONE penicillins_11\NNS\antibiotic.n.01| (r_pobj) to_10\IN\entity.n.01|penicillins (r_prep) is_2\VBZ\be.v.01|myocarditis|manifestation|to|. (l_attr) manifestation_7\NN\appearance.n.02|a|rare|of (l_prep) of_8\IN\entity.n.01|allergy (l_pobj) allergy_9\NN\hypersensitivity_reaction.n.01|
18809400
D008063_D028361 NONE acid_3\NN\compound.n.02|lipoic (r_nsubj) prevents_4\VBZ\prevent.v.01|acid|damage|. (l_dobj) damage_6\NN\change.n.01|mitochondrial|and|neurotoxicity|in
D008063_D028361 NONE acid_7\NN\compound.n.02|lipoic (r_nsubj) is_8\VBZ\be.v.01|if|acid|neuroprotective|induced|,|plays (l_advcl) plays_18\VBZ\dramatic_composition.n.01|if|damage|role|,|and|depend (l_nsubj) damage_17\NN\change.n.01|mitochondrial
D008063_D028361 NONE acid_35\NN\compound.n.02|lipoic (r_pobj) of_31\IN\entity.n.01|acid (r_prep) effects_30\NNS\personal_property.n.01|neuroprotective|of (r_nsubj) depend_36\VBP\be.v.01|if|effects|on (r_conj) plays_18\VBZ\dramatic_composition.n.01|if|damage|role|,|and|depend (l_nsubj) damage_17\NN\change.n.01|mitochondrial
D008063_D028361 NONE acid_3\NN\compound.n.02|lipoic (r_nsubj) exerts_4\VBZ\use.v.01|acid|effects|induced (r_ccomp) rescues_16\VBZ\recovery.n.03|exerts|:|it|toxicity|and|induces|. (l_dobj) toxicity_19\NN\definite_quantity.n.01|the|mitochondrial
D008063_D020258 NONE acid_3\NN\compound.n.02|lipoic (r_nsubj) prevents_4\VBZ\prevent.v.01|acid|damage|. (l_dobj) damage_6\NN\change.n.01|mitochondrial|and|neurotoxicity|in (l_conj) neurotoxicity_8\NN\entity.n.01|
D008063_D020258 NONE acid_7\NN\compound.n.02|lipoic (r_nsubj) is_8\VBZ\be.v.01|if|acid|neuroprotective|induced|,|plays (l_advcl) induced_12\VBN\generate.v.01|neurotoxicity (l_dobj) neurotoxicity_13\NN\entity.n.01|
D008063_D020258 NONE acid_35\NN\compound.n.02|lipoic (r_pobj) of_31\IN\entity.n.01|acid (r_prep) effects_30\NNS\personal_property.n.01|neuroprotective|of (r_nsubj) depend_36\VBP\be.v.01|if|effects|on (r_conj) plays_18\VBZ\dramatic_composition.n.01|if|damage|role|,|and|depend (r_advcl) is_8\VBZ\be.v.01|if|acid|neuroprotective|induced|,|plays (l_advcl) induced_12\VBN\generate.v.01|neurotoxicity (l_dobj) neurotoxicity_13\NN\entity.n.01|
D008063_D020258 NONE acid_3\NN\compound.n.02|lipoic (r_nsubj) exerts_4\VBZ\use.v.01|acid|effects|induced (l_conj) induced_9\VBN\generate.v.01|neurotoxicity (l_dobj) neurotoxicity_10\NN\entity.n.01|in
D008063_D009422 NONE acid_3\NN\compound.n.02|lipoic (r_nsubj) prevents_4\VBZ\prevent.v.01|acid|damage|. (l_dobj) damage_6\NN\change.n.01|mitochondrial|and|neurotoxicity|in (l_prep) in_9\IN\linear_unit.n.01|neuropathy (l_pobj) neuropathy_12\NN\pathology.n.02|experimental|chemotherapy
D008063_D009410 NONE acid_7\NN\compound.n.02|lipoic (r_nsubj) is_8\VBZ\be.v.01|if|acid|neuroprotective|induced|,|plays (l_advcl) plays_18\VBZ\dramatic_composition.n.01|if|damage|role|,|and|depend (l_dobj) role_21\NN\duty.n.02|a|critical|in (l_prep) in_22\IN\linear_unit.n.01|cascade (l_pobj) cascade_25\NN\waterfall.n.01|toxic|neurodegenerative
D008063_D009410 NONE acid_35\NN\compound.n.02|lipoic (r_pobj) of_31\IN\entity.n.01|acid (r_prep) effects_30\NNS\personal_property.n.01|neuroprotective|of (r_nsubj) depend_36\VBP\be.v.01|if|effects|on (r_conj) plays_18\VBZ\dramatic_composition.n.01|if|damage|role|,|and|depend (l_dobj) role_21\NN\duty.n.02|a|critical|in (l_prep) in_22\IN\linear_unit.n.01|cascade (l_pobj) cascade_25\NN\waterfall.n.01|toxic|neurodegenerative
D017239_D010523 CID paclitaxel_32\NN\entity.n.01|and|cisplatin (r_pobj) to_31\IN\entity.n.01|paclitaxel (r_prep) neurons_30\NNS\somatic_cell.n.01|(|drg|)|sensory|to (r_appos) ganglion_25\NN\neural_structure.n.01|dorsal|root|neurons (r_pobj) of_22\IN\entity.n.01|ganglion (r_prep) cultures_21\NNS\society.n.01|primary|of (r_dobj) exposing_19\VBG\subject.v.01|cultures (r_pcomp) by_18\IN\by.r.01|exposing (r_prep) mimic_13\VBP\impersonator.n.01|that|closely|in|by|drugs (r_relcl) model_5\NN\hypothesis.n.02|an|in|vitro|of|mimic (r_dobj) used_1\VBD\use.v.01|we|model|induced|. (l_xcomp) induced_8\VBD\generate.v.01|neuropathy (l_dobj) neuropathy_10\NN\pathology.n.02|peripheral
D002945_D010523 CID cisplatin_34\NN\entity.n.01| (r_conj) paclitaxel_32\NN\entity.n.01|and|cisplatin (r_pobj) to_31\IN\entity.n.01|paclitaxel (r_prep) neurons_30\NNS\somatic_cell.n.01|(|drg|)|sensory|to (r_appos) ganglion_25\NN\neural_structure.n.01|dorsal|root|neurons (r_pobj) of_22\IN\entity.n.01|ganglion (r_prep) cultures_21\NNS\society.n.01|primary|of (r_dobj) exposing_19\VBG\subject.v.01|cultures (r_pcomp) by_18\IN\by.r.01|exposing (r_prep) mimic_13\VBP\impersonator.n.01|that|closely|in|by|drugs (r_relcl) model_5\NN\hypothesis.n.02|an|in|vitro|of|mimic (r_dobj) used_1\VBD\use.v.01|we|model|induced|. (l_xcomp) induced_8\VBD\generate.v.01|neuropathy (l_dobj) neuropathy_10\NN\pathology.n.02|peripheral
D008063_D001480 NONE acid_10\NN\compound.n.02|lipoic (r_pobj) of_6\IN\entity.n.01|acid (r_prep) efficacy_5\NN\effectiveness.n.01|the|of|in (l_prep) in_11\IN\linear_unit.n.01|preventing (l_pcomp) preventing_12\VBG\prevent.v.01|damage (l_dobj) damage_14\NN\change.n.01|axonal
D008063_D001480 NONE acid_34\NN\compound.n.02|lipoic (r_conj) agents_29\NNS\causal_agent.n.01|toxic|and|acid (r_pobj) to_27\IN\entity.n.01|agents (r_prep) exposure_26\NN\vulnerability.n.02|to (r_pobj) after_25\IN\after.s.01|exposure (r_prep) function_19\NN\mathematical_relation.n.01|the|and|morphology|of|after (r_conj) apoptosis_16\NN\necrobiosis.n.01|and|function (r_conj) investigating_3\VBG\work.n.01|efficacy|and|apoptosis (l_dobj) efficacy_5\NN\effectiveness.n.01|the|of|in (l_prep) in_11\IN\linear_unit.n.01|preventing (l_pcomp) preventing_12\VBG\prevent.v.01|damage (l_dobj) damage_14\NN\change.n.01|axonal
D002945_D028361 NONE cisplatin_5\NN\entity.n.01|both|and|paclitaxel (r_nsubj) cause_8\VBP\origin.n.03|that|cisplatin|impairment (l_dobj) impairment_11\NN\change.n.01|early|mitochondrial|with
D002945_D028361 NONE cisplatin_13\NN\entity.n.01| (r_conj) in_10\IN\linear_unit.n.01|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\psychological_feature.n.01|an|early|common|in (r_attr) is_4\VBZ\be.v.01|in|toxicity|event|induced|. (l_nsubj) toxicity_3\NN\definite_quantity.n.01|mitochondrial
D017239_D028361 NONE paclitaxel_7\NN\entity.n.01| (r_conj) cisplatin_5\NN\entity.n.01|both|and|paclitaxel (r_nsubj) cause_8\VBP\origin.n.03|that|cisplatin|impairment (l_dobj) impairment_11\NN\change.n.01|early|mitochondrial|with
D017239_D028361 NONE paclitaxel_11\NN\entity.n.01| (r_pobj) in_10\IN\linear_unit.n.01|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\psychological_feature.n.01|an|early|common|in (r_attr) is_4\VBZ\be.v.01|in|toxicity|event|induced|. (l_nsubj) toxicity_3\NN\definite_quantity.n.01|mitochondrial
D017239_D020258 NONE paclitaxel_11\NN\entity.n.01| (r_pobj) in_10\IN\linear_unit.n.01|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\psychological_feature.n.01|an|early|common|in (r_attr) is_4\VBZ\be.v.01|in|toxicity|event|induced|. (l_advcl) induced_14\VBN\generate.v.01|neurotoxicity (l_dobj) neurotoxicity_15\NN\entity.n.01|
D002945_D020258 NONE cisplatin_13\NN\entity.n.01| (r_conj) in_10\IN\linear_unit.n.01|both|paclitaxel|and|cisplatin (r_prep) event_8\NN\psychological_feature.n.01|an|early|common|in (r_attr) is_4\VBZ\be.v.01|in|toxicity|event|induced|. (l_advcl) induced_14\VBN\generate.v.01|neurotoxicity (l_dobj) neurotoxicity_15\NN\entity.n.01|
D008063_D010523 NONE acid_7\NN\compound.n.02|lipoic (r_nsubj) reduce_9\VB\decrease.v.02|that|acid|might|risk|and|encourage (l_dobj) risk_11\NN\danger.n.03|the|of (l_prep) of_12\IN\entity.n.01|developing (l_pcomp) developing_13\VBG\processing.n.01|toxicity (l_dobj) toxicity_16\NN\definite_quantity.n.01|nerve|in
9746003
D002220_D004832 CID carbamazepine_3\NN\entity.n.01|and|vigabatrin (l_conj) vigabatrin_5\VBP\entity.n.01|in (l_prep) in_6\IN\linear_unit.n.01|seizures (l_pobj) seizures_9\NNS\attack.n.07|typical|absence
D002220_D004832 CID carbamazepine_0\NNP\entity.n.01|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\rede.v.02|carbamazepine|are|in|. (l_prep) in_5\IN\linear_unit.n.01|seizures (l_pobj) seizures_8\NNS\attack.n.07|typical|absence
D020888_D004832 CID vigabatrin_5\VBP\entity.n.01|in (l_prep) in_6\IN\linear_unit.n.01|seizures (l_pobj) seizures_9\NNS\attack.n.07|typical|absence
D020888_D004832 CID vigabatrin_2\NN\entity.n.01| (r_conj) carbamazepine_0\NNP\entity.n.01|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\rede.v.02|carbamazepine|are|in|. (l_prep) in_5\IN\linear_unit.n.01|seizures (l_pobj) seizures_8\NNS\attack.n.07|typical|absence
D002220_D009207 CID carbamazepine_9\NN\entity.n.01|and|two (l_conj) two_11\CD\digit.n.01|of (l_prep) of_12\IN\entity.n.01|jerks (l_pobj) jerks_16\NNS\misfit.n.01|these|developed|myoclonic|,|resolved
D002220_D009207 CID carbamazepine_23\NN\entity.n.01| (r_pobj) of_22\IN\entity.n.01|carbamazepine (r_prep) withdrawal_21\NN\retraction.n.01|of (r_pobj) on_20\IN\on.a.01|withdrawal (r_prep) resolved_19\VBD\end.v.02|which|on (r_relcl) jerks_16\NNS\misfit.n.01|these|developed|myoclonic|,|resolved
8829025
D016559_D006973 CID tacrolimus_5\NNS\entity.n.01| (r_dobj) receiving_4\VBG\get.v.01|tacrolimus (r_acl) patients_3\NNS\case.n.06|receiving (r_pobj) of_2\IN\entity.n.01|patients (r_prep) groups_1\NNS\abstraction.n.06|two|of (r_nsubjpass) compared_7\VBN\analyze.v.01|groups|were|over|,|group|. (l_appos) group_16\NN\abstraction.n.06|one|comprising|,|and|other (l_acl) comprising_17\VBG\be.v.01|patients (l_dobj) patients_19\NNS\case.n.06|hypertensive|receiving (l_amod) hypertensive_18\JJ\patient.n.01|
D016559_D006973 CID tacrolimus_12\NN\entity.n.01|in (r_pobj) with_11\IN\entity.n.01|tacrolimus (r_prep) associated_10\VBN\think.v.03|with (r_acl) nephrotoxicity_9\NN\entity.n.01|the|associated (r_dobj) reducing_7\VBG\chemical_reaction.n.01|nephrotoxicity (r_pcomp) on_6\IN\on.a.01|reducing (r_prep) impact_3\NN\contact.n.04|the|observed|positive|of|on (r_nsubj) be_18\VB\metallic_element.n.01|impact|should|factor|. (l_attr) factor_21\NN\cause.n.01|an|important|in (l_prep) in_22\IN\linear_unit.n.01|selecting (l_pcomp) selecting_23\VBG\decide.v.01|agent|treat (l_xcomp) treat_27\VB\nutriment.n.01|to|hypertension (l_dobj) hypertension_28\NN\cardiovascular_disease.n.01|in
D009543_D006973 NONE nifedipine_23\NN\calcium_blocker.n.01| (r_dobj) receiving_22\VBG\get.v.01|who|were|nifedipine (r_relcl) patients_19\NNS\case.n.06|hypertensive|receiving (l_amod) hypertensive_18\JJ\patient.n.01|
D009543_D006973 NONE nifedipine_33\NN\calcium_blocker.n.01| (r_dobj) receiving_32\VBG\get.v.01|not|nifedipine (r_acl) patients_30\NNS\case.n.06|nonhypertensive|receiving (r_dobj) comprising_28\VBG\be.v.01|patients (r_acl) other_27\JJ\other.a.01|the|comprising (r_conj) group_16\NN\abstraction.n.06|one|comprising|,|and|other (l_acl) comprising_17\VBG\be.v.01|patients (l_dobj) patients_19\NNS\case.n.06|hypertensive|receiving (l_amod) hypertensive_18\JJ\patient.n.01|
D009543_D006973 NONE nifedipine_5\NN\calcium_blocker.n.01| (r_pobj) of_4\IN\entity.n.01|nifedipine (r_prep) impact_3\NN\contact.n.04|the|observed|positive|of|on (r_nsubj) be_18\VB\metallic_element.n.01|impact|should|factor|. (l_attr) factor_21\NN\cause.n.01|an|important|in (l_prep) in_22\IN\linear_unit.n.01|selecting (l_pcomp) selecting_23\VBG\decide.v.01|agent|treat (l_xcomp) treat_27\VB\nutriment.n.01|to|hypertension (l_dobj) hypertension_28\NN\cardiovascular_disease.n.01|in
D009543_D007674 NONE nifedipine_5\NN\calcium_blocker.n.01| (r_pobj) of_4\IN\entity.n.01|nifedipine (r_prep) impact_3\NN\contact.n.04|the|observed|positive|of|on (l_prep) on_6\IN\on.a.01|reducing (l_pcomp) reducing_7\VBG\chemical_reaction.n.01|nephrotoxicity (l_dobj) nephrotoxicity_9\NN\entity.n.01|the|associated
D016559_D007674 NONE tacrolimus_12\NN\entity.n.01|in (r_pobj) with_11\IN\entity.n.01|tacrolimus (r_prep) associated_10\VBN\think.v.03|with (r_acl) nephrotoxicity_9\NN\entity.n.01|the|associated
11334364
D000082_D009336 CID acetaminophen_13\RB\analgesic.n.01| (r_advmod) induced_15\VBN\generate.v.01|acetaminophen|- (r_amod) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity (r_pobj) during_12\IN\entity.n.01|nephrotoxicity (r_prep) deaths_11\NNS\change.n.01|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\entity.n.01|and|necrotic (l_conj) necrotic_9\JJ\necrotic.a.01|
D000082_D009336 CID aap_9\NNP\entity.n.01|,|ami (r_appos) drugs_4\NNS\agent.n.03|all|the|,|as|aap (r_nsubj) induced_14\VBD\generate.v.01|interestingly|,|drugs|death|in|. (l_prep) in_17\IN\linear_unit.n.01|addition (l_pobj) addition_18\NN\component.n.03|to (l_prep) to_19\IN\entity.n.01|necrosis (l_pobj) necrosis_20\NN\death.n.02|in|blocked
D000082_D007674 CID acetaminophen_13\RB\analgesic.n.01| (r_advmod) induced_15\VBN\generate.v.01|acetaminophen|- (r_amod) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity
D000082_D007674 CID acetaminophen_16\RB\analgesic.n.01| (r_advmod) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
D000082_D007674 CID aap)-induced_18\VBN\entity.n.01| (r_compound) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
D000082_D008171 NONE acetaminophen_13\RB\analgesic.n.01| (r_advmod) induced_15\VBN\generate.v.01|acetaminophen|- (r_amod) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity (l_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity
D000082_D008171 NONE acetaminophen_16\RB\analgesic.n.01| (r_advmod) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000082_D008171 NONE aap)-induced_18\VBN\entity.n.01| (r_compound) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000082_D066126 NONE acetaminophen_13\RB\analgesic.n.01| (r_advmod) induced_15\VBN\generate.v.01|acetaminophen|- (r_amod) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity (l_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_27\NN\entity.n.01|induced|by
D000082_D066126 NONE acetaminophen_16\RB\analgesic.n.01| (r_advmod) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
D000082_D066126 NONE aap)-induced_18\VBN\entity.n.01| (r_compound) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
D000638_D009336 CID amiodarone_18\NN\antiarrhythmic.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|amiodarone|- (r_amod) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity (r_pobj) during_12\IN\entity.n.01|nephrotoxicity (r_prep) deaths_11\NNS\change.n.01|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\entity.n.01|and|necrotic (l_conj) necrotic_9\JJ\necrotic.a.01|
D000638_D009336 CID ami_11\NNP\entity.n.01|and|dox (r_conj) aap_9\NNP\entity.n.01|,|ami (r_appos) drugs_4\NNS\agent.n.03|all|the|,|as|aap (r_nsubj) induced_14\VBD\generate.v.01|interestingly|,|drugs|death|in|. (l_prep) in_17\IN\linear_unit.n.01|addition (l_pobj) addition_18\NN\component.n.03|to (l_prep) to_19\IN\entity.n.01|necrosis (l_pobj) necrosis_20\NN\death.n.02|in|blocked
D000638_D007674 NONE amiodarone_18\NN\antiarrhythmic.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|amiodarone|- (r_amod) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity
D000638_D007674 NONE amiodarone_21\NN\antiarrhythmic.n.01| (r_appos) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
D000638_D007674 NONE ami)-induced_23\JJ\entity.n.01| (r_amod) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
D000638_D008171 CID amiodarone_18\NN\antiarrhythmic.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|amiodarone|- (r_amod) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity
D000638_D008171 CID amiodarone_21\NN\antiarrhythmic.n.01| (r_appos) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000638_D008171 CID ami)-induced_23\JJ\entity.n.01| (r_amod) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D000638_D066126 NONE amiodarone_18\NN\antiarrhythmic.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|amiodarone|- (r_amod) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (l_conj) cardiotoxicity_27\NN\entity.n.01|induced|by
D000638_D066126 NONE amiodarone_21\NN\antiarrhythmic.n.01| (r_appos) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone (r_nmod) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
D000638_D066126 NONE ami)-induced_23\JJ\entity.n.01| (r_amod) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
D004317_D009336 CID doxorubicin_24\NN\antibiotic.n.01| (r_npadvmod) induced_26\VBN\generate.v.01|doxorubicin|- (r_amod) cardiotoxicity_27\NN\entity.n.01|induced|by (r_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity (r_pobj) during_12\IN\entity.n.01|nephrotoxicity (r_prep) deaths_11\NNS\change.n.01|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\entity.n.01|and|necrotic (l_conj) necrotic_9\JJ\necrotic.a.01|
D004317_D009336 CID dox_13\NNP\entity.n.01| (r_conj) ami_11\NNP\entity.n.01|and|dox (r_conj) aap_9\NNP\entity.n.01|,|ami (r_appos) drugs_4\NNS\agent.n.03|all|the|,|as|aap (r_nsubj) induced_14\VBD\generate.v.01|interestingly|,|drugs|death|in|. (l_prep) in_17\IN\linear_unit.n.01|addition (l_pobj) addition_18\NN\component.n.03|to (l_prep) to_19\IN\entity.n.01|necrosis (l_pobj) necrosis_20\NN\death.n.02|in|blocked
D004317_D007674 NONE doxorubicin_24\NN\antibiotic.n.01| (r_npadvmod) induced_26\VBN\generate.v.01|doxorubicin|- (r_amod) cardiotoxicity_27\NN\entity.n.01|induced|by (r_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity
D004317_D007674 NONE doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (r_conj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
D004317_D007674 NONE dox)-induced_30\JJ\entity.n.01| (r_amod) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in (r_dobj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (r_conj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
D004317_D008171 NONE doxorubicin_24\NN\antibiotic.n.01| (r_npadvmod) induced_26\VBN\generate.v.01|doxorubicin|- (r_amod) cardiotoxicity_27\NN\entity.n.01|induced|by (r_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity
D004317_D008171 NONE doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (r_conj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D004317_D008171 NONE dox)-induced_30\JJ\entity.n.01| (r_amod) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in (r_dobj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (r_conj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
D004317_D066126 CID doxorubicin_24\NN\antibiotic.n.01| (r_npadvmod) induced_26\VBN\generate.v.01|doxorubicin|- (r_amod) cardiotoxicity_27\NN\entity.n.01|induced|by
D004317_D066126 CID doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
D004317_D066126 CID dox)-induced_30\JJ\entity.n.01| (r_amod) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
C511402_D009336 NONE extract_35\NN\solution.n.01|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\by.r.01|extract (r_prep) cardiotoxicity_27\NN\entity.n.01|induced|by (r_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity (r_pobj) during_12\IN\entity.n.01|nephrotoxicity (r_prep) deaths_11\NNS\change.n.01|associated|apoptotic|cell|during (l_amod) apoptotic_7\JJ\entity.n.01|and|necrotic (l_conj) necrotic_9\JJ\necrotic.a.01|
C511402_D009336 NONE gspe_31\NNP\entity.n.01| (r_pobj) by_30\IN\by.r.01|gspe (r_agent) blocked_29\VBN\obstruct.v.02|which|was|effectively|by (r_relcl) necrosis_20\NN\death.n.02|in|blocked
C511402_D007674 NONE extract_35\NN\solution.n.01|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\by.r.01|extract (r_prep) cardiotoxicity_27\NN\entity.n.01|induced|by (r_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity (r_conj) nephrotoxicity_16\NN\entity.n.01|induced|,|toxicity
C511402_D007674 NONE extract_10\NN\solution.n.01|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\entity.n.01|extract (r_prep) ability_4\NN\quality.n.01|the|of|prevent (l_acl) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
C511402_D007674 NONE gspe_12\NNP\entity.n.01| (r_appos) extract_10\NN\solution.n.01|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\entity.n.01|extract (r_prep) ability_4\NN\quality.n.01|the|of|prevent (l_acl) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_nmod) nephrotoxicity_19\NN\entity.n.01|(|aap)-induced|,|amiodarone
C511402_D008171 NONE extract_35\NN\solution.n.01|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\by.r.01|extract (r_prep) cardiotoxicity_27\NN\entity.n.01|induced|by (r_conj) toxicity_22\NN\definite_quantity.n.01|induced|lung|and|cardiotoxicity
C511402_D008171 NONE extract_10\NN\solution.n.01|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\entity.n.01|extract (r_prep) ability_4\NN\quality.n.01|the|of|prevent (l_acl) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
C511402_D008171 NONE gspe_12\NNP\entity.n.01| (r_appos) extract_10\NN\solution.n.01|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\entity.n.01|extract (r_prep) ability_4\NN\quality.n.01|the|of|prevent (l_acl) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin
C511402_D066126 NONE extract_35\NN\solution.n.01|a|novel|ih636|proanthocyanidin (r_pobj) by_28\IN\by.r.01|extract (r_prep) cardiotoxicity_27\NN\entity.n.01|induced|by
C511402_D066126 NONE extract_10\NN\solution.n.01|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\entity.n.01|extract (r_prep) ability_4\NN\quality.n.01|the|of|prevent (l_acl) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
C511402_D066126 NONE gspe_12\NNP\entity.n.01| (r_appos) extract_10\NN\solution.n.01|ih636|proanthocyanidin|(|gspe|) (r_pobj) of_5\IN\entity.n.01|extract (r_prep) ability_4\NN\quality.n.01|the|of|prevent (l_acl) prevent_15\VB\prevent.v.01|to|acetaminophen|toxicity (l_dobj) toxicity_25\NN\definite_quantity.n.01|nephrotoxicity|(|ami)-induced|lung|,|and|doxorubicin (l_conj) doxorubicin_28\NN\antibiotic.n.01|cardiotoxicity (l_dobj) cardiotoxicity_31\NN\entity.n.01|(|dox)-induced|in
C511402_D017695 NONE gspe_30\NNP\entity.n.01| (r_compound) preexposure_31\NN\entity.n.01|gspe|than (r_pobj) of_29\IN\entity.n.01|preexposure (r_prep) absence_28\NN\lack.n.01|the|of (r_pobj) in_26\IN\linear_unit.n.01|absence (r_prep) variety_17\NN\collection.n.01|a|of|by|in (r_pobj) with_15\IN\entity.n.01|variety (r_prep) damage_14\NN\change.n.01|massive|tissue|with
8643971
D017239_D006258 NONE paclitaxel_7\NN\entity.n.01| (r_pobj) of_6\IN\entity.n.01|paclitaxel (r_prep) study_5\NN\examination.n.01|ii|of (r_dobj) phase_1\NN\time_period.n.01|a|study|plus|cisplatin|. (l_conj) cisplatin_9\NN\entity.n.01|as (l_prep) as_10\IN\chemical_element.n.01|therapy (l_pobj) therapy_14\NN\medical_care.n.01|line|for|:|results (l_prep) for_15\IN\entity.n.01|cancers (l_pobj) cancers_19\NNS\malignant_tumor.n.01|head
D017239_D006258 NONE paclitaxel_13\NN\entity.n.01|agent|taxol (r_pobj) of_9\IN\entity.n.01|paclitaxel (r_prep) study_8\NN\examination.n.01|an|group|of (r_pobj) of_2\IN\entity.n.01|study (r_prep) results_1\NNS\phenomenon.n.01|preliminary|of (r_nsubj) reported_27\VBD\inform.v.01|results|rate|used|. (l_dobj) rate_32\NN\magnitude_relation.n.01|a|%|response|in|,|and (l_prep) in_33\IN\linear_unit.n.01|patients (l_pobj) patients_34\NNS\case.n.06|with (l_prep) with_35\IN\entity.n.01|cancer (l_pobj) cancer_39\NN\malignant_tumor.n.01|head
D017239_D006258 NONE taxol_15\NNP\entity.n.01|(|;|company|) (r_appos) paclitaxel_13\NN\entity.n.01|agent|taxol (r_pobj) of_9\IN\entity.n.01|paclitaxel (r_prep) study_8\NN\examination.n.01|an|group|of (r_pobj) of_2\IN\entity.n.01|study (r_prep) results_1\NNS\phenomenon.n.01|preliminary|of (r_nsubj) reported_27\VBD\inform.v.01|results|rate|used|. (l_dobj) rate_32\NN\magnitude_relation.n.01|a|%|response|in|,|and (l_prep) in_33\IN\linear_unit.n.01|patients (l_pobj) patients_34\NNS\case.n.06|with (l_prep) with_35\IN\entity.n.01|cancer (l_pobj) cancer_39\NN\malignant_tumor.n.01|head
D017239_D006258 NONE paclitaxel_43\NN\entity.n.01| (r_nmod) combination_46\NN\collection.n.01|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\use.v.01|combination|has|been|successfully|and|improved (r_conj) reported_27\VBD\inform.v.01|results|rate|used|. (l_dobj) rate_32\NN\magnitude_relation.n.01|a|%|response|in|,|and (l_prep) in_33\IN\linear_unit.n.01|patients (l_pobj) patients_34\NNS\case.n.06|with (l_prep) with_35\IN\entity.n.01|cancer (l_pobj) cancer_39\NN\malignant_tumor.n.01|head
D017239_D006258 NONE paclitaxel_16\NN\entity.n.01| (r_compound) doses_17\NNS\medicine.n.02|escalating|paclitaxel|combined (l_acl) combined_18\VBN\have.v.02|with|with (l_prep) with_24\IN\entity.n.01|support (l_pobj) support_30\NN\activity.n.01|granulocyte|factor|in (l_prep) in_31\IN\linear_unit.n.01|patients (l_pobj) patients_32\NNS\case.n.06|with (l_prep) with_33\IN\entity.n.01|head (l_pobj) head_38\NN\external_body_part.n.01|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_41\NN\cancer.n.01|neck
D017239_D006258 NONE paclitaxel_0\NNP\entity.n.01| (r_nsubj) is_3\VBZ\be.v.01|paclitaxel|cisplatin|regimen|warranted (l_attr) regimen_9\NN\plan.n.01|an|effective|line|for|and (l_prep) for_10\IN\entity.n.01|head (l_pobj) head_13\NN\external_body_part.n.01|advanced|and|cancer (l_conj) cancer_16\NN\malignant_tumor.n.01|neck
D002945_D006258 NONE cisplatin_9\NN\entity.n.01|as (l_prep) as_10\IN\chemical_element.n.01|therapy (l_pobj) therapy_14\NN\medical_care.n.01|line|for|:|results (l_prep) for_15\IN\entity.n.01|cancers (l_pobj) cancers_19\NNS\malignant_tumor.n.01|head
D002945_D006258 NONE cisplatin_45\NN\entity.n.01|/ (r_compound) combination_46\NN\collection.n.01|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\use.v.01|combination|has|been|successfully|and|improved (r_conj) reported_27\VBD\inform.v.01|results|rate|used|. (l_dobj) rate_32\NN\magnitude_relation.n.01|a|%|response|in|,|and (l_prep) in_33\IN\linear_unit.n.01|patients (l_pobj) patients_34\NNS\case.n.06|with (l_prep) with_35\IN\entity.n.01|cancer (l_pobj) cancer_39\NN\malignant_tumor.n.01|head
D002945_D006258 NONE cisplatin_23\NN\entity.n.01|dose (r_pobj) with_19\IN\entity.n.01|cisplatin (r_prep) combined_18\VBN\have.v.02|with|with (l_prep) with_24\IN\entity.n.01|support (l_pobj) support_30\NN\activity.n.01|granulocyte|factor|in (l_prep) in_31\IN\linear_unit.n.01|patients (l_pobj) patients_32\NNS\case.n.06|with (l_prep) with_33\IN\entity.n.01|head (l_pobj) head_38\NN\external_body_part.n.01|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_41\NN\cancer.n.01|neck
D002945_D006258 NONE cisplatin_2\NN\entity.n.01|/ (r_advmod) is_3\VBZ\be.v.01|paclitaxel|cisplatin|regimen|warranted (l_attr) regimen_9\NN\plan.n.01|an|effective|line|for|and (l_prep) for_10\IN\entity.n.01|head (l_pobj) head_13\NN\external_body_part.n.01|advanced|and|cancer (l_conj) cancer_16\NN\malignant_tumor.n.01|neck
D017239_D010051 NONE paclitaxel_13\NN\entity.n.01|agent|taxol (r_pobj) of_9\IN\entity.n.01|paclitaxel (r_prep) study_8\NN\examination.n.01|an|group|of (r_pobj) of_2\IN\entity.n.01|study (r_prep) results_1\NNS\phenomenon.n.01|preliminary|of (r_nsubj) reported_27\VBD\inform.v.01|results|rate|used|. (l_conj) used_49\VBN\use.v.01|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\change.v.01|has|significantly|duration (l_dobj) duration_57\NN\time_period.n.01|median|response|in (l_prep) in_58\IN\linear_unit.n.01|patients (l_pobj) patients_61\NNS\case.n.06|ovarian|cancer (l_compound) cancer_60\NN\malignant_tumor.n.01|
D017239_D010051 NONE taxol_15\NNP\entity.n.01|(|;|company|) (r_appos) paclitaxel_13\NN\entity.n.01|agent|taxol (r_pobj) of_9\IN\entity.n.01|paclitaxel (r_prep) study_8\NN\examination.n.01|an|group|of (r_pobj) of_2\IN\entity.n.01|study (r_prep) results_1\NNS\phenomenon.n.01|preliminary|of (r_nsubj) reported_27\VBD\inform.v.01|results|rate|used|. (l_conj) used_49\VBN\use.v.01|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\change.v.01|has|significantly|duration (l_dobj) duration_57\NN\time_period.n.01|median|response|in (l_prep) in_58\IN\linear_unit.n.01|patients (l_pobj) patients_61\NNS\case.n.06|ovarian|cancer (l_compound) cancer_60\NN\malignant_tumor.n.01|
D017239_D010051 NONE paclitaxel_43\NN\entity.n.01| (r_nmod) combination_46\NN\collection.n.01|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\use.v.01|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\change.v.01|has|significantly|duration (l_dobj) duration_57\NN\time_period.n.01|median|response|in (l_prep) in_58\IN\linear_unit.n.01|patients (l_pobj) patients_61\NNS\case.n.06|ovarian|cancer (l_compound) cancer_60\NN\malignant_tumor.n.01|
D002945_D010051 NONE cisplatin_45\NN\entity.n.01|/ (r_compound) combination_46\NN\collection.n.01|the|paclitaxel|cisplatin (r_nsubjpass) used_49\VBN\use.v.01|combination|has|been|successfully|and|improved (l_conj) improved_54\VBN\change.v.01|has|significantly|duration (l_dobj) duration_57\NN\time_period.n.01|median|response|in (l_prep) in_58\IN\linear_unit.n.01|patients (l_pobj) patients_61\NNS\case.n.06|ovarian|cancer (l_compound) cancer_60\NN\malignant_tumor.n.01|
D017239_D064420 NONE paclitaxel_16\NN\entity.n.01| (r_compound) doses_17\NNS\medicine.n.02|escalating|paclitaxel|combined (r_pobj) of_14\IN\entity.n.01|doses (r_prep) response_11\NN\consequence.n.01|the|and|toxicity|of (l_conj) toxicity_13\NN\definite_quantity.n.01|
D017239_D064420 NONE paclitaxel_5\NN\entity.n.01| (r_compound) doses_6\NNS\medicine.n.02|escalating|paclitaxel (r_dobj) incorporate_3\VBP\compound.v.05|levels|doses|,|and|permitted (l_conj) permitted_17\VBN\accept.v.03|escalations|are|permits|. (l_advcl) permits_20\VBZ\legal_document.n.01|if|toxicity (l_nsubj) toxicity_19\NN\definite_quantity.n.01|
D002945_D064420 NONE cisplatin_23\NN\entity.n.01|dose (r_pobj) with_19\IN\entity.n.01|cisplatin (r_prep) combined_18\VBN\have.v.02|with|with (r_acl) doses_17\NNS\medicine.n.02|escalating|paclitaxel|combined (r_pobj) of_14\IN\entity.n.01|doses (r_prep) response_11\NN\consequence.n.01|the|and|toxicity|of (l_conj) toxicity_13\NN\definite_quantity.n.01|
20667451
D003474_D003072 NONE curcumin_0\NN\entity.n.01| (r_nsubj) ameliorates_1\VBZ\change.v.01|curcumin|dysfunction|. (l_dobj) dysfunction_3\NN\pathology.n.02|cognitive|and|damage|administered
D003474_D003072 NONE curcumin_14\NN\entity.n.01| (r_compound) administration_15\NN\management.n.01|chronic|curcumin (r_pobj) of_12\IN\entity.n.01|administration (r_prep) effect_11\NN\phenomenon.n.01|the|of|on (l_prep) on_16\IN\on.a.01|impairment (l_pobj) impairment_23\NN\change.n.01|phenobarbitone-|cognitive|and|stress
D003474_D003072 NONE curcumin_1\NN\entity.n.01| (r_compound) administration_2\NN\management.n.01|concomitant|curcumin (r_nsubj) prevented_3\VBD\prevent.v.01|administration|impairment|and|decreased|. (l_dobj) impairment_6\NN\change.n.01|the|cognitive
D003474_D003072 NONE curcumin_4\NN\entity.n.01| (r_nsubj) has_5\VBZ\angular_distance.n.01|that|curcumin|effect (l_dobj) effect_7\NN\phenomenon.n.01|beneficial|in (l_prep) in_8\IN\linear_unit.n.01|mitigating (l_pcomp) mitigating_9\VBG\apologize.v.02|deterioration (l_dobj) deterioration_11\NN\decay.n.04|the|of (l_prep) of_12\IN\entity.n.01|functions (l_pobj) functions_14\NNS\mathematical_relation.n.01|cognitive|and|damage
D003474_D003072 NONE curcumin_4\NN\entity.n.01| (r_nsubjpass) considered_7\VBN\think.v.01|that|curcumin|can|be|as|phenobarbitone (l_advcl) phenobarbitone_16\NN\barbiturate.n.01|to|and|therapy|in (l_prep) in_20\IN\linear_unit.n.01|preventing (l_pcomp) preventing_21\VBG\prevent.v.01|impairment (l_dobj) impairment_23\NN\change.n.01|cognitive|associated
D010634_D003072 CID phenobarbitone_8\NN\barbiturate.n.01|and|carbamazepine (r_pobj) in_7\IN\linear_unit.n.01|phenobarbitone (r_prep) damage_6\NN\change.n.01|oxidative|in (r_conj) dysfunction_3\NN\pathology.n.02|cognitive|and|damage|administered
D010634_D003072 CID phenobarbitone_4\NN\barbiturate.n.01|and|carbamazepine (r_conj) drugs_2\NNS\agent.n.03|the|antiepileptic|,|phenobarbitone (r_nsubj) are_7\VBP\area_unit.n.01|drugs|known|. (l_acomp) known_9\JJ\know.v.01|well|cause (l_xcomp) cause_11\VB\origin.n.03|to|impairment (l_dobj) impairment_13\NN\change.n.01|cognitive|on
D010634_D003072 CID phenobarbitone-_17\JJ\entity.n.01|and|induced (r_nmod) impairment_23\NN\change.n.01|phenobarbitone-|cognitive|and|stress
D010634_D003072 CID phenobarbitone_3\NN\barbiturate.n.01|and|carbamazepine (r_pobj) of_2\IN\entity.n.01|phenobarbitone (r_prep) administration_1\NN\management.n.01|the|of|for (r_nsubj) caused_8\VBD\make.v.03|administration|impairment|. (l_dobj) impairment_11\NN\change.n.01|a|significant|of (l_prep) of_12\IN\entity.n.01|learning|stress (l_pobj) learning_13\NN\basic_cognitive_process.n.01|and|memory|as (l_conj) memory_15\NN\representation.n.01|
D010634_D003072 CID phenobarbitone_22\NN\barbiturate.n.01|and|carbamazepine (r_pobj) with_21\IN\entity.n.01|phenobarbitone (r_prep) treated_20\VBN\interact.v.01|with|without (r_acl) rats_19\NNS\rodent.n.01|treated (r_pobj) in_18\IN\linear_unit.n.01|rats (r_prep) damage_17\NN\change.n.01|oxidative|in (r_conj) functions_14\NNS\mathematical_relation.n.01|cognitive|and|damage
D010634_D003072 CID phenobarbitone_16\NN\barbiturate.n.01|to|and|therapy|in (l_prep) in_20\IN\linear_unit.n.01|preventing (l_pcomp) preventing_21\VBG\prevent.v.01|impairment (l_dobj) impairment_23\NN\change.n.01|cognitive|associated
D002220_D003072 CID carbamazepine_10\NN\entity.n.01| (r_conj) phenobarbitone_8\NN\barbiturate.n.01|and|carbamazepine (r_pobj) in_7\IN\linear_unit.n.01|phenobarbitone (r_prep) damage_6\NN\change.n.01|oxidative|in (r_conj) dysfunction_3\NN\pathology.n.02|cognitive|and|damage|administered
D002220_D003072 CID carbamazepine_6\NN\entity.n.01| (r_conj) phenobarbitone_4\NN\barbiturate.n.01|and|carbamazepine (r_conj) drugs_2\NNS\agent.n.03|the|antiepileptic|,|phenobarbitone (r_nsubj) are_7\VBP\area_unit.n.01|drugs|known|. (l_acomp) known_9\JJ\know.v.01|well|cause (l_xcomp) cause_11\VB\origin.n.03|to|impairment (l_dobj) impairment_13\NN\change.n.01|cognitive|on
D002220_D003072 CID carbamazepine_19\NN\entity.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|carbamazepine|- (r_conj) phenobarbitone-_17\JJ\entity.n.01|and|induced (r_nmod) impairment_23\NN\change.n.01|phenobarbitone-|cognitive|and|stress
D002220_D003072 CID carbamazepine_5\NN\entity.n.01| (r_conj) phenobarbitone_3\NN\barbiturate.n.01|and|carbamazepine (r_pobj) of_2\IN\entity.n.01|phenobarbitone (r_prep) administration_1\NN\management.n.01|the|of|for (r_nsubj) caused_8\VBD\make.v.03|administration|impairment|. (l_dobj) impairment_11\NN\change.n.01|a|significant|of (l_prep) of_12\IN\entity.n.01|learning|stress (l_pobj) learning_13\NN\basic_cognitive_process.n.01|and|memory|as (l_conj) memory_15\NN\representation.n.01|
D002220_D003072 CID carbamazepine_24\NN\entity.n.01| (r_conj) phenobarbitone_22\NN\barbiturate.n.01|and|carbamazepine (r_pobj) with_21\IN\entity.n.01|phenobarbitone (r_prep) treated_20\VBN\interact.v.01|with|without (r_acl) rats_19\NNS\rodent.n.01|treated (r_pobj) in_18\IN\linear_unit.n.01|rats (r_prep) damage_17\NN\change.n.01|oxidative|in (r_conj) functions_14\NNS\mathematical_relation.n.01|cognitive|and|damage
D002220_D003072 CID carbamazepine_18\NN\entity.n.01| (r_compound) therapy_19\NN\medical_care.n.01|carbamazepine (r_conj) phenobarbitone_16\NN\barbiturate.n.01|to|and|therapy|in (l_prep) in_20\IN\linear_unit.n.01|preventing (l_pcomp) preventing_21\VBG\prevent.v.01|impairment (l_dobj) impairment_23\NN\change.n.01|cognitive|associated
7582165
D000305_D004342 NONE corticosteroids_5\NNS\steroid_hormone.n.01| (r_pobj) to_4\IN\entity.n.01|corticosteroids (r_prep) reactions_3\NNS\chemical_process.n.01|allergic|to|:|diagnosis|.
D010248_D004342 NONE paramethasone_3\NN\entity.n.01| (r_pobj) from_2\IN\entity.n.01|paramethasone (r_prep) different_1\JJ\different.a.01|from (r_amod) corticosteroids_0\NNS\steroid_hormone.n.01|different (r_nsubj) produced_5\VBD\make.v.03|corticosteroids|also|reactions (l_dobj) reactions_7\NNS\chemical_process.n.01|hypersensitivity|in (l_compound) hypersensitivity_6\NN\sensitivity.n.04|
D010248_D004342 NONE paramethasone_16\NN\entity.n.01| (r_pobj) by_15\IN\by.r.01|paramethasone (r_agent) caused_14\VBN\make.v.03|by (r_acl) allergy_13\NN\hypersensitivity_reaction.n.01|a|pseudo|-|caused
8421099
D015282_D042882 CID octreotide_12\NN\entity.n.01| (r_appos) analog_10\NN\similarity.n.01|somatostatin|(|octreotide|) (r_pobj) of_8\IN\entity.n.01|analog (r_prep) effects_7\NNS\personal_property.n.01|the|term|of|on (l_prep) on_14\IN\on.a.01|function (l_pobj) function_16\NN\mathematical_relation.n.01|gallbladder|and|formation|in (l_conj) formation_19\NN\arrangement.n.02|gallstone (l_compound) gallstone_18\NN\calculus.n.01|
D015282_D042882 CID octreotide_3\NN\entity.n.01| (r_pobj) with_2\IN\entity.n.01|octreotide (r_prep) treatment_1\NN\care.n.01|with (r_pobj) during_0\IN\entity.n.01|treatment (r_prep) developed_7\VBD\create.v.02|during|,|patients|sludge|had|. (l_conj) had_11\VBD\have.v.01|10|gallstones|,|and|developed (l_dobj) gallstones_12\NNS\calculus.n.01|
D015282_D042882 CID octreotide_3\NN\entity.n.01| (r_pobj) of_2\IN\entity.n.01|octreotide (r_prep) withdrawal_1\NN\retraction.n.01|of|in (l_prep) in_4\IN\linear_unit.n.01|patients (l_pobj) patients_6\NNS\case.n.06|10|without (l_prep) without_7\IN\entity.n.01|gallstones (l_pobj) gallstones_8\NNS\calculus.n.01|
D015282_D042882 CID octreotide_25\NN\entity.n.01| (r_compound) therapy_26\NN\medical_care.n.01|octreotide|in (r_pobj) during_24\IN\entity.n.01|therapy (r_prep) formation_15\NN\arrangement.n.02|the|successive|of|during (l_prep) of_16\IN\entity.n.01|sludge (l_pobj) sludge_18\NN\precipitate.n.01|bile|,|gallstones (l_conj) gallstones_20\NNS\calculus.n.01|,|and|cholecystitis
D015282_D000172 NONE octreotide_12\NN\entity.n.01| (r_appos) analog_10\NN\similarity.n.01|somatostatin|(|octreotide|) (r_pobj) of_8\IN\entity.n.01|analog (r_prep) effects_7\NNS\personal_property.n.01|the|term|of|on (l_prep) on_14\IN\on.a.01|function (l_pobj) function_16\NN\mathematical_relation.n.01|gallbladder|and|formation|in (l_prep) in_20\IN\linear_unit.n.01|patients (l_pobj) patients_23\NNS\case.n.06|chinese|acromegalic (l_compound) acromegalic_22\JJ\acromegalic.s.01|
D015282_D000172 NONE octreotide_26\NN\entity.n.01| (r_appos) analog_25\NN\similarity.n.01|the|somatostatin|octreotide (r_pobj) of_22\IN\entity.n.01|analog (r_prep) injection_21\NN\insertion.n.02|sc|of (r_pobj) with_19\IN\entity.n.01|injection (r_prep) treated_18\VBN\interact.v.01|with|in|day|for (r_acl) patients_14\NNS\case.n.06|20|chinese|with|treated (l_prep) with_15\IN\entity.n.01|acromegaly (l_pobj) acromegaly_17\NNS\hypertrophy.n.01|active
D015282_D000172 NONE octreotide_25\NN\entity.n.01| (r_compound) therapy_26\NN\medical_care.n.01|octreotide|in (l_prep) in_27\IN\linear_unit.n.01|patients (l_pobj) patients_30\NNS\case.n.06|chinese|acromegalic (l_compound) acromegalic_29\JJ\acromegalic.s.01|
D015282_D000172 NONE octreotide_16\NN\entity.n.01| (r_compound) therapy_17\NN\medical_care.n.01|term|octreotide|of (l_prep) of_18\IN\entity.n.01|patients (l_pobj) patients_20\NNS\case.n.06|acromegalic (l_compound) acromegalic_19\JJ\acromegalic.s.01|
D015282_D041881 CID octreotide_3\NN\entity.n.01| (r_pobj) with_2\IN\entity.n.01|octreotide (r_prep) treatment_1\NN\care.n.01|with (r_pobj) during_0\IN\entity.n.01|treatment (r_prep) developed_7\VBD\create.v.02|during|,|patients|sludge|had|. (l_conj) had_11\VBD\have.v.01|10|gallstones|,|and|developed (l_conj) developed_16\VBD\create.v.02|1|cholecystitis|requiring (l_dobj) cholecystitis_18\NN\inflammation.n.01|acute
D015282_D002764 NONE octreotide_25\NN\entity.n.01| (r_compound) therapy_26\NN\medical_care.n.01|octreotide|in (r_pobj) during_24\IN\entity.n.01|therapy (r_prep) formation_15\NN\arrangement.n.02|the|successive|of|during (l_prep) of_16\IN\entity.n.01|sludge (l_pobj) sludge_18\NN\precipitate.n.01|bile|,|gallstones (l_conj) gallstones_20\NNS\calculus.n.01|,|and|cholecystitis (l_conj) cholecystitis_23\NN\inflammation.n.01|
2385256
D008274_D009157 CID magnesium_6\NN\metallic_element.n.01| (r_compound) administration_7\NN\management.n.01|magnesium (r_pobj) after_5\IN\after.s.01|administration (r_prep) weakness_4\NN\imperfection.n.01|after (r_pobj) as_3\IN\chemical_element.n.01|weakness (r_prep) presenting_2\VBG\show.v.04|as (r_acl) gravis_1\NN\entity.n.01|myasthenia|presenting|.
D008274_D009157 CID magnesium_3\NN\metallic_element.n.01| (r_compound) administration_4\NN\management.n.01|magnesium (r_pobj) after_2\IN\after.s.01|administration (r_prep) paralysis_1\NN\dysfunction.n.01|after (r_nsubjpass) described_7\VBN\set_forth.v.01|although|paralysis|has|been|in (l_prep) in_8\IN\linear_unit.n.01|patients (l_pobj) patients_9\NNS\case.n.06|with (l_prep) with_10\IN\entity.n.01|gravis (l_pobj) gravis_13\NN\entity.n.01|known|myasthenia
D008274_D009468 NONE magnesium_17\NN\metallic_element.n.01| (r_compound) administration_18\NN\management.n.01|parenteral|magnesium|for (r_pobj) after_15\IN\after.s.01|administration (r_prep) became_12\VBD\change_state.v.01|who|quadriplegic|after (r_relcl) disease_10\NN\illness.n.01|neuromuscular|became
D008274_D011782 NONE magnesium_17\NN\metallic_element.n.01| (r_compound) administration_18\NN\management.n.01|parenteral|magnesium|for (r_pobj) after_15\IN\after.s.01|administration (r_prep) became_12\VBD\change_state.v.01|who|quadriplegic|after (l_acomp) quadriplegic_14\JJ\handicapped_person.n.01|virtually
D008274_D011225 NONE magnesium_17\NN\metallic_element.n.01| (r_compound) administration_18\NN\management.n.01|parenteral|magnesium|for (l_prep) for_19\IN\entity.n.01|preeclampsia (l_pobj) preeclampsia_20\NN\toxemia_of_pregnancy.n.01|
D008274_D010243 NONE magnesium_3\NN\metallic_element.n.01| (r_compound) administration_4\NN\management.n.01|magnesium (r_pobj) after_2\IN\after.s.01|administration (r_prep) paralysis_1\NN\dysfunction.n.01|after
D008274_D020511 NONE magnesium_10\NN\metallic_element.n.01| (r_pobj) of_9\IN\entity.n.01|magnesium (r_prep) effects_8\NNS\personal_property.n.01|the|neuromuscular|of (r_pobj) to_5\IN\entity.n.01|effects (r_prep) sensitive_4\JJ\psychic.n.01|unusually|to (r_acomp) are_2\VBP\area_unit.n.01|who|sensitive (r_relcl) patients_0\NNS\case.n.06|are (r_nsubjpass) suspected_13\VBN\guess.v.02|patients|should|be|of|. (l_prep) of_14\IN\entity.n.01|having (l_pcomp) having_15\VBG\have.v.01|disorder (l_dobj) disorder_18\NN\physical_condition.n.01|an|underlying|of (l_prep) of_19\IN\entity.n.01|transmission (l_pobj) transmission_21\NN\sending.n.01|neuromuscular
7988234
D008790_D000799 CID metoprolol_6\NN\beta_blocker.n.01| (r_pobj) of_5\IN\entity.n.01|metoprolol (r_prep) administration_4\NN\management.n.01|the|intravenous|of (r_dobj) following_1\VBG\multitude.n.03|administration (r_prep) angioedema_0\NNP\edema.n.01|following|.
D008790_D000799 CID metoprolol_12\NN\beta_blocker.n.01|intravenous (r_nsubjpass) given_14\VBN\assumption.n.02|during|,|metoprolol|was|,|resulting|. (l_advcl) resulting_16\VBG\prove.v.01|in (l_prep) in_17\IN\linear_unit.n.01|angioedema (l_pobj) angioedema_19\NN\edema.n.01|severe
D017706_D000799 CID lisinopril_6\NN\ace_inhibitor.n.01| (r_compound) therapy_7\NN\medical_care.n.01|lisinopril (r_pobj) to_5\IN\entity.n.01|therapy (r_prep) history_1\NN\past.n.01|a|of|to (l_prep) of_2\IN\entity.n.01|angioedema (l_pobj) angioedema_3\NN\edema.n.01|secondary
D013256_D000799 NONE steroids_7\NNS\organic_compound.n.01|intravenous|and|diphenhydramine (r_pobj) with_5\IN\entity.n.01|steroids (r_prep) resolved_2\VBD\end.v.02|angioedema|after|with|. (l_nsubj) angioedema_1\NN\edema.n.01|the
D004155_D000799 NONE diphenhydramine_9\NN\antihistamine.n.01|hydrochloride (r_conj) steroids_7\NNS\organic_compound.n.01|intravenous|and|diphenhydramine (r_pobj) with_5\IN\entity.n.01|steroids (r_prep) resolved_2\VBD\end.v.02|angioedema|after|with|. (l_nsubj) angioedema_1\NN\edema.n.01|the
2611118
D004008_D006521 NONE sodium_6\NN\metallic_element.n.01| (r_compound) therapy_7\NN\medical_care.n.01|diclofenac|sodium (r_pobj) with_4\IN\entity.n.01|therapy (r_prep) associated_3\VBN\think.v.03|with (r_acl) hepatitis_2\NN\infectious_disease.n.01|chronic|active|associated|.
D004008_D006521 NONE sodium_13\NN\metallic_element.n.01|diclofenac (r_pobj) with_11\IN\entity.n.01|sodium (r_prep) therapy_10\NN\medical_care.n.01|months|with|progressed (r_pobj) after_7\IN\after.s.01|therapy (r_prep) developed_3\VBD\create.v.02|patient|hepatitis|after|,|finding|. (l_dobj) hepatitis_6\NN\infectious_disease.n.01|chronic|active
D004008_D056486 CID diclofenac_23\NNP\entity.n.01| (r_pobj) by_22\IN\by.r.01|diclofenac (r_agent) induced_21\VBN\generate.v.01|,|commonly|,|hepatitis|by|. (r_conj) recorded_13\VBN\save.v.02|tolerated|,|abnormalities|have|been|and|induced (l_nsubjpass) abnormalities_7\NNS\physical_condition.n.01|asymptomatic|of (l_prep) of_8\IN\entity.n.01|function (l_pobj) function_10\NN\mathematical_relation.n.01|liver
D004008_D056486 CID diclofenac_23\NNP\entity.n.01| (r_pobj) by_22\IN\by.r.01|diclofenac (r_agent) induced_21\VBN\generate.v.01|,|commonly|,|hepatitis|by|. (l_nsubj) hepatitis_20\NN\infectious_disease.n.01|severe
10457883
11745184
D002945_D001943 NONE cisplatin_5\NN\entity.n.01|plus (r_nmod) amifostine_9\NN\entity.n.01|cisplatin|wr-2721|(|) (r_pobj) of_4\IN\entity.n.01|amifostine (r_prep) trial_3\NN\attempt.n.01|a|ii|of|for|:|e8188|. (l_prep) for_11\IN\entity.n.01|carcinoma (l_pobj) carcinoma_14\NN\cancer.n.01|metastatic|breast
D002945_D001943 NONE cisplatin_0\NNP\entity.n.01| (r_nsubj) has_1\VBZ\angular_distance.n.01|cisplatin|activity|used|. (l_advcl) used_6\VBN\use.v.01|when|as (l_prep) as_7\IN\chemical_element.n.01|treatment (l_pobj) treatment_13\NN\care.n.01|second-|line|of (l_prep) of_14\IN\entity.n.01|carcinoma (l_pobj) carcinoma_17\NN\cancer.n.01|metastatic|breast
D002945_D001943 NONE cisplatin_10\NN\entity.n.01| (r_pobj) with_9\IN\entity.n.01|cisplatin (r_prep) observed_8\VBN\spy.v.03|although|effect|has|been|with (r_advcl) limited_31\VBN\public_transport.n.01|observed|,|toxicities|have|use|. (l_dobj) use_33\NN\activity.n.01|its|as (l_prep) as_34\IN\chemical_element.n.01|treatment (l_pobj) treatment_36\NN\care.n.01|a|for (l_prep) for_37\IN\entity.n.01|carcinoma (l_pobj) carcinoma_39\NN\cancer.n.01|breast
D002945_D001943 NONE cisplatin_19\NN\entity.n.01|nephrotoxicity (r_pcomp) with_18\IN\entity.n.01|cisplatin (r_prep) associated_17\VBN\think.v.03|with (r_acl) toxicities_16\NNS\definite_quantity.n.01|the|limiting|associated (r_nsubj) limited_31\VBN\public_transport.n.01|observed|,|toxicities|have|use|. (l_dobj) use_33\NN\activity.n.01|its|as (l_prep) as_34\IN\chemical_element.n.01|treatment (l_pobj) treatment_36\NN\care.n.01|a|for (l_prep) for_37\IN\entity.n.01|carcinoma (l_pobj) carcinoma_39\NN\cancer.n.01|breast
D002945_D001943 NONE cisplatin_8\NN\entity.n.01|plus|amifostine (r_pobj) of_7\IN\entity.n.01|cisplatin (r_prep) combination_6\NN\collection.n.01|the|of (r_pobj) of_4\IN\entity.n.01|combination (r_prep) study_3\NN\examination.n.01|a|ii|of (r_nsubjpass) conducted_12\VBN\manage.v.02|study|was|in|,|but|regimen (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|carcinoma (l_pobj) carcinoma_19\NN\cancer.n.01|progressive|metastatic|breast|received
D004999_D001943 NONE wr-2721_7\NNP\entity.n.01| (r_nmod) amifostine_9\NN\entity.n.01|cisplatin|wr-2721|(|) (r_pobj) of_4\IN\entity.n.01|amifostine (r_prep) trial_3\NN\attempt.n.01|a|ii|of|for|:|e8188|. (l_prep) for_11\IN\entity.n.01|carcinoma (l_pobj) carcinoma_14\NN\cancer.n.01|metastatic|breast
D004999_D001943 NONE amifostine_9\NN\entity.n.01|cisplatin|wr-2721|(|) (r_pobj) of_4\IN\entity.n.01|amifostine (r_prep) trial_3\NN\attempt.n.01|a|ii|of|for|:|e8188|. (l_prep) for_11\IN\entity.n.01|carcinoma (l_pobj) carcinoma_14\NN\cancer.n.01|metastatic|breast
D004999_D001943 NONE amifostine_10\NN\entity.n.01| (r_conj) cisplatin_8\NN\entity.n.01|plus|amifostine (r_pobj) of_7\IN\entity.n.01|cisplatin (r_prep) combination_6\NN\collection.n.01|the|of (r_pobj) of_4\IN\entity.n.01|combination (r_prep) study_3\NN\examination.n.01|a|ii|of (r_nsubjpass) conducted_12\VBN\manage.v.02|study|was|in|,|but|regimen (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|carcinoma (l_pobj) carcinoma_19\NN\cancer.n.01|progressive|metastatic|breast|received
D002945_D064420 NONE cisplatin_10\NN\entity.n.01| (r_pobj) with_9\IN\entity.n.01|cisplatin (r_prep) observed_8\VBN\spy.v.03|although|effect|has|been|with (r_advcl) limited_31\VBN\public_transport.n.01|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\definite_quantity.n.01|the|limiting|associated
D002945_D064420 NONE cisplatin_19\NN\entity.n.01|nephrotoxicity (r_pcomp) with_18\IN\entity.n.01|cisplatin (r_prep) associated_17\VBN\think.v.03|with (r_acl) toxicities_16\NNS\definite_quantity.n.01|the|limiting|associated
D002945_D064420 NONE cisplatin_20\VB\entity.n.01|to|in (r_acl) amifostine_18\NN\entity.n.01|cisplatin (r_pobj) of_17\IN\entity.n.01|amifostine (r_prep) addition_16\NN\component.n.03|the|of (r_pobj) with_14\IN\entity.n.01|addition (r_prep) observed_13\VBN\spy.v.03|effect|was|with|. (l_nsubjpass) effect_5\NN\phenomenon.n.01|neither|a|protective|nor|reduced (l_conj) reduced_7\VBN\decrease.v.02|toxicity|to (l_dobj) toxicity_8\NN\definite_quantity.n.01|
D002945_D007674 CID cisplatin_10\NN\entity.n.01| (r_pobj) with_9\IN\entity.n.01|cisplatin (r_prep) observed_8\VBN\spy.v.03|although|effect|has|been|with (r_advcl) limited_31\VBN\public_transport.n.01|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\definite_quantity.n.01|the|limiting|associated (l_acl) associated_17\VBN\think.v.03|with (l_prep) with_18\IN\entity.n.01|cisplatin (l_pcomp) cisplatin_19\NN\entity.n.01|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\entity.n.01|(|e.g.|,|,|ototoxicity|)
D002945_D007674 CID cisplatin_19\NN\entity.n.01|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\entity.n.01|(|e.g.|,|,|ototoxicity|)
D002945_D007674 CID cisplatin_3\NN\entity.n.01|and|amifostine (r_pobj) of_2\IN\entity.n.01|cisplatin (r_prep) trials_1\NNS\attempt.n.01|early|of (r_nsubj) suggested_7\VBD\declare.v.01|trials|also|reduced|. (l_ccomp) reduced_24\VBN\decrease.v.02|that|incidence|were (l_nsubjpass) incidence_10\NN\frequency.n.02|the|and|severity|of (l_prep) of_13\IN\entity.n.01|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity
D002945_D007674 CID cisplatin_14\NN\entity.n.01| (r_advmod) induced_16\VBN\generate.v.01|cisplatin|- (r_amod) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity
D002945_D006311 CID cisplatin_10\NN\entity.n.01| (r_pobj) with_9\IN\entity.n.01|cisplatin (r_prep) observed_8\VBN\spy.v.03|although|effect|has|been|with (r_advcl) limited_31\VBN\public_transport.n.01|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\definite_quantity.n.01|the|limiting|associated (l_acl) associated_17\VBN\think.v.03|with (l_prep) with_18\IN\entity.n.01|cisplatin (l_pcomp) cisplatin_19\NN\entity.n.01|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\entity.n.01|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\entity.n.01|,|and|neurotoxicity
D002945_D006311 CID cisplatin_19\NN\entity.n.01|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\entity.n.01|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\entity.n.01|,|and|neurotoxicity
D002945_D006311 CID cisplatin_3\NN\entity.n.01|and|amifostine (r_pobj) of_2\IN\entity.n.01|cisplatin (r_prep) trials_1\NNS\attempt.n.01|early|of (r_nsubj) suggested_7\VBD\declare.v.01|trials|also|reduced|. (l_ccomp) reduced_24\VBN\decrease.v.02|that|incidence|were (l_nsubjpass) incidence_10\NN\frequency.n.02|the|and|severity|of (l_prep) of_13\IN\entity.n.01|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\entity.n.01|,|and|neuropathy
D002945_D006311 CID cisplatin_14\NN\entity.n.01| (r_advmod) induced_16\VBN\generate.v.01|cisplatin|- (r_amod) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\entity.n.01|,|and|neuropathy
D002945_D020258 NONE cisplatin_10\NN\entity.n.01| (r_pobj) with_9\IN\entity.n.01|cisplatin (r_prep) observed_8\VBN\spy.v.03|although|effect|has|been|with (r_advcl) limited_31\VBN\public_transport.n.01|observed|,|toxicities|have|use|. (l_nsubj) toxicities_16\NNS\definite_quantity.n.01|the|limiting|associated (l_acl) associated_17\VBN\think.v.03|with (l_prep) with_18\IN\entity.n.01|cisplatin (l_pcomp) cisplatin_19\NN\entity.n.01|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\entity.n.01|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\entity.n.01|,|and|neurotoxicity (l_conj) neurotoxicity_28\NN\entity.n.01|
D002945_D020258 NONE cisplatin_19\NN\entity.n.01|nephrotoxicity (l_preconj) nephrotoxicity_23\NN\entity.n.01|(|e.g.|,|,|ototoxicity|) (l_conj) ototoxicity_25\NN\entity.n.01|,|and|neurotoxicity (l_conj) neurotoxicity_28\NN\entity.n.01|
D002945_D009422 CID cisplatin_3\NN\entity.n.01|and|amifostine (r_pobj) of_2\IN\entity.n.01|cisplatin (r_prep) trials_1\NNS\attempt.n.01|early|of (r_nsubj) suggested_7\VBD\declare.v.01|trials|also|reduced|. (l_ccomp) reduced_24\VBN\decrease.v.02|that|incidence|were (l_nsubjpass) incidence_10\NN\frequency.n.02|the|and|severity|of (l_prep) of_13\IN\entity.n.01|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\entity.n.01|,|and|neuropathy (l_conj) neuropathy_22\NN\pathology.n.02|
D002945_D009422 CID cisplatin_14\NN\entity.n.01| (r_advmod) induced_16\VBN\generate.v.01|cisplatin|- (r_amod) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\entity.n.01|,|and|neuropathy (l_conj) neuropathy_22\NN\pathology.n.02|
D004999_D007674 NONE amifostine_5\NN\entity.n.01| (r_conj) cisplatin_3\NN\entity.n.01|and|amifostine (r_pobj) of_2\IN\entity.n.01|cisplatin (r_prep) trials_1\NNS\attempt.n.01|early|of (r_nsubj) suggested_7\VBD\declare.v.01|trials|also|reduced|. (l_ccomp) reduced_24\VBN\decrease.v.02|that|incidence|were (l_nsubjpass) incidence_10\NN\frequency.n.02|the|and|severity|of (l_prep) of_13\IN\entity.n.01|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity
D004999_D006311 NONE amifostine_5\NN\entity.n.01| (r_conj) cisplatin_3\NN\entity.n.01|and|amifostine (r_pobj) of_2\IN\entity.n.01|cisplatin (r_prep) trials_1\NNS\attempt.n.01|early|of (r_nsubj) suggested_7\VBD\declare.v.01|trials|also|reduced|. (l_ccomp) reduced_24\VBN\decrease.v.02|that|incidence|were (l_nsubjpass) incidence_10\NN\frequency.n.02|the|and|severity|of (l_prep) of_13\IN\entity.n.01|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\entity.n.01|,|and|neuropathy
D004999_D009422 NONE amifostine_5\NN\entity.n.01| (r_conj) cisplatin_3\NN\entity.n.01|and|amifostine (r_pobj) of_2\IN\entity.n.01|cisplatin (r_prep) trials_1\NNS\attempt.n.01|early|of (r_nsubj) suggested_7\VBD\declare.v.01|trials|also|reduced|. (l_ccomp) reduced_24\VBN\decrease.v.02|that|incidence|were (l_nsubjpass) incidence_10\NN\frequency.n.02|the|and|severity|of (l_prep) of_13\IN\entity.n.01|nephrotoxicity (l_pobj) nephrotoxicity_17\NN\entity.n.01|induced|,|ototoxicity (l_conj) ototoxicity_19\NN\entity.n.01|,|and|neuropathy (l_conj) neuropathy_22\NN\pathology.n.02|
D004999_D009369 NONE amifostine_18\NN\entity.n.01|cisplatin (r_pobj) of_17\IN\entity.n.01|amifostine (r_prep) addition_16\NN\component.n.03|the|of (r_pobj) with_14\IN\entity.n.01|addition (r_prep) observed_13\VBN\spy.v.03|effect|was|with|. (l_nsubjpass) effect_5\NN\phenomenon.n.01|neither|a|protective|nor|reduced (l_amod) protective_4\JJ\protective.a.01|tumor|- (l_npadvmod) tumor_2\NN\growth.n.06|
D004999_D064420 NONE amifostine_18\NN\entity.n.01|cisplatin (r_pobj) of_17\IN\entity.n.01|amifostine (r_prep) addition_16\NN\component.n.03|the|of (r_pobj) with_14\IN\entity.n.01|addition (r_prep) observed_13\VBN\spy.v.03|effect|was|with|. (l_nsubjpass) effect_5\NN\phenomenon.n.01|neither|a|protective|nor|reduced (l_conj) reduced_7\VBN\decrease.v.02|toxicity|to (l_dobj) toxicity_8\NN\definite_quantity.n.01|
D002945_D009369 NONE cisplatin_20\VB\entity.n.01|to|in (r_acl) amifostine_18\NN\entity.n.01|cisplatin (r_pobj) of_17\IN\entity.n.01|amifostine (r_prep) addition_16\NN\component.n.03|the|of (r_pobj) with_14\IN\entity.n.01|addition (r_prep) observed_13\VBN\spy.v.03|effect|was|with|. (l_nsubjpass) effect_5\NN\phenomenon.n.01|neither|a|protective|nor|reduced (l_amod) protective_4\JJ\protective.a.01|tumor|- (l_npadvmod) tumor_2\NN\growth.n.06|
3714122
C005238_D020258 NONE mipafox_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|mipafox|- (r_amod) damage_11\NN\change.n.01|induced|neuropathic|in (r_conj) inhibition_5\NN\abstinence.n.02|neurotoxic|esterase|and|damage (l_amod) neurotoxic_3\JJ\neurotoxic.a.01|
C005238_D020258 NONE mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of (l_prep) of_7\IN\entity.n.01|esterase (l_pobj) esterase_9\NN\entity.n.01|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\neurotoxic.a.01|
C005238_D020258 NONE mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN\insecticide.n.01|a|neurotoxic (l_amod) neurotoxic_32\JJ\neurotoxic.a.01|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\entity.n.01|(|n|, (r_appos) mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of (l_prep) of_7\IN\entity.n.01|esterase (l_pobj) esterase_9\NN\entity.n.01|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\neurotoxic.a.01|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\entity.n.01|(|n|, (r_appos) mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN\insecticide.n.01|a|neurotoxic (l_amod) neurotoxic_32\JJ\neurotoxic.a.01|
C005238_D009422 NONE mipafox_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|mipafox|- (r_amod) damage_11\NN\change.n.01|induced|neuropathic|in
C005238_D009422 NONE mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of
C005238_D009422 NONE mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of (l_prep) of_7\IN\entity.n.01|esterase (l_pobj) esterase_9\NN\entity.n.01|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\catalyst.n.01|target|(|nte|) (l_compound) target_12\NN\reference_point.n.01|neuropathy (l_compound) neuropathy_11\NN\pathology.n.02|
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\entity.n.01|(|n|, (r_appos) mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\entity.n.01|(|n|, (r_appos) mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of (l_prep) of_7\IN\entity.n.01|esterase (l_pobj) esterase_9\NN\entity.n.01|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\catalyst.n.01|target|(|nte|) (l_compound) target_12\NN\reference_point.n.01|neuropathy (l_compound) neuropathy_11\NN\pathology.n.02|
C005238_D009422 NONE mipafox_18\NNP\entity.n.01| (r_compound) exposure_19\NN\vulnerability.n.02|mipafox (r_nsubj) predict_21\VB\guess.v.02|shortly|after|exposure|can|damage|later (l_dobj) damage_23\NN\change.n.01|neuropathic|in
D010755_D009422 NONE organophosphate_33\NN\insecticide.n.01|a|neurotoxic (r_appos) mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of
D010755_D009422 NONE organophosphate_33\NN\insecticide.n.01|a|neurotoxic (r_appos) mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of (l_prep) of_7\IN\entity.n.01|esterase (l_pobj) esterase_9\NN\entity.n.01|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\catalyst.n.01|target|(|nte|) (l_compound) target_12\NN\reference_point.n.01|neuropathy (l_compound) neuropathy_11\NN\pathology.n.02|
D010755_D020258 NONE organophosphate_33\NN\insecticide.n.01|a|neurotoxic (r_appos) mipafox_24\NNP\entity.n.01|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_pobj) to_23\IN\entity.n.01|mipafox (r_prep) exposed_22\VBN\subject.v.01|acutely|to (r_acl) rats_20\NNS\rodent.n.01|exposed (r_pobj) in_19\IN\linear_unit.n.01|rats (r_prep) examined_18\VBN\analyze.v.01|correlation|was|in|. (l_nsubjpass) correlation_1\NN\reciprocality.n.01|the|between (l_prep) between_2\IN\between.r.01|damage (l_pobj) damage_4\NN\change.n.01|neuropathic|and|inhibition|of (l_prep) of_7\IN\entity.n.01|esterase (l_pobj) esterase_9\NN\entity.n.01|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\neurotoxic.a.01|
D010755_D020258 NONE organophosphate_33\NN\insecticide.n.01|a|neurotoxic (l_amod) neurotoxic_32\JJ\neurotoxic.a.01|
C005238_D013118 CID mipafox_5\NNP\entity.n.01| (r_pobj) of_4\IN\entity.n.01|mipafox (r_prep) dosages_3\NNS\indefinite_quantity.n.01|of|less|inhibited (r_nsubj) produced_39\VBN\make.v.03|in|,|dosages|degree|in|. (l_dobj) degree_41\NN\property.n.02|this|of (l_prep) of_42\IN\entity.n.01|damage (l_pobj) damage_44\NN\change.n.01|cord
9195768
D018170_D010292 CID sumatriptan_7\NN\entity.n.01|subcutaneous (r_pobj) of_5\IN\entity.n.01|sumatriptan (r_prep) use_4\NN\activity.n.01|the|of (r_dobj) following_2\VBG\multitude.n.03|use (r_prep) sensations_1\NNS\perception.n.03|atypical|following
6387529
D003975_D016584 NONE diazepam_3\NN\benzodiazepine.n.01| (r_pobj) of_2\IN\entity.n.01|diazepam (r_prep) effects_1\NNS\personal_property.n.01|behavioral|of|and|propranolol|. (l_conj) propranolol_5\NN\entity.n.01|in (l_prep) in_6\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|with (l_prep) with_8\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|panic|and|agoraphobia
D003975_D016584 NONE diazepam_6\NN\benzodiazepine.n.01| (r_pobj) of_5\IN\entity.n.01|diazepam (r_prep) doses_4\NNS\medicine.n.02|oral|of|(|dose|and (r_pobj) of_2\IN\entity.n.01|doses (r_prep) effects_1\NNS\personal_property.n.01|the|of (r_nsubj) propranolol_27\NN\entity.n.01|effects|dose (r_advcl) investigated_58\VBN\analyze.v.01|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\medicine.n.02|a|median|of|for|)|on (l_prep) on_47\IN\on.a.01|performance (l_pobj) performance_49\NN\show.n.03|psychological|of (l_prep) of_50\IN\entity.n.01|patients (l_pobj) patients_51\NNS\case.n.06|with (l_prep) with_52\IN\entity.n.01|disorders (l_pobj) disorders_54\NNS\physical_condition.n.01|panic|and|agoraphobia
D003975_D000379 NONE diazepam_3\NN\benzodiazepine.n.01| (r_pobj) of_2\IN\entity.n.01|diazepam (r_prep) effects_1\NNS\personal_property.n.01|behavioral|of|and|propranolol|. (l_conj) propranolol_5\NN\entity.n.01|in (l_prep) in_6\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|with (l_prep) with_8\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|panic|and|agoraphobia (l_conj) agoraphobia_12\NNP\phobia.n.01|
D003975_D000379 NONE diazepam_6\NN\benzodiazepine.n.01| (r_pobj) of_5\IN\entity.n.01|diazepam (r_prep) doses_4\NNS\medicine.n.02|oral|of|(|dose|and (r_pobj) of_2\IN\entity.n.01|doses (r_prep) effects_1\NNS\personal_property.n.01|the|of (r_nsubj) propranolol_27\NN\entity.n.01|effects|dose (r_advcl) investigated_58\VBN\analyze.v.01|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\medicine.n.02|a|median|of|for|)|on (l_prep) on_47\IN\on.a.01|performance (l_pobj) performance_49\NN\show.n.03|psychological|of (l_prep) of_50\IN\entity.n.01|patients (l_pobj) patients_51\NNS\case.n.06|with (l_prep) with_52\IN\entity.n.01|disorders (l_pobj) disorders_54\NNS\physical_condition.n.01|panic|and|agoraphobia (l_conj) agoraphobia_56\NNP\phobia.n.01|
D011433_D016584 NONE propranolol_5\NN\entity.n.01|in (l_prep) in_6\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|with (l_prep) with_8\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|panic|and|agoraphobia
D011433_D016584 NONE propranolol_27\NN\entity.n.01|effects|dose (r_advcl) investigated_58\VBN\analyze.v.01|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\medicine.n.02|a|median|of|for|)|on (l_prep) on_47\IN\on.a.01|performance (l_pobj) performance_49\NN\show.n.03|psychological|of (l_prep) of_50\IN\entity.n.01|patients (l_pobj) patients_51\NNS\case.n.06|with (l_prep) with_52\IN\entity.n.01|disorders (l_pobj) disorders_54\NNS\physical_condition.n.01|panic|and|agoraphobia
D011433_D000379 NONE propranolol_5\NN\entity.n.01|in (l_prep) in_6\IN\linear_unit.n.01|patients (l_pobj) patients_7\NNS\case.n.06|with (l_prep) with_8\IN\entity.n.01|disorder (l_pobj) disorder_10\NN\physical_condition.n.01|panic|and|agoraphobia (l_conj) agoraphobia_12\NNP\phobia.n.01|
D011433_D000379 NONE propranolol_27\NN\entity.n.01|effects|dose (r_advcl) investigated_58\VBN\analyze.v.01|propranolol|dose|were|in|. (l_nsubjpass) dose_37\NN\medicine.n.02|a|median|of|for|)|on (l_prep) on_47\IN\on.a.01|performance (l_pobj) performance_49\NN\show.n.03|psychological|of (l_prep) of_50\IN\entity.n.01|patients (l_pobj) patients_51\NNS\case.n.06|with (l_prep) with_52\IN\entity.n.01|disorders (l_pobj) disorders_54\NNS\physical_condition.n.01|panic|and|agoraphobia (l_conj) agoraphobia_56\NNP\phobia.n.01|
D003975_D008569 CID diazepam_12\NN\benzodiazepine.n.01|propranolol (r_pobj) for_11\IN\entity.n.01|diazepam (r_prep) greater_10\JJR\greater.a.01|for (r_acomp) was_9\VBD\washington.n.02|decrease|greater|. (r_conj) impaired_2\VBD\damage.v.01|drugs|recall|but|was (l_dobj) recall_5\NN\request.n.02|immediate|free
D011433_D008569 CID propranolol_14\NN\entity.n.01|than (r_advcl) diazepam_12\NN\benzodiazepine.n.01|propranolol (r_pobj) for_11\IN\entity.n.01|diazepam (r_prep) greater_10\JJR\greater.a.01|for (r_acomp) was_9\VBD\washington.n.02|decrease|greater|. (r_conj) impaired_2\VBD\damage.v.01|drugs|recall|but|was (l_dobj) recall_5\NN\request.n.02|immediate|free
9034419
C047426_D012640 CID venlafaxine_4\NNP\entity.n.01| (r_amod) overdose_5\NN\drug.v.01|a|venlafaxine (r_pobj) from_2\IN\entity.n.01|overdose (r_prep) resulting_1\VBG\prove.v.01|from (r_acl) seizure_0\NN\attack.n.07|resulting|.
C047426_D012640 CID venlafaxine_5\NNP\entity.n.01|26 (r_pobj) of_3\IN\entity.n.01|venlafaxine (r_prep) ingestion_2\NN\bodily_process.n.01|the|of|tablets (r_pobj) after_0\IN\after.s.01|ingestion (r_prep) experienced_11\VBD\undergo.v.01|after|,|patient|seizure|. (l_dobj) seizure_15\NN\attack.n.07|a|witnessed|generalized
C047426_D012640 CID venlafaxine_11\NNP\entity.n.01| (r_amod) overdose_12\NN\drug.v.01|venlafaxine (r_pobj) of_10\IN\entity.n.01|overdose (r_prep) case_9\NN\happening.n.01|the|first|reported|of|resulted (l_relcl) resulted_14\VBD\prove.v.01|that|in (l_prep) in_15\IN\linear_unit.n.01|seizure (l_pobj) seizure_18\NN\attack.n.07|a|generalized
C047426_D012640 CID venlafaxine_1\NNP\entity.n.01| (r_amod) overdose_2\NN\drug.v.01|the|venlafaxine|in (r_nsubj) resulted_6\VBD\prove.v.01|overdose|in|but|elicited|. (l_prep) in_7\IN\linear_unit.n.01|episode (l_pobj) episode_10\NN\happening.n.01|a|single|of (l_prep) of_11\IN\entity.n.01|seizure (l_pobj) seizure_13\NN\attack.n.07|generalized
C047426_D062787 CID venlafaxine_4\NNP\entity.n.01| (r_amod) overdose_5\NN\drug.v.01|a|venlafaxine
C047426_D062787 CID venlafaxine_5\NNP\entity.n.01| (r_amod) overdose_6\NN\drug.v.01|venlafaxine
C047426_D062787 CID venlafaxine_12\NN\entity.n.01| (r_pobj) of_11\IN\entity.n.01|venlafaxine (r_prep) overdose_10\NN\drug.v.01|an|of
C047426_D062787 CID venlafaxine_11\NNP\entity.n.01| (r_amod) overdose_12\NN\drug.v.01|venlafaxine
C047426_D062787 CID venlafaxine_1\NNP\entity.n.01| (r_amod) overdose_2\NN\drug.v.01|the|venlafaxine|in
C047426_D003865 NONE venlafaxine_12\NN\entity.n.01| (r_pobj) of_11\IN\entity.n.01|venlafaxine (r_prep) overdose_10\NN\drug.v.01|an|of (r_dobj) took_8\VBD\act.v.01|woman|overdose|in|. (l_nsubj) woman_4\NN\adult.n.01|a|old|with (l_prep) with_5\IN\entity.n.01|depression (l_pobj) depression_7\NN\psychological_state.n.01|major
14976857
D011405_-1 NONE propafenone_9\NN\entity.n.01| (r_compound) overdose_10\NN\drug.v.01|propafenone|in (r_pobj) by_8\IN\by.r.01|overdose (r_agent) induced_7\VBN\generate.v.01|by (r_acl) syndrome_6\NN\complex.n.01|transient|like|induced|.
D011405_D062787 NONE propafenone_9\NN\entity.n.01| (r_compound) overdose_10\NN\drug.v.01|propafenone|in
D011405_D062787 NONE propafenone_26\NN\entity.n.01| (r_compound) overdose_27\NN\drug.v.01|a|propafenone
D011405_D004437 NONE propafenone_9\NN\entity.n.01| (r_compound) overdose_10\NN\drug.v.01|propafenone|in (l_prep) in_11\IN\linear_unit.n.01|woman (l_pobj) woman_14\NN\adult.n.01|a|young|with (l_prep) with_15\IN\entity.n.01|anomaly (l_pobj) anomaly_18\NN\abnormality.n.01|ebstein
D011405_D054092 NONE propafenone_26\NN\entity.n.01| (r_compound) overdose_27\NN\drug.v.01|a|propafenone (r_pobj) by_24\IN\by.r.01|overdose (r_agent) precipitated_23\VBN\effect.v.01|was|probably|by (r_conj) occurred_9\VBD\happen.v.01|shunt|in|,|and|precipitated|. (l_nsubj) shunt_1\NN\passage.n.07|this|of|via (l_prep) via_4\IN\entity.n.01|ovale (l_pobj) ovale_8\NN\entity.n.01|a|foramen
9522143
D011318_D034381 CID prilocaine_2\NN\entity.n.01| (r_dobj) given_1\VBN\assumption.n.02|prilocaine (r_acl) patients_0\NNS\case.n.06|given|p (r_nsubj) were_3\VBD\be.v.01|patients|likely|. (l_acomp) likely_5\JJ\likely.a.01|more|develop (l_xcomp) develop_7\VB\create.v.02|to|hearing (l_xcomp) hearing_8\VBG\proceeding.n.01|loss (l_dobj) loss_9\NN\transferred_property.n.01|10|than
D011318_D034381 CID prilocaine_12\NN\entity.n.01|and|db (r_pobj) after_11\IN\after.s.01|prilocaine (r_prep) was_7\VBD\washington.n.02|loss|db|after|. (l_nsubj) loss_3\NN\transferred_property.n.01|the|average|hearing|for
D002045_D034381 CID bupivacaine_19\NN\entity.n.01|those|given|4 (r_pobj) than_16\IN\entity.n.01|bupivacaine (r_prep) loss_9\NN\transferred_property.n.01|10|than
D002045_D034381 CID bupivacaine_17\NN\entity.n.01| (r_pobj) after_16\IN\after.s.01|bupivacaine (r_prep) db_15\NN\chemical_element.n.01|15|after (r_conj) prilocaine_12\NN\entity.n.01|and|db (r_pobj) after_11\IN\after.s.01|prilocaine (r_prep) was_7\VBD\washington.n.02|loss|db|after|. (l_nsubj) loss_3\NN\transferred_property.n.01|the|average|hearing|for
1835291
D009241_D029424 NONE bromide_5\NN\halide.n.01|ipratropium|and|theophylline (r_pobj) of_3\IN\entity.n.01|bromide (r_prep) effects_2\NNS\personal_property.n.01|acute|bronchodilating|of|in|. (l_prep) in_8\IN\linear_unit.n.01|disease (l_pobj) disease_12\NN\illness.n.01|chronic|obstructive|pulmonary
D009241_D029424 NONE bromide_9\NN\halide.n.01| (r_compound) aerosol_10\NN\cloud.n.01|ipratropium|bromide|(|micrograms|)|and|tablets (r_pobj) of_7\IN\entity.n.01|aerosol (r_prep) dose_6\NN\medicine.n.02|a|single|of|titrated (r_pobj) of_3\IN\entity.n.01|dose (r_prep) effects_2\NNS\personal_property.n.01|the|bronchodilator|of (r_nsubjpass) compared_37\VBN\analyze.v.01|effects|were|in|. (l_prep) in_38\IN\linear_unit.n.01|study (l_pobj) study_48\NN\examination.n.01|a|blind|,|controlled|crossover|in (l_prep) in_49\IN\linear_unit.n.01|patients (l_pobj) patients_51\NNS\case.n.06|21|with (l_prep) with_52\IN\entity.n.01|disease (l_pobj) disease_58\NN\illness.n.01|stable|,|chronic|obstructive|pulmonary
D009241_D029424 NONE ipratropium_4\NN\entity.n.01| (r_nsubj) is_5\VBZ\be.v.01|that|ipratropium|bronchodilator|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|obstruction (l_pobj) obstruction_18\NN\structure.n.01|chronic|airflow
D013806_D029424 NONE theophylline_7\NN\bronchodilator.n.01| (r_conj) bromide_5\NN\halide.n.01|ipratropium|and|theophylline (r_pobj) of_3\IN\entity.n.01|bromide (r_prep) effects_2\NNS\personal_property.n.01|acute|bronchodilating|of|in|. (l_prep) in_8\IN\linear_unit.n.01|disease (l_pobj) disease_12\NN\illness.n.01|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_19\NN\bronchodilator.n.01| (r_amod) tablets_20\NNS\slab.n.01|acting|theophylline (r_conj) aerosol_10\NN\cloud.n.01|ipratropium|bromide|(|micrograms|)|and|tablets (r_pobj) of_7\IN\entity.n.01|aerosol (r_prep) dose_6\NN\medicine.n.02|a|single|of|titrated (r_pobj) of_3\IN\entity.n.01|dose (r_prep) effects_2\NNS\personal_property.n.01|the|bronchodilator|of (r_nsubjpass) compared_37\VBN\analyze.v.01|effects|were|in|. (l_prep) in_38\IN\linear_unit.n.01|study (l_pobj) study_48\NN\examination.n.01|a|blind|,|controlled|crossover|in (l_prep) in_49\IN\linear_unit.n.01|patients (l_pobj) patients_51\NNS\case.n.06|21|with (l_prep) with_52\IN\entity.n.01|disease (l_pobj) disease_58\NN\illness.n.01|stable|,|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_12\NN\bronchodilator.n.01|oral (r_pobj) than_10\IN\entity.n.01|theophylline (r_prep) bronchodilator_9\NN\medicine.n.02|a|potent|than (r_attr) is_5\VBZ\be.v.01|that|ipratropium|bronchodilator|in (l_prep) in_13\IN\linear_unit.n.01|patients (l_pobj) patients_14\NNS\case.n.06|with (l_prep) with_15\IN\entity.n.01|obstruction (l_pobj) obstruction_18\NN\structure.n.01|chronic|airflow
D013806_D002318 CID theophylline_9\JJ\bronchodilator.n.01| (r_amod) use_10\NN\activity.n.01|theophylline (r_pobj) after_8\IN\after.s.01|use (r_prep) experienced_7\VBN\undergo.v.01|after (r_acl) those_6\DT\entity.n.01|experienced (r_nsubj) involve_12\VB\refer.v.02|were|,|those|did|systems|. (l_dobj) systems_17\NNS\instrumentality.n.03|the|cardiovascular
D013806_D005767 CID theophylline_9\JJ\bronchodilator.n.01| (r_amod) use_10\NN\activity.n.01|theophylline (r_pobj) after_8\IN\after.s.01|use (r_prep) experienced_7\VBN\undergo.v.01|after (r_acl) those_6\DT\entity.n.01|experienced (r_nsubj) involve_12\VB\refer.v.02|were|,|those|did|systems|. (l_dobj) systems_17\NNS\instrumentality.n.03|the|cardiovascular
6287825
D013831_D010523 CID thiamine_7\NN\b-complex_vitamin.n.01|and|riboflavin (r_pobj) of_6\IN\entity.n.01|thiamine (r_prep) deficiency_5\NN\need.n.01|nutritional|of (r_pobj) due_2\IN\right.n.01|to|deficiency (r_prep) neuropathy_1\NNS\pathology.n.02|peripheral|due
D013831_D010523 CID thiamine_7\NN\b-complex_vitamin.n.01|and|riboflavin (r_pobj) of_6\IN\entity.n.01|thiamine (r_prep) deficiency_5\NN\need.n.01|nutritional|of (r_pobj) due_2\IN\right.n.01|to|deficiency (r_prep) neuropathy_1\NNS\pathology.n.02|peripheral|due (r_nsubj) was_10\VBD\washington.n.02|neuropathy|common|%|and|presented|. (l_conj) presented_17\VBN\show.v.04|as (l_prep) as_19\IN\chemical_element.n.01|mainly|neuropathy (l_pobj) neuropathy_25\NN\pathology.n.02|sensory
D013831_D044342 NONE thiamine_7\NN\b-complex_vitamin.n.01|and|riboflavin (r_pobj) of_6\IN\entity.n.01|thiamine (r_prep) deficiency_5\NN\need.n.01|nutritional|of
D012256_D010523 CID riboflavin_9\NN\b-complex_vitamin.n.01| (r_conj) thiamine_7\NN\b-complex_vitamin.n.01|and|riboflavin (r_pobj) of_6\IN\entity.n.01|thiamine (r_prep) deficiency_5\NN\need.n.01|nutritional|of (r_pobj) due_2\IN\right.n.01|to|deficiency (r_prep) neuropathy_1\NNS\pathology.n.02|peripheral|due
D012256_D010523 CID riboflavin_9\NN\b-complex_vitamin.n.01| (r_conj) thiamine_7\NN\b-complex_vitamin.n.01|and|riboflavin (r_pobj) of_6\IN\entity.n.01|thiamine (r_prep) deficiency_5\NN\need.n.01|nutritional|of (r_pobj) due_2\IN\right.n.01|to|deficiency (r_prep) neuropathy_1\NNS\pathology.n.02|peripheral|due (r_nsubj) was_10\VBD\washington.n.02|neuropathy|common|%|and|presented|. (l_conj) presented_17\VBN\show.v.04|as (l_prep) as_19\IN\chemical_element.n.01|mainly|neuropathy (l_pobj) neuropathy_25\NN\pathology.n.02|sensory
D012256_D044342 NONE riboflavin_9\NN\b-complex_vitamin.n.01| (r_conj) thiamine_7\NN\b-complex_vitamin.n.01|and|riboflavin (r_pobj) of_6\IN\entity.n.01|thiamine (r_prep) deficiency_5\NN\need.n.01|nutritional|of
D007538_D009422 NONE isoniazid_0\NNP\antibacterial.n.01| (r_nsubj) was_1\VBD\washington.n.02|isoniazid|agent|. (l_attr) agent_5\NN\causal_agent.n.01|the|frequent|in (l_prep) in_6\IN\linear_unit.n.01|neuropathy (l_pobj) neuropathy_10\NN\pathology.n.02|induced
19269743
D002211_D010146 CID capsaicin_9\NN\chemical_irritant.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|capsaicin|- (r_amod) pain_12\NN\symptom.n.01|induced
D002211_D010146 CID capsaicin_21\NN\chemical_irritant.n.01| (r_pobj) of_20\IN\entity.n.01|capsaicin (r_prep) doses_19\NNS\medicine.n.02|three|of|microg (r_pobj) of_17\IN\entity.n.01|doses (r_prep) injections_16\NNS\insertion.n.02|intradermal|of|separated (r_dobj) received_14\VBD\get.v.01|in|,|volunteers|injections|)|,|given|. (l_prep) in_0\IN\linear_unit.n.01|order (l_pobj) order_1\NN\command.n.01|address (l_acl) address_3\VB\code.n.03|to|memory (l_dobj) memory_8\NN\representation.n.01|term|pain (l_compound) pain_7\NN\symptom.n.01|
D002211_D010146 CID capsaicin_11\NN\chemical_irritant.n.01| (r_compound) doses_12\NNS\medicine.n.02|capsaicin|(|p<0.001|) (r_pobj) across_10\IN\across.r.01|doses (r_prep) discriminate_5\VB\distinguish.v.01|to|reliably|magnitude|across|,|regardless (l_dobj) magnitude_7\NN\property.n.02|pain|and|duration (l_compound) pain_6\NN\symptom.n.01|
15130900
D003520_D001749 CID cyclophosphamide_12\NN\entity.n.01| (r_pobj) to_11\IN\entity.n.01|cyclophosphamide (r_prep) risks_8\NNS\danger.n.03|and|relation|to (r_appos) granulomatosis_6\NN\entity.n.01|wegener|:|risks (r_pobj) in_3\IN\linear_unit.n.01|granulomatosis (r_prep) cancer_2\NN\malignant_tumor.n.01|urinary|bladder|in|.
D003520_D001749 CID cyclophosphamide_16\NN\entity.n.01| (r_pobj) to_15\IN\entity.n.01|cyclophosphamide (r_prep) relation_14\NN\abstraction.n.06|its|to|,|in (r_conj) assess_3\VB\body_part.n.01|to|and|characterise|,|and|relation (l_conj) characterise_5\VB\distinguish.v.03|risk (l_dobj) risk_7\NN\danger.n.03|the|of (l_prep) of_8\IN\entity.n.01|cancer (l_pobj) cancer_10\NN\malignant_tumor.n.01|bladder
D003520_D001749 CID cyclophosphamide_18\NN\entity.n.01|and|cancer (l_conj) cancer_21\NN\malignant_tumor.n.01|bladder
D003520_D001749 CID cyclophosphamide_12\NN\entity.n.01| (r_pobj) in_11\IN\linear_unit.n.01|cyclophosphamide (r_prep) increment_10\NN\process.n.06|every|10|g|in|(|or (r_pobj) for_6\IN\entity.n.01|increment (r_prep) doubled_5\VBD\multiply.v.02|risk|for|. (l_nsubj) risk_1\NN\danger.n.03|the|of (l_prep) of_2\IN\entity.n.01|cancer (l_pobj) cancer_4\NN\malignant_tumor.n.01|bladder
D003520_D001749 CID cyclophosphamide_9\NN\entity.n.01| (r_pobj) between_8\IN\between.r.01|cyclophosphamide (r_prep) relationship_7\NN\relation.n.01|a|response|between|and|risk (l_conj) risk_12\NN\danger.n.03|the|of|,|risks (l_prep) of_13\IN\entity.n.01|cancer (l_pobj) cancer_15\NN\malignant_tumor.n.01|bladder
D003520_D014890 NONE cyclophosphamide_12\NN\entity.n.01| (r_pobj) to_11\IN\entity.n.01|cyclophosphamide (r_prep) risks_8\NNS\danger.n.03|and|relation|to (r_appos) granulomatosis_6\NN\entity.n.01|wegener|:|risks
D003520_D014890 NONE cyclophosphamide_16\NN\entity.n.01| (r_pobj) to_15\IN\entity.n.01|cyclophosphamide (r_prep) relation_14\NN\abstraction.n.06|its|to|,|in (l_prep) in_18\IN\linear_unit.n.01|patients (l_pobj) patients_19\NNS\case.n.06|with (l_prep) with_20\IN\entity.n.01|granulomatosis (l_pobj) granulomatosis_23\NN\entity.n.01|wegener
D003520_D014890 NONE cyclophosphamide_9\NN\entity.n.01| (r_pobj) between_8\IN\between.r.01|cyclophosphamide (r_prep) relationship_7\NN\relation.n.01|a|response|between|and|risk (l_conj) risk_12\NN\danger.n.03|the|of|,|risks (l_conj) risks_19\NNS\danger.n.03|high|cumulative|in|,|and|possibility (l_conj) possibility_28\NN\expectation.n.01|the|of (l_prep) of_29\IN\entity.n.01|factors (l_pobj) factors_31\NNS\cause.n.01|risk|operating (l_acl) operating_32\VBG\direct.v.04|before (l_prep) before_34\IN\earlier.r.01|even|granulomatosis (l_pobj) granulomatosis_37\NN\entity.n.01|wegener
17612891
D003024_D009205 CID clozapine_4\NN\major_tranquilizer.n.01| (r_pobj) with_3\IN\entity.n.01|clozapine (r_prep) associated_2\VBN\think.v.03|with (r_acl) myocarditis_1\NN\carditis.n.01|acute|associated|.
D003024_D009205 CID clozapine_10\NN\major_tranquilizer.n.01| (r_pobj) of_9\IN\entity.n.01|clozapine (r_prep) commencement_8\NN\point.n.06|the|of (r_pobj) with_6\IN\entity.n.01|commencement (r_prep) associated_5\VBN\think.v.03|with (r_acl) case_1\NN\happening.n.01|a|of|associated (l_prep) of_2\IN\entity.n.01|myocarditis (l_pobj) myocarditis_4\NN\carditis.n.01|acute
D003024_D009205 CID clozapine_16\NN\major_tranquilizer.n.01| (r_pobj) of_15\IN\entity.n.01|clozapine (r_prep) commencement_14\NN\point.n.06|of (r_pobj) after_13\IN\after.s.01|commencement (r_prep) developed_7\VBD\create.v.02|male|onset|after|. (l_dobj) onset_10\NN\start.n.01|a|sudden|of (l_prep) of_11\IN\entity.n.01|myocarditis (l_pobj) myocarditis_12\NN\carditis.n.01|
D003024_D009205 CID clozapine_11\NN\major_tranquilizer.n.01| (r_pobj) of_10\IN\entity.n.01|clozapine (r_prep) use_9\NN\activity.n.01|the|of (r_pobj) with_7\IN\entity.n.01|use (r_prep) associated_6\VBN\think.v.03|with (r_acl) complication_5\NN\hindrance.n.03|an|recognized|associated (r_attr) is_1\VBZ\be.v.01|myocarditis|complication|. (l_nsubj) myocarditis_0\NNP\carditis.n.01|
D003024_D012559 NONE clozapine_16\NN\major_tranquilizer.n.01| (r_pobj) of_15\IN\entity.n.01|clozapine (r_prep) commencement_14\NN\point.n.06|of (r_pobj) after_13\IN\after.s.01|commencement (r_prep) developed_7\VBD\create.v.02|male|onset|after|. (l_nsubj) male_4\NN\animal.n.01|a|old|with (l_prep) with_5\IN\entity.n.01|schizophrenia (l_pobj) schizophrenia_6\NN\psychosis.n.01|
D003024_D011618 NONE clozapine_2\NN\major_tranquilizer.n.01|that (r_pobj) considering_0\VBG\think.v.01|clozapine (r_csubj) remains_3\VBZ\object.n.01|considering|standard (l_attr) standard_6\NN\system_of_measurement.n.01|the|gold|in (l_prep) in_7\IN\linear_unit.n.01|treatment (l_pobj) treatment_8\NN\care.n.01|of (l_prep) of_9\IN\entity.n.01|psychosis (l_pobj) psychosis_11\NN\mental_illness.n.01|resistant
1428568
D013999_D005901 NONE timolol_6\NN\beta_blocker.n.01| (r_compound) 0.5%/12h_7\CD\entity.n.01|timolol (r_pobj) with_5\IN\entity.n.01|0.5%/12h (r_prep) treated_4\VBN\interact.v.01|patients|chronically|with|,|suffering (l_nsubj) patients_2\NNS\case.n.06|eight|glaucomatous (l_amod) glaucomatous_1\JJ\entity.n.01|
D013999_D003866 CID timolol_6\NN\beta_blocker.n.01| (r_compound) 0.5%/12h_7\CD\entity.n.01|timolol (r_pobj) with_5\IN\entity.n.01|0.5%/12h (r_prep) treated_4\VBN\interact.v.01|patients|chronically|with|,|suffering (l_advcl) suffering_9\VBG\pain.n.01|from|diagnosed (l_prep) from_10\IN\entity.n.01|depression (l_pobj) depression_11\NN\psychological_state.n.01|
D013999_D003866 CID timolol_15\NN\beta_blocker.n.01| (r_compound) treatment_16\NN\care.n.01|timolol (r_pobj) under_14\IN\nether.s.03|treatment (r_prep) patients_13\NNS\case.n.06|the|under (r_nsubj) presented_17\VBD\show.v.04|in|,|patients|values|. (l_dobj) values_20\NNS\belief.n.01|higher|depression|measured|0.001 (l_compound) depression_19\NN\psychological_state.n.01|
D013999_D003866 CID timolol_14\NN\beta_blocker.n.01|in (r_pobj) than_13\IN\entity.n.01|timolol (r_prep) less_7\JJR\autoimmune_disease.n.01|of|than (l_prep) of_8\IN\entity.n.01|inducer (l_pobj) inducer_12\NN\agent.n.03|a|depression|- (l_compound) depression_10\NN\psychological_state.n.01|
D015784_D003866 NONE betaxolol_4\NN\entity.n.01| (r_nsubj) be_6\VB\metallic_element.n.01|that|betaxolol|could|less (l_attr) less_7\JJR\autoimmune_disease.n.01|of|than (l_prep) of_8\IN\entity.n.01|inducer (l_pobj) inducer_12\NN\agent.n.03|a|depression|- (l_compound) depression_10\NN\psychological_state.n.01|
10721819
D007545_D013610 NONE isoproterenol_7\NN\medicine.n.02|on (l_prep) on_8\IN\on.a.01|tachycardia (l_pobj) tachycardia_12\NN\cardiac_arrhythmia.n.01|induced
D007545_D013610 NONE isoproterenol_10\NN\medicine.n.02| (r_pobj) with_9\IN\entity.n.01|isoproterenol (r_prep) pretreatment_8\NN\entity.n.01|prolonged|with (r_nsubj) abolish_12\VB\abolish.v.01|whether|pretreatment|could|tachycardia|in (l_dobj) tachycardia_16\NN\cardiac_arrhythmia.n.01|induced
D007545_D013610 NONE isoproterenol_7\JJ\medicine.n.02| (r_compound) pretreatment_8\NN\entity.n.01|isoproterenol (r_pobj) by_6\IN\by.r.01|pretreatment (r_prep) unaffected_5\JJ\unaffected.a.01|by (r_acomp) was_4\VBD\washington.n.02|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\change.v.02|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN\cardiac_arrhythmia.n.01|
D007545_D013610 NONE isoproterenol_5\JJ\medicine.n.02| (r_compound) pretreatment_6\NN\entity.n.01|15-day|isoproterenol (r_nsubj) abolished_9\VBD\abolish.v.01|that|pretreatment|not|but|reversed (l_conj) reversed_11\VBD\change.v.02|tachycardia|to|,|effect (l_dobj) tachycardia_15\NN\cardiac_arrhythmia.n.01|induced
D001971_D013610 CID bromocriptine_9\NN\entity.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|bromocriptine|- (r_amod) tachycardia_12\NN\cardiac_arrhythmia.n.01|induced
D001971_D013610 CID bromocriptine_5\NN\entity.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|bromocriptine|- (r_amod) tachycardia_8\NN\cardiac_arrhythmia.n.01|induced|,|persisted|,
D001971_D013610 CID bromocriptine_13\NN\entity.n.01| (r_npadvmod) induced_15\VBN\generate.v.01|bromocriptine|- (r_amod) tachycardia_16\NN\cardiac_arrhythmia.n.01|induced
D001971_D013610 CID bromocriptine_5\NN\entity.n.01|intravenous|(|kg|) (r_nsubj) induced_12\VBD\generate.v.01|in|,|bromocriptine|hypotension|. (l_dobj) hypotension_14\NN\cardiovascular_disease.n.01|significant|and|tachycardia (l_conj) tachycardia_16\NN\cardiac_arrhythmia.n.01|
D001971_D013610 CID bromocriptine_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|bromocriptine|- (r_amod) hypotension_3\NN\cardiovascular_disease.n.01|induced (r_nsubj) was_4\VBD\washington.n.02|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\change.v.02|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN\cardiac_arrhythmia.n.01|
D001971_D013610 CID bromocriptine_12\NN\entity.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|bromocriptine|- (r_amod) tachycardia_15\NN\cardiac_arrhythmia.n.01|induced
D001971_D013610 CID bromocriptine_13\NN\entity.n.01| (r_pobj) of_12\IN\entity.n.01|bromocriptine (r_prep) tachycardia_11\NN\cardiac_arrhythmia.n.01|the|central|of
D007545_D006332 CID isoproterenol_0\JJ\medicine.n.02| (r_compound) pretreatment_1\NN\entity.n.01|isoproterenol|for (r_nsubj) caused_5\VBD\make.v.03|pretreatment|hypertrophy|without|. (l_dobj) hypertrophy_7\NN\dysplasia.n.01|cardiac
D001971_D007022 CID bromocriptine_5\NN\entity.n.01|intravenous|(|kg|) (r_nsubj) induced_12\VBD\generate.v.01|in|,|bromocriptine|hypotension|. (l_dobj) hypotension_14\NN\cardiovascular_disease.n.01|significant|and|tachycardia
D001971_D007022 CID bromocriptine_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|bromocriptine|- (r_amod) hypotension_3\NN\cardiovascular_disease.n.01|induced
D001971_D001919 NONE bromocriptine_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|bromocriptine|- (r_amod) hypotension_3\NN\cardiovascular_disease.n.01|induced (r_nsubj) was_4\VBD\washington.n.02|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\change.v.02|while|tachycardia|was|to|,|effect (l_prep) to_14\IN\entity.n.01|bradycardia (l_pobj) bradycardia_16\NNS\cardiac_arrhythmia.n.01|significant
D001971_D001919 NONE bromocriptine_12\NN\entity.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|bromocriptine|- (r_amod) tachycardia_15\NN\cardiac_arrhythmia.n.01|induced (r_dobj) reversed_11\VBD\change.v.02|tachycardia|to|,|effect (l_prep) to_16\IN\entity.n.01|bradycardia (l_pobj) bradycardia_17\NNP\cardiac_arrhythmia.n.01|
D001971_D001919 NONE bromocriptine_13\NN\entity.n.01| (r_pobj) of_12\IN\entity.n.01|bromocriptine (r_prep) tachycardia_11\NN\cardiac_arrhythmia.n.01|the|central|of (r_nsubj) appears_14\VBZ\be.v.01|that|,|in|,|tachycardia|predominate (l_xcomp) predominate_16\VB\predominate.v.01|to|and|mask (l_conj) mask_19\VB\covering.n.02|to|bradycardia (l_dobj) bradycardia_21\NN\cardiac_arrhythmia.n.01|the|of|at
D007545_D007022 NONE isoproterenol_7\JJ\medicine.n.02| (r_compound) pretreatment_8\NN\entity.n.01|isoproterenol (r_pobj) by_6\IN\by.r.01|pretreatment (r_prep) unaffected_5\JJ\unaffected.a.01|by (r_acomp) was_4\VBD\washington.n.02|hypotension|unaffected|,|reversed|. (l_nsubj) hypotension_3\NN\cardiovascular_disease.n.01|induced
D007545_D001919 CID isoproterenol_7\JJ\medicine.n.02| (r_compound) pretreatment_8\NN\entity.n.01|isoproterenol (r_pobj) by_6\IN\by.r.01|pretreatment (r_prep) unaffected_5\JJ\unaffected.a.01|by (r_acomp) was_4\VBD\washington.n.02|hypotension|unaffected|,|reversed|. (l_advcl) reversed_13\VBN\change.v.02|while|tachycardia|was|to|,|effect (l_prep) to_14\IN\entity.n.01|bradycardia (l_pobj) bradycardia_16\NNS\cardiac_arrhythmia.n.01|significant
D007545_D001919 CID isoproterenol_5\JJ\medicine.n.02| (r_compound) pretreatment_6\NN\entity.n.01|15-day|isoproterenol (r_nsubj) abolished_9\VBD\abolish.v.01|that|pretreatment|not|but|reversed (l_conj) reversed_11\VBD\change.v.02|tachycardia|to|,|effect (l_prep) to_16\IN\entity.n.01|bradycardia (l_pobj) bradycardia_17\NNP\cardiac_arrhythmia.n.01|
D004294_D007022 NONE domperidone_26\NN\entity.n.01|i.v. (r_pobj) by_24\IN\by.r.01|domperidone (r_agent) reduced_23\VBN\decrease.v.02|that|was|partly|by (r_relcl) effect_19\NN\phenomenon.n.01|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN\change.v.02|while|tachycardia|was|to|,|effect (r_advcl) was_4\VBD\washington.n.02|hypotension|unaffected|,|reversed|. (l_nsubj) hypotension_3\NN\cardiovascular_disease.n.01|induced
D004294_D013610 NONE domperidone_26\NN\entity.n.01|i.v. (r_pobj) by_24\IN\by.r.01|domperidone (r_agent) reduced_23\VBN\decrease.v.02|that|was|partly|by (r_relcl) effect_19\NN\phenomenon.n.01|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN\change.v.02|while|tachycardia|was|to|,|effect (l_nsubjpass) tachycardia_11\NN\cardiac_arrhythmia.n.01|
D004294_D001919 CID domperidone_26\NN\entity.n.01|i.v. (r_pobj) by_24\IN\by.r.01|domperidone (r_agent) reduced_23\VBN\decrease.v.02|that|was|partly|by (r_relcl) effect_19\NN\phenomenon.n.01|an|reduced|mg/kg|) (r_npadvmod) reversed_13\VBN\change.v.02|while|tachycardia|was|to|,|effect (l_prep) to_14\IN\entity.n.01|bradycardia (l_pobj) bradycardia_16\NNS\cardiac_arrhythmia.n.01|significant
D004298_D013610 NONE dopamine_27\NN\monoamine_neurotransmitter.n.01| (r_compound) d2_28\NN\entity.n.01|dopamine (r_compound) receptors_29\NNS\structure.n.04|peripheral|d2 (r_pobj) at_25\IN\chemical_element.n.01|receptors (r_prep) bradycardia_21\NN\cardiac_arrhythmia.n.01|the|of|at (r_dobj) mask_19\VB\covering.n.02|to|bradycardia (r_conj) predominate_16\VB\predominate.v.01|to|and|mask (r_xcomp) appears_14\VBZ\be.v.01|that|,|in|,|tachycardia|predominate (l_nsubj) tachycardia_11\NN\cardiac_arrhythmia.n.01|the|central|of
D004298_D001919 NONE dopamine_27\NN\monoamine_neurotransmitter.n.01| (r_compound) d2_28\NN\entity.n.01|dopamine (r_compound) receptors_29\NNS\structure.n.04|peripheral|d2 (r_pobj) at_25\IN\chemical_element.n.01|receptors (r_prep) bradycardia_21\NN\cardiac_arrhythmia.n.01|the|of|at
17854040
D019259_D006509 NONE lamivudine_3\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) resistance_5\NN\action.n.01|lamivudine|-|in (r_pobj) with_2\IN\entity.n.01|resistance (r_prep) associated_1\VBN\think.v.03|with (r_acl) mutations_0\NNS\organism.n.01|associated (r_nsubj) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_amod) infected_17\JJ\give.v.01|
D019259_D006509 NONE lamivudine_3\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) resistance_5\NN\action.n.01|lamivudine|-|in (r_pobj) with_2\IN\entity.n.01|resistance (r_prep) associated_1\VBN\think.v.03|with (r_acl) mutations_0\NNS\organism.n.01|associated (r_nsubj) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_prep) with_19\IN\entity.n.01|and|without (l_conj) without_21\IN\entity.n.01|implications (l_pobj) implications_27\NNS\inference.n.01|:|for|patients (l_conj) patients_40\NNS\case.n.06|infected|african (l_amod) infected_37\VBN\give.v.01|-
D019259_D006509 NONE lamivudine_7\JJ\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) resistant_9\JJ\immune.s.03|lamivudine|- (r_amod) virus_12\NN\infectious_agent.n.01|resistant|b (l_compound) b_11\NN\eubacteria.n.01|hepatitis
D019259_D006509 NONE lamivudine_19\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) na_21\NN\metallic_element.n.01|selected|lamivudine|- (r_aux) ve_22\VB\entity.n.01|na|carriers|with (r_acl) study_4\NN\examination.n.01|an|exploratory|investigate|strains|ve (l_acl) investigate_6\VB\analyze.v.01|to|virus (l_dobj) virus_12\NN\infectious_agent.n.01|resistant|b (l_compound) b_11\NN\eubacteria.n.01|hepatitis
D019259_D006509 NONE lamivudine_1\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) resistant_3\JJ\immune.s.03|lamivudine|- (r_amod) strains_4\NNS\deformation.n.02|hbv|resistant (r_nsubjpass) detected_6\VBN\spy.v.03|strains|were|in|and|patients|. (l_prep) in_7\IN\linear_unit.n.01|patients (l_pobj) patients_17\NNS\case.n.06|15|infected|chronic|b (l_compound) b_16\NNP\eubacteria.n.01|hepatitis
D019259_D006509 NONE lamivudine_1\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) resistant_3\JJ\immune.s.03|lamivudine|- (r_amod) strains_4\NNS\deformation.n.02|hbv|resistant (r_nsubjpass) detected_6\VBN\spy.v.03|strains|were|in|and|patients|. (l_conj) patients_28\NNS\case.n.06|20|infected (l_amod) infected_27\VBN\give.v.01|hiv|-
D019259_D006509 NONE lamivudine_14\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) resistant_16\JJ\immune.s.03|lamivudine|- (r_amod) strains_17\NNS\deformation.n.02|hbv|resistant|in (l_prep) in_18\IN\linear_unit.n.01|ve (l_pcomp) ve_22\VB\entity.n.01|na|patients (l_dobj) patients_29\NNS\case.n.06|infected (l_amod) infected_28\VBN\give.v.01|hiv|-
D019259_D006509 NONE lamivudine_22\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) containing_24\VBG\include.v.01|when|lamivudine|-|treatment (r_advcl) emergence_16\NN\beginning.n.01|widespread|of|containing (r_pobj) in_14\IN\linear_unit.n.01|emergence (r_prep) result_13\VB\phenomenon.n.01|whether|mutations|could|in|applied (l_conj) applied_38\VBN\use.v.01|regimens|become|widely|in|,|is (l_advcl) is_45\VBZ\be.v.01|as|this|likely (l_acomp) likely_46\JJ\likely.a.01|have (l_xcomp) have_48\VB\person.n.01|to|implications (l_dobj) implications_50\NNS\inference.n.01|potential|in (l_prep) in_51\IN\linear_unit.n.01|management (l_pobj) management_53\NN\social_control.n.01|the|of (l_prep) of_54\IN\entity.n.01|patients (l_pobj) patients_61\NNS\case.n.06|infected (l_amod) infected_60\VBN\give.v.01|hiv|-
D019259_D015658 NONE lamivudine_3\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) resistance_5\NN\action.n.01|lamivudine|-|in (r_pobj) with_2\IN\entity.n.01|resistance (r_prep) associated_1\VBN\think.v.03|with (r_acl) mutations_0\NNS\organism.n.01|associated (r_nsubj) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_prep) with_19\IN\entity.n.01|and|without (l_conj) without_21\IN\entity.n.01|implications (l_pobj) implications_27\NNS\inference.n.01|:|for|patients (l_punct) :_26\:\entity.n.01|infection (l_punct) infection_25\NN\ill_health.n.01|hiv|-
D019259_D015658 NONE lamivudine_3\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) resistance_5\NN\action.n.01|lamivudine|-|in (r_pobj) with_2\IN\entity.n.01|resistance (r_prep) associated_1\VBN\think.v.03|with (r_acl) mutations_0\NNS\organism.n.01|associated (r_nsubj) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_prep) with_19\IN\entity.n.01|and|without (l_conj) without_21\IN\entity.n.01|implications (l_pobj) implications_27\NNS\inference.n.01|:|for|patients (l_conj) patients_40\NNS\case.n.06|infected|african (l_amod) infected_37\VBN\give.v.01|-
D019259_D015658 NONE lamivudine_7\JJ\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) resistant_9\JJ\immune.s.03|lamivudine|- (r_amod) virus_12\NN\infectious_agent.n.01|resistant|b (r_dobj) investigate_6\VB\analyze.v.01|to|virus (r_acl) study_4\NN\examination.n.01|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD\washington.n.02|this|study|. (l_punct) ._41\.\entity.n.01|in (l_punct) in_37\IN\linear_unit.n.01|infection|patients (l_punct) infection_36\NN\ill_health.n.01|-
D019259_D015658 NONE lamivudine_19\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) na_21\NN\metallic_element.n.01|selected|lamivudine|- (r_aux) ve_22\VB\entity.n.01|na|carriers|with (r_acl) study_4\NN\examination.n.01|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD\washington.n.02|this|study|. (l_punct) ._41\.\entity.n.01|in (l_punct) in_37\IN\linear_unit.n.01|infection|patients (l_punct) infection_36\NN\ill_health.n.01|-
D019259_D015658 NONE lamivudine_1\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) resistant_3\JJ\immune.s.03|lamivudine|- (r_amod) strains_4\NNS\deformation.n.02|hbv|resistant (r_nsubjpass) detected_6\VBN\spy.v.03|strains|were|in|and|patients|. (l_conj) patients_28\NNS\case.n.06|20|infected (l_amod) infected_27\VBN\give.v.01|hiv|-
D019259_D015658 NONE lamivudine_14\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) resistant_16\JJ\immune.s.03|lamivudine|- (r_amod) strains_17\NNS\deformation.n.02|hbv|resistant|in (l_prep) in_18\IN\linear_unit.n.01|ve (l_pcomp) ve_22\VB\entity.n.01|na|patients (l_dobj) patients_29\NNS\case.n.06|infected (l_amod) infected_28\VBN\give.v.01|hiv|-
D019259_D015658 NONE lamivudine_22\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_npadvmod) containing_24\VBG\include.v.01|when|lamivudine|-|treatment (r_advcl) emergence_16\NN\beginning.n.01|widespread|of|containing (r_pobj) in_14\IN\linear_unit.n.01|emergence (r_prep) result_13\VB\phenomenon.n.01|whether|mutations|could|in|applied (l_conj) applied_38\VBN\use.v.01|regimens|become|widely|in|,|is (l_advcl) is_45\VBZ\be.v.01|as|this|likely (l_acomp) likely_46\JJ\likely.a.01|have (l_xcomp) have_48\VB\person.n.01|to|implications (l_dobj) implications_50\NNS\inference.n.01|potential|in (l_prep) in_51\IN\linear_unit.n.01|management (l_pobj) management_53\NN\social_control.n.01|the|of (l_prep) of_54\IN\entity.n.01|patients (l_pobj) patients_61\NNS\case.n.06|infected (l_amod) infected_60\VBN\give.v.01|hiv|-
D012964_D006509 NONE na_9\TO\metallic_element.n.01|therapy|- (r_aux) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_amod) infected_17\JJ\give.v.01|
D012964_D006509 NONE na_9\TO\metallic_element.n.01|therapy|- (r_aux) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_prep) with_19\IN\entity.n.01|and|without (l_conj) without_21\IN\entity.n.01|implications (l_pobj) implications_27\NNS\inference.n.01|:|for|patients (l_conj) patients_40\NNS\case.n.06|infected|african (l_amod) infected_37\VBN\give.v.01|-
D012964_D006509 NONE na_21\NN\metallic_element.n.01|selected|lamivudine|- (r_aux) ve_22\VB\entity.n.01|na|carriers|with (r_acl) study_4\NN\examination.n.01|an|exploratory|investigate|strains|ve (l_acl) investigate_6\VB\analyze.v.01|to|virus (l_dobj) virus_12\NN\infectious_agent.n.01|resistant|b (l_compound) b_11\NN\eubacteria.n.01|hepatitis
D012964_D006509 NONE na_21\TO\metallic_element.n.01|therapy|- (r_aux) ve_22\VB\entity.n.01|na|patients (l_dobj) patients_29\NNS\case.n.06|infected (l_amod) infected_28\VBN\give.v.01|hiv|-
D012964_D015658 NONE na_9\TO\metallic_element.n.01|therapy|- (r_aux) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_prep) with_19\IN\entity.n.01|and|without (l_conj) without_21\IN\entity.n.01|implications (l_pobj) implications_27\NNS\inference.n.01|:|for|patients (l_punct) :_26\:\entity.n.01|infection (l_punct) infection_25\NN\ill_health.n.01|hiv|-
D012964_D015658 NONE na_9\TO\metallic_element.n.01|therapy|- (r_aux) ve_10\VB\entity.n.01|mutations|na|virus|. (l_dobj) virus_13\NN\infectious_agent.n.01|b|(|hbv|)|patients (l_appos) patients_18\NNS\case.n.06|infected|with (l_prep) with_19\IN\entity.n.01|and|without (l_conj) without_21\IN\entity.n.01|implications (l_pobj) implications_27\NNS\inference.n.01|:|for|patients (l_conj) patients_40\NNS\case.n.06|infected|african (l_amod) infected_37\VBN\give.v.01|-
D012964_D015658 NONE na_21\NN\metallic_element.n.01|selected|lamivudine|- (r_aux) ve_22\VB\entity.n.01|na|carriers|with (r_acl) study_4\NN\examination.n.01|an|exploratory|investigate|strains|ve (r_attr) was_1\VBD\washington.n.02|this|study|. (l_punct) ._41\.\entity.n.01|in (l_punct) in_37\IN\linear_unit.n.01|infection|patients (l_punct) infection_36\NN\ill_health.n.01|-
D012964_D015658 NONE na_21\TO\metallic_element.n.01|therapy|- (r_aux) ve_22\VB\entity.n.01|na|patients (l_dobj) patients_29\NNS\case.n.06|infected (l_amod) infected_28\VBN\give.v.01|hiv|-
9334596
D013739_D007172 NONE testosterone_6\NN\androgen.n.01|serum|and|determination (r_pobj) of_4\IN\entity.n.01|testosterone (r_prep) results_3\NNS\phenomenon.n.01|the|of|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_12\NNS\case.n.06|1,022|referred (l_acl) referred_13\VBD\think_of.v.04|because (l_prep) because_14\IN\entity.n.01|of|dysfunction (l_pobj) dysfunction_17\NN\pathology.n.02|erectile
D013739_D007172 NONE testosterone_5\NN\androgen.n.01| (r_compound) levels_6\NNS\property.n.02|the|other|low|testosterone (r_pobj) of_1\IN\entity.n.01|levels (r_prep) most_0\JJS\most.a.01|of (r_nsubj) seemed_7\VBD\be.v.01|most|result|. (l_xcomp) result_9\VB\phenomenon.n.01|to|from|because (l_prep) because_14\IN\entity.n.01|of|hormone|and|have (l_conj) have_24\VB\person.n.01|to|role (l_dobj) role_28\NN\duty.n.02|only|a|small|in (l_prep) in_29\IN\linear_unit.n.01|dysfunction (l_pobj) dysfunction_31\NN\pathology.n.02|erectile|(|improvement|)
D013739_D007172 NONE testosterone_6\NN\androgen.n.01|low|and|prolactin (r_pobj) of_4\IN\entity.n.01|testosterone (r_prep) effects_3\NNS\personal_property.n.01|of|in (l_prep) in_10\IN\linear_unit.n.01|dysfunction (l_pobj) dysfunction_12\NN\pathology.n.02|erectile
D013739_D020018 CID testosterone_5\NN\androgen.n.01|and|451 (r_pobj) for_4\IN\entity.n.01|testosterone (r_prep) screened_3\VBN\check.v.02|patient|was|for|screened|. (l_conj) screened_9\VBN\check.v.02|were|for|on (l_prep) on_12\IN\on.a.01|basis (l_pobj) basis_14\NN\foundation.n.01|the|of (l_prep) of_15\IN\entity.n.01|desire (l_pobj) desire_18\NN\feeling.n.01|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_22\NN\androgen.n.01|ng./ml (r_conj) gynecomastia_20\NN\abnormality.n.01|or|testosterone (r_conj) desire_18\NN\feeling.n.01|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_1\NN\androgen.n.01| (r_dobj) determining_0\VBG\determine.v.01|testosterone|in (l_prep) in_3\IN\linear_unit.n.01|only|cases (l_pobj) cases_4\NNS\happening.n.01|of (l_prep) of_5\IN\entity.n.01|desire (l_pobj) desire_8\NN\feeling.n.01|low|sexual|or|examination
D013739_D020018 CID testosterone_23\NN\androgen.n.01|low|,|including (r_pobj) with_21\IN\entity.n.01|testosterone (r_prep) cases_20\NNS\happening.n.01|the|with (r_pobj) of_18\IN\entity.n.01|cases (r_prep) %_17\NN\entity.n.01|40|of (r_dobj) missed_15\VBN\miss.v.01|determining|would|have|%|. (l_csubj) determining_0\VBG\determine.v.01|testosterone|in (l_prep) in_3\IN\linear_unit.n.01|only|cases (l_pobj) cases_4\NNS\happening.n.01|of (l_prep) of_5\IN\entity.n.01|desire (l_pobj) desire_8\NN\feeling.n.01|low|sexual|or|examination
D013739_D020018 CID testosterone_8\NN\androgen.n.01|years (r_nsubjpass) determined_10\VBN\determine.v.01|that|before|testosterone|be|in|but|measured (l_prep) in_12\IN\linear_unit.n.01|only|cases (l_pobj) cases_13\NNS\happening.n.01|of (l_prep) of_14\IN\entity.n.01|desire (l_pobj) desire_17\NN\feeling.n.01|low|sexual|and|examination
D013739_D020018 CID testosterone_14\NN\androgen.n.01|ng./ml (r_conj) gynecomastia_12\NN\abnormality.n.01|and/or|testosterone (r_conj) desire_10\NN\feeling.n.01|low|sexual|,|gynecomastia
D013739_D006177 NONE testosterone_5\NN\androgen.n.01|and|451 (r_pobj) for_4\IN\entity.n.01|testosterone (r_prep) screened_3\VBN\check.v.02|patient|was|for|screened|. (l_conj) screened_9\VBN\check.v.02|were|for|on (l_prep) on_12\IN\on.a.01|basis (l_pobj) basis_14\NN\foundation.n.01|the|of (l_prep) of_15\IN\entity.n.01|desire (l_pobj) desire_18\NN\feeling.n.01|low|sexual|,|gynecomastia (l_conj) gynecomastia_20\NN\abnormality.n.01|or|testosterone
D013739_D006177 NONE testosterone_22\NN\androgen.n.01|ng./ml (r_conj) gynecomastia_20\NN\abnormality.n.01|or|testosterone
D013739_D006177 NONE testosterone_14\NN\androgen.n.01|ng./ml (r_conj) gynecomastia_12\NN\abnormality.n.01|and/or|testosterone
C004648_D007006 NONE heptylate_5\NN\entity.n.01|testosterone|or|gonadotropin (l_conj) gonadotropin_9\NN\hormone.n.01|human|chorionic|for (l_prep) for_10\IN\entity.n.01|hypogonadism (l_pobj) hypogonadism_11\NN\incompetence.n.02|and|bromocriptine
C004648_D006966 NONE heptylate_5\NN\entity.n.01|testosterone|or|gonadotropin (l_conj) gonadotropin_9\NN\hormone.n.01|human|chorionic|for (l_prep) for_10\IN\entity.n.01|hypogonadism (l_pobj) hypogonadism_11\NN\incompetence.n.02|and|bromocriptine (l_conj) bromocriptine_13\NN\entity.n.01|for (l_prep) for_14\IN\entity.n.01|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN\entity.n.01|
D001971_D007006 NONE bromocriptine_13\NN\entity.n.01|for (r_conj) hypogonadism_11\NN\incompetence.n.02|and|bromocriptine
D001971_D006966 NONE bromocriptine_13\NN\entity.n.01|for (l_prep) for_14\IN\entity.n.01|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN\entity.n.01|
D013739_D010911 NONE testosterone_6\NN\androgen.n.01| (r_compound) determination_7\NN\discovery.n.01|testosterone (r_pobj) after_5\IN\after.s.01|determination (r_prep) discovered_4\VBN\spy.v.03|tumors|were|after|. (l_nsubjpass) tumors_2\NNS\growth.n.06|two|pituitary
D013739_D007027 NONE testosterone_5\NN\androgen.n.01| (r_compound) levels_6\NNS\property.n.02|the|other|low|testosterone (r_pobj) of_1\IN\entity.n.01|levels (r_prep) most_0\JJS\most.a.01|of (r_nsubj) seemed_7\VBD\be.v.01|most|result|. (l_xcomp) result_9\VB\phenomenon.n.01|to|from|because (l_prep) from_10\IN\entity.n.01|dysfunction (l_pobj) dysfunction_13\NN\pathology.n.02|nonorganic|hypothalamic
1987816
D008094_D011141 CID lithium_0\NN\metallic_element.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|lithium|- (r_amod) polyuria_3\NN\kidney_disease.n.01|induced
20619828
D002997_D001008 CID clomipramine_0\NNP\tricyclic.n.01| (r_compound) exposure_1\NN\vulnerability.n.02|clomipramine|in (r_nsubj) produced_5\VBD\make.v.03|exposure|changes|inflexibility|. (l_dobj) changes_10\NNS\happening.n.01|significant|behavioral|include (l_relcl) include_12\VBP\include.v.01|that|anxiety (l_dobj) anxiety_14\NN\psychological_state.n.01|enhanced|(|elevated|)
D002997_-1 NONE clomipramine_0\NNP\tricyclic.n.01| (r_compound) exposure_1\NN\vulnerability.n.02|clomipramine|in (r_nsubj) produced_5\VBD\make.v.03|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\rigidity.n.01|,|behavioral|(|perseveration|,|impairment
D002997_-1 NONE clomipramine_0\NNP\tricyclic.n.01| (r_compound) exposure_1\NN\vulnerability.n.02|clomipramine|in (r_nsubj) produced_5\VBD\make.v.03|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\rigidity.n.01|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN\change.n.01|working|memory|(|paradigm|,|hoarding (l_conj) hoarding_51\NN\signboard.n.01|,|and|dysfunction (l_conj) dysfunction_55\NN\pathology.n.02|corticostriatal
D002997_D008569 CID clomipramine_0\NNP\tricyclic.n.01| (r_compound) exposure_1\NN\vulnerability.n.02|clomipramine|in (r_nsubj) produced_5\VBD\make.v.03|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\rigidity.n.01|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN\change.n.01|working|memory|(|paradigm|,|hoarding
D002997_D060845 CID clomipramine_0\NNP\tricyclic.n.01| (r_compound) exposure_1\NN\vulnerability.n.02|clomipramine|in (r_nsubj) produced_5\VBD\make.v.03|exposure|changes|inflexibility|. (l_npadvmod) inflexibility_25\NN\rigidity.n.01|,|behavioral|(|perseveration|,|impairment (l_appos) impairment_41\NN\change.n.01|working|memory|(|paradigm|,|hoarding (l_conj) hoarding_51\NN\signboard.n.01|,|and|dysfunction
10704919
D013629_D006461 CID tamoxifen_6\NN\antagonist.n.03| (r_pobj) by_5\IN\by.r.01|tamoxifen (r_agent) induced_4\VBN\generate.v.01|hemolysis|by|related|. (l_nsubj) hemolysis_0\NNP\lysis.n.02|of
D013629_D006461 CID tam_0\NNP\cap.n.01| (r_nsubj) induces_1\VBZ\generate.v.01|tam|hemolysis|. (l_dobj) hemolysis_2\NN\lysis.n.02|of
D013629_D006461 CID tam_13\NNP\cap.n.01|12.5|microm (r_nsubj) induces_14\VBZ\generate.v.01|tam|hemolysis|. (r_conj) is_4\VBZ\be.v.01|extension|variable|,|but|induces (l_nsubj) extension_1\NN\delay.n.01|the|of (l_prep) of_2\IN\entity.n.01|hemolysis (l_pobj) hemolysis_3\NN\lysis.n.02|
D013629_D006461 CID tam_13\NNP\cap.n.01|12.5|microm (r_nsubj) induces_14\VBZ\generate.v.01|tam|hemolysis|. (l_dobj) hemolysis_16\NN\lysis.n.02|total|of
D013629_D006461 CID tam_4\NNP\cap.n.01| (r_pobj) of_3\IN\entity.n.01|tam (r_prep) effect_2\NN\phenomenon.n.01|the|hemolytic|of (l_amod) hemolytic_1\JJ\hemolytic.a.01|
D013629_D006461 CID tam_4\NNP\cap.n.01| (r_pobj) of_3\IN\entity.n.01|tam (r_prep) effect_2\NN\phenomenon.n.01|the|hemolytic|of (r_nsubjpass) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\tell.v.02|related (l_ccomp) related_42\VBN\think.v.03|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\lysis.n.02|induced
D013629_D006461 CID tam_36\NNP\cap.n.01| (r_npadvmod) induced_38\VBN\generate.v.01|tam|- (r_amod) hemolysis_39\NN\lysis.n.02|induced (r_nsubjpass) related_42\VBN\think.v.03|that|hemolysis|is|not|to (r_ccomp) indicating_34\VBG\tell.v.02|related (r_advcl) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\phenomenon.n.01|the|hemolytic|of (l_amod) hemolytic_1\JJ\hemolytic.a.01|
D013629_D006461 CID tam_36\NNP\cap.n.01| (r_npadvmod) induced_38\VBN\generate.v.01|tam|- (r_amod) hemolysis_39\NN\lysis.n.02|induced
D013629_D006461 CID tam_17\NNP\cap.n.01| (r_npadvmod) induced_19\VBN\generate.v.01|tam|- (r_amod) hemolysis_20\NN\lysis.n.02|induced
D013629_D006461 CID tam_3\NNP\cap.n.01| (r_pobj) by_2\IN\by.r.01|tam (r_agent) caused_1\VBN\make.v.03|by (r_acl) hemolysis_0\NNP\lysis.n.02|caused
D013629_D006461 CID tam_3\NNP\cap.n.01| (r_pobj) by_2\IN\by.r.01|tam (r_agent) caused_1\VBN\make.v.03|by (r_acl) hemolysis_0\NNP\lysis.n.02|caused (r_nsubjpass) preceded_6\VBN\predate.v.01|hemolysis|was|not|by|,|excluding|,|according|. (l_prep) excluding_18\VBG\extinguish.v.04|also|mechanism (l_pobj) mechanism_24\NN\chemical_process.n.01|a|osmotic|type|of (l_prep) of_25\IN\entity.n.01|hemolysis (l_pobj) hemolysis_26\NN\lysis.n.02|
D013629_D006461 CID tam_15\NNP\cap.n.01| (r_compound) incorporation_16\NN\consolidation.n.02|a|decreased|tam|in|and (r_pobj) to_12\IN\entity.n.01|incorporation (r_prep) related_11\VBN\think.v.03|that|protection|is|to (l_nsubjpass) protection_5\NN\activity.n.01|the|from|by (l_prep) from_6\IN\entity.n.01|hemolysis (l_pobj) hemolysis_7\NN\lysis.n.02|
D013629_D006461 CID tam_2\NNP\cap.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|tam|- (r_amod) results_6\NNS\phenomenon.n.01|therefore|,|induced|hemolysis|from|,|leading|. (l_compound) hemolysis_5\NN\lysis.n.02|
D013629_D001943 NONE tamoxifen_0\NNP\antagonist.n.03|tam|, (r_nsubj) induces_18\VBZ\generate.v.01|tamoxifen|drug|,|changes|. (l_nsubj) drug_7\NN\agent.n.03|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\inflict.v.01|widely|in (l_prep) in_11\IN\linear_unit.n.01|chemotherapy (l_pobj) chemotherapy_13\NN\therapy.n.01|the|of (l_prep) of_14\IN\entity.n.01|cancer (l_pobj) cancer_16\NN\malignant_tumor.n.01|breast
D013629_D001943 NONE tam_2\NNP\cap.n.01|(|) (r_appos) tamoxifen_0\NNP\antagonist.n.03|tam|, (r_nsubj) induces_18\VBZ\generate.v.01|tamoxifen|drug|,|changes|. (l_nsubj) drug_7\NN\agent.n.03|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\inflict.v.01|widely|in (l_prep) in_11\IN\linear_unit.n.01|chemotherapy (l_pobj) chemotherapy_13\NN\therapy.n.01|the|of (l_prep) of_14\IN\entity.n.01|cancer (l_pobj) cancer_16\NN\malignant_tumor.n.01|breast
D013629_D000743 CID tamoxifen_0\NNP\antagonist.n.03|tam|, (r_nsubj) induces_18\VBZ\generate.v.01|tamoxifen|drug|,|changes|. (l_dobj) changes_19\NNS\happening.n.01|in (l_prep) in_20\IN\linear_unit.n.01|shape (l_pobj) shape_23\NN\spatial_property.n.01|normal|discoid|of (l_prep) of_24\IN\entity.n.01|erythrocytes (l_pobj) erythrocytes_25\NNS\blood_cell.n.01|and|anemia (l_conj) anemia_28\NN\blood_disease.n.01|hemolytic
D013629_D000743 CID tam_2\NNP\cap.n.01|(|) (r_appos) tamoxifen_0\NNP\antagonist.n.03|tam|, (r_nsubj) induces_18\VBZ\generate.v.01|tamoxifen|drug|,|changes|. (l_dobj) changes_19\NNS\happening.n.01|in (l_prep) in_20\IN\linear_unit.n.01|shape (l_pobj) shape_23\NN\spatial_property.n.01|normal|discoid|of (l_prep) of_24\IN\entity.n.01|erythrocytes (l_pobj) erythrocytes_25\NNS\blood_cell.n.01|and|anemia (l_conj) anemia_28\NN\blood_disease.n.01|hemolytic
D013629_D000743 CID tam_6\NNP\cap.n.01| (r_pobj) of_5\IN\entity.n.01|tam (r_prep) effects_4\NNS\personal_property.n.01|the|of|on (r_dobj) evaluates_2\VBZ\evaluate.v.02|work|effects|,|attempting|. (l_advcl) attempting_12\VBG\act.v.01|identify (l_xcomp) identify_14\VB\determine.v.03|to|mechanisms (l_dobj) mechanisms_17\NNS\chemical_process.n.01|the|underlying|on|and|involvement (l_prep) on_18\IN\on.a.01|anemia (l_pobj) anemia_23\NN\blood_disease.n.01|induced|hemolytic
D013629_D000743 CID tam_19\NNP\cap.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|tam|- (r_amod) anemia_23\NN\blood_disease.n.01|induced|hemolytic
D013629_D000743 CID tam_13\NNP\cap.n.01| (r_pobj) by_12\IN\by.r.01|tam (r_agent) promoted_11\VBN\support.v.01|by (r_acl) stability_10\NN\steadiness.n.02|mechanical|promoted (r_dobj) decreased_8\VBD\change_magnitude.v.01|stability|,|resulting (l_conj) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|anemia (l_pobj) anemia_18\NN\blood_disease.n.01|hemolytic
D024502_D006461 NONE tocopherol_13\NN\antioxidant.n.01|alpha|-|(|t|) (r_pobj) of_10\IN\entity.n.01|tocopherol (r_prep) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\phenomenon.n.01|the|hemolytic|of (l_amod) hemolytic_1\JJ\hemolytic.a.01|
D024502_D006461 NONE tocopherol_13\NN\antioxidant.n.01|alpha|-|(|t|) (r_pobj) of_10\IN\entity.n.01|tocopherol (r_prep) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\tell.v.02|related (l_ccomp) related_42\VBN\think.v.03|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\lysis.n.02|induced
D024502_D006461 NONE t_17\NNP\pyrimidine.n.01|alpha|- (r_appos) tocopherol_13\NN\antioxidant.n.01|alpha|-|(|t|) (r_pobj) of_10\IN\entity.n.01|tocopherol (r_prep) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\phenomenon.n.01|the|hemolytic|of (l_amod) hemolytic_1\JJ\hemolytic.a.01|
D024502_D006461 NONE t_17\NNP\pyrimidine.n.01|alpha|- (r_appos) tocopherol_13\NN\antioxidant.n.01|alpha|-|(|t|) (r_pobj) of_10\IN\entity.n.01|tocopherol (r_prep) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\tell.v.02|related (l_ccomp) related_42\VBN\think.v.03|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\lysis.n.02|induced
D024502_D006461 NONE acetate_23\NN\salt.n.01|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\phenomenon.n.01|the|hemolytic|of (l_amod) hemolytic_1\JJ\hemolytic.a.01|
D024502_D006461 NONE acetate_23\NN\salt.n.01|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\tell.v.02|related (l_ccomp) related_42\VBN\think.v.03|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\lysis.n.02|induced
D024502_D006461 NONE tac_27\NNS\entity.n.01|alpha|- (r_appos) acetate_23\NN\salt.n.01|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\phenomenon.n.01|the|hemolytic|of (l_amod) hemolytic_1\JJ\hemolytic.a.01|
D024502_D006461 NONE tac_27\NNS\entity.n.01|alpha|- (r_appos) acetate_23\NN\salt.n.01|tocopherol|(|tac|) (r_conj) concentrations_9\NNS\property.n.02|low|of|and|acetate (r_pobj) by_7\IN\by.r.01|concentrations (r_agent) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\tell.v.02|related (l_ccomp) related_42\VBN\think.v.03|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\lysis.n.02|induced
D017665_D006461 NONE hydroxyl_32\NN\group.n.02|functional (r_dobj) inactivated_30\VBN\discharge.v.10|(|hydroxyl|) (r_parataxis) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_nsubjpass) effect_2\NN\phenomenon.n.01|the|hemolytic|of (l_amod) hemolytic_1\JJ\hemolytic.a.01|
D017665_D006461 NONE hydroxyl_32\NN\group.n.02|functional (r_dobj) inactivated_30\VBN\discharge.v.10|(|hydroxyl|) (r_parataxis) prevented_6\VBN\prevent.v.01|effect|is|by|inactivated|indicating|. (l_advcl) indicating_34\VBG\tell.v.02|related (l_ccomp) related_42\VBN\think.v.03|that|hemolysis|is|not|to (l_nsubjpass) hemolysis_39\NN\lysis.n.02|induced
D010100_D006461 NONE oxygen_7\NN\chemical_element.n.01| (r_compound) consumption_8\NN\bodily_process.n.01|oxygen|and|oxidation (r_pobj) of_6\IN\entity.n.01|consumption (r_prep) absence_5\NN\lack.n.01|of (r_pobj) by_4\IN\by.r.01|absence (r_agent) evidenced_3\VBN\testify.v.02|this|was|further|by|determined|. (l_conj) determined_13\VBN\determine.v.01|in (l_prep) in_14\IN\linear_unit.n.01|parallel (l_pobj) parallel_15\NN\similarity.n.01|with (l_prep) with_16\IN\entity.n.01|hemolysis (l_pobj) hemolysis_20\NN\lysis.n.02|induced
D011188_D006461 NONE k(+_11\NNP\entity.n.01| (r_pobj) of_10\IN\entity.n.01|k(+ (r_prep) leakage_9\NN\discharge.n.06|the|of|)|from (r_pobj) by_7\IN\by.r.01|leakage (r_agent) preceded_6\VBN\predate.v.01|hemolysis|was|not|by|,|excluding|,|according|. (l_nsubjpass) hemolysis_0\NNP\lysis.n.02|caused
D011188_D006461 NONE k(+_11\NNP\entity.n.01| (r_pobj) of_10\IN\entity.n.01|k(+ (r_prep) leakage_9\NN\discharge.n.06|the|of|)|from (r_pobj) by_7\IN\by.r.01|leakage (r_agent) preceded_6\VBN\predate.v.01|hemolysis|was|not|by|,|excluding|,|according|. (l_prep) excluding_18\VBG\extinguish.v.04|also|mechanism (l_pobj) mechanism_24\NN\chemical_process.n.01|a|osmotic|type|of (l_prep) of_25\IN\entity.n.01|hemolysis (l_pobj) hemolysis_26\NN\lysis.n.02|
D024505_D006461 NONE tocopherols_9\NNS\antioxidant.n.01| (r_pobj) by_8\IN\by.r.01|tocopherols (r_prep) protection_5\NN\activity.n.01|the|from|by (l_prep) from_6\IN\entity.n.01|hemolysis (l_pobj) hemolysis_7\NN\lysis.n.02|
8864707
D010672_D004827 NONE phenytoin_10\NNP\hydantoin.n.01| (r_compound) overdosages_11\NNS\entity.n.01|phenytoin (r_pobj) after_9\IN\after.s.01|overdosages (r_prep) volumetry_2\NN\entity.n.01|resonance|of|in|after|. (l_prep) in_6\IN\linear_unit.n.01|patients (l_pobj) patients_8\NNS\case.n.06|epileptic (l_amod) epileptic_7\JJ\sick_person.n.01|
D010672_D062787 CID phenytoin_10\NNP\hydantoin.n.01| (r_compound) overdosages_11\NNS\entity.n.01|phenytoin
D010672_D062787 CID phenytoin_3\JJ\hydantoin.n.01| (r_compound) overdosage_4\NN\entity.n.01|phenytoin
D010672_D062787 CID phenytoin_17\JJ\hydantoin.n.01| (r_compound) medication_18\NN\drug.n.01|phenytoin (r_nsubj) was_19\VBD\washington.n.02|that|medication|cause (r_ccomp) is_14\VBZ\be.v.01|it|unlikely|was (r_conj) result_8\VB\phenomenon.n.01|that|overdosage|does|not|necessarily|in|and|is (l_nsubj) overdosage_4\NN\entity.n.01|phenytoin
D010672_D002526 NONE phenytoin_11\JJ\hydantoin.n.01| (r_compound) medication_12\NN\drug.n.01|phenytoin|and|atrophy (l_conj) atrophy_15\NN\symptom.n.01|cerebellar|in
D010672_D002526 NONE phenytoin_3\JJ\hydantoin.n.01| (r_compound) overdosage_4\NN\entity.n.01|phenytoin (r_nsubj) result_8\VB\phenomenon.n.01|that|overdosage|does|not|necessarily|in|and|is (l_prep) in_9\IN\linear_unit.n.01|atrophy (l_pobj) atrophy_11\NN\symptom.n.01|cerebellar
D010672_D002526 NONE phenytoin_3\JJ\hydantoin.n.01| (r_compound) overdosage_4\NN\entity.n.01|phenytoin (r_nsubj) result_8\VB\phenomenon.n.01|that|overdosage|does|not|necessarily|in|and|is (l_conj) is_14\VBZ\be.v.01|it|unlikely|was (l_ccomp) was_19\VBD\washington.n.02|that|medication|cause (l_attr) cause_22\NN\origin.n.03|the|only|of (l_prep) of_23\IN\entity.n.01|atrophy (l_pobj) atrophy_25\NN\symptom.n.01|cerebellar|in
D010672_D002526 NONE phenytoin_17\JJ\hydantoin.n.01| (r_compound) medication_18\NN\drug.n.01|phenytoin (r_nsubj) was_19\VBD\washington.n.02|that|medication|cause (r_ccomp) is_14\VBZ\be.v.01|it|unlikely|was (r_conj) result_8\VB\phenomenon.n.01|that|overdosage|does|not|necessarily|in|and|is (l_prep) in_9\IN\linear_unit.n.01|atrophy (l_pobj) atrophy_11\NN\symptom.n.01|cerebellar
D010672_D002526 NONE phenytoin_17\JJ\hydantoin.n.01| (r_compound) medication_18\NN\drug.n.01|phenytoin (r_nsubj) was_19\VBD\washington.n.02|that|medication|cause (l_attr) cause_22\NN\origin.n.03|the|only|of (l_prep) of_23\IN\entity.n.01|atrophy (l_pobj) atrophy_25\NN\symptom.n.01|cerebellar|in
D010672_D012640 NONE phenytoin_15\JJ\hydantoin.n.01| (r_compound) levels_17\NNS\property.n.02|phenytoin|serum|and|volume (r_pobj) of_14\IN\entity.n.01|levels (r_prep) elevation_13\NN\rise.n.04|of (r_conj) duration_11\NN\time_period.n.01|seizure|,|elevation (l_compound) seizure_10\NN\attack.n.07|
14765563
D011803_D020922 NONE quinine_23\NN\antimalarial.n.01| (r_nsubj) is_24\VBZ\be.v.01|banned|,|quinine|available|. (l_advcl) banned_8\VBD\outlaw.v.01|although|administration|use|due (l_dobj) use_10\NN\activity.n.01|its|for (l_prep) for_11\IN\entity.n.01|cramps (l_pobj) cramps_14\NNS\symptom.n.01|nocturnal|leg
D011803_D002493 NONE quinine_7\NN\antimalarial.n.01| (r_dobj) containing_6\VBG\include.v.01|quinine (r_acl) products_5\NNS\commodity.n.01|containing (r_nsubj) produce_9\VB\food.n.02|that|products|may|complications|status|in (l_dobj) complications_11\NNS\hindrance.n.03|neurological|,|including|,
D011803_D003221 CID quinine_7\NN\antimalarial.n.01| (r_dobj) containing_6\VBG\include.v.01|quinine (r_acl) products_5\NNS\commodity.n.01|containing (r_nsubj) produce_9\VB\food.n.02|that|products|may|complications|status|in (l_dobj) complications_11\NNS\hindrance.n.03|neurological|,|including|, (l_prep) including_13\VBG\include.v.01|confusion (l_pobj) confusion_14\NN\disorder.n.03|
D011803_D012640 CID quinine_7\NN\antimalarial.n.01| (r_dobj) containing_6\VBG\include.v.01|quinine (r_acl) products_5\NNS\commodity.n.01|containing (r_nsubj) produce_9\VB\food.n.02|that|products|may|complications|status|in (l_dobj) status_18\NN\state.n.02|altered|mental|,|seizures|, (l_conj) seizures_20\NNS\attack.n.07|,|and|coma
D011803_D003128 CID quinine_7\NN\antimalarial.n.01| (r_dobj) containing_6\VBG\include.v.01|quinine (r_acl) products_5\NNS\commodity.n.01|containing (r_nsubj) produce_9\VB\food.n.02|that|products|may|complications|status|in (l_dobj) status_18\NN\state.n.02|altered|mental|,|seizures|, (l_conj) seizures_20\NNS\attack.n.07|,|and|coma (l_conj) coma_23\NN\unconsciousness.n.01|
12369736
D003042_D009069 CID cocaine_14\NN\hard_drug.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|cocaine|- (r_amod) hyperactivity_18\NN\disorder.n.01|the|induced|locomotor|in
D003042_D009069 CID cocaine_34\NN\hard_drug.n.01|in (r_pobj) by_33\IN\by.r.01|cocaine (r_agent) induced_32\VBN\generate.v.01|by (r_acl) hyperactivity_31\NN\disorder.n.01|the|locomotor|induced
D003042_D009069 CID cocaine_18\NN\hard_drug.n.01|, (r_pobj) to_17\IN\entity.n.01|cocaine (r_prep) prior_16\RB\superior.n.02|to (r_advmod) administered_11\VBN\manage.v.02|gr|shell|prior|attenuated|. (l_conj) attenuated_23\VBD\weaken.v.01|dependently|hyperactivity (l_dobj) hyperactivity_29\NN\disorder.n.01|the|induced|locomotor
D003042_D009069 CID cocaine_4\NN\hard_drug.n.01| (r_nsubj) induced_5\VBN\generate.v.01|that|cocaine (r_ccomp) indicate_2\VBP\tell.v.02|findings|induced|modified (l_ccomp) modified_8\VBN\change.v.02|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN\entity.n.01|
C103477_D009069 NONE 55562_1\CD\entity.n.01| (r_nummod) gr_0\NNP\entity.n.01|55562|side|, (r_nsubj) administered_11\VBN\manage.v.02|gr|shell|prior|attenuated|. (l_conj) attenuated_23\VBD\weaken.v.01|dependently|hyperactivity (l_dobj) hyperactivity_29\NN\disorder.n.01|the|induced|locomotor
C103477_D009069 NONE 55562_38\CD\entity.n.01| (r_nummod) gr_37\NNP\entity.n.01|55562 (r_appos) antagonist_35\NN\person.n.01|the|5-ht1b|receptor|(|gr|) (r_pobj) of_31\IN\entity.n.01|antagonist (r_prep) effects_30\NNS\personal_property.n.01|inhibitory|of (r_pobj) in_26\IN\linear_unit.n.01|effects (r_prep) consisting_25\VBG\exist.v.01|in (r_acl) modification_24\NN\change.n.03|core|,|this|consisting|and|agonist|respectively (r_conj) shell_17\NN\ammunition.n.01|the|accumbens|,|but|modification (r_pobj) into_14\IN\entity.n.01|shell (r_prep) microinjected_13\VBN\entity.n.01|into (r_acl) ligands_12\NNS\substance.n.07|5-ht1b|receptor|microinjected (r_pobj) by_9\IN\by.r.01|ligands (r_agent) modified_8\VBN\change.v.02|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN\entity.n.01|
C065046_D009069 CID 93129_44\CD\entity.n.01| (r_nummod) cp_43\NNP\entity.n.01|(|93129|) (r_appos) agonist_41\NN\protagonist.n.02|cp|, (r_conj) modification_24\NN\change.n.03|core|,|this|consisting|and|agonist|respectively (r_conj) shell_17\NN\ammunition.n.01|the|accumbens|,|but|modification (r_pobj) into_14\IN\entity.n.01|shell (r_prep) microinjected_13\VBN\entity.n.01|into (r_acl) ligands_12\NNS\substance.n.07|5-ht1b|receptor|microinjected (r_pobj) by_9\IN\by.r.01|ligands (r_agent) modified_8\VBN\change.v.02|hyperlocomotion|is|by|. (l_nsubjpass) hyperlocomotion_6\NN\entity.n.01|
17261653
D003000_D001919 CID clonidine_0\NNP\antihypertensive.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|clonidine|-|bradycardia|in (l_dobj) bradycardia_3\NN\cardiac_arrhythmia.n.01|
1601297
D003042_D009202 NONE cocaine_8\NN\hard_drug.n.01| (r_compound) abusers_9\NNS\wrongdoer.n.01|hospitalized|cocaine (r_pobj) in_5\IN\linear_unit.n.01|abusers (r_prep) injury_4\NN\ill_health.n.01|myocardial|in
D003042_D009202 NONE cocaine_3\NN\hard_drug.n.01| (r_compound) abusers_4\NNS\wrongdoer.n.01|the|cocaine (r_pobj) of_1\IN\entity.n.01|abusers (r_prep) eleven_0\CD\large_integer.n.01|of|and|none (r_nsubj) had_10\VBD\have.v.01|eleven|evidence|. (l_dobj) evidence_12\NN\information.n.02|ecg|of (l_prep) of_13\IN\entity.n.01|injury (l_pobj) injury_16\NN\ill_health.n.01|significant|myocardial|defined
D003042_D012559 NONE cocaine_7\NN\hard_drug.n.01| (r_npadvmod) abusing_9\VBG\treat.v.01|cocaine|- (r_amod) patients_10\NNS\case.n.06|99|abusing (r_pobj) of_5\IN\entity.n.01|patients (r_prep) ecg_3\NNP\graph.n.01|(|)|of (r_appos) electrocardiograms_1\NNS\graph.n.01|the|ecg (r_nsubjpass) compared_12\VBN\analyze.v.01|electrocardiograms|were|with|. (l_prep) with_13\IN\entity.n.01|ecgs (l_pobj) ecgs_15\NNS\graph.n.01|the|of (l_prep) of_16\IN\entity.n.01|controls (l_pobj) controls_19\NNS\power.n.01|50|schizophrenic (l_amod) schizophrenic_18\JJ\psychotic.n.01|
D003042_D009203 CID cocaine_3\NN\hard_drug.n.01| (r_compound) abusers_4\NNS\wrongdoer.n.01|the|cocaine (r_pobj) of_1\IN\entity.n.01|abusers (r_prep) eleven_0\CD\large_integer.n.01|of|and|none (r_nsubj) had_10\VBD\have.v.01|eleven|evidence|. (l_dobj) evidence_12\NN\information.n.02|ecg|of (l_prep) of_13\IN\entity.n.01|injury (l_pobj) injury_16\NN\ill_health.n.01|significant|myocardial|defined (l_acl) defined_17\VBN\be.v.01|as (l_prep) as_18\IN\chemical_element.n.01|infarction (l_pobj) infarction_20\NN\pathology.n.02|myocardial|,|ischemia
D003042_D007511 NONE cocaine_3\NN\hard_drug.n.01| (r_compound) abusers_4\NNS\wrongdoer.n.01|the|cocaine (r_pobj) of_1\IN\entity.n.01|abusers (r_prep) eleven_0\CD\large_integer.n.01|of|and|none (r_nsubj) had_10\VBD\have.v.01|eleven|evidence|. (l_dobj) evidence_12\NN\information.n.02|ecg|of (l_prep) of_13\IN\entity.n.01|injury (l_pobj) injury_16\NN\ill_health.n.01|significant|myocardial|defined (l_acl) defined_17\VBN\be.v.01|as (l_prep) as_18\IN\chemical_element.n.01|infarction (l_pobj) infarction_20\NN\pathology.n.02|myocardial|,|ischemia (l_conj) ischemia_22\NN\anemia.n.01|,|and|block
D003042_D002037 CID cocaine_3\NN\hard_drug.n.01| (r_compound) abusers_4\NNS\wrongdoer.n.01|the|cocaine (r_pobj) of_1\IN\entity.n.01|abusers (r_prep) eleven_0\CD\large_integer.n.01|of|and|none (r_nsubj) had_10\VBD\have.v.01|eleven|evidence|. (l_dobj) evidence_12\NN\information.n.02|ecg|of (l_prep) of_13\IN\entity.n.01|injury (l_pobj) injury_16\NN\ill_health.n.01|significant|myocardial|defined (l_acl) defined_17\VBN\be.v.01|as (l_prep) as_18\IN\chemical_element.n.01|infarction (l_pobj) infarction_20\NN\pathology.n.02|myocardial|,|ischemia (l_conj) ischemia_22\NN\anemia.n.01|,|and|block (l_conj) block_27\NN\artifact.n.01|bundle|branch
11279304
D018943_D066126 NONE anthracycline_7\NN\entity.n.01| (r_advmod) induced_9\VBN\generate.v.01|anthracycline|- (r_amod) cardiotoxicity_10\NN\entity.n.01|induced
D018943_D066126 NONE anthracyclines_0\NNS\entity.n.01| (r_nsubj) are_1\VBP\area_unit.n.01|anthracyclines|drugs|,|but|cause (l_conj) cause_9\VBP\origin.n.03|they|frequently|cardiotoxicity|. (l_dobj) cardiotoxicity_13\NN\entity.n.01|related
D018943_D066126 NONE anthracycline_4\NN\entity.n.01| (r_amod) therapy_5\NN\medical_care.n.01|conventional|anthracycline (r_pobj) of_2\IN\entity.n.01|therapy (r_prep) cardiotoxicity_1\NN\entity.n.01|the|of
D018943_D066126 NONE anthracycline_24\NN\entity.n.01| (r_advmod) induced_26\VBN\generate.v.01|anthracycline|- (r_amod) cardiotoxicity_27\NN\entity.n.01|induced|in
D018943_D066126 NONE anthracycline_16\NN\entity.n.01| (r_advmod) induced_18\VBN\generate.v.01|anthracycline|- (r_compound) cardiotoxicity_19\NN\entity.n.01|induced
D018943_D006331 NONE anthracycline_4\NN\entity.n.01| (r_amod) therapy_5\NN\medical_care.n.01|conventional|anthracycline (r_pobj) of_2\IN\entity.n.01|therapy (r_prep) cardiotoxicity_1\NN\entity.n.01|the|of (r_nsubj) highlights_6\VBZ\detail.n.02|cardiotoxicity|need|. (l_dobj) need_8\NN\condition.n.01|a|search (l_acl) search_10\VB\activity.n.01|to|for (l_prep) for_11\IN\entity.n.01|methods (l_pobj) methods_12\NNS\know-how.n.01|are (l_relcl) are_14\VBP\area_unit.n.01|that|sensitive (l_acomp) sensitive_16\JJ\psychic.n.01|highly|and|capable (l_conj) capable_18\JJ\capable.a.01|of (l_prep) of_19\IN\entity.n.01|predicting (l_pcomp) predicting_20\VBG\guess.v.02|dysfunction (l_dobj) dysfunction_22\NN\pathology.n.02|cardiac
D018943_D015470 NONE anthracycline_24\NN\entity.n.01| (r_advmod) induced_26\VBN\generate.v.01|anthracycline|- (r_amod) cardiotoxicity_27\NN\entity.n.01|induced|in (l_prep) in_28\IN\linear_unit.n.01|patients (l_pobj) patients_29\NNS\case.n.06|with (l_prep) with_30\IN\entity.n.01|leukemia (l_pobj) leukemia_32\NN\cancer.n.01|acute|treated
D003630_D066126 NONE daunorubicin_36\NN\entity.n.01|a|(|regimen (r_pobj) with_34\IN\entity.n.01|daunorubicin (r_prep) treated_33\VBN\interact.v.01|with (r_acl) leukemia_32\NN\cancer.n.01|acute|treated (r_pobj) with_30\IN\entity.n.01|leukemia (r_prep) patients_29\NNS\case.n.06|with (r_pobj) in_28\IN\linear_unit.n.01|patients (r_prep) cardiotoxicity_27\NN\entity.n.01|induced|in
D003630_D066126 NONE dnr)-containing_38\NN\entity.n.01| (r_compound) regimen_39\NNS\plan.n.01|dnr)-containing (r_appos) daunorubicin_36\NN\entity.n.01|a|(|regimen (r_pobj) with_34\IN\entity.n.01|daunorubicin (r_prep) treated_33\VBN\interact.v.01|with (r_acl) leukemia_32\NN\cancer.n.01|acute|treated (r_pobj) with_30\IN\entity.n.01|leukemia (r_prep) patients_29\NNS\case.n.06|with (r_pobj) in_28\IN\linear_unit.n.01|patients (r_prep) cardiotoxicity_27\NN\entity.n.01|induced|in
D003630_D015470 NONE daunorubicin_36\NN\entity.n.01|a|(|regimen (r_pobj) with_34\IN\entity.n.01|daunorubicin (r_prep) treated_33\VBN\interact.v.01|with (r_acl) leukemia_32\NN\cancer.n.01|acute|treated
D003630_D015470 NONE dnr)-containing_38\NN\entity.n.01| (r_compound) regimen_39\NNS\plan.n.01|dnr)-containing (r_appos) daunorubicin_36\NN\entity.n.01|a|(|regimen (r_pobj) with_34\IN\entity.n.01|daunorubicin (r_prep) treated_33\VBN\interact.v.01|with (r_acl) leukemia_32\NN\cancer.n.01|acute|treated
D003630_D015470 NONE dnr_9\NNP\entity.n.01| (r_npadvmod) containing_11\VBG\include.v.01|dnr|- (r_amod) regimen_12\NN\plan.n.01|a|containing (r_pobj) with_7\IN\entity.n.01|regimen (r_prep) treated_6\VBN\interact.v.01|patients|were|with|. (l_nsubjpass) patients_1\NNS\case.n.06|thirteen|with (l_prep) with_2\IN\entity.n.01|leukemia (l_pobj) leukemia_4\NN\cancer.n.01|acute
D003630_D006333 CID dnr_16\NNP\entity.n.01| (r_pobj) given_15\VBN\assumption.n.02|dnr (r_acl) failure_14\NN\nonaccomplishment.n.01|heart|given
3341566
D009599_D006470 NONE nitroprusside_10\RB\entity.n.01| (r_advmod) induced_12\VBN\generate.v.01|nitroprusside|- (r_amod) hypotension_13\NN\cardiovascular_disease.n.01|sodium|induced|in (r_pobj) during_8\IN\entity.n.01|hypotension (r_prep) than_7\IN\entity.n.01|during (r_prep) is_3\VBZ\be.v.01|variation|greater|during|than|. (l_prep) during_5\IN\entity.n.01|hemorrhage (l_pobj) hemorrhage_6\NN\injury.n.01|
D009599_D006470 NONE nitroprusside_28\NN\entity.n.01|n (r_advcl) decreased_4\VBN\change_magnitude.v.01|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\entity.n.01|minutes (l_pobj) minutes_11\NNS\written_record.n.01|30|by (l_prep) by_13\IN\by.r.01|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\injury.n.01|hem
D009599_D006470 NONE nitroprusside_28\NN\entity.n.01|n (r_advcl) decreased_4\VBN\change_magnitude.v.01|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\entity.n.01|minutes (l_pobj) minutes_11\NNS\written_record.n.01|30|by (l_prep) by_13\IN\by.r.01|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\injury.n.01|hem (l_appos) hem_16\NNP\edge.n.06|(|,|n|7|)
D009599_D006470 NONE snp_30\NNP\polymorphism.n.01| (r_dep) n_32\CC\chemical_element.n.01|(|snp|,|7|) (r_npadvmod) nitroprusside_28\NN\entity.n.01|n (r_advcl) decreased_4\VBN\change_magnitude.v.01|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\entity.n.01|minutes (l_pobj) minutes_11\NNS\written_record.n.01|30|by (l_prep) by_13\IN\by.r.01|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\injury.n.01|hem
D009599_D006470 NONE snp_30\NNP\polymorphism.n.01| (r_dep) n_32\CC\chemical_element.n.01|(|snp|,|7|) (r_npadvmod) nitroprusside_28\NN\entity.n.01|n (r_advcl) decreased_4\VBN\change_magnitude.v.01|pressure|was|to|for|nitroprusside|. (l_prep) for_9\IN\entity.n.01|minutes (l_pobj) minutes_11\NNS\written_record.n.01|30|by (l_prep) by_13\IN\by.r.01|either|hemorrhage|or|by (l_pobj) hemorrhage_14\NN\injury.n.01|hem (l_appos) hem_16\NNP\edge.n.06|(|,|n|7|)
D009599_D006470 NONE snp_21\NNP\polymorphism.n.01| (r_compound) group_22\NN\abstraction.n.06|the|snp (r_pobj) in_19\IN\linear_unit.n.01|group (r_prep) that_18\DT\entity.n.01|in (r_pobj) with_17\IN\entity.n.01|that (r_prep) compared_16\VBN\analyze.v.01|with (r_prep) higher_15\RBR\higher.s.01|compared (r_acomp) was_8\VBD\washington.n.02|during|output|lower|higher|. (l_prep) during_0\IN\entity.n.01|hypotension (l_pobj) hypotension_4\NN\cardiovascular_disease.n.01|induced (l_amod) induced_3\VBN\generate.v.01|hem|- (l_npadvmod) hem_1\NNP\edge.n.06|
D009599_D006470 NONE snp_17\NNP\polymorphism.n.01| (r_compound) group_18\NN\abstraction.n.06|the|snp (r_pobj) in_15\IN\linear_unit.n.01|group (r_prep) hg_14\NNP\metallic_element.n.01|in (r_appos) mm_13\NN\metric_linear_unit.n.01|+/-|2.0|hg|p (r_pobj) with_9\IN\entity.n.01|mm (r_prep) compared_8\VBN\analyze.v.01|with (r_prep) hg_2\NNP\metallic_element.n.01|mm|in|,|compared|. (l_prep) in_3\IN\linear_unit.n.01|group (l_pobj) group_6\NN\abstraction.n.06|the|hem (l_compound) hem_5\NNP\edge.n.06|
D009599_D006470 NONE snp_7\NNP\polymorphism.n.01| (r_compound) groups_8\NNS\abstraction.n.06|hem|snp (l_nmod) hem_5\NNP\edge.n.06|the|and
D009599_D007022 CID nitroprusside_10\RB\entity.n.01| (r_advmod) induced_12\VBN\generate.v.01|nitroprusside|- (r_amod) hypotension_13\NN\cardiovascular_disease.n.01|sodium|induced|in
D009599_D007022 CID snp_21\NNP\polymorphism.n.01| (r_compound) group_22\NN\abstraction.n.06|the|snp (r_pobj) in_19\IN\linear_unit.n.01|group (r_prep) that_18\DT\entity.n.01|in (r_pobj) with_17\IN\entity.n.01|that (r_prep) compared_16\VBN\analyze.v.01|with (r_prep) higher_15\RBR\higher.s.01|compared (r_acomp) was_8\VBD\washington.n.02|during|output|lower|higher|. (l_prep) during_0\IN\entity.n.01|hypotension (l_pobj) hypotension_4\NN\cardiovascular_disease.n.01|induced
D009599_D007022 CID snp_7\NNP\polymorphism.n.01| (r_compound) groups_8\NNS\abstraction.n.06|hem|snp (r_pobj) in_3\IN\linear_unit.n.01|groups (r_prep) hg_2\NNP\metallic_element.n.01|mm|in|,|respectively|,|during|p|. (l_prep) during_12\IN\entity.n.01|hypotension (l_pobj) hypotension_13\NN\cardiovascular_disease.n.01|
12695819
D016559_D020258 NONE tacrolimus_7\NN\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|tacrolimus|- (r_amod) neurotoxicity_10\NN\entity.n.01|induced|in
D016559_D020258 NONE tacrolimus_15\NN\entity.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|tacrolimus|- (r_amod) neurotoxicity_18\NN\entity.n.01|induced
D016559_D009422 NONE tacrolimus_17\NNS\entity.n.01|developed (l_relcl) developed_19\VBD\create.v.02|who|complications (l_dobj) complications_21\NNS\hindrance.n.03|neurologic
1592014
D003042_D012640 CID cocaine_4\NN\hard_drug.n.01| (r_compound) metabolite_5\NN\substance.n.07|cocaine (r_amod) benzoylecgonine_6\NN\entity.n.01|the|metabolite|in (r_pobj) by_2\IN\by.r.01|benzoylecgonine (r_agent) induced_1\VBN\generate.v.01|seizures|by|. (l_nsubj) seizures_0\NNS\attack.n.07|
D003042_D012640 CID cocaine_8\NN\hard_drug.n.01| (r_pobj) of_7\IN\entity.n.01|cocaine (r_prep) t1/2_5\NN\entity.n.01|(|)|of (r_appos) life_3\NN\being.n.01|half|-|t1/2 (r_nsubj) is_9\VBZ\be.v.01|the|life|short|,|but|occur (l_conj) occur_29\VB\happen.v.01|some|can|hours|. (l_nsubj) some_14\DT\some.a.01|of (l_prep) of_15\IN\entity.n.01|consequences (l_pobj) consequences_17\NNS\phenomenon.n.01|the|of (l_prep) of_18\IN\entity.n.01|use (l_pobj) use_20\NN\activity.n.01|its|,|as|, (l_prep) as_23\IN\chemical_element.n.01|such|seizures (l_pobj) seizures_24\NNS\attack.n.07|and|strokes
D003042_D012640 CID cocaine_9\NN\hard_drug.n.01|, (r_pobj) of_8\IN\entity.n.01|cocaine (r_prep) metabolite_7\NN\substance.n.07|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN\entity.n.01|metabolite (r_prep) potential_3\NN\possibility.n.02|the|of (r_dobj) evaluated_1\VBD\evaluate.v.02|we|potential|,|cause|. (l_advcl) cause_17\VB\origin.n.03|to|seizures (l_dobj) seizures_18\NNS\attack.n.07|
D003042_D012640 CID cocaine_19\NN\hard_drug.n.01| (r_pobj) of_18\IN\entity.n.01|cocaine (r_prep) amounts_17\NNS\assets.n.01|equimolar|of (r_pobj) by_15\IN\by.r.01|amounts (r_agent) induced_14\VBN\generate.v.01|by (r_acl) those_13\DT\entity.n.01|induced (r_pobj) than_12\IN\entity.n.01|those (r_prep) latencies_11\NNS\time_interval.n.01|longer|than (r_dobj) had_8\VBD\have.v.01|latencies (r_conj) occurred_4\VBD\happen.v.01|seizures|frequently|and|had|. (l_nsubj) seizures_3\NNS\attack.n.07|induced
D003042_D012640 CID cocaine_1\NN\hard_drug.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|cocaine|- (r_amod) seizures_4\NNS\attack.n.07|induced
D003042_D012640 CID cocaine_15\NN\hard_drug.n.01| (r_npadvmod) injected_17\VBN\administer.v.04|cocaine|- (r_amod) animals_18\NNS\organism.n.01|injected (r_pobj) than_14\IN\entity.n.01|animals (r_prep) activity_13\NN\act.n.02|more|locomotor|than (r_dobj) had_9\VBD\have.v.01|rats|activity|without|. (l_nsubj) rats_3\NNS\rodent.n.01|injected|have (l_relcl) have_7\VB\person.n.01|that|did|not|seizures (l_dobj) seizures_8\NNS\attack.n.07|
D003042_D012640 CID cocaine_15\NN\hard_drug.n.01| (r_npadvmod) injected_17\VBN\administer.v.04|cocaine|- (r_amod) animals_18\NNS\organism.n.01|injected (r_pobj) than_14\IN\entity.n.01|animals (r_prep) activity_13\NN\act.n.02|more|locomotor|than (r_dobj) had_9\VBD\have.v.01|rats|activity|without|. (l_prep) without_19\IN\entity.n.01|seizures (l_pobj) seizures_20\NNS\attack.n.07|
D003042_D012640 CID cocaine-_3\NN\entity.n.01|and|induced (r_nmod) seizures_8\NNS\attack.n.07|cocaine-
D003042_D012640 CID cocaine-_3\NN\entity.n.01|and|induced (r_nmod) seizures_8\NNS\attack.n.07|cocaine- (r_nsubj) differ_9\VBP\differ.v.01|seizures|in (r_relcl) finding_1\NN\discovery.n.01|the|differ (r_nsubj) suggests_13\VBZ\declare.v.01|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\chemical_process.n.01|one|for (l_prep) for_18\IN\entity.n.01|seizures (l_pobj) seizures_22\NNS\attack.n.07|induced
D003042_D012640 CID cocaine_19\NN\hard_drug.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|cocaine|- (r_amod) seizures_22\NNS\attack.n.07|induced (r_pobj) for_18\IN\entity.n.01|seizures (r_prep) mechanism_17\NN\chemical_process.n.01|one|for (r_dobj) suggests_13\VBZ\declare.v.01|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\discovery.n.01|the|differ (l_relcl) differ_9\VBP\differ.v.01|seizures|in (l_nsubj) seizures_8\NNS\attack.n.07|cocaine-
D003042_D012640 CID cocaine_19\NN\hard_drug.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|cocaine|- (r_amod) seizures_22\NNS\attack.n.07|induced
D003042_D012640 CID cocaine_29\NN\hard_drug.n.01| (r_compound) metabolite_30\NN\substance.n.07|a|cocaine (r_pobj) of_27\IN\entity.n.01|metabolite (r_prep) importance_26\NN\value.n.02|the|of (r_dobj) emphasizes_24\VBZ\express.v.01|importance|,|be (r_conj) suggests_13\VBZ\declare.v.01|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\discovery.n.01|the|differ (l_relcl) differ_9\VBP\differ.v.01|seizures|in (l_nsubj) seizures_8\NNS\attack.n.07|cocaine-
D003042_D012640 CID cocaine_29\NN\hard_drug.n.01| (r_compound) metabolite_30\NN\substance.n.07|a|cocaine (r_pobj) of_27\IN\entity.n.01|metabolite (r_prep) importance_26\NN\value.n.02|the|of (r_dobj) emphasizes_24\VBZ\express.v.01|importance|,|be (r_conj) suggests_13\VBZ\declare.v.01|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\chemical_process.n.01|one|for (l_prep) for_18\IN\entity.n.01|seizures (l_pobj) seizures_22\NNS\attack.n.07|induced
C005618_D012640 CID benzoylecgonine_6\NN\entity.n.01|the|metabolite|in (r_pobj) by_2\IN\by.r.01|benzoylecgonine (r_agent) induced_1\VBN\generate.v.01|seizures|by|. (l_nsubj) seizures_0\NNS\attack.n.07|
C005618_D012640 CID benzoylecgonine_11\NN\entity.n.01| (r_appos) metabolite_7\NN\substance.n.07|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN\entity.n.01|metabolite (r_prep) potential_3\NN\possibility.n.02|the|of (r_dobj) evaluated_1\VBD\evaluate.v.02|we|potential|,|cause|. (l_advcl) cause_17\VB\origin.n.03|to|seizures (l_dobj) seizures_18\NNS\attack.n.07|
C005618_D012640 CID be_13\VB\metallic_element.n.01|(|) (r_appos) metabolite_7\NN\substance.n.07|the|major|of|benzoylecgonine|be (r_pobj) of_4\IN\entity.n.01|metabolite (r_prep) potential_3\NN\possibility.n.02|the|of (r_dobj) evaluated_1\VBD\evaluate.v.02|we|potential|,|cause|. (l_advcl) cause_17\VB\origin.n.03|to|seizures (l_dobj) seizures_18\NNS\attack.n.07|
C005618_D012640 CID be_0\VB\metallic_element.n.01| (r_advmod) induced_2\VBN\generate.v.01|be|- (r_amod) seizures_3\NNS\attack.n.07|induced
C005618_D012640 CID be_23\NNP\metallic_element.n.01| (r_pobj) by_22\IN\by.r.01|be (r_agent) induced_21\VBN\generate.v.01|by (r_acl) those_20\DT\entity.n.01|induced (r_nsubj) were_24\VBD\be.v.01|characterized|,|those|multiple|,|and|resulted|. (l_advcl) characterized_7\VBN\remember.v.02|whereas|seizures|were|best|as|and|resulted (l_nsubjpass) seizures_4\NNS\attack.n.07|induced
C005618_D012640 CID be_0\VB\metallic_element.n.01| (r_advmod) injected_2\VBN\administer.v.04|be|- (r_amod) rats_3\NNS\rodent.n.01|injected|have (l_relcl) have_7\VB\person.n.01|that|did|not|seizures (l_dobj) seizures_8\NNS\attack.n.07|
C005618_D012640 CID be_0\VB\metallic_element.n.01| (r_advmod) injected_2\VBN\administer.v.04|be|- (r_amod) rats_3\NNS\rodent.n.01|injected|have (r_nsubj) had_9\VBD\have.v.01|rats|activity|without|. (l_prep) without_19\IN\entity.n.01|seizures (l_pobj) seizures_20\NNS\attack.n.07|
C005618_D012640 CID be_5\VB\metallic_element.n.01| (r_advmod) induced_7\VBN\generate.v.01|be|- (r_conj) cocaine-_3\NN\entity.n.01|and|induced (r_nmod) seizures_8\NNS\attack.n.07|cocaine-
C005618_D012640 CID be_5\VB\metallic_element.n.01| (r_advmod) induced_7\VBN\generate.v.01|be|- (r_conj) cocaine-_3\NN\entity.n.01|and|induced (r_nmod) seizures_8\NNS\attack.n.07|cocaine- (r_nsubj) differ_9\VBP\differ.v.01|seizures|in (r_relcl) finding_1\NN\discovery.n.01|the|differ (r_nsubj) suggests_13\VBZ\declare.v.01|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\chemical_process.n.01|one|for (l_prep) for_18\IN\entity.n.01|seizures (l_pobj) seizures_22\NNS\attack.n.07|induced
C005618_D012640 CID be_32\VB\metallic_element.n.01| (r_conj) emphasizes_24\VBZ\express.v.01|importance|,|be (r_conj) suggests_13\VBZ\declare.v.01|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\discovery.n.01|the|differ (l_relcl) differ_9\VBP\differ.v.01|seizures|in (l_nsubj) seizures_8\NNS\attack.n.07|cocaine-
C005618_D012640 CID be_32\VB\metallic_element.n.01| (r_conj) emphasizes_24\VBZ\express.v.01|importance|,|be (r_conj) suggests_13\VBZ\declare.v.01|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_17\NN\chemical_process.n.01|one|for (l_prep) for_18\IN\entity.n.01|seizures (l_pobj) seizures_22\NNS\attack.n.07|induced
D003042_D020521 NONE cocaine_8\NN\hard_drug.n.01| (r_pobj) of_7\IN\entity.n.01|cocaine (r_prep) t1/2_5\NN\entity.n.01|(|)|of (r_appos) life_3\NN\being.n.01|half|-|t1/2 (r_nsubj) is_9\VBZ\be.v.01|the|life|short|,|but|occur (l_conj) occur_29\VB\happen.v.01|some|can|hours|. (l_nsubj) some_14\DT\some.a.01|of (l_prep) of_15\IN\entity.n.01|consequences (l_pobj) consequences_17\NNS\phenomenon.n.01|the|of (l_prep) of_18\IN\entity.n.01|use (l_pobj) use_20\NN\activity.n.01|its|,|as|, (l_prep) as_23\IN\chemical_element.n.01|such|seizures (l_pobj) seizures_24\NNS\attack.n.07|and|strokes (l_conj) strokes_26\NNS\maneuver.n.03|
D003042_D003643 NONE cocaine_1\NN\hard_drug.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|cocaine|- (r_amod) seizures_4\NNS\attack.n.07|induced (r_nsubjpass) characterized_7\VBN\remember.v.02|whereas|seizures|were|best|as|and|resulted (l_conj) resulted_16\VBD\prove.v.01|in (l_prep) in_17\IN\linear_unit.n.01|death (l_pobj) death_18\NN\change.n.01|
D003042_D003643 NONE cocaine_1\NN\hard_drug.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|cocaine|- (r_amod) seizures_4\NNS\attack.n.07|induced (r_nsubjpass) characterized_7\VBN\remember.v.02|whereas|seizures|were|best|as|and|resulted (r_advcl) were_24\VBD\be.v.01|characterized|,|those|multiple|,|and|resulted|. (l_conj) resulted_36\VBD\prove.v.01|rarely|in (l_prep) in_37\IN\linear_unit.n.01|death (l_pobj) death_38\NN\change.n.01|
C005618_D003643 NONE be_23\NNP\metallic_element.n.01| (r_pobj) by_22\IN\by.r.01|be (r_agent) induced_21\VBN\generate.v.01|by (r_acl) those_20\DT\entity.n.01|induced (r_nsubj) were_24\VBD\be.v.01|characterized|,|those|multiple|,|and|resulted|. (l_advcl) characterized_7\VBN\remember.v.02|whereas|seizures|were|best|as|and|resulted (l_conj) resulted_16\VBD\prove.v.01|in (l_prep) in_17\IN\linear_unit.n.01|death (l_pobj) death_18\NN\change.n.01|
C005618_D003643 NONE be_23\NNP\metallic_element.n.01| (r_pobj) by_22\IN\by.r.01|be (r_agent) induced_21\VBN\generate.v.01|by (r_acl) those_20\DT\entity.n.01|induced (r_nsubj) were_24\VBD\be.v.01|characterized|,|those|multiple|,|and|resulted|. (l_conj) resulted_36\VBD\prove.v.01|rarely|in (l_prep) in_37\IN\linear_unit.n.01|death (l_pobj) death_38\NN\change.n.01|
18619688
D004317_D003643 NONE adriamycin_0\NNP\entity.n.01| (r_advmod) induced_2\VBN\generate.v.01|adriamycin|- (r_amod) death_5\NN\change.n.01|induced|cardiomyocyte
D004317_D003643 NONE adriamycin_17\NNS\entity.n.01| (r_pobj) by_16\IN\by.r.01|adriamycin (r_agent) induced_15\VBN\generate.v.01|by (r_advcl) plays_3\VBZ\dramatic_composition.n.01|death|role|in|induced|. (l_nsubj) death_2\NN\change.n.01|autophagic|cardiomyocyte
D004317_D006333 CID adriamycin_0\NNP\entity.n.01| (r_advmod) induced_2\VBN\generate.v.01|adriamycin|- (r_amod) death_5\NN\change.n.01|induced|cardiomyocyte (r_nsubj) plays_6\VBZ\dramatic_composition.n.01|death|role|in|. (l_prep) in_10\IN\linear_unit.n.01|model (l_pobj) model_13\NN\hypothesis.n.02|a|rat|of (l_prep) of_14\IN\entity.n.01|failure (l_pobj) failure_16\NN\nonaccomplishment.n.01|heart
D004317_D006333 CID adriamycin_7\NNS\entity.n.01| (r_pobj) by_6\IN\by.r.01|adriamycin (r_agent) induced_5\VBN\generate.v.01|by (r_acl) failure_4\NN\nonaccomplishment.n.01|mechanisms|underlying|heart|induced
D004317_D006333 CID adriamycin_20\NNS\entity.n.01| (r_pobj) by_19\IN\by.r.01|adriamycin (r_agent) induced_18\VBN\generate.v.01|by (r_acl) progression_14\NN\series.n.01|the|of|induced (l_prep) of_15\IN\entity.n.01|failure (l_pobj) failure_17\NN\nonaccomplishment.n.01|heart
D004317_D006333 CID adriamycin_20\NNS\entity.n.01| (r_pobj) by_19\IN\by.r.01|adriamycin (r_agent) induced_18\VBN\generate.v.01|by (r_acl) progression_14\NN\series.n.01|the|of|induced (r_pobj) in_12\IN\linear_unit.n.01|progression (r_prep) involved_11\VBN\refer.v.02|whether|autophagy|was|in (r_ccomp) investigate_7\VB\analyze.v.01|to|involved|,|develop (l_advcl) develop_26\VB\create.v.02|so|that|we|can|strategy (l_dobj) strategy_30\NN\plan_of_action.n.01|a|novel|treatment|for (l_prep) for_31\IN\entity.n.01|failure (l_pobj) failure_33\NN\nonaccomplishment.n.01|heart
D004317_D006333 CID adriamycin_23\NNS\entity.n.01| (r_pobj) by_22\IN\by.r.01|adriamycin (r_agent) induced_21\VBN\generate.v.01|by (r_acl) model_18\NN\hypothesis.n.02|a|heart|failure|of|induced (l_compound) failure_17\NN\nonaccomplishment.n.01|
D004317_D006333 CID adriamycin_17\NNS\entity.n.01| (r_pobj) by_16\IN\by.r.01|adriamycin (r_agent) induced_15\VBN\generate.v.01|by (r_advcl) plays_3\VBZ\dramatic_composition.n.01|death|role|in|induced|. (l_prep) in_7\IN\linear_unit.n.01|pathogenesis (l_pobj) pathogenesis_9\NN\pathologic_process.n.01|the|of (l_prep) of_10\IN\entity.n.01|failure (l_pobj) failure_12\NN\nonaccomplishment.n.01|heart|in
D004317_D006333 CID adriamycin_13\NNS\entity.n.01| (r_pobj) by_12\IN\by.r.01|adriamycin (r_agent) caused_11\VBN\make.v.03|by|via (r_acl) failure_10\NN\nonaccomplishment.n.01|heart|caused
C025946_D006333 NONE 3-methyladenine_2\LS\entity.n.01|3ma (r_appos) methods_0\NNS\know-how.n.01|:|3-methyladenine|, (r_nsubjpass) used_13\VBN\use.v.01|methods|inhibitor|was|in|. (l_prep) in_14\IN\linear_unit.n.01|model (l_pobj) model_18\NN\hypothesis.n.02|a|heart|failure|of|induced (l_compound) failure_17\NN\nonaccomplishment.n.01|
C025946_D006333 NONE 3ma_4\VBN\entity.n.01|(|) (r_appos) 3-methyladenine_2\LS\entity.n.01|3ma (r_appos) methods_0\NNS\know-how.n.01|:|3-methyladenine|, (r_nsubjpass) used_13\VBN\use.v.01|methods|inhibitor|was|in|. (l_prep) in_14\IN\linear_unit.n.01|model (l_pobj) model_18\NN\hypothesis.n.02|a|heart|failure|of|induced (l_compound) failure_17\NN\nonaccomplishment.n.01|
18221780
D016202_D010146 NONE nmda_3\NNP\entity.n.01| (r_compound) enhancement_5\NN\improvement.n.02|nmda|antagonist|of (r_pobj) in_2\IN\linear_unit.n.01|enhancement (r_prep) differences_1\NNS\quality.n.01|sex|in|in|:|comparisons|. (l_prep) in_9\IN\linear_unit.n.01|model (l_pobj) model_12\NN\hypothesis.n.02|a|capsaicin|of (l_prep) of_13\IN\entity.n.01|pain (l_pobj) pain_15\NN\symptom.n.01|persistent
D016202_D010146 NONE nmda_9\NNP\entity.n.01| (r_compound) antagonists_10\NNS\person.n.01|nmda|and|morphine (r_pobj) between_8\IN\between.r.01|antagonists (r_prep) interaction_7\NN\action.n.01|a|dimorphic|between|in (l_prep) in_13\IN\linear_unit.n.01|model (l_pobj) model_17\NN\hypothesis.n.02|a|persistent|pain|distinguished (l_compound) pain_16\NN\symptom.n.01|
D016202_D059787 NONE nmda_3\NNP\entity.n.01| (r_compound) enhancement_5\NN\improvement.n.02|nmda|antagonist|of (r_pobj) in_2\IN\linear_unit.n.01|enhancement (r_prep) differences_1\NNS\quality.n.01|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS\examination.n.01|to (l_prep) to_18\IN\entity.n.01|models (l_pobj) models_20\NNS\hypothesis.n.02|two|of (l_prep) of_21\IN\entity.n.01|pain (l_pobj) pain_23\NN\symptom.n.01|acute
D016202_D059787 NONE aspartate_11\NNP\entity.n.01|d|- (r_nmod) antagonists_15\NNS\person.n.01|methyl|aspartate|(|nmda|) (r_nsubj) enhance_16\VBP\intensify.v.02|in|antagonists|effects|to|. (l_prep) in_0\IN\linear_unit.n.01|models|, (l_pobj) models_3\NNS\hypothesis.n.02|acute|pain (l_compound) pain_2\NN\symptom.n.01|
D016202_D059787 NONE nmda_13\NNP\entity.n.01| (r_nmod) antagonists_15\NNS\person.n.01|methyl|aspartate|(|nmda|) (r_nsubj) enhance_16\VBP\intensify.v.02|in|antagonists|effects|to|. (l_prep) in_0\IN\linear_unit.n.01|models|, (l_pobj) models_3\NNS\hypothesis.n.02|acute|pain (l_compound) pain_2\NN\symptom.n.01|
D016202_D059787 NONE nmda_9\NNP\entity.n.01| (r_compound) antagonists_10\NNS\person.n.01|nmda|and|morphine (r_pobj) between_8\IN\between.r.01|antagonists (r_prep) interaction_7\NN\action.n.01|a|dimorphic|between|in (l_prep) in_13\IN\linear_unit.n.01|model (l_pobj) model_17\NN\hypothesis.n.02|a|persistent|pain|distinguished (l_relcl) distinguished_21\VBN\identify.v.01|that|can|be|from (l_prep) from_22\IN\entity.n.01|those (l_pobj) those_23\DT\entity.n.01|observed (l_acl) observed_24\VBN\spy.v.03|in (l_prep) in_25\IN\linear_unit.n.01|models (l_pobj) models_28\NNS\hypothesis.n.02|acute|pain (l_compound) pain_27\NN\symptom.n.01|
D009020_D010146 NONE morphine_7\NN\analgesic.n.01| (r_compound) antihyperalgesia_8\NN\entity.n.01|morphine (r_pobj) of_6\IN\entity.n.01|antihyperalgesia (r_prep) enhancement_5\NN\improvement.n.02|nmda|antagonist|of (r_pobj) in_2\IN\linear_unit.n.01|enhancement (r_prep) differences_1\NNS\quality.n.01|sex|in|in|:|comparisons|. (l_prep) in_9\IN\linear_unit.n.01|model (l_pobj) model_12\NN\hypothesis.n.02|a|capsaicin|of (l_prep) of_13\IN\entity.n.01|pain (l_pobj) pain_15\NN\symptom.n.01|persistent
D009020_D010146 NONE morphine_12\NN\analgesic.n.01| (r_conj) antagonists_10\NNS\person.n.01|nmda|and|morphine (r_pobj) between_8\IN\between.r.01|antagonists (r_prep) interaction_7\NN\action.n.01|a|dimorphic|between|in (l_prep) in_13\IN\linear_unit.n.01|model (l_pobj) model_17\NN\hypothesis.n.02|a|persistent|pain|distinguished (l_compound) pain_16\NN\symptom.n.01|
D009020_D059787 NONE morphine_7\NN\analgesic.n.01| (r_compound) antihyperalgesia_8\NN\entity.n.01|morphine (r_pobj) of_6\IN\entity.n.01|antihyperalgesia (r_prep) enhancement_5\NN\improvement.n.02|nmda|antagonist|of (r_pobj) in_2\IN\linear_unit.n.01|enhancement (r_prep) differences_1\NNS\quality.n.01|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS\examination.n.01|to (l_prep) to_18\IN\entity.n.01|models (l_pobj) models_20\NNS\hypothesis.n.02|two|of (l_prep) of_21\IN\entity.n.01|pain (l_pobj) pain_23\NN\symptom.n.01|acute
D009020_D059787 NONE morphine_21\NN\analgesic.n.01| (r_pobj) of_20\IN\entity.n.01|morphine (r_prep) effects_19\NNS\personal_property.n.01|the|antinociceptive|of (r_dobj) enhance_16\VBP\intensify.v.02|in|antagonists|effects|to|. (l_prep) in_0\IN\linear_unit.n.01|models|, (l_pobj) models_3\NNS\hypothesis.n.02|acute|pain (l_compound) pain_2\NN\symptom.n.01|
D009020_D059787 NONE morphine_2\NN\analgesic.n.01| (r_compound) antinociception_3\NN\entity.n.01|morphine (r_pobj) of_1\IN\entity.n.01|antinociception (r_prep) enhancement_0\NN\improvement.n.02|of|by (r_nsubjpass) seen_7\VBN\perceive.v.01|enhancement|was|in|,|with|. (l_prep) in_8\IN\linear_unit.n.01|males (l_pobj) males_10\NNS\animal.n.01|both|and|females|in (l_prep) in_13\IN\linear_unit.n.01|models (l_pobj) models_17\NNS\hypothesis.n.02|the|acute|pain (l_compound) pain_16\NN\symptom.n.01|
D009020_D059787 NONE morphine_12\NN\analgesic.n.01| (r_conj) antagonists_10\NNS\person.n.01|nmda|and|morphine (r_pobj) between_8\IN\between.r.01|antagonists (r_prep) interaction_7\NN\action.n.01|a|dimorphic|between|in (l_prep) in_13\IN\linear_unit.n.01|model (l_pobj) model_17\NN\hypothesis.n.02|a|persistent|pain|distinguished (l_relcl) distinguished_21\VBN\identify.v.01|that|can|be|from (l_prep) from_22\IN\entity.n.01|those (l_pobj) those_23\DT\entity.n.01|observed (l_acl) observed_24\VBN\spy.v.03|in (l_prep) in_25\IN\linear_unit.n.01|models (l_pobj) models_28\NNS\hypothesis.n.02|acute|pain (l_compound) pain_27\NN\symptom.n.01|
D002211_D010146 NONE capsaicin_11\NN\chemical_irritant.n.01| (r_compound) model_12\NN\hypothesis.n.02|a|capsaicin|of (l_prep) of_13\IN\entity.n.01|pain (l_pobj) pain_15\NN\symptom.n.01|persistent
D002211_D059787 NONE capsaicin_11\NN\chemical_irritant.n.01| (r_compound) model_12\NN\hypothesis.n.02|a|capsaicin|of (r_pobj) in_9\IN\linear_unit.n.01|model (r_prep) differences_1\NNS\quality.n.01|sex|in|in|:|comparisons|. (l_appos) comparisons_17\NNS\examination.n.01|to (l_prep) to_18\IN\entity.n.01|models (l_pobj) models_20\NNS\hypothesis.n.02|two|of (l_prep) of_21\IN\entity.n.01|pain (l_pobj) pain_23\NN\symptom.n.01|acute
D002211_D006930 CID capsaicin_11\NN\chemical_irritant.n.01| (r_pobj) of_10\IN\entity.n.01|capsaicin (r_prep) administration_9\NN\management.n.01|of|in (r_pobj) by_8\IN\by.r.01|administration (r_agent) induced_7\VBN\generate.v.01|to|,|hyperalgesia|was|by|,|immersed|. (l_nsubjpass) hyperalgesia_5\NN\entity.n.01|persistent
D003915_D059787 NONE dextromethorphan_5\NNP\entity.n.01| (r_pobj) by_4\IN\by.r.01|dextromethorphan (r_prep) enhancement_0\NN\improvement.n.02|of|by (r_nsubjpass) seen_7\VBN\perceive.v.01|enhancement|was|in|,|with|. (l_prep) in_8\IN\linear_unit.n.01|males (l_pobj) males_10\NNS\animal.n.01|both|and|females|in (l_prep) in_13\IN\linear_unit.n.01|models (l_pobj) models_17\NNS\hypothesis.n.02|the|acute|pain (l_compound) pain_16\NN\symptom.n.01|
11391224
D003042_D006974 NONE cocaine_23\NN\hard_drug.n.01| (r_npadvmod) related_25\VBN\think.v.03|cocaine|- (r_amod) failure_28\NN\nonaccomplishment.n.01|related|acute|renal (r_conj) glomerulonephritis_20\NN\nephritis.n.01|crescentic|,|and|failure (r_conj) nephritis_17\NN\kidney_disease.n.01|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\kidney_disease.n.01|,|nephritis (r_dobj) lupus_11\NN\skin_disease.n.01|microangiopathy|nephritis (r_conj) included_2\VBD\include.v.01|13|cases|,|lupus|. (l_dobj) cases_3\NNS\happening.n.01|of (l_prep) of_4\IN\entity.n.01|hypertension (l_pobj) hypertension_6\NN\cardiovascular_disease.n.01|malignant
D003042_D057049 NONE cocaine_23\NN\hard_drug.n.01| (r_npadvmod) related_25\VBN\think.v.03|cocaine|- (r_amod) failure_28\NN\nonaccomplishment.n.01|related|acute|renal (r_conj) glomerulonephritis_20\NN\nephritis.n.01|crescentic|,|and|failure (r_conj) nephritis_17\NN\kidney_disease.n.01|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\kidney_disease.n.01|,|nephritis (r_dobj) lupus_11\NN\skin_disease.n.01|microangiopathy|nephritis (l_nsubj) microangiopathy_9\NN\entity.n.01|thrombotic|,
D003042_D008181 NONE cocaine_23\NN\hard_drug.n.01| (r_npadvmod) related_25\VBN\think.v.03|cocaine|- (r_amod) failure_28\NN\nonaccomplishment.n.01|related|acute|renal (r_conj) glomerulonephritis_20\NN\nephritis.n.01|crescentic|,|and|failure (r_conj) nephritis_17\NN\kidney_disease.n.01|schonlein|,|glomerulonephritis (r_conj) nephritis_12\NN\kidney_disease.n.01|,|nephritis
D003042_D011695 NONE cocaine_23\NN\hard_drug.n.01| (r_npadvmod) related_25\VBN\think.v.03|cocaine|- (r_amod) failure_28\NN\nonaccomplishment.n.01|related|acute|renal (r_conj) glomerulonephritis_20\NN\nephritis.n.01|crescentic|,|and|failure (r_conj) nephritis_17\NN\kidney_disease.n.01|schonlein|,|glomerulonephritis
D003042_D005921 NONE cocaine_23\NN\hard_drug.n.01| (r_npadvmod) related_25\VBN\think.v.03|cocaine|- (r_amod) failure_28\NN\nonaccomplishment.n.01|related|acute|renal (r_conj) glomerulonephritis_20\NN\nephritis.n.01|crescentic|,|and|failure
D003042_D058186 CID cocaine_23\NN\hard_drug.n.01| (r_npadvmod) related_25\VBN\think.v.03|cocaine|- (r_amod) failure_28\NN\nonaccomplishment.n.01|related|acute|renal
10739826
D003276_D054556 CID contraceptives_5\NNS\device.n.01|newer|oral|and|risk (l_conj) risk_8\NN\danger.n.03|the|of (l_prep) of_9\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_11\NN\occlusion.n.01|venous
D003276_D054556 CID contraceptives_17\NNS\device.n.01|newer|oral|oc (r_pobj) with_14\IN\entity.n.01|contraceptives (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated
D003276_D054556 CID contraceptives_17\NNS\device.n.01|newer|oral|oc (r_pobj) with_14\IN\entity.n.01|contraceptives (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated (l_appos) vte_11\NNP\entity.n.01|
D003276_D054556 CID oc_19\NNP\entity.n.01|(|) (r_appos) contraceptives_17\NNS\device.n.01|newer|oral|oc (r_pobj) with_14\IN\entity.n.01|contraceptives (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated
D003276_D054556 CID oc_19\NNP\entity.n.01|(|) (r_appos) contraceptives_17\NNS\device.n.01|newer|oral|oc (r_pobj) with_14\IN\entity.n.01|contraceptives (r_prep) associated_13\VBN\think.v.03|with (r_acl) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated (l_appos) vte_11\NNP\entity.n.01|
D003276_D054556 CID oc_27\NNP\entity.n.01| (r_compound) use_28\NN\activity.n.01|oc|,|users (r_pobj) of_26\IN\entity.n.01|use (r_prep) patterns_25\NNS\structure.n.03|of (r_pobj) between_24\IN\between.r.01|patterns (r_prep) distinguish_23\VB\identify.v.01|studies|did|not|between|. (l_nsubj) studies_2\NNS\examination.n.01|the|epidemiological|assessed (l_relcl) assessed_4\VBD\evaluate.v.02|that|risk (l_dobj) risk_6\NN\danger.n.03|the|of (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated
D003276_D054556 CID oc_27\NNP\entity.n.01| (r_compound) use_28\NN\activity.n.01|oc|,|users (r_pobj) of_26\IN\entity.n.01|use (r_prep) patterns_25\NNS\structure.n.03|of (r_pobj) between_24\IN\between.r.01|patterns (r_prep) distinguish_23\VB\identify.v.01|studies|did|not|between|. (l_nsubj) studies_2\NNS\examination.n.01|the|epidemiological|assessed (l_relcl) assessed_4\VBD\evaluate.v.02|that|risk (l_dobj) risk_6\NN\danger.n.03|the|of (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)|associated (l_appos) vte_11\NNP\entity.n.01|
D003276_D054556 CID oc_12\NNP\entity.n.01|generation (r_pobj) of_9\IN\entity.n.01|oc (r_prep) users_8\NNS\person.n.01|repeat|of (r_pobj) for_6\IN\entity.n.01|users (r_prep) ratio_3\NN\magnitude_relation.n.01|the|adjusted|rate|of|for (l_prep) of_4\IN\entity.n.01|vte (l_pobj) vte_5\NN\entity.n.01|
15145918
D004967_D007022 NONE estrogen_3\NN\steroid_hormone.n.01|of (l_prep) of_4\IN\entity.n.01|hypotension (l_pobj) hypotension_11\NN\cardiovascular_disease.n.01|alpha2-adrenergic|in
D004967_D007022 NONE estrogen_5\NN\steroid_hormone.n.01| (r_nsubj) modulates_7\VBZ\play.v.06|that|estrogen|negatively|effect|and|implicates (l_dobj) effect_10\NN\phenomenon.n.01|the|hypotensive|of (l_amod) hypotensive_9\JJ\patient.n.01|
D004967_D007022 NONE estrogen_4\NN\steroid_hormone.n.01| (r_nsubj) downregulates_5\VBZ\entity.n.01|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN\cardiovascular_disease.n.01|not|mediated
D004967_D007022 NONE estrogen_27\NN\steroid_hormone.n.01|methyldopa|- (r_compound) interaction_28\NN\action.n.01|estrogen (r_pobj) in_22\IN\linear_unit.n.01|interaction (r_prep) control_21\NN\power.n.01|the|cardiac|autonomic|in (r_pobj) for_17\IN\entity.n.01|control (r_prep) role_16\NN\duty.n.02|a|for (r_dobj) highlight_14\VB\detail.n.02|role (r_conj) downregulates_5\VBZ\entity.n.01|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN\cardiovascular_disease.n.01|not|mediated
D048288_D007022 NONE i1-imidazoline_7\NNP\entity.n.01| (r_punct) mediated_10\VBN\negociate.v.06|i1-imidazoline|receptor|- (r_conj) alpha2-adrenergic_5\JJ\entity.n.01|and|mediated (r_amod) hypotension_11\NN\cardiovascular_disease.n.01|alpha2-adrenergic|in
D003000_D007022 NONE clonidine_12\NN\antihypertensive.n.01|agonist (r_pobj) of_11\IN\entity.n.01|clonidine (r_prep) effect_10\NN\phenomenon.n.01|the|hypotensive|of (l_amod) hypotensive_9\JJ\patient.n.01|
C032302_D007022 CID rilmenidine_6\NN\entity.n.01|or|methyldopa (r_amod) rats_4\NNS\rodent.n.01|operated|,|rilmenidine (r_pobj) in_0\IN\linear_unit.n.01|rats (r_prep) elicited_11\VBD\make.v.03|in|hypotension|. (l_dobj) hypotension_13\NN\cardiovascular_disease.n.01|similar|lasted
C032302_D007022 CID rilmenidine_17\JJ\entity.n.01| (r_amod) hypotension_18\NN\cardiovascular_disease.n.01|rilmenidine (r_pobj) on_16\IN\on.a.01|hypotension (r_prep) effect_15\NN\phenomenon.n.01|no|on (r_pobj) to_13\IN\entity.n.01|effect (r_prep) contrast_12\NN\opposition.n.02|to (r_pobj) in_11\IN\linear_unit.n.01|contrast (r_prep) enhanced_2\VBD\intensify.v.02|ovx|significantly|response|,|in|. (l_dobj) response_5\NN\consequence.n.01|the|hypotensive|to (l_amod) hypotensive_4\JJ\patient.n.01|
C032302_D007022 CID rilmenidine_17\JJ\entity.n.01| (r_amod) hypotension_18\NN\cardiovascular_disease.n.01|rilmenidine
D008750_D007022 CID methyldopa_10\NN\antihypertensive.n.01|alpha|- (r_conj) rilmenidine_6\NN\entity.n.01|or|methyldopa (r_amod) rats_4\NNS\rodent.n.01|operated|,|rilmenidine (r_pobj) in_0\IN\linear_unit.n.01|rats (r_prep) elicited_11\VBD\make.v.03|in|hypotension|. (l_dobj) hypotension_13\NN\cardiovascular_disease.n.01|similar|lasted
D008750_D007022 CID methyldopa_9\NN\antihypertensive.n.01|alpha|- (r_pobj) to_6\IN\entity.n.01|methyldopa (r_prep) response_5\NN\consequence.n.01|the|hypotensive|to (l_amod) hypotensive_4\JJ\patient.n.01|
D008750_D007022 CID methyldopa_9\NN\antihypertensive.n.01|alpha|- (r_pobj) to_6\IN\entity.n.01|methyldopa (r_prep) response_5\NN\consequence.n.01|the|hypotensive|to (r_dobj) enhanced_2\VBD\intensify.v.02|ovx|significantly|response|,|in|. (l_prep) in_11\IN\linear_unit.n.01|contrast (l_pobj) contrast_12\NN\opposition.n.02|to (l_prep) to_13\IN\entity.n.01|effect (l_pobj) effect_15\NN\phenomenon.n.01|no|on (l_prep) on_16\IN\on.a.01|hypotension (l_pobj) hypotension_18\NN\cardiovascular_disease.n.01|rilmenidine
D008750_D007022 CID methyldopa_4\NN\antihypertensive.n.01|alpha|- (r_compound) hypotension_5\NN\cardiovascular_disease.n.01|the|enhanced|methyldopa|in
D008750_D007022 CID methyldopa_25\NN\antihypertensive.n.01|alpha|- (r_compound) estrogen_27\NN\steroid_hormone.n.01|methyldopa|- (r_compound) interaction_28\NN\action.n.01|estrogen (r_pobj) in_22\IN\linear_unit.n.01|interaction (r_prep) control_21\NN\power.n.01|the|cardiac|autonomic|in (r_pobj) for_17\IN\entity.n.01|control (r_prep) role_16\NN\duty.n.02|a|for (r_dobj) highlight_14\VB\detail.n.02|role (r_conj) downregulates_5\VBZ\entity.n.01|that|estrogen|alpha2-|but|hypotension|and|highlight (l_conj) hypotension_12\NN\cardiovascular_disease.n.01|not|mediated
D008750_D001523 NONE methyldopa_4\NN\antihypertensive.n.01|alpha|- (r_compound) hypotension_5\NN\cardiovascular_disease.n.01|the|enhanced|methyldopa|in (r_nsubjpass) paralleled_10\VBN\match.v.01|hypotension|was|with|. (l_prep) with_11\IN\entity.n.01|reduction (l_pobj) reduction_13\NN\change_of_magnitude.n.01|further|in|and|activity (l_conj) activity_20\NN\act.n.02|a|reduced|locomotor
20470218
D008727_D056784 NONE methotrexate_32\NN\antimetabolite.n.01| (r_compound) toxicity_33\NN\definite_quantity.n.01|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN\complex.n.01|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_compound) leukoencephalopathy_5\JJ\entity.n.01|
D008727_D020521 NONE methotrexate_32\NN\antimetabolite.n.01| (r_compound) toxicity_33\NN\definite_quantity.n.01|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN\complex.n.01|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_conj) stroke_13\NN\maneuver.n.03|(|n|5|)|,|epilepsy
D008727_D004833 NONE methotrexate_32\NN\antimetabolite.n.01| (r_compound) toxicity_33\NN\definite_quantity.n.01|dose|methotrexate|(|n|2|)|,|syndrome (r_conj) syndrome_6\NN\complex.n.01|posterior|reversible|leukoencephalopathy|(|n|)|,|stroke|,|toxicity (l_conj) stroke_13\NN\maneuver.n.03|(|n|5|)|,|epilepsy (l_conj) epilepsy_22\NN\brain_disorder.n.01|temporal|lobe|(|n|)
D008727_D064420 NONE methotrexate_32\NN\antimetabolite.n.01| (r_compound) toxicity_33\NN\definite_quantity.n.01|dose|methotrexate|(|n|2|)|,|syndrome
D008727_D007177 NONE methotrexate_32\NN\antimetabolite.n.01| (r_compound) toxicity_33\NN\definite_quantity.n.01|dose|methotrexate|(|n|2|)|,|syndrome (l_conj) syndrome_40\NN\complex.n.01|of|,|and|events (l_prep) of_41\IN\entity.n.01|secretion (l_pobj) secretion_45\NN\organic_process.n.01|inappropriate|antidiuretic|hormone|(|n|)
4008111
D000638_D012848 CID amiodarone_0\NN\antiarrhythmic.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|amiodarone|- (r_amod) block_4\NN\artifact.n.01|induced|sinoatrial|.
D000638_D012848 CID amiodarone_7\NN\antiarrhythmic.n.01| (r_compound) administration_8\NN\management.n.01|chronic|amiodarone|in (r_pobj) due_4\JJ\right.n.01|to|administration (r_prep) observed_1\VBD\spy.v.03|we|block|due|,|syndrome|. (l_dobj) block_3\NN\artifact.n.01|sinoatrial
D000638_D012848 CID amiodarone_5\NN\antiarrhythmic.n.01| (r_pobj) of_4\IN\entity.n.01|amiodarone (r_prep) dosage_3\NN\indefinite_quantity.n.01|the|of (r_pobj) in_1\IN\linear_unit.n.01|dosage (r_prep) reduction_0\NN\change_of_magnitude.n.01|in (r_nsubj) resulted_6\VBD\prove.v.01|reduction|in|. (l_prep) in_7\IN\linear_unit.n.01|disappearance (l_pobj) disappearance_9\NN\departure.n.01|the|of|and|persistence (l_prep) of_10\IN\entity.n.01|block (l_pobj) block_13\NN\artifact.n.01|the|sinoatrial
D000638_D009202 NONE amiodarone_7\NN\antiarrhythmic.n.01| (r_compound) administration_8\NN\management.n.01|chronic|amiodarone|in (l_prep) in_9\IN\linear_unit.n.01|boy (l_pobj) boy_14\NN\male.n.02|a|old|with (l_prep) with_15\IN\entity.n.01|cardiomyopathy (l_pobj) cardiomyopathy_17\NN\heart_disease.n.01|primary
D000638_D014927 NONE amiodarone_7\NN\antiarrhythmic.n.01| (r_compound) administration_8\NN\management.n.01|chronic|amiodarone|in (r_pobj) due_4\JJ\right.n.01|to|administration (r_prep) observed_1\VBD\spy.v.03|we|block|due|,|syndrome|. (l_dobj) syndrome_24\NN\complex.n.01|white|and|tachycardia
D000638_D013617 NONE amiodarone_7\NN\antiarrhythmic.n.01| (r_compound) administration_8\NN\management.n.01|chronic|amiodarone|in (r_pobj) due_4\JJ\right.n.01|to|administration (r_prep) observed_1\VBD\spy.v.03|we|block|due|,|syndrome|. (l_dobj) syndrome_24\NN\complex.n.01|white|and|tachycardia (l_conj) tachycardia_27\NN\cardiac_arrhythmia.n.01|supraventricular
D000638_D012804 NONE amiodarone_5\NN\antiarrhythmic.n.01| (r_pobj) of_4\IN\entity.n.01|amiodarone (r_prep) dosage_3\NN\indefinite_quantity.n.01|the|of (r_pobj) in_1\IN\linear_unit.n.01|dosage (r_prep) reduction_0\NN\change_of_magnitude.n.01|in (r_nsubj) resulted_6\VBD\prove.v.01|reduction|in|. (l_prep) in_7\IN\linear_unit.n.01|disappearance (l_pobj) disappearance_9\NN\departure.n.01|the|of|and|persistence (l_conj) persistence_16\NN\lastingness.n.01|the|of (l_prep) of_17\IN\entity.n.01|bradycardia (l_pobj) bradycardia_20\NNP\cardiac_arrhythmia.n.01|asymptomatic|sinus
9390208
D008942_D001943 NONE mitoxantrone_8\NN\entity.n.01|and (r_pobj) by_7\IN\by.r.01|mitoxantrone (r_prep) cancer_6\NN\malignant_tumor.n.01|treated|metastatic|breast|by
D008942_D001943 NONE mitoxantrone_20\NN\entity.n.01| (r_pobj) by_19\IN\by.r.01|mitoxantrone (r_prep) treated_8\VBD\interact.v.01|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS\case.n.06|13|with (l_prep) with_11\IN\entity.n.01|cancer (l_pobj) cancer_18\NN\malignant_tumor.n.01|treated|metastatic|breast
D008942_D064420 NONE mitoxantrone_8\NN\entity.n.01|and (r_pobj) by_7\IN\by.r.01|mitoxantrone (r_prep) cancer_6\NN\malignant_tumor.n.01|treated|metastatic|breast|by (r_pobj) of_1\IN\entity.n.01|cancer (r_prep) treatment_0\NN\care.n.01|of|infusion|. (l_conj) infusion_12\NN\solution.n.01|48-hour|continuous|of (l_prep) of_13\IN\entity.n.01|5-fu (l_pobj) 5-fu_17\CD\entity.n.01|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\payment.n.01|low|palliative|and|toxicity (l_conj) toxicity_32\NN\definite_quantity.n.01|high|related
D005472_D001943 NONE 5-fu_17\CD\entity.n.01|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN\entity.n.01|5-fu (r_prep) infusion_12\NN\solution.n.01|48-hour|continuous|of (r_conj) treatment_0\NN\care.n.01|of|infusion|. (l_prep) of_1\IN\entity.n.01|cancer (l_pobj) cancer_6\NN\malignant_tumor.n.01|treated|metastatic|breast|by
D005472_D001943 NONE 5-fu_34\CD\entity.n.01|,|m2 (r_pobj) of_33\IN\entity.n.01|5-fu (r_prep) infusion_32\NN\solution.n.01|continuous|of (r_conj) day_28\NN\time_unit.n.01|1|and|infusion (r_pobj) on_27\IN\on.a.01|day (r_prep) treated_8\VBD\interact.v.01|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS\case.n.06|13|with (l_prep) with_11\IN\entity.n.01|cancer (l_pobj) cancer_18\NN\malignant_tumor.n.01|treated|metastatic|breast
D005472_D064420 NONE 5-fu_17\CD\entity.n.01|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\payment.n.01|low|palliative|and|toxicity (l_conj) toxicity_32\NN\definite_quantity.n.01|high|related
D002955_D001943 NONE leucovorin_19\NN\entity.n.01| (r_conj) 5-fu_17\CD\entity.n.01|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN\entity.n.01|5-fu (r_prep) infusion_12\NN\solution.n.01|48-hour|continuous|of (r_conj) treatment_0\NN\care.n.01|of|infusion|. (l_prep) of_1\IN\entity.n.01|cancer (l_pobj) cancer_6\NN\malignant_tumor.n.01|treated|metastatic|breast|by
D002955_D001943 NONE leucovorin_43\NN\entity.n.01| (r_pobj) with_42\IN\entity.n.01|together|leucovorin (r_prep) treated_8\VBD\interact.v.01|from|,|we|patients|by|,|m2|on|,|with|,|m2|for|. (l_dobj) patients_10\NNS\case.n.06|13|with (l_prep) with_11\IN\entity.n.01|cancer (l_pobj) cancer_18\NN\malignant_tumor.n.01|treated|metastatic|breast
D002955_D064420 NONE leucovorin_19\NN\entity.n.01| (r_conj) 5-fu_17\CD\entity.n.01|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\payment.n.01|low|palliative|and|toxicity (l_conj) toxicity_32\NN\definite_quantity.n.01|high|related
C085788_D001943 NONE mfl_21\NNP\entity.n.01| (r_appos) 5-fu_17\CD\entity.n.01|dose|and|leucovorin|(|mfl|)|:|benefit (r_pobj) of_13\IN\entity.n.01|5-fu (r_prep) infusion_12\NN\solution.n.01|48-hour|continuous|of (r_conj) treatment_0\NN\care.n.01|of|infusion|. (l_prep) of_1\IN\entity.n.01|cancer (l_pobj) cancer_6\NN\malignant_tumor.n.01|treated|metastatic|breast|by
C085788_D064420 NONE mfl_21\NNP\entity.n.01| (r_appos) 5-fu_17\CD\entity.n.01|dose|and|leucovorin|(|mfl|)|:|benefit (l_conj) benefit_26\NN\payment.n.01|low|palliative|and|toxicity (l_conj) toxicity_32\NN\definite_quantity.n.01|high|related
C085788_D064420 NONE regimen_2\NN\plan.n.01|the|mfl (r_nsubj) achieves_3\VBZ\succeed.v.01|regimen|benefit|and|induces|. (l_conj) induces_8\VBZ\generate.v.01|toxicity|at (l_dobj) toxicity_10\NN\definite_quantity.n.01|severe
12443032
D003042_D002637 CID cocaine_0\NN\hard_drug.n.01| (r_nsubj) related_1\VBN\think.v.03|cocaine|pain (l_dobj) pain_3\NN\symptom.n.01|chest
D003042_D002637 CID cocaine_6\NN\hard_drug.n.01| (r_pobj) of_5\IN\entity.n.01|cocaine (r_prep) tendency_4\NN\attitude.n.01|the|of|produce (l_acl) produce_8\VB\food.n.02|to|pain (l_dobj) pain_10\NN\symptom.n.01|chest
D003042_D002637 CID cocaine_6\NN\hard_drug.n.01| (r_pobj) of_5\IN\entity.n.01|cocaine (r_prep) tendency_4\NN\attitude.n.01|the|of|produce (r_nsubj) ought_11\MD\entity.n.01|in|,|tendency|be|. (l_xcomp) be_13\VB\metallic_element.n.01|to|in|faced (l_advcl) faced_22\VBN\set_about.v.01|when|with (l_prep) with_23\IN\entity.n.01|victim (l_pobj) victim_26\NN\unfortunate.n.01|a|young|of|is (l_prep) of_27\IN\entity.n.01|pain (l_pobj) pain_29\NN\symptom.n.01|chest
D003042_D002637 CID cocaine_7\NN\hard_drug.n.01| (r_compound) use_8\NN\activity.n.01|cocaine (r_pobj) to_6\IN\entity.n.01|use (r_prep) related_5\VBN\think.v.03|to (r_acl) mechanism_1\NN\chemical_process.n.01|the|of|related (l_prep) of_2\IN\entity.n.01|pain (l_pobj) pain_4\NN\symptom.n.01|chest
19346865
D008795_D001927 CID metronidazole_5\NN\antiprotozoal.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|metronidazole|- (r_amod) encephalopathy_8\NN\nervous_disorder.n.01|induced (r_pobj) in_4\IN\linear_unit.n.01|encephalopathy (r_prep) lesion_3\NN\pathology.n.02|reversible|inferior|colliculus|in|:|findings|.
D008795_D001927 CID metronidazole_5\NN\antiprotozoal.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|metronidazole|- (r_amod) encephalopathy_8\NN\nervous_disorder.n.01|induced
D008795_D001927 CID metronidazole_9\NN\antiprotozoal.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|metronidazole|- (r_amod) encephalopathy_12\NN\nervous_disorder.n.01|induced (r_pobj) in_8\IN\linear_unit.n.01|encephalopathy (r_prep) lesions_7\NNS\pathology.n.02|reversible|inferior|colliculus|in
D008795_D001927 CID metronidazole_9\NN\antiprotozoal.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|metronidazole|- (r_amod) encephalopathy_12\NN\nervous_disorder.n.01|induced
D008795_D001927 CID metronidazole_20\NN\antiprotozoal.n.01| (r_npadvmod) induced_22\VBN\generate.v.01|metronidazole|- (r_amod) encephalopathy_23\NN\nervous_disorder.n.01|induced|(|range|;|years
D008795_D001927 CID metronidazole_11\NN\antiprotozoal.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|metronidazole|- (r_amod) encephalopathy_14\NN\nervous_disorder.n.01|induced (r_pobj) for_10\IN\entity.n.01|encephalopathy (r_prep) characteristic_9\NN\property.n.04|the|for (r_pobj) as_7\IN\chemical_element.n.01|characteristic (r_prep) considered_6\VBN\think.v.01|lesions|could|be|as|,|next|. (l_nsubjpass) lesions_3\NNS\pathology.n.02|reversible|inferior|colliculus
D008795_D001927 CID metronidazole_11\NN\antiprotozoal.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|metronidazole|- (r_amod) encephalopathy_14\NN\nervous_disorder.n.01|induced
D008795_D007239 NONE metronidazole_4\NN\antiprotozoal.n.01| (r_dobj) taking_3\VBG\action.n.01|they|had|been|metronidazole|(|dosage|)|treat|. (l_advcl) treat_23\VB\nutriment.n.01|to|infection (l_dobj) infection_25\NN\ill_health.n.01|the|in
3403780
D000082_D003128 NONE paracetamol_0\NN\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|paracetamol|- (r_amod) coma_3\NN\unconsciousness.n.01|associated|,|acidosis|.
D000082_D000138 CID paracetamol_0\NN\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|paracetamol|- (r_amod) coma_3\NN\unconsciousness.n.01|associated|,|acidosis|. (l_appos) acidosis_6\NN\pathology.n.02|metabolic|,|failure
D000082_D000138 CID paracetamol_13\JJ\entity.n.01| (r_compound) ingestion_14\NN\bodily_process.n.01|paracetamol (r_pobj) following_12\VBG\multitude.n.03|ingestion (r_prep) failure_8\NN\nonaccomplishment.n.01|acute|renal|and|failure|following (r_nsubjpass) presented_16\VBN\show.v.04|case|,|failure|is|. (l_nsubjpass) case_1\NN\happening.n.01|a|of (l_prep) of_2\IN\entity.n.01|acidosis (l_pobj) acidosis_4\NN\pathology.n.02|metabolic
D000082_D058186 CID paracetamol_13\JJ\entity.n.01| (r_compound) ingestion_14\NN\bodily_process.n.01|paracetamol (r_pobj) following_12\VBG\multitude.n.03|ingestion (r_prep) failure_8\NN\nonaccomplishment.n.01|acute|renal|and|failure|following (l_conj) failure_11\NN\nonaccomplishment.n.01|hepatic
D000082_D058186 NONE paracetamol_0\NN\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|paracetamol|- (r_amod) coma_3\NN\unconsciousness.n.01|associated|,|acidosis|. (l_appos) acidosis_6\NN\pathology.n.02|metabolic|,|failure (l_conj) failure_11\NN\nonaccomplishment.n.01|renal
D000082_D017093 NONE paracetamol_0\NN\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|paracetamol|- (r_amod) coma_3\NN\unconsciousness.n.01|associated|,|acidosis|. (l_appos) acidosis_6\NN\pathology.n.02|metabolic|,|failure (l_conj) failure_11\NN\nonaccomplishment.n.01|renal
D000082_D017114 CID paracetamol_13\JJ\entity.n.01| (r_compound) ingestion_14\NN\bodily_process.n.01|paracetamol (r_pobj) following_12\VBG\multitude.n.03|ingestion (r_prep) failure_8\NN\nonaccomplishment.n.01|acute|renal|and|failure|following (l_conj) failure_11\NN\nonaccomplishment.n.01|hepatic
8701950
D016559_D000743 CID fk506_4\NNP\entity.n.01|(|therapy (r_dobj) complicating_3\VBG\change.v.01|anemia|fk506|. (l_nsubj) anemia_2\NN\blood_disease.n.01|microangiopathic|hemolytic
D016559_D000743 CID tacrolimus_6\NNP\entity.n.01|) (r_nmod) therapy_8\NN\medical_care.n.01|tacrolimus (r_appos) fk506_4\NNP\entity.n.01|(|therapy (r_dobj) complicating_3\VBG\change.v.01|anemia|fk506|. (l_nsubj) anemia_2\NN\blood_disease.n.01|microangiopathic|hemolytic
D016559_D000743 CID fk506_17\NNP\entity.n.01|( (r_nmod) therapy_21\NN\medical_care.n.01|fk506|tacrolimus (r_pobj) under_16\IN\nether.s.03|therapy (r_prep) recipients_15\NNS\acquirer.n.01|2|solid|organ|under (r_pobj) in_11\IN\linear_unit.n.01|recipients (r_prep) episodes_3\NNS\happening.n.01|3|of|in (l_prep) of_4\IN\entity.n.01|anemia (l_pobj) anemia_7\NN\blood_disease.n.01|microangiopathic|hemolytic|(|maha|)
D016559_D000743 CID fk506_17\NNP\entity.n.01|( (r_nmod) therapy_21\NN\medical_care.n.01|fk506|tacrolimus (r_pobj) under_16\IN\nether.s.03|therapy (r_prep) recipients_15\NNS\acquirer.n.01|2|solid|organ|under (r_pobj) in_11\IN\linear_unit.n.01|recipients (r_prep) episodes_3\NNS\happening.n.01|3|of|in (l_prep) of_4\IN\entity.n.01|anemia (l_pobj) anemia_7\NN\blood_disease.n.01|microangiopathic|hemolytic|(|maha|) (l_appos) maha_9\NNP\dhegiha.n.01|
D016559_D000743 CID tacrolimus_19\NNP\entity.n.01|) (r_nmod) therapy_21\NN\medical_care.n.01|fk506|tacrolimus (r_pobj) under_16\IN\nether.s.03|therapy (r_prep) recipients_15\NNS\acquirer.n.01|2|solid|organ|under (r_pobj) in_11\IN\linear_unit.n.01|recipients (r_prep) episodes_3\NNS\happening.n.01|3|of|in (l_prep) of_4\IN\entity.n.01|anemia (l_pobj) anemia_7\NN\blood_disease.n.01|microangiopathic|hemolytic|(|maha|)
D016559_D000743 CID tacrolimus_19\NNP\entity.n.01|) (r_nmod) therapy_21\NN\medical_care.n.01|fk506|tacrolimus (r_pobj) under_16\IN\nether.s.03|therapy (r_prep) recipients_15\NNS\acquirer.n.01|2|solid|organ|under (r_pobj) in_11\IN\linear_unit.n.01|recipients (r_prep) episodes_3\NNS\happening.n.01|3|of|in (l_prep) of_4\IN\entity.n.01|anemia (l_pobj) anemia_7\NN\blood_disease.n.01|microangiopathic|hemolytic|(|maha|) (l_appos) maha_9\NNP\dhegiha.n.01|
D016559_D000743 CID fk506_6\NNP\entity.n.01|and|treatment (r_pobj) of_5\IN\entity.n.01|fk506 (r_prep) discontinuation_4\NN\termination.n.05|of|,|replacement (r_nsubj) led_24\VBD\diode.n.02|in|,|discontinuation|to|. (l_prep) to_25\IN\entity.n.01|resolution (l_pobj) resolution_26\NN\document.n.01|of (l_prep) of_27\IN\entity.n.01|maha (l_pobj) maha_28\NNP\dhegiha.n.01|
D016559_D000743 CID fk506_6\NNP\entity.n.01| (r_pobj) of_5\IN\entity.n.01|fk506 (r_prep) reintroduction_4\NN\presentation.n.06|of (r_nsubj) led_7\VBD\diode.n.02|in|,|reintroduction|to|. (l_prep) to_8\IN\entity.n.01|recurrence (l_pobj) recurrence_10\NN\repeat.n.01|rapid|of (l_prep) of_11\IN\entity.n.01|maha (l_pobj) maha_12\NNP\dhegiha.n.01|
D016559_D000743 CID fk506-associated_0\VBN\entity.n.01| (r_amod) maha_1\NNP\dhegiha.n.01|fk506-associated
D016559_D000743 CID fk506_9\NNP\entity.n.01| (r_nsubj) seem_12\VB\be.v.01|in|,|fk506|does|not|a|. (l_oprd) a_19\NNP\metric_linear_unit.n.01|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN\agent.n.03|an|suppressive|known (l_acl) known_30\VBN\know.v.01|already|induce (l_xcomp) induce_32\VB\generate.v.01|to|maha (l_dobj) maha_33\NNP\dhegiha.n.01|
D000305_D000743 NONE corticosteroids_18\NNS\steroid_hormone.n.01|,|aspirin (r_conj) replacement_16\NN\substitution.n.02|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN\termination.n.05|of|,|replacement (r_nsubj) led_24\VBD\diode.n.02|in|,|discontinuation|to|. (l_prep) to_25\IN\entity.n.01|resolution (l_pobj) resolution_26\NN\document.n.01|of (l_prep) of_27\IN\entity.n.01|maha (l_pobj) maha_28\NNP\dhegiha.n.01|
D001241_D000743 NONE aspirin_20\NN\analgesic.n.01|,|and|dipyridamole (r_conj) corticosteroids_18\NNS\steroid_hormone.n.01|,|aspirin (r_conj) replacement_16\NN\substitution.n.02|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN\termination.n.05|of|,|replacement (r_nsubj) led_24\VBD\diode.n.02|in|,|discontinuation|to|. (l_prep) to_25\IN\entity.n.01|resolution (l_pobj) resolution_26\NN\document.n.01|of (l_prep) of_27\IN\entity.n.01|maha (l_pobj) maha_28\NNP\dhegiha.n.01|
D004176_D000743 NONE dipyridamole_23\NN\entity.n.01| (r_conj) aspirin_20\NN\analgesic.n.01|,|and|dipyridamole (r_conj) corticosteroids_18\NNS\steroid_hormone.n.01|,|aspirin (r_conj) replacement_16\NN\substitution.n.02|fresh|plasma|,|corticosteroids (r_appos) discontinuation_4\NN\termination.n.05|of|,|replacement (r_nsubj) led_24\VBD\diode.n.02|in|,|discontinuation|to|. (l_prep) to_25\IN\entity.n.01|resolution (l_pobj) resolution_26\NN\document.n.01|of (l_prep) of_27\IN\entity.n.01|maha (l_pobj) maha_28\NNP\dhegiha.n.01|
D016572_D000743 NONE a_19\NNP\metric_linear_unit.n.01|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN\agent.n.03|an|suppressive|known (l_acl) known_30\VBN\know.v.01|already|induce (l_xcomp) induce_32\VB\generate.v.01|to|maha (l_dobj) maha_33\NNP\dhegiha.n.01|
D016572_D000743 NONE cya_21\NN\entity.n.01|(|) (r_appos) a_19\NNP\metric_linear_unit.n.01|react|with|cyclosporin|cya|,|drug (l_appos) drug_28\NN\agent.n.03|an|suppressive|known (l_acl) known_30\VBN\know.v.01|already|induce (l_xcomp) induce_32\VB\generate.v.01|to|maha (l_dobj) maha_33\NNP\dhegiha.n.01|
12589964
D004317_D009202 CID doxorubicin_14\NN\antibiotic.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|doxorubicin|- (r_amod) rats_18\NNS\rodent.n.01|induced|cardiomyopathy (r_pobj) in_13\IN\linear_unit.n.01|rats (r_prep) damage_12\NN\change.n.01|myocardial|in
D004317_D009202 CID doxorubicin_14\NN\antibiotic.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|doxorubicin|- (r_amod) rats_18\NNS\rodent.n.01|induced|cardiomyopathy (l_amod) cardiomyopathy_17\NN\heart_disease.n.01|
D004317_D009202 CID doxorubicin_20\NN\antibiotic.n.01| (r_pobj) of_19\IN\entity.n.01|doxorubicin (r_prep) model_18\NN\hypothesis.n.02|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\linear_unit.n.01|model (r_prep) damage_14\NN\change.n.01|myocardial|in
D004317_D009202 CID doxorubicin_20\NN\antibiotic.n.01| (r_pobj) of_19\IN\entity.n.01|doxorubicin (r_prep) model_18\NN\hypothesis.n.02|a|rat|of|cardiomyopathy (l_appos) cardiomyopathy_23\NN\heart_disease.n.01|(|dox)-induced
D004317_D009202 CID dox)-induced_22\VBN\entity.n.01| (r_amod) cardiomyopathy_23\NN\heart_disease.n.01|(|dox)-induced (r_appos) model_18\NN\hypothesis.n.02|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\linear_unit.n.01|model (r_prep) damage_14\NN\change.n.01|myocardial|in
D004317_D009202 CID dox)-induced_22\VBN\entity.n.01| (r_amod) cardiomyopathy_23\NN\heart_disease.n.01|(|dox)-induced
D004317_D009202 CID dox_6\NNP\entity.n.01|in (r_pobj) after_5\IN\after.s.01|dox (r_prep) markers_1\NNS\artifact.n.01|of|after (r_pobj) among_0\IN\entity.n.01|markers (r_prep) showed_11\VBD\show.v.04|among|,|ctnt|ability|. (l_dobj) ability_14\NN\quality.n.01|the|greatest|detect (l_acl) detect_16\VB\spy.v.03|to|damage (l_dobj) damage_18\NN\change.n.01|myocardial|assessed
D004317_D006331 NONE doxorubicin_20\NN\antibiotic.n.01| (r_pobj) of_19\IN\entity.n.01|doxorubicin (r_prep) model_18\NN\hypothesis.n.02|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\linear_unit.n.01|model (r_prep) damage_14\NN\change.n.01|myocardial|in (r_pobj) of_12\IN\entity.n.01|damage (r_prep) diagnosis_11\NN\designation.n.03|the|of (r_pobj) for_9\IN\entity.n.01|diagnosis (r_prep) investigated_1\VBD\analyze.v.01|we|value|for|,|and|examined (l_conj) examined_27\VBD\analyze.v.01|we|relationship|. (l_dobj) relationship_29\NN\relation.n.01|the|between|with (l_prep) with_35\IN\entity.n.01|development (l_pobj) development_37\NN\improvement.n.02|the|of (l_prep) of_38\IN\entity.n.01|disorders (l_pobj) disorders_40\NNS\physical_condition.n.01|cardiac|monitored
D004317_D006331 NONE dox)-induced_22\VBN\entity.n.01| (r_amod) cardiomyopathy_23\NN\heart_disease.n.01|(|dox)-induced (r_appos) model_18\NN\hypothesis.n.02|a|rat|of|cardiomyopathy (r_pobj) in_15\IN\linear_unit.n.01|model (r_prep) damage_14\NN\change.n.01|myocardial|in (r_pobj) of_12\IN\entity.n.01|damage (r_prep) diagnosis_11\NN\designation.n.03|the|of (r_pobj) for_9\IN\entity.n.01|diagnosis (r_prep) investigated_1\VBD\analyze.v.01|we|value|for|,|and|examined (l_conj) examined_27\VBD\analyze.v.01|we|relationship|. (l_dobj) relationship_29\NN\relation.n.01|the|between|with (l_prep) with_35\IN\entity.n.01|development (l_pobj) development_37\NN\improvement.n.02|the|of (l_prep) of_38\IN\entity.n.01|disorders (l_pobj) disorders_40\NNS\physical_condition.n.01|cardiac|monitored
D004317_D064420 NONE dox_3\NNP\entity.n.01| (r_compound) rats_4\NNS\rodent.n.01|the|dox (r_pobj) of_1\IN\entity.n.01|rats (r_prep) eighteen_0\CD\large_integer.n.01|of (r_nsubj) died_5\VBD\change_state.v.01|eighteen|prematurely|of|during|. (l_prep) of_7\IN\entity.n.01|toxicity (l_pobj) toxicity_9\NN\definite_quantity.n.01|general
D004317_D005355 NONE dox_8\NNP\entity.n.01| (r_pobj) given_7\VBN\assumption.n.02|dox (r_prep) rats_6\NNS\rodent.n.01|all|given (r_pobj) from_4\IN\entity.n.01|rats (r_prep) hearts_3\NNS\whist.n.01|from (r_pobj) of_2\IN\entity.n.01|hearts (r_prep) evaluation_1\NN\judgment.n.02|histological|of (r_nsubj) revealed_9\VBD\show.v.04|evaluation|degrees|. (l_dobj) degrees_12\NNS\property.n.02|significant|slight|of (l_prep) of_13\IN\entity.n.01|fibrosis (l_pobj) fibrosis_17\NN\pathology.n.02|perivascular
D004317_D017202 NONE dox_6\NNP\entity.n.01|in (r_pobj) after_5\IN\after.s.01|dox (r_prep) markers_1\NNS\artifact.n.01|of|after (l_prep) of_2\IN\entity.n.01|injury (l_pobj) injury_4\NN\ill_health.n.01|ischemic
D004317_D066126 NONE dox_13\NNP\entity.n.01| (r_pobj) after_12\IN\after.s.01|dox (r_prep) amount_7\NN\assets.n.01|the|of|after|, (r_pobj) between_5\IN\between.r.01|amount (r_prep) discrepancy_4\NN\difference.n.01|a|between (r_attr) was_2\VBD\washington.n.02|although|there|discrepancy|due (r_advcl) is_33\VBZ\be.v.01|was|,|it|likely|. (l_acomp) likely_34\JJ\likely.a.01|indicates (l_ccomp) indicates_41\VBZ\tell.v.02|that|ctnt|after|dox|damage|induced|and|be (l_conj) be_55\VB\metallic_element.n.01|that|ctnt|should|marker (l_attr) marker_58\NN\artifact.n.01|a|useful|for (l_prep) for_59\IN\entity.n.01|prediction (l_pobj) prediction_61\NN\reasoning.n.01|the|of (l_prep) of_62\IN\entity.n.01|cardiotoxicity (l_pobj) cardiotoxicity_65\NN\entity.n.01|induced|and|for
D004317_D066126 NONE dox_40\NNP\entity.n.01| (r_nsubj) indicates_41\VBZ\tell.v.02|that|ctnt|after|dox|damage|induced|and|be (l_conj) be_55\VB\metallic_element.n.01|that|ctnt|should|marker (l_attr) marker_58\NN\artifact.n.01|a|useful|for (l_prep) for_59\IN\entity.n.01|prediction (l_pobj) prediction_61\NN\reasoning.n.01|the|of (l_prep) of_62\IN\entity.n.01|cardiotoxicity (l_pobj) cardiotoxicity_65\NN\entity.n.01|induced|and|for
19037603
D019259_D012216 NONE lamivudine_3\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) of_2\IN\entity.n.01|lamivudine (r_prep) use_1\NN\activity.n.01|prophylactic|of|with|. (l_prep) with_4\IN\entity.n.01|therapy (l_pobj) therapy_7\NN\medical_care.n.01|chronic|immunosuppressive|for (l_prep) for_8\IN\entity.n.01|disorders (l_pobj) disorders_10\NNS\physical_condition.n.01|rheumatologic
D019259_D012216 NONE lamivudine_18\NN\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_pobj) of_17\IN\entity.n.01|lamivudine (r_prep) administration_16\NN\management.n.01|the|prophylactic|of|in (r_pobj) of_13\IN\entity.n.01|administration (r_prep) effectiveness_12\NN\power.n.01|the|of (r_pobj) concerning_10\VBG\refer.v.02|effectiveness (r_prep) report_7\VB\document.n.01|to|experience|concerning (r_xcomp) was_5\VBD\washington.n.02|objective|report|patients|. (l_attr) patients_30\NNS\case.n.06|)|positive|with (l_prep) with_31\IN\entity.n.01|disease (l_pobj) disease_33\NN\illness.n.01|rheumatologic
D019259_D012216 NONE lamivudine_23\JJ\nucleoside_reverse_transcriptase_inhibitor.n.01| (r_compound) therapies_24\NNS\medical_care.n.01|immunosuppressive|lamivudine (r_pobj) on_18\IN\on.a.01|therapies (r_prep) were_17\VBD\be.v.01|who|on (r_relcl) diseases_14\NNS\illness.n.01|rheumatologic|,|were
D006514_D012216 NONE antigen_24\NN\substance.n.07|virus|surface|ag (r_pobj) in_19\IN\linear_unit.n.01|antigen (r_prep) administration_16\NN\management.n.01|the|prophylactic|of|in (r_pobj) of_13\IN\entity.n.01|administration (r_prep) effectiveness_12\NN\power.n.01|the|of (r_pobj) concerning_10\VBG\refer.v.02|effectiveness (r_prep) report_7\VB\document.n.01|to|experience|concerning (r_xcomp) was_5\VBD\washington.n.02|objective|report|patients|. (l_attr) patients_30\NNS\case.n.06|)|positive|with (l_prep) with_31\IN\entity.n.01|disease (l_pobj) disease_33\NN\illness.n.01|rheumatologic
D006514_D012216 NONE ag_27\NNP\conductor.n.02|(|hbs (r_appos) antigen_24\NN\substance.n.07|virus|surface|ag (r_pobj) in_19\IN\linear_unit.n.01|antigen (r_prep) administration_16\NN\management.n.01|the|prophylactic|of|in (r_pobj) of_13\IN\entity.n.01|administration (r_prep) effectiveness_12\NN\power.n.01|the|of (r_pobj) concerning_10\VBG\refer.v.02|effectiveness (r_prep) report_7\VB\document.n.01|to|experience|concerning (r_xcomp) was_5\VBD\washington.n.02|objective|report|patients|. (l_attr) patients_30\NNS\case.n.06|)|positive|with (l_prep) with_31\IN\entity.n.01|disease (l_pobj) disease_33\NN\illness.n.01|rheumatologic
D006514_D012216 NONE ag_9\NNP\conductor.n.02|11|hbs (r_nmod) patients_11\NNS\case.n.06|ag|positive|with (l_prep) with_12\IN\entity.n.01|diseases (l_pobj) diseases_14\NNS\illness.n.01|rheumatologic|,|were
12653683
D012964_D009404 NONE sodium_1\NN\metallic_element.n.01| (r_compound) channel_2\NN\transmission.n.02|epithelial|sodium|(|enac|)|subunit|. (l_appos) subunit_6\NN\monetary_unit.n.01|mrna (l_appos) mrna_7\NN\ribonucleic_acid.n.01|and|expression (l_conj) expression_10\NN\countenance.n.01|protein|in (l_prep) in_11\IN\linear_unit.n.01|rats (l_pobj) rats_12\NNS\rodent.n.01|with (l_prep) with_13\IN\entity.n.01|syndrome (l_pobj) syndrome_19\NN\complex.n.01|puromycin|induced|nephrotic
D012964_D009404 NONE sodium_6\NN\metallic_element.n.01|urinary (r_compound) excretion_7\NN\discharge.n.04|sodium (r_nsubjpass) decreased_9\VBN\change_magnitude.v.01|in|,|excretion|is|during|. (l_prep) in_0\IN\linear_unit.n.01|syndrome (l_pobj) syndrome_3\NN\complex.n.01|experimental|nephrotic
D011692_D009404 CID aminonucleoside_15\RB\entity.n.01| (r_advmod) induced_17\VBN\generate.v.01|aminonucleoside|- (r_amod) syndrome_19\NN\complex.n.01|puromycin|induced|nephrotic
D011692_D009404 CID aminonucleoside_12\NN\entity.n.01|syndrome (l_pobj) syndrome_16\NN\complex.n.01|pan)-induced|nephrotic
D011692_D009404 CID pan)-induced_14\VBN\entity.n.01|( (r_amod) syndrome_16\NN\complex.n.01|pan)-induced|nephrotic
D011692_D009404 CID pan_22\NNP\cooking_utensil.n.01| (r_npadvmod) induced_24\VBN\generate.v.01|pan|- (r_amod) syndrome_26\NN\complex.n.01|induced|nephrotic|in
D012964_D011507 NONE sodium_5\NN\metallic_element.n.01|urinary (r_compound) excretion_6\NN\discharge.n.04|sodium|,|concentration (l_conj) concentration_10\NN\property.n.02|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\symptom.n.01|
D012964_D011507 NONE sodium_4\NN\metallic_element.n.01|urinary (r_compound) excretion_5\NN\discharge.n.04|sodium (r_pobj) of_2\IN\entity.n.01|excretion (r_prep) kinetics_1\NNS\mechanics.n.01|the|of|and|appearance (l_conj) appearance_8\NN\quality.n.01|the|of (l_prep) of_9\IN\entity.n.01|proteinuria (l_pobj) proteinuria_10\NN\symptom.n.01|
D000450_D011507 NONE aldosterone_9\NN\mineralocorticoid.n.01|plasma (r_compound) concentration_10\NN\property.n.02|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\symptom.n.01|
D011692_D011507 CID pan_28\NNP\cooking_utensil.n.01|either|or|vehicle (r_pobj) of_26\IN\entity.n.01|pan (r_prep) dose_25\NN\medicine.n.02|a|single|of (r_pobj) with_22\IN\entity.n.01|dose (r_prep) treated_21\VBN\interact.v.01|with (r_acl) rats_20\NNS\rodent.n.01|male|dawley|treated (r_pobj) in_15\IN\linear_unit.n.01|rats (r_prep) studied_14\VBN\analyze.v.01|courses|were|in|. (l_nsubjpass) courses_2\NNS\education.n.01|the|time|of (l_prep) of_3\IN\entity.n.01|excretion (l_pobj) excretion_6\NN\discharge.n.04|sodium|,|concentration (l_conj) concentration_10\NN\property.n.02|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\symptom.n.01|
D000450_D009404 NONE aldosterone_38\NN\mineralocorticoid.n.01| (r_pobj) by_37\IN\by.r.01|aldosterone (r_prep) regulation_36\NN\rule.n.03|the|by (r_pobj) from_34\IN\entity.n.01|regulation (r_prep) escape_33\VB\running_away.n.01|to|from|after (r_xcomp) appears_31\VBZ\be.v.01|escape (r_conj) increased_11\VBN\change_magnitude.v.01|in|,|expression|is|in|,|but|appears|. (l_prep) in_12\IN\linear_unit.n.01|phase (l_pobj) phase_16\NN\time_period.n.01|the|early|of (l_prep) of_17\IN\entity.n.01|model (l_pobj) model_20\NN\hypothesis.n.02|the|experimental|of (l_prep) of_21\IN\entity.n.01|syndrome (l_pobj) syndrome_26\NN\complex.n.01|induced|nephrotic|in
12090760
D015215_D000740 CID azidothymidine_9\RB\entity.n.01| (r_advmod) induced_11\VBN\generate.v.01|azidothymidine|- (r_amod) anemia_12\NN\blood_disease.n.01|induced
D015215_D000740 CID azidothymidine_0\NNP\entity.n.01| (r_nsubjpass) reversed_8\VBN\change.v.02|azidothymidine|anemia|can|be|by|and|interleukin|. (l_nsubjpass) anemia_3\NN\blood_disease.n.01|(|azt)-induced|in
D015215_D000740 CID azt)-induced_2\VBN\entity.n.01| (r_compound) anemia_3\NN\blood_disease.n.01|(|azt)-induced|in
20080419
D010862_D004827 CID pilocarpine_24\NN\alkaloid.n.01| (r_pobj) by_23\IN\by.r.01|pilocarpine (r_agent) induced_22\VBN\generate.v.01|by|in (r_acl) model_19\NN\hypothesis.n.02|a|of|induced (l_prep) of_20\IN\entity.n.01|epilepsy (l_pobj) epilepsy_21\NN\brain_disorder.n.01|
11419773
D002110_D001145 NONE caffeine_0\NN\alkaloid.n.01| (r_nsubj) induced_2\VBN\generate.v.01|caffeine|- (r_amod) arrhythmia_4\NN\heart_disease.n.01|induced|cardiac|:|danger|.
D002110_D008945 NONE caffeine_34\NN\alkaloid.n.01| (r_pobj) of_33\IN\entity.n.01|caffeine (r_prep) concentration_32\NN\property.n.02|a|high|of (r_dobj) containing_29\VBG\include.v.01|concentration (r_acl) drink_28\NN\helping.n.01|a|"|energy|"|guarana|health|containing (r_dobj) consuming_20\VBG\eat.v.01|drink (r_pcomp) after_19\IN\after.s.01|consuming (r_prep) developed_15\VBD\create.v.02|who|fibrillation|after (r_relcl) woman_6\NN\adult.n.01|a|old|with|developed (l_prep) with_7\IN\entity.n.01|prolapse (l_pobj) prolapse_13\NN\disability.n.01|existing|mitral|valve
D002110_D014693 CID caffeine_34\NN\alkaloid.n.01| (r_pobj) of_33\IN\entity.n.01|caffeine (r_prep) concentration_32\NN\property.n.02|a|high|of (r_dobj) containing_29\VBG\include.v.01|concentration (r_acl) drink_28\NN\helping.n.01|a|"|energy|"|guarana|health|containing (r_dobj) consuming_20\VBG\eat.v.01|drink (r_pcomp) after_19\IN\after.s.01|consuming (r_prep) developed_15\VBD\create.v.02|who|fibrillation|after (l_dobj) fibrillation_18\NN\twitch.n.01|intractable|ventricular
12627929
C067311_D054556 CID docetaxel_9\NNS\entity.n.01|and|thalidomide (r_pobj) of_8\IN\entity.n.01|docetaxel (r_prep) combination_7\NN\collection.n.01|the|of|in (r_pobj) with_5\IN\entity.n.01|combination (r_prep) thromboembolism_4\NN\occlusion.n.01|venous|with
C067311_D054556 CID docetaxel_26\NNS\entity.n.01| (r_pobj) with_25\IN\entity.n.01|docetaxel (r_prep) treated_24\VBN\interact.v.01|who|were|with|alone (r_relcl) cancer_21\NN\malignant_tumor.n.01|advanced|independent|prostate|treated (r_pobj) with_15\IN\entity.n.01|cancer (r_prep) patients_14\NNS\case.n.06|with (r_pobj) in_13\IN\linear_unit.n.01|patients (r_prep) frequency_6\NN\rate.n.01|the|of|in (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)
C067311_D054556 CID docetaxel_26\NNS\entity.n.01| (r_pobj) with_25\IN\entity.n.01|docetaxel (r_prep) treated_24\VBN\interact.v.01|who|were|with|alone (r_relcl) cancer_21\NN\malignant_tumor.n.01|advanced|independent|prostate|treated (r_pobj) with_15\IN\entity.n.01|cancer (r_prep) patients_14\NNS\case.n.06|with (r_pobj) in_13\IN\linear_unit.n.01|patients (r_prep) frequency_6\NN\rate.n.01|the|of|in (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|) (l_appos) vte_11\NNP\entity.n.01|
C067311_D054556 CID docetaxel_6\NNS\entity.n.01| (r_dobj) received_5\VBD\get.v.01|who|docetaxel|alone (r_relcl) patients_3\NNS\case.n.06|23|received (r_pobj) of_1\IN\entity.n.01|patients (r_prep) none_0\NN\hour.n.02|of (r_nsubj) developed_8\VBN\create.v.02|none|vte|,|developed|. (l_dobj) vte_9\NNP\entity.n.01|
C067311_D054556 CID docetaxel_6\NNS\entity.n.01| (r_dobj) received_5\VBD\get.v.01|who|docetaxel|alone (r_relcl) patients_3\NNS\case.n.06|23|received (r_pobj) of_1\IN\entity.n.01|patients (r_prep) none_0\NN\hour.n.02|of (r_nsubj) developed_8\VBN\create.v.02|none|vte|,|developed|. (l_advcl) developed_25\VBD\create.v.02|whereas|9|vte (l_dobj) vte_26\NNP\entity.n.01|p=0.025
C067311_D054556 CID docetaxel_22\NNS\entity.n.01| (r_dobj) received_21\VBD\get.v.01|who|docetaxel (r_relcl) patients_15\NNS\case.n.06|47|(|%|)|received (r_pobj) of_13\IN\entity.n.01|patients (r_prep) 9_12\CD\digit.n.01|of|plus|thalidomide (r_nsubj) developed_25\VBD\create.v.02|whereas|9|vte (r_advcl) developed_8\VBN\create.v.02|none|vte|,|developed|. (l_dobj) vte_9\NNP\entity.n.01|
C067311_D054556 CID docetaxel_22\NNS\entity.n.01| (r_dobj) received_21\VBD\get.v.01|who|docetaxel (r_relcl) patients_15\NNS\case.n.06|47|(|%|)|received (r_pobj) of_13\IN\entity.n.01|patients (r_prep) 9_12\CD\digit.n.01|of|plus|thalidomide (r_nsubj) developed_25\VBD\create.v.02|whereas|9|vte (l_dobj) vte_26\NNP\entity.n.01|p=0.025
C067311_D054556 CID docetaxel_5\NNS\entity.n.01|to|in (r_relcl) addition_1\NN\component.n.03|the|of|docetaxel (r_nsubj) increases_13\VBZ\indefinite_quantity.n.01|addition|significantly|frequency|. (l_dobj) frequency_15\NN\rate.n.01|the|of (l_prep) of_16\IN\entity.n.01|vte (l_pobj) vte_17\NNP\entity.n.01|
C067311_D011471 NONE docetaxel_9\NNS\entity.n.01|and|thalidomide (r_pobj) of_8\IN\entity.n.01|docetaxel (r_prep) combination_7\NN\collection.n.01|the|of|in (l_prep) in_12\IN\linear_unit.n.01|patients (l_pobj) patients_13\NNS\case.n.06|with (l_prep) with_14\IN\entity.n.01|cancer (l_pobj) cancer_20\NN\malignant_tumor.n.01|metastatic|independent|prostate
C067311_D011471 NONE docetaxel_26\NNS\entity.n.01| (r_pobj) with_25\IN\entity.n.01|docetaxel (r_prep) treated_24\VBN\interact.v.01|who|were|with|alone (r_relcl) cancer_21\NN\malignant_tumor.n.01|advanced|independent|prostate|treated
C067311_D011471 NONE docetaxel_5\NNS\entity.n.01|to|in (l_prep) in_6\IN\linear_unit.n.01|treatment (l_pobj) treatment_8\NN\care.n.01|the|of (l_prep) of_9\IN\entity.n.01|cancer (l_pobj) cancer_11\NN\malignant_tumor.n.01|prostate
D013792_D054556 CID thalidomide_11\NN\sedative-hypnotic.n.01| (r_conj) docetaxel_9\NNS\entity.n.01|and|thalidomide (r_pobj) of_8\IN\entity.n.01|docetaxel (r_prep) combination_7\NN\collection.n.01|the|of|in (r_pobj) with_5\IN\entity.n.01|combination (r_prep) thromboembolism_4\NN\occlusion.n.01|venous|with
D013792_D054556 CID thalidomide_32\NN\sedative-hypnotic.n.01| (r_pobj) with_31\IN\entity.n.01|thalidomide (r_prep) combination_30\NN\collection.n.01|with (r_pobj) in_29\IN\linear_unit.n.01|combination (r_conj) alone_27\RB\alone.s.01|or|in (r_advmod) treated_24\VBN\interact.v.01|who|were|with|alone (r_relcl) cancer_21\NN\malignant_tumor.n.01|advanced|independent|prostate|treated (r_pobj) with_15\IN\entity.n.01|cancer (r_prep) patients_14\NNS\case.n.06|with (r_pobj) in_13\IN\linear_unit.n.01|patients (r_prep) frequency_6\NN\rate.n.01|the|of|in (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|)
D013792_D054556 CID thalidomide_32\NN\sedative-hypnotic.n.01| (r_pobj) with_31\IN\entity.n.01|thalidomide (r_prep) combination_30\NN\collection.n.01|with (r_pobj) in_29\IN\linear_unit.n.01|combination (r_conj) alone_27\RB\alone.s.01|or|in (r_advmod) treated_24\VBN\interact.v.01|who|were|with|alone (r_relcl) cancer_21\NN\malignant_tumor.n.01|advanced|independent|prostate|treated (r_pobj) with_15\IN\entity.n.01|cancer (r_prep) patients_14\NNS\case.n.06|with (r_pobj) in_13\IN\linear_unit.n.01|patients (r_prep) frequency_6\NN\rate.n.01|the|of|in (l_prep) of_7\IN\entity.n.01|thromboembolism (l_pobj) thromboembolism_9\NN\occlusion.n.01|venous|(|vte|) (l_appos) vte_11\NNP\entity.n.01|
D013792_D054556 CID thalidomide_24\NN\sedative-hypnotic.n.01| (r_conj) 9_12\CD\digit.n.01|of|plus|thalidomide (r_nsubj) developed_25\VBD\create.v.02|whereas|9|vte (r_advcl) developed_8\VBN\create.v.02|none|vte|,|developed|. (l_dobj) vte_9\NNP\entity.n.01|
D013792_D054556 CID thalidomide_24\NN\sedative-hypnotic.n.01| (r_conj) 9_12\CD\digit.n.01|of|plus|thalidomide (r_nsubj) developed_25\VBD\create.v.02|whereas|9|vte (l_dobj) vte_26\NNP\entity.n.01|p=0.025
D013792_D054556 CID thalidomide_3\NN\sedative-hypnotic.n.01| (r_pobj) of_2\IN\entity.n.01|thalidomide (r_prep) addition_1\NN\component.n.03|the|of|docetaxel (r_nsubj) increases_13\VBZ\indefinite_quantity.n.01|addition|significantly|frequency|. (l_dobj) frequency_15\NN\rate.n.01|the|of (l_prep) of_16\IN\entity.n.01|vte (l_pobj) vte_17\NNP\entity.n.01|
D013792_D011471 NONE thalidomide_11\NN\sedative-hypnotic.n.01| (r_conj) docetaxel_9\NNS\entity.n.01|and|thalidomide (r_pobj) of_8\IN\entity.n.01|docetaxel (r_prep) combination_7\NN\collection.n.01|the|of|in (l_prep) in_12\IN\linear_unit.n.01|patients (l_pobj) patients_13\NNS\case.n.06|with (l_prep) with_14\IN\entity.n.01|cancer (l_pobj) cancer_20\NN\malignant_tumor.n.01|metastatic|independent|prostate
D013792_D011471 NONE thalidomide_32\NN\sedative-hypnotic.n.01| (r_pobj) with_31\IN\entity.n.01|thalidomide (r_prep) combination_30\NN\collection.n.01|with (r_pobj) in_29\IN\linear_unit.n.01|combination (r_conj) alone_27\RB\alone.s.01|or|in (r_advmod) treated_24\VBN\interact.v.01|who|were|with|alone (r_relcl) cancer_21\NN\malignant_tumor.n.01|advanced|independent|prostate|treated
D013792_D011471 NONE thalidomide_3\NN\sedative-hypnotic.n.01| (r_pobj) of_2\IN\entity.n.01|thalidomide (r_prep) addition_1\NN\component.n.03|the|of|docetaxel (l_relcl) docetaxel_5\NNS\entity.n.01|to|in (l_prep) in_6\IN\linear_unit.n.01|treatment (l_pobj) treatment_8\NN\care.n.01|the|of (l_prep) of_9\IN\entity.n.01|cancer (l_pobj) cancer_11\NN\malignant_tumor.n.01|prostate
11256525
D019808_D001002 CID losartan_4\NN\entity.n.01| (r_amod) administration_5\NN\management.n.01|losartan (r_dobj) following_3\VBG\multitude.n.03|administration|in (r_prep) anuria_2\NN\illness.n.01|repeated|transient|following|.
D019808_D001002 CID losartan_27\NN\entity.n.01| (r_amod) administration_28\NN\management.n.01|losartan (r_pobj) after_26\IN\after.s.01|administration (r_prep) developed_20\VBD\create.v.02|who|episodes|after (l_dobj) episodes_22\NNS\happening.n.01|two|of (l_prep) of_23\IN\entity.n.01|anuria (l_pobj) anuria_25\NN\illness.n.01|transient
D019808_D001002 CID losartan_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|losartan (r_prep) mg_7\NN\metric_weight_unit.n.01|50|of (r_pobj) of_5\IN\entity.n.01|mg (r_prep) dose_4\NN\medicine.n.02|the|first|of (r_nsubj) resulted_10\VBD\prove.v.01|surprisingly|,|dose|in|. (l_prep) in_11\IN\linear_unit.n.01|anuria (l_pobj) anuria_14\NN\illness.n.01|a|sudden|,|lasted
D019808_D001002 CID losartan_7\NN\entity.n.01| (r_nsubjpass) prescribed_9\VBN\inflict.v.01|later|,|by|,|losartan|was|again|and|developed (l_conj) developed_22\VBD\create.v.02|after|,|patient|episode|. (l_dobj) episode_25\NN\happening.n.01|a|second|of|lasting (l_prep) of_26\IN\entity.n.01|anuria (l_pobj) anuria_28\NN\illness.n.01|transient
D019808_D006973 NONE losartan_27\NN\entity.n.01| (r_amod) administration_28\NN\management.n.01|losartan (r_pobj) after_26\IN\after.s.01|administration (r_prep) developed_20\VBD\create.v.02|who|episodes|after (r_relcl) kidney_14\NN\excretory_organ.n.01|a|solitary|and|insufficiency|developed (r_pobj) with_11\IN\entity.n.01|kidney (r_prep) man_10\NN\adult.n.01|a|old|hypertensive|with (l_amod) hypertensive_9\JJ\patient.n.01|
D019808_D051436 NONE losartan_27\NN\entity.n.01| (r_amod) administration_28\NN\management.n.01|losartan (r_pobj) after_26\IN\after.s.01|administration (r_prep) developed_20\VBD\create.v.02|who|episodes|after (r_relcl) kidney_14\NN\excretory_organ.n.01|a|solitary|and|insufficiency|developed (l_conj) insufficiency_18\NN\failing.n.01|chronic|renal
D019808_D006331 NONE losartan_5\NN\entity.n.01|dysfunction (l_compound) dysfunction_4\NN\pathology.n.02|severe|systolic
D005665_D001002 NONE furosemide_24\NN\diuretic_drug.n.01|and|amine (r_nmod) infusion_27\NN\solution.n.01|dose|furosemide (r_pobj) despite_20\IN\dislike.n.02|infusion (r_prep) lasted_17\VBD\measure.v.03|which|hours|despite (r_relcl) anuria_14\NN\illness.n.01|a|sudden|,|lasted
D000588_D001002 NONE amine_26\NN\methane_series.n.01| (r_conj) furosemide_24\NN\diuretic_drug.n.01|and|amine (r_nmod) infusion_27\NN\solution.n.01|dose|furosemide (r_pobj) despite_20\IN\dislike.n.02|infusion (r_prep) lasted_17\VBD\measure.v.03|which|hours|despite (r_relcl) anuria_14\NN\illness.n.01|a|sudden|,|lasted
D000809_D012078 NONE angiotensin_24\NN\vasoconstrictor.n.01|renin|- (r_compound) system_25\NN\instrumentality.n.03|the|angiotensin|(|ras|) (r_pobj) of_20\IN\entity.n.01|system (r_prep) activation_19\NN\stimulation.n.03|a|strong|of (r_pobj) in_16\IN\linear_unit.n.01|activation (r_prep) resulted_15\VBD\prove.v.01|in|,|stenosis|certainly|in|. (l_nsubj) stenosis_6\NN\pathology.n.02|renal|artery|combined
D000809_D006333 NONE angiotensin_24\NN\vasoconstrictor.n.01|renin|- (r_compound) system_25\NN\instrumentality.n.03|the|angiotensin|(|ras|) (r_pobj) of_20\IN\entity.n.01|system (r_prep) activation_19\NN\stimulation.n.03|a|strong|of (r_pobj) in_16\IN\linear_unit.n.01|activation (r_prep) resulted_15\VBD\prove.v.01|in|,|stenosis|certainly|in|. (l_nsubj) stenosis_6\NN\pathology.n.02|renal|artery|combined (l_acl) combined_7\VBN\have.v.02|with (l_prep) with_8\IN\entity.n.01|failure (l_pobj) failure_10\NN\nonaccomplishment.n.01|heart|and|therapy
D000804_D014652 NONE ii_9\NNP\digit.n.01| (r_compound) antagonist_11\NN\person.n.01|ii|receptor (r_compound) losartan_12\NN\entity.n.01|the|angiotensin|antagonist (r_nsubj) cause_14\VB\origin.n.03|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS\hindrance.n.03|serious|unexpected|in (l_prep) in_18\IN\linear_unit.n.01|patients (l_pobj) patients_19\NNS\case.n.06|with (l_prep) with_20\IN\entity.n.01|disease (l_pobj) disease_22\NN\illness.n.01|renovascular
D019808_D014652 NONE losartan_12\NN\entity.n.01|the|angiotensin|antagonist (r_nsubj) cause_14\VB\origin.n.03|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS\hindrance.n.03|serious|unexpected|in (l_prep) in_18\IN\linear_unit.n.01|patients (l_pobj) patients_19\NNS\case.n.06|with (l_prep) with_20\IN\entity.n.01|disease (l_pobj) disease_22\NN\illness.n.01|renovascular
3358181
D012312_D014693 CID ritodrine_6\JJ\entity.n.01| (r_compound) therapy_7\NN\medical_care.n.01|ritodrine (r_pobj) after_5\IN\after.s.01|therapy (r_prep) section_4\NN\music.n.01|cesarean|after (r_pobj) during_2\IN\entity.n.01|section (r_prep) tachyarrhythmias_1\NNS\entity.n.01|ventricular|during|:|interaction|.
D012312_D007752 NONE ritodrine_6\RB\entity.n.01|for (l_prep) for_7\IN\entity.n.01|labor (l_pobj) labor_9\NN\class.n.03|preterm
D012312_D007752 NONE ritodrine_19\NN\entity.n.01| (r_pobj) of_18\IN\entity.n.01|ritodrine (r_prep) effects_17\NNS\personal_property.n.01|the|residual|betamimetic|of|and|effects (r_pobj) between_13\IN\between.r.01|effects (r_prep) interactions_12\NNS\action.n.01|between (r_dobj) risk_11\VB\danger.n.03|that|patients|may|interactions (l_nsubj) patients_4\NNS\case.n.06|receiving (l_acl) receiving_5\VBG\get.v.01|ritodrine (l_dobj) ritodrine_6\RB\entity.n.01|for (l_prep) for_7\IN\entity.n.01|labor (l_pobj) labor_9\NN\class.n.03|preterm
D012312_D002318 NONE ritodrine_15\NN\entity.n.01| (r_pobj) of_14\IN\entity.n.01|ritodrine (r_prep) infusion_13\NN\solution.n.01|an|of (r_pobj) of_11\IN\entity.n.01|infusion (r_prep) cessation_10\NN\stop.n.01|of (r_pobj) after_9\IN\after.s.01|even|cessation (r_prep) complications_7\NNS\hindrance.n.03|serious|cardiovascular|after
D010656_D007022 NONE phenylephrine_22\NN\adrenergic.n.01|treat (l_relcl) treat_24\VB\nutriment.n.01|to|patients|with (l_dobj) patients_26\NNS\case.n.06|hypotensive (l_amod) hypotensive_25\JJ\patient.n.01|
D010656_D013610 NONE phenylephrine_22\NN\adrenergic.n.01|treat (l_relcl) treat_24\VB\nutriment.n.01|to|patients|with (l_prep) with_27\IN\entity.n.01|tachycardia (l_pobj) tachycardia_28\NNS\cardiac_arrhythmia.n.01|
11581460
D005283_D016055 CID fentanyl_12\NN\analgesic.n.01| (r_pobj) of_11\IN\entity.n.01|fentanyl (r_prep) infusion_10\NN\solution.n.01|continuous|intravenous|of (r_pobj) of_7\IN\entity.n.01|infusion (r_prep) result_6\NN\phenomenon.n.01|a|of (r_pobj) as_4\IN\chemical_element.n.01|result (r_prep) retention_1\NN\possession.n.01|bladder|of|as (l_prep) of_2\IN\entity.n.01|urine (l_pobj) urine_3\NN\body_waste.n.01|
D005283_D009127 NONE fentanyl_5\NN\analgesic.n.01| (r_compound) administration_6\NN\management.n.01|fentanyl (r_pobj) of_4\IN\entity.n.01|administration (r_prep) effects_3\NNS\personal_property.n.01|various|reported|side|of (r_nsubj) include_7\VBP\include.v.01|effects|rigidity|. (l_dobj) rigidity_10\NN\inelasticity.n.01|chest|wall|,|hypotension
D005283_D007022 CID fentanyl_5\NN\analgesic.n.01| (r_compound) administration_6\NN\management.n.01|fentanyl (r_pobj) of_4\IN\entity.n.01|administration (r_prep) effects_3\NNS\personal_property.n.01|various|reported|side|of (r_nsubj) include_7\VBP\include.v.01|effects|rigidity|. (l_dobj) rigidity_10\NN\inelasticity.n.01|chest|wall|,|hypotension (l_conj) hypotension_12\NN\cardiovascular_disease.n.01|,|depression
D005283_D012131 CID fentanyl_5\NN\analgesic.n.01| (r_compound) administration_6\NN\management.n.01|fentanyl (r_pobj) of_4\IN\entity.n.01|administration (r_prep) effects_3\NNS\personal_property.n.01|various|reported|side|of (r_nsubj) include_7\VBP\include.v.01|effects|rigidity|. (l_dobj) rigidity_10\NN\inelasticity.n.01|chest|wall|,|hypotension (l_conj) hypotension_12\NN\cardiovascular_disease.n.01|,|depression (l_conj) depression_15\NN\psychological_state.n.01|respiratory|,|and|bradycardia
D005283_D001919 CID fentanyl_5\NN\analgesic.n.01| (r_compound) administration_6\NN\management.n.01|fentanyl (r_pobj) of_4\IN\entity.n.01|administration (r_prep) effects_3\NNS\personal_property.n.01|various|reported|side|of (r_nsubj) include_7\VBP\include.v.01|effects|rigidity|. (l_dobj) rigidity_10\NN\inelasticity.n.01|chest|wall|,|hypotension (l_conj) hypotension_12\NN\cardiovascular_disease.n.01|,|depression (l_conj) depression_15\NN\psychological_state.n.01|respiratory|,|and|bradycardia (l_conj) bradycardia_18\NN\cardiac_arrhythmia.n.01|
D005283_D001745 CID fentanyl_22\NN\analgesic.n.01| (r_pobj) of_21\IN\entity.n.01|fentanyl (r_prep) infusion_20\NN\solution.n.01|continuous|of (r_pobj) of_18\IN\entity.n.01|infusion (r_prep) result_17\NN\phenomenon.n.01|a|of (r_pobj) as_15\IN\chemical_element.n.01|result (r_prep) mimicking_13\VBG\imitate.v.01|hydronephrosis|as (r_acl) dilatation_12\NN\physical_condition.n.01|renal|pelvocalyceal|mimicking (r_pobj) to_9\IN\entity.n.01|dilatation (r_prep) leading_8\VBG\strip.n.02|to (r_acl) cases_3\NNS\happening.n.01|2|of|leading (l_prep) of_4\IN\entity.n.01|retention (l_pobj) retention_7\NN\possession.n.01|urinary|bladder
D005283_D006869 NONE fentanyl_22\NN\analgesic.n.01| (r_pobj) of_21\IN\entity.n.01|fentanyl (r_prep) infusion_20\NN\solution.n.01|continuous|of (r_pobj) of_18\IN\entity.n.01|infusion (r_prep) result_17\NN\phenomenon.n.01|a|of (r_pobj) as_15\IN\chemical_element.n.01|result (r_prep) mimicking_13\VBG\imitate.v.01|hydronephrosis|as (l_dobj) hydronephrosis_14\NN\pathology.n.02|
2396046
D002794_D006528 CID choline_13\NN\b-complex_vitamin.n.01| (r_npadvmod) supplemented_15\VBN\add.v.01|choline|- (r_amod) diet_16\NN\fare.n.04|the|plain|supplemented (r_dobj) fed_10\VBD\agent.n.05|nodules|diet|,|developed|fed|. (l_nsubj) nodules_3\NNS\node.n.07|no|hepatic|preneoplastic|or|carcinomas|developed (l_conj) carcinomas_6\NNS\cancer.n.01|hepatocellular
D002794_D006528 CID choline_13\NN\b-complex_vitamin.n.01| (r_npadvmod) supplemented_15\VBN\add.v.01|choline|- (r_amod) diet_16\NN\fare.n.04|the|plain|supplemented (r_dobj) fed_10\VBD\agent.n.05|nodules|diet|,|developed|fed|. (l_advcl) developed_26\VBN\create.v.02|while|nodule|in (l_nsubj) nodule_21\NN\node.n.07|one|preneoplastic|and|carcinoma (l_conj) carcinoma_25\NN\cancer.n.01|one|hepatocellular
D002794_D006528 CID choline_23\NN\b-complex_vitamin.n.01| (r_npadvmod) devoid_25\JJ\barren.s.03|choline|- (r_amod) diet_26\NN\fare.n.04|the|plain|devoid (r_dobj) fed_20\VBD\agent.n.05|in|rats|diet|,|and|%|,|in (r_conj) was_9\VBD\washington.n.02|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN\frequency.n.02|the|of (l_prep) of_2\IN\entity.n.01|nodules|and|of (l_conj) of_6\IN\entity.n.01|carcinomas (l_pobj) carcinomas_8\NNS\cancer.n.01|hepatocellular
D002794_D006528 CID choline_42\NN\b-complex_vitamin.n.01| (r_npadvmod) devoid_44\JJ\barren.s.03|choline|- (r_amod) diet_45\NN\fare.n.04|the|containing|devoid (r_dobj) fed_37\VBD\agent.n.05|diet (r_conj) was_9\VBD\washington.n.02|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN\frequency.n.02|the|of (l_prep) of_2\IN\entity.n.01|nodules|and|of (l_conj) of_6\IN\entity.n.01|carcinomas (l_pobj) carcinomas_8\NNS\cancer.n.01|hepatocellular
D010634_D006528 NONE phenobarbital_35\NN\barbiturate.n.01| (r_dobj) containing_34\VBG\include.v.01|phenobarbital (r_acl) diet_33\NN\fare.n.04|the|same|containing (r_dobj) fed_30\VBD\agent.n.05|diet (r_conj) fed_10\VBD\agent.n.05|nodules|diet|,|developed|fed|. (l_nsubj) nodules_3\NNS\node.n.07|no|hepatic|preneoplastic|or|carcinomas|developed (l_conj) carcinomas_6\NNS\cancer.n.01|hepatocellular
D010634_D006528 NONE phenobarbital_35\NN\barbiturate.n.01| (r_dobj) containing_34\VBG\include.v.01|phenobarbital (r_acl) diet_33\NN\fare.n.04|the|same|containing (r_dobj) fed_30\VBD\agent.n.05|diet (r_conj) fed_10\VBD\agent.n.05|nodules|diet|,|developed|fed|. (l_advcl) developed_26\VBN\create.v.02|while|nodule|in (l_nsubj) nodule_21\NN\node.n.07|one|preneoplastic|and|carcinoma (l_conj) carcinoma_25\NN\cancer.n.01|one|hepatocellular
D010634_D006528 NONE phenobarbital_39\RB\barbiturate.n.01| (r_npadvmod) containing_41\VBG\include.v.01|phenobarbital|- (r_amod) diet_45\NN\fare.n.04|the|containing|devoid (r_dobj) fed_37\VBD\agent.n.05|diet (r_conj) was_9\VBD\washington.n.02|incidence|%|,|respectively|,|fed|fed|. (l_nsubj) incidence_1\NN\frequency.n.02|the|of (l_prep) of_2\IN\entity.n.01|nodules|and|of (l_conj) of_6\IN\entity.n.01|carcinomas (l_pobj) carcinomas_8\NNS\cancer.n.01|hepatocellular
18754075
D004164_D011507 NONE bisphosphonate_8\NN\entity.n.01|oral (r_nmod) administration_12\NN\management.n.01|bisphosphonate|alendronate|in (r_pobj) after_6\IN\after.s.01|administration (r_prep) proteinuria_1\NN\symptom.n.01|massive|and|failure|after|.
D004164_D011507 NONE bisphosphonates_11\NNS\entity.n.01|oral (r_nsubj) aggravate_13\VB\change.v.01|that|intravenous|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\symptom.n.01|and|failure
D004164_D058186 NONE bisphosphonate_8\NN\entity.n.01|oral (r_nmod) administration_12\NN\management.n.01|bisphosphonate|alendronate|in (r_pobj) after_6\IN\after.s.01|administration (r_prep) proteinuria_1\NN\symptom.n.01|massive|and|failure|after|. (l_conj) failure_5\NN\nonaccomplishment.n.01|acute|renal
D004164_D058186 NONE bisphosphonate_6\NN\entity.n.01|the|oral (r_pobj) of_3\IN\entity.n.01|bisphosphonate (r_prep) days_2\NNS\life.n.07|14|of (r_pobj) within_0\IN\inside.r.02|days (r_prep) increased_19\VBD\change_magnitude.v.01|within|administration|amount|rapidly|up|with|. (l_prep) with_25\IN\entity.n.01|failure (l_pobj) failure_28\NN\nonaccomplishment.n.01|acute|renal
D004164_D058186 NONE bisphosphonates_11\NNS\entity.n.01|oral (r_nsubj) aggravate_13\VB\change.v.01|that|intravenous|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\symptom.n.01|and|failure (l_conj) failure_18\NN\nonaccomplishment.n.01|acute|renal
D004164_D005923 NONE bisphosphonate_8\NN\entity.n.01|oral (r_nmod) administration_12\NN\management.n.01|bisphosphonate|alendronate|in (l_prep) in_13\IN\linear_unit.n.01|patient (l_pobj) patient_15\NN\case.n.06|a|with (l_prep) with_16\IN\entity.n.01|glomerulosclerosis (l_pobj) glomerulosclerosis_19\NN\entity.n.01|focal|segmental
D019386_D011507 CID alendronate_10\JJ\medicine.n.02|(|) (r_nmod) administration_12\NN\management.n.01|bisphosphonate|alendronate|in (r_pobj) after_6\IN\after.s.01|administration (r_prep) proteinuria_1\NN\symptom.n.01|massive|and|failure|after|.
D019386_D058186 CID alendronate_10\JJ\medicine.n.02|(|) (r_nmod) administration_12\NN\management.n.01|bisphosphonate|alendronate|in (r_pobj) after_6\IN\after.s.01|administration (r_prep) proteinuria_1\NN\symptom.n.01|massive|and|failure|after|. (l_conj) failure_5\NN\nonaccomplishment.n.01|acute|renal
D019386_D058186 CID sodium_9\NN\metallic_element.n.01|(|alendronate|) (r_nmod) administration_11\NN\management.n.01|sodium|, (r_nsubj) increased_19\VBD\change_magnitude.v.01|within|administration|amount|rapidly|up|with|. (l_prep) with_25\IN\entity.n.01|failure (l_pobj) failure_28\NN\nonaccomplishment.n.01|acute|renal
D019386_D005923 NONE alendronate_10\JJ\medicine.n.02|(|) (r_nmod) administration_12\NN\management.n.01|bisphosphonate|alendronate|in (l_prep) in_13\IN\linear_unit.n.01|patient (l_pobj) patient_15\NN\case.n.06|a|with (l_prep) with_16\IN\entity.n.01|glomerulosclerosis (l_pobj) glomerulosclerosis_19\NN\entity.n.01|focal|segmental
D013256_D009404 NONE steroid_19\NN\organic_compound.n.01| (r_compound) therapy_20\NN\medical_care.n.01|steroid (r_pobj) to_18\IN\entity.n.01|therapy (r_prep) responding_16\VBG\act.v.01|man|was|initially|well|to|. (l_nsubj) man_5\NN\adult.n.01|a|old|japanese|with|due (l_prep) with_6\IN\entity.n.01|syndrome (l_pobj) syndrome_8\NN\complex.n.01|nephrotic
D013256_D005923 NONE steroid_19\NN\organic_compound.n.01| (r_compound) therapy_20\NN\medical_care.n.01|steroid (r_pobj) to_18\IN\entity.n.01|therapy (r_prep) responding_16\VBG\act.v.01|man|was|initially|well|to|. (l_nsubj) man_5\NN\adult.n.01|a|old|japanese|with|due (l_amod) due_9\IN\right.n.01|to|glomerulosclerosis (l_pobj) glomerulosclerosis_13\NN\entity.n.01|focal|segmental
10683478
D001058_D007035 CID apomorphine_0\NNP\morphine.n.01|,|agonist|, (r_nsubjpass) selected_8\VBN\decide.v.01|apomorphine|was|due|,|ability|. (l_dobj) ability_17\NN\quality.n.01|its|induce (l_acl) induce_19\VB\generate.v.01|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\physical_condition.n.01|
D001058_D007035 CID apomorphine_11\NN\morphine.n.01|to|as (l_prep) as_13\IN\chemical_element.n.01|such|hypothermia (l_pobj) hypothermia_17\NN\physical_condition.n.01|induced
D018491_D007035 NONE agonist_5\NN\protagonist.n.02|a|nonselective|dopamine (r_appos) apomorphine_0\NNP\morphine.n.01|,|agonist|, (r_nsubjpass) selected_8\VBN\decide.v.01|apomorphine|was|due|,|ability|. (l_dobj) ability_17\NN\quality.n.01|its|induce (l_acl) induce_19\VB\generate.v.01|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\physical_condition.n.01|
D004298_D007035 NONE dopamine_28\NN\monoamine_neurotransmitter.n.01|to|turnover (r_relcl) changes_26\NNS\happening.n.01|distinct|dopamine (r_dobj) produce_24\VB\food.n.02|to|changes (r_conj) induce_19\VB\generate.v.01|to|hypothermia|,|and|produce (l_dobj) hypothermia_20\NN\physical_condition.n.01|
D001058_D006948 CID apomorphine_5\NN\morphine.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|apomorphine|- (r_amod) hyperactivity_8\NN\disorder.n.01|induced
15859940
D016572_D064420 NONE cyclosporine_7\NN\entity.n.01|,|tacrolimus (r_nmod) toxicity_11\NN\definite_quantity.n.01|related|(|cyclosporine|,|status
D016559_D064420 NONE tacrolimus_9\NN\entity.n.01|) (r_conj) cyclosporine_7\NN\entity.n.01|,|tacrolimus (r_nmod) toxicity_11\NN\definite_quantity.n.01|related|(|cyclosporine|,|status
D016572_D057049 CID cyclosporine_18\NN\entity.n.01| (r_pobj) to_17\IN\entity.n.01|mainly|cyclosporine (r_prep) secondary_15\JJ\formation.n.01|to (r_amod) related_13\VBN\think.v.03|drug|,|secondary (r_acomp) was_11\VBD\washington.n.02|that|cause|related (l_nsubj) cause_7\NN\origin.n.03|the|frequent|of (l_prep) of_8\IN\entity.n.01|microangiopathy (l_pobj) microangiopathy_10\NN\entity.n.01|thrombotic
18343374
D002996_D012170 CID clomiphene_6\NN\fertility_drug.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|clomiphene|- (r_amod) ovulation_9\NN\organic_process.n.01|induced (r_pobj) with_5\IN\entity.n.01|ovulation (r_prep) associated_4\VBN\think.v.03|with (r_acl) occlusion_3\NN\attack.n.07|central|vein|associated|.
D002996_D012170 CID citrate_12\NN\ester.n.01|clomiphene|(|cc|) (r_pobj) with_10\IN\entity.n.01|citrate (r_prep) associated_9\VBN\think.v.03|with (r_acl) occlusion_8\NN\attack.n.07|central|vein|associated
D002996_D012170 CID cc_14\NN\metric_capacity_unit.n.01| (r_appos) citrate_12\NN\ester.n.01|clomiphene|(|cc|) (r_pobj) with_10\IN\entity.n.01|citrate (r_prep) associated_9\VBN\think.v.03|with (r_acl) occlusion_8\NN\attack.n.07|central|vein|associated
D002996_D012170 CID cc_13\NN\metric_capacity_unit.n.01| (r_pobj) with_12\IN\entity.n.01|cc (r_prep) induction_11\NN\ceremony.n.01|ovulation|with (r_pobj) after_9\IN\after.s.01|induction (r_prep) occlusion_8\NN\attack.n.07|central|vein|after
D002996_D012170 CID cc_18\NN\metric_capacity_unit.n.01| (r_pobj) of_17\IN\entity.n.01|cc (r_prep) courses_16\NNS\education.n.01|eight|of (r_pobj) after_14\IN\after.s.01|courses (r_prep) developed_9\VBD\create.v.02|result(s|:|woman|occlusion|after|. (l_dobj) occlusion_13\NN\attack.n.07|central|vein
D002996_D012170 CID cc_15\NN\metric_capacity_unit.n.01| (r_pobj) with_14\IN\entity.n.01|cc (r_prep) treatment_13\NN\care.n.01|with (r_pobj) after_12\IN\after.s.01|treatment (r_prep) occlusion_11\NN\attack.n.07|vein|after
D002996_D013923 NONE cc_10\NN\metric_capacity_unit.n.01| (r_pobj) of_9\IN\entity.n.01|cc (r_prep) complications_8\NNS\hindrance.n.03|the|thromboembolic|of (l_compound) thromboembolic_7\JJ\entity.n.01|
D002996_D013923 NONE cc_24\NN\metric_capacity_unit.n.01| (r_compound) intake_25\NN\bodily_process.n.01|cc (r_pobj) after_23\IN\after.s.01|intake (r_prep) disturbance_22\NN\activity.n.01|mild|visual|after (r_nsubj) is_26\VBZ\be.v.01|although|disturbance|not|uncommon (r_advcl) include_13\VB\include.v.01|search|does|not|complication|,|is|. (l_nsubj) search_1\NN\activity.n.01|a|of|on (l_prep) on_5\IN\on.a.01|complications (l_pobj) complications_8\NNS\hindrance.n.03|the|thromboembolic|of (l_compound) thromboembolic_7\JJ\entity.n.01|
D002996_D014786 CID cc_10\NN\metric_capacity_unit.n.01| (r_pobj) of_9\IN\entity.n.01|cc (r_prep) complications_8\NNS\hindrance.n.03|the|thromboembolic|of (r_pobj) on_5\IN\on.a.01|complications (r_prep) search_1\NN\activity.n.01|a|of|on (r_nsubj) include_13\VB\include.v.01|search|does|not|complication|,|is|. (l_advcl) is_26\VBZ\be.v.01|although|disturbance|not|uncommon (l_nsubj) disturbance_22\NN\activity.n.01|mild|visual|after
D002996_D014786 CID cc_24\NN\metric_capacity_unit.n.01| (r_compound) intake_25\NN\bodily_process.n.01|cc (r_pobj) after_23\IN\after.s.01|intake (r_prep) disturbance_22\NN\activity.n.01|mild|visual|after
D002996_D007247 NONE cc_9\NN\metric_capacity_unit.n.01| (r_pobj) with_8\IN\entity.n.01|cc (r_prep) treating_5\VBG\interact.v.01|patients|with (l_dobj) patients_7\NNS\case.n.06|infertility (l_compound) infertility_6\NN\physical_condition.n.01|
2425813
D011239_D006529 CID prednisolone_14\NN\anti-inflammatory.n.01| (r_pobj) of_13\IN\entity.n.01|prednisolone (r_prep) administration_12\NN\management.n.01|the|subcutaneous|of (r_pobj) following_9\VBG\multitude.n.03|administration (r_prep) occurred_5\VBD\happen.v.01|enlargement|in|following|. (l_nsubj) enlargement_1\NN\increase.n.05|liver|and|wastage
D011239_D009133 CID prednisolone_14\NN\anti-inflammatory.n.01| (r_pobj) of_13\IN\entity.n.01|prednisolone (r_prep) administration_12\NN\management.n.01|the|subcutaneous|of (r_pobj) following_9\VBG\multitude.n.03|administration (r_prep) occurred_5\VBD\happen.v.01|enlargement|in|following|. (l_nsubj) enlargement_1\NN\increase.n.05|liver|and|wastage (l_conj) wastage_4\NN\decrease.n.02|muscle
18726058
D010208_D020301 NONE hydrochloride_1\NN\complex.n.02|papaverine (r_nsubj) is_2\VBZ\be.v.01|hydrochloride|vasodilator|. (l_attr) vasodilator_7\NN\dilator.n.02|a|acting|used (l_acl) used_8\VBD\use.v.01|manage (l_xcomp) manage_10\VB\succeed.v.01|to|vasospasm|during (l_dobj) vasospasm_11\NN\entity.n.01|
D010208_D020301 NONE papaverine_18\NN\muscle_relaxant.n.01|topical (r_dobj) received_16\VBD\get.v.01|who|papaverine|for (l_prep) for_19\IN\entity.n.01|vasospasm (l_pobj) vasospasm_20\NN\entity.n.01|
D010208_D020301 NONE papaverine_1\NN\muscle_relaxant.n.01|topical (r_nsubjpass) used_3\VBN\use.v.01|papaverine|was|as|. (l_prep) as_4\IN\chemical_element.n.01|action (l_pobj) action_8\NN\act.n.02|a|direct|therapeutic|manage (l_acl) manage_10\VB\succeed.v.01|to|vasospasm|in (l_dobj) vasospasm_11\NN\entity.n.01|
D010208_D020301 NONE papaverine_1\NN\muscle_relaxant.n.01|topical|for (l_prep) for_2\IN\entity.n.01|treatment (l_pobj) treatment_4\NN\care.n.01|the|of (l_prep) of_5\IN\entity.n.01|vasospasm (l_pobj) vasospasm_6\NN\entity.n.01|
D010208_D003389 NONE papaverine_13\NN\muscle_relaxant.n.01|topical (r_pobj) with_11\IN\entity.n.01|papaverine (r_prep) cases_10\NNS\happening.n.01|a|few|with (r_pobj) in_7\IN\linear_unit.n.01|cases (r_prep) described_6\VBN\set_forth.v.01|dysfunction|has|been|in|. (l_nsubjpass) dysfunction_3\NN\pathology.n.02|transient|cranial|nerve
D010208_D003389 NONE papaverine_8\NN\muscle_relaxant.n.01| (r_pobj) from_7\IN\entity.n.01|papaverine (r_prep) deficits_6\NNS\insufficiency.n.03|potential|nerve|from
11752354
D003276_D009203 CID contraceptives_1\NNS\device.n.01|oral|and|risk|. (l_conj) risk_4\NN\danger.n.03|the|of (l_prep) of_5\IN\entity.n.01|infarction (l_pobj) infarction_7\NN\pathology.n.02|myocardial
D003276_D009203 CID contraceptives_7\NNS\device.n.01|oral (r_pobj) of_5\IN\entity.n.01|contraceptives (r_prep) use_4\NN\activity.n.01|the|of|and|risk (l_conj) risk_10\NN\danger.n.03|the|of (l_prep) of_11\IN\entity.n.01|infarction (l_pobj) infarction_13\NN\pathology.n.02|myocardial
D003276_D009203 CID contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between
D003276_D009203 CID contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between (l_prep) between_82\IN\between.r.01|1990 (l_pobj) 1990_83\CD\entity.n.01|and|1995|and|women (l_conj) women_89\NNS\adult.n.01|925|control|had (l_relcl) had_93\VBN\have.v.01|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\pathology.n.02|a|myocardial
D003276_D009203 CID contraceptive_39\NN\device.n.01|combined|oral (r_pobj) of_36\IN\entity.n.01|contraceptive (r_prep) type_35\NN\kind.n.01|any|of (r_dobj) used_33\VBD\use.v.01|who|type|,|compared (r_relcl) women_31\NNS\adult.n.01|used (r_pobj) among_30\IN\entity.n.01|women (r_prep) infarction_29\NN\pathology.n.02|myocardial|among
D003276_D009203 CID contraceptives_5\NNS\device.n.01|oral (r_dobj) used_3\VBD\use.v.01|who|contraceptives (r_relcl) women_1\NNS\adult.n.01|used (r_pobj) among_0\IN\entity.n.01|women (r_prep) was_10\VBD\washington.n.02|among|,|ratio|interval|for|: (r_ccomp) increased_53\VBN\change_magnitude.v.01|was|risk|was|among|. (l_nsubjpass) risk_48\NN\danger.n.03|the|of (l_prep) of_49\IN\entity.n.01|infarction (l_pobj) infarction_51\NN\pathology.n.02|myocardial
D003276_D009203 CID contraceptives_62\NNS\device.n.01|generation|oral (r_dobj) used_57\VBD\use.v.01|who|contraceptives (r_relcl) women_55\NNS\adult.n.01|used (r_pobj) among_54\IN\entity.n.01|women (r_prep) increased_53\VBN\change_magnitude.v.01|was|risk|was|among|. (l_nsubjpass) risk_48\NN\danger.n.03|the|of (l_prep) of_49\IN\entity.n.01|infarction (l_pobj) infarction_51\NN\pathology.n.02|myocardial
D003276_D009203 CID contraceptives_12\NNS\device.n.01|oral (r_dobj) used_10\VBD\use.v.01|who|contraceptives|had (r_relcl) women_8\NNS\adult.n.01|used (r_pobj) among_7\IN\entity.n.01|women (r_prep) similar_6\JJ\similar.a.01|among (r_acomp) was_5\VBD\washington.n.02|risk|similar|. (l_nsubj) risk_1\NN\danger.n.03|the|of (l_prep) of_2\IN\entity.n.01|infarction (l_pobj) infarction_4\NN\pathology.n.02|myocardial
D011372_D009203 NONE progestagen_10\NN\entity.n.01| (r_pobj) of_9\IN\entity.n.01|progestagen (r_prep) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between
D011372_D009203 NONE progestagen_10\NN\entity.n.01| (r_pobj) of_9\IN\entity.n.01|progestagen (r_prep) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between (l_prep) between_82\IN\between.r.01|1990 (l_pobj) 1990_83\CD\entity.n.01|and|1995|and|women (l_conj) women_89\NNS\adult.n.01|925|control|had (l_relcl) had_93\VBN\have.v.01|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\pathology.n.02|a|myocardial
D017135_D009203 NONE desogestrel_19\NN\entity.n.01|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\people.n.01|third|-|desogestrel (r_nmod) contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between
D017135_D009203 NONE desogestrel_19\NN\entity.n.01|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\people.n.01|third|-|desogestrel (r_nmod) contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between (l_prep) between_82\IN\between.r.01|1990 (l_pobj) 1990_83\CD\entity.n.01|and|1995|and|women (l_conj) women_89\NNS\adult.n.01|925|control|had (l_relcl) had_93\VBN\have.v.01|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\pathology.n.02|a|myocardial
C033273_D009203 NONE gestodene_21\NN\entity.n.01| (r_conj) desogestrel_19\NN\entity.n.01|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\people.n.01|third|-|desogestrel (r_nmod) contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between
C033273_D009203 NONE gestodene_21\NN\entity.n.01| (r_conj) desogestrel_19\NN\entity.n.01|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\people.n.01|third|-|desogestrel (r_nmod) contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between (l_prep) between_82\IN\between.r.01|1990 (l_pobj) 1990_83\CD\entity.n.01|and|1995|and|women (l_conj) women_89\NNS\adult.n.01|925|control|had (l_relcl) had_93\VBN\have.v.01|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\pathology.n.02|a|myocardial
D016912_D009203 NONE levonorgestrel_30\JJ\entity.n.01|generation|(|i.e.|,|) (r_conj) desogestrel_19\NN\entity.n.01|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\people.n.01|third|-|desogestrel (r_nmod) contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between
D016912_D009203 NONE levonorgestrel_30\JJ\entity.n.01|generation|(|i.e.|,|) (r_conj) desogestrel_19\NN\entity.n.01|(|i.e.|,|or|gestodene|)|and|levonorgestrel (r_appos) generation_15\NN\people.n.01|third|-|desogestrel (r_nmod) contraceptives_33\NNS\device.n.01|generation|oral (r_pobj) in_12\IN\linear_unit.n.01|contraceptives (r_prep) included_11\VBN\include.v.01|in (r_acl) type_8\NN\kind.n.01|the|of|included (r_pobj) to_6\IN\entity.n.01|type (r_prep) according_5\VBG\match.v.01|to (r_prep) investigated_1\VBD\analyze.v.01|we|association|,|according|identified (l_conj) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between (l_prep) between_82\IN\between.r.01|1990 (l_pobj) 1990_83\CD\entity.n.01|and|1995|and|women (l_conj) women_89\NNS\adult.n.01|925|control|had (l_relcl) had_93\VBN\have.v.01|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\pathology.n.02|a|myocardial
D004967_D009203 NONE estrogen_38\NN\steroid_hormone.n.01| (r_pobj) of_37\IN\entity.n.01|estrogen (r_prep) dose_36\NN\medicine.n.02|the|of|,|and|presence (r_dep) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between
D004967_D009203 NONE estrogen_38\NN\steroid_hormone.n.01| (r_pobj) of_37\IN\entity.n.01|estrogen (r_prep) dose_36\NN\medicine.n.02|the|of|,|and|presence (r_dep) identified_64\VBD\determine.v.03|,|dose|:|in|,|we|and|enrolled|. (l_conj) enrolled_66\VBD\register.v.01|women|18|through|,|year (l_dobj) women_68\NNS\adult.n.01|248|had (l_relcl) had_77\VBN\have.v.01|who|had|infarction (l_dobj) infarction_81\NN\pathology.n.02|a|first|myocardial|between (l_prep) between_82\IN\between.r.01|1990 (l_pobj) 1990_83\CD\entity.n.01|and|1995|and|women (l_conj) women_89\NNS\adult.n.01|925|control|had (l_relcl) had_93\VBN\have.v.01|who|had|not|infarction|and|matched (l_dobj) infarction_96\NN\pathology.n.02|a|myocardial
9721172
D007052_D001649 NONE ibuprofen_30\JJ\nonsteroidal_anti-inflammatory.n.01| (r_compound) use_31\NN\activity.n.01|ibuprofen (r_pobj) with_29\IN\entity.n.01|use (r_prep) associated_28\VBN\think.v.03|child|;|this|was|temporally|with|. (l_nsubjpass) child_3\NN\juvenile.n.01|a|healthy|developed|described (l_relcl) developed_5\VBD\create.v.02|who|syndrome (l_dobj) syndrome_15\NN\complex.n.01|acute|,|severe|,|progressive|duct
D007052_D013262 CID ibuprofen_30\JJ\nonsteroidal_anti-inflammatory.n.01| (r_compound) use_31\NN\activity.n.01|ibuprofen (r_pobj) with_29\IN\entity.n.01|use (r_prep) associated_28\VBN\think.v.03|child|;|this|was|temporally|with|. (l_nsubjpass) child_3\NN\juvenile.n.01|a|healthy|developed|described (l_relcl) described_23\VBN\set_forth.v.01|after|syndrome|is (l_nsubjpass) syndrome_21\NN\complex.n.01|johnson
D014580_D002779 NONE acid_4\NN\compound.n.02|ursodeoxycholic|,|prednisone (l_conj) prednisone_6\NN\anti-inflammatory.n.01|,|and|tacrolimus (l_conj) tacrolimus_10\VB\entity.n.01|then|,|disease (l_conj) disease_14\NN\illness.n.01|her|cholestatic
D014580_D005355 NONE acid_4\NN\compound.n.02|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN\entity.n.01|acid (r_prep) therapy_1\NN\medical_care.n.01|with (r_pobj) despite_0\IN\dislike.n.02|therapy (r_prep) was_15\VBD\washington.n.02|despite|unrelenting|,|with|. (l_prep) with_18\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_19\NN\liver_disease.n.01|shown
D011241_D002779 NONE prednisone_6\NN\anti-inflammatory.n.01|,|and|tacrolimus (l_conj) tacrolimus_10\VB\entity.n.01|then|,|disease (l_conj) disease_14\NN\illness.n.01|her|cholestatic
D011241_D005355 NONE prednisone_6\NN\anti-inflammatory.n.01|,|and|tacrolimus (r_conj) acid_4\NN\compound.n.02|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN\entity.n.01|acid (r_prep) therapy_1\NN\medical_care.n.01|with (r_pobj) despite_0\IN\dislike.n.02|therapy (r_prep) was_15\VBD\washington.n.02|despite|unrelenting|,|with|. (l_prep) with_18\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_19\NN\liver_disease.n.01|shown
D016559_D002779 NONE tacrolimus_10\VB\entity.n.01|then|,|disease (l_conj) disease_14\NN\illness.n.01|her|cholestatic
D016559_D005355 NONE tacrolimus_10\VB\entity.n.01|then|,|disease (r_conj) prednisone_6\NN\anti-inflammatory.n.01|,|and|tacrolimus (r_conj) acid_4\NN\compound.n.02|ursodeoxycholic|,|prednisone (r_pobj) with_2\IN\entity.n.01|acid (r_prep) therapy_1\NN\medical_care.n.01|with (r_pobj) despite_0\IN\dislike.n.02|therapy (r_prep) was_15\VBD\washington.n.02|despite|unrelenting|,|with|. (l_prep) with_18\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_19\NN\liver_disease.n.01|shown
9587734
D013390_D006323 CID suxamethonium_0\NN\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|suxamethonium|- (r_amod) arrest_4\NN\capture.n.01|induced|cardiac|and|death|following|.
D013390_D006323 CID suxamethonium_21\NN\entity.n.01|in (r_pobj) of_20\IN\entity.n.01|suxamethonium (r_prep) use_19\NN\activity.n.01|the|of (r_pobj) following_17\VBG\multitude.n.03|use (r_prep) case_5\NN\happening.n.01|a|of|following (l_prep) of_6\IN\entity.n.01|arrest (l_pobj) arrest_8\NN\capture.n.01|cardiac|and|death
D013390_D006323 CID suxamethonium_5\NN\entity.n.01|,|arrest (l_appos) arrest_10\NN\capture.n.01|bradycardia|cardiac
D013390_D003643 NONE suxamethonium_0\NN\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|suxamethonium|- (r_amod) arrest_4\NN\capture.n.01|induced|cardiac|and|death|following|. (l_conj) death_6\NN\change.n.01|
D013390_D003643 NONE suxamethonium_21\NN\entity.n.01|in (r_pobj) of_20\IN\entity.n.01|suxamethonium (r_prep) use_19\NN\activity.n.01|the|of (r_pobj) following_17\VBG\multitude.n.03|use (r_prep) case_5\NN\happening.n.01|a|of|following (l_prep) of_6\IN\entity.n.01|arrest (l_pobj) arrest_8\NN\capture.n.01|cardiac|and|death (l_conj) death_11\NN\change.n.01|subsequent|as
D013390_D003643 NONE suxamethonium_11\NN\entity.n.01| (r_pobj) to_10\IN\entity.n.01|suxamethonium (r_prep) hypersensitivity_9\NN\sensitivity.n.04|to (r_pobj) by_8\IN\by.r.01|hypersensitivity (r_agent) caused_7\VBN\make.v.03|that|death|was|by|,|associated (l_nsubjpass) death_5\NN\change.n.01|her
D013390_D006947 CID suxamethonium_21\NN\entity.n.01|in (r_pobj) of_20\IN\entity.n.01|suxamethonium (r_prep) use_19\NN\activity.n.01|the|of (r_pobj) following_17\VBG\multitude.n.03|use (r_prep) case_5\NN\happening.n.01|a|of|following (l_prep) of_6\IN\entity.n.01|arrest (l_pobj) arrest_8\NN\capture.n.01|cardiac|and|death (l_conj) death_11\NN\change.n.01|subsequent|as (l_prep) as_12\IN\chemical_element.n.01|result (l_pobj) result_14\NN\phenomenon.n.01|a|of (l_prep) of_15\IN\entity.n.01|hyperkalaemia (l_pobj) hyperkalaemia_16\NN\entity.n.01|
D013390_D006947 CID suxamethonium_35\NN\entity.n.01| (r_pobj) of_34\IN\entity.n.01|suxamethonium (r_prep) administration_33\NN\management.n.01|the|of (r_pobj) following_31\VBG\multitude.n.03|administration (r_prep) signs_15\NNS\clue.n.02|no|of|following (l_prep) of_16\IN\entity.n.01|damage|or|of (l_conj) of_21\IN\entity.n.01|any (l_pobj) any_22\DT\any.s.01|of (l_prep) of_23\IN\entity.n.01|conditions (l_pobj) conditions_28\NNS\context.n.02|the|other|known|predisposing|for (l_prep) for_29\IN\entity.n.01|hyperkalaemia (l_pobj) hyperkalaemia_30\NN\entity.n.01|
D013390_D001919 CID suxamethonium_5\NN\entity.n.01|,|arrest (l_appos) arrest_10\NN\capture.n.01|bradycardia|cardiac (l_amod) bradycardia_7\NN\cardiac_arrhythmia.n.01|and
D013390_D004342 CID suxamethonium_11\NN\entity.n.01| (r_pobj) to_10\IN\entity.n.01|suxamethonium (r_prep) hypersensitivity_9\NN\sensitivity.n.04|to
3856631
D008727_D008577 NONE methotrexate_10\NNP\antimetabolite.n.01|dose|intravenous (r_pobj) with_5\IN\entity.n.01|methotrexate (r_prep) leukemia_4\NN\cancer.n.01|meningeal|with
D008727_D054198 NONE methotrexate_18\NNP\antimetabolite.n.01| (r_compound) regimen_19\NN\plan.n.01|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\entity.n.01|regimen (r_prep) treated_11\VBN\interact.v.01|children|were|with|. (l_nsubjpass) children_1\NNS\juvenile.n.01|twenty|with|developed (l_prep) with_2\IN\entity.n.01|leukemia (l_pobj) leukemia_5\NN\cancer.n.01|acute|lymphoblastic
D008727_D054198 NONE methotrexate_28\NNP\antimetabolite.n.01| (r_compound) concentrations_29\NNS\property.n.02|csf|methotrexate|of (r_dobj) maintain_26\VB\keep.v.01|concentrations|without (r_conj) achieve_24\VB\succeed.v.01|to|and|maintain (r_xcomp) designed_22\VBN\create_by_mental_act.v.01|that|was|achieve (r_relcl) regimen_19\NN\plan.n.01|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\entity.n.01|regimen (r_prep) treated_11\VBN\interact.v.01|children|were|with|. (l_nsubjpass) children_1\NNS\juvenile.n.01|twenty|with|developed (l_prep) with_2\IN\entity.n.01|leukemia (l_pobj) leukemia_5\NN\cancer.n.01|acute|lymphoblastic
D008727_D054198 NONE methotrexate_4\NN\antimetabolite.n.01|dose|intravenous (r_nsubj) is_5\VBZ\be.v.01|methotrexate|treatment|. (l_attr) treatment_8\NN\care.n.01|an|effective|for (l_prep) for_9\IN\entity.n.01|induction (l_pobj) induction_11\NN\ceremony.n.01|the|of|after (l_prep) after_14\IN\after.s.01|relapse (l_pobj) relapse_16\NN\failure.n.01|meningeal|in (l_prep) in_17\IN\linear_unit.n.01|leukemia (l_pobj) leukemia_20\NN\cancer.n.01|acute|lymphoblastic
D008727_D002493 NONE methotrexate_18\NNP\antimetabolite.n.01| (r_compound) regimen_19\NN\plan.n.01|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\entity.n.01|regimen (r_prep) treated_11\VBN\interact.v.01|children|were|with|. (l_nsubjpass) children_1\NNS\juvenile.n.01|twenty|with|developed (l_relcl) developed_7\VBD\create.v.02|who|disease (l_dobj) disease_9\NN\illness.n.01|meningeal
D008727_D002493 NONE methotrexate_28\NNP\antimetabolite.n.01| (r_compound) concentrations_29\NNS\property.n.02|csf|methotrexate|of (r_dobj) maintain_26\VB\keep.v.01|concentrations|without (r_conj) achieve_24\VB\succeed.v.01|to|and|maintain (r_xcomp) designed_22\VBN\create_by_mental_act.v.01|that|was|achieve (r_relcl) regimen_19\NN\plan.n.01|a|dose|intravenous|methotrexate|designed (r_pobj) with_12\IN\entity.n.01|regimen (r_prep) treated_11\VBN\interact.v.01|children|were|with|. (l_nsubjpass) children_1\NNS\juvenile.n.01|twenty|with|developed (l_relcl) developed_7\VBD\create.v.02|who|disease (l_dobj) disease_9\NN\illness.n.01|meningeal
D001663_D064420 NONE bilirubin_10\NN\animal_pigment.n.01| (r_amod) elevations_11\NNS\rise.n.04|bilirubin (r_conj) transaminase_8\NN\transferase.n.01|transient|serum|and|elevations|,|neutropenia (r_attr) were_5\VBD\be.v.01|toxicities|transaminase|. (l_nsubj) toxicities_3\NNS\definite_quantity.n.01|the|common|encountered
D001663_D009503 NONE bilirubin_10\NN\animal_pigment.n.01| (r_amod) elevations_11\NNS\rise.n.04|bilirubin (r_conj) transaminase_8\NN\transferase.n.01|transient|serum|and|elevations|,|neutropenia (l_appos) neutropenia_13\NN\leukopenia.n.01|,|and|mucositis
D001663_D052016 NONE bilirubin_10\NN\animal_pigment.n.01| (r_amod) elevations_11\NNS\rise.n.04|bilirubin (r_conj) transaminase_8\NN\transferase.n.01|transient|serum|and|elevations|,|neutropenia (l_appos) neutropenia_13\NN\leukopenia.n.01|,|and|mucositis (l_conj) mucositis_16\NN\entity.n.01|
15804801
D017239_D003323 CID paclitaxel_6\NN\entity.n.01| (r_compound) eluting_8\VBG\wash.v.01|paclitaxel|- (r_amod) stent_9\NN\tube.n.01|a|eluting (r_pobj) of_4\IN\entity.n.01|stent (r_prep) implantation_3\NN\organic_process.n.01|of (r_pobj) after_2\IN\after.s.01|implantation (r_prep) aneurysm_1\NN\cardiovascular_disease.n.01|coronary|after|.
D017239_D003323 CID paclitaxel_22\NN\entity.n.01| (r_compound) eluting_24\VBG\wash.v.01|paclitaxel|- (r_amod) stent_25\NN\tube.n.01|a|eluting (r_dobj) receiving_20\VBG\get.v.01|stent (r_pcomp) after_19\IN\after.s.01|months|receiving (r_prep) developed_8\VBD\create.v.02|who|aneurysm|in|after (l_dobj) aneurysm_11\NN\cardiovascular_disease.n.01|a|coronary
6634932
C002616_D017180 NONE um-272_0\NNP\entity.n.01| (r_punct) dimethylpropranolol_6\NNP\entity.n.01|um-272|(|n|,|n|-|)|,|agent (r_nsubjpass) administered_15\VBN\manage.v.02|dimethylpropranolol|,|was|sublingually|to|. (l_prep) to_17\IN\entity.n.01|dogs (l_pobj) dogs_18\NNS\canine.n.02|with (l_prep) with_19\IN\entity.n.01|tachycardias (l_pobj) tachycardias_24\NNS\cardiac_arrhythmia.n.01|induced|ventricular
C002616_D017180 NONE dimethylpropranolol_6\NNP\entity.n.01|um-272|(|n|,|n|-|)|,|agent (r_nsubjpass) administered_15\VBN\manage.v.02|dimethylpropranolol|,|was|sublingually|to|. (l_prep) to_17\IN\entity.n.01|dogs (l_pobj) dogs_18\NNS\canine.n.02|with (l_prep) with_19\IN\entity.n.01|tachycardias (l_pobj) tachycardias_24\NNS\cardiac_arrhythmia.n.01|induced|ventricular
C002616_D017180 NONE um-272_1\NNP\entity.n.01| (r_punct) converted_2\VBD\change.v.01|sublingual|um-272|tachycardia|sinus|. (l_dobj) tachycardia_4\NN\cardiac_arrhythmia.n.01|ventricular
D010042_D017180 CID ouabain_20\RB\entity.n.01| (r_npadvmod) induced_22\VBN\generate.v.01|ouabain|- (r_amod) tachycardias_24\NNS\cardiac_arrhythmia.n.01|induced|ventricular
6640832
D004317_D001749 NONE adriamycin_2\NNS\entity.n.01|in (l_prep) in_3\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_6\NN\cancer.n.01|superficial|bladder
D004317_D001749 NONE adriamycin_0\NNP\entity.n.01|ml (r_nsubjpass) administered_7\VBN\manage.v.02|adriamycin|was|intravesically|within|after|. (l_prep) after_12\IN\after.s.01|resection (l_pobj) resection_14\NN\operation.n.06|transurethral|of (l_prep) of_15\IN\entity.n.01|tumors (l_pobj) tumors_25\NNS\growth.n.06|t1|(|a|)|bladder
D004317_D002277 NONE adriamycin_2\NNS\entity.n.01|in (l_prep) in_3\IN\linear_unit.n.01|carcinoma (l_pobj) carcinoma_6\NN\cancer.n.01|superficial|bladder
8741744
D009538_D009069 NONE nicotine_29\NN\alkaloid.n.01| (r_pobj) by_28\IN\by.r.01|nicotine (r_agent) caused_27\VBN\make.v.03|by (r_acl) hypoactivity_26\NN\entity.n.01|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|)
D009538_D009069 NONE nicotine_48\NN\alkaloid.n.01| (r_npadvmod) induced_50\VBN\generate.v.01|nicotine|- (r_amod) hyperactivity_51\NN\disorder.n.01|the|later|(|min|induced (r_dobj) enhanced_39\VBD\intensify.v.02|hyperactivity|,|and|raised (r_advcl) blunted_14\VBD\weaken.v.01|compared|,|lesions|hypoactivity|,|enhanced|. (l_dobj) hypoactivity_26\NN\entity.n.01|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|)
D009538_D006948 CID nicotine_29\NN\alkaloid.n.01| (r_pobj) by_28\IN\by.r.01|nicotine (r_agent) caused_27\VBN\make.v.03|by (r_acl) hypoactivity_26\NN\entity.n.01|the|early|(|min|)|field|locomotor|caused|(|kg(-1|)|,|i.m.|) (r_dobj) blunted_14\VBD\weaken.v.01|compared|,|lesions|hypoactivity|,|enhanced|. (l_advcl) enhanced_39\VBD\intensify.v.02|hyperactivity|,|and|raised (l_dobj) hyperactivity_51\NN\disorder.n.01|the|later|(|min|induced
D009538_D006948 CID nicotine_48\NN\alkaloid.n.01| (r_npadvmod) induced_50\VBN\generate.v.01|nicotine|- (r_amod) hyperactivity_51\NN\disorder.n.01|the|later|(|min|induced
1147734
D011441_D008107 NONE propylthiouracil_4\NN\organic_compound.n.01| (r_pobj) by_3\IN\by.r.01|propylthiouracil (r_agent) caused_2\VBN\make.v.03|by (r_acl) disease_1\NN\illness.n.01|liver|caused|.
D011441_D006521 CID propylthiouracil_29\NN\organic_compound.n.01| (r_pobj) of_28\IN\entity.n.01|propylthiouracil (r_prep) administration_27\NN\management.n.01|the|of (r_pobj) by_25\IN\by.r.01|administration (r_agent) caused_24\VBN\make.v.03|by (r_acl) hepatitis_23\NN\infectious_disease.n.01|chronic|active|(|aggressive|)|caused
1720453
D007069_D007674 CID ifosfamide_7\JJ\entity.n.01| (r_amod) toxicity_9\NN\definite_quantity.n.01|ifosfamide|renal|in
D007069_C535700 NONE ifosfamide_7\JJ\entity.n.01| (r_amod) toxicity_9\NN\definite_quantity.n.01|ifosfamide|renal|in (r_pobj) of_6\IN\entity.n.01|toxicity (r_prep) up_5\NN\increase.v.02|term|follow|-|of (r_nsubj) treated_12\VBN\interact.v.01|up|for|:|society|. (l_prep) for_13\IN\entity.n.01|tumors (l_pobj) tumors_16\NNS\growth.n.06|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\JJ\entity.n.01| (r_compound) protocol_21\NN\rule.n.03|the|same|ifosfamide|chemotherapy|(|society|mmt|) (r_dobj) received_16\VBN\get.v.01|who|have|protocol (r_relcl) function_2\NN\mathematical_relation.n.01|the|renal|of|with|in|and|received (l_prep) with_6\IN\entity.n.01|tumors (l_pobj) tumors_9\NNS\growth.n.06|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\JJ\entity.n.01| (r_compound) protocol_21\NN\rule.n.03|the|same|ifosfamide|chemotherapy|(|society|mmt|) (l_appos) society_24\NNP\social_group.n.01|international|of (l_prep) of_25\IN\entity.n.01|study (l_pobj) study_31\NNP\examination.n.01|oncology|malignant|mesenchymal|tumor (l_compound) tumor_30\NNP\growth.n.06|
D007069_C535700 NONE ifosfamide_18\NN\entity.n.01| (r_pobj) of_17\IN\entity.n.01|ifosfamide (r_prep) efficacy_16\NN\effectiveness.n.01|the|of|in (l_prep) in_19\IN\linear_unit.n.01|treatment (l_pobj) treatment_21\NN\care.n.01|the|of|in (l_prep) of_22\IN\entity.n.01|tumors (l_pobj) tumors_24\NNS\growth.n.06|mesenchymal
D003404_D006030 NONE creatinine_22\NN\entity.n.01| (r_compound) clearance_23\NN\interval.n.03|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\entity.n.01|,|clearance (r_conj) ph_18\NN\hydrogen_ion_concentration.n.01|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\symptom.n.01|,|ph (r_conj) proteinuria_13\NN\symptom.n.01|,|aminoaciduria (r_conj) glucosuria_11\NN\glycosuria.n.01|,|proteinuria
D003404_D011507 NONE creatinine_22\NN\entity.n.01| (r_compound) clearance_23\NN\interval.n.03|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\entity.n.01|,|clearance (r_conj) ph_18\NN\hydrogen_ion_concentration.n.01|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\symptom.n.01|,|ph (r_conj) proteinuria_13\NN\symptom.n.01|,|aminoaciduria
D003404_D000608 NONE creatinine_22\NN\entity.n.01| (r_compound) clearance_23\NN\interval.n.03|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\entity.n.01|,|clearance (r_conj) ph_18\NN\hydrogen_ion_concentration.n.01|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\symptom.n.01|,|ph
D010710_D006030 NONE phosphate_25\NN\salt.n.01| (r_nmod) reabsorption_27\NN\organic_process.n.01|phosphate|tubular (r_conj) clearance_23\NN\interval.n.03|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\entity.n.01|,|clearance (r_conj) ph_18\NN\hydrogen_ion_concentration.n.01|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\symptom.n.01|,|ph (r_conj) proteinuria_13\NN\symptom.n.01|,|aminoaciduria (r_conj) glucosuria_11\NN\glycosuria.n.01|,|proteinuria
D010710_D011507 NONE phosphate_25\NN\salt.n.01| (r_nmod) reabsorption_27\NN\organic_process.n.01|phosphate|tubular (r_conj) clearance_23\NN\interval.n.03|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\entity.n.01|,|clearance (r_conj) ph_18\NN\hydrogen_ion_concentration.n.01|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\symptom.n.01|,|ph (r_conj) proteinuria_13\NN\symptom.n.01|,|aminoaciduria
D010710_D000608 NONE phosphate_25\NN\salt.n.01| (r_nmod) reabsorption_27\NN\organic_process.n.01|phosphate|tubular (r_conj) clearance_23\NN\interval.n.03|creatinine|,|reabsorption (r_conj) osmolarity_20\NN\entity.n.01|,|clearance (r_conj) ph_18\NN\hydrogen_ion_concentration.n.01|urinary|,|osmolarity (r_conj) aminoaciduria_15\JJ\symptom.n.01|,|ph
D010710_D064420 NONE phosphate_51\NN\salt.n.01|low (r_compound) reabsorption_52\NN\organic_process.n.01|phosphate (r_conj) microglobulinuria_48\NN\entity.n.01|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN\entity.n.01|microglobulinuria (r_prep) patients_43\NNS\case.n.06|five|with (r_dobj) included_41\VBD\include.v.01|group|patients|. (r_conj) included_13\VBD\include.v.01|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS\case.n.06|four|(|%|)|developed (l_relcl) developed_25\VBD\create.v.02|who|toxicity (l_dobj) toxicity_27\NN\definite_quantity.n.01|major|resulting
D010710_D005198 NONE phosphate_51\NN\salt.n.01|low (r_compound) reabsorption_52\NN\organic_process.n.01|phosphate (r_conj) microglobulinuria_48\NN\entity.n.01|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN\entity.n.01|microglobulinuria (r_prep) patients_43\NNS\case.n.06|five|with (r_dobj) included_41\VBD\include.v.01|group|patients|. (r_conj) included_13\VBD\include.v.01|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS\case.n.06|four|(|%|)|developed (l_relcl) developed_25\VBD\create.v.02|who|toxicity (l_dobj) toxicity_27\NN\definite_quantity.n.01|major|resulting (l_acl) resulting_28\VBG\prove.v.01|in (l_prep) in_29\IN\linear_unit.n.01|syndrome (l_pobj) syndrome_32\NN\complex.n.01|fanconi|(|tdfs|)
D010710_D005198 NONE phosphate_51\NN\salt.n.01|low (r_compound) reabsorption_52\NN\organic_process.n.01|phosphate (r_conj) microglobulinuria_48\NN\entity.n.01|elevated|beta|2|and|reabsorption (r_pobj) with_44\IN\entity.n.01|microglobulinuria (r_prep) patients_43\NNS\case.n.06|five|with (r_dobj) included_41\VBD\include.v.01|group|patients|. (r_conj) included_13\VBD\include.v.01|identified|:|first|patients|;|and|included (l_dobj) patients_15\NNS\case.n.06|four|(|%|)|developed (l_relcl) developed_25\VBD\create.v.02|who|toxicity (l_dobj) toxicity_27\NN\definite_quantity.n.01|major|resulting (l_acl) resulting_28\VBG\prove.v.01|in (l_prep) in_29\IN\linear_unit.n.01|syndrome (l_pobj) syndrome_32\NN\complex.n.01|fanconi|(|tdfs|) (l_appos) tdfs_34\NNP\entity.n.01|
D007069_D064420 NONE ifosfamide_15\NN\entity.n.01| (r_pobj) of_14\IN\entity.n.01|ifosfamide (r_prep) m2_13\NN\money_supply.n.01|60|g|/|of (r_pobj) of_9\IN\entity.n.01|m2 (r_prep) dose_8\NN\medicine.n.02|the|higher|cumulative|of|,|age|,|and|predominance (r_pobj) with_4\IN\entity.n.01|dose (r_prep) correlated_3\VBN\match.v.01|toxicity|was|with|. (l_nsubjpass) toxicity_1\NN\definite_quantity.n.01|severe
D007069_D009369 NONE ifosfamide_15\NN\entity.n.01| (r_pobj) of_14\IN\entity.n.01|ifosfamide (r_prep) m2_13\NN\money_supply.n.01|60|g|/|of (r_pobj) of_9\IN\entity.n.01|m2 (r_prep) dose_8\NN\medicine.n.02|the|higher|cumulative|of|,|age|,|and|predominance (l_conj) predominance_31\NN\dominance.n.02|a|of (l_prep) of_32\IN\entity.n.01|involvement (l_pobj) involvement_35\NN\group_action.n.01|vesicoprostatic|tumor (l_compound) tumor_34\NN\growth.n.06|
7352670
D009599_D006973 NONE nitroprusside_4\NN\entity.n.01|after|sodium (r_advmod) hypertensive_1\JJ\patient.n.01|rebound|nitroprusside|prevented|.
D009599_D006973 NONE snp_2\NNP\polymorphism.n.01| (r_compound) infusion_3\NN\solution.n.01|the|snp (r_pobj) during_0\IN\entity.n.01|infusion (r_prep) demonstrated_7\VBD\show.v.04|during|animals|increase|,|showed|. (l_dobj) increase_10\NN\indefinite_quantity.n.01|a|progressive|in|to (l_prep) in_11\IN\linear_unit.n.01|pressure (l_pobj) pressure_13\NN\physical_phenomenon.n.01|blood
D012504_D006973 NONE saralasin_7\NN\entity.n.01|in (r_pobj) by_6\IN\by.r.01|saralasin (r_agent) prevented_5\VBN\prevent.v.01|by (r_acl) hypertensive_1\JJ\patient.n.01|rebound|nitroprusside|prevented|.
D012504_D006973 NONE saralasin_20\NN\entity.n.01| (r_npadvmod) treated_22\VBN\interact.v.01|saralasin|- (r_amod) animals_23\NNS\organism.n.01|the|treated (r_nsubj) showed_24\VBD\show.v.04|whereas|animals|change (r_advcl) demonstrated_7\VBD\show.v.04|during|animals|increase|,|showed|. (l_dobj) increase_10\NN\indefinite_quantity.n.01|a|progressive|in|to (l_prep) in_11\IN\linear_unit.n.01|pressure (l_pobj) pressure_13\NN\physical_phenomenon.n.01|blood
D000809_D007022 NONE angiotensin_6\NN\vasoconstrictor.n.01| (r_compound) system_7\NN\instrumentality.n.03|angiotensin|in (l_prep) in_8\IN\linear_unit.n.01|maintenance (l_pobj) maintenance_10\NN\repair.n.01|the|of|during (l_prep) during_14\IN\entity.n.01|anesthesia (l_pobj) anesthesia_16\NN\physical_condition.n.01|halothane|and|sodium|nitroprusside (l_conj) nitroprusside_19\NN\entity.n.01|evaluated (l_parataxis) evaluated_24\VBN\evaluate.v.02|(|hypotension|was (l_nsubjpass) hypotension_22\NN\cardiovascular_disease.n.01|snp)-induced
D000809_D007022 NONE angiotensin_8\NN\vasoconstrictor.n.01| (r_compound) system_9\NN\instrumentality.n.03|angiotensin|in (l_prep) in_10\IN\linear_unit.n.01|antagonizing (l_pcomp) antagonizing_11\VBG\annoy.v.01|effects (l_dobj) effects_15\NNS\personal_property.n.01|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ\patient.n.01|
D006221_D007022 CID halothane_15\NN\inhalation_anesthetic.n.01| (r_compound) anesthesia_16\NN\physical_condition.n.01|halothane|and|sodium|nitroprusside (l_conj) nitroprusside_19\NN\entity.n.01|evaluated (l_parataxis) evaluated_24\VBN\evaluate.v.02|(|hypotension|was (l_nsubjpass) hypotension_22\NN\cardiovascular_disease.n.01|snp)-induced
D006221_D007022 CID halothane_17\NN\inhalation_anesthetic.n.01|and|snp (r_pobj) of_16\IN\entity.n.01|halothane (r_prep) effects_15\NNS\personal_property.n.01|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ\patient.n.01|
D009599_D007022 CID nitroprusside_19\NN\entity.n.01|evaluated (l_parataxis) evaluated_24\VBN\evaluate.v.02|(|hypotension|was (l_nsubjpass) hypotension_22\NN\cardiovascular_disease.n.01|snp)-induced
D009599_D007022 CID snp)-induced_21\VBN\entity.n.01| (r_amod) hypotension_22\NN\cardiovascular_disease.n.01|snp)-induced
D009599_D007022 CID snp_19\NNP\polymorphism.n.01| (r_conj) halothane_17\NN\inhalation_anesthetic.n.01|and|snp (r_pobj) of_16\IN\entity.n.01|halothane (r_prep) effects_15\NNS\personal_property.n.01|the|combined|hypotensive|of (l_amod) hypotensive_14\JJ\patient.n.01|
9100294
D002118_D018376 NONE calcium_7\NN\metallic_element.n.01| (r_compound) channel_8\NN\transmission.n.02|calcium (r_compound) blockers_9\NNS\football_player.n.01|channel (r_pobj) to_6\IN\entity.n.01|blockers (r_prep) exposed_5\VBN\subject.v.01|to (r_acl) alterations_1\NNS\happening.n.01|cardiovascular|in|exposed|.
D002118_D018376 NONE calcium_7\NN\metallic_element.n.01| (r_compound) channel_8\NN\transmission.n.02|new|calcium (r_compound) blocker_9\NN\football_player.n.01|a|channel|,|ro (r_nsubj) induced_16\VBD\generate.v.01|that|blocker|,|alterations (l_dobj) alterations_18\NNS\happening.n.01|cardiovascular|in|exposed
D002118_D018376 NONE calcium_10\NN\metallic_element.n.01| (r_compound) channel_11\NN\transmission.n.02|calcium (r_compound) blockers_12\NNS\football_player.n.01|channel|in (r_nsubj) induce_15\VBP\generate.v.01|that|blockers|malformations (l_dobj) malformations_17\NNS\affliction.n.02|cardiovascular|indicating
D002118_D018376 NONE calcium_7\NN\metallic_element.n.01| (r_compound) channel_8\NN\transmission.n.02|calcium (r_compound) blockers_9\NNS\football_player.n.01|these|channel (r_pobj) of_5\IN\entity.n.01|blockers (r_prep) one_4\CD\digit.n.01|of (r_dobj) administered_3\VBN\manage.v.02|rats|were|one|during|. (l_prep) during_10\IN\entity.n.01|period (l_pobj) period_12\NN\fundamental_quantity.n.01|the|of (l_prep) of_13\IN\entity.n.01|morphogenesis (l_pobj) morphogenesis_15\NN\growth.n.01|cardiac|and|offspring (l_conj) offspring_18\NN\relative.n.01|the|examined (l_acl) examined_19\VBD\analyze.v.01|on (l_prep) on_20\IN\on.a.01|day (l_pobj) day_21\NN\time_unit.n.01|20|of (l_prep) of_23\IN\entity.n.01|gestation (l_pobj) gestation_24\NN\biological_time.n.01|for (l_prep) for_25\IN\entity.n.01|malformations (l_pobj) malformations_27\NNS\affliction.n.02|cardiovascular
D002118_D018376 NONE calcium_15\NN\metallic_element.n.01| (r_compound) channel_16\NN\transmission.n.02|calcium (r_compound) blockers_17\NNS\football_player.n.01|the|four|channel (r_pobj) of_12\IN\entity.n.01|blockers (r_prep) each_11\DT\each.s.01|of (r_pobj) to_10\IN\entity.n.01|each (r_prep) exposure_9\NN\vulnerability.n.02|to (r_pobj) after_8\IN\after.s.01|exposure (r_prep) observed_7\VBN\spy.v.03|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN\frequency.n.02|a|low|of (l_prep) of_3\IN\entity.n.01|malformations (l_pobj) malformations_5\NNS\affliction.n.02|cardiovascular
D020748_D018376 CID 5967_14\CD\entity.n.01|- (r_prep) 40_12\CD\large_integer.n.01|5967 (r_nummod) ro_11\NNP\artificial_language.n.01|40 (r_appos) blocker_9\NN\football_player.n.01|a|channel|,|ro (r_nsubj) induced_16\VBD\generate.v.01|that|blocker|,|alterations (l_dobj) alterations_18\NNS\happening.n.01|cardiovascular|in|exposed
D014700_D018376 CID verapamil_27\NN\calcium_blocker.n.01|and|nifedipine (r_pobj) for_26\IN\entity.n.01|only|verapamil (r_prep) significant_24\JJ\significant.a.01|statistically|for (r_acomp) was_22\VBD\washington.n.02|incidence|significant|. (r_conj) observed_7\VBN\spy.v.03|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN\frequency.n.02|a|low|of (l_prep) of_3\IN\entity.n.01|malformations (l_pobj) malformations_5\NNS\affliction.n.02|cardiovascular
D009543_D018376 CID nifedipine_29\NN\calcium_blocker.n.01| (r_conj) verapamil_27\NN\calcium_blocker.n.01|and|nifedipine (r_pobj) for_26\IN\entity.n.01|only|verapamil (r_prep) significant_24\JJ\significant.a.01|statistically|for (r_acomp) was_22\VBD\washington.n.02|incidence|significant|. (r_conj) observed_7\VBN\spy.v.03|incidence|was|after|,|but|was (l_nsubjpass) incidence_2\NN\frequency.n.02|a|low|of (l_prep) of_3\IN\entity.n.01|malformations (l_pobj) malformations_5\NNS\affliction.n.02|cardiovascular
18083142
D009638_D001008 NONE norepinephrine_0\NN\catecholamine.n.01| (r_compound) signaling_1\VBG\communication.n.02|norepinephrine|through (r_nsubj) is_7\VBZ\be.v.01|signaling|critical|. (l_acomp) critical_8\JJ\critical.a.01|for (l_prep) for_9\IN\entity.n.01|expression (l_pobj) expression_10\NN\countenance.n.01|of (l_prep) of_11\IN\entity.n.01|anxiety (l_pobj) anxiety_15\NN\psychological_state.n.01|induced
D009638_D001008 NONE norepinephrine_22\NN\catecholamine.n.01|ne (r_dobj) lack_21\VBP\need.n.01|which|norepinephrine (r_relcl) mice_18\NNS\rodent.n.01|(|dbh|-/-|)|,|lack|, (r_appos) knockout_13\NN\woman.n.01|dopamine|hydroxylase|mice (r_pobj) of_8\IN\entity.n.01|knockout (r_prep) performance_7\NN\show.n.03|the|of (r_dobj) evaluated_5\VBD\evaluate.v.02|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB\analyze.v.01|to|contribution (l_dobj) contribution_38\NN\attempt.n.01|the|of (l_prep) of_39\IN\entity.n.01|signaling (l_pobj) signaling_41\NN\communication.n.02|noradrenergic|to (l_prep) to_42\IN\entity.n.01|anxiety (l_pobj) anxiety_46\NN\psychological_state.n.01|induced
D009638_D001008 NONE ne_24\NNP\chemical_element.n.01|(|) (r_appos) norepinephrine_22\NN\catecholamine.n.01|ne (r_dobj) lack_21\VBP\need.n.01|which|norepinephrine (r_relcl) mice_18\NNS\rodent.n.01|(|dbh|-/-|)|,|lack|, (r_appos) knockout_13\NN\woman.n.01|dopamine|hydroxylase|mice (r_pobj) of_8\IN\entity.n.01|knockout (r_prep) performance_7\NN\show.n.03|the|of (r_dobj) evaluated_5\VBD\evaluate.v.02|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB\analyze.v.01|to|contribution (l_dobj) contribution_38\NN\attempt.n.01|the|of (l_prep) of_39\IN\entity.n.01|signaling (l_pobj) signaling_41\NN\communication.n.02|noradrenergic|to (l_prep) to_42\IN\entity.n.01|anxiety (l_pobj) anxiety_46\NN\psychological_state.n.01|induced
D003042_D001008 CID cocaine_12\NN\hard_drug.n.01| (r_npadvmod) induced_14\VBN\generate.v.01|cocaine|- (r_amod) anxiety_15\NN\psychological_state.n.01|induced
D003042_D001008 CID cocaine_4\NN\hard_drug.n.01|'s (r_poss) effects_7\NNS\personal_property.n.01|underlying|cocaine|rewarding (r_nsubjpass) studied_10\VBN\analyze.v.01|while|mechanisms|effects|have|been|extensively (r_advcl) paid_17\VBN\give.v.03|studied|,|attention|has|been|to|. (l_dative) to_18\IN\entity.n.01|states (l_pobj) states_22\NNS\administrative_district.n.01|the|unpleasant|behavioral|induced (l_acl) induced_23\VBN\generate.v.01|by (l_agent) by_24\IN\by.r.01|cocaine (l_pobj) cocaine_25\NN\hard_drug.n.01|,|as (l_prep) as_28\IN\chemical_element.n.01|such|anxiety (l_pobj) anxiety_29\NN\psychological_state.n.01|
D003042_D001008 CID cocaine_25\NN\hard_drug.n.01|,|as (l_prep) as_28\IN\chemical_element.n.01|such|anxiety (l_pobj) anxiety_29\NN\psychological_state.n.01|
D003042_D001008 CID cocaine_43\NN\hard_drug.n.01| (r_npadvmod) induced_45\VBN\generate.v.01|cocaine|- (r_amod) anxiety_46\NN\psychological_state.n.01|induced
D003042_D001008 CID cocaine_4\NN\hard_drug.n.01| (r_nsubj) increased_8\VBN\change_magnitude.v.01|that|cocaine|dependently|behavior|,|measured (l_dobj) behavior_12\NN\activity.n.01|like|in (l_amod) like_11\JJ\kind.n.01|anxiety (l_npadvmod) anxiety_9\NN\psychological_state.n.01|-
D003042_D001008 CID cocaine_0\NN\hard_drug.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|cocaine|- (r_amod) anxiety_3\NN\psychological_state.n.01|induced
D003042_D001008 CID cocaine_20\NN\hard_drug.n.01| (r_npadvmod) induced_22\VBN\generate.v.01|cocaine|- (r_amod) behavior_26\NN\activity.n.01|blocked|induced|like (l_amod) like_25\JJ\kind.n.01|anxiety|- (l_npadvmod) anxiety_23\NN\psychological_state.n.01|
D003042_D001008 CID cocaine_14\NN\hard_drug.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|cocaine|- (r_amod) anxiety_17\NN\psychological_state.n.01|induced|in
D004298_D001008 NONE dopamine_9\NN\monoamine_neurotransmitter.n.01| (r_compound) knockout_13\NN\woman.n.01|dopamine|hydroxylase|mice (r_pobj) of_8\IN\entity.n.01|knockout (r_prep) performance_7\NN\show.n.03|the|of (r_dobj) evaluated_5\VBD\evaluate.v.02|in|,|we|performance|in|examine|. (l_advcl) examine_36\VB\analyze.v.01|to|contribution (l_dobj) contribution_38\NN\attempt.n.01|the|of (l_prep) of_39\IN\entity.n.01|signaling (l_pobj) signaling_41\NN\communication.n.02|noradrenergic|to (l_prep) to_42\IN\entity.n.01|anxiety (l_pobj) anxiety_46\NN\psychological_state.n.01|induced
D004298_D001008 NONE dopamine_17\NN\monoamine_neurotransmitter.n.01| (r_nmod) hydroxylase_20\NN\entity.n.01|a|dopamine|beta|- (r_nmod) inhibitor_24\NN\substance.n.07|hydroxylase|(|dbh|) (r_appos) administration_12\NN\management.n.01|of|,|inhibitor (r_pobj) following_11\VBG\multitude.n.03|administration (r_prep) attenuated_6\VBN\weaken.v.01|anxiety|was|also|in|following|. (l_nsubjpass) anxiety_3\NN\psychological_state.n.01|induced
D004221_D001008 NONE disulfiram_14\NN\medicine.n.02| (r_pobj) of_13\IN\entity.n.01|disulfiram (r_prep) administration_12\NN\management.n.01|of|,|inhibitor (r_pobj) following_11\VBG\multitude.n.03|administration (r_prep) attenuated_6\VBN\weaken.v.01|anxiety|was|also|in|following|. (l_nsubjpass) anxiety_3\NN\psychological_state.n.01|induced
D011433_D001008 NONE propranolol_18\NN\entity.n.01|behavior|in (l_dobj) behavior_26\NN\activity.n.01|blocked|induced|like (l_amod) like_25\JJ\kind.n.01|anxiety|- (l_npadvmod) anxiety_23\NN\psychological_state.n.01|
D011224_D001008 NONE prazosin_42\NN\alpha_blocker.n.01|the|antagonist|and|antagonist (r_nsubj) had_49\VBD\have.v.01|while|prazosin|effect (r_advcl) pretreatment_10\NN\entity.n.01|that|with|,|had (l_prep) with_11\IN\entity.n.01|antagonist (l_pobj) antagonist_17\NN\person.n.01|the|adrenergic|receptor|propranolol (l_acl) propranolol_18\NN\entity.n.01|behavior|in (l_dobj) behavior_26\NN\activity.n.01|blocked|induced|like (l_amod) like_25\JJ\kind.n.01|anxiety|- (l_npadvmod) anxiety_23\NN\psychological_state.n.01|
D015016_D001008 NONE yohimbine_48\NN\entity.n.01| (r_appos) antagonist_47\NN\person.n.01|the|alpha(2|)|yohimbine (r_conj) prazosin_42\NN\alpha_blocker.n.01|the|antagonist|and|antagonist (r_nsubj) had_49\VBD\have.v.01|while|prazosin|effect (r_advcl) pretreatment_10\NN\entity.n.01|that|with|,|had (l_prep) with_11\IN\entity.n.01|antagonist (l_pobj) antagonist_17\NN\person.n.01|the|adrenergic|receptor|propranolol (l_acl) propranolol_18\NN\entity.n.01|behavior|in (l_dobj) behavior_26\NN\activity.n.01|blocked|induced|like (l_amod) like_25\JJ\kind.n.01|anxiety|- (l_npadvmod) anxiety_23\NN\psychological_state.n.01|
2234245
D003676_D014786 NONE desferrioxamine_8\NN\entity.n.01| (r_dobj) receiving_7\VBG\get.v.01|desferrioxamine (r_acl) patients_6\NNS\case.n.06|hemodialyzed|receiving (r_pobj) in_4\IN\linear_unit.n.01|patients (r_prep) toxicity_3\NN\definite_quantity.n.01|ocular|in|.
D003676_D014786 NONE desferrioxamine_10\NN\entity.n.01| (r_dobj) receiving_9\VBG\get.v.01|desferrioxamine (r_acl) patients_8\NNS\case.n.06|41|hemodialyzed|receiving|weekly (r_pobj) during_0\IN\entity.n.01|period|patients (r_prep) monitored_25\VBN\observe.v.04|during|for|were|for|. (l_prep) for_26\IN\entity.n.01|detection (l_pobj) detection_27\NN\perception.n.03|of (l_prep) of_28\IN\entity.n.01|toxicity (l_pobj) toxicity_30\NN\definite_quantity.n.01|audiovisual
D003676_D014786 NONE desferrioxamine_15\NN\entity.n.01| (r_dobj) receiving_14\VBG\get.v.01|desferrioxamine (r_acl) patients_13\NNS\case.n.06|hemodialyzed|receiving (r_pobj) in_11\IN\linear_unit.n.01|patients (r_prep) complication_10\NN\hindrance.n.03|an|infrequent|in (r_attr) is_6\VBZ\be.v.01|that|toxicity|not|complication (l_nsubj) toxicity_5\NN\definite_quantity.n.01|audiovisual
D003676_D006311 NONE desferrioxamine_8\NN\entity.n.01| (r_dobj) receiving_7\VBG\get.v.01|desferrioxamine (r_acl) patients_6\NNS\case.n.06|hemodialyzed|receiving (r_pobj) in_4\IN\linear_unit.n.01|patients (r_prep) toxicity_3\NN\definite_quantity.n.01|ocular|in|.
D003676_D006311 NONE desferrioxamine_10\NN\entity.n.01| (r_dobj) receiving_9\VBG\get.v.01|desferrioxamine (r_acl) patients_8\NNS\case.n.06|41|hemodialyzed|receiving|weekly (r_pobj) during_0\IN\entity.n.01|period|patients (r_prep) monitored_25\VBN\observe.v.04|during|for|were|for|. (l_prep) for_26\IN\entity.n.01|detection (l_pobj) detection_27\NN\perception.n.03|of (l_prep) of_28\IN\entity.n.01|toxicity (l_pobj) toxicity_30\NN\definite_quantity.n.01|audiovisual
D003676_D006311 NONE desferrioxamine_15\NN\entity.n.01| (r_dobj) receiving_14\VBG\get.v.01|desferrioxamine (r_acl) patients_13\NNS\case.n.06|hemodialyzed|receiving (r_pobj) in_11\IN\linear_unit.n.01|patients (r_prep) complication_10\NN\hindrance.n.03|an|infrequent|in (r_attr) is_6\VBZ\be.v.01|that|toxicity|not|complication (l_nsubj) toxicity_5\NN\definite_quantity.n.01|audiovisual
D003676_D034381 NONE desferrioxamine_0\NNP\entity.n.01| (r_compound) withdrawal_1\NN\retraction.n.01|desferrioxamine (r_nsubj) resulted_2\VBD\prove.v.01|withdrawal|in|,|and|reversal|. (l_conj) reversal_22\NN\change_of_state.n.01|a|complete|of (l_prep) of_23\IN\entity.n.01|hearing (l_pcomp) hearing_24\NN\proceeding.n.01|loss|in|in (l_dobj) loss_25\NN\transferred_property.n.01|
D003676_D064420 NONE desferrioxamine_10\NN\entity.n.01| (r_pobj) of_9\IN\entity.n.01|desferrioxamine (r_prep) doses_8\NNS\medicine.n.02|the|higher|of (r_dobj) receiving_5\VBG\get.v.01|doses (r_acl) patients_4\NNS\case.n.06|receiving (r_pobj) in_3\IN\linear_unit.n.01|patients (r_prep) appeared_2\VBD\be.v.01|toxicity|in|or|coincided|. (l_nsubj) toxicity_1\NN\definite_quantity.n.01|this
-1_D064420 NONE aluminium_19\NN\metallic_element.n.01| (r_conj) ferritin_17\NN\protein.n.01|or|aluminium (r_nmod) levels_21\NNS\property.n.02|ferritin|serum (r_pobj) of_16\IN\entity.n.01|levels (r_prep) normalization_15\NN\social_control.n.01|the|of (r_pobj) with_13\IN\entity.n.01|normalization (r_prep) coincided_12\VBD\coexist.v.02|with (r_conj) appeared_2\VBD\be.v.01|toxicity|in|or|coincided|. (l_nsubj) toxicity_1\NN\definite_quantity.n.01|this
18217897
D013792_D008228 NONE thalidomide_0\NNP\sedative-hypnotic.n.01| (r_nsubj) limited_2\VBN\public_transport.n.01|thalidomide|has|activity|in (l_prep) in_7\IN\linear_unit.n.01|lymphomas (l_pobj) lymphomas_15\NNS\cancer.n.01|relapsed|indolent|hodgkin|:|trial
D013792_D009369 NONE thalidomide_0\NNP\sedative-hypnotic.n.01| (r_nsubj) limited_2\VBN\public_transport.n.01|thalidomide|has|activity|in (l_prep) in_7\IN\linear_unit.n.01|lymphomas (l_pobj) lymphomas_15\NNS\cancer.n.01|relapsed|indolent|hodgkin|:|trial (l_appos) trial_20\NN\attempt.n.01|a|phase|ii|of (l_prep) of_21\IN\entity.n.01|cancer (l_pobj) cancer_23\NNP\malignant_tumor.n.01|the|and|b.
D013792_D007938 NONE thalidomide_0\NNP\sedative-hypnotic.n.01| (r_nsubj) limited_2\VBN\public_transport.n.01|thalidomide|has|activity|in (l_prep) in_7\IN\linear_unit.n.01|lymphomas (l_pobj) lymphomas_15\NNS\cancer.n.01|relapsed|indolent|hodgkin|:|trial (l_appos) trial_20\NN\attempt.n.01|a|phase|ii|of (l_prep) of_21\IN\entity.n.01|cancer (l_pobj) cancer_23\NNP\malignant_tumor.n.01|the|and|b. (l_conj) b._27\NNP\entity.n.01|leukemia|group (l_compound) leukemia_25\NNP\cancer.n.01|
D013792_D009101 NONE thalidomide_0\NNP\sedative-hypnotic.n.01| (r_nsubj) is_1\VBZ\be.v.01|thalidomide|agent|. (l_attr) agent_4\NN\causal_agent.n.01|an|immunomodulatory|with (l_prep) with_5\IN\entity.n.01|activity (l_pobj) activity_7\NN\act.n.02|demonstrated|in (l_prep) in_8\IN\linear_unit.n.01|myeloma (l_pobj) myeloma_10\NN\malignant_tumor.n.01|multiple|,|lymphoma
D013792_D020522 NONE thalidomide_0\NNP\sedative-hypnotic.n.01| (r_nsubj) is_1\VBZ\be.v.01|thalidomide|agent|. (l_attr) agent_4\NN\causal_agent.n.01|an|immunomodulatory|with (l_prep) with_5\IN\entity.n.01|activity (l_pobj) activity_7\NN\act.n.02|demonstrated|in (l_prep) in_8\IN\linear_unit.n.01|myeloma (l_pobj) myeloma_10\NN\malignant_tumor.n.01|multiple|,|lymphoma (l_conj) lymphoma_14\NN\cancer.n.01|mantle|cell|and|lymphoma
D013792_D008223 NONE thalidomide_0\NNP\sedative-hypnotic.n.01| (r_nsubj) is_1\VBZ\be.v.01|thalidomide|agent|. (l_attr) agent_4\NN\causal_agent.n.01|an|immunomodulatory|with (l_prep) with_5\IN\entity.n.01|activity (l_pobj) activity_7\NN\act.n.02|demonstrated|in (l_prep) in_8\IN\linear_unit.n.01|myeloma (l_pobj) myeloma_10\NN\malignant_tumor.n.01|multiple|,|lymphoma (l_conj) lymphoma_14\NN\cancer.n.01|mantle|cell|and|lymphoma (l_conj) lymphoma_17\NN\cancer.n.01|lymphoplasmacytic
D013792_D008223 NONE thalidomide_16\NN\sedative-hypnotic.n.01| (r_dobj) received_15\VBD\get.v.01|between|,|patients|thalidomide|daily|with|tolerated|. (l_nsubj) patients_8\NNS\case.n.06|24|with (l_prep) with_9\IN\entity.n.01|lymphomas (l_pobj) lymphomas_14\NNS\cancer.n.01|relapsed|/|refractory|indolent
D013792_D008223 NONE thalidomide_12\NN\sedative-hypnotic.n.01|agent (r_pobj) to_9\IN\entity.n.01|thalidomide (r_prep) rate_8\NN\magnitude_relation.n.01|an|important|response|to|in (l_prep) in_13\IN\linear_unit.n.01|lymphomas (l_pobj) lymphomas_15\NNS\cancer.n.01|indolent
C467567_D008223 NONE lenalidomide_31\NN\entity.n.01| (r_appos) agent_29\NN\causal_agent.n.01|the|generation|immunomodulatory|,|lenalidomide (r_pobj) with_24\IN\entity.n.01|agent (r_prep) reported_23\VBN\inform.v.01|with (r_acl) level_22\NN\property.n.02|the|higher|activity|reported (r_pobj) with_18\IN\entity.n.01|level (r_prep) contrast_17\NN\opposition.n.02|with (r_conj) demonstrate_4\VB\show.v.04|to|rate|and|contrast (l_dobj) rate_8\NN\magnitude_relation.n.01|an|important|response|to|in (l_prep) in_13\IN\linear_unit.n.01|lymphomas (l_pobj) lymphomas_15\NNS\cancer.n.01|indolent
3101906
D007654_D003643 NONE ketoconazole_9\JJ\entity.n.01| (r_compound) treatment_10\NN\care.n.01|ketoconazole (r_pobj) with_8\IN\entity.n.01|treatment (r_prep) associated_7\VBN\think.v.03|probably|with (r_acl) deaths_5\NNS\change.n.01|the|three|associated
D007654_D007565 CID ketoconazole_9\JJ\entity.n.01| (r_compound) treatment_10\NN\care.n.01|ketoconazole (r_pobj) with_8\IN\entity.n.01|treatment (r_prep) associated_7\VBN\think.v.03|probably|with (r_acl) deaths_5\NNS\change.n.01|the|three|associated (r_pobj) of_2\IN\entity.n.01|deaths (r_prep) two_1\CD\digit.n.01|of (r_pobj) in_0\IN\linear_unit.n.01|two (r_prep) continued_15\VBN\act.v.01|in|drug|had|been|after|. (l_prep) after_16\IN\after.s.01|onset (l_pobj) onset_18\NN\start.n.01|the|of (l_prep) of_19\IN\entity.n.01|jaundice (l_pobj) jaundice_20\NN\symptom.n.01|and|symptoms
D007654_D056486 CID ketoconazole_9\JJ\entity.n.01| (r_compound) treatment_10\NN\care.n.01|ketoconazole (r_pobj) with_8\IN\entity.n.01|treatment (r_prep) associated_7\VBN\think.v.03|probably|with (r_acl) deaths_5\NNS\change.n.01|the|three|associated (r_pobj) of_2\IN\entity.n.01|deaths (r_prep) two_1\CD\digit.n.01|of (r_pobj) in_0\IN\linear_unit.n.01|two (r_prep) continued_15\VBN\act.v.01|in|drug|had|been|after|. (l_prep) after_16\IN\after.s.01|onset (l_pobj) onset_18\NN\start.n.01|the|of (l_prep) of_19\IN\entity.n.01|jaundice (l_pobj) jaundice_20\NN\symptom.n.01|and|symptoms (l_conj) symptoms_23\NNS\evidence.n.01|other|of (l_prep) of_24\IN\entity.n.01|hepatitis (l_pobj) hepatitis_25\NN\infectious_disease.n.01|
D007654_D056486 CID ketoconazole_18\NN\entity.n.01| (r_pobj) with_17\IN\entity.n.01|ketoconazole (r_prep) treatment_16\NN\care.n.01|term|with (r_pobj) during_13\IN\entity.n.01|treatment (r_prep) advised_12\VBN\hash_out.v.01|monitoring|is|during|prevent|. (l_nsubjpass) monitoring_3\NN\observation.n.02|clinical|at|for (l_prep) for_7\IN\entity.n.01|evidence (l_pobj) evidence_8\NN\information.n.02|of (l_prep) of_9\IN\entity.n.01|hepatitis (l_pobj) hepatitis_10\NN\infectious_disease.n.01|
D007654_D056486 CID ketoconazole_18\NN\entity.n.01| (r_pobj) with_17\IN\entity.n.01|ketoconazole (r_prep) treatment_16\NN\care.n.01|term|with (r_pobj) during_13\IN\entity.n.01|treatment (r_prep) advised_12\VBN\hash_out.v.01|monitoring|is|during|prevent|. (l_advcl) prevent_20\VB\prevent.v.01|to|injury (l_dobj) injury_24\NN\ill_health.n.01|possible|serious|hepatic
2273650
D012601_D000647 CID scopolamine_3\NN\alkaloid.n.01|and|cycloheximide (r_pobj) by_2\IN\by.r.01|scopolamine (r_agent) produced_1\VBN\make.v.03|by (r_acl) amnesia_0\NNP\cognitive_state.n.01|produced
D012601_D000647 CID scopolamine_5\NN\alkaloid.n.01|test (r_nsubj) reversed_7\VBD\change.v.02|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN\cognitive_state.n.01|the|induced
D012601_D000647 CID scopolamine_5\NN\alkaloid.n.01|test (r_nsubj) reversed_7\VBD\change.v.02|similarly|scopolamine|partially|amnesia|,|but|failed (l_conj) failed_23\VBD\fail.v.01|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB\opposition.n.02|to|amnesia (l_dobj) amnesia_30\NN\cognitive_state.n.01|the|induced
D012601_D000647 CID scopolamine_9\NN\alkaloid.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|scopolamine|- (r_amod) amnesia_12\NN\cognitive_state.n.01|the|induced
D012601_D000647 CID scopolamine_9\NN\alkaloid.n.01| (r_npadvmod) induced_11\VBN\generate.v.01|scopolamine|- (r_amod) amnesia_12\NN\cognitive_state.n.01|the|induced (r_dobj) reversed_7\VBD\change.v.02|similarly|scopolamine|partially|amnesia|,|but|failed (l_conj) failed_23\VBD\fail.v.01|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB\opposition.n.02|to|amnesia (l_dobj) amnesia_30\NN\cognitive_state.n.01|the|induced
D003513_D000647 CID cycloheximide_5\NN\entity.n.01| (r_conj) scopolamine_3\NN\alkaloid.n.01|and|cycloheximide (r_pobj) by_2\IN\by.r.01|scopolamine (r_agent) produced_1\VBN\make.v.03|by (r_acl) amnesia_0\NNP\cognitive_state.n.01|produced
D003513_D000647 CID cycloheximide_22\NN\entity.n.01|test (r_nsubj) failed_23\VBD\fail.v.01|significantly|cycloheximide|reverse|. (r_conj) reversed_7\VBD\change.v.02|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN\cognitive_state.n.01|the|induced
D003513_D000647 CID cycloheximide_22\NN\entity.n.01|test (r_nsubj) failed_23\VBD\fail.v.01|significantly|cycloheximide|reverse|. (l_xcomp) reverse_25\VB\opposition.n.02|to|amnesia (l_dobj) amnesia_30\NN\cognitive_state.n.01|the|induced
D003513_D000647 CID cycloheximide_27\RB\entity.n.01| (r_advmod) induced_29\VBN\generate.v.01|cycloheximide|- (r_amod) amnesia_30\NN\cognitive_state.n.01|the|induced (r_dobj) reverse_25\VB\opposition.n.02|to|amnesia (r_xcomp) failed_23\VBD\fail.v.01|significantly|cycloheximide|reverse|. (r_conj) reversed_7\VBD\change.v.02|similarly|scopolamine|partially|amnesia|,|but|failed (l_dobj) amnesia_12\NN\cognitive_state.n.01|the|induced
D003513_D000647 CID cycloheximide_27\RB\entity.n.01| (r_advmod) induced_29\VBN\generate.v.01|cycloheximide|- (r_amod) amnesia_30\NN\cognitive_state.n.01|the|induced
D009020_D000647 NONE morphine_9\NN\analgesic.n.01| (r_pobj) by_8\IN\by.r.01|morphine (r_agent) reversed_7\VBN\change.v.02|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) amnesia_0\NNP\cognitive_state.n.01|produced
D009020_D000647 NONE morphine_27\NN\analgesic.n.01|test (r_nsubj) facilitated_29\VBD\help.v.01|morphine|also|retrieval|. (r_conj) reversed_7\VBN\change.v.02|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) amnesia_0\NNP\cognitive_state.n.01|produced
D009270_D000647 NONE naloxone_37\NN\narcotic_antagonist.n.01| (r_dobj) administered_36\VBN\manage.v.02|naloxone|during (r_acl) retrieval_32\NN\computer_operation.n.01|the|memory|in|administered (r_dobj) facilitated_29\VBD\help.v.01|morphine|also|retrieval|. (r_conj) reversed_7\VBN\change.v.02|amnesia|were|by|given|,|and|facilitated (l_nsubjpass) amnesia_0\NNP\cognitive_state.n.01|produced
6538499
D011092_D064420 NONE 400_4\CD\four_hundred.s.01|on (r_nummod) glycol_3\NN\antifreeze.n.01|effect|400|adriamycin|. (l_advcl) adriamycin_6\JJ\entity.n.01|toxicity (l_dobj) toxicity_7\NN\definite_quantity.n.01|in
D004317_D064420 NONE adriamycin_6\JJ\entity.n.01|toxicity (l_dobj) toxicity_7\NN\definite_quantity.n.01|in
D004317_D009202 CID adr_8\NNP\entity.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|adr|- (r_amod) alterations_13\NNS\happening.n.01|induced|cardiac|morphological
D004317_D007939 NONE adr_6\NNP\entity.n.01| (r_compound) activity_8\NN\act.n.02|the|adr|antitumor|in|tumor (l_prep) in_9\IN\linear_unit.n.01|leukemia|and (l_pobj) leukemia_11\NN\cancer.n.01|l1210
D004317_D002286 NONE adr_6\NNP\entity.n.01| (r_compound) activity_8\NN\act.n.02|the|adr|antitumor|in|tumor (l_relcl) tumor_16\NN\growth.n.06|in|ascites
9351491
D018967_D011618 NONE risperidone_6\NN\entity.n.01|'s (r_poss) profile_9\NN\chart.n.01|risperidone|pharmacologic (r_nsubj) produce_11\VB\food.n.02|that|profile|may|efficacy|and|decreased (l_dobj) efficacy_13\NN\effectiveness.n.01|improved|for (l_prep) for_14\IN\entity.n.01|symptoms (l_pobj) symptoms_17\NNS\evidence.n.01|negative|psychotic
D018967_D010302 CID risperidone_10\NN\entity.n.01|(|%|)|and|haloperidol (r_pobj) with_9\IN\entity.n.01|risperidone (r_prep) treated_8\VBN\interact.v.01|with (r_acl) subjects_7\NNS\message.n.02|treated (r_pobj) in_6\IN\linear_unit.n.01|subjects (r_prep) observed_5\VBN\spy.v.03|parkinsonism|was|in|and|observed|. (l_nsubjpass) parkinsonism_3\NN\brain_disorder.n.01|induced
D006220_D010302 CID haloperidol_16\NN\major_tranquilizer.n.01|(|%|) (r_conj) risperidone_10\NN\entity.n.01|(|%|)|and|haloperidol (r_pobj) with_9\IN\entity.n.01|risperidone (r_prep) treated_8\VBN\interact.v.01|with (r_acl) subjects_7\NNS\message.n.02|treated (r_pobj) in_6\IN\linear_unit.n.01|subjects (r_prep) observed_5\VBN\spy.v.03|parkinsonism|was|in|and|observed|. (l_nsubjpass) parkinsonism_3\NN\brain_disorder.n.01|induced
15120741
D010862_D013226 CID pilocarpine_5\NN\alkaloid.n.01| (r_compound) injection_6\NN\insertion.n.02|systemic|pilocarpine (r_nsubj) causes_7\VBZ\origin.n.03|similar|,|injection|se|,|but|identified (l_dobj) se_11\NNP\antioxidant.n.01|status|epilepticus|(|)|and|development (l_nmod) epilepticus_9\NN\entity.n.01|
D010862_D013226 CID pilocarpine_5\NN\alkaloid.n.01| (r_compound) injection_6\NN\insertion.n.02|systemic|pilocarpine (r_nsubj) causes_7\VBZ\origin.n.03|similar|,|injection|se|,|but|identified (l_dobj) se_11\NNP\antioxidant.n.01|status|epilepticus|(|)|and|development
D010862_D013226 CID pilocarpine_34\NN\alkaloid.n.01| (r_npadvmod) treated_36\VBN\interact.v.01|pilocarpine|- (r_amod) mice_37\NNS\rodent.n.01|treated (r_conj) mice_32\NNS\rodent.n.01|control|and|mice (r_pobj) from_30\IN\entity.n.01|mice (r_prep) cells_29\NNS\compartment.n.01|granule|from (r_pobj) in_27\IN\linear_unit.n.01|cells (r_prep) spike_26\NN\electrical_discharge.n.01|a|single|population|in|experience (l_relcl) experience_41\VB\education.n.02|that|did|not|se (l_dobj) se_42\NNP\antioxidant.n.01|
D010862_D012640 CID pilocarpine_5\NN\alkaloid.n.01| (r_compound) injection_6\NN\insertion.n.02|systemic|pilocarpine (r_nsubj) causes_7\VBZ\origin.n.03|similar|,|injection|se|,|but|identified (l_dobj) se_11\NNP\antioxidant.n.01|status|epilepticus|(|)|and|development (l_conj) development_16\NN\improvement.n.02|the|eventual|of (l_prep) of_17\IN\entity.n.01|seizures (l_pobj) seizures_19\NNS\attack.n.07|spontaneous|and|fiber|sprouting
D008274_D013226 NONE mg(2+)-free_1\JJ\entity.n.01| (r_pobj) in_0\IN\linear_unit.n.01|mg(2+)-free|bicuculline (r_prep) resulted_21\VBD\prove.v.01|in|,|conditions|,|stimulation|in|. (l_prep) in_22\IN\linear_unit.n.01|spike (l_pobj) spike_26\NN\electrical_discharge.n.01|a|single|population|in|experience (l_relcl) experience_41\VB\education.n.02|that|did|not|se (l_dobj) se_42\NNP\antioxidant.n.01|
D001640_D013226 NONE bicuculline_5\NN\entity.n.01|bathing|containing (r_pobj) in_0\IN\linear_unit.n.01|mg(2+)-free|bicuculline (r_prep) resulted_21\VBD\prove.v.01|in|,|conditions|,|stimulation|in|. (l_prep) in_22\IN\linear_unit.n.01|spike (l_pobj) spike_26\NN\electrical_discharge.n.01|a|single|population|in|experience (l_relcl) experience_41\VB\education.n.02|that|did|not|se (l_dobj) se_42\NNP\antioxidant.n.01|
D018698_D013226 NONE glutamate_37\NN\salt.n.01| (r_compound) receptor_38\NN\structure.n.04|glutamate (r_compound) antagonists_39\NNS\person.n.01|ionotropic|receptor (r_pobj) by_35\IN\by.r.01|antagonists (r_agent) blocked_34\VBN\obstruct.v.02|which|were|by (r_relcl) duration_30\NN\time_period.n.01|s|,|blocked (r_pobj) of_25\IN\entity.n.01|duration (r_prep) afterdischarges_24\NNS\entity.n.01|repetitive|of (r_conj) shifts_21\NNS\translation.n.02|negative|dc|and|afterdischarges (r_pobj) by_18\IN\by.r.01|shifts (r_prep) followed_11\VBD\travel.v.01|,|at|,|by (r_advcl) resulted_6\VBD\prove.v.01|in|,|stimulation|in|followed|. (l_prep) in_0\IN\linear_unit.n.01|survivors (l_pobj) survivors_2\NNS\unfortunate.n.01|se (l_compound) se_1\NNP\antioxidant.n.01|
D018698_D013226 NONE glutamate_1\NN\salt.n.01| (r_compound) photostimulation_2\NN\entity.n.01|focal|glutamate|of|at (r_nsubj) resulted_15\VBD\prove.v.01|photostimulation|in|. (l_prep) in_16\IN\linear_unit.n.01|responses (l_pobj) responses_18\NNS\consequence.n.01|population|of (l_prep) of_19\IN\entity.n.01|duration (l_pobj) duration_24\NN\time_period.n.01|s|in|but|groups (l_prep) in_25\IN\linear_unit.n.01|slices (l_pobj) slices_26\NNS\share.n.01|from (l_prep) from_27\IN\entity.n.01|survivors (l_pobj) survivors_29\NNS\unfortunate.n.01|se (l_compound) se_28\NNP\antioxidant.n.01|
2578334
D001374_D011230 CID 5-azacytidine_0\RB\entity.n.01| (r_nsubj) potentiates_1\VBZ\enhance.v.01|5-azacytidine|initiation|. (l_dobj) initiation_2\NN\ceremony.n.01|induced (l_acl) induced_3\VBN\generate.v.01|by (l_agent) by_4\IN\by.r.01|carcinogens (l_pobj) carcinogens_5\NNS\substance.n.07|in
D001374_D011230 CID 5-azacytidine_22\JJ\entity.n.01| (r_punct) 5-azc_24\CD\entity.n.01|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\experiment.n.02|to|validity (l_dobj) validity_3\NN\credibility.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypothesis (l_pobj) hypothesis_6\NN\proposal.n.01|the|plays (l_acl) plays_11\VBZ\dramatic_composition.n.01|that|hypomethylation|role|in (l_prep) in_15\IN\linear_unit.n.01|initiation (l_pobj) initiation_17\NN\ceremony.n.01|the|of (l_prep) of_18\IN\entity.n.01|process (l_pobj) process_20\NN\activity.n.01|carcinogenic
D001374_D011230 CID 5-azc_24\CD\entity.n.01|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\experiment.n.02|to|validity (l_dobj) validity_3\NN\credibility.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypothesis (l_pobj) hypothesis_6\NN\proposal.n.01|the|plays (l_acl) plays_11\VBZ\dramatic_composition.n.01|that|hypomethylation|role|in (l_prep) in_15\IN\linear_unit.n.01|initiation (l_pobj) initiation_17\NN\ceremony.n.01|the|of (l_prep) of_18\IN\entity.n.01|process (l_pobj) process_20\NN\activity.n.01|carcinogenic
D001564_D011230 CID benzo[a]-pyrene_53\NN\entity.n.01|(|mg/kg|) (r_appos) carcinogens_51\NNS\substance.n.07|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\by.r.01|carcinogens (r_agent) induced_47\VBN\generate.v.01|by (r_acl) phase_43\NN\time_period.n.01|the|of|induced (r_pobj) during_41\IN\entity.n.01|phase (r_prep) given_38\VBN\assumption.n.02|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\entity.n.01|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\experiment.n.02|to|validity (l_dobj) validity_3\NN\credibility.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypothesis (l_pobj) hypothesis_6\NN\proposal.n.01|the|plays (l_acl) plays_11\VBZ\dramatic_composition.n.01|that|hypomethylation|role|in (l_prep) in_15\IN\linear_unit.n.01|initiation (l_pobj) initiation_17\NN\ceremony.n.01|the|of (l_prep) of_18\IN\entity.n.01|process (l_pobj) process_20\NN\activity.n.01|carcinogenic
D008770_D011230 CID nitrosourea_65\NN\entity.n.01|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS\substance.n.07|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\by.r.01|carcinogens (r_agent) induced_47\VBN\generate.v.01|by (r_acl) phase_43\NN\time_period.n.01|the|of|induced (r_pobj) during_41\IN\entity.n.01|phase (r_prep) given_38\VBN\assumption.n.02|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\entity.n.01|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\experiment.n.02|to|validity (l_dobj) validity_3\NN\credibility.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypothesis (l_pobj) hypothesis_6\NN\proposal.n.01|the|plays (l_acl) plays_11\VBZ\dramatic_composition.n.01|that|hypomethylation|role|in (l_prep) in_15\IN\linear_unit.n.01|initiation (l_pobj) initiation_17\NN\ceremony.n.01|the|of (l_prep) of_18\IN\entity.n.01|process (l_pobj) process_20\NN\activity.n.01|carcinogenic
D019813_D011230 CID 1,2-dimethylhydrazine_71\CD\entity.n.01| (r_conj) 60_67\CD\large_integer.n.01|(|mg/kg|)|and|1,2-dimethylhydrazine (r_appos) nitrosourea_65\NN\entity.n.01|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS\substance.n.07|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\by.r.01|carcinogens (r_agent) induced_47\VBN\generate.v.01|by (r_acl) phase_43\NN\time_period.n.01|the|of|induced (r_pobj) during_41\IN\entity.n.01|phase (r_prep) given_38\VBN\assumption.n.02|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\entity.n.01|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\experiment.n.02|to|validity (l_dobj) validity_3\NN\credibility.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypothesis (l_pobj) hypothesis_6\NN\proposal.n.01|the|plays (l_acl) plays_11\VBZ\dramatic_composition.n.01|that|hypomethylation|role|in (l_prep) in_15\IN\linear_unit.n.01|initiation (l_pobj) initiation_17\NN\ceremony.n.01|the|of (l_prep) of_18\IN\entity.n.01|process (l_pobj) process_20\NN\activity.n.01|carcinogenic
D019813_D011230 CID 1,2-dmh_73\NNP\entity.n.01|(|) (r_appos) nitrosourea_65\NN\entity.n.01|methyl|-|n|-|60|1,2-dmh|mg/kg (r_appos) carcinogens_51\NNS\substance.n.07|the|three|,|benzo[a]-pyrene|,|nitrosourea (r_pobj) by_48\IN\by.r.01|carcinogens (r_agent) induced_47\VBN\generate.v.01|by (r_acl) phase_43\NN\time_period.n.01|the|of|induced (r_pobj) during_41\IN\entity.n.01|phase (r_prep) given_38\VBN\assumption.n.02|5-azc|was|to|during|. (l_nsubjpass) 5-azc_24\CD\entity.n.01|test|,|5-azacytidine|(|)|mg/kg|,|inhibitor|, (l_advcl) test_1\VB\experiment.n.02|to|validity (l_dobj) validity_3\NN\credibility.n.01|the|of (l_prep) of_4\IN\entity.n.01|hypothesis (l_pobj) hypothesis_6\NN\proposal.n.01|the|plays (l_acl) plays_11\VBZ\dramatic_composition.n.01|that|hypomethylation|role|in (l_prep) in_15\IN\linear_unit.n.01|initiation (l_pobj) initiation_17\NN\ceremony.n.01|the|of (l_prep) of_18\IN\entity.n.01|process (l_pobj) process_20\NN\activity.n.01|carcinogenic
8410052
D019344_D001480 NONE lactate_10\NN\ester.n.01| (r_pobj) of_9\IN\entity.n.01|lactate (r_prep) infusion_8\NN\solution.n.01|of|at (r_pobj) by_7\IN\by.r.01|infusion|or|by (r_agent) produced_6\VBN\make.v.03|injury|was|by|. (l_nsubjpass) injury_1\NN\ill_health.n.01|focal|in (l_prep) in_2\IN\linear_unit.n.01|cortex (l_pobj) cortex_4\NN\neural_structure.n.01|the
D010862_D002544 CID pilocarpine_10\NN\alkaloid.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|pilocarpine|- (r_amod) status_13\NN\state.n.02|prolonged|induced (r_pobj) by_8\IN\by.r.01|status (r_agent) evoked_7\VBN\make.v.03|infarcts|were|by|epilepticus|. (l_nsubjpass) infarcts_0\NNS\pathology.n.02|in (l_prep) in_1\IN\linear_unit.n.01|reticulata (l_pobj) reticulata_5\NNS\entity.n.01|substantia|pars
D010862_D013226 CID pilocarpine_10\NN\alkaloid.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|pilocarpine|- (r_amod) status_13\NN\state.n.02|prolonged|induced (r_pobj) by_8\IN\by.r.01|status (r_agent) evoked_7\VBN\make.v.03|infarcts|were|by|epilepticus|. (l_advmod) epilepticus_14\NN\entity.n.01|
11807648
D014148_D004827 NONE acid_10\NN\compound.n.02|tranexamic (r_dobj) containing_8\VBG\include.v.01|acid|in (r_acl) sealants_7\NNS\sealing_material.n.01|fibrin|containing (r_pobj) of_5\IN\entity.n.01|sealants (r_prep) application_4\NN\use.n.01|cortical|of (r_dobj) following_2\VBG\multitude.n.03|application (r_prep) seizures_1\NNS\attack.n.07|epileptic|following|.
D014148_D004827 NONE tamca_2\NN\entity.n.01| (r_nsubjpass) shown_5\VBN\show.v.04|however|,|tamca|has|been|cause|. (l_xcomp) cause_7\VB\origin.n.03|to|seizures (l_dobj) seizures_9\NNS\attack.n.07|epileptic
D014148_D012640 CID tamca_5\NN\entity.n.01| (r_nsubj) retains_6\VBZ\hold.v.11|whether|tamca|action|incorporated (l_dobj) action_9\NN\act.n.02|its|convulsive (l_amod) convulsive_8\JJ\convulsive.s.01|
D014148_D012640 CID tamca_4\NN\entity.n.01| (r_appos) findings_0\NNS\collection.n.01|:|fs|tamca (r_nsubj) caused_5\VBD\make.v.03|findings|activity|. (l_dobj) activity_8\NN\act.n.02|paroxysmal|brain|associated (l_relcl) associated_11\VBN\think.v.03|which|was|with (l_prep) with_12\IN\entity.n.01|behaviours (l_pobj) behaviours_15\NNS\action.n.02|distinct|convulsive (l_amod) convulsive_14\JJ\convulsive.s.01|
D014148_D012640 CID tamca_10\CD\entity.n.01| (r_pobj) of_9\IN\entity.n.01|tamca (r_prep) concentration_8\NN\property.n.02|increasing|of (r_pobj) with_6\IN\entity.n.01|concentration (r_prep) increased_5\VBD\change_magnitude.v.01|degree|with|. (l_nsubj) degree_1\NN\property.n.02|the|of (l_prep) of_2\IN\entity.n.01|seizures (l_pobj) seizures_4\NNS\attack.n.07|these
D014148_D012640 CID tamca_0\NN\entity.n.01| (r_advmod) evoked_1\VBD\make.v.03|tamca|seizures|evoked|. (l_dobj) seizures_3\NNS\attack.n.07|generalized|in
D014148_D012640 CID tamca_0\NN\entity.n.01| (r_advmod) evoked_1\VBD\make.v.03|tamca|seizures|evoked|. (l_advcl) evoked_24\VBD\make.v.03|while|concentration|)|only|episodes (l_dobj) episodes_26\NNS\happening.n.01|brief|of (l_prep) of_27\IN\entity.n.01|potentials (l_pobj) potentials_32\NNS\possibility.n.02|correlated|convulsive|in (l_amod) convulsive_31\JJ\convulsive.s.01|
D014148_D012640 CID tamca_16\NN\entity.n.01| (r_nmod) ml_21\NNS\metric_capacity_unit.n.01|tamca|(|0.5|mg|/ (r_pobj) of_15\IN\entity.n.01|ml (r_prep) concentration_14\NN\property.n.02|the|lowest|of (r_nsubj) evoked_24\VBD\make.v.03|while|concentration|)|only|episodes (r_advcl) evoked_1\VBD\make.v.03|tamca|seizures|evoked|. (l_dobj) seizures_3\NNS\attack.n.07|generalized|in
D014148_D012640 CID tamca_16\NN\entity.n.01| (r_nmod) ml_21\NNS\metric_capacity_unit.n.01|tamca|(|0.5|mg|/ (r_pobj) of_15\IN\entity.n.01|ml (r_prep) concentration_14\NN\property.n.02|the|lowest|of (r_nsubj) evoked_24\VBD\make.v.03|while|concentration|)|only|episodes (l_dobj) episodes_26\NNS\happening.n.01|brief|of (l_prep) of_27\IN\entity.n.01|potentials (l_pobj) potentials_32\NNS\possibility.n.02|correlated|convulsive|in (l_amod) convulsive_31\JJ\convulsive.s.01|
D014148_D012640 CID acid_1\NN\compound.n.02|tranexamic (r_nsubj) retains_2\VBZ\hold.v.11|acid|action|. (l_dobj) action_5\NN\act.n.02|its|convulsive|within (l_amod) convulsive_4\JJ\convulsive.s.01|
7234705
D011342_D017180 CID procainamide_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|procainamide|-|tachycardia|. (l_dobj) tachycardia_5\NN\cardiac_arrhythmia.n.01|polymorphous|ventricular
D011342_D017180 CID procainamide_3\RB\entity.n.01| (r_advmod) induced_5\VBN\generate.v.01|procainamide|- (r_amod) tachycardia_8\NNS\cardiac_arrhythmia.n.01|induced|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\entity.n.01| (r_pobj) of_16\IN\entity.n.01|procainamide (r_prep) mg_15\IN\metric_weight_unit.n.01|400|of (r_pobj) of_11\IN\entity.n.01|mg (r_prep) administration_10\NN\management.n.01|intravenous|of|for (r_pobj) after_8\IN\after.s.01|administration (r_prep) appeared_7\VBD\be.v.01|in|,|tachycardia|after|. (l_nsubj) tachycardia_6\NN\cardiac_arrhythmia.n.01|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\entity.n.01| (r_pobj) of_16\IN\entity.n.01|procainamide (r_prep) mg_15\IN\metric_weight_unit.n.01|400|of (r_pobj) of_11\IN\entity.n.01|mg (r_prep) administration_10\NN\management.n.01|intravenous|of|for (l_prep) for_18\IN\entity.n.01|treatment (l_pobj) treatment_20\NN\care.n.01|the|of (l_prep) of_21\IN\entity.n.01|tachycardia (l_pobj) tachycardia_24\NN\cardiac_arrhythmia.n.01|sustained|ventricular
D011342_D017180 CID procainamide_16\NN\entity.n.01| (r_amod) therapy_17\NN\medical_care.n.01|procainamide (r_pobj) of_15\IN\entity.n.01|therapy (r_prep) continuation_14\NN\activity.n.01|of (r_pobj) despite_13\IN\dislike.n.02|continuation (r_prep) reoccur_24\VB\entity.n.01|despite|,|tachycardia|did|not|. (l_nsubj) tachycardia_21\NN\cardiac_arrhythmia.n.01|polymorphous|ventricular
D011342_D017180 CID procainamide_5\NN\entity.n.01| (r_nsubj) produce_7\VB\food.n.02|that|procainamide|can|syndrome|with (l_prep) with_15\IN\entity.n.01|tachycardia (l_pobj) tachycardia_18\NN\cardiac_arrhythmia.n.01|polymorphous|ventricular
D011342_D018879 NONE procainamide_6\NN\entity.n.01| (r_nsubjpass) administered_8\VBN\manage.v.02|in|,|procainamide|was|orally|for|. (l_prep) for_10\IN\entity.n.01|treatment (l_pobj) treatment_11\NN\care.n.01|of (l_prep) of_12\IN\entity.n.01|contractions (l_pobj) contractions_16\NNS\shortening.n.02|chronic|premature|ventricular|or|flutter
D011342_D001282 NONE procainamide_6\NN\entity.n.01| (r_nsubjpass) administered_8\VBN\manage.v.02|in|,|procainamide|was|orally|for|. (l_prep) for_10\IN\entity.n.01|treatment (l_pobj) treatment_11\NN\care.n.01|of (l_prep) of_12\IN\entity.n.01|contractions (l_pobj) contractions_16\NNS\shortening.n.02|chronic|premature|ventricular|or|flutter (l_conj) flutter_19\NN\motion.n.03|atrial
D011342_D008133 NONE procainamide_5\NN\entity.n.01| (r_nsubj) produce_7\VB\food.n.02|that|procainamide|can|syndrome|with (l_dobj) syndrome_14\NN\complex.n.01|an|acquired|prolonged|t
15278670
C009250_D012640 NONE sevoflurane_3\NN\entity.n.01| (r_pobj) of_2\IN\entity.n.01|sevoflurane (r_prep) effects_1\NNS\personal_property.n.01|the|of|on|. (l_prep) on_4\IN\on.a.01|convulsions (l_pobj) convulsions_8\NNS\attack.n.07|induced
C009250_D012640 NONE sevoflurane_3\NN\entity.n.01|on (l_prep) on_4\IN\on.a.01|convulsions (l_pobj) convulsions_8\NNS\attack.n.07|induced
C009250_D012640 NONE sevoflurane_40\NN\entity.n.01| (r_pobj) of_39\IN\entity.n.01|sevoflurane (r_prep) concentration_38\NN\property.n.02|the|tidal|of (r_nsubj) was_41\VBD\washington.n.02|when|concentration|% (r_relcl) l(-1_31\NN\entity.n.01|mg.|)|was (r_pobj) to_26\IN\entity.n.01|l(-1 (r_prep) increasing_24\VBG\change_magnitude.v.01|significantly|to (r_advcl) was_8\VBD\washington.n.02|threshold|+/-|)|with|)|,|increasing|. (l_nsubj) threshold_2\NN\beginning.n.02|the|convulsive|(|mean|) (l_amod) convulsive_1\JJ\convulsive.s.01|
C009250_D012640 NONE sevoflurane_10\NN\entity.n.01|and|enflurane (r_pobj) between_9\IN\between.r.01|sevoflurane (r_prep) threshold_8\NN\beginning.n.02|the|convulsive|between (l_amod) convulsive_7\JJ\convulsive.s.01|
C009250_D012640 NONE sevoflurane_12\NN\entity.n.01|or|enflurane (r_pobj) of_11\IN\entity.n.01|sevoflurane (r_prep) concentrations_10\NNS\property.n.02|higher|of (r_nsubjpass) administered_16\VBN\manage.v.02|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\change_magnitude.v.01|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\physical_phenomenon.n.01|the|blood|at (l_prep) at_21\IN\chemical_element.n.01|convulsions (l_pobj) convulsions_22\NNS\attack.n.07|
C009250_D012640 NONE sevoflurane_28\NN\entity.n.01|% (r_pobj) in_25\IN\linear_unit.n.01|sevoflurane (r_prep) decreased_23\VBD\change_magnitude.v.01|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\physical_phenomenon.n.01|the|blood|at (l_prep) at_21\IN\chemical_element.n.01|convulsions (l_pobj) convulsions_22\NNS\attack.n.07|
C009250_D012640 NONE sevoflurane_4\NN\entity.n.01| (r_nsubj) reduces_5\VBZ\decrease.v.02|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\phenomenon.n.01|the|convulsive|of (l_amod) convulsive_7\JJ\convulsive.s.01|
D008012_D012640 CID lidocaine_5\NN\local_anesthetic.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|lidocaine|- (r_amod) convulsions_8\NNS\attack.n.07|induced
D008012_D012640 CID lidocaine_5\NN\local_anesthetic.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|lidocaine|- (r_amod) convulsions_8\NNS\attack.n.07|induced
D008012_D012640 CID lidocaine_16\NN\local_anesthetic.n.01| (r_compound) infusion_17\NN\solution.n.01|lidocaine|(|mg.kg(-1).min(-1|) (r_pobj) with_15\IN\entity.n.01|infusion (r_prep) was_8\VBD\washington.n.02|threshold|+/-|)|with|)|,|increasing|. (l_nsubj) threshold_2\NN\beginning.n.02|the|convulsive|(|mean|) (l_amod) convulsive_1\JJ\convulsive.s.01|
D008012_D012640 CID lidocaine_10\JJ\local_anesthetic.n.01| (r_compound) toxicity_11\NN\definite_quantity.n.01|lidocaine (r_pobj) of_9\IN\entity.n.01|toxicity (r_prep) effect_8\NN\phenomenon.n.01|the|convulsive|of (l_amod) convulsive_7\JJ\convulsive.s.01|
D004737_D012640 NONE enflurane_12\NN\ether.n.04| (r_conj) sevoflurane_10\NN\entity.n.01|and|enflurane (r_pobj) between_9\IN\between.r.01|sevoflurane (r_prep) threshold_8\NN\beginning.n.02|the|convulsive|between (l_amod) convulsive_7\JJ\convulsive.s.01|
D004737_D012640 NONE enflurane_14\NN\ether.n.04| (r_conj) sevoflurane_12\NN\entity.n.01|or|enflurane (r_pobj) of_11\IN\entity.n.01|sevoflurane (r_prep) concentrations_10\NNS\property.n.02|higher|of (r_nsubjpass) administered_16\VBN\manage.v.02|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\change_magnitude.v.01|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\physical_phenomenon.n.01|the|blood|at (l_prep) at_21\IN\chemical_element.n.01|convulsions (l_pobj) convulsions_22\NNS\attack.n.07|
D004737_D012640 NONE enflurane_37\NN\ether.n.04|% (r_conj) %_33\NN\entity.n.01|0.8|and|enflurane (r_pobj) in_31\IN\linear_unit.n.01|% (r_conj) decreased_23\VBD\change_magnitude.v.01|pressure|significantly|in|,|and|in (l_nsubj) pressure_20\NN\physical_phenomenon.n.01|the|blood|at (l_prep) at_21\IN\chemical_element.n.01|convulsions (l_pobj) convulsions_22\NNS\attack.n.07|
D001030_D012640 NONE apamin_0\NNP\entity.n.01|ng (r_nsubj) had_5\VBD\have.v.01|apamin|tendency|)|but|was (l_dobj) tendency_7\NN\attitude.n.01|a|decrease (l_acl) decrease_9\VB\change.n.01|to|threshold (l_dobj) threshold_12\NN\beginning.n.02|the|convulsive|(|+/-|) (l_amod) convulsive_11\JJ\convulsive.s.01|
C009250_D064420 NONE sevoflurane_4\NN\entity.n.01| (r_nsubj) reduces_5\VBZ\decrease.v.02|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\phenomenon.n.01|the|convulsive|of (l_prep) of_9\IN\entity.n.01|toxicity (l_pobj) toxicity_11\NN\definite_quantity.n.01|lidocaine
C009250_D003866 NONE sevoflurane_4\NN\entity.n.01| (r_nsubj) reduces_5\VBZ\decrease.v.02|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\transportation.n.02|risk|due (l_prep) due_16\IN\right.n.01|to (l_pcomp) to_17\IN\entity.n.01|depression (l_pobj) depression_19\NN\psychological_state.n.01|circulatory
D008012_D064420 NONE lidocaine_10\JJ\local_anesthetic.n.01| (r_compound) toxicity_11\NN\definite_quantity.n.01|lidocaine
D008012_D003866 NONE lidocaine_10\JJ\local_anesthetic.n.01| (r_compound) toxicity_11\NN\definite_quantity.n.01|lidocaine (r_pobj) of_9\IN\entity.n.01|toxicity (r_prep) effect_8\NN\phenomenon.n.01|the|convulsive|of (r_dobj) reduces_5\VBZ\decrease.v.02|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\transportation.n.02|risk|due (l_prep) due_16\IN\right.n.01|to (l_pcomp) to_17\IN\entity.n.01|depression (l_pobj) depression_19\NN\psychological_state.n.01|circulatory
6209318
D008801_D001145 NONE mexiletine_1\NN\antiarrhythmic.n.01|and|placebo (r_nmod) trial_6\NN\attempt.n.01|international|mexiletine|antiarrhythmic|coronary|:|report|. (l_appos) report_9\NNP\document.n.01|i.|on (l_prep) on_10\IN\on.a.01|arrhythmia (l_pobj) arrhythmia_11\NN\heart_disease.n.01|and|findings
D008801_D009203 NONE mexiletine_9\NN\antiarrhythmic.n.01| (r_pobj) of_8\IN\entity.n.01|mexiletine|perlongets (r_prep) form_7\NN\word.n.01|the|sustained|release|of (r_pobj) of_3\IN\entity.n.01|form (r_prep) effects_2\NNS\personal_property.n.01|the|antiarrhythmic|of (r_nsubjpass) evaluated_16\VBN\evaluate.v.02|effects|were|in|. (l_prep) in_17\IN\linear_unit.n.01|trial (l_pobj) trial_23\NN\attempt.n.01|a|blind|placebo|in (l_prep) in_24\IN\linear_unit.n.01|patients (l_pobj) patients_26\NNS\case.n.06|630|with (l_prep) with_27\IN\entity.n.01|infarction (l_pobj) infarction_31\NN\pathology.n.02|recent|documented|myocardial
D008801_D009203 NONE perlongets_13\NNP\entity.n.01|(|mexitil|-|) (r_pobj) of_8\IN\entity.n.01|mexiletine|perlongets (r_prep) form_7\NN\word.n.01|the|sustained|release|of (r_pobj) of_3\IN\entity.n.01|form (r_prep) effects_2\NNS\personal_property.n.01|the|antiarrhythmic|of (r_nsubjpass) evaluated_16\VBN\evaluate.v.02|effects|were|in|. (l_prep) in_17\IN\linear_unit.n.01|trial (l_pobj) trial_23\NN\attempt.n.01|a|blind|placebo|in (l_prep) in_24\IN\linear_unit.n.01|patients (l_pobj) patients_26\NNS\case.n.06|630|with (l_prep) with_27\IN\entity.n.01|infarction (l_pobj) infarction_31\NN\pathology.n.02|recent|documented|myocardial
D008801_D003643 NONE mexiletine_6\NN\antiarrhythmic.n.01| (r_amod) group_7\NN\abstraction.n.06|the|mexiletine|(|%|) (r_pobj) in_4\IN\linear_unit.n.01|group (r_prep) deaths_3\NNS\change.n.01|more|in|than
D008801_D014202 CID mexiletine_16\NN\antiarrhythmic.n.01| (r_amod) group_17\NN\abstraction.n.06|the|mexiletine (r_pobj) in_14\IN\linear_unit.n.01|group (r_prep) frequent_13\JJ\support.v.01|more|in|than (r_acomp) were_11\VBD\be.v.01|effects|frequent|. (l_nsubj) effects_3\NNS\personal_property.n.01|recognized|side|,|tremor|, (l_appos) tremor_6\JJ\vibration.n.01|particularly|and|problems
D008801_D012817 CID mexiletine_16\NN\antiarrhythmic.n.01| (r_amod) group_17\NN\abstraction.n.06|the|mexiletine (r_pobj) in_14\IN\linear_unit.n.01|group (r_prep) frequent_13\JJ\support.v.01|more|in|than (r_acomp) were_11\VBD\be.v.01|effects|frequent|. (l_nsubj) effects_3\NNS\personal_property.n.01|recognized|side|,|tremor|, (l_appos) tremor_6\JJ\vibration.n.01|particularly|and|problems (l_conj) problems_9\NNS\difficulty.n.03|gastrointestinal
2071257
D005997_D000647 NONE phosphorylcholine_8\NN\entity.n.01|glyceryl|- (r_pobj) of_1\IN\entity.n.01|phosphorylcholine (r_prep) effect_0\NN\phenomenon.n.01|of|on|. (l_prep) on_9\IN\on.a.01|amnesia (l_pobj) amnesia_10\NN\cognitive_state.n.01|caused
D012601_D000647 NONE scopolamine_13\NN\alkaloid.n.01| (r_pobj) by_12\IN\by.r.01|scopolamine (r_agent) caused_11\VBN\make.v.03|by (r_acl) amnesia_10\NN\cognitive_state.n.01|caused
D005997_D008569 NONE glycerylphosphorylcholine_15\NN\entity.n.01|l|-|alpha|-|gfc (r_pobj) of_10\IN\entity.n.01|glycerylphosphorylcholine (r_prep) effects_9\NNS\personal_property.n.01|the|of|on (l_prep) on_23\IN\on.a.01|impairment (l_pobj) impairment_25\NN\change.n.01|memory|induced
D005997_D008569 NONE gfc_21\NNP\entity.n.01|(|l|-|alpha|-|) (r_appos) glycerylphosphorylcholine_15\NN\entity.n.01|l|-|alpha|-|gfc (r_pobj) of_10\IN\entity.n.01|glycerylphosphorylcholine (r_prep) effects_9\NNS\personal_property.n.01|the|of|on (l_prep) on_23\IN\on.a.01|impairment (l_pobj) impairment_25\NN\change.n.01|memory|induced
D012601_D008569 CID scopolamine_28\NN\alkaloid.n.01|in (r_pobj) by_27\IN\by.r.01|scopolamine (r_agent) induced_26\VBN\generate.v.01|by (r_acl) impairment_25\NN\change.n.01|memory|induced
D012601_D008569 CID scopolamine_20\NN\alkaloid.n.01| (r_pobj) by_19\IN\by.r.01|scopolamine (r_agent) induced_18\VBN\generate.v.01|by (r_acl) impairment_13\NN\change.n.01|of|induced (l_prep) of_14\IN\entity.n.01|attention (l_pobj) attention_15\NN\basic_cognitive_process.n.01|and|memory (l_conj) memory_17\NN\representation.n.01|
17437408
D010862_D012640 CID pilocarpine_11\NN\alkaloid.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|pilocarpine|- (r_amod) seizures_14\NNS\attack.n.07|induced|in
4812392
D001379_D011565 NONE azathioprine_4\NN\medicine.n.02| (r_pobj) with_3\IN\entity.n.01|azathioprine (r_prep) psoriasis_2\NN\skin_disease.n.01|with
D001379_D011565 NONE azathioprine_0\JJ\medicine.n.02| (r_det) treatment_1\NN\care.n.01|azathioprine (r_nsubj) benefited_2\VBD\get.v.01|treatment|%|out|. (l_prep) out_8\IN\failure.n.01|of (l_prep) of_9\IN\entity.n.01|patients (l_pobj) patients_11\NNS\case.n.06|29|suffering (l_acl) suffering_12\VBG\pain.n.01|from (l_prep) from_13\IN\entity.n.01|psoriasis (l_pobj) psoriasis_15\NN\skin_disease.n.01|severe
D001379_D056486 NONE azathioprine_9\JJ\medicine.n.02| (r_amod) therapy_10\NN\medical_care.n.01|azathioprine (r_nsubjpass) continued_12\VBN\act.v.01|if|therapy|is|detected (l_advcl) detected_20\VBN\spy.v.03|so|that|damage|may|be|at (l_nsubjpass) damage_17\NN\change.n.01|structural|liver
1786266
D000928_D001480 NONE antidepressant_3\NN\medicine.n.02| (r_compound) use_4\NN\activity.n.01|antidepressant|,|and|findings (r_conj) syndrome_1\NN\complex.n.01|rabbit|,|use|.
12523465
C022189_D006212 CID zonisamide_4\NN\entity.n.01| (r_pobj) with_3\IN\entity.n.01|zonisamide (r_prep) associated_2\VBN\think.v.03|with (r_acl) hallucinations_1\NNS\delusion.n.01|visual|associated|.
C022189_D006212 CID zonisamide_29\NN\entity.n.01| (r_amod) treatment_30\NN\care.n.01|zonisamide (r_pobj) after_28\IN\after.s.01|treatment (r_prep) altered_25\VBD\change.v.01|status|after (r_conj) experienced_20\VBD\undergo.v.01|who|hallucinations|and|altered (r_relcl) patients_18\NNS\case.n.06|three|experienced (r_dobj) describe_16\VBP\set_forth.v.01|reported|,|we|patients|begun|. (l_advcl) reported_6\VBN\inform.v.01|although|hallucinations|have|not|been|as (l_nsubjpass) hallucinations_2\NNS\delusion.n.01|visual
C022189_D006212 CID zonisamide_29\NN\entity.n.01| (r_amod) treatment_30\NN\care.n.01|zonisamide (r_pobj) after_28\IN\after.s.01|treatment (r_prep) altered_25\VBD\change.v.01|status|after (r_conj) experienced_20\VBD\undergo.v.01|who|hallucinations|and|altered (l_dobj) hallucinations_23\NNS\delusion.n.01|complex|visual
C022189_D012640 NONE zonisamide_0\NNP\entity.n.01| (r_nsubj) is_1\VBZ\be.v.01|zonisamide|drug|. (l_attr) drug_7\NN\agent.n.03|a|spectrum|antiepileptic|used (l_acl) used_8\VBN\use.v.01|treat (l_xcomp) treat_10\VB\nutriment.n.01|to|types (l_dobj) types_12\NNS\kind.n.01|various|of (l_prep) of_13\IN\entity.n.01|seizures (l_pobj) seizures_14\NNS\attack.n.07|
2355241
D007980_D002543 NONE levodopa_23\NN\dopa.n.01| (r_pobj) of_22\IN\entity.n.01|levodopa (r_prep) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\indicate.v.02|incidence|may|effect|. (l_nsubj) incidence_2\NN\frequency.n.02|the|low|of|as (l_prep) of_3\IN\entity.n.01|haemorrhage (l_pobj) haemorrhage_5\NN\injury.n.01|cerebral
D007980_D003643 NONE levodopa_23\NN\dopa.n.01| (r_pobj) of_22\IN\entity.n.01|levodopa (r_prep) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\indicate.v.02|incidence|may|effect|. (l_nsubj) incidence_2\NN\frequency.n.02|the|low|of|as (l_prep) as_6\IN\chemical_element.n.01|cause (l_pobj) cause_8\NN\origin.n.03|a|of|in (l_prep) of_9\IN\entity.n.01|death (l_pobj) death_10\NN\change.n.01|
D007980_D010300 NONE levodopa_23\NN\dopa.n.01| (r_pobj) of_22\IN\entity.n.01|levodopa (r_prep) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\indicate.v.02|incidence|may|effect|. (l_nsubj) incidence_2\NN\frequency.n.02|the|low|of|as (l_prep) as_6\IN\chemical_element.n.01|cause (l_pobj) cause_8\NN\origin.n.03|a|of|in (l_prep) in_11\IN\linear_unit.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|disease (l_pobj) disease_16\NN\illness.n.01|parkinson
D007980_D010300 NONE levodopa_23\NN\dopa.n.01| (r_pobj) of_22\IN\entity.n.01|levodopa (r_prep) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (l_conj) mechanism_27\NN\chemical_process.n.01|a|hypotensive|due (l_amod) due_28\IN\right.n.01|to|levels (l_pobj) levels_32\NNS\property.n.02|reduced|noradrenaline|in (l_prep) in_33\IN\linear_unit.n.01|brain (l_pobj) brain_36\NN\neural_structure.n.01|the|parkinsonian (l_amod) parkinsonian_35\JJ\entity.n.01|
D007980_D007022 CID levodopa_23\NN\dopa.n.01| (r_pobj) of_22\IN\entity.n.01|levodopa (r_prep) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (l_amod) hypotensive_20\JJ\patient.n.01|
D007980_D007022 CID levodopa_23\NN\dopa.n.01| (r_pobj) of_22\IN\entity.n.01|levodopa (r_prep) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (l_conj) mechanism_27\NN\chemical_process.n.01|a|hypotensive|due (l_amod) hypotensive_26\JJ\patient.n.01|
D009638_D002543 NONE noradrenaline_31\NN\catecholamine.n.01| (r_amod) levels_32\NNS\property.n.02|reduced|noradrenaline|in (r_pobj) due_28\IN\right.n.01|to|levels (r_amod) mechanism_27\NN\chemical_process.n.01|a|hypotensive|due (r_conj) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\indicate.v.02|incidence|may|effect|. (l_nsubj) incidence_2\NN\frequency.n.02|the|low|of|as (l_prep) of_3\IN\entity.n.01|haemorrhage (l_pobj) haemorrhage_5\NN\injury.n.01|cerebral
D009638_D003643 NONE noradrenaline_31\NN\catecholamine.n.01| (r_amod) levels_32\NNS\property.n.02|reduced|noradrenaline|in (r_pobj) due_28\IN\right.n.01|to|levels (r_amod) mechanism_27\NN\chemical_process.n.01|a|hypotensive|due (r_conj) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\indicate.v.02|incidence|may|effect|. (l_nsubj) incidence_2\NN\frequency.n.02|the|low|of|as (l_prep) as_6\IN\chemical_element.n.01|cause (l_pobj) cause_8\NN\origin.n.03|a|of|in (l_prep) of_9\IN\entity.n.01|death (l_pobj) death_10\NN\change.n.01|
D009638_D010300 NONE noradrenaline_31\NN\catecholamine.n.01| (r_amod) levels_32\NNS\property.n.02|reduced|noradrenaline|in (r_pobj) due_28\IN\right.n.01|to|levels (r_amod) mechanism_27\NN\chemical_process.n.01|a|hypotensive|due (r_conj) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (r_dobj) reflect_18\VB\indicate.v.02|incidence|may|effect|. (l_nsubj) incidence_2\NN\frequency.n.02|the|low|of|as (l_prep) as_6\IN\chemical_element.n.01|cause (l_pobj) cause_8\NN\origin.n.03|a|of|in (l_prep) in_11\IN\linear_unit.n.01|patients (l_pobj) patients_12\NNS\case.n.06|with (l_prep) with_13\IN\entity.n.01|disease (l_pobj) disease_16\NN\illness.n.01|parkinson
D009638_D010300 NONE noradrenaline_31\NN\catecholamine.n.01| (r_amod) levels_32\NNS\property.n.02|reduced|noradrenaline|in (l_prep) in_33\IN\linear_unit.n.01|brain (l_pobj) brain_36\NN\neural_structure.n.01|the|parkinsonian (l_amod) parkinsonian_35\JJ\entity.n.01|
D009638_D007022 NONE noradrenaline_31\NN\catecholamine.n.01| (r_amod) levels_32\NNS\property.n.02|reduced|noradrenaline|in (r_pobj) due_28\IN\right.n.01|to|levels (r_amod) mechanism_27\NN\chemical_process.n.01|a|hypotensive|due (r_conj) effect_21\NN\phenomenon.n.01|the|hypotensive|of|and|mechanism (l_amod) hypotensive_20\JJ\patient.n.01|
D009638_D007022 NONE noradrenaline_31\NN\catecholamine.n.01| (r_amod) levels_32\NNS\property.n.02|reduced|noradrenaline|in (r_pobj) due_28\IN\right.n.01|to|levels (r_amod) mechanism_27\NN\chemical_process.n.01|a|hypotensive|due (l_amod) hypotensive_26\JJ\patient.n.01|
1378968
D008094_D007676 CID lithium_8\NN\metallic_element.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|lithium|- (r_amod) failure_13\NN\nonaccomplishment.n.01|induced|chronic|renal|in
D008094_D007674 NONE lithium_2\NN\metallic_element.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|lithium|- (r_amod) nephropathy_5\NN\uropathy.n.01|induced
D008094_D007674 NONE li_4\NNP\metallic_element.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|li|- (r_amod) nephropathy_7\NN\uropathy.n.01|induced|,|reduced|,
D008094_D051437 NONE lithium_2\NN\metallic_element.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|lithium|- (r_amod) nephropathy_5\NN\uropathy.n.01|induced (r_pobj) with_1\IN\entity.n.01|nephropathy (r_prep) rats_0\NNS\rodent.n.01|with (r_nsubjpass) subjected_7\VBN\affect.v.01|rats|were|to|,|in|. (l_prep) in_26\IN\linear_unit.n.01|attempt (l_pobj) attempt_28\NN\activity.n.01|an|induce (l_acl) induce_30\VB\generate.v.01|to|hyperfiltration (l_dobj) hyperfiltration_32\NN\entity.n.01|glomerular|and|progression (l_conj) progression_35\NN\series.n.01|further|of (l_prep) of_36\IN\entity.n.01|failure (l_pobj) failure_38\NN\nonaccomplishment.n.01|renal
D008094_D051437 NONE lithium_21\NN\metallic_element.n.01| (r_nmod) rats_23\NNS\rodent.n.01|lithium|pretreated (r_pobj) in_20\IN\linear_unit.n.01|rats (r_prep) levels_19\NNS\property.n.02|plasma|creatinine|in (r_dobj) decrease_16\NN\change.n.01|levels (r_conj) increase_13\VB\indefinite_quantity.n.01|to|gfr|decrease (r_xcomp) tended_11\VBD\be.v.01|in|increase|. (r_conj) failed_1\VBD\fail.v.01|hp|accentuante|and|tended (l_xcomp) accentuante_3\NN\entity.n.01|to|progression (l_dobj) progression_4\NN\series.n.01|of (l_prep) of_5\IN\entity.n.01|failure (l_pobj) failure_7\NN\nonaccomplishment.n.01|renal
D008094_D011507 CID lithium_0\NN\metallic_element.n.01| (r_nsubj) caused_2\VBD\make.v.03|lithium|also|proteinuria|in|. (l_dobj) proteinuria_3\NN\symptom.n.01|and|hypertension
D008094_D011507 CID li_4\NNP\metallic_element.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|li|- (r_amod) nephropathy_7\NN\uropathy.n.01|induced|,|reduced|, (r_nsubjpass) associated_19\VBN\think.v.03|that|nephropathy|is|with (l_prep) with_20\IN\entity.n.01|proteinuria (l_pobj) proteinuria_21\NN\symptom.n.01|and|hypertension
D008094_D006973 CID lithium_0\NN\metallic_element.n.01| (r_nsubj) caused_2\VBD\make.v.03|lithium|also|proteinuria|in|. (l_dobj) proteinuria_3\NN\symptom.n.01|and|hypertension (l_conj) hypertension_6\NN\cardiovascular_disease.n.01|systolic
D008094_D006973 CID li_4\NNP\metallic_element.n.01| (r_npadvmod) induced_6\VBN\generate.v.01|li|- (r_amod) nephropathy_7\NN\uropathy.n.01|induced|,|reduced|, (r_nsubjpass) associated_19\VBN\think.v.03|that|nephropathy|is|with (l_prep) with_20\IN\entity.n.01|proteinuria (l_pobj) proteinuria_21\NN\symptom.n.01|and|hypertension (l_conj) hypertension_25\NN\cardiovascular_disease.n.01|arterial|systolic
D008094_D005921 NONE lithium_0\NN\metallic_element.n.01| (r_nsubj) caused_2\VBD\make.v.03|lithium|also|proteinuria|in|. (l_prep) in_7\IN\linear_unit.n.01|absence (l_pobj) absence_8\NN\lack.n.01|of (l_prep) of_9\IN\entity.n.01|glomerulosclerosis (l_pobj) glomerulosclerosis_10\NN\entity.n.01|
D003404_D051437 NONE creatinine_18\NN\entity.n.01| (r_compound) levels_19\NNS\property.n.02|plasma|creatinine|in (r_dobj) decrease_16\NN\change.n.01|levels (r_conj) increase_13\VB\indefinite_quantity.n.01|to|gfr|decrease (r_xcomp) tended_11\VBD\be.v.01|in|increase|. (r_conj) failed_1\VBD\fail.v.01|hp|accentuante|and|tended (l_xcomp) accentuante_3\NN\entity.n.01|to|progression (l_dobj) progression_4\NN\series.n.01|of (l_prep) of_5\IN\entity.n.01|failure (l_pobj) failure_7\NN\nonaccomplishment.n.01|renal
9766615
D003024_D001480 NONE clozapine_40\NN\major_tranquilizer.n.01|primarily (r_appos) threshold_37\NN\beginning.n.02|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (r_conj) associated_13\VBN\think.v.03|are|in|,|lowered (r_conj) have_4\VBP\person.n.01|agents|risk|,|but|associated|. (l_dobj) risk_7\NN\danger.n.03|a|lower|of (l_prep) of_8\IN\entity.n.01|eps (l_pobj) eps_9\NNP\entity.n.01|
D003024_D001480 NONE clozapine_46\NN\major_tranquilizer.n.01|(|only|) (r_appos) agranulocytosis_44\NN\blood_disease.n.01|clozapine (r_conj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (r_conj) associated_13\VBN\think.v.03|are|in|,|lowered (r_conj) have_4\VBP\person.n.01|agents|risk|,|but|associated|. (l_dobj) risk_7\NN\danger.n.03|a|lower|of (l_prep) of_8\IN\entity.n.01|eps (l_pobj) eps_9\NNP\entity.n.01|
D003024_D015430 NONE clozapine_40\NN\major_tranquilizer.n.01|primarily (r_appos) threshold_37\NN\beginning.n.02|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\personal_property.n.01|cardiovascular|,|effects|, (l_conj) effects_24\NNS\personal_property.n.01|anticholinergic|,|gain (l_conj) gain_27\NN\indefinite_quantity.n.01|weight|,|dysfunction
D003024_D015430 NONE clozapine_46\NN\major_tranquilizer.n.01|(|only|) (r_appos) agranulocytosis_44\NN\blood_disease.n.01|clozapine (r_conj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\personal_property.n.01|cardiovascular|,|effects|, (l_conj) effects_24\NNS\personal_property.n.01|anticholinergic|,|gain (l_conj) gain_27\NN\indefinite_quantity.n.01|weight|,|dysfunction
D003024_D012735 NONE clozapine_40\NN\major_tranquilizer.n.01|primarily (r_appos) threshold_37\NN\beginning.n.02|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\personal_property.n.01|cardiovascular|,|effects|, (l_conj) effects_24\NNS\personal_property.n.01|anticholinergic|,|gain (l_conj) gain_27\NN\indefinite_quantity.n.01|weight|,|dysfunction (l_conj) dysfunction_30\NN\pathology.n.02|sexual|,|effects
D003024_D012735 NONE clozapine_46\NN\major_tranquilizer.n.01|(|only|) (r_appos) agranulocytosis_44\NN\blood_disease.n.01|clozapine (r_conj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (l_nsubj) effects_21\NNS\personal_property.n.01|cardiovascular|,|effects|, (l_conj) effects_24\NNS\personal_property.n.01|anticholinergic|,|gain (l_conj) gain_27\NN\indefinite_quantity.n.01|weight|,|dysfunction (l_conj) dysfunction_30\NN\pathology.n.02|sexual|,|effects
D003024_D012640 NONE clozapine_40\NN\major_tranquilizer.n.01|primarily (r_appos) threshold_37\NN\beginning.n.02|seizure|(|clozapine|) (l_compound) seizure_36\NN\attack.n.07|
D003024_D012640 NONE clozapine_46\NN\major_tranquilizer.n.01|(|only|) (r_appos) agranulocytosis_44\NN\blood_disease.n.01|clozapine (r_conj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (l_dobj) threshold_37\NN\beginning.n.02|seizure|(|clozapine|) (l_compound) seizure_36\NN\attack.n.07|
D003024_D000380 CID clozapine_40\NN\major_tranquilizer.n.01|primarily (r_appos) threshold_37\NN\beginning.n.02|seizure|(|clozapine|) (r_dobj) lowered_35\VBD\move.v.02|effects|threshold|,|and|agranulocytosis (l_conj) agranulocytosis_44\NN\blood_disease.n.01|clozapine
D003024_D000380 CID clozapine_46\NN\major_tranquilizer.n.01|(|only|) (r_appos) agranulocytosis_44\NN\blood_disease.n.01|clozapine
15899738
D003401_D001281 CID creatine_5\NN\amino_acid.n.01| (r_compound) supplementation_7\NN\increase.n.04|creatine|monohydrate (r_pobj) with_4\IN\entity.n.01|supplementation (r_prep) associated_3\VBN\think.v.03|with (r_acl) fibrillation_2\NN\twitch.n.01|lone|atrial|associated|.
D003401_D001145 NONE creatine_5\NN\amino_acid.n.01|to (l_prep) to_6\IN\entity.n.01|development (l_pobj) development_8\NN\improvement.n.02|the|of (l_prep) of_9\IN\entity.n.01|arrhythmia (l_pobj) arrhythmia_10\NN\heart_disease.n.01|
1992636
D009853_D000743 CID omeprazole_7\NN\antacid.n.01| (r_pobj) of_6\IN\entity.n.01|omeprazole (r_prep) use_5\NN\activity.n.01|the|of (r_pobj) with_3\IN\entity.n.01|use (r_prep) associated_2\VBN\think.v.03|with (r_acl) anemia_1\NN\blood_disease.n.01|hemolytic|associated|.
D009853_D000743 CID omeprazole_17\NN\antacid.n.01| (r_pobj) of_16\IN\entity.n.01|omeprazole (r_prep) use_15\NN\activity.n.01|the|of (r_pobj) with_13\IN\entity.n.01|use (r_prep) reaction_12\NN\chemical_process.n.01|a|serious|term|adverse|with (r_pobj) of_5\IN\entity.n.01|reaction (r_prep) case_4\NN\happening.n.01|the|first|of|:|anemia (l_appos) anemia_20\NN\blood_disease.n.01|hemolytic
D009853_D000743 CID omeprazole_4\NN\antacid.n.01| (r_nsubj) caused_5\VBD\make.v.03|by|omeprazole|is (l_ccomp) is_11\VBZ\be.v.01|anemia|uncertain (l_nsubj) anemia_10\NN\blood_disease.n.01|patient|hemolytic
D009853_D053609 CID omeprazole_17\NN\antacid.n.01| (r_pobj) with_16\IN\entity.n.01|omeprazole (r_prep) starting_14\VBG\turn.n.03|therapy|with (r_pcomp) after_13\IN\after.s.01|days|starting (r_prep) weakness_3\NN\imperfection.n.01|developed|,|lethargy|after|. (l_conj) lethargy_5\NN\torpor.n.01|,|and|shortness
D009853_D004417 CID omeprazole_17\NN\antacid.n.01| (r_pobj) with_16\IN\entity.n.01|omeprazole (r_prep) starting_14\VBG\turn.n.03|therapy|with (r_pcomp) after_13\IN\after.s.01|days|starting (r_prep) weakness_3\NN\imperfection.n.01|developed|,|lethargy|after|. (l_conj) lethargy_5\NN\torpor.n.01|,|and|shortness (l_conj) shortness_8\NN\length.n.01|of (l_prep) of_9\IN\entity.n.01|breath (l_pobj) breath_10\NN\bodily_process.n.01|
2951327
D009638_D013610 NONE norepinephrine_76\NN\catecholamine.n.01| (r_amod) rate_78\NN\magnitude_relation.n.01|the|norepinephrine|release|( (r_pobj) of_74\IN\entity.n.01|rate (r_prep) augmentation_73\NN\increase.n.02|no|of (r_conj) tachycardia_70\NN\cardiac_arrhythmia.n.01|no|and|augmentation|min|)
D009638_D007022 NONE norepinephrine_76\NN\catecholamine.n.01| (r_amod) rate_78\NN\magnitude_relation.n.01|the|norepinephrine|release|( (r_pobj) of_74\IN\entity.n.01|rate (r_prep) augmentation_73\NN\increase.n.02|no|of (r_conj) tachycardia_70\NN\cardiac_arrhythmia.n.01|no|and|augmentation|min|) (r_conj) +/-_45\NN\entity.n.01|93|1|p|,|or|%|but|tachycardia (r_appos) was_29\VBD\washington.n.02|pressure|+/-|,|+/-|observed|. (l_conj) observed_90\VBN\spy.v.03|were|,|is (l_advcl) is_93\VBZ\be.v.01|which|in (l_prep) in_94\IN\linear_unit.n.01|contrast (l_pobj) contrast_95\NN\opposition.n.02|to (l_prep) to_96\IN\entity.n.01|hypotension (l_pobj) hypotension_98\NN\cardiovascular_disease.n.01|comparable|induced
D006830_D013610 NONE hydralazine_101\NN\antihypertensive.n.01|or|nitroglycerin (r_pobj) by_100\IN\by.r.01|hydralazine (r_agent) induced_99\VBN\generate.v.01|by (r_acl) hypotension_98\NN\cardiovascular_disease.n.01|comparable|induced (r_pobj) to_96\IN\entity.n.01|hypotension (r_prep) contrast_95\NN\opposition.n.02|to (r_pobj) in_94\IN\linear_unit.n.01|contrast (r_prep) is_93\VBZ\be.v.01|which|in (r_advcl) observed_90\VBN\spy.v.03|were|,|is (r_conj) was_29\VBD\washington.n.02|pressure|+/-|,|+/-|observed|. (l_appos) +/-_45\NN\entity.n.01|93|1|p|,|or|%|but|tachycardia (l_conj) tachycardia_70\NN\cardiac_arrhythmia.n.01|no|and|augmentation|min|)
D006830_D007022 CID hydralazine_101\NN\antihypertensive.n.01|or|nitroglycerin (r_pobj) by_100\IN\by.r.01|hydralazine (r_agent) induced_99\VBN\generate.v.01|by (r_acl) hypotension_98\NN\cardiovascular_disease.n.01|comparable|induced
D005996_D013610 NONE nitroglycerin_103\NN\nitrate.n.01| (r_conj) hydralazine_101\NN\antihypertensive.n.01|or|nitroglycerin (r_pobj) by_100\IN\by.r.01|hydralazine (r_agent) induced_99\VBN\generate.v.01|by (r_acl) hypotension_98\NN\cardiovascular_disease.n.01|comparable|induced (r_pobj) to_96\IN\entity.n.01|hypotension (r_prep) contrast_95\NN\opposition.n.02|to (r_pobj) in_94\IN\linear_unit.n.01|contrast (r_prep) is_93\VBZ\be.v.01|which|in (r_advcl) observed_90\VBN\spy.v.03|were|,|is (r_conj) was_29\VBD\washington.n.02|pressure|+/-|,|+/-|observed|. (l_appos) +/-_45\NN\entity.n.01|93|1|p|,|or|%|but|tachycardia (l_conj) tachycardia_70\NN\cardiac_arrhythmia.n.01|no|and|augmentation|min|)
D005996_D007022 CID nitroglycerin_103\NN\nitrate.n.01| (r_conj) hydralazine_101\NN\antihypertensive.n.01|or|nitroglycerin (r_pobj) by_100\IN\by.r.01|hydralazine (r_agent) induced_99\VBN\generate.v.01|by (r_acl) hypotension_98\NN\cardiovascular_disease.n.01|comparable|induced
10669626
D014859_D061205 CID warfarin_0\NNP\anticoagulant.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|warfarin|- (r_amod) calcification_4\NN\chemical_process.n.01|induced|artery
D014859_D061205 CID warfarin_22\NNP\anticoagulant.n.01| (r_pobj) of_21\IN\entity.n.01|warfarin (r_prep) doses_20\NNS\medicine.n.02|sufficient|of (r_dobj) given_18\VBN\assumption.n.02|doses|inhibit (r_prep) enhance_10\VB\intensify.v.02|that|treatment|extent|given (l_dobj) extent_12\NN\degree.n.02|the|of (l_prep) of_13\IN\entity.n.01|calcification (l_pobj) calcification_15\NN\chemical_process.n.01|artery|in
D014859_D061205 CID warfarin_17\NNP\anticoagulant.n.01| (r_npadvmod) treated_19\VBN\interact.v.01|warfarin|- (r_amod) rats_20\NNS\rodent.n.01|treated (r_pobj) in_16\IN\linear_unit.n.01|rats (r_prep) calcification_15\NN\chemical_process.n.01|artery|in
D014859_D061205 CID warfarin_5\NNP\anticoagulant.n.01| (r_pobj) with_4\IN\entity.n.01|warfarin (r_prep) treatment_0\NN\care.n.01|for|with (r_nsubj) caused_6\VBD\make.v.03|treatment|calcification|. (l_dobj) calcification_9\NN\chemical_process.n.01|massive|focal|of|in|and|calcification (l_prep) of_10\IN\entity.n.01|media (l_pobj) media_13\NNS\instrumentality.n.03|the|artery (l_compound) artery_12\NN\blood_vessel.n.01|
D014859_D061205 CID warfarin_20\NNP\anticoagulant.n.01| (r_compound) treatment_21\NN\care.n.01|warfarin (r_pobj) of_19\IN\entity.n.01|treatment (r_prep) weeks_18\NNS\time_period.n.01|4|of (r_pobj) after_16\IN\after.s.01|even|weeks (r_prep) detected_8\VBN\spy.v.03|in|,|calcification|could|be|in|after|. (l_nsubjpass) calcification_5\NN\chemical_process.n.01|no|artery
D014859_D061205 CID warfarin_8\NNP\anticoagulant.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|warfarin|- (r_amod) calcification_12\NN\chemical_process.n.01|induced|artery|in
D014859_D061205 CID warfarin_7\NNP\anticoagulant.n.01| (r_pobj) with_6\IN\entity.n.01|warfarin (r_prep) groups_5\NNS\abstraction.n.06|both|dietary|with (r_pobj) of_2\IN\entity.n.01|groups (r_prep) treatment_1\NN\care.n.01|concurrent|of (r_nsubj) produced_8\VBD\make.v.03|treatment|calcification|. (l_dobj) calcification_11\NN\chemical_process.n.01|massive|focal|of|in|but|calcification (l_prep) of_12\IN\entity.n.01|media (l_pobj) media_15\NNS\instrumentality.n.03|the|artery (l_compound) artery_14\NN\blood_vessel.n.01|
D014859_D061205 CID warfarin_7\NNP\anticoagulant.n.01| (r_pobj) with_6\IN\entity.n.01|warfarin (r_prep) groups_5\NNS\abstraction.n.06|both|dietary|with (r_pobj) of_2\IN\entity.n.01|groups (r_prep) treatment_1\NN\care.n.01|concurrent|of (r_nsubj) produced_8\VBD\make.v.03|treatment|calcification|. (l_dobj) calcification_11\NN\chemical_process.n.01|massive|focal|of|in|but|calcification (l_conj) calcification_27\NN\chemical_process.n.01|no|detectable|artery|in
D014859_D061205 CID warfarin_61\NNP\anticoagulant.n.01| (r_npadvmod) induced_63\VBN\generate.v.01|warfarin|- (r_amod) calcification_65\NN\chemical_process.n.01|induced|artery (r_pobj) to_60\IN\entity.n.01|calcification (r_prep) resistant_59\JJ\immune.s.03|to (r_acomp) was_58\VBD\washington.n.02|that|resistant (r_relcl) groups_56\NNS\abstraction.n.06|the|was (r_pobj) of_54\IN\entity.n.01|groups (r_prep) either_53\DT\either.r.01|of (r_pobj) with_52\IN\entity.n.01|either (r_prep) compared_51\VBN\analyze.v.01|with|rats (r_prep) rats_50\NNS\rodent.n.01|ad|fed|compared (r_appos) relationship_24\NN\relation.n.01|a|between|,|with|,|rats (r_attr) was_22\VBD\washington.n.02|determined|,|there|relationship|. (l_advcl) determined_15\VBN\determine.v.01|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN\statement.n.01|the|for (l_prep) for_3\IN\entity.n.01|association (l_pobj) association_5\NN\organization.n.01|the|between (l_prep) between_6\IN\between.r.01|calcification (l_pobj) calcification_8\NN\chemical_process.n.01|artery|and|status
D014859_D061205 CID warfarin_61\NNP\anticoagulant.n.01| (r_npadvmod) induced_63\VBN\generate.v.01|warfarin|- (r_amod) calcification_65\NN\chemical_process.n.01|induced|artery (r_pobj) to_60\IN\entity.n.01|calcification (r_prep) resistant_59\JJ\immune.s.03|to (r_acomp) was_58\VBD\washington.n.02|that|resistant (r_relcl) groups_56\NNS\abstraction.n.06|the|was (r_pobj) of_54\IN\entity.n.01|groups (r_prep) either_53\DT\either.r.01|of (r_pobj) with_52\IN\entity.n.01|either (r_prep) compared_51\VBN\analyze.v.01|with|rats (r_prep) rats_50\NNS\rodent.n.01|ad|fed|compared (r_appos) relationship_24\NN\relation.n.01|a|between|,|with|,|rats (l_prep) between_25\IN\between.r.01|phosphate (l_pobj) phosphate_28\NN\salt.n.01|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\condition.n.01|to (l_prep) to_31\IN\entity.n.01|calcification (l_pobj) calcification_33\NN\chemical_process.n.01|artery
D014859_D061205 CID warfarin_61\NNP\anticoagulant.n.01| (r_npadvmod) induced_63\VBN\generate.v.01|warfarin|- (r_amod) calcification_65\NN\chemical_process.n.01|induced|artery
D014859_D061205 CID warfarin_7\NNP\anticoagulant.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|warfarin|- (r_amod) calcification_11\NN\chemical_process.n.01|induced|artery
D014859_D061205 CID warfarin_13\NNP\anticoagulant.n.01| (r_conj) d_11\NN\fat-soluble_vitamin.n.01|vitamin|and|warfarin (r_pobj) between_9\IN\between.r.01|d (r_prep) synergy_8\NN\natural_process.n.01|the|possible|between|in (l_prep) in_14\IN\linear_unit.n.01|calcification (l_pobj) calcification_16\NN\chemical_process.n.01|artery
D014859_D061205 CID warfarin_0\NNP\anticoagulant.n.01| (r_nsubjpass) known_3\VBN\know.v.01|warfarin|are|also|cause|,|but|at|. (l_xcomp) cause_5\VB\origin.n.03|to|calcification (l_dobj) calcification_6\NN\chemical_process.n.01|of (l_prep) of_7\IN\entity.n.01|media (l_pobj) media_10\NNS\instrumentality.n.03|the|artery (l_compound) artery_9\NN\blood_vessel.n.01|
D014859_D061205 CID warfarin_20\NNP\anticoagulant.n.01| (r_conj) d_18\NNP\fat-soluble_vitamin.n.01|vitamin|plus|warfarin (r_pobj) with_16\IN\entity.n.01|d (r_prep) treated_15\VBN\interact.v.01|with (r_acl) rats_14\NNS\rodent.n.01|treated (r_pobj) in_13\IN\linear_unit.n.01|rats (r_prep) calcification_12\NN\chemical_process.n.01|artery|in
D014807_D061205 NONE d._11\NNP\entity.n.01| (r_conj) growth_8\NN\organic_process.n.01|and|vitamin|d. (r_pobj) by_7\IN\by.r.01|growth (r_agent) accelerated_6\VBN\intensify.v.03|calcification|is|by (l_nsubjpass) calcification_4\NN\chemical_process.n.01|induced|artery
D014807_D061205 NONE d_8\JJ\fat-soluble_vitamin.n.01|vitamin (r_conj) growth_5\NN\organic_process.n.01|and|d (r_nmod) treatment_9\NN\care.n.01|growth (r_nsubj) enhance_10\VB\intensify.v.02|that|treatment|extent|given (l_dobj) extent_12\NN\degree.n.02|the|of (l_prep) of_13\IN\entity.n.01|calcification (l_pobj) calcification_15\NN\chemical_process.n.01|artery|in
D014807_D061205 NONE d_11\NN\fat-soluble_vitamin.n.01|vitamin|and|warfarin (r_pobj) between_9\IN\between.r.01|d (r_prep) synergy_8\NN\natural_process.n.01|the|possible|between|in (l_prep) in_14\IN\linear_unit.n.01|calcification (l_pobj) calcification_16\NN\chemical_process.n.01|artery
D014807_D061205 NONE d_4\NNP\fat-soluble_vitamin.n.01|vitamin (r_pobj) of_2\IN\entity.n.01|d (r_prep) doses_1\NNS\medicine.n.02|high|of (r_nsubjpass) known_6\VBN\know.v.01|doses|are|cause|. (l_xcomp) cause_8\VB\origin.n.03|to|calcification|in (l_dobj) calcification_9\NN\chemical_process.n.01|of (l_prep) of_10\IN\entity.n.01|media (l_pobj) media_13\NNS\instrumentality.n.03|the|artery (l_compound) artery_12\NN\blood_vessel.n.01|
D014807_D061205 NONE d_10\NN\fat-soluble_vitamin.n.01|vitamin (r_compound) dose_11\NN\medicine.n.02|d|on (l_prep) on_12\IN\on.a.01|calcification (l_pobj) calcification_14\NN\chemical_process.n.01|artery
D014807_D061205 NONE d_10\NN\fat-soluble_vitamin.n.01|vitamin (r_compound) dose_11\NN\medicine.n.02|d|on (r_pobj) of_8\IN\entity.n.01|dose (r_prep) effect_7\NN\phenomenon.n.01|the|of|and|effect (l_conj) effect_17\NN\phenomenon.n.01|the|of (l_prep) of_18\IN\entity.n.01|dose (l_pobj) dose_21\NN\medicine.n.02|d|on (l_prep) on_22\IN\on.a.01|elevation (l_pobj) elevation_24\NN\rise.n.04|the|of|,|suggests (l_relcl) suggests_30\VBZ\declare.v.01|which|induce (l_ccomp) induce_35\VB\generate.v.01|that|d|may|calcification|through (l_dobj) calcification_37\NN\chemical_process.n.01|artery
D014807_D061205 NONE d_20\NNP\fat-soluble_vitamin.n.01|vitamin (r_compound) dose_21\NN\medicine.n.02|d|on (r_pobj) of_18\IN\entity.n.01|dose (r_prep) effect_17\NN\phenomenon.n.01|the|of (r_conj) effect_7\NN\phenomenon.n.01|the|of|and|effect (l_prep) of_8\IN\entity.n.01|dose (l_pobj) dose_11\NN\medicine.n.02|d|on (l_prep) on_12\IN\on.a.01|calcification (l_pobj) calcification_14\NN\chemical_process.n.01|artery
D014807_D061205 NONE d_20\NNP\fat-soluble_vitamin.n.01|vitamin (r_compound) dose_21\NN\medicine.n.02|d|on (l_prep) on_22\IN\on.a.01|elevation (l_pobj) elevation_24\NN\rise.n.04|the|of|,|suggests (l_relcl) suggests_30\VBZ\declare.v.01|which|induce (l_ccomp) induce_35\VB\generate.v.01|that|d|may|calcification|through (l_dobj) calcification_37\NN\chemical_process.n.01|artery
D014807_D061205 NONE d_33\NN\fat-soluble_vitamin.n.01|vitamin (r_nsubj) induce_35\VB\generate.v.01|that|d|may|calcification|through (r_ccomp) suggests_30\VBZ\declare.v.01|which|induce (r_relcl) elevation_24\NN\rise.n.04|the|of|,|suggests (r_pobj) on_22\IN\on.a.01|elevation (r_prep) dose_21\NN\medicine.n.02|d|on (r_pobj) of_18\IN\entity.n.01|dose (r_prep) effect_17\NN\phenomenon.n.01|the|of (r_conj) effect_7\NN\phenomenon.n.01|the|of|and|effect (l_prep) of_8\IN\entity.n.01|dose (l_pobj) dose_11\NN\medicine.n.02|d|on (l_prep) on_12\IN\on.a.01|calcification (l_pobj) calcification_14\NN\chemical_process.n.01|artery
D014807_D061205 NONE d_33\NN\fat-soluble_vitamin.n.01|vitamin (r_nsubj) induce_35\VB\generate.v.01|that|d|may|calcification|through (l_dobj) calcification_37\NN\chemical_process.n.01|artery
D014807_D061205 NONE d_18\NNP\fat-soluble_vitamin.n.01|vitamin|plus|warfarin (r_pobj) with_16\IN\entity.n.01|d (r_prep) treated_15\VBN\interact.v.01|with (r_acl) rats_14\NNS\rodent.n.01|treated (r_pobj) in_13\IN\linear_unit.n.01|rats (r_prep) calcification_12\NN\chemical_process.n.01|artery|in
D014807_D002114 NONE d_8\JJ\fat-soluble_vitamin.n.01|vitamin (r_conj) growth_5\NN\organic_process.n.01|and|d (r_nmod) treatment_9\NN\care.n.01|growth (r_nsubj) enhance_10\VB\intensify.v.02|that|treatment|extent|given (l_prep) given_18\VBN\assumption.n.02|doses|inhibit (l_advcl) inhibit_24\VB\control.v.02|to|carboxylation (l_dobj) carboxylation_27\NN\entity.n.01|gamma|-|of (l_prep) of_28\IN\entity.n.01|protein (l_pobj) protein_31\NN\macromolecule.n.01|matrix|gla|,|inhibitor (l_appos) inhibitor_35\NN\substance.n.07|calcification|known (l_compound) calcification_34\NN\chemical_process.n.01|a
D014807_D002114 NONE d_30\NN\fat-soluble_vitamin.n.01| (r_npadvmod) treated_32\VBN\interact.v.01|d|- (r_amod) rats_33\NNS\rodent.n.01|vitamin|treated (r_pobj) of_28\IN\entity.n.01|rats (r_prep) media_27\NNS\instrumentality.n.03|the|of (r_pobj) in_25\IN\linear_unit.n.01|media (r_prep) calcification_24\NN\chemical_process.n.01|in|at
D014807_D002114 NONE d_15\NN\fat-soluble_vitamin.n.01|vitamin|,|synergy (r_pobj) by_13\IN\by.r.01|d (r_agent) produced_12\VBN\make.v.03|by (r_acl) calcium_11\NN\metallic_element.n.01|serum|produced (r_pobj) in_9\IN\linear_unit.n.01|calcium (r_prep) elevation_8\NN\rise.n.04|the|in (r_pobj) on_6\IN\on.a.01|elevation (r_prep) effect_5\NN\phenomenon.n.01|no|on (r_dobj) had_3\VBD\have.v.01|because|treatment|effect (r_advcl) explained_27\VBN\inform.v.01|had|is|probably|best|by|. (l_agent) by_28\IN\by.r.01|hypothesis (l_pobj) hypothesis_30\NN\proposal.n.01|the|inhibits (l_acl) inhibits_33\VBZ\control.v.02|that|warfarin|activity|as (l_prep) as_40\IN\chemical_element.n.01|inhibitor (l_pobj) inhibitor_43\NN\substance.n.07|a|calcification (l_compound) calcification_42\NN\chemical_process.n.01|
D014807_D002114 NONE d_23\NN\fat-soluble_vitamin.n.01|warfarin (r_pobj) between_19\IN\between.r.01|d (r_prep) synergy_18\NN\natural_process.n.01|the|between (r_appos) d_15\NN\fat-soluble_vitamin.n.01|vitamin|,|synergy (r_pobj) by_13\IN\by.r.01|d (r_agent) produced_12\VBN\make.v.03|by (r_acl) calcium_11\NN\metallic_element.n.01|serum|produced (r_pobj) in_9\IN\linear_unit.n.01|calcium (r_prep) elevation_8\NN\rise.n.04|the|in (r_pobj) on_6\IN\on.a.01|elevation (r_prep) effect_5\NN\phenomenon.n.01|no|on (r_dobj) had_3\VBD\have.v.01|because|treatment|effect (r_advcl) explained_27\VBN\inform.v.01|had|is|probably|best|by|. (l_agent) by_28\IN\by.r.01|hypothesis (l_pobj) hypothesis_30\NN\proposal.n.01|the|inhibits (l_acl) inhibits_33\VBZ\control.v.02|that|warfarin|activity|as (l_prep) as_40\IN\chemical_element.n.01|inhibitor (l_pobj) inhibitor_43\NN\substance.n.07|a|calcification (l_compound) calcification_42\NN\chemical_process.n.01|
D014859_D002114 NONE warfarin_22\NNP\anticoagulant.n.01| (r_pobj) of_21\IN\entity.n.01|warfarin (r_prep) doses_20\NNS\medicine.n.02|sufficient|of (r_dobj) given_18\VBN\assumption.n.02|doses|inhibit (l_advcl) inhibit_24\VB\control.v.02|to|carboxylation (l_dobj) carboxylation_27\NN\entity.n.01|gamma|-|of (l_prep) of_28\IN\entity.n.01|protein (l_pobj) protein_31\NN\macromolecule.n.01|matrix|gla|,|inhibitor (l_appos) inhibitor_35\NN\substance.n.07|calcification|known (l_compound) calcification_34\NN\chemical_process.n.01|a
D014859_D002114 NONE warfarin_5\NNP\anticoagulant.n.01| (r_pobj) with_4\IN\entity.n.01|warfarin (r_prep) treatment_0\NN\care.n.01|for|with (r_nsubj) caused_6\VBD\make.v.03|treatment|calcification|. (l_dobj) calcification_9\NN\chemical_process.n.01|massive|focal|of|in|and|calcification (l_conj) calcification_23\NN\chemical_process.n.01|less|extensive|focal|in
D014859_D002114 NONE warfarin_17\NNP\anticoagulant.n.01| (r_compound) administration_18\NN\management.n.01|concurrent|warfarin (r_nsubj) increased_20\VBD\change_magnitude.v.01|that|administration|dramatically|extent (l_dobj) extent_22\NN\degree.n.02|the|of (l_prep) of_23\IN\entity.n.01|calcification (l_pobj) calcification_24\NN\chemical_process.n.01|in|at
D014859_D002114 NONE warfarin_1\NNP\anticoagulant.n.01| (r_compound) treatment_2\NN\care.n.01|warfarin (r_nsubj) had_3\VBD\have.v.01|because|treatment|effect (r_advcl) explained_27\VBN\inform.v.01|had|is|probably|best|by|. (l_agent) by_28\IN\by.r.01|hypothesis (l_pobj) hypothesis_30\NN\proposal.n.01|the|inhibits (l_acl) inhibits_33\VBZ\control.v.02|that|warfarin|activity|as (l_prep) as_40\IN\chemical_element.n.01|inhibitor (l_pobj) inhibitor_43\NN\substance.n.07|a|calcification (l_compound) calcification_42\NN\chemical_process.n.01|
D014859_D002114 NONE warfarin_20\NNP\anticoagulant.n.01|and|vitamin (r_nmod) d_23\NN\fat-soluble_vitamin.n.01|warfarin (r_pobj) between_19\IN\between.r.01|d (r_prep) synergy_18\NN\natural_process.n.01|the|between (r_appos) d_15\NN\fat-soluble_vitamin.n.01|vitamin|,|synergy (r_pobj) by_13\IN\by.r.01|d (r_agent) produced_12\VBN\make.v.03|by (r_acl) calcium_11\NN\metallic_element.n.01|serum|produced (r_pobj) in_9\IN\linear_unit.n.01|calcium (r_prep) elevation_8\NN\rise.n.04|the|in (r_pobj) on_6\IN\on.a.01|elevation (r_prep) effect_5\NN\phenomenon.n.01|no|on (r_dobj) had_3\VBD\have.v.01|because|treatment|effect (r_advcl) explained_27\VBN\inform.v.01|had|is|probably|best|by|. (l_agent) by_28\IN\by.r.01|hypothesis (l_pobj) hypothesis_30\NN\proposal.n.01|the|inhibits (l_acl) inhibits_33\VBZ\control.v.02|that|warfarin|activity|as (l_prep) as_40\IN\chemical_element.n.01|inhibitor (l_pobj) inhibitor_43\NN\substance.n.07|a|calcification (l_compound) calcification_42\NN\chemical_process.n.01|
D014859_D002114 NONE warfarin_32\NNP\anticoagulant.n.01| (r_nsubj) inhibits_33\VBZ\control.v.02|that|warfarin|activity|as (l_prep) as_40\IN\chemical_element.n.01|inhibitor (l_pobj) inhibitor_43\NN\substance.n.07|a|calcification (l_compound) calcification_42\NN\chemical_process.n.01|
D010710_D061205 NONE phosphate_28\NN\salt.n.01|higher|serum|and|susceptibility (r_pobj) between_25\IN\between.r.01|phosphate (r_prep) relationship_24\NN\relation.n.01|a|between|,|with|,|rats (r_attr) was_22\VBD\washington.n.02|determined|,|there|relationship|. (l_advcl) determined_15\VBN\determine.v.01|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN\statement.n.01|the|for (l_prep) for_3\IN\entity.n.01|association (l_pobj) association_5\NN\organization.n.01|the|between (l_prep) between_6\IN\between.r.01|calcification (l_pobj) calcification_8\NN\chemical_process.n.01|artery|and|status
D010710_D061205 NONE phosphate_28\NN\salt.n.01|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\condition.n.01|to (l_prep) to_31\IN\entity.n.01|calcification (l_pobj) calcification_33\NN\chemical_process.n.01|artery
D010710_D061205 NONE phosphate_28\NN\salt.n.01|higher|serum|and|susceptibility (r_pobj) between_25\IN\between.r.01|phosphate (r_prep) relationship_24\NN\relation.n.01|a|between|,|with|,|rats (l_appos) rats_50\NNS\rodent.n.01|ad|fed|compared (l_prep) compared_51\VBN\analyze.v.01|with|rats (l_prep) with_52\IN\entity.n.01|either (l_pobj) either_53\DT\either.r.01|of (l_prep) of_54\IN\entity.n.01|groups (l_pobj) groups_56\NNS\abstraction.n.06|the|was (l_relcl) was_58\VBD\washington.n.02|that|resistant (l_acomp) resistant_59\JJ\immune.s.03|to (l_prep) to_60\IN\entity.n.01|calcification (l_pobj) calcification_65\NN\chemical_process.n.01|induced|artery
D010710_D061205 NONE phosphate_42\NN\salt.n.01|serum (r_pobj) of_40\IN\entity.n.01|phosphate (r_prep) levels_39\NNS\property.n.02|higher|of|in (r_pobj) with_35\IN\entity.n.01|levels (r_prep) relationship_24\NN\relation.n.01|a|between|,|with|,|rats (r_attr) was_22\VBD\washington.n.02|determined|,|there|relationship|. (l_advcl) determined_15\VBN\determine.v.01|although|explanation|can|not|be|from (l_nsubjpass) explanation_2\NN\statement.n.01|the|for (l_prep) for_3\IN\entity.n.01|association (l_pobj) association_5\NN\organization.n.01|the|between (l_prep) between_6\IN\between.r.01|calcification (l_pobj) calcification_8\NN\chemical_process.n.01|artery|and|status
D010710_D061205 NONE phosphate_42\NN\salt.n.01|serum (r_pobj) of_40\IN\entity.n.01|phosphate (r_prep) levels_39\NNS\property.n.02|higher|of|in (r_pobj) with_35\IN\entity.n.01|levels (r_prep) relationship_24\NN\relation.n.01|a|between|,|with|,|rats (l_prep) between_25\IN\between.r.01|phosphate (l_pobj) phosphate_28\NN\salt.n.01|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\condition.n.01|to (l_prep) to_31\IN\entity.n.01|calcification (l_pobj) calcification_33\NN\chemical_process.n.01|artery
D010710_D061205 NONE phosphate_42\NN\salt.n.01|serum (r_pobj) of_40\IN\entity.n.01|phosphate (r_prep) levels_39\NNS\property.n.02|higher|of|in (r_pobj) with_35\IN\entity.n.01|levels (r_prep) relationship_24\NN\relation.n.01|a|between|,|with|,|rats (l_appos) rats_50\NNS\rodent.n.01|ad|fed|compared (l_prep) compared_51\VBN\analyze.v.01|with|rats (l_prep) with_52\IN\entity.n.01|either (l_pobj) either_53\DT\either.r.01|of (l_prep) of_54\IN\entity.n.01|groups (l_pobj) groups_56\NNS\abstraction.n.06|the|was (l_relcl) was_58\VBD\washington.n.02|that|resistant (l_acomp) resistant_59\JJ\immune.s.03|to (l_prep) to_60\IN\entity.n.01|calcification (l_pobj) calcification_65\NN\chemical_process.n.01|induced|artery
D010710_D061205 NONE phosphate_18\NN\salt.n.01|serum (r_compound) levels_19\NNS\property.n.02|higher|phosphate (r_pobj) to_15\IN\entity.n.01|levels (r_prep) related_14\VBN\think.v.03|that|susceptibility|could|be|to (l_nsubjpass) susceptibility_5\NN\condition.n.01|increased|to (l_prep) to_6\IN\entity.n.01|calcification (l_pobj) calcification_11\NN\chemical_process.n.01|induced|artery
D002118_D061205 NONE calcium_27\NN\metallic_element.n.01|serum (r_pobj) of_25\IN\entity.n.01|calcium (r_prep) elevation_24\NN\rise.n.04|the|of|,|suggests (r_pobj) on_22\IN\on.a.01|elevation (r_prep) dose_21\NN\medicine.n.02|d|on (r_pobj) of_18\IN\entity.n.01|dose (r_prep) effect_17\NN\phenomenon.n.01|the|of (r_conj) effect_7\NN\phenomenon.n.01|the|of|and|effect (l_prep) of_8\IN\entity.n.01|dose (l_pobj) dose_11\NN\medicine.n.02|d|on (l_prep) on_12\IN\on.a.01|calcification (l_pobj) calcification_14\NN\chemical_process.n.01|artery
D002118_D061205 NONE calcium_27\NN\metallic_element.n.01|serum (r_pobj) of_25\IN\entity.n.01|calcium (r_prep) elevation_24\NN\rise.n.04|the|of|,|suggests (l_relcl) suggests_30\VBZ\declare.v.01|which|induce (l_ccomp) induce_35\VB\generate.v.01|that|d|may|calcification|through (l_dobj) calcification_37\NN\chemical_process.n.01|artery
D002118_D061205 NONE calcium_43\NN\metallic_element.n.01|serum (r_pobj) on_41\IN\on.a.01|calcium (r_prep) effect_40\NN\phenomenon.n.01|its|on (r_pobj) through_38\IN\done.s.01|effect (r_prep) induce_35\VB\generate.v.01|that|d|may|calcification|through (r_ccomp) suggests_30\VBZ\declare.v.01|which|induce (r_relcl) elevation_24\NN\rise.n.04|the|of|,|suggests (r_pobj) on_22\IN\on.a.01|elevation (r_prep) dose_21\NN\medicine.n.02|d|on (r_pobj) of_18\IN\entity.n.01|dose (r_prep) effect_17\NN\phenomenon.n.01|the|of (r_conj) effect_7\NN\phenomenon.n.01|the|of|and|effect (l_prep) of_8\IN\entity.n.01|dose (l_pobj) dose_11\NN\medicine.n.02|d|on (l_prep) on_12\IN\on.a.01|calcification (l_pobj) calcification_14\NN\chemical_process.n.01|artery
D002118_D061205 NONE calcium_43\NN\metallic_element.n.01|serum (r_pobj) on_41\IN\on.a.01|calcium (r_prep) effect_40\NN\phenomenon.n.01|its|on (r_pobj) through_38\IN\done.s.01|effect (r_prep) induce_35\VB\generate.v.01|that|d|may|calcification|through (l_dobj) calcification_37\NN\chemical_process.n.01|artery
D002118_D002114 NONE calcium_11\NN\metallic_element.n.01|serum|produced (r_pobj) in_9\IN\linear_unit.n.01|calcium (r_prep) elevation_8\NN\rise.n.04|the|in (r_pobj) on_6\IN\on.a.01|elevation (r_prep) effect_5\NN\phenomenon.n.01|no|on (r_dobj) had_3\VBD\have.v.01|because|treatment|effect (r_advcl) explained_27\VBN\inform.v.01|had|is|probably|best|by|. (l_agent) by_28\IN\by.r.01|hypothesis (l_pobj) hypothesis_30\NN\proposal.n.01|the|inhibits (l_acl) inhibits_33\VBZ\control.v.02|that|warfarin|activity|as (l_prep) as_40\IN\chemical_element.n.01|inhibitor (l_pobj) inhibitor_43\NN\substance.n.07|a|calcification (l_compound) calcification_42\NN\chemical_process.n.01|
D015055_D061205 NONE carboxylated_36\JJ\process.v.01|not|gamma|- (r_acomp) was_31\VBD\washington.n.02|that|protein|indeed|carboxylated (r_ccomp) showed_25\VBD\show.v.04|analysis|was|. (r_conj) found_7\VBN\wage.n.01|levels|are|at|,|and|showed (l_prep) at_8\IN\chemical_element.n.01|sites (l_pobj) sites_9\NNS\tract.n.01|of (l_prep) of_10\IN\entity.n.01|calcification (l_pobj) calcification_12\NN\chemical_process.n.01|artery|in
D015055_D002114 NONE carboxyglutamate_8\NN\entity.n.01|gamma|- (r_compound) residues_9\NNS\matter.n.03|the|carboxyglutamate|of (r_nsubjpass) required_16\VBN\necessitate.v.01|although|residues|are|apparently|for|as (l_prep) as_20\IN\chemical_element.n.01|inhibitor (l_pobj) inhibitor_23\NN\substance.n.07|a|calcification (l_compound) calcification_22\NN\chemical_process.n.01|
D015055_D002114 NONE carboxyglutamate_8\NN\entity.n.01|gamma|- (r_compound) residues_9\NNS\matter.n.03|the|carboxyglutamate|of (r_nsubjpass) required_16\VBN\necessitate.v.01|although|residues|are|apparently|for|as (r_advcl) required_28\VBN\necessitate.v.01|that|required|,|they|are|not|for (l_prep) for_29\IN\entity.n.01|accumulation (l_pobj) accumulation_31\NN\increase.n.03|its|at (l_prep) at_32\IN\chemical_element.n.01|sites (l_pobj) sites_34\NNS\tract.n.01|calcification (l_compound) calcification_33\NN\chemical_process.n.01|
17147461
D020123_D011507 CID sirolimus_0\NNP\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|sirolimus|- (r_amod) proteinuria_3\NN\symptom.n.01|associated|and|dysfunction|.
D020123_D011507 CID sirolimus_11\NN\entity.n.01| (r_nsubjpass) associated_13\VBN\think.v.03|that|,|under|,|sirolimus|is|with (l_prep) with_14\IN\entity.n.01|proteinuria (l_pobj) proteinuria_15\NN\symptom.n.01|and|dysfunction
D020123_D011507 CID sirolimus_3\NN\entity.n.01| (r_npadvmod) associated_5\VBN\think.v.03|sirolimus|- (r_amod) proteinuria_6\NN\symptom.n.01|associated
D020123_D011507 CID sirolimus_21\NN\entity.n.01| (r_pobj) of_20\IN\entity.n.01|sirolimus (r_prep) effects_19\NNS\personal_property.n.01|the|molecular|of|on (r_pobj) of_16\IN\entity.n.01|effects (r_prep) knowledge_15\NN\psychological_feature.n.01|of (r_pobj) by_14\IN\by.r.01|knowledge (r_agent) minimised_13\VBN\inform.v.01|occur|,|occurrence|could|be|by|,|use|. (l_dep) use_27\NN\activity.n.01|the|of|in|,|monitoring (l_appos) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_prep) of_37\IN\entity.n.01|proteinuria (l_pobj) proteinuria_38\NN\symptom.n.01|and|function
D020123_D011507 CID sirolimus_21\NN\entity.n.01| (r_pobj) of_20\IN\entity.n.01|sirolimus (r_prep) effects_19\NNS\personal_property.n.01|the|molecular|of|on (r_pobj) of_16\IN\entity.n.01|effects (r_prep) knowledge_15\NN\psychological_feature.n.01|of (r_pobj) by_14\IN\by.r.01|knowledge (r_agent) minimised_13\VBN\inform.v.01|occur|,|occurrence|could|be|by|,|use|. (l_dep) use_27\NN\activity.n.01|the|of|in|,|monitoring (l_appos) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\happen.v.01|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\symptom.n.01|
D020123_D011507 CID sirolimus_29\NN\entity.n.01| (r_pobj) of_28\IN\entity.n.01|sirolimus (r_prep) use_27\NN\activity.n.01|the|of|in|,|monitoring (l_appos) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_prep) of_37\IN\entity.n.01|proteinuria (l_pobj) proteinuria_38\NN\symptom.n.01|and|function
D020123_D011507 CID sirolimus_29\NN\entity.n.01| (r_pobj) of_28\IN\entity.n.01|sirolimus (r_prep) use_27\NN\activity.n.01|the|of|in|,|monitoring (l_appos) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\happen.v.01|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\symptom.n.01|
D020123_D007674 CID sirolimus_0\NNP\entity.n.01| (r_npadvmod) associated_2\VBN\think.v.03|sirolimus|- (r_amod) proteinuria_3\NN\symptom.n.01|associated|and|dysfunction|. (l_conj) dysfunction_6\NN\pathology.n.02|renal
D020123_D007674 CID sirolimus_0\NNP\entity.n.01| (r_nsubj) represents_1\VBZ\equal.v.01|sirolimus|advance|. (l_dobj) advance_5\NN\change_of_location.n.01|a|major|therapeutic|in (l_prep) in_6\IN\linear_unit.n.01|prevention (l_pobj) prevention_8\NN\hindrance.n.03|the|of (l_prep) of_9\IN\entity.n.01|rejection (l_pobj) rejection_13\NN\act.n.02|acute|allograft|and|nephropathy (l_conj) nephropathy_17\NN\uropathy.n.01|chronic|allograft
D020123_D007674 CID sirolimus_1\NN\entity.n.01| (r_nsubj) share_4\VB\assets.n.01|because|sirolimus|does|not|vasomotor|effects (r_advcl) designated_18\VBN\designate.v.01|share|,|it|has|been|drug|. (l_oprd) drug_24\NN\agent.n.03|a|'|nephrotoxic|' (l_amod) nephrotoxic_23\JJ\nephrotoxic.s.01|-
D020123_D058186 NONE sirolimus_11\NN\entity.n.01| (r_nsubjpass) associated_13\VBN\think.v.03|that|,|under|,|sirolimus|is|with (l_prep) with_14\IN\entity.n.01|proteinuria (l_pobj) proteinuria_15\NN\symptom.n.01|and|dysfunction (l_conj) dysfunction_19\NN\pathology.n.02|acute|renal
D020123_D058186 NONE sirolimus_6\NN\entity.n.01| (r_pobj) with_5\IN\entity.n.01|sirolimus (r_prep) associated_4\VBN\think.v.03|with (r_acl) dysfunction_3\NN\pathology.n.02|the|acute|renal|associated|(|as|)
D000809_D011507 NONE angiotensin_45\NN\vasoconstrictor.n.01| (r_npadvmod) converting_47\VBG\change.v.01|angiotensin|- (r_amod) inhibitors_49\NNS\substance.n.07|converting|enzyme|or|blockers (r_pobj) of_44\IN\entity.n.01|inhibitors (r_prep) use_43\NN\activity.n.01|of (r_conj) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_prep) of_37\IN\entity.n.01|proteinuria (l_pobj) proteinuria_38\NN\symptom.n.01|and|function
D000809_D011507 NONE angiotensin_45\NN\vasoconstrictor.n.01| (r_npadvmod) converting_47\VBG\change.v.01|angiotensin|- (r_amod) inhibitors_49\NNS\substance.n.07|converting|enzyme|or|blockers (r_pobj) of_44\IN\entity.n.01|inhibitors (r_prep) use_43\NN\activity.n.01|of (r_conj) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\happen.v.01|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\symptom.n.01|
D000804_D011507 NONE ii_52\CD\digit.n.01| (r_compound) blockers_54\NNS\football_player.n.01|angiotensin|ii|receptor (r_conj) inhibitors_49\NNS\substance.n.07|converting|enzyme|or|blockers (r_pobj) of_44\IN\entity.n.01|inhibitors (r_prep) use_43\NN\activity.n.01|of (r_conj) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_prep) of_37\IN\entity.n.01|proteinuria (l_pobj) proteinuria_38\NN\symptom.n.01|and|function
D000804_D011507 NONE ii_52\CD\digit.n.01| (r_compound) blockers_54\NNS\football_player.n.01|angiotensin|ii|receptor (r_conj) inhibitors_49\NNS\substance.n.07|converting|enzyme|or|blockers (r_pobj) of_44\IN\entity.n.01|inhibitors (r_prep) use_43\NN\activity.n.01|of (r_conj) monitoring_36\NN\observation.n.02|close|of|,|use|occurs (l_advcl) occurs_57\VBZ\happen.v.01|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_56\NN\symptom.n.01|
6308277
D002110_D064420 NONE caffeine_2\NN\alkaloid.n.01| (r_compound) toxicity_3\NN\definite_quantity.n.01|caffeine
D002110_D064420 NONE caffeine_11\NN\alkaloid.n.01| (r_pobj) of_10\IN\entity.n.01|caffeine (r_prep) effects_9\NNS\personal_property.n.01|the|stimulatory|of|on (r_dobj) augment_6\VB\increase.v.02|to|effects (r_xcomp) reported_4\VBN\inform.v.01|because|salicylates|have|been|augment (r_advcl) focused_18\VBN\think.v.03|reported|,|attention|was|on|. (l_prep) on_19\IN\on.a.01|possibility (l_pobj) possibility_21\NN\expectation.n.01|the|reduced (l_acl) reduced_33\VBD\decrease.v.02|that|presence|(|micrograms|toxicity (l_dobj) toxicity_36\NN\definite_quantity.n.01|the|cns|of
D002110_D064420 NONE caffeine_38\NN\alkaloid.n.01| (r_pobj) of_37\IN\entity.n.01|caffeine (r_prep) toxicity_36\NN\definite_quantity.n.01|the|cns|of
D000082_D064420 NONE acetaminophen_5\NN\analgesic.n.01| (r_pobj) by_4\IN\by.r.01|acetaminophen (r_prep) reduction_0\NN\change_of_magnitude.n.01|in|by|. (l_prep) in_1\IN\linear_unit.n.01|toxicity (l_pobj) toxicity_3\NN\definite_quantity.n.01|caffeine
D000082_D064420 NONE acetaminophen_26\NN\analgesic.n.01| (r_pobj) of_25\IN\entity.n.01|acetaminophen (r_prep) presence_24\NN\being.n.01|the|of (r_nsubj) reduced_33\VBD\decrease.v.02|that|presence|(|micrograms|toxicity (l_dobj) toxicity_36\NN\definite_quantity.n.01|the|cns|of
D000082_D012640 NONE acetaminophen_11\NN\analgesic.n.01|mg/kg (r_pobj) with_10\IN\entity.n.01|acetaminophen (r_prep) pretreatment_9\NN\entity.n.01|:|1|with|) (r_nsubj) increased_16\VBD\change_magnitude.v.01|that|pretreatment|interval|reduced (l_dobj) interval_18\NN\measure.n.02|the|between (l_prep) between_19\IN\between.r.01|administration (l_pobj) administration_21\NN\management.n.01|the|of|ip|and|onset (l_conj) onset_33\NN\start.n.01|the|of|by|;|and|pretreatment (l_prep) of_34\IN\entity.n.01|convulsions (l_pobj) convulsions_36\NNS\attack.n.07|fatal
D000082_D012640 NONE acetaminophen_11\NN\analgesic.n.01|mg/kg (r_pobj) with_10\IN\entity.n.01|acetaminophen (r_prep) pretreatment_9\NN\entity.n.01|:|1|with|) (r_nsubj) increased_16\VBD\change_magnitude.v.01|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD\decrease.v.02|incidence|(|ip|) (l_dobj) incidence_56\NN\frequency.n.02|the|of (l_prep) of_57\IN\entity.n.01|seizures (l_pobj) seizures_59\NNS\attack.n.07|audiogenic|produced
D000082_D012640 NONE acetaminophen_49\NN\analgesic.n.01|mg/kg (r_pobj) with_48\IN\entity.n.01|acetaminophen (r_prep) pretreatment_47\NN\entity.n.01|2|with|) (r_conj) onset_33\NN\start.n.01|the|of|by|;|and|pretreatment (l_prep) of_34\IN\entity.n.01|convulsions (l_pobj) convulsions_36\NNS\attack.n.07|fatal
D000082_D012640 NONE acetaminophen_49\NN\analgesic.n.01|mg/kg (r_pobj) with_48\IN\entity.n.01|acetaminophen (r_prep) pretreatment_47\NN\entity.n.01|2|with|) (r_conj) onset_33\NN\start.n.01|the|of|by|;|and|pretreatment (r_conj) administration_21\NN\management.n.01|the|of|ip|and|onset (r_pobj) between_19\IN\between.r.01|administration (r_prep) interval_18\NN\measure.n.02|the|between (r_dobj) increased_16\VBD\change_magnitude.v.01|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD\decrease.v.02|incidence|(|ip|) (l_dobj) incidence_56\NN\frequency.n.02|the|of (l_prep) of_57\IN\entity.n.01|seizures (l_pobj) seizures_59\NNS\attack.n.07|audiogenic|produced
D000082_D012640 NONE acetaminophen_21\NN\analgesic.n.01| (r_pobj) by_20\IN\by.r.01|acetaminophen (r_agent) reduced_14\VBN\decrease.v.02|frequency|was|from|by|. (l_nsubjpass) frequency_1\NN\rate.n.01|the|of|after (l_prep) of_2\IN\entity.n.01|seizures (l_pobj) seizures_6\NNS\attack.n.07|induced
D000082_D012640 NONE acetaminophen_6\FW\analgesic.n.01|mg/kg|) (r_nsubj) modify_15\VB\change.v.02|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS\attack.n.07|the|induced
D002110_D012640 CID caffeine_23\NN\alkaloid.n.01| (r_pobj) of_22\IN\entity.n.01|caffeine (r_prep) administration_21\NN\management.n.01|the|of|ip|and|onset (l_conj) onset_33\NN\start.n.01|the|of|by|;|and|pretreatment (l_prep) of_34\IN\entity.n.01|convulsions (l_pobj) convulsions_36\NNS\attack.n.07|fatal
D002110_D012640 CID caffeine_23\NN\alkaloid.n.01| (r_pobj) of_22\IN\entity.n.01|caffeine (r_prep) administration_21\NN\management.n.01|the|of|ip|and|onset (r_pobj) between_19\IN\between.r.01|administration (r_prep) interval_18\NN\measure.n.02|the|between (r_dobj) increased_16\VBD\change_magnitude.v.01|that|pretreatment|interval|reduced (l_conj) reduced_54\VBD\decrease.v.02|incidence|(|ip|) (l_dobj) incidence_56\NN\frequency.n.02|the|of (l_prep) of_57\IN\entity.n.01|seizures (l_pobj) seizures_59\NNS\attack.n.07|audiogenic|produced
D002110_D012640 CID caffeine_65\NN\alkaloid.n.01| (r_pobj) of_64\IN\entity.n.01|caffeine (r_prep) presence_63\NN\being.n.01|the|of (r_pobj) in_61\IN\linear_unit.n.01|presence (r_prep) produced_60\VBN\make.v.03|in (r_acl) seizures_59\NNS\attack.n.07|audiogenic|produced (r_pobj) of_57\IN\entity.n.01|seizures (r_prep) incidence_56\NN\frequency.n.02|the|of (r_dobj) reduced_54\VBD\decrease.v.02|incidence|(|ip|) (r_conj) increased_16\VBD\change_magnitude.v.01|that|pretreatment|interval|reduced (l_dobj) interval_18\NN\measure.n.02|the|between (l_prep) between_19\IN\between.r.01|administration (l_pobj) administration_21\NN\management.n.01|the|of|ip|and|onset (l_conj) onset_33\NN\start.n.01|the|of|by|;|and|pretreatment (l_prep) of_34\IN\entity.n.01|convulsions (l_pobj) convulsions_36\NNS\attack.n.07|fatal
D002110_D012640 CID caffeine_65\NN\alkaloid.n.01| (r_pobj) of_64\IN\entity.n.01|caffeine (r_prep) presence_63\NN\being.n.01|the|of (r_pobj) in_61\IN\linear_unit.n.01|presence (r_prep) produced_60\VBN\make.v.03|in (r_acl) seizures_59\NNS\attack.n.07|audiogenic|produced
D002110_D012640 CID caffeine_12\NN\alkaloid.n.01|12.5 (r_pobj) after_7\IN\after.s.01|caffeine (r_prep) frequency_1\NN\rate.n.01|the|of|after (l_prep) of_2\IN\entity.n.01|seizures (l_pobj) seizures_6\NNS\attack.n.07|induced
D002110_D012640 CID caffeine_4\NN\alkaloid.n.01| (r_pobj) of_3\IN\entity.n.01|caffeine (r_prep) absence_2\NN\lack.n.01|the|of (r_pobj) in_0\IN\linear_unit.n.01|absence (r_prep) modify_15\VB\change.v.02|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS\attack.n.07|the|induced
D010433_D012640 CID pentylenetetrezol_30\NN\entity.n.01| (r_pobj) of_29\IN\entity.n.01|pentylenetetrezol (r_prep) dose_28\NN\medicine.n.02|the|convulsant|of|in|tests (r_dobj) alter_25\VB\change.v.01|did|not|dose (r_conj) modify_15\VB\change.v.02|in|,|acetaminophen|did|not|seizures|and|alter|. (l_dobj) seizures_17\NNS\attack.n.07|the|induced
19211690
D013739_D006973 NONE testosterone_0\NN\androgen.n.01| (r_npadvmod) dependent_2\JJ\recipient.n.01|testosterone|- (r_amod) hypertension_3\NN\cardiovascular_disease.n.01|dependent|and|upregulation|.
D013739_D006973 NONE testosterone_0\NN\androgen.n.01| (r_nsubj) contributes_1\VBZ\change.v.01|testosterone|to|through|. (l_prep) to_2\IN\entity.n.01|development (l_pobj) development_4\NN\improvement.n.02|the|of (l_prep) of_5\IN\entity.n.01|hypertension (l_pobj) hypertension_6\NN\cardiovascular_disease.n.01|and|injury|in
D017673_D006973 NONE salt_11\NN\compound.n.02| (r_npadvmod) sensitive_13\JJ\psychic.n.01|salt|- (r_amod) rats_14\NNS\rodent.n.01|dahl|sensitive (r_pobj) in_9\IN\linear_unit.n.01|rats (r_prep) upregulation_5\NN\entity.n.01|of|in (r_conj) hypertension_3\NN\cardiovascular_disease.n.01|dependent|and|upregulation|.
D013739_D007674 NONE testosterone_24\NN\androgen.n.01| (r_pobj) by_23\IN\by.r.01|testosterone (r_agent) mediated_22\VBN\negociate.v.06|by (r_acl) angiotensinogen_21\NN\entity.n.01|intrarenal|mediated (r_pobj) of_19\IN\entity.n.01|angiotensinogen (r_prep) upregulation_18\NN\entity.n.01|induced|of (r_pobj) in_14\IN\linear_unit.n.01|upregulation (r_prep) dimorphism_13\NN\polymorphism.n.02|a|sexual|in|causes (l_relcl) causes_27\VBZ\origin.n.03|that|also|increases (l_dobj) increases_28\NNS\indefinite_quantity.n.01|in (l_prep) in_29\IN\linear_unit.n.01|bp (l_pobj) bp_30\NNP\entity.n.01|and|injury (l_conj) injury_33\NN\ill_health.n.01|renal
D013739_D007674 NONE testosterone_0\NN\androgen.n.01| (r_compound) replacement_1\NN\substitution.n.02|testosterone|in (r_nsubj) increased_6\VBD\change_magnitude.v.01|replacement|bp|. (l_npadvmod) bp_7\NNP\entity.n.01|,|injury (l_appos) injury_10\NN\ill_health.n.01|renal|,|and|upregulation
D013739_D007674 NONE testosterone_0\NN\androgen.n.01| (r_nsubj) contributes_1\VBZ\change.v.01|testosterone|to|through|. (l_prep) to_2\IN\entity.n.01|development (l_pobj) development_4\NN\improvement.n.02|the|of (l_prep) of_5\IN\entity.n.01|hypertension (l_pobj) hypertension_6\NN\cardiovascular_disease.n.01|and|injury|in (l_conj) injury_9\NN\ill_health.n.01|renal
D000809_D006973 NONE angiotensin_25\NN\vasoconstrictor.n.01|renin|- (r_compound) system_26\NN\instrumentality.n.03|the|intrarenal|angiotensin (r_pobj) of_20\IN\entity.n.01|system (r_prep) upregulation_19\NN\entity.n.01|of (r_pobj) through_18\IN\done.s.01|possibly|upregulation (r_prep) contributes_1\VBZ\change.v.01|testosterone|to|through|. (l_prep) to_2\IN\entity.n.01|development (l_pobj) development_4\NN\improvement.n.02|the|of (l_prep) of_5\IN\entity.n.01|hypertension (l_pobj) hypertension_6\NN\cardiovascular_disease.n.01|and|injury|in
D000809_D007674 NONE angiotensin_25\NN\vasoconstrictor.n.01|renin|- (r_compound) system_26\NN\instrumentality.n.03|the|intrarenal|angiotensin (r_pobj) of_20\IN\entity.n.01|system (r_prep) upregulation_19\NN\entity.n.01|of (r_pobj) through_18\IN\done.s.01|possibly|upregulation (r_prep) contributes_1\VBZ\change.v.01|testosterone|to|through|. (l_prep) to_2\IN\entity.n.01|development (l_pobj) development_4\NN\improvement.n.02|the|of (l_prep) of_5\IN\entity.n.01|hypertension (l_pobj) hypertension_6\NN\cardiovascular_disease.n.01|and|injury|in (l_conj) injury_9\NN\ill_health.n.01|renal
8302922
D000527_D007022 CID e1_5\NNP\entity.n.01|prostaglandin|or|trimethaphan (r_pobj) during_3\IN\entity.n.01|e1 (r_prep) flow_2\NN\change_of_location.n.01|epidural|blood|during (r_nsubj) induced_8\VBD\generate.v.01|flow|hypotension|. (l_dobj) hypotension_9\NN\cardiovascular_disease.n.01|
D000527_D007022 CID e1_6\NNP\entity.n.01| (r_nmod) pge1_8\NNP\entity.n.01|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\entity.n.01|pge1 (r_prep) effect_3\NN\phenomenon.n.01|the|of (r_dobj) evaluate_1\VB\evaluate.v.02|to|effect (r_csubj) induced_15\VBN\generate.v.01|evaluate|hypotension|during (l_dobj) hypotension_16\NN\cardiovascular_disease.n.01|on
D000527_D007022 CID pge1_8\NNP\entity.n.01|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\entity.n.01|pge1 (r_prep) effect_3\NN\phenomenon.n.01|the|of (r_dobj) evaluate_1\VB\evaluate.v.02|to|effect (r_csubj) induced_15\VBN\generate.v.01|evaluate|hypotension|during (l_dobj) hypotension_16\NN\cardiovascular_disease.n.01|on
D000527_D007022 CID pge1_2\NNP\entity.n.01|or|tmp|product (r_dobj) starting_1\VBG\turn.n.03|pge1 (r_pcomp) after_0\IN\after.s.01|starting (r_prep) decreased_14\VBD\change_magnitude.v.01|after|significantly|compared|,|and|remained (l_conj) remained_34\VBD\be.v.01|degree|constant|until|. (l_nsubj) degree_28\NN\property.n.02|the|of|due (l_prep) of_29\IN\entity.n.01|hypotension (l_pobj) hypotension_30\NN\cardiovascular_disease.n.01|
D000527_D007022 CID pge1_33\NNP\entity.n.01| (r_pobj) to_32\IN\entity.n.01|pge1 (r_pcomp) due_31\IN\right.n.01|to (r_prep) degree_28\NN\property.n.02|the|of|due (l_prep) of_29\IN\entity.n.01|hypotension (l_pobj) hypotension_30\NN\cardiovascular_disease.n.01|
D000527_D007022 CID pge1_4\NNP\entity.n.01| (r_nsubj) be_6\VB\metallic_element.n.01|that|pge1|may|preferable|decreased (l_acomp) preferable_7\JJ\preferable.s.01|tmp (l_xcomp) tmp_9\VB\entity.n.01|to|for (l_prep) for_10\IN\entity.n.01|anaesthesia (l_pobj) anaesthesia_12\NN\physical_condition.n.01|hypotensive|in (l_amod) hypotensive_11\JJ\patient.n.01|
D014294_D007022 CID trimethaphan_7\RB\entity.n.01| (r_conj) e1_5\NNP\entity.n.01|prostaglandin|or|trimethaphan (r_pobj) during_3\IN\entity.n.01|e1 (r_prep) flow_2\NN\change_of_location.n.01|epidural|blood|during (r_nsubj) induced_8\VBD\generate.v.01|flow|hypotension|. (l_dobj) hypotension_9\NN\cardiovascular_disease.n.01|
D014294_D007022 CID trimethaphan_11\NN\entity.n.01|tmp (r_conj) pge1_8\NNP\entity.n.01|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\entity.n.01|pge1 (r_prep) effect_3\NN\phenomenon.n.01|the|of (r_dobj) evaluate_1\VB\evaluate.v.02|to|effect (r_csubj) induced_15\VBN\generate.v.01|evaluate|hypotension|during (l_dobj) hypotension_16\NN\cardiovascular_disease.n.01|on
D014294_D007022 CID tmp_13\NNP\entity.n.01|(|) (r_appos) trimethaphan_11\NN\entity.n.01|tmp (r_conj) pge1_8\NNP\entity.n.01|prostaglandin|e1|(|)|or|trimethaphan (r_pobj) of_4\IN\entity.n.01|pge1 (r_prep) effect_3\NN\phenomenon.n.01|the|of (r_dobj) evaluate_1\VB\evaluate.v.02|to|effect (r_csubj) induced_15\VBN\generate.v.01|evaluate|hypotension|during (l_dobj) hypotension_16\NN\cardiovascular_disease.n.01|on
D014294_D007022 CID tmp_4\NNP\entity.n.01|,|map (r_conj) pge1_2\NNP\entity.n.01|or|tmp|product (r_dobj) starting_1\VBG\turn.n.03|pge1 (r_pcomp) after_0\IN\after.s.01|starting (r_prep) decreased_14\VBD\change_magnitude.v.01|after|significantly|compared|,|and|remained (l_conj) remained_34\VBD\be.v.01|degree|constant|until|. (l_nsubj) degree_28\NN\property.n.02|the|of|due (l_prep) of_29\IN\entity.n.01|hypotension (l_pobj) hypotension_30\NN\cardiovascular_disease.n.01|
D014294_D007022 CID tmp_9\VB\entity.n.01|to|for (l_prep) for_10\IN\entity.n.01|anaesthesia (l_pobj) anaesthesia_12\NN\physical_condition.n.01|hypotensive|in (l_amod) hypotensive_11\JJ\patient.n.01|
D014294_D007022 CID tmp_17\NNP\entity.n.01| (r_nsubj) decreased_18\VBD\change_magnitude.v.01|because|tmp|ebf (r_advcl) be_6\VB\metallic_element.n.01|that|pge1|may|preferable|decreased (l_acomp) preferable_7\JJ\preferable.s.01|tmp (l_xcomp) tmp_9\VB\entity.n.01|to|for (l_prep) for_10\IN\entity.n.01|anaesthesia (l_pobj) anaesthesia_12\NN\physical_condition.n.01|hypotensive|in (l_amod) hypotensive_11\JJ\patient.n.01|
D007530_D007022 NONE isoflurane_47\JJ\inhalation_anesthetic.n.01| (r_amod) anaesthesia_48\NN\physical_condition.n.01|isoflurane (r_pobj) under_46\IN\nether.s.03|anaesthesia (r_prep) fusion_45\NN\union.n.09|lateral|interbody|under (r_dobj) underwent_40\VBD\change.v.02|who|fusion (r_relcl) patients_38\NNS\case.n.06|30|underwent (r_pobj) in_36\IN\linear_unit.n.01|patients (r_prep) using_31\VBG\mistreatment.n.01|method|in (r_advcl) measured_30\VBN\decide.v.01|induced|,|ebf|was|using|. (l_advcl) induced_15\VBN\generate.v.01|evaluate|hypotension|during (l_dobj) hypotension_16\NN\cardiovascular_disease.n.01|on
16337777
D010862_D004827 NONE pilocarpine_12\NN\alkaloid.n.01| (r_pobj) by_11\IN\by.r.01|pilocarpine (r_agent) induced_10\VBN\generate.v.01|by (r_acl) model_7\NN\hypothesis.n.02|the|experimental|of|induced (l_prep) of_8\IN\entity.n.01|epilepsy (l_pobj) epilepsy_9\NN\brain_disorder.n.01|
D010862_D013226 NONE pilocarpine_49\NN\alkaloid.n.01| (r_amod) model_50\NN\hypothesis.n.02|the|pilocarpine|of (r_pobj) of_47\IN\entity.n.01|model (r_prep) phase_46\NN\time_period.n.01|the|chronic|of (r_pobj) in_43\IN\linear_unit.n.01|phase (r_prep) provoke_18\VB\make.v.03|to|abnormalities|in (r_xcomp) sufficient_16\JJ\sufficient.a.01|provoke (r_acomp) be_15\VB\metallic_element.n.01|whether|generation|would|sufficient (l_nsubj) generation_8\NN\people.n.01|increased|of|during (l_prep) during_11\IN\entity.n.01|epilepticus (l_pobj) epilepticus_13\NN\entity.n.01|status
D010862_D004833 CID pilocarpine_49\NN\alkaloid.n.01| (r_amod) model_50\NN\hypothesis.n.02|the|pilocarpine|of (l_prep) of_51\IN\entity.n.01|epilepsy (l_pobj) epilepsy_54\NN\brain_disorder.n.01|temporal|lobe
2070391
D008012_D010146 CID lidocaine_6\NN\local_anesthetic.n.01|buffered (r_dobj) using_4\VBG\mistreatment.n.01|lidocaine|as (r_acl) reduction_0\NN\change_of_magnitude.n.01|in|using|. (l_prep) in_1\IN\linear_unit.n.01|pain (l_pobj) pain_3\NN\symptom.n.01|injection
D008012_D010146 CID lidocaine_11\NN\local_anesthetic.n.01| (r_pobj) of_10\IN\entity.n.01|lidocaine (r_prep) injection_9\NN\insertion.n.02|the|of (r_pobj) with_7\IN\entity.n.01|injection (r_prep) associated_6\VBN\think.v.03|with (r_acl) pain_5\NN\symptom.n.01|associated
D008012_D010146 CID lidocaine_14\NN\local_anesthetic.n.01| (r_pobj) of_13\IN\entity.n.01|lidocaine (r_prep) ph_12\NN\hydrogen_ion_concentration.n.01|the|of (r_dobj) adjust_10\VB\change.v.01|to|ph|into (r_relcl) solution_8\NN\mixture.n.01|a|buffering|adjust (r_pobj) of_5\IN\entity.n.01|solution (r_prep) addition_4\NN\component.n.03|the|of (r_nsubj) reduce_20\VB\decrease.v.02|if|addition|would|pain|during (l_dobj) pain_21\NN\symptom.n.01|
D008012_D010146 CID lidocaine_13\NN\local_anesthetic.n.01|standard (r_dobj) receiving_11\VBG\get.v.01|lidocaine|in|and|lidocaine (r_pcomp) after_10\IN\after.s.01|receiving (r_prep) quantify_5\VB\specify.v.02|to|severity|after (l_dobj) severity_7\NN\intensity.n.02|the|of (l_prep) of_8\IN\entity.n.01|pain (l_pobj) pain_9\NN\symptom.n.01|
D008012_D010146 CID lidocaine_20\NN\local_anesthetic.n.01|buffered|in (r_conj) receiving_11\VBG\get.v.01|lidocaine|in|and|lidocaine (r_pcomp) after_10\IN\after.s.01|receiving (r_prep) quantify_5\VB\specify.v.02|to|severity|after (l_dobj) severity_7\NN\intensity.n.02|the|of (l_prep) of_8\IN\entity.n.01|pain (l_pobj) pain_9\NN\symptom.n.01|
D008012_D010146 CID lidocaine_6\NN\local_anesthetic.n.01|buffered (r_pobj) for_4\IN\entity.n.01|lidocaine (r_prep) score_3\NN\evaluation.n.02|the|mean|pain|for (l_compound) pain_2\NN\symptom.n.01|
D008012_D010146 CID lidocaine_16\NN\local_anesthetic.n.01|standard (r_pobj) for_14\IN\entity.n.01|lidocaine (r_prep) score_13\NN\evaluation.n.02|the|mean|for|(|+/-|,|p|) (r_pobj) than_10\IN\entity.n.01|score (r_prep) lower_9\JJR\berth.n.03|significantly|than (r_acomp) was_7\VBD\washington.n.02|score|lower|. (l_nsubj) score_3\NN\evaluation.n.02|the|mean|pain|for (l_compound) pain_2\NN\symptom.n.01|
D008012_D010146 CID lidocaine_5\NN\local_anesthetic.n.01|standard (r_pobj) of_3\IN\entity.n.01|lidocaine (r_prep) adjustment_2\NN\improvement.n.01|the|ph|of (r_nsubjpass) accomplished_8\VBN\complete.v.01|adjustment|can|be|easily|in|. (l_prep) in_10\IN\linear_unit.n.01|laboratory (l_pobj) laboratory_13\NN\workplace.n.01|the|catheterization|before (l_prep) before_14\IN\earlier.r.01|injection (l_pobj) injection_15\NN\insertion.n.02|and|results|in (l_prep) in_18\IN\linear_unit.n.01|reduction (l_pobj) reduction_20\NN\change_of_magnitude.n.01|a|of (l_prep) of_21\IN\entity.n.01|pain (l_pobj) pain_23\NN\symptom.n.01|the|occurring
7834920
D012293_D005921 CID rifampin_6\NN\antibacterial.n.01| (r_amod) therapy_7\NN\medical_care.n.01|intermittent|rifampin|for (r_pobj) with_4\IN\entity.n.01|therapy (r_prep) associated_3\VBN\think.v.03|with (r_acl) glomerulonephritis_2\NN\nephritis.n.01|associated
D012293_D005921 CID rifampin_17\NN\antibacterial.n.01| (r_pobj) with_16\IN\entity.n.01|rifampin (r_prep) treated_15\VBN\interact.v.01|with (r_acl) patient_14\NN\case.n.06|a|treated (r_pobj) in_12\IN\linear_unit.n.01|patient (r_prep) finding_6\NN\discovery.n.01|an|unusual|of|in|had (l_prep) of_7\IN\entity.n.01|glomerulonephritis (l_pobj) glomerulonephritis_11\NN\nephritis.n.01|proliferative|crescentic
D012293_D005921 CID rifampin_20\NN\antibacterial.n.01| (r_pobj) with_19\IN\entity.n.01|rifampin (r_prep) treated_18\VBN\interact.v.01|with (r_acl) patient_17\NN\case.n.06|a|treated (r_pobj) in_15\IN\linear_unit.n.01|patient (r_prep) occurrence_5\NN\event.n.01|the|unusual|of|in (l_prep) of_6\IN\entity.n.01|glomerulonephritis (l_pobj) glomerulonephritis_9\NN\nephritis.n.01|progressive|with
D012293_D005921 CID rifampin_20\NN\antibacterial.n.01| (r_pobj) with_19\IN\entity.n.01|rifampin (r_prep) treated_18\VBN\interact.v.01|with (r_acl) patient_17\NN\case.n.06|a|treated (r_pobj) in_15\IN\linear_unit.n.01|patient (r_prep) occurrence_5\NN\event.n.01|the|unusual|of|in (l_prep) of_6\IN\entity.n.01|glomerulonephritis (l_pobj) glomerulonephritis_9\NN\nephritis.n.01|progressive|with (l_prep) with_10\IN\entity.n.01|crescents (l_pobj) crescents_11\NNS\curve.n.01|and|glomerulonephritis (l_conj) glomerulonephritis_14\NN\nephritis.n.01|fibrillar
D012293_D014397 NONE rifampin_6\NN\antibacterial.n.01| (r_amod) therapy_7\NN\medical_care.n.01|intermittent|rifampin|for (l_prep) for_8\IN\entity.n.01|tuberculosis (l_pobj) tuberculosis_10\NN\infectious_disease.n.01|pulmonary
D012293_D014397 NONE rifampin_7\NN\antibacterial.n.01| (r_pobj) of_6\IN\entity.n.01|rifampin (r_prep) regimen_5\NN\plan.n.01|a|10-month|of (r_dobj) underwent_2\VBD\change.v.02|patient|regimen|and|isoniazid|and|discovered|. (l_conj) isoniazid_9\NN\antibacterial.n.01|for (l_prep) for_10\IN\entity.n.01|tuberculosis (l_pobj) tuberculosis_12\NN\infectious_disease.n.01|pulmonary
D012293_D051437 CID rifampin_7\NN\antibacterial.n.01| (r_pobj) of_6\IN\entity.n.01|rifampin (r_prep) regimen_5\NN\plan.n.01|a|10-month|of (r_dobj) underwent_2\VBD\change.v.02|patient|regimen|and|isoniazid|and|discovered|. (l_conj) discovered_15\VBN\spy.v.03|was|developed (l_xcomp) developed_18\VBN\create.v.02|to|have|signs|after (l_dobj) signs_19\NNS\clue.n.02|of (l_prep) of_20\IN\entity.n.01|failure (l_pobj) failure_23\NN\nonaccomplishment.n.01|severe|renal
D007538_D014397 NONE isoniazid_9\NN\antibacterial.n.01|for (l_prep) for_10\IN\entity.n.01|tuberculosis (l_pobj) tuberculosis_12\NN\infectious_disease.n.01|pulmonary
D007538_D051437 NONE isoniazid_9\NN\antibacterial.n.01|for (r_conj) underwent_2\VBD\change.v.02|patient|regimen|and|isoniazid|and|discovered|. (l_conj) discovered_15\VBN\spy.v.03|was|developed (l_xcomp) developed_18\VBN\create.v.02|to|have|signs|after (l_dobj) signs_19\NNS\clue.n.02|of (l_prep) of_20\IN\entity.n.01|failure (l_pobj) failure_23\NN\nonaccomplishment.n.01|severe|renal
12789195
D008914_D004194 NONE minoxidil_9\NN\vasodilator.n.01| (r_pobj) of_8\IN\entity.n.01|minoxidil (r_prep) use_7\NN\activity.n.01|the|term|of (r_pobj) by_2\IN\by.r.01|use (r_agent) induced_1\VBN\generate.v.01|pseudoacromegaly|by|. (l_nsubj) pseudoacromegaly_0\NNS\entity.n.01|
D008914_D004194 NONE minoxidil_15\NN\vasodilator.n.01| (r_pobj) of_14\IN\entity.n.01|minoxidil (r_prep) use_13\NN\activity.n.01|the|term|of|at (r_pobj) from_8\IN\entity.n.01|use (r_prep) resulted_7\VBD\prove.v.01|that|from (r_relcl) patient_3\NN\case.n.06|a|with|resulted (l_prep) with_4\IN\entity.n.01|pseudoacromegaly (l_pobj) pseudoacromegaly_5\NNS\entity.n.01|
D008914_D004194 NONE minoxidil_13\JJ\vasodilator.n.01| (r_amod) use_14\NN\activity.n.01|minoxidil (r_pobj) of_12\IN\entity.n.01|use (r_prep) effect_11\NN\phenomenon.n.01|a|side|of (r_pobj) as_8\IN\chemical_element.n.01|effect (r_prep) report_5\NN\document.n.01|the|first|case|of|as (l_prep) of_6\IN\entity.n.01|pseudoacromegaly (l_pobj) pseudoacromegaly_7\NNS\entity.n.01|
3693336
D014229_D001714 CID triazolam_0\NNP\benzodiazepine.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|triazolam|-|episodes|. (l_dobj) episodes_4\NNS\happening.n.01|brief|of|in (l_prep) of_5\IN\entity.n.01|mania (l_pobj) mania_7\NN\irrational_motive.n.01|secondary
D014229_D001714 CID triazolam_3\NN\benzodiazepine.n.01| (r_pobj) of_2\IN\entity.n.01|triazolam (r_prep) doses_1\NNS\medicine.n.02|large|of (r_nsubj) induced_5\VBD\generate.v.01|doses|repeatedly|episodes|. (l_dobj) episodes_7\NNS\happening.n.01|brief|of|in (l_prep) of_8\IN\entity.n.01|mania (l_pobj) mania_9\NN\irrational_motive.n.01|
D014229_D001714 CID triazolam_10\NN\benzodiazepine.n.01| (r_pobj) of_9\IN\entity.n.01|triazolam (r_prep) action_8\NN\act.n.02|of (r_pobj) of_7\IN\entity.n.01|action (r_prep) duration_6\NN\time_period.n.01|the|of (r_pobj) with_4\IN\entity.n.01|duration (r_prep) coincident_3\JJ\coincident.s.01|with (r_acomp) was_2\VBD\washington.n.02|excitement|coincident|. (l_nsubj) excitement_1\NN\joy.n.01|manic (l_amod) manic_0\JJ\frenzied.s.01|
D014229_D003866 NONE triazolam_0\NNP\benzodiazepine.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|triazolam|-|episodes|. (l_dobj) episodes_4\NNS\happening.n.01|brief|of|in (l_prep) in_8\IN\linear_unit.n.01|patient (l_pobj) patient_11\NN\case.n.06|a|depressed (l_amod) depressed_10\JJ\discourage.v.02|
D014229_D003866 NONE triazolam_3\NN\benzodiazepine.n.01| (r_pobj) of_2\IN\entity.n.01|triazolam (r_prep) doses_1\NNS\medicine.n.02|large|of (r_nsubj) induced_5\VBD\generate.v.01|doses|repeatedly|episodes|. (l_dobj) episodes_7\NNS\happening.n.01|brief|of|in (l_prep) in_10\IN\linear_unit.n.01|woman (l_pobj) woman_14\NN\adult.n.01|a|depressed|elderly (l_amod) depressed_12\JJ\discourage.v.02|
7862923
D002220_D012559 NONE carbamazepine_0\NNP\entity.n.01| (r_nsubjpass) switched_2\VBN\change_by_reversal.v.01|carbamazepine|was|to|among|. (l_prep) among_8\IN\entity.n.01|patients (l_pobj) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\psychotic.n.01|or|organic
D002220_D019965 NONE carbamazepine_0\NNP\entity.n.01| (r_nsubjpass) switched_2\VBN\change_by_reversal.v.01|carbamazepine|was|to|among|. (l_prep) among_8\IN\entity.n.01|patients (l_pobj) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\sick_person.n.01|
C036006_D012559 NONE oxcarbazepine_7\NN\entity.n.01|its|analogue (r_pobj) to_3\IN\entity.n.01|oxcarbazepine (r_prep) switched_2\VBN\change_by_reversal.v.01|carbamazepine|was|to|among|. (l_prep) among_8\IN\entity.n.01|patients (l_pobj) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\psychotic.n.01|or|organic
C036006_D019965 NONE oxcarbazepine_7\NN\entity.n.01|its|analogue (r_pobj) to_3\IN\entity.n.01|oxcarbazepine (r_prep) switched_2\VBN\change_by_reversal.v.01|carbamazepine|was|to|among|. (l_prep) among_8\IN\entity.n.01|patients (l_pobj) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\sick_person.n.01|
D006220_D012559 NONE haloperidol_22\NN\major_tranquilizer.n.01|,|chlorpromazine (r_dobj) using_20\VBG\mistreatment.n.01|concomitantly|haloperidol (r_acl) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\psychotic.n.01|or|organic
D006220_D019965 NONE haloperidol_22\NN\major_tranquilizer.n.01|,|chlorpromazine (r_dobj) using_20\VBG\mistreatment.n.01|concomitantly|haloperidol (r_acl) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\sick_person.n.01|
D002746_D012559 NONE chlorpromazine_24\NN\major_tranquilizer.n.01|or|clozapine (r_conj) haloperidol_22\NN\major_tranquilizer.n.01|,|chlorpromazine (r_dobj) using_20\VBG\mistreatment.n.01|concomitantly|haloperidol (r_acl) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\psychotic.n.01|or|organic
D002746_D019965 NONE chlorpromazine_24\NN\major_tranquilizer.n.01|or|clozapine (r_conj) haloperidol_22\NN\major_tranquilizer.n.01|,|chlorpromazine (r_dobj) using_20\VBG\mistreatment.n.01|concomitantly|haloperidol (r_acl) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\sick_person.n.01|
D003024_D012559 NONE clozapine_26\NN\major_tranquilizer.n.01| (r_conj) chlorpromazine_24\NN\major_tranquilizer.n.01|or|clozapine (r_conj) haloperidol_22\NN\major_tranquilizer.n.01|,|chlorpromazine (r_dobj) using_20\VBG\mistreatment.n.01|concomitantly|haloperidol (r_acl) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) schizophrenic_15\JJ\psychotic.n.01|or|organic
D003024_D019965 NONE clozapine_26\NN\major_tranquilizer.n.01| (r_conj) chlorpromazine_24\NN\major_tranquilizer.n.01|or|clozapine (r_conj) haloperidol_22\NN\major_tranquilizer.n.01|,|chlorpromazine (r_dobj) using_20\VBG\mistreatment.n.01|concomitantly|haloperidol (r_acl) patients_19\NNS\case.n.06|six|difficult|schizophrenic|psychotic|using (l_amod) psychotic_18\JJ\sick_person.n.01|
15233872
C007145_D009203 NONE crataegus_5\NNP\rosid_dicot_genus.n.01| (r_pobj) of_4\IN\entity.n.01|crataegus (r_prep) tincture_3\NN\coloring_material.n.01|of (r_pobj) of_2\IN\entity.n.01|tincture (r_prep) effect_1\NN\phenomenon.n.01|cardioprotective|of|on|. (l_prep) on_6\IN\on.a.01|infarction (l_pobj) infarction_11\NN\pathology.n.02|induced|myocardial|in
C007145_D009203 NONE tcr_11\NNP\entity.n.01| (r_pobj) of_10\IN\entity.n.01|tcr (r_prep) effect_9\NN\phenomenon.n.01|the|protective|of|on (l_prep) on_12\IN\on.a.01|infarction (l_pobj) infarction_16\NN\pathology.n.02|induced|myocardial|in
D007545_D009203 CID isoproterenol_7\NN\medicine.n.02| (r_npadvmod) induced_9\VBN\generate.v.01|isoproterenol|- (r_amod) infarction_11\NN\pathology.n.02|induced|myocardial|in
19445921
C066201_D009203 NONE a_5\NN\metric_linear_unit.n.01|acid|on (l_prep) on_6\IN\on.a.01|infarction (l_pobj) infarction_11\NN\pathology.n.02|induced|myocardial|in
C066201_D009203 NONE a_13\NN\metric_linear_unit.n.01|acid (r_pobj) of_10\IN\entity.n.01|salvianolic|a (r_prep) potential_9\NN\possibility.n.02|the|cardioprotective|of|on (l_prep) on_14\IN\on.a.01|infarction (l_pobj) infarction_19\NN\pathology.n.02|induced|myocardial|in
C066201_D009203 NONE a_9\DT\metric_linear_unit.n.01|acid|possessing (r_appos) salvianolic_7\JJ\entity.n.01|that|a (r_nsubj) has_13\VBZ\angular_distance.n.01|salvianolic|effect (l_dobj) effect_17\NN\phenomenon.n.01|a|significant|protective|against (l_prep) against_18\IN\entity.n.01|infarction (l_pobj) infarction_23\NN\pathology.n.02|induced|myocardial
D007545_D009203 CID isoproterenol_7\NN\medicine.n.02| (r_npadvmod) induced_9\VBN\generate.v.01|isoproterenol|- (r_amod) infarction_11\NN\pathology.n.02|induced|myocardial|in
D007545_D009203 CID isoproterenol_15\NN\medicine.n.02| (r_npadvmod) induced_17\VBN\generate.v.01|isoproterenol|- (r_amod) infarction_19\NN\pathology.n.02|induced|myocardial|in
D007545_D009203 CID isoproterenol_19\NN\medicine.n.02| (r_npadvmod) induced_21\VBN\generate.v.01|isoproterenol|- (r_amod) infarction_23\NN\pathology.n.02|induced|myocardial
D000244_D012131 NONE adp_13\NNP\nucleotide.n.01| (r_nmod) o_15\NNP\chemical_element.n.01|adp|/ (r_conj) ratio_11\NN\magnitude_relation.n.01|decreased|control|and|o (r_pobj) by_7\IN\by.r.01|ratio (r_agent) characterized_6\VBN\remember.v.02|by (r_acl) dysfunction_5\NN\pathology.n.02|mitochondrial|respiratory|characterized
D007545_D012131 NONE isoproterenol_19\NN\medicine.n.02| (r_npadvmod) treated_21\VBN\interact.v.01|isoproterenol|- (r_amod) rats_22\NNS\rodent.n.01|treated (r_pobj) in_18\IN\linear_unit.n.01|rats (r_prep) observed_17\VBN\spy.v.03|in|,|dysfunction|was|in|. (l_nsubjpass) dysfunction_5\NN\pathology.n.02|mitochondrial|respiratory|characterized
C066201_D006331 NONE a_4\NN\metric_linear_unit.n.01|acid (r_appos) administration_0\NN\management.n.01|of|a|for|dysfunction|and|improved (l_conj) dysfunction_17\NN\pathology.n.02|attenuated|induced|cardiac|and|injury
C066201_D009202 NONE a_4\NN\metric_linear_unit.n.01|acid (r_appos) administration_0\NN\management.n.01|of|a|for|dysfunction|and|improved (l_conj) dysfunction_17\NN\pathology.n.02|attenuated|induced|cardiac|and|injury (l_conj) injury_20\NN\ill_health.n.01|myocardial
C066201_D009202 NONE a_6\NN\metric_linear_unit.n.01|acid (r_pobj) of_3\IN\entity.n.01|salvianolic|a (r_prep) role_2\NN\duty.n.02|the|protective|of|against (l_prep) against_7\IN\entity.n.01|damage (l_pobj) damage_12\NN\change.n.01|induced|myocardial
D007545_D006331 NONE isoproterenol_13\NN\medicine.n.02| (r_npadvmod) induced_15\VBN\generate.v.01|isoproterenol|- (r_amod) dysfunction_17\NN\pathology.n.02|attenuated|induced|cardiac|and|injury
D007545_D009202 NONE isoproterenol_13\NN\medicine.n.02| (r_npadvmod) induced_15\VBN\generate.v.01|isoproterenol|- (r_amod) dysfunction_17\NN\pathology.n.02|attenuated|induced|cardiac|and|injury (l_conj) injury_20\NN\ill_health.n.01|myocardial
D007545_D009202 NONE isoproterenol_8\NN\medicine.n.02| (r_npadvmod) induced_10\VBN\generate.v.01|isoproterenol|- (r_amod) damage_12\NN\change.n.01|induced|myocardial
1527456
D008012_D014012 NONE lignocaine_7\NN\entity.n.01|lidocaine (r_pobj) of_6\IN\entity.n.01|lignocaine (r_prep) instillation_5\NN\insertion.n.02|intratympanic|of (r_pobj) by_3\IN\by.r.01|instillation (r_prep) treatment_0\NN\care.n.01|of|by|2|through|. (l_prep) of_1\IN\entity.n.01|tinnitus (l_pobj) tinnitus_2\NN\symptom.n.01|
D008012_D014012 NONE lidocaine_9\NN\local_anesthetic.n.01|(|) (r_appos) lignocaine_7\NN\entity.n.01|lidocaine (r_pobj) of_6\IN\entity.n.01|lignocaine (r_prep) instillation_5\NN\insertion.n.02|intratympanic|of (r_pobj) by_3\IN\by.r.01|instillation (r_prep) treatment_0\NN\care.n.01|of|by|2|through|. (l_prep) of_1\IN\entity.n.01|tinnitus (l_pobj) tinnitus_2\NN\symptom.n.01|
D008012_D014012 NONE lignocaine_12\NN\entity.n.01|lidocaine (r_pobj) of_11\IN\entity.n.01|lignocaine (r_prep) instillation_10\NN\insertion.n.02|intratympanic|of (r_pobj) by_8\IN\by.r.01|instillation (r_prep) treating_6\VBG\interact.v.01|ist|by (l_dobj) ist_7\NNP\entity.n.01|
D008012_D014012 NONE lidocaine_14\NN\local_anesthetic.n.01|(|) (r_appos) lignocaine_12\NN\entity.n.01|lidocaine (r_pobj) of_11\IN\entity.n.01|lignocaine (r_prep) instillation_10\NN\insertion.n.02|intratympanic|of (r_pobj) by_8\IN\by.r.01|instillation (r_prep) treating_6\VBG\interact.v.01|ist|by (l_dobj) ist_7\NNP\entity.n.01|
9523805
D011318_D009422 CID prilocaine_11\NN\entity.n.01|and|bupivacaine (r_pobj) with_10\IN\entity.n.01|prilocaine (r_prep) incidence_9\NN\frequency.n.02|a|lower|with|than (r_appos) symptoms_2\NNS\evidence.n.01|transient|neurologic|after|:|incidence|.
D011318_D009422 CID prilocaine_11\JJ\entity.n.01|with (l_prep) with_12\IN\entity.n.01|lidocaine (l_pobj) lidocaine_13\NN\local_anesthetic.n.01|and|bupivacaine (l_conj) bupivacaine_15\NN\entity.n.01|with (l_prep) with_16\IN\entity.n.01|respect (l_pobj) respect_17\NN\detail.n.01|to (l_prep) to_18\IN\entity.n.01|duration (l_pobj) duration_19\NN\time_period.n.01|of (l_prep) of_20\IN\entity.n.01|action (l_pobj) action_21\NN\act.n.02|and|risk (l_conj) risk_24\NN\danger.n.03|relative|of (l_prep) of_25\IN\entity.n.01|tnss (l_pobj) tnss_26\NNS\tennessee.n.01|
D011318_D009422 CID prilocaine_15\NN\entity.n.01|(|p|) (r_dobj) receiving_14\VBG\get.v.01|prilocaine (r_acl) patients_13\NNS\case.n.06|30|receiving (r_nsubj) had_21\VBD\have.v.01|:|patients|,|patients|them|,|and|had (l_nsubj) patients_4\NNS\case.n.06|30|receiving (l_acl) receiving_5\VBG\get.v.01|lidocaine|tnss (l_dobj) tnss_8\NNS\tennessee.n.01|experienced
D011318_D009422 CID prilocaine_15\NN\entity.n.01|(|p|) (r_dobj) receiving_14\VBG\get.v.01|prilocaine (r_acl) patients_13\NNS\case.n.06|30|receiving (r_nsubj) had_21\VBD\have.v.01|:|patients|,|patients|them|,|and|had (l_conj) had_31\VBD\have.v.01|none|tnss|. (l_dobj) tnss_32\NNS\tennessee.n.01|
D011318_D009422 CID prilocaine_0\NNP\entity.n.01| (r_nsubj) be_2\VB\metallic_element.n.01|prilocaine|may|preferable|has|. (l_advcl) has_12\VBZ\angular_distance.n.01|because|it|duration (l_dobj) duration_15\NN\time_period.n.01|a|similar|of|but|incidence (l_conj) incidence_21\NN\frequency.n.02|a|lower|of (l_prep) of_22\IN\entity.n.01|tnss (l_pobj) tnss_23\NNS\tennessee.n.01|
D002045_D009422 NONE bupivacaine_13\NN\entity.n.01| (r_conj) prilocaine_11\NN\entity.n.01|and|bupivacaine (r_pobj) with_10\IN\entity.n.01|prilocaine (r_prep) incidence_9\NN\frequency.n.02|a|lower|with|than (r_appos) symptoms_2\NNS\evidence.n.01|transient|neurologic|after|:|incidence|.
D002045_D009422 NONE bupivacaine_19\NN\entity.n.01| (r_pobj) with_18\IN\entity.n.01|bupivacaine (r_prep) infrequent_17\JJ\infrequent.a.01|with (r_acomp) are_16\VBP\area_unit.n.01|infrequent (r_conj) follow_11\VBP\travel.v.01|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\evidence.n.01|transient|neurologic|(|tnss|)
D002045_D009422 NONE bupivacaine_19\NN\entity.n.01| (r_pobj) with_18\IN\entity.n.01|bupivacaine (r_prep) infrequent_17\JJ\infrequent.a.01|with (r_acomp) are_16\VBP\area_unit.n.01|infrequent (r_conj) follow_11\VBP\travel.v.01|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\evidence.n.01|transient|neurologic|(|tnss|) (l_appos) tnss_8\NNS\tennessee.n.01|
D002045_D009422 NONE bupivacaine_15\NN\entity.n.01|with (l_prep) with_16\IN\entity.n.01|respect (l_pobj) respect_17\NN\detail.n.01|to (l_prep) to_18\IN\entity.n.01|duration (l_pobj) duration_19\NN\time_period.n.01|of (l_prep) of_20\IN\entity.n.01|action (l_pobj) action_21\NN\act.n.02|and|risk (l_conj) risk_24\NN\danger.n.03|relative|of (l_prep) of_25\IN\entity.n.01|tnss (l_pobj) tnss_26\NNS\tennessee.n.01|
D002045_D009422 NONE bupivacaine_30\NN\entity.n.01| (r_dobj) receiving_29\VBG\get.v.01|bupivacaine (r_acl) patients_28\NNS\case.n.06|30|receiving (r_pobj) of_26\IN\entity.n.01|patients (r_prep) none_25\NN\hour.n.02|of (r_nsubj) had_31\VBD\have.v.01|none|tnss|. (r_conj) had_21\VBD\have.v.01|:|patients|,|patients|them|,|and|had (l_nsubj) patients_4\NNS\case.n.06|30|receiving (l_acl) receiving_5\VBG\get.v.01|lidocaine|tnss (l_dobj) tnss_8\NNS\tennessee.n.01|experienced
D002045_D009422 NONE bupivacaine_30\NN\entity.n.01| (r_dobj) receiving_29\VBG\get.v.01|bupivacaine (r_acl) patients_28\NNS\case.n.06|30|receiving (r_pobj) of_26\IN\entity.n.01|patients (r_prep) none_25\NN\hour.n.02|of (r_nsubj) had_31\VBD\have.v.01|none|tnss|. (l_dobj) tnss_32\NNS\tennessee.n.01|
D008012_D009422 CID lidocaine_16\NN\local_anesthetic.n.01| (r_pobj) with_15\IN\entity.n.01|lidocaine (r_prep) than_14\IN\entity.n.01|with (r_prep) incidence_9\NN\frequency.n.02|a|lower|with|than (r_appos) symptoms_2\NNS\evidence.n.01|transient|neurologic|after|:|incidence|.
D008012_D009422 CID lidocaine_12\NN\local_anesthetic.n.01| (r_amod) anesthesia_14\NN\physical_condition.n.01|lidocaine|spinal (r_dobj) follow_11\VBP\travel.v.01|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\evidence.n.01|transient|neurologic|(|tnss|)
D008012_D009422 CID lidocaine_12\NN\local_anesthetic.n.01| (r_amod) anesthesia_14\NN\physical_condition.n.01|lidocaine|spinal (r_dobj) follow_11\VBP\travel.v.01|that|symptoms|frequently|anesthesia|but|are (l_nsubj) symptoms_6\NNS\evidence.n.01|transient|neurologic|(|tnss|) (l_appos) tnss_8\NNS\tennessee.n.01|
D008012_D009422 CID lidocaine_13\NN\local_anesthetic.n.01|and|bupivacaine (l_conj) bupivacaine_15\NN\entity.n.01|with (l_prep) with_16\IN\entity.n.01|respect (l_pobj) respect_17\NN\detail.n.01|to (l_prep) to_18\IN\entity.n.01|duration (l_pobj) duration_19\NN\time_period.n.01|of (l_prep) of_20\IN\entity.n.01|action (l_pobj) action_21\NN\act.n.02|and|risk (l_conj) risk_24\NN\danger.n.03|relative|of (l_prep) of_25\IN\entity.n.01|tnss (l_pobj) tnss_26\NNS\tennessee.n.01|
D008012_D009422 CID lidocaine_6\NN\local_anesthetic.n.01| (r_dobj) receiving_5\VBG\get.v.01|lidocaine|tnss (l_dobj) tnss_8\NNS\tennessee.n.01|experienced
D008012_D009422 CID lidocaine_6\NN\local_anesthetic.n.01| (r_dobj) receiving_5\VBG\get.v.01|lidocaine|tnss (r_acl) patients_4\NNS\case.n.06|30|receiving (r_nsubj) had_21\VBD\have.v.01|:|patients|,|patients|them|,|and|had (l_conj) had_31\VBD\have.v.01|none|tnss|. (l_dobj) tnss_32\NNS\tennessee.n.01|
D008012_D009422 CID lidocaine_5\NN\local_anesthetic.n.01|to|for (r_xcomp) preferable_3\JJ\preferable.s.01|lidocaine (r_acomp) be_2\VB\metallic_element.n.01|prilocaine|may|preferable|has|. (l_advcl) has_12\VBZ\angular_distance.n.01|because|it|duration (l_dobj) duration_15\NN\time_period.n.01|a|similar|of|but|incidence (l_conj) incidence_21\NN\frequency.n.02|a|lower|of (l_prep) of_22\IN\entity.n.01|tnss (l_pobj) tnss_23\NNS\tennessee.n.01|
137340
D009020_D006948 CID morphine_5\NN\analgesic.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|morphine|- (r_amod) increase_8\NN\indefinite_quantity.n.01|induced|in (l_prep) in_9\IN\linear_unit.n.01|activity (l_pobj) activity_11\NN\act.n.02|locomotor|of
D009020_D006948 CID morphine_7\NN\analgesic.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|morphine|- (r_amod) increase_10\NN\indefinite_quantity.n.01|the|induced|in (l_prep) in_11\IN\linear_unit.n.01|activity (l_pobj) activity_13\NN\act.n.02|locomotor|of
D009020_D006948 CID morphine_7\NN\analgesic.n.01| (r_compound) hc1_9\NNP\entity.n.01|morphine|- (r_pobj) of_6\IN\entity.n.01|hc1 (r_prep) mg/kg_5\NN\entity.n.01|10|of (r_pobj) of_3\IN\entity.n.01|mg/kg (r_prep) administration_2\NN\management.n.01|the|subcutaneous|of (r_nsubj) produced_10\VBD\make.v.03|administration|increase|. (l_dobj) increase_13\NN\indefinite_quantity.n.01|a|marked|in (l_prep) in_14\IN\linear_unit.n.01|activity (l_pobj) activity_16\NN\act.n.02|locomotor|in
D009020_D006948 CID morphine_1\NN\analgesic.n.01| (r_npadvmod) induced_3\VBN\generate.v.01|morphine|- (r_amod) hyperactivity_4\NN\disorder.n.01|the|induced
D009020_D006948 CID morphine_26\NN\analgesic.n.01| (r_pobj) by_25\IN\by.r.01|morphine (r_agent) produced_24\VBN\make.v.03|by (r_acl) hyperactivity_23\NN\disorder.n.01|the|produced
D012601_D006948 CID scopolamine_8\NN\alkaloid.n.01| (r_pobj) by_7\IN\by.r.01|scopolamine (r_agent) potentiated_6\VBN\enhance.v.01|hyperactivity|was|by|and|attenuated|. (l_nsubjpass) hyperactivity_4\NN\disorder.n.01|the|induced
D010830_D006948 NONE physostigmine_12\NN\alkaloid.n.01| (r_pobj) by_11\IN\by.r.01|physostigmine (r_agent) attenuated_10\VBN\weaken.v.01|by (r_conj) potentiated_6\VBN\enhance.v.01|hyperactivity|was|by|and|attenuated|. (l_nsubjpass) hyperactivity_4\NN\disorder.n.01|the|induced
D019832_D006948 NONE methscopolamine_4\NN\entity.n.01|both|and|neostigmine|,|penetrate (r_nsubj) had_18\VBD\have.v.01|in|,|methscopolamine|,|effect|. (l_dobj) effect_20\NN\phenomenon.n.01|no|on (l_prep) on_21\IN\on.a.01|hyperactivity (l_pobj) hyperactivity_23\NN\disorder.n.01|the|produced
D009388_D006948 NONE neostigmine_6\NN\anticholinesterase.n.01| (r_conj) methscopolamine_4\NN\entity.n.01|both|and|neostigmine|,|penetrate (r_nsubj) had_18\VBD\have.v.01|in|,|methscopolamine|,|effect|. (l_dobj) effect_20\NN\phenomenon.n.01|no|on (l_prep) on_21\IN\on.a.01|hyperactivity (l_pobj) hyperactivity_23\NN\disorder.n.01|the|produced
D010134_D006948 NONE chlorophenylalamine_9\NN\entity.n.01|p|-|(|i.p.|,|hr|) (r_pobj) with_6\IN\entity.n.01|chlorophenylalamine (r_prep) pretreatment_5\NN\entity.n.01|with (r_nsubj) caused_25\VBD\make.v.03|on|,|pretreatment|,|depletor|,|change|. (l_dobj) change_28\NN\happening.n.01|no|significant|in (l_prep) in_29\IN\linear_unit.n.01|hyperactivity (l_pobj) hyperactivity_31\NN\disorder.n.01|the
D012701_D006948 NONE serotonin_22\NN\monoamine_neurotransmitter.n.01| (r_compound) depletor_23\NN\entity.n.01|a|serotonin (r_nsubj) caused_25\VBD\make.v.03|on|,|pretreatment|,|depletor|,|change|. (l_dobj) change_28\NN\happening.n.01|no|significant|in (l_prep) in_29\IN\linear_unit.n.01|hyperactivity (l_pobj) hyperactivity_31\NN\disorder.n.01|the
18162529
D012313_D006966 NONE acid_5\NN\compound.n.02|ribonucleic (r_compound) levels_6\NNS\property.n.02|hypothalamic|prolactin|messenger|acid|,|signaling (l_conj) signaling_9\NN\communication.n.02|prolactin|,|and|inhibition (l_conj) inhibition_13\NN\abstinence.n.02|hyperprolactinemic|of (l_amod) hyperprolactinemic_12\JJ\entity.n.01|
D004958_D006966 NONE estradiol_22\NN\estrogen.n.01| (r_pobj) on_21\IN\on.a.01|estradiol (r_prep) dependent_20\JJ\recipient.n.01|on (r_acomp) are_19\VBP\area_unit.n.01|levels|dependent|. (l_nsubj) levels_6\NNS\property.n.02|hypothalamic|prolactin|messenger|acid|,|signaling (l_conj) signaling_9\NN\communication.n.02|prolactin|,|and|inhibition (l_conj) inhibition_13\NN\abstinence.n.02|hyperprolactinemic|of (l_amod) hyperprolactinemic_12\JJ\entity.n.01|
D004958_D006966 NONE estradiol_30\NN\estrogen.n.01| (r_pobj) of_29\IN\entity.n.01|estradiol (r_prep) levels_28\NNS\property.n.02|chronic|low|of (r_pobj) of_25\IN\entity.n.01|levels (r_prep) presence_24\NN\being.n.01|the|of (r_pobj) in_22\IN\linear_unit.n.01|only|presence (r_conj) caused_8\VBD\make.v.03|hyperprolactinemia|frequency|,|but|in|. (l_nsubj) hyperprolactinemia_1\NN\entity.n.01|chronic|induced
D004967_D006966 NONE estrogen_20\NN\steroid_hormone.n.01| (r_npadvmod) induced_22\VBN\generate.v.01|estrogen|- (r_amod) surge_24\NN\flow.n.01|the|induced|lh (r_conj) secretion_17\NN\organic_process.n.01|pulsatile|lh|and|surge (r_appos) parameters_9\NNS\constant.n.01|two|neuroendocrine|necessary|:|secretion (r_dobj) inhibited_6\VBD\control.v.02|whether|hyperprolactinemia|parameters (l_nsubj) hyperprolactinemia_5\NN\entity.n.01|chronic
D004298_D006966 NONE dopamine_5\NN\monoamine_neurotransmitter.n.01| (r_compound) antagonist_6\NN\person.n.01|dopamine (r_compound) sulpiride_7\NN\entity.n.01|the|antagonist (r_pobj) by_3\IN\by.r.01|sulpiride (r_agent) induced_2\VBN\generate.v.01|by (r_acl) hyperprolactinemia_1\NN\entity.n.01|chronic|induced
D013469_D006966 CID sulpiride_7\NN\entity.n.01|the|antagonist (r_pobj) by_3\IN\by.r.01|sulpiride (r_agent) induced_2\VBN\generate.v.01|by (r_acl) hyperprolactinemia_1\NN\entity.n.01|chronic|induced
D013256_D006966 NONE steroid_14\NN\organic_compound.n.01| (r_npadvmod) dependent_16\JJ\recipient.n.01|steroid|- (r_amod) manner_17\NN\property.n.02|a|dependent (r_pobj) in_12\IN\linear_unit.n.01|manner (r_prep) inhibited_8\VBN\control.v.02|that|frequency|is|by|in (l_agent) by_9\IN\by.r.01|hyperprolactinemia (l_pobj) hyperprolactinemia_11\NN\entity.n.01|chronic
16904497
D013256_D011128 NONE steroid_5\NN\organic_compound.n.01| (r_compound) injection_6\NN\insertion.n.02|epidural|steroid (r_pobj) after_3\IN\after.s.01|injection (r_prep) syndrome_2\NN\complex.n.01|equina|after|:|report|.
D013256_D011843 NONE steroid_11\NN\organic_compound.n.01| (r_compound) injections_12\NNS\insertion.n.02|epidural|steroid|,|medications (r_conj) therapy_8\NN\medical_care.n.01|physical|,|injections (r_attr) are_6\VBP\area_unit.n.01|methods|therapy|. (l_nsubj) methods_2\NNS\know-how.n.01|conventional|treatment|of (l_prep) of_3\IN\entity.n.01|radiculopathy (l_pobj) radiculopathy_5\NN\entity.n.01|lumbusacral
D014221_D011128 NONE triamcinolone_16\NN\corticosteroid.n.01|and|bupivacaine (r_pobj) of_15\IN\entity.n.01|triamcinolone (r_prep) injection_14\NN\insertion.n.02|epidural|of (r_pobj) by_12\IN\by.r.01|injection (r_agent) caused_11\VBN\make.v.03|possibly|by (r_acl) report_5\NN\document.n.01|a|of|caused (l_prep) of_6\IN\entity.n.01|syndrome (l_pobj) syndrome_9\NN\complex.n.01|cauda|equina
D002045_D011128 CID bupivacaine_18\NN\entity.n.01| (r_conj) triamcinolone_16\NN\corticosteroid.n.01|and|bupivacaine (r_pobj) of_15\IN\entity.n.01|triamcinolone (r_prep) injection_14\NN\insertion.n.02|epidural|of (r_pobj) by_12\IN\by.r.01|injection (r_agent) caused_11\VBN\make.v.03|possibly|by (r_acl) report_5\NN\document.n.01|a|of|caused (l_prep) of_6\IN\entity.n.01|syndrome (l_pobj) syndrome_9\NN\complex.n.01|cauda|equina
D013256_D017116 NONE steroid_16\NN\organic_compound.n.01| (r_compound) injection_17\NN\insertion.n.02|epidural|steroid (r_pobj) for_14\IN\entity.n.01|injection (r_prep) scheduled_13\VBN\plan.v.02|woman|was|for|. (l_nsubjpass) woman_4\NN\adult.n.01|a|old|with (l_prep) with_5\IN\entity.n.01|pain (l_pobj) pain_11\NN\symptom.n.01|back|leg
D013256_D010146 NONE steroid_16\NN\organic_compound.n.01| (r_compound) injection_17\NN\insertion.n.02|epidural|steroid (r_pobj) for_14\IN\entity.n.01|injection (r_prep) scheduled_13\VBN\plan.v.02|woman|was|for|. (l_nsubjpass) woman_4\NN\adult.n.01|a|old|with (l_prep) with_5\IN\entity.n.01|pain (l_pobj) pain_11\NN\symptom.n.01|back|leg
D013256_D009422 NONE steroid_10\NN\organic_compound.n.01| (r_compound) injections_11\NNS\insertion.n.02|epidural|steroid (r_pobj) after_8\IN\after.s.01|injections (r_prep) vigilance_4\NN\attention.n.05|continued|for|after (l_prep) for_5\IN\entity.n.01|deterioration (l_pobj) deterioration_7\NN\decay.n.04|neurologic
19884587
D013449_D000757 CID sulfonamides_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|sulfonamides|were|with (l_prep) with_3\IN\entity.n.01|aor (l_pobj) aor_9\NNP\entity.n.01|anencephaly|(|adjusted|or|[|]|3.4 (l_amod) anencephaly_4\NNS\birth_defect.n.01|
D013449_D018636 CID sulfonamides_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|sulfonamides|were|with (r_ccomp) interval_17\NN\measure.n.02|associated|;|%|confidence|ci|,|1.3|)|,|syndrome (l_appos) syndrome_30\NN\complex.n.01|hypoplastic|left|heart
D009582_D000853 CID nitrofurantoins_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|nitrofurantoins|were|with|aor|. (l_prep) with_3\IN\entity.n.01|anophthalmia (l_pobj) anophthalmia_4\NN\entity.n.01|or|microphthalmos
D009582_D008850 CID nitrofurantoins_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|nitrofurantoins|were|with|aor|. (l_prep) with_3\IN\entity.n.01|anophthalmia (l_pobj) anophthalmia_4\NN\entity.n.01|or|microphthalmos (l_conj) microphthalmos_6\NNS\entity.n.01|
D009582_D018636 CID nitrofurantoins_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\entity.n.01|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) syndrome_24\NN\complex.n.01|hypoplastic|left|heart
D009582_D006344 CID nitrofurantoins_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\entity.n.01|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) aor_26\NNP\entity.n.01|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_appos) defects_41\NNS\imperfection.n.01|atrial|septal
D009582_D002971 CID nitrofurantoins_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\entity.n.01|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) aor_26\NNP\entity.n.01|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_conj) lip_58\NN\articulator.n.02|cleft|with
D009582_D002972 CID nitrofurantoins_0\NNS\antibacterial.n.01| (r_nsubjpass) associated_2\VBN\think.v.03|nitrofurantoins|were|with|aor|. (l_appos) aor_8\NNP\entity.n.01|(|=|3.7|;|ci|,|syndrome|aor|aor (l_appos) aor_26\NNP\entity.n.01|(|=|4.2|;|ci|)|,|defects|(|aor|;|ci|)|,|and|lip (l_conj) lip_58\NN\articulator.n.02|cleft|with (l_prep) with_59\IN\entity.n.01|palate (l_pobj) palate_61\NN\surface.n.02|cleft
D010406_D000014 NONE penicillins_2\NNS\antibiotic.n.01|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN\think.v.03|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN\entity.n.01|defects (l_pobj) defects_22\NNS\imperfection.n.01|many|birth
D004917_D000014 NONE erythromycins_4\NNS\antibiotic.n.01|,|and|cephalosporins (r_conj) penicillins_2\NNS\antibiotic.n.01|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN\think.v.03|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN\entity.n.01|defects (l_pobj) defects_22\NNS\imperfection.n.01|many|birth
D002511_D000014 NONE cephalosporins_7\NNS\antibiotic.n.01| (r_conj) erythromycins_4\NNS\antibiotic.n.01|,|and|cephalosporins (r_conj) penicillins_2\NNS\antibiotic.n.01|,|erythromycins|,|used|, (r_nsubjpass) associated_18\VBN\think.v.03|reassuringly|,|penicillins|were|not|with|. (l_prep) with_19\IN\entity.n.01|defects (l_pobj) defects_22\NNS\imperfection.n.01|many|birth
D013449_D000014 CID sulfonamides_0\NNS\antibacterial.n.01|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\think.v.03|sulfonamides|were|with|,|indicating|. (l_prep) with_5\IN\entity.n.01|defects (l_pobj) defects_8\NNS\imperfection.n.01|several|birth
D009582_D000014 CID nitrofurantoins_2\NNS\antibacterial.n.01| (r_conj) sulfonamides_0\NNS\antibacterial.n.01|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\think.v.03|sulfonamides|were|with|,|indicating|. (l_prep) with_5\IN\entity.n.01|defects (l_pobj) defects_8\NNS\imperfection.n.01|several|birth
7248170
D010634_D006529 CID phenobarbitone_0\NNP\barbiturate.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|phenobarbitone|- (r_amod) enlargement_3\NN\increase.n.05|induced|of|:|relationship|. (l_prep) of_4\IN\entity.n.01|liver (l_pobj) liver_6\NN\internal_organ.n.01|the|in
D010634_D006529 CID phenobarbitone_60\NN\barbiturate.n.01| (r_npadvmod) primed_62\VBN\fix.v.12|phenobarbitone|- (r_amod) rat_63\NN\rodent.n.01|the|primed (r_pobj) in_58\IN\linear_unit.n.01|rat (r_prep) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_conj) increased_65\VBN\change_magnitude.v.01|was|from|by (l_prep) by_72\IN\by.r.01|giving (l_pcomp) giving_73\VBG\sharing.n.04|calibrating|at (l_prep) at_83\IN\chemical_element.n.01|peak (l_pobj) peak_85\NN\limit.n.06|the|of (l_prep) of_86\IN\entity.n.01|enlargement (l_pobj) enlargement_91\NN\increase.n.05|the|induced|of (l_prep) of_92\IN\entity.n.01|liver (l_pobj) liver_94\NN\internal_organ.n.01|the
D010634_D006529 CID phenobarbitone_88\NN\barbiturate.n.01| (r_npadvmod) induced_90\VBN\generate.v.01|phenobarbitone|- (r_amod) enlargement_91\NN\increase.n.05|the|induced|of (l_prep) of_92\IN\entity.n.01|liver (l_pobj) liver_94\NN\internal_organ.n.01|the
D010634_D005355 NONE phenobarbitone_0\NNP\barbiturate.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|phenobarbitone|- (r_amod) enlargement_3\NN\increase.n.05|induced|of|:|relationship|. (l_appos) relationship_12\NN\relation.n.01|its|to (l_prep) to_13\TO\entity.n.01|cirrhosis (l_pobj) cirrhosis_18\NN\liver_disease.n.01|carbon|induced
D002251_D006529 NONE tetrachloride_15\NN\compound.n.02| (r_advmod) induced_17\VBN\generate.v.01|tetrachloride|- (r_amod) cirrhosis_18\NN\liver_disease.n.01|carbon|induced (r_pobj) to_13\TO\entity.n.01|cirrhosis (r_prep) relationship_12\NN\relation.n.01|its|to (r_appos) enlargement_3\NN\increase.n.05|induced|of|:|relationship|. (l_prep) of_4\IN\entity.n.01|liver (l_pobj) liver_6\NN\internal_organ.n.01|the|in
D002251_D006529 NONE tetrachloride_55\NN\compound.n.02| (r_advmod) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_conj) increased_65\VBN\change_magnitude.v.01|was|from|by (l_prep) by_72\IN\by.r.01|giving (l_pcomp) giving_73\VBG\sharing.n.04|calibrating|at (l_prep) at_83\IN\chemical_element.n.01|peak (l_pobj) peak_85\NN\limit.n.06|the|of (l_prep) of_86\IN\entity.n.01|enlargement (l_pobj) enlargement_91\NN\increase.n.05|the|induced|of (l_prep) of_92\IN\entity.n.01|liver (l_pobj) liver_94\NN\internal_organ.n.01|the
D002251_D006529 NONE tetrachloride_82\NN\compound.n.02| (r_advmod) calibrating_77\VBG\adjust.v.01|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\sharing.n.04|calibrating|at (l_prep) at_83\IN\chemical_element.n.01|peak (l_pobj) peak_85\NN\limit.n.06|the|of (l_prep) of_86\IN\entity.n.01|enlargement (l_pobj) enlargement_91\NN\increase.n.05|the|induced|of (l_prep) of_92\IN\entity.n.01|liver (l_pobj) liver_94\NN\internal_organ.n.01|the
D002251_D005355 NONE tetrachloride_15\NN\compound.n.02| (r_advmod) induced_17\VBN\generate.v.01|tetrachloride|- (r_amod) cirrhosis_18\NN\liver_disease.n.01|carbon|induced
D002251_D008103 CID tetrachloride_55\NN\compound.n.02| (r_advmod) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_nsubj) yield_1\NN\production.n.07|the|of (l_prep) of_2\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_4\NN\liver_disease.n.01|severe|of (l_prep) of_5\IN\entity.n.01|liver (l_pobj) liver_7\NN\internal_organ.n.01|the|(|defined|,
D002251_D008103 CID tetrachloride_82\NN\compound.n.02| (r_advmod) calibrating_77\VBG\adjust.v.01|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_nsubj) yield_1\NN\production.n.07|the|of (l_prep) of_2\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_4\NN\liver_disease.n.01|severe|of (l_prep) of_5\IN\entity.n.01|liver (l_pobj) liver_7\NN\internal_organ.n.01|the|(|defined|,
D002251_D001201 NONE tetrachloride_55\NN\compound.n.02| (r_advmod) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin
D002251_D001201 NONE tetrachloride_82\NN\compound.n.02| (r_advmod) calibrating_77\VBG\adjust.v.01|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin
D002251_D013163 NONE tetrachloride_55\NN\compound.n.02| (r_advmod) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after
D002251_D013163 NONE tetrachloride_82\NN\compound.n.02| (r_advmod) calibrating_77\VBG\adjust.v.01|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after
D002251_D001284 NONE tetrachloride_55\NN\compound.n.02| (r_advmod) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after (l_conj) atrophy_44\NN\symptom.n.01|testicular|weight|)
D002251_D001284 NONE tetrachloride_82\NN\compound.n.02| (r_advmod) calibrating_77\VBG\adjust.v.01|the|initial|"|"|dose|tetrachloride (r_dative) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after (l_conj) atrophy_44\NN\symptom.n.01|testicular|weight|)
D010634_D008103 CID phenobarbitone_60\NN\barbiturate.n.01| (r_npadvmod) primed_62\VBN\fix.v.12|phenobarbitone|- (r_amod) rat_63\NN\rodent.n.01|the|primed (r_pobj) in_58\IN\linear_unit.n.01|rat (r_prep) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_nsubj) yield_1\NN\production.n.07|the|of (l_prep) of_2\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_4\NN\liver_disease.n.01|severe|of (l_prep) of_5\IN\entity.n.01|liver (l_pobj) liver_7\NN\internal_organ.n.01|the|(|defined|,
D010634_D008103 CID phenobarbitone_88\NN\barbiturate.n.01| (r_npadvmod) induced_90\VBN\generate.v.01|phenobarbitone|- (r_amod) enlargement_91\NN\increase.n.05|the|induced|of (r_pobj) of_86\IN\entity.n.01|enlargement (r_prep) peak_85\NN\limit.n.06|the|of (r_pobj) at_83\IN\chemical_element.n.01|peak (r_prep) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_nsubj) yield_1\NN\production.n.07|the|of (l_prep) of_2\IN\entity.n.01|cirrhosis (l_pobj) cirrhosis_4\NN\liver_disease.n.01|severe|of (l_prep) of_5\IN\entity.n.01|liver (l_pobj) liver_7\NN\internal_organ.n.01|the|(|defined|,
D010634_D001201 NONE phenobarbitone_60\NN\barbiturate.n.01| (r_npadvmod) primed_62\VBN\fix.v.12|phenobarbitone|- (r_amod) rat_63\NN\rodent.n.01|the|primed (r_pobj) in_58\IN\linear_unit.n.01|rat (r_prep) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin
D010634_D001201 NONE phenobarbitone_88\NN\barbiturate.n.01| (r_npadvmod) induced_90\VBN\generate.v.01|phenobarbitone|- (r_amod) enlargement_91\NN\increase.n.05|the|induced|of (r_pobj) of_86\IN\entity.n.01|enlargement (r_prep) peak_85\NN\limit.n.06|the|of (r_pobj) at_83\IN\chemical_element.n.01|peak (r_prep) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin
D010634_D013163 NONE phenobarbitone_60\NN\barbiturate.n.01| (r_npadvmod) primed_62\VBN\fix.v.12|phenobarbitone|- (r_amod) rat_63\NN\rodent.n.01|the|primed (r_pobj) in_58\IN\linear_unit.n.01|rat (r_prep) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after
D010634_D013163 NONE phenobarbitone_88\NN\barbiturate.n.01| (r_npadvmod) induced_90\VBN\generate.v.01|phenobarbitone|- (r_amod) enlargement_91\NN\increase.n.05|the|induced|of (r_pobj) of_86\IN\entity.n.01|enlargement (r_prep) peak_85\NN\limit.n.06|the|of (r_pobj) at_83\IN\chemical_element.n.01|peak (r_prep) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after
D010634_D001284 NONE phenobarbitone_60\NN\barbiturate.n.01| (r_npadvmod) primed_62\VBN\fix.v.12|phenobarbitone|- (r_amod) rat_63\NN\rodent.n.01|the|primed (r_pobj) in_58\IN\linear_unit.n.01|rat (r_prep) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after (l_conj) atrophy_44\NN\symptom.n.01|testicular|weight|)
D010634_D001284 NONE phenobarbitone_88\NN\barbiturate.n.01| (r_npadvmod) induced_90\VBN\generate.v.01|phenobarbitone|- (r_amod) enlargement_91\NN\increase.n.05|the|induced|of (r_pobj) of_86\IN\entity.n.01|enlargement (r_prep) peak_85\NN\limit.n.06|the|of (r_pobj) at_83\IN\chemical_element.n.01|peak (r_prep) giving_73\VBG\sharing.n.04|calibrating|at (r_pcomp) by_72\IN\by.r.01|giving (r_prep) increased_65\VBN\change_magnitude.v.01|was|from|by (r_conj) given_56\VBN\assumption.n.02|ascites|tetrachloride|intragastrically|in|increased|. (l_nsubj) ascites_20\VBZ\pathology.n.02|yield|greater|,|albumin (l_conj) albumin_27\NN\simple_protein.n.01|plasma|less|,|splenomegaly (l_conj) splenomegaly_35\JJ\hypertrophy.n.01|2|,|and|atrophy|after (l_conj) atrophy_44\NN\symptom.n.01|testicular|weight|)
3782049
D008972_D012206 CID molindone_6\NN\major_tranquilizer.n.01| (r_compound) administration_7\NN\management.n.01|molindone (r_pobj) following_5\VBG\multitude.n.03|administration (r_prep) rhabdomyolysis_4\NN\entity.n.01|massive|following
D008972_D012206 CID molindone_18\NN\major_tranquilizer.n.01| (r_compound) administration_19\NN\management.n.01|molindone (r_pobj) following_17\VBG\multitude.n.03|administration (r_prep) rhabdomyolysis_11\NN\entity.n.01|massive|and|failure|following
D008972_D012559 NONE molindone_18\NN\major_tranquilizer.n.01| (r_compound) administration_19\NN\management.n.01|molindone (r_pobj) following_17\VBG\multitude.n.03|administration (r_prep) rhabdomyolysis_11\NN\entity.n.01|massive|and|failure|following (r_dobj) illustrate_9\VB\elaborate.v.01|to|rhabdomyolysis (r_xcomp) reported_7\VBN\inform.v.01|case|is|illustrate|. (l_nsubjpass) case_1\NN\happening.n.01|the|of (l_prep) of_2\IN\entity.n.01|patient (l_pobj) patient_5\NN\case.n.06|a|schizophrenic (l_amod) schizophrenic_4\JJ\psychotic.n.01|
D008972_D058186 CID molindone_18\NN\major_tranquilizer.n.01| (r_compound) administration_19\NN\management.n.01|molindone (r_pobj) following_17\VBG\multitude.n.03|administration (r_prep) rhabdomyolysis_11\NN\entity.n.01|massive|and|failure|following (l_conj) failure_16\NN\nonaccomplishment.n.01|subsequent|acute|renal
17608141
D008694_D020258 NONE methamphetamine_2\NN\amphetamine.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|attenuation|methamphetamine|-|neurotoxicity|. (l_dobj) neurotoxicity_7\NN\entity.n.01|nigrostriatal|dopaminergic|in|by
D008694_D020258 NONE methamphetamine_23\NN\amphetamine.n.01| (r_npadvmod) induced_25\VBN\generate.v.01|methamphetamine|- (r_amod) neurotoxicity_28\NN\entity.n.01|the|induced|nigrostriatal|dopamine
D008694_D020258 NONE methamphetamine_15\NN\amphetamine.n.01| (r_npadvmod) induced_17\VBN\generate.v.01|methamphetamine|- (r_amod) neurotoxicity_20\NN\entity.n.01|induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_11\NN\entity.n.01| (r_compound) pretreatment_12\NN\entity.n.01|lipopolysaccharide (r_pobj) by_10\IN\by.r.01|pretreatment (r_prep) neurotoxicity_7\NN\entity.n.01|nigrostriatal|dopaminergic|in|by
D008070_D020258 NONE lipopolysaccharide_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|lipopolysaccharide (r_prep) roles_7\NNS\duty.n.02|the|of|,|factor (l_appos) factor_17\NN\cause.n.01|a|inflammatory|,|treatment (l_conj) treatment_19\NN\care.n.01|in (l_prep) in_20\IN\linear_unit.n.01|modulating (l_pcomp) modulating_21\VBG\play.v.06|neurotoxicity (l_dobj) neurotoxicity_28\NN\entity.n.01|the|induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_8\NN\entity.n.01| (r_compound) pretreatment_9\NN\entity.n.01|systemic|lipopolysaccharide|in (l_prep) in_10\IN\linear_unit.n.01|exerting (l_pcomp) exerting_11\VBG\use.v.01|protection (l_dobj) protection_13\NN\activity.n.01|effective|against (l_prep) against_14\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_20\NN\entity.n.01|induced|nigrostriatal|dopamine
D008694_D009422 NONE methamphetamine_10\NN\amphetamine.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|methamphetamine|- (r_amod) damage_15\NN\change.n.01|induced|dopaminergic|terminal
D004298_D020258 NONE dopamine_27\NN\monoamine_neurotransmitter.n.01| (r_compound) neurotoxicity_28\NN\entity.n.01|the|induced|nigrostriatal|dopamine
D004298_D020258 NONE dopamine_19\NN\monoamine_neurotransmitter.n.01| (r_compound) neurotoxicity_20\NN\entity.n.01|induced|nigrostriatal|dopamine
D008070_D005334 NONE lipopolysaccharide_0\JJ\entity.n.01| (r_compound) pretreatment_1\NN\entity.n.01|lipopolysaccharide (r_nsubj) affect_4\VB\feeling.n.01|pretreatment|did|not|temperature|later|. (l_dobj) temperature_8\NN\fundamental_quantity.n.01|the|basal|body|or|hyperthermia (l_conj) hyperthermia_13\NN\physical_condition.n.01|elicited
D008694_D005334 CID methamphetamine_10\NN\amphetamine.n.01| (r_npadvmod) elicited_12\VBN\make.v.03|methamphetamine|- (r_amod) hyperthermia_13\NN\physical_condition.n.01|elicited
9088814
D000527_D007022 CID e1-induced_5\JJ\entity.n.01| (r_amod) hypotension_6\NN\cardiovascular_disease.n.01|prolonged|prostaglandin|e1-induced|and|haemodilution|on
D000527_D007022 CID e1_5\NN\entity.n.01|prolonged|prostaglandin|hypotension (l_appos) hypotension_8\NN\cardiovascular_disease.n.01|(|pge1)-induced|and|haemodilution
D000527_D007022 CID pge1)-induced_7\JJ\entity.n.01| (r_amod) hypotension_8\NN\cardiovascular_disease.n.01|(|pge1)-induced|and|haemodilution
D000527_D007022 CID pge1_10\NNP\entity.n.01| (r_pobj) with_9\IN\entity.n.01|pge1 (r_prep) induced_8\VBN\generate.v.01|hypotension|was|with|maintain|. (l_nsubjpass) hypotension_1\NN\cardiovascular_disease.n.01|controlled|in
D000527_D007022 CID pge1-induced_13\JJ\entity.n.01| (r_amod) hypotension_14\NN\cardiovascular_disease.n.01|pge1-induced|and|haemodilution
D000527_D020141 NONE e1-induced_5\JJ\entity.n.01| (r_amod) hypotension_6\NN\cardiovascular_disease.n.01|prolonged|prostaglandin|e1-induced|and|haemodilution|on (l_conj) haemodilution_8\NN\entity.n.01|
D000527_D020141 NONE e1_5\NN\entity.n.01|prolonged|prostaglandin|hypotension (l_appos) hypotension_8\NN\cardiovascular_disease.n.01|(|pge1)-induced|and|haemodilution (l_conj) haemodilution_10\NN\entity.n.01|on
D000527_D020141 NONE pge1)-induced_7\JJ\entity.n.01| (r_amod) hypotension_8\NN\cardiovascular_disease.n.01|(|pge1)-induced|and|haemodilution (l_conj) haemodilution_10\NN\entity.n.01|on
D000527_D020141 NONE pge1-induced_13\JJ\entity.n.01| (r_amod) hypotension_14\NN\cardiovascular_disease.n.01|pge1-induced|and|haemodilution (l_conj) haemodilution_17\NN\entity.n.01|moderate
D003911_D020141 NONE dextran_23\NN\entity.n.01| (r_amod) solution_24\NN\mixture.n.01|dextran (r_pobj) of_22\IN\entity.n.01|solution (r_prep) amount_21\NN\assets.n.01|the|same|of (r_pobj) with_18\IN\entity.n.01|amount (r_prep) replacing_16\VBG\substitution.n.02|it|with (r_conj) withdrawing_9\VBG\travel.v.01|ml|and|replacing (r_pcomp) by_8\IN\by.r.01|withdrawing (r_prep) produced_7\VBN\make.v.03|haemodilution|was|by|,|and|were (l_nsubjpass) haemodilution_0\NN\entity.n.01|in
D001663_D007022 NONE bilirubin_68\NN\animal_pigment.n.01|total (r_conj) ldh_65\NNP\entity.n.01|and|bilirubin (r_conj) sgpt_63\NNP\entity.n.01|,|ldh (r_appos) sgot_61\NNP\entity.n.01|,|sgpt (r_nsubj) showed_69\VBD\show.v.04|sgot|increases|. (r_conj) showed_23\VBD\show.v.04|showed|,|akbr|decrease|and|at|after|,|and|showed (l_prep) after_42\IN\after.s.01|start|and|at|after (l_pobj) start_44\NN\beginning.n.01|the|of (l_prep) of_45\IN\entity.n.01|hypotension (l_pobj) hypotension_46\NN\cardiovascular_disease.n.01|
D000527_D008107 CID pge1-induced_13\JJ\entity.n.01| (r_amod) hypotension_14\NN\cardiovascular_disease.n.01|pge1-induced|and|haemodilution (r_pobj) of_12\IN\entity.n.01|hypotension (r_prep) min_11\NN\time_unit.n.01|120|of (r_pobj) of_7\IN\entity.n.01|min (r_prep) combination_6\NN\collection.n.01|a|prolonged|of (r_nsubj) cause_19\VB\origin.n.03|that|combination|would|impairment (l_dobj) impairment_20\NN\change.n.01|of (l_prep) of_21\IN\entity.n.01|function (l_pobj) function_23\NN\mathematical_relation.n.01|hepatic
3615541
D000661_D006948 CID amphetamine_6\NN\drug_of_abuse.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|amphetamine|- (r_amod) hyperactivity_9\NN\disorder.n.01|induced
D002116_D006948 NONE calcitonin_12\NN\thyroid_hormone.n.01| (r_compound) injections_13\NNS\insertion.n.02|intracerebral|calcitonin (r_pobj) by_10\IN\by.r.01|injections (r_prep) antagonism_4\NN\state.n.02|the|of|by (l_prep) of_5\IN\entity.n.01|hyperactivity (l_pobj) hyperactivity_9\NN\disorder.n.01|induced
2572625
C084599_D056486 CID clotiazepam_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|clotiazepam|- (r_amod) hepatitis_4\NN\infectious_disease.n.01|induced|acute|.
C084599_D056486 CID clotiazepam_24\NN\entity.n.01| (r_pobj) of_23\IN\entity.n.01|clotiazepam (r_prep) administration_22\NN\management.n.01|of (r_pobj) of_21\IN\entity.n.01|administration (r_prep) onset_20\NN\start.n.01|the|of (r_pobj) after_18\IN\after.s.01|months|onset (r_prep) developed_8\VBD\create.v.02|who|hepatitis|with|after (l_dobj) hepatitis_10\NN\infectious_disease.n.01|acute
C084599_D056486 CID clotiazepam_9\NN\entity.n.01|to (r_xcomp) related_7\VBN\think.v.03|chemically|clotiazepam (r_acl) administration_1\NN\management.n.01|the|of|,|related (r_nsubj) interfere_13\VB\impede.v.01|administration|,|did|not|with|and|induce|. (l_conj) induce_19\VB\generate.v.01|did|not|relapse (l_dobj) relapse_21\NN\failure.n.01|any|of (l_prep) of_22\IN\entity.n.01|hepatitis (l_pobj) hepatitis_23\NN\infectious_disease.n.01|
C084599_D056486 CID clotiazepam_4\NN\entity.n.01| (r_nsubj) induce_6\VB\generate.v.01|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\infectious_disease.n.01|acute
C084599_D056486 CID clotiazepam_4\NN\entity.n.01| (r_nsubj) induce_6\VB\generate.v.01|that|clotiazepam|can|hepatitis|and|suggests (l_conj) suggests_10\VBZ\declare.v.01|is (l_ccomp) is_13\VBZ\be.v.01|that|there|hepatotoxicity (l_attr) hepatotoxicity_16\NN\entity.n.01|cross|between
C084599_D056486 CID clotiazepam_18\NN\entity.n.01|and|benzodiazepines (r_pobj) between_17\IN\between.r.01|clotiazepam (r_prep) hepatotoxicity_16\NN\entity.n.01|cross|between (r_attr) is_13\VBZ\be.v.01|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\declare.v.01|is (r_conj) induce_6\VB\generate.v.01|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\infectious_disease.n.01|acute
C084599_D056486 CID clotiazepam_18\NN\entity.n.01|and|benzodiazepines (r_pobj) between_17\IN\between.r.01|clotiazepam (r_prep) hepatotoxicity_16\NN\entity.n.01|cross|between
C084599_D047508 NONE clotiazepam_24\NN\entity.n.01| (r_pobj) of_23\IN\entity.n.01|clotiazepam (r_prep) administration_22\NN\management.n.01|of (r_pobj) of_21\IN\entity.n.01|administration (r_prep) onset_20\NN\start.n.01|the|of (r_pobj) after_18\IN\after.s.01|months|onset (r_prep) developed_8\VBD\create.v.02|who|hepatitis|with|after (l_prep) with_11\IN\entity.n.01|necrosis (l_pobj) necrosis_14\NN\death.n.02|extensive|hepatocellular|,
C013295_D056486 NONE thienodiazepine_27\NN\entity.n.01| (r_amod) derivative_28\NN\calculation.n.02|a|thienodiazepine (r_appos) patient_6\NN\case.n.06|a|developed|,|derivative (l_relcl) developed_8\VBD\create.v.02|who|hepatitis|with|after (l_dobj) hepatitis_10\NN\infectious_disease.n.01|acute
C013295_D047508 NONE thienodiazepine_27\NN\entity.n.01| (r_amod) derivative_28\NN\calculation.n.02|a|thienodiazepine (r_appos) patient_6\NN\case.n.06|a|developed|,|derivative (l_relcl) developed_8\VBD\create.v.02|who|hepatitis|with|after (l_prep) with_11\IN\entity.n.01|necrosis (l_pobj) necrosis_14\NN\death.n.02|extensive|hepatocellular|,
D001569_D056486 NONE benzodiazepines_4\NNS\minor_tranquilizer.n.01|several (r_pobj) of_2\IN\entity.n.01|benzodiazepines (r_prep) administration_1\NN\management.n.01|the|of|,|related (r_nsubj) interfere_13\VB\impede.v.01|administration|,|did|not|with|and|induce|. (l_conj) induce_19\VB\generate.v.01|did|not|relapse (l_dobj) relapse_21\NN\failure.n.01|any|of (l_prep) of_22\IN\entity.n.01|hepatitis (l_pobj) hepatitis_23\NN\infectious_disease.n.01|
D001569_D056486 NONE benzodiazepines_21\NNS\minor_tranquilizer.n.01|several (r_conj) clotiazepam_18\NN\entity.n.01|and|benzodiazepines (r_pobj) between_17\IN\between.r.01|clotiazepam (r_prep) hepatotoxicity_16\NN\entity.n.01|cross|between (r_attr) is_13\VBZ\be.v.01|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\declare.v.01|is (r_conj) induce_6\VB\generate.v.01|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\infectious_disease.n.01|acute
D001569_D056486 NONE benzodiazepines_21\NNS\minor_tranquilizer.n.01|several (r_conj) clotiazepam_18\NN\entity.n.01|and|benzodiazepines (r_pobj) between_17\IN\between.r.01|clotiazepam (r_prep) hepatotoxicity_16\NN\entity.n.01|cross|between
6229975
D013999_D009203 NONE timolol_8\NN\beta_blocker.n.01| (r_compound) treatment_9\NN\care.n.01|term|timolol|after (l_prep) after_10\IN\after.s.01|infarction (l_pobj) infarction_12\NN\pathology.n.02|myocardial
D013999_D009203 NONE timolol_6\NN\beta_blocker.n.01| (r_compound) treatment_7\NN\care.n.01|term|timolol|on (r_pobj) of_2\IN\entity.n.01|treatment (r_prep) effect_1\NN\phenomenon.n.01|the|of|after (l_prep) after_11\IN\after.s.01|infarction (l_pobj) infarction_13\NN\pathology.n.02|myocardial
D013999_D009203 NONE timolol_33\NN\beta_blocker.n.01|115|) (r_conj) evaluated_15\VBN\evaluate.v.02|effect|was|by|in|timolol|. (l_nsubjpass) effect_1\NN\phenomenon.n.01|the|of|after (l_prep) after_11\IN\after.s.01|infarction (l_pobj) infarction_13\NN\pathology.n.02|myocardial
D013999_D001919 NONE timolol_6\NN\beta_blocker.n.01| (r_npadvmod) induced_8\VBN\generate.v.01|timolol|- (r_amod) bradycardia_9\NN\cardiac_arrhythmia.n.01|induced|and|increase
D013999_D007238 NONE timolol_17\NN\beta_blocker.n.01| (r_compound) group_18\NN\abstraction.n.06|the|timolol (r_pobj) in_15\IN\linear_unit.n.01|group (r_prep) remained_13\VBD\be.v.01|unchanged|in (r_conj) increased_7\VBD\change_magnitude.v.01|after|,|size|in|and|remained|. (l_punct) ,_4\,\entity.n.01|infarction (l_punct) infarction_3\NN\pathology.n.02|-
891050
D003276_D006463 CID contraceptives_17\NNS\device.n.01|oral (r_dobj) taking_15\VBG\action.n.01|contraceptives (r_acl) woman_14\NN\adult.n.01|a|taking (r_pobj) in_12\IN\linear_unit.n.01|woman (r_prep) syndrome_8\NN\complex.n.01|the|hemolytic|uremic|(|hus|)|in
D003276_D006463 CID contraceptives_17\NNS\device.n.01|oral (r_dobj) taking_15\VBG\action.n.01|contraceptives (r_acl) woman_14\NN\adult.n.01|a|taking (r_pobj) in_12\IN\linear_unit.n.01|woman (r_prep) syndrome_8\NN\complex.n.01|the|hemolytic|uremic|(|hus|)|in (l_appos) hus_10\NNP\huss.n.01|
D006493_D001002 NONE heparin_4\JJ\anticoagulant.n.01|,|dipyridamole (r_pobj) with_3\IN\entity.n.01|heparin (r_prep) treated_2\VBN\interact.v.01|she|was|with|;|and|rose (l_conj) rose_20\VBD\shrub.n.01|after|,|output|above|;|and|stopped|. (l_conj) stopped_37\VBN\stop.v.01|after|,|treatment|was (l_prep) after_28\IN\after.s.01|months|onset (l_pobj) onset_30\NN\start.n.01|the|of (l_prep) of_31\IN\entity.n.01|anuria (l_pobj) anuria_32\NN\illness.n.01|
D004176_D001002 NONE dipyridamole_6\NN\entity.n.01|and|hemodialysis (r_conj) heparin_4\JJ\anticoagulant.n.01|,|dipyridamole (r_pobj) with_3\IN\entity.n.01|heparin (r_prep) treated_2\VBN\interact.v.01|she|was|with|;|and|rose (l_conj) rose_20\VBD\shrub.n.01|after|,|output|above|;|and|stopped|. (l_conj) stopped_37\VBN\stop.v.01|after|,|treatment|was (l_prep) after_28\IN\after.s.01|months|onset (l_pobj) onset_30\NN\start.n.01|the|of (l_prep) of_31\IN\entity.n.01|anuria (l_pobj) anuria_32\NN\illness.n.01|
2894766
D012460_D008180 CID sulfasalazine_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|sulfasalazine|- (r_amod) erythematosus_4\NN\entity.n.01|induced|lupus|.
D012460_D008180 CID sulfasalazine_7\RB\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|sulfasalazine|- (r_amod) lupus_10\NN\skin_disease.n.01|induced|,|manifested
D012460_D008180 CID sulfasalazine_3\NN\entity.n.01| (r_dobj) use_2\VBP\activity.n.01|who|sulfasalazine|treat (r_relcl) physicians_0\NNS\medical_practitioner.n.01|use (r_nsubj) be_12\VB\metallic_element.n.01|physicians|should|aware|. (l_acomp) aware_13\JJ\aware.a.01|of (l_prep) of_14\IN\entity.n.01|signs (l_pobj) signs_16\NNS\clue.n.02|the|of (l_prep) of_17\IN\entity.n.01|syndrome (l_pobj) syndrome_22\NN\complex.n.01|induced|lupus
D012460_D008180 CID sulfasalazine_18\NN\entity.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|sulfasalazine|- (r_amod) syndrome_22\NN\complex.n.01|induced|lupus
D012460_D011014 CID sulfasalazine_29\NN\entity.n.01| (r_compound) therapy_30\NN\medical_care.n.01|term|sulfasalazine (r_dobj) receiving_25\VBG\get.v.01|who|was|therapy|for (r_relcl) man_21\NN\adult.n.01|a|old|,|receiving (r_pobj) in_16\IN\linear_unit.n.01|man (r_prep) developed_15\VBN\create.v.02|in (r_acl) autoantibodies_14\NNS\antibody.n.01|positive|developed (r_conj) evidence_7\NN\information.n.02|echocardiographic|of|,|and|autoantibodies (r_appos) effusions_4\NNS\expression.n.02|pneumonitis|,|bilateral|pleural|,|evidence|. (l_dep) pneumonitis_0\NNP\inflammation.n.01|
D012460_D010996 CID sulfasalazine_29\NN\entity.n.01| (r_compound) therapy_30\NN\medical_care.n.01|term|sulfasalazine (r_dobj) receiving_25\VBG\get.v.01|who|was|therapy|for (r_relcl) man_21\NN\adult.n.01|a|old|,|receiving (r_pobj) in_16\IN\linear_unit.n.01|man (r_prep) developed_15\VBN\create.v.02|in (r_acl) autoantibodies_14\NNS\antibody.n.01|positive|developed (r_conj) evidence_7\NN\information.n.02|echocardiographic|of|,|and|autoantibodies (r_appos) effusions_4\NNS\expression.n.02|pneumonitis|,|bilateral|pleural|,|evidence|.
D012460_D002305 CID sulfasalazine_29\NN\entity.n.01| (r_compound) therapy_30\NN\medical_care.n.01|term|sulfasalazine (r_dobj) receiving_25\VBG\get.v.01|who|was|therapy|for (r_relcl) man_21\NN\adult.n.01|a|old|,|receiving (r_pobj) in_16\IN\linear_unit.n.01|man (r_prep) developed_15\VBN\create.v.02|in (r_acl) autoantibodies_14\NNS\antibody.n.01|positive|developed (r_conj) evidence_7\NN\information.n.02|echocardiographic|of|,|and|autoantibodies (l_prep) of_8\IN\entity.n.01|tamponade (l_pobj) tamponade_10\NN\obstruction.n.02|cardiac
D012460_D003093 NONE sulfasalazine_29\NN\entity.n.01| (r_compound) therapy_30\NN\medical_care.n.01|term|sulfasalazine (r_dobj) receiving_25\VBG\get.v.01|who|was|therapy|for (l_prep) for_31\IN\entity.n.01|colitis (l_pobj) colitis_34\NN\inflammation.n.01|chronic|ulcerative
D012460_D012700 NONE sulfasalazine_7\RB\entity.n.01| (r_npadvmod) induced_9\VBN\generate.v.01|sulfasalazine|- (r_amod) lupus_10\NN\skin_disease.n.01|induced|,|manifested (l_relcl) manifested_13\VBD\testify.v.02|which|with|in (l_prep) with_14\IN\entity.n.01|serositis (l_pobj) serositis_15\NN\entity.n.01|and|involvement
D012460_D015212 NONE sulfasalazine_3\NN\entity.n.01| (r_dobj) use_2\VBP\activity.n.01|who|sulfasalazine|treat (l_xcomp) treat_5\VB\nutriment.n.01|to|patients (l_dobj) patients_6\NNS\case.n.06|with (l_prep) with_7\IN\entity.n.01|disease (l_pobj) disease_10\NN\illness.n.01|inflammatory|bowel
D012460_D015212 NONE sulfasalazine_18\NN\entity.n.01| (r_npadvmod) induced_20\VBN\generate.v.01|sulfasalazine|- (r_amod) syndrome_22\NN\complex.n.01|induced|lupus (r_pobj) of_17\IN\entity.n.01|syndrome (r_prep) signs_16\NNS\clue.n.02|the|of (r_pobj) of_14\IN\entity.n.01|signs (r_prep) aware_13\JJ\aware.a.01|of (r_acomp) be_12\VB\metallic_element.n.01|physicians|should|aware|. (l_nsubj) physicians_0\NNS\medical_practitioner.n.01|use (l_relcl) use_2\VBP\activity.n.01|who|sulfasalazine|treat (l_xcomp) treat_5\VB\nutriment.n.01|to|patients (l_dobj) patients_6\NNS\case.n.06|with (l_prep) with_7\IN\entity.n.01|disease (l_pobj) disease_10\NN\illness.n.01|inflammatory|bowel
6727060
D008787_D004409 CID metoclopramide_7\NN\entity.n.01| (r_pobj) by_6\IN\by.r.01|metoclopramide (r_agent) caused_5\VBN\make.v.03|by (r_acl) dyskinesia_4\JJ\nervous_disorder.n.01|tardive|caused
D008787_D004409 CID metoclopramide_23\RB\entity.n.01| (r_dobj) took_22\VBD\act.v.01|after|he|metoclopramide|for|in (r_advcl) appeared_3\VBD\be.v.01|movements|in|took|. (l_nsubj) movements_2\NNS\change.n.03|abnormal|involuntary
D008787_D004409 CID metoclopramide_2\JJ\entity.n.01| (r_compound) administration_3\NN\management.n.01|the|metoclopramide (r_nsubjpass) discontinued_5\VBN\discontinue.v.01|when|administration|was (r_advcl) improved_11\VBD\change.v.01|discontinued|,|movements|gradually|to|. (l_nsubj) movements_9\NNS\change.n.03|the|abnormal
D008787_D005767 NONE metoclopramide_23\RB\entity.n.01| (r_dobj) took_22\VBD\act.v.01|after|he|metoclopramide|for|in (l_prep) for_24\IN\entity.n.01|disorder (l_pobj) disorder_26\NN\physical_condition.n.01|gastrointestinal
2696505
D007741_D007022 CID labetalol_4\NN\antihypertensive.n.01|and|nitroprusside (l_conj) nitroprusside_6\RB\entity.n.01|for (l_prep) for_7\IN\entity.n.01|hypotension (l_pobj) hypotension_9\NN\cardiovascular_disease.n.01|induced
D007741_D007022 CID labetalol_5\RB\antihypertensive.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|labetalol|- (r_amod) hypotension_8\NN\cardiovascular_disease.n.01|induced|and|hypotension
D007741_D007022 CID labetalol_5\RB\antihypertensive.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|labetalol|- (r_amod) hypotension_8\NN\cardiovascular_disease.n.01|induced|and|hypotension (l_conj) hypotension_13\NN\cardiovascular_disease.n.01|induced
D009599_D007022 CID nitroprusside_6\RB\entity.n.01|for (l_prep) for_7\IN\entity.n.01|hypotension (l_pobj) hypotension_9\NN\cardiovascular_disease.n.01|induced
D009599_D007022 CID nitroprusside_10\RB\entity.n.01| (r_advmod) induced_12\VBN\generate.v.01|nitroprusside|- (r_amod) hypotension_13\NN\cardiovascular_disease.n.01|induced (r_conj) hypotension_8\NN\cardiovascular_disease.n.01|induced|and|hypotension
D009599_D007022 CID nitroprusside_10\RB\entity.n.01| (r_advmod) induced_12\VBN\generate.v.01|nitroprusside|- (r_amod) hypotension_13\NN\cardiovascular_disease.n.01|induced
D009599_D016534 CID nitroprusside_31\NN\entity.n.01| (r_pobj) of_30\IN\entity.n.01|nitroprusside (r_prep) discontinuation_29\NN\termination.n.05|of (r_pobj) after_28\IN\after.s.01|discontinuation (r_prep) observed_24\VBN\spy.v.03|associated|;|hypertension|was|in|after|. (l_ccomp) associated_3\VBN\think.v.03|infusion|was|with|increase (l_advcl) increase_13\NN\indefinite_quantity.n.01|in (l_prep) in_14\IN\linear_unit.n.01|rate (l_pobj) rate_16\NN\magnitude_relation.n.01|heart|and|output (l_conj) output_19\NN\product.n.02|cardiac
D009599_D006973 NONE nitroprusside_31\NN\entity.n.01| (r_pobj) of_30\IN\entity.n.01|nitroprusside (r_prep) discontinuation_29\NN\termination.n.05|of (r_pobj) after_28\IN\after.s.01|discontinuation (r_prep) observed_24\VBN\spy.v.03|associated|;|hypertension|was|in|after|. (l_nsubjpass) hypertension_22\NN\cardiovascular_disease.n.01|rebound
17562951
D007479_D051436 NONE iopamidol_14\NN\entity.n.01|and|iodixanol (r_pobj) of_13\IN\entity.n.01|iopamidol (r_prep) comparison_12\NN\examination.n.01|a|multicenter|,|randomized|,|blind|of|in (l_prep) in_17\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|with (l_prep) with_19\IN\entity.n.01|disease (l_pobj) disease_22\NN\illness.n.01|chronic|kidney
C044834_D051436 NONE iodixanol_16\NN\entity.n.01| (r_conj) iopamidol_14\NN\entity.n.01|and|iodixanol (r_pobj) of_13\IN\entity.n.01|iopamidol (r_prep) comparison_12\NN\examination.n.01|a|multicenter|,|randomized|,|blind|of|in (l_prep) in_17\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|with (l_prep) with_19\IN\entity.n.01|disease (l_pobj) disease_22\NN\illness.n.01|chronic|kidney
D000111_D003920 NONE acetylcysteine_16\NN\entity.n.01|n|- (r_pobj) of_13\IN\entity.n.01|acetylcysteine (r_prep) use_12\NN\activity.n.01|of (r_appos) volume_5\NN\measure.n.02|contrast|,|presence|,|use (l_appos) presence_7\NN\being.n.01|of (l_prep) of_8\IN\entity.n.01|mellitus (l_pobj) mellitus_10\NN\entity.n.01|diabetes
D007479_D003920 NONE iopamidol_24\NN\entity.n.01|and|%|(|patients|) (r_pobj) with_23\IN\entity.n.01|iopamidol|with (r_prep) were_14\VBD\be.v.01|dl|%|with|,|increases (r_conj) increases_6\VBZ\indefinite_quantity.n.01|in|,|scr|>|were|. (l_prep) in_0\IN\linear_unit.n.01|patients (l_pobj) patients_1\NNS\case.n.06|with (l_prep) with_2\IN\entity.n.01|diabetes (l_pobj) diabetes_3\NNS\polygenic_disorder.n.01|
D007479_D003920 NONE iopamidol_23\NN\entity.n.01|or|iodixanol (r_pobj) of_22\IN\entity.n.01|iopamidol (r_prep) administration_21\NN\management.n.01|the|intraarterial|of|to|, (r_pobj) after_18\IN\after.s.01|administration (r_prep) is_14\VBZ\be.v.01|rate|not|different|after|with|. (l_prep) with_32\IN\entity.n.01|or|without (l_conj) without_34\IN\entity.n.01|mellitus (l_pobj) mellitus_36\NN\entity.n.01|diabetes
C044834_D003920 NONE iodixanol_35\NN\entity.n.01|(|p=0.11|) (r_pobj) with_34\IN\entity.n.01|iodixanol (r_prep) with_23\IN\entity.n.01|iopamidol|with (r_prep) were_14\VBD\be.v.01|dl|%|with|,|increases (r_conj) increases_6\VBZ\indefinite_quantity.n.01|in|,|scr|>|were|. (l_prep) in_0\IN\linear_unit.n.01|patients (l_pobj) patients_1\NNS\case.n.06|with (l_prep) with_2\IN\entity.n.01|diabetes (l_pobj) diabetes_3\NNS\polygenic_disorder.n.01|
C044834_D003920 NONE iodixanol_25\NN\entity.n.01| (r_conj) iopamidol_23\NN\entity.n.01|or|iodixanol (r_pobj) of_22\IN\entity.n.01|iopamidol (r_prep) administration_21\NN\management.n.01|the|intraarterial|of|to|, (r_pobj) after_18\IN\after.s.01|administration (r_prep) is_14\VBZ\be.v.01|rate|not|different|after|with|. (l_prep) with_32\IN\entity.n.01|or|without (l_conj) without_34\IN\entity.n.01|mellitus (l_pobj) mellitus_36\NN\entity.n.01|diabetes
D007479_D007674 CID iopamidol_23\NN\entity.n.01|or|iodixanol (r_pobj) of_22\IN\entity.n.01|iopamidol (r_prep) administration_21\NN\management.n.01|the|intraarterial|of|to|, (r_pobj) after_18\IN\after.s.01|administration (r_prep) is_14\VBZ\be.v.01|rate|not|different|after|with|. (l_nsubj) rate_1\NN\magnitude_relation.n.01|the|of|,|defined|, (l_prep) of_2\IN\entity.n.01|nephropathy (l_pobj) nephropathy_6\NN\uropathy.n.01|induced
C044834_D007674 CID iodixanol_25\NN\entity.n.01| (r_conj) iopamidol_23\NN\entity.n.01|or|iodixanol (r_pobj) of_22\IN\entity.n.01|iopamidol (r_prep) administration_21\NN\management.n.01|the|intraarterial|of|to|, (r_pobj) after_18\IN\after.s.01|administration (r_prep) is_14\VBZ\be.v.01|rate|not|different|after|with|. (l_nsubj) rate_1\NN\magnitude_relation.n.01|the|of|,|defined|, (l_prep) of_2\IN\entity.n.01|nephropathy (l_pobj) nephropathy_6\NN\uropathy.n.01|induced
1749407
D003042_D009203 CID cocaine_0\NN\hard_drug.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|cocaine|- (r_amod) infarction_4\NN\pathology.n.02|induced|myocardial|:|observations|.
D003042_D009203 CID cocaine_13\NN\hard_drug.n.01| (r_nsubj) result_15\VB\phenomenon.n.01|by|cocaine|may|in (l_prep) in_16\IN\linear_unit.n.01|infarction (l_pobj) infarction_19\NN\pathology.n.02|acute|myocardial
D003042_D009203 CID cocaine_26\NN\hard_drug.n.01| (r_npadvmod) induced_28\VBN\generate.v.01|cocaine|- (r_amod) increase_29\NN\indefinite_quantity.n.01|induced|in (r_pobj) with_25\IN\entity.n.01|increase (r_prep) associated_24\VBN\think.v.03|with (r_acl) demand_23\NN\request.n.01|myocardial|oxygen|associated (r_pobj) in_20\IN\linear_unit.n.01|demand (r_prep) increase_19\NN\indefinite_quantity.n.01|an|in (r_pobj) from_17\IN\entity.n.01|increase (r_prep) result_16\VB\phenomenon.n.01|in|,|infarction|may|from|. (l_nsubj) infarction_14\NN\pathology.n.02|acute|myocardial
D010100_D009203 NONE oxygen_22\NN\chemical_element.n.01| (r_compound) demand_23\NN\request.n.01|myocardial|oxygen|associated (r_pobj) in_20\IN\linear_unit.n.01|demand (r_prep) increase_19\NN\indefinite_quantity.n.01|an|in (r_pobj) from_17\IN\entity.n.01|increase (r_prep) result_16\VB\phenomenon.n.01|in|,|infarction|may|from|. (l_nsubj) infarction_14\NN\pathology.n.02|acute|myocardial
D003042_D013035 NONE cocaine_16\NN\hard_drug.n.01| (r_npadvmod) induced_18\VBN\generate.v.01|cocaine|- (r_amod) vasoconstriction_19\NN\constriction.n.04|induced (r_pobj) of_15\IN\entity.n.01|vasoconstriction (r_prep) locus_14\NN\scene.n.01|the|of (r_nsubj) remains_20\VBZ\object.n.01|locus|speculative|. (r_conj) are_8\VBP\area_unit.n.01|with|,|findings|circumstantial|,|and|remains (l_prep) with_0\IN\entity.n.01|regard (l_pobj) regard_1\NN\detail.n.01|to (l_prep) to_2\IN\entity.n.01|spasm (l_pobj) spasm_3\NN\symptom.n.01|
D003042_D013927 NONE cocaine_11\NN\hard_drug.n.01| (r_pobj) of_10\IN\entity.n.01|cocaine (r_prep) effect_9\NN\phenomenon.n.01|a|primary|,|thrombotic|of (l_amod) thrombotic_8\JJ\entity.n.01|
8595686
D013874_D010146 NONE thiopentone_0\NN\entity.n.01| (r_compound) pretreatment_1\NN\entity.n.01|thiopentone|for|. (l_prep) for_2\IN\entity.n.01|pain (l_pobj) pain_5\NN\symptom.n.01|propofol|injection|in
D013874_D010146 NONE thiopentone_17\NN\entity.n.01| (r_nsubj) reduces_19\VBZ\decrease.v.02|whereas|thiopentone|only|severity (r_advcl) reduces_4\VBZ\decrease.v.02|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\frequency.n.02|the|and|severity|of (l_prep) of_9\IN\entity.n.01|pain (l_pobj) pain_12\NN\symptom.n.01|propofol|injection|in
D015742_D010146 CID propofol_3\JJ\entity.n.01| (r_amod) pain_5\NN\symptom.n.01|propofol|injection|in
D015742_D010146 CID propofol_3\JJ\entity.n.01| (r_amod) pain_5\NN\symptom.n.01|propofol|injection|in
D015742_D010146 CID propofol_10\JJ\entity.n.01| (r_amod) pain_12\NN\symptom.n.01|propofol|injection|in
D008012_D010146 NONE lidocaine_3\NN\local_anesthetic.n.01| (r_nsubj) reduces_4\VBZ\decrease.v.02|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\frequency.n.02|the|and|severity|of (l_prep) of_9\IN\entity.n.01|pain (l_pobj) pain_12\NN\symptom.n.01|propofol|injection|in
12198388
D000109_D012640 NONE acetylcholine_4\NN\neurotransmitter.n.01| (r_compound) release_5\NN\merchandise.n.01|hippocampal|acetylcholine|and|sensitivity (l_conj) sensitivity_9\NN\sense.n.03|cholinergic|convulsant|in (l_prep) in_10\IN\linear_unit.n.01|lines (l_pobj) lines_22\NNS\formation.n.01|withdrawal|prone|resistant|selected|mouse (l_amod) prone_14\JJ\prone.s.01|seizure|-|and|withdrawal (l_npadvmod) seizure_12\NN\attack.n.07|
D000109_D012640 NONE acetylcholine_4\NN\neurotransmitter.n.01| (r_compound) release_5\NN\merchandise.n.01|hippocampal|acetylcholine|and|sensitivity (l_conj) sensitivity_9\NN\sense.n.03|cholinergic|convulsant|in (l_prep) in_10\IN\linear_unit.n.01|lines (l_pobj) lines_22\NNS\formation.n.01|withdrawal|prone|resistant|selected|mouse (l_amod) resistant_19\JJ\immune.s.03|seizure|- (l_npadvmod) seizure_17\NN\attack.n.07|
D000109_D012640 NONE ach_1\NNS\entity.n.01|hippocampal (r_nsubjpass) measured_4\VBN\decide.v.01|ach|also|was|during|. (l_prep) during_5\IN\entity.n.01|testing (l_pobj) testing_6\VBG\experiment.n.01|for (l_prep) for_7\IN\entity.n.01|convulsions (l_pobj) convulsions_11\NNS\attack.n.07|induced
D000109_D012640 NONE ach_2\NNS\entity.n.01|hippocampal (r_nsubjpass) measured_4\VBN\decide.v.01|when|ach|was|during (l_prep) during_5\IN\entity.n.01|testing (l_pobj) testing_6\VBG\experiment.n.01|for (l_prep) for_7\IN\entity.n.01|convulsions (l_pobj) convulsions_11\NNS\attack.n.07|induced
D000109_D012640 NONE ach_14\NNS\entity.n.01|extracellular (r_nsubjpass) elevated_17\JJ\railway.n.01|measured|,|ach|was|significantly|%|in|,|but|elevated|. (l_advcl) measured_4\VBN\decide.v.01|when|ach|was|during (l_prep) during_5\IN\entity.n.01|testing (l_pobj) testing_6\VBG\experiment.n.01|for (l_prep) for_7\IN\entity.n.01|convulsions (l_pobj) convulsions_11\NNS\attack.n.07|induced
D000431_D012640 NONE alcohol_6\NN\beverage.n.01| (r_compound) na_8\TO\metallic_element.n.01|alcohol|- (r_aux) ve_9\VB\entity.n.01|na|mice (l_dobj) mice_23\NNS\rodent.n.01|prone|(|wsr|) (l_nmod) prone_13\NNP\prone.s.01|withdrawal|seizure|-|(|wsp|and|resistant (l_compound) seizure_11\NN\attack.n.07|
D000431_D012640 NONE ethanol_18\NN\alcohol.n.02| (r_compound) withdrawal_19\NN\retraction.n.01|ethanol (r_compound) severity_20\NN\intensity.n.02|withdrawal (r_pobj) with_17\IN\entity.n.01|severity (r_prep) associated_16\VBN\think.v.03|that|differences|may|be|with|and|implicate (l_nsubjpass) differences_4\NNS\quality.n.01|in (l_prep) in_5\IN\linear_unit.n.01|activity (l_pobj) activity_7\NN\act.n.02|cholinergic|and|sensitivity (l_conj) sensitivity_10\NN\sense.n.03|postsynaptic|to (l_prep) to_11\IN\entity.n.01|convulsants (l_pobj) convulsants_13\NNS\entity.n.01|cholinergic
D000431_D012640 NONE alcohol_26\NN\beverage.n.01| (r_compound) withdrawal_27\NN\retraction.n.01|alcohol (r_pobj) in_25\IN\linear_unit.n.01|withdrawal (r_prep) mechanisms_24\NNS\chemical_process.n.01|cholinergic|in (r_dobj) implicate_22\VB\involve.v.01|mechanisms (r_conj) associated_16\VBN\think.v.03|that|differences|may|be|with|and|implicate (l_nsubjpass) differences_4\NNS\quality.n.01|in (l_prep) in_5\IN\linear_unit.n.01|activity (l_pobj) activity_7\NN\act.n.02|cholinergic|and|sensitivity (l_conj) sensitivity_10\NN\sense.n.03|postsynaptic|to (l_prep) to_11\IN\entity.n.01|convulsants (l_pobj) convulsants_13\NNS\entity.n.01|cholinergic
D009538_D014202 NONE nicotine_3\NN\alkaloid.n.01|,|carbachol (r_dobj) administered_2\VBN\manage.v.02|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN\save.v.02|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\time_interval.n.01|the|onset (l_relcl) onset_19\VB\start.n.01|to|of (l_prep) of_20\IN\entity.n.01|tremor (l_pobj) tremor_21\NN\vibration.n.01|and|clonus
D002217_D014202 NONE carbachol_5\NN\entity.n.01|,|or|neostigmine (r_conj) nicotine_3\NN\alkaloid.n.01|,|carbachol (r_dobj) administered_2\VBN\manage.v.02|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN\save.v.02|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\time_interval.n.01|the|onset (l_relcl) onset_19\VB\start.n.01|to|of (l_prep) of_20\IN\entity.n.01|tremor (l_pobj) tremor_21\NN\vibration.n.01|and|clonus
D009388_D014202 NONE neostigmine_8\JJ\anticholinesterase.n.01|via (r_conj) carbachol_5\NN\entity.n.01|,|or|neostigmine (r_conj) nicotine_3\NN\alkaloid.n.01|,|carbachol (r_dobj) administered_2\VBN\manage.v.02|animals|were|nicotine|,|and|recorded (l_conj) recorded_25\VBN\save.v.02|latencies|were|and|converted|. (l_nsubjpass) latencies_17\NNS\time_interval.n.01|the|onset (l_relcl) onset_19\VB\start.n.01|to|of (l_prep) of_20\IN\entity.n.01|tremor (l_pobj) tremor_21\NN\vibration.n.01|and|clonus
D009538_D012640 CID nicotine_7\NN\alkaloid.n.01|,|carbachol (r_pobj) by_6\IN\by.r.01|nicotine (r_agent) induced_5\VBN\generate.v.01|by (r_acl) endpoints_4\NNS\end.n.01|several|convulsion|induced (l_compound) convulsion_3\NN\attack.n.07|
D002217_D012640 CID carbachol_9\NN\entity.n.01| (r_conj) nicotine_7\NN\alkaloid.n.01|,|carbachol (r_pobj) by_6\IN\by.r.01|nicotine (r_agent) induced_5\VBN\generate.v.01|by (r_acl) endpoints_4\NNS\end.n.01|several|convulsion|induced (l_compound) convulsion_3\NN\attack.n.07|
D009388_D012640 CID neostigmine_12\NN\anticholinesterase.n.01| (r_conj) sensitivity_0\NN\sense.n.03|to|,|and|neostigmine (l_prep) to_1\IN\entity.n.01|endpoints (l_pobj) endpoints_4\NNS\end.n.01|several|convulsion|induced (l_compound) convulsion_3\NN\attack.n.07|
18791946
D002939_D013921 CID ciprofloxacin_7\NNS\antibiotic.n.01| (r_pobj) with_6\IN\entity.n.01|ciprofloxacin (r_prep) associated_5\VBN\think.v.03|with (r_acl) thrombocytopenia_1\JJ\blood_disease.n.01|severe|and|anaemia|associated
D002939_D013921 CID ciprofloxacin_5\NNS\antibiotic.n.01| (r_nsubj) precipitate_7\VB\solid.n.01|that|ciprofloxacin|may|thrombocytopenia|,|in (l_dobj) thrombocytopenia_11\JJ\blood_disease.n.01|threatening|and|anaemia
D002939_D000743 CID ciprofloxacin_7\NNS\antibiotic.n.01| (r_pobj) with_6\IN\entity.n.01|ciprofloxacin (r_prep) associated_5\VBN\think.v.03|with (r_acl) thrombocytopenia_1\JJ\blood_disease.n.01|severe|and|anaemia|associated (l_conj) anaemia_4\NN\symptom.n.01|haemolytic
D002939_D000743 CID ciprofloxacin_5\NNS\antibiotic.n.01| (r_nsubj) precipitate_7\VB\solid.n.01|that|ciprofloxacin|may|thrombocytopenia|,|in (l_dobj) thrombocytopenia_11\JJ\blood_disease.n.01|threatening|and|anaemia (l_conj) anaemia_14\NN\symptom.n.01|haemolytic
D002939_D015746 CID ciprofloxacin_16\NNS\antibiotic.n.01|oral (r_pobj) of_14\IN\entity.n.01|ciprofloxacin (r_prep) administration_13\NN\management.n.01|3-day|of|for (r_pobj) after_11\IN\after.s.01|administration (r_prep) reported_5\VBN\inform.v.01|man|with|after|. (l_prep) with_6\IN\entity.n.01|pain (l_pobj) pain_8\NN\symptom.n.01|abdominal|and|jaundice
D002939_D007565 CID ciprofloxacin_16\NNS\antibiotic.n.01|oral (r_pobj) of_14\IN\entity.n.01|ciprofloxacin (r_prep) administration_13\NN\management.n.01|3-day|of|for (r_pobj) after_11\IN\after.s.01|administration (r_prep) reported_5\VBN\inform.v.01|man|with|after|. (l_prep) with_6\IN\entity.n.01|pain (l_pobj) pain_8\NN\symptom.n.01|abdominal|and|jaundice (l_conj) jaundice_10\NN\symptom.n.01|
D002939_D014552 NONE ciprofloxacin_16\NNS\antibiotic.n.01|oral (r_pobj) of_14\IN\entity.n.01|ciprofloxacin (r_prep) administration_13\NN\management.n.01|3-day|of|for (l_prep) for_17\IN\entity.n.01|suspect (l_pobj) suspect_19\NN\person.n.01|a|of (l_prep) of_20\IN\entity.n.01|infection (l_pobj) infection_23\NN\ill_health.n.01|urinary|tract
7890216
D015282_D042882 CID octreotide_7\NN\entity.n.01| (r_pobj) with_6\IN\entity.n.01|octreotide (r_prep) associated_5\VBN\think.v.03|with (r_acl) stones_4\NNS\natural_object.n.01|gall|bladder|associated
D015282_D042882 CID octreotide_0\NNP\entity.n.01|,|treatment (r_nsubj) induces_8\VBZ\generate.v.01|octreotide|,|stones|in|. (l_dobj) stones_11\NNS\natural_object.n.01|gall|bladder
D015282_D042882 CID octreotide_28\NN\entity.n.01|14 (r_pobj) in_26\IN\linear_unit.n.01|octreotide (r_prep) methods_25\NNS\know-how.n.01|direct|in (r_pobj) by_21\IN\by.r.01|methods (r_agent) investigated_20\VBN\analyze.v.01|is|,|this|was|by|treated|. (l_conj) treated_29\VBD\interact.v.01|patients|with (l_prep) with_32\IN\entity.n.01|stones (l_pobj) stones_34\NNS\natural_object.n.01|gall
D015282_D042882 CID octreotide_3\NN\entity.n.01| (r_advmod) induced_4\VBN\generate.v.01|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS\natural_object.n.01|gall
D015282_D042882 CID octreotide_3\NN\entity.n.01| (r_advmod) induced_4\VBN\generate.v.01|in|,|octreotide|stones|are|have (l_ccomp) are_7\VBP\area_unit.n.01|generally|small|although|,|in|, (l_prep) in_18\IN\linear_unit.n.01|common (l_pobj) common_19\JJ\tract.n.01|with (l_prep) with_20\IN\entity.n.01|disease (l_pobj) disease_24\NN\illness.n.01|spontaneous|gall|stone
D015282_D042882 CID octreotide_3\NN\entity.n.01| (r_advmod) induced_4\VBN\generate.v.01|in|,|octreotide|stones|are|have (l_conj) have_31\VB\person.n.01|at|patients|will|duct|. (l_dobj) duct_35\NN\passage.n.07|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\natural_object.n.01|some|gall|containing
D014580_D042882 NONE acid_13\NN\compound.n.02|ursodeoxycholic (r_pobj) to_10\IN\entity.n.01|acid (r_prep) response_9\NN\consequence.n.01|to (r_appos) composition_0\NN\placement.n.01|of|:|response|. (l_prep) of_1\IN\entity.n.01|stones (l_pobj) stones_4\NNS\natural_object.n.01|gall|bladder|associated
D015282_D000172 NONE octreotide_0\NNP\entity.n.01|,|treatment (l_appos) treatment_4\NN\care.n.01|an|effective|for (l_prep) for_5\IN\entity.n.01|acromegaly (l_pobj) acromegaly_6\NNS\hypertrophy.n.01|
D015282_D000172 NONE octreotide_28\NN\entity.n.01|14 (r_pobj) in_26\IN\linear_unit.n.01|octreotide (r_prep) methods_25\NNS\know-how.n.01|direct|in (r_pobj) by_21\IN\by.r.01|methods (r_agent) investigated_20\VBN\analyze.v.01|is|,|this|was|by|treated|. (l_conj) treated_29\VBD\interact.v.01|patients|with (l_dobj) patients_31\NNS\case.n.06|acromegalic (l_compound) acromegalic_30\JJ\acromegalic.s.01|
D002784_D042882 NONE cholesterol_21\NN\sterol.n.01|%|by (r_conj) %_17\NN\entity.n.01|71|and|cholesterol (r_dobj) contained_15\VBD\include.v.01|that|they|% (r_ccomp) showed_12\VBD\show.v.04|analysis|,|contained|. (l_nsubj) analysis_1\NN\investigation.n.02|chemical|of (l_prep) of_2\IN\entity.n.01|stones (l_pobj) stones_4\NNS\natural_object.n.01|gall|retrieved
D002784_D042882 NONE cholesterol_36\NN\sterol.n.01| (r_nsubj) rich_37\JJ\people.n.01|cholesterol (r_acomp) were_35\VBD\be.v.01|that|stones|rich (r_ccomp) suggesting_31\VBG\declare.v.01|were (r_advcl) showed_12\VBD\show.v.04|after|,|five|dissolution|,|suggesting|. (l_dobj) dissolution_29\NN\natural_process.n.01|either|partial|gall|stone (l_compound) stone_28\NN\natural_object.n.01|
D002784_D042882 NONE cholesterol_14\NN\sterol.n.01| (r_conj) multiple_11\JJ\product.n.03|,|and|cholesterol|rich (r_conj) small_9\JJ\body_part.n.01|,|multiple (r_acomp) are_7\VBP\area_unit.n.01|generally|small|although|,|in|, (r_ccomp) induced_4\VBN\generate.v.01|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS\natural_object.n.01|gall
D002784_D042882 NONE cholesterol_14\NN\sterol.n.01| (r_conj) multiple_11\JJ\product.n.03|,|and|cholesterol|rich (r_conj) small_9\JJ\body_part.n.01|,|multiple (r_acomp) are_7\VBP\area_unit.n.01|generally|small|although|,|in|, (l_prep) in_18\IN\linear_unit.n.01|common (l_pobj) common_19\JJ\tract.n.01|with (l_prep) with_20\IN\entity.n.01|disease (l_pobj) disease_24\NN\illness.n.01|spontaneous|gall|stone
D002784_D042882 NONE cholesterol_14\NN\sterol.n.01| (r_conj) multiple_11\JJ\product.n.03|,|and|cholesterol|rich (r_conj) small_9\JJ\body_part.n.01|,|multiple (r_acomp) are_7\VBP\area_unit.n.01|generally|small|although|,|in|, (r_ccomp) induced_4\VBN\generate.v.01|in|,|octreotide|stones|are|have (l_conj) have_31\VB\person.n.01|at|patients|will|duct|. (l_dobj) duct_35\NN\passage.n.07|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\natural_object.n.01|some|gall|containing
D002118_D042882 NONE calcium_41\NN\metallic_element.n.01| (r_dobj) containing_40\VBG\include.v.01|calcium (r_acl) stones_39\NNS\natural_object.n.01|some|gall|containing (r_conj) duct_35\NN\passage.n.07|a|blocked|cystic|and|stones (r_dobj) have_31\VB\person.n.01|at|patients|will|duct|. (r_conj) induced_4\VBN\generate.v.01|in|,|octreotide|stones|are|have (l_dobj) stones_6\NNS\natural_object.n.01|gall
D002118_D042882 NONE calcium_41\NN\metallic_element.n.01| (r_dobj) containing_40\VBG\include.v.01|calcium (r_acl) stones_39\NNS\natural_object.n.01|some|gall|containing (r_conj) duct_35\NN\passage.n.07|a|blocked|cystic|and|stones (r_dobj) have_31\VB\person.n.01|at|patients|will|duct|. (r_conj) induced_4\VBN\generate.v.01|in|,|octreotide|stones|are|have (l_ccomp) are_7\VBP\area_unit.n.01|generally|small|although|,|in|, (l_prep) in_18\IN\linear_unit.n.01|common (l_pobj) common_19\JJ\tract.n.01|with (l_prep) with_20\IN\entity.n.01|disease (l_pobj) disease_24\NN\illness.n.01|spontaneous|gall|stone
D002118_D042882 NONE calcium_41\NN\metallic_element.n.01| (r_dobj) containing_40\VBG\include.v.01|calcium (r_acl) stones_39\NNS\natural_object.n.01|some|gall|containing
11679859
D011346_D017109 CID prochlorperazine_3\NN\antiemetic.n.01|by (r_pobj) of_2\IN\entity.n.01|prochlorperazine (r_prep) administration_1\NN\management.n.01|intravenous|of (r_nsubj) affect_12\VB\feeling.n.01|administration|does|not|incidence|. (l_dobj) incidence_14\NN\frequency.n.02|the|of (l_prep) of_15\IN\entity.n.01|akathisia (l_pobj) akathisia_16\NN\entity.n.01|:|trial
D011346_D017109 CID prochlorperazine_12\NN\antiemetic.n.01|intravenous|as (r_pobj) of_10\IN\entity.n.01|prochlorperazine (r_prep) administration_9\NN\management.n.01|of (r_pobj) after_8\IN\after.s.01|administration (r_prep) akathisia_7\NN\entity.n.01|after
D011346_D017109 CID prochlorperazine_10\NN\antiemetic.n.01| (r_nsubjpass) administered_12\VBN\manage.v.02|when|prochlorperazine|was|by (r_advcl) reduction_3\NN\change_of_magnitude.n.01|a|%|in|administered (l_prep) in_4\IN\linear_unit.n.01|incidence (l_pobj) incidence_6\NN\frequency.n.02|the|of (l_prep) of_7\IN\entity.n.01|akathisia (l_pobj) akathisia_8\NN\entity.n.01|
D011346_D006261 NONE prochlorperazine_8\NN\antiemetic.n.01|for (l_prep) for_9\IN\entity.n.01|headache (l_pobj) headache_10\NN\negative_stimulus.n.01|,|nausea
D011346_D006261 NONE prochlorperazine_3\NN\antiemetic.n.01| (r_pobj) of_2\IN\entity.n.01|prochlorperazine (r_prep) efficacy_1\NN\effectiveness.n.01|the|of|in (l_prep) in_4\IN\linear_unit.n.01|treatment (l_pobj) treatment_6\NN\care.n.01|the|of (l_prep) of_7\IN\entity.n.01|headache (l_pobj) headache_8\NN\negative_stimulus.n.01|and|nausea
D011346_D009325 NONE prochlorperazine_8\NN\antiemetic.n.01|for (l_prep) for_9\IN\entity.n.01|headache (l_pobj) headache_10\NN\negative_stimulus.n.01|,|nausea (l_conj) nausea_12\NN\symptom.n.01|,|or|vomiting
D011346_D009325 NONE prochlorperazine_3\NN\antiemetic.n.01| (r_pobj) of_2\IN\entity.n.01|prochlorperazine (r_prep) efficacy_1\NN\effectiveness.n.01|the|of|in (l_prep) in_4\IN\linear_unit.n.01|treatment (l_pobj) treatment_6\NN\care.n.01|the|of (l_prep) of_7\IN\entity.n.01|headache (l_pobj) headache_8\NN\negative_stimulus.n.01|and|nausea (l_conj) nausea_10\NN\symptom.n.01|
D011346_D014839 NONE prochlorperazine_8\NN\antiemetic.n.01|for (l_prep) for_9\IN\entity.n.01|headache (l_pobj) headache_10\NN\negative_stimulus.n.01|,|nausea (l_conj) nausea_12\NN\symptom.n.01|,|or|vomiting (l_conj) vomiting_15\NN\expulsion.n.03|
1967484
D013469_D004421 CID sulpiride_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|sulpiride|-|dystonia|. (l_dobj) dystonia_4\NN\entity.n.01|tardive
D013469_D004421 CID sulpiride_17\NN\entity.n.01| (r_compound) therapy_18\NN\medical_care.n.01|sulpiride (r_dobj) starting_16\VBG\turn.n.03|therapy (r_pcomp) after_15\IN\after.s.01|starting (r_prep) developed_8\VBD\create.v.02|who|dystonia|within|after (l_dobj) dystonia_11\NN\entity.n.01|persistent|segmental
D013469_D004421 CID sulpiride_8\NN\entity.n.01| (r_npadvmod) induced_10\VBN\generate.v.01|sulpiride|- (r_amod) dystonia_12\NN\entity.n.01|induced|tardive
D013469_D004409 NONE sulpiride_11\NN\entity.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|thought|,|sulpiride|-|dyskinesia (l_dobj) dyskinesia_15\JJ\nervous_disorder.n.01|tardive|and|parkinsonism
D013469_D010302 NONE sulpiride_11\NN\entity.n.01| (r_npadvmod) induced_13\VBN\generate.v.01|thought|,|sulpiride|-|dyskinesia (l_dobj) dyskinesia_15\JJ\nervous_disorder.n.01|tardive|and|parkinsonism (l_conj) parkinsonism_17\NN\brain_disorder.n.01|
12716030
D006493_D002543 NONE heparin_7\VBN\anticoagulant.n.01| (r_nsubj) enhanced_8\VBD\intensify.v.02|in|,|heparin|volume|. (l_prep) in_0\IN\linear_unit.n.01|induction (l_pobj) induction_2\NN\ceremony.n.01|ich|using (l_compound) ich_1\NNP\entity.n.01|
D006493_D002543 NONE heparin_7\VBN\anticoagulant.n.01| (r_nsubj) enhanced_8\VBD\intensify.v.02|in|,|heparin|volume|. (l_dobj) volume_11\NN\measure.n.02|the|hematoma|3.4-fold|over (l_prep) over_13\IN\part.n.09|that (l_pobj) that_14\DT\entity.n.01|seen (l_acl) seen_15\VBN\perceive.v.01|in (l_prep) in_16\IN\linear_unit.n.01|control (l_pobj) control_17\NN\power.n.01|animals (l_dobj) animals_19\NNS\organism.n.01|ich|and|bleeding (l_compound) ich_18\NNP\entity.n.01|
D006493_D006406 CID heparin_7\VBN\anticoagulant.n.01| (r_nsubj) enhanced_8\VBD\intensify.v.02|in|,|heparin|volume|. (l_dobj) volume_11\NN\measure.n.02|the|hematoma|3.4-fold|over (l_compound) hematoma_10\NN\intumescence.n.01|
D006493_D006470 NONE heparin_7\VBN\anticoagulant.n.01| (r_nsubj) enhanced_8\VBD\intensify.v.02|in|,|heparin|volume|. (l_dobj) volume_11\NN\measure.n.02|the|hematoma|3.4-fold|over (l_prep) over_13\IN\part.n.09|that (l_pobj) that_14\DT\entity.n.01|seen (l_acl) seen_15\VBN\perceive.v.01|in (l_prep) in_16\IN\linear_unit.n.01|control (l_pobj) control_17\NN\power.n.01|animals (l_dobj) animals_19\NNS\organism.n.01|ich|and|bleeding (l_conj) bleeding_22\NN\injury.n.01|the|7.6-fold
10520387
D004809_D007022 NONE ephedrine_11\NN\alkaloid.n.01| (r_pobj) of_10\IN\entity.n.01|ephedrine (r_prep) doses_9\NNS\medicine.n.02|different|of (r_dobj) adding_7\VBG\increase.v.01|doses|propofol (l_xcomp) propofol_13\NN\entity.n.01|to|in (l_prep) in_14\IN\linear_unit.n.01|order (l_pobj) order_15\NN\command.n.01|obtund (l_acl) obtund_17\VB\deaden.v.06|to|response (l_dobj) response_20\NN\consequence.n.01|the|hypotensive (l_amod) hypotensive_19\JJ\patient.n.01|
D004809_D007022 NONE ephedrine_3\NN\alkaloid.n.01| (r_pobj) of_2\IN\entity.n.01|ephedrine (r_prep) addition_1\NN\component.n.03|the|of|propofol (r_nsubj) appears_6\VBZ\be.v.01|addition|be|. (l_xcomp) be_8\VB\metallic_element.n.01|to|method (l_attr) method_11\NN\know-how.n.01|an|effective|of (l_prep) of_12\IN\entity.n.01|obtunding (l_pcomp) obtunding_13\VBG\deaden.v.06|response|propofol (l_dobj) response_16\NN\consequence.n.01|the|hypotensive (l_amod) hypotensive_15\JJ\patient.n.01|
D015742_D007022 CID propofol_13\NN\entity.n.01|to|in (l_prep) in_14\IN\linear_unit.n.01|order (l_pobj) order_15\NN\command.n.01|obtund (l_acl) obtund_17\VB\deaden.v.06|to|response (l_dobj) response_20\NN\consequence.n.01|the|hypotensive (l_amod) hypotensive_19\JJ\patient.n.01|
D015742_D007022 CID propofol_5\NN\entity.n.01|to (r_acl) addition_1\NN\component.n.03|the|of|propofol (r_nsubj) appears_6\VBZ\be.v.01|addition|be|. (l_xcomp) be_8\VB\metallic_element.n.01|to|method (l_attr) method_11\NN\know-how.n.01|an|effective|of (l_prep) of_12\IN\entity.n.01|obtunding (l_pcomp) obtunding_13\VBG\deaden.v.06|response|propofol (l_dobj) response_16\NN\consequence.n.01|the|hypotensive (l_amod) hypotensive_15\JJ\patient.n.01|
D015742_D007022 CID propofol_18\NN\entity.n.01|to|at (r_advcl) obtunding_13\VBG\deaden.v.06|response|propofol (l_dobj) response_16\NN\consequence.n.01|the|hypotensive (l_amod) hypotensive_15\JJ\patient.n.01|
D004809_D013610 CID ephedrine_9\NN\alkaloid.n.01| (r_pobj) of_8\IN\entity.n.01|ephedrine (r_prep) use_7\NN\activity.n.01|the|of|in (r_pobj) with_5\IN\entity.n.01|use (r_prep) associated_4\VBN\think.v.03|with (r_acl) tachycardia_3\NNS\cardiac_arrhythmia.n.01|marked|associated
D004809_D013610 CID ephedrine_24\NN\alkaloid.n.01| (r_nmod) mixtures_28\NNS\substance.n.01|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\entity.n.01|mixtures (r_prep) any_21\DT\any.s.01|of (r_pobj) of_20\IN\entity.n.01|any (r_prep) patients_19\NNS\case.n.06|elderly|of (r_pobj) in_17\IN\linear_unit.n.01|patients (r_prep) use_16\NN\activity.n.01|the|in|studied (r_dobj) recommend_14\VB\propose.v.01|due|,|we|would|not|use|. (l_prep) due_0\IN\right.n.01|to|risk (l_pobj) risk_3\NN\danger.n.03|the|of (l_prep) of_4\IN\entity.n.01|tachycardia (l_pobj) tachycardia_6\NN\cardiac_arrhythmia.n.01|this|inducing
D015742_D013610 CID propofol_13\NN\entity.n.01| (r_pobj) with_12\IN\entity.n.01|propofol (r_prep) combination_11\NN\collection.n.01|with (r_pobj) in_10\IN\linear_unit.n.01|combination (r_prep) use_7\NN\activity.n.01|the|of|in (r_pobj) with_5\IN\entity.n.01|use (r_prep) associated_4\VBN\think.v.03|with (r_acl) tachycardia_3\NNS\cardiac_arrhythmia.n.01|marked|associated
D015742_D013610 CID propofol_26\NN\entity.n.01| (r_nmod) mixtures_28\NNS\substance.n.01|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\entity.n.01|mixtures (r_prep) any_21\DT\any.s.01|of (r_pobj) of_20\IN\entity.n.01|any (r_prep) patients_19\NNS\case.n.06|elderly|of (r_pobj) in_17\IN\linear_unit.n.01|patients (r_prep) use_16\NN\activity.n.01|the|in|studied (r_dobj) recommend_14\VB\propose.v.01|due|,|we|would|not|use|. (l_prep) due_0\IN\right.n.01|to|risk (l_pobj) risk_3\NN\danger.n.03|the|of (l_prep) of_4\IN\entity.n.01|tachycardia (l_pobj) tachycardia_6\NN\cardiac_arrhythmia.n.01|this|inducing
D004809_D017202 NONE ephedrine_24\NN\alkaloid.n.01| (r_nmod) mixtures_28\NNS\substance.n.01|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\entity.n.01|mixtures (r_prep) any_21\DT\any.s.01|of (r_pobj) of_20\IN\entity.n.01|any (r_prep) patients_19\NNS\case.n.06|elderly|of (r_pobj) in_17\IN\linear_unit.n.01|patients (r_prep) use_16\NN\activity.n.01|the|in|studied (r_dobj) recommend_14\VB\propose.v.01|due|,|we|would|not|use|. (l_prep) due_0\IN\right.n.01|to|risk (l_pobj) risk_3\NN\danger.n.03|the|of (l_prep) of_4\IN\entity.n.01|tachycardia (l_pobj) tachycardia_6\NN\cardiac_arrhythmia.n.01|this|inducing (l_acl) inducing_7\VBG\causing.n.01|ischemia (l_dobj) ischemia_9\NN\anemia.n.01|myocardial
D015742_D017202 NONE propofol_26\NN\entity.n.01| (r_nmod) mixtures_28\NNS\substance.n.01|the|ephedrine|/|propofol|/ (r_pobj) of_22\IN\entity.n.01|mixtures (r_prep) any_21\DT\any.s.01|of (r_pobj) of_20\IN\entity.n.01|any (r_prep) patients_19\NNS\case.n.06|elderly|of (r_pobj) in_17\IN\linear_unit.n.01|patients (r_prep) use_16\NN\activity.n.01|the|in|studied (r_dobj) recommend_14\VB\propose.v.01|due|,|we|would|not|use|. (l_prep) due_0\IN\right.n.01|to|risk (l_pobj) risk_3\NN\danger.n.03|the|of (l_prep) of_4\IN\entity.n.01|tachycardia (l_pobj) tachycardia_6\NN\cardiac_arrhythmia.n.01|this|inducing (l_acl) inducing_7\VBG\causing.n.01|ischemia (l_dobj) ischemia_9\NN\anemia.n.01|myocardial
19058010
D010936_D009203 NONE tea_3\NN\beverage.n.01|green|and|e (r_nmod) combination_7\NN\collection.n.01|tea|in (r_pobj) of_1\IN\entity.n.01|combination (r_prep) effect_0\NN\phenomenon.n.01|of (r_nsubj) induced_10\VBN\generate.v.01|effect|infarction|. (l_dobj) infarction_12\NN\pathology.n.02|myocardial|in
D010936_D009203 NONE tea_12\NN\beverage.n.01|green|and|e (r_pobj) of_10\IN\entity.n.01|tea (r_prep) effects_9\NNS\personal_property.n.01|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_xcomp) aimed_4\VBN\position.v.01|study|was|investigate|iso)-induced|. (l_parataxis) iso)-induced_39\VBN\entity.n.01|(|infarction (l_dobj) infarction_41\NN\pathology.n.02|myocardial|in
D010936_D009203 NONE tea_9\NN\beverage.n.01|green|and|e (r_pobj) of_7\IN\entity.n.01|tea (r_prep) effect_6\NN\phenomenon.n.01|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP\tell.v.02|findings|effect|induced|. (l_ccomp) induced_15\VBN\generate.v.01|infarction (l_dobj) infarction_17\NN\pathology.n.02|myocardial|in
D014810_D009203 NONE e_6\NN\antioxidant.n.01|vitamin (r_conj) tea_3\NN\beverage.n.01|green|and|e (r_nmod) combination_7\NN\collection.n.01|tea|in (r_pobj) of_1\IN\entity.n.01|combination (r_prep) effect_0\NN\phenomenon.n.01|of (r_nsubj) induced_10\VBN\generate.v.01|effect|infarction|. (l_dobj) infarction_12\NN\pathology.n.02|myocardial|in
D014810_D009203 NONE e_15\NN\antioxidant.n.01|vitamin (r_conj) tea_12\NN\beverage.n.01|green|and|e (r_pobj) of_10\IN\entity.n.01|tea (r_prep) effects_9\NNS\personal_property.n.01|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_xcomp) aimed_4\VBN\position.v.01|study|was|investigate|iso)-induced|. (l_parataxis) iso)-induced_39\VBN\entity.n.01|(|infarction (l_dobj) infarction_41\NN\pathology.n.02|myocardial|in
D014810_D009203 NONE e_12\NN\antioxidant.n.01|vitamin (r_conj) tea_9\NN\beverage.n.01|green|and|e (r_pobj) of_7\IN\entity.n.01|tea (r_prep) effect_6\NN\phenomenon.n.01|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP\tell.v.02|findings|effect|induced|. (l_ccomp) induced_15\VBN\generate.v.01|infarction (l_dobj) infarction_17\NN\pathology.n.02|myocardial|in
D007545_D009203 CID isoproterenol_9\JJ\medicine.n.02| (r_pobj) in_8\IN\linear_unit.n.01|isoproterenol (r_prep) combination_7\NN\collection.n.01|tea|in (r_pobj) of_1\IN\entity.n.01|combination (r_prep) effect_0\NN\phenomenon.n.01|of (r_nsubj) induced_10\VBN\generate.v.01|effect|infarction|. (l_dobj) infarction_12\NN\pathology.n.02|myocardial|in
D007545_D009203 CID isoproterenol_37\NN\medicine.n.02| (r_pobj) in_36\IN\linear_unit.n.01|isoproterenol (r_prep) bound_34\VBN\line.n.04|atpases|in (r_acl) effects_9\NNS\personal_property.n.01|the|combined|of|on|,|weight|bound (r_dobj) investigate_6\VB\analyze.v.01|to|effects (r_xcomp) aimed_4\VBN\position.v.01|study|was|investigate|iso)-induced|. (l_parataxis) iso)-induced_39\VBN\entity.n.01|(|infarction (l_dobj) infarction_41\NN\pathology.n.02|myocardial|in
D007545_D009203 CID iso)-induced_39\VBN\entity.n.01|(|infarction (l_dobj) infarction_41\NN\pathology.n.02|myocardial|in
D007545_D009203 CID iso_14\NN\entity.n.01| (r_pobj) during_13\IN\entity.n.01|iso (r_prep) effect_6\NN\phenomenon.n.01|the|synergistic|protective|of|during (r_dobj) indicate_2\VBP\tell.v.02|findings|effect|induced|. (l_ccomp) induced_15\VBN\generate.v.01|infarction (l_dobj) infarction_17\NN\pathology.n.02|myocardial|in
6203452
D002945_D002277 NONE cisplatin_24\NN\entity.n.01| (r_pobj) with_23\IN\entity.n.01|cisplatin (r_prep) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS\case.n.06|five|with (l_prep) with_2\IN\entity.n.01|carcinoma (l_pobj) carcinoma_3\NN\cancer.n.01|
D002945_D057049 NONE cisplatin_24\NN\entity.n.01| (r_pobj) with_23\IN\entity.n.01|cisplatin (r_prep) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized
D002945_D051437 NONE cisplatin_24\NN\entity.n.01| (r_pobj) with_23\IN\entity.n.01|cisplatin (r_prep) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_agent) by_9\IN\by.r.01|insufficiency (l_pobj) insufficiency_11\NN\failing.n.01|renal
D002945_D051437 NONE cisplatin_30\VB\entity.n.01| (r_amod) nephrotoxicity_31\NN\entity.n.01|cisplatin|and|anemia|and|thrombocytopenia (r_pobj) to_29\IN\entity.n.01|nephrotoxicity (r_prep) ascribed_28\VBN\evaluate.v.02|because|failure|may|be|to (l_nsubjpass) failure_25\NN\nonaccomplishment.n.01|renal
D002945_D000743 NONE cisplatin_24\NN\entity.n.01| (r_pobj) with_23\IN\entity.n.01|cisplatin (r_prep) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_conj) anemia_15\NN\blood_disease.n.01|microangiopathic|hemolytic|,|and|thrombocytopenia
D002945_D013921 NONE cisplatin_24\NN\entity.n.01| (r_pobj) with_23\IN\entity.n.01|cisplatin (r_prep) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_conj) anemia_15\NN\blood_disease.n.01|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ\blood_disease.n.01|usually
D002945_D013921 NONE cisplatin_30\VB\entity.n.01| (r_amod) nephrotoxicity_31\NN\entity.n.01|cisplatin|and|anemia|and|thrombocytopenia (l_conj) thrombocytopenia_36\NN\blood_disease.n.01|to
D001761_D002277 NONE bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS\case.n.06|five|with (l_prep) with_2\IN\entity.n.01|carcinoma (l_pobj) carcinoma_3\NN\cancer.n.01|
D001761_D057049 NONE bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized
D001761_D051437 NONE bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_agent) by_9\IN\by.r.01|insufficiency (l_pobj) insufficiency_11\NN\failing.n.01|renal
D001761_D000743 NONE bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_conj) anemia_15\NN\blood_disease.n.01|microangiopathic|hemolytic|,|and|thrombocytopenia
D001761_D013921 NONE bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_conj) anemia_15\NN\blood_disease.n.01|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ\blood_disease.n.01|usually
D014748_D002277 NONE alkaloid_31\NN\organic_compound.n.01| (r_amod) vinca_30\JJ\dicot_genus.n.01|a|alkaloid (r_conj) bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_nsubj) patients_1\NNS\case.n.06|five|with (l_prep) with_2\IN\entity.n.01|carcinoma (l_pobj) carcinoma_3\NN\cancer.n.01|
D014748_D057049 NONE alkaloid_31\NN\organic_compound.n.01| (r_amod) vinca_30\JJ\dicot_genus.n.01|a|alkaloid (r_conj) bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized
D014748_D051437 NONE alkaloid_31\NN\organic_compound.n.01| (r_amod) vinca_30\JJ\dicot_genus.n.01|a|alkaloid (r_conj) bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_agent) by_9\IN\by.r.01|insufficiency (l_pobj) insufficiency_11\NN\failing.n.01|renal
D014748_D000743 NONE alkaloid_31\NN\organic_compound.n.01| (r_amod) vinca_30\JJ\dicot_genus.n.01|a|alkaloid (r_conj) bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_conj) anemia_15\NN\blood_disease.n.01|microangiopathic|hemolytic|,|and|thrombocytopenia
D014748_D013921 NONE alkaloid_31\NN\organic_compound.n.01| (r_amod) vinca_30\JJ\dicot_genus.n.01|a|alkaloid (r_conj) bleomycin_26\NNS\entity.n.01|,|and|vinca (r_conj) treatment_22\NN\care.n.01|with|,|bleomycin (r_pobj) after_21\IN\after.s.01|treatment (r_prep) developed_4\VBD\create.v.02|patients|microangiopathy|after|. (l_dobj) microangiopathy_6\NN\entity.n.01|thrombotic|characterized (l_acl) characterized_8\VBN\remember.v.02|(|by|,|anemia|) (l_conj) anemia_15\NN\blood_disease.n.01|microangiopathic|hemolytic|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\JJ\blood_disease.n.01|usually
D002945_D007674 CID cisplatin_30\VB\entity.n.01| (r_amod) nephrotoxicity_31\NN\entity.n.01|cisplatin|and|anemia|and|thrombocytopenia
D002945_D000740 NONE cisplatin_30\VB\entity.n.01| (r_amod) nephrotoxicity_31\NN\entity.n.01|cisplatin|and|anemia|and|thrombocytopenia (l_conj) anemia_34\NN\blood_disease.n.01|the
D002945_D001855 NONE cisplatin_30\VB\entity.n.01| (r_amod) nephrotoxicity_31\NN\entity.n.01|cisplatin|and|anemia|and|thrombocytopenia (l_conj) thrombocytopenia_36\NN\blood_disease.n.01|to (l_prep) to_37\IN\entity.n.01|suppression (l_pobj) suppression_43\NN\growth.n.01|induced|marrow
12684739
D020888_D019966 NONE gvg_35\NNP\entity.n.01|chronic|dose|on (r_pobj) of_29\IN\entity.n.01|gvg (r_prep) effects_28\NNS\personal_property.n.01|the|of (r_dobj) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk
D020888_D005128 CID gvg_35\NNP\entity.n.01|chronic|dose|on (r_pobj) of_29\IN\entity.n.01|gvg (r_prep) effects_28\NNS\personal_property.n.01|the|of (r_dobj) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated
D020888_D005128 CID gvg_35\NNP\entity.n.01|chronic|dose|on (r_pobj) of_29\IN\entity.n.01|gvg (r_prep) effects_28\NNS\personal_property.n.01|the|of (r_dobj) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated (l_appos) vfd_17\NNP\entity.n.01|(|)
D003042_D019966 NONE cocaine_37\NN\hard_drug.n.01| (r_npadvmod) induced_39\VBN\generate.v.01|cocaine|- (r_amod) increases_40\NNS\indefinite_quantity.n.01|induced|in (r_pobj) on_36\IN\on.a.01|increases (r_prep) gvg_35\NNP\entity.n.01|chronic|dose|on (r_pobj) of_29\IN\entity.n.01|gvg (r_prep) effects_28\NNS\personal_property.n.01|the|of (r_dobj) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk
D003042_D005128 NONE cocaine_37\NN\hard_drug.n.01| (r_npadvmod) induced_39\VBN\generate.v.01|cocaine|- (r_amod) increases_40\NNS\indefinite_quantity.n.01|induced|in (r_pobj) on_36\IN\on.a.01|increases (r_prep) gvg_35\NNP\entity.n.01|chronic|dose|on (r_pobj) of_29\IN\entity.n.01|gvg (r_prep) effects_28\NNS\personal_property.n.01|the|of (r_dobj) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated
D003042_D005128 NONE cocaine_37\NN\hard_drug.n.01| (r_npadvmod) induced_39\VBN\generate.v.01|cocaine|- (r_amod) increases_40\NNS\indefinite_quantity.n.01|induced|in (r_pobj) on_36\IN\on.a.01|increases (r_prep) gvg_35\NNP\entity.n.01|chronic|dose|on (r_pobj) of_29\IN\entity.n.01|gvg (r_prep) effects_28\NNS\personal_property.n.01|the|of (r_dobj) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated (l_appos) vfd_17\NNP\entity.n.01|(|)
D004298_D019966 NONE dopamine_47\NN\monoamine_neurotransmitter.n.01|nacc|)|(|da|) (r_appos) accumbens_43\NNS\entity.n.01|(|dopamine (r_oprd) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk
D004298_D019966 NONE da_49\NNP\prosecutor.n.01| (r_appos) dopamine_47\NN\monoamine_neurotransmitter.n.01|nacc|)|(|da|) (r_appos) accumbens_43\NNS\entity.n.01|(|dopamine (r_oprd) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk
D004298_D005128 NONE dopamine_47\NN\monoamine_neurotransmitter.n.01|nacc|)|(|da|) (r_appos) accumbens_43\NNS\entity.n.01|(|dopamine (r_oprd) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated
D004298_D005128 NONE dopamine_47\NN\monoamine_neurotransmitter.n.01|nacc|)|(|da|) (r_appos) accumbens_43\NNS\entity.n.01|(|dopamine (r_oprd) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated (l_appos) vfd_17\NNP\entity.n.01|(|)
D004298_D005128 NONE da_49\NNP\prosecutor.n.01| (r_appos) dopamine_47\NN\monoamine_neurotransmitter.n.01|nacc|)|(|da|) (r_appos) accumbens_43\NNS\entity.n.01|(|dopamine (r_oprd) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated
D004298_D005128 NONE da_49\NNP\prosecutor.n.01| (r_appos) dopamine_47\NN\monoamine_neurotransmitter.n.01|nacc|)|(|da|) (r_appos) accumbens_43\NNS\entity.n.01|(|dopamine (r_oprd) explored_26\VBD\investigate.v.01|given|,|we|effects|accumbens|. (l_prep) given_0\VBN\assumption.n.02|success (l_pobj) success_3\NN\happening.n.01|its|preclinical|for (l_prep) for_4\IN\entity.n.01|treating (l_pcomp) treating_5\VBG\interact.v.01|abuse (l_dobj) abuse_7\NN\mistreatment.n.01|substance|and|risk (l_conj) risk_11\NN\danger.n.03|the|increased|of (l_prep) of_12\IN\entity.n.01|defects (l_pobj) defects_15\NNS\imperfection.n.01|visual|field|vfd|associated (l_appos) vfd_17\NNP\entity.n.01|(|)
19889778
9727773
D001067_D006976 CID suppressants_9\NNS\drug.n.01|appetite|in (r_pobj) with_7\IN\entity.n.01|suppressants (r_prep) associated_6\VBN\think.v.03|with (r_acl) incidence_1\NN\frequency.n.02|high|of|associated|. (l_prep) of_2\IN\entity.n.01|hypertension (l_pobj) hypertension_5\NN\cardiovascular_disease.n.01|primary|pulmonary
D001067_D006976 CID suppressant_21\NN\drug.n.01|appetite (r_compound) drugs_22\NNS\agent.n.03|suppressant (r_pobj) of_19\IN\entity.n.01|drugs (r_prep) intake_18\NN\bodily_process.n.01|the|of (r_pobj) with_16\IN\entity.n.01|intake (r_prep) associated_15\VBN\think.v.03|which|has|been|with (r_relcl) disease_10\NN\illness.n.01|a|rare|,|associated (r_attr) is_3\VBZ\be.v.01|hypertension|disease|. (l_nsubj) hypertension_2\NN\cardiovascular_disease.n.01|primary|pulmonary
D001067_D006976 CID suppressants_18\NNS\drug.n.01|appetite (r_dobj) taken_16\VBN\act.v.01|was|,|5|had|suppressants|. (l_ccomp) was_9\VBD\washington.n.02|in|diagnosis|uncertain (l_nsubj) diagnosis_4\NN\designation.n.03|the|of (l_prep) of_5\IN\entity.n.01|hypertension (l_pobj) hypertension_8\NN\cardiovascular_disease.n.01|primary|pulmonary
D001067_D006976 CID suppressants_7\NNS\drug.n.01|appetite (r_pobj) of_5\IN\entity.n.01|suppressants (r_prep) prescription_4\NN\direction.n.06|unrestricted|of (r_pobj) of_2\IN\entity.n.01|prescription (r_prep) policy_1\NN\plan_of_action.n.01|a|of (r_nsubj) lead_9\VB\advantage.n.01|policy|may|to|. (l_prep) to_10\IN\entity.n.01|incidence (l_pobj) incidence_13\NN\frequency.n.02|a|high|of (l_prep) of_14\IN\entity.n.01|hypertension (l_pobj) hypertension_18\NN\cardiovascular_disease.n.01|associated|primary|pulmonary
14513889
D007654_D009422 NONE ketoconazole_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|ketoconazole|-|sequelae|. (l_dobj) sequelae_4\NNS\abnormality.n.01|neurologic
983936
D001241_D009202 NONE acid_3\NN\compound.n.02|acetylsalicylic|,|dipyridamole (l_conj) dipyridamole_5\NN\entity.n.01|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN\corticosteroid.n.01|on (l_prep) on_9\IN\on.a.01|injury (l_pobj) injury_14\NN\ill_health.n.01|induced|myocardial|in
D004176_D009202 NONE dipyridamole_5\NN\entity.n.01|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN\corticosteroid.n.01|on (l_prep) on_9\IN\on.a.01|injury (l_pobj) injury_14\NN\ill_health.n.01|induced|myocardial|in
D006854_D009202 NONE hydrocortisone_8\NN\corticosteroid.n.01|on (l_prep) on_9\IN\on.a.01|injury (l_pobj) injury_14\NN\ill_health.n.01|induced|myocardial|in
D004837_D009202 CID epinephrine_10\NN\catecholamine.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|epinephrine|- (r_amod) injury_14\NN\ill_health.n.01|induced|myocardial|in
D004837_D009202 CID epinephrine_9\NN\catecholamine.n.01| (r_amod) infusion_10\NN\solution.n.01|(|epinephrine (r_appos) injury_7\NN\ill_health.n.01|diffuse|myocardial|infusion
D004837_D009203 NONE epinephrine_9\NN\catecholamine.n.01| (r_amod) infusion_10\NN\solution.n.01|(|epinephrine (r_appos) injury_7\NN\ill_health.n.01|diffuse|myocardial|infusion (r_dobj) producing_4\VBG\make.v.03|injury (r_pcomp) for_3\IN\entity.n.01|producing (r_prep) model_2\NN\hypothesis.n.02|a|reproducible|for|) (r_nsubjpass) developed_14\VBN\create.v.02|model|has|been|study|. (l_advcl) study_16\VB\examination.n.01|to|effects (l_dobj) effects_19\NNS\personal_property.n.01|the|cardioprotective|of (l_prep) of_20\IN\entity.n.01|agents (l_pobj) agents_21\NNS\causal_agent.n.01|or|maneuvers|alter (l_relcl) alter_26\VB\change.v.01|which|might|evolution (l_dobj) evolution_28\NN\process.n.06|the|of (l_prep) of_29\IN\entity.n.01|infarction (l_pobj) infarction_32\NN\pathology.n.02|acute|myocardial
18182964
D003000_D001289 NONE clonidine_0\NNP\antihypertensive.n.01|for|ii (l_prep) for_1\IN\entity.n.01|disorder (l_pobj) disorder_7\NN\physical_condition.n.01|hyperactivity
D003000_D001289 NONE clonidine_7\NN\antihypertensive.n.01| (r_pobj) of_6\IN\entity.n.01|clonidine (r_prep) safety_3\NN\condition.n.01|the|and|tolerability|of (r_dobj) examine_1\VB\analyze.v.01|to|safety (r_csubj) used_8\VBN\use.v.01|examine|alone|or|with (l_conj) with_11\IN\entity.n.01|methylphenidate (l_pobj) methylphenidate_12\NN\stimulant.n.02|in|with (l_prep) with_15\IN\entity.n.01|disorder (l_pobj) disorder_21\NN\physical_condition.n.01|hyperactivity|(|adhd|)
D003000_D001289 NONE clonidine_7\NN\antihypertensive.n.01| (r_pobj) of_6\IN\entity.n.01|clonidine (r_prep) safety_3\NN\condition.n.01|the|and|tolerability|of (r_dobj) examine_1\VB\analyze.v.01|to|safety (r_csubj) used_8\VBN\use.v.01|examine|alone|or|with (l_conj) with_11\IN\entity.n.01|methylphenidate (l_pobj) methylphenidate_12\NN\stimulant.n.02|in|with (l_prep) with_15\IN\entity.n.01|disorder (l_pobj) disorder_21\NN\physical_condition.n.01|hyperactivity|(|adhd|) (l_appos) adhd_23\NNP\syndrome.n.02|
D003000_D001289 NONE clonidine_18\NN\antihypertensive.n.01|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\appoint.v.02|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\juvenile.n.01|122|with (l_prep) with_12\IN\entity.n.01|adhd (l_pobj) adhd_13\NNP\syndrome.n.02|
D003000_D001289 NONE clonidine_32\NN\antihypertensive.n.01|and|methylphenidate (r_conj) methylphenidate_25\NN\stimulant.n.02|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN\antihypertensive.n.01|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\appoint.v.02|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\juvenile.n.01|122|with (l_prep) with_12\IN\entity.n.01|adhd (l_pobj) adhd_13\NNP\syndrome.n.02|
D003000_D001289 NONE clonidine_0\NNP\antihypertensive.n.01|,|used|, (r_nsubj) appears_8\VBZ\be.v.01|clonidine|safe|and|tolerated|. (l_conj) tolerated_12\VBN\permit.v.01|well|in (l_prep) in_13\IN\linear_unit.n.01|adhd (l_pobj) adhd_15\NNP\syndrome.n.02|childhood
D008774_D001289 NONE methylphenidate_12\NN\stimulant.n.02|in|with (l_prep) with_15\IN\entity.n.01|disorder (l_pobj) disorder_21\NN\physical_condition.n.01|hyperactivity|(|adhd|)
D008774_D001289 NONE methylphenidate_12\NN\stimulant.n.02|in|with (l_prep) with_15\IN\entity.n.01|disorder (l_pobj) disorder_21\NN\physical_condition.n.01|hyperactivity|(|adhd|) (l_appos) adhd_23\NNP\syndrome.n.02|
D008774_D001289 NONE methylphenidate_25\NN\stimulant.n.02|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN\antihypertensive.n.01|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\appoint.v.02|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\juvenile.n.01|122|with (l_prep) with_12\IN\entity.n.01|adhd (l_pobj) adhd_13\NNP\syndrome.n.02|
D008774_D001289 NONE methylphenidate_34\NN\stimulant.n.02| (r_conj) clonidine_32\NN\antihypertensive.n.01|and|methylphenidate (r_conj) methylphenidate_25\NN\stimulant.n.02|(|n|29|)|,|clonidine|(|n|32|,|or|placebo (r_conj) clonidine_18\NN\antihypertensive.n.01|to|n|,|methylphenidate (r_xcomp) assigned_16\VBN\appoint.v.02|in|,|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\juvenile.n.01|122|with (l_prep) with_12\IN\entity.n.01|adhd (l_pobj) adhd_13\NNP\syndrome.n.02|
D008774_D001289 NONE methylphenidate_6\NN\stimulant.n.02| (r_pobj) with_5\IN\entity.n.01|methylphenidate (r_conj) used_2\VBN\use.v.01|alone|or|with (r_acl) clonidine_0\NNP\antihypertensive.n.01|,|used|, (r_nsubj) appears_8\VBZ\be.v.01|clonidine|safe|and|tolerated|. (l_conj) tolerated_12\VBN\permit.v.01|well|in (l_prep) in_13\IN\linear_unit.n.01|adhd (l_pobj) adhd_15\NNP\syndrome.n.02|childhood
D003000_D001919 CID clonidine_10\NN\antihypertensive.n.01| (r_pobj) with_9\IN\entity.n.01|clonidine (r_prep) treated_8\VBN\interact.v.01|with|compared (r_acl) subjects_7\NNS\message.n.02|treated (r_pobj) in_6\IN\linear_unit.n.01|subjects (r_prep) incidents_3\NNS\happening.n.01|more|of|in (l_prep) of_4\IN\entity.n.01|bradycardia (l_pobj) bradycardia_5\NN\cardiac_arrhythmia.n.01|
D003000_D001919 CID clonidine_17\NN\antihypertensive.n.01| (r_pobj) with_16\IN\entity.n.01|clonidine (r_prep) treated_15\VBN\interact.v.01|not|with (r_acl) those_13\DT\entity.n.01|treated|%|but|differences (r_pobj) with_12\IN\entity.n.01|those (r_prep) compared_11\VBN\analyze.v.01|with (r_prep) treated_8\VBN\interact.v.01|with|compared (r_acl) subjects_7\NNS\message.n.02|treated (r_pobj) in_6\IN\linear_unit.n.01|subjects (r_prep) incidents_3\NNS\happening.n.01|more|of|in (l_prep) of_4\IN\entity.n.01|bradycardia (l_pobj) bradycardia_5\NN\cardiac_arrhythmia.n.01|
D003000_D001919 CID clonidine_2\NN\antihypertensive.n.01| (r_dobj) prescribing_1\VBG\inflict.v.01|clonidine (r_acl) physicians_0\NNS\medical_practitioner.n.01|prescribing (r_nsubj) monitor_4\VB\supervisor.n.01|physicians|should|for|and|advise|. (l_prep) for_5\IN\entity.n.01|bradycardia (l_pobj) bradycardia_6\NN\cardiac_arrhythmia.n.01|
D003000_D006970 NONE clonidine_4\NN\antihypertensive.n.01| (r_pobj) on_3\IN\on.a.01|clonidine (r_prep) was_1\VBD\washington.n.02|drowsiness|common|on|,|but|resolved|. (l_nsubj) drowsiness_0\NN\temporary_state.n.01|
D003000_D006970 NONE clonidine_2\NN\antihypertensive.n.01| (r_dobj) prescribing_1\VBG\inflict.v.01|clonidine (r_acl) physicians_0\NNS\medical_practitioner.n.01|prescribing (r_nsubj) monitor_4\VB\supervisor.n.01|physicians|should|for|and|advise|. (l_conj) advise_8\VB\hash_out.v.01|patients (l_dobj) patients_9\NNS\case.n.06|about (l_prep) about_10\IN\about.s.01|likelihood (l_pobj) likelihood_13\NN\probability.n.02|the|high|of (l_prep) of_14\IN\entity.n.01|drowsiness (l_pobj) drowsiness_16\NN\temporary_state.n.01|initial
2950248
D004176_D017202 NONE dipyridamole_0\NNP\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|dipyridamole|- (r_amod) ischemia_4\NN\anemia.n.01|induced|myocardial|.
D004176_D017202 NONE dipyridamole_16\NN\entity.n.01| (r_compound) therapy_17\NN\medical_care.n.01|preoperative|dipyridamole (r_pobj) of_14\IN\entity.n.01|therapy (r_prep) effect_13\NN\phenomenon.n.01|a|side|of (r_pobj) as_10\IN\chemical_element.n.01|effect (r_prep) reported_9\VBN\inform.v.01|to|,|this|has|not|previously|been|as|,|demonstrated|. (l_advcl) demonstrated_27\VBN\show.v.04|although|ischemia|has|been|occur (l_nsubjpass) ischemia_24\NN\anemia.n.01|induced|myocardial
D004176_D017202 NONE dipyridamole_20\NN\entity.n.01| (r_dep) induced_22\VBN\generate.v.01|dipyridamole|- (r_amod) ischemia_24\NN\anemia.n.01|induced|myocardial
D004176_D000787 CID dipyridamole_10\NN\entity.n.01|oral (r_pobj) of_8\IN\entity.n.01|dipyridamole (r_prep) administration_7\NN\management.n.01|of (r_pobj) after_6\IN\after.s.01|administration (r_prep) occurred_5\VBD\happen.v.01|angina|after|in|. (l_nsubj) angina_0\NNP\inflammatory_disease.n.01|and|changes
D004176_D003324 NONE dipyridamole_16\NN\entity.n.01| (r_compound) therapy_17\NN\medical_care.n.01|preoperative|dipyridamole (r_pobj) of_14\IN\entity.n.01|therapy (r_prep) effect_13\NN\phenomenon.n.01|a|side|of (r_pobj) as_10\IN\chemical_element.n.01|effect (r_prep) reported_9\VBN\inform.v.01|to|,|this|has|not|previously|been|as|,|demonstrated|. (l_advcl) demonstrated_27\VBN\show.v.04|although|ischemia|has|been|occur (l_xcomp) occur_29\VB\happen.v.01|to|in|with (l_prep) with_34\IN\entity.n.01|disease (l_pobj) disease_37\NN\illness.n.01|coronary|artery
D004176_D003324 NONE dipyridamole_20\NN\entity.n.01| (r_dep) induced_22\VBN\generate.v.01|dipyridamole|- (r_amod) ischemia_24\NN\anemia.n.01|induced|myocardial (r_nsubjpass) demonstrated_27\VBN\show.v.04|although|ischemia|has|been|occur (l_xcomp) occur_29\VB\happen.v.01|to|in|with (l_prep) with_34\IN\entity.n.01|disease (l_pobj) disease_37\NN\illness.n.01|coronary|artery
D004176_D007511 NONE dipyridamole_23\NN\entity.n.01| (r_npadvmod) induced_25\VBN\generate.v.01|dipyridamole|- (r_amod) ischemia_26\NN\anemia.n.01|the|induced
3828020
D010665_D002544 CID phenylpropanolamine_8\NN\adrenergic.n.01| (r_pobj) of_7\IN\entity.n.01|phenylpropanolamine (r_prep) dose_6\NN\medicine.n.02|a|single|oral|of (r_pobj) with_2\IN\entity.n.01|dose (r_prep) infarction_1\NN\pathology.n.02|cerebral|with|.
D010665_D002544 CID ppa_20\NNP\entity.n.01| (r_pobj) of_19\IN\entity.n.01|ppa (r_prep) dose_18\NN\medicine.n.02|a|single|oral|of (r_dobj) taking_14\VBG\action.n.01|dose (r_pcomp) after_13\IN\after.s.01|taking (r_prep) suffered_9\VBD\experience.v.01|who|infarction|after (l_dobj) infarction_12\NN\pathology.n.02|a|cerebral
15325671
D003520_D066126 NONE cyclophosphamide_9\NN\entity.n.01| (r_npadvmod) based_11\VBN\establish.v.08|cyclophosphamide|- (r_amod) chemotherapy_12\NN\therapy.n.01|dose|based|for (r_pobj) with_5\IN\entity.n.01|chemotherapy (r_prep) association_4\NN\organization.n.01|with (r_pobj) in_3\IN\linear_unit.n.01|association (r_prep) observed_2\VBD\spy.v.03|toxicity|in|. (l_nsubj) toxicity_1\NN\definite_quantity.n.01|cardiac
D003520_D066126 NONE cyclophosphamide_3\NN\entity.n.01| (r_npadvmod) related_5\VBN\think.v.03|cyclophosphamide|- (r_amod) toxicity_7\NN\definite_quantity.n.01|transient|related|cardiac|(|%|)
D003520_D001943 NONE cyclophosphamide_9\NN\entity.n.01| (r_npadvmod) based_11\VBN\establish.v.08|cyclophosphamide|- (r_amod) chemotherapy_12\NN\therapy.n.01|dose|based|for (l_prep) for_13\IN\entity.n.01|cancer (l_pobj) cancer_16\NN\malignant_tumor.n.01|metastatic|breast
D003520_D001943 NONE cyclophosphamide_9\NN\entity.n.01|dose|,|thiotepa (l_conj) thiotepa_11\NNS\antineoplastic.n.01|,|and|carboplatin (l_conj) carboplatin_14\VB\entity.n.01|in|regimen (l_dobj) regimen_22\NN\plan.n.01|a|triple|sequential|dose|for (l_prep) for_23\IN\entity.n.01|patients (l_pobj) patients_24\NNS\case.n.06|with (l_prep) with_25\IN\entity.n.01|cancer (l_pobj) cancer_28\NN\malignant_tumor.n.01|metastatic|breast
D003520_D001943 NONE cyclophosphamide_16\NN\entity.n.01|96-h|infusional (r_dobj) receiving_13\VBG\get.v.01|cyclophosphamide|as (r_acl) cancer_12\NN\malignant_tumor.n.01|responsive|metastatic|breast|receiving|and|characteristics
D017239_D001943 NONE paclitaxel_2\NN\entity.n.01|combined|,|melphalan (l_conj) melphalan_4\NN\antineoplastic.n.01|and|cyclophosphamide (l_conj) cyclophosphamide_9\NN\entity.n.01|dose|,|thiotepa (l_conj) thiotepa_11\NNS\antineoplastic.n.01|,|and|carboplatin (l_conj) carboplatin_14\VB\entity.n.01|in|regimen (l_dobj) regimen_22\NN\plan.n.01|a|triple|sequential|dose|for (l_prep) for_23\IN\entity.n.01|patients (l_pobj) patients_24\NNS\case.n.06|with (l_prep) with_25\IN\entity.n.01|cancer (l_pobj) cancer_28\NN\malignant_tumor.n.01|metastatic|breast
D008558_D001943 NONE melphalan_4\NN\antineoplastic.n.01|and|cyclophosphamide (l_conj) cyclophosphamide_9\NN\entity.n.01|dose|,|thiotepa (l_conj) thiotepa_11\NNS\antineoplastic.n.01|,|and|carboplatin (l_conj) carboplatin_14\VB\entity.n.01|in|regimen (l_dobj) regimen_22\NN\plan.n.01|a|triple|sequential|dose|for (l_prep) for_23\IN\entity.n.01|patients (l_pobj) patients_24\NNS\case.n.06|with (l_prep) with_25\IN\entity.n.01|cancer (l_pobj) cancer_28\NN\malignant_tumor.n.01|metastatic|breast
D013852_D001943 NONE thiotepa_11\NNS\antineoplastic.n.01|,|and|carboplatin (l_conj) carboplatin_14\VB\entity.n.01|in|regimen (l_dobj) regimen_22\NN\plan.n.01|a|triple|sequential|dose|for (l_prep) for_23\IN\entity.n.01|patients (l_pobj) patients_24\NNS\case.n.06|with (l_prep) with_25\IN\entity.n.01|cancer (l_pobj) cancer_28\NN\malignant_tumor.n.01|metastatic|breast
D016190_D001943 NONE carboplatin_14\VB\entity.n.01|in|regimen (l_dobj) regimen_22\NN\plan.n.01|a|triple|sequential|dose|for (l_prep) for_23\IN\entity.n.01|patients (l_pobj) patients_24\NNS\case.n.06|with (l_prep) with_25\IN\entity.n.01|cancer (l_pobj) cancer_28\NN\malignant_tumor.n.01|metastatic|breast
D003520_D006333 CID cyclophosphamide_16\NN\entity.n.01|96-h|infusional (r_dobj) receiving_13\VBG\get.v.01|cyclophosphamide|as (l_prep) as_17\IN\chemical_element.n.01|part (l_pobj) part_18\NN\relation.n.01|of (l_prep) of_19\IN\entity.n.01|regimen (l_pobj) regimen_26\NN\plan.n.01|a|triple|sequential|dose|assess (l_acl) assess_28\VB\body_part.n.01|to|association (l_dobj) association_29\NN\organization.n.01|between (l_prep) between_30\IN\between.r.01|presence (l_pobj) presence_31\NN\being.n.01|of (l_prep) of_32\IN\entity.n.01|failure (l_pobj) failure_36\NN\nonaccomplishment.n.01|peritransplant|heart|chf
D003520_D006333 CID cyclophosphamide_16\NN\entity.n.01|96-h|infusional (r_dobj) receiving_13\VBG\get.v.01|cyclophosphamide|as (l_prep) as_17\IN\chemical_element.n.01|part (l_pobj) part_18\NN\relation.n.01|of (l_prep) of_19\IN\entity.n.01|regimen (l_pobj) regimen_26\NN\plan.n.01|a|triple|sequential|dose|assess (l_acl) assess_28\VB\body_part.n.01|to|association (l_dobj) association_29\NN\organization.n.01|between (l_prep) between_30\IN\between.r.01|presence (l_pobj) presence_31\NN\being.n.01|of (l_prep) of_32\IN\entity.n.01|failure (l_pobj) failure_36\NN\nonaccomplishment.n.01|peritransplant|heart|chf (l_appos) chf_38\NNP\entity.n.01|(|)
D003520_D006333 CID cyclophosphamide_16\NN\entity.n.01|infusional (r_dobj) following_14\VBG\multitude.n.03|cyclophosphamide|with (r_prep) developed_8\VBD\create.v.02|six|grade|following|. (l_dobj) grade_11\NN\gathering.n.01|reversible|chf (l_appos) chf_13\NNP\entity.n.01|3
D003520_D006333 CID cyclophosphamide_5\NN\entity.n.01|infusional (r_pobj) during_3\IN\entity.n.01|cyclophosphamide (r_prep) monitoring_2\NN\observation.n.02|ekg|during (r_nsubj) predict_8\VB\guess.v.02|monitoring|did|not|development|. (l_dobj) development_10\NN\improvement.n.02|chf (l_compound) chf_9\NNP\entity.n.01|
D003520_D006973 NONE cyclophosphamide_16\NN\entity.n.01|96-h|infusional (r_dobj) receiving_13\VBG\get.v.01|cyclophosphamide|as (r_acl) cancer_12\NN\malignant_tumor.n.01|responsive|metastatic|breast|receiving|and|characteristics (l_conj) characteristics_44\NNS\property.n.04|the|following|pretreatment|:|presence (l_appos) presence_46\NN\being.n.01|of|,|history (l_prep) of_47\IN\entity.n.01|electrocardiogram (l_pobj) electrocardiogram_48\NN\graph.n.01|(|ekg|abnormalities (l_appos) abnormalities_52\NNS\physical_condition.n.01|,|age|hypertension (l_appos) hypertension_56\NN\cardiovascular_disease.n.01|
D003520_D003920 NONE cyclophosphamide_16\NN\entity.n.01|96-h|infusional (r_dobj) receiving_13\VBG\get.v.01|cyclophosphamide|as (r_acl) cancer_12\NN\malignant_tumor.n.01|responsive|metastatic|breast|receiving|and|characteristics (l_conj) characteristics_44\NNS\property.n.04|the|following|pretreatment|:|presence (l_appos) presence_46\NN\being.n.01|of|,|history (l_appos) history_60\NN\past.n.01|prior|cardiac|,|smoking (l_conj) smoking_62\NN\breathing.n.01|,|mellitus (l_conj) mellitus_65\NN\entity.n.01|diabetes|,|use
D018943_D001943 NONE anthracyclines_70\NNS\entity.n.01| (r_pobj) of_69\IN\entity.n.01|anthracyclines (r_prep) use_68\NN\activity.n.01|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\entity.n.01|diabetes|,|use (r_conj) smoking_62\NN\breathing.n.01|,|mellitus (r_conj) history_60\NN\past.n.01|prior|cardiac|,|smoking (r_appos) presence_46\NN\being.n.01|of|,|history (r_appos) characteristics_44\NNS\property.n.04|the|following|pretreatment|:|presence (r_conj) cancer_12\NN\malignant_tumor.n.01|responsive|metastatic|breast|receiving|and|characteristics
D018943_D006333 NONE anthracyclines_70\NNS\entity.n.01| (r_pobj) of_69\IN\entity.n.01|anthracyclines (r_prep) use_68\NN\activity.n.01|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\entity.n.01|diabetes|,|use (r_conj) smoking_62\NN\breathing.n.01|,|mellitus (r_conj) history_60\NN\past.n.01|prior|cardiac|,|smoking (r_appos) presence_46\NN\being.n.01|of|,|history (r_appos) characteristics_44\NNS\property.n.04|the|following|pretreatment|:|presence (r_conj) cancer_12\NN\malignant_tumor.n.01|responsive|metastatic|breast|receiving|and|characteristics (l_acl) receiving_13\VBG\get.v.01|cyclophosphamide|as (l_prep) as_17\IN\chemical_element.n.01|part (l_pobj) part_18\NN\relation.n.01|of (l_prep) of_19\IN\entity.n.01|regimen (l_pobj) regimen_26\NN\plan.n.01|a|triple|sequential|dose|assess (l_acl) assess_28\VB\body_part.n.01|to|association (l_dobj) association_29\NN\organization.n.01|between (l_prep) between_30\IN\between.r.01|presence (l_pobj) presence_31\NN\being.n.01|of (l_prep) of_32\IN\entity.n.01|failure (l_pobj) failure_36\NN\nonaccomplishment.n.01|peritransplant|heart|chf
D018943_D006333 NONE anthracyclines_70\NNS\entity.n.01| (r_pobj) of_69\IN\entity.n.01|anthracyclines (r_prep) use_68\NN\activity.n.01|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\entity.n.01|diabetes|,|use (r_conj) smoking_62\NN\breathing.n.01|,|mellitus (r_conj) history_60\NN\past.n.01|prior|cardiac|,|smoking (r_appos) presence_46\NN\being.n.01|of|,|history (r_appos) characteristics_44\NNS\property.n.04|the|following|pretreatment|:|presence (r_conj) cancer_12\NN\malignant_tumor.n.01|responsive|metastatic|breast|receiving|and|characteristics (l_acl) receiving_13\VBG\get.v.01|cyclophosphamide|as (l_prep) as_17\IN\chemical_element.n.01|part (l_pobj) part_18\NN\relation.n.01|of (l_prep) of_19\IN\entity.n.01|regimen (l_pobj) regimen_26\NN\plan.n.01|a|triple|sequential|dose|assess (l_acl) assess_28\VB\body_part.n.01|to|association (l_dobj) association_29\NN\organization.n.01|between (l_prep) between_30\IN\between.r.01|presence (l_pobj) presence_31\NN\being.n.01|of (l_prep) of_32\IN\entity.n.01|failure (l_pobj) failure_36\NN\nonaccomplishment.n.01|peritransplant|heart|chf (l_appos) chf_38\NNP\entity.n.01|(|)
D018943_D006973 NONE anthracyclines_70\NNS\entity.n.01| (r_pobj) of_69\IN\entity.n.01|anthracyclines (r_prep) use_68\NN\activity.n.01|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\entity.n.01|diabetes|,|use (r_conj) smoking_62\NN\breathing.n.01|,|mellitus (r_conj) history_60\NN\past.n.01|prior|cardiac|,|smoking (r_appos) presence_46\NN\being.n.01|of|,|history (l_prep) of_47\IN\entity.n.01|electrocardiogram (l_pobj) electrocardiogram_48\NN\graph.n.01|(|ekg|abnormalities (l_appos) abnormalities_52\NNS\physical_condition.n.01|,|age|hypertension (l_appos) hypertension_56\NN\cardiovascular_disease.n.01|
D018943_D003920 NONE anthracyclines_70\NNS\entity.n.01| (r_pobj) of_69\IN\entity.n.01|anthracyclines (r_prep) use_68\NN\activity.n.01|prior|of|,|and|irradiation (r_conj) mellitus_65\NN\entity.n.01|diabetes|,|use
3503576
D003676_D006311 NONE deferoxamine_8\NN\entity.n.01| (r_compound) therapy_9\NN\medical_care.n.01|deferoxamine (r_dobj) receiving_7\VBG\get.v.01|therapy (r_acl) patients_6\NNS\case.n.06|receiving (r_pobj) in_5\IN\linear_unit.n.01|patients (r_prep) studies_1\NNS\examination.n.01|serial|of|in|. (l_prep) of_2\IN\entity.n.01|neurotoxicity (l_pobj) neurotoxicity_4\NN\entity.n.01|auditory
D003676_D006311 NONE deferoxamine_26\NN\entity.n.01|daily|subcutaneous (r_pobj) with_23\IN\entity.n.01|deferoxamine (r_prep) receiving_19\VBG\get.v.01|who|were|therapy|with (r_relcl) anemia_16\NN\blood_disease.n.01|dependent|receiving (r_pobj) with_12\IN\entity.n.01|anemia (r_prep) patients_11\NNS\case.n.06|89|with (r_pobj) in_7\IN\linear_unit.n.01|patients (r_prep) documented_6\VBN\record.v.01|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\entity.n.01|visual
D003676_D006311 NONE deferoxamine_9\NN\entity.n.01| (r_compound) doses_10\NNS\medicine.n.02|deferoxamine (r_dobj) receiving_8\VBG\get.v.01|since|18|were|initially|doses|in (r_advcl) restarted_24\VBN\start.v.08|receiving|,|therapy|was|with|,|and|demonstrated (l_prep) with_25\IN\entity.n.01|doses (l_pobj) doses_27\NNS\medicine.n.02|lower|,|mg/kg|depending (l_prep) depending_36\VBG\be.v.01|on (l_prep) on_37\IN\on.a.01|degree (l_pobj) degree_39\NN\property.n.02|the|of (l_prep) of_40\IN\entity.n.01|abnormality (l_pobj) abnormality_42\NN\physical_condition.n.01|auditory
D003676_D006311 NONE deferoxamine_14\NN\entity.n.01| (r_dobj) receiving_13\VBG\get.v.01|not|deferoxamine (r_conj) receiving_10\VBG\get.v.01|and|receiving (r_acl) patients_9\NNS\case.n.06|individual|receiving (r_pobj) in_7\IN\linear_unit.n.01|patients (r_prep) demonstrated_5\VBD\show.v.04|deterioration|,|serially|in|,|respectively|,|provided|. (l_prep) provided_18\VBD\give.v.03|convincing (l_pcomp) convincing_19\JJ\persuade.v.02|evidence (l_dobj) evidence_20\NN\information.n.02|for (l_prep) for_21\IN\entity.n.01|relation (l_pobj) relation_28\NN\abstraction.n.06|a|cause|between (l_prep) between_29\IN\between.r.01|administration (l_pobj) administration_31\NN\management.n.01|deferoxamine|and|ototoxicity (l_conj) ototoxicity_33\NN\entity.n.01|
D003676_D006311 NONE deferoxamine_30\NN\entity.n.01| (r_compound) administration_31\NN\management.n.01|deferoxamine|and|ototoxicity (l_conj) ototoxicity_33\NN\entity.n.01|
D007501_D014786 NONE iron_20\NN\metallic_element.n.01| (r_compound) therapy_22\NN\medical_care.n.01|iron|chelation (r_dobj) receiving_19\VBG\get.v.01|who|were|therapy|with (r_relcl) anemia_16\NN\blood_disease.n.01|dependent|receiving (r_pobj) with_12\IN\entity.n.01|anemia (r_prep) patients_11\NNS\case.n.06|89|with (r_pobj) in_7\IN\linear_unit.n.01|patients (r_prep) documented_6\VBN\record.v.01|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\entity.n.01|visual
D007501_D006311 NONE iron_20\NN\metallic_element.n.01| (r_compound) therapy_22\NN\medical_care.n.01|iron|chelation (r_dobj) receiving_19\VBG\get.v.01|who|were|therapy|with (r_relcl) anemia_16\NN\blood_disease.n.01|dependent|receiving (r_pobj) with_12\IN\entity.n.01|anemia (r_prep) patients_11\NNS\case.n.06|89|with (r_pobj) in_7\IN\linear_unit.n.01|patients (r_prep) documented_6\VBN\record.v.01|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\entity.n.01|visual
D007501_D000740 NONE iron_20\NN\metallic_element.n.01| (r_compound) therapy_22\NN\medical_care.n.01|iron|chelation (r_dobj) receiving_19\VBG\get.v.01|who|were|therapy|with (r_relcl) anemia_16\NN\blood_disease.n.01|dependent|receiving
D003676_D014786 NONE deferoxamine_26\NN\entity.n.01|daily|subcutaneous (r_pobj) with_23\IN\entity.n.01|deferoxamine (r_prep) receiving_19\VBG\get.v.01|who|were|therapy|with (r_relcl) anemia_16\NN\blood_disease.n.01|dependent|receiving (r_pobj) with_12\IN\entity.n.01|anemia (r_prep) patients_11\NNS\case.n.06|89|with (r_pobj) in_7\IN\linear_unit.n.01|patients (r_prep) documented_6\VBN\record.v.01|neurotoxicity|was|previously|in|. (l_nsubjpass) neurotoxicity_3\NN\entity.n.01|visual
D003676_D000740 NONE deferoxamine_26\NN\entity.n.01|daily|subcutaneous (r_pobj) with_23\IN\entity.n.01|deferoxamine (r_prep) receiving_19\VBG\get.v.01|who|were|therapy|with (r_relcl) anemia_16\NN\blood_disease.n.01|dependent|receiving
D003676_D064420 NONE deferoxamine_9\NN\entity.n.01| (r_compound) doses_10\NNS\medicine.n.02|deferoxamine (r_dobj) receiving_8\VBG\get.v.01|since|18|were|initially|doses|in (r_advcl) restarted_24\VBN\start.v.08|receiving|,|therapy|was|with|,|and|demonstrated (l_conj) demonstrated_55\VBN\show.v.04|with|toxicity|was|. (l_nsubjpass) toxicity_53\NN\definite_quantity.n.01|no|further
16330293
8996652
D000617_D006311 NONE aminoglycosides_17\NNS\entity.n.01|particularly|and|furosemide (r_appos) administration_7\NN\management.n.01|a|prolonged|and|dose|,|aminoglycosides (r_pobj) to_4\IN\entity.n.01|administration (r_prep) related_3\JJ\think.v.03|closely|to (r_oprd) appeared_1\VBD\be.v.01|ototoxicity|related|. (l_nsubj) ototoxicity_0\NN\entity.n.01|
D000617_D006311 NONE aminoglycosides_17\NNS\entity.n.01|particularly|and|furosemide (r_appos) administration_7\NN\management.n.01|a|prolonged|and|dose|,|aminoglycosides (l_conj) dose_11\NN\medicine.n.02|higher|total|of (l_prep) of_12\IN\entity.n.01|drugs (l_pobj) drugs_14\NNS\agent.n.03|ototoxic (l_compound) ototoxic_13\JJ\ototoxic.s.01|
D005665_D006311 NONE furosemide_19\NN\diuretic_drug.n.01| (r_conj) aminoglycosides_17\NNS\entity.n.01|particularly|and|furosemide (r_appos) administration_7\NN\management.n.01|a|prolonged|and|dose|,|aminoglycosides (r_pobj) to_4\IN\entity.n.01|administration (r_prep) related_3\JJ\think.v.03|closely|to (r_oprd) appeared_1\VBD\be.v.01|ototoxicity|related|. (l_nsubj) ototoxicity_0\NN\entity.n.01|
D005665_D006311 NONE furosemide_19\NN\diuretic_drug.n.01| (r_conj) aminoglycosides_17\NNS\entity.n.01|particularly|and|furosemide (r_appos) administration_7\NN\management.n.01|a|prolonged|and|dose|,|aminoglycosides (l_conj) dose_11\NN\medicine.n.02|higher|total|of (l_prep) of_12\IN\entity.n.01|drugs (l_pobj) drugs_14\NNS\agent.n.03|ototoxic (l_compound) ototoxic_13\JJ\ototoxic.s.01|
14596845
D000661_D019966 NONE amphetamine_15\NN\drug_of_abuse.n.01| (r_pobj) of_14\IN\entity.n.01|amphetamine (r_prep) dose_13\NN\medicine.n.02|a|low|of (r_pobj) to_10\IN\entity.n.01|dose (r_prep) sensitization_9\NN\sensitivity.n.04|behavioral|cross|-|to (r_dobj) causes_5\VBZ\origin.n.03|diet|sensitization|. (l_nsubj) diet_1\NN\fare.n.04|a|promoting (l_acl) promoting_2\VBG\support.v.01|dependency (l_dobj) dependency_4\NN\state.n.02|sugar
D000661_D006948 CID amphetamine_15\NN\drug_of_abuse.n.01| (r_pobj) of_14\IN\entity.n.01|amphetamine (r_prep) dose_13\NN\medicine.n.02|a|low|of (r_pobj) to_10\IN\entity.n.01|dose (r_prep) sensitization_9\NN\sensitivity.n.04|behavioral|cross|-|to
D000661_D006948 CID amphetamine_24\NN\drug_of_abuse.n.01| (r_pobj) of_23\IN\entity.n.01|amphetamine (r_prep) dose_22\NN\medicine.n.02|a|low|of (r_pobj) to_19\IN\entity.n.01|dose (r_prep) show_14\VB\entertainment.n.01|whether|rats|would|sensitization|to (l_dobj) sensitization_18\NN\sensitivity.n.04|behavioral|cross|-
D000661_D006948 CID amphetamine_14\NN\drug_of_abuse.n.01| (r_pobj) to_13\IN\entity.n.01|amphetamine (r_prep) response_12\NN\consequence.n.01|to (r_pobj) in_11\IN\linear_unit.n.01|response (r_prep) were_9\VBD\be.v.01|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\hyperactive.s.01|
D000661_D006948 CID amphetamine_30\NN\drug_of_abuse.n.01| (r_compound) injection_31\NN\insertion.n.02|amphetamine (r_pobj) by_29\IN\by.r.01|injection (r_agent) followed_28\VBN\travel.v.01|by (r_acl) sucrose_25\NN\disaccharide.n.01|libitum|%|and|chow|followed (r_appos) groups_19\NNS\abstraction.n.06|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\entity.n.01|groups (r_prep) compared_15\VBN\analyze.v.01|with (r_prep) were_9\VBD\be.v.01|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\hyperactive.s.01|
D000661_D006948 CID amphetamine_37\NN\drug_of_abuse.n.01| (r_compound) injection_38\NN\insertion.n.02|amphetamine (r_pobj) by_36\IN\by.r.01|injection (r_agent) followed_35\VBN\travel.v.01|by (r_acl) chow_34\NN\dynasty.n.01|cyclic|followed (r_appos) groups_19\NNS\abstraction.n.06|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\entity.n.01|groups (r_prep) compared_15\VBN\analyze.v.01|with (r_prep) were_9\VBD\be.v.01|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\hyperactive.s.01|
D000661_D006948 CID amphetamine_44\NN\drug_of_abuse.n.01|,|or|sucrose (r_pobj) with_43\IN\entity.n.01|amphetamine (r_prep) chow_42\NN\dynasty.n.01|ad|libitum|with (r_appos) groups_19\NNS\abstraction.n.06|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\entity.n.01|groups (r_prep) compared_15\VBN\analyze.v.01|with (r_prep) were_9\VBD\be.v.01|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\hyperactive.s.01|
D013395_D006948 CID sucrose_6\NN\disaccharide.n.01|cyclic|and|chow (r_dobj) experienced_4\VBN\undergo.v.01|that|had|sucrose (r_relcl) animals_1\NNS\organism.n.01|the|experienced (r_nsubj) were_9\VBD\be.v.01|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\hyperactive.s.01|
D013395_D006948 CID sucrose_25\NN\disaccharide.n.01|libitum|%|and|chow|followed (r_appos) groups_19\NNS\abstraction.n.06|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\entity.n.01|groups (r_prep) compared_15\VBN\analyze.v.01|with (r_prep) were_9\VBD\be.v.01|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\hyperactive.s.01|
D013395_D006948 CID sucrose_50\NN\disaccharide.n.01|cyclic|%|and|chow|with (r_conj) amphetamine_44\NN\drug_of_abuse.n.01|,|or|sucrose (r_pobj) with_43\IN\entity.n.01|amphetamine (r_prep) chow_42\NN\dynasty.n.01|ad|libitum|with (r_appos) groups_19\NNS\abstraction.n.06|four|control|(|sucrose|,|chow|,|chow|) (r_pobj) with_16\IN\entity.n.01|groups (r_prep) compared_15\VBN\analyze.v.01|with (r_prep) were_9\VBD\be.v.01|animals|hyperactive|in|compared|. (l_acomp) hyperactive_10\JJ\hyperactive.s.01|
3719553
D005472_D004342 NONE 5-fluorouracil_3\CD\entity.n.01| (r_punct) infusion_4\NN\solution.n.01|5-fluorouracil (r_pobj) to_2\IN\entity.n.01|infusion (r_prep) reaction_1\NN\chemical_process.n.01|allergic|to|.
D005472_D004342 NONE 5-fluorouracil_11\CD\entity.n.01| (r_punct) reaction_2\NN\chemical_process.n.01|an|allergic|consisting|5-fluorouracil
D005472_D000799 CID 5-fluorouracil_11\CD\entity.n.01| (r_punct) reaction_2\NN\chemical_process.n.01|an|allergic|consisting|5-fluorouracil (l_acl) consisting_3\VBG\exist.v.01|of (l_prep) of_4\IN\entity.n.01|angioneurotic|edema (l_pobj) edema_6\NN\swelling.n.01|secondary
D005472_D009062 NONE 5-fluorouracil_11\CD\entity.n.01| (r_punct) reaction_2\NN\chemical_process.n.01|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD\happen.v.01|reaction|in|. (l_prep) in_13\IN\linear_unit.n.01|patient (l_pobj) patient_15\NN\case.n.06|a|with (l_prep) with_16\IN\entity.n.01|carcinoma (l_pobj) carcinoma_18\NN\cancer.n.01|recurrent|of (l_prep) of_19\IN\entity.n.01|cavity (l_pobj) cavity_22\NN\hole.n.05|the|oral|,|cirrhosis
D005472_D005355 NONE 5-fluorouracil_11\CD\entity.n.01| (r_punct) reaction_2\NN\chemical_process.n.01|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD\happen.v.01|reaction|in|. (l_prep) in_13\IN\linear_unit.n.01|patient (l_pobj) patient_15\NN\case.n.06|a|with (l_prep) with_16\IN\entity.n.01|carcinoma (l_pobj) carcinoma_18\NN\cancer.n.01|recurrent|of (l_prep) of_19\IN\entity.n.01|cavity (l_pobj) cavity_22\NN\hole.n.05|the|oral|,|cirrhosis (l_conj) cirrhosis_24\NN\liver_disease.n.01|,|and|function
D005472_D007674 NONE 5-fluorouracil_11\CD\entity.n.01| (r_punct) reaction_2\NN\chemical_process.n.01|an|allergic|consisting|5-fluorouracil (r_nsubj) occurred_12\VBD\happen.v.01|reaction|in|. (l_prep) in_13\IN\linear_unit.n.01|patient (l_pobj) patient_15\NN\case.n.06|a|with (l_prep) with_16\IN\entity.n.01|carcinoma (l_pobj) carcinoma_18\NN\cancer.n.01|recurrent|of (l_prep) of_19\IN\entity.n.01|cavity (l_pobj) cavity_22\NN\hole.n.05|the|oral|,|cirrhosis (l_conj) cirrhosis_24\NN\liver_disease.n.01|,|and|function (l_conj) function_32\NN\mathematical_relation.n.01|induced|impaired|renal
D002945_D004342 NONE cisplatin_27\NN\entity.n.01| (r_advmod) induced_29\VBN\generate.v.01|cisplatin|- (r_amod) function_32\NN\mathematical_relation.n.01|induced|impaired|renal (r_conj) cirrhosis_24\NN\liver_disease.n.01|,|and|function (r_conj) cavity_22\NN\hole.n.05|the|oral|,|cirrhosis (r_pobj) of_19\IN\entity.n.01|cavity (r_prep) carcinoma_18\NN\cancer.n.01|recurrent|of (r_pobj) with_16\IN\entity.n.01|carcinoma (r_prep) patient_15\NN\case.n.06|a|with (r_pobj) in_13\IN\linear_unit.n.01|patient (r_prep) occurred_12\VBD\happen.v.01|reaction|in|. (l_nsubj) reaction_2\NN\chemical_process.n.01|an|allergic|consisting|5-fluorouracil
D002945_D000799 NONE cisplatin_27\NN\entity.n.01| (r_advmod) induced_29\VBN\generate.v.01|cisplatin|- (r_amod) function_32\NN\mathematical_relation.n.01|induced|impaired|renal (r_conj) cirrhosis_24\NN\liver_disease.n.01|,|and|function (r_conj) cavity_22\NN\hole.n.05|the|oral|,|cirrhosis (r_pobj) of_19\IN\entity.n.01|cavity (r_prep) carcinoma_18\NN\cancer.n.01|recurrent|of (r_pobj) with_16\IN\entity.n.01|carcinoma (r_prep) patient_15\NN\case.n.06|a|with (r_pobj) in_13\IN\linear_unit.n.01|patient (r_prep) occurred_12\VBD\happen.v.01|reaction|in|. (l_nsubj) reaction_2\NN\chemical_process.n.01|an|allergic|consisting|5-fluorouracil (l_acl) consisting_3\VBG\exist.v.01|of (l_prep) of_4\IN\entity.n.01|angioneurotic|edema (l_pobj) edema_6\NN\swelling.n.01|secondary
D002945_D009062 NONE cisplatin_27\NN\entity.n.01| (r_advmod) induced_29\VBN\generate.v.01|cisplatin|- (r_amod) function_32\NN\mathematical_relation.n.01|induced|impaired|renal (r_conj) cirrhosis_24\NN\liver_disease.n.01|,|and|function (r_conj) cavity_22\NN\hole.n.05|the|oral|,|cirrhosis
D002945_D005355 NONE cisplatin_27\NN\entity.n.01| (r_advmod) induced_29\VBN\generate.v.01|cisplatin|- (r_amod) function_32\NN\mathematical_relation.n.01|induced|impaired|renal (r_conj) cirrhosis_24\NN\liver_disease.n.01|,|and|function
D002945_D007674 NONE cisplatin_27\NN\entity.n.01| (r_advmod) induced_29\VBN\generate.v.01|cisplatin|- (r_amod) function_32\NN\mathematical_relation.n.01|induced|impaired|renal
D004155_D004342 NONE diphenhydramine_1\NN\antihistamine.n.01|oral|and|prednisone (r_nsubj) were_4\VBD\be.v.01|diphenhydramine|ineffective|in|. (l_prep) in_6\IN\linear_unit.n.01|preventing (l_pcomp) preventing_7\VBG\prevent.v.01|recurrence (l_dobj) recurrence_9\NN\repeat.n.01|the|of (l_prep) of_10\IN\entity.n.01|reaction (l_pobj) reaction_13\NN\chemical_process.n.01|the|allergic
D011241_D004342 NONE prednisone_3\NNP\anti-inflammatory.n.01| (r_conj) diphenhydramine_1\NN\antihistamine.n.01|oral|and|prednisone (r_nsubj) were_4\VBD\be.v.01|diphenhydramine|ineffective|in|. (l_prep) in_6\IN\linear_unit.n.01|preventing (l_pcomp) preventing_7\VBG\prevent.v.01|recurrence (l_dobj) recurrence_9\NN\repeat.n.01|the|of (l_prep) of_10\IN\entity.n.01|reaction (l_pobj) reaction_13\NN\chemical_process.n.01|the|allergic
8649546
D007980_D004409 CID levodopa_2\NN\dopa.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|levodopa|- (r_amod) dyskinesia_5\NN\nervous_disorder.n.01|induced
D007980_D004409 CID levodopa_14\RB\dopa.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|levodopa|- (r_amod) dyskinesia_20\NN\nervous_disorder.n.01|induced|ballistic|in
D007980_D010300 NONE levodopa_2\NN\dopa.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|levodopa|- (r_amod) dyskinesia_5\NN\nervous_disorder.n.01|induced (r_pobj) of_1\IN\entity.n.01|dyskinesia (r_prep) improvement_0\NN\transformation.n.01|of|by|. (l_prep) by_6\IN\by.r.01|propranolol (l_pcomp) propranolol_7\NN\entity.n.01|in (l_prep) in_8\IN\linear_unit.n.01|disease (l_pobj) disease_11\NN\illness.n.01|parkinson
D007980_D010300 NONE levodopa_14\RB\dopa.n.01| (r_npadvmod) induced_16\VBN\generate.v.01|levodopa|- (r_amod) dyskinesia_20\NN\nervous_disorder.n.01|induced|ballistic|in (l_prep) in_21\IN\linear_unit.n.01|pd (l_pobj) pd_22\NNP\metallic_element.n.01|
D011433_D004409 NONE propranolol_7\NN\entity.n.01|in (r_pcomp) by_6\IN\by.r.01|propranolol (r_prep) improvement_0\NN\transformation.n.01|of|by|. (l_prep) of_1\IN\entity.n.01|dyskinesia (l_pobj) dyskinesia_5\NN\nervous_disorder.n.01|induced
D011433_D004409 NONE propranolol_18\NN\entity.n.01|dose|as (r_dobj) received_14\VBN\get.v.01|patients|propranolol|. (l_nsubj) patients_1\NNS\case.n.06|seven|suffering (l_acl) suffering_2\VBG\pain.n.01|from|with (l_prep) with_10\IN\entity.n.01|dyskinesia (l_pobj) dyskinesia_13\NN\nervous_disorder.n.01|disabling
D011433_D010300 NONE propranolol_7\NN\entity.n.01|in (l_prep) in_8\IN\linear_unit.n.01|disease (l_pobj) disease_11\NN\illness.n.01|parkinson
D011433_D010300 NONE propranolol_18\NN\entity.n.01|dose|as (r_dobj) received_14\VBN\get.v.01|patients|propranolol|. (l_nsubj) patients_1\NNS\case.n.06|seven|suffering (l_acl) suffering_2\VBG\pain.n.01|from|with (l_prep) from_3\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|parkinson|(|pd|)
D011433_D010300 NONE propranolol_18\NN\entity.n.01|dose|as (r_dobj) received_14\VBN\get.v.01|patients|propranolol|. (l_nsubj) patients_1\NNS\case.n.06|seven|suffering (l_acl) suffering_2\VBG\pain.n.01|from|with (l_prep) from_3\IN\entity.n.01|disease (l_pobj) disease_6\NN\illness.n.01|parkinson|(|pd|) (l_appos) pd_8\NNP\metallic_element.n.01|
9812111
D006220_D011618 NONE haloperidol_11\NN\major_tranquilizer.n.01|for (l_prep) for_12\IN\entity.n.01|psychosis (l_pobj) psychosis_13\NN\mental_illness.n.01|and|behaviors|in
D006220_D011618 NONE haloperidol_17\NN\major_tranquilizer.n.01|and|placebo (r_pobj) of_16\IN\entity.n.01|haloperidol (r_prep) doses_15\NNS\medicine.n.02|two|of (r_pobj) of_13\IN\entity.n.01|doses (r_prep) efficacy_9\NN\effectiveness.n.01|the|and|effects|of (r_dobj) compare_7\VB\likeness.n.01|to|efficacy|in (l_prep) in_20\IN\linear_unit.n.01|treatment (l_pobj) treatment_22\NN\care.n.01|the|of|in (l_prep) of_23\IN\entity.n.01|psychosis (l_pobj) psychosis_24\NN\mental_illness.n.01|and|behaviors
D006220_D011618 NONE haloperidol_12\NN\major_tranquilizer.n.01|dose (r_appos) a_7\NNP\metric_linear_unit.n.01|phase|,|haloperidol (r_dobj) completed_5\VBD\end.v.02|who|a (r_relcl) patients_3\NNS\case.n.06|the|60|completed (r_pobj) for_0\IN\entity.n.01|patients (r_prep) was_13\VBD\washington.n.02|for|efficacious|. (l_acomp) efficacious_14\JJ\efficacious.a.01|and|superior|to (l_prep) to_17\IN\entity.n.01|haloperidol (l_pobj) haloperidol_22\NN\major_tranquilizer.n.01|both|dose|and|placebo|for (l_prep) for_25\IN\entity.n.01|scores (l_pobj) scores_26\NNS\large_indefinite_quantity.n.01|on (l_prep) on_27\IN\on.a.01|factor|and|on (l_pobj) factor_34\NN\cause.n.01|the|brief|scale|psychosis (l_compound) psychosis_33\NN\mental_illness.n.01|
D006220_D011618 NONE haloperidol_22\NN\major_tranquilizer.n.01|both|dose|and|placebo|for (l_prep) for_25\IN\entity.n.01|scores (l_pobj) scores_26\NNS\large_indefinite_quantity.n.01|on (l_prep) on_27\IN\on.a.01|factor|and|on (l_pobj) factor_34\NN\cause.n.01|the|brief|scale|psychosis (l_compound) psychosis_33\NN\mental_illness.n.01|
D006220_D011618 NONE haloperidol_6\NN\major_tranquilizer.n.01| (r_pobj) with_5\IN\entity.n.01|haloperidol (r_prep) observed_4\VBN\spy.v.03|window|with (r_nsubj) apply_9\VB\use.v.01|observed|may|also|to|. (l_prep) to_10\IN\entity.n.01|neuroleptics (l_pobj) neuroleptics_12\NNS\tranquilizer.n.01|other|used (l_acl) used_13\VBN\use.v.01|in (l_prep) in_14\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|alzheimer|disease|with (l_prep) with_19\IN\entity.n.01|psychosis (l_pobj) psychosis_20\NN\mental_illness.n.01|and|behaviors
D006220_D019958 NONE haloperidol_11\NN\major_tranquilizer.n.01|for (l_prep) for_12\IN\entity.n.01|psychosis (l_pobj) psychosis_13\NN\mental_illness.n.01|and|behaviors|in (l_conj) behaviors_16\NNS\activity.n.01|disruptive
D006220_D019958 NONE haloperidol_17\NN\major_tranquilizer.n.01|and|placebo (r_pobj) of_16\IN\entity.n.01|haloperidol (r_prep) doses_15\NNS\medicine.n.02|two|of (r_pobj) of_13\IN\entity.n.01|doses (r_prep) efficacy_9\NN\effectiveness.n.01|the|and|effects|of (r_dobj) compare_7\VB\likeness.n.01|to|efficacy|in (l_prep) in_20\IN\linear_unit.n.01|treatment (l_pobj) treatment_22\NN\care.n.01|the|of|in (l_prep) of_23\IN\entity.n.01|psychosis (l_pobj) psychosis_24\NN\mental_illness.n.01|and|behaviors (l_conj) behaviors_27\NNS\activity.n.01|disruptive
D006220_D019958 NONE haloperidol_6\NN\major_tranquilizer.n.01| (r_pobj) with_5\IN\entity.n.01|haloperidol (r_prep) observed_4\VBN\spy.v.03|window|with (r_nsubj) apply_9\VB\use.v.01|observed|may|also|to|. (l_prep) to_10\IN\entity.n.01|neuroleptics (l_pobj) neuroleptics_12\NNS\tranquilizer.n.01|other|used (l_acl) used_13\VBN\use.v.01|in (l_prep) in_14\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|alzheimer|disease|with (l_prep) with_19\IN\entity.n.01|psychosis (l_pobj) psychosis_20\NN\mental_illness.n.01|and|behaviors (l_conj) behaviors_23\NNS\activity.n.01|disruptive
D006220_D000544 NONE haloperidol_11\NN\major_tranquilizer.n.01|for (l_prep) for_12\IN\entity.n.01|psychosis (l_pobj) psychosis_13\NN\mental_illness.n.01|and|behaviors|in (l_prep) in_17\IN\linear_unit.n.01|disease (l_pobj) disease_20\NN\illness.n.01|alzheimer
D006220_D000544 NONE haloperidol_17\NN\major_tranquilizer.n.01|and|placebo (r_pobj) of_16\IN\entity.n.01|haloperidol (r_prep) doses_15\NNS\medicine.n.02|two|of (r_pobj) of_13\IN\entity.n.01|doses (r_prep) efficacy_9\NN\effectiveness.n.01|the|and|effects|of (r_dobj) compare_7\VB\likeness.n.01|to|efficacy|in (l_prep) in_20\IN\linear_unit.n.01|treatment (l_pobj) treatment_22\NN\care.n.01|the|of|in (l_prep) in_28\IN\linear_unit.n.01|patients (l_pobj) patients_29\NNS\case.n.06|with (l_prep) with_30\IN\entity.n.01|disease (l_pobj) disease_33\NN\illness.n.01|alzheimer
D006220_D000544 NONE haloperidol_20\NN\major_tranquilizer.n.01|,|day|(|dose|) (r_appos) phase_16\NN\time_period.n.01|(|a|)|,|haloperidol|,|and|haloperidol (r_preconj) in_0\IN\linear_unit.n.01|trial|phase (r_prep) compared_48\VBN\analyze.v.01|in|,|were|in|. (l_prep) in_49\IN\linear_unit.n.01|outpatients (l_pobj) outpatients_51\NNS\patient.n.01|71|with (l_prep) with_52\IN\entity.n.01|disease (l_pobj) disease_55\NN\illness.n.01|alzheimer
D006220_D000544 NONE haloperidol_34\NN\major_tranquilizer.n.01|,|day|(|dose|) (r_conj) phase_16\NN\time_period.n.01|(|a|)|,|haloperidol|,|and|haloperidol (r_preconj) in_0\IN\linear_unit.n.01|trial|phase (r_prep) compared_48\VBN\analyze.v.01|in|,|were|in|. (l_prep) in_49\IN\linear_unit.n.01|outpatients (l_pobj) outpatients_51\NNS\patient.n.01|71|with (l_prep) with_52\IN\entity.n.01|disease (l_pobj) disease_55\NN\illness.n.01|alzheimer
D006220_D000544 NONE haloperidol_6\NN\major_tranquilizer.n.01| (r_pobj) with_5\IN\entity.n.01|haloperidol (r_prep) observed_4\VBN\spy.v.03|window|with (r_nsubj) apply_9\VB\use.v.01|observed|may|also|to|. (l_prep) to_10\IN\entity.n.01|neuroleptics (l_pobj) neuroleptics_12\NNS\tranquilizer.n.01|other|used (l_acl) used_13\VBN\use.v.01|in (l_prep) in_14\IN\linear_unit.n.01|patients (l_pobj) patients_18\NNS\case.n.06|alzheimer|disease|with (l_compound) disease_17\NN\illness.n.01|
D006220_D011595 NONE haloperidol_12\NN\major_tranquilizer.n.01|dose (r_appos) a_7\NNP\metric_linear_unit.n.01|phase|,|haloperidol (r_dobj) completed_5\VBD\end.v.02|who|a (r_relcl) patients_3\NNS\case.n.06|the|60|completed (r_pobj) for_0\IN\entity.n.01|patients (r_prep) was_13\VBD\washington.n.02|for|efficacious|. (l_acomp) efficacious_14\JJ\efficacious.a.01|and|superior|to (l_prep) to_17\IN\entity.n.01|haloperidol (l_pobj) haloperidol_22\NN\major_tranquilizer.n.01|both|dose|and|placebo|for (l_prep) for_25\IN\entity.n.01|scores (l_pobj) scores_26\NNS\large_indefinite_quantity.n.01|on (l_prep) on_27\IN\on.a.01|factor|and|on (l_conj) on_36\IN\on.a.01|agitation (l_pobj) agitation_38\NN\psychological_state.n.01|psychomotor
D006220_D011595 NONE haloperidol_22\NN\major_tranquilizer.n.01|both|dose|and|placebo|for (l_prep) for_25\IN\entity.n.01|scores (l_pobj) scores_26\NNS\large_indefinite_quantity.n.01|on (l_prep) on_27\IN\on.a.01|factor|and|on (l_conj) on_36\IN\on.a.01|agitation (l_pobj) agitation_38\NN\psychological_state.n.01|psychomotor
D006220_D001480 CID haloperidol_8\NN\major_tranquilizer.n.01| (r_pobj) for_7\IN\entity.n.01|haloperidol (r_prep) profile_6\NN\chart.n.01|a|favorable|therapeutic|for|in (r_dobj) indicated_2\VBD\tell.v.02|results|profile|,|developed|. (l_advcl) developed_22\VBD\create.v.02|although|subgroup|moderate (l_acomp) moderate_23\JJ\adult.n.01|to (l_prep) to_24\TO\entity.n.01|signs (l_pobj) signs_27\NNS\clue.n.02|severe|extrapyramidal
3560096
D013467_D006947 CID sulindac_3\NN\nonsteroidal_anti-inflammatory.n.01| (r_compound) therapy_4\NN\medical_care.n.01|sulindac (r_pobj) with_2\IN\entity.n.01|therapy (r_prep) associated_1\VBN\think.v.03|with (r_acl) hyperkalemia_0\NNP\symptom.n.01|associated|.
D013467_D006947 CID sulindac_22\NN\nonsteroidal_anti-inflammatory.n.01| (r_compound) administration_23\NN\management.n.01|sulindac (r_pobj) of_21\IN\entity.n.01|administration (r_prep) days_20\NNS\life.n.07|8|of (r_pobj) within_16\IN\inside.r.02|days (r_prep) developed_15\VBD\create.v.02|hyperkalemia|within (l_nsubj) hyperkalemia_6\VBD\symptom.n.01|in|ranging
D013467_D006947 CID sulindac_29\NN\nonsteroidal_anti-inflammatory.n.01|and|hyperkalemia (l_conj) hyperkalemia_31\NN\symptom.n.01|
D007213_D006947 CID indomethacin_17\NN\nonsteroidal_anti-inflammatory.n.01| (r_pobj) as_16\IN\chemical_element.n.01|such|indomethacin (r_prep) nsaid_13\NNP\anti-inflammatory.n.01|(|)|as (r_appos) agents_11\NNS\causal_agent.n.01|nonsteroidal|antiinflammatory|nsaid (r_pobj) of_8\IN\entity.n.01|agents (r_prep) complication_7\NN\hindrance.n.03|a|of (r_pobj) as_5\IN\chemical_element.n.01|complication (r_prep) recognized_4\VBN\accept.v.01|hyperkalemia|has|recently|been|as|. (l_nsubjpass) hyperkalemia_0\NNP\symptom.n.01|
D011188_D006947 NONE potassium_8\NN\metallic_element.n.01|serum (r_dobj) effect_6\NN\phenomenon.n.01|to|potassium (r_xcomp) known_4\VBN\know.v.01|effect (r_acl) medications_3\NNS\drug.n.01|no|other|known (r_nsubjpass) given_11\VBN\assumption.n.02|as|medications|had|been|concomitantly (r_advcl) is_18\VBZ\be.v.01|given|,|course|suggestive|. (l_acomp) suggestive_19\JJ\implicative.s.01|of (l_prep) of_20\IN\entity.n.01|relationship (l_pobj) relationship_27\NN\relation.n.01|a|cause|between (l_prep) between_28\IN\between.r.01|sulindac (l_pobj) sulindac_29\NN\nonsteroidal_anti-inflammatory.n.01|and|hyperkalemia (l_conj) hyperkalemia_31\NN\symptom.n.01|
2096243
C017367_D019965 CID carmofur_0\NN\entity.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|carmofur|- (r_amod) disorders_5\NNS\physical_condition.n.01|induced|organic|mental|.
C017367_D019965 CID carmofur_19\NN\entity.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|carmofur|- (r_amod) leukoencephalopathy_22\NN\entity.n.01|induced (r_pobj) of_18\IN\entity.n.01|leukoencephalopathy (r_prep) onset_17\NN\start.n.01|the|of (r_pobj) after_15\IN\after.s.01|onset (r_prep) period_14\NN\fundamental_quantity.n.01|the|prognostic|after (r_pobj) in_11\IN\linear_unit.n.01|period (r_prep) female_10\NN\animal.n.01|a|old|in (r_pobj) in_5\IN\linear_unit.n.01|female (r_prep) observed_4\VBN\spy.v.03|disorder|was|in|. (l_nsubjpass) disorder_2\NN\physical_condition.n.01|organic|mental
C017367_D056784 CID carmofur_19\NN\entity.n.01| (r_npadvmod) induced_21\VBN\generate.v.01|carmofur|- (r_amod) leukoencephalopathy_22\NN\entity.n.01|induced
C017367_D056784 CID carmofur_2\NN\entity.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|carmofur|- (r_amod) leukoencephalopathy_5\JJ\entity.n.01|induced
C017367_D010554 NONE carmofur_2\NN\entity.n.01| (r_npadvmod) induced_4\VBN\generate.v.01|carmofur|- (r_amod) leukoencephalopathy_5\JJ\entity.n.01|induced (r_nsubj) result_8\VB\phenomenon.n.01|consequently|,|leukoencephalopathy|may|uncommonly|in|. (l_prep) in_9\IN\linear_unit.n.01|syndrome (l_pobj) syndrome_12\NN\complex.n.01|personality|in
14657095
D000666_D002311 CID b_6\NNP\eubacteria.n.01| (r_compound) therapy_7\NN\medical_care.n.01|amphotericin|b (r_pobj) to_4\IN\entity.n.01|therapy (r_prep) related_3\VBN\think.v.03|to (r_acl) cardiomyopathy_2\NN\heart_disease.n.01|reversible|dilated|related|.
D000666_D002311 CID b_20\NNP\eubacteria.n.01|amphotericin|amb (r_pobj) with_18\IN\entity.n.01|b (r_prep) developed_5\VBD\create.v.02|who|failure|after|with|for (l_dobj) failure_12\NN\nonaccomplishment.n.01|dilated|cardiomyopathy|heart (l_amod) cardiomyopathy_7\NN\heart_disease.n.01|and|clinical
D000666_D002311 CID amb_22\NNP\entity.n.01|(|) (r_appos) b_20\NNP\eubacteria.n.01|amphotericin|amb (r_pobj) with_18\IN\entity.n.01|b (r_prep) developed_5\VBD\create.v.02|who|failure|after|with|for (l_dobj) failure_12\NN\nonaccomplishment.n.01|dilated|cardiomyopathy|heart (l_amod) cardiomyopathy_7\NN\heart_disease.n.01|and|clinical
D000666_D006333 CID b_20\NNP\eubacteria.n.01|amphotericin|amb (r_pobj) with_18\IN\entity.n.01|b (r_prep) developed_5\VBD\create.v.02|who|failure|after|with|for (l_dobj) failure_12\NN\nonaccomplishment.n.01|dilated|cardiomyopathy|heart
D000666_D006333 CID amb_22\NNP\entity.n.01|(|) (r_appos) b_20\NNP\eubacteria.n.01|amphotericin|amb (r_pobj) with_18\IN\entity.n.01|b (r_prep) developed_5\VBD\create.v.02|who|failure|after|with|for (l_dobj) failure_12\NN\nonaccomplishment.n.01|dilated|cardiomyopathy|heart
D000666_D006333 CID amb._12\NN\entity.n.01| (r_pobj) for_11\IN\entity.n.01|amb. (r_prep) substituted_10\VBN\change.v.01|after|posaconazole|was|for (r_advcl) resolved_6\VBD\end.v.02|substituted (r_acl) abnormalities_2\NNS\physical_condition.n.01|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN\nonaccomplishment.n.01|heart
D000666_D003047 NONE b_20\NNP\eubacteria.n.01|amphotericin|amb (r_pobj) with_18\IN\entity.n.01|b (r_prep) developed_5\VBD\create.v.02|who|failure|after|with|for (l_prep) for_24\IN\entity.n.01|coccidioidomycosis (l_pobj) coccidioidomycosis_26\NN\fungal_infection.n.01|disseminated
D000666_D003047 NONE amb_22\NNP\entity.n.01|(|) (r_appos) b_20\NNP\eubacteria.n.01|amphotericin|amb (r_pobj) with_18\IN\entity.n.01|b (r_prep) developed_5\VBD\create.v.02|who|failure|after|with|for (l_prep) for_24\IN\entity.n.01|coccidioidomycosis (l_pobj) coccidioidomycosis_26\NN\fungal_infection.n.01|disseminated
C101425_D006333 NONE posaconazole_8\NN\entity.n.01| (r_nsubjpass) substituted_10\VBN\change.v.01|after|posaconazole|was|for (r_advcl) resolved_6\VBD\end.v.02|substituted (r_acl) abnormalities_2\NNS\physical_condition.n.01|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN\nonaccomplishment.n.01|heart
D000666_D064420 NONE amb._12\NN\entity.n.01| (r_pobj) of_11\IN\entity.n.01|amb. (r_prep) toxicity_10\NN\definite_quantity.n.01|the|rare|of
18023325
D004221_D014826 CID disulfiram_6\NN\medicine.n.02| (r_compound) intoxication_7\NN\physical_condition.n.01|acute|disulfiram (r_pobj) after_4\IN\after.s.01|intoxication (r_prep) palsy_3\JJ\dysfunction.n.01|acute|fold|after|.
D004221_D014826 CID disulfiram_6\NN\medicine.n.02| (r_compound) overdose_7\NN\drug.v.01|a|disulfiram (r_pobj) by_4\IN\by.r.01|overdose (r_agent) caused_3\VBN\make.v.03|by (r_acl) neuropathy_2\NN\pathology.n.02|acute|peripheral|caused (r_nsubj) is_8\VBZ\be.v.01|neuropathy|rare|and|is (l_conj) is_13\VBZ\be.v.01|there|report|. (l_attr) report_15\NN\document.n.01|no|of|leading (l_acl) leading_18\VBG\strip.n.02|to (l_prep) to_19\IN\entity.n.01|palsy (l_pobj) palsy_22\JJ\dysfunction.n.01|fold
D004221_D010523 CID disulfiram_6\NN\medicine.n.02| (r_compound) overdose_7\NN\drug.v.01|a|disulfiram (r_pobj) by_4\IN\by.r.01|overdose (r_agent) caused_3\VBN\make.v.03|by (r_acl) neuropathy_2\NN\pathology.n.02|acute|peripheral|caused
D004221_D062787 NONE disulfiram_6\NN\medicine.n.02| (r_compound) overdose_7\NN\drug.v.01|a|disulfiram
D004221_D010243 NONE disulfiram_24\NN\medicine.n.02| (r_compound) intoxication_25\NN\physical_condition.n.01|dose|disulfiram (r_pobj) by_20\IN\by.r.01|intoxication (r_agent) caused_19\VBN\make.v.03|by (r_acl) polyneuropathy_18\NN\entity.n.01|severe|acute|sensorimotor|axonal|caused (r_dobj) superimposed_13\VBN\put.v.01|polyneuropathy (r_conj) was_1\VBD\washington.n.02|this|case|and|superimposed|. (l_attr) case_3\NN\happening.n.01|a|of (l_prep) of_4\IN\entity.n.01|palsy (l_pobj) palsy_6\JJ\dysfunction.n.01|acute|of
D004221_D011115 NONE disulfiram_24\NN\medicine.n.02| (r_compound) intoxication_25\NN\physical_condition.n.01|dose|disulfiram (r_pobj) by_20\IN\by.r.01|intoxication (r_agent) caused_19\VBN\make.v.03|by (r_acl) polyneuropathy_18\NN\entity.n.01|severe|acute|sensorimotor|axonal|caused
2484011
D000547_D003866 NONE amantadine_4\JJ\entity.n.01| (r_nmod) activity_7\NN\act.n.02|amantadine|depressed|locomotor (l_amod) depressed_5\JJ\discourage.v.02|
D000547_D011596 CID amantadine_2\NN\entity.n.01| (r_pobj) of_1\IN\entity.n.01|amantadine (r_prep) readministration_0\NN\entity.n.01|of (r_nsubj) increased_12\VBN\change_magnitude.v.01|readministration|,|after|,|motility|from|in|with|. (l_prep) with_21\IN\entity.n.01|exception (l_pobj) exception_22\NN\omission.n.04|of (l_prep) of_23\IN\entity.n.01|mice (l_pobj) mice_28\NNS\rodent.n.01|the|c|occurred (l_relcl) occurred_33\VBD\happen.v.01|where|suppression (l_nsubj) suppression_30\NN\growth.n.01|of (l_prep) of_31\IN\entity.n.01|motility (l_pobj) motility_32\NN\mobility.n.01|
D000547_D011596 CID amantadine_45\NN\entity.n.01| (r_pobj) by_44\IN\by.r.01|amantadine (r_agent) caused_43\VBN\make.v.03|by|in (r_acl) depression_42\NN\psychological_state.n.01|a|behavioral|caused
D000588_D011596 NONE amines_6\NNS\methane_series.n.01|brain|biogenic|of (r_pobj) of_3\IN\entity.n.01|amines (r_prep) results_2\NNS\phenomenon.n.01|the|biochemical|of (r_nsubj) suggest_13\VBP\declare.v.01|results|decrease|. (l_dobj) decrease_16\NN\change.n.01|a|probable|of|by|and|increase (l_conj) increase_29\NN\indefinite_quantity.n.01|a|resulting|in|account (l_relcl) account_38\VB\record.n.01|which|may|for (l_prep) for_39\IN\entity.n.01|depression (l_pobj) depression_42\NN\psychological_state.n.01|a|behavioral|caused
D002395_D011596 NONE catecholamine_18\NN\hormone.n.01| (r_compound) rate_20\NN\magnitude_relation.n.01|catecholamine|turnover|and/or|metabolism (r_pobj) of_17\IN\entity.n.01|rate (r_prep) decrease_16\NN\change.n.01|a|probable|of|by|and|increase (l_conj) increase_29\NN\indefinite_quantity.n.01|a|resulting|in|account (l_relcl) account_38\VB\record.n.01|which|may|for (l_prep) for_39\IN\entity.n.01|depression (l_pobj) depression_42\NN\psychological_state.n.01|a|behavioral|caused
D009638_D011596 NONE norepinephrine_35\NN\catecholamine.n.01| (r_pobj) of_34\IN\entity.n.01|norepinephrine (r_prep) methylation_33\NN\entity.n.01|o|-|of (r_pobj) in_30\IN\linear_unit.n.01|methylation (r_prep) increase_29\NN\indefinite_quantity.n.01|a|resulting|in|account (l_relcl) account_38\VB\record.n.01|which|may|for (l_prep) for_39\IN\entity.n.01|depression (l_pobj) depression_42\NN\psychological_state.n.01|a|behavioral|caused
7420681
D014031_D007674 NONE tobramycin_3\JJ\antibiotic.n.01| (r_pobj) of_2\IN\entity.n.01|tobramycin (r_prep) nephrotoxicity_1\NN\entity.n.01|clinical|of|and|gentamicin|.
D014031_D007674 NONE sulfate_4\NN\salt.n.01|tobramycin (r_conj) sulfate_1\NN\salt.n.01|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\act.v.01|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\show.v.04|to|ototoxicity (l_dobj) ototoxicity_8\NN\entity.n.01|and|nephrotoxicity|in (l_conj) nephrotoxicity_10\NN\entity.n.01|
D005839_D007674 NONE gentamicin_5\NN\antibiotic.n.01| (r_conj) nephrotoxicity_1\NN\entity.n.01|clinical|of|and|gentamicin|.
D005839_D007674 NONE sulfate_1\NN\salt.n.01|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\act.v.01|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\show.v.04|to|ototoxicity (l_dobj) ototoxicity_8\NN\entity.n.01|and|nephrotoxicity|in (l_conj) nephrotoxicity_10\NN\entity.n.01|
D005839_D006311 NONE sulfate_1\NN\salt.n.01|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\act.v.01|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\show.v.04|to|ototoxicity (l_dobj) ototoxicity_8\NN\entity.n.01|and|nephrotoxicity|in
D014031_D006311 NONE sulfate_4\NN\salt.n.01|tobramycin (r_conj) sulfate_1\NN\salt.n.01|gentamicin|and|sulfate (r_nsubj) continue_5\VBP\act.v.01|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\show.v.04|to|ototoxicity (l_dobj) ototoxicity_8\NN\entity.n.01|and|nephrotoxicity|in
D005839_D051437 CID sulfate_25\NN\salt.n.01|gentamicin|or|sulfate|for (r_pobj) of_23\IN\entity.n.01|sulfate (r_prep) day_22\NN\time_unit.n.01|of (r_appos) kg_20\NNS\metric_weight_unit.n.01|5|mg|/|/|day (r_pobj) with_14\IN\entity.n.01|kg (r_prep) treated_13\VBN\interact.v.01|with (r_conj) patients_5\NNS\case.n.06|62|with|and|treated (r_nsubjpass) followed_36\VBN\travel.v.01|in|,|patients|were|up|prospectively|for|. (l_prep) for_39\IN\entity.n.01|development (l_pobj) development_41\NN\improvement.n.02|the|of (l_prep) of_42\IN\entity.n.01|failure (l_pobj) failure_47\NN\nonaccomplishment.n.01|related|renal|,|defined
D005839_D051437 CID gentamicin_23\NN\antibiotic.n.01| (r_npadvmod) treated_25\VBN\interact.v.01|gentamicin|- (r_amod) patients_26\NNS\case.n.06|the|treated (r_pobj) of_21\IN\entity.n.01|patients (r_prep) 16_14\CD\large_integer.n.01|of|%|)|of (r_nsubj) had_27\VBD\have.v.01|five|16|failure|. (l_dobj) failure_29\NN\nonaccomplishment.n.01|renal
D005839_D051437 CID gentamicin_2\NN\antibiotic.n.01| (r_nsubjpass) associated_4\VBN\think.v.03|thus|,|gentamicin|was|with|was|. (l_prep) with_5\IN\entity.n.01|failure (l_pobj) failure_7\NN\nonaccomplishment.n.01|renal
D014031_D051437 CID sulfate_28\NN\salt.n.01|tobramycin (r_conj) sulfate_25\NN\salt.n.01|gentamicin|or|sulfate|for (r_pobj) of_23\IN\entity.n.01|sulfate (r_prep) day_22\NN\time_unit.n.01|of (r_appos) kg_20\NNS\metric_weight_unit.n.01|5|mg|/|/|day (r_pobj) with_14\IN\entity.n.01|kg (r_prep) treated_13\VBN\interact.v.01|with (r_conj) patients_5\NNS\case.n.06|62|with|and|treated (r_nsubjpass) followed_36\VBN\travel.v.01|in|,|patients|were|up|prospectively|for|. (l_prep) for_39\IN\entity.n.01|development (l_pobj) development_41\NN\improvement.n.02|the|of (l_prep) of_42\IN\entity.n.01|failure (l_pobj) failure_47\NN\nonaccomplishment.n.01|related|renal|,|defined
D014031_D051437 CID tobramycin_9\RB\antibiotic.n.01| (r_npadvmod) treated_11\VBN\interact.v.01|tobramycin|- (r_amod) patients_12\NNS\case.n.06|the|treated (r_pobj) of_7\IN\entity.n.01|patients (r_prep) %_5\NN\entity.n.01|33|(|15|)|of|and (r_pobj) of_1\IN\entity.n.01|% (r_prep) five_0\CD\digit.n.01|of (r_nsubj) had_27\VBD\have.v.01|five|16|failure|. (l_dobj) failure_29\NN\nonaccomplishment.n.01|renal
D014031_D051437 CID tobramycin_16\JJ\antibiotic.n.01| (r_acomp) was_15\VBD\washington.n.02|often|as|tobramycin (r_advcl) associated_4\VBN\think.v.03|thus|,|gentamicin|was|with|was|. (l_prep) with_5\IN\entity.n.01|failure (l_pobj) failure_7\NN\nonaccomplishment.n.01|renal
D000617_D051437 NONE aminoglycoside_43\NN\entity.n.01| (r_npadvmod) related_45\VBN\think.v.03|aminoglycoside|- (r_amod) failure_47\NN\nonaccomplishment.n.01|related|renal|,|defined
347884
D006220_D019967 NONE haloperidol_6\NN\major_tranquilizer.n.01| (r_pobj) with_5\IN\entity.n.01|haloperidol (r_prep) study_4\NN\examination.n.01|the|double|blind|with (r_pobj) in_0\IN\linear_unit.n.01|study (r_prep) found_11\VBN\wage.n.01|in|,|substances|were|be|. (l_xcomp) be_13\VB\metallic_element.n.01|to|effective (l_acomp) effective_15\JJ\effective.a.01|highly|in (l_prep) in_16\IN\linear_unit.n.01|treatment (l_pobj) treatment_18\NN\care.n.01|the|of (l_prep) of_19\IN\entity.n.01|syndromes (l_pobj) syndromes_21\NNS\complex.n.01|psychotic|belonging (l_acl) belonging_22\VBG\happiness.n.02|predominantly|to (l_prep) to_24\IN\entity.n.01|group (l_pobj) group_27\NN\abstraction.n.06|the|schizophrenia
1420741
D005672_D003424 NONE acid_7\NN\compound.n.02|fusidic (r_pobj) with_5\IN\entity.n.01|acid (r_prep) disease_4\NN\illness.n.01|crohn|with
D005672_D003424 NONE acid_28\NN\compound.n.02| (r_compound) treatment_29\NN\care.n.01|fusidic|acid|in (r_pobj) of_26\IN\entity.n.01|treatment (r_prep) tolerability_25\NN\entity.n.01|of (r_conj) pharmacodynamics_23\NNS\entity.n.01|the|and|tolerability (r_dobj) estimate_21\VB\calculation.n.02|to|pharmacodynamics (r_advcl) undertaken_19\VBN\initiate.v.02|because|,|study|was|estimate|. (l_prep) because_0\IN\entity.n.01|of|need (l_pobj) need_3\NN\condition.n.01|the|for (l_prep) for_4\IN\entity.n.01|development (l_pobj) development_6\NN\improvement.n.02|the|of (l_prep) of_7\IN\entity.n.01|treatments (l_pobj) treatments_9\NNS\care.n.01|new|for (l_prep) for_10\IN\entity.n.01|disease (l_pobj) disease_13\NN\illness.n.01|crohn
D005672_D003424 NONE acid_9\NN\compound.n.02| (r_nsubj) be_11\VB\metallic_element.n.01|that|fusidic|acid|may|of|in (l_prep) in_14\IN\linear_unit.n.01|patients (l_pobj) patients_21\NNS\case.n.06|selected|chronic|active|crohn|disease|is (l_compound) disease_20\NN\illness.n.01|
D016572_D003424 NONE cyclosporin_16\NN\entity.n.01| (r_pobj) to_15\IN\entity.n.01|cyclosporin (r_prep) similar_14\JJ\similar.a.01|to (r_amod) properties_13\NNS\possession.n.02|immunosuppressive|similar (r_pobj) with_11\IN\entity.n.01|properties (r_prep) antibiotic_10\NN\antibacterial.n.01|an|with (r_appos) treatment_0\NN\care.n.01|of|:|antibiotic|. (l_prep) of_1\IN\entity.n.01|disease (l_pobj) disease_4\NN\illness.n.01|crohn|with
D005672_D015212 NONE acid_13\NN\compound.n.02|fusidic (r_pobj) of_11\IN\entity.n.01|acid (r_prep) use_10\NN\activity.n.01|the|of|at (l_prep) at_14\IN\chemical_element.n.01|level (l_pobj) level_17\NN\property.n.02|the|cytokine|in (l_prep) in_18\IN\linear_unit.n.01|disease (l_pobj) disease_21\NN\illness.n.01|inflammatory|bowel
17400887
D013726_D020078 NONE terbutaline_6\JJ\entity.n.01| (r_compound) treatment_7\NN\care.n.01|neonatal|terbutaline|in (r_pobj) after_4\IN\after.s.01|treatment (r_prep) abnormalities_3\NNS\physical_condition.n.01|neuroinflammation|after|:|implications|. (l_nmod) neuroinflammation_0\NN\entity.n.01|and|behavioral
D013726_D001523 NONE terbutaline_6\JJ\entity.n.01| (r_compound) treatment_7\NN\care.n.01|neonatal|terbutaline|in (r_pobj) after_4\IN\after.s.01|treatment (r_prep) abnormalities_3\NNS\physical_condition.n.01|neuroinflammation|after|:|implications|.
D013726_D001321 CID terbutaline_6\JJ\entity.n.01| (r_compound) treatment_7\NN\care.n.01|neonatal|terbutaline|in (r_pobj) after_4\IN\after.s.01|treatment (r_prep) abnormalities_3\NNS\physical_condition.n.01|neuroinflammation|after|:|implications|. (l_appos) implications_11\NNS\inference.n.01|for (l_prep) for_12\IN\entity.n.01|autism (l_pobj) autism_13\NN\syndrome.n.02|
D013726_D001321 CID terbutaline_0\NNP\entity.n.01|,|agonist|, (r_nsubjpass) associated_13\VBN\think.v.03|terbutaline|has|been|with|. (l_prep) with_14\IN\entity.n.01|concordance (l_pobj) concordance_16\NN\order.n.03|increased|for (l_prep) for_17\IN\entity.n.01|autism (l_pobj) autism_18\NN\syndrome.n.02|in
D013726_D007752 NONE terbutaline_0\NNP\entity.n.01|,|agonist|, (l_appos) agonist_4\NN\protagonist.n.02|a|beta2-adrenoceptor|used (l_acl) used_5\VBN\use.v.01|arrest (l_xcomp) arrest_7\VB\capture.n.01|to|labor (l_dobj) labor_9\NN\class.n.03|preterm
1130930
D002512_D007674 NONE cephalothin_3\NN\cephalosporin.n.01| (r_compound) gentamicin_5\NN\antibiotic.n.01|cephalothin|- (r_compound) regimen_6\NN\plan.n.01|combined|gentamicin (r_pobj) of_1\IN\entity.n.01|regimen (r_prep) nephrotoxicity_0\NN\entity.n.01|of|.
D005839_D007674 NONE gentamicin_5\NN\antibiotic.n.01|cephalothin|- (r_compound) regimen_6\NN\plan.n.01|combined|gentamicin (r_pobj) of_1\IN\entity.n.01|regimen (r_prep) nephrotoxicity_0\NN\entity.n.01|of|.
D002512_D007683 CID sodium_23\NN\metallic_element.n.01|cephalothin (r_pobj) of_21\IN\entity.n.01|sodium (r_prep) combination_20\NN\collection.n.01|a|of (r_dobj) receiving_18\VBG\get.v.01|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\create.v.02|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\death.n.02|acute|tubular|,|characterized
D002512_D009846 NONE sodium_23\NN\metallic_element.n.01|cephalothin (r_pobj) of_21\IN\entity.n.01|sodium (r_prep) combination_20\NN\collection.n.01|a|of (r_dobj) receiving_18\VBG\get.v.01|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\create.v.02|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\death.n.02|acute|tubular|,|characterized (l_acl) characterized_7\VBN\remember.v.02|by (l_agent) by_9\IN\by.r.01|clinically|failure (l_pobj) failure_13\NN\nonaccomplishment.n.01|acute|oliguric|renal
D002512_D051437 NONE sodium_23\NN\metallic_element.n.01|cephalothin (r_pobj) of_21\IN\entity.n.01|sodium (r_prep) combination_20\NN\collection.n.01|a|of (r_dobj) receiving_18\VBG\get.v.01|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\create.v.02|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\death.n.02|acute|tubular|,|characterized (l_acl) characterized_7\VBN\remember.v.02|by (l_agent) by_9\IN\by.r.01|clinically|failure (l_pobj) failure_13\NN\nonaccomplishment.n.01|acute|oliguric|renal
D005839_D007683 CID sulfate_26\NN\salt.n.01| (r_compound) therapy_27\NN\medical_care.n.01|sulfate (r_dobj) gentamicin_25\NN\antibiotic.n.01|therapy (r_conj) receiving_18\VBG\get.v.01|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\create.v.02|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\death.n.02|acute|tubular|,|characterized
D005839_D009846 NONE sulfate_26\NN\salt.n.01| (r_compound) therapy_27\NN\medical_care.n.01|sulfate (r_dobj) gentamicin_25\NN\antibiotic.n.01|therapy (r_conj) receiving_18\VBG\get.v.01|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\create.v.02|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\death.n.02|acute|tubular|,|characterized (l_acl) characterized_7\VBN\remember.v.02|by (l_agent) by_9\IN\by.r.01|clinically|failure (l_pobj) failure_13\NN\nonaccomplishment.n.01|acute|oliguric|renal
D005839_D051437 NONE sulfate_26\NN\salt.n.01| (r_compound) therapy_27\NN\medical_care.n.01|sulfate (r_dobj) gentamicin_25\NN\antibiotic.n.01|therapy (r_conj) receiving_18\VBG\get.v.01|while|they|were|combination|and|gentamicin (r_advcl) developed_2\VBD\create.v.02|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\death.n.02|acute|tubular|,|characterized (l_acl) characterized_7\VBN\remember.v.02|by (l_agent) by_9\IN\by.r.01|clinically|failure (l_pobj) failure_13\NN\nonaccomplishment.n.01|acute|oliguric|renal
19581773
C417083_D009157 CID interferon_6\NN\antiviral.n.01|and|ribavirin (r_nmod) treatment_9\NN\care.n.01|pegylated|interferon|for (r_pobj) during_4\IN\entity.n.01|treatment (r_prep) development_0\NN\improvement.n.02|of|during (l_prep) of_1\IN\entity.n.01|myasthenia (l_pobj) myasthenia_3\NN\autoimmune_disease.n.01|ocular
C417083_D009157 CID alpha-2b_10\CD\entity.n.01|pegylated|ifn|and|ribavirin|for (r_pobj) of_7\IN\entity.n.01|alpha-2b (r_prep) therapy_6\NN\medical_care.n.01|combination|of (r_pobj) with_4\IN\entity.n.01|therapy (r_prep) associated_3\VBN\think.v.03|with (r_acl) myasthenia_2\NN\autoimmune_disease.n.01|the|ocular|associated
C417083_D009157 CID ifn_35\NNP\entity.n.01| (r_compound) therapy_36\NN\medical_care.n.01|ifn (r_pobj) of_34\IN\entity.n.01|therapy (r_prep) complications_33\NNS\hindrance.n.03|the|various|eye|of (r_pobj) of_29\IN\entity.n.01|complications (r_prep) review_28\NN\appraisal.n.01|a|of (r_pobj) with_26\IN\entity.n.01|review (r_prep) present_23\VBP\time.n.05|reported|;|therefore|,|we|case|with|. (l_ccomp) reported_18\VBN\inform.v.01|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN\autoimmune_disease.n.01|the|ocular|associated
C417083_D019698 NONE interferon_6\NN\antiviral.n.01|and|ribavirin (r_nmod) treatment_9\NN\care.n.01|pegylated|interferon|for (l_prep) for_10\IN\entity.n.01|c. (l_pobj) c._13\NNP\entity.n.01|chronic|hepatitis
C417083_D019698 NONE alpha-2b_19\CD\entity.n.01|and|ribavirin (r_conj) ifn_17\NNP\entity.n.01|(|)|alpha-2b (r_appos) interferon_15\NN\antiviral.n.01|pegylated|ifn (r_pobj) of_13\IN\entity.n.01|interferon (r_prep) administration_12\NN\management.n.01|of (r_pobj) of_11\IN\entity.n.01|administration (r_prep) weeks_10\NNS\time_period.n.01|9|of (r_pobj) after_8\IN\after.s.01|weeks (r_prep) diplopia_7\NN\visual_impairment.n.01|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\entity.n.01|c (l_pobj) c_25\NNP\degree.n.06|chronic|hepatitis|(|chc|)
C417083_D019698 NONE alpha-2b_19\CD\entity.n.01|and|ribavirin (r_conj) ifn_17\NNP\entity.n.01|(|)|alpha-2b (r_appos) interferon_15\NN\antiviral.n.01|pegylated|ifn (r_pobj) of_13\IN\entity.n.01|interferon (r_prep) administration_12\NN\management.n.01|of (r_pobj) of_11\IN\entity.n.01|administration (r_prep) weeks_10\NNS\time_period.n.01|9|of (r_pobj) after_8\IN\after.s.01|weeks (r_prep) diplopia_7\NN\visual_impairment.n.01|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\entity.n.01|c (l_pobj) c_25\NNP\degree.n.06|chronic|hepatitis|(|chc|) (l_appos) chc_27\NNP\entity.n.01|
C417083_D019698 NONE alpha-2b_10\CD\entity.n.01|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN\entity.n.01|chc (l_pobj) chc_14\NNP\entity.n.01|
C417083_D019698 NONE ifn_35\NNP\entity.n.01| (r_compound) therapy_36\NN\medical_care.n.01|ifn (r_pobj) of_34\IN\entity.n.01|therapy (r_prep) complications_33\NNS\hindrance.n.03|the|various|eye|of (r_pobj) of_29\IN\entity.n.01|complications (r_prep) review_28\NN\appraisal.n.01|a|of (r_pobj) with_26\IN\entity.n.01|review (r_prep) present_23\VBP\time.n.05|reported|;|therefore|,|we|case|with|. (l_ccomp) reported_18\VBN\inform.v.01|myasthenia|is|rarely (l_nsubjpass) myasthenia_2\NN\autoimmune_disease.n.01|the|ocular|associated (l_acl) associated_3\VBN\think.v.03|with (l_prep) with_4\IN\entity.n.01|therapy (l_pobj) therapy_6\NN\medical_care.n.01|combination|of (l_prep) of_7\IN\entity.n.01|alpha-2b (l_pobj) alpha-2b_10\CD\entity.n.01|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN\entity.n.01|chc (l_pobj) chc_14\NNP\entity.n.01|
D012254_D009157 CID ribavirin_8\JJ\antiviral.n.01| (r_conj) interferon_6\NN\antiviral.n.01|and|ribavirin (r_nmod) treatment_9\NN\care.n.01|pegylated|interferon|for (r_pobj) during_4\IN\entity.n.01|treatment (r_prep) development_0\NN\improvement.n.02|of|during (l_prep) of_1\IN\entity.n.01|myasthenia (l_pobj) myasthenia_3\NN\autoimmune_disease.n.01|ocular
D012254_D009157 CID ribavirin_12\RB\antiviral.n.01| (r_conj) alpha-2b_10\CD\entity.n.01|pegylated|ifn|and|ribavirin|for (r_pobj) of_7\IN\entity.n.01|alpha-2b (r_prep) therapy_6\NN\medical_care.n.01|combination|of (r_pobj) with_4\IN\entity.n.01|therapy (r_prep) associated_3\VBN\think.v.03|with (r_acl) myasthenia_2\NN\autoimmune_disease.n.01|the|ocular|associated
D012254_D019698 NONE ribavirin_8\JJ\antiviral.n.01| (r_conj) interferon_6\NN\antiviral.n.01|and|ribavirin (r_nmod) treatment_9\NN\care.n.01|pegylated|interferon|for (l_prep) for_10\IN\entity.n.01|c. (l_pobj) c._13\NNP\entity.n.01|chronic|hepatitis
D012254_D019698 NONE ribavirin_21\RB\antiviral.n.01| (r_conj) alpha-2b_19\CD\entity.n.01|and|ribavirin (r_conj) ifn_17\NNP\entity.n.01|(|)|alpha-2b (r_appos) interferon_15\NN\antiviral.n.01|pegylated|ifn (r_pobj) of_13\IN\entity.n.01|interferon (r_prep) administration_12\NN\management.n.01|of (r_pobj) of_11\IN\entity.n.01|administration (r_prep) weeks_10\NNS\time_period.n.01|9|of (r_pobj) after_8\IN\after.s.01|weeks (r_prep) diplopia_7\NN\visual_impairment.n.01|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\entity.n.01|c (l_pobj) c_25\NNP\degree.n.06|chronic|hepatitis|(|chc|)
D012254_D019698 NONE ribavirin_21\RB\antiviral.n.01| (r_conj) alpha-2b_19\CD\entity.n.01|and|ribavirin (r_conj) ifn_17\NNP\entity.n.01|(|)|alpha-2b (r_appos) interferon_15\NN\antiviral.n.01|pegylated|ifn (r_pobj) of_13\IN\entity.n.01|interferon (r_prep) administration_12\NN\management.n.01|of (r_pobj) of_11\IN\entity.n.01|administration (r_prep) weeks_10\NNS\time_period.n.01|9|of (r_pobj) after_8\IN\after.s.01|weeks (r_prep) diplopia_7\NN\visual_impairment.n.01|a|old|experienced|sudden|after|for|. (l_prep) for_22\IN\entity.n.01|c (l_pobj) c_25\NNP\degree.n.06|chronic|hepatitis|(|chc|) (l_appos) chc_27\NNP\entity.n.01|
D012254_D019698 NONE ribavirin_12\RB\antiviral.n.01| (r_conj) alpha-2b_10\CD\entity.n.01|pegylated|ifn|and|ribavirin|for (l_prep) for_13\IN\entity.n.01|chc (l_pobj) chc_14\NNP\entity.n.01|
C417083_D004172 NONE alpha-2b_19\CD\entity.n.01|and|ribavirin (r_conj) ifn_17\NNP\entity.n.01|(|)|alpha-2b (r_appos) interferon_15\NN\antiviral.n.01|pegylated|ifn (r_pobj) of_13\IN\entity.n.01|interferon (r_prep) administration_12\NN\management.n.01|of (r_pobj) of_11\IN\entity.n.01|administration (r_prep) weeks_10\NNS\time_period.n.01|9|of (r_pobj) after_8\IN\after.s.01|weeks (r_prep) diplopia_7\NN\visual_impairment.n.01|a|old|experienced|sudden|after|for|.
D012254_D004172 NONE ribavirin_21\RB\antiviral.n.01| (r_conj) alpha-2b_19\CD\entity.n.01|and|ribavirin (r_conj) ifn_17\NNP\entity.n.01|(|)|alpha-2b (r_appos) interferon_15\NN\antiviral.n.01|pegylated|ifn (r_pobj) of_13\IN\entity.n.01|interferon (r_prep) administration_12\NN\management.n.01|of (r_pobj) of_11\IN\entity.n.01|administration (r_prep) weeks_10\NNS\time_period.n.01|9|of (r_pobj) after_8\IN\after.s.01|weeks (r_prep) diplopia_7\NN\visual_impairment.n.01|a|old|experienced|sudden|after|for|.
88336
D002719_D013375 NONE chlormethiazole_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|chlormethiazole (r_prep) doses_4\NNS\medicine.n.02|high|of (r_dobj) received_2\VBD\get.v.01|patients|doses|for|,|and|took (l_prep) for_7\IN\entity.n.01|symptoms (l_pobj) symptoms_10\NNS\evidence.n.01|withdrawal
D002719_D062787 NONE chlormethiazole_6\NN\entity.n.01| (r_pobj) of_5\IN\entity.n.01|chlormethiazole (r_prep) doses_4\NNS\medicine.n.02|high|of (r_dobj) received_2\VBD\get.v.01|patients|doses|for|,|and|took (l_conj) took_14\VBD\act.v.01|one|overdose|. (l_dobj) overdose_17\NN\drug.v.01|a|suicidal|of
D002719_D062787 NONE chlormethiazole_10\NN\entity.n.01| (r_compound) intoxication_11\NN\physical_condition.n.01|chlormethiazole (r_pobj) with_9\IN\entity.n.01|intoxication (r_prep) those_8\DT\entity.n.01|with (r_pobj) of_7\IN\entity.n.01|those (r_prep) two_6\CD\digit.n.01|of (r_conj) overdose_4\NN\drug.v.01|nitrazepam|and|two
D000431_D013375 NONE alcohol_8\NN\beverage.n.01| (r_compound) withdrawal_9\NN\retraction.n.01|alcohol (r_compound) symptoms_10\NNS\evidence.n.01|withdrawal
D000431_D062787 NONE alcohol_8\NN\beverage.n.01| (r_compound) withdrawal_9\NN\retraction.n.01|alcohol (r_compound) symptoms_10\NNS\evidence.n.01|withdrawal (r_pobj) for_7\IN\entity.n.01|symptoms (r_prep) received_2\VBD\get.v.01|patients|doses|for|,|and|took (l_conj) took_14\VBD\act.v.01|one|overdose|. (l_dobj) overdose_17\NN\drug.v.01|a|suicidal|of
D009567_D013375 NONE nitrazepam_19\NN\benzodiazepine.n.01| (r_pobj) of_18\IN\entity.n.01|nitrazepam (r_prep) overdose_17\NN\drug.v.01|a|suicidal|of (r_dobj) took_14\VBD\act.v.01|one|overdose|. (r_conj) received_2\VBD\get.v.01|patients|doses|for|,|and|took (l_prep) for_7\IN\entity.n.01|symptoms (l_pobj) symptoms_10\NNS\evidence.n.01|withdrawal
D009567_D062787 CID nitrazepam_19\NN\benzodiazepine.n.01| (r_pobj) of_18\IN\entity.n.01|nitrazepam (r_prep) overdose_17\NN\drug.v.01|a|suicidal|of
D009567_D062787 CID nitrazepam_3\JJ\benzodiazepine.n.01| (r_amod) overdose_4\NN\drug.v.01|nitrazepam|and|two
D009567_D003128 CID nitrazepam_3\JJ\benzodiazepine.n.01| (r_amod) overdose_4\NN\drug.v.01|nitrazepam|and|two (r_pobj) with_2\IN\entity.n.01|overdose (r_prep) patient_1\NN\case.n.06|the|with (r_nsubj) conformed_12\VBD\conform.v.01|patient|to|,|showing|. (l_prep) to_13\IN\entity.n.01|criteria (l_pobj) criteria_15\NNS\system_of_measurement.n.01|the|of (l_prep) of_16\IN\entity.n.01|'|coma|' (l_pobj) coma_19\NN\unconsciousness.n.01|alpha
D002719_D003128 CID chlormethiazole_10\NN\entity.n.01| (r_compound) intoxication_11\NN\physical_condition.n.01|chlormethiazole (r_pobj) with_9\IN\entity.n.01|intoxication (r_prep) those_8\DT\entity.n.01|with (r_pobj) of_7\IN\entity.n.01|those (r_prep) two_6\CD\digit.n.01|of (r_conj) overdose_4\NN\drug.v.01|nitrazepam|and|two (r_pobj) with_2\IN\entity.n.01|overdose (r_prep) patient_1\NN\case.n.06|the|with (r_nsubj) conformed_12\VBD\conform.v.01|patient|to|,|showing|. (l_prep) to_13\IN\entity.n.01|criteria (l_pobj) criteria_15\NNS\system_of_measurement.n.01|the|of (l_prep) of_16\IN\entity.n.01|'|coma|' (l_pobj) coma_19\NN\unconsciousness.n.01|alpha
12483326
D016190_D005128 NONE carboplatin_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|carboplatin (r_prep) injection_7\NN\insertion.n.02|intracarotid|of|for (r_pobj) after_5\IN\after.s.01|injection (r_prep) toxicity_4\NN\definite_quantity.n.01|severe|ocular|after|.
D016190_D005128 NONE carboplatin_2\NN\entity.n.01| (r_nsubjpass) said_4\VBN\express.v.02|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\know.v.01|are|well (l_auxpass) are_18\VBP\area_unit.n.01|toxicity (l_nsubj) toxicity_17\NN\definite_quantity.n.01|whose|ocular
D016190_D005128 NONE carboplatin_16\NN\entity.n.01| (r_pobj) of_15\IN\entity.n.01|carboplatin (r_prep) injection_14\NN\insertion.n.02|intracarotid|of|,|reported (r_pobj) after_12\IN\after.s.01|injection (r_prep) experienced_3\VBD\undergo.v.01|however|,|we|case|after|. (l_dobj) case_5\NN\happening.n.01|a|of (l_prep) of_6\IN\entity.n.01|toxicity (l_pobj) toxicity_11\NN\definite_quantity.n.01|severe|ocular
D016190_D005128 NONE carboplatin_5\NN\entity.n.01| (r_pobj) of_4\IN\entity.n.01|carboplatin (r_prep) injection_3\NN\insertion.n.02|intracarotid|of (r_dobj) performing_1\VBG\activity.n.01|when|injection (r_advcl) be_9\VB\metallic_element.n.01|performing|,|we|must|aware|. (l_acomp) aware_10\JJ\aware.a.01|of (l_prep) of_11\IN\entity.n.01|toxicity (l_pobj) toxicity_16\NN\definite_quantity.n.01|its|blinding|ocular
D016190_D009916 NONE carboplatin_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|carboplatin (r_prep) injection_7\NN\insertion.n.02|intracarotid|of|for (r_pobj) after_5\IN\after.s.01|injection (r_prep) toxicity_4\NN\definite_quantity.n.01|severe|ocular|after|.
D016190_D009916 NONE carboplatin_2\NN\entity.n.01| (r_nsubjpass) said_4\VBN\express.v.02|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\know.v.01|are|well (l_auxpass) are_18\VBP\area_unit.n.01|toxicity (l_nsubj) toxicity_17\NN\definite_quantity.n.01|whose|ocular
D016190_D009916 NONE carboplatin_16\NN\entity.n.01| (r_pobj) of_15\IN\entity.n.01|carboplatin (r_prep) injection_14\NN\insertion.n.02|intracarotid|of|,|reported (r_pobj) after_12\IN\after.s.01|injection (r_prep) experienced_3\VBD\undergo.v.01|however|,|we|case|after|. (l_dobj) case_5\NN\happening.n.01|a|of (l_prep) of_6\IN\entity.n.01|toxicity (l_pobj) toxicity_11\NN\definite_quantity.n.01|severe|ocular
D016190_D005909 NONE carboplatin_9\NN\entity.n.01| (r_pobj) of_8\IN\entity.n.01|carboplatin (r_prep) injection_7\NN\insertion.n.02|intracarotid|of|for (l_prep) for_10\IN\entity.n.01|glioblastomas (l_pobj) glioblastomas_12\NNS\brain_tumor.n.01|recurrent
D016190_D005909 NONE carboplatin_10\NN\entity.n.01| (r_pobj) of_9\IN\entity.n.01|carboplatin (r_prep) injection_8\NN\insertion.n.02|an|intracarotid|of|for|in (l_prep) for_11\IN\entity.n.01|glioblastomas (l_pobj) glioblastomas_13\NNS\brain_tumor.n.01|recurrent
D002945_D005128 NONE cisplatin_11\NN\entity.n.01| (r_pcomp) than_10\IN\entity.n.01|cisplatin (r_prep) effects_9\NNS\personal_property.n.01|milder|side|than|, (r_dobj) have_6\VB\person.n.01|to|effects (r_xcomp) said_4\VBN\express.v.02|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\know.v.01|are|well (l_auxpass) are_18\VBP\area_unit.n.01|toxicity (l_nsubj) toxicity_17\NN\definite_quantity.n.01|whose|ocular
D002945_D009916 NONE cisplatin_11\NN\entity.n.01| (r_pcomp) than_10\IN\entity.n.01|cisplatin (r_prep) effects_9\NNS\personal_property.n.01|milder|side|than|, (r_dobj) have_6\VB\person.n.01|to|effects (r_xcomp) said_4\VBN\express.v.02|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\know.v.01|are|well (l_auxpass) are_18\VBP\area_unit.n.01|toxicity (l_nsubj) toxicity_17\NN\definite_quantity.n.01|whose|ocular
D016190_D064420 NONE carboplatin_7\NN\entity.n.01| (r_amod) toxicity_8\NN\definite_quantity.n.01|carboplatin
17919553
C106791_D056486 CID telithromycin_6\NNS\entity.n.01|to (r_relcl) exposure_4\NN\vulnerability.n.02|telithromycin (r_pobj) after_3\IN\after.s.01|exposure (r_prep) attack_2\NN\operation.n.05|acute|hepatitis|after|. (l_compound) hepatitis_1\NNP\infectious_disease.n.01|
C106791_D056486 CID telithromycin_19\NNS\entity.n.01| (r_compound) usage_20\NN\activity.n.01|telithromycin (r_pobj) after_18\IN\after.s.01|usage (r_prep) occurred_17\VBD\happen.v.01|suffered|,|"|that|after|. (l_ccomp) suffered_3\VBN\experience.v.01|patient|had|episode (l_dobj) episode_6\NN\happening.n.01|a|previous|of (l_prep) of_7\IN\entity.n.01|hepatitis (l_pobj) hepatitis_10\NN\infectious_disease.n.01|"|acute|of
C106791_D056486 CID telithromycin_15\NNS\entity.n.01| (r_nsubj) was_16\VBD\washington.n.02|based|,|telithromycin|cause|,|and|suggested (l_attr) cause_19\NN\origin.n.03|the|probable|of (l_prep) of_20\IN\entity.n.01|hepatitis (l_pobj) hepatitis_22\NN\infectious_disease.n.01|acute|in
C106791_D056486 CID telithromycin_15\NNS\entity.n.01| (r_nsubj) was_16\VBD\washington.n.02|based|,|telithromycin|cause|,|and|suggested (l_conj) suggested_30\VBD\declare.v.01|findings|hepatitis|. (l_dobj) hepatitis_35\NN\infectious_disease.n.01|induced|toxic
C106791_D056486 CID telithromycin_21\NNS\entity.n.01| (r_dobj) prescribed_20\VBD\inflict.v.01|who|telithromycin|time (r_relcl) physician_18\NN\medical_practitioner.n.01|the|attending|prescribed (r_pobj) to_15\IN\entity.n.01|physician (r_prep) communicated_14\VBN\convey.v.03|if|incident|had|been|to (r_advcl) avoided_7\VBN\avoid.v.01|recurrence|might|have|been|communicated|. (l_nsubjpass) recurrence_0\NN\repeat.n.01|of (l_prep) of_1\IN\entity.n.01|attack (l_pobj) attack_3\NN\operation.n.05|hepatitis (l_compound) hepatitis_2\NN\infectious_disease.n.01|
C106791_D056486 CID telithromycin_14\NNS\entity.n.01| (r_pobj) of_13\IN\entity.n.01|telithromycin (r_prep) administration_12\NN\management.n.01|the|of (r_pobj) with_10\IN\entity.n.01|administration (r_prep) associated_9\VBN\think.v.03|probably|with (r_acl) case_4\NN\happening.n.01|a|of|associated (l_prep) of_5\IN\entity.n.01|hepatitis (l_pobj) hepatitis_7\NN\infectious_disease.n.01|acute
C106791_D064420 NONE telithromycin_15\NNS\entity.n.01| (r_nsubj) was_16\VBD\washington.n.02|based|,|telithromycin|cause|,|and|suggested (l_prep) based_0\VBN\establish.v.08|on (l_prep) on_1\IN\on.a.01|score (l_pobj) score_3\NN\evaluation.n.02|a|of|on (l_prep) on_6\IN\on.a.01|scale (l_pobj) scale_13\NN\standard.n.01|the|probability (l_compound) probability_12\NN\measure.n.02|reaction (l_compound) reaction_11\NN\chemical_process.n.01|naranjo|adverse|drug
2522601
D002220_D004342 CID carbamazepine_2\NN\entity.n.01| (r_pobj) to_1\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_0\NN\sensitivity.n.04|to|presenting|.
D002220_D004342 CID carbamazepine_8\NN\entity.n.01| (r_pobj) to_7\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_6\NN\sensitivity.n.04|to
D002220_D007955 CID carbamazepine_2\NN\entity.n.01| (r_pobj) to_1\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_0\NN\sensitivity.n.04|to|presenting|. (l_acl) presenting_3\VBG\show.v.04|with (l_prep) with_4\IN\entity.n.01|reaction (l_pobj) reaction_7\NN\chemical_process.n.01|a|leukemoid|,|eosinophilia|failure
D002220_D007955 CID carbamazepine_8\NN\entity.n.01| (r_pobj) to_7\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_6\NN\sensitivity.n.04|to (r_nsubj) presented_9\VBN\show.v.04|in|hypersensitivity|with (r_relcl) patient_3\NN\case.n.06|a|presented|,|reaction (l_conj) reaction_17\NN\chemical_process.n.01|a|severe|leukemoid|,|eosinophilia
D002220_D004802 NONE carbamazepine_2\NN\entity.n.01| (r_pobj) to_1\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_0\NN\sensitivity.n.04|to|presenting|. (l_acl) presenting_3\VBG\show.v.04|with (l_prep) with_4\IN\entity.n.01|reaction (l_pobj) reaction_7\NN\chemical_process.n.01|a|leukemoid|,|eosinophilia|failure (l_conj) eosinophilia_9\NN\symptom.n.01|,|erythroderma
D002220_D004802 NONE carbamazepine_8\NN\entity.n.01| (r_pobj) to_7\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_6\NN\sensitivity.n.04|to (r_nsubj) presented_9\VBN\show.v.04|in|hypersensitivity|with (r_relcl) patient_3\NN\case.n.06|a|presented|,|reaction (l_conj) reaction_17\NN\chemical_process.n.01|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN\symptom.n.01|,|hyponatremia
D002220_D003873 CID carbamazepine_2\NN\entity.n.01| (r_pobj) to_1\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_0\NN\sensitivity.n.04|to|presenting|. (l_acl) presenting_3\VBG\show.v.04|with (l_prep) with_4\IN\entity.n.01|reaction (l_pobj) reaction_7\NN\chemical_process.n.01|a|leukemoid|,|eosinophilia|failure (l_conj) eosinophilia_9\NN\symptom.n.01|,|erythroderma (l_conj) erythroderma_11\NN\skin_disease.n.01|,|and
D002220_D003873 CID carbamazepine_8\NN\entity.n.01| (r_pobj) to_7\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_6\NN\sensitivity.n.04|to (r_nsubj) presented_9\VBN\show.v.04|in|hypersensitivity|with (l_prep) with_10\IN\entity.n.01|erythroderma (l_pobj) erythroderma_12\NN\skin_disease.n.01|generalized
D002220_D051437 CID carbamazepine_2\NN\entity.n.01| (r_pobj) to_1\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_0\NN\sensitivity.n.04|to|presenting|. (l_acl) presenting_3\VBG\show.v.04|with (l_prep) with_4\IN\entity.n.01|reaction (l_pobj) reaction_7\NN\chemical_process.n.01|a|leukemoid|,|eosinophilia|failure (l_conj) failure_15\NN\nonaccomplishment.n.01|renal
D002220_D051437 CID carbamazepine_8\NN\entity.n.01| (r_pobj) to_7\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_6\NN\sensitivity.n.04|to (r_nsubj) presented_9\VBN\show.v.04|in|hypersensitivity|with (r_relcl) patient_3\NN\case.n.06|a|presented|,|reaction (l_conj) reaction_17\NN\chemical_process.n.01|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN\symptom.n.01|,|hyponatremia (l_conj) hyponatremia_21\NN\symptom.n.01|,|and|failure (l_conj) failure_25\NN\nonaccomplishment.n.01|renal
D002220_D007010 CID carbamazepine_8\NN\entity.n.01| (r_pobj) to_7\IN\entity.n.01|carbamazepine (r_prep) hypersensitivity_6\NN\sensitivity.n.04|to (r_nsubj) presented_9\VBN\show.v.04|in|hypersensitivity|with (r_relcl) patient_3\NN\case.n.06|a|presented|,|reaction (l_conj) reaction_17\NN\chemical_process.n.01|a|severe|leukemoid|,|eosinophilia (l_conj) eosinophilia_19\NN\symptom.n.01|,|hyponatremia (l_conj) hyponatremia_21\NN\symptom.n.01|,|and|failure
19820426
C558899_D066126 NONE ritonavir_10\NNS\protease_inhibitor.n.01| (r_compound) therapy_11\NN\medical_care.n.01|ritonavir (r_appos) lopinavir_8\NNS\entity.n.01|/|therapy (r_pobj) to_7\IN\entity.n.01|lopinavir (r_prep) related_6\VBN\think.v.03|to (r_acl) toxicity_5\NN\definite_quantity.n.01|cardiac|related
C558899_D006327 CID ritonavir_15\NNS\protease_inhibitor.n.01| (r_compound) therapy_16\NN\medical_care.n.01|ritonavir|,|agent (r_appos) lopinavir_13\NNS\entity.n.01|/|therapy (r_pobj) to_12\IN\entity.n.01|lopinavir (r_prep) related_11\VBN\think.v.03|to (r_acl) cardiomyopathy_10\NN\heart_disease.n.01|dilated|related (r_conj) block_7\NN\artifact.n.01|complete|heart|and|cardiomyopathy
C558899_D002311 CID ritonavir_15\NNS\protease_inhibitor.n.01| (r_compound) therapy_16\NN\medical_care.n.01|ritonavir|,|agent (r_appos) lopinavir_13\NNS\entity.n.01|/|therapy (r_pobj) to_12\IN\entity.n.01|lopinavir (r_prep) related_11\VBN\think.v.03|to (r_acl) cardiomyopathy_10\NN\heart_disease.n.01|dilated|related
C558899_D001919 CID ritonavir_15\NNS\protease_inhibitor.n.01| (r_compound) therapy_16\NN\medical_care.n.01|ritonavir|,|agent (r_appos) lopinavir_13\NNS\entity.n.01|/|therapy (r_pobj) to_12\IN\entity.n.01|lopinavir (r_prep) related_11\VBN\think.v.03|to (r_acl) cardiomyopathy_10\NN\heart_disease.n.01|dilated|related (r_conj) block_7\NN\artifact.n.01|complete|heart|and|cardiomyopathy (r_dobj) developed_4\VBD\create.v.02|one|block|,|developed|. (l_advcl) developed_29\VBD\create.v.02|while|twin|bradycardia (l_dobj) bradycardia_31\NNS\cardiac_arrhythmia.n.01|mild
11928786
D016642_D064420 NONE bupropion_0\NNP\entity.n.01| (r_nmod) toxicity_4\NN\definite_quantity.n.01|bupropion|(|zyban|)|.
D016642_D064420 NONE zyban_2\NNP\entity.n.01| (r_nmod) toxicity_4\NN\definite_quantity.n.01|bupropion|(|zyban|)|.
D003975_D012640 NONE diazepam_5\NN\benzodiazepine.n.01|and|tachycardia (r_pobj) with_4\IN\entity.n.01|diazepam (r_prep) treated_3\VBN\interact.v.01|seizures|were|with|treated|. (l_nsubjpass) seizures_1\NNS\attack.n.07|recurrent
D003975_D013610 NONE diazepam_5\NN\benzodiazepine.n.01|and|tachycardia (l_conj) tachycardia_9\NN\cardiac_arrhythmia.n.01|broad|complex
D000241_D012640 NONE adenosine_14\NN\nucleoside.n.01| (r_pobj) with_13\IN\entity.n.01|adenosine (r_prep) treated_12\VBN\interact.v.01|was|successfully|with (r_conj) treated_3\VBN\interact.v.01|seizures|were|with|treated|. (l_nsubjpass) seizures_1\NNS\attack.n.07|recurrent
D000241_D013610 NONE adenosine_14\NN\nucleoside.n.01| (r_pobj) with_13\IN\entity.n.01|adenosine (r_prep) treated_12\VBN\interact.v.01|was|successfully|with (r_conj) treated_3\VBN\interact.v.01|seizures|were|with|treated|. (l_prep) with_4\IN\entity.n.01|diazepam (l_pobj) diazepam_5\NN\benzodiazepine.n.01|and|tachycardia (l_conj) tachycardia_9\NN\cardiac_arrhythmia.n.01|broad|complex
D016642_D020258 NONE zyban_0\NNP\entity.n.01| (r_nsubj) caused_1\VBD\make.v.03|zyban|toxicity|. (l_dobj) toxicity_6\NN\definite_quantity.n.01|significant|neurological|in
D016642_D002318 NONE zyban_0\NNP\entity.n.01| (r_nsubj) caused_1\VBD\make.v.03|zyban|toxicity|. (l_dobj) toxicity_6\NN\definite_quantity.n.01|significant|neurological|in
D016642_D062787 NONE zyban_0\NNP\entity.n.01| (r_nsubj) caused_1\VBD\make.v.03|zyban|toxicity|. (l_dobj) toxicity_6\NN\definite_quantity.n.01|significant|neurological|in (l_prep) in_7\IN\linear_unit.n.01|overdose (l_pobj) overdose_8\NN\drug.v.01|
15036754
D010755_D012640 NONE organophosphate_0\NNP\insecticide.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|organophosphate|- (r_amod) convulsions_3\NNS\attack.n.07|induced|and|prevention|of|.
D010755_D004194 NONE organophosphate_0\NNP\insecticide.n.01| (r_npadvmod) induced_2\VBN\generate.v.01|organophosphate|- (r_amod) convulsions_3\NNS\attack.n.07|induced|and|prevention|of|. (l_prep) of_6\IN\entity.n.01|damages (l_pobj) damages_8\NNS\compensation.n.01|neuropathological
D010755_D064420 NONE ops_4\NNS\ops.n.01| (r_pobj) of_3\IN\entity.n.01|ops (r_prep) toxicity_2\NN\definite_quantity.n.01|the|acute|of
D010755_D064420 NONE op_10\NN\entity.n.01| (r_npadvmod) induced_12\VBN\generate.v.01|op|- (r_amod) signs_14\NNS\clue.n.02|severe|typical|induced|toxicity (l_compound) toxicity_13\NN\definite_quantity.n.01|
D000109_D064420 NONE acetylcholine_25\NN\neurotransmitter.n.01| (r_nmod) levels_29\NNS\property.n.02|acetylcholine|(|ach|) (r_dobj) elevates_24\VBZ\delegate.v.02|which|levels (r_relcl) system_18\NN\instrumentality.n.03|the|central|nervous|(|cns|)|,|elevates (r_pobj) in_14\IN\linear_unit.n.01|system (r_prep) aches_13\NNP\pain.n.01|in (r_pobj) with_12\IN\entity.n.01|aches (r_prep) binding_11\NN\attraction.n.03|their|irreversible|with (r_pobj) of_8\IN\entity.n.01|binding (r_prep) result_7\NN\phenomenon.n.01|the|of (r_attr) is_5\VBZ\be.v.01|toxicity|result|. (l_nsubj) toxicity_2\NN\definite_quantity.n.01|the|acute|of
D000109_D064420 NONE ach_27\NNS\entity.n.01| (r_nmod) levels_29\NNS\property.n.02|acetylcholine|(|ach|) (r_dobj) elevates_24\VBZ\delegate.v.02|which|levels (r_relcl) system_18\NN\instrumentality.n.03|the|central|nervous|(|cns|)|,|elevates (r_pobj) in_14\IN\linear_unit.n.01|system (r_prep) aches_13\NNP\pain.n.01|in (r_pobj) with_12\IN\entity.n.01|aches (r_prep) binding_11\NN\attraction.n.03|their|irreversible|with (r_pobj) of_8\IN\entity.n.01|binding (r_prep) result_7\NN\phenomenon.n.01|the|of (r_attr) is_5\VBZ\be.v.01|toxicity|result|. (l_nsubj) toxicity_2\NN\definite_quantity.n.01|the|acute|of
D007531_D064420 NONE dfp_4\NNP\entity.n.01| (r_compound) atropine_6\NN\alkaloid.n.01|dfp|- (r_pobj) with_3\IN\entity.n.01|atropine (r_prep) treated_2\VBD\interact.v.01|rats|with|showed|. (l_conj) showed_7\VBD\show.v.04|signs (l_dobj) signs_14\NNS\clue.n.02|severe|typical|induced|toxicity (l_compound) toxicity_13\NN\definite_quantity.n.01|
D007531_D064420 NONE dfp_10\NNP\entity.n.01| (r_compound) toxicity_11\NN\definite_quantity.n.01|dfp
D007531_D064420 NONE dfp_26\NNP\entity.n.01| (r_pobj) of_25\IN\entity.n.01|dfp (r_prep) toxicity_24\NN\definite_quantity.n.01|the|of|in
D001285_D064420 NONE atropine_6\NN\alkaloid.n.01|dfp|- (r_pobj) with_3\IN\entity.n.01|atropine (r_prep) treated_2\VBD\interact.v.01|rats|with|showed|. (l_conj) showed_7\VBD\show.v.04|signs (l_dobj) signs_14\NNS\clue.n.02|severe|typical|induced|toxicity (l_compound) toxicity_13\NN\definite_quantity.n.01|
D001285_D064420 NONE atropine_0\NNP\alkaloid.n.01| (r_compound) mk801_2\NNP\entity.n.01|atropine|- (r_nsubj) offer_5\VB\speech_act.n.01|mk801|did|not|protection|. (l_dobj) protection_8\NN\activity.n.01|any|additional|against (l_prep) against_9\IN\entity.n.01|toxicity (l_pobj) toxicity_11\NN\definite_quantity.n.01|dfp
D001285_D064420 NONE atropine_11\NN\alkaloid.n.01| (r_pobj) with_10\IN\entity.n.01|atropine (r_prep) combination_9\NN\collection.n.01|with (r_pobj) in_8\IN\linear_unit.n.01|combination (r_prep) diazepam_5\NN\benzodiazepine.n.01|and|2pam|in (r_conj) cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\decrease.v.02|thus|toxicity (l_dobj) toxicity_24\NN\definite_quantity.n.01|the|of|in
C048599_D011041 NONE cpa_1\NN\accountant.n.01| (r_nsubjpass) given_7\VBN\assumption.n.02|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\prevent.v.01|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\decelerate.v.01|or|shortened (l_conj) shortened_20\VBN\reduce.v.01|occurrence (l_dobj) occurrence_22\NN\event.n.01|the|of (l_prep) of_23\IN\entity.n.01|signs (l_pobj) signs_25\NNS\clue.n.02|serious|of (l_prep) of_26\IN\entity.n.01|poisoning (l_pobj) poisoning_27\NN\physical_condition.n.01|
C048599_D011041 NONE cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\event.n.01|the|of (l_prep) of_15\IN\entity.n.01|signs (l_pobj) signs_17\NNS\clue.n.02|serious|of (l_prep) of_18\IN\entity.n.01|poisoning (l_pobj) poisoning_19\NN\physical_condition.n.01|
D003975_D011041 NONE diazepam_3\NN\benzodiazepine.n.01|or|2pam (r_nsubjpass) given_7\VBN\assumption.n.02|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\prevent.v.01|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\decelerate.v.01|or|shortened (l_conj) shortened_20\VBN\reduce.v.01|occurrence (l_dobj) occurrence_22\NN\event.n.01|the|of (l_prep) of_23\IN\entity.n.01|signs (l_pobj) signs_25\NNS\clue.n.02|serious|of (l_prep) of_26\IN\entity.n.01|poisoning (l_pobj) poisoning_27\NN\physical_condition.n.01|
D003975_D011041 NONE diazepam_5\NN\benzodiazepine.n.01|and|2pam|in (r_conj) cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\event.n.01|the|of (l_prep) of_15\IN\entity.n.01|signs (l_pobj) signs_17\NNS\clue.n.02|serious|of (l_prep) of_18\IN\entity.n.01|poisoning (l_pobj) poisoning_19\NN\physical_condition.n.01|
D011220_D011041 NONE 2pam_5\CD\entity.n.01| (r_conj) diazepam_3\NN\benzodiazepine.n.01|or|2pam (r_nsubjpass) given_7\VBN\assumption.n.02|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\prevent.v.01|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\decelerate.v.01|or|shortened (l_conj) shortened_20\VBN\reduce.v.01|occurrence (l_dobj) occurrence_22\NN\event.n.01|the|of (l_prep) of_23\IN\entity.n.01|signs (l_pobj) signs_25\NNS\clue.n.02|serious|of (l_prep) of_26\IN\entity.n.01|poisoning (l_pobj) poisoning_27\NN\physical_condition.n.01|
D011220_D011041 NONE 2pam_7\CD\entity.n.01| (r_conj) diazepam_5\NN\benzodiazepine.n.01|and|2pam|in (r_conj) cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\event.n.01|the|of (l_prep) of_15\IN\entity.n.01|signs (l_pobj) signs_17\NNS\clue.n.02|serious|of (l_prep) of_18\IN\entity.n.01|poisoning (l_pobj) poisoning_19\NN\physical_condition.n.01|
D007531_D011041 NONE dfp_10\NNP\entity.n.01| (r_compound) atropine_12\NN\alkaloid.n.01|dfp|- (r_pobj) after_9\IN\after.s.01|atropine (r_prep) given_7\VBN\assumption.n.02|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\prevent.v.01|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\decelerate.v.01|or|shortened (l_conj) shortened_20\VBN\reduce.v.01|occurrence (l_dobj) occurrence_22\NN\event.n.01|the|of (l_prep) of_23\IN\entity.n.01|signs (l_pobj) signs_25\NNS\clue.n.02|serious|of (l_prep) of_26\IN\entity.n.01|poisoning (l_pobj) poisoning_27\NN\physical_condition.n.01|
D007531_D011041 NONE dfp_26\NNP\entity.n.01| (r_pobj) of_25\IN\entity.n.01|dfp (r_prep) toxicity_24\NN\definite_quantity.n.01|the|of|in (r_dobj) reduced_22\VBD\decrease.v.02|thus|toxicity (r_conj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\event.n.01|the|of (l_prep) of_15\IN\entity.n.01|signs (l_pobj) signs_17\NNS\clue.n.02|serious|of (l_prep) of_18\IN\entity.n.01|poisoning (l_pobj) poisoning_19\NN\physical_condition.n.01|
D001285_D011041 NONE atropine_12\NN\alkaloid.n.01|dfp|- (r_pobj) after_9\IN\after.s.01|atropine (r_prep) given_7\VBN\assumption.n.02|when|cpa|,|diazepam|was|immediately|after (r_advcl) prevented_16\VBD\prevent.v.01|given|,|treatments|,|delayed|. (l_conj) delayed_18\VBN\decelerate.v.01|or|shortened (l_conj) shortened_20\VBN\reduce.v.01|occurrence (l_dobj) occurrence_22\NN\event.n.01|the|of (l_prep) of_23\IN\entity.n.01|signs (l_pobj) signs_25\NNS\clue.n.02|serious|of (l_prep) of_26\IN\entity.n.01|poisoning (l_pobj) poisoning_27\NN\physical_condition.n.01|
D001285_D011041 NONE atropine_11\NN\alkaloid.n.01| (r_pobj) with_10\IN\entity.n.01|atropine (r_prep) combination_9\NN\collection.n.01|with (r_pobj) in_8\IN\linear_unit.n.01|combination (r_prep) diazepam_5\NN\benzodiazepine.n.01|and|2pam|in (r_conj) cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\event.n.01|the|of (l_prep) of_15\IN\entity.n.01|signs (l_pobj) signs_17\NNS\clue.n.02|serious|of (l_prep) of_18\IN\entity.n.01|poisoning (l_pobj) poisoning_19\NN\physical_condition.n.01|
D016291_D064420 NONE mk801_2\NNP\entity.n.01|atropine|- (r_nsubj) offer_5\VB\speech_act.n.01|mk801|did|not|protection|. (l_dobj) protection_8\NN\activity.n.01|any|additional|against (l_prep) against_9\IN\entity.n.01|toxicity (l_pobj) toxicity_11\NN\definite_quantity.n.01|dfp
C048599_D064420 NONE cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\decrease.v.02|thus|toxicity (l_dobj) toxicity_24\NN\definite_quantity.n.01|the|of|in
D003975_D064420 NONE diazepam_5\NN\benzodiazepine.n.01|and|2pam|in (r_conj) cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\decrease.v.02|thus|toxicity (l_dobj) toxicity_24\NN\definite_quantity.n.01|the|of|in
D011220_D064420 NONE 2pam_7\CD\entity.n.01| (r_conj) diazepam_5\NN\benzodiazepine.n.01|and|2pam|in (r_conj) cpa_3\NN\accountant.n.01|,|diazepam (r_nsubj) prevented_12\VBD\prevent.v.01|in|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\decrease.v.02|thus|toxicity (l_dobj) toxicity_24\NN\definite_quantity.n.01|the|of|in
9199746
D000583_D064420 NONE amikacin_4\RB\entity.n.01|toxicity|. (l_nsubj) toxicity_1\NN\definite_quantity.n.01|macula|after
D000617_D009877 NONE aminoglycosides_2\NNS\entity.n.01|intravitreal (r_nsubj) improved_5\VBN\change.v.01|although|aminoglycosides|have|substantially|prognosis (l_dobj) prognosis_7\NN\prediction.n.02|visual|in (l_prep) in_8\IN\linear_unit.n.01|endophthalmitis (l_pobj) endophthalmitis_9\NN\entity.n.01|
D000617_D007238 NONE aminoglycosides_2\NNS\entity.n.01|intravitreal (r_nsubj) improved_5\VBN\change.v.01|although|aminoglycosides|have|substantially|prognosis (r_advcl) impair_14\VB\damage.v.01|improved|,|infarction|may|recovery|. (l_nsubj) infarction_12\NN\pathology.n.02|macular
D000583_D012164 CID amikacin_6\JJ\entity.n.01|toxicity (l_pobj) toxicity_8\NN\definite_quantity.n.01|retinal
D000583_D012164 CID amikacin_12\JJ\entity.n.01|and|vancomycin (r_pobj) with_11\IN\entity.n.01|amikacin (r_prep) treatment_10\NN\care.n.01|with (r_pobj) following_9\VBG\multitude.n.03|treatment (r_prep) presumed_5\VBN\expect.v.01|amikacin|following (l_prep) amikacin_6\JJ\entity.n.01|toxicity (l_pobj) toxicity_8\NN\definite_quantity.n.01|retinal
D000583_D013290 NONE amikacin_6\JJ\entity.n.01|toxicity (r_prep) presumed_5\VBN\expect.v.01|amikacin|following (l_prep) following_9\VBG\multitude.n.03|treatment (l_pobj) treatment_10\NN\care.n.01|with (l_prep) with_11\IN\entity.n.01|amikacin (l_pobj) amikacin_12\JJ\entity.n.01|and|vancomycin (l_conj) vancomycin_14\NNP\antibiotic.n.01|for (l_prep) for_15\IN\entity.n.01|endophthalmitis (l_pobj) endophthalmitis_20\NN\entity.n.01|haemolytic|streptococcal
D000583_D013290 NONE amikacin_12\JJ\entity.n.01|and|vancomycin (l_conj) vancomycin_14\NNP\antibiotic.n.01|for (l_prep) for_15\IN\entity.n.01|endophthalmitis (l_pobj) endophthalmitis_20\NN\entity.n.01|haemolytic|streptococcal
D014640_D012164 NONE vancomycin_14\NNP\antibiotic.n.01|for (r_conj) amikacin_12\JJ\entity.n.01|and|vancomycin (r_pobj) with_11\IN\entity.n.01|amikacin (r_prep) treatment_10\NN\care.n.01|with (r_pobj) following_9\VBG\multitude.n.03|treatment (r_prep) presumed_5\VBN\expect.v.01|amikacin|following (l_prep) amikacin_6\JJ\entity.n.01|toxicity (l_pobj) toxicity_8\NN\definite_quantity.n.01|retinal
D014640_D013290 NONE vancomycin_14\NNP\antibiotic.n.01|for (l_prep) for_15\IN\entity.n.01|endophthalmitis (l_pobj) endophthalmitis_20\NN\entity.n.01|haemolytic|streptococcal
D019793_D013684 NONE fluorescein_1\NN\absorption_indicator.n.01| (r_amod) angiography_2\NN\roentgenography.n.01|fluorescein (r_nsubj) confirmed_3\VBD\confirm.v.01|fundus|angiography|closure|. (l_dobj) closure_6\NN\approach.n.02|macular|capillary|and|telangiectasis (l_conj) telangiectasis_8\NN\entity.n.01|
18951540
D007980_D004409 CID levodopa_5\NN\dopa.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_8\NNS\nervous_disorder.n.01|induced|in
D007980_D010300 NONE levodopa_5\NN\dopa.n.01| (r_npadvmod) induced_7\VBN\generate.v.01|levodopa|- (r_amod) dyskinesias_8\NNS\nervous_disorder.n.01|induced|in (l_prep) in_9\IN\linear_unit.n.01|disease (l_pobj) disease_12\NN\illness.n.01|parkinson
17111419
C102006_D064420 NONE citrate_1\JJ\ester.n.01| (r_compound) toxicity_2\NN\definite_quantity.n.01|severe|citrate
C102006_D064420 NONE citrate_6\JJ\ester.n.01| (r_compound) toxicity_7\NN\definite_quantity.n.01|severe|citrate
C102006_D064420 NONE citrate_22\JJ\ester.n.01| (r_compound) toxicity_23\NN\definite_quantity.n.01|citrate
D002125_C536214 NONE gluconate_5\NN\entity.n.01|intravenous|calcium (r_pobj) with_2\IN\entity.n.01|gluconate (r_prep) treatment_1\NN\care.n.01|empirical|with (r_nsubjpass) initiated_7\VBN\make.v.03|treatment|was|,|and|subsided (l_conj) subsided_13\VBD\weaken.v.02|contractions|slowly|over|. (l_nsubj) contractions_11\NNS\shortening.n.02|muscle
D002118_D006996 NONE calcium_9\NN\metallic_element.n.01| (r_compound) chelation_10\NN\process.n.06|calcium (r_pobj) to_8\IN\entity.n.01|chelation (r_prep) reaction_7\NN\chemical_process.n.01|a|severe|to|by|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|hypocalcemia (l_pobj) hypocalcemia_19\NN\symptom.n.01|symptomatic|systemic
C102006_D006996 CID citrate_13\NN\ester.n.01|sodium (r_compound) anticoagulant_14\NN\medicine.n.02|citrate (r_pobj) by_11\IN\by.r.01|anticoagulant (r_prep) reaction_7\NN\chemical_process.n.01|a|severe|to|by|resulting (l_acl) resulting_15\VBG\prove.v.01|in (l_prep) in_16\IN\linear_unit.n.01|hypocalcemia (l_pobj) hypocalcemia_19\NN\symptom.n.01|symptomatic|systemic
C102006_D006996 CID citrate_22\JJ\ester.n.01| (r_compound) toxicity_23\NN\definite_quantity.n.01|citrate (r_pobj) to_21\IN\entity.n.01|toxicity (r_pcomp) due_20\IN\right.n.01|to (r_amod) reactions_19\NNS\chemical_process.n.01|severe|due (r_dobj) prevent_17\VB\prevent.v.01|reactions (r_xcomp) help_16\VB\activity.n.01|to|prevent (r_xcomp) recommended_14\VBN\propose.v.01|that|screening|is|help (l_nsubjpass) screening_4\NN\display.n.05|careful|for (l_prep) for_5\IN\entity.n.01|medications (l_pobj) medications_6\NNS\drug.n.01|and|conditions (l_conj) conditions_9\NNS\context.n.02|underlying|predisposing (l_acl) predisposing_10\VBG\dispose.v.03|to (l_prep) to_11\IN\entity.n.01|hypocalcemia (l_pobj) hypocalcemia_12\NN\symptom.n.01|
D002034_D006996 NONE bumetanide_9\NN\entity.n.01| (r_nsubj) is_10\VBZ\be.v.01|that|bumetanide|loop (l_attr) loop_12\NN\fastener.n.02|a|diuretic|cause (l_relcl) cause_16\VB\origin.n.03|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\symptom.n.01|significant
D049994_D006996 NONE diuretic_13\NN\drug.n.01| (r_amod) loop_12\NN\fastener.n.02|a|diuretic|cause (l_relcl) cause_16\VB\origin.n.03|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\symptom.n.01|significant
18560792
D010479_D006349 NONE pergolide_11\NN\entity.n.01| (r_pobj) with_10\IN\entity.n.01|pergolide (r_prep) treated_9\VBN\interact.v.01|disease|with|. (l_nsubj) disease_2\NN\illness.n.01|valvular|heart|in
D010479_D006349 NONE pergolide_17\NN\entity.n.01| (r_pobj) with_16\IN\entity.n.01|pergolide (r_prep) treated_15\VBN\interact.v.01|with (r_acl) patients_7\NNS\case.n.06|with|treated (r_pobj) in_6\IN\linear_unit.n.01|patients (r_prep) reported_5\VBN\inform.v.01|abnormalities|have|been|in|. (l_nsubjpass) abnormalities_2\NNS\physical_condition.n.01|valvular|heart
D010479_D006349 NONE pergolide_12\NN\entity.n.01| (r_pobj) of_11\IN\entity.n.01|pergolide (r_prep) role_10\NN\duty.n.02|the|of (r_pobj) of_8\IN\entity.n.01|role (r_prep) suggestive_7\JJ\implicative.s.01|of (r_amod) pattern_2\NN\structure.n.03|a|restrictive|of|,|suggestive (l_prep) of_3\IN\entity.n.01|regurgitation (l_pobj) regurgitation_5\NN\backflow.n.01|valvular
D010479_D006349 NONE pergolide_0\NNP\entity.n.01| (r_nsubjpass) discontinued_2\VBN\discontinue.v.01|pergolide|was|in|,|resulting|returned|. (l_prep) in_3\IN\linear_unit.n.01|patients (l_pobj) patients_5\NNS\case.n.06|10|with (l_prep) with_6\IN\entity.n.01|disease (l_pobj) disease_9\NN\illness.n.01|valvular|heart
D010479_D006349 NONE pergolide_15\NN\entity.n.01| (r_pobj) with_14\IN\entity.n.01|pergolide (r_prep) treated_13\VBN\interact.v.01|with|and|reveals (r_acl) frequency_5\NN\rate.n.01|the|high|of|treated (l_prep) of_6\IN\entity.n.01|regurgitation (l_pobj) regurgitation_9\NN\backflow.n.01|restrictive|valve|in
D010479_D010300 NONE pergolide_11\NN\entity.n.01| (r_pobj) with_10\IN\entity.n.01|pergolide (r_prep) treated_9\VBN\interact.v.01|disease|with|. (l_nsubj) disease_2\NN\illness.n.01|valvular|heart|in (l_prep) in_3\IN\linear_unit.n.01|patients (l_pobj) patients_4\NNS\case.n.06|with (l_prep) with_5\IN\entity.n.01|disease (l_pobj) disease_8\NN\illness.n.01|parkinson
D010479_D010300 NONE pergolide_17\NN\entity.n.01| (r_pobj) with_16\IN\entity.n.01|pergolide (r_prep) treated_15\VBN\interact.v.01|with (r_acl) patients_7\NNS\case.n.06|with|treated (l_prep) with_8\IN\entity.n.01|disease (l_pobj) disease_11\NN\illness.n.01|parkinson|(|pd|)
D010479_D010300 NONE pergolide_17\NN\entity.n.01| (r_pobj) with_16\IN\entity.n.01|pergolide (r_prep) treated_15\VBN\interact.v.01|with (r_acl) patients_7\NNS\case.n.06|with|treated (l_prep) with_8\IN\entity.n.01|disease (l_pobj) disease_11\NN\illness.n.01|parkinson|(|pd|) (l_appos) pd_13\NNP\metallic_element.n.01|
D010479_D010300 NONE pergolide_9\NN\entity.n.01| (r_pobj) with_8\IN\entity.n.01|pergolide (r_prep) treated_7\VBN\interact.v.01|patients|with (l_nsubj) patients_2\NNS\case.n.06|all|pd|in (l_compound) pd_1\NNP\metallic_element.n.01|
D010479_D010300 NONE pergolide_15\NN\entity.n.01| (r_pobj) with_14\IN\entity.n.01|pergolide (r_prep) treated_13\VBN\interact.v.01|with|and|reveals (r_acl) frequency_5\NN\rate.n.01|the|high|of|treated (l_prep) of_6\IN\entity.n.01|regurgitation (l_pobj) regurgitation_9\NN\backflow.n.01|restrictive|valve|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_12\NNS\case.n.06|pd (l_compound) pd_11\NNP\metallic_element.n.01|
D010479_D006333 NONE pergolide_12\NN\entity.n.01| (r_pobj) of_11\IN\entity.n.01|pergolide (r_prep) role_10\NN\duty.n.02|the|of (r_pobj) of_8\IN\entity.n.01|role (r_prep) suggestive_7\JJ\implicative.s.01|of (r_amod) pattern_2\NN\structure.n.03|a|restrictive|of|,|suggestive (r_nsubjpass) observed_15\VBN\spy.v.03|pattern|,|was|in|patients|. (l_dobj) patients_22\NNS\case.n.06|including (l_prep) including_23\VBG\include.v.01|two (l_pobj) two_24\CD\digit.n.01|with (l_prep) with_25\IN\entity.n.01|failure (l_pobj) failure_27\NN\nonaccomplishment.n.01|heart
D010479_D006333 NONE pergolide_0\NNP\entity.n.01| (r_nsubjpass) discontinued_2\VBN\discontinue.v.01|pergolide|was|in|,|resulting|returned|. (l_advcl) resulting_11\VBG\prove.v.01|in (l_prep) in_12\IN\linear_unit.n.01|grade (l_pobj) grade_16\NN\gathering.n.01|a|lower|regurgitation|p=0.01|at (l_prep) at_20\IN\chemical_element.n.01|transthoracic (l_pobj) transthoracic_23\NN\entity.n.01|the|second|echocardiography|and|patients (l_conj) patients_28\NNS\case.n.06|the|two|with (l_prep) with_29\IN\entity.n.01|failure (l_pobj) failure_31\NN\nonaccomplishment.n.01|heart
D004298_D006349 NONE dopamine_33\NN\monoamine_neurotransmitter.n.01| (r_compound) agonists_34\NNS\protagonist.n.02|ergot|dopamine (r_pobj) to_29\IN\entity.n.01|agonists (r_prep) converted_28\VBN\change.v.01|when|treatment|is|to (r_advcl) is_22\VBZ\be.v.01|that|improvement|usual|converted (r_ccomp) reveals_17\VBZ\show.v.04|is (r_conj) treated_13\VBN\interact.v.01|with|and|reveals (r_acl) frequency_5\NN\rate.n.01|the|high|of|treated (l_prep) of_6\IN\entity.n.01|regurgitation (l_pobj) regurgitation_9\NN\backflow.n.01|restrictive|valve|in
D004298_D010300 NONE dopamine_33\NN\monoamine_neurotransmitter.n.01| (r_compound) agonists_34\NNS\protagonist.n.02|ergot|dopamine (r_pobj) to_29\IN\entity.n.01|agonists (r_prep) converted_28\VBN\change.v.01|when|treatment|is|to (r_advcl) is_22\VBZ\be.v.01|that|improvement|usual|converted (r_ccomp) reveals_17\VBZ\show.v.04|is (r_conj) treated_13\VBN\interact.v.01|with|and|reveals (r_acl) frequency_5\NN\rate.n.01|the|high|of|treated (l_prep) of_6\IN\entity.n.01|regurgitation (l_pobj) regurgitation_9\NN\backflow.n.01|restrictive|valve|in (l_prep) in_10\IN\linear_unit.n.01|patients (l_pobj) patients_12\NNS\case.n.06|pd (l_compound) pd_11\NNP\metallic_element.n.01|
11569530
D016593_D016171 CID terfenadine_19\NN\entity.n.01|e.g.|and|terodiline (r_appos) market_16\NN\activity.n.01|the|(|terfenadine|) (r_pobj) from_14\IN\entity.n.01|market (r_prep) withdrawal_10\NN\retraction.n.01|of|from (r_pobj) to_9\IN\entity.n.01|withdrawal (r_prep) led_8\VBN\diode.n.02|that|has|to (r_relcl) effect_5\NN\phenomenon.n.01|a|side|-|led (r_attr) is_1\VBZ\be.v.01|tdp|effect|. (l_nsubj) tdp_0\NNP\entity.n.01|
D016593_D016171 CID terfenadine_13\NN\entity.n.01|,|terodiline (r_appos) investigated_11\VBN\analyze.v.01|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\entity.n.01|
D016593_D016171 CID terfenadine_10\NN\entity.n.01|,|terodiline (r_appos) clinic_8\NN\medical_institution.n.01|the|(|terfenadine|) (r_pobj) in_6\IN\linear_unit.n.01|clinic (r_prep) shown_4\VBN\show.v.04|that|have|tdp|in (l_dobj) tdp_5\NNP\entity.n.01|
C010637_D016171 CID terodiline_21\NN\entity.n.01| (r_conj) terfenadine_19\NN\entity.n.01|e.g.|and|terodiline (r_appos) market_16\NN\activity.n.01|the|(|terfenadine|) (r_pobj) from_14\IN\entity.n.01|market (r_prep) withdrawal_10\NN\retraction.n.01|of|from (r_pobj) to_9\IN\entity.n.01|withdrawal (r_prep) led_8\VBN\diode.n.02|that|has|to (r_relcl) effect_5\NN\phenomenon.n.01|a|side|-|led (r_attr) is_1\VBZ\be.v.01|tdp|effect|. (l_nsubj) tdp_0\NNP\entity.n.01|
C010637_D016171 CID terodiline_15\NN\entity.n.01|,|cisapride (r_conj) terfenadine_13\NN\entity.n.01|,|terodiline (r_appos) investigated_11\VBN\analyze.v.01|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\entity.n.01|
C010637_D016171 CID terodiline_12\NN\entity.n.01|,|cisapride (r_conj) terfenadine_10\NN\entity.n.01|,|terodiline (r_appos) clinic_8\NN\medical_institution.n.01|the|(|terfenadine|) (r_pobj) in_6\IN\linear_unit.n.01|clinic (r_prep) shown_4\VBN\show.v.04|that|have|tdp|in (l_dobj) tdp_5\NNP\entity.n.01|
D020117_D016171 CID cisapride_17\NN\entity.n.01|and|e4031 (r_conj) terodiline_15\NN\entity.n.01|,|cisapride (r_conj) terfenadine_13\NN\entity.n.01|,|terodiline (r_appos) investigated_11\VBN\analyze.v.01|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\entity.n.01|
D020117_D016171 CID cisapride_14\JJ\entity.n.01| (r_conj) terodiline_12\NN\entity.n.01|,|cisapride (r_conj) terfenadine_10\NN\entity.n.01|,|terodiline (r_appos) clinic_8\NN\medical_institution.n.01|the|(|terfenadine|) (r_pobj) in_6\IN\linear_unit.n.01|clinic (r_prep) shown_4\VBN\show.v.04|that|have|tdp|in (l_dobj) tdp_5\NNP\entity.n.01|
C063968_D016171 NONE e4031_19\NNP\entity.n.01| (r_conj) cisapride_17\NN\entity.n.01|and|e4031 (r_conj) terodiline_15\NN\entity.n.01|,|cisapride (r_conj) terfenadine_13\NN\entity.n.01|,|terodiline (r_appos) investigated_11\VBN\analyze.v.01|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NNP\entity.n.01|
